PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bustamante, CD; Fledel-Alon, A; Williamson, S; Nielsen, R; Hubisz, MT; Glanowski, S; Tanenbaum, DM; White, TJ; Sninsky, JJ; Hernandez, RD; Civello, D; Adams, MD; Cargill, M; Clark, AG				Bustamante, CD; Fledel-Alon, A; Williamson, S; Nielsen, R; Hubisz, MT; Glanowski, S; Tanenbaum, DM; White, TJ; Sninsky, JJ; Hernandez, RD; Civello, D; Adams, MD; Cargill, M; Clark, AG			Natural selection on protein-coding genes in the human genome	NATURE			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; POPULATION-GENETICS; MOLECULAR EVOLUTION; PATTERNS; LOCUS	Comparisons of DNA polymorphism within species to divergence between species enables the discovery of molecular adaptation in evolutionarily constrained genes as well as the differentiation of weak from strong purifying selection(1-4). The extent to which weak negative and positive darwinian selection have driven the molecular evolution of different species varies greatly(5-16), with some species, such as Drosophila melanogaster, showing strong evidence of pervasive positive selection(6-9), and others, such as the selfing weed Arabidopsis thaliana, showing an excess of deleterious variation within local populations(9,10). Here we contrast patterns of coding sequence polymorphism identified by direct sequencing of 39 humans for over 11,000 genes to divergence between humans and chimpanzees, and find strong evidence that natural selection has shaped the recent molecular evolution of our species. Our analysis discovered 304 (9.0%) out of 3,377 potentially informative loci showing evidence of rapid amino acid evolution. Furthermore, 813 (13.5%) out of 6,033 potentially informative loci show a paucity of amino acid differences between humans and chimpanzees, indicating weak negative selection and/or balancing selection operating on mutations at these loci. We find that the distribution of negatively and positively selected genes varies greatly among biological processes and molecular functions, and that some classes, such as transcription factors, show an excess of rapidly evolving genes, whereas others, such as cytoskeletal proteins, show an excess of genes with extensive amino acid polymorphism within humans and yet little amino acid divergence between humans and chimpanzees.	Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY 14853 USA; Univ Copenhagen, Ctr Bioinformat, DK-2100 Copenhagen, Denmark; Appl Biosyst Inc, Rockville, MD 20850 USA; Celera Diagnost, Alameda, CA 94502 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University; University of Copenhagen; Thermo Fisher Scientific; Applied Biosystems; Case Western Reserve University; Cornell University	Bustamante, CD (corresponding author), Cornell Univ, Dept Biol Stat & Computat Biol, 101 Biotechnol Bldg, Ithaca, NY 14853 USA.	cdb28@cornell.edu	Nielsen, Rasmus/D-4405-2009	Nielsen, Rasmus/0000-0003-0513-6591; Bustamante, Carlos D./0000-0002-4187-7920; Clark, Andrew/0000-0001-7159-8511; Hubisz, Melissa/0000-0002-9561-6830	NHGRI NIH HHS [R01 HG003229-01, R01 HG003229] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003229] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Barrier M, 2003, GENETICS, V163, P723; Bustamante CD, 2002, NATURE, V416, P531, DOI 10.1038/416531a; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Eyre-Walker A, 1999, NATURE, V397, P344, DOI 10.1038/16915; Fay JC, 2002, NATURE, V415, P1024, DOI 10.1038/4151024a; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; HUDSON RR, 1987, GENETICS, V116, P153; IOERGER TR, 1990, P NATL ACAD SCI USA, V87, P9732, DOI 10.1073/pnas.87.24.9732; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Kimura M., 1983, NEUTRAL THEORY MOL E; Livingston RJ, 2004, GENOME RES, V14, P1821, DOI 10.1101/gr.2730004; Manunta P, 1998, KIDNEY INT, V53, P1471, DOI 10.1046/j.1523-1755.1998.00931.x; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Morrison AC, 2002, HYPERTENSION, V39, P1053, DOI 10.1161/01.HYP.0000019128.94483.3A; Nielsen R, 2005, PLOS BIOL, V3, P976, DOI 10.1371/journal.pbio.0030170; Nordborg M, 2005, PLOS BIOL, V3, P1289, DOI 10.1371/journal.pbio.0030196; SAWYER SA, 1992, GENETICS, V132, P1161; Sawyer SA, 2003, J MOL EVOL, V57, pS154, DOI 10.1007/s00239-003-0022-3; Smith NGC, 2002, NATURE, V415, P1022, DOI 10.1038/4151022a; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591; Weinreich DM, 2000, GENETICS, V156, P385; Williamson S, 2004, GENETICS, V168, P463, DOI 10.1534/genetics.103.024745; Williamson SH, 2005, P NATL ACAD SCI USA, V102, P7882, DOI 10.1073/pnas.0502300102	24	585	595	1	137	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 20	2005	437	7062					1153	1157		10.1038/nature04240	http://dx.doi.org/10.1038/nature04240			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16237444				2022-12-28	WOS:000232660500044
J	Toppani, A; Robert, F; Libourel, G; de Donato, P; Barres, O; d'Hendecourt, L; Ghanbaja, J				Toppani, A; Robert, F; Libourel, G; de Donato, P; Barres, O; d'Hendecourt, L; Ghanbaja, J			A 'dry' condensation origin for circumstellar carbonates	NATURE			English	Article							MINERAL FORMATION; STELLAR WINDS; DUST; SPECTROSCOPY; DISCOVERY; EMISSION; SILICATE	The signature of carbonate minerals has long been suspected in the mid-infrared spectra of various astrophysical environments such as protostars(1). Abiogenic carbonates are considered as indicators of aqueous mineral alteration(2) in the presence of CO2-rich liquid water. The recent claimed detection of calcite associated with amorphous silicates in two planetary nebulae(3) and protostars(4,5) devoid of planetary bodies questions the relevance of this indicator; but in the absence of an alternative mode of formation under circumstellar conditions, this detection remains controversial(6-8). The main dust component observed in circumstellar envelopes is amorphous silicates(9), which are thought to have formed by non-equilibrium condensation(10). Here we report experiments demonstrating that carbonates can be formed with amorphous silicates during the non-equilibrium condensation of a silicate gas in a H2O-CO2-rich vapour. We propose that the observed astrophysical carbonates have condensed in H2O(g)-CO2(g)-rich, high-temperature and high-density regions such as evolved stellar winds, or those induced by grain sputtering upon shocks in protostellar outflows.	Ctr Rech Petrog & Geochim, CNRS, UPR 2300, F-54501 Vandoeuvre Les Nancy, France; INPL, Ecole Natl Super Geol, F-54501 Vandoeuvre Les Nancy, France; Lab Environm & Mineral, CNRS, UMR 7569, F-54501 Vandoeuvre Les Nancy, France; Museum Natl Hist Nat, Lab Etud Mat Extraterr, CNRS, UMS 2679, F-75005 Paris, France; Univ Paris 11, Inst Astrophys Spatiale, CNRS, UMR 8617, F-91405 Orsay, France; Univ Nancy 1, Fac Sci, Serv Commun Microscopie Elect Transmiss, F-54506 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Universite de Lorraine	Toppani, A (corresponding author), Lawrence Livermore Natl Lab, Inst Geophys & Planetary Phys, 7000 East Ave,L-413, Livermore, CA 94550 USA.	toppani2@llnl.gov	Appourchaux, Thierry/F-4692-2010	BARRES, Odile/0000-0002-6930-4315				Abraham F.F.., 1974, HOMOGENEOUS NUCL THE, P263; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; Cami J, 2000, ASTRON ASTROPHYS, V360, P562; Ceccarelli C, 2002, ASTRON ASTROPHYS, V395, pL29, DOI 10.1051/0004-6361:20021490; CHEN LC, 1994, PULSED LASER DEPOSIT, P167; Chiavassa A, 2005, ASTRON ASTROPHYS, V432, P547, DOI 10.1051/0004-6361:20041891; deGraauw T, 1996, ASTRON ASTROPHYS, V315, pL345; DHENDECOURT LB, 1989, ASTRON ASTROPHYS, V223, pL5; Feigelson ED, 1999, ANNU REV ASTRON ASTR, V37, P363, DOI 10.1146/annurev.astro.37.1.363; Ferrarotti AS, 2005, ASTRON ASTROPHYS, V430, P959, DOI 10.1051/0004-6361:20041856; Gail HP, 1999, ASTRON ASTROPHYS, V347, P594; Gueth F, 1997, ASTRON ASTROPHYS, V323, P943; Hofmeister AM, 2004, GEOCHIM COSMOCHIM AC, V68, P4485, DOI 10.1016/j.gca.2004.03.011; IHINGER PD, 1994, REV MINERAL, V30, P67; Kemper F, 2002, NATURE, V415, P295, DOI 10.1038/415295a; Kemper F, 2002, ASTRON ASTROPHYS, V394, P679, DOI 10.1051/0004-6361:20021119; Maret S, 2002, ASTRON ASTROPHYS, V395, P573, DOI 10.1051/0004-6361:20021334; McMillan PF, 1995, REV MINERAL, V32, P247; Molster FJ, 2001, ASTRON ASTROPHYS, V372, P165, DOI 10.1051/0004-6361:20010465; Nisini B, 2002, ASTRON ASTROPHYS, V395, pL25, DOI 10.1051/0004-6361:20021472; Onaka T, 2003, ASTROPHYS J, V585, P872, DOI 10.1086/346178; PAYNE HE, 1988, ASTROPHYS J, V326, P368, DOI 10.1086/166098; SANDFORD SA, 1986, SCIENCE, V231, P1540, DOI 10.1126/science.231.4745.1540; Tielens AGGM, 1998, ASTROPHYS SPACE SCI, V255, P415; TOPPANI A, 2004, LUNAR PLANET SCI C, V35; van Dishoeck EF, 2004, ANNU REV ASTRON ASTR, V42, P119, DOI 10.1146/annurev.astro.42.053102.134010; White W.B., 1974, INFRARED SPECTRA MIN, P227; Wood RF, 1998, APPL SURF SCI, V127, P151, DOI 10.1016/S0169-4332(97)00625-9	30	33	33	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 20	2005	437	7062					1121	1124		10.1038/nature04128	http://dx.doi.org/10.1038/nature04128			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16237436				2022-12-28	WOS:000232660500036
J	Okamoto, N; Inouye, I				Okamoto, N; Inouye, I			A secondary symbiosis in progress?	SCIENCE			English	Article							LIGHT		Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba	Inouye, I (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058572, Japan.	iinouye@sakura.cc.tsukuba.ac.jp	Okamoto, Noriko/J-6570-2012	Okamoto, Noriko/0000-0001-5493-8051				Bhattacharya D, 2004, BIOESSAYS, V26, P50, DOI 10.1002/bies.10376; FOSTER KW, 1980, MICROBIOL REV, V44, P572, DOI 10.1128/MMBR.44.4.572-630.1980; Gilson PR, 2002, GENETICA, V115, P13, DOI 10.1023/A:1016011812442; Hackett JD, 2004, AM J BOT, V91, P1523, DOI 10.3732/ajb.91.10.1523; INOUYE I, 1984, NORD J BOT, V4, P409; Okamoto N, 2005, PROTIST, V156, P163, DOI 10.1016/j.protis.2004.12.003	6	67	78	0	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					287	287		10.1126/science.1116125	http://dx.doi.org/10.1126/science.1116125			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224014				2022-12-28	WOS:000232670100043
J	Berggren, R				Berggren, R			Hurricane Katrina - Unexpected necessities - Inside charity hospital	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Char Hosp, New Orleans, LA USA; Tulane Univ Med Ctr Hosp & Clin, New Orleans, LA USA	Tulane University	Berggren, R (corresponding author), Char Hosp, New Orleans, LA USA.								0	13	13	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1550	+		10.1056/NEJMp058239	http://dx.doi.org/10.1056/NEJMp058239			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221776				2022-12-28	WOS:000232486000007
J	Falcon, LM; Pham, L				Falcon, LM; Pham, L			Hemorrhagic cellulitis after consumption of raw oysters	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Earl K Long Med Ctr, Baton Rouge, LA 70805 USA		Falcon, LM (corresponding author), Earl K Long Med Ctr, Baton Rouge, LA 70805 USA.								0	0	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1604	1604		10.1056/NEJMicm040739	http://dx.doi.org/10.1056/NEJMicm040739			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221783				2022-12-28	WOS:000232486000014
J	Shi, QH; King, RW				Shi, QH; King, RW			Chromosome nondisjunction yields tetraploid rather than aneuploid cells in human cell lines	NATURE			English	Article							MITOTIC CHECKPOINT; CYCLE PROGRESSION; MAMMALIAN-CELLS; INSTABILITY; CANCER; CYTOKINESIS; MECHANISM; DIFFERENTIATION; INACTIVATION; SEGREGATION	Although mutations in cell cycle regulators or spindle proteins can perturb chromosome segregation(1-7), the causes and consequences of spontaneous mitotic chromosome nondisjunction in human cells are not well understood. It has been assumed that nondisjunction of a chromosome during mitosis will yield two aneuploid daughter cells. Here we show that chromosome nondisjunction is tightly coupled to regulation of cytokinesis in human cell lines, such that nondisjunction results in the formation of tetraploid rather than aneuploid cells. We observed that spontaneously arising binucleated cells exhibited chromosome mis-segregation rates up to 166-fold higher than the overall mitotic population. Long-term imaging experiments indicated that most binucleated cells arose through a bipolar mitosis followed by regression of the cleavage furrow hours later. Nondisjunction occurred with high frequency in cells that became binucleated by furrow regression, but not in cells that completed cytokinesis to form two mononucleated cells. Our findings indicate that nondisjunction does not directly yield aneuploid cells, but rather tetraploid cells that may subsequently become aneuploid through further division. The coupling of spontaneous segregation errors to furrow regression provides a potential explanation for the prevalence of hyperdiploid chromosome number and centrosome amplification observed in many cancers(8,9).	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	King, RW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	randy_king@hms.harvard.edu	Yang, Weimei/N-2928-2013; Shi, Qinghua/N-2950-2013	King, Randall/0000-0001-7882-8180; Shi, QingHua/0000-0003-1180-9799				Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; BURHOLT DR, 1989, CANCER RES, V49, P3355; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carere A, 1999, MUTAGENESIS, V14, P491, DOI 10.1093/mutage/14.5.491; Cimini D, 1999, MUTAGENESIS, V14, P563, DOI 10.1093/mutage/14.6.563; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Draviam VM, 2004, CURR OPIN GENET DEV, V14, P120, DOI 10.1016/j.gde.2004.02.007; Duesberg P, 2003, CELL CYCLE, V2, P202, DOI 10.4161/cc.2.3.382; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kaneko Y, 2000, GENE CHROMOSOME CANC, V29, P89, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1021>3.0.CO;2-Y; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Macville M, 1999, CANCER RES, V59, P141; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mitelman F, 2005, MITELMAN DATABASE CH; MULLINS JM, 1977, J CELL BIOL, V73, P672, DOI 10.1083/jcb.73.3.672; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; SHACKNEY SE, 1989, CANCER RES, V49, P3344; Shi QH, 2000, MUTAT RES-FUND MOL M, V452, P27, DOI 10.1016/S0027-5107(00)00032-4; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; TANABE K, 1991, CANCER RES, V51, P4903; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6	30	319	331	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	2005	437	7061					1038	1042		10.1038/nature03958	http://dx.doi.org/10.1038/nature03958			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16222248				2022-12-28	WOS:000232496100048
J	Demers, C; McMurray, JJV; Swedberg, K; Pfeffer, MA; Granger, CB; Olofsson, B; McKelvie, RS; Ostergren, J; Michelson, EL; Johansson, PA; Wang, DL; Yusuf, S				Demers, C; McMurray, JJV; Swedberg, K; Pfeffer, MA; Granger, CB; Olofsson, B; McKelvie, RS; Ostergren, J; Michelson, EL; Johansson, PA; Wang, DL; Yusuf, S		CHARM Investigators	Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR DYSFUNCTION; ACE; MORBIDITY; CAPTOPRIL; MORTALITY; INHIBITION; ENALAPRIL; SURVIVAL; OUTCOMES	Context Angiotensin-converting enzyme (ACE) inhibitors reduce the risk of myocardial infarction (MI), but it is not known whether angiotensin receptor blockers have the same effect. Objective To assess the impact of the angiotensin receptor blocker candesartan on MI and other coronary events in patients with heart failure. Design, Setting, and Participants The Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program, a randomized, placebo-controlled study enrolling patients (mean age, 66 [SD,11] years) with NewYork Heart Association class II to IV symptoms who were randomly allocated to receive candesartan (target dose, 32 mg once daily) or matching placebo given in addition to optimal therapy for heart failure. Patients were enrolled from March 1999 through March 2001. Of 7599 patients allocated, 4004 (53%) had experienced a previous MI, and 1808 (24%) currently had angina. At baseline, 3125 (41%) were receiving an ACE inhibitor; 4203 (55%), a beta-blocker; 3153 (42%), a lipid-lowering drug; 4246 (56%), aspirin; and 6286 (83%), a diuretic. Main Outcome Measure. The primary outcome of the present analysis was the composite of cardiovascular death or nonfatal MI in patients with heart failure receiving candesartan or placebo. Results During the median follow-up of 37.7 months, the primary outcome of cardiovascular death or nonfatal MI was significantly reduced in the candesartan group (775 patients [20.4%]) vs the placebo group (868 [22.9%]) (hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.79-0.96; P=.004; number needed to treat [NNT], 40). Noonfatal MI alone was also significantly reduced in the candesartan group (116 [3.1%]) vs the placebo group (148 [3.9%]) (HR, 0.77; 95% CI, 0.60-0.98; P=.03; NNT, 118). The secondary outcome of fatal MI, sudden death, or nonfatal MI was significantly reduced with candesartan (459 [12.1%]) vs placebo (522 [13.8%]) (HR, 0.86; 95% CI, 0.75-0.97; P=.02; NNT, 59). Risk reductions in cardiovascular death or nonfatal MI were similar across predetermined subgroups and the component CHARM trials. There was no impact on hospitalizations for unstable angina or coronary revascularization procedures with candesartan. Conclusion In patients with heart failure, candesartan significantly reduces the risk of the composite outcome of cardiovascular death or nonfatal MI.	McMaster Univ, Hamilton, ON L8L 2X2, Canada; Univ Glasgow, Glasgow, Lanark, Scotland; Sahlgrens Univ Hosp, Gothenburg, Sweden; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Duke Univ, Med Ctr, Durham, NC USA; AstraZeneca Res & Dev, Molndal, Sweden; Karolinska Hosp, S-10401 Stockholm, Sweden; AstraZeneca LP, Wilmington, DE USA; London Sch Hyg & Trop Med, London WC1, England	McMaster University; University of Glasgow; Sahlgrenska University Hospital; Harvard University; Brigham & Women's Hospital; Duke University; AstraZeneca; Karolinska Institutet; Karolinska University Hospital; AstraZeneca; University of London; London School of Hygiene & Tropical Medicine	Yusuf, S (corresponding author), McMaster Univ, Populat Hlth Res Inst, McMaster Clin, Hamilton Gen Hosp, Room 252,237 Barton St E, Hamilton, ON L8L 2X2, Canada.	yusuf@ccc.mcmaster.ca	mcmurray, John/B-2467-2013; Swedberg, Karl/B-2475-2008; Granger, Christopher B/D-3458-2014	mcmurray, John/0000-0002-6317-3975; Granger, Christopher B/0000-0002-0045-3291; Yusuf, Salim/0000-0003-4776-5601				Braunwald E, 2004, NEW ENGL J MED, V351, P2058; *CONS TRIAL STUD G, 1987, NEW ENGL J MED, V326, P1429; Dagenais GR, 2001, CIRCULATION, V104, P522, DOI 10.1161/hc3001.093502; Dickstein K, 2002, LANCET, V360, P752, DOI 10.1016/S0140-6736(02)09895-1; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Fox KM, 2003, LANCET, V362, P782; McKelvie RS, 1999, CIRCULATION, V100, P1056, DOI 10.1161/01.CIR.100.10.1056; MCMURRAY J, IN PRESS J AM COLL C; Petrie MC, 2001, J AM COLL CARDIOL, V37, P1056, DOI 10.1016/S0735-1097(01)01111-1; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1; Swedberg K, 1999, J Card Fail, V5, P276, DOI 10.1016/S1071-9164(99)90013-1; Teo KK, 2004, AM HEART J, V148, P52, DOI 10.1016/j.ahj.2004.03.020; Torp-Pedersen C, 1999, LANCET, V354, P9, DOI 10.1016/S0140-6736(98)09374-X; Uretsky BF, 2000, CIRCULATION, V102, P611, DOI 10.1161/01.CIR.102.6.611; Verma S, 2004, BMJ-BRIT MED J, V329, P1248, DOI 10.1136/bmj.329.7477.1248; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N; Yusuf S, 2005, NEW ENGL J MED, V352, P937; Yusuf S, 2002, AM HEART J, V143, P22, DOI 10.1067/mhj.2002.119770	21	48	50	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	2005	294	14					1794	1798		10.1001/jama.294.14.1794	http://dx.doi.org/10.1001/jama.294.14.1794			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972RX	16219883	Green Accepted, Bronze			2022-12-28	WOS:000232472000019
J	Rodrigues, LC; Pereira, SM; Cunha, SS; Genser, B; Ichihara, MY; de Brito, SC; Hijjar, MA; Dourado, I; Cruz, AA; Sant'Anna, C; Bierrenbach, AL; Barreto, ML				Rodrigues, LC; Pereira, SM; Cunha, SS; Genser, B; Ichihara, MY; de Brito, SC; Hijjar, MA; Dourado, I; Cruz, AA; Sant'Anna, C; Bierrenbach, AL; Barreto, ML			Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial	LANCET			English	Article							CALMETTE-GUERIN REVACCINATION; MYCOBACTERIAL ANTIGENS; COMMUNITY TRIAL; VACCINATION; MENINGITIS; VACCINES; EFFICACY; PROGRAM; DESIGN; RATES	Background Many countries offer a second BCG vaccination to prevent tuberculosis, although there is little evidence of whether this confers additional protection. BCG vaccination is routine in Brazil but BCG revaccination procedures vary by state. We studied revaccination efficacy in two Brazilian cities with tuberculosis prevalence representative of Brazil. Methods We did a cluster-randomised trial of the protection against tuberculosis from BCG revaccination in school-aged children who had had one BCG vaccination as infants. 767 schools in the cities of Salvador and Manaus, Brazil, participated; schools were the unit of randomisation. The study was open label with no placebo. Cases of tuberculosis were identified through record linkage to the Tuberculosis Control Programme. Revaccination status was masked during linkage and validation of cases. The incidence of tuberculosis was the primary outcome. Analysis was by intention to treat. Findings 386 schools (176 846 children) were assigned BCG revaccination and 365 (171293 children) no revaccination. 42 053 children in the vaccine group and 47 006 in the control group were absent from school on the day of the visit and were excluded. 31163 and 27146, respectively were also excluded because they had no BCG scar, two or more scars, or a doubtful scar on assessment. The crude incidence of tuberculosis in the intervention group was 29.3 per 100 000 person years and in the control group 30.2 per 100 000 person-years (crude-rate ratio 0.97; 95% CI 0.76-1.28). The efficacy of BCG revaccination was 9% (-16 to 29%). Interpretation Revaccination given to children aged 7-14 years in this setting does not provide substantial additional protection and should not be recommended. Follow-up is ongoing and needed to assess the effect of other factors on revaccination efficacy: time since vaccination, age at vaccination, and high or low prevalence of environmental mycobacteria.	Univ Fed Bahia, Inst Saude Coletiva, BR-40110179 Salvador, BA, Brazil; London Sch Hyg & Trop Med, London WC1, England; Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, Graz, Austria; Minist Hlth, Coordenacao Reg Fdn Nacl Saude Bahia, Salvador, BA, Brazil; Minist Hlth, Ctr Referencia Helio Fraga, FUNASA, Rio De Janeiro, Brazil; Univ Fed Bahia, Fac Med, BR-41170290 Salvador, BA, Brazil; Univ Fed Rio de Janeiro, Fac Med, BR-21941 Rio De Janeiro, Brazil	Universidade Federal da Bahia; University of London; London School of Hygiene & Tropical Medicine; Medical University of Graz; Universidade Federal da Bahia; Universidade Federal do Rio de Janeiro	Barreto, ML (corresponding author), Univ Fed Bahia, Inst Saude Coletiva, Rua Padre Feijo 29, BR-40110179 Salvador, BA, Brazil.	mauricio@ufba.br	RODRIGUES, LAURA CUNHA/AAO-4130-2021; Cruz, Alvaro A/I-1676-2012; Barreto, Mauricio L/B-1752-2008; Dourado, Ines/Q-6535-2016; Anna, Clemax Sant/H-7923-2019; Oliveira, Claudia DL/G-8618-2011; Bierrenbach, Ana L/F-3185-2014	Cruz, Alvaro A/0000-0002-7403-3871; Barreto, Mauricio L/0000-0002-0215-4930; Dourado, Ines/0000-0003-1675-2146; Anna, Clemax Sant/0000-0001-8732-8065; Bierrenbach, Ana L/0000-0002-6837-0636; Genser, Bernd/0000-0001-5787-0902; Souza da Cunha, Sergio/0000-0002-4926-3827; Rodrigues, Laura Cunha/0000-0001-9008-660X				Barbosa T, 2003, VACCINE, V21, P2152, DOI 10.1016/S0264-410X(02)00721-1; Barreto ML, 2002, CONTROL CLIN TRIALS, V23, P540, DOI 10.1016/S0197-2456(02)00216-7; Bierrenbach AL, 2001, INT J TUBERC LUNG D, V5, P656; CAMARGOS PAM, 1988, INT J EPIDEMIOL, V17, P193, DOI 10.1093/ije/17.1.193; Chee CB, 2003, B WORLD HEALTH ORGAN, V81, P217; Dourado I, 2003, INT J TUBERC LUNG D, V7, P399; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Elias D, 2001, CLIN EXP IMMUNOL, V123, P219, DOI 10.1046/j.1365-2249.2001.01446.x; Ellner JJ, 2000, CLIN INFECT DIS, V30, pS279, DOI 10.1086/313874; Fine P., 1999, ISSUES RELATING USE; FINE PEM, 1990, LANCET, V335, P1016, DOI 10.1016/0140-6736(90)91074-K; Fine PEM, 1996, LANCET, V348, P17, DOI 10.1016/S0140-6736(96)02166-6; GARDNER W, 1995, PSYCHOL BULL, V118, P392, DOI 10.1037/0033-2909.118.3.392; Ginsberg AM, 2002, B WORLD HEALTH ORGAN, V80, P483; Global Programme on Tuberculosis Global Programme on Vaccines, 1995, WEEKLY EPIDEMIOLOGIC, V70, P229; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Leung CC, 2001, INT J TUBERC LUNG D, V5, P717; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; McMurray DN, 2003, INT J PARASITOL, V33, P547, DOI 10.1016/S0020-7519(03)00061-4; Mustafa AS, 2002, MOL IMMUNOL, V39, P113, DOI 10.1016/S0161-5890(02)00048-2; Nascimento-Costa M, 1991, B OFICINA SANIT PANA, V110, P26; Pathania VS, 1999, VACCINE, V17, P1926, DOI 10.1016/S0264-410X(98)00462-9; Pereira SM, 2001, INT J TUBERC LUNG D, V5, P1067; PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4; Prado Md, 2001, Rev Soc Bras Med Trop, V34, P99; Rahman M, 2002, PREV MED, V35, P70, DOI 10.1006/pmed.2002.1043; RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154; SALEM J I, 1989, Acta Amazonica, V19, P349; Snider DE, 2000, CLIN INFECT DIS, V30, pS271, DOI 10.1086/313872; Tala-Heikkila MM, 1998, AM J RESP CRIT CARE, V157, P1324, DOI 10.1164/ajrccm.157.4.9706037; Thompson SG, 1997, STAT MED, V16, P2063, DOI 10.1002/(SICI)1097-0258(19970930)16:18<2063::AID-SIM642>3.0.CO;2-8; Trnka L, 1998, B WORLD HEALTH ORGAN, V76, P85; von Reyn CF, 2002, CLIN INFECT DIS, V35, P465, DOI 10.1086/341901; *WHO IN VACC RES, STAT ART NEW VACC RE; WUNSCH V, 1990, B WORLD HEALTH ORGAN, V68, P69; 2001, WKLY EPIDEMIOL REC, V76, P33	36	191	202	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 8	2005	366	9493					1290	1295		10.1016/S0140-6736(05)67145-0	http://dx.doi.org/10.1016/S0140-6736(05)67145-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971ST	16214599				2022-12-28	WOS:000232405700027
J	Robins, RW				Robins, RW			The nature of personality: Genes, culture, and national character	SCIENCE			English	Editorial Material									Univ Calif Davis, Dept Psychol, Davis, CA 95616 USA	University of California System; University of California Davis	Robins, RW (corresponding author), Univ Calif Davis, Dept Psychol, 1 Shields Ave, Davis, CA 95616 USA.	rwrobins@ucdavis.edu						BOUCHARD TJ, 1994, SCIENCE, V264, P1700, DOI 10.1126/science.8209250; Caspi A, 2005, ANNU REV PSYCHOL, V56, P453, DOI 10.1146/annurev.psych.55.090902.141913; Gosling SD, 1999, CURR DIR PSYCHOL SCI, V8, P69, DOI 10.1111/1467-8721.00017; HAMILTON DL, 1994, HDB SOCIAL COGNITION, V2, P1; MCCRAE RR, IN PRESS J PERS SOC; Meyer GJ, 2001, AM PSYCHOL, V56, P128, DOI 10.1037//0003-066X.56.2.128; OZER DJ, IN PRESS ANN REV PSY; Pinker S., 2002, BLANK SLATE; Terracciano A, 2005, SCIENCE, V310, P96, DOI 10.1126/science.1117199; Watson J. B., 1930, BEHAVIORISM	10	21	21	4	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 7	2005	310	5745					62	63		10.1126/science.1119736	http://dx.doi.org/10.1126/science.1119736			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	972TV	16210523	Green Submitted			2022-12-28	WOS:000232477000032
J	Schwabe, T; Bainton, RJ; Fetter, RD; Heberlein, U; Gaul, U				Schwabe, T; Bainton, RJ; Fetter, RD; Heberlein, U; Gaul, U			GPCR signaling is required for blood-brain barrier formation in Drosophila	CELL			English	Article							HETEROTRIMERIC G-PROTEINS; ASYMMETRIC CELL-DIVISION; SEPTATE JUNCTION; COUPLED RECEPTOR; NERVOUS-SYSTEM; GLIAL-CELLS; ALPHA; GENE; DIFFERENTIATION; EXPRESSION	The blood-brain barrier of Drosophila is established by surface glia, which ensheath the nerve cord and insulate it against the potassium-rich hemolymph by forming intercellular septate junctions. The mechanisms underlying the formation of this barrier remain obscure. Here, we show that the G protein-coupled receptor (GPCR) Moody, the G protein subunits G alpha i and G alpha o, and the regulator of G protein signaling Loco are required in the surface glia to achieve effective insulation. Our data suggest that the four proteins act in a complex common pathway. At the cellular level, the components function by regulating the cortical actin and thereby stabilizing the extended morphology of the surface glia, which in turn is necessary for the formation of septate junctions of sufficient length to achieve proper sealing of the nerve cord. Our study demonstrates the importance of morphogenetic regulation in blood-brain barrier development and places GPCR signaling at its core.	Rockefeller Univ, Lab Dev Neurogenet, New York, NY 10021 USA; Rockefeller Univ, Lab Neural Circuits & Behav, New York, NY 10021 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	Rockefeller University; Rockefeller University; University of California System; University of California San Francisco	Gaul, U (corresponding author), Rockefeller Univ, Lab Dev Neurogenet, 1230 York Ave, New York, NY 10021 USA.	gaul@mail.rockefeller.edu	Schwabe, Tina/AAA-3822-2021		NATIONAL EYE INSTITUTE [R01EY011560, R55EY011560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA014809] Funding Source: NIH RePORTER; NEI NIH HHS [EY011560, R01 EY011560-08, R01 EY011560] Funding Source: Medline; NIDA NIH HHS [DA444906-33821, DA14809] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ABBOTT NJ, 1991, ANN NY ACAD SCI, V633, P378; AULD VJ, 1995, CELL, V81, P757, DOI 10.1016/0092-8674(95)90537-5; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Carlson SD, 2000, ANNU REV ENTOMOL, V45, P151, DOI 10.1146/annurev.ento.45.1.151; Casso D, 2000, MECH DEVELOP, V91, P449; Cho H, 2000, MOL PHARMACOL, V58, P569, DOI 10.1124/mol.58.3.569; EDWARDS JS, 1993, J COMP NEUROL, V333, P301, DOI 10.1002/cne.903330214; Edwards KA, 1997, DEV BIOL, V191, P103, DOI 10.1006/dbio.1997.8707; Faivre-Sarrailh C, 2004, DEVELOPMENT, V131, P4931, DOI 10.1242/dev.01372; Freeman MR, 2003, NEURON, V38, P567, DOI 10.1016/S0896-6273(03)00289-7; Genova JL, 2003, J CELL BIOL, V161, P979, DOI 10.1083/jcb.200212054; Granderath S, 1999, DEVELOPMENT, V126, P1781; HALTER DA, 1995, DEVELOPMENT, V121, P317; Huber AB, 2003, ANNU REV NEUROSCI, V26, P509, DOI 10.1146/annurev.neuro.26.010302.081139; ITO K, 1995, ROUX ARCH DEV BIOL, V204, P284, DOI 10.1007/BF02179499; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; Katanaev VL, 2005, CELL, V120, P111, DOI 10.1016/j.cell.2004.11.014; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Kunwar PS, 2003, PLOS BIOL, V1, P372, DOI 10.1371/journal.pbio.0000080; Leiserson WM, 2000, NEURON, V28, P793, DOI 10.1016/S0896-6273(00)00154-9; Madden K, 1998, ANNU REV MICROBIOL, V52, P687, DOI 10.1146/annurev.micro.52.1.687; Manahan CL, 2004, ANNU REV CELL DEV BI, V20, P223, DOI 10.1146/annurev.cellbio.20.011303.132633; McCartney BM, 2001, NAT CELL BIOL, V3, P933, DOI 10.1038/ncb1001-933; Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Poliak S, 2003, NAT REV NEUROSCI, V4, P968, DOI 10.1038/nrn1253; QUAN F, 1993, P NATL ACAD SCI USA, V90, P4236, DOI 10.1073/pnas.90.9.4236; Salzer JL, 2002, TRENDS NEUROSCI, V25, P2, DOI 10.1016/S0166-2236(00)02006-3; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; Schier AF, 2003, CURR BIOL, V13, pR192, DOI 10.1016/S0960-9822(03)00122-2; Schmidt H, 1997, DEV BIOL, V189, P186, DOI 10.1006/dbio.1997.8660; Sepp KJ, 2003, DEVELOPMENT, V130, P1825, DOI 10.1242/dev.00413; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Stapleton M., 2002, GENOME BIOL, V3, DOI [10.1186/gb-2002-3-12-research0080, DOI 10.1186/GB-2002-3-12-RESEARCH0080]; Tatenhorst L, 2004, J NEUROPATH EXP NEUR, V63, P210, DOI 10.1093/jnen/63.3.210; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; Wittenberger T, 2001, J MOL BIOL, V307, P799, DOI 10.1006/jmbi.2001.4520; WOLFGANG WJ, 1990, J NEUROSCI, V10, P1014; Wu DQ, 2005, CELL RES, V15, P52, DOI 10.1038/sj.cr.7290265; YARFITZ S, 1988, P NATL ACAD SCI USA, V85, P7134, DOI 10.1073/pnas.85.19.7134; Yousefi S, 2001, J LEUKOCYTE BIOL, V69, P1045; Yu FW, 2005, GENE DEV, V19, P1341, DOI 10.1101/gad.1295505; Yu FW, 2003, J CELL BIOL, V162, P623, DOI 10.1083/jcb.200303174	47	163	169	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 7	2005	123	1					133	144		10.1016/j.cell.2005.08.037	http://dx.doi.org/10.1016/j.cell.2005.08.037			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	973QD	16213218	Bronze			2022-12-28	WOS:000232536800014
J	Macario, AJL; de Macario, EC				Macario, AJL; de Macario, EC			Mechanisms of disease - Sick chaperones, cellular stress, and disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HEAT-SHOCK PROTEINS; ALPHA-B-CRYSTALLIN; MOLECULAR CHAPERONES; A-CRYSTALLIN; PROMOTER REGION; EXPRESSION; HEAT-SHOCK-PROTEIN-70; AGGREGATION; BETA; GENE		New York State Dept Hlth, Wadsworth Ctr, Div Mol Med, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Macario, AJL (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Div Mol Med, Room B-749,Empire State Plaza,POB 509, Albany, NY 12201 USA.	macario@wadsworth.org						Alberti S, 2003, CELL STRESS CHAPERON, V8, P225, DOI 10.1379/1466-1268(2003)008<0225:BNEFOH>2.0.CO;2; Altomare K, 2003, BIOGERONTOLOGY, V4, P215, DOI 10.1023/A:1025182615693; Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Askanas V, 2003, CURR OPIN RHEUMATOL, V15, P737, DOI 10.1097/00002281-200311000-00009; Banwell BL, 2000, NEUROLOGY, V54, P1033, DOI 10.1212/WNL.54.5.1033; Bernstein SL, 2000, INVEST OPHTH VIS SCI, V41, P2857; Bloemendal H, 2004, PROG BIOPHYS MOL BIO, V86, P407, DOI 10.1016/j.pbiomolbio.2003.11.012; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; Campisi J, 2003, CELL STRESS CHAPERON, V8, P272, DOI 10.1379/1466-1268(2003)008<0272:SEHIAF>2.0.CO;2; Caplan AJ, 2003, CELL STRESS CHAPERON, V8, P105, DOI 10.1379/1466-1268(2003)008<0105:WIAC>2.0.CO;2; Chapple JP, 2001, TRENDS MOL MED, V7, P414, DOI 10.1016/S1471-4914(01)02103-7; CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V208, P675, DOI 10.1006/bbrc.1995.1391; Cloos PAC, 2004, BIOGERONTOLOGY, V5, P139, DOI 10.1023/B:BGEN.0000031152.31352.8b; Cobb BA, 2002, BIOCHEMISTRY-US, V41, P483, DOI 10.1021/bi0112457; Cobb BA, 2000, BIOCHEMISTRY-US, V39, P15791, DOI 10.1021/bi001453j; Csermely P, 2001, TRENDS GENET, V17, P701, DOI 10.1016/S0168-9525(01)02495-7; Dabir DV, 2004, AM J PATHOL, V164, P155, DOI 10.1016/S0002-9440(10)63106-9; Derham BK, 2003, EUR J BIOCHEM, V270, P2605, DOI 10.1046/j.1432-1033.2003.03631.x; Djabali K, 1997, J CELL SCI, V110, P2759; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; Epstein Charles J., 2004, P3; Esser C, 2004, BBA-MOL CELL RES, V1695, P171, DOI 10.1016/j.bbamcr.2004.09.020; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; Fonager J, 2002, EXP GERONTOL, V37, P1223, DOI 10.1016/S0531-5565(02)00128-6; Gao HC, 2004, J BACTERIOL, V186, P7796, DOI 10.1128/JB.186.22.7796-7803.2004; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Guagliardi A, 2004, BIOCHEM J, V381, P249, DOI 10.1042/BJ20040131; Gutsmann-Conrad A, 1998, EXP CELL RES, V241, P404, DOI 10.1006/excr.1998.4069; HAMOS JE, 1991, NEUROLOGY, V41, P345, DOI 10.1212/WNL.41.3.345; Hay DG, 2004, HUM MOL GENET, V13, P1389, DOI 10.1093/hmg/ddh144; Heon E, 1999, AM J HUM GENET, V65, P1261, DOI 10.1086/302619; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; IWAKI T, 1993, AM J PATHOL, V143, P487; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; Jin XF, 2004, AM J MED, V117, P406, DOI 10.1016/j.amjmed.2004.03.026; Jin XF, 2004, CELL STRESS CHAPERON, V9, P69, DOI 10.1379/477.1; Jing Z, 2005, NEUROBIOL AGING, V26, P207, DOI 10.1016/j.neurobiolaging.2004.03.012; Kapphahn RJ, 2003, BIOCHEMISTRY-US, V42, P15310, DOI 10.1021/bi034774e; Kaufmann S., 1994, BIOL HEAT SHOCK PROT, P495; Kleizen B, 2004, CURR OPIN CELL BIOL, V16, P343, DOI 10.1016/j.ceb.2004.06.012; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; Koyama Y, 1999, AM J PATHOL, V154, P1563, DOI 10.1016/S0002-9440(10)65409-0; Kumaraguru U, 2003, CELL STRESS CHAPERON, V8, P134, DOI 10.1379/1466-1268(2003)008<0134:APCTPD>2.0.CO;2; Lehner T, 2004, BIOCHEM SOC T, V32, P629, DOI 10.1042/BST0320629; Liang JJN, 2004, PROTEIN SCI, V13, P2476, DOI 10.1110/ps.04815104; Lindner RA, 1998, EUR J BIOCHEM, V258, P170, DOI 10.1046/j.1432-1327.1998.2580170.x; Lum R, 2004, J BIOL CHEM, V279, P29139, DOI 10.1074/jbc.M403777200; Ma ZX, 1998, EXP EYE RES, V67, P21, DOI 10.1006/exer.1998.0482; Maatkamp A, 2004, EUR J NEUROSCI, V20, P14, DOI 10.1111/j.1460-9568.2004.03430.x; Macario A.J.L., 2001, ADV CELL AGING GERON, V7, P131, DOI [DOI 10.1016/S1566-3124(01)07018-3, 10.1016/S1566-3124(01)07018-3]; Macario AJL, 2000, INT J CLIN LAB RES, V30, P49, DOI 10.1007/s005990070016; Macario AJL, 1999, MICROBIOL MOL BIOL R, V63, P923, DOI 10.1128/MMBR.63.4.923-967.1999; Macario AJL, 2004, STRESS, V7, P243, DOI 10.1080/10253890400019706; Macario AJL, 2005, GENET MED, V7, P3, DOI 10.1097/01.GIM.0000151351.11876.C3; Macario AJL, 2002, AGEING RES REV, V1, P295, DOI 10.1016/S1568-1637(01)00005-8; MACARIO AJL, 1995, INT J CLIN LAB RES, V25, P59, DOI 10.1007/BF02592359; Magrane J, 2004, J NEUROSCI, V24, P1700, DOI 10.1523/JNEUROSCI.4330-03.2004; Maher Eamonn R., 2004, P823; Martin J, 2004, J MOL RECOGNIT, V17, P465, DOI 10.1002/jmr.707; Martin J, 2004, TRENDS BIOCHEM SCI, V29, P455, DOI 10.1016/j.tibs.2004.07.004; Maruyama T, 2004, FRONT BIOSCI-LANDMRK, V9, P1680, DOI 10.2741/1361; Maupin-Furlow JA, 2004, FRONT BIOSCI-LANDMRK, V9, P1743, DOI 10.2741/1363; Maurizi MR, 2004, STRUCTURE, V12, P175, DOI 10.1016/j.str.2004.01.021; Mogk A, 2003, MOL MICROBIOL, V50, P585, DOI 10.1046/j.1365-2958.2003.03710.x; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Muchowski PJ, 1999, INVEST OPHTH VIS SCI, V40, P951; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; Nardai G, 2002, EXP GERONTOL, V37, P1257, DOI 10.1016/S0531-5565(02)00134-1; Odunuga OO, 2004, BIOESSAYS, V26, P1058, DOI 10.1002/bies.20107; Okada M, 2004, J BIOL CHEM, V279, P4221, DOI 10.1074/jbc.M309014200; PEREZ N, 1991, MOL BRAIN RES, V11, P249, DOI 10.1016/0169-328X(91)90033-T; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Pockley AG, 1999, CELL STRESS CHAPERON, V4, P29, DOI 10.1379/1466-1268(1999)004<0029:IOHHSP>2.3.CO;2; Poirier MA, 2005, HUM MOL GENET, V14, P765, DOI 10.1093/hmg/ddi071; Prakash S, 2004, TRENDS BIOCHEM SCI, V29, P593, DOI 10.1016/j.tibs.2004.09.011; Rea IM, 2001, EXP GERONTOL, V36, P341, DOI 10.1016/S0531-5565(00)00215-1; Rekas A, 2004, J MOL BIOL, V340, P1167, DOI 10.1016/j.jmb.2004.05.054; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Ross OA, 2003, EXP GERONTOL, V38, P561, DOI 10.1016/S0531-5565(03)00006-8; Schlee S, 2004, J MOL BIOL, V336, P275, DOI 10.1016/j.jmb.2003.12.013; Sghaier Haitham, 2004, In Silico Biol, V4, P311; Singh R, 2004, BIOGERONTOLOGY, V5, P169, DOI 10.1023/B:BGEN.0000031154.57176.4f; Slavotinek AM, 2001, TRENDS GENET, V17, P528, DOI 10.1016/S0168-9525(01)02413-1; Snoeckx LHEH, 2001, PHYSIOL REV, V81, P1461, DOI 10.1152/physrev.2001.81.4.1461; Soti C, 2003, EXP GERONTOL, V38, P1037, DOI 10.1016/S0531-5565(03)00185-2; Spiess C, 2004, TRENDS CELL BIOL, V14, P598, DOI 10.1016/j.tcb.2004.09.015; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; Verbeke P, 2001, CELL BIOL INT, V25, P845, DOI 10.1006/cbir.2001.0789; Werten PJL, 1999, EXP EYE RES, V68, P99, DOI 10.1006/exer.1998.0584; WU B, 1993, J GERONTOL, V48, pB50, DOI 10.1093/geronj/48.2.B50; Wu YR, 2004, HUM GENET, V114, P236, DOI 10.1007/s00439-003-1050-1; Yang M, 2004, CELL STRESS CHAPERON, V9, P207, DOI 10.1379/CSC-12R.1; Yokota SI, 2003, BIOCHEM BIOPH RES CO, V303, P413, DOI 10.1016/S0006-291X(03)00352-8; Yoo BC, 2001, BIOCHEM BIOPH RES CO, V280, P249, DOI 10.1006/bbrc.2000.4109; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009; Zabel C, 2002, MOL CELL PROTEOMICS, V1, P366, DOI 10.1074/mcp.M200016-MCP200	100	258	270	2	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 6	2005	353	14					1489	1501		10.1056/NEJMra050111	http://dx.doi.org/10.1056/NEJMra050111			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970LZ	16207851				2022-12-28	WOS:000232313000009
J	Palmer, LJ; Cordon, LR				Palmer, LJ; Cordon, LR			Genetic Epidemiology 4 - Shaking the tree: mapping complex disease genes with linkage disequilibrium	LANCET			English	Review							SINGLE-NUCLEOTIDE POLYMORPHISMS; HAPLOTYPE BLOCKS; POPULATION STRATIFICATION; BREAST-CANCER; HUMAN-GENOME; CLINICAL-TRIALS; CANDIDATE GENES; DRUG DISCOVERY; ASSOCIATION; FUTURE	Much effort and expense are being spent internationally to detect genetic polymorphisms contributing to susceptibility to complex human disease. Concomitantly, the technology for detecting and genotyping single nucleotide polymorphisms (SNPs) has undergone rapid development, yielding extensive catalogues of these polymorphisms across the genome. Population-based maps of the correlations amongst SNPs (linkage disequilibrium) are now being developed to accelerate the discovery of genes for complex human diseases. These genomic advances coincide with an increasing recognition of the importance of very large sample sizes for studying genetic effects. Together, these new genetic and epidemiological data hold renewed promise for the identification of susceptibility genes for complex traits. We review the state of knowledge about the structure of the human genome as related to SNPs and linkage disequilibrium, discuss the potential applications of this knowledge to mapping complex disease genes, and consider the issues facing whole genome association scanning using SNPs.	Univ Western Australia, Queen Elizabeth II Med Ctr, Western Australian Inst Med Res, Nedlands, WA 6009, Australia; Univ Western Australia, Queen Elizabeth II Med Ctr, Med Res Ctr, Nedlands, WA 6009, Australia; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England	University of Western Australia; University of Western Australia; University of Oxford; Wellcome Centre for Human Genetics	Palmer, LJ (corresponding author), Univ Western Australia, Queen Elizabeth II Med Ctr, Western Australian Inst Med Res, B Block,Hosp Ave, Nedlands, WA 6009, Australia.	lyle.palmer@cyllene.uwa.edu.au	Palmer, Lyle John/K-3196-2014; Palmer, Lyle John/N-1948-2019	Palmer, Lyle John/0000-0002-1628-3055; Palmer, Lyle John/0000-0002-1628-3055	NATIONAL EYE INSTITUTE [R01EY012562] Funding Source: NIH RePORTER; NEI NIH HHS [EY-12562] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Abecasis GR, 2000, AM J HUM GENET, V67, P327; Andersson L, 2004, NAT REV GENET, V5, P202, DOI 10.1038/nrg1294; [Anonymous], 1986, Lancet, V2, P57; Ardlie KG, 2002, NAT REV GENET, V3, P299, DOI 10.1038/nrg777; Austin Melissa A, 2003, Community Genet, V6, P37, DOI 10.1159/000069544; Bacanu SA, 2002, GENET EPIDEMIOL, V22, P78, DOI 10.1002/gepi.1045; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Brookes AJ, 1999, GENE, V234, P177, DOI 10.1016/S0378-1119(99)00219-X; Burke W, 2003, NEW ENGL J MED, V349, P969, DOI 10.1056/NEJMra012479; Burton PR, 2005, LANCET, V366, P941, DOI 10.1016/S0140-6736(05)67322-9; Cardon LR, 2003, LANCET, V361, P598, DOI 10.1016/S0140-6736(03)12520-2; Cardon LR, 2000, BRIT MED J, V320, P1223, DOI 10.1136/bmj.320.7244.1223; Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543; Cardon LR, 2003, TRENDS GENET, V19, P135, DOI 10.1016/S0168-9525(03)00022-2; Carlson CS, 2003, NAT GENET, V33, P518, DOI 10.1038/ng1128; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Chakravarti A, 1998, NAT GENET, V19, P216, DOI 10.1038/885; Chanda SK, 2003, DRUG DISCOV TODAY, V8, P168, DOI 10.1016/S1359-6446(02)02595-3; Chapman JM, 2003, HUM HERED, V56, P18, DOI 10.1159/000073729; Collins A, 1999, P NATL ACAD SCI USA, V96, P15173, DOI 10.1073/pnas.96.26.15173; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Cordell HJ, 2005, LANCET, V366, P1121, DOI 10.1016/S0140-6736(05)67424-7; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Crawford DC, 2004, AM J HUM GENET, V74, P610, DOI 10.1086/382227; Dahlman I, 2002, NAT GENET, V30, P149, DOI 10.1038/ng825; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; Dawson E, 2002, NATURE, V418, P544, DOI 10.1038/nature00864; Devlin B, 2001, THEOR POPUL BIOL, V60, P155, DOI 10.1006/tpbi.2001.1542; Devlin B, 2001, GENET EPIDEMIOL, V21, P273, DOI 10.1002/gepi.1034; Eberle MA, 2000, GENET EPIDEMIOL, V19, pS29, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI5>3.0.CO;2-P; Edwards Joanne, 2003, Methods Mol Biol, V226, P287; EWENS WJ, 1995, AM J HUM GENET, V57, P455; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; EXCOFFIER L, 1992, GENETICS, V131, P479; Feldman MW, 2003, NATURE, V424, P374, DOI 10.1038/424374a; Fields S, 1997, NAT GENET, V15, P325, DOI 10.1038/ng0497-325; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Freedman ML, 2004, NAT GENET, V36, P388, DOI 10.1038/ng1333; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Goddard KAB, 2000, AM J HUM GENET, V66, P216, DOI 10.1086/302727; Goldstein DB, 2003, NAT REV GENET, V4, P937, DOI 10.1038/nrg1229; Goldstein DB, 2003, TRENDS GENET, V19, P615, DOI 10.1016/j.tig.2003.09.006; Goring HHH, 2001, AM J HUM GENET, V69, P1357, DOI 10.1086/324471; Gray IC, 2000, HUM MOL GENET, V9, P2403, DOI 10.1093/hmg/9.16.2403; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; Hirschhorn JN, 2001, AM J HUM GENET, V69, P106, DOI 10.1086/321287; Horne BD, 2004, GENET EPIDEMIOL, V26, P11, DOI 10.1002/gepi.10292; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233; Johnson JA, 2003, TRENDS GENET, V19, P660, DOI 10.1016/j.tig.2003.09.008; Jorde LB, 2000, GENOME RES, V10, P1435, DOI 10.1101/gr.144500; JORDE LB, 1994, AM J HUM GENET, V54, P884; JORDE LB, 1995, AM J HUM GENET, V56, P11; Judson R, 2002, PHARMACOGENOMICS, V3, P379, DOI 10.1517/14622416.3.3.379; Ke XY, 2003, BIOINFORMATICS, V19, P287, DOI 10.1093/bioinformatics/19.2.287; Ke XY, 2004, HUM MOL GENET, V13, P2557, DOI 10.1093/hmg/ddh294; Ke XY, 2004, HUM MOL GENET, V13, P577, DOI 10.1093/hmg/ddh060; Kelada SN, 2003, ENVIRON HEALTH PERSP, V111, P1055, DOI 10.1289/ehp.6065; Khoury MJ, 1997, EPIDEMIOL REV, V19, P175, DOI 10.1093/oxfordjournals.epirev.a017940; Khoury MJ, 2003, NEW ENGL J MED, V348, P50, DOI 10.1056/NEJMra013182; Kruglyak L, 1997, NAT GENET, V17, P21, DOI 10.1038/ng0997-21; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Kuhner MK, 2000, GENETICS, V156, P439; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lazarus R, 2002, IMMUNOL REV, V190, P9, DOI 10.1034/j.1600-065X.2002.19002.x; Lee WC, 2002, EPIDEMIOLOGY, V13, P545, DOI 10.1097/00001648-200209000-00010; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Long AD, 1999, GENOME RES, V9, P720; Lowe CE, 2004, GENES IMMUN, V5, P301, DOI 10.1038/sj.gene.6364064; Mackay TFC, 2001, ANNU REV GENET, V35, P303, DOI 10.1146/annurev.genet.35.102401.090633; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Mallinckrodt CH, 2003, BIOL PSYCHIAT, V53, P754, DOI 10.1016/S0006-3223(02)01867-X; Marchini J, 2004, NAT GENET, V36, P512, DOI 10.1038/ng1337; Matsuzaki H, 2004, GENOME RES, V14, P414, DOI 10.1101/gr.2014904; McKeigue PM, 1998, AM J HUM GENET, V63, P241, DOI 10.1086/301908; McVean GAT, 2004, SCIENCE, V304, P581, DOI 10.1126/science.1092500; Merikangas KR, 2003, SCIENCE, V302, P599, DOI 10.1126/science.1091468; Mira MT, 2004, NATURE, V427, P636, DOI 10.1038/nature02326; Molenberghs G, 2002, STAT MED, V21, P1387, DOI 10.1002/sim.1118; Morris AP, 2004, AM J HUM GENET, V74, P945, DOI 10.1086/420773; Nagy A, 2003, NAT GENET, V33, P276, DOI 10.1038/ng1115; Neale BM, 2004, AM J HUM GENET, V75, P353, DOI 10.1086/423901; NICKERSON DA, 1992, GENOMICS, V12, P377, DOI 10.1016/0888-7543(92)90388-9; Niu TH, 2002, AM J HUM GENET, V70, P157, DOI 10.1086/338446; Ohlstein EH, 2000, ANNU REV PHARMACOL, V40, P177, DOI 10.1146/annurev.pharmtox.40.1.177; Olson JM, 1999, STAT MED, V18, P2961, DOI 10.1002/(SICI)1097-0258(19991115)18:21<2961::AID-SIM206>3.0.CO;2-U; Overall ADJ, 2001, MOL BIOL EVOL, V18, P2048, DOI 10.1093/oxfordjournals.molbev.a003746; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; Palmer LJ, 2001, RESP RES, V2, P102, DOI 10.1186/rr45; Palmer LJ, 2000, GENOME RES, V10, P1280, DOI 10.1101/gr.143400; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Peltonen L, 2001, SCIENCE, V291, P1224, DOI 10.1126/science.291.5507.1224; Phillips MS, 2003, NAT GENET, V33, P382, DOI 10.1038/ng1100; Pritchard JK, 2000, AM J HUM GENET, V67, P170, DOI 10.1086/302959; Pritchard JK, 1999, AM J HUM GENET, V65, P220, DOI 10.1086/302449; Raghunathan TE, 2004, ANNU REV PUBL HEALTH, V25, P99, DOI 10.1146/annurev.publhealth.25.102802.124410; Reich DE, 2003, NAT GENET, V33, P457, DOI 10.1038/ng1133; RIBOLI E, 1992, ANN ONCOL, V3, P783, DOI 10.1093/oxfordjournals.annonc.a058097; Risch N, 1998, GENOME RES, V8, P1273, DOI 10.1101/gr.8.12.1273; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Risch N., 2002, GENOME BIOL, V3, pcomm, DOI [10.1186/gb-2002-3-7-comment2007, 10.1186/GB-2002-3-7-COMMENT2007]; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Roses AD, 2001, HUM MOL GENET, V10, P2261, DOI 10.1093/hmg/10.20.2261; Rosner B, 1990, FUNDAMENTAL BIOSTATI; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Satten GA, 2001, AM J HUM GENET, V68, P466, DOI 10.1086/318195; Schaid DJ, 2002, GENET EPIDEMIOL, V23, P426, DOI 10.1002/gepi.10184; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Schork NJ, 2000, CLIN GENET, V58, P250, DOI 10.1034/j.1399-0004.2000.580402.x; Schulze TG, 2004, HUM MOL GENET, V13, P335, DOI 10.1093/hmg/ddh035; Sebastiani P, 2003, P NATL ACAD SCI USA, V100, P9900, DOI 10.1073/pnas.1633613100; Shifman S, 2003, HUM MOL GENET, V12, P771, DOI 10.1093/hmg/ddg088; Shostak S, 2003, SOC SCI MED, V56, P2327, DOI 10.1016/S0277-9536(02)00231-9; Silverman EK, 2000, AM J RESP CELL MOL, V22, P645, DOI 10.1165/ajrcmb.22.6.f191; STALLINGS RL, 1991, GENOMICS, V10, P807, DOI 10.1016/0888-7543(91)90467-S; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Tabor HK, 2002, NAT REV GENET, V3, P391, DOI 10.1038/nrg796; Templeton AR, 1996, CIBA F SYMP, V197, P259; Terwilliger JD, 2000, HUM BIOL, V72, P63; Terwilliger JD, 2003, ANN MED, V35, P532, DOI 10.1080/07853890310015181; The Million Women Study Collaborative Group, 1999, BREAST CANCER RES, V1, P73, DOI DOI 10.1186/BCR16; Thomas S, 2004, GENET EPIDEMIOL, V26, P116, DOI 10.1002/gepi.10300; Toivonen HTT, 2000, AM J HUM GENET, V67, P133, DOI 10.1086/302954; Varmus H, 2002, NAT GENET, V32, P3, DOI 10.1038/ng963; Venter JC, 2003, NAT GENET, V33, P219, DOI 10.1038/ng1114; Verbeke G, 2000, LINEAR MIXED MODELS; Wall JD, 2003, NAT REV GENET, V4, P587, DOI 10.1038/nrg1123; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WATKINS WS, 1994, AM J HUM GENET, V55, P348; Weale ME, 2003, AM J HUM GENET, V73, P551, DOI 10.1086/378098; WEEKS DE, 1995, TRENDS GENET, V11, P513, DOI 10.1016/S0168-9525(00)89163-5; Weiss KM, 2000, NAT GENET, V26, P151, DOI 10.1038/79866; Weiss KM, 2002, TRENDS GENET, V18, P19, DOI 10.1016/S0168-9525(01)02550-1; Weiss S. T., 2001, Pharmacogenomics Journal, V1, P157; White IR, 2003, INT J METH PSYCH RES, V12, P139, DOI 10.1002/mpr.150; Witte JS, 2000, STAT MED, V19, P369, DOI 10.1002/(SICI)1097-0258(20000215)19:3<369::AID-SIM335>3.0.CO;2-N; Wiuf C, 2003, MATH BIOSCI, V185, P205, DOI 10.1016/S0025-5564(03)00089-0; Wolfe KH, 2003, NAT GENET, V33, P255, DOI 10.1038/ng1088; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; Wright A. F., 2002, Pharmacogenomics Journal, V2, P75, DOI 10.1038/sj.tpj.6500085; Wright AF, 2001, GENOME BIOL, V2; Zavattari P, 2000, HUM MOL GENET, V9, P2947, DOI 10.1093/hmg/9.20.2947; Zerhouni E, 2003, SCIENCE, V302, P63, DOI 10.1126/science.1091867; Zhang K, 2002, AM J HUM GENET, V71, P1386, DOI 10.1086/344780; Zhao LP, 1998, AM J HUM GENET, V63, P225, DOI 10.1086/301909; Zondervan KT, 2004, NAT REV GENET, V5, P89, DOI 10.1038/nrg1270	153	147	152	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	2005	366	9492					1223	1234		10.1016/S0140-6736(05)67485-5	http://dx.doi.org/10.1016/S0140-6736(05)67485-5			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970LK	16198771				2022-12-28	WOS:000232311300032
J	Gates, GA; Mills, JH				Gates, GA; Mills, JH			Presbycusis	LANCET			English	Article							QUIET-AGED GERBILS; CENTRAL AUDITORY DYSFUNCTION; HEARING-LOSS; OLDER-ADULTS; COGNITIVE DYSFUNCTION; COCHLEAR PATHOLOGY; ALZHEIMERS-DISEASE; FRAMINGHAM COHORT; STRIA VASCULARIS; RANDOMIZED TRIAL	The inevitable deterioration in hearing ability that occurs with age-presbycusis-is a multifactorial process that can vary in severity from mild to substantial. Left untreated, presbycusis of a moderate or greater degree affects communication and can contribute to isolation, depression, and, possibly, dementia. These psychological effects are largely reversible with rehabilitative treatment. Comprehensive rehabilitation is widely available but underused because, in part, of social attitudes that undervalue hearing, in addition to the cost and stigma of hearing aids. Remediation of presbycusis is an important contributor to quality of life in geriatric medicine and can include education about communication effectiveness, hearing aids, assistive listening devices, and cochlear implants for severe hearing loss. Primary care physicians should screen and refer their elderly patients for assessment and remediation. Where hearing aids no longer provide benefit, cochlear implantation is the treatment of choice with excellent results even in octogenarians.	Univ Washington, Seattle, WA 98195 USA; Med Univ S Carolina, Charleston, SC 29425 USA	University of Washington; University of Washington Seattle; Medical University of South Carolina	Gates, GA (corresponding author), Univ Washington, 1959 NE Pacific St, Seattle, WA 98195 USA.	ggates@u.washington.edu						[Anonymous], 1988, J Acoust Soc Am, V83, P859; Bermingham-McDonogh O, 2003, CURR OPIN NEUROBIOL, V13, P119, DOI 10.1016/S0959-4388(03)00018-7; BILGER RC, 1984, J SPEECH HEAR RES, V27, P32, DOI 10.1044/jshr.2701.32; Brant L J, 1996, J Am Acad Audiol, V7, P152; COOPER JC, 1991, EAR HEARING, V12, P304, DOI 10.1097/00003446-199110000-00002; COOPER JC, 1976, ARCH OTOLARYNGOL, V102, P148; Cruickshanks KJ, 1998, JAMA-J AM MED ASSOC, V279, P1715, DOI 10.1001/jama.279.21.1715; Davis A C, 1990, Acta Otolaryngol Suppl, V476, P23; DAYAL V S, 1971, Acta Oto-Laryngologica, V71, P382, DOI 10.3109/00016487109125378; GATES GA, 1995, ARCH NEUROL-CHICAGO, V52, P626, DOI 10.1001/archneur.1995.00540300108020; Gates GA, 1997, WESTERN J MED, V167, P247; Gates GA, 1996, ARCH OTOLARYNGOL, V122, P161; GATES GA, 1990, EAR HEARING, V11, P247, DOI 10.1097/00003446-199008000-00001; Gates GA, 2003, J FAM PRACTICE, V52, P56; GATES GA, 1993, ARCH OTOLARYNGOL, V119, P156; Gates GA, 2002, J AM GERIATR SOC, V50, P482, DOI 10.1046/j.1532-5415.2002.50114.x; Gates GA, 1999, ARCH OTOLARYNGOL, V125, P654, DOI 10.1001/archotol.125.6.654; Gates George A, 2003, J Am Acad Audiol, V14, P574, DOI 10.3766/jaaa.14.10.6; GENNIS V, 1991, ARCH INTERN MED, V151, P2259, DOI 10.1001/archinte.151.11.2259; GOYCOOLEA MV, 1986, LARYNGOSCOPE, V96, P1391; GRATTON MA, 1995, HEARING RES, V82, P44; Hands S, 2000, J LARYNGOL OTOL, V114, P661; Hanratty B, 2000, J PUBLIC HEALTH MED, V22, P512, DOI 10.1093/pubmed/22.4.512; HELLSTROM LI, 1990, HEARING RES, V50, P163, DOI 10.1016/0378-5955(90)90042-N; Jerger J, 2000, J Am Acad Audiol, V11, pcontents; JERGER J, 1976, J SPEECH HEAR DISORD, V41, P556; Jerger J, 1973, Adv Otorhinolaryngol, V20, P115; KATSARKAS A, 1986, J OTOLARYNGOL, V15, P239; Katz J, 1991, Ann N Y Acad Sci, V620, P233; Kochkin S, 1997, HEARING J, V50, P31; Larson VD, 2002, EAR HEARING, V23, P269, DOI 10.1097/00003446-200208000-00001; MCBRIDE WS, 1994, AM J MED SCI, V307, P40, DOI 10.1097/00000441-199401000-00007; MILLS JH, 1990, HEARING RES, V46, P201, DOI 10.1016/0378-5955(90)90002-7; MILLS JH, 2001, OTOLARYNGOLOGY HEAD, V3, P1621; MULROW CD, 1990, ANN INTERN MED, V113, P188, DOI 10.7326/0003-4819-113-3-188; Nilsson P, 1997, AUDIOLOGY, V36, P325; PEDERSEN KE, 1989, AUDIOLOGY, V28, P194; Popelka MM, 1998, J AM GERIATR SOC, V46, P1075, DOI 10.1111/j.1532-5415.1998.tb06643.x; RIES PW, 1994, VITAL HLTH STAT, V10, P1; ROBINSON D W, 1988, British Journal of Audiology, V22, P5, DOI 10.3109/03005368809077793; ROSEN S, 1970, ACTA OTO-LARYNGOL, V70, P242, DOI 10.3109/00016487009181884; ROSEN S, 1962, ANN OTO RHINOL LARYN, V71, P727, DOI 10.1177/000348946207100313; Schmiedt RA, 2002, J NEUROSCI, V22, P9643; Scholtz AW, 2001, HEARING RES, V157, P77, DOI 10.1016/S0378-5955(01)00279-9; SCHUKNECHT H F, 1955, Laryngoscope, V65, P402; SCHUKNECHT HF, 1974, LARYNGOSCOPE, V84, P1777; SCHUKNECHT HF, 1964, ARCHIV OTOLARYNGOL, V80, P369; SCHUKNECHT HF, 1993, ANN OTO RHINOL LARYN, V102, P1; SCHULTE BA, 1992, HEARING RES, V61, P35, DOI 10.1016/0378-5955(92)90034-K; SINHA UK, 1993, NEUROLOGY, V43, P779, DOI 10.1212/WNL.43.4.779; Spelman FA, 2004, APPARATUS METHOD TRE; Spicer SS, 2002, HEARING RES, V172, P172, DOI 10.1016/S0378-5955(02)00581-6; Spiess AC, 2002, LARYNGOSCOPE, V112, P1635, DOI 10.1097/00005537-200209000-00020; Starr A, 2001, EAR HEARING, V22, P91, DOI 10.1097/00003446-200104000-00002; UHLMANN RF, 1989, JAMA-J AM MED ASSOC, V261, P1916, DOI 10.1001/jama.261.13.1916; Wiley T L, 1999, J Am Acad Audiol, V10, P173; WILLOTT JF, 1995, HEARING RES, V88, P143, DOI 10.1016/0378-5955(95)00107-F; Yueh B, 2001, ARCH OTOLARYNGOL, V127, P1197, DOI 10.1001/archotol.127.10.1197	58	726	783	9	152	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 24	2005	366	9491					1111	1120		10.1016/S0140-6736(05)67423-5	http://dx.doi.org/10.1016/S0140-6736(05)67423-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TL	16182900				2022-12-28	WOS:000232114000030
J	Oransky, I				Oransky, I			Vincent J Fontana - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com						FONTANA VJ, PUBLICATION LIST	1	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 27	2005	366	9487					710	710		10.1016/S0140-6736(05)67165-6	http://dx.doi.org/10.1016/S0140-6736(05)67165-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958UV	16193615	Bronze			2022-12-28	WOS:000231474600016
J	Allen, E; Ding, JQ; Wang, W; Pramanik, S; Chou, J; Yau, V; Yang, YM				Allen, E; Ding, JQ; Wang, W; Pramanik, S; Chou, J; Yau, V; Yang, YM			Gigaxonin-controlled degradation of MAP1B light chain is critical to neuronal survival	NATURE			English	Article							GIANT AXONAL NEUROPATHY; UBIQUITIN-PROTEASOME SYSTEM; MICROTUBULE-ASSOCIATED PROTEINS; CYTOPLASMIC DYNEIN; WALLERIAN DEGENERATION; 1B; BINDING; KINESIN; BTB; LIGASES	Giant axonal neuropathy (GAN) is a devastating sensory and motor neuropathy caused by mutations in the GAN gene, which encodes the ubiquitously expressed protein gigaxonin(1-5). Cytopathological features of GAN include axonal degeneration, with accumulation and aggregation of cytoskeletal components(6-7). Little is currently known about the molecular mechanisms underlying this recessive disorder. Here we show that gigaxonin controls protein degradation, and is essential for neuronal function and survival. We present evidence that gigaxonin binds to the ubiquitin-activating enzyme E1 through its amino-terminal BTB domain, while the carboxy-terminal kelch repeat domain interacts directly with the light chain (LC) of microtubule-associated protein 1B (MAP1B)(8). Overexpression of gigaxonin leads to enhanced degradation of MAP1B-LC, which can be antagonized by proteasome inhibitors. Ablation of gigaxonin causes a substantial accumulation of MAP1B-LC in GAN-null neurons. Moreover, we show that overexpression of MAP1B in wild-type cortical neurons leads to cell death characteristic of GAN-null neurons, whereas reducing MAP1B levels significantly improves the survival rate of null neurons. Our results identify gigaxonin as a ubiquitin scaffolding protein that controls MAP1B-LC degradation, and provide insight into the molecular mechanisms underlying human neurodegenerative disorders.	Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Stanford University	Yang, YM (corresponding author), Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, 1201 Welch Rd, Stanford, CA 94305 USA.	yyanmin@stanford.edu		Ding, Jianqing/0000-0002-2038-2603				Bomont P, 2000, NAT GENET, V26, P370, DOI 10.1038/81701; Bomont P, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9122; Bruno C, 2004, NEUROLOGY, V62, P13, DOI 10.1212/01.WNL.0000101676.41505.A7; Ding JQ, 2002, J CELL BIOL, V158, P427, DOI 10.1083/jcb.200202055; Edelmann W, 1996, P NATL ACAD SCI USA, V93, P1270, DOI 10.1073/pnas.93.3.1270; Ehlers MD, 2004, TRENDS NEUROSCI, V27, P3, DOI 10.1016/j.tins.2003.10.015; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; HAGIWARA H, 1994, J BIOL CHEM, V269, P3581; LAMPL Y, 1992, DEV MED CHILD NEUROL, V34, P164; LOPEZ LA, 1993, CELL MOTIL CYTOSKEL, V24, P1, DOI 10.1002/cm.970240102; Lu R, 2004, P NATL ACAD SCI USA, V101, P15201, DOI 10.1073/pnas.0404995101; Mei X, 2000, J NEUROSCI RES, V62, P56, DOI 10.1002/1097-4547(20001001)62:1<56::AID-JNR6>3.0.CO;2-#; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; TANDAN R, 1987, J NEUROL SCI, V82, P205, DOI 10.1016/0022-510X(87)90019-0; Tazir M, 2002, NEUROMUSCULAR DISORD, V12, P849, DOI 10.1016/S0960-8966(02)00029-9; Timmerman V, 2000, NAT GENET, V26, P254, DOI 10.1038/81521; Togel M, 1998, J CELL BIOL, V143, P695, DOI 10.1083/jcb.143.3.695; TUCKER RP, 1987, DEVELOPMENT, V101, P535; van den Heuvel S, 2004, CURR BIOL, V14, pR59, DOI 10.1016/j.cub.2003.12.044; Vicario-Abejon Carlos, 2004, Curr Protoc Neurosci, VChapter 3, DOI 10.1002/0471142301.ns0302s26; VONMASSOW A, 1989, CELL MOTIL CYTOSKEL, V14, P562, DOI 10.1002/cm.970140413; Watts RJ, 2003, NEURON, V38, P871, DOI 10.1016/S0896-6273(03)00295-2; Zhai QW, 2003, NEURON, V39, P217, DOI 10.1016/S0896-6273(03)00429-X	25	97	103	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2005	438	7065					224	228		10.1038/nature04256	http://dx.doi.org/10.1038/nature04256			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16227972				2022-12-28	WOS:000233133500049
J	Maxmen, A; Browne, WE; Martindale, MQ; Giribet, G				Maxmen, A; Browne, WE; Martindale, MQ; Giribet, G			Neuroanatomy of sea spiders implies an appendicular origin of the protocerebral segment	NATURE			English	Article							HEAD SEGMENTATION; EXPRESSION; BRAIN; CRUSTACEANS; ARTHROPODA; MORPHOLOGY; PHYLOGENY; SEROTONIN; POSITION; PATTERN	Independent specialization of arthropod body segments has led to more than a century of debate on the homology of morphologically diverse segments(1,2), each defined by a lateral appendage and a ganglion of the central nervous system. The plesiomorphic composition of the arthropod head remains enigmatic because variation in segments and corresponding appendages is extreme. Within extant arthropod classes (Chelicerata, Myriapoda, Crustacea and Hexapoda-including the insects), correspondences between the appendage-bearing second (deutocerebral) and third (tritocerebral) cephalic neuromeres have been recently resolved on the basis of immunohistochemistry(1) and Hox gene expression patterns(3,4). However, no appendage targets the first ganglion, the protocerebrum, and the corresponding segmental identity of this anterior region remains unclear(5). Reconstructions of stem-group arthropods indicate that the anteriormost region originally might have borne an ocular apparatus and a frontal appendage innervated by the protocerebrum(6). However, no study of the central nervous system in extant arthropods has been able to corroborate this idea directly, although recent analyses of cephalic gene expression patterns in insects suggest a segmental status for the protocerebral region(7-10). Here we investigate the developmental neuroanatomy of a putative basal arthropod(11), the pycnogonid sea spider, with immunohistochemical techniques. We show that the first pair of appendages, the chelifores, are innervated at an anterior position on the protocerebrum. This is the first true appendage shown to be innervated by the protocerebrum, and thus pycnogonid chelifores are not positionally homologous to appendages of extant arthropods but might, in fact, be homologous to the 'great appendages' of certain Cambrian stem-group arthropods.	Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA; Univ Hawaii, Pacific Biosci Res Ctr, Kewalo Marine Lab, Honolulu, HI 96813 USA	Harvard University; Harvard University; University of Hawaii System	Maxmen, A (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, 26 Oxford St, Cambridge, MA 02138 USA.	amaxmen@oeb.harvard.edu	Browne, William E/D-4267-2013; Browne, William E./AAV-4035-2021; Giribet, Gonzalo/P-1086-2015	Browne, William E/0000-0001-8200-6489; Browne, William E./0000-0001-8200-6489; Giribet, Gonzalo/0000-0002-5467-8429				Bain BA, 2003, INVERTEBR REPROD DEV, V43, P193, DOI 10.1080/07924259.2003.9652540; Boyan G, 2003, ARTHROPOD STRUCT DEV, V32, P61, DOI 10.1016/S1467-8039(03)00037-9; Boyan G, 2002, ARTHROPOD STRUCT DEV, V30, P207, DOI 10.1016/S1467-8039(01)00034-2; Brusca RC, 2003, INVERTEBRATES; Budd GE, 2002, NATURE, V417, P271, DOI 10.1038/417271a; Bullock T., 1965, STRUCTURE FUNCTION N; Damen WGM, 1998, P NATL ACAD SCI USA, V95, P10665, DOI 10.1073/pnas.95.18.10665; Dickinson AJG, 2000, BIOL BULL-US, V199, P305, DOI 10.2307/1543187; Dunlop JA, 2005, J ZOOL SYST EVOL RES, V43, P8, DOI 10.1111/j.1439-0469.2004.00284.x; Eriksson BJ, 2003, J MORPHOL, V255, P1, DOI 10.1002/jmor.10034; Eriksson BJ, 2000, ARTHROPOD STRUCT DEV, V29, P197, DOI 10.1016/S1467-8039(00)00027-X; FAGE, 1949, TRAITE ZOOLOGIE ANAT, P906; Giribet G, 2001, NATURE, V413, P157, DOI 10.1038/35093097; GOODRICH ES, 1897, Q J MICROSC SCI, V247, P248; Hedgpeth Joel W., 1947, SMITHSONIAN MISC COLL, V106, P1; King P., 1973, PYCNOGONIDS; Mittmann B, 2003, DEV GENES EVOL, V213, P9, DOI 10.1007/s00427-002-0285-5; Miyazaki K, 2002, J MAR BIOL ASSOC UK, V82, P1037, DOI 10.1017/S0025315402006628; Morgan T.H, 1891, STUDIES BIOLOGICAL L, V5, P1; Regier JC, 2005, P ROY SOC B-BIOL SCI, V272, P395, DOI 10.1098/rspb.2004.2917; Rogers BT, 1996, DEVELOPMENT, V122, P3419; SANDEMAN DC, 1988, J COMP NEUROL, V269, P465, DOI 10.1002/cne.902690402; SCHMIDTOTT U, 1995, ROUX ARCH DEV BIOL, V205, P31, DOI 10.1007/BF00188841; Siveter DJ, 2004, NATURE, V431, P978, DOI 10.1038/nature02928; Telford MJ, 1998, P NATL ACAD SCI USA, V95, P10671, DOI 10.1073/pnas.95.18.10671; Urbach R, 2003, ARTHROPOD STRUCT DEV, V32, P103, DOI 10.1016/S1467-8039(03)00042-2; Vilpoux K, 2003, ARTHROPOD STRUCT DEV, V32, P349, DOI 10.1016/j.asd.2003.09.004; WALOSSEK D, 1990, LETHAIA, V23, P409, DOI 10.1111/j.1502-3931.1990.tb01373.x; Waloszek D, 2002, PALAEONTOLOGY, V45, P421, DOI 10.1111/1475-4983.00244; Whitington PM, 2004, CRUSTACEAN ISS, V15, P135; WINTER G, 1980, Z ZOOL SYST EVOL, V18, P27; Wiren E, 1918, ZOOL BIDR UPPS, V6, P41	32	68	69	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 20	2005	437	7062					1144	1148		10.1038/nature03984	http://dx.doi.org/10.1038/nature03984			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16237442				2022-12-28	WOS:000232660500042
J	Ahmed, S				Ahmed, S			Tie it and trust	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									YSM IV, New Haven, CT 06520 USA		Ahmed, S (corresponding author), YSM IV, New Haven, CT 06520 USA.	shobi.ahmed@yale.edu							0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	2005	294	15					1873	1874		10.1001/jama.294.15.1873	http://dx.doi.org/10.1001/jama.294.15.1873			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974OZ	16234487				2022-12-28	WOS:000232602600001
J	Henderson, GS				Henderson, GS			Hurricane Katrina - Finding supplies	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ochsner Clin Fdn, New Orleans, LA 70121 USA	Ochsner Health System	Henderson, GS (corresponding author), Ochsner Clin Fdn, New Orleans, LA 70121 USA.								0	5	5	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1542	1542		10.1056/NEJMp058230	http://dx.doi.org/10.1056/NEJMp058230			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221771				2022-12-28	WOS:000232486000002
J	Shah, MR; Hasselblad, V; Stevenson, LW; Binanay, C; O'Connor, CM; Sopko, G; Califf, RM				Shah, MR; Hasselblad, V; Stevenson, LW; Binanay, C; O'Connor, CM; Sopko, G; Califf, RM			Impact of the pulmonary artery catheter in critically ill patients - Meta-analysis of randomized clinical trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RESPIRATORY-DISTRESS-SYNDROME; ADVANCED HEART-FAILURE; RISK SURGICAL PATIENTS; VASCULAR-SURGERY; MORBIDITY; THERAPY; CARE; MANAGEMENT; SURVIVORS	Context Randomized clinical trials (RCTs) evaluating the pulmonary artery catheter (PAC) have been limited by small sample size. Some nonrandomized studies suggest that PAC use is associated with increased morbidity and mortality. Objective To-estimate the impact of the PAC device in critically ill patients. Data Sources MEDLINE (1985-2005), the Cochrane Controlled Trials Registry (19882005), the National Institutes of Health ClinicalTrials.gov database, and the US Food and Drug Administration Web site for RCTs in which patients Were randomly assigned to PAC or no PAC were searched. Results from the ESCAPE trial of patients with severe heart failure were also included. Search terms included pulmonary artery catheter, right heart catheter, catheter, and Swan-Ganz. Study Selection Eligible studies included patients who were undergoing surgery, in the intensive care unit (ICU), admitted with advanced heart failure, or diagnosed with acute respiratory distress syndrome and/or sepsis; and studies that reported death and the number of days hospitalized or the number of days in the ICU as outcome measures. Data Extraction Information on eligibility criteria, baseline characteristics, interventions, outcomes, and methodological quality was extracted by 2 reviewers. Disagreements were resolved by consensus. Data Synthesis In 13 RCTs, 5051 patients were randomized. Hemodynamic goals and treatment strategies varied among trials. A random-effects model was used to estimate the odds ratios (ORs) for death, number of days hospitalized, and use of inotropes and intravenous vasodilators. The combined OR foe mortality was 1.04 (95% confidence interval [CI], 0.90-1.20; P=.59). The difference in the mean number of days hospitalized for PAC minus the mean for no PAC was 0.11 (95% CI, -0.51 to 0.74; P=73). Use of the PAC was associated with a higher use of inotropes (OR, 1.58; 95% CI, 1.19-2.12; P=.002) and intravenous vasodilators (OR, 2.35; 95% CI, 1.75-3.15; P<.001). Conclusions In critically ill patients, use of the PAC neither increased overall mortality or days in hospital nor conferred benefit. Despite almost 20 years of RCTs, a clear strategy leading to improved survival with the PAC has not been devised. The neutrality of the PAC for clinical outcomes may result from the absence of effective evidence-based treatments to use in combination with PAC information across the spectrum of critically ill patients.	Duke Clin Res Inst, Biostat & Bioinformat, Durham, NC 27705 USA; Columbia Univ, Med Ctr, Dept Cardiol, New York, NY USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Duke Clin Res Inst, Project Leadership, Durham, NC 27705 USA; Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA; NHLBI, Div Heart & Vasc Dis, NIH, Bethesda, MD 20892 USA	Duke University; Columbia University; Harvard University; Brigham & Women's Hospital; Duke University; Duke University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hasselblad, V (corresponding author), Duke Clin Res Inst, Biostat & Bioinformat, POB 17969, Durham, NC 27705 USA.	victor.hasselblad@duke.edu						Bender JS, 1997, ANN SURG, V226, P229, DOI 10.1097/00000658-199709000-00002; BERLAUK JF, 1991, ANN SURG, V214, P289, DOI 10.1097/00000658-199109000-00011; Bonazzi M, 2002, EUR J VASC ENDOVASC, V23, P445, DOI 10.1053/ejvs.2002.1617; Chalfin D B, 1997, New Horiz, V5, P292; Chomsky DB, 1997, J HEART LUNG TRANSPL, V16, P846; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; *CYT SOFTW CORP, 1999, EGRET WIND; Dalen JE, 2001, JAMA-J AM MED ASSOC, V286, P348, DOI 10.1001/jama.286.3.348; Drazen JM, 2003, NEW ENGL J MED, V348, P1377, DOI 10.1056/NEJMe030031; EDDY DM, 1992, FAST PRO SOFTWARE ME; Fonarow GC, 1997, J AM COLL CARDIOL, V30, P725, DOI 10.1016/S0735-1097(97)00208-8; Guyatt G, 1991, J Intensive Care Med, V6, P91; Harvey S, 2005, LANCET, V366, P472, DOI 10.1016/S0140-6736(05)67061-4; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hedges LV, 2014, STAT METHODS META AN; ISAACSON IJ, 1990, J VASC SURG, V12, P754, DOI 10.1067/mva.1990.24456; Ivanov R, 2000, CRIT CARE MED, V28, P615, DOI 10.1097/00003246-200003000-00002; Ivanov R I, 1997, New Horiz, V5, P268; Johnson W, 2002, J AM COLL CARDIOL, V39, P1623, DOI 10.1016/S0735-1097(02)01814-4; Matuschak G M, 1997, New Horiz, V5, P233; Rhodes A, 2002, INTENS CARE MED, V28, P256, DOI 10.1007/s00134-002-1206-9; Richard C, 2003, JAMA-J AM MED ASSOC, V290, P2713, DOI 10.1001/jama.290.20.2713; Sackner-Bernstein JD, 2005, JAMA-J AM MED ASSOC, V293, P1900, DOI 10.1001/jama.293.15.1900; Sandham JD, 2003, NEW ENGL J MED, V348, P5, DOI 10.1056/NEJMoa021108; SCHULTZ RJ, 1985, J TRAUMA, V25, P309, DOI 10.1097/00005373-198504000-00005; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; Steimle AE, 1997, CIRCULATION, V96, P1165, DOI 10.1161/01.CIR.96.4.1165; Steinbrook R, 2003, NEW ENGL J MED, V348, P1393, DOI 10.1056/NEJMhpr030349; Stevenson LW, 2005, JAMA-J AM MED ASSOC, V294, P1625; Stevenson LW, 2003, CIRCULATION, V108, P367, DOI 10.1161/01.CIR.0000078348.44634.BA; STEVENSON LW, 1995, J AM COLL CARDIOL, V25, P163, DOI 10.1016/0735-1097(94)00357-V; Trottier S J, 1997, New Horiz, V5, P201; Valentine RJ, 1998, J VASC SURG, V27, P203, DOI 10.1016/S0741-5214(98)70351-9	33	415	444	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	2005	294	13					1664	1670		10.1001/jama.294.13.1664	http://dx.doi.org/10.1001/jama.294.13.1664			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970DC	16204666				2022-12-28	WOS:000232284400019
J	Grant, RM; Buchbinder, S; Cates, W; Clarke, E; Coates, T; Cohen, MS; Delaney, M; Flores, G; Goicochea, P; Gonsalves, G; Harrington, M; Lama, JR; MacQueen, KM; Moore, JP; Peterson, L; Sanchez, J; Thompson, M; Wainberg, MA				Grant, RM; Buchbinder, S; Cates, W; Clarke, E; Coates, T; Cohen, MS; Delaney, M; Flores, G; Goicochea, P; Gonsalves, G; Harrington, M; Lama, JR; MacQueen, KM; Moore, JP; Peterson, L; Sanchez, J; Thompson, M; Wainberg, MA			Promote HIV chemoprophylaxis research, don't prevent it	SCIENCE			English	Editorial Material							SIMIAN IMMUNODEFICIENCY VIRUS; NEWBORN MACAQUES; TENOFOVIR; INFECTION; TRIAL; EFFICACY; VACCINE; SAFETY		Gladstone Inst Virol & Immunol, San Francisco, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; San Francisco Dept Publ Hlth, San Francisco, CA USA; Family Hlth Int, Res Triangle Pk, NC 27709 USA; Ghana Hlth Serv, Accra, Ghana; Univ Calif Los Angeles, Los Angeles, CA 90024 USA; Univ N Carolina, Chapel Hill, NC USA; Project Inform, San Francisco, CA USA; Asociac Civil Impacta Salud & Educ, Lima, Peru; Gay Mens Hlth Crisis Inc, New York, NY USA; Treatment Act Grp, New York, NY USA; Cornell Univ, Weill Med Coll, New York, NY USA; AIDS Res Consortium Atlanta, Atlanta, GA USA; McGill Univ, AIDS Ctr, Montreal, PQ, Canada	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; San Francisco Department of Public Health; Ghana Health Service; University of California System; University of California Los Angeles; University of North Carolina; University of North Carolina Chapel Hill; Cornell University; McGill University	Grant, RM (corresponding author), Gladstone Inst Virol & Immunol, San Francisco, CA USA.	rgrant@itsa.ucsf.edu	Flores, Gonzalo/B-1807-2014; Flores, Gonzalo/A-3787-2009	Grant, Robert/0000-0002-0851-7085				Barditch-Crovo P, 2001, ANTIMICROB AGENTS CH, V45, P2733, DOI 10.1128/AAC.45.10.2733-2739.2001; Bartholow BN, 2005, JAIDS-J ACQ IMM DEF, V39, P90, DOI 10.1097/01.qai.0000143600.41363.78; Birkus G, 2002, ANTIMICROB AGENTS CH, V46, P716, DOI 10.1128/AAC.46.3.716-723.2002; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; HALIMA Y, 2005, INT AIDS SOC STAK HO; HAWKINS T, 2004, 15 INT AIDS C BANGK; Horton R, 2004, NEW YORK REV BOOKS, V51, P7; *JOINT UN PROGR HI, 2004, REP GLOB AIDS EP; Koblin B, 2004, LANCET, V364, P41, DOI 10.1016/S0140-6736(04)16588-4; MAYER K, 2004, 2004 INT AIDS C BANG; Mills Edward, 2005, BMC Int Health Hum Rights, V5, P6, DOI 10.1186/1472-698X-5-6; PAGESHAFER K, 2005, LANCET; RUIZ MS, 2001, NO TIME LOSE GETTING; Singh JA, 2005, PLOS MED, V2, P824, DOI 10.1371/journal.pmed.0020234; SUBBARAO S, 2005, 12 C RETR OPP INF BO; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; Van Rompay KKA, 2001, J INFECT DIS, V184, P429, DOI 10.1086/322781; Van Rompay KKA, 2000, J VIROL, V74, P1767, DOI 10.1128/JVI.74.4.1767-1774.2000; Youle M, 2003, AIDS, V17, P937, DOI 10.1097/00002030-200304110-00027	19	61	70	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 30	2005	309	5744					2170	2171		10.1126/science.1116204	http://dx.doi.org/10.1126/science.1116204			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	970NX	16195446				2022-12-28	WOS:000232318000027
J	Beigel, H; Farrar, H; Han, AM; Hayden, FG; Hyer, R; de Jong, MD; Lochindarat, S; Tien, NTK; Hien, NT; Hien, TT; Nicoll, A; Touch, S; Yuen, KY				Beigel, H; Farrar, H; Han, AM; Hayden, FG; Hyer, R; de Jong, MD; Lochindarat, S; Tien, NTK; Hien, NT; Hien, TT; Nicoll, A; Touch, S; Yuen, KY		WHO Consultation Human Influenza	Current concepts - Avian influenza A (H5N1) infection in humans	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE WORKERS; HONG-KONG; VIRUS-INFECTION; HUMAN-DISEASE; MF59-ADJUVANTED INFLUENZA; NEURAMINIDASE INHIBITORS; OSELTAMIVIR PHOSPHATE; IN-VITRO; TRANSMISSION		Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Charlottesville, VA 22908 USA; NIAID, NIH, Bethesda, MD 20892 USA; Hosp Trop Dis, Ho Chi Minh City, Vietnam; Inst Med, Dept Child Hlth, Yangon, Myanmar; World Hlth Org, Geneva, Switzerland; Queen Sirikit Natl Inst Child Hlth, Bangkok, Thailand; Inst Pasteur, Ho Chi Minh City, Vietnam; Natl Inst Hyg & Epidemiol, Hanoi, Vietnam; Hlth Protect Agcy, London, England; Minist Hlth, Phnom Penh, Cambodia; Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China	University of Virginia; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); World Health Organization; National Institute of Hygiene & Epidemiology (NIHE); Health Protection Agency; University of Hong Kong	Hayden, FG (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Internal Med, POB 800473, Charlottesville, VA 22908 USA.	vgh@virginia.edu	Han, Aye/J-3814-2012	Farrar, Jeremy/0000-0002-2700-623X; Yuen, Kwok-yung/0000-0002-2083-1552; Beigel, John/0000-0002-4879-4941	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000936, Z01AI000936] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTMAN LC, 2005, NY TIMES        0807; [Anonymous], [No title captured]; Apisarnthanarak A, 2004, EMERG INFECT DIS, V10, P1321; *AV INFL H5N1, 2004, WEEKLY EPIDEMIOL REV, V79, P65; BARON S, 1962, BMJ-BRIT MED J, V5270, P18; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; Bridges CB, 2000, J INFECT DIS, V181, P344, DOI 10.1086/315213; Bridges CB, 2002, J INFECT DIS, V185, P1005, DOI 10.1086/340044; Bridges CB, 2003, CLIN INFECT DIS, V37, P1094, DOI 10.1086/378292; *CDCP, 2005, UPD NOT TRAV AV INFL; Chan PKS, 2002, CLIN INFECT DIS, V34, pS58, DOI 10.1086/338820; Chen H, 2005, NATURE, V436, P191, DOI 10.1038/nature03974; Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; Chotpitayasunondh T, 2005, EMERG INFECT DIS, V11, P201, DOI 10.3201/eid1102.041061; Cooper NJ, 2003, BRIT MED J, V326, P1235, DOI 10.1136/bmj.326.7401.1235; de Jong MD, 2005, NEW ENGL J MED, V352, P686, DOI 10.1056/NEJMoa044307; Derrick JL, 2005, J HOSP INFECT, V59, P365, DOI 10.1016/j.jhin.2004.10.013; Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P1356, DOI 10.1073/pnas.0308352100; Govorkova EA, 2005, J VIROL, V79, P2191, DOI 10.1128/JVI.79.4.2191-2198.2005; Govorkova EA, 2001, ANTIMICROB AGENTS CH, V45, P2723, DOI 10.1128/AAC.45.10.2723-2732.2001; Guan Y, 2002, P NATL ACAD SCI USA, V99, P8950, DOI 10.1073/pnas.132268999; Guarner J, 2000, AM J CLIN PATHOL, V114, P227, DOI 10.1309/HV74-N24T-2K2C-3E8Q; Gubareva LV, 1998, J INFECT DIS, V178, P1592, DOI 10.1086/314515; Gubareva LV, 2001, ANTIMICROB AGENTS CH, V45, P3403, DOI 10.1128/AAC.45.12.3403-3408.2001; Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882; Hayden FG, 2004, J INFECT DIS, V189, P440, DOI 10.1086/381128; Herlocher ML, 2004, J INFECT DIS, V190, P1627, DOI 10.1086/424572; Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419; Horimoto T, 2004, J VET MED SCI, V66, P303, DOI 10.1292/jvms.66.303; Ives JAL, 2002, ANTIVIR RES, V55, P307, DOI 10.1016/S0166-3542(02)00053-0; Kaiser L, 1999, J CLIN VIROL, V14, P191, DOI 10.1016/S1386-6532(99)00058-X; Katz JM, 1999, J INFECT DIS, V180, P1763, DOI 10.1086/315137; Keawcharoen J, 2004, EMERG INFECT DIS, V10, P2189, DOI 10.3201/eid1012.040759; Knight V, 1987, Infect Dis Clin North Am, V1, P441; Kuiken T, 2004, SCIENCE, V306, P241, DOI 10.1126/science.1102287; Leneva IA, 2001, ANTIMICROB AGENTS CH, V45, P1216, DOI 10.1128/AAC.45.4.1216-1224.2001; Leneva IA, 2000, ANTIVIR RES, V48, P101, DOI 10.1016/S0166-3542(00)00123-6; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; Liem NT, 2005, EMERG INFECT DIS, V11, P210, DOI 10.3201/eid1102.041075; Liu J, 2005, SCIENCE, V309, P1206, DOI 10.1126/science.1115273; MADREN LK, 1995, ANTIVIR CHEM CHEMOTH, V6, P109, DOI 10.1177/095632029500600205; Monto AS, 1999, J INFECT DIS, V180, P254, DOI 10.1086/314904; Mounts AW, 1999, J INFECT DIS, V180, P505, DOI 10.1086/314903; Nicholson KG, 2001, LANCET, V357, P1937, DOI 10.1016/S0140-6736(00)05066-2; Peiris JSM, 2004, LANCET, V363, P617, DOI 10.1016/S0140-6736(04)15595-5; Perkins LEL, 2002, AVIAN DIS, V46, P53, DOI 10.1637/0005-2086(2002)046[0053:POAHKO]2.0.CO;2; Salgado CD, 2002, LANCET INFECT DIS, V2, P383; Schultsz C, 2005, EMERG INFECT DIS, V11, P1158; Seo SH, 2002, NAT MED, V8, P950, DOI 10.1038/nm757; Shinya K, 2004, VIROLOGY, V320, P258, DOI 10.1016/j.virol.2003.11.030; Sims LD, 2003, AVIAN DIS, V47, P832, DOI 10.1637/0005-2086-47.s3.832; Stephenson I, 2005, J INFECT DIS, V191, P1210, DOI 10.1086/428948; Sturm-Ramirez KM, 2004, J VIROL, V78, P4892, DOI 10.1128/JVI.78.9.4892-4901.2004; Tam JS, 2002, VACCINE, V20, pS77, DOI 10.1016/S0264-410X(02)00137-8; Thanawongnuwech R, 2005, EMERG INFECT DIS, V11, P699, DOI 10.3201/eid1105.050007; To KF, 2001, J MED VIROL, V63, P242, DOI 10.1002/1096-9071(200103)63:3&lt;242::AID-JMV1007&gt;3.0.CO;2-N; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; Treanor JJ, 2001, VACCINE, V19, P1732, DOI 10.1016/S0264-410X(00)00395-9; Uiprasertkul M, 2005, EMERG INFECT DIS, V11, P1036, DOI 10.3201/eid1107.041313; Ungchusak K, 2005, NEW ENGL J MED, V352, P333, DOI 10.1056/NEJMoa044021; Ward Penelope, 2005, J Antimicrob Chemother, V55 Suppl 1, pi5, DOI 10.1093/jac/dki018; Webby RJ, 2004, LANCET, V363, P1099, DOI 10.1016/S0140-6736(04)15892-3; Webby RJ, 2003, SCIENCE, V302, P1519, DOI 10.1126/science.1090350; Welliver R, 2001, JAMA-J AM MED ASSOC, V285, P748, DOI 10.1001/jama.285.6.748; Wetherall NT, 2003, J CLIN MICROBIOL, V41, P742, DOI 10.1128/JCM.41.2.742-750.2003; *WHO, 2005, REC LAB TESTS ID INF; *WHO, 2004, WHO INT GUID CLIN MA; *WHO, 2005, WHO INT COUNTR CONS; Yen HL, 2005, J INFECT DIS, V192, P665, DOI 10.1086/432008; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9; Zitzow LA, 2002, J VIROL, V76, P4420, DOI 10.1128/JVI.76.9.4420-4429.2002	71	968	1067	7	141	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2005	353	13					1374	1385		10.1056/NEJMra052211	http://dx.doi.org/10.1056/NEJMra052211			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968FB	16192482	Bronze			2022-12-28	WOS:000232146200009
J	Fischle, W; Tseng, BS; Dormann, HL; Ueberheide, BM; Garcia, BA; Shabanowitz, J; Hunt, DF; Funabiki, H; Allis, CD				Fischle, W; Tseng, BS; Dormann, HL; Ueberheide, BM; Garcia, BA; Shabanowitz, J; Hunt, DF; Funabiki, H; Allis, CD			Regulation of HP1-chromatin binding by histone H3 methylation and phosphorylation	NATURE			English	Article							HP1 CHROMO DOMAIN; AURORA-B; MAMMALIAN-CELLS; HETEROCHROMATIN DOMAINS; FISSION YEAST; LYSINE 9; CENTROMERE; LOCALIZATION; KINETOCHORE; PROTEINS	Tri-methylation of histone H3 lysine 9 is important for recruiting heterochromatin protein 1 (HP1) to discrete regions of the genome, thereby regulating gene expression, chromatin packaging and heterochromatin formation. Here we show that HP1 alpha, -beta, and -gamma are released from chromatin during the M phase of the cell cycle, even though tri-methylation levels of histone H3 lysine 9 remain unchanged. However, the additional, transient modification of histone H3 by phosphorylation of serine 10 next to the more stable methyl-lysine 9 mark is sufficient to eject HP1 proteins from their binding sites. Inhibition or depletion of the mitotic kinase Aurora B, which phosphorylates serine 10 on histone H3, causes retention of HP1 proteins on mitotic chromosomes, suggesting that H3 serine 10 phosphorylation is necessary for the dissociation of HP1 from chromatin in M phase. These findings establish a regulatory mechanism of protein - protein interactions, through a combinatorial readout of two adjacent post-translational modifications: a stable methylation and a dynamic phosphorylation mark.	Rockefeller Univ, Lab Chromatin Biol, New York, NY 10021 USA; Rockefeller Univ, Lab Chromosome & Cell Biol, New York, NY 10021 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22904 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22904 USA	Rockefeller University; Rockefeller University; University of Virginia; University of Virginia	Fischle, W (corresponding author), Rockefeller Univ, Lab Chromatin Biol, 1230 York Ave, New York, NY 10021 USA.	fischlw@rockefeller.edu; funabih@rockefeller.edu	Tseng, Boo Shan/M-6279-2018; Jansen, Nils/G-1835-2011; Hunt, Donald F/I-6936-2012	Tseng, Boo Shan/0000-0001-7563-0232; Hunt, Donald F/0000-0003-2815-6368; Funabiki, Hironori/0000-0003-4831-4087; Ueberheide, Beatrix/0000-0003-2512-0204	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM066699] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Chen J, 2003, J BIOL CHEM, V278, P486, DOI 10.1074/jbc.M211119200; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Dai J, 2005, GENE DEV, V19, P472, DOI 10.1101/gad.1267105; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Grewal SIS, 2002, CURR OPIN GENET DEV, V12, P178, DOI 10.1016/S0959-437X(02)00284-8; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hayakawa T, 2003, J CELL SCI, V116, P3327, DOI 10.1242/jcs.00635; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Jacobs SA, 2004, METHOD ENZYMOL, V376, P131; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Li YH, 2002, P NATL ACAD SCI USA, V99, P16462, DOI 10.1073/pnas.162371699; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; Mateescu B, 2004, EMBO REP, V5, P490, DOI 10.1038/sj.embor.7400139; Mellone BG, 2003, CURR BIOL, V13, P1748, DOI 10.1016/j.cub.2003.09.031; Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Obuse C, 2004, NAT CELL BIOL, V6, P1135, DOI 10.1038/ncb1187; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Pidoux AL, 2004, CHROMOSOME RES, V12, P521, DOI 10.1023/B:CHRO.0000036586.81775.8b; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Schmiedeberg L, 2004, MOL BIOL CELL, V15, P2819, DOI 10.1091/mbc.E03-11-0827; SCHOTTA, 2004, NOVARTIS FDN S, V259, P22; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005; Sugimoto K, 2001, CELL STRUCT FUNCT, V26, P705, DOI 10.1247/csf.26.705; Syka JEP, 2004, J PROTEOME RES, V3, P621, DOI 10.1021/pr0499794; Thiru A, 2004, EMBO J, V23, P489, DOI 10.1038/sj.emboj.7600088; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Yasui Y, 2004, J BIOL CHEM, V279, P12997, DOI 10.1074/jbc.M311128200	47	709	729	3	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	2005	438	7071					1116	1122		10.1038/nature04219	http://dx.doi.org/10.1038/nature04219			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	995OF	16222246				2022-12-28	WOS:000234111500041
J	Okamoto, I; Arnaud, D; Le Baccon, P; Otte, AP; Disteche, CM; Avner, P; Heard, E				Okamoto, I; Arnaud, D; Le Baccon, P; Otte, AP; Disteche, CM; Avner, P; Heard, E			Evidence for de novo imprinted X-chromosome inactivation independent of meiotic inactivation in mice	NATURE			English	Article							EXPRESSION; MECHANISMS; SMCX	In mammals, one of the two X chromosomes is inactivated in females to enable dosage compensation for X-linked gene products1. In rodents and marsupials, only the X chromosome of paternal origin (Xp) is silenced during early embryogenesis. This could be due to a carry-over effect of the X chromosome's passage through the male germ line, where it becomes transiently silenced together with the Y chromosome, during meiotic sex chromosome inactivation (MSCI)(2). Here we show that Xist (X inactive specific transcript) transgenes, located on autosomes, do not undergo MSCI in the male germ line of mice and yet can induce imprinted cis-inactivation when paternally inherited, with identical kinetics to the Xp chromosome. This suggests that MSCI is not necessary for imprinted X-chromosome inactivation in mice. We also show that the Xp is transcribed, like autosomes, at zygotic gene activation rather than being 'pre-inactivated'(3). We propose that expression of the paternal Xist gene at zygotic gene activation is sufficient to trigger cis-inactivation of the X chromosome, or of an autosome carrying a Xist transgene.	Inst Curie, CNRS, UMR 218, F-75248 Paris, France; Inst Pasteur, F-75015 Paris, France; Univ Amsterdam, Swammerdam Inst Life Sci, NL-1098 SM Amsterdam, Netherlands; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Amsterdam; University of Washington; University of Washington Seattle	Heard, E (corresponding author), Inst Curie, CNRS, UMR 218, 26 Rue Ulm, F-75248 Paris, France.	Edith.Heard@curie.fr	Heard, Edith/D-7197-2017	Heard, Edith/0000-0001-8052-7117				Baarends WM, 1999, DEV BIOL, V207, P322, DOI 10.1006/dbio.1998.9155; Baart EB, 2000, CHROMOSOMA, V109, P139, DOI 10.1007/s004120050422; Carrel L, 1996, HUM MOL GENET, V5, P1361, DOI 10.1093/hmg/5.9.1361; Carrel L, 1996, HUM MOL GENET, V5, P391, DOI 10.1093/hmg/5.3.391; Cooper D.W., 1993, Seminars in Developmental Biology, V4, P117, DOI 10.1006/sedb.1993.1014; Fernandez-Capetillo O, 2003, DEV CELL, V4, P497, DOI 10.1016/S1534-5807(03)00093-5; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; Heard E, 1996, HUM MOL GENET, V5, P441, DOI 10.1093/hmg/5.4.441; Heard E, 2004, COLD SPRING HARB SYM, V69, P89, DOI 10.1101/sqb.2004.69.89; Heard E, 1999, MOL CELL BIOL, V19, P3156; Heard E, 2004, CURR OPIN CELL BIOL, V16, P247, DOI 10.1016/j.ceb.2004.03.005; Hoyer-Fender S, 2000, EXP CELL RES, V258, P254, DOI 10.1006/excr.2000.4951; Huynh KD, 2003, NATURE, V426, P857, DOI 10.1038/nature02222; KAY GF, 1994, CELL, V77, P639, DOI 10.1016/0092-8674(94)90049-3; LIFSCHYTZ E, 1972, P NATL ACAD SCI USA, V69, P182, DOI 10.1073/pnas.69.1.182; Lingenfelter PA, 1998, NAT GENET, V18, P212, DOI 10.1038/ng0398-212; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; LYON MF, 1984, DIFFERENTIATION, V26, P63, DOI 10.1111/j.1432-0436.1984.tb01375.x; Mak W, 2004, SCIENCE, V303, P666, DOI 10.1126/science.1092674; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MONK M, 1981, J EMBRYOL EXP MORPH, V63, P75; Okamoto I, 2004, SCIENCE, V303, P644, DOI 10.1126/science.1092727; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; SHAO CS, 1990, DEVELOPMENT, V110, P969; Simmler MC, 1997, MAMM GENOME, V8, P760, DOI 10.1007/s003359900561; TADA T, 1993, GENET RES, V62, P139, DOI 10.1017/S0016672300031736; Tada T, 2000, DEVELOPMENT, V127, P3101; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; Turner JMA, 2005, NAT GENET, V37, P41, DOI 10.1038/ng1484; VANDEBERG JL, 1987, ISOZYM C T, V15, P225	30	153	158	1	9	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					369	373		10.1038/nature04155	http://dx.doi.org/10.1038/nature04155			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16227973				2022-12-28	WOS:000233300200051
J	Courcoulas, AP; Flum, DR				Courcoulas, AP; Flum, DR			Filling the gaps in bariatric surgical research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							Y GASTRIC BYPASS; MORBID-OBESITY; SURGERY; TRIAL		Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA USA	University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Flum, DR (corresponding author), Univ Washington, Dept Surg, 1959 NE Pacific St,Box 356410,BB431, Seattle, WA 98195 USA.	daveflum@u.washington.edu	Flum, David/GPX-7976-2022					ANDERSEN B, 1979, LANCET, V2, P1255; BEELE S, 2005, AM SOC BARIATRIC SUR, V1, P145; Buchwald H, 2004, JAMA-J AM MED ASSOC, V292, P1724, DOI 10.1001/jama.292.14.1724; FIERRO M, COST CONTAINMENT STA; GRADY D, 2000, NY TIMES        1017; Kral JG, 2005, SURGERY, V137, P279, DOI 10.1016/j.surg.2004.11.004; Meguid MM, 2004, J GASTROINTEST SURG, V8, P621, DOI 10.1016/j.gassur.2004.02.003; O'Brien P, 2004, OBES RES, V12, pA33; O'Brien PE, 2004, ANZ J SURG, V74, P200, DOI 10.1111/j.1445-2197.2004.03014.x; Schauer P, 2003, SURG ENDOSC, V17, P212, DOI 10.1007/s00464-002-8857-z; Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622; SUGERMAN HJ, 1989, AM J SURG, V157, P93, DOI 10.1016/0002-9610(89)90427-3; Zingmond DS, 2005, JAMA-J AM MED ASSOC, V294, P1918, DOI 10.1001/jama.294.15.1918; 1992, AM J NUCL NUTR S, V55, pS487	14	32	32	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	2005	294	15					1957	1960		10.1001/jama.294.15.1957	http://dx.doi.org/10.1001/jama.294.15.1957			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974OZ	16234502				2022-12-28	WOS:000232602600025
J	Marfin, AA; Gubler, DJ				Marfin, AA; Gubler, DJ			Japanese encephalitis: the need for a more effective vaccine	LANCET			English	Editorial Material							IMMUNIZATION; SA14-14-2		US Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA; Univ Hawaii Manoa, John A Burns Sch Med, Asia Pacific Inst Trop Med & Infect Dis, Honolulu, HI 96822 USA	Centers for Disease Control & Prevention - USA; University of Hawaii System; University of Hawaii Manoa	Marfin, AA (corresponding author), US Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA.	aam0@cdc.gov						Akiba T, 2001, EPIDEMIOL INFECT, V126, P81, DOI 10.1017/S0950268801004769; [Anonymous], 2005, Wkly Epidemiol Rec, V80, P242; [Anonymous], 1998, Wkly Epidemiol Rec, V73, P337; BENLI Z, 2001, CHIN J BIOL, V14; Bista MB, 2001, LANCET, V358, P791, DOI 10.1016/S0140-6736(01)05967-0; Ding D, 2003, B WORLD HEALTH ORGAN, V81, P334; Halstead S.B., 2004, VACCINES, P919; Hennessy S, 1996, LANCET, V347, P1583, DOI 10.1016/S0140-6736(96)91075-2; HOKE CH, 1988, NEW ENGL J MED, V319, P608, DOI 10.1056/NEJM198809083191004; Igarashi Akira, 1992, World Health Statistics Quarterly, V45, P299; *INT RIC RES I, 2005, WORLD RICE STAT  MAY; Liu ZL, 1997, J INFECT DIS, V176, P1366, DOI 10.1086/517323; Monath TP, 2002, CURR TOP MICROBIOL, V267, P105; Ohrr H, 2005, LANCET, V366, P1375, DOI 10.1016/S0140-6736(05)67567-8; *PATH JAP ENC PROJ, 2005, CONS INTRO NEW UND V; YU YX, 1988, AM J TROP MED HYG, V39, P214, DOI 10.4269/ajtmh.1988.39.214	16	10	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 15	2005	366	9494					1335	1337		10.1016/S0140-6736(05)67543-5	http://dx.doi.org/10.1016/S0140-6736(05)67543-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	973ZW	16226596				2022-12-28	WOS:000232562100005
J	Stixrude, L; Karki, B				Stixrude, L; Karki, B			Structure and freezing of MgSiO3 liquid in Earth's lower mantle	SCIENCE			English	Article							MOLECULAR-DYNAMICS; MELTING TEMPERATURE; SILICATE LIQUIDS; PEROVSKITE; COMPRESSION; TRANSITION; MINERALS; CURVE; MODEL; IRON	First-principles molecular-dynamics simulations show that over the pressure regime of Earth's mantle the mean silicon-oxygen coordination number of magnesium metasilicate liquid changes nearly linearly from 4 to 6. The density contrast between liquid and crystal decreases by a factor of nearly 5 over the mantle pressure regime and is 4% at the core-mantle boundary. The ab initio melting curve, obtained by integration of the Clausius-Clapeyron equation, yields a melting temperature at the core-mantle boundary of 5400 +/- 600 kelvins.	Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; Louisiana State Univ, Dept Comp Sci, Baton Rouge, LA 70803 USA	University of California System; University of California Berkeley; Louisiana State University System; Louisiana State University	Stixrude, L (corresponding author), Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA.	stixrude@umich.edu	Stixrude, Lars/C-5625-2012	Stixrude, Lars/0000-0003-3778-2432				Akins JA, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020237; Alfe D, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.235701; Belonoshko AB, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.195701; Boehler R, 1996, ANNU REV EARTH PL SC, V24, P15, DOI 10.1146/annurev.earth.24.1.15; BOEHLER R, 1977, J APPL PHYS, V48, P4183, DOI 10.1063/1.323455; Boehler R, 1996, PHYS REV B, V53, P556, DOI 10.1103/PhysRevB.53.556; FLYVBJERG H, 1989, J CHEM PHYS, V91, P461, DOI 10.1063/1.457480; HEINZ DL, 1987, J GEOPHYS RES-SOLID, V92, P11437, DOI 10.1029/JB092iB11p11437; Ito E., 1992, HIGH PRESSURE RES AP, P315; Jeanloz R, 1996, PHILOS T R SOC A, V354, P1279, DOI 10.1098/rsta.1996.0049; JEANLOZ R, 1982, J GEOPHYS RES, V87, P763, DOI 10.1029/JB087iB13p10763; JEANLOZ R, 1986, ANNU REV EARTH PL SC, V14, P377, DOI 10.1146/annurev.ea.14.050186.002113; JEANLOZ R, 1990, P GIBBS S YALE U, P211; KNITTLE E, 1989, GEOPHYS RES LETT, V16, P421, DOI 10.1029/GL016i005p00421; Kresse G, 1996, COMP MATER SCI, V6, P15, DOI 10.1016/0927-0256(96)00008-0; KRESSE G, 1992, J PHYS-CONDENS MAT, V4, P7451, DOI 10.1088/0953-8984/4/36/018; LANGE RA, 1987, GEOCHIM COSMOCHIM AC, V51, P2931, DOI 10.1016/0016-7037(87)90368-1; Luo SN, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002860; Matsui M, 1996, GEOPHYS RES LETT, V23, P395, DOI 10.1029/96GL00260; MERMIN ND, 1965, PHYS REV, V137, P1441, DOI 10.1103/PhysRev.137.A1441; MILLER GH, 1991, J GEOPHYS RES-SOLID, V96, P11831, DOI 10.1029/91JB01204; NOSE S, 1984, J CHEM PHYS, V81, P511, DOI 10.1063/1.447334; Oganov AR, 2001, NATURE, V411, P934, DOI 10.1038/35082048; RIGDEN SM, 1988, J GEOPHYS RES-SOLID, V93, P367, DOI 10.1029/JB093iB01p00367; ROSS M, 1985, PHYS REV B, V31, P1463, DOI 10.1103/PhysRevB.31.1463; SHEN GY, 1995, J GEOPHYS RES-SOL EA, V100, P17699, DOI 10.1029/95JB01864; STEBBINS JF, 1984, CONTRIB MINERAL PETR, V86, P131, DOI 10.1007/BF00381840; Stixrude L, 2005, GEOPHYS J INT, V162, P610, DOI 10.1111/j.1365-246X.2005.02642.x; SWEENEY JS, 1993, GEOPHYS RES LETT, V20, P855, DOI 10.1029/93GL00556; Tronnes RG, 2002, EARTH PLANET SC LETT, V197, P117, DOI 10.1016/S0012-821X(02)00466-1; Tsuchiya T, 2004, EARTH PLANET SC LETT, V224, P241, DOI 10.1016/j.epsl.2004.05.017; Vocadlo L, 2003, PHYS EARTH PLANET IN, V140, P101, DOI 10.1016/j.pepi.2003.08.001; WASSERMAN EA, 1993, PHYS EARTH PLANET IN, V77, P189, DOI 10.1016/0031-9201(93)90098-T; Wentzcovitch RM, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.018501; Williams Q, 1996, SCIENCE, V273, P1528, DOI 10.1126/science.273.5281.1528; WILLIAMS Q, 1988, SCIENCE, V239, P902, DOI 10.1126/science.239.4842.902; Young DA, 1991, PHASE DIAGRAMS ELEME; ZERR A, 1993, SCIENCE, V262, P553, DOI 10.1126/science.262.5133.553; Zhou YH, 1997, GEOCHIM COSMOCHIM AC, V61, P2957, DOI 10.1016/S0016-7037(97)00120-8	39	236	241	24	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					297	299		10.1126/science.1116952	http://dx.doi.org/10.1126/science.1116952			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224018				2022-12-28	WOS:000232670100047
J	Tanaka, KL				Tanaka, KL			Geology and insolation-driven climatic history of Amazonian north polar materials on Mars	NATURE			English	Article							SURFACE; EVOLUTION; MORPHOLOGY; DEPOSITS; ORIGIN; ICE	Mariner 9 and Viking spacecraft images revealed that the polar regions of Mars, like those of Earth, record the planet's climate history. However, fundamental uncertainties regarding the materials, features, ages and processes constituting the geologic record remained(1-6). Recently acquired Mars Orbiter Laser Altimeter data(7) and Mars Orbiter Camera high-resolution images(8) from the Mars Global Surveyor spacecraft and moderately high-resolution Thermal Emission Imaging System visible images(9) from the Mars Odyssey spacecraft permit more comprehensive geologic and climatic analyses(10-17). Here I map and show the history of geologic materials and features in the north polar region that span the Amazonian period (similar to 3.0 Gyr ago to present) (18,19). Erosion and redeposition of putative circumpolar mud volcano deposits(15) ( formed by eruption of liquefied, fine-grained material) led to the formation of an Early Amazonian polar plateau consisting of dark layered materials. Crater ejecta superposed on pedestals indicate that a thin mantle was present during most of the Amazonian, suggesting generally higher obliquity and insolation conditions at the poles than at present. Brighter polar layered deposits rest unconformably on the dark layers and formed mainly during lower obliquity over the past 4 - 5Myr (ref. 20). Finally, the uppermost layers post-date the latest downtrend in obliquity < 20,000 years ago(20).	US Geol Survey, Astrogeol Team, Flagstaff, AZ 86001 USA	United States Department of the Interior; United States Geological Survey	Tanaka, KL (corresponding author), US Geol Survey, Astrogeol Team, 2255 N Gemini Dr, Flagstaff, AZ 86001 USA.	ktanaka@usgs.gov						BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; Byrne S, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001615; Christensen PR, 2003, SCIENCE, V300, P2056, DOI 10.1126/science.1080885; CUTTS JA, 1982, ICARUS, V50, P216, DOI 10.1016/0019-1035(82)90124-5; Fishbaugh KE, 2005, ICARUS, V174, P444, DOI 10.1016/j.icarus.2004.06.021; FISHBAUGH KE, 2005, LUN PLAN SCI C, V36; Hartmann WK, 2001, SPACE SCI REV, V96, P165, DOI 10.1023/A:1011945222010; Herkenhoff KE, 2000, ICARUS, V144, P243, DOI 10.1006/icar.1999.6287; HOWARD AD, 1982, ICARUS, V50, P161, DOI 10.1016/0019-1035(82)90123-3; HOWARD AD, 1978, ICARUS, V34, P581, DOI 10.1016/0019-1035(78)90047-7; Kolb EJ, 2001, ICARUS, V154, P22, DOI 10.1006/icar.2001.6676; Koutnik M, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001805; Laskar J, 2004, ICARUS, V170, P343, DOI 10.1016/j.icarus.2004.04.005; Laskar J, 2002, NATURE, V419, P375, DOI 10.1038/nature01066; Malin MC, 2001, J GEOPHYS RES-PLANET, V106, P23429, DOI 10.1029/2000JE001455; MELLON MT, 1995, J GEOPHYS RES-PLANET, V100, P11781, DOI 10.1029/95JE01027; Milkovich SM, 2005, J GEOPHYS RES-PLANET, V110, DOI 10.1029/2004JE002349; Mustard JF, 2001, NATURE, V412, P411, DOI 10.1038/35086515; PARKER TJ, 1989, ICARUS, V82, P111, DOI 10.1016/0019-1035(89)90027-4; Rahmstorf S, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017115; Robertson A, 1996, GEOLOGY, V24, P239, DOI 10.1130/0091-7613(1996)024<0239:MVOTMR>2.3.CO;2; Smith DE, 2001, J GEOPHYS RES-PLANET, V106, P23689, DOI 10.1029/2000JE001364; SQUYRES SW, 1979, ICARUS, V40, P244, DOI 10.1016/0019-1035(79)90070-8; Tanaka KL, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE001908; TANAKA KL, 1986, J GEOPHYS RES-SOLID, V91, pE139, DOI 10.1029/JB091iB13p0E139; Thomas PC, 2000, NATURE, V404, P161, DOI 10.1038/35004528; Wyatt MB, 2004, GEOLOGY, V32, P645, DOI 10.1130/G20527.1	27	60	60	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	2005	437	7061					991	994		10.1038/nature04065	http://dx.doi.org/10.1038/nature04065			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16222294				2022-12-28	WOS:000232496100038
J	Bonfil, R; Meyer, M; Scholl, MC; Johnson, R; O'Brien, S; Oosthuizen, H; Swanson, S; Kotze, D; Paterson, M				Bonfil, R; Meyer, M; Scholl, MC; Johnson, R; O'Brien, S; Oosthuizen, H; Swanson, S; Kotze, D; Paterson, M			Transoceanic migration, spatial dynamics, and population linkages of white sharks	SCIENCE			English	Article							CARCHARODON-CARCHARIAS LINNAEUS; COMMERCIAL PRAWN TRAWLERS; BASKING SHARK; BLUEFIN TUNA; SOUTH-AFRICA; SATELLITE; MOVEMENTS; TRACKING; BIOLOGY; SEA	The large-scale spatial dynamics and population structure of marine top predators are poorly known. We present electronic tag and photographic identification data showing a complex suite of behavioral patterns in white sharks. These include coastal return migrations and the fastest known transoceanic return migration among swimming fauna, which provide direct evidence of a link between widely separated populations in South Africa and Australia. Transoceanic return migration involved a return to the original capture location, dives to depths of 980 meters, and the tolerance of water temperatures as low as 3.4 degrees C. These findings contradict previous ideas that female white sharks do not make transoceanic. migrations, and they suggest natal homing behavior.	Wildlife Conservat Soc, Bronx, NY 10460 USA; Dept Environm Affairs & Tourism, Marine & Coastal Management Branch, ZA-8012 Cape Town, Western Cape, South Africa; White Shark Trust, ZA-7220 Gansbaai, Western Cape, South Africa; Univ Cape Town, ZA-7700 Rondebosch, Western Cape, South Africa; Univ Pretoria, Dept Zool & Entomol, ZA-0002 Pretoria, South Africa	Wildlife Conservation Society; University of Cape Town; University of Pretoria	Bonfil, R (corresponding author), Wildlife Conservat Soc, 2300 Southern Blvd, Bronx, NY 10460 USA.	rbonfil@wcs.or	Bonfil, Ramón/K-1226-2012; Scholl, Michael Christoph/ABF-5665-2021	Bonfil, Ramon/0000-0002-5753-464X				[Anonymous], 1996, GREAT WHITE SHARKS B; BAKER RR, 1982, MIGRATION PATHS TIME; Block BA, 1998, P NATL ACAD SCI USA, V95, P9384, DOI 10.1073/pnas.95.16.9384; Block BA, 2001, SCIENCE, V293, P1310, DOI 10.1126/science.1061197; Boustany AM, 2002, NATURE, V415, P35, DOI 10.1038/415035b; CAREY FG, 1982, COPEIA, P254; Clarke SC, 2003, THESIS U LONDON; Cliff G, 2000, S AFR J SCI, V96, P365; Compagno L.J.V., 1989, GUIDE SHARKS RAYS SO; Compagno LJV, 1997, ENVIRON BIOL FISH, V50, P61, DOI 10.1023/A:1007308406137; Compagno LJV, 2001, SHARKS WORLD ANNOT; CURY P, 1994, CAN J FISH AQUAT SCI, V51, P1664, DOI 10.1139/f94-167; Eckert SA, 2001, ENVIRON BIOL FISH, V60, P299, DOI 10.1023/A:1007674716437; Feldheim KA, 2002, P ROY SOC B-BIOL SCI, V269, P1655, DOI 10.1098/rspb.2002.2051; FENNESSY ST, 1994, S AFR J MARINE SCI, V14, P287; FENNESSY ST, 1994, S AFR J MARINE SCI, V14, P263; Francis MP, 1996, GREAT WHITE SHARKS, P157, DOI 10.1016/B978-012415031-7/50016-1; HILTONTAYLOR C, 2000, 2002 IUCN RED LIST T; Hueter R. E., 2005, Journal of Northwest Atlantic Fishery Science, V35, P239; Inagake Denzo, 2001, Bulletin of the National Research Institute of Far Seas Fisheries, V38, P53; Itoh T, 2003, FISH B-NOAA, V101, P514; JOHNSON RL, 2003, THESIS U PRETORIA S; JOHNSON RL, 2004, M CONS RES GREAT WHI; Kohler NE, 2001, ENVIRON BIOL FISH, V60, P191, DOI 10.1023/A:1007679303082; Pardini AT, 2001, NATURE, V412, P139, DOI 10.1038/35084125; PRIEDE IG, 1984, FISH RES, V2, P201, DOI 10.1016/0165-7836(84)90003-1; QUINN TP, 1994, TRENDS ECOL EVOL, V9, P277, DOI 10.1016/0169-5347(94)90027-2; Soldo A, 2002, PERIOD BIOL, V104, P195	28	319	336	7	289	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 7	2005	310	5745					100	103		10.1126/science.1114898	http://dx.doi.org/10.1126/science.1114898			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210537				2022-12-28	WOS:000232477000046
J	Koprivica, V; Cho, KS; Park, JB; Yiu, G; Atwal, J; Gore, B; Kim, JA; Lin, E; Tessier-Lavigne, M; Chen, DF; He, ZG				Koprivica, V; Cho, KS; Park, JB; Yiu, G; Atwal, J; Gore, B; Kim, JA; Lin, E; Tessier-Lavigne, M; Chen, DF; He, ZG			EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; RETINAL GANGLION-CELLS; RECEPTOR FAMILY-MEMBER; NOGO RECEPTOR; NEURITE OUTGROWTH; SIGNALING PATHWAY; CALCIUM; GLYCOPROTEIN; INACTIVATION; CORECEPTOR	Inhibitory molecules associated with myelin and the glial. scar limit axon regeneration in the adult central nervous system (CNS), but the underlying signaling mechanisms of regeneration inhibition are not fully understood. Here, we show that suppressing the kinase function of the epidermal growth factor receptor (EGFR) blocks the activities of both myelin inhibitors and chondroitin sulfate proteoglycans in inhibiting neurite outgrowth. In addition, regeneration inhibitors trigger the phosphorylation of EGFR in a calcium-dependent manner. Local administration of EGFR inhibitors promotes significant regeneration of injured optic nerve fibers, pointing to a promising therapeutic avenue for enhancing axon regeneration after CNS injury.	Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, Boston, MA 02114 USA; Genentech Inc, Div Res, San Francisco, CA 94080 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Schepens Eye Research Institute; Roche Holding; Genentech	He, ZG (corresponding author), Childrens Hosp, Div Neurosci, 300 Longwood Ave, Boston, MA 02115 USA.	zhigang.he@childrens.harvard.edu	Yiu, Glenn/AAF-2858-2020	Yiu, Glenn/0000-0003-3061-3310; Cho, Kin-Sang/0000-0003-4285-615X				Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; BANDTLOW CE, 1993, SCIENCE, V259, P80, DOI 10.1126/science.8418499; Bomze HM, 2001, NAT NEUROSCI, V4, P38, DOI 10.1038/82881; Cho KS, 2005, J CELL SCI, V118, P863, DOI 10.1242/jcs.01658; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fischer D, 2004, J NEUROSCI, V24, P8726, DOI 10.1523/JNEUROSCI.2774-04.2004; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Goldberg JL, 2002, SCIENCE, V296, P1860, DOI 10.1126/science.1068428; He ZG, 2004, ANNU REV NEUROSCI, V27, P341, DOI 10.1146/annurev.neuro.27.070203.144340; Henley JR, 2004, NEURON, V44, P909, DOI 10.1016/j.neuron.2004.11.030; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; KOPRIVICA V, UNPUB; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; McGee AW, 2003, TRENDS NEUROSCI, V26, P193, DOI 10.1016/S0166-2236(03)00062-6; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; Shim S, 2005, NAT NEUROSCI, V8, P730, DOI 10.1038/nn1459; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; SNOW DM, 1994, DEV BIOL, V166, P87, DOI 10.1006/dbio.1994.1298; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	30	282	304	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	2005	310	5745					106	110		10.1126/science.1115462	http://dx.doi.org/10.1126/science.1115462			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210539				2022-12-28	WOS:000232477000048
J	Hjorth, J; Watson, D; Fynbo, JPU; Price, PA; Jensen, BL; Jorgensen, UG; Kubas, D; Gorosabel, J; Jakobsson, P; Sollerman, J; Pedersen, K; Kouveliotou, C				Hjorth, J; Watson, D; Fynbo, JPU; Price, PA; Jensen, BL; Jorgensen, UG; Kubas, D; Gorosabel, J; Jakobsson, P; Sollerman, J; Pedersen, K; Kouveliotou, C			The optical afterglow of the short gamma-ray burst GRB 050709	NATURE			English	Article							SUPERNOVA; CONSTRAINTS; DISCOVERY; PROSPECTS; SPECTRA; MODEL	It has long been known that there are two classes(1) of gamma-ray bursts (GRBs), mainly distinguished by their durations. The breakthrough in our understanding of long-duration GRBs ( those lasting more than similar to 2 s), which ultimately linked them with energetic type Ic supernovae(2-4), came from the discovery of their long-lived X-ray(5) and optical(6,7) 'afterglows', when precise and rapid localizations of the sources could finally be obtained. X-ray localizations have recently become available(8,9) for short ( duration < 2 s) GRBs, which have evaded optical detection for more than 30 years. Here we report the first discovery of transient optical emission (R-band magnitude similar to 23) associated with a short burst: GRB 050709. The optical afterglow was localized with subarcsecond accuracy, and lies in the outskirts of a blue dwarf galaxy. The optical and X-ray(10) afterglow properties 34 h after the GRB are reminiscent of the afterglows of long GRBs, which are attributable to synchrotron emission from ultrarelativistic ejecta. We did not, however, detect a supernova, as found in most nearby long GRB afterglows, which suggests a different origin for the short GRBs.	Univ Copenhagen, Niels Bohr Inst, Dark Cosmol Ctr, DK-2100 Copenhagen, Denmark; Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; European So Observ, Santiago 19, Chile; CSIC, Inst Astrofis Andalucia, E-18080 Granada, Spain; Stockholm Univ, Dept Astron, S-10691 Stockholm, Sweden; NASA, George C Marshall Space Flight Ctr, Natl Space Sci Technol Ctr, Huntsville, AL 35805 USA	University of Copenhagen; Niels Bohr Institute; University of Hawaii System; European Southern Observatory; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Astrofisica de Andalucia (IAA); Stockholm University; National Aeronautics & Space Administration (NASA); NASA Marshall Space Flight Center	Hjorth, J (corresponding author), Univ Copenhagen, Niels Bohr Inst, Dark Cosmol Ctr, Juliane Maries Vej, DK-2100 Copenhagen, Denmark.	jens@astro.ku.dk	Hjorth, Jens/M-5787-2014; Fynbo, Johan P. U./L-8496-2014; Jensen, Brian Lindgren/E-1275-2015; Jakobsson, Pall/L-9950-2015; Watson, Darach/E-4521-2015	Hjorth, Jens/0000-0002-4571-2306; Fynbo, Johan P. U./0000-0002-8149-8298; Jensen, Brian Lindgren/0000-0002-0906-9771; Jakobsson, Pall/0000-0002-9404-5650; Watson, Darach/0000-0002-4465-8264				Amati L, 2002, ASTRON ASTROPHYS, V390, P81, DOI 10.1051/0004-6361:20020722; BARRIS BJ, 2005, IN PRESS ASTRON J; Berger E, 2003, ASTROPHYS J, V590, P379, DOI 10.1086/374892; Bloom JS, 2002, ASTRON J, V123, P1111, DOI 10.1086/338893; BLOOM JS, 2005, IN PRESS ASTROPHYS J; Christensen L, 2004, ASTRON ASTROPHYS, V425, P913, DOI 10.1051/0004-6361:20040361; Connaughton V, 2002, ASTROPHYS J, V567, P1028, DOI 10.1086/338695; Costa E, 1997, NATURE, V387, P783, DOI 10.1038/42885; FRUCHTER AS, 2004, ASTROPHYS J, V617, pL21; Galama TJ, 1998, NATURE, V395, P670, DOI 10.1038/27150; Ghirlanda G, 2004, ASTRON ASTROPHYS, V422, pL55, DOI 10.1051/0004-6361:20048008; Hjorth J, 2003, NATURE, V423, P847, DOI 10.1038/nature01750; Hjorth J, 2005, ASTROPHYS J, V630, pL117, DOI 10.1086/491733; KOUVELIOTOU C, 1993, ASTROPHYS J, V413, pL101, DOI 10.1086/186969; Lazzati D, 2001, ASTRON ASTROPHYS, V379, pL39, DOI 10.1051/0004-6361:20011485; Lee WH, 2005, ASTROPHYS J, V630, pL165, DOI 10.1086/496882; Li LX, 1998, ASTROPHYS J, V507, pL59, DOI 10.1086/311680; Metzger MR, 1997, NATURE, V387, P878, DOI 10.1038/43132; Panaitescu A, 2001, ASTROPHYS J, V561, pL171, DOI 10.1086/324678; Piran T, 2004, REV MOD PHYS, V76, P1143, DOI 10.1103/RevModPhys.76.1143; ROSSWOG S, 2005, NEUTRON STAR BINARIE; Stanek KZ, 2003, ASTROPHYS J, V591, pL17, DOI 10.1086/376976; vanParadijs J, 1997, NATURE, V386, P686, DOI 10.1038/386686a0; Voss R, 2003, MON NOT R ASTRON SOC, V342, P1169, DOI 10.1046/j.1365-8711.2003.06616.x; Yamazaki R, 2004, ASTROPHYS J, V607, pL103, DOI 10.1086/421872; Zhang WQ, 2003, ASTROPHYS J, V586, P356, DOI 10.1086/367609	26	252	255	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					859	861		10.1038/nature04174	http://dx.doi.org/10.1038/nature04174			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208365	Green Submitted			2022-12-28	WOS:000232338600040
J	Partida-Martinez, LP; Hertweck, C				Partida-Martinez, LP; Hertweck, C			Pathogenic fungus harbours endosymbiotic bacteria for toxin production	NATURE			English	Article							MACROCYCLIC LACTONE ANTIBIOTICS; POLYKETIDE SYNTHASES; RHIZOPUS-CHINENSIS; GENE-CLUSTER; RHIZOXIN; BIOSYNTHESIS; SYMBIONT; BURKHOLDERIA; METABOLITE; AGENTS	A number of plant pathogenic fungi belonging to the genus Rhizopus are infamous for causing rice seedling blight. This plant disease is typically initiated by an abnormal swelling of the seedling roots without any sign of infection by the pathogen(1-4). This characteristic symptom is in fact caused by the macrocyclic polyketide metabolite rhizoxin that has been isolated from cultures of Rhizopus sp.(5,6). The phytotoxin exerts its destructive effect by binding to rice beta-tubulin, which results in inhibition of mitosis and cell cycle arrest(7,8). Owing to its remarkably strong antimitotic activity in most eukaryotic cells, including various human cancer cell lines, rhizoxin has attracted considerable interest as a potential antitumour drug(9,10). Here we show that rhizoxin is not biosynthesized by the fungus itself, but by endosymbiotic, that is, intracellular living, bacteria of the genus Burkholderia. Our unexpected findings unveil a remarkably complex symbiotic-pathogenic relationship that extends the fungus - plant interaction to a third, bacterial, key-player, and opens new perspectives for pest control.	HKI, Leibniz Inst Nat Prod Res & Infect Biol, D-07745 Jena, Germany	Hans Knoll Institute (HKI)	Hertweck, C (corresponding author), HKI, Leibniz Inst Nat Prod Res & Infect Biol, Beutenbergstr 11a, D-07745 Jena, Germany.	Christian.Hertweck@hki-jena.de	Hertweck, Christian/AAZ-8452-2021; Hertweck, Christian/G-1896-2014; Partida, Laila Pamela/A-5935-2009	Hertweck, Christian/0000-0002-0367-337X; Hertweck, Christian/0000-0002-0367-337X; Partida, Laila Pamela/0000-0001-8037-2856				Bianciotto V, 1996, APPL ENVIRON MICROB, V62, P3005, DOI 10.1128/AEM.62.8.3005-3010.1996; Bonfante P, 2003, BIOL BULL-US, V204, P215, DOI 10.2307/1543562; Coenye T, 2003, ENVIRON MICROBIOL, V5, P719, DOI 10.1046/j.1462-2920.2003.00471.x; FURUYA S, 1974, P ASS PL PROT SHIKOK, V9, P49; Gho N., 1978, P ASS PLANT PROTECT, V26, P90; He J, 2003, CHEM BIOL, V10, P1225, DOI 10.1016/j.chembiol.2003.11.009; Hildebrand M, 2004, NAT PROD REP, V21, P122, DOI 10.1039/b302336m; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; IBARAKI T, 1973, Annals of the Phytopathological Society of Japan, V39, P141; IWASAKI S, 1986, J ANTIBIOT, V39, P424, DOI 10.7164/antibiotics.39.424; IWASAKI S, 1984, J ANTIBIOT, V37, P354, DOI 10.7164/antibiotics.37.354; Jennessen J, 2005, J AGR FOOD CHEM, V53, P1833, DOI 10.1021/jf048147n; Jordan A, 1998, MED RES REV, V18, P259, DOI 10.1002/(SICI)1098-1128(199807)18:4<259::AID-MED3>3.3.CO;2-T; Kenny DJ, 1999, ANTIMICROB AGENTS CH, V43, P2773, DOI 10.1128/AAC.43.11.2773; KOBAYASHI H, 1986, J CHEM SOC CHEM COMM, P1702, DOI 10.1039/c39860001702; Kobayashi M, 2001, MYCOSES, V44, P311, DOI 10.1111/j.1439-0507.2001.00642.x; Koga-Ban Y, 1995, DNA Res, V2, P21, DOI 10.1093/dnares/2.1.21; Nicholson TP, 2001, CHEM BIOL, V8, P157, DOI 10.1016/S1074-5521(00)90064-4; NODA T, 1980, Annals of the Phytopathological Society of Japan, V46, P40, DOI 10.3186/jjphytopath.46.40; Piel J, 2004, ENVIRON MICROBIOL, V6, P921, DOI 10.1111/j.1462-2920.2004.00531.x; Piel J, 2004, NAT PROD REP, V21, P519, DOI 10.1039/b310175b; Piel J, 2002, P NATL ACAD SCI USA, V99, P14002, DOI 10.1073/pnas.222481399; Piel J, 2004, P NATL ACAD SCI USA, V101, P16222, DOI 10.1073/pnas.0405976101; Ribes JA, 2000, CLIN MICROBIOL REV, V13, P236, DOI 10.1128/CMR.13.2.236-301.2000; Roberge M, 2000, CANCER RES, V60, P5052; TAKAHASHI M, 1987, J ANTIBIOT, V40, P66, DOI 10.7164/antibiotics.40.66; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TSURUO T, 1986, CANCER RES, V46, P381	28	426	443	6	142	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					884	888		10.1038/nature03997	http://dx.doi.org/10.1038/nature03997			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208371				2022-12-28	WOS:000232338600046
J	Sawalha, AH; Saint, S; Ike, RW; Bronze, MS				Sawalha, AH; Saint, S; Ike, RW; Bronze, MS			Still consider the source	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SALMONELLA-ENTERICA; INFECTION; AORTITIS		Univ Michigan, Dept Internal Med, Div Rheumatol, Taubman Ctr 3918, Ann Arbor, MI 48109 USA; Ann Arbor Vet Affairs Med Ctr, Ann Arbor Vet Affairs Hlth Serv Res & Dev Ctr Exc, Ann Arbor, MI USA; Ann Arbor Vet Affairs Med Ctr, Patient Safety Enhancement Program, Ann Arbor, MI USA; Univ Michigan Hlth Syst, Ann Arbor, MI USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University of Oklahoma System; University of Oklahoma Health Sciences Center	Sawalha, AH (corresponding author), Univ Michigan, Dept Internal Med, Div Rheumatol, Taubman Ctr 3918, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	amr-sawalha@omrf.ouhsc.edu	Saint, Sanjay/AAF-5126-2019; Ike, Robert William/AAC-3582-2021		AHRQ HHS [P20-HS11540] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Altekruse SF, 1997, EMERG INFECT DIS, V3, P285, DOI 10.3201/eid0303.970304; Bender JB, 2001, NEW ENGL J MED, V344, P189, DOI 10.1056/NEJM200101183440305; COHEN PS, 1978, ANN INTERN MED, V89, P931, DOI 10.7326/0003-4819-89-6-931; DEVERETYNDALL A, 1984, ANN RHEUM DIS, V43, P1, DOI 10.1136/ard.43.1.1; Guerrero MLF, 2004, MEDICINE, V83, P123, DOI 10.1097/01.md.0000125652.75260.cf; Hohmann EL, 2001, CLIN INFECT DIS, V32, P263, DOI 10.1086/318457; Narigasawa Y, 2000, Rinsho Ketsueki, V41, P729; OSKOUI R, 1993, ARCH INTERN MED, V153, P517, DOI 10.1001/archinte.153.4.517; POUCHOT J, 1991, MEDICINE, V70, P118, DOI 10.1097/00005792-199103000-00004; Soravia-Dunand VA, 1999, CLIN INFECT DIS, V29, P862, DOI 10.1086/520450	10	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 6	2005	353	14					1503	1507		10.1056/NEJMcps050056	http://dx.doi.org/10.1056/NEJMcps050056			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970LZ	16207853				2022-12-28	WOS:000232313000011
J	Choi, HK; Mount, DB; Reginato, AM				Choi, HK; Mount, DB; Reginato, AM			Pathogenesis of gout	ANNALS OF INTERNAL MEDICINE			English	Review							MONOSODIUM URATE MONOHYDRATE; BRUSH-BORDER MEMBRANE; SERUM URIC-ACID; INSULIN-RESISTANCE SYNDROME; CYCLOSPORINE-INDUCED HYPERURICEMIA; CRYSTAL-INDUCED INFLAMMATION; NUTRITION EXAMINATION SURVEY; AIR-POUCH MODEL; FRUCTOSE-INDUCED HYPERURICEMIA; PARA-AMINOHIPPURATE TRANSPORT		Univ British Columbia, Dept Med, Div Rheumatol, Arthrit Res Ctr, Vancouver, BC V5Z 1L7, Canada	University of British Columbia	Choi, HK (corresponding author), Univ British Columbia, Dept Med, Div Rheumatol, Arthrit Res Ctr, 895 W 10th Ave, Vancouver, BC V5Z 1L7, Canada.	hchoi@partners.org						AHN KJ, 1992, TRANSPLANT P, V24, P1391; Akahoshi T, 2003, ARTHRITIS RHEUM, V48, P231, DOI 10.1002/art.10709; AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; Arromdee E, 2002, J RHEUMATOL, V29, P2403; Aslamkhan A, 2003, AM J PHYSIOL-RENAL, V285, pF775, DOI 10.1152/ajprenal.00140.2003; August P, 2003, NEW ENGL J MED, V348, P610, DOI 10.1056/NEJMcp010357; Bakhiya N, 2003, CELL PHYSIOL BIOCHEM, V13, P249, DOI 10.1159/000074539; Bakker SJL, 2001, ATHEROSCLEROSIS, V155, P283, DOI 10.1016/S0021-9150(00)00745-0; Balakrishnan VS, 1996, AM J PHYSIOL-RENAL, V271, pF374, DOI 10.1152/ajprenal.1996.271.2.F374; BALAKRISHNAN VS, 1993, AM J PHYSIOL, V265, pF504, DOI 10.1152/ajprenal.1993.265.4.F504; Barabe F, 1998, FASEB J, V12, P209, DOI 10.1096/fasebj.12.2.209; Bedir A, 2003, JPN HEART J, V44, P527, DOI 10.1536/jhj.44.527; BLOMSTEDT JW, 1980, J CLIN INVEST, V65, P931, DOI 10.1172/JCI109748; BOMALASKI JS, 1990, J IMMUNOL, V145, P3391; Boots JMM, 2001, TRANSPL INT, V14, P370, DOI 10.1111/j.1432-2277.2001.tb00075.x; Bouchard L, 2002, J IMMUNOL, V168, P5310, DOI 10.4049/jimmunol.168.10.5310; BOUMENDILPODEVIN EF, 1981, AM J PHYSIOL, V240, pF185, DOI 10.1152/ajprenal.1981.240.3.F185; Bray GA, 2004, AM J CLIN NUTR, V79, P537; BURT HM, 1986, ANN RHEUM DIS, V45, P858, DOI 10.1136/ard.45.10.858; Campion E W, 1987, Am J Med, V82, P421, DOI 10.1016/0002-9343(87)90441-4; Caspi D, 2000, ARTHRITIS RHEUM-US, V43, P103, DOI 10.1002/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C; Cha SH, 2001, MOL PHARMACOL, V59, P1277, DOI 10.1124/mol.59.5.1277; Chanard J, 2003, NEPHROL DIAL TRANSPL, V18, P2147, DOI 10.1093/ndt/gfg341; Choi HK, 2005, ARCH INTERN MED, V165, P742, DOI 10.1001/archinte.165.7.742; Choi HK, 2004, ARTHRIT RHEUM-ARTHR, V51, P1023, DOI 10.1002/art.20821; Choi HK, 2004, LANCET, V363, P1277, DOI 10.1016/S0140-6736(04)16000-5; Choi HK, 2004, NEW ENGL J MED, V350, P1093, DOI 10.1056/NEJMoa035700; CLIFFORD AJ, 1976, J NUTR, V106, P428, DOI 10.1093/jn/106.3.428; Clive DM, 2000, J AM SOC NEPHROL, V11, P974, DOI 10.1681/ASN.V115974; Coady MJ, 2004, J PHYSIOL-LONDON, V557, P719, DOI 10.1113/jphysiol.2004.063859; COE FL, 1976, J CHRON DIS, V29, P793, DOI 10.1016/0021-9681(76)90053-9; CRONSTEIN BN, 1995, J CLIN INVEST, V96, P994, DOI 10.1172/JCI118147; Dessein PH, 2000, ANN RHEUM DIS, V59, P539, DOI 10.1136/ard.59.7.539; DIAMOND HS, 1973, J CLIN INVEST, V52, P1491, DOI 10.1172/JCI107323; Emmerson B, 1998, ANN RHEUM DIS, V57, P509, DOI 10.1136/ard.57.9.509; EMMERSON BT, 1974, ANN RHEUM DIS, V33, P276, DOI 10.1136/ard.33.3.276; Emmerson BT, 1996, NEW ENGL J MED, V334, P445, DOI 10.1056/NEJM199602153340707; EMMERSON BT, 1973, AUST NZ J MED, V3, P410, DOI 10.1111/j.1445-5994.1973.tb03115.x; Enomoto A, 2002, NATURE, V417, P447, DOI 10.1038/nature742; FALLER J, 1982, NEW ENGL J MED, V307, P1598, DOI 10.1056/NEJM198212233072602; Fam AG, 2002, J RHEUMATOL, V29, P1350; Fam AG, 1996, J RHEUMATOL, V23, P684; FANELLI GM, 1973, J CLIN INVEST, V52, P1946, DOI 10.1172/JCI107379; FERRIS TF, 1968, AM J MED, V44, P359, DOI 10.1016/0002-9343(68)90107-1; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; FOX IH, 1987, NEW ENGL J MED, V317, P111, DOI 10.1056/NEJM198707093170209; FOX IH, 1985, J LAB CLIN MED, V106, P101; FOX IH, 1972, METABOLISM, V21, P713, DOI 10.1016/0026-0495(72)90120-5; FRANSEN R, 1995, J AM SOC NEPHROL, V6, P1491; Freedman DS, 2002, JAMA-J AM MED ASSOC, V288, P1758, DOI 10.1001/jama.288.14.1758; Fruehwald-Schultes B, 1999, METABOLISM, V48, P677, DOI 10.1016/S0026-0495(99)90163-4; Fujiwara K, 2002, LAB INVEST, V82, P1297, DOI 10.1097/01.LAB.0000029206.27080.D2; GALVAN AQ, 1995, AM J PHYSIOL-ENDOC M, V268, pE1, DOI 10.1152/ajpendo.1995.268.1.E1; GARCIA ML, 1980, BIOCHIM BIOPHYS ACTA, V600, P922, DOI 10.1016/0005-2736(80)90494-0; GAUDRY M, 1995, BLOOD, V86, P3567, DOI 10.1182/blood.V86.9.3567.bloodjournal8693567; GERSHON SL, 1974, J LAB CLIN MED, V84, P179; Getting SJ, 1997, J PHARMACOL EXP THER, V283, P123; GIBSON T, 1984, BRIT J RHEUMATOL, V23, P203; GIBSON T, 1983, ANN RHEUM DIS, V42, P123, DOI 10.1136/ard.42.2.123; GIEBISCH G, 2003, MED PHYSL, P790; GLYNN RJ, 1983, ARTHRITIS RHEUM-US, V26, P87, DOI 10.1002/art.1780260115; Griebsch A, 1974, Adv Exp Med Biol, V41, P443; Gross LS, 2004, AM J CLIN NUTR, V79, P774; GUGGINO SE, 1983, AM J PHYSIOL, V244, pF612, DOI 10.1152/ajprenal.1983.244.6.F612; GUGGINO SE, 1985, J CLIN INVEST, V76, P543, DOI 10.1172/JCI112004; GUPTA AK, 1991, ARCH INTERN MED, V151, P356, DOI 10.1001/archinte.151.2.356; Hansen JM, 1998, NEPHRON, V80, P450, DOI 10.1159/000045219; Haskard DO, 2002, ARTHRITIS RES THER, V4, pS91, DOI 10.1186/ar562; Hediger MA, 2002, NATURE, V417, P393, DOI 10.1038/417393a; HOCHBERG M, 2003, RHEUMATOLOGY; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI11638; Ichida K, 2003, KIDNEY INT, V63, P143, DOI 10.1046/j.1523-1755.2003.00710.x; Ichida K, 2004, J AM SOC NEPHROL, V15, P164, DOI 10.1097/01.ASN.0000105320.04395.D0; Jaramillo M, 2004, J BIOL CHEM, V279, P52797, DOI 10.1074/jbc.M403823200; JINNAI K, 1993, EUR NEUROL, V33, P204, DOI 10.1159/000116937; Johnson RJ, 2004, NEW ENGL J MED, V350, P1071, DOI 10.1056/NEJMp048015; Jutabha P, 2003, J BIOL CHEM, V278, P27930, DOI 10.1074/jbc.M303210200; KAHN AM, 1985, AM J PHYSIOL, V249, pF789, DOI 10.1152/ajprenal.1985.249.6.F789; KAHN AM, 1983, AM J PHYSIOL, V244, pF56, DOI 10.1152/ajprenal.1983.244.1.F56; KAHN AM, 1983, AM J PHYSIOL, V245, pF151, DOI 10.1152/ajprenal.1983.245.2.F151; KAHN AM, 1985, AM J PHYSIOL, V249, pF654, DOI 10.1152/ajprenal.1985.249.5.F654; Kasper D. L., 2004, HARRISONS PRINCIPLES; KLIPPEL JH, 2001, PRIMER RHEUMATIC DIS; Koopman WJ, 2001, ARTHRITIS ALLIED CON; Kramer HM, 2002, AM J KIDNEY DIS, V40, P37, DOI 10.1053/ajkd.2002.33911; Landis RC, 2002, ARTHRITIS RHEUM, V46, P3026, DOI 10.1002/art.10614; LEE J, 1995, AM J EPIDEMIOL, V142, P288, DOI 10.1093/oxfordjournals.aje.a117634; LIEBER CS, 1962, J CLIN INVEST, V41, P1863, DOI 10.1172/JCI104643; LIN HY, 1989, NEW ENGL J MED, V321, P287, DOI 10.1056/NEJM198908033210504; Lin KC, 2000, J RHEUMATOL, V27, P1501; Liote F, 1996, ARTHRITIS RHEUM, V39, P1192, DOI 10.1002/art.1780390718; Lipkowitz MS, 2001, J CLIN INVEST, V107, P1103, DOI 10.1172/JCI12471; Liu R, 2004, ARTHRITIS RHEUM, V50, P247, DOI 10.1002/art.11486; Liu R, 2001, J LEUKOCYTE BIOL, V70, P961; Liu R, 2000, ARTHRITIS RHEUM, V43, P1145, DOI 10.1002/1529-0131(200005)43:5<1145::AID-ANR25>3.0.CO;2-T; MANGANEL M, 1985, AM J PHYSIOL, V249, pF400, DOI 10.1152/ajprenal.1985.249.3.F400; Matsukawa A, 1998, LAB INVEST, V78, P973; Matsukawa A, 1998, LAB INVEST, V78, P559; MCCARTHY GM, 1991, ARTHRITIS RHEUM-US, V34, P1489; MCGILL NW, 1991, J RHEUMATOL, V18, P1042; MESSERLI FH, 1980, ANN INTERN MED, V93, P817, DOI 10.7326/0003-4819-93-6-817; MINEO I, 1987, NEW ENGL J MED, V317, P75, DOI 10.1056/NEJM198707093170203; MINTZ DH, 1961, NEW ENGL J MED, V265, P112, DOI 10.1056/NEJM196107202650302; Moriwaki Y, 2002, METABOLISM, V51, P893, DOI 10.1053/meta.2002.32801; Murakami Y, 2002, ARTHRITIS RHEUM, V46, P2504, DOI 10.1002/art.10468; Muscelli E, 1996, AM J HYPERTENS, V9, P746, DOI 10.1016/0895-7061(96)00098-2; Nishimura A, 1997, J LEUKOCYTE BIOL, V62, P444, DOI 10.1002/jlb.62.4.444; Oda M, 2002, MOL BIOL EVOL, V19, P640, DOI 10.1093/oxfordjournals.molbev.a004123; Oparil S, 2003, ANN INTERN MED, V139, P761, DOI 10.7326/0003-4819-139-9-200311040-00011; ORTIZBRAVO E, 1993, ARTHRITIS RHEUM-US, V36, P1274, DOI 10.1002/art.1780360912; PADOVA J, 1962, NEW ENGL J MED, V267, P530, DOI 10.1056/NEJM196209132671102; Pascual E, 1999, ANN INTERN MED, V131, P756, DOI 10.7326/0003-4819-131-10-199911160-00007; PREBIS JW, 1981, J PEDIATR-US, V98, P702, DOI 10.1016/S0022-3476(81)80828-1; PUIG JG, 1984, J CLIN INVEST, V74, P936, DOI 10.1172/JCI111512; RAIVIO KO, 1975, METABOLISM, V24, P861, DOI 10.1016/0026-0495(75)90133-X; Rathmann W, 1998, ANN EPIDEMIOL, V8, P250, DOI 10.1016/S1047-2797(97)00204-4; Reyes AJ, 2003, CARDIOVASC DRUG THER, V17, P397, DOI 10.1023/B:CARD.0000015855.02485.e3; Roch-Ramel F, 1999, NEWS PHYSIOL SCI, V14, P80; RochRamel F, 1996, AM J PHYSIOL-RENAL, V270, pF61, DOI 10.1152/ajprenal.1996.270.1.F61; ROCHRAMEL F, 1994, AM J PHYSIOL, V266, pF797, DOI 10.1152/ajprenal.1994.266.5.F797; RochRamel F, 1997, J PHARMACOL EXP THER, V280, P839; ROUBENOFF R, 1991, JAMA-J AM MED ASSOC, V266, P3004, DOI 10.1001/jama.266.21.3004; Rouleau P, 2003, CLIN IMMUNOL, V107, P46, DOI 10.1016/S1521-6616(02)00043-8; Ryckman C, 2003, ARTHRITIS RHEUM-US, V48, P2310, DOI 10.1002/art.11079; Schiltz C, 2002, ARTHRITIS RHEUM, V46, P1643, DOI 10.1002/art.10326; Schlesinger N, 2001, CURR OPIN RHEUMATOL, V13, P240, DOI 10.1097/00002281-200105000-00016; Shoji A, 2004, ARTHRIT RHEUM-ARTHR, V51, P321, DOI 10.1002/art.20405; SIMKIN PA, 1974, J APPL PHYSIOL, V36, P581, DOI 10.1152/jappl.1974.36.5.581; SIMMONDS HA, 1976, AM J PHYSIOL, V230, P1654, DOI 10.1152/ajplegacy.1976.230.6.1654; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STARZL TE, 1990, JAMA-J AM MED ASSOC, V264, P63, DOI 10.1001/jama.264.1.63; Steele TH, 1999, NEPHRON, V81, P45, DOI 10.1159/000046298; STEELE TH, 1969, J LAB CLIN MED, V74, P288; STEELE TH, 1969, AM J MED, V47, P564, DOI 10.1016/0002-9343(69)90187-9; STIRPE F, 1970, LANCET, V2, P1310; Sweet DH, 2003, AM J PHYSIOL-RENAL, V284, pF763, DOI 10.1152/ajprenal.00405.2002; Takahashi S, 2003, ANN RHEUM DIS, V62, P572, DOI 10.1136/ard.62.6.572; TERKELTAUB R, 1991, ARTHRITIS RHEUM, V34, P894, DOI 10.1002/art.1780340716; TERKELTAUB R, 1984, J CLIN INVEST, V73, P1719, DOI 10.1172/JCI111380; Terkeltaub R, 1998, ARTHRITIS RHEUM, V41, P900, DOI 10.1002/1529-0131(199805)41:5<900::AID-ART18>3.0.CO;2-K; TERKELTAUB RA, 1990, J IMMUNOL, V144, P2719; Terkeltaub RA, 2003, NEW ENGL J MED, V349, P1647, DOI 10.1056/NEJMcp030733; TERKELTAUB RA, 1991, J CLIN INVEST, V87, P20, DOI 10.1172/JCI114971; terMaaten JC, 1997, CLIN SCI, V92, P51; Tramontini NL, 2002, INFLAMMATION, V26, P311, DOI 10.1023/A:1021420903355; Van Aubel RAMH, 2005, AM J PHYSIOL-RENAL, V288, pF327, DOI 10.1152/ajprenal.00133.2004; Watanabe S, 2002, HYPERTENSION, V40, P355, DOI 10.1161/01.HYP.0000028589.66335.AA; Watson A R, 1984, Adv Exp Med Biol, V165 Pt A, P53; WEBSTER ME, 1972, IMMUNOL COMMUN, V1, P185, DOI 10.3109/08820137209022934; WEINMAN EJ, 1975, J CLIN INVEST, V55, P283, DOI 10.1172/JCI107931; WERNER D, 1991, AM J PHYSIOL, V261, pF265, DOI 10.1152/ajprenal.1991.261.2.F265; Willett WC, 2003, SCI AM, V288, P64, DOI 10.1038/scientificamerican0103-64; WOOLLISCROFT JO, 1986, AM J MED, V81, P472, DOI 10.1016/0002-9343(86)90302-5; WOOLLISCROFT JO, 1982, AM J MED, V72, P58, DOI 10.1016/0002-9343(82)90578-2; WU XW, 1989, P NATL ACAD SCI USA, V86, P9412, DOI 10.1073/pnas.86.23.9412; WU XW, 1992, J MOL EVOL, V34, P78, DOI 10.1007/BF00163854; WYNGAARDEN JB, 1976, GOUT HYPERURICEMIA; Yagnik DR, 2000, ARTHRITIS RHEUM, V43, P1779, DOI 10.1002/1529-0131(200008)43:8<1779::AID-ANR14>3.0.CO;2-2; YAMANAKA H, 1992, METABOLISM, V41, P364, DOI 10.1016/0026-0495(92)90069-M; YAMASHITA S, 1986, INT J OBESITY, V10, P255; Yu KH, 2003, J RHEUMATOL, V30, P1868; YU TF, 1959, J CLIN INVEST, V38, P1298, DOI 10.1172/JCI103905; Zandi-Nejad K, 2004, J AM SOC NEPHROL, V15, p89A; Zollner N, 1974, Adv Exp Med Biol, V41, P435	165	652	698	7	177	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 4	2005	143	7					499	516		10.7326/0003-4819-143-7-200510040-00009	http://dx.doi.org/10.7326/0003-4819-143-7-200510040-00009			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970FM	16204163				2022-12-28	WOS:000232290600005
J	Cohen, D				Cohen, D			Achieving food security in vulnerable populations	BRITISH MEDICAL JOURNAL			English	Editorial Material									BMJ, London WC1H 9JR, England		Cohen, D (corresponding author), BMJ, London WC1H 9JR, England.	dcohen@bmj.com						Akabwai DMO, 1992, EXTENSION LIVESTOCK; FAO, 2004, STAT FOOD INS WORLD; *FEWS NET, 2005, KEN MONTHL FOOD SEC; Odigwe C, 2005, BRIT MED J, V331, P255; United States Agency for International Development, 1992, POL DET DEF FOOD SEC; *US AG INT DEV, 1995, FOOD AID FOOD SEC PO; 1999, ECONOMIST       0624; 2005, ECONOMIST       0818	8	4	4	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 1	2005	331	7519					775	777		10.1136/bmj.331.7519.775	http://dx.doi.org/10.1136/bmj.331.7519.775			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971XB	16195300	Bronze, Green Published			2022-12-28	WOS:000232417100030
J	Guan, Y; Chen, HL				Guan, Y; Chen, HL			Resistance to anti-influenza agents	LANCET			English	Editorial Material							INFLUENZA		Shantou Univ Med Coll, Joint Influenza Res Ctr SUMC & HKU, Shantou 515031, Guangdong, Peoples R China; Univ Hong Kong, Dept Microbiol, Pokfulam, Hong Kong, Peoples R China; Univ Hong Kong, State Key Lab Emerging Infect Dis, Pokfulam, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Guan, Y (corresponding author), Shantou Univ Med Coll, Joint Influenza Res Ctr SUMC & HKU, Shantou 515031, Guangdong, Peoples R China.	yguan@hkucc.hku.hk	Chen, Honglin/C-4224-2009	Chen, Honglin/0000-0001-5108-8338; Guan, Yi/0000-0001-6057-9243				Bright RA, 2005, LANCET, V366, P1175, DOI 10.1016/S0140-6736(05)67338-2; Cyranoski D, 2005, NATURE, V435, P1009, DOI 10.1038/4351009a; Gubareva LV, 2000, LANCET, V355, P827, DOI 10.1016/S0140-6736(99)11433-8; Hillman MR, 2002, VACCINE, V20, P3068, DOI 10.1016/S0264-410X(02)00254-2; Jefferson T, 2005, LANCET, V366, P1165, DOI 10.1016/S0140-6736(05)67339-4; *NEUR INH SUSC NET, 2005, WKLY EPIDEMIOL REC, V80, P156; Schmidt AC, 2004, DRUGS, V64, P2031, DOI 10.2165/00003495-200464180-00003; Suzuki Hiroshi, 2003, Journal of Infection and Chemotherapy, V9, P195	8	15	18	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	2005	366	9492					1139	1140		10.1016/S0140-6736(05)67340-0	http://dx.doi.org/10.1016/S0140-6736(05)67340-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970LK	16198748	Green Published, Bronze			2022-12-28	WOS:000232311300004
J	Melton, L				Melton, L			Imaging: The big picture	NATURE			English	Article									Novartis Fdn, London, England	Novartis	Melton, L (corresponding author), Novartis Fdn, London, England.								0	17	19	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 29	2005	437	7059					775	+		10.1038/437775a	http://dx.doi.org/10.1038/437775a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193058	Bronze			2022-12-28	WOS:000232157900061
J	Chapman, RS; He, XZ; Blair, AE; Lan, Q				Chapman, RS; He, XZ; Blair, AE; Lan, Q			Improvement in household stoves and risk of chronic obstructive pulmonary disease in Xuanwei, China: retrospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INDOOR AIR-POLLUTION; LUNG-CANCER; DEVELOPING-COUNTRIES; CHRONIC-BRONCHITIS; GLOBAL BURDEN; EXPOSURE; MORTALITY; SMOKING; COMBUSTION; WEI	Objective To test whether improvement in household coal stoves affected the incidence of chronic obstructive pulmonary disease (COPD) in Xuanwei County, China. Design Retrospective cohort study (follow-up 1976-92) comparing incidence of COPD between groups with and without chimneys. Participants 20 453 people born into homes with unvented coal stoves; 16 606 (81.2%) subsequently changed to stoves with chimneys. Intervention Installation of a chimney in households in which unvented stoves had been used previously. Results Installation of a chimney was associated with distinct reduction in the incidence of COPD. Compared with people who did not have chimneys, the Cox-modelled risk ratio (relative risk) was 0.58 (95% confidence interval 0.49 to 0.70, P < 0.001) in men and 0.75 (0.62 to 0.92, P = 0.005) in women. Modelled risk ratios were robust to different Cox model specifications. Relative risks decreased with time since stove improvement. In both sexes, the reduction in risk became unequivocal about 10 years after stove improvement. Conclusions In Xuanwei, incidence of COPD decreased markedly after household coal stoves were improved.	NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, Bethesda, MD 20892 USA; Chulalongkorn Univ, Coll Publ Hlth, Bangkok 10330, Thailand; Chinese Acad Prevent Med, Inst Environm Hlth & Engn, Beijing 100050, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Chulalongkorn University; Chinese Center for Disease Control & Prevention; National Institute of Environmental Health, Chinese Center for Disease Control & Prevention	Lan, Q (corresponding author), NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, MSC 7240,6120 Execut Blvd,EPS 8111, Bethesda, MD 20892 USA.	qingl@mail.nih.gov			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Albalak R, 1999, THORAX, V54, P1004, DOI 10.1136/thx.54.11.1004; Bruce N, 2000, B WORLD HEALTH ORGAN, V78, P1078; Dennis RJ, 1996, CHEST, V109, P115, DOI 10.1378/chest.109.1.115; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DOSSING M, 1994, RESP MED, V88, P519, DOI 10.1016/S0954-6111(05)80334-8; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Ezzati M, 2003, LANCET, V362, P271, DOI 10.1016/S0140-6736(03)13968-2; Ezzati M, 2002, ENVIRON HEALTH PERSP, V110, P1057, DOI 10.1289/ehp.021101057; Gupta BN, 1997, ENERGY ENV REV, V13, P61; Kishi K, 2002, EUR RESPIR J, V19, P1093, DOI 10.1183/09031936.02.00264202; Lam TH, 2002, ANN EPIDEMIOL, V12, P316, DOI 10.1016/S1047-2797(01)00258-7; Lan Q, 2002, J NATL CANCER I, V94, P826, DOI 10.1093/jnci/94.11.826; Malik S K, 1985, Indian J Chest Dis Allied Sci, V27, P171; MUMFORD JL, 1989, ENVIRON INT, V15, P315, DOI 10.1016/0160-4120(89)90044-5; MUMFORD JL, 1987, SCIENCE, V235, P217, DOI 10.1126/science.3798109; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; PANDEY MR, 1984, THORAX, V39, P337, DOI 10.1136/thx.39.5.337; PerezPadilla R, 1996, AM J RESP CRIT CARE, V154, P701, DOI 10.1164/ajrccm.154.3.8810608; Smith K.R., 2004, COMP QUANTIFICATION, V18, P1435; *US DEP HHS, 1990, DHHS PUBL CDC; WHO, 2002, RED RISKS PROM HLTH; Yang GH, 2001, TOB CONTROL, V10, P170, DOI 10.1136/tc.10.2.170; Zhou Xiaotie, 1995, Zhonghua Yufang Yixue Zazhi, V29, P38	24	122	130	2	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	2005	331	7524					1050	1052A		10.1136/bmj.38628.676088.55	http://dx.doi.org/10.1136/bmj.38628.676088.55			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983DL	16234255	Green Published, Bronze			2022-12-28	WOS:000233211200018
J	Rhen, T; Cidlowski, JA				Rhen, T; Cidlowski, JA			Antiinflammatory action of glucocorticoids - New mechanisms for old drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FACTOR-KAPPA-B; LIGAND-BINDING DOMAIN; MESSENGER-RNA; RECEPTOR-BETA; CORTICOSTEROID RESISTANCE; RHEUMATOID-ARTHRITIS; MEDIATED INHIBITION; ACTIVATOR PROTEIN-1; GENE-EXPRESSION; UNITED-STATES		NIEHS, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA; Univ N Dakota, Dept Biol, Grand Forks, ND 58202 USA; NIH, US Dept HHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Dakota Grand Forks; National Institutes of Health (NIH) - USA	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	cidlows1@niehs.rlh.gov	Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090079, Z01ES090079, ZIAES090057, Z01ES090057] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allen David B, 2003, J Allergy Clin Immunol, V112, pS1, DOI 10.1016/S0091-6749(03)01859-1; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Antonicelli F, 2001, EUR J BIOCHEM, V268, P62, DOI 10.1046/j.1432-1327.2001.01840.x; Barnes PJ, 1998, EUR RESPIR J, V12, P221, DOI 10.1183/09031936.98.12010221; Beer H D, 2000, Vitam Horm, V59, P217, DOI 10.1016/S0083-6729(00)59008-6; Bladh LG, 2005, MOL PHARMACOL, V67, P815, DOI 10.1124/mol.104.005801; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; Breuner CW, 2002, J ENDOCRINOL, V175, P99, DOI 10.1677/joe.0.1750099; Brieva J, 2001, J APPL PHYSIOL, V90, P665, DOI 10.1152/jappl.2001.90.2.665; Brieva JL, 2000, AM J RESP CRIT CARE, V161, P293, DOI 10.1164/ajrccm.161.1.9905068; Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749-6632.2002.tb04204.x; Cato A.C., 2002, SCI STKE, V2002, pre9, DOI [10.1126/stke.2002.138.re9, DOI 10.1126/STKE.2002.138.RE9]; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chikanza IC, 2002, ANN NY ACAD SCI, V966, P39, DOI 10.1111/j.1749-6632.2002.tb04200.x; Chrysis D, 2005, ENDOCRINOLOGY, V146, P1391, DOI 10.1210/en.2004-1152; Coghlan MJ, 2003, CURR TOP MED CHEM, V3, P1617, DOI 10.2174/1568026033451718; Cooper GS, 2003, AUTOIMMUN REV, V2, P119, DOI 10.1016/S1568-9972(03)00006-5; Croxtall JD, 2002, BRIT J PHARMACOL, V135, P511, DOI 10.1038/sj.bjp.0704474; Cutroneo KR, 2003, J CELL BIOCHEM, V90, P1, DOI 10.1002/jcb.10599; DALLMAN MF, 1993, FRONT NEUROENDOCRIN, V14, P303, DOI 10.1006/frne.1993.1010; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; DELBENDE C, 1992, BRIT J PSYCHIAT, V160, P24, DOI 10.1192/S0007125000296657; Dostert A, 2004, CURR PHARM DESIGN, V10, P2807; Einstein M, 2004, J STEROID BIOCHEM, V92, P345, DOI 10.1016/j.jsbmb.2004.10.009; ELLMAN M, 1992, DISINTEGRATION OF THE SOVIET ECONOMIC SYSTEM, P1; Gagliardo R, 2001, RESPIR RES, V2, P1, DOI 10.1186/rr31; Garside H, 2004, J BIOL CHEM, V279, P50050, DOI 10.1074/jbc.M407309200; Gille J, 2001, J INVEST DERMATOL, V117, P1581, DOI 10.1046/j.0022-202x.2001.01573.x; Hafezi-Moghadam A, 2002, NAT MED, V8, P473, DOI 10.1038/nm0502-473; Hebbar PB, 2003, CHROMOSOMA, V111, P495, DOI 10.1007/s00412-003-0232-x; Hirabayashi T, 2004, BIOL PHARM BULL, V27, P1168, DOI 10.1248/bpb.27.1168; Holmstrom S, 2003, P NATL ACAD SCI USA, V100, P15758, DOI 10.1073/pnas.2136933100; Ismaili N, 2004, ANN NY ACAD SCI, V1024, P86, DOI 10.1196/annals.1321.007; Iwamoto J, 2004, CURR PHARM DESIGN, V10, P2557, DOI 10.2174/1381612043383782; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Kapcala LP, 1995, ANN NY ACAD SCI, V771, P419, DOI 10.1111/j.1749-6632.1995.tb44699.x; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Kauppi B, 2003, J BIOL CHEM, V278, P22748, DOI 10.1074/jbc.M212711200; Kemp JP, 2003, CLIN THER, V25, pC15, DOI 10.1016/S0149-2918(03)80303-X; Kim SW, 2001, J BIOL CHEM, V276, P15712, DOI 10.1074/jbc.M009905200; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Leal-Cerro A, 2001, Pituitary, V4, P111, DOI 10.1023/A:1012903330944; Li LB, 2004, J ALLERGY CLIN IMMUN, V114, P1059, DOI 10.1016/j.jaci.2004.08.005; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; Lionakis MS, 2003, LANCET, V362, P1828, DOI 10.1016/S0140-6736(03)14904-5; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; Lu NZ, 2005, MOL CELL, V18, P331, DOI 10.1016/j.molcel.2005.03.025; Lu NZ, 2004, ANN NY ACAD SCI, V1024, P102, DOI 10.1196/annals.1321.008; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; Meduri GU, 2004, ANN NY ACAD SCI, V1024, P24, DOI 10.1196/annals.1321.004; Miller DB, 2002, METABOLISM, V51, P5, DOI 10.1053/meta.2002.33184; Mitch W E, 2000, Trans Am Clin Climatol Assoc, V111, P258; Mizuno H, 1997, BRAIN RES, V746, P256, DOI 10.1016/S0006-8993(96)01259-0; Mulla A, 2005, J CLIN ENDOCR METAB, V90, P557, DOI 10.1210/jc.2004-1230; Nagaich AK, 2004, ANN NY ACAD SCI, V1024, P213, DOI 10.1196/annals.1321.002; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Nuutinen P, 2003, BRIT J DERMATOL, V148, P39, DOI 10.1046/j.1365-2133.2003.05018.x; Ortiz PA, 2003, AM J PHYSIOL-REG I, V284, pR628, DOI 10.1152/ajpregu.00401.2002; Pedersen KB, 2003, BIOCHEMISTRY-US, V42, P10978, DOI 10.1021/bi034651u; Perretti M, 2000, MICROCIRCULATION, V7, P147, DOI 10.1038/sj.mn.7300108; Pitzalis C, 2002, ANN NY ACAD SCI, V966, P108, DOI 10.1111/j.1749-6632.2002.tb04208.x; Pujols L, 2001, AM J RESP CELL MOL, V24, P49, DOI 10.1165/ajrcmb.24.1.4024; Rhen T, 2004, YEN JAFFES REPROD EN, P155; RHEN T, 2004, ENCY ENDOCRINE DISEA, V3, P391; Richardson DW, 2003, INFLAMM RES, V52, P39, DOI 10.1007/s000110300012; Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523; Rivest S, 2001, PSYCHONEUROENDOCRINO, V26, P761, DOI 10.1016/S0306-4530(01)00064-6; Roviezzo F, 2002, J PHYSIOL PHARMACOL, V53, P541; Saklatvala J, 2003, BIOCHEM SOC SYMP, V70, P95, DOI 10.1042/bss0700095; SATO S, 1986, JPN J PHARMACOL, V42, P71, DOI 10.1254/jjp.42.71; Schacke H, 2004, P NATL ACAD SCI USA, V101, P227, DOI 10.1073/pnas.0300372101; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; Seidenberg AB, 2004, PHARMACOL RES, V50, P151, DOI 10.1016/j.phrs.2003.12.017; Solito E, 1998, CYTOKINE, V10, P514, DOI 10.1006/cyto.1997.0325; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; Toh ML, 2004, ARTHRITIS RHEUM-US, V50, P3118, DOI 10.1002/art.20580; Torrego A, 2004, AM J RESP CRIT CARE, V170, P420, DOI 10.1164/rccm.200308-1143OC; Trence DL, 2003, PRIMARY CARE, V30, P593, DOI 10.1016/S0095-4543(03)00038-1; Tsitoura DC, 2004, J CLIN INVEST, V113, P619, DOI 10.1172/JCI200418975; Ullian ME, 1999, CARDIOVASC RES, V41, P55, DOI 10.1016/S0008-6363(98)00230-2; Umland SP, 2002, PULM PHARMACOL THER, V15, P35, DOI 10.1006/pupt.2001.0312; van der Eerden BCJ, 2003, ENDOCR REV, V24, P782, DOI 10.1210/er.2002-0033; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Wang XJ, 2002, MOL ENDOCRINOL, V16, P1987, DOI 10.1210/me.2001-0287; Webster JC, 2001, P NATL ACAD SCI USA, V98, P6865, DOI 10.1073/pnas.121455098; Webster JI, 2002, ANNU REV IMMUNOL, V20, P125, DOI 10.1146/annurev.immunol.20.082401.104914; Yang Shumei, 2004, Current Vascular Pharmacology, V2, P1, DOI 10.2174/1570161043476483; Yudt MR, 2001, MOL ENDOCRINOL, V15, P1093, DOI 10.1210/me.15.7.1093; Zhang T, 2004, GENOME RES, V14, P79, DOI 10.1101/gr.1225204	92	1988	2104	5	194	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 20	2005	353	16					1711	1723		10.1056/NEJMra050541	http://dx.doi.org/10.1056/NEJMra050541			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975IC	16236742				2022-12-28	WOS:000232653200011
J	Higgs, ZCJ; Macafee, DAL; Braithwaite, BD; Maxwell-Armstrong, CA				Higgs, ZCJ; Macafee, DAL; Braithwaite, BD; Maxwell-Armstrong, CA			The Seldinger technique: 50 years on	LANCET			English	Editorial Material									Queens Med Ctr, Div Gastrointestinal Surg, Nottingham NG7 2UH, England; Queens Med Ctr, Div Vasc Surg, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Macafee, DAL (corresponding author), Queens Med Ctr, Div Gastrointestinal Surg, Nottingham NG7 2UH, England.	david.macafee@nottingham.ac.uk	Braithwaite, Bruce/AAG-3970-2019					DOTTER CT, 1964, CIRCULATION, V30, P654, DOI 10.1161/01.CIR.30.5.654; Farinas PL, 1941, AM J ROENTGENOL RADI, V46, P641; FORSMANN W, 1929, KLIN WOCHENSCHR, V45, P2085; Greitz T, 1999, AM J NEURORADIOL, V20, P1180; GRUENTZIG AR, 1981, SEMIN ROENTGENOL, V16, P152, DOI 10.1016/0037-198X(81)90049-3; LUFT FC, 1994, ANN INTERN MED, V120, P974, DOI 10.7326/0003-4819-120-11-199406010-00023; OMURCHU B, 2002, PERCUTANEOUS TRANSLU; Pierce EC, 1951, SURG GYNECOL OBSTET, V93, P56; RADNER S, 1947, ACTA RADIOL, V28, P838; SELDINGER SI, 1953, ACTA RADIOL, V39, P368, DOI 10.3109/00016925309136722	10	84	92	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 15	2005	366	9494					1407	1409		10.1016/S0140-6736(05)66878-X	http://dx.doi.org/10.1016/S0140-6736(05)66878-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	973ZW	16226619				2022-12-28	WOS:000232562100033
J	Henderson, GS				Henderson, GS			Hurricane Katrina - Triaging tragedy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ochsner Clin Fdn, New Orleans, LA 70121 USA	Ochsner Health System	Henderson, GS (corresponding author), Ochsner Clin Fdn, New Orleans, LA 70121 USA.								0	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1551	1551		10.1056/NEJMp058252	http://dx.doi.org/10.1056/NEJMp058252			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221777				2022-12-28	WOS:000232486000008
J	Mygind, PH; Fischer, RL; Schnorr, KM; Hansen, MT; Sonksen, CP; Ludvigsen, S; Raventos, D; Buskov, S; Christensen, B; De Maria, L; Taboureau, O; Yaver, D; Elvig-Jorgensen, SG; Sorensen, MV; Christensen, BE; Kjaerulff, S; Frimodt-Moller, N; Lehrer, RI; Zasloff, M; Kristensen, HH				Mygind, PH; Fischer, RL; Schnorr, KM; Hansen, MT; Sonksen, CP; Ludvigsen, S; Raventos, D; Buskov, S; Christensen, B; De Maria, L; Taboureau, O; Yaver, D; Elvig-Jorgensen, SG; Sorensen, MV; Christensen, BE; Kjaerulff, S; Frimodt-Moller, N; Lehrer, RI; Zasloff, M; Kristensen, HH			Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus	NATURE			English	Article							ANTIMICROBIAL PEPTIDES; ANTIBACTERIAL ACTIVITY; DIRECT INACTIVATION; MECHANISM; DEFENSIN; PROTEIN; INNATE; CATHELICIDINS; DIVERGENCE; PENICILLIN	Animals and higher plants express endogenous peptide antibiotics called defensins. These small cysteine-rich peptides are active against bacteria, fungi and viruses. Here we describe plectasin - the first defensin to be isolated from a fungus, the saprophytic ascomycete Pseudoplectania nigrella. Plectasin has primary, secondary and tertiary structures that closely resemble those of defensins found in spiders, scorpions, dragonflies and mussels. Recombinant plectasin was produced at a very high, and commercially viable, yield and purity. In vitro, the recombinant peptide was especially active against Streptococcus pneumoniae, including strains resistant to conventional antibiotics. Plectasin showed extremely low toxicity in mice, and cured them of experimental peritonitis and pneumonia caused by S. pneumoniae as efficaciously as vancomycin and penicillin. These findings identify fungi as a novel source of antimicrobial defensins, and show the therapeutic potential of plectasin. They also suggest that the defensins of insects, molluscs and fungi arose from a common ancestral gene.	Novozymes AS, DK-2880 Bagsvaerd, Denmark; Statens Serum Inst, Natl Ctr Antimicrobials & Infect Control, DK-2300 Copenhagen, Denmark; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark; Novozymes Inc, Davis, CA 95616 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Georgetown Univ, Med Ctr, Dept Surg, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pediat, Washington, DC 20007 USA	Novozymes; Statens Serum Institut; Novo Nordisk; Novozymes; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Georgetown University; Georgetown University	Kristensen, HH (corresponding author), Novozymes AS, DK-2880 Bagsvaerd, Denmark.	hahk@novozymes.com	Frimodt-Moller, Niels/G-1187-2018; De Maria, Leonardo/AAH-1026-2021	Frimodt-Moller, Niels/0000-0003-1966-8302; De Maria, Leonardo/0000-0002-8061-4242; Schnorr, Kirk Mtthew/0000-0002-2694-6772; LUDVIGSEN, SVEND/0000-0002-5671-4542; Yaver, Debbie/0000-0003-4150-6756				[Anonymous], 1997, MMWR MORB MORT WKLY, V46, P1; Bayles KW, 2000, TRENDS MICROBIOL, V8, P274, DOI 10.1016/S0966-842X(00)01762-5; Becker F, 2004, J MICROBIOL METH, V57, P123, DOI 10.1016/j.mimet.2003.12.002; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Boman HG, 2000, IMMUNOL REV, V173, P5, DOI 10.1034/j.1600-065X.2000.917301.x; BULET P, 1992, EUR J BIOCHEM, V209, P977, DOI 10.1111/j.1432-1033.1992.tb17371.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clinical and Laboratory Standards Institute, M7A6 CLIN LAB STAND; Cole AM, 2003, EXPERT OPIN THER TAR, V7, P329, DOI 10.1517/eott.7.3.329.22436; DAHER KA, 1986, J VIROL, V60, P1068, DOI 10.1128/JVI.60.3.1068-1074.1986; del Castillo FJ, 2001, J BACTERIOL, V183, P2137, DOI 10.1128/JB.183.6.2137-2140.2001; DeLano W.L, PYMOL MOL GRAPHICS S; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; Erlendsdottir H, 2001, ANTIMICROB AGENTS CH, V45, P1078, DOI 10.1128/AAC.45.4.1078-1085.2001; Fleming A, 1929, BRIT J EXP PATHOL, V10, P226; Frimodt-Moller N., 1999, HDB ANIMAL MODELS IN, P127, DOI [10.1016/B978-012775390-4/50153-6, DOI 10.1016/B978-012775390-4/50153-6]; Froy O, 2004, J PEPT SCI, V10, P714, DOI 10.1002/psc.578; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Gennaro R, 2002, CURR PHARM DESIGN, V8, P763, DOI 10.2174/1381612023395394; Hjort C. M., 2003, Genetically engineered food: methods and detection, P86; KJAER M, 1994, METHODS ENZYMOL, V239, P288; Klugman KP, 2002, EUR RESPIR J, V20, p3S, DOI 10.1183/09031936.02.00400402; Kragol G, 2001, BIOCHEMISTRY-US, V40, P3016, DOI 10.1021/bi002656a; Landon C, 1997, PROTEIN SCI, V6, P1878, DOI 10.1002/pro.5560060908; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976; LEHRER RI, 1985, J VIROL, V54, P467, DOI 10.1128/JVI.54.2.467-472.1985; Lehrer RI, 2002, CURR OPIN HEMATOL, V9, P18, DOI 10.1097/00062752-200201000-00004; Ludvigsen S, 2001, BIOCHEMISTRY-US, V40, P9082, DOI 10.1021/bi010433u; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; Nakajima Y, 2003, BBA-GEN SUBJECTS, V1624, P125, DOI 10.1016/j.bbagen.2003.10.004; Park CB, 1998, BIOCHEM BIOPH RES CO, V244, P253, DOI 10.1006/bbrc.1998.8159; Schnorr K.M., 2003, International patent application, Patent No. [2003044049, W02003044049 -A1]; SELSTED ME, 1985, INFECT IMMUN, V49, P202, DOI 10.1128/IAI.49.1.202-206.1985; SELSTED ME, 1984, INFECT IMMUN, V45, P150, DOI 10.1128/IAI.45.1.150-154.1984; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Steinberg D A, 1997, Methods Mol Biol, V78, P169; Tossi A, 2000, BIOPOLYMERS, V55, P4; Volkoff AN, 2003, GENE, V319, P43, DOI 10.1016/S0378-1119(03)00789-3; Williams DH, 1999, ANGEW CHEM INT EDIT, V38, P1173, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1172::AID-ANIE1172>3.0.CO;2-C; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yang L, 2000, BIOPHYS J, V79, P2002, DOI 10.1016/S0006-3495(00)76448-4; Yang YS, 2000, BIOCHEMISTRY-US, V39, P14436, DOI 10.1021/bi0011835; Yoder WT, 2004, ADV FUNGAL BIOTECHNO, P201; Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	46	470	519	7	119	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	2005	437	7061					975	980		10.1038/nature04051	http://dx.doi.org/10.1038/nature04051			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16222292				2022-12-28	WOS:000232496100035
J	Hattersley, AT; McCarthy, MI				Hattersley, AT; McCarthy, MI			Genetic Epidemiology 5 - What makes a good genetic association study?	LANCET			English	Article							COMPLEMENT FACTOR-H; SINGLE-NUCLEOTIDE POLYMORPHISMS; NUCLEAR FACTOR-4-ALPHA GENE; HAPLOTYPE RECONSTRUCTION; STATISTICAL SIGNIFICANCE; GENOTYPING ERRORS; LINKAGE DISEQUILIBRIUM; ALZHEIMERS-DISEASE; DIABETES-MELLITUS; UPSTREAM PROMOTER	Genetic association studies are central to efforts to identify and characterise genomic variants underlying susceptibility to multifactorial disease. However, obtaining robust replication of initial association findings has proved difficult. Much of this inconsistency can be attributed to inadequacies in study design, implementation, and interpretation-inadequately powered sample groups are a major concern. Several additional factors affect the quality of any given association study, with appropriate sample-recruitment strategy, logical variant selection, minimum genotyping error, relevant data analysis, and valid interpretation all essential to generation of robust findings. Replication has a vital role in showing that associations that are identified reflect interesting biological processes rather than methodological quirks. For an unbiased view of the evidence for and against any particular association, study quality, rather than significance value, needs to play the dominant part.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England; Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter, Devon, England; Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7LJ, England	University of Oxford; Wellcome Centre for Human Genetics; University of Exeter; University of Oxford	McCarthy, MI (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England.	mark.mccarthy@drl.ox.ac.uk	; McCarthy, Mark/M-3763-2015	Hattersley, Andrew/0000-0001-5620-473X; McCarthy, Mark/0000-0002-4393-0510	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altmuller J, 2001, AM J HUM GENET, V69, P936, DOI 10.1086/324069; Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; Bacanu SA, 2000, AM J HUM GENET, V66, P1933, DOI 10.1086/302929; Bennett ST, 1996, ANNU REV GENET, V30, P343, DOI 10.1146/annurev.genet.30.1.343; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Bogardus ST, 1999, JAMA-J AM MED ASSOC, V281, P1919, DOI 10.1001/jama.281.20.1919; Boj SF, 2001, P NATL ACAD SCI USA, V98, P14481, DOI 10.1073/pnas.241349398; CAMPBELL MJ, 1995, BRIT MED J, V311, P1145, DOI 10.1136/bmj.311.7013.1145; Cardon LR, 2003, LANCET, V361, P598, DOI 10.1016/S0140-6736(03)12520-2; Carlson CS, 2004, NATURE, V429, P446, DOI 10.1038/nature02623; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Chistiakov DA, 2003, J MOL ENDOCRINOL, V31, P21, DOI 10.1677/jme.0.0310021; CLARK AG, 1990, MOL BIOL EVOL, V7, P111; Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8; Cordell HJ, 2005, LANCET, V366, P1121, DOI 10.1016/S0140-6736(05)67424-7; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CURTIS D, 1995, AM J HUM GENET, V56, P811; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Engel LS, 2002, AM J EPIDEMIOL, V156, P95, DOI 10.1093/aje/kwf018; Epstein MP, 2003, AM J HUM GENET, V73, P1316, DOI 10.1086/380204; Ewen KR, 2000, AM J HUM GENET, V67, P727, DOI 10.1086/303048; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Fingerlin TE, 2004, AM J HUM GENET, V74, P432, DOI 10.1086/381652; Frayling TM, 2003, DIABETES, V52, P1857, DOI 10.2337/diabetes.52.7.1857; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gloyn AL, 2003, DIABETES, V52, P568, DOI 10.2337/diabetes.52.2.568; Gordon D, 2002, HUM HERED, V54, P22, DOI 10.1159/000066696; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; HOPPER JL, IN PRESS LANCET; Hudson TJ, 2003, NAT GENET, V33, P439, DOI 10.1038/ng0403-439; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P281, DOI 10.1001/jama.279.4.281; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Jellema A, 2003, DIABETOLOGIA, V46, P990, DOI 10.1007/s00125-003-1126-4; Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233; Kang SJ, 2004, GENET EPIDEMIOL, V26, P132, DOI 10.1002/gepi.10301; Keavney B, 2000, LANCET, V355, P434; Kirk KM, 2002, EUR J HUM GENET, V10, P616, DOI 10.1038/sj.ejhg.5200855; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Knapp M, 2004, AM J HUM GENET, V74, P589, DOI 10.1086/382287; Knight JC, 2003, NAT GENET, V33, P469, DOI 10.1038/ng1124; Kraft P, 2004, AM J HUM GENET, V74, P582, DOI 10.1086/382051; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Little J, 2002, AM J EPIDEMIOL, V156, P300, DOI 10.1093/oxfordjournals.aje.a000179; Lo HS, 2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; Love-Gregory LD, 2004, DIABETES, V53, P1134, DOI 10.2337/diabetes.53.4.1134; LYKKEN DT, 1968, PSYCHOL BULL, V70, P151, DOI 10.1037/h0026141; Mann V, 2001, J CLIN INVEST, V107, P899, DOI 10.1172/JCI10347; Mann V, 2003, BONE, V32, P711, DOI 10.1016/S8756-3282(03)00087-5; Marchini J, 2004, NAT GENET, V36, P512, DOI 10.1038/ng1337; Marron MP, 1997, HUM MOL GENET, V6, P1275, DOI 10.1093/hmg/6.8.1275; McCarthy MI, 2004, HUM MOL GENET, V13, pR33, DOI 10.1093/hmg/ddh057; McCarthy MI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-119; Mein CA, 2000, GENOME RES, V10, P330, DOI 10.1101/gr.10.3.330; Mitchell AA, 2003, AM J HUM GENET, V72, P598, DOI 10.1086/368203; Niu TH, 2002, AM J HUM GENET, V70, P157, DOI 10.1086/338446; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; Oliphant A, 2002, BIOTECHNIQUES, P56; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; Page GP, 2003, AM J HUM GENET, V73, P711, DOI 10.1086/378900; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Redden DT, 2003, J NUTR, V133, P3323, DOI 10.1093/jn/133.11.3323; Reich DE, 2001, TRENDS GENET, V17, P502, DOI 10.1016/S0168-9525(01)02410-6; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Rubinsztein DC, 1999, DEMENT GERIATR COGN, V10, P199, DOI 10.1159/000017120; Schaid DJ, 2002, AM J HUM GENET, V71, P992, DOI 10.1086/342666; Schaid DJ, 1996, GENET EPIDEMIOL, V13, P423, DOI 10.1002/(SICI)1098-2272(1996)13:5<423::AID-GEPI1>3.0.CO;2-3; Silander K, 2004, DIABETES, V53, P1141, DOI 10.2337/diabetes.53.4.1141; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Tabor HK, 2002, NAT REV GENET, V3, P391, DOI 10.1038/nrg796; Teng J, 1999, GENOME RES, V9, P234; Thomas H, 2001, HUM MOL GENET, V10, P2089, DOI 10.1093/hmg/10.19.2089; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075; Weedon MN, 2003, AM J HUM GENET, V73, P1208, DOI 10.1086/379285; Weinberg CR, 1999, AM J HUM GENET, V65, P229, DOI 10.1086/302466; Weiss KM, 2002, TRENDS GENET, V18, P19, DOI 10.1016/S0168-9525(01)02550-1; Wright FA, 2001, GENOME BIOL, V2; Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426; Zondervan KT, 2004, NAT REV GENET, V5, P89, DOI 10.1038/nrg1270	87	357	440	1	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 8	2005	366	9493					1315	1323		10.1016/S0140-6736(05)67531-9	http://dx.doi.org/10.1016/S0140-6736(05)67531-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971ST	16214603				2022-12-28	WOS:000232405700031
J	Li, JS; Yang, HB; Peer, WA; Richter, G; Blakeslee, J; Bandyopadhyay, A; Titapiwantakun, B; Undurraga, S; Khodakovskaya, M; Richards, EL; Krizek, B; Murphy, AS; Gilroy, S; Gaxiola, R				Li, JS; Yang, HB; Peer, WA; Richter, G; Blakeslee, J; Bandyopadhyay, A; Titapiwantakun, B; Undurraga, S; Khodakovskaya, M; Richards, EL; Krizek, B; Murphy, AS; Gilroy, S; Gaxiola, R			Arabidopsis H+-PPase AVP1 regulates auxin-mediated organ development	SCIENCE			English	Article							THALIANA; ATPASE; EXPRESSION; EFFLUX; GENES; ROOT; ORGANIZATION; TRANSPORT; PROTEINS; GROWTH	The transport of auxin controls developmental events in plants. Here, we report that in addition to maintaining vacuolar pH, the H+-pyrophosphatase, AVP1, controls auxin transport and consequently auxin-dependent development. AVP1 overexpression results in increased cell division at the onset of organ formation, hyperplasia, and increased auxin transport. In contrast, avp1-1 null mutants have severely disrupted root and shoot development and reduced auxin transport. Changes in the expression of AVP1 affect the distribution and abundance of the P-adenosine triphosphatase and Pinformed 1 auxin efflux facilitator, two proteins implicated in auxin distribution. Thus, AVP1 facilitates the auxin fluxes that regulate organogenesis.	Univ Connecticut, Dept Plant Sci, Storrs, CT 06268 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA; Purdue Univ, Dept Hort, W Lafayette, IN 47907 USA; Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of Connecticut; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Gaxiola, R (corresponding author), Univ Connecticut, Dept Plant Sci, Storrs, CT 06268 USA.	roberto.gaxiola@uconn.edu	Peer, Wendy/H-2970-2013; Blakeslee, Joshua/G-4420-2011; Khodakovskaya, Mariya V/F-3681-2010	Peer, Wendy/0000-0003-0046-7324; Gilroy, Simon/0000-0001-9597-6839				Aida M, 1997, PLANT CELL, V9, P841, DOI 10.1105/tpc.9.6.841; Aloni R, 2003, PLANTA, V216, P841, DOI 10.1007/s00425-002-0937-8; Baxter IR, 2005, P NATL ACAD SCI USA, V102, P2649, DOI 10.1073/pnas.0406377102; Blakeslee JJ, 2005, CURR OPIN PLANT BIOL, V8, P494, DOI 10.1016/j.pbi.2005.07.014; Blilou I, 2005, NATURE, V433, P39, DOI 10.1038/nature03184; BOERJAN W, 1995, PLANT CELL, V7, P1405, DOI 10.1105/tpc.7.9.1405; Davies JM, 1997, TRENDS PLANT SCI, V2, P9, DOI 10.1016/S1360-1385(97)82732-X; DOLAN L, 1993, DEVELOPMENT, V119, P71; Frias I, 1996, PLANT CELL, V8, P1533; Friml J, 2002, CELL, V108, P661, DOI 10.1016/S0092-8674(02)00656-6; Geldner N, 2001, NATURE, V413, P425, DOI 10.1038/35096571; Li J. P. H., UNPUB; LOMAX TL, 1985, P NATL ACAD SCI USA, V82, P6541, DOI 10.1073/pnas.82.19.6541; Mitsuda N, 2004, PLANT CELL PHYSIOL, V45, P845, DOI 10.1093/pcp/pch101; Mitsuda N, 2001, FEBS LETT, V488, P29, DOI 10.1016/S0014-5793(00)02400-5; Paciorek T, 2005, NATURE, V435, P1251, DOI 10.1038/nature03633; Padmanaban S, 2004, PLANT PHYSIOL, V134, P1514, DOI 10.1104/pp.103.034025; Peer WA, 2004, PLANT CELL, V16, P1898, DOI 10.1105/tpc.021501; Sabatini S, 1999, CELL, V99, P463, DOI 10.1016/S0092-8674(00)81535-4; SARAFIAN V, 1992, P NATL ACAD SCI USA, V89, P1775, DOI 10.1073/pnas.89.5.1775; SERRANO R, 1993, FEBS LETT, V325, P108, DOI 10.1016/0014-5793(93)81424-X; Strompen G, 2005, PLANT J, V41, P125, DOI 10.1111/j.1365-313X.2004.02283.x; Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677; Ulmasov T, 1997, PLANT CELL, V9, P1963, DOI 10.1105/tpc.9.11.1963; Zhen RG, 1997, ADV BOT RES, V25, P297, DOI 10.1016/S0065-2296(08)60156-1	25	325	381	6	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	2005	310	5745					121	125		10.1126/science.1115711	http://dx.doi.org/10.1126/science.1115711			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210544				2022-12-28	WOS:000232477000053
J	Shekhawat, GS; Dravid, VP				Shekhawat, GS; Dravid, VP			Nanoscale imaging of buried structures via scanning near-field ultrasound holography	SCIENCE			English	Article							ATOMIC-FORCE MICROSCOPY; ACOUSTIC MICROSCOPY; POLYMER; ERYTHROCYTES; INDENTATION; RESOLUTION	A nondestructive imaging method, scanning near-field ultrasound holography (SNFUH), has been developed that provides depth information as well as spatial resolution at the 10- to 100-nanometer scale. In SNFUH, the phase and amplitude of the scattered specimen ultrasound wave, reflected in perturbation to the surface acoustic standing wave, are mapped with a scanning probe microscopy platform to provide nanoscale-resolution images of the internal substructure of diverse materials. We have used SNFUH to image buried nanostructures, to perform subsurface metrology in microelectronic structures, and to image malaria parasites in red blood cells.	Northwestern Univ, Inst Nanotechnol, Evanston, IL 60208 USA; Northwestern Univ, NUANCE Ctr, Evanston, IL 60208 USA; Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA	Northwestern University; Northwestern University; Northwestern University	Dravid, VP (corresponding author), Northwestern Univ, Inst Nanotechnol, Evanston, IL 60208 USA.	v-dravid@northwestern.edu	Dravid, Vinayak/B-6688-2009					ALTEMUS B, 2001, P SPIE, V458; Bhushan B, 2004, NANOTECHNOLOGY, V15, P1785, DOI 10.1088/0957-4484/15/12/016; BRIGGS GAD, 1992, ACOUSTIC MICROSCOPY, P33; Cheng L, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.255503; Cuberes MT, 2000, J PHYS D APPL PHYS, V33, P2347, DOI 10.1088/0022-3727/33/19/301; Dickson W, 2005, IEEE T NANOTECHNOL, V4, P229, DOI 10.1109/TNANO.2004.837850; Gaur D, 2004, INT J PARASITOL, V34, P1413, DOI 10.1016/j.ijpara.2004.10.010; Geer RE, 2002, J APPL PHYS, V91, P4549, DOI 10.1063/1.1447330; HALDAR K, 1985, J BIOL CHEM, V260, P4969; HIROTSUGU O, 2003, APPL PHYS LETT, V83, P464; HUANG DZ, 2004, CHIN J MED IMAGING T, V20, P1815; Hurley DC, 2003, J APPL PHYS, V94, P2347, DOI 10.1063/1.1592632; Inagaki K, 2000, APPL PHYS LETT, V76, P1836, DOI 10.1063/1.126184; Keller RR, 1999, J APPL PHYS, V86, P1167, DOI 10.1063/1.370860; Kolosov OV, 1998, PHYS REV LETT, V81, P1046, DOI 10.1103/PhysRevLett.81.1046; Kostli KP, 2003, APPL OPTICS, V42, P1899, DOI 10.1364/AO.42.001899; Larson BC, 2002, NATURE, V415, P887, DOI 10.1038/415887a; Lin HN, 1999, APPL PHYS LETT, V74, P2785, DOI 10.1063/1.124013; Lindfors K, 2004, OPT LASER TECHNOL, V36, P651, DOI 10.1016/j.optlastec.2004.01.018; Muthuswami L, 2004, APPL PHYS LETT, V84, P5082, DOI 10.1063/1.1756673; Nagao E, 2000, J STRUCT BIOL, V130, P34, DOI 10.1006/jsbi.2000.4236; Nelson TM, 2004, ADV MATER PROCESS, V162, P29; OGAMA ET, 2002, IEEE INT REL PHYS S, P312; QUATE CF, 1994, SURF SCI, V299, P980, DOI 10.1016/0039-6028(94)90711-0; SHEKHAWAT GS, 1996, APPL PHYS LETT, V68, P779; SHULL KR, 1995, J POLYM SCI POL PHYS, V33, P1417, DOI 10.1002/polb.1995.090330911; Tinkham BP, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.035404; Vanlandingham MR, 1997, J MATER SCI LETT, V16, P117, DOI 10.1023/A:1018533708655; Vanlandingham MR, 1997, J ADHESION, V64, P31, DOI 10.1080/00218469708010531; Vanlandingham MR, 1997, MAT RES S C, V458, P313; Wang XD, 2003, OPT LETT, V28, P1739, DOI 10.1364/OL.28.001739	31	183	198	4	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 7	2005	310	5745					89	92		10.1126/science.1117694	http://dx.doi.org/10.1126/science.1117694			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210534				2022-12-28	WOS:000232477000043
J	Terracciano, A; Abdel-Khalek, AM; Adam, N; Adamovova, L; Ahn, C; Ahn, HN; Alansari, BM; Alcalay, L; Allik, J; Angleitner, A; Avia, MD; Ayearst, LE; Barbaranelli, C; Beer, A; Borg-Cunen, MA; Bratko, D; Brunner-Sciarra, M; Budzinski, L; Camart, N; Dahourou, D; De Fruyt, F; de Lima, MP; del Pilar, GEH; Diener, E; Falzon, R; Fernando, K; Fickova, E; Fischer, R; Flores-Mendoza, C; Ghayur, MA; Gulgoz, S; Hagberg, B; Halberstadt, J; Halim, MS; Hrebickova, M; Humrichouse, J; Jensen, HH; Jocic, DD; Jonsson, FH; Khoury, B; Klinkosz, W; Knezevic, G; Lauri, MA; Leibovich, N; Martin, TA; Marusic, I; Mastor, KA; Matsumoto, D; McRorie, M; Meshcheriakov, B; Mortensen, EL; Munyae, M; Nagy, J; Nakazato, K; Nansubuga, F; Oishi, S; Ojedokun, AO; Ostendorf, F; Paulhus, DL; Pelevin, S; Petot, JM; Podobnik, N; Porrata, JL; Pramila, VS; Prentice, G; Realo, A; Reategui, N; Rolland, JP; Rossier, J; Ruch, W; Rus, VS; Sanchez-Bernardos, ML; Schmidt, V; Sciculna-Calleja, S; Sekowski, A; Shakespeare-Finch, J; Shimonaka, Y; Simonetti, F; Sineshaw, T; Siuta, J; Smith, PB; Trapnell, PD; Trobst, KK; Wang, L; Yik, M; Zupancic, A; McCrae, RR				Terracciano, A; Abdel-Khalek, AM; Adam, N; Adamovova, L; Ahn, C; Ahn, HN; Alansari, BM; Alcalay, L; Allik, J; Angleitner, A; Avia, MD; Ayearst, LE; Barbaranelli, C; Beer, A; Borg-Cunen, MA; Bratko, D; Brunner-Sciarra, M; Budzinski, L; Camart, N; Dahourou, D; De Fruyt, F; de Lima, MP; del Pilar, GEH; Diener, E; Falzon, R; Fernando, K; Fickova, E; Fischer, R; Flores-Mendoza, C; Ghayur, MA; Gulgoz, S; Hagberg, B; Halberstadt, J; Halim, MS; Hrebickova, M; Humrichouse, J; Jensen, HH; Jocic, DD; Jonsson, FH; Khoury, B; Klinkosz, W; Knezevic, G; Lauri, MA; Leibovich, N; Martin, TA; Marusic, I; Mastor, KA; Matsumoto, D; McRorie, M; Meshcheriakov, B; Mortensen, EL; Munyae, M; Nagy, J; Nakazato, K; Nansubuga, F; Oishi, S; Ojedokun, AO; Ostendorf, F; Paulhus, DL; Pelevin, S; Petot, JM; Podobnik, N; Porrata, JL; Pramila, VS; Prentice, G; Realo, A; Reategui, N; Rolland, JP; Rossier, J; Ruch, W; Rus, VS; Sanchez-Bernardos, ML; Schmidt, V; Sciculna-Calleja, S; Sekowski, A; Shakespeare-Finch, J; Shimonaka, Y; Simonetti, F; Sineshaw, T; Siuta, J; Smith, PB; Trapnell, PD; Trobst, KK; Wang, L; Yik, M; Zupancic, A; McCrae, RR			National character does not reflect mean personality trait levels in 49 cultures	SCIENCE			English	Article							ACCURACY	Most people hold beliefs about personality characteristics typical of members of their own and others' cultures. These perceptions of national character may be generalizations from personal experience, stereotypes with a "kernel of truth," or inaccurate stereotypes. We obtained national character ratings of 3989 people from 49 cultures and compared them with the average personality scores of culture members assessed by observer ratings and self-reports. National character ratings were reliable but did not converge with assessed traits. Perceptions of national character thus appear to be unfounded stereotypes that may serve the function of maintaining a national identity.	NIA, NIH, DHHS, Gerontol Res Ctr, Baltimore, MD 21224 USA; Kuwait Univ, Fac Social Sci, Dept Psychol, Kaifan 71962, Kuwait; Eotvos Lorand Univ, Fac Educ & Psychol, H-1075 Budapest, Hungary; Slovak Acad Sci, Inst Expt Psychol, Bratislava 81364, Slovakia; Pusan Natl Univ, Dept Educ, Pusan 609735, South Korea; Pusan Natl Univ, Dept Psychol, Pusan 609735, South Korea; Pontificia Univ Catolica Chile, Escuela Psicol, Santiago, Chile; Univ Tartu, Dept Psychol, EE-50090 Tartu, Estonia; Univ Bielefeld, Dept Psychol, D-33501 Bielefeld, Germany; Univ Complutense Madrid, Fac Psicol, Madrid, Spain; York Univ, Dept Psychol, N York, ON M3J 1P3, Canada; Univ Roma La Sapienza, Dept Psychol, I-00185 Rome, Italy; Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA; Univ Malta, Dept Psychol, Msida MSD 06, Malta; Univ Zagreb, Filozofski Fak, Dept Psychol, HR-10002 Zagreb, Croatia; Univ Peruana Cayetano Heredia, Fac Psicol, Lima, Peru; Univ Melbourne, Dept Psychol, Parkville, Vic 3010, Australia; Univ Paris 10, Lab Psychol Clin Faits Culturels, F-92001 Nanterre, France; Univ Ouagadougou, Dept Psychol, Ouagadougou 03, Burkina Faso; Dept Psychol, B-9000 Ghent, Belgium; Univ Coimbra, Fac Psicol Ciencias Educacao, Coimbra, Portugal; Univ Philippines, Dept Psychol, Quezon City 1101, Philippines; Univ Illinois, Dept Psychol, Champaign, IL 61820 USA; Univ Otago, Dept Psychol, Dunedin, New Zealand; Victoria Univ Wellington, Sch Psychol, Wellington, New Zealand; Univ Fed Minas Gerais, Dept Psicol, Belo Horizonte, MG, Brazil; Al Akhawayn Univ, Ifrane, Morocco; Koc Univ, TR-80910 Istanbul, Turkey; Lund Univ, Unit Gerontol & Care Elderly, S-22220 Lund, Sweden; Atma Jaya Indonesia Catholic Univ, Fac Psychol, Jakarta 12930, Indonesia; Acad Sci Czech Republ, Brno 60200, Czech Republic; Univ Copenhagen, Inst Publ Hlth, Dept Hlth Psychol, DK-2200 Copenhagen, Denmark; Inst Psychiat, Belgrade, Serbia Monteneg; Univ Iceland, Fac Social Sci, IS-101 Reykjavik, Iceland; Amer Univ Beirut, Med Ctr, Dept Psychiat, Beirut 1107 2020, Lebanon; Catholic Univ Lublin, Dept Psychol, PL-20950 Lublin, Poland; Univ Belgrade, Dept Psychol, YU-11000 Belgrade, Serbia Monteneg; Univ Buenos Aires, Fac Psychol, Buenos Aires, DF, Argentina; Susquehanna Univ, Dept Psychol, Selinsgrove, PA 17870 USA; Univ Kebangsaan Malaysia, Ctr Gen Studies, Bangi, Darul Ehsan, Malaysia; San Francisco State Univ, Dept Psychol, San Francisco, CA 94132 USA; Queens Univ Belfast, Sch Psychol, Belfast BT7 1NN, Antrim, North Ireland; Int Univ Dubna, Dept Psychol, Dubna 141980, Russia; Univ Botswana, Ctr Continuing Educ, Gaborone, Botswana; Iwate Prefectural Univ, Dept Psychol, Takizawa, Iwate 0200193, Japan; Makerere Univ, Dept Org Psychol, Kampala, Uganda; Univ Virginia, Dept Psychol, Charlottesville, VA 22904 USA; Univ Ibadan, Dept Psychol, Ibadan, Nigeria; Univ British Columbia, Dept Psychol, Vancouver, BC V6T 1Z4, Canada; Psychiat Hosp Idrija, Idrija 5280, Slovenia; Univ Puerto Rico, Escuela Grad Adm Publ, Rio Piedras, PR 00931 USA; Andhra Univ, Dept Psychol, Visakhapatnam 530003, Andhra Pradesh, India; Univ Paris 10, STAPS Dept, F-92001 Nanterre, France; Univ Lausanne, Inst Psychol, CH-1015 Lausanne, Switzerland; Inst Psychol, CH-8044 Zurich, Switzerland; Univ Ljubljana, Fac Arts, Ljubljana, Slovenia; Queensland Univ Technol, Sch Psychol & Counselling, Brisbane, Qld, Australia; Bunkyo Gakuin Univ, Dept Psychol, Oi Machi, Saitama 3568533, Japan; Ramapo Coll, Dept Psychol, Mahwah, NJ 07430 USA; Jagiellonian Univ, Inst Psychol, Krakow, Poland; Univ Sussex, Dept Psychol, Brighton, E Sussex, England; Univ Winnipeg, Dept Psychol, Winnipeg, MB R3B 2E9, Canada; Peking Univ, Dept Psychol, Beijing 100871, Peoples R China; Hong Kong Univ Sci & Technol, Div Social Sci, Kowloon, Hong Kong, Peoples R China; Minist Hlth, Ljubljana 1000, Slovenia	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Kuwait University; Eotvos Lorand University; Slovak Academy of Sciences; Pusan National University; Pusan National University; Pontificia Universidad Catolica de Chile; University of Tartu; University of Bielefeld; Complutense University of Madrid; York University - Canada; Sapienza University Rome; University of Iowa; University of Malta; University of Zagreb; Universidad Peruana Cayetano Heredia; University of Melbourne; Universite Paris Nanterre; Universidade de Coimbra; University of the Philippines System; University of the Philippines Diliman; University of Illinois System; University of Illinois Urbana-Champaign; University of Otago; Victoria University Wellington; Universidade Federal de Minas Gerais; Al Akhawayn University; Koc University; Lund University; University Katolik Indonesia Atma Jaya; Czech Academy of Sciences; University of Copenhagen; University of Iceland; American University of Beirut; Catholic University of Lublin; University of Belgrade; University of Buenos Aires; Susquehanna University; Universiti Kebangsaan Malaysia; California State University System; San Francisco State University; Queens University Belfast; Dubna State University; University of Botswana; Iwate Prefectural University; Makerere University; University of Virginia; University of Ibadan; University of British Columbia; University of Puerto Rico; University of Puerto Rico Rio Piedras; Andhra University; Universite Paris Nanterre; University of Lausanne; University of Ljubljana; Queensland University of Technology (QUT); Ramapo College New Jersey (RCNJ); Jagiellonian University; University of Sussex; University of Winnipeg; Peking University; Hong Kong University of Science & Technology	Terracciano, A (corresponding author), NIA, NIH, DHHS, Gerontol Res Ctr, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	terraccianoa@grc.nia.nih.gov; mccraej@grc.nia.nih.gov	Marusic, Ivan/M-1903-2015; Allik, Jüri/D-5609-2009; Knezevic, Goran D/G-6420-2019; Flores-Mendoza, Carmen/GXH-1100-2022; Mastor, Khairul Anwar/ABI-1466-2020; Fischer, Ronald/G-6447-2017; Realo, Anu/M-9524-2016; Ayearst, Lindsay E./AAO-5518-2021; /AFM-5266-2022; De Fruyt, Filip/A-3083-2009; Avia, Maria Dolores/C-7061-2011; /ABI-3948-2020; Wang, Lei/D-2501-2016; Sanchez-Bernardos, Maria Luisa/C-6038-2011; Marusic, Ivan/N-8456-2019; Halim, Magdalena S/G-2910-2015; Hrebickova, Martina/H-4410-2014; Rossier, Jérôme/A-3494-2009; Terracciano, Antonio/H-7403-2019; Ojedokun, Oluyinka/E-5800-2018; Nagy, Janos/I-7246-2017; Allik, Jüri/N-3038-2019; Ruch, Willibald/G-3124-2011	Marusic, Ivan/0000-0003-2700-8435; Allik, Jüri/0000-0002-8358-4747; Knezevic, Goran D/0000-0001-8951-3774; Fischer, Ronald/0000-0002-3055-3955; /0000-0002-1262-2347; /0000-0002-1262-2347; Wang, Lei/0000-0002-6156-9028; Sanchez-Bernardos, Maria Luisa/0000-0003-4931-867X; Marusic, Ivan/0000-0003-2700-8435; Halim, Magdalena S/0000-0003-2158-7587; Hrebickova, Martina/0000-0003-4356-567X; Rossier, Jérôme/0000-0002-9924-3672; Terracciano, Antonio/0000-0001-5799-8885; Ojedokun, Oluyinka/0000-0002-3497-4618; Nagy, Janos/0000-0002-1076-9038; Allik, Jüri/0000-0002-8358-4747; Ruch, Willibald/0000-0001-5368-3616; P. de Lima, Margarida/0000-0002-6239-1137; Reategui, Norma/0000-0003-0484-9936; Oishi, Shigehiro/0000-0002-4185-960X; Shakespeare-Finch, Jane/0000-0003-4237-1320; Mastor, Khairul Anwar/0000-0002-4505-6433; Mortensen, Erik Lykke/0000-0002-6985-451X; Ostendorf, Fritz/0000-0001-9072-443X; Bratko, Denis/0000-0002-2482-4413; YIK, Michelle/0000-0003-0104-3662	Intramural NIH HHS [ZIA AG000180-25, ZIA AG000180-26, Z99 AG999999] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [Z01AG000180, ZIAAG000180] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adorno T.W., 1969, AUTHORITARIAN PERSON; Allik J, 2004, J CROSS CULT PSYCHOL, V35, P13, DOI 10.1177/0022022103260382; Allport F. H., 1954, NATURE PREJUDICE; BOUCHARD TJ, 1994, SCIENCE, V264, P1700, DOI 10.1126/science.8209250; BRIGHAM JC, 1971, PSYCHOL BULL, V76, P15, DOI 10.1037/h0031446; Church AT, 2002, INT CUL PSY, P129; Costa PT, 2001, J PERS SOC PSYCHOL, V81, P322, DOI 10.1037//0022-3514.81.2.322; Costa PT., 1992, REVISED NEO PERSONAL; DIGMAN JM, 1990, ANNU REV PSYCHOL, V41, P417, DOI 10.1146/annurev.psych.41.1.417; GRIFFIN D, 1995, PSYCHOL BULL, V118, P430, DOI 10.1037/0033-2909.118.3.430; HAMILTON DL, 1980, J PERS SOC PSYCHOL, V39, P832, DOI 10.1037/0022-3514.39.5.832; Heine SJ, 2002, J PERS SOC PSYCHOL, V82, P903, DOI 10.1037//0022-3514.82.6.903; Hewstone M., 1996, STEREOTYPES STEREOTY; JUDD CM, 1993, PSYCHOL REV, V100, P109, DOI 10.1037/0033-295X.100.1.109; Lee Y. H., 1995, STEREOTYPE ACCURACY; Madon S, 2001, PERS SOC PSYCHOL B, V27, P996, DOI 10.1177/0146167201278007; MARTIN CL, 1987, J PERS SOC PSYCHOL, V52, P489, DOI 10.1037/0022-3514.52.3.489; MCCAULEY C, 1978, J PERS SOC PSYCHOL, V36, P929, DOI 10.1037/0022-3514.36.9.929; McCrae RR, 2004, J RES PERS, V38, P179, DOI 10.1016/S0092-6566(03)00056-4; McCrae RR, 2005, J PERS SOC PSYCHOL, V88, P547, DOI 10.1037/0022-3514.88.3.547; McCrae RR, 2002, INT CUL PSY, P105; McCrae RR, 2001, J PERS, V69, P819, DOI 10.1111/1467-6494.696166; MCCRAE RR, IN PRESS J PERS SOC; Peabody D., 1985, NATL CHARACTERISTICS; SWIM JK, 1994, J PERS SOC PSYCHOL, V66, P21, DOI 10.1037/0022-3514.66.1.21; TERRACCIANO A, 2005, 113 ANN CONV AM PSYC; van de Vijver FJR, 2001, J PERS, V69, P1007, DOI 10.1111/1467-6494.696173; Williams John E., 1982, MEASURING SEX STEREO	28	278	279	3	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	2005	310	5745					96	100		10.1126/science.1117199	http://dx.doi.org/10.1126/science.1117199			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	972TV	16210536	Green Submitted, Green Accepted			2022-12-28	WOS:000232477000045
J	Davies, P				Davies, P			A quantum recipe for life	NATURE			English	Editorial Material									Macquarie Univ, Australian Ctr Astrobiol, Sydney, NSW 2109, Australia	Macquarie University	Davies, P (corresponding author), Macquarie Univ, Australian Ctr Astrobiol, Sydney, NSW 2109, Australia.								0	7	9	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 6	2005	437	7060					819	819		10.1038/437819a	http://dx.doi.org/10.1038/437819a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208350	Bronze			2022-12-28	WOS:000232338600025
J	Montgomery, RA; Zachary, AA; Ratner, LE; Segev, DL; Hiller, JM; Houp, J; Cooper, M; Kavoussi, L; Jarrett, T; Burdick, J; Maley, WR; Melancon, JK; Kozlowski, T; Simpkins, CE; Phillips, M; Desai, A; Collins, V; Reeb, B; Kraus, E; Rabb, H; Leffell, MS; Warren, DS				Montgomery, RA; Zachary, AA; Ratner, LE; Segev, DL; Hiller, JM; Houp, J; Cooper, M; Kavoussi, L; Jarrett, T; Burdick, J; Maley, WR; Melancon, JK; Kozlowski, T; Simpkins, CE; Phillips, M; Desai, A; Collins, V; Reeb, B; Kraus, E; Rabb, H; Leffell, MS; Warren, DS			Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WAIT-LIST CANDIDATES; CROSS-MATCH; RENAL-TRANSPLANTATION; EXCHANGE PROGRAMS; REJECTION; PLASMAPHERESIS; GLOBULIN	Context First proposed 2 decades ago, live kidney paired donation (KPD) was considered a promising new approach to addressing the shortage of organs for transplantation. Ethical, administrative, and logistical barriers initially proved formidable and prevented the implementation of KPD programs in the United States. Objective To determine the feasibility and effectiveness of KPD for the management of patients with incompatible donors. Design, Setting, and Patients Prospective series of paired donations matched and transplanted from a pool of blood type or crossmatch incompatible donors and recipients with end-stage renal disease (6 conventional and 4 unconventional KPD transplants) at a US tertiary referral center (between June 2001 and November 2004) with expertise in performing transplants in patients with high immunologic risk. Intervention Kidney paired donation and live donor renal transplantation. Main Outcome Measures Patient survival, graft survival, serum creatinine levels, rejection episodes. Results A total of 22 patients received transplants through 10 paired donations including 2 triple exchanges at Johns Hopkins Hospital. At a median follow-up of 13 months (range, 1-42 months), the patient survival rate was 100% and the graft survival rate was 95.5%. Twenty-one of the 22 patients have functioning grafts with a median 6-month serum creatinine level of 1.2 mg/dL (range, 0.8-1.8 mg/dl) (106.1 mu mol/L [range, 70.7-159.1 mu mol/L]). There were no instances of antibody-mediated rejection despite the inclusion of 5 patients who were highly sensitized to HLA antigens due to previous exposure to foreign tissue. Four patients developed acute cellular rejection (18%). Conclusions This series of patients who received transplants from a single-center KPD pool provides evidence that recipients with incompatible live donors, even those with rare blood type combinations or high degrees of HLA antigen sensitization, can receive transplants through KPD with graft survival rates that appear to be equivalent to directed, compatible live donor transplants, if these results can be generalized, broader availability of KPD to the estimated 6000 patients with incompatible donors could result in a large expansion of the donor pool.	Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA; Columbia Univ, Dept Surg, New York, NY 10027 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Columbia University	Montgomery, RA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Surg, 720 Rutland Ave,Ross 765, Baltimore, MD 21205 USA.	rmonty@jhmi.edu	Phillips, Melissa/AAX-4174-2020	Phillips, Melissa/0000-0001-8997-4853				Fuller TF, 2004, TRANSPLANTATION, V78, P1030, DOI 10.1097/01.TP.0000135464.11616.5A; Gentry SE, 2005, AM J TRANSPLANT, V5, P1914, DOI 10.1111/j.1600-6143.2005.00964.x; Gloor JM, 2003, TRANSPLANTATION, V75, P971, DOI 10.1097/01.TP.0000058226.397.32; Glotz D, 2002, AM J TRANSPLANT, V2, P758, DOI 10.1034/j.1600-6143.2002.20809.x; Jordan Stanley C, 2003, Clin Transpl, P193; KISSMEYE F, 1966, LANCET, V2, P662, DOI 10.1016/S0140-6736(66)92829-7; McLellan F, 2003, LANCET, V362, P456, DOI 10.1016/S0140-6736(03)14106-2; Montgomery RA, 2004, PEDIATR TRANSPLANT, V8, P535, DOI 10.1111/j.1399-3046.2004.00214.x; Montgomery RA, 2000, TRANSPLANTATION, V70, P887, DOI 10.1097/00007890-200009270-00006; Park K, 1999, TRANSPLANTATION, V67, P336, DOI 10.1097/00007890-199901270-00027; Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x; Racusen Lorraine C, 2004, Am J Transplant, V4, P1562, DOI 10.1111/j.1600-6143.2004.00585.x; RAPAPORT FT, 1986, TRANSPLANT P, V18, P5; Ross LF, 2004, TRANSPLANTATION, V78, P641, DOI 10.1097/01.tp.0000134522.31554.05; Ross LF, 2004, AM J TRANSPLANT, V4, P1553, DOI 10.1111/j.1600-6143.2004.00574.x; Ross LF, 1997, NEW ENGL J MED, V336, P1752, DOI 10.1056/NEJM199706123362412; Ross LF, 2000, TRANSPLANTATION, V69, P1539; Roth AE, 2004, Q J ECON, V119, P457, DOI 10.1162/0033553041382157; Segev DL, 2005, AM J TRANSPLANT, V5, P2448, DOI 10.1111/j.1600-6143.2005.01048.x; Segev DL, 2005, JAMA-J AM MED ASSOC, V293, P1883, DOI 10.1001/jama.293.15.1883; Sonnenday CJ, 2004, AM J TRANSPLANT, V4, P1315, DOI 10.1111/j.1600-6143.2004.00507.x; Terasaki PI, 1998, TRANSPLANTATION, V65, P291; Terasaki PI, 2003, AM J TRANSPLANT, V3, P665, DOI 10.1034/j.1600-6143.2003.00135.x; United Network for Organ Sharing, ORG PROC TRANSPL NET; Warren DS, 2004, AM J TRANSPLANT, V4, P561, DOI 10.1111/j.1600-6143.2004.00364.x; WILLIAMS GM, 1968, NEW ENGL J MED, V279, P611, DOI 10.1056/NEJM196809192791201; ZACHARY AA, 1985, TRANSPLANTATION, V39, P316, DOI 10.1097/00007890-198503000-00024; Zachary AA, 2003, TRANSPLANTATION, V76, P1519, DOI 10.1097/01.TP.0000090868.88895.E0; Zenios SA, 2001, TRANSPLANTATION, V72, P648, DOI 10.1097/00007890-200108270-00015	29	143	144	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	2005	294	13					1655	1663		10.1001/jama.294.13.1655	http://dx.doi.org/10.1001/jama.294.13.1655			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970DC	16204665				2022-12-28	WOS:000232284400018
J	Jefferson, T; Rivetti, D; Rivetti, A; Rudin, M; Di Pietrantonj, C; Demicheli, V				Jefferson, T; Rivetti, D; Rivetti, A; Rudin, M; Di Pietrantonj, C; Demicheli, V			Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review	LANCET			English	Article							NURSING-HOME RESIDENTS; AGED 65 YEARS; A H3N2; PREVENTING HOSPITALIZATION; PNEUMOCOCCAL VACCINES; COST-EFFECTIVENESS; VACCINATION; OUTBREAK; REDUCTION; MORTALITY	Background Influenza vaccination of elderly individuals is recommended worldwide. Our aim was to review the evidence of efficacy and effectiveness of influenza vaccines in individuals aged 65 years or older. Methods We searched five electronic databases to December, 2004, in any language, for randomised (n=5), cohort (n=49), and case-control (n=10) studies, assessing efficacy against influenza (reduction in laboratory-confirmed cases) or effectiveness against influenza-like illness (reduction in symptomatic cases). We expressed vaccine efficacy or effectiveness as a proportion, using the formula VE=l-relative risk (RR) or VE*=1-odds ratio (OR). We analysed the following outcomes: influenza, influenza-like illness, hospital admissions, complications, and deaths. Findings in homes for elderly individuals (with good vaccine match and high viral circulation) the effectiveness of vaccines against influenza-like illness was 23% (95% CI 6-36) and non-significant against influenza (RR 1.04, 0.43-2-51). Well matched vaccines prevented pneumonia (VE 46%, 30-58) and hospital admission (VE 45%, 16-64) for and deaths from influenza or pneumonia (VE 42%, 17-59), and reduced all-cause mortality (VE 60%, 23-79). In elderly individuals living in the community, vaccines were not significantly effective against influenza (RR 0.19, 0.02-2.01), influenza-like illness (RR 1. 05, 0.58-1.89), or pneumonia (RR 0. 88, 0.64-1.20). Well matched vaccines prevented hospital admission for influenza and pneumonia (VE 26%, 12-38) and all-cause mortality (VE 42%, 24-55). After adjustment for confounders, vaccine performance was improved for admissions to hospital for influenza or pneumonia (VE* 27%, 21-33), respiratory diseases (VE* 22%, 15-28), and cardiac disease (VE* 24%, 18-30), and for all-cause mortality (VE* 47%, 39-54). Interpretation In long-term care facilities, where vaccination is most effective against complications, the aims of the vaccination campaign are fulfilled, at least in part. However, according to reliable evidence the usefulness of vaccines in the community is modest.	ASL 20, Cochrane Vaccines Field, I-15100 Alessandria, Italy		Jefferson, T (corresponding author), ASL 20, Cochrane Vaccines Field, I-15100 Alessandria, Italy.	Toj1@aol.com	Di Pietrantonj, Carlo/AAK-1340-2020	Di Pietrantonj, Carlo/0000-0002-7302-5714				AHMED AEH, 1995, LANCET, V346, P591, DOI 10.1016/S0140-6736(95)91434-X; Ahmed AH, 1997, EPIDEMIOL INFECT, V118, P27, DOI 10.1017/S0950268896007121; Allsup S, 2004, VACCINE, V23, P639, DOI 10.1016/j.vaccine.2004.07.008; ARDEN NH, 1988, ARCH INTERN MED, V148, P865, DOI 10.1001/archinte.148.4.865; ARROYO JC, 1984, AM J INFECT CONTROL, V12, P329, DOI 10.1016/0196-6553(84)90005-1; Aymard M, 1979, Dev Biol Stand, V43, P231; BADIA JG, 1991, GAC SANIT, V5, P203; Birn AE, 2005, LANCET, V366, P514, DOI 10.1016/S0140-6736(05)66479-3; Caminiti C., 1994, Igiene Moderna, V101, P163; CARTTER ML, 1990, INFECT CONT HOSP EP, V11, P473; CATES CJ, 2003, COCHRANE DB SYST REV, V4; *CDC, UPD INT INFL VACC RE; Christenson B, 2001, LANCET, V357, P1008, DOI 10.1016/S0140-6736(00)04237-9; Christenson B, 2004, EUR RESPIR J, V23, P363, DOI 10.1183/09031936.04.00063504; *COCHR COLL, 2003, REV MAN REVMAN 4 2; COLES FB, 1992, J AM GERIATR SOC, V40, P589, DOI 10.1111/j.1532-5415.1992.tb02108.x; Comeri L, 1995, IG MOD, V103, P651; CONSONNI S, 2004, J PREVENTIVE MED HYG, V45, P45; Crocetti E, 2001, EUR J EPIDEMIOL, V17, P163, DOI 10.1023/A:1017978420601; CROVARI PC, 1980, B I SIEROTER MILAN, V59, P306; CURRIER M, 1988, MMJ (Maryland Medical Journal), V37, P781; DALESSIO DJ, 1969, J AMER MED ASSOC, V210, P485, DOI 10.1001/jama.210.3.485; Davis JW, 2001, MED CARE, V39, P1273, DOI 10.1097/00005650-200112000-00003; DEEKS JJ, 2004, COCHRANE REV HDB; Deguchi Y, 2001, J GERONTOL A-BIOL, V56, pM391, DOI 10.1093/gerona/56.6.M391; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EDMONDSON WP, 1971, AM J EPIDEMIOL, V93, P480, DOI 10.1093/oxfordjournals.aje.a121282; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; FEERY BJ, 1979, J INFECT DIS, V139, P237, DOI 10.1093/infdis/139.2.237; Fleming DM, 1995, EPIDEMIOL INFECT, V115, P581, DOI 10.1017/S095026880005874X; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; FYSON RE, 1983, CANADIAN DIS WEEKLY, V9, P37; GOODMAN RA, 1982, JAMA-J AM MED ASSOC, V247, P1451, DOI 10.1001/jama.247.10.1451; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; GROSS PA, 1988, ARCH INTERN MED, V148, P562, DOI 10.1001/archinte.148.3.562; Hak E, 2002, CLIN INFECT DIS, V35, P370, DOI 10.1086/341403; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; HORMAN JT, 1986, AM J PUBLIC HEALTH, V76, P501, DOI 10.2105/AJPH.76.5.501; HOWARTH DM, 1987, MED J AUSTRALIA, V146, P514, DOI 10.5694/j.1326-5377.1987.tb120390.x; HOWELLS CHL, 1975, LANCET, V1, P381; IGLESIAS FJG, 1987, REV SANID HIG PUBL, V61, P759; Isaacs S, 1997, Can Commun Dis Rep, V23, P105; Kawai N, 2003, VACCINE, V21, P4507, DOI 10.1016/S0264-410X(03)00508-5; Lopez Hernandez B, 1994, Aten Primaria, V14, P532; Luby SP, 2005, LANCET, V366, P225, DOI 10.1016/S0140-6736(05)66912-7; Mangtani P, 2004, J INFECT DIS, V190, P1, DOI 10.1086/421274; Mast Eric E., 2005, Morbidity and Mortality Weekly Report, V54, P1; MEIKLEJOHN G, 1987, J AM GERIATR SOC, V35, P742, DOI 10.1111/j.1532-5415.1987.tb06352.x; Monto AS, 2001, AM J EPIDEMIOL, V154, P155, DOI 10.1093/aje/154.2.155; MORENS DM, 1995, INFECT CONT HOSP EP, V16, P275; MUKERJEE A, 1994, J EPIDEMIOL COMMUN H, V48, P602, DOI 10.1136/jech.48.6.602; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; Murayama N, 1999, TOHOKU J EXP MED, V188, P289, DOI 10.1620/tjem.188.289; Nichol KL, 2003, NEW ENGL J MED, V348, P1322, DOI 10.1056/NEJMoa025028; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; Nicholson KG, 1999, EPIDEMIOL INFECT, V123, P103, DOI 10.1017/S095026889900271X; Nordin J, 2001, J INFECT DIS, V184, P665, DOI 10.1086/323085; Ohmit SE, 1995, INT J EPIDEMIOL, V24, P1240, DOI 10.1093/ije/24.6.1240; Ohmit SE, 1999, J AM GERIATR SOC, V47, P165, DOI 10.1111/j.1532-5415.1999.tb04574.x; PATRIARCA PA, 1985, JAMA-J AM MED ASSOC, V253, P1136, DOI 10.1001/jama.253.8.1136; POOLE PJ, 2000, COCHRANE DB SYST REV, V3; PREGLIASCO F, 2002, VACCINE GLANCE, V1, P2; Puig-Barbera J, 2004, VACCINE, V23, P283, DOI 10.1016/j.vaccine.2004.07.017; PuigBarbera J, 1997, J EPIDEMIOL COMMUN H, V51, P526, DOI 10.1136/jech.51.5.526; RIVETTI D, 2005, COCHRANE DB SYST REV, V1; RUBEN FL, 1974, JAMA-J AM MED ASSOC, V230, P863; Rudenko LG, 2000, VACCINE, V19, P308, DOI 10.1016/S0264-410X(00)00153-5; SAAH AJ, 1986, ARCH INTERN MED, V146, P2353, DOI 10.1001/archinte.146.12.2353; Saito R, 2002, INFECT CONT HOSP EP, V23, P82, DOI 10.1086/502011; Shapiro Y, 2003, ISRAEL MED ASSOC J, V5, P706; STRASSBURG MA, 1986, VACCINE, V4, P38, DOI 10.1016/S0264-410X(86)80002-0; STUART WH, 1969, J AMER MED ASSOC, V209, P232, DOI 10.1001/jama.209.2.232; TAN A, 2000, COCHRANE DB SYST REV, V1; TAYLOR JL, 1992, INFECT CONT HOSP EP, V13, P93; THOMAS R, 2005, COCHRANE DB SYST REV, V2; van Essen GA, 2003, VACCINE, V21, P1780, DOI 10.1016/S0264-410X(03)00072-0; Voordouw BCG, 2003, ARCH INTERN MED, V163, P1089, DOI 10.1001/archinte.163.9.1089; Vu T, 2002, VACCINE, V20, P1831, DOI 10.1016/S0264-410X(02)00041-5; Wells G., NEWCASTLE OTTAWA SCA; *WHO GLOB INFL PRO, NUMB INFL VACC DOS D	84	453	471	0	44	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	2005	366	9492					1165	1174		10.1016/S0140-6736(05)67339-4	http://dx.doi.org/10.1016/S0140-6736(05)67339-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970LK	16198765				2022-12-28	WOS:000232311300026
J	Sevene, E; Lewin, S; Mariano, A; Woelk, G; Oxman, AD; Matinhure, S; Cliff, J; Fernandes, B; Daniels, K				Sevene, E; Lewin, S; Mariano, A; Woelk, G; Oxman, AD; Matinhure, S; Cliff, J; Fernandes, B; Daniels, K			System and market failures: the unavailability of magnesium sulphate for the treatment of eclampsia and pre-eclampsia in Mozambique and Zimbabwe	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							MATERNAL MORTALITY		Eduardo Mondlane Univ, Fac Med, Dept Pharmacol, Maputo, Mozambique; Univ Zimbabwe, Dept Community Med, Harare, Zimbabwe; Minist Hlth, Natl Inst Hlth, Maputo, Mozambique; MRC S Africa, Hlth Syst Res Unit, Durban, South Africa	Eduardo Mondlane University; University of Zimbabwe	Lewin, S (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Keppel St, London WC1E 7HT, England.	simon.lewin@lshum.ac.uk	Sevene, Esperança/AAI-3532-2020; Oxman, Andrew/Y-3004-2019; Daniels, Karen/AAY-8659-2020	Oxman, Andrew/0000-0002-5608-5061; Daniels, Karen/0000-0002-4345-5406				AASERUD M, 2005, IN PRESS BMC HLTH SE; DULEY L, 1995, LANCET, V345, P1455; DULEY L, 1992, BRIT J OBSTET GYNAEC, V99, P547, DOI 10.1111/j.1471-0528.1992.tb13818.x; Duley L, 2002, LANCET, V359, P1877, DOI 10.1016/s0140-6736(02)08778-0; Duley L, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002960.pub2; Granja AC, 1998, ANN TROP MED PARASIT, V92, P257, DOI 10.1080/00034989859816; Gravelle H., 2004, MICROECONOMICS; Green J., 2004, QUALITATIVE METHODS; Kaplan WA, 2003, HEALTH POLICY PLANN, V18, P237, DOI 10.1093/heapol/czg030; *MIN HLTH CHILD WE, 2000, ZIMB NAT HLTH PROF 2; Olliaro Piero, 2004, J HIV Ther, V9, P53; Sheth SS, 2002, LANCET, V359, P1872, DOI 10.1016/S0140-6736(02)08783-4; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7; *UN, 2000, 552 UN; *UN, 2000, 552 UN GEN ASS; WHO, 2003, WHO MOD LIST ESS MED; WHO Commission on Macroeconomics and Health, 2001, MACR HLTH INV HLTH E; *WHO UN, 2004, MAT MORT 2000 EST DE; World Health Organization, 2004, PRIOR MED EUR WORLD; World Health Organization, 2005, WORLD HLTH REP 2005	20	39	39	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	2005	331	7519					765	769		10.1136/bmj.331.7519.765	http://dx.doi.org/10.1136/bmj.331.7519.765			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971XB	16195297	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000232417100027
J	Futatsugi, A; Nakamura, T; Yamada, MK; Ebisui, E; Nakamura, K; Uchida, K; Kitaguchi, T; Takahashi-Iwanaga, H; Noda, T; Aruga, J; Mikoshiba, K				Futatsugi, A; Nakamura, T; Yamada, MK; Ebisui, E; Nakamura, K; Uchida, K; Kitaguchi, T; Takahashi-Iwanaga, H; Noda, T; Aruga, J; Mikoshiba, K			IP3 receptor types 2 and 3 mediate exocrine secretion underlying energy metabolism	SCIENCE			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; PANCREATIC ACINAR-CELLS; GLAND-CELLS; MICE; CHANNELS; TRISPHOSPHATE; EXPRESSION; INOSITOL-1,4,5-TRISPHOSPHATE; LOCALIZATION; INITIATION	Type 2 and type 3 inositol 1,4,5-trisphosphate receptors (IP3 R2 and IP(3)R3) are intracellular calcium-release channels whose physiological roles are unknown. We show exocrine dysfunction in IP3 R2 and IP3 R3 double knock-out mice, which caused difficulties in nutrient digestion. Severely impaired calcium signaling in acinar cells of the salivary glands and the pancreas in the double mutants ascribed the secretion deficits to a tack of intracellular calcium release. Despite a normal caloric intake, the double mutants were hypoglycemic and lean. These results reveal IP3 R2 and IP3 R3 as key molecules in exocrine physiology underlying energy metabolism and animal growth.	Japan Sci & Technol Agcy, Calcium Oscillat, Int Cooperat Res Project, Tokyo 1080071, Japan; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Brain Dev Res Grp, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Tokyo 1088639, Japan; Hokkaido Univ, Sch Med, Dept Anat, Sapporo, Hokkaido 0608638, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Tokyo 1708455, Japan	Japan Science & Technology Agency (JST); RIKEN; University of Tokyo; Hokkaido University; Japanese Foundation for Cancer Research	Futatsugi, A (corresponding author), Japan Sci & Technol Agcy, Calcium Oscillat, Int Cooperat Res Project, Tokyo 1080071, Japan.	afutatsu@brain.riken.jp; mikosiba@ims.u-tokyo.ac.jp	Aruga, Jun/H-5837-2011; KITAGUCHI, TETSUYA/AAR-1895-2021; Kitaguchi, Tetsuya/F-5260-2017; Noda, Tetsuo/B-1667-2016; Yamada, Maki/U-5251-2019; Yamada, Maki K./A-1573-2015; Takahashi-Iwanaga, Hiromi/A-4294-2012; Mikoshiba, Katsuhiko/N-7943-2015	Aruga, Jun/0000-0001-7936-1375; KITAGUCHI, TETSUYA/0000-0001-6701-1933; Kitaguchi, Tetsuya/0000-0001-6701-1933; Yamada, Maki K./0000-0002-1956-6069; 				Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; EPSTEIN AN, 1964, NATURE, V201, P1342, DOI 10.1038/2011342a0; Fujii S, 2000, LEARN MEMORY, V7, P312, DOI 10.1101/lm.34100; FUJINO I, 1995, CELL TISSUE RES, V280, P201, DOI 10.1007/s004410050345; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; Krane CM, 2001, J BIOL CHEM, V276, P23413, DOI 10.1074/jbc.M008760200; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Matsumoto M, 1996, NATURE, V379, P168, DOI 10.1038/379168a0; Nakamura T, 2004, J PHYSIOL-LONDON, V558, P561, DOI 10.1113/jphysiol.2004.064626; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; Nishiyama M, 2000, NATURE, V408, P584, DOI 10.1038/35046067; Petersen OH, 2003, CELL CALCIUM, V33, P337, DOI 10.1016/S0143-4160(03)00047-2; PETERSEN OH, 1986, AM J PHYSIOL, V251, pG1, DOI 10.1152/ajpgi.1986.251.1.G1; PUTNEY JW, 1986, ANNU REV PHYSIOL, V48, P75, DOI 10.1146/annurev.ph.48.030186.000451; Shin DM, 2003, J CELL BIOL, V162, P293, DOI 10.1083/jcb.200210109; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; Yamamoto-Hino M, 1998, J CELL BIOL, V141, P135, DOI 10.1083/jcb.141.1.135; Yule DI, 1997, J BIOL CHEM, V272, P9093	25	238	246	2	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	2005	309	5744					2232	2234		10.1126/science.1114110	http://dx.doi.org/10.1126/science.1114110			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195467				2022-12-28	WOS:000232318000049
J	Elbelrhiti, H; Claudin, P; Andreotti, B				Elbelrhiti, H; Claudin, P; Andreotti, B			Field evidence for surface-wave-induced instability of sand dunes	NATURE			English	Article							BARCHAN DUNES; DYNAMICS; MODEL; WIND	Field studies of barchans - crescent- shaped dunes that propagate over solid ground under conditions of unidirectional wind(1) - have long focused on the investigation of an equilibrium between sand transport by wind and the control of air flow by dune topography(2-4), which are thought to control dune morphology and kinematics(5-7). Because of the long timescale involved, however, the underlying dynamic processes responsible for the evolution of dune fields remain poorly understood(8). Here we combine data from a three-year field study in the Moroccan Sahara with a model study to show that barchans are fundamentally unstable and do not necessarily behave like stable solitary waves, as suggested previously(9-12). We find that dune collisions and changes in wind direction destabilize the dunes and generate surface waves on the barchans. Because the resulting surface waves propagate at a higher speed than the dunes themselves, they can produce a series of new barchans of elementary size by breaking the horns of large dunes. The creation of these new dunes provides a mechanism for sand loss that prevents dune fields from merging into a single giant dune and therefore plays a fundamental role in the control of size selection and the development of dune patterns.	Phys & Mecan Milieux Heterogenes Lab, CNRS, UMR 7636, F-75005 Paris, France; Univ Ibn Zohr, Dept Geol, Agadir 80000, Morocco	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Sorbonne Universite; Universite Paris Cite; Ibn Zohr University of Agadir	Andreotti, B (corresponding author), Phys & Mecan Milieux Heterogenes Lab, CNRS, UMR 7636, 10 Rue Vauquelin, F-75005 Paris, France.	andreotti@pmmh.espci.fr		Andreotti, Bruno/0000-0001-8328-6232; Elbelrhiti, hicham/0000-0001-5530-2514				Andreotti B, 2004, J FLUID MECH, V510, P47, DOI 10.1017/S0022112004009073; Andreotti B, 2002, EUR PHYS J B, V28, P321, DOI 10.1140/epjb/e2002-00236-4; [Anonymous], 1967, Z GEOMORPHOL; Bagnold R., 1941, PHYS BLOWN SAND DESE; Besler H, 2002, Z GEOMORPHOL, V126, P59; *EUR SPAC AG, 2005, MARS EXPR; FINKEL HJ, 1959, J GEOL, V67, P614, DOI 10.1086/626622; Fryberger S. G., 1979, U.S. Geological Survey, Professional Paper, P137; Hersen P, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.264301; Hersen P, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.011304; HUERRE P, 1990, ANNU REV FLUID MECH, V22, P473, DOI 10.1146/annurev.fl.22.010190.002353; Katsuki A, 2005, J PHYS SOC JPN, V74, P538, DOI 10.1143/JPSJ.74.538; Lancaster N, 1996, GEOMORPHOLOGY, V17, P55, DOI 10.1016/0169-555X(95)00095-M; Livingstone I, 2005, EARTH SURF PROC LAND, V30, P255, DOI 10.1002/esp.1206; *MARS ROV BLOG, 2005, MARS ROV PHOT; MCKENNANEUMAN C, 1997, SEDIMENTOLOGY, V44, P1103; Schwammle V, 2003, NATURE, V426, P619, DOI 10.1038/426619a; Wiggs GFS, 1996, GEOMORPHOLOGY, V17, P29, DOI 10.1016/0169-555X(95)00093-K	18	170	182	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					720	723		10.1038/nature04058	http://dx.doi.org/10.1038/nature04058			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193049				2022-12-28	WOS:000232157900049
J	Rolles, D; Braune, M; Cvejanovic, S; Gessner, O; Hentges, R; Korica, S; Langer, B; Lischke, T; Prumper, G; Reinkoster, A; Viefhaus, J; Zimmermann, BR; McKoy, V; Becker, U				Rolles, D; Braune, M; Cvejanovic, S; Gessner, O; Hentges, R; Korica, S; Langer, B; Lischke, T; Prumper, G; Reinkoster, A; Viefhaus, J; Zimmermann, BR; McKoy, V; Becker, U			Isotope-induced partial localization of core electrons in the homonuclear molecule N-2	NATURE			English	Article							PHOTOELECTRON ANGULAR-DISTRIBUTION; GERADE SYMMETRY-BREAKING; K-SHELL PHOTOIONIZATION; SHAPE RESONANCES; IONIZATION; DECAY; SPECTROSCOPY; TRANSITION; EMISSION	Because of inversion symmetry and particle exchange, all constituents of homonuclear diatomic molecules are in a quantum mechanically non-local coherent state; this includes the nuclei and deep-lying core electrons. Hence, the molecular photoemission can be regarded as a natural double-slit experiment(1): coherent electron emission originates from two identical sites, and should give rise to characteristic interference patterns(2). However, the quantum coherence is obscured if the two possible symmetry states of the electronic wavefunction ('gerade' and 'ungerade') are degenerate; the sum of the two exactly resembles the distinguishable, incoherent emission from two localized core sites. Here we observe the coherence of core electrons in N-2 through a direct measurement of the interference exhibited in their emission. We also explore the gradual transition to a symmetry-broken system of localized electrons by comparing different isotope-substituted species - a phenomenon analogous to the acquisition of partial 'which-way' information in macroscopic double-slit experiments(3).	Max Planck Gesell, Fritz Haber Inst, D-14195 Berlin, Germany; Max Born Inst Nichtlineare Opt & Kurzzeitspektros, D-12489 Berlin, Germany; CALTECH, Pasadena, CA 91125 USA	Max Planck Society; Fritz Haber Institute of the Max Planck Society; Max Born Institute for Nonlinear Optics & Short Term Spectroscopy; California Institute of Technology	Becker, U (corresponding author), Max Planck Gesell, Fritz Haber Inst, D-14195 Berlin, Germany.	becker_u@fhi-berlin.mpg.de	Becker, Uwe/A-6604-2013; Lischke, Toralf/B-8369-2013; Langer, Burkhard/Q-5351-2019; Rolles, Daniel/C-2384-2008; Langer, Burkhard/A-6504-2013	Langer, Burkhard/0000-0002-5334-5112; Viefhaus, Jens/0000-0003-1154-0750				Bayer M, 2001, SCIENCE, V291, P451, DOI 10.1126/science.291.5503.451; Becker U, 2000, J ELECTRON SPECTROSC, V112, P47, DOI 10.1016/S0368-2048(00)00202-4; Bjorneholm O, 2000, PHYS REV LETT, V84, P2826, DOI 10.1103/PhysRevLett.84.2826; Bouloufa N, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.042507; Briggs JS, 2000, PHYS ESSAYS, V13, P297, DOI 10.4006/1.3028823; Broer R, 1999, J MOL STRUC-THEOCHEM, V458, P19, DOI 10.1016/S0166-1280(98)00345-5; Cacciani P, 2000, PHYS REV LETT, V84, P5296, DOI 10.1103/PhysRevLett.84.5296; Cherepkov NA, 2000, PHYS REV LETT, V84, P250, DOI 10.1103/PhysRevLett.84.250; Critchley ADJ, 2001, PHYS REV LETT, V86, P1725, DOI 10.1103/PhysRevLett.86.1725; DEHMER JL, 1975, PHYS REV LETT, V35, P213, DOI 10.1103/PhysRevLett.35.213; DOMCKE W, 1977, CHEM PHYS, V25, P189, DOI 10.1016/0301-0104(77)87075-4; Golovin AV, 1997, PHYS REV LETT, V79, P4554, DOI 10.1103/PhysRevLett.79.4554; Hackermuller L, 2004, NATURE, V427, P711, DOI 10.1038/nature02276; Hayashi T, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.226804; Heiser F, 1997, PHYS REV LETT, V79, P2435, DOI 10.1103/PhysRevLett.79.2435; Hergenhahn U, 2001, J PHYS CHEM A, V105, P5704, DOI 10.1021/jp0038456; HERZBERG G, 1989, SPECTRA DIATOMIC MOL, V1, P139; Jahnke T, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.073002; Kosugi N, 2004, J ELECTRON SPECTROSC, V137, P335, DOI 10.1016/j.elspec.2004.02.084; Lindner F, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.040401; Mulliken RS, 1929, T FARADAY SOC, V25, P0634, DOI 10.1039/tf9292500634; Pavlychev AA, 1998, PHYS REV LETT, V81, P3623, DOI 10.1103/PhysRevLett.81.3623; PIQUE JP, 1984, PHYS REV LETT, V52, P267, DOI 10.1103/PhysRevLett.52.267; Semenov SK, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.022708; SHIGEMASA E, 1995, PHYS REV LETT, V74, P359, DOI 10.1103/PhysRevLett.74.359; Siegban K., 1967, ESCA ATOMIC MOL SOLI, V20; Skytt P, 1996, PHYS REV LETT, V77, P5035, DOI 10.1103/PhysRevLett.77.5035; Stener M, 2002, CHEM PHYS LETT, V351, P469, DOI 10.1016/S0009-2614(01)01408-7; Wabnitz H, 2002, NATURE, V420, P482, DOI 10.1038/nature01197; Weber T, 2001, J PHYS B-AT MOL OPT, V34, P3669, DOI 10.1088/0953-4075/34/18/305; YANG CN, 1948, PHYS REV, V74, P764, DOI 10.1103/PhysRev.74.764; Zimmermann B, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.042711	33	147	149	3	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					711	715		10.1038/nature04040	http://dx.doi.org/10.1038/nature04040			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193047				2022-12-28	WOS:000232157900047
J	Coutinho, SB; de Lira, PIC; Lima, MD; Ashworth, A				Coutinho, SB; de Lira, PIC; Lima, MD; Ashworth, A			Comparison of the effect of two systems for the promotion of exclusive breastfeeding	LANCET			English	Article							RANDOMIZED CONTROLLED-TRIAL; HEALTH; MORTALITY; RATES	Background Promotion of breastfeeding is an important child-survival intervention, yet little is known about which promotional strategies are the most effective. We aimed to compare the effects on rates of breastfeeding of two systems for promotion of breastfeeding in Brazil-a hospital-based system and the same system combined with a programme of home visits. Methods In February, 2001, maternity staff from two hospitals in Pernambuco, Brazil, were trained according to the Baby-Friendly Hospital Initiative (BFHI). In a randomised trial between March and August, 2001, 350 mothers giving birth at these hospitals were assigned ten postnatal home visits to promote and support breastfeeding (n=175) or no home visits (n=175). Breastfeeding practices were studied on days 1, 10, 30, 60, 90, 120, 150, and 180 by researchers unaware of group allocation. The primary outcome measure was the rate of exclusive breastfeeding from birth to 6 months. Analyses were by intention to treat. Findings The hospital-training intervention achieved a high rate (70%) of exclusive breastfeeding in the hospitals, but this rate was not sustained at home and at 10 days of age only 30% of infants were exclusively breastfed The patterns of exclusive breastfeeding in the two trial groups for days 10-180 differed significantly (p<0.0001), with a mean aggregated prevalence of 45% among the group assigned home visits compared with 13% for the group assigned none. Interpretation The BFHI achieves high rates of exclusive breastfeeding in hospital; however, in Brazil at least, the rates fall rapidly thereafter. Reliance on the BFHI as a strategy for breastfeeding promotion should be reassessed. A combination of promotional systems (hospital-based and in the community) is needed.	Univ London London Sch Hyg & Trop Med, Nutr & Publ Hlth Intervent Res Unit, London WC1E 7HT, England; Univ Fed Pernambuco, Dept Maternal & Child Hlth, Recife, PE, Brazil; Univ Fed Pernambuco, Dept Nutr, Recife, PE, Brazil	University of London; London School of Hygiene & Tropical Medicine; Universidade Federal de Pernambuco; Universidade Federal de Pernambuco	Ashworth, A (corresponding author), Univ London London Sch Hyg & Trop Med, Nutr & Publ Hlth Intervent Res Unit, Keppel St, London WC1E 7HT, England.	ann.hill@lshtm.ac.uk	de C Lima, Marilia/I-5165-2013					Bhandari N, 2003, LANCET, V361, P1418, DOI 10.1016/S0140-6736(03)13134-0; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Braun MLG, 2003, AM J PUBLIC HEALTH, V93, P1277, DOI 10.2105/AJPH.93.8.1277; Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; Cattaneo A, 2001, BMJ-BRIT MED J, V323, P1358, DOI 10.1136/bmj.323.7325.1358; Claeson M, 2003, LANCET, V362, P323, DOI 10.1016/S0140-6736(03)13977-3; Good P., 1993, PERMUTATION TESTS; Haider R, 2000, LANCET, V356, P1643, DOI 10.1016/S0140-6736(00)03159-7; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; KING SS, 1997, COM AJ MAES AM; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; LEITE AJM, 1998, CLIN EPIDEMIOLOGY S, V51, pS10; Marques NM, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e66; Morrow AL, 1999, LANCET, V353, P1226, DOI 10.1016/S0140-6736(98)08037-4; PEREZESCAMILLA R, 1994, AM J PUBLIC HEALTH, V84, P89, DOI 10.2105/AJPH.84.1.89; *UNICEF WHO, 1993, MAN PROM AL MAT NUM; *UNICEF WHO, 1997, AC AM CURS TREIN; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7; WESTPHAL MF, 1995, B WORLD HEALTH ORGAN, V73, P461; *WHO, 1992, IND ASS BREATF PRACT; WHO, 1998, 10 STEPS SUCC BREAST; World Health Organization, 1998, EV 10 STEPS SUCC BRE	22	137	145	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 24	2005	366	9491					1094	1100		10.1016/S0140-6736(05)67421-1	http://dx.doi.org/10.1016/S0140-6736(05)67421-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TL	16182897				2022-12-28	WOS:000232114000027
J	Fleischmann, E; Lenhardt, R; Kurz, A; Herbst, F; Fulesdi, A; Greif, R; Sessler, DI; Akca, O; Hopf, H; Scheuenstuhl, H; Niedermayer, F; Krasser, K; Rudel, V; Bartok, T; Hamza, J; Orosz, L; Kanyari, Z; Scheck, T; Kober, A; Fleischhackl, R; Treschan, T; Kimberger, O; Yuecel, Y; Freitag, M; Schlechta, U; Schebesta, K; Lackner, F; Werba, A; Zimpfer, M; Hager, H; Kabon, B; Fuegger, R; Stift, A				Fleischmann, E; Lenhardt, R; Kurz, A; Herbst, F; Fulesdi, A; Greif, R; Sessler, DI; Akca, O; Hopf, H; Scheuenstuhl, H; Niedermayer, F; Krasser, K; Rudel, V; Bartok, T; Hamza, J; Orosz, L; Kanyari, Z; Scheck, T; Kober, A; Fleischhackl, R; Treschan, T; Kimberger, O; Yuecel, Y; Freitag, M; Schlechta, U; Schebesta, K; Lackner, F; Werba, A; Zimpfer, M; Hager, H; Kabon, B; Fuegger, R; Stift, A		Outcomes Res Grp	Nitrous oxide and risk of surgical wound infection: a randomised trial	LANCET			English	Article							COLONIC SURGERY; ISOFLURANE; MAC; ANESTHESIA; HALOTHANE; REDUCE; OXYGEN; RATS	Background Nitrous oxide inactivates vitamin B12 and methionine synthase, thereby impairing DNA formation and, consequently, new cell formation. The gas also inhibits methionine production, which can reduce scar formation and depresses chemotactic migration by monocytes. Therefore, we assessed whether nitrous oxide increases the incidence of surgical wound infection. Methods We recruited 418 patients aged 18-80 years, scheduled for colon resection that was expected to last more than 2 h, at three hospitals in Austria and Hungary. Patients were randomly assigned 65% intraoperative nitrous oxide (n=208) or nitrogen (n=206), with remifentanil and isoflurane. The primary outcome was the incidence of clinical postoperative wound infection, analysed by intention to treat. Findings 206 patients in the nitrous oxide group and 202 in the nitrogen group were included in the final analysis. Duration of surgery was longer in the nitrogen group (3.4 h [1.5]) than in the nitrous oxide group (3.0 h [SD 1.3]) and arterial pressure (84 mm Hg [10] vs 81 mm Hg [9]), bispectral index values (53 [9] vs 44 [8]), and end-tidal isoflurane concentration (0.64% [0.14] vs 0.56% [0.13]) were greater in patients given nitrogen than in those given nitrous oxide. Infection rate was 15% (31/206) in patients given nitrous oxide and 20% (40/202) in those given nitrogen (p=0.205). Additionally, the ASEPSIS wound healing score, wound Collagen deposition, number of patients admitted to critical care unit, time to first food ingestion, duration of hospital stay, and mortality did not differ between treatment groups. Interpretation Nitrous oxide does not increase the incidence of surgical wound infection.	Univ Louisville, Outcomes Res Inst, Louisville, KY 40202 USA; Med Univ Vienna, Dept Anaesthesia & Intens Care Med, Vienna, Austria; Univ Bern, Dept Anaesthesia, Bern, Switzerland; Univ Med Sch Debrecen, Dept Anaesthesiol & Intens Care, Debrecen, Hungary; Donauspital, SMZ Ost, Dept Anaesthesiol & Intens Care Med, Vienna, Austria; Univ Louisville, Dept Anaesthesiol & Perioperat Med, Louisville, KY 40292 USA; Cleveland Clin Fdn, Dept Outcomes Res, Cleveland, OH 44195 USA	University of Louisville; Medical University of Vienna; University of Bern; University of Debrecen; Donauspital; University of Louisville; Cleveland Clinic Foundation	Akca, O (corresponding author), Univ Louisville, Outcomes Res Inst, 501 E Broadway,Suite 210, Louisville, KY 40202 USA.	ozan.akca@louisville.edu	Robert, Greif/O-6392-2016; Akca, Ozan/I-8856-2019; Schebesta, Karl/V-4626-2019; Hopf, Harriet W./V-5506-2019; Meyer-Treschan, Tanja A./S-6624-2017; Sessler, Daniel/D-3504-2011	Robert, Greif/0000-0003-0160-2073; Akca, Ozan/0000-0002-7275-1060; Hopf, Harriet W./0000-0002-3603-5569; Meyer-Treschan, Tanja A./0000-0001-9363-1028; Sessler, Daniel/0000-0001-9932-3077; Kurz, Andrea/0000-0001-5887-3099	NIDCR NIH HHS [R03 DE014879-02, DE 14879-01A1] Funding Source: Medline; NIGMS NIH HHS [R01 GM061655-03, GM 61655] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE014879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061655] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akca O, 2004, ACTA ANAESTH SCAND, V48, P894, DOI 10.1111/j.0001-5172.2004.00427.x; BENHAIM P, 1992, Journal of Burn Care and Rehabilitation, V13, P287, DOI 10.1097/00004630-199203000-00022; BOYCE JM, 1990, INFECT CONT HOSP EP, V11, P89; Brand JM, 1997, CLIN IMMUNOL IMMUNOP, V83, P190, DOI 10.1006/clin.1997.4351; BRUNNER MD, 1994, BRIT J ANAESTH, V72, P42, DOI 10.1093/bja/72.1.42; BYRNE DJ, 1989, BIOMED PHARMACOTHER, V43, P669, DOI 10.1016/0753-3322(89)90085-1; Caille V, 2004, PRESSE MED, V33, P256, DOI 10.1016/S0755-4982(04)98551-X; CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501; COLE DJ, 1990, ANESTHESIOLOGY, V73, P93, DOI 10.1097/00000542-199007000-00014; Culver DH, 1991, AM J MED S3B, V91, P152, DOI DOI 10.1016/0002-9343(91)90361-Z; EDWARDS AE, 1984, ANAESTHESIA, V39, P1071, DOI 10.1111/j.1365-2044.1984.tb08925.x; EGER EI, 1990, ANESTH ANALG, V71, P575; GONSOWSKI CT, 1994, ANESTH ANALG, V79, P710; Greif R, 2000, NEW ENGL J MED, V342, P161, DOI 10.1056/NEJM200001203420303; GUIRGUIS SS, 1990, BRIT J IND MED, V47, P490; HALEY RW, 1985, AM J EPIDEMIOL, V121, P206, DOI 10.1093/oxfordjournals.aje.a113991; Hassanain HH, 2005, SURGERY, V137, P92, DOI 10.1016/j.surg.2004.06.012; HILL GE, 1978, BRIT J ANAESTH, V50, P555, DOI 10.1093/bja/50.6.555; Hopf HW, 1997, ARCH SURG-CHICAGO, V132, P997; JONSSON K, 1986, Surgical Forum (Chicago), V37, P86; KOBLIN DD, 1982, ANESTH ANALG, V61, P75; Kotani N, 1998, ANESTHESIOLOGY, V89, P1125, DOI 10.1097/00000542-199811000-00012; Kripke B J, 1987, Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi, V20, P302; KROGH B, 1994, BRIT J ANAESTH, V72, P55, DOI 10.1093/bja/72.1.55; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; LIENERS C, 1989, INFLAMMATION, V13, P621, DOI 10.1007/BF00914306; LINDBLAD WJ, 1984, ANAL BIOCHEM, V138, P390, DOI 10.1016/0003-2697(84)90827-3; Mapleson WW, 1996, BRIT J ANAESTH, V76, P179, DOI 10.1093/bja/76.2.179; MILES AA, 1957, BRIT J EXP PATHOL, V38, P79; PERRY J, 1983, J CLIN INVEST, V71, P1183, DOI 10.1172/JCI110867; ROWLAND AS, 1995, AM J EPIDEMIOL, V141, P531, DOI 10.1093/oxfordjournals.aje.a117468; SCHEININ B, 1990, BRIT J ANAESTH, V64, P154, DOI 10.1093/bja/64.2.154; Sessler DI, 2002, CLIN INFECT DIS, V35, P1397, DOI 10.1086/344275; SKACEL PO, 1983, BRIT J HAEMATOL, V53, P693	34	55	55	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 24	2005	366	9491					1101	1107		10.1016/S0140-6736(05)67422-3	http://dx.doi.org/10.1016/S0140-6736(05)67422-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TL	16182898				2022-12-28	WOS:000232114000028
J	Fitzmaurice, DA; Murray, ET; McCahon, D; Holder, R; Raftery, JP; Hussain, S; Sandhar, H; Hobbs, FDR				Fitzmaurice, DA; Murray, ET; McCahon, D; Holder, R; Raftery, JP; Hussain, S; Sandhar, H; Hobbs, FDR			Self management of oral anticoagulation: randomised trial	BRITISH MEDICAL JOURNAL			English	Article							ATRIAL-FIBRILLATION; THERAPY; GUIDELINES	Objective To determine the clinical effectiveness of self management compared with routine care in patients on long term oral anticoagulants. Design Multicentre open randomised controlled trial. Setting Midlands region of the UK. Participants 617 patients aged over 18 and receiving warfarin randomised to intervention (n = 337) and routine care (n = 280) Front 2470 invited; 193/337 (57%) completed the 12 month intervention. Intervention Intervention patients used a point of care device to measure international normalised ratio twice a week mid a simple closing chart to interpret their dose of warfarin. Main outcome measure Percentage of time spent within the therapeutic range of international normalised ratio. Results No significant differences were found in percentage of time in the therapeutic range between self management and routine care (70% v 68%). Self managed patients with poor control before the study showed an improvement in control that was not seen in die routine care group. Nine patients (2.8/100 patient years) had serious adverse events in the self managed group, compared with seven (2.7/100 patient years) in the routine care arm (chi(2)(df = 1) = 0.02, P = 0.89). Conclusion With appropriate training, self management is safe and reliable for a sizeable proportion of patients receiving oral anticoagulation treatment. It may improve die time spent within the therapeutic range for patients with initially poor control.	Univ Birmingham, Dept Primary Care Gen Practice, Birmingham B15 2TT, W Midlands, England; Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England	University of Birmingham; University of Birmingham	Fitzmaurice, DA (corresponding author), Univ Birmingham, Dept Primary Care Gen Practice, Birmingham B15 2TT, W Midlands, England.	d.a.fitzmaurice@bham.ac.uk		hobbs, richard/0000-0001-7976-7172				Ansell J, 2005, INT J CARDIOL, V99, P37, DOI 10.1016/j.ijcard.2003.11.008; BAGLIN T, 1994, CLIN LAB HAEMATOL, V16, P327; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; COLVIN BT, 1990, J CLIN PATHOL, V43, P177; Cromheecke ME, 2000, LANCET, V356, P97, DOI 10.1016/S0140-6736(00)02470-3; Fitzmaurice DA, 2002, J CLIN PATHOL, V55, P845, DOI 10.1136/jcp.55.11.845; Fitzmaurice DA, 2001, BRIT MED J, V323, P985, DOI 10.1136/bmj.323.7319.985; Gadisseur APA, 2003, ARCH INTERN MED, V163, P2639, DOI 10.1001/archinte.163.21.2639; Hasenkam JM, 1997, EUR J CARDIO-THORAC, V11, P935, DOI 10.1016/S1010-7940(97)01204-9; *IMS HLTH, 1999, MP990207 IMS HLTH; Menendez-Jandula B, 2005, ANN INTERN MED, V142, P1, DOI 10.7326/0003-4819-142-1-200501040-00006; Morsdorf S, 1999, SEMIN THROMB HEMOST, V25, P109, DOI 10.1055/s-2007-996433; Murray E, 2004, BRIT MED J, V328, P437, DOI 10.1136/bmj.328.7437.437; Murray ET, 1999, J CLIN PATHOL, V52, P842, DOI 10.1136/jcp.52.11.842; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; Rose PE, 1996, J CLIN PATHOL, V49, P5, DOI 10.1136/jcp.49.1.5; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; Sawicki PT, 1999, JAMA-J AM MED ASSOC, V281, P145, DOI 10.1001/jama.281.2.145; Siebenhofer A, 2004, THROMB HAEMOSTASIS, V91, P225, DOI 10.1160/TH03-09-0598; SUDLOW CM, 1995, BRIT MED J, V311, P558, DOI 10.1136/bmj.311.7004.558; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529; TAYLOR F, 1993, BRIT MED J, V307, P1493, DOI 10.1136/bmj.307.6917.1493	22	86	89	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	NOV 5	2005	331	7524					1057	1059		10.1136/bmj.38618.580903.AE	http://dx.doi.org/10.1136/bmj.38618.580903.AE			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983DL	16216821	Bronze, Green Published			2022-12-28	WOS:000233211200020
J	Barnes, TD; Kubota, Y; Hu, D; Jin, DZZ; Graybiel, AM				Barnes, TD; Kubota, Y; Hu, D; Jin, DZZ; Graybiel, AM			Activity of striatal neurons reflects dynamic encoding and recoding of procedural memories	NATURE			English	Article							BASAL GANGLIA; PREDICTION; EXTINCTION; SELECTION; HABITS; CORTEX	Learning to perform a behavioural procedure as a well-ingrained habit requires extensive repetition of the behavioural sequence, and learning not to perform such behaviours is notoriously difficult. Yet regaining a habit can occur quickly, with even one or a few exposures to cues previously triggering the behaviour(1-3). To identify neural mechanisms that might underlie such learning dynamics, we made long-term recordings from multiple neurons in the sensorimotor striatum, a basal ganglia structure implicated in habit formation(4-8), in rats successively trained on a reward-based procedural task, given extinction training and then given reacquisition training. The spike activity of striatal output neurons, nodal points in cortico-basal ganglia circuits, changed markedly across multiple dimensions during each of these phases of learning. First, new patterns of task-related ensemble firing successively formed, reversed and then re-emerged. Second, task-irrelevant firing was suppressed, then rebounded, and then was suppressed again. These changing spike activity patterns were highly correlated with changes in behavioural performance. We propose that these changes in task representation in cortico-basal ganglia circuits represent neural equivalents of the explore-exploit behaviour characteristic of habit learning.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA; Penn State Univ, Dept Phys, Davey Lab 0104, University Pk, PA 16802 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Graybiel, AM (corresponding author), MIT, Dept Brain & Cognit Sci, 43 Vassar St,46-6133, Cambridge, MA 02139 USA.	graybiel@mit.edu	Jin, Dezhe/AAE-6788-2020	Graybiel, Ann/0000-0002-4326-7720	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038372] Funding Source: NIH RePORTER; NINDS NIH HHS [P50 NS038372] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beiser, 1995, MODELS INFORM PROCES, P215; Bouton ME, 2004, LEARN MEMORY, V11, P485, DOI 10.1101/lm.78804; DICKINSON A, 1985, PHILOS T ROY SOC B, V308, P67, DOI 10.1098/rstb.1985.0010; DICKINSON A, 1994, ANIM LEARN BEHAV, V22, P1, DOI 10.3758/BF03199951; Djurfeldt M, 2001, NEUROCOMPUTING, V38, P573, DOI 10.1016/S0925-2312(01)00413-1; Doya K, 2002, NEURAL NETWORKS, V15, P495, DOI 10.1016/S0893-6080(02)00044-8; Doya K, 1996, ADV NEURAL INFORMATI, P101; Doya Kenji, 2000, P469; Frank MJ, 2001, COGN AFFECT BEHAV NE, V1, P137, DOI 10.3758/CABN.1.2.137; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; Graybiel AM, 1998, NEUROBIOL LEARN MEM, V70, P119, DOI 10.1006/nlme.1998.3843; Gurney K, 2001, BIOL CYBERN, V84, P401, DOI 10.1007/PL00007984; HOUK JC, 1995, CEREB CORTEX, V5, P95, DOI 10.1093/cercor/5.2.95; James W, 1890, PRINCIPLES PSYCHOL, P104; Jog MS, 1999, SCIENCE, V286, P1745, DOI 10.1126/science.286.5445.1745; Kao MH, 2005, NATURE, V433, P638, DOI 10.1038/nature03127; McClure SM, 2003, NEURON, V38, P339, DOI 10.1016/S0896-6273(03)00154-5; Mink JW, 1996, PROG NEUROBIOL, V50, P381, DOI 10.1016/S0301-0082(96)00042-1; Montague PR, 2004, NATURE, V431, P760, DOI 10.1038/nature03015; Myers KM, 2002, NEURON, V36, P567, DOI 10.1016/S0896-6273(02)01064-4; Olveczky BP, 2005, PLOS BIOL, V3, P902, DOI 10.1371/journal.pbio.0030153; Packard MG, 2002, ANNU REV NEUROSCI, V25, P563, DOI 10.1146/annurev.neuro.25.112701.142937; Pavlov I.P., 1927, CONDITIONED REFLEXES; Poldrack RA, 2001, NATURE, V414, P546, DOI 10.1038/35107080; Reynolds JNJ, 2001, NATURE, V413, P67, DOI 10.1038/35092560; ROUTTENBERG A, 1978, CHOLINERGIC MONOAMIN, P305; Tanaka SC, 2004, NAT NEUROSCI, V7, P887, DOI 10.1038/nn1279; WILSON CJ, 2004, SYNAPTIC ORG BRAIN, P361, DOI DOI 10.1093/ACPROF:0S0/9780195159561.003.0009; Yin HH, 2004, EUR J NEUROSCI, V19, P181, DOI 10.1111/j.1460-9568.2004.03095.x	30	427	432	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 20	2005	437	7062					1158	1161		10.1038/nature04053	http://dx.doi.org/10.1038/nature04053			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16237445				2022-12-28	WOS:000232660500045
J	Reich, K; Nestle, FO; Papp, K; Ortonne, JP; Evans, R; Guzzo, C; Li, S; Dooley, LT; Griffiths, CEM				Reich, K; Nestle, FO; Papp, K; Ortonne, JP; Evans, R; Guzzo, C; Li, S; Dooley, LT; Griffiths, CEM		EXPRESS Study Investigators	Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial	LANCET			English	Article							NECROSIS-FACTOR-ALPHA; CHRONIC PLAQUE PSORIASIS; EFALIZUMAB THERAPY; RANDOMIZED TRIAL; DISEASE SEVERITY; TNF-ALPHA; PLACEBO; SAFETY; LOCALIZATION; METHOTREXATE	Background Tumour necrosis factor alpha (TNF alpha) is thought to play a part in the pathogenesis of psoriasis. We assessed the efficacy and safety of continuous treatment with infliximab, a monoclonal antibody that binds to and neutralises the activity of TNF alpha, in patients with psoriasis. Methods In this phase III, multicentre, double-blind trial, 378 patients with moderate-to-severe plaque psoriasis were allocated in a 4:1 ratio to receive infusions of either infliximab 5 mg/kg or placebo at weeks 0, 2, and 6, then every 8 weeks to week 46. At week 24, placebo-treated patients crossed over to infliximab treatment. Skin and nail signs of psoriasis were assessed using the psoriasis area and severity index (PASI) and nail psoriasis severity index (NAPSI), respectively. The primary endpoint, analysed on an intention-to-treat-basis, was the proportion of patients achieving at least a 75% improvement in PASI from baseline to week 10. Findings At week 10, 80% (242/301) of patients treated with infliximab achieved at least a 75% improvement from their baseline PASI (PASI 75) and 57% (172/301) achieved at least a 90% improvement (PASI 90), compared with 3% and 1% in the placebo group, respectively (p<0.0001). At week 24, PASI 75 (82% for infliximab VS 4% for placebo) and PASI 90 (58% vs 1%) were maintained (p<0.0001). At week 50, 61% achieved PASI 75 and 45% achieved PASI 90 in the infliximab group. Infliximab was generally well tolerated in most patients. Interpretation Infliximab is effective in both an induction and maintenance regimen for the treatment of moderate-to-severe psoriasis, with a high percentage of patients achieving sustained PASI 75 and PASI 90 improvement through 1 year.	Univ Manchester, Hope Hosp, Dermatol Ctr, Manchester M6 8HD, Lancs, England; Univ Gottingen, Dept Dermatol, D-3400 Gottingen, Germany; Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; Prob Med Res, Waterloo, ON, Canada; Univ Western Ontario, London, ON, Canada; Hop Archet, Nice, France; Scios Nova Inc, Fremont, CA USA; Centocor Inc, Malvern, PA USA; Univ Manchester, Hope Hosp, Dermatol Ctr, Manchester, Lancs, England	University of Manchester; University of Gottingen; University of Zurich; University Zurich Hospital; Western University (University of Western Ontario); CHU Nice; Scios; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; University of Manchester	Griffiths, CEM (corresponding author), Univ Manchester, Hope Hosp, Dermatol Ctr, Manchester M6 8HD, Lancs, England.	Christopher.griffiths@manchester.ac.uk	Griffiths, Christopher E.M./P-5448-2014	Griffiths, Christopher E.M./0000-0001-5371-4427; Papp, Kim A./0000-0001-9557-3642				Antoni C, 2005, ANN RHEUM DIS, V64, P1150, DOI 10.1136/ard.2004.032268; Bakleh M, 2005, INT J DERMATOL, V44, P443, DOI 10.1111/j.1365-4632.2004.02571.x; BONIFATI C, 1994, CLIN EXP DERMATOL, V19, P383, DOI 10.1111/j.1365-2230.1994.tb02687.x; Boyman O, 2004, J EXP MED, V199, P731, DOI 10.1084/jem.20031482; Chaudhari U, 2001, LANCET, V357, P1842, DOI 10.1016/S0140-6736(00)04954-0; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; Gordon KB, 2003, JAMA-J AM MED ASSOC, V290, P3073, DOI 10.1001/jama.290.23.3073; Gottlieb AB, 2004, J AM ACAD DERMATOL, V51, P534, DOI 10.1016/j.jaad.2004.02.021; Gottlieb AB, 2005, NAT REV DRUG DISCOV, V4, P19, DOI 10.1038/nrd1607; Hanauer SB, 2002, LANCET, V359, P1541, DOI 10.1016/S0140-6736(02)08512-4; Hanauer SB, 2004, CLIN GASTROENTEROL H, V2, P542, DOI 10.1016/S1542-3565(04)00238-1; Heydendael VMR, 2003, NEW ENGL J MED, V349, P658, DOI 10.1056/NEJMoa021359; *IMM CORP, 2003, ENBREL PACK INS; Khanna D, 2004, DRUG SAFETY, V27, P307, DOI 10.2165/00002018-200427050-00003; KRISTENSEN M, 1993, CLIN EXP IMMUNOL, V94, P354; Lebwohl M, 2003, NEW ENGL J MED, V349, P2004, DOI 10.1056/NEJMoa030002; Lebwohl M, 2003, ARCH DERMATOL, V139, P719, DOI 10.1001/archderm.139.6.719; Lebwohl M, 2003, LANCET, V361, P1197, DOI 10.1016/S0140-6736(03)12954-6; Leonardi CL, 2005, J AM ACAD DERMATOL, V52, P425, DOI 10.1016/j.jaad.2004.09.029; Leonardi CL, 2003, NEW ENGL J MED, V349, P2014, DOI 10.1056/NEJMoa030409; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; *MED EC CO, 2005, REM INL PHYS DESK RE; Menter A, 2005, ARCH DERMATOL, V141, P31, DOI 10.1001/archderm.141.1.31; Mussi A, 1997, J BIOL REG HOMEOS AG, V11, P115; Nickoloff BJ, 2004, J CLIN INVEST, V113, P1664, DOI 10.1172/JCI200422147; NICKOLOFF BJ, 1991, AM J PATHOL, V138, P129; Reich K, 2001, J INVEST DERMATOL, V116, P319, DOI 10.1046/j.1523-1747.2001.01248.x; Rich P, 2003, J AM ACAD DERMATOL, V49, P206, DOI 10.1067/S0190-9622(03)00910-1; Schon MP, 2005, NEW ENGL J MED, V352, P1899, DOI 10.1056/NEJMra041320; Sterry W, 2004, BRIT J DERMATOL, V151, P3, DOI 10.1111/j.1365-2133.2004.06070.x	30	844	889	3	37	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 15	2005	366	9494					1367	1374		10.1016/S0140-6736(05)67566-6	http://dx.doi.org/10.1016/S0140-6736(05)67566-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	973ZW	16226614				2022-12-28	WOS:000232562100028
J	Hoffmann, DE; Rothenberg, KH				Hoffmann, DE; Rothenberg, KH			Science and law - When should judges admit or compel genetic tests?	SCIENCE			English	Editorial Material									Univ Maryland, Sch Law, Baltimore, MD 21210 USA	University System of Maryland; University of Maryland Baltimore	Hoffmann, DE (corresponding author), Univ Maryland, Sch Law, Baltimore, MD 21210 USA.	dhoffman@law.umaryland.edu						Casey DK, 1999, JUDICATURE, V83, P105; Marchant G E, 2001, Seton Hall Law Rev, V31, P949; Niedwiecki A S, 2000, Univ San Francisco Law Rev, V34, P295	3	3	3	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 14	2005	310	5746					241	242		10.1126/science.1117972	http://dx.doi.org/10.1126/science.1117972			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	975NV	16224007	Green Submitted			2022-12-28	WOS:000232670100030
J	Lu, HY; Yang, XY; Ye, ML; Liu, KB; Xia, ZK; Ren, XY; Cai, LH; Wu, NQ; Liu, TS				Lu, HY; Yang, XY; Ye, ML; Liu, KB; Xia, ZK; Ren, XY; Cai, LH; Wu, NQ; Liu, TS			Millet noodles in Late Neolithic China - A remarkable find allows the reconstruction of the earliest recorded preparation of noodles.	NATURE			English	Editorial Material							PHYTOLITHS; STARCH		Chinese Acad Sci, Inst Geol & Geophys, Beijing 100029, Peoples R China; Chinese Acad Sci, Inst Tibetan Plateau Res, Beijing 100085, Peoples R China; Chinese Acad Social Sci, Inst Archaeol, Beijing 100710, Peoples R China; Louisiana State Univ, Dept Geog & Anthropol, Baton Rouge, LA 70803 USA; Peking Univ, Coll Environm Sci, Beijing 100871, Peoples R China; Qinghai Prov Inst Cultural Rel & Archaeol, Sining 810007, Peoples R China	Chinese Academy of Sciences; Institute of Geology & Geophysics, CAS; Chinese Academy of Sciences; Institute of Tibetan Plateau Research, CAS; Chinese Academy of Social Sciences; Louisiana State University System; Louisiana State University; Peking University	Lu, HY (corresponding author), Chinese Acad Sci, Inst Geol & Geophys, Beijing 100029, Peoples R China.	houyuanlu@mail.iggcas.ac.cn	Lu, houyuan/L-8661-2019; Lu, houyuan/AAD-3100-2019; Liu, Kam-Biu/B-4966-2012	Lu, houyuan/0000-0001-5721-6679; Liu, Kam-Biu/0000-0002-0038-2198; Yang, Xiaoyan/0000-0002-9088-1838				Ball TB, 1999, AM J BOT, V86, P1615, DOI 10.2307/2656798; *CHIN AC SOC SCI Q, 2004, ARCHAEOL CULT RELICS, V2, P85; Fujita S, 1996, FOOD CHEM, V55, P209, DOI 10.1016/0308-8146(95)00107-7; Hou G, 2001, Adv Food Nutr Res, V43, P143; *I ARCH, 2003, ARCHAEOLOGY, V12, P58; Institute of Archaeology Gansu-Qinghai Research Team Chinese Academy of Social Sciences, 2002, KAOGU, P12; Lu HY, 2003, DIVERS DISTRIB, V9, P73, DOI 10.1046/j.1472-4642.2003.00166.x; Pearsall DM., 2015, PALEOETHNOBOTANY HDB; Piperno DR, 2004, NATURE, V430, P670, DOI 10.1038/nature02734; REN S, 1995, KAOGU, V1, P37; Shelach G, 2000, J WORLD PREHIST, V14, P363, DOI 10.1023/A:1011124209079; Yang XY, 2003, CHINESE SCI BULL, V48, P1877, DOI 10.1360/02wd0610	12	111	149	11	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	2005	437	7061					967	968		10.1038/437967a	http://dx.doi.org/10.1038/437967a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16222289				2022-12-28	WOS:000232496100032
J	Danesh, J; Lewington, S; Thompson, SG; Lowe, GDO; Collins, R				Danesh, J; Lewington, S; Thompson, SG; Lowe, GDO; Collins, R		Fibrinogen Studies Collaboration	Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality - An individual participant meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; BASE-LINE FINDINGS; MYOCARDIAL-INFARCTION; HEMOSTATIC FACTORS; BLOOD-VISCOSITY; RELATIVE RISK; FACTOR-VII; FOLLOW-UP; PREDICTION	Context Plasma fibrinogen levels may be associated with the risk of coronary heart disease (CHD) and stroke. Objective To assess the relationships of fibrinogen levels with risk of major vascular and with risk of nonvascular outcomes based on individual participant data. Data Sources Relevant studies were identified by computer-assisted searches, hand searches of reference lists, and personal communication with relevant investigators. Study Selection All identified prospective studies were included with information available on baseline fibrinogen levels and details of subsequent major vascular morbidity and/or cause-specific mortality during at least 1 year of follow-up. Studies were excluded if they recruited participants on the basis of having had a previous history of cardiovascular disease; participants with known preexisting CHD or stroke were excluded. Data Extraction Individual records were provided on each of 154211 participants in 31 prospective studies. During 1.38 million person-years of follow-up, there were 6944 first nonfatal myocardial infarctions or stroke events and 13 210 deaths. Cause-specific mortality was generally available. Analyses involved proportional hazards modeling with adjustment for confounding by known cardiovascular risk factors and for regression dilution bias. Data Synthesis Within each age group considered (40-59, 60-69, and >= 70 years), there was an approximately log-linear association with usual fibrinogen level for the risk of any CHD, any stroke, other vascular (eg, non-CHD, nonstroke) mortality, and nonvascular mortality. There was no evidence of a threshold within the range of usual fibrinogen level studied at any age. The age- and sex-adjusted hazard ratio per 1-g/L increase in usual fibrinogen level for CHD was 2.42 (95% confidence interval [CI], 2.24-2.60); stroke, 2.06 (95% CI, 1.83-2.33); other vascular mortality, 2.76 (95% CI, 2.28-3.35); and nonvascular mortality, 2.03 (95% CI, 1.90-2.18). The hazard ratios for CHD and stroke were reduced to about 1.8 after further adjustment for measured values of several established vascular risk factors. In a subset of 7011 participants with available C-reactive protein values, the findings for CHD were essentially unchanged following additional adjustment for C-reactive protein. The associations of fibrinogen level with CHD or stroke did not differ substantially according to sex, smoking, blood pressure, blood lipid levels, or several features of study design. Conclusions in this large individual participant meta-analysis, moderately strong associations were found between usual plasma fibrinogen level and the risks of CHD, stroke, other vascular mortality, and nonvascular mortality in a wide range of circumstances in healthy middle-aged adults. Assessment of any causal relevance of elevated fibrinogen levels to disease requires additional research.	Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England; Univ Oxford, Clin Trial Serv Unit, Oxford, England; MRC, Inst Publ Hlth, Biostat Unit, Cambridge, England; Univ Glasgow, Div Cardiovasc & Med Sci, Glasgow, Lanark, Scotland	University of Cambridge; University of Oxford; MRC Biostatistics Unit; University of Cambridge; University of Glasgow	Danesh, J (corresponding author), Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Strangeways Site,Worts Causeway, Cambridge CB1 8RN, England.		Brunner, Eric/H-2114-2011; Tosetto, Alberto/AAM-3200-2020; Davey Smith, George/A-7407-2013; Wu, Kenneth Kun-Yu/B-1070-2010; Wilson, Peter W.F./J-2455-2016; Lamarche, Benoit/ABA-4785-2021; Ferrieres, Jean/S-7993-2016	Brunner, Eric/0000-0002-0595-4474; Tosetto, Alberto/0000-0002-0119-5204; Davey Smith, George/0000-0002-1407-8314; Lamarche, Benoit/0000-0002-4443-5378; Venkatasubramanian, Siddharth/0000-0002-5860-0768; Ryder, Elena/0000-0003-4613-6424; s, hema/0000-0002-3440-9475; Woodward, Mark/0000-0001-9800-5296; Lewington, Sarah/0000-0002-4496-4771; Amouyel, Philippe/0000-0001-9088-234X; Ferrieres, Jean/0000-0001-6144-1297; De Stavola, Bianca Lucia/0000-0001-7853-0528; Feskens, Edith/0000-0001-5819-2488				Benderly M, 1996, ARTERIOSCL THROM VAS, V16, P351, DOI 10.1161/01.ATV.16.3.351; Brunner E, 1996, LANCET, V347, P1008, DOI 10.1016/S0140-6736(96)90147-6; Cantin B, 2002, AM J CARDIOL, V89, P662, DOI 10.1016/S0002-9149(01)02336-0; Clarke R, 1999, AM J EPIDEMIOL, V150, P341; Cooper JA, 2000, CIRCULATION, V102, P2816; Cremer P, 1997, ATHEROSCLEROSIS, V129, P221, DOI 10.1016/S0021-9150(96)06030-3; Danesh J, 2000, EUR HEART J, V21, P515, DOI 10.1053/euhj.1999.1699; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; ELWOOD PC, 1984, J EPIDEMIOL COMMUN H, V38, P259, DOI 10.1136/jech.38.3.259; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; FESKENS EJM, 1997, CAN J CARDIOL SB, V13, pB282; FOLSOM AR, 1995, EUR HEART J, V16, P21, DOI 10.1093/eurheartj/16.suppl_A.21; Folsom AR, 1997, CIRCULATION, V96, P1102, DOI 10.1161/01.CIR.96.4.1102; GREENLAND S, 1980, AM J EPIDEMIOL, V112, P564, DOI 10.1093/oxfordjournals.aje.a113025; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Jousilahti P, 2001, ATHEROSCLEROSIS, V156, P451, DOI 10.1016/S0021-9150(00)00681-X; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; Kostis JB, 2004, EUR J CARDIOV PREV R, V11, P9, DOI 10.1097/01.hjr.0000114968.39211.01; KOSTIS JB, 1982, CHEST, V81, P571, DOI 10.1378/chest.81.5.571; KROBOT K, 1992, ARTERIOSCLER THROMB, V12, P780, DOI 10.1161/01.ATV.12.7.780; LAKKA TA, 1993, J CLIN EPIDEMIOL, V46, P1119, DOI 10.1016/0895-4356(93)90111-D; Lee AJ, 1998, CIRCULATION, V97, P1467; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Lind P, 2001, ARTERIOSCL THROM VAS, V21, P452, DOI 10.1161/01.ATV.21.3.452; Lowe G, 2000, THROMB HAEMOSTASIS, V84, P553, DOI 10.1055/s-0037-1614066; Lowe GDO, 2004, ANN CLIN BIOCHEM, V41, P430, DOI 10.1258/0004563042466884; Lowe GDO, 2005, J THROMB HAEMOST, V3, P635, DOI 10.1111/j.1538-7836.2005.01256.x; LOWE GDO, 1995, EUR HEART J, V16, P2, DOI 10.1093/eurheartj/16.suppl_A.2; LOWE GDO, 1993, CIRCULATION, V87, P1915, DOI 10.1161/01.CIR.87.6.1915; Ma J, 1999, J AM COLL CARDIOL, V33, P1347, DOI 10.1016/S0735-1097(99)00007-8; Maresca G, 1999, ARTERIOSCL THROM VAS, V19, P1368, DOI 10.1161/01.ATV.19.6.1368; Meade TW, 1998, LANCET, V351, P233; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; Mijares M, 2000, INFOR MED, V2, P613; Palmieri V, 2003, AM HEART J, V145, P467, DOI 10.1067/mhj.2003.144; Rodeghiero F, 1997, THROMB HAEMOSTASIS, V78, P636; Rosengren A, 1996, J INTERN MED, V239, P499, DOI 10.1046/j.1365-2796.1996.485821000.x; ROSNER B, 1989, STAT MED, V8, P1051, DOI 10.1002/sim.4780080905; Rothwell PM, 2004, STROKE, V35, P2300, DOI 10.1161/01.STR.0000141701.36371.d1; Salomaa V, 2002, ARTERIOSCL THROM VAS, V22, P353, DOI 10.1161/hq0202.104078; Sato S, 2000, AM J EPIDEMIOL, V152, P420, DOI 10.1093/aje/152.5.420; Scarabin PY, 1998, THROMB HAEMOSTASIS, V80, P749; SMITH EB, 1995, EUR HEART J, V16, P11, DOI 10.1093/eurheartj/16.suppl_A.11; SMITH EB, 1992, FIBRINOGEN NEW CARDI, P4; Smith FB, 1998, BRIT J HAEMATOL, V100, P758; Smith FB, 1997, ARTERIOSCL THROM VAS, V17, P3321, DOI 10.1161/01.ATV.17.11.3321; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Sweetnam PM, 1998, BRIT J HAEMATOL, V100, P582, DOI 10.1046/j.1365-2141.1998.00604.x; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; Tracy RP, 1999, ARTERIOSCL THROM VAS, V19, P1776, DOI 10.1161/01.ATV.19.7.1776; TybjaergHansen A, 1997, J CLIN INVEST, V99, P3034, DOI 10.1172/JCI119499; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Walldius G, 2001, LANCET, V358, P2026, DOI 10.1016/S0140-6736(01)07098-2; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; Willeit J, 2000, ARTERIOSCL THROM VAS, V20, P529, DOI 10.1161/01.ATV.20.2.529; Woodward M, 1998, EUR HEART J, V19, P55, DOI 10.1053/euhj.1997.0573; Yano K, 2001, ARTERIOSCL THROM VAS, V21, P1065, DOI 10.1161/01.ATV.21.6.1065; Youngman LD, 2000, CIRCULATION, V102, P31; 1987, BAILLIERES CLIN HAEM, V1, P597	61	935	969	1	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	2005	294	14					1799	1809		10.1001/jama.294.14.1799	http://dx.doi.org/10.1001/jama.294.14.1799			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972RX	16219884	Green Accepted			2022-12-28	WOS:000232472000020
J	Dormandy, JA; Charbonnel, B; Eckland, DJA; Erdmann, E; Massi-Benedetti, M; Kmoules, IK; Skene, AM; Tan, MH; Lefebvre, PJ; Murray, GD; Standl, E; Wilcox, RG; Wlhelmsen, L; Betteridge, J; Birkeland, K; Golay, A; Heine, RJ; Koranyi, L; Laakso, M; Mokan, M; Norkus, A; Pirags, V; Podar, T; Scheen, A; Scherbaum, W; Schernthaner, G; Schmitz, O; Skrha, J; Smith, U; Taton, J				Dormandy, JA; Charbonnel, B; Eckland, DJA; Erdmann, E; Massi-Benedetti, M; Kmoules, IK; Skene, AM; Tan, MH; Lefebvre, PJ; Murray, GD; Standl, E; Wilcox, RG; Wlhelmsen, L; Betteridge, J; Birkeland, K; Golay, A; Heine, RJ; Koranyi, L; Laakso, M; Mokan, M; Norkus, A; Pirags, V; Podar, T; Scheen, A; Scherbaum, W; Schernthaner, G; Schmitz, O; Skrha, J; Smith, U; Taton, J		PROactive Investigators	Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial	LANCET			English	Article							MORTALITY; MEN	Background Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke. There is indirect evidence that agonists of peroxisome proliferator-activated receptor gamma (PPAR gamma) could reduce macrovascular complications. Our aim, therefore, was to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients with type 2 diabetes. Methods We did a prospective, randomised controlled trial in 5238 patients with type 2 diabetes who had evidence of macrovascular disease. We recruited patients from primary-care practices and hospitals. We assigned patients to oral pioglitazone titrated from 15 mg to 45 mg (n=2605) or matching placebo (n=2633), to be taken in addition to their glucose-lowering drugs and other medications. Our primary endpoint was the composite of all-cause mortality, non-fatal myocardial infarction (including silent myocardial infarction), stroke, acute coronary syndrome, endovascular or surgical intervention in the coronary or leg arteries, and amputation above the ankle. Analysis was by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN NCT00174993. Findings Two patients were lost to follow-up, but were included in analyses. The average time of observation was 34.5 months. 514 of 2605 patients in the pioglitazone group and 572 of 2633 patients in the placebo group had at least one event in the primary composite endpoint (HR 0.90, 95% CI 0.80-1.02, p=0.095). The main secondary endpoint was the composite of all-cause mortality, non-fatal myocardial infarction, and stroke. 301 patients in the pioglitazone group and 358 in the placebo group reached this endpoint (0.84, 0.72-0.98, p=0.027). Overall safety and tolerability was good with no change in the safety profile of pioglitazone identified. 6% (149 of 2065) and 4% (108 of 2633) of those in the pioglitazone and placebo groups, respectively, were admitted to hospital with heart failure; mortality rates from heart failure did not differ between groups. Interpretation Pioglitazone reduces the composite of all-cause mortality, non-fatal myocardial infarction, and stroke in patients with type 2 diabetes who have a high risk of macrovascular events.	Univ London St Georges Hosp, Dept Clin Vasc Res, London SW17 0QT, England; Hop Hotel Dieu, Clin Endocrinol, Nantes 1, France; Univ Cologne, Innere Med Klin 3, Cologne, Germany; Univ Perugia, I-06100 Perugia, Italy; Takeda Europe R&D Ctr, London, England; Nottingham Clin Res Ltd, Isaac Newton Ctr, Nottingham, England; Eli Lilly & Co, Lilly Corp Ctr, Diabet & Endocrine Platform, Indianapolis, IN 46285 USA; CHU Sart Tilman, Int Diabet Federat, Div Diabet, Dept Med, B-4000 Liege, Belgium; Univ Edinburgh, Sch Med, Dept Publ Hlth Sci, Edinburgh, Midlothian, Scotland; Munich Diabet Res Inst, Munich, Germany; Univ Hosp, Dept Cardiovasc Med, Nottingham, England; Univ Gothenburg, Inst Cardiovasc Med, Gothenburg, Sweden; UCL, Middlesex Hosp, Dept Med, London, England; Univ Oslo, Aker Univ Hosp, Res Ctr, Oslo, Norway; Univ Hosp Geneva, Serv Therapeut Educ Chron Dis, Geneva, Switzerland; Vrije Univ Amsterdam Med Ctr, Ctr Diabet, Amsterdam, Netherlands; Kuopio Univ Hosp, Dept Med, SF-70210 Kuopio, Finland; Comenius Univ, Martin Fac Hosp, Jessenius Med Fac, Internal Clin 1, Martin, Slovakia; Kaunas Univ Med, Inst Endocrinol, Kaunas, Lithuania; Univ Slimnica, Paula Strandina Klin, Riga, Latvia; Endocrinol Ctr, Tartu, Estonia; Univ Liege, CHU Sart Tilman, Div Diabet Nutr & Metab Disorders, Liege, Belgium; Univ Dusseldorf, German Diabet Ctr, Dusseldorf, Germany; Rudolfstiftung Hosp, Dept Med 1, Vienna, Austria; Univ Aarhus, Inst Clin Pharmacol, Aarhus, Denmark; Czech Diabet Soc, Clin Dept Endocrinol & Metab, Dept Med 3, Prague, Czech Republic; Gothenburg Univ, Lundberg Lab Diabet Res, S-41124 Gothenburg, Sweden; Warsaw Med Univ, Dept Internal Med & Diabetol, Warsaw, Poland	St Georges University London; Nantes Universite; CHU de Nantes; University of Cologne; University of Perugia; Takeda Pharmaceutical Company Ltd; Takeda Development Centre Europe Ltd.; Eli Lilly; University of Liege; University of Edinburgh; Nottingham University Hospital NHS Trust; University of Nottingham; University of Gothenburg; University of London; University College London; University of Oslo; University of Geneva; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Kuopio University Hospital; University of Eastern Finland; Comenius University Bratislava; Lithuanian University of Health Sciences; University of Liege; Deutsches Diabetes-Zentrum (DDZ); Heinrich Heine University Dusseldorf; Rudolfstiftung Hospital; Aarhus University; University of Gothenburg; Medical University of Warsaw	Dormandy, JA (corresponding author), Univ London St Georges Hosp, Dept Clin Vasc Res, Ingelby House,Blackshaw Rd, London SW17 0QT, England.	john.dormandy@btinternet.com	Orda, Ulrich/I-3034-2019; Pirags, Valdis/AAQ-5492-2020; Birkeland, Kåre I/E-9750-2010; Skrha, Jan/C-3095-2017; folli, franco/J-2795-2018; Thorsby, Per Medbøe/A-1268-2017; Urbanavicius, Vaidotas/D-4907-2016	Orda, Ulrich/0000-0003-4887-5060; Pirags, Valdis/0000-0002-3650-7394; Skrha, Jan/0000-0001-8012-8802; folli, franco/0000-0001-9824-5222; Thorsby, Per Medbøe/0000-0002-9615-1035; Madsbad, Sten/0000-0002-5017-1815; Urbanavicius, Vaidotas/0000-0002-8601-4563; kerlan, veronique/0000-0001-8105-6628; Murray, Gordon/0000-0001-9866-4734				[Anonymous], 1999, Diabet Med, V16, P716; Charbonnel B, 2005, DIABETOLOGIA, V48, P553, DOI 10.1007/s00125-004-1651-9; Charbonnel B, 2004, DIABETES CARE, V27, P1647, DOI 10.2337/diacare.27.7.1647; Collins R, 2003, LANCET, V361, P2005; Feinglos MN, 1999, AM HEART J, V138, pS346; Goldberg RB, 2005, DIABETES CARE, V28, P1547, DOI 10.2337/diacare.28.7.1547; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Khaw KT, 2001, BMJ-BRIT MED J, V322, P15, DOI 10.1136/bmj.322.7277.15; LAN KKG, 1989, STAT MED, V8, P1191, DOI 10.1002/sim.4780081003; Pfutzner A, 2005, J AM COLL CARDIOL, V45, P1925, DOI 10.1016/j.jacc.2005.03.041; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Roper NA, 2001, BRIT MED J, V322, P1389, DOI 10.1136/bmj.322.7299.1389; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; *US DEP HHS, 2005, NIH NEWS         JUN, P12; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001	18	3006	3141	7	139	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 8	2005	366	9493					1279	1289		10.1016/S0140-6736(05)67528-9	http://dx.doi.org/10.1016/S0140-6736(05)67528-9			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971ST	16214598	Green Submitted			2022-12-28	WOS:000232405700026
J	Sullivan, F; Wyatt, JC				Sullivan, F; Wyatt, JC			ABC of health informatics - How decision support tools help define clinical problems	BRITISH MEDICAL JOURNAL			English	Review							TECHNOLOGY; CARE		Univ Dundee, Dundee DD1 4HN, Scotland	University of Dundee	Sullivan, F (corresponding author), Univ Dundee, Dundee DD1 4HN, Scotland.		Sullivan, Frank/L-8286-2019; Wyatt, Jeremy/F-8160-2010; Sullivan, Frank m/A-7767-2009	Sullivan, Frank/0000-0002-6623-4964; Wyatt, Jeremy/0000-0001-7008-1473; 				Bodenheimer T, 2003, JAMA-J AM MED ASSOC, V290, P259, DOI 10.1001/jama.290.2.259; Bray PF, 2000, CURR OPIN HEMATOL, V7, P284, DOI 10.1097/00062752-200009000-00005; FEINSTEIN AR, 1972, LANCET, V297, P421; Field MJ., 1992, GUIDELINES CLIN PRAC; McCusker MT, 2002, QJM-INT J MED, V95, P591, DOI 10.1093/qjmed/95.9.591; Page J., 2003, EVID-BASED MED, V8, P132; Smith R, 1997, BRIT MED J, V314, P1495, DOI 10.1136/bmj.314.7093.1495; Wyatt JC, 2001, CLIN KNOWLEDGE PRACT	8	16	16	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 8	2005	331	7520					831	833		10.1136/bmj.331.7520.831	http://dx.doi.org/10.1136/bmj.331.7520.831			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974BC	16210284	Green Published			2022-12-28	WOS:000232565300026
J	Baylis, HA				Baylis, HA			VAV's got rhythm	CELL			English	Editorial Material							CAENORHABDITIS-ELEGANS; C-ELEGANS; RECEPTOR; ACTIVATION	Biological rhythms with periods of less than a day are physiologically important but poorly understood. In this issue of Cell, Norman, Maricq, and colleagues (Norman et al., 2005) show that VAV-1, a guanine nucleotide exchange factor for Rho-family GTPases, is necessary for three rhythmic behaviors in the nematode Caenorhabditis elegans: feeding, defecation, and ovulation.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	University of Cambridge	Baylis, HA (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.			Baylis, Howard/0000-0002-5959-3256				Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Clandinin TR, 1998, CELL, V92, P523, DOI 10.1016/S0092-8674(00)80945-9; Dal Santo P, 1999, CELL, V98, P757, DOI 10.1016/S0092-8674(00)81510-X; ESPELT MV, 2005, IN PRESS J GEN PHYSL, V98; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Lupu VD, 1998, J BIOL CHEM, V273, P14067, DOI 10.1074/jbc.273.23.14067; Tybulewicz VL, 2005, CURR OPIN IMMUNOL, V17, P267, DOI 10.1016/j.coi.2005.04.003; Walker DS, 2002, MOL BIOL CELL, V13, P1329, DOI 10.1091/mbc.01-08-0422; Yin XY, 2004, MOL BIOL CELL, V15, P3938, DOI 10.1091/mbc.E04-03-0198	9	5	6	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 7	2005	123	1					5	7		10.1016/j.cell.2005.09.018	http://dx.doi.org/10.1016/j.cell.2005.09.018			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	973QD	16213207	Bronze			2022-12-28	WOS:000232536800003
J	Schwartz, RS				Schwartz, RS			Faith healers and physicians - Teaching pseudoscience by mandate	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	2	2	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 6	2005	353	14					1437	1439		10.1056/NEJMp058244	http://dx.doi.org/10.1056/NEJMp058244			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970LZ	16207844				2022-12-28	WOS:000232313000002
J	Kim, JC; Watts, CH				Kim, JC; Watts, CH			Gaining a foothold: tackling poverty, gender inequality, and HIV in Africa	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CREDIT PROGRAMS; BANGLADESH; WOMEN; VIOLENCE; HEALTH; POWER		Univ Witwatersrand, Sch Publ Hlth, Rural AIDs & Dev Act Res Programme, ZA-1360 Acornhoek, South Africa; Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, London WC1E 7HT, England	University of Witwatersrand; University of London; London School of Hygiene & Tropical Medicine	Kim, JC (corresponding author), Univ Witwatersrand, Sch Publ Hlth, Rural AIDs & Dev Act Res Programme, POB 2, ZA-1360 Acornhoek, South Africa.	jkiiu@soft.co.za						Ahmed SM, 2005, J HEALTH POPUL NUTR, V23, P95; ANNAN K, 2002, NY TIMES        1229; CHESTON S, 2002, PATHWAYS OUT POVERTY, P167; Cohen S, 2004, REPROD HEALTH MATTER, V12, P132; *COMM IN, PROGR EXP RUS GIRLS; DALEYHARRIS S, 2004, STAT MICR SUMM CAMP; Goetz AM, 1996, WORLD DEV, V24, P45, DOI 10.1016/0305-750X(95)00124-U; Gupta GR, 2002, BRIT MED J, V324, P183, DOI 10.1136/bmj.324.7331.183; HARGREAVES J, INTERVENTION MICROFI; Holden S., 2004, MAINSTREAMING HIV AI; *HUM RIGHTS WATCH, 2003, DOUBL STAND WOM PROP; KIRUBI M, 1994, IMPACT SOCIAL EC SEX; MAYOUX L, 1998, 41 OP U; *MICR SUMM CAMP, WHAT OTH AFR; *MICR SUMM CAMP, AFR MICR AIDS IN; *POP COUNC, 1999, TOST BREAKTHR SEN EN; Population Council, 2001, POW SEX REL OP DIAL; PRONYK PM, IN PRESS SMALL ENTER; Rojanapithayakorn W, 1996, AIDS, V10, P1, DOI 10.1097/00002030-199601000-00001; Sachs J., 2005, END POVERTY WE CAN M; Sanders D, 2004, B WORLD HEALTH ORGAN, V82, P757; Schuler SR, 1996, SOC SCI MED, V43, P1729, DOI 10.1016/S0277-9536(96)00068-8; Schuler SR, 1997, WORLD DEV, V25, P563, DOI 10.1016/S0305-750X(96)00119-2; Sumartojo E, 2000, AIDS, V14, pS1, DOI 10.1097/00002030-200006001-00001; UNAIDS, 2004, 4 UNAIDS; *UNAIDS, 1999, GEND HIV AIDS TAK ST; *UNAIDS UN POP FUN, 2004, WOM HIV AIDS CONFR C; United Nations General Assembly Special Session, 2001, DECL COMM HIV AIDS; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472	29	53	53	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	2005	331	7519					769	772		10.1136/bmj.331.7519.769	http://dx.doi.org/10.1136/bmj.331.7519.769			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	971XB	16195298	Green Accepted, Green Published, Bronze			2022-12-28	WOS:000232417100028
J	Oransky, I				Oransky, I			Margot Kruskall - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com						KRUSKALL M, PUBLICATION LIST	1	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 1	2005	366	9492					1158	1158		10.1016/S0140-6736(05)67469-7	http://dx.doi.org/10.1016/S0140-6736(05)67469-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970LK	16217878				2022-12-28	WOS:000232311300014
J	Timm, RM; Ramey, RR				Timm, RM; Ramey, RR		Amer Soc Mammalogists	What constitutes a proper description?	SCIENCE			English	Letter									Univ Kansas, Dept Ecol & Evolutionary Biol, Lawrence, KS 66045 USA; Univ Kansas, Biodivers Res Ctr, Lawrence, KS 66045 USA; Denver Museum Nat & Sci, Dept Zool, Denver, CO 80205 USA	University of Kansas; University of Kansas	Timm, RM (corresponding author), Univ Kansas, Dept Ecol & Evolutionary Biol, Lawrence, KS 66045 USA.			Timm, Robert/0000-0001-6203-3316				ICZN, 1999, INT CODE ZOOLOGICAL	1	13	14	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 30	2005	309	5744					2163	2164						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195444				2022-12-28	WOS:000232318000018
J	Palter, JB; Lozier, MS; Barber, RT				Palter, JB; Lozier, MS; Barber, RT			The effect of advection on the nutrient reservoir in the North Atlantic subtropical gyre	NATURE			English	Article							VARIABILITY; WATER; CIRCULATION; SEA	Though critically important in sustaining the ocean's biological pump, the cycling of nutrients in the subtropical gyres is poorly understood. The supply of nutrients to the sunlit surface layer of the ocean has traditionally been attributed solely to vertical processes. However, horizontal advection may also be important in establishing the availability of nutrients. Here we show that the production and advection of North Atlantic Subtropical Mode Water introduces spatial and temporal variability in the subsurface nutrient reservoir beneath the North Atlantic subtropical gyre. As the mode water is formed, its nutrients are depleted by biological utilization. When the depleted water mass is exported to the gyre, it injects a wedge of low-nutrient water into the upper layers of the ocean. Contrary to intuition, cold winters that promote deep convective mixing and vigorous mode water formation may diminish downstream primary productivity by altering the subsurface delivery of nutrients.	Duke Univ, Nicholas Sch Environm & Earth Sci, Div Earth & Ocean Sci, Durham, NC 27708 USA; Duke Univ, Marine Lab, Nicholas Sch Environm & Earth Sci, Div Coastal Syst Sci & Policy, Beaufort, NC 28516 USA	Duke University; Duke University	Palter, JB (corresponding author), Duke Univ, Nicholas Sch Environm & Earth Sci, Div Earth & Ocean Sci, Durham, NC 27708 USA.	jbp3@duke.edu	Palter, Jaime B/B-9484-2011	Palter, Jaime/0000-0002-2656-8062				Bahamon N, 2003, DEEP-SEA RES PT I, V50, P1189, DOI 10.1016/S0967-0637(03)00145-6; Barber RT, 2001, DEEP-SEA RES PT II, V48, P1127, DOI 10.1016/S0967-0645(00)00134-X; Dickson R, 1996, PROG OCEANOGR, V38, P241, DOI 10.1016/S0079-6611(97)00002-5; FITZWATER SE, 1982, LIMNOL OCEANOGR, V27, P544, DOI 10.4319/lo.1982.27.3.0544; Fratantoni DM, 2001, J GEOPHYS RES-OCEANS, V106, P22067, DOI 10.1029/2000JC000730; Gruber N, 2002, SCIENCE, V298, P2374, DOI 10.1126/science.1077077; JENKINS WJ, 1982, NATURE, V300, P246, DOI 10.1038/300246a0; Joyce TM, 2000, J CLIMATE, V13, P2550, DOI 10.1175/1520-0442(2000)013<2550:TRBDVO>2.0.CO;2; Kara AB, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2000JC000736; LEDWELL JR, 1993, NATURE, V364, P701, DOI 10.1038/364701a0; LEWIS MR, 1988, J GEOPHYS RES-OCEANS, V93, P6847, DOI 10.1029/JC093iC06p06847; LEWIS MR, 1986, SCIENCE, V234, P870, DOI 10.1126/science.234.4778.870; Lozier MS, 1995, PROG OCEANOGR, V36, P1, DOI 10.1016/0079-6611(95)00013-5; Mann KH, 1996, DYNAMICS MARINE ECOS, P480, DOI 10.2307/2960585; McCartney MS, 1982, J MAR RES, V40, P427; McClain CR, 2004, DEEP-SEA RES PT II, V51, P281, DOI 10.1016/j.dsr2.2003.08.002; McGillicuddy DJ, 1998, NATURE, V394, P263, DOI 10.1038/28367; McGillicuddy DJ, 1997, DEEP-SEA RES PT I, V44, P1427, DOI 10.1016/S0967-0637(97)00024-1; MENZEL DW, 1961, DEEP-SEA RES, V7, P282, DOI 10.1016/0146-6313(61)90046-6; Oschlies A, 1998, NATURE, V394, P266, DOI 10.1038/28373; PELEGRI JL, 1991, J GEOPHYS RES-OCEANS, V96, P2577, DOI 10.1029/90JC02535; Sarmiento JL, 2004, NATURE, V427, P56, DOI 10.1038/nature02127; Siegel DA, 2002, SCIENCE, V296, P730, DOI 10.1126/science.1069174; TAKAHASHI T, 1985, J GEOPHYS RES-OCEANS, V90, P6907, DOI 10.1029/JC090iC04p06907; Talley LD, 1982, J MAR RES, V40, P757; Talley LD, 1996, PHYSICA D, V98, P625, DOI 10.1016/0167-2789(96)00123-6; TRENBERTH KE, 1989, NCARTN388STR; Walker SJ, 2000, J GEOPHYS RES-OCEANS, V105, P14285, DOI 10.1029/1999JC900273; WARNER MJ, 1985, DEEP-SEA RES, V32, P1485, DOI 10.1016/0198-0149(85)90099-8; Williams RG, 1998, DEEP-SEA RES PT I, V45, P461, DOI 10.1016/S0967-0637(97)00094-0; Wilson C, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014063; Worthington L.V., 1976, N ATLANTIC CIRCULATI	32	145	146	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					687	692		10.1038/nature03969	http://dx.doi.org/10.1038/nature03969			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193044				2022-12-28	WOS:000232157900043
J	Schabath, MB; Hernandez, LM; Wu, XF; Pillow, PC; Spitz, MR				Schabath, MB; Hernandez, LM; Wu, XF; Pillow, PC; Spitz, MR			Dietary phytoestrogens and lung cancer risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN-RECEPTOR-BETA; IN-VITRO; ENDOMETRIAL CANCER; PROSTATE-CANCER; SOY; CONSUMPTION; PHYTOSTEROLS; ISOFLAVONES; EXPRESSION; GENISTEIN	Context Despite lung-specific in vitro and in vivo studies that support a chemopreventive role for phytoestrogens, there has been little epidemiologic research focused on dietary intake of phytoestrogens and risk of lung cancer. Objective To examine the relationship between dietary intake of phytoestrogens and risk of lung cancer. Design, Setting, and Participants Ongoing US case-control study of 1674 patients with lung cancer (cases) and 1735 matched healthy controls. From July 1995 through October 2003, participants were personally interviewed, with epidemiologic and food frequency questionnaires to collect demographic information and to quantify dietary intake of 12 individual phytoestrogens. Main Outcome Measure Risk of lung cancer, estimated using unconditional multivariable logistic regression analyses stratified by sex and smoking status and adjusted for established and putative lung cancer risk factors. Results Reductions in risk of lung cancer tended to increase with each increasing quartile of phytoestrogen intake. The highest quartiles of total phytosterols, isoflavones, lignans, and phytoestrogens were each associated with reductions in risk of lung cancer ranging from 21% for phytosterols (odds ratio [OR], 0.79; 95% confidence interval [Cl], 0.64-0.97; P=.03 for trend) to 46% for total phytoestrogens from food sources only (OR, 0.54; 95% Cl, 0.42-0.70; P<.001 for trend). Sex-specific effects were also apparent. For men, statistically significant trends for decreasing risk with increasing intake were noted for each phytoestrogen group, with protective effects for the highest quartile of intake ranging from 24% for phytosterols (OR, 0.76; 95% Cl, 0.56-1.02; P=.04 for trend) to 44% for isoflavones (OR, 0.56; 95% Cl, 0.41 0,76; P<.001 for trend), while in women, significant trends were only present for intake of total phytoestrogens from food sources only, with a 34% (OR, 0.66; 95% Cl, 0.46-0.96; P=.01 for trend) protective effect for the highest quartile of intake. The apparent benefits of high phytoestrogen intake were evident in both never and current smokers but less apparent in former smokers. In women, statistically significant joint effects were evident between hormone therapy use and phytoestrogen intake. Specifically, high intake of the lignans enterolactone and enterodiol and use of hormone therapy were associated with a 50% (OR, 0.50; 95% Cl, 0.31-0.68; P=.04 for interaction) reduction in risk of lung cancer. Conclusions While there are limitations and concerns regarding case-control studies of diet and cancer, these data provide further support for the limited but growing epidemiologic evidence that phytoestrogens are associated with a decrease in risk of lung cancer. Confirmation of these findings is still required in large-scale, hypothesis-driven, prospective studies.	Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Unit 1340, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Spitz, MR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Unit 1340, POB 301439, Houston, TX 77030 USA.	mspitz@mdanderson.org	Schabath, Matthew/J-3763-2016	Schabath, Matthew/0000-0003-3241-3216	NATIONAL CANCER INSTITUTE [P50CA070907, R25CA057730, R01CA055769, U01CA086390] Funding Source: NIH RePORTER; NCI NIH HHS [CA 70907, R25 CA 57730, CA 55769, CA 86390, L30 CA117768] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adlercreutz H, 2002, LANCET ONCOL, V3, P364, DOI 10.1016/S1470-2045(02)00777-5; Adlercreutz H, 1997, ANN MED, V29, P95, DOI 10.3109/07853899709113696; Adlercreutz H, 2000, J NUTR, V130, p658S, DOI 10.1093/jn/130.3.658S; Anderson JJB, 1999, PUBLIC HEALTH NUTR, V2, P489, DOI 10.1017/S1368980099000671; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BLOCK G, 1992, J AM DIET ASSOC, V92, P686; BLOCK G, 1994, AM J EPIDEMIOL, V139, P1190, DOI 10.1093/oxfordjournals.aje.a116965; Bouic P J, 1999, Altern Med Rev, V4, P170; CANVER CC, 1994, J THORAC CARDIOV SUR, V108, P153; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; de Kleijn MJJ, 2001, J NUTR, V131, P1826; De Stefani E, 2000, NUTR CANCER, V37, P140, DOI 10.1207/S15327914NC372_4; Ding H, 2003, BIOCHEM BIOPH RES CO, V305, P950, DOI 10.1016/S0006-291X(03)00873-8; Duncan AM, 2003, BEST PRACT RES CL EN, V17, P253, DOI 10.1016/S1521-690X(02)00103-3; Ettinger B, 1996, OBSTET GYNECOL, V87, P6, DOI 10.1016/0029-7844(95)00358-4; Fasco MJ, 2002, MOL CELL ENDOCRINOL, V188, P125, DOI 10.1016/S0303-7207(01)00750-X; FOTSIS T, 1995, J NUTR, V125, pS790, DOI 10.1093/jn/125.suppl_3.790S; Fournier DB, 1998, CANCER EPIDEM BIOMAR, V7, P1055; GIOVANNUCCI E, 1993, AM J EPIDEMIOL, V137, P502, DOI 10.1093/oxfordjournals.aje.a116703; Goldbohm RA, 1996, J NATL CANCER I, V88, P93, DOI 10.1093/jnci/88.2.93; Goodman MT, 1997, AM J EPIDEMIOL, V146, P294, DOI 10.1093/oxfordjournals.aje.a009270; GUPTA MB, 1980, PLANTA MED, V39, P157, DOI 10.1055/s-2008-1074919; Gutendorf B, 2001, TOXICOLOGY, V166, P79, DOI 10.1016/S0300-483X(01)00437-1; Hebert JR, 1998, JNCI-J NATL CANCER I, V90, P1637, DOI 10.1093/jnci/90.21.1637; Horn-Ross PL, 2003, J NATL CANCER I, V95, P1158, DOI 10.1093/jnci/djg015; Horn-Ross PL, 2000, CANCER CAUSE CONTROL, V11, P289, DOI 10.1023/A:1008995606699; Hu JF, 1997, INT J CANCER, V71, P924, DOI 10.1002/(SICI)1097-0215(19970611)71:6&lt;924::AID-IJC2&gt;3.0.CO;2-#; Hudmon KS, 1997, CANCER EPIDEM BIOMAR, V6, P565; Jiang X., 2001, THEORY RANDOM LASER; Ju YH, 2004, J NUTR, V134, P1145, DOI 10.1093/jn/134.5.1145; KINLEN LJ, 1988, BRIT J CANCER, V58, P397, DOI 10.1038/bjc.1988.227; Knekt P, 1997, AM J EPIDEMIOL, V146, P223, DOI 10.1093/oxfordjournals.aje.a009257; KOO LC, 1988, NUTR CANCER, V11, P155, DOI 10.1080/01635588809513983; Kreuzer M, 2003, INT J EPIDEMIOL, V32, P263, DOI 10.1093/ije/dyg064; Kubik AK, 2004, EUR J CANCER PREV, V13, P471, DOI 10.1097/00008469-200412000-00002; Lagiou P, 2002, P NUTR SOC, V61, P217, DOI 10.1079/PNS2002145; Law M, 2000, BMJ-BRIT MED J, V320, P861, DOI 10.1136/bmj.320.7238.861; LEE HP, 1991, LANCET, V337, P1197, DOI 10.1016/0140-6736(91)92867-2; LEE Y-S, 1991, Journal of Korean Medical Science, V6, P325; Li DH, 1999, J NUTR, V129, P1075, DOI 10.1093/jn/129.5.1075; Lian FR, 1999, NUTR CANCER, V33, P125, DOI 10.1207/S15327914NC330202; LING WH, 1995, LIFE SCI, V57, P195, DOI 10.1016/0024-3205(95)00263-6; Mazur W, 1998, BAILLIERE CLIN ENDOC, V12, P729, DOI 10.1016/S0950-351X(98)80013-X; Mazur W, 1998, PURE APPL CHEM, V70, P1759, DOI 10.1351/pac199870091759; McCann SE, 2000, CANCER CAUSE CONTROL, V11, P965, DOI 10.1023/A:1026551309873; McCann SE, 2003, J NUTR, V133, P1937, DOI 10.1093/jn/133.6.1937; Mendilaharsu M, 1998, LUNG CANCER-J IASLC, V19, P101, DOI 10.1016/S0169-5002(97)00075-5; Mendilaharsu M, 1998, LUNG CANCER-J IASLC, V21, P37, DOI 10.1016/S0169-5002(98)00044-0; Michels KB, 2005, INT J CANCER, V114, P163, DOI 10.1002/ijc.20662; Moreau RA, 2002, PROG LIPID RES, V41, P457, DOI 10.1016/S0163-7827(02)00006-1; Murkies AL, 1998, J CLIN ENDOCR METAB, V83, P297, DOI 10.1210/jc.83.2.297; Olsson H, 2003, OBSTET GYNECOL, V102, P565, DOI 10.1016/S0029-7844(03)00564-7; Omoto Y, 2001, BIOCHEM BIOPH RES CO, V285, P340, DOI 10.1006/bbrc.2001.5158; Pillow PC, 1999, NUTR CANCER, V33, P3, DOI 10.1080/01635589909514742; Sarkar FH, 2002, CANCER METAST REV, V21, P265, DOI 10.1023/A:1021210910821; Schabath MB, 2004, CLIN CANCER RES, V10, P113, DOI 10.1158/1078-0432.CCR-0911-3; Seow A, 2002, INT J CANCER, V97, P365, DOI 10.1002/ijc.1615; Shen HB, 2003, CANCER EPIDEM BIOMAR, V12, P980; Spitz MR, 2000, CANCER EPIDEM BIOMAR, V9, P1017; Stabile LP, 2002, CANCER RES, V62, P2141; STENSVOLD I, 1994, CANCER CAUSE CONTROL, V5, P401, DOI 10.1007/BF01694753; Strom SS, 1999, NUTR CANCER, V33, P20, DOI 10.1080/01635589909514743; Sun AS, 2001, NUTR CANCER, V39, P85, DOI 10.1207/S15327914nc391_12; SWANSON CA, 1992, INT J CANCER, V50, P876, DOI 10.1002/ijc.2910500609; Takasaki M, 1997, BIOL PHARM BULL, V20, P776, DOI 10.1248/bpb.20.776; Tham DM, 1998, J CLIN ENDOCR METAB, V83, P2223, DOI 10.1210/jc.83.7.2223; Tsourounis C, 2001, CLIN OBSTET GYNECOL, V44, P836, DOI 10.1097/00003081-200112000-00021; United States Department of Agriculture, 1998, CONT SURV FOOD INT I; *USDA, 2004, USDA NAT NUTR DAT ST; Valsta LM, 2003, BRIT J NUTR, V89, pS31, DOI 10.1079/BJN2002794; Wakai K, 1999, NUTR CANCER, V33, P139, DOI 10.1207/S15327914NC330204; Walcott FL, 2002, NUTR CANCER, V44, P44, DOI 10.1207/S15327914NC441_6; Willet W, 1998, NUTR EPIDEMIOLOGY; WU X, 2004, P AM ASSOC CANC RES, P45	74	79	82	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	2005	294	12					1493	1504		10.1001/jama.294.12.1493	http://dx.doi.org/10.1001/jama.294.12.1493			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TF	16189362				2022-12-28	WOS:000232113400019
J	Branthwaite, MA				Branthwaite, MA			Taking the final step: changing the law on euthanasia and physician assisted suicide - Time for change	BRITISH MEDICAL JOURNAL			English	Editorial Material							DEATH; NEED											Doyal L, 2001, BMJ-BRIT MED J, V323, P1079, DOI 10.1136/bmj.323.7321.1079; Grayling AC, 2005, BRIT MED J, V330, P799, DOI 10.1136/bmj.330.7495.799; Hemmings Philip, 2003, Nurs Times, V99, P20; *HOUS LORDS REP, 1994, SEL COMM MED ETH; Huxtable R, 2004, BRIT MED J, V328, P1088, DOI 10.1136/bmj.328.7448.1088; Kravitz RL, 2001, BRIT MED J, V323, P584, DOI 10.1136/bmj.323.7313.584; *OR DEP HUM SERV, 2005, 7 OR DEP HUM SERV OF; Smith R, 2000, BMJ-BRIT MED J, V320, P129, DOI 10.1136/bmj.320.7228.129; WISSELMANN B, 2005, BRIT MED J, V330, P1389	9	9	9	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	SEP 24	2005	331	7518					681	683		10.1136/bmj.331.7518.681	http://dx.doi.org/10.1136/bmj.331.7518.681			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970HH	16179704	Green Published			2022-12-28	WOS:000232295400021
J	Sullivan, F; Wyatt, JC				Sullivan, F; Wyatt, JC			ABC of health informatics - Why is this patient here today?	BRITISH MEDICAL JOURNAL			English	Review									Univ Dundee, Dundee DD1 4HN, Scotland	University of Dundee	Sullivan, F (corresponding author), Univ Dundee, Dundee DD1 4HN, Scotland.		Sullivan, Frank m/A-7767-2009; Sullivan, Frank/L-8286-2019; Wyatt, Jeremy/F-8160-2010	Sullivan, Frank/0000-0002-6623-4964; Wyatt, Jeremy/0000-0001-7008-1473				Benson T, 2002, BRIT MED J, V325, P1086, DOI 10.1136/bmj.325.7372.1086; BLAU JN, 1982, BRIT MED J, V285, P1249, DOI 10.1136/bmj.285.6350.1249; Murff HJ, 2003, INT J MED INFORM, V71, P137, DOI 10.1016/S1386-5056(03)00133-3; Schoenberg R, 2000, BMJ-BRIT MED J, V321, P1199, DOI 10.1136/bmj.321.7270.1199; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	6	1	1	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	SEP 24	2005	331	7518					678	680		10.1136/bmj.331.7518.678	http://dx.doi.org/10.1136/bmj.331.7518.678			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970HH	16179703	Green Published			2022-12-28	WOS:000232295400020
J	Li, WD; Shi, ZL; Yu, M; Ren, WZ; Smith, C; Epstein, JH; Wang, HZ; Crameri, G; Hu, ZH; Zhang, HJ; Zhang, JH; McEachern, J; Field, H; Daszak, P; Eaton, BT; Zhang, SY; Wang, LF				Li, WD; Shi, ZL; Yu, M; Ren, WZ; Smith, C; Epstein, JH; Wang, HZ; Crameri, G; Hu, ZH; Zhang, HJ; Zhang, JH; McEachern, J; Field, H; Daszak, P; Eaton, BT; Zhang, SY; Wang, LF			Bats are natural reservoirs of SARS-like coronaviruses	SCIENCE			English	Article							RESPIRATORY SYNDROME CORONAVIRUS; NIPAH VIRUS; IDENTIFICATION; ANTIBODIES; PROTEIN	Severe acute respiratory syndrome (SARS) emerged in 2002 to 2003 in southern China. The origin of its etiological agent, the SARS coronavirus (SARS-CoV), remains elusive. Here we report that species of bats are a natural host of coronaviruses closely related to those responsible for the SARS, outbreak. These viruses, termed SARS-like coronaviruses (SL-CoVs), display greater genetic variation than SARS-CoV isolated from humans or from civets. The human and civet isolates of SARS-CoV nestle phylogenetically within the spectrum of SL-CoVs, indicating that the virus responsible for the SARS outbreak Was a member of this coronavirus group.	Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan, Peoples R China; Chinese Acad Sci, Inst Zool, Beijing, Peoples R China; CSIRO Livestock Ind, Australian Anim Hlth Lab, Geelong, Vic, Australia; Dept Primary Ind & Fisheries, Moorooka, Qld, Australia; Consortium Conservat Med, New York, NY USA; Guangzhou Inst Biomed & Hlth, Guangzhou, Peoples R China	Chinese Academy of Sciences; Wuhan Institute of Virology, CAS; Chinese Academy of Sciences; Institute of Zoology, CAS; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS	Shi, ZL (corresponding author), Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan, Peoples R China.	zlshi@wh.iov.cn; zhangsy@ioz.ac.cn; linfa.wang@csiro.au	Shi, Zhengli/A-1013-2013; Hu, Zhihong/AAS-2215-2020; Ren, Wuze/D-2926-2011; Crameri, Gary/H-8441-2013; daszak, peter/U-4588-2017; Barr, Jennifer A/H-9254-2013; Eaton, Bryan Thomas/AAV-2103-2021; Zhang, Shuyi/B-5117-2011	Shi, Zhengli/0000-0001-8089-163X; Hu, Zhihong/0000-0002-1560-0928; daszak, peter/0000-0002-2046-5695; Barr, Jennifer/0000-0001-5266-9142; Zhang, Shuyi/0000-0001-6582-5319	FOGARTY INTERNATIONAL CENTER [R01TW005869] Funding Source: NIH RePORTER; FIC NIH HHS [R01-TW05869] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		AbuBakar S, 2004, EMERG INFECT DIS, V10, P2228, DOI 10.3201/eid1012.040452; Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1; Chua KB, 2000, SCIENCE, V288, P1432, DOI 10.1126/science.288.5470.1432; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; Harcourt BH, 2005, EMERG INFECT DIS, V11, P1594, DOI 10.3201/eid1110.050513; He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002; He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908; Hsu VP, 2004, EMERG INFECT DIS, V10, P2082, DOI 10.3201/eid1012.040701; Hudson P., 2002, ECOLOGY WILDLIFE DIS; Kunz TH, 2003, BAT ECOLOGY, P3; LAI MC, 2001, FIELDS VIROLOGY, V2, pCH35; Lio P, 2004, TRENDS MICROBIOL, V12, P106, DOI 10.1016/j.tim.2004.01.005; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Mickleburgh SP, 2002, ORYX, V36, P18, DOI 10.1017/S0030605301000011; MURRAY K, 1995, SCIENCE, V268, P94, DOI 10.1126/science.7701348; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; POON LLM, 2005, J VIROL, V79, P2110; Reynes JM, 2005, EMERG INFECT DIS, V11, P1042, DOI 10.3201/eid1107.041350; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102; SULKIN SE, 1974, MONOGR VIROL, V8, P170; Tripp RA, 2005, J VIROL METHODS, V128, P21, DOI 10.1016/j.jviromet.2005.03.021; Tu CC, 2004, EMERG INFECT DIS, V10, P2244, DOI 10.3201/eid1012.040520; Wang L.-F., 2001, INFECT DIS REV, V3, P52; Wang Lin-Fa, 2003, Current Genomics, V4, P263, DOI 10.2174/1389202033490385; Wu DL, 2005, J VIROL, V79, P2620, DOI 10.1128/JVI.79.4.2620-2625.2005	27	1502	1644	11	450	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2005	310	5748					676	679		10.1126/science.1118391	http://dx.doi.org/10.1126/science.1118391			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	980ET	16195424	Green Published			2022-12-28	WOS:000232997700042
J	Olcott, AN; Sessions, AL; Corsetti, FA; Kaufman, AJ; de Oliviera, TF				Olcott, AN; Sessions, AL; Corsetti, FA; Kaufman, AJ; de Oliviera, TF			Biomarker evidence for photosynthesis during Neoproterozoic glaciation	SCIENCE			English	Article							HYDROCARBON BIOMARKERS; CENTRALIAN SUPERBASIN; MICROBIAL MATS; DEATH-VALLEY; ICE SHELF; MICROFOSSILS; SEDIMENTS; GAMMACERANE; ECOSYSTEMS; SHALES	Laterally extensive black shales were deposited on the Sao Francisco craton in southeastern Brazil during low-latitude Neoproterozoic glaciation similar to 740 to 700 million years ago. These rocks contain up to 3.0 weight % organic carbon, which we interpret as representing the preserved record of abundant marine primary productivity from glacial times. Extractable biomarkers reflect a complex and productive microbial ecosystem, including both phototrophic bacteria and eukaryotes, living in a stratified ocean with thin or absent sea ice, oxic surface waters, and euxinic conditions within the photic zone. Such an environment provides important constraints for parts of the "Snowball Earth" hypothesis.	Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA; CALTECH, Pasadena, CA 91125 USA; Univ Maryland, College Pk, MD 20742 USA	University of Southern California; California Institute of Technology; University System of Maryland; University of Maryland College Park	Olcott, AN (corresponding author), Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA.	olcott@usc.edu	Sessions, Alex/ABC-9207-2020; Olcott, Alison N./AAL-2020-2021; Sessions, Alex L/C-2752-2008	Sessions, Alex/0000-0001-6120-2763; Sessions, Alex L/0000-0001-6120-2763; Olcott, Alison/0000-0002-6854-646X				Arouri K, 2000, PRECAMBRIAN RES, V100, P235, DOI 10.1016/S0301-9268(99)00076-5; Azmy K, 2001, PRECAMBRIAN RES, V112, P303, DOI 10.1016/S0301-9268(01)00194-2; Babinski M, 2005, J S AM EARTH SCI, V18, P293, DOI 10.1016/j.jsames.2004.11.010; BRODY KB, 2004, GEOL SOC AM ANN M DE; Brown TC, 2004, PALAEOGEOGR PALAEOCL, V215, P59, DOI 10.1016/j.palaeo.2004.08.004; Corsetti FA, 2003, GEOL SOC AM BULL, V115, P916, DOI 10.1130/B25066.1; Corsetti FA, 2003, P NATL ACAD SCI USA, V100, P4399, DOI 10.1073/pnas.0730560100; CORSETTI FA, IN PRESS PALAEOGEOGR; DAMSTE JSS, 1995, GEOCHIM COSMOCHIM AC, V59, P1895, DOI 10.1016/0016-7037(95)00073-9; Fairchild TR, 1996, PRECAMBRIAN RES, V80, P125, DOI 10.1016/S0301-9268(96)00009-5; Grice K, 2005, SCIENCE, V307, P706, DOI 10.1126/science.1104323; Halverson GP, 2004, BASIN RES, V16, P297, DOI 10.1111/j.1365-2117.2004.00234.x; HEDGES JI, 1995, MAR CHEM, V49, P137, DOI 10.1016/0304-4203(95)00013-H; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Hoffman PF, 2002, TERRA NOVA, V14, P129, DOI 10.1046/j.1365-3121.2002.00408.x; Hyde WT, 2000, NATURE, V405, P425, DOI 10.1038/35013005; Jacobsen SB, 1999, CHEM GEOL, V161, P37, DOI 10.1016/S0009-2541(99)00080-7; James NP, 2005, GEOLOGY, V33, P9, DOI 10.1130/G20938.1; Kaufman AJ, 1997, P NATL ACAD SCI USA, V94, P6600, DOI 10.1073/pnas.94.13.6600; Kennedy MJ, 2001, GEOLOGY, V29, P443, DOI 10.1130/0091-7613(2001)029<0443:APCCAI>2.0.CO;2; Kenny C, 2001, WORLD DEV, V29, P1, DOI 10.1016/S0305-750X(00)00088-7; KNAUER GA, 1993, BIOGEOCHEMICAL CYCLE, P211; Koopmans MP, 1996, GEOCHIM COSMOCHIM AC, V60, P4467, DOI 10.1016/S0016-7037(96)00238-4; Li C, 2003, PRECAMBRIAN RES, V125, P337, DOI 10.1016/S0301-9268(03)00111-6; Logan GA, 1999, GEOCHIM COSMOCHIM AC, V63, P1345, DOI 10.1016/S0016-7037(99)00033-2; Logan GA, 1997, GEOCHIM COSMOCHIM AC, V61, P5391, DOI 10.1016/S0016-7037(97)00290-1; Mueller D.R., 2001, NOVA HEDWIGIA S, V123, P173; Pollard D, 2005, J GEOPHYS RES-OCEANS, V110, DOI 10.1029/2004JC002525; Priscu JC, 1998, SCIENCE, V280, P2095, DOI 10.1126/science.280.5372.2095; REVILL AT, 1994, GEOCHIM COSMOCHIM AC, V58, P3803, DOI 10.1016/0016-7037(94)90365-4; Runnegar B, 2000, NATURE, V405, P403, DOI 10.1038/35013168; Simons DJH, 2003, ORG GEOCHEM, V34, P1177, DOI 10.1016/S0146-6380(03)00064-0; Smith WO, 1997, GEOPHYS RES LETT, V24, P233, DOI 10.1029/96GL03926; SUMMONS RE, 1992, BIOLOGICAL MARKERS IN SEDIMENTS AND PETROLEUM, P182; SUMMONS RE, 1987, GEOCHIM COSMOCHIM AC, V51, P557, DOI 10.1016/0016-7037(87)90069-X; Summons RE, 1999, NATURE, V400, P554, DOI 10.1038/23005; SUMMONS RE, 1988, GEOCHIM COSMOCHIM AC, V52, P2625, DOI 10.1016/0016-7037(88)90031-2; SUMMONS RE, 1990, AM J SCI, V290A, P212; TENHAVEN HL, 1989, GEOCHIM COSMOCHIM AC, V53, P3073; Thomas DN, 2002, SCIENCE, V295, P641, DOI 10.1126/science.1063391; Vincent WF, 2000, NATURWISSENSCHAFTEN, V87, P137, DOI 10.1007/s001140050692; Vincent WF, 2004, CRYOBIOLOGY, V48, P103, DOI 10.1016/j.cryobiol.2004.01.006; Xiao S, 2004, GEOPHYS MONOGR SER, V146, P199, DOI 10.1029/146GM16; [No title captured]	44	91	98	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	2005	310	5747					471	474		10.1126/science.1115769	http://dx.doi.org/10.1126/science.1115769			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16195425				2022-12-28	WOS:000232786000040
J	Callaghan, AJ; Marcaida, MJ; Stead, JA; McDowall, KJ; Scott, WG; Luisi, BF				Callaghan, AJ; Marcaida, MJ; Stead, JA; McDowall, KJ; Scott, WG; Luisi, BF			Structure of Escherichia coli RNase E catalytic domain and implications for RNA turnover	NATURE			English	Article							16S RIBOSOMAL-RNA; MESSENGER-RNA; RIBONUCLEASE-E; QUATERNARY STRUCTURE; TERMINAL HALF; GENE; DEGRADATION; SPECIFICITY; DEGRADOSOME; SITE	The coordinated regulation of gene expression is required for homeostasis, growth and development in all organisms. Such coordination may be partly achieved at the level of messenger RNA stability(1), in which the targeted destruction of subsets of transcripts generates the potential for cross-regulating metabolic pathways. In Escherichia coli, the balance and composition of the transcript population is affected by RNase E, an essential endoribonuclease that not only turns over RNA but also processes certain key RNA precursors(2-10). RNase E cleaves RNA internally, but its catalytic power is determined by the 50 terminus of the substrate, even if this lies at a distance from the cutting site(11-14). Here we report crystal structures of the catalytic domain of RNase E as trapped allosteric intermediates with RNA substrates. Four subunits of RNase E catalytic domain associate into an interwoven quaternary structure, explaining why the subunit organization is required for catalytic activity. The subdomain encompassing the active site is structurally congruent to a deoxyribonuclease, making an unexpected link in the evolutionary history of RNA and DNA nucleases. The structure explains how the recognition of the 50 terminus of the substrate may trigger catalysis and also sheds light on the question of how RNase E might selectively process, rather than destroy, specific RNA precursors.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA	University of Cambridge; University of Leeds; University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Luisi, BF (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	ben@cryst.bioc.cam.ac.uk	Marcaida, Maria Jose/I-1644-2017; McDowall, Kenneth/GYA-5735-2022	Marcaida, Maria Jose/0000-0003-0663-5309; Scott, William/0000-0002-9273-3564; Stead, Jonathan/0000-0002-8133-3733; McDowall, Kenneth/0000-0003-2528-2190	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APIRION D, 1978, J BIOL CHEM, V253, P1738; AVARIND L, 2001, METHOD ENZYMOL, V341, P3; Bernstein JA, 2004, P NATL ACAD SCI USA, V101, P2758, DOI 10.1073/pnas.0308747101; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; Callaghan AJ, 2005, BIOCHEMISTRY-US, V44, P4667, DOI 10.1021/bi0478244; Callaghan AJ, 2004, J MOL BIOL, V340, P965, DOI 10.1016/j.jmb.2004.05.046; Callaghan AJ, 2003, BIOCHEMISTRY-US, V42, P13848, DOI 10.1021/bi0351099; Carpousis AJ, 2002, BIOCHEM SOC T, V30, P150, DOI 10.1042/bst0300150; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; Cohen SN, 1997, MOL MICROBIOL, V23, P1099, DOI 10.1111/j.1365-2958.1997.tb02593.x; Grunberg-Manago M, 1999, ANNU REV GENET, V33, P193, DOI 10.1146/annurev.genet.33.1.193; Jiang XQ, 2004, P NATL ACAD SCI USA, V101, P9211, DOI 10.1073/pnas.0401382101; Kaberdin VR, 2003, NUCLEIC ACIDS RES, V31, P4710, DOI 10.1093/nar/gkg690; Kido M, 1996, J BACTERIOL, V178, P3917, DOI 10.1128/jb.178.13.3917-3925.1996; Kim KS, 2004, NUCLEIC ACIDS RES, V32, P6057, DOI 10.1093/nar/gkh939; KUWANO M, 1977, MOL GEN GENET, V154, P279, DOI 10.1007/BF00571283; Li ZW, 1999, EMBO J, V18, P2878, DOI 10.1093/emboj/18.10.2878; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LUNDBERG U, 1995, RNA, V1, P327; Mackie GA, 1998, NATURE, V395, P720, DOI 10.1038/27246; Mackie GA, 2000, J BIOL CHEM, V275, P25069, DOI 10.1074/jbc.C000363200; MCDOWALL KJ, 1993, J BACTERIOL, V175, P4245, DOI 10.1128/JB.175.13.4245-4249.1993; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; McDowall KJ, 1996, J MOL BIOL, V255, P349, DOI 10.1006/jmbi.1996.0027; MUDD EA, 1993, MOL MICROBIOL, V9, P557, DOI 10.1111/j.1365-2958.1993.tb01716.x; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; Ow MC, 2002, GENE DEV, V16, P1102, DOI 10.1101/gad.983502; Redko Y, 2003, J BIOL CHEM, V278, P44001, DOI 10.1074/jbc.M306760200; Wachi M, 1999, BIOCHEM BIOPH RES CO, V259, P483, DOI 10.1006/bbrc.1999.0806	30	208	211	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 20	2005	437	7062					1187	1191		10.1038/nature04084	http://dx.doi.org/10.1038/nature04084			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16237448	Green Published			2022-12-28	WOS:000232660500051
J	Ghedin, E; Sengamalay, NA; Shumway, M; Zaborsky, J; Feldblyum, T; Subbu, V; Spiro, DJ; Sitz, J; Koo, H; Bolotov, P; Dernovoy, D; Tatusova, T; Bao, YM; St George, K; Taylor, J; Lipman, DJ; Fraser, CM; Taubenberger, JK; Salzberg, SL				Ghedin, E; Sengamalay, NA; Shumway, M; Zaborsky, J; Feldblyum, T; Subbu, V; Spiro, DJ; Sitz, J; Koo, H; Bolotov, P; Dernovoy, D; Tatusova, T; Bao, YM; St George, K; Taylor, J; Lipman, DJ; Fraser, CM; Taubenberger, JK; Salzberg, SL			Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution	NATURE			English	Article							VIRUS NEURAMINIDASE; ANTIGENIC SITES; REASSORTMENT; PROTEIN; HOSPITALIZATIONS; PB1-F2; ASIA	Influenza viruses are remarkably adept at surviving in the human population over a long timescale. The human influenza A virus continues to thrive even among populations with widespread access to vaccines, and continues to be a major cause of morbidity and mortality(1,2). The virus mutates from year to year, making the existing vaccines ineffective on a regular basis, and requiring that new strains be chosen for a new vaccine. Less-frequent major changes, known as antigenic shift, create new strains against which the human population has little protective immunity, thereby causing worldwide pandemics. The most recent pandemics include the 1918 'Spanish' flu, one of the most deadly outbreaks in recorded history, which killed 30-50 million people worldwide, the 1957 'Asian' flu, and the 1968 'Hong Kong' flu(3). Motivated by the need for a better understanding of influenza evolution, we have developed flexible protocols that make it possible to apply large-scale sequencing techniques to the highly variable influenza genome. Here we report the results of sequencing 209 complete genomes of the human influenza A virus, encompassing a total of 2,821,103 nucleotides. In addition to increasing markedly the number of publicly available, complete influenza virus genomes, we have discovered several anomalies in these first 209 genomes that demonstrate the dynamic nature of influenza transmission and evolution. This new, large-scale sequencing effort promises to provide a more comprehensive picture of the evolution of influenza viruses and of their pattern of transmission through human and animal populations. All data from this project are being deposited, without delay, in public archives.	Inst Genom Res, Rockville, MD 20850 USA; NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; Armed Forces Inst Pathol, Dept Mol Pathol, Rockville, MD 20850 USA; Univ Maryland, Inst Adv Comp Studies, Ctr Bioinformat & Computat Biol, College Pk, MD 20742 USA	J. Craig Venter Institute; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); State University of New York (SUNY) System; Wadsworth Center; United States Department of Defense; University System of Maryland; University of Maryland College Park	Salzberg, SL (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	salzberg@umd.edu	Salzberg, Steven/Q-6514-2019; Taubenberger, Jeffery/AAQ-1407-2021; Ghedin, Elodie/Y-5654-2019; Salzberg, Steven L/F-6162-2011	Salzberg, Steven/0000-0002-8859-7432; Ghedin, Elodie/0000-0002-1515-725X; Salzberg, Steven L/0000-0002-8859-7432; Fraser, Claire/0000-0003-1462-2428	NATIONAL LIBRARY OF MEDICINE [ZIALM000077, Z01LM000160, Z01LM000077] Funding Source: NIH RePORTER	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Abbott A, 2004, NATURE, V427, P472, DOI 10.1038/427472a; AIR GM, 1985, VIROLOGY, V145, P237, DOI 10.1016/0042-6822(85)90157-6; Bin L, 2005, J VIROL, V79, P6763, DOI 10.1128/JVI.79.11.6763-6771.2005; Chanturiya AN, 2004, J VIROL, V78, P6304, DOI 10.1128/JVI.78.12.6304-6312.2004; COLMAN PM, 1983, NATURE, V303, P41, DOI 10.1038/303041a0; Cox NJ, 2000, ANNU REV MED, V51, P407, DOI 10.1146/annurev.med.51.1.407; Cyranoski D, 2003, NATURE, V422, P6, DOI 10.1038/422006a; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Fanning TG, 2000, VIROLOGY, V276, P417, DOI 10.1006/viro.2000.0578; Fauci AS, 2005, NATURE, V435, P423, DOI 10.1038/435423a; Gajer P, 2004, NUCLEIC ACIDS RES, V32, P562, DOI 10.1093/nar/gkh216; Gibbs JS, 2003, J VIROL, V77, P7214, DOI 10.1128/JVI.77.13.7214-7224.2003; Harris ME, 2002, AIDS RES HUM RETROV, V18, P1281, DOI 10.1089/088922202320886325; Holmes EC, 2005, PLOS BIOL, V3, P1579, DOI 10.1371/journal.pbio.0030300; Jin H, 2005, VIROLOGY, V336, P113, DOI 10.1016/j.virol.2005.03.010; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; Lindstrom SE, 2004, VIROLOGY, V328, P101, DOI 10.1016/j.virol.2004.06.009; Malide D, 2001, MOL BIOL CELL, V12, P101, DOI 10.1091/mbc.12.1.101; Marozin S, 2002, J GEN VIROL, V83, P735, DOI 10.1099/0022-1317-83-4-735; Mikhail M, 2005, AIDS RES HUM RETROV, V21, P575, DOI 10.1089/aid.2005.21.575; Pop M, 2004, BRIEF BIOINFORM, V5, P237, DOI 10.1093/bib/5.3.237; Reid AH, 2004, NAT REV MICROBIOL, V2, P909, DOI 10.1038/nrmicro1027; Salzberg SL, 2004, PLOS BIOL, V2, P1273, DOI 10.1371/journal.pbio.0020285; Simonsen L, 2000, J INFECT DIS, V181, P831, DOI 10.1086/315320; Szymkowiak C, 2003, J VIROL METHODS, V107, P15, DOI 10.1016/S0166-0934(02)00184-2; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Xu XY, 2004, VIRUS RES, V103, P55, DOI 10.1016/j.virusres.2004.02.013	27	334	359	1	80	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 20	2005	437	7062					1162	1166		10.1038/nature04239	http://dx.doi.org/10.1038/nature04239			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16208317	hybrid			2022-12-28	WOS:000232660500046
J	Schneider, LS; Dagerman, KS; Insel, P				Schneider, LS; Dagerman, KS; Insel, P			Risk of death with atypical antipsychotic drug treatment for dementia - Meta-analysis of randomized placebo-controlled trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ALZHEIMERS-DISEASE; DOUBLE-BLIND; COGNITIVE DECLINE; BEHAVIORAL DISTURBANCES; PSYCHOLOGICAL SYMPTOMS; CEREBROVASCULAR EVENTS; EXTRAPYRAMIDAL SIGNS; RISPERIDONE; PSYCHOSIS; OLANZAPINE	Context Atypical antipsychotic medications are widely used to treat delusions, aggression, and agitation in people with Alzheimer disease and other dementia; however, concerns have arisen about the increased risk for cerebrovascular adverse events, rapid cognitive decline, and mortality with their use. Objective To assess the evidence for increased mortality from atypical antipsychotic drug treatment for people with dementia. Data Sources MEDLINE (1966 to April 2005), the Cochrane Controlled Trials Register (2005, Issue 1), meetings presentations (1997-2004), and information from the sponsors were searched using the terms for atypical antipsychotic drugs (aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone), dementia, Alzheimer disease, and clinical trial. Study Selection Published and unpublished randomized placebo-controlled, parallel-group clinical trials of atypical antipsychotic drugs marketed in the United States to treat patients with Alzheimer disease or dementia were selected by consensus of the authors. Data Extraction Trials, baseline characteristics, outcomes, all-cause dropouts, and deaths were extracted by one reviewer; treatment exposure was obtained or estimated. Data were checked by a second reviewer. Data Synthesis Fifteen trials (9 unpublished), generally 10 to 12 weeks in duration, including 16 contrasts of atypical antipsychotic drugs with placebo met criteria (aripiprazole [n=3], olanzapine [n=5], quetiapine [n=3], rispericlone [n=5]). A total of 3353 patients were randomized to study drug and 1757 were randomized to placebo. Outcomes were assessed using standard methods (with random- or fixed-effects model,) to calculate odds ratios (ORs) and risk differences based on patients randomized and relative risks based on total exposure to treatment. There were no differences in dropouts. Death occurred more often among patients randomized to drugs (118 [3.5 %] vs 40 [2.3 %]. The OR by meta-analysis was 1.54; 95% confidence interval [CI], 1.06-2.23; P=.02; and risk difference was 0.01; 95% Cl, 0.004-0.02; P=.01). Sensitivity analyses did not show evidence for differential risks for individual drugs, severity, sample selection, or diagnosis. Conclusions Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo. This risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives. Individual patient analyses modeling survival and causes of death are needed.	Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ So Calif, Leonard Davis Sch Gerontol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California	Schneider, LS (corresponding author), Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, 1510 San Pablo St,HCC 600, Los Angeles, CA 90033 USA.	lschneid@usc.edu			NIA NIH HHS [AG 05142, U19 AG010483] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U19AG010483, P50AG005142] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALEXOPOULOS GS, 2005, EXPERT CONSENSUS GUI, P1; ALEXOPOULOS GS, 1998, EXPERT CONSENSUS GUI, P1; [Anonymous], 14 ANN M AM ASS GER; Ballard C, 2005, BMJ-BRIT MED J, V330, P874, DOI 10.1136/bmj.38369.459988.8F; BREDER C, 2004, 9 INT C ALZH DIS REL; *BRIST MYERS SQUIB, 2005, LAB CHANG AB RISK CV; Brodaty H, 2003, J CLIN PSYCHIAT, V64, P134, DOI 10.4088/JCP.v64n0205; CAVAZZONI P, 2004, 44 ANN NEW CLIN DRUG; Chan WC, 2001, INT J GERIATR PSYCH, V16, P1156, DOI 10.1002/gps.504; CHUI HC, 1994, ARCH NEUROL-CHICAGO, V51, P676, DOI 10.1001/archneur.1994.00540190056015; De Deyn PP, 1999, NEUROLOGY, V53, P946, DOI 10.1212/WNL.53.5.946; De Deyn PP, 2004, INT J GERIATR PSYCH, V19, P115, DOI 10.1002/gps.1032; DEBERDT W, 2004, AM GER SOC MAY 17 21; DEDEYN P, 1997, 8 C INT PSYCH ASS AU; DEDEYN PPJ, 2003, 16 ANN M AM ASS GER; Deeks~ JJ, 2001, SYSTEMATIC REV HLTH; DREVETS WC, 1989, BIOL PSYCHIAT, V25, P39, DOI 10.1016/0006-3223(89)90145-5; Health Canada Therapeutic Products Directorate, 2002, RISP WARN LETT; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Jeste DV, 2000, AM J GERIAT PSYCHIAT, V8, P29, DOI 10.1097/00019442-200002000-00004; Katz IR, 1999, J CLIN PSYCHIAT, V60, P107, DOI 10.4088/JCP.v60n0207; KENNEDY JS, 2004, INT COLL GER PSYCH O; KENNEDY JS, 2002, INT COLL GER PSYCH O; KUJAWA M, 2004, 9 INT C ALZH DIS REL; Lee PE, 2004, BMJ-BRIT MED J, V329, P75, DOI 10.1136/bmj.38125.465579.55; LOPEZ OL, 1991, NEUROLOGY, V41, P906, DOI 10.1212/WNL.41.6.906; McShane R, 1997, BMJ-BRIT MED J, V314, P266, DOI 10.1136/bmj.314.7076.266; *MED HEALTHC PROD, 2004, SUMM CLIN TRIAL DAT; MINTZER J, 2004, INT COLL GER PSYCH O; MOSHOLDER A, 2002, 42 ANN NEW CLIN DRUG; RACOOSIN JA, 2004, 17 ANN M AM ASS GER; Satterlee Winston G., 1995, Psychopharmacology Bulletin, V31, P534; Schneeweiss S, 2003, AM J MED QUAL, V18, P3, DOI 10.1177/106286060301800102; Sink KM, 2005, JAMA-J AM MED ASSOC, V293, P596, DOI 10.1001/jama.293.5.596; STERN Y, 1987, NEUROLOGY, V37, P1649, DOI 10.1212/WNL.37.10.1649; STERN Y, 1994, NEUROLOGY, V44, P2300, DOI 10.1212/WNL.44.12.2300; STOCK E, 2004, AM PSYCH ASS ANN M M; Street JS, 2000, ARCH GEN PSYCHIAT, V57, P968, DOI 10.1001/archpsyc.57.10.968; Street JS, 2000, PSYCHIAT ANN, V30, P191, DOI 10.3928/0048-5713-20000301-12; STREET JS, 2000, OLANZAPINE ZYPREXA N, P416; STREIM J, 2004, 157 AM PSYCH ASS ANN; TARIOT P, 2002, 15 ANN M AM ASS GER; Tariot PN, 2002, AM J GERIAT PSYCHIAT, V10, P93; U.S. Food and Drug Administration Center for Drug Evaluation and Research, FDA PUBL HLTH ADV DE; *US FOOD DRUG ADM, SAF DAT ZYPR OL HYP; Wooltorton E, 2002, CAN MED ASSOC J, V167, P1269; Wooltorton E, 2004, CAN MED ASSOC J, V170, P1395, DOI 10.1503/cmaj.1040539; ZHONG K, 2004, 9 INT C ALZH DIS REL; 2005, MED LETT DRUGS THER, V47, P61; 2005, COCHRANE LIB	50	1115	1142	1	80	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	2005	294	15					1934	1943		10.1001/jama.294.15.1934	http://dx.doi.org/10.1001/jama.294.15.1934			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	974OZ	16234500				2022-12-28	WOS:000232602600023
J	Jaeger, JJ; Marivaux, L				Jaeger, JJ; Marivaux, L			Paleontology - Shaking the earliest branches of anthropoid primate evolution	SCIENCE			English	Editorial Material							EOCENE PONDAUNG FORMATION; MIDDLE EOCENE; OLIGOCENE; MYANMAR; ORIGIN		Univ Montpellier 2, Lab Paleontol, Inst Sci Evolut, F-34095 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier	Jaeger, JJ (corresponding author), Univ Montpellier 2, Lab Paleontol, Inst Sci Evolut, F-34095 Montpellier, France.	jaeger@isem.univ-montp2.fr; marivaux@isem.univ-montp2.fr						Beard K.C., 2004, HUNT DAWN MONKEY UNE; BEARD KC, 1994, NATURE, V368, P604, DOI 10.1038/368604a0; DEBONIS L, 1988, CR ACAD SCI II, V306, P929; Ducrocq Stephane, 1997, Stuttgarter Beitraege zur Naturkunde Serie B (Geologie und Palaeontologie), V250, P1; Gheerbrant Emmanuel, 1995, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V237, P39; GODINOT M, 1992, NATURE, V357, P324, DOI 10.1038/357324a0; Heesy Christopher P., 2004, P665; Jaeger JJ, 1999, SCIENCE, V286, P528, DOI 10.1126/science.286.5439.528; Kay Richard F., 2004, P91; Marivaux L, 2005, P NATL ACAD SCI USA, V102, P8436, DOI 10.1073/pnas.0503469102; Marivaux L, 2005, J VERTEBR PALEONTOL, V25, P214, DOI 10.1671/0272-4634(2005)025[0214:NROPAR]2.0.CO;2; Marivaux L, 2003, P NATL ACAD SCI USA, V100, P13173, DOI 10.1073/pnas.2332542100; Marivaux L, 2002, ZOOL SCR, V31, P225, DOI 10.1046/j.1463-6409.2002.00074.x; Miller ER, 1997, P NATL ACAD SCI USA, V94, P13760, DOI 10.1073/pnas.94.25.13760; Seiffert ER, 2005, SCIENCE, V310, P300, DOI 10.1126/science.1116569; SIGE B, 1990, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V214, P31; Simons E, 1995, YEARB PHYS ANTHROPOL, V38, P199	17	17	17	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					244	245		10.1126/science.1118124	http://dx.doi.org/10.1126/science.1118124			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224009				2022-12-28	WOS:000232670100032
J	Rosenthal, MB; Frank, RG; Li, ZH; Epstein, AM				Rosenthal, MB; Frank, RG; Li, ZH; Epstein, AM			Early experience with pay-for-performance - From concept to practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY; INCENTIVES; MEDICARE; IMPACT; RATES; CARE	Context The adoption of pay-for-performance mechanisms for quality improvement is growing rapidly. Although there is intense interest in and optimism about pay-for-performance programs, there is little published research on pay-for-performance in health care. Objective To evaluate the impact of a prototypical physician pay-for-performance program on quality of care. Design, Setting, and Participants We evaluated a natural experiment with pay-for-performance using administrative reports of physician group quality from a large health plan for an intervention group (California physician groups) and a contemporaneous comparison group (Pacific Northwest physician groups). Quality improvement reports were included from October 2001 through April 2004 issued to approximately 300 large physician organizations. Main Outcome Measures Three process measures of clinical quality: cervical cancer screening, mammography, and hemoglobin A(1c) testing. Results Improvements in clinical quality scores were as follows: for cervical cancer screening, 5.3% for California vs 1.7% for Pacific Northwest; for mammography, 1.9% vs 0.2%; and for hemoglobin A(1c), 2.1% vs 2.1%. Compared with physician groups in the Pacific Northwest, the California network demonstrated greater quality improvement after the pay-for-performance intervention only in cervical cancer screening (a 3.6% difference in improvement [P=.02]). In total, the plan awarded $3.4 million (27% of the amount set aside) in bonus payments between July 2003 and April 2004, the first year of the program. For all 3 measures, physician groups with baseline performance at or above the performance threshold for receipt of a bonus improved the least but garnered the largest share of the bonus payments. Conclusion Paying clinicians to reach a common, fixed performance target may produce little gain in quality for the money spent and will largely reward those with higher performance at baseline.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Natl Bur Econ Res, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; National Bureau of Economic Research	Rosenthal, MB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.	meredith-rosenthal@harvard.edu		Rosenthal, Meredith/0000-0003-3410-0184				Amundson Gail, 2003, Jt Comm J Qual Saf, V29, P59; BAKER G, 2004, EVOLUTION PAY PERFOR; Berwick DM, 2003, HEALTH AFFAIR, V22, P8, DOI 10.1377/hlthaff.22.6.8; DUDLEY RA, 2004, 04P024 AHRQ; Epstein AM, 2004, NEW ENGL J MED, V350, P406, DOI 10.1056/NEJMsb035374; Fairbrother G, 1999, AM J PUBLIC HEALTH, V89, P171, DOI 10.2105/AJPH.89.2.171; Kouides RW, 1998, AM J PREV MED, V14, P89, DOI 10.1016/S0749-3797(97)00028-7; Rosenthal MB, 2004, HEALTH AFFAIR, V23, P127, DOI 10.1377/hlthaff.23.2.127; Rosenthal MB, 2001, HEALTH AFFAIR, V20, P109, DOI 10.1377/hlthaff.20.4.109; ROSENTHAL MB, IN PRESS MED CARE RE; Roski J, 2003, PREV MED, V36, P291, DOI 10.1016/S0091-7435(02)00052-X; Schneider EC, 2001, MED CARE, V39, P1313, DOI 10.1097/00005650-200112000-00007	12	483	485	5	60	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	2005	294	14					1788	1793		10.1001/jama.294.14.1788	http://dx.doi.org/10.1001/jama.294.14.1788			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972RX	16219882	Bronze			2022-12-28	WOS:000232472000018
J	Quigley, C				Quigley, C			The role of opioids in cancer pain	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TRANSDERMAL FENTANYL; ORAL MORPHINE; DOUBLE-BLIND; MANAGEMENT; EFFICACY; STRATEGIES; GUIDELINES; QUALITY; RELIEF		Hammersmith Hosp, Ctr Canc, London W12 0HZ, England	Imperial College London	Quigley, C (corresponding author), Hammersmith Hosp, Ctr Canc, London W12 0HZ, England.	cquigley@hhnt.nhs.uk						Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Bruera E, 1998, J CLIN ONCOL, V16, P3222, DOI 10.1200/JCO.1998.16.10.3222; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; CHERNY NJ, 1995, CANCER-AM CANCER SOC, V76, P1283, DOI 10.1002/1097-0142(19951001)76:7<1283::AID-CNCR2820760728>3.0.CO;2-0; Collins SL, 1998, J PAIN SYMPTOM MANAG, V16, P388, DOI 10.1016/S0885-3924(98)00094-3; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Gourlay GK, 1997, PAIN, V69, P295, DOI 10.1016/S0304-3959(96)03269-1; GROND S, 1991, INT J CLIN PHARM RES, V11, P253; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; HANKS GW, 2000, UK KEY ADV CLIN PRAC, P57; JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870; LASAGNA L, 1965, NARCOTICS, P53; Megens AAHP, 1998, J PAIN SYMPTOM MANAG, V15, P253, DOI 10.1016/S0885-3924(97)00371-0; Mercadante S, 1999, CANCER-AM CANCER SOC, V85, P1849, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1849::AID-CNCR27>3.0.CO;2-6; Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P448, DOI 10.1016/S0885-3924(01)00289-5; Mercadante S, 2002, EUR J CANCER, V38, P1358, DOI 10.1016/S0959-8049(02)00102-8; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; *NAT COUNC HOSP SP, 1986, GUID MAN CANC PAIN A; NIHOLSON AB, 2004, COCHRANE DATABASE SY; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; PORTENOY RK, 1993, OXFORD TXB PALLIATIV, P187; Quigley C, 2003, J PAIN SYMPTOM MANAG, V25, P169, DOI 10.1016/S0885-3924(02)00643-7; Quigley C, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD004847; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; Raja SN, 2002, NEUROLOGY, V59, P1015, DOI 10.1212/WNL.59.7.1015; Ripamonti C, 1991, J Palliat Care, V7, P30; Ross JR, 2003, EUR J PAIN, V7, P481, DOI 10.1016/S1090-3801(02)00148-9; Sorge J, 2004, CLIN THER, V26, P1808, DOI 10.1016/j.clinthera.2004.11.008; Twycross R, 2002, PALLIATIVE CARE FORM; Twycross R, 2001, SYMPTOM MANAGEMENT A; TWYCROSS RG, 1994, PAIN RELIEF ADV CANC, P255; VAINIO A, 1995, LANCET, V346, P667, DOI 10.1016/S0140-6736(95)92281-4; VANPEER A, 1986, EUR J CLIN PHARMACOL, V30, P245, DOI 10.1007/BF00614313; VENTAFRIDDA V, 1987, CANCER, V59, P851; *WHO, 1998, CANC PAIN REL GUID O; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M	36	52	54	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 8	2005	331	7520					825	829		10.1136/bmj.331.7520.825	http://dx.doi.org/10.1136/bmj.331.7520.825			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974BC	16210282	Green Published			2022-12-28	WOS:000232565300024
J	Mishra, L; Derynck, R; Mishra, B				Mishra, L; Derynck, R; Mishra, B			Transforming growth factor-beta signaling in stem cells and cancer	SCIENCE			English	Article							DIFFERENTIATION; DISRUPTION; SMAD4; FATE; INDUCTION; PATHWAYS; PROTEIN; GENES; MICE; ELF	Transforming growth factor-beta(TGF-beta) and TGF-beta-related proteins, such as the bone morphogenetic proteins, have emerged as key regulators of stem cell renewal and differentiation. These proteins have disparate roles in regulating the biology of embryonic stem cells and tumor suppression, and they help define the selection of cell fate and the progression of differentiation along a lineage. Here we illustrate their roles in embryonic stem cells and in the differentiation of neural, hematopoietic, mesenchymal, and gastrointestinal epithelial stem cells.	Georgetown Univ, Dept Surg, Med Lombardi Canc Ctr, Lab CNS Dev, Washington, DC 20007 USA; Dept Vet Affairs, Washington, DC 20049 USA; Univ Calif San Francisco, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Dev Biol, San Francisco, CA 94143 USA	Georgetown University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Mishra, L (corresponding author), Georgetown Univ, Dept Surg, Med Lombardi Canc Ctr, Lab CNS Dev, Univ Med Dent Bldg,NW 212,3900 Reservoir Rd NW, Washington, DC 20007 USA.	lm229@georgetown.edu		Mishra, Lopa/0000-0002-6850-0808	NCI NIH HHS [R01 CA106614A, R01 CA63101] Funding Source: Medline; NIDCR NIH HHS [P60 DE 13058] Funding Source: Medline; NIDDK NIH HHS [R01 DK58637, R01 DK56111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P60DE013058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLAKE T, 2005, SCI STKE         SEP; Chadwick K, 2005, BLOOD, V105, P1905, DOI 10.1182/blood-2004-03-0881; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chiba S, 2003, P NATL ACAD SCI USA, V100, P15577, DOI 10.1073/pnas.2536757100; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Fogarty MP, 2005, J NEUROBIOL, V64, P458, DOI 10.1002/neu.20166; Gangemi RMR, 2004, J NEUROCHEM, V89, P286, DOI 10.1046/j.1471-4159.2004.02310.x; GOLESTANEH N, 2005, SCI STKE         SEP; KITISIN AK, 2005, SCI STKE         SEP; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; Larsson J, 2005, ONCOGENE, V24, P5676, DOI 10.1038/sj.onc.1208920; Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836; Lin HK, 2005, ONCOGENE, V24, P5693, DOI 10.1038/sj.onc.1208923; Liu B, 2003, BLOOD, V101, P124, DOI 10.1182/blood-2002-02-0398; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mishra L, 2005, CANCER BIOL THER, V4, P694, DOI 10.4161/cbt.4.7.2015; Munoz-Sanjuan I, 2002, NAT REV NEUROSCI, V3, P271, DOI 10.1038/nrn786; Parisi S, 2003, J CELL BIOL, V163, P303, DOI 10.1083/jcb.200303010; Park C, 2004, DEVELOPMENT, V131, P2749, DOI 10.1242/dev.01130; Roberts A, 2005, ONCOGENE, V24, P5667, DOI 10.1038/sj.onc.1208915; Ruscetti FW, 2005, ONCOGENE, V24, P5751, DOI 10.1038/sj.onc.1208921; Scandura JM, 2004, P NATL ACAD SCI USA, V101, P15231, DOI 10.1073/pnas.0406771101; Schuldiner M, 2000, P NATL ACAD SCI USA, V97, P11307, DOI 10.1073/pnas.97.21.11307; Skillington J, 2002, J CELL BIOL, V159, P135, DOI 10.1083/jcb.200204060; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tang Y, 2005, CANCER RES, V65, P4228, DOI 10.1158/0008-5472.CAN-04-4585; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Zhou YX, 2003, J BIOL CHEM, V278, P42313, DOI 10.1074/jbc.M308287200	31	167	184	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	2005	310	5745					68	71		10.1126/science.1118389	http://dx.doi.org/10.1126/science.1118389			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210527				2022-12-28	WOS:000232477000036
J	Johnson, PA; Jia, X				Johnson, PA; Jia, X			Nonlinear dynamics, granular media and dynamic earthquake triggering	NATURE			English	Article							SLOW DYNAMICS; SEISMICITY; ELASTICITY; TRANSIENT; LANDERS; FIELD	The 1992 magnitude 7.3 Landers earthquake triggered an exceptional number of additional earthquakes within California and as far north as Yellowstone and Montana(1-3). Since this observation, other large earthquakes have been shown to induce dynamic triggering at remote distances - for example, after the 1999 magnitude 7.1 Hector Mine(1) and the 2002 magnitude 7.9 Denali(4) earthquakes - and in the near-field as aftershocks(5). The physical origin of dynamic triggering, however, remains one of the least understood aspects of earthquake nucleation(1-5). The dynamic strain amplitudes from a large earthquake are exceedingly small once the waves have propagated more than several fault radii. For example, a strain wave amplitude of 10(-6) and wavelength 1 m corresponds to a displacement amplitude of about 10(-7) m. Here we show that the dynamic, elastic-nonlinear behaviour of fault gouge perturbed by a seismic wave may trigger earthquakes, even with such small strains. We base our hypothesis on recent laboratory dynamic experiments conducted in granular media, a fault gouge surrogate(6,7). From these we infer that, if the fault is weak(8-10), seismic waves cause the fault core modulus to decrease abruptly and weaken further. If the fault is already near failure, this process could therefore induce fault slip.	Los Alamos Natl Lab, Geophys Grp EES11, Los Alamos, NM 87545 USA; Univ Marne la Vallee, CNRS, UMR 8108, Lab Phys Mat Divises & Interfaces, F-77454 Marne La Vallee, France	United States Department of Energy (DOE); Los Alamos National Laboratory; Centre National de la Recherche Scientifique (CNRS); Universite Gustave-Eiffel	Johnson, PA (corresponding author), Los Alamos Natl Lab, Geophys Grp EES11, MS D443, Los Alamos, NM 87545 USA.	paj@lanl.gov						Astrom JA, 2000, PHYS REV LETT, V84, P638, DOI 10.1103/PhysRevLett.84.638; Brodsky EE, 2000, GEOPHYS RES LETT, V27, P2741, DOI 10.1029/2000GL011534; DAS S, 1981, B SEISMOL SOC AM, V71, P1669; GOMBERG J, 1994, B SEISMOL SOC AM, V84, P844; Gomberg J, 2001, NATURE, V411, P462, DOI 10.1038/35078053; Gomberg J, 2004, NATURE, V427, P621, DOI 10.1038/nature02335; Gomberg J, 1998, J GEOPHYS RES-SOL EA, V103, P24411, DOI 10.1029/98JB01125; Gomberg J, 2003, B SEISMOL SOC AM, V93, P118, DOI 10.1785/0120020075; Guyer RA, 1999, PHYS TODAY, V52, P30, DOI 10.1063/1.882648; Hardebeck JL, 1999, SCIENCE, V285, P236, DOI 10.1126/science.285.5425.236; Hardebeck JL, 2001, J GEOPHYS RES-SOL EA, V106, P21859, DOI 10.1029/2001JB000292; Hartley RR, 2003, NATURE, V421, P928, DOI 10.1038/nature01394; HILL DP, 1993, SCIENCE, V260, P1617, DOI 10.1126/science.260.5114.1617; Hough SE, 2001, B SEISMOL SOC AM, V91, P1574, DOI 10.1785/0120000259; Jia X, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.154303; Johnson KL, 1985, CONTACT MECH, DOI 10.1201/b17110-2; Johnson P, 2005, J ACOUST SOC AM, V117, P124, DOI 10.1121/1.1823351; Marone C, 1998, ANNU REV EARTH PL SC, V26, P643, DOI 10.1146/annurev.earth.26.1.643; Miller SA, 2004, NATURE, V427, P724, DOI 10.1038/nature02251; Miller SA, 1996, NATURE, V382, P799, DOI 10.1038/382799a0; Mohamad R., 2000, SEISMOL RES LETT, V71, P47, DOI DOI 10.1785/GSSRL.71.1.47; Ostrovsky LA, 2001, RIV NUOVO CIMENTO, V24, P1; PEARD M, 2004, AUST J PHARM, V85, P42; RICE JR, 1979, J GEOPHYS RES, V84, P2177, DOI 10.1029/JB084iB05p02177; RUDNICKI JW, 1977, J GEOPHYS RES, V82, P844, DOI 10.1029/JB082i005p00844; Scholz C.H., 2002, MECH EARTHQUAKES FAU, V2, DOI [10.1017/CBO9780511818516, DOI 10.1017/CBO9780511818516]; SINGH SK, 1998, GEOFIS INT, V37, P3; TenCate JA, 1996, GEOPHYS RES LETT, V23, P3019, DOI 10.1029/96GL02884	28	285	294	1	69	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					871	874		10.1038/nature04015	http://dx.doi.org/10.1038/nature04015			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208368				2022-12-28	WOS:000232338600043
J	D'Autreaux, B; Tucker, NP; Dixon, R; Spiro, S				D'Autreaux, B; Tucker, NP; Dixon, R; Spiro, S			A non-haem iron centre in the transcription factor NorR senses nitric oxide	NATURE			English	Article							ESCHERICHIA-COLI; NITROSYL COMPLEXES; ELECTRONIC-STRUCTURE; SIGNAL-TRANSDUCTION; PROTEIN; ACTIVATION; BINDING; FLAVORUBREDOXIN; INHIBITION; REDUCTION	Nitric oxide ( NO), synthesized in eukaryotes by the NO synthases, has multiple roles in signalling pathways and in protection against pathogens(1,2). Pathogenic microorganisms have apparently evolved defence mechanisms that counteract the effects of NO and related reactive nitrogen species. Regulatory proteins that sense NO mediate the primary response to NO and nitrosative stress(3-9). The only regulatory protein in enteric bacteria known to serve exclusively as an NO-responsive transcription factor is the enhancer binding protein NorR (refs 9 - 11). In Escherichia coli, NorR activates the transcription of the nor VW genes encoding a flavorubredoxin (FlRd) and an associated flavoprotein, respectively, which together have NADH-dependent NO reductase activity(10,12-14). The NO-responsive activity of NorR raises important questions concerning the mechanism of NO sensing. Here we show that the regulatory domain of NorR contains a mononuclear non-haem iron centre, which reversibly binds NO. Binding of NO stimulates the ATPase activity of NorR, enabling the activation of transcription by RNA polymerase. The mechanism of NorR reveals an unprecedented biological role for a non-haem mononitrosyl - iron complex in NO sensing.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England; Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University System of Georgia; Georgia Institute of Technology	Spiro, S (corresponding author), John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England.	stephen.spiro@biology.gatech.edu	Spiro, Stephen/B-1838-2009; D'Autreaux, Benoit/M-8520-2018	Spiro, Stephen/0000-0001-5975-9984; Tucker, Nicholas/0000-0002-6331-3704; D'Autreaux, Benoit/0000-0002-1276-3019; Dixon, Ray/0000-0002-6348-639X	Biotechnology and Biological Sciences Research Council [BBS/E/J/00000016] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; ARCIERO DM, 1983, J BIOL CHEM, V258, P4981; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BROWN CA, 1995, J AM CHEM SOC, V117, P715, DOI 10.1021/ja00107a015; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; Clay MD, 2003, P NATL ACAD SCI USA, V100, P3796, DOI 10.1073/pnas.0636858100; Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339; D'Autreaux B, 2002, P NATL ACAD SCI USA, V99, P16619, DOI 10.1073/pnas.252591299; D'Autreaux B, 2004, J AM CHEM SOC, V126, P6005, DOI 10.1021/ja031671a; Ding HG, 2000, P NATL ACAD SCI USA, V97, P5146, DOI 10.1073/pnas.97.10.5146; ENEMARK JH, 1974, COORDIN CHEM REV, V13, P339, DOI 10.1016/S0010-8545(00)80259-3; Fang FC, 2004, NAT REV MICROBIOL, V2, P820, DOI 10.1038/nrmicro1004; Gardner AM, 2003, J BIOL CHEM, V278, P10081, DOI 10.1074/jbc.M212462200; Gomes CM, 2002, J BIOL CHEM, V277, P25273, DOI 10.1074/jbc.M203886200; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Hauser C, 2000, J AM CHEM SOC, V122, P4352, DOI 10.1021/ja994161i; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hutchings MI, 2002, J BACTERIOL, V184, P4640, DOI 10.1128/JB.184.16.4640-4643.2002; Li M, 2002, INORG CHEM, V41, P3444, DOI 10.1021/ic011243a; Little R, 2000, EMBO J, V19, P6041, DOI 10.1093/emboj/19.22.6041; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mukhopadhyay P, 2004, P NATL ACAD SCI USA, V101, P745, DOI 10.1073/pnas.0307741100; Pohlmann A, 2000, MOL MICROBIOL, V38, P626, DOI 10.1046/j.1365-2958.2000.02157.x; Ray M, 1999, INORG CHEM, V38, P3110, DOI 10.1021/ic990070a; Roy S, 2004, IMMUNOLOGY, V112, P471, DOI 10.1046/j.1365-2567.2004.01905.x; Serres RG, 2004, J AM CHEM SOC, V126, P5138, DOI 10.1021/ja030645+; Studholme DJ, 2003, J BACTERIOL, V185, P1757, DOI 10.1128/JB.185.6.1757-1767.2003; Tucker NP, 2004, J BACTERIOL, V186, P6656, DOI 10.1128/JB.186.19.6656-6660.2004; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753	30	241	244	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					769	772		10.1038/nature03953	http://dx.doi.org/10.1038/nature03953			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193057				2022-12-28	WOS:000232157900060
J	Soden, BJ; Jackson, DL; Ramaswamy, V; Schwarzkopf, MD; Huang, XL				Soden, BJ; Jackson, DL; Ramaswamy, V; Schwarzkopf, MD; Huang, XL			The radiative signature of upper tropospheric moistening	SCIENCE			English	Article							WATER-VAPOR FEEDBACK; SATELLITE DATA; INTERANNUAL VARIABILITY; RELATIVE-HUMIDITY; CLIMATE FEEDBACK; TRENDS; TEMPERATURE; MODEL; GREENHOUSE; SIMULATIONS	Climate models predict that the concentration of water vapor in the upper troposphere could double by the end of the century as a result of increases in greenhouse gases. Such moistening plays a key rote in amplifying the rate at which the climate warms in response to anthropogenic activities, but has been difficult to detect because of deficiencies in conventional observing systems. We use satellite measurements to highlight a distinct radiative signature of upper tropospheric moistening over the period 1982 to 2004. The observed moistening is accurately captured by climate model simulations and lends further credence to model projections of future global warming.	Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; Univ Colorado, Cooperat Inst Res Environm Sci, Boulder, CO 80305 USA; NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA; Princeton Univ, Atmospher & Ocean Sci Program, Princeton, NJ 08542 USA	University of Miami; University of Colorado System; University of Colorado Boulder; National Oceanic Atmospheric Admin (NOAA) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; Princeton University	Soden, BJ (corresponding author), Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, 4600 Rickenbacker Causeway, Miami, FL 33149 USA.	bsoden@rsmas.miami.edu	Huang, Xianglei/E-6273-2018; Soden, Brian/ABC-3659-2021; Jackson, Darren/D-5506-2015; Ramaswamy, Venkatachalam/AAJ-6265-2021; Huang, Xianglei/G-6127-2011	Huang, Xianglei/0000-0002-7129-614X; Jackson, Darren/0000-0001-5211-7866; Ramaswamy, Venkatachalam/0000-0002-1984-6423; Huang, Xianglei/0000-0002-7129-614X; Soden, Brian/0000-0001-9693-8236				Allan RP, 2003, Q J ROY METEOR SOC, V129, P3371, DOI 10.1256/qj.02.217; Bates JJ, 1996, J CLIMATE, V9, P427, DOI 10.1175/1520-0442(1996)009<0427:IVOUTW>2.0.CO;2; Bates JJ, 2001, GEOPHYS RES LETT, V28, P1695, DOI 10.1029/2000GL012544; CESS RD, 1990, J GEOPHYS RES-ATMOS, V95, P16601, DOI 10.1029/JD095iD10p16601; Christy JR, 2000, J ATMOS OCEAN TECH, V17, P1153, DOI 10.1175/1520-0426(2000)017<1153:MTTDCA>2.0.CO;2; Colman R, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020708; DELGENIO AD, 1994, GEOPHYS RES LETT, V21, P2701, DOI 10.1029/94GL02658; DICKINSON RE, 1996, CLIMATE CHANGE 1995, P193; ELLIOTT WP, 1991, B AM METEOROL SOC, V72, P1507, DOI 10.1175/1520-0477(1991)072<1507:OTUORH>2.0.CO;2; Geer AJ, 1999, J CLIMATE, V12, P1940, DOI 10.1175/1520-0442(1999)012<1940:SPOCVI>2.0.CO;2; *GLOB ATM MOD DEV, 2004, J CLIMATOL, V17, P461; Held IM, 2000, ANNU REV ENERG ENV, V25, P441, DOI 10.1146/annurev.energy.25.1.441; Kiehl JT, 1997, B AM METEOROL SOC, V78, P197, DOI 10.1175/1520-0477(1997)078<0197:EAGMEB>2.0.CO;2; LINDZEN RS, 1990, B AM METEOROL SOC, V71, P288, DOI 10.1175/1520-0477(1990)071<0288:SCCGW>2.0.CO;2; Lindzen RS, 2001, B AM METEOROL SOC, V82, P417, DOI 10.1175/1520-0477(2001)082<0417:DTEHAA>2.3.CO;2; McCarthy MP, 2004, J CLIMATE, V17, P3181, DOI 10.1175/1520-0442(2004)017<3181:OIVOTT>2.0.CO;2; Mears CA, 2005, SCIENCE, V309, P1548, DOI 10.1126/science.1114772; Mears CA, 2003, J CLIMATE, V16, P3650, DOI 10.1175/1520-0442(2003)016<3650:AROTMC>2.0.CO;2; Minschwaner K, 2004, J CLIMATE, V17, P1272, DOI 10.1175/1520-0442(2004)017<1272:WVFITT>2.0.CO;2; PIERREHUMBERT RT, 1995, J ATMOS SCI, V52, P1784, DOI 10.1175/1520-0469(1995)052<1784:TRFATL>2.0.CO;2; RAVAL A, 1989, NATURE, V342, P758, DOI 10.1038/342758a0; RIND D, 1991, NATURE, V349, P500, DOI 10.1038/349500a0; Ross RJ, 2001, J CLIMATE, V14, P1602, DOI 10.1175/1520-0442(2001)014<1602:RBNHTW>2.0.CO;2; Santer BD, 2005, SCIENCE, V309, P1551, DOI 10.1126/science.1114867; Soden B, 2000, B AM METEOROL SOC, V81, P797, DOI 10.1175/1520-0477(2000)081<0797:AIORCF>2.3.CO;2; SODEN BJ, 1995, J CLIMATE, V8, P2333, DOI 10.1175/1520-0442(1995)008<2333:ASAODC>2.0.CO;2; SODEN BJ, 1993, J GEOPHYS RES-ATMOS, V98, P16669, DOI 10.1029/93JD01283; Soden BJ, 2002, SCIENCE, V296, P727, DOI 10.1126/science.296.5568.727; STOCKER TF, 2001, CLIMATE CHANGE 2001, P418; SUN DZ, 1993, J ATMOS SCI, V50, P1643, DOI 10.1175/1520-0469(1993)050<1643:DOTTWV>2.0.CO;2; Trenberth KE, 2005, CLIM DYNAM, V24, P741, DOI 10.1007/s00382-005-0017-4; Weatherhead EC, 1998, J GEOPHYS RES-ATMOS, V103, P17149, DOI 10.1029/98JD00995; Wentz FJ, 2000, NATURE, V403, P414, DOI 10.1038/35000184; WETHERALD RT, 1988, J ATMOS SCI, V45, P1397, DOI 10.1175/1520-0469(1988)045<1397:CFPIAG>2.0.CO;2; Wylie D, 2005, J CLIMATE, V18, P3021, DOI 10.1175/JCLI3461.1; Zhai PM, 1997, J CLIMATE, V10, P2643, DOI 10.1175/1520-0442(1997)010<2643:AWVOC>2.0.CO;2; [No title captured]	37	204	211	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2005	310	5749					841	844		10.1126/science.1115602	http://dx.doi.org/10.1126/science.1115602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16210499				2022-12-28	WOS:000233121800042
J	Lindell, D; Jaffe, JD; Johnson, ZI; Church, GM; Chisholm, SW				Lindell, D; Jaffe, JD; Johnson, ZI; Church, GM; Chisholm, SW			Photosynthesis genes in marine viruses yield proteins during host infection	NATURE			English	Article							SYNECHOCOCCUS STRAINS; PROCHLOROCOCCUS; GENOME; METABOLISM; PHAGE; LIGHT	Cyanobacteria, and the viruses ( phages) that infect them, are significant contributors to the oceanic 'gene pool'(1,2). This pool is dynamic, and the transfer of genetic material between hosts and their phages(3-6) probably influences the genetic and functional diversity of both. For example, photosynthesis genes of cyanobacterial origin have been found in phages that infect Prochlorococcus(5,7) and Synechococcus(8,9), the numerically dominant phototrophs in ocean ecosystems. These genes include psbA, which encodes the photosystem II core reaction centre protein D1, and high-light-inducible ( hli) genes. Here we show that phage psbA and hli genes are expressed during infection of Prochlorococcus and are cotranscribed with essential phage capsid genes, and that the amount of phage D1 protein increases steadily over the infective period. We also show that the expression of host photosynthesis genes declines over the course of infection and that replication of the phage genome is a function of photosynthesis. We thus propose that the phage genes are functional in photosynthesis and that they may be increasing phage fitness by supplementing the host production of these proteins.	MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Chisholm, SW (corresponding author), MIT, Dept Civil & Environm Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	chisholm@mit.edu	Johnson, Zackary I/E-4601-2011	Johnson, Zackary I/0000-0003-0793-8512; Lindell, Debbie/0000-0003-0612-4517; church, george/0000-0001-6232-9969; Chisholm, Sallie/0000-0003-1480-2445				Adir N, 2003, PHOTOSYNTH RES, V76, P343, DOI 10.1023/A:1024969518145; ADOLPH KW, 1972, VIROLOGY, V47, P370, DOI 10.1016/0042-6822(72)90272-3; Arias MC, 2003, J PHYTOPATHOL, V151, P267, DOI 10.1046/j.1439-0434.2003.00718.x; Breitbart M, 2002, P NATL ACAD SCI USA, V99, P14250, DOI 10.1073/pnas.202488399; Bruyant F, 2005, LIMNOL OCEANOGR, V50, P850, DOI 10.4319/lo.2005.50.3.0850; Canchaya C, 2003, CURR OPIN MICROBIOL, V6, P417, DOI 10.1016/S1369-5274(03)00086-9; Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100; GINZBURG D, 1968, J VIROL, V2, P695, DOI 10.1128/JVI.2.7.695-701.1968; Havaux M, 2003, BBA-BIOENERGETICS, V1557, P21, DOI 10.1016/S0005-2728(02)00391-2; Hendrix RW, 2000, TRENDS MICROBIOL, V8, P504, DOI 10.1016/S0966-842X(00)01863-1; Johnson ZI, 2004, MAR ECOL PROG SER, V283, P73, DOI 10.3354/meps283073; Kolber ZS, 1998, BBA-BIOENERGETICS, V1367, P88, DOI 10.1016/S0005-2728(98)00135-2; Lindell D, 2004, P NATL ACAD SCI USA, V101, P11013, DOI 10.1073/pnas.0401526101; MACKENZIE JJ, 1972, VIROLOGY, V49, P517, DOI 10.1016/0042-6822(72)90503-X; Mann NH, 2005, J BACTERIOL, V187, P3188, DOI 10.1128/JB.187.9.3188-3200.2005; Mann NH, 2003, NATURE, V424, P741, DOI 10.1038/424741a; Millard A, 2004, P NATL ACAD SCI USA, V101, P11007, DOI 10.1073/pnas.0401478101; Moore LR, 2002, LIMNOL OCEANOGR, V47, P989, DOI 10.4319/lo.2002.47.4.0989; Palenik B, 2003, NATURE, V424, P1037, DOI 10.1038/nature01943; Partensky F, 1999, MICROBIOL MOL BIOL R, V63, P106, DOI 10.1128/MMBR.63.1.106-127.1999; Rahoutei J, 2000, PHYSIOL PLANTARUM, V110, P286, DOI 10.1034/j.1399-3054.2000.110220.x; SHERMAN LA, 1976, VIROLOGY, V71, P199, DOI 10.1016/0042-6822(76)90105-7; Sullivan MB, 2005, PLOS BIOL, V3, P790, DOI 10.1371/journal.pbio.0030144; Sullivan MB, 2003, NATURE, V424, P1047, DOI 10.1038/nature01929; SUTTLE CA, 1993, MAR ECOL PROG SER, V92, P99, DOI 10.3354/meps092099; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Xu H, 2004, J BIOL CHEM, V279, P27971, DOI 10.1074/jbc.M403307200; Zeidner G, 2005, ENVIRON MICROBIOL, V7, P1505, DOI 10.1111/j.1462-2920.2005.00833.x; ZINSER ER, IN PRESS APPL ENV MI	29	329	352	5	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 3	2005	438	7064					86	89		10.1038/nature04111	http://dx.doi.org/10.1038/nature04111			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16222247				2022-12-28	WOS:000232979000046
J	Crawford, PC; Dubovi, EJ; Castleman, WL; Stephenson, I; Gibbs, EPJ; Chen, L; Smith, C; Hill, RC; Ferro, P; Pompey, J; Bright, RA; Medina, MJ; Johnson, CM; Olsen, CW; Cox, NJ; Klimov, AI; Katz, JM; Donis, RO				Crawford, PC; Dubovi, EJ; Castleman, WL; Stephenson, I; Gibbs, EPJ; Chen, L; Smith, C; Hill, RC; Ferro, P; Pompey, J; Bright, RA; Medina, MJ; Johnson, CM; Olsen, CW; Cox, NJ; Klimov, AI; Katz, JM; Donis, RO		Influenza Genomics Grp	Transmission of equine influenza virus to dogs	SCIENCE			English	Article							RECEPTOR-BINDING PROPERTIES; A-VIRUSES; SIALIC-ACID; HOST-RANGE; HEMAGGLUTININS; INFECTION; DISEASE; CHILD	Molecular and antigenic analyses of three influenza viruses isolated from outbreaks of severe respiratory disease in racing greyhounds revealed that they are closely related to H3N8 equine influenza virus. Phylogenetic analysis indicated that the canine influenza virus genomes form a monophyletic group, consistent with a single interspecies virus transfer. Molecular changes in the hemagglutinin suggested adaptive evolution in the new host. The etiologic role of this virus in respiratory disease was supported by the temporal association of rising antibody titers with disease and by experimental inoculation studies. The geographic expansion of the infection and its persistence for several years indicate efficient transmission of canine influenza virus among greyhounds. Evidence of infection in pet dogs suggests that this infection may also become enzootic in this population.	Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Atlanta, GA 30333 USA; Univ Florida, Coll Vet Med, Gainesville, FL 32611 USA; Cornell Univ, Coll Vet Med, Ithaca, NY 14853 USA; Texas A&M Univ, Coll Vet Med, College Stn, TX 77841 USA; Auburn Univ, Coll Vet Med, Auburn, AL 36849 USA; Univ Wisconsin, Sch Vet Med, Madison, WI 53706 USA	Centers for Disease Control & Prevention - USA; State University System of Florida; University of Florida; Cornell University; Texas A&M University System; Texas A&M University College Station; Auburn University System; Auburn University; University of Wisconsin System; University of Wisconsin Madison	Donis, RO (corresponding author), Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Atlanta, GA 30333 USA.	rvd6@cdc.gov						CHANG C P, 1976, International Journal of Zoonoses, V3, P61; DACSO CC, 1984, J CLIN MICROBIOL, V20, P833, DOI 10.1128/JCM.20.4.833-835.1984; Guan Y, 2004, P NATL ACAD SCI USA, V101, P8156, DOI 10.1073/pnas.0402443101; HOUSE SM, 1980, OECOLOGIA, V44, P396; Karasin AI, 2000, J VIROL, V74, P9322, DOI 10.1128/JVI.74.19.9322-9327.2000; KAWAOKA Y, 1989, J VIROL, V63, P4603, DOI 10.1128/JVI.63.11.4603-4608.1989; KILBOURNE ED, 1976, INTERVIROLOGY, V6, P315, DOI 10.1159/000149485; Kimura K, 1998, MAYO CLIN PROC, V73, P243, DOI 10.4065/73.3.243; Kovacova A, 2002, VIRUS GENES, V24, P57, DOI 10.1023/A:1014038120979; Lai ACK, 2004, VIRUS RES, V100, P159, DOI 10.1016/j.virusres.2003.11.019; Lipatov AS, 2004, J VIROL, V78, P8951, DOI 10.1128/JVI.78.17.8951-8959.2004; Matrosovich M, 2000, J VIROL, V74, P8502, DOI 10.1128/JVI.74.18.8502-8512.2000; NIKITIN T, 1972, B WORLD HEALTH ORGAN, V47, P471; NOBUSAWA E, 1991, VIROLOGY, V182, P475, DOI 10.1016/0042-6822(91)90588-3; PATRIARCA PA, 1984, AM J EPIDEMIOL, V119, P152, DOI 10.1093/oxfordjournals.aje.a113733; Peiris JSM, 2004, LANCET, V363, P617, DOI 10.1016/S0140-6736(04)15595-5; Peiris M, 1999, LANCET, V354, P916, DOI 10.1016/S0140-6736(99)03311-5; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; Suzuki Y, 2000, J VIROL, V74, P11825, DOI 10.1128/JVI.74.24.11825-11831.2000; TOP FH, 1977, J INFECT DIS, V136, pS376, DOI 10.1093/infdis/136.Supplement_3.S376; Vines A, 1998, J VIROL, V72, P7626, DOI 10.1128/JVI.72.9.7626-7631.1998; Wagner R, 2002, J GEN VIROL, V83, P601, DOI 10.1099/0022-1317-83-3-601; Webby R, 2004, NAT MED, V10, pS77, DOI 10.1038/nm1151; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; Webster RG, 1998, EMERG INFECT DIS, V4, P436, DOI 10.3201/eid0403.980325; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0	26	469	554	2	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	2005	310	5747					482	485		10.1126/science.1117950	http://dx.doi.org/10.1126/science.1117950			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16186182				2022-12-28	WOS:000232786000044
J	Pop, C; Salvesen, GS				Pop, C; Salvesen, GS			The nematode death machine in 3D	CELL			English	Editorial Material							ACTIVATION; PROTEINS; CED-4; CELL	Regulated apoptosis is part of the development of the nematode Caenorhabditis elegans. In a recent paper in Nature, Yan et al. (2005) describe the in vitro reconstitution of the core components of the worm apoptotic pathway. Based on a structural analysis of the complex between the death activator CED-4 and the antiapoptotic protein CED-9, the authors explain the regulation of activity of CED-4. Intriguingly, CED-4 comprises a AAA+ type ATPase domain yet does not seem to need ATP hydrolysis for activity.	Burnham Inst Med Res, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pop, C (corresponding author), Burnham Inst Med Res, Program Apoptosis & Cell Death Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Horvitz HR, 2003, BIOSCIENCE REP, V23, P239, DOI 10.1023/B:BIRE.0000019187.19019.e6; Jaroszewski L, 2000, PROTEINS, V39, P197, DOI 10.1002/(SICI)1097-0134(20000515)39:3<197::AID-PROT10>3.0.CO;2-V; Lelpe DD, 2004, J MOL BIOL, V343, P1, DOI 10.1016/j.jmb.2004.08.023; LI R, 1997, CELL, V1, P479; Riedl SJ, 2005, NATURE, V434, P926, DOI 10.1038/nature03465; Yan N, 2005, NATURE, V437, P831, DOI 10.1038/nature04002; Yan NG, 2004, MOL CELL, V15, P999, DOI 10.1016/j.molcel.2004.08.022	11	3	11	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	2005	123	2					192	193		10.1016/j.cell.2005.10.010	http://dx.doi.org/10.1016/j.cell.2005.10.010			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239138	Bronze			2022-12-28	WOS:000232794100007
J	Caldwell, DM; Ades, AE; Higgins, JPT				Caldwell, DM; Ades, AE; Higgins, JPT			Simultaneous comparison of multiple treatments: combining direct and indirect evidence	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PRIMARY ANGIOPLASTY; COST-EFFECTIVENESS; NEWER DRUGS; METAANALYSIS; THROMBOLYSIS; COMBINATION; EFFICACY; THERAPY; TRIALS		Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England; Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England	University of Bristol; MRC Biostatistics Unit; University of Cambridge	Caldwell, DM (corresponding author), Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England.	d.m.caldwell@bristol.ac.uk	Higgins, Julian PT/H-4008-2011	Higgins, Julian PT/0000-0002-8323-2514; , Deborah/0000-0001-8014-7480; Ades, Tony/0000-0001-7822-3552	MRC [MC_U145079307] Funding Source: UKRI; Medical Research Council [MC_U145079307] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Auer J, 2003, LANCET, V361, P965, DOI 10.1016/S0140-6736(03)12746-8; Bridle C, 2004, HEALTH TECHNOL ASSES, V8, P1; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Bucher HC, 1997, J ACQ IMMUN DEF SYND, V15, P104, DOI 10.1097/00042560-199706010-00002; Deeks JJ, 2002, STAT MED, V21, P1575, DOI 10.1002/sim.1188; Dundar Y, 2004, HEALTH TECHNOL ASSES, V8, P1; Fresco C, 2003, LANCET, V361, P1303, DOI 10.1016/S0140-6736(03)13010-3; Glenny AM, 2005, HEALTH TECHNOL ASSES, V9, P1; Hasselblad V, 1998, MED DECIS MAKING, V18, P37, DOI 10.1177/0272989X9801800110; Higgins JPT, 1996, STAT MED, V15, P2733, DOI 10.1002/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0; HIGGINS JPT, 2005, COCHRANE LIB; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875; Lumley T, 2002, STAT MED, V21, P2313, DOI 10.1002/sim.1201; MULROW CD, 1995, SYSTEMATIC REV, P1; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; Rawlins M, 1999, LANCET, V353, P1079, DOI 10.1016/S0140-6736(99)02381-8; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; Spiegelhalter DJ, 1999, BRIT MED J, V319, P508, DOI 10.1136/bmj.319.7208.508; Thompson SG, 1997, STAT MED, V16, P2741, DOI 10.1002/(SICI)1097-0258(19971215)16:23<2741::AID-SIM703>3.0.CO;2-0; Wilby J, 2005, HEALTH TECHNOL ASSES, V9, P1; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; Yazdanpanah Y, 2004, BMJ-BRIT MED J, V328, P249, DOI 10.1136/bmj.37995.435787.A6	23	1117	1134	0	31	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 15	2005	331	7521					897	900		10.1136/bmj.331.7521.897	http://dx.doi.org/10.1136/bmj.331.7521.897			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975SX	16223826	Green Published			2022-12-28	WOS:000232683300029
J	Clayton, TC; Lubsen, J; Pocock, SJ; Voko, Z; Kirwan, BA; Fox, KAA; Poole-Wilson, PA				Clayton, TC; Lubsen, J; Pocock, SJ; Voko, Z; Kirwan, BA; Fox, KAA; Poole-Wilson, PA		ACTION investigators	Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; SERUM CREATININE; PREVENTION; CARDIOLOGY; MORTALITY; EVENTS	Objective To derive a risk score for the combination of death from all causes, myocardial infarction, and disabling stroke in patients with stable symptomatic angina who require treatment for angina and have preserved left ventricular function. Design Multivariate Cox regression analysis of data from a large multicentre trial. Setting Outpatient cardiology clinics in western Europe, Israel, Canada, Australia, and New Zealand. Participants 7311 patients with all required data available. Main outcome measure Death from any cause or myocardial infarction or disabling stroke during a mean follow-up of 4.9 years. Results 1063 patients either died from any cause or sustained myocardial infarction or disabling stroke. The five year risk of this composite ranged from 4% for patients in the lowest tenth of risk to 35% for patients in the highest tenth. The risk score combines 16 routinely available clinical variables (in order of decreasing contribution): age, left ventricular ejection fraction, smoking, white blood cell count, diabetes, casual blood glucose concentration, creatinine concentration, previous stroke, at least one angina attack a week, coronary angiographic findings (if available), lipid lowering treatment, QT interval, systolic blood pressure >= 155 mm Hg, number of drugs used for angina, previous myocardial infarction, and sex. Fitting the same model separately to all cause death, myocardial infarction, and stroke gave similar results. The risk score,did not seem to predict the nature of the event (death in 39%, myocardial infarction in 46%, and disabling stroke in 15%) or the incidence of angiography or revascularisation, which occurred in 29% of patients. Conclusion This risk score is an objective aid in deciding on further management of patients with stable angina with the aim of reducing serious outcome events. The score can also be used in planning future trials.	Erasmus MC, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England; SOCAR Res SA, CH-1260 Nyon, Switzerland; Univ Debrecen, Sch Publ Hlth, H-4028 Debrecen, Hungary; Univ Edinburgh, Cardiovasc Res Unit, Edinburgh EH16 4SB, Midlothian, Scotland; Univ London Imperial Coll Sci & Technol, Natl Heart & Lung Inst, London SW3 6LY, England	Erasmus University Rotterdam; Erasmus MC; University of London; London School of Hygiene & Tropical Medicine; University of Debrecen; University of Edinburgh; Imperial College London	Lubsen, J (corresponding author), Erasmus MC, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands.	jlubsen@compuserve.com	Fox, keith A A/I-3742-2013; Vokó, Zoltán/H-1153-2017; Vokó, Zoltán/O-3747-2019	Vokó, Zoltán/0000-0002-1004-1848; Vokó, Zoltán/0000-0002-1004-1848; Kirwan, Bridget-Anne/0000-0002-3814-3598; Clayton, Tim/0000-0002-1266-3288; Fox, Keith/0000-0002-0140-2752				Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; Daly C, 2003, EUR HEART J, V24, P534, DOI 10.1016/S0195-668X(02)00820-5; De Backer G, 2003, EUR HEART J, V24, P1601, DOI 10.1016/S0195-668X(03)00347-6; Eagle KA, 2004, JAMA-J AM MED ASSOC, V291, P2727, DOI 10.1001/jama.291.22.2727; Fox KM, 2003, LANCET, V362, P782; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; Lubsen J, 1998, EUR HEART J, V19, pI20; MATTS JP, 1993, J FAM PRACTICE, V36, P497; O'Toole L, 2003, BRIT MED J, V326, P1185, DOI 10.1136/bmj.326.7400.1185; Pearson TA, 2004, CIRCULATION, V110, pE543, DOI 10.1161/01.CIR.0000148979.11121.6B; Pocock SJ, 2001, BMJ-BRIT MED J, V323, P75, DOI 10.1136/bmj.323.7304.75; Poole-Wilson PA, 2004, LANCET, V364, P849, DOI 10.1016/S0140-6736(04)16980-8; Schillaci G, 2001, ARCH INTERN MED, V161, P886, DOI 10.1001/archinte.161.6.886; Wei L, 2005, BMJ-BRIT MED J, V330, P821, DOI 10.1136/bmj.38398.408032.8F; Yusuf S, 2000, NEW ENGL J MED, V342, P145	16	93	100	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 15	2005	331	7521					869	872B		10.1136/bmj.38603.656076.63	http://dx.doi.org/10.1136/bmj.38603.656076.63			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975SX	16210253	Bronze, Green Accepted, Green Published, Green Submitted			2022-12-28	WOS:000232683300015
J	Abelson, JF; Kwan, KY; O'Roak, BJ; Baek, DY; Stillman, AA; Morgan, TM; Mathews, CA; Pauls, DA; Rasin, MR; Gunel, M; Davis, NR; Ercan-Sencicek, AG; Guez, DH; Spertus, JA; Leckman, JF; Dure, LS; Kurlan, R; Singer, HS; Gilbert, DL; Farhi, A; Louvi, A; Lifton, RP; Sestan, N; State, MW				Abelson, JF; Kwan, KY; O'Roak, BJ; Baek, DY; Stillman, AA; Morgan, TM; Mathews, CA; Pauls, DA; Rasin, MR; Gunel, M; Davis, NR; Ercan-Sencicek, AG; Guez, DH; Spertus, JA; Leckman, JF; Dure, LS; Kurlan, R; Singer, HS; Gilbert, DL; Farhi, A; Louvi, A; Lifton, RP; Sestan, N; State, MW			Sequence variants in SLITRK1 are associated with Tourette's syndrome	SCIENCE			English	Article							BILINEAL TRANSMISSION; SIB PAIRS; FAMILY; EXPRESSION; INHERITANCE; MUTATIONS; LINKAGE; BRAIN	Tourette's syndrome (TS) is a genetically influenced developmental neuropsychiatric disorder characterized by chronic vocal and motor tics. We studied Slit and Trk-like 1 (SLITRK1) as a candidate gene on chromosome 13q31.1 because of its proximity to a de novo chromosomal inversion in a child with TS. Among 174 unrelated probands, we identified a frameshift mutation and two independent occurrences of the identical variant in the binding site for microRNA hsa-miR-189. These variants were absent from 3600 control chromosomes. SLITRK1 mRNA and hsa-miR-189 showed an overlapping expression pattern in brain regions previously implicated in TS. Wild-type SLITRK1, but not the frameshift mutant, enhanced dendritic growth in primary neuronal cultures. Collectively, these findings support the association of rare SLITRK1 sequence variants with TS.	Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Interdepartmental Neurosci Program, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ctr Human Genet & Genom, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA; Univ Missouri, Dept Med, Kansas City, MO 64111 USA; Univ Alabama, Dept Pediat, Div Pediat Neurol, Birmingham, AL 35233 USA; Univ Rochester, Sch Med, Dept Neurol, Rochester, NY 14642 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA; Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati, OH 45229 USA	Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; Howard Hughes Medical Institute; Yale University; University of California System; University of California San Diego; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Missouri System; University of Missouri Kansas City; University of Alabama System; University of Alabama Birmingham; University of Rochester; Johns Hopkins University; Johns Hopkins University; Cincinnati Children's Hospital Medical Center	State, MW (corresponding author), Yale Univ, Sch Med, Ctr Child Study, 333 Cedar St, New Haven, CT 06520 USA.	matthew.state@yale.edu	Mathews, Carol A A/M-8922-2017; State, Matthew/W-2256-2019; Gilbert, Donald L./D-6443-2016; Kwan, Kenneth Y/F-8489-2011; Kwan, Kenneth/AAI-2841-2021; Spertus, John/ABD-3075-2021; ravegnini, gloria/K-1330-2016; Leckman, James/O-2426-2015; Morgan, Tom/C-3478-2012	Mathews, Carol A A/0000-0003-2208-7058; Gilbert, Donald L./0000-0002-9245-6878; Kwan, Kenneth Y/0000-0003-4711-071X; Kwan, Kenneth/0000-0003-4711-071X; ravegnini, gloria/0000-0002-7774-402X; O'Roak, Brian/0000-0002-4141-0095; State, Matthew/0000-0003-1624-8302; Barber, Danielle/0000-0002-1086-8001	NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR016118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043520, R01NS054273] Funding Source: NIH RePORTER; NCRR NIH HHS [K23 RR16118] Funding Source: Medline; NINDS NIH HHS [R01 NS054273, R01 NS43520] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aruga J, 2003, GENE, V315, P87, DOI 10.1016/S0378-1119(03)00715-7; Aruga J, 2003, MOL CELL NEUROSCI, V24, P117, DOI 10.1016/S1044-7431(03)00129-5; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Hanna PA, 1999, NEUROLOGY, V53, P813, DOI 10.1212/WNL.53.4.813; Hornsey H, 2001, J CHILD PSYCHOL PSYC, V42, P1035, DOI 10.1111/1469-7610.00802; Kleinjan DA, 2005, AM J HUM GENET, V76, P8, DOI 10.1086/426833; Kurlan R, 2002, NEUROLOGY, V59, P414, DOI 10.1212/WNL.59.3.414; KURLAN R, 1994, NEUROLOGY, V44, P2336, DOI 10.1212/WNL.44.12.2336; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Leckman JF, 2002, LANCET, V360, P1577, DOI 10.1016/S0140-6736(02)11526-1; Merette C, 2000, AM J HUM GENET, V67, P1008, DOI 10.1086/303093; Miska EA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r68; NOUSPIKEL T, 1994, HUM MOL GENET, V3, P963, DOI 10.1093/hmg/3.6.963; Oelkers P, 1997, J CLIN INVEST, V99, P1880, DOI 10.1172/JCI119355; OSullivan RL, 1997, BIOL PSYCHIAT, V42, P39, DOI 10.1016/S0006-3223(96)00297-1; Paschou P, 2004, AM J HUM GENET, V75, P545, DOI 10.1086/424389; Paula D, 1999, AM J HUM GENET, V65, P1428; Pauls DL, 2003, J PSYCHOSOM RES, V55, P7, DOI 10.1016/S0022-3999(02)00586-X; PAULS DL, 1986, NEW ENGL J MED, V315, P993, DOI 10.1056/NEJM198610163151604; Robertson MM, 2003, J PSYCHOSOM RES, V55, P3, DOI 10.1016/S0022-3999(02)00580-9; Singer HS, 2005, LANCET NEUROL, V4, P149, DOI 10.1016/S1474-4422(05)01012-4; SINGH J, 2003, ADV COND MAT SCI, V5, P1; Walkup JT, 1996, AM J HUM GENET, V59, P684; Whitford KL, 2002, NEURON, V33, P47, DOI 10.1016/S0896-6273(01)00566-9; Zhang HP, 2002, AM J HUM GENET, V70, P896, DOI 10.1086/339520	26	676	733	5	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					317	320		10.1126/science.1116502	http://dx.doi.org/10.1126/science.1116502			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224024				2022-12-28	WOS:000232670100053
J	Nelissen, K; Luppino, G; Vanduffel, W; Rizzolatti, G; Orban, GA				Nelissen, K; Luppino, G; Vanduffel, W; Rizzolatti, G; Orban, GA			Observing others: Multiple action representation in the frontal lobe	SCIENCE			English	Article							PREMOTOR CORTEX; MACAQUE; MONKEY; CONNECTIONS; MECHANISMS; SHAPE; AREA; F5	Observation of actions performed by-others activates monkey ventral premotor cortex, where action meaning, but not object identity, is coded. In a functional MRI (fMRI) study, we investigated whether other monkey frontal areas respond to actions performed by others. Observation of a hand grasping objects activated four frontal areas: rostral F5 and areas 45B, 45A, and 46. Observation of an individual grasping an object also activated caudal F5, which indicates,different degrees of action abstraction in F5. Observation of shapes activated area 45, but not premotor F5. Convergence of object and action information in area 45 may be important for full comprehension of actions.	Katholieke Univ Leuven, Sch Med, Lab Neuro Psychofysiol, Louvain, Belgium; Univ Parma, Dipartimento Neurosci, I-43100 Parma, Italy; Harvard Univ, Sch Med, Massachusetts Gen Hosp, MIT,Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA	KU Leuven; University of Parma; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT)	Orban, GA (corresponding author), Katholieke Univ Leuven, Sch Med, Lab Neuro Psychofysiol, Louvain, Belgium.	guy.orban@med.kuleuven.ac.be		Luppino, Giuseppe/0000-0002-0220-0618; Orban, Guy/0000-0002-8179-9584				Blakemore SJ, 2005, NEUROPSYCHOLOGIA, V43, P260, DOI 10.1016/j.neuropsychologia.2004.11.012; Denys K, 2004, J NEUROSCI, V24, P2551, DOI 10.1523/JNEUROSCI.3569-03.2004; Gallese V, 1996, BRAIN, V119, P593, DOI 10.1093/brain/119.2.593; JEANNEROD M, 1995, TRENDS NEUROSCI, V18, P314, DOI 10.1016/0166-2236(95)93921-J; Jeannerod M., 2004, INT J SPORT EXERC PS, V2, P376, DOI [10.1080/1612197X.2004.9671752, DOI 10.1080/1612197X.2004.9671752]; Kohler E, 2002, SCIENCE, V297, P846, DOI 10.1126/science.1070311; Kourtzi Z, 2000, J NEUROSCI, V20, P3310, DOI 10.1523/JNEUROSCI.20-09-03310.2000; Koyama M, 2004, NEURON, V41, P795, DOI 10.1016/S0896-6273(04)00047-9; LIEBERMAN AM, 1993, HASKINS LAB STATUS R, V113, P1; Luppino G, 1999, EXP BRAIN RES, V128, P181, DOI 10.1007/s002210050833; MIYASHITA Y, 1993, ANNU REV NEUROSCI, V16, P245, DOI 10.1146/annurev.ne.16.030193.001333; Murata A, 1997, J NEUROPHYSIOL, V78, P2226, DOI 10.1152/jn.1997.78.4.2226; Petrides M, 2005, NATURE, V435, P1235, DOI 10.1038/nature03628; Petrides M, 2002, EUR J NEUROSCI, V16, P291, DOI 10.1046/j.1460-9568.2001.02090.x; PETRIDES M, 1984, J COMP NEUROL, V228, P105, DOI 10.1002/cne.902280110; Rizzolatti G, 2001, NAT REV NEUROSCI, V2, P661, DOI 10.1038/35090060; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Rizzolatti G, 1998, TRENDS NEUROSCI, V21, P188, DOI 10.1016/S0166-2236(98)01260-0; RIZZOLATTI G, 1996, BRAIN RES COGN BRAIN, V3, P131, DOI DOI 10.1016/0926-6410(95)00038-0; Sakata Hideo, 1994, Current Opinion in Neurobiology, V4, P847, DOI 10.1016/0959-4388(94)90133-3; Saxe R, 2004, ANNU REV PSYCHOL, V55, P87, DOI 10.1146/annurev.psych.55.090902.142044; SCHALL JD, 1995, J NEUROSCI, V15, P4464; Vanduffel W, 2001, NEURON, V32, P565, DOI 10.1016/S0896-6273(01)00502-5	23	262	268	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					332	336		10.1126/science.1115593	http://dx.doi.org/10.1126/science.1115593			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224029	Green Accepted			2022-12-28	WOS:000232670100058
J	Przeworski, M				Przeworski, M			Genetics - Motivating hotspots	SCIENCE			English	Editorial Material							HUMAN GENOME; MEIOTIC RECOMBINATION; COLD SPOTS; CHIMPANZEES; PATTERNS; HUMANS; RATES; HOT		Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	University of Chicago	Przeworski, M (corresponding author), Univ Chicago, Dept Human Genet, 920 E 57th St,507F CLSC, Chicago, IL 60637 USA.	mfp@uchicago.edu						Arnheim N, 2003, AM J HUM GENET, V73, P5, DOI 10.1086/376419; Crawford DC, 2004, NAT GENET, V36, P700, DOI 10.1038/ng1376; FEARNHEAD P, AM J HUM GENET; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; Kauppi L, 2004, NAT REV GENET, V5, P413, DOI 10.1038/nrg1346; Lupski JR, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-242; Lynn A, 2004, ANNU REV GENOM HUM G, V5, P317, DOI 10.1146/annurev.genom.4.070802.110217; McVean GAT, 2004, SCIENCE, V304, P581, DOI 10.1126/science.1092500; Myers S, 2005, SCIENCE, V310, P321, DOI 10.1126/science.1117196; Petes TD, 2001, NAT REV GENET, V2, P360, DOI 10.1038/35072078; Ptak SE, 2005, NAT GENET, V37, P429, DOI 10.1038/ng1529; Winckler W, 2005, SCIENCE, V308, P107, DOI 10.1126/science.1105322	13	3	3	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					247	248		10.1126/science.1120154	http://dx.doi.org/10.1126/science.1120154			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224010				2022-12-28	WOS:000232670100033
J	Cohen, AJ				Cohen, AJ			Hurricane Katrina - Lethal levels	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ochsner Clin Fdn, New Orleans, LA 70121 USA	Ochsner Health System	Cohen, AJ (corresponding author), Ochsner Clin Fdn, New Orleans, LA 70121 USA.								0	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1549	1549		10.1056/NEJMp058250	http://dx.doi.org/10.1056/NEJMp058250			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221775				2022-12-28	WOS:000232486000006
J	Lo, B; Rubenfeld, G				Lo, B; Rubenfeld, G			Palliative sedation in dying patients - "We turn to it when everything else hasn't worked"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-ASSISTED SUICIDE; INTENSIVE-CARE-UNIT; OPIOID-RELATED MYOCLONUS; LIFE DECISION-MAKING; TERMINAL SEDATION; CANCER-PATIENTS; SUPREME-COURT; ILL PATIENTS; END; EUTHANASIA		Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA; Univ Washington, Harborview Med Ctr, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98104 USA	University of California System; University of California San Francisco; Harborview Medical Center; University of Washington; University of Washington Seattle	Lo, B (corresponding author), Room C 126,521 Parnassus Ave, San Francisco, CA 94143 USA.	bernie@medicine.ucsf.edu			NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR005226] Funding Source: NIH RePORTER; NINR NIH HHS [R01NR005226] Funding Source: Medline	NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Alpers A, 1999, ARCH FAM MED, V8, P200, DOI 10.1001/archfami.8.3.200; Back AL, 2005, JAMA-J AM MED ASSOC, V293, P1374, DOI 10.1001/jama.293.11.1374; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P206; BEAUCHAMP TL, 2001, PRINCIPLES BIOMEDICA, P128; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; Boyle J, 2004, THEOR MED BIOETH, V25, P51; Braun Ted C, 2003, J Palliat Med, V6, P345, DOI 10.1089/109662103322144655; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Cherny N I, 1994, J Palliat Care, V10, P31; Clarke EB, 2004, J CRIT CARE, V19, P108, DOI 10.1016/j.jcrc.2004.05.001; Cowan JD, 2001, SUPPORT CARE CANCER, V9, P403, DOI 10.1007/s005200100235; CURTIS J, 2001, MANAGING DEATH ICU T; Fainsinger RL, 2000, J PALLIAT CARE, V16, P5, DOI 10.1177/082585970001600202; Gillon R, 1999, BMJ-BRIT MED J, V318, P1431, DOI 10.1136/bmj.318.7196.1431; Gorsuch NM, 2000, HARVARD J LAW PUBL P, V23, P599; Green Kelly, 2003, Indiana Int Comp Law Rev, V13, P639; Hagen N, 1997, J PAIN SYMPTOM MANAG, V14, P51, DOI 10.1016/S0885-3924(97)00001-8; Hough CL, 2005, J CRIT CARE, V20, P20, DOI 10.1016/j.jcrc.2004.09.006; Jackson W Clay, 2002, Am J Hosp Palliat Care, V19, P81, DOI 10.1177/104990910201900202; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Jansen LA, 2002, ANN INTERN MED, V136, P845, DOI 10.7326/0003-4819-136-11-200206040-00014; Lanuke Kathryn, 2004, J Palliat Med, V7, P257, DOI 10.1089/109662104773709378; Li Denise, 2004, Crit Care Nurse, V24, P72; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; Lo B, 2002, JAMA-J AM MED ASSOC, V287, P749, DOI 10.1001/jama.287.6.749; LO B, 2005, RESOLVING ETHICAL DI, P107; Lo Bernard, 2003, J Palliat Med, V6, P409, DOI 10.1089/109662103322144727; Lo Bernard, 2003, Palliat Support Care, V1, P3; McIntyre A, 2004, THEOR MED BIOETH, V25, P61, DOI 10.1023/B:META.0000025095.73394.34; McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X; Mercadante S, 1998, PAIN, V74, P5, DOI 10.1016/S0304-3959(97)00090-0; MERCADANTE S, 1995, ANESTH ANALG, V81, P1307, DOI 10.1097/00000539-199512000-00034; Mercadante S, 2001, SUPPORT CARE CANCER, V9, P205, DOI 10.1007/s005200000230; Morita T, 2004, PALLIATIVE MED, V18, P550, DOI 10.1191/0269216304pm911oa; Morita T, 2002, J PAIN SYMPTOM MANAG, V24, P447, DOI 10.1016/S0885-3924(02)00499-2; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; Parker RA, 1999, JAMA-J AM MED ASSOC, V281, P1937, DOI 10.1001/jama.281.20.1937; President ' Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DEC FOR LIF SUST TRE, P73; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; Rousseau Paul, 2003, J Palliat Med, V6, P425, DOI 10.1089/109662103322144745; Rousseau Paul, 2005, J Palliat Med, V8, P10, DOI 10.1089/jpm.2005.8.10; Rubenfeld GD, 2004, CRIT CARE CLIN, V20, P435, DOI 10.1016/j.ccc.2004.03.005; RUBENFELD GD, 2000, MANAGING DEATH ICU T; Shafer A, 1998, CRIT CARE MED, V26, P947, DOI 10.1097/00003246-199805000-00034; Sheldon Tony, 2005, BMJ, V330, P61, DOI 10.1136/bmj.330.7482.61; Sulmasy DP, 1999, ARCH INTERN MED, V159, P545, DOI 10.1001/archinte.159.6.545; Sykes N, 2003, LANCET ONCOL, V4, P312, DOI 10.1016/S1470-2045(03)01079-9; Sykes N, 2003, ARCH INTERN MED, V163, P341, DOI 10.1001/archinte.163.3.341; Tannsjo T., 2004, TERMINAL SEDATION EU; Taylor Brigit R, 2005, J Palliat Med, V8, P144, DOI 10.1089/jpm.2005.8.144; Truog RD, 2001, CRIT CARE MED, V29, P2332, DOI 10.1097/00003246-200112000-00017; Truog RD, 2000, NEW ENGL J MED, V342, P508, DOI 10.1056/NEJM200002173420712; WARNOCK M, 1998, INTELLIGENT PERSONS, P27; Wilson Robin K, 2004, J Palliat Med, V7, P580, DOI 10.1089/1096621041838461; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	60	132	132	1	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	2005	294	14					1810	1816		10.1001/jama.294.14.1810	http://dx.doi.org/10.1001/jama.294.14.1810			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	972RX	16219885				2022-12-28	WOS:000232472000021
J	Tumpey, TM; Basler, CF; Aguilar, PV; Zeng, H; Solorzano, A; Swayne, DE; Cox, NJ; Katz, JM; Taubenberger, JK; Palese, P; Garcia-Sastre, A				Tumpey, TM; Basler, CF; Aguilar, PV; Zeng, H; Solorzano, A; Swayne, DE; Cox, NJ; Katz, JM; Taubenberger, JK; Palese, P; Garcia-Sastre, A			Characterization of the reconstructed 1918 Spanish influenza pandemic virus	SCIENCE			English	Article							A VIRUS; NEURAMINIDASE DETERMINES; GENE; HEMAGGLUTININ; VIRULENCE; PATHOGENICITY; SEGMENT; ORIGIN	The pandemic influenza virus of 1918-1919 killed an estimated 20 to 50 million people worldwide. With the recent availability of the complete 1918 influenza virus coding sequence, we used reverse genetics to generate an influenza virus bearing all eight gene segments of the pandemic virus to study the properties associated with its extraordinary virulence. In stark contrast to contemporary human influenza H1N1 viruses, the 1918 pandemic virus had the ability to replicate in the absence of trypsin, caused death in mice and embryonated chicken eggs, and displayed a high-growth phenotype in human bronchial epithelial cells. Moreover, the coordinated expression of the 1918 virus genes most certainly confers, the unique high-virulence phenotype observed with this pandemic virus.	Ctr Dis Control & Prevent, Influenza Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; Armed Forces Inst Pathol, Dept Mol Pathol, Rockville, MD 20850 USA; ARS, SE Poultry Res Lab, USDA, Athens, GA 30606 USA	Centers for Disease Control & Prevention - USA; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; United States Department of Defense; United States Department of Agriculture (USDA)	Tumpey, TM (corresponding author), Ctr Dis Control & Prevent, Influenza Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Mailstop G-16,1600 Clifton Rd NE, Atlanta, GA 30333 USA.	tft9@cdc.gov	Taubenberger, Jeffery/AAQ-1407-2021; Basler, Christopher/AAG-8346-2019; Swayne, David/AAP-7166-2020	Basler, Christopher/0000-0003-4195-425X; Solorzano, Alicia/0000-0003-0072-3463; Swayne, David/0000-0001-7472-1992; Garcia-Sastre, Adolfo/0000-0002-6551-1827	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI062623, U54AI057158, P01AI058113] Funding Source: NIH RePORTER; NIAID NIH HHS [U54 AI57158, U19 AI62623, P01 AI058113-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Basler CF, 2001, P NATL ACAD SCI USA, V98, P2746, DOI 10.1073/pnas.031575198; Crosby A., 1989, AM FORGOTTEN PANDEMI; Fodor E, 1999, J VIROL, V73, P9679, DOI 10.1128/JVI.73.11.9679-9682.1999; Glaser L, 2005, J VIROL, V79, P11533, DOI 10.1128/JVI.79.17.11533-11536.2005; Glezen WP, 1996, EPIDEMIOL REV, V18, P64, DOI 10.1093/oxfordjournals.epirev.a017917; Goto H, 1998, P NATL ACAD SCI USA, V95, P10224, DOI 10.1073/pnas.95.17.10224; Goto H, 2001, J VIROL, V75, P9297, DOI 10.1128/JVI.75.19.9297-9301.2001; Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Kilbourne Edwin D., 1975, INFLUENZA VIRUSES IN, P483; Kobasa D, 2004, NATURE, V431, P703, DOI 10.1038/nature02951; LI SQ, 1993, J VIROL, V67, P6667, DOI 10.1128/JVI.67.11.6667-6673.1993; REED L. J., 1938, AMER JOUR HYG, V27, P493; Reid AH, 2000, P NATL ACAD SCI USA, V97, P6785, DOI 10.1073/pnas.100140097; Reid AH, 2004, J VIROL, V78, P12462, DOI 10.1128/JVI.78.22.12462-12470.2004; Reid AH, 1999, P NATL ACAD SCI USA, V96, P1651, DOI 10.1073/pnas.96.4.1651; Reid AH, 2002, J VIROL, V76, P10717, DOI 10.1128/JVI.76.21.10717-10723.2002; Taubenberger JK, 1997, SCIENCE, V275, P1793, DOI 10.1126/science.275.5307.1793; Taubenberger JK, 2005, NATURE, V437, P889, DOI 10.1038/nature04230; Tseng CTK, 2005, J VIROL, V79, P9470, DOI 10.1128/JVI.79.15.9470-9479.2005; Tumpey TM, 2004, P NATL ACAD SCI USA, V101, P3166, DOI 10.1073/pnas.0308391100; Tumpey TM, 2002, P NATL ACAD SCI USA, V99, P13849, DOI 10.1073/pnas.212519699; TUMPEY TM, IN PRESS J VIROL; Webby RJ, 2003, SCIENCE, V302, P1519, DOI 10.1126/science.1090350; Winternitz MC, 1920, PATHOLOGY INFLUENZA	25	876	999	6	295	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	2005	310	5745					77	80		10.1126/science.1119392	http://dx.doi.org/10.1126/science.1119392			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210530				2022-12-28	WOS:000232477000039
J	Gehrels, N; Sarazin, CL; O'Brien, PT; Zhang, B; Barbier, L; Barthelmy, SD; Blustin, A; Burrows, DN; Cannizzo, J; Cummings, JR; Goad, M; Holland, ST; Hurkett, CP; Kennea, JA; Levan, A; Markwardt, CB; Mason, KO; Meszaros, P; Page, M; Palmer, DM; Rol, E; Sakamoto, T; Willingale, R; Angelini, L; Beardmore, A; Boyd, PT; Breeveld, A; Campana, S; Chester, MM; Chincarini, G; Cominsky, LR; Cusumano, G; de Pasquale, M; Fenimore, EE; Giommi, P; Gronwall, C; Grupe, D; Hill, JE; Hinshaw, D; Hjorth, J; Hullinger, D; Hurley, KC; Klose, S; Kobayashi, S; Kouveliotou, C; Krimm, HA; Mangano, V; Marshall, FE; McGowan, K; Moretti, A; Mushotzky, RF; Nakazawa, K; Norris, JP; Nousek, JA; Osborne, JP; Page, K; Parsons, AM; Patel, S; Perri, M; Poole, T; Romano, P; Roming, PWA; Rosen, S; Sato, G; Schady, P; Smale, AP; Sollerman, J; Starling, R; Still, M; Suzuki, M; Tagliaferri, G; Takahashi, T; Tashiro, M; Tueller, J; Wells, AA; White, NE; Wijers, RAMJ				Gehrels, N; Sarazin, CL; O'Brien, PT; Zhang, B; Barbier, L; Barthelmy, SD; Blustin, A; Burrows, DN; Cannizzo, J; Cummings, JR; Goad, M; Holland, ST; Hurkett, CP; Kennea, JA; Levan, A; Markwardt, CB; Mason, KO; Meszaros, P; Page, M; Palmer, DM; Rol, E; Sakamoto, T; Willingale, R; Angelini, L; Beardmore, A; Boyd, PT; Breeveld, A; Campana, S; Chester, MM; Chincarini, G; Cominsky, LR; Cusumano, G; de Pasquale, M; Fenimore, EE; Giommi, P; Gronwall, C; Grupe, D; Hill, JE; Hinshaw, D; Hjorth, J; Hullinger, D; Hurley, KC; Klose, S; Kobayashi, S; Kouveliotou, C; Krimm, HA; Mangano, V; Marshall, FE; McGowan, K; Moretti, A; Mushotzky, RF; Nakazawa, K; Norris, JP; Nousek, JA; Osborne, JP; Page, K; Parsons, AM; Patel, S; Perri, M; Poole, T; Romano, P; Roming, PWA; Rosen, S; Sato, G; Schady, P; Smale, AP; Sollerman, J; Starling, R; Still, M; Suzuki, M; Tagliaferri, G; Takahashi, T; Tashiro, M; Tueller, J; Wells, AA; White, NE; Wijers, RAMJ			A short gamma-ray burst apparently associated with an elliptical galaxy at redshift z=0.225	NATURE			English	Article							SHORT-DURATION; AFTERGLOWS; BINARIES; FLARE	Gamma-ray bursts (GRBs) come in two classes(1): long (> 2 s), soft-spectrum bursts and short, hard events. Most progress has been made on understanding the long GRBs, which are typically observed at high redshift ( z approximate to 1) and found in subluminous star-forming host galaxies. They are likely to be produced in core-collapse explosions of massive stars(2). In contrast, no short GRB had been accurately (< 1000) and rapidly ( minutes) located. Here we report the detection of the X-ray afterglow from - and the localization of - the short burst GRB 050509B. Its position on the sky is near a luminous, non-star-forming elliptical galaxy at a redshift of 0.225, which is the location one would expect(3,4) if the origin of this GRB is through the merger of neutron-star or blackhole binaries. The X-ray afterglow was weak and faded below the detection limit within a few hours; no optical afterglow was detected to stringent limits, explaining the past difficulty in localizing short GRBs.	NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Univ Virginia, Dept Astron, Charlottesville, VA 22903 USA; Univ Leicester, Dept Phys & Astron, Leicester LE1 7RH, Leics, England; Univ Nevada, Dept Phys, Las Vegas, NV 89154 USA; UCL, Mullard Space Sci Lab, Dorking RH5 6NT, Surrey, England; Penn State Univ, Dept Astron & Astrophys, University Pk, PA 16802 USA; Univ Maryland Baltimore Cty, Joint Ctr Astrophys, Baltimore, MD 21250 USA; CNR, Washington, DC 20418 USA; Univ Space Res Assoc, Columbia, MD 21044 USA; Univ Maryland, Dept Astron, College Pk, MD 20742 USA; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; INAF, Osservatorio Astron Brera, I-23807 Merate, Italy; Univ Milano Bicocca, I-20126 Milan, Italy; Sonoma State Univ, Dept Phys & Astron, Rohnert Pk, CA 94928 USA; INAF, Ist Astrofis Spaziale & Cosm, I-90146 Palermo, Italy; ASI Sci Data Ctr, I-00044 Frascati, Italy; SP Syst Inc, Greenbelt, MD 20770 USA; Univ Copenhagen, Niels Bohr Inst, DK-2100 Copenhagen, Denmark; Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; Thuringer Landessternwarte Tautenburg, D-07778 Tautenburg, Germany; NASA, George C Marshall Space Flight Ctr, NSSTC, Huntsville, AL 35805 USA; JAXA, Inst Space & Astronaut Sci, Kanagawa 2298510, Japan; Univ Space Res Assoc, NSSTC, Huntsville, AL 35805 USA; NASA Headquarters, Off Space Sci, Washington, DC 20546 USA; Stockholm Observ, Dept Astron, S-10691 Stockholm, Sweden; Univ Amsterdam, Astron Inst Anton Pannekoek, NL-1098 SJ Amsterdam, Netherlands; Saitama Univ, Dept Phys, Sakura, Saitama 3388570, Japan	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Virginia; University of Leicester; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; University of London; University College London; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University System of Maryland; University of Maryland Baltimore County; Universities Space Research Association (USRA); University System of Maryland; University of Maryland College Park; United States Department of Energy (DOE); Los Alamos National Laboratory; Istituto Nazionale Astrofisica (INAF); University of Milano-Bicocca; California State University System; Sonoma State University; Istituto Nazionale Astrofisica (INAF); Agenzia Spaziale Italiana (ASI); University of Copenhagen; Niels Bohr Institute; University of California System; University of California Berkeley; National Aeronautics & Space Administration (NASA); NASA Marshall Space Flight Center; Japan Aerospace Exploration Agency (JAXA); Institute of Space & Astronautical Science (ISAS); Universities Space Research Association (USRA); National Aeronautics & Space Administration (NASA); Stockholm University; University of Amsterdam; Saitama University	Gehrels, N (corresponding author), NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA.	gehrels@milkyway.gsfc.nasa.gov	Tashiro, Makoto S/J-4562-2012; Hjorth, Jens/M-5787-2014; Tagliaferri, Gianpiero/ABD-7556-2021; Boyd, Patricia/D-3274-2012; Gehrels, Neil/D-2971-2012; Mushotzky, Richard/AAW-9465-2021; De Pasquale, Massimiliano/AAC-5695-2020; Barthelmy, Scott D/D-2943-2012; White, Nicholas/B-6428-2012; Kennea, Jamie/AAF-2090-2019; Parsons, Ann/I-6604-2012; Tueller, Jack/D-5334-2012; Campana, Sergio/AAL-6012-2020; giommi, paolo/L-1006-2018; Levan, Andrew/F-6179-2014	Tashiro, Makoto S/0000-0002-5097-1257; Hjorth, Jens/0000-0002-4571-2306; Tagliaferri, Gianpiero/0000-0003-0121-0723; White, Nicholas/0000-0003-3853-3462; Kennea, Jamie/0000-0002-6745-4790; Campana, Sergio/0000-0001-6278-1576; Perri, Matteo/0000-0003-3613-4409; Cusumano, Giancarlo/0000-0002-8151-1990; Mangano, Vanessa/0000-0003-4262-8616; Goad, Michael/0000-0002-2908-7360; giommi, paolo/0000-0002-2265-5003; Beardmore, Andrew/0000-0001-5186-5950; Levan, Andrew/0000-0001-7821-9369; Breeveld, Alice/0000-0002-0001-7270; Hurkett, Cheryl/0000-0001-8136-4807; Romano, Patrizia/0000-0003-0258-7469; Schady, Patricia/0000-0002-1214-770X; Wijers, Ralph/0000-0002-3101-1808				ANDERSON SB, 1990, NATURE, V346, P42, DOI 10.1038/346042a0; Bloom JS, 1999, MON NOT R ASTRON SOC, V305, P763, DOI 10.1046/j.1365-8711.1999.02437.x; BLOOM JS, UNPUB ASTORPHYS J; CENKO SB, 2005, 3409 GCN; CENKO SB, 2005, 3401 GCN; Connaughton V, 2002, ASTROPHYS J, V567, P1028, DOI 10.1086/338695; EICHLER D, 1989, NATURE, V340, P126, DOI 10.1038/340126a0; Gal RR, 2003, ASTRON J, V125, P2064, DOI 10.1086/368240; HJORTH J, 2005, 3410 GCN; HURKETT C, 2005, 3381 GCN; Hurley K, 2005, NATURE, V434, P1098, DOI 10.1038/nature03519; Hurley K, 2002, ASTROPHYS J, V567, P447, DOI 10.1086/338420; KENNEA JA, 2005, 3383 GCN; Kochanek CS, 2001, ASTROPHYS J, V560, P566, DOI 10.1086/322488; KOUVELIOTOU C, 1993, ASTROPHYS J, V413, pL101, DOI 10.1086/186969; Lazzati D, 2001, ASTRON ASTROPHYS, V379, pL39, DOI 10.1051/0004-6361:20011485; Le Floc'h E, 2003, ASTRON ASTROPHYS, V400, P499, DOI 10.1051/0004-6361:20030001; Madau P, 1998, ASTROPHYS J, V498, P106, DOI 10.1086/305523; MOCHKOVITCH R, 1993, NATURE, V361, P236, DOI 10.1038/361236a0; NAKAR E, 2005, DISTANCE SHORT HARD; Palmer DM, 2005, NATURE, V434, P1107, DOI 10.1038/nature03525; Panaitescu A, 2001, ASTROPHYS J, V561, pL171, DOI 10.1086/324678; Panaitescu A, 2000, ASTROPHYS J, V543, P66, DOI 10.1086/317090; PROCHASKA JX, 2005, 3390 GCN; Sarazin C. L., 2000, APJ, V544, p101L; Sarazin CL, 2003, ASTROPHYS J, V595, P743, DOI 10.1086/377467; van Paradijs J, 2000, ANNU REV ASTRON ASTR, V38, P379, DOI 10.1146/annurev.astro.38.1.379; Vreeswijk PM, 2001, ASTROPHYS J, V546, P672, DOI 10.1086/318308; Willems B, 2004, ASTROPHYS J, V616, P414, DOI 10.1086/424812	30	465	475	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					851	854		10.1038/nature04142	http://dx.doi.org/10.1038/nature04142			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208363	Green Submitted			2022-12-28	WOS:000232338600038
J	Baumgart, DC				Baumgart, DC			Personal digital assistants in health care: experienced clinicians in the palm of your hand?	LANCET			English	Review							DECISION-SUPPORT; HELD COMPUTERS; INFORMATION-TECHNOLOGY; RESIDENCY PROGRAMS; DRUG-INTERACTIONS; CONTROLLED-TRIAL; PATIENT DATA; SOFTWARE; DOCUMENTATION; MEDICINE	Physicians and other health-care professionals are rapidly adopting personal digital assistants (PDA). Palm pilots and other hand-held computers are also increasingly popular among medical students. PDAs can be used for medical student education and physician training, daily clinical practice, and research. PDAs and their increasing integration with information technology in hospitals could change the way health care is delivered in the future. But despite the increasing use of PDAs, evidence from well-designed research studies is still needed to show how much these devices can improve the quality of care, save patients' lives, and ultimately reduce health-care expenses. In this Review of PDA use in health care, the operating systems, basic functionality, security and safety, limitations, and future implications of PDAs are examined. A personal perspective and an introduction to medical PDA applications, software, guidelines, and programmes for health-care professionals is also provided.	Humboldt Univ, Virchow Hosp, Charite Med Sch, Dept Med, D-13344 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Baumgart, DC (corresponding author), Humboldt Univ, Virchow Hosp, Charite Med Sch, Dept Med, D-13344 Berlin, Germany.	daniel.baumgart@charite.de	Tao, Youyou/D-2367-2014; Baumgart, Daniel C./AAU-2930-2021	Baumgart, Daniel C./0000-0003-2146-507X				*AHRQ, QUIT SMOK CONS INT T; Anderson P, 2004, J CLIN PSYCHOL, V60, P253, DOI 10.1002/jclp.10262; Astrahan Melvin A, 2004, Med Dosim, V29, P166, DOI 10.1016/j.meddos.2004.04.003; Autry AM, 2002, AM J OBSTET GYNECOL, V187, pS19, DOI 10.1067/mob.2002.127367; Bakken Suzanne, 2003, AMIA Annu Symp Proc, P41; Barber N, 2004, QUAL SAF HEALTH CARE, V13, P450, DOI 10.1136/qshc.2004.012104; Barrett JR, 2004, INT J MED INFORM, V73, P25, DOI 10.1016/j.ijmedinf.2003.12.005; Barrons R, 2004, AM J HEALTH-SYST PH, V61, P380, DOI 10.1093/ajhp/61.4.380; Barshick Bryan, 2004, Nursing, V34, P68; BARTON J, 20 000 HANDHELDS DEP; Bashford Curt, 2002, JEMS, V27, P82; *BD BIOSC, BD ID PAT ID SYST; Bird SB, 2001, ACAD EMERG MED, V8, P1200, DOI 10.1111/j.1553-2712.2001.tb01141.x; Bonsanto MM, 2001, ACTA NEUROCHIR SUPPL, V78, P139; Brilla Roland, 2004, J Med Syst, V28, P57, DOI 10.1023/B:JOMS.0000021520.50986.48; BROWN E, HEALTHCARE ITS NEXT; Cady G, 2002, JEMS 2002, V27, P46; Carroll AE, 2004, PEDIATRICS, V113, P450, DOI 10.1542/peds.113.3.450; Carroll AE, 2004, PEDIATRICS, V113, P238, DOI 10.1542/peds.113.2.238; Chan J. C. W., 2004, Hong Kong Medical Journal, V10, P166; Chang Betty L, 2003, AACN Clin Issues, V14, P379, DOI 10.1097/00044067-200308000-00013; Chang PL, 2004, ST HEAL T, V107, P1421; Chen Dongquan, 2004, BMC Med Inform Decis Mak, V4, P12, DOI 10.1186/1472-6947-4-12; Chen ES, 2004, J AM MED INFORM ASSN, V11, P19, DOI 10.1197/jamia.M1387; Clauson KA, 2004, AM J HEALTH-SYST PH, V61, P1015, DOI 10.1093/ajhp/61.10.1015; *CMS, CMS INF SEC; Crelinsten GL, 2004, NEW ENGL J MED, V350, P1059, DOI 10.1056/NEJM200403043501022; De Groote SL, 2004, J MED LIBR ASSOC, V92, P341; Denton G D, 2003, AMIA Annu Symp Proc, P827; Dong P, 2004, MED INFORM INTERNET, V29, P43, DOI 10.1080/14639230310001655849; Enders SJ, 2002, PHARMACOTHERAPY, V22, P1036, DOI 10.1592/phco.22.12.1036.33601; Engum SA, 2003, AM J SURG, V186, P175, DOI 10.1016/S0002-9610(03)00182-X; Esakof DD, 2004, J AM SOC ECHOCARDIOG, V17, P298, DOI 10.1016/j.echo.2003.10.020; Farzanfar Ramesh, 2004, J Med Syst, V28, P143, DOI 10.1023/B:JOMS.0000023297.50379.3c; Fischer S, 2002, CAN J SURG, V45, P345; France Daniel J, 2003, Jt Comm J Qual Saf, V29, P171; Frenzel John C, 2003, J Med Syst, V27, P163, DOI 10.1023/A:1021865011765; Fu Qiang, 2003, Stud Health Technol Inform, V95, P629; Gaertner J, 2004, J PAIN SYMPTOM MANAG, V28, P259, DOI 10.1016/j.jpainsymman.2003.12.017; Gandsas A, 2004, STUD HEALTH TECHNOL, V98, P99; Gandsas A, 2004, SURG ENDOSC, V18, P997, DOI 10.1007/s00464-003-8282-y; Goss Linda, 2002, J Infus Nurs, V25, P274, DOI 10.1097/00129804-200207000-00011; Grasso BC, 2002, PSYCHIAT SERV, V53, P1325, DOI 10.1176/appi.ps.53.10.1325; Gross Todd M, 2003, Diabetes Technol Ther, V5, P365, DOI 10.1089/152091503765691848; Hanada E, 2003, IEEE T NEUR SYS REH, V11, P386, DOI 10.1109/TNSRE.2003.819887; Handler Steven M, 2004, J Am Med Dir Assoc, V5, P337, DOI 10.1097/01.JAM.0000137011.49874.CE; Hart T, 2003, BRAIN INJURY, V17, P401, DOI 10.1080/0269905021000038438; Houston Thomas K, 2003, AMIA Annu Symp Proc, P299; Howard William R, 2004, Respir Care, V49, P1339; Hughes Rhidian A, 2004, Int J Health Care Qual Assur Inc Leadersh Health Serv, V17, P47, DOI 10.1108/09526860410515936; Jamison RN, 2002, PAIN, V99, P341, DOI 10.1016/S0304-3959(02)00178-1; Johnson ED, 2004, J MED LIBR ASSOC, V92, P438; Johnston JM, 2004, MED EDUC, V38, P628, DOI 10.1111/j.1365-2929.2004.01842.x; Joy S, 2004, SOUTH MED J, V97, P430, DOI 10.1097/00007611-200405000-00002; Kaushal R, 2002, QUAL SAF HEALTH CARE, V11, P261, DOI 10.1136/qhc.11.3.261; KAWAMOTO K, 2004, MEDINFO, P1677; Kerkenbush Nicole L, 2003, AMIA Annu Symp Proc, P887; Kester Mark, 2004, Health Manag Technol, V25, P42; Krause A, 2004, INT J MED INFORM, V73, P461, DOI 10.1016/j.ijmedinf.2004.04.003; Kurth RJ, 2002, MED TEACH, V24, P488, DOI 10.1080/0142159021000012513; Kwak Miyoung, 2003, AMIA Annu Symp Proc, P902; Lee JS, 2002, AMIA 2002 SYMPOSIUM, PROCEEDINGS, P425; Leung GM, 2003, BMJ-BRIT MED J, V327, P1090, DOI 10.1136/bmj.327.7423.1090; Liao WY, 2004, BIOSENS BIOELECTRON, V20, P482, DOI 10.1016/j.bios.2004.02.014; Lindberg DAB, 2005, NEW ENGL J MED, V352, P1067, DOI 10.1056/NEJMp048190; Lou E, 2003, MED BIOL ENG COMPUT, V41, P346, DOI 10.1007/BF02348441; Lye P, 2003, AMBUL PEDIATR, V3, P93, DOI 10.1367/1539-4409(2003)003<0093:ECEITC>2.0.CO;2; MacNeily Andrew E, 2003, Can J Urol, V10, P1885; Magos A, 2004, BRIT MED J, V328, P1565, DOI 10.1136/bmj.328.7455.1565; MARTIN S, 2003, CMAJ, P169; McGowan Julie J, 2003, AMIA Annu Symp Proc, P930; MCKESSON, HORIZON ADM RX ROBOT; McLeod TG, 2003, J AM MED INFORM ASSN, V10, P605, DOI 10.1197/jamia.M1313; *MEDCALC, MEDCALC PALM OS; Menon AS, 2004, J AM MED INFORM ASSN, V11, P217, DOI 10.1197/jamia.M1468; *MICR, WIND MOB BAS POCK PC; Miller Robert H, 2004, J Healthc Inf Manag, V18, P72; Miller SM, 2003, CLIN INFECT DIS, V36, P1018, DOI 10.1086/368198; *NLM LIST HILL NAT, PUBMED TAP; Quaglini Silvana, 2003, AMIA Annu Symp Proc, P534; Raman B, 2004, RADIOGRAPHICS, V24, P299, DOI 10.1148/rg.241035127; Ray HN, 2002, AMIA 2002 SYMPOSIUM, PROCEEDINGS, P637; Reponen J, 2000, J TELEMED TELECARE, V6, P45, DOI 10.1258/1357633001933943; Robertson Jane, 2003, Qual Manag Health Care, V12, P115; Robinson RL, 2004, AM J MED, V116, P357, DOI 10.1016/j.amjmed.2003.09.025; Saleh KJ, 2002, J ORTHOPAED RES, V20, P1146, DOI 10.1016/S0736-0266(02)00059-1; Schulze H, 2004, TELEMED J E-HEALTH, V10, P233, DOI 10.1089/1530562041641228; Seago BL, 2002, J MED LIBR ASSOC, V90, P202; Sellors JW, 2002, BMC PUBLIC HEALTH, V2, DOI 10.1186/1471-2458-2-14; Sequist Thomas D, 2003, AMIA Annu Symp Proc, P1002; SIEGEL J, ACTIVE ECG; Silva MA, 2003, AM J HEALTH-SYST PH, V60, P911, DOI 10.1093/ajhp/60.9.911; *SOC TEACH FAM MED, 2005, SHOTS; Stengel D, 2004, J BONE JOINT SURG AM, V86A, P553, DOI 10.2106/00004623-200403000-00014; Sutton J, 2004, ACAD MED, V79, P1114, DOI 10.1097/00001888-200411000-00024; TESSIER C, INTRO MOBILE HEALTHC; Toffel MW, 2004, ENVIRON SCI TECHNOL, V38, P2961, DOI 10.1021/es035035o; Topps D, 2003, FAM MED, V35, P55; Tri JL, 2004, MAYO CLIN PROC, V79, P1527, DOI 10.4065/79.12.1527; Turner CL, 2003, TRANSFUSION, V43, P1200, DOI 10.1046/j.1537-2995.2003.00428.x; *US DHHS, PDA US STUD; *US FDA, BAR COD LAB REQ HUM; VanDenKerkhof EG, 2003, CAN J ANAESTH, V50, P368, DOI 10.1007/BF03021034; Varkevisser M, 2003, CHRONOBIOL INT, V20, P109, DOI 10.1081/CBI-120017685; Vincent C, 2003, FAM MED, V35, P264; *VIV CORP, VIV LIF; Wang DH, 2002, J NUTR SCI VITAMINOL, V48, P498, DOI 10.3177/jnsv.48.498; WEINFELD J, RX PREVENTION RECS 1; Weissman JS, 2005, NEW ENGL J MED, V352, P1171, DOI 10.1056/NEJMp048280; 2004, POSTGRAD MED S, V115, pR1; 2003, HEALTHCARE BENCHMARK, V10, P71	112	90	94	1	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	2005	366	9492					1210	1222		10.1016/S0140-6736(05)67484-3	http://dx.doi.org/10.1016/S0140-6736(05)67484-3			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970LK	16198770				2022-12-28	WOS:000232311300031
J	Hoj, L; Cardoso, P; Nielsen, BB; Hvidman, L; Nielsen, J; Aaby, P				Hoj, L; Cardoso, P; Nielsen, BB; Hvidman, L; Nielsen, J; Aaby, P			Effect of sublingual misoprostol on severe postpartum haemorrhage in a primary health centre in Guinea-Bissau: randomised double blind clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							3RD STAGE; ORAL MISOPROSTOL; MATERNAL MORTALITY; BLOOD-LOSS; LABOR	Objective To evaluate whether routine administration of sublingual misoprostol 600 mu g after delivery reduces postpartum haemorrhage. Design Randomised double blind placebo controlled trial. Setting Primary health centre in Bissau, Guinea-Bissau, West Africa. Participants 661 women undergoing vaginal delivery. Intervention Misoprostol 600 mu g or placebo administered sublingually immediately after delivery. Main outcome measures Postpartum haemorrhage, defined as a loss of >= 500 ml and decrease in haemoglobin concentration after delivery. Results The incidence of postpartum haemorrhage was not significantly different between the two groups, the relative risk being 0.89 (95% confidence interval 0.76 to 1.04) in the misoprostol group compared with the placebo group. Mean blood loss was 10.5% (- 0.5% to 20.4%) lower in the misoprostol group than in the control group. Severe postpartum haemorrhage of >= 1000 ml or >= 1500 ml occurred in 17% (56) and 8% (25) in the placebo group and 11% (37) and 2% (7) in the misoprostol group. Significantly fewer women in the misoprostol group experienced a loss of >= 1000 ml (0.66,0.45 to 0.98) or >= 1500 ml (0.28, 0.12 to 0.64). The decrease in haemoglobin concentration tended to be less in the misoprostol group, the mean difference between the two groups being 0.16 mmol/l (- 0.01 mmol/l to 0.32 mmol/l). Conclusion Sublingual misoprostol reduces the frequency of severe postpartum haemorrhage.	Aarhus Univ Hosp, Dept Obstet & Gynaecol, DK-8200 Aarhus, Denmark; Projecto Saude Bandim, Bissau, Guinea Bissau; Statens Serum Inst, Bandim Hlth Project, Danish Epidemiol Sci Ctr, DK-2300 Copenhagen, Denmark	Aarhus University; Aarhus University; Statens Serum Institut	Hoj, L (corresponding author), Aarhus Univ Hosp, Dept Obstet & Gynaecol, DK-8200 Aarhus, Denmark.	lars.hoj@dadlnet.dk		Aaby, Peter/0000-0001-8331-1389				Bamigboye AA, 1998, AM J OBSTET GYNECOL, V179, P1043, DOI 10.1016/S0002-9378(98)70212-1; Brabin BJ, 2001, J NUTR, V131, p604S, DOI 10.1093/jn/131.2.604S; Gulmezoglu AM, 2001, LANCET, V358, P689, DOI 10.1016/S0140-6736(01)05835-4; Hofmeyr GJ, 1998, BRIT J OBSTET GYNAEC, V105, P971; Hofmeyr GJ, 2001, S AFR MED J, V91, P432; Hoj L, 1999, INT J EPIDEMIOL, V28, P70, DOI 10.1093/ije/28.1.70; Hoj L, 2002, BJOG-INT J OBSTET GY, V109, P792, DOI 10.1111/j.1471-0528.2002.01259.x; KAESTEL P, 2004, THESIS STATENS SERUM; Kwast B E, 1991, Midwifery, V7, P64, DOI 10.1016/S0266-6138(05)80229-3; Lam H, 2004, ACTA OBSTET GYN SCAN, V83, P647, DOI 10.1111/j.0001-6349.2004.00572.x; Lumbiganon P, 2002, BJOG-INT J OBSTET GY, V109, P1222, DOI 10.1016/S1470-0328(02)02919-1; *MAT NEON HLTH PRO, 2005, PREV POSTP HEM COMM; Prasertcharoensuk W, 2000, INT J GYNECOL OBSTET, V71, P69, DOI 10.1016/S0020-7292(00)00294-0; PRENDIVILLE WJ, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000007, DOI 10.1002/14651858.CD000007]; Rush D, 2000, AM J CLIN NUTR, V72, p212S, DOI 10.1093/ajcn/72.1.212S; Surbek DV, 1999, OBSTET GYNECOL, V94, P255, DOI 10.1016/S0029-7844(99)00271-9; Tang OS, 2002, HUM REPROD, V17, P332, DOI 10.1093/humrep/17.2.332	17	94	96	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	2005	331	7519					723	727		10.1136/bmj.331.7519.723	http://dx.doi.org/10.1136/bmj.331.7519.723			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971XB	16195287	Green Published, Bronze			2022-12-28	WOS:000232417100017
J	James, C; Morris, SS; Keith, R; Taylor, A				James, C; Morris, SS; Keith, R; Taylor, A			Impact on child mortality of removing user fees: simulation model	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; ATTENDANCE	Objective To estimate how many child deaths might be prevented if user fees were removed in 20 African countries Design Simulation model combining evidence on key health interventions' impacts on reducing child mortality with analysis of the effect of fee abolition on access to healthcare services. Results Elimination of user fees could prevent approximately 233 000 (estimate range 153 000-305 000) deaths annually in children aged under 5 in 20 African countries. Conclusion Given the relatively low cost of abolition, replacing user fees with alternative financing mechanisms should be seen as an effective first step towards improving households' access to health care and achieving the millennium development goals for health.	Save Children UK, London EC1M 4AR, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	Save the Children; University of London; London School of Hygiene & Tropical Medicine	James, C (corresponding author), Springwood Lane, Henley On Thames RG9 5JJ, Oxon, England.	chrisjamesuk@hotmail.com		Morris, Saul/0000-0002-9372-7342				ARHINTENKORANG D, 2000, MOBILIZING RESOURCES; ARHINTENKORANG D, 2000, CMH WORKING PAPERS S; BITRAIN R, 2003, SOCIAL PROTECTION DI, V308; Bitran RA, 2003, WAIVERS EXEMPTIONS H; Burnham GM, 2004, B WORLD HEALTH ORGAN, V82, P187; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; FAFCHAMPS M, 2004, WP155 CORN FOOD NUTR; Gertler P., 1990, WILLINGNESS PAY MED; Gilson L, 1997, HEALTH POLICY PLANN, V12, P273, DOI 10.1093/oxfordjournals.heapol.a018882; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Mpuga Paul, 2004, 3276 WORLD BANK; MWABU G, 1995, HEALTH POLICY PLANN, V10, P164, DOI 10.1093/heapol/10.2.164; Nabyonga J, 2005, HEALTH POLICY PLANN, V20, P100, DOI 10.1093/heapol/czi012; PAFCHAMPS M, 2004, WP155 CORN FOOD NUTR; SAUERBORN R, 1994, HEALTH POLICY PLANN, V9, P185, DOI 10.1093/heapol/9.2.185; UN Millennium Project, 2005, INV DEV PRACT PLAN A; Wilkinson D, 2001, B WORLD HEALTH ORGAN, V79, P665; Witter S., 2005, UNNECESSARY EVIL USE; Xu K, 2003, LANCET, V362, P111, DOI 10.1016/S0140-6736(03)13861-5	19	46	46	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	2005	331	7519					747	749		10.1136/bmj.331.7519.747	http://dx.doi.org/10.1136/bmj.331.7519.747			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971XB	16195292	Bronze, Green Published			2022-12-28	WOS:000232417100022
J	Allara, DL				Allara, DL			A perspective on surfaces and interfaces	NATURE			English	Editorial Material							SELF-ASSEMBLED MONOLAYERS		Penn State Univ, Dept Polymer Sci & Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Allara, DL (corresponding author), Penn State Univ, Dept Polymer Sci & Chem, 206 Chem Bldg, University Pk, PA 16802 USA.	dla3@psu.edu						BAIER RE, 1968, SCIENCE, V162, P1360, DOI 10.1126/science.162.3860.1360; Bowden F, 2001, AM J PHYS, DOI DOI 10.1119/1.1933017; Duke CB, 2003, P NATL ACAD SCI USA, V100, P3858, DOI 10.1073/pnas.0730358100; Love JC, 2005, CHEM REV, V105, P1103, DOI 10.1021/cr0300789; Ulman A, 1996, CHEM REV, V96, P1533, DOI 10.1021/cr9502357	5	57	62	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 29	2005	437	7059					638	639		10.1038/nature04234	http://dx.doi.org/10.1038/nature04234			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193037				2022-12-28	WOS:000232157900036
J	Block, SD; Billings, JA				Block, SD; Billings, JA			Becoming a physician - Learning from dying	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Dana Farber Canc Inst, Div Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Ctr Palliat Care, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Block, SD (corresponding author), Dana Farber Canc Inst, Div Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA.							GERTEIS M, 1993, PATIENTS EYES PROMOT; Hafferty F.W., 1991, VALLEY DEATH SOCIALI; Kubler-Ross E., 1969, DEATH DYING	3	30	31	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2005	353	13					1313	1315		10.1056/NEJMp048171	http://dx.doi.org/10.1056/NEJMp048171			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	968FB	16192474				2022-12-28	WOS:000232146200001
J	Ford, CN				Ford, CN			Evaluation and management of laryngopharyngeal reflux	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LARYNGEAL EPITHELIAL DEFENSES; ESOPHAGEAL ACID EXPOSURE; PUMP INHIBITOR THERAPY; GASTROESOPHAGEAL-REFLUX; MEDICAL THERAPY; CELL BIOLOGY; DISEASE; LARYNGITIS; SYMPTOMS; ASSOCIATION	Context Laryngopharyngeal reflux (LPR) is a major cause of laryngeal inflammation and presents with a constellation of symptoms different from classic gastroesophageal reflux disease. Objective To provide a practical approach to evaluating and managing cases of LPR. Evidence Acquisition The PubMed database and the Ovid Database of Systematic Reviews were systematically searched for laryngopharyngeal reflux, laryngopharyngeal reflux fundoplication, laryngopharyngeal reflux PPI treatment, and gastroesophageal reflux AND laryngitis. Pertinent subject matter journals and reference lists of key research articles were also hand-searched for articles relevant to the analysis. Evidence Synthesis Reflux of gastric contents is a major cause of laryngeal pathology. The pathophysiology and symptom complex of LPR differs from gastroesophageal reflux disease. Laryngeal pathology results from small amounts of refluxate-typically occurring while upright during the daytime-causing damage to laryngeal tissues and producing localized symptoms. Unlike classic gastroesophageal reflux, LPR is not usually associated with esophagitis, heartburn, or complaints of regurgitation. There is no pathognomonic symptom or finding, but characteristic symptoms and laryngoscopic findings provide the basis for validated assessment instruments (the Reflux Symptom Index and Reflux Finding Score) useful in initial diagnosis. There are 3 approaches to confirming the diagnosis of LPR: (1) response of symptoms to behavioral and empirical medical treatment, (2) endoscopic observation of mucosal injury, and (3) demonstration of reflux events by impedance and pH-monitoring studies and barium swallow esophagram. While pH monitoring remains the standard for confirming the diagnosis of gastroesophageal reflux, the addition of multichannel intraluminal impedance. technology improves diagnostic accuracy for describing LPR events. Ambulatory multichannel intraluminal impedance assessment allows for identification of gaseous as well as liquid refluxate and detection of nonacid reflux events that are likely significant in confirming LPR. Although some patients respond to conservative behavioral and medical management, as is the case with gastroesophageal reflux, most require more aggressive and prolonged treatment to achieve regression of symptoms and laryngeal tissue changes. Surgical intervention such as laparoscopic fundoplication is useful in selected recalcitrant cases with laxity of the gastroesophageal sphincter. Conclusions Laryngopharyngeal reflux should be suspected when the history and laryngoscopy findings are suggestive of the diagnosis. Failure to respond to a 3-month trial of behavioral change and gastric acid suppression by adequate doses of proton pump inhibitor medication dictates need for confirmatory studies. Multichannel intraluminal impedance and pH-monitoring studies are most useful in confirming LPR and assessing the magnitude of the problem.	Univ Wisconsin, Ctr Clin Sci, Dept Surg, Div Otolaryngol, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Ford, CN (corresponding author), Univ Wisconsin, Ctr Clin Sci, Dept Surg, Div Otolaryngol, 600 Highland Ave,K4-714, Madison, WI 53792 USA.	ford@surgery.wisc.edu						Axford SE, 2001, ANN OTO RHINOL LARYN, V110, P1099, DOI 10.1177/000348940111001203; Baldi Fabio, 2002, Curr Gastroenterol Rep, V4, P99, DOI 10.1007/s11894-002-0043-x; Belafsky PC, 2001, LARYNGOSCOPE, V111, P1313, DOI 10.1097/00005537-200108000-00001; Belafsky PC, 2002, J VOICE, V16, P274, DOI 10.1016/S0892-1997(02)00097-8; Belafsky PC, 2002, OTOLARYNG HEAD NECK, V126, P649, DOI 10.1067/mhn.2002.125603; Berardi RR, 2000, AM J MANAG CARE, V6, pS491; Book DT, 2002, LARYNGOSCOPE, V112, P1399, DOI 10.1097/00005537-200208000-00014; Bothwell M, 2004, LARYNGOSCOPE, V114, P786, DOI 10.1097/00005537-200404000-00039; CASTELL DO, 1986, J CLIN GASTROENTEROL, V8, P81; de Caestecker J, 2002, EUR J GASTROEN HEPAT, V14, P5, DOI 10.1097/00042737-200201000-00002; DOBHAN R, 1993, AM J GASTROENTEROL, V88, P25; Eherer AJ, 2003, SCAND J GASTROENTERO, V38, P462, DOI 10.1080/00365520310001860; El-Serag HB, 2001, AM J GASTROENTEROL, V96, P979; Fackler WK, 2002, GASTROENTEROLOGY, V122, P625, DOI 10.1053/gast.2002.31876; Fass R, 2000, DIGEST DIS, V18, P20, DOI 10.1159/000016930; Ford CN, 1996, ANN OTO RHINOL LARYN, V105, P189, DOI 10.1177/000348949610500304; Ford CN, 1999, LARYNGOSCOPE, V109, P1891, DOI 10.1097/00005537-199912000-00001; Fuchs KH, 2005, LANGENBECK ARCH SURG, V390, P197, DOI 10.1007/s00423-004-0489-4; Galli J, 2003, Acta Otorhinolaryngol Ital, V23, P377; Hanson David G., 2000, American Journal of Medicine, V108, p112S; Hicks DM, 2002, J VOICE, V16, P564, DOI 10.1016/S0892-1997(02)00132-7; Hickson C, 2001, LARYNGOSCOPE, V111, P1742, DOI 10.1097/00005537-200110000-00014; HOPKINS C, 2005, COCHRANE DATABASE SY; Johnston N, 2004, LARYNGOSCOPE, V114, P2129, DOI 10.1097/01.mlg.0000149445.07146.03; Johnston N, 2003, ANN OTO RHINOL LARYN, V112, P481, DOI 10.1177/000348940311200601; Kahrilas PJ, 2000, ALIMENT PHARM THER, V14, P1503, DOI 10.1046/j.1365-2036.2000.00854.x; Katz Philip O., 2000, American Journal of Medicine, V108, p170S; Kawamura O, 2004, AM J GASTROENTEROL, V99, P1000, DOI 10.1111/j.1572-0241.2004.30349.x; Koufman J, 1996, J VOICE, V10, P215, DOI 10.1016/S0892-1997(96)80001-4; KOUFMAN JA, 1991, LARYNGOSCOPE, V101, P1; Lundy DS, 1999, OTOLARYNG HEAD NECK, V121, P69, DOI 10.1016/S0194-5998(99)70128-2; Maronian NC, 2001, ANN OTO RHINOL LARYN, V110, P606, DOI 10.1177/000348940111000703; McMurray JS, 2000, CONNS CURRENT THERAP, P25; MORRISON MD, 1988, OTOLARYNG HEAD NECK, V99, P370, DOI 10.1177/019459988809900403; Noordzij JP, 2002, LARYNGOSCOPE, V112, P2192, DOI 10.1097/00005537-200212000-00013; Noordzij JP, 2001, LARYNGOSCOPE, V111, P2147, DOI 10.1097/00005537-200112000-00013; Nostrant Timothy T., 2000, American Journal of Medicine, V108, p149S; Oelschlager BK, 2002, SURG ENDOSC, V16, P1032, DOI 10.1007/s00464-001-8252-1; OHMAN L, 1983, ANN OTO RHINOL LARYN, V92, P228; Park W, 2005, LARYNGOSCOPE, V115, P1230, DOI 10.1097/01.MLG.0000163746.81766.45; PELLEGRINI CA, 1978, AM J SURG, V135, P177, DOI 10.1016/0002-9610(78)90093-4; Postma GN, 2000, ANN OTO RHINOL LARYN, V109, P10, DOI 10.1177/0003489400109S1003; Reavis KM, 2004, ANN SURG, V239, P849, DOI 10.1097/01.sla.0000128303.05898.ee; RICHARDS DA, 1983, J CLIN GASTROENTEROL, V5, P81, DOI 10.1097/00004836-198312001-00008; Rothstein Richard I, 2003, Gastrointest Endosc Clin N Am, V13, P89, DOI 10.1016/S1052-5157(02)00107-1; Sasaki CT, 2005, ANN OTO RHINOL LARYN, V114, P192, DOI 10.1177/000348940511400304; Sermon F, 2004, DIGEST LIVER DIS, V36, P105, DOI 10.1016/j.dld.2003.07.008; Srinivasan R, 2001, AM J PHYSIOL-GASTR L, V280, pG457, DOI 10.1152/ajpgi.2001.280.3.G457; Steward DL, 2004, OTOLARYNG HEAD NECK, V131, P342, DOI 10.1016/j.otohns.2004.03.037; Storr M, 2000, DIGEST DIS, V18, P93, DOI 10.1159/000016970; Tauber S, 2002, LARYNGOSCOPE, V112, P879, DOI 10.1097/00005537-200205000-00019; Toohill RJ, 2005, ANN OTO RHINOL LARYN, V114, P177, DOI 10.1177/000348940511400302; Vaezi MF, 2004, AM J GASTROENTEROL, V99, P786, DOI 10.1111/j.1572-0241.2004.40290.x; Vaezi Michael F, 2003, Clin Cornerstone, V5, P32, DOI 10.1016/S1098-3597(03)90097-4; Wetscher GJ, 2001, ANN SURG, V234, P627, DOI 10.1097/00000658-200111000-00007; Williams RBH, 2004, AM J GASTROENTEROL, V99, P777, DOI 10.1111/j.1572-0241.2004.04151.x; Ylitalo R, 2002, ANN OTO RHINOL LARYN, V111, P441, DOI 10.1177/000348940211100509; Ylitalo R, 2001, LARYNGOSCOPE, V111, P1735, DOI 10.1097/00005537-200110000-00013	58	298	329	2	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	2005	294	12					1534	1540		10.1001/jama.294.12.1534	http://dx.doi.org/10.1001/jama.294.12.1534			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TF	16189367	Bronze			2022-12-28	WOS:000232113400024
J	Robinson, JK				Robinson, JK			Sun exposure, sun protection, and vitamin D	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; CUTANEOUS MALIGNANT-MELANOMA; SUNSCREEN USE; BREAST-CANCER; RISK; CHILDREN; SUPPLEMENTATION; ADOLESCENTS; POPULATION; PREVENTION		Dartmouth Hitchcock Med Ctr, Lebanon, NH 03756 USA	Dartmouth College	Robinson, JK (corresponding author), Dartmouth Hitchcock Med Ctr, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	archdermatol@jama-archives.org						Arranz JE, 1999, MELANOMA RES, V9, P199, DOI 10.1097/00008390-199904000-00013; AUTIER P, 1995, INT J CANCER, V61, P749, DOI 10.1002/ijc.2910610602; Autier P, 1998, INT J CANCER, V77, P533, DOI 10.1002/(SICI)1097-0215(19980812)77:4<533::AID-IJC10>3.0.CO;2-7; Bakos L, 2002, INT J DERMATOL, V41, P557, DOI 10.1046/j.1365-4362.2002.01412.x; BEITNER H, 1990, BRIT J DERMATOL, V122, P43, DOI 10.1111/j.1365-2133.1990.tb08238.x; Borissova AM, 2003, INT J CLIN PRACT, V57, P258; Chiu KC, 2004, AM J CLIN NUTR, V79, P820; Dietrich T, 2004, AM J CLIN NUTR, V80, P108; Dupuy A, 2005, ARCH DERMATOL, V141, P950, DOI 10.1001/archderm.141.8.950; Feskanich D, 2004, CANCER EPIDEM BIOMAR, V13, P1502; [Food and Nutrition Board Institute of Medicine Standing Committee on the Scientific Evaluation of Dietary Reference Intakes], 1997, DIET REF INT CALC PH, DOI 10.17226/5776; Gallagher RDP, 2000, JAMA-J AM MED ASSOC, V283, P2955, DOI 10.1001/jama.283.22.2955; Godar DE, 2003, PHOTOCHEM PHOTOBIOL, V77, P453, DOI 10.1562/0031-8655(2003)077<0453:UDOYA>2.0.CO;2; Godar DE, 2001, PHOTOCHEM PHOTOBIOL, V74, P787, DOI 10.1562/0031-8655(2001)074&lt;0787:UDOACA&gt;2.0.CO;2; Gordon CM, 2004, ARCH PEDIAT ADOL MED, V158, P531, DOI 10.1001/archpedi.158.6.531; GRAHAM S, 1985, AM J EPIDEMIOL, V122, P606, DOI 10.1093/oxfordjournals.aje.a114140; Green A, 1999, LANCET, V354, P723, DOI 10.1016/S0140-6736(98)12168-2; Hester EJ, 2005, ARCH DERMATOL, V141, P959, DOI 10.1001/archderm.141.8.959; Hillhouse J, 2005, ARCH DERMATOL, V141, P1028, DOI 10.1001/archderm.141.8.1028; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; John EM, 1999, CANCER EPIDEM BIOMAR, V8, P399; Lane NE, 1999, ARTHRITIS RHEUM-US, V42, P854, DOI 10.1002/1529-0131(199905)42:5&lt;854::AID-ANR3&gt;3.0.CO;2-I; Lim HW, 2005, J AM ACAD DERMATOL, V52, P868, DOI 10.1016/j.jaad.2005.03.015; Lindinger W, 2001, ADV GAS P I, V4, P1; Munger KL, 2004, NEUROLOGY, V62, P60, DOI 10.1212/01.WNL.0000101723.79681.38; NAYLOR MF, 1995, ARCH DERMATOL, V131, P170, DOI 10.1001/archderm.131.2.170; *NIH, 2001, 9 NIH US DEP HHS NAT; Pfeifer M, 2001, J CLIN ENDOCR METAB, V86, P1633, DOI 10.1210/jc.86.4.1633; Rigel DS, 2005, ARCH DERMATOL, V141, P1032, DOI 10.1001/archderm.141.8.1032; Robinson JK, 2000, J AM ACAD DERMATOL, V42, P746, DOI 10.1067/mjd.2000.103984; Robinson JK, 1998, J AM ACAD DERMATOL, V38, P774, DOI 10.1016/S0190-9622(98)70213-0; Robsahm TE, 2004, CANCER CAUSE CONTROL, V15, P149, DOI 10.1023/B:CACO.0000019494.34403.09; Rodenas JM, 1996, CANCER CAUSE CONTROL, V7, P275, DOI 10.1007/BF00051303; Thieden E, 2005, ARCH DERMATOL, V141, P967, DOI 10.1001/archderm.141.8.967; THOMPSON SC, 1993, NEW ENGL J MED, V329, P1147, DOI 10.1056/NEJM199310143291602; Tsao HS, 1998, J AM ACAD DERMATOL, V38, P669, DOI 10.1016/S0190-9622(98)70195-1; WESTERDAHL J, 1995, MELANOMA RES, V5, P59, DOI 10.1097/00008390-199502000-00007	38	113	115	1	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	2005	294	12					1541	1543		10.1001/jama.294.12.1541	http://dx.doi.org/10.1001/jama.294.12.1541			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TF	16193624				2022-12-28	WOS:000232113400025
J	Rubenstein, L; Pross, C; Davidoff, F; Iacopino, V				Rubenstein, L; Pross, C; Davidoff, F; Iacopino, V			Coercive US interrogation policies - A challenge to medical ethics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DOCTORS		Phys Human Rights, Cambridge, MA USA; Ctr Treatment Torture Victims, Berlin, Germany; Hamburg Fdn Advancement Res & Culture, Hamburg, Germany; Annals Internal Med, Philadelphia, PA USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Rubenstein, L (corresponding author), 1156 15th St NW, Washington, DC 20005 USA.	lrubenstein@phrusa.org						*AM MED ASS, 2004, E102 AM MED ASS; Amnesty International, 1977, TORTURE GREECE 1 TOR; *ASS SECR DEF HLTH, 2005, MED PROGR PRINC PROC; Bloche MG, 2005, NEW ENGL J MED, V353, P6, DOI 10.1056/NEJMp058145; Bloche MG, 2005, NEW ENGL J MED, V352, P3, DOI 10.1056/NEJMp048346; BORCHELT G, 2005, BREAK THEM DOWN SYST; *BRIT MED ASS, 1992, MED BETR PART DOCT H, P40; BYBEE JS, 2002, STAND COND INT 18 US; *CUB DET FAC, 2005, INV FBI ALL DET AB G; *DEP ARM, 2004, CJTF 7 INT RUL ENG M; *DEP ARM, 1997, ARM FIELD MAN, P34; *DEP DEF WORK GROU, 2003, REP DET INT GLOB WAR; GONZALES AR, 2002, APPL GENEVA CONV PRI; HARRINGTON TJ, 2004, COMMUNICATION   0714; HAYNES WJ, 2002, COUNTER RESISTANCE T; Iacopino V, 2001, MANUAL EFFECTIVE INV; IVY A, REPORT WAR CRIMES ME; LEE BJ, 2005, WASHINGTON POST 0701, pA25; LEVIN D, 2004, LEGAL STANDARDS APPL; Lewis Neil A, 2005, N Y Times Web, pA19; Lewis Neil A, 2004, N Y Times Web, pA14; Lifton RJ, 2004, NEW ENGL J MED, V351, P415, DOI 10.1056/NEJMp048065; Miles SH, 2004, LANCET, V364, P725, DOI 10.1016/S0140-6736(04)16902-X; *OFF SURG GEN, ASS DET MED OP OEF G; Peel M., 2002, MED DOCUMENTATION TO; PROSS C, 1988, MED SCI COMP FALL M; RUMSFELD D, 2003, COUNT RES TECHN WAR; Sanchez R., 2003, CJTF 7 INTERROGATION; Stover Eric, 1987, OPEN SECRET TORTURE; TAGUBA A, 2004, CFLCC DEPUTY COMMAND; *U CAP TOWN SCH PU, PHYS HUM RIGHTS; United Nations Office of the High Commissioner for Human Rights, INT COV CIV POL RIGH; United Nations Office of the High Commissioner for Human Rights, CONV TORT OTH CRUEL; *US STAT DEP, 2005, REP HUM RIGHTS 2004; *WORLD MED ASS, DECL TOK 1975 GUID P; World Medical Association, 2003, RES RESP PHYS DEN AC	36	22	23	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	2005	294	12					1544	1549		10.1001/jama.294.12.1544	http://dx.doi.org/10.1001/jama.294.12.1544			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TF	16189368				2022-12-28	WOS:000232113400026
J	Walker, M				Walker, M			Status epilepticus: an evidence based guide	BRITISH MEDICAL JOURNAL			English	Review							REFRACTORY STATUS EPILEPTICUS; CONVULSIVE STATUS EPILEPTICUS; RECTAL DIAZEPAM; INTRAVENOUS DIAZEPAM; REPETITIVE SEIZURES; MIDAZOLAM; LORAZEPAM; DIAGNOSIS; PLACEBO; TRIAL		Inst Neurol, London WC1N 3BG, England; UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Walker, M (corresponding author), Inst Neurol, Queen Sq, London WC1N 3BG, England.	mwalker@doctors.org.uk	Walker, Matthew C/C-1577-2008	Walker, Matthew C/0000-0002-0812-0352				Alldredge BK, 2001, NEW ENGL J MED, V345, P631, DOI 10.1056/NEJMoa002141; APPLETON R, 1995, DEV MED CHILD NEUROL, V37, P682; Burneo JG, 2001, EPILEPSIA, V42, P1156, DOI 10.1046/j.1528-1157.2001.12901.x; Cereghino JJ, 1998, NEUROLOGY, V51, P1274, DOI 10.1212/WNL.51.5.1274; Chamberlain JM, 1997, PEDIATR EMERG CARE, V13, P92, DOI 10.1097/00006565-199704000-00002; Claassen J, 2002, EPILEPSIA, V43, P146, DOI 10.1046/j.1528-1157.2002.28501.x; Coeytaux A, 2000, NEUROLOGY, V55, P693, DOI 10.1212/WNL.55.5.693; DeLorenzo RJ, 1996, NEUROLOGY, V46, P1029, DOI 10.1212/WNL.46.4.1029; Dreifus FE, 1998, NEW ENGL J MED, V338, P1869, DOI 10.1056/NEJM199806253382602; Hesdorffer DC, 1998, NEUROLOGY, V50, P735, DOI 10.1212/WNL.50.3.735; Kendall JL, 1997, ANN EMERG MED, V29, P415, DOI 10.1016/S0196-0644(97)70356-1; Knake S, 2001, EPILEPSIA, V42, P714, DOI 10.1046/j.1528-1157.2001.01101.x; LEPPIK IE, 1983, JAMA-J AM MED ASSOC, V249, P1452, DOI 10.1001/jama.249.11.1452; Mayer SA, 2002, ARCH NEUROL-CHICAGO, V59, P205, DOI 10.1001/archneur.59.2.205; MILLIGAN NM, 1984, J NEUROL NEUROSUR PS, V47, P235, DOI 10.1136/jnnp.47.3.235; PRENSKY AL, 1967, NEW ENGL J MED, V276, P779, DOI 10.1056/NEJM196704062761404; Scott RC, 1999, LANCET, V353, P623, DOI 10.1016/S0140-6736(98)06425-3; SHANER DM, 1988, NEUROLOGY, V38, P202, DOI 10.1212/WNL.38.2.202; Shorvon S., 1994, STATUS EPILEPTICUS I, P218; SIMON RP, 1985, EPILEPSIA, V26, pS58, DOI 10.1111/j.1528-1157.1985.tb05725.x; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Walker MC, 2001, CNS DRUGS, V15, P931, DOI 10.2165/00023210-200115120-00003; WALKER MC, 1995, ANAESTHESIA, V50, P130, DOI 10.1111/j.1365-2044.1995.tb15095.x; Walker MC, 1996, QJM-INT J MED, V89, P913	24	56	59	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 24	2005	331	7518					673	677		10.1136/bmj.331.7518.673	http://dx.doi.org/10.1136/bmj.331.7518.673			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970HH	16179702	Green Published			2022-12-28	WOS:000232295400019
J	Gershon, D				Gershon, D			DNA microarrays: More than than gene expression	NATURE			English	Article																			0	37	46	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 20	2005	437	7062					1195	1200		10.1038/4371195a	http://dx.doi.org/10.1038/4371195a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16237450	Bronze			2022-12-28	WOS:000232660500052
J	Russell, JC; Towns, DR; Anderson, SH; Clout, MN				Russell, JC; Towns, DR; Anderson, SH; Clout, MN			Intercepting the first rat ashore	NATURE			English	Editorial Material							NORVEGICUS; INVASION; ISLANDS		Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand; Univ Auckland, Dept Stat, Auckland 1, New Zealand; Dept Conservat, Auckland, New Zealand	University of Auckland; University of Auckland	Russell, JC (corresponding author), Univ Auckland, Sch Biol Sci, Private Bag 92019, Auckland 1, New Zealand.	j.russell@auckland.ac.nz		Anderson, Sandra/0000-0002-6164-7380; Clout, Mick/0000-0003-2864-4628				ATKINSON IAE, 1985, CONSERVATION ISLAND, P35; CLOUT MN, IN PRESS P INT C ASS; DILKS PJ, 2002, DOC SCI INT SER, V59; Holway DA, 1999, TRENDS ECOL EVOL, V14, P328, DOI 10.1016/S0169-5347(99)01636-5; Lacey EA, 2003, J MAMMAL, V84, P1135, DOI 10.1644/BLe-016; Macdonald David W., 1999, ACIAR Monograph Series, V59, P49; MOORS PJ, 1985, NEW ZEAL J ECOL, V8, P37; Simberloff Daniel, 2001, Trends in Ecology and Evolution, V16, P273, DOI 10.1016/S0169-5347(01)02154-1; Thorsen M, 2000, BIOL CONSERV, V96, P133, DOI 10.1016/S0006-3207(00)00059-8; Towns DR, 2003, NEW ZEAL J ZOOL, V30, P377, DOI 10.1080/03014223.2003.9518348	10	88	95	1	27	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 20	2005	437	7062					1107	1107		10.1038/4371107a	http://dx.doi.org/10.1038/4371107a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16237434	Bronze			2022-12-28	WOS:000232660500032
J	Myers, S; Bottolo, L; Freeman, C; McVean, G; Donnelly, P				Myers, S; Bottolo, L; Freeman, C; McVean, G; Donnelly, P			A fine-scale map of recombination rates and hotspots across the human genome	SCIENCE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; DOUBLE-STRAND BREAKS; ELEMENT COPY NUMBER; MEIOTIC RECOMBINATION; HOT-SPOT; PATTERNS; SEQUENCE; CHIMPANZEES; FREQUENCY	Genetic maps, which document the way in which recombination rates vary over a genome, are an essential tool for many genetic analyses. We present a high-resolution genetic map of the human genome, based on statistical analyses of genetic variation data, and identify more than 25,000 recombination hotspots, together with motifs and sequence contexts that play a role in hotspot activity. Differences between the behavior of recombination rates over large (megabase) and small (kilobase) scales lead us to suggest a two-stage model for recombination in which hotspots are stochastic features, within a framework in which large-scale rates are constrained.	Univ Oxford, Dept Stat, Oxford OX1 3TG, England	University of Oxford	Donnelly, P (corresponding author), Univ Oxford, Dept Stat, 1 S Parks Rd, Oxford OX1 3TG, England.	donnelly@stats.ox.ac.uk	Peng, Bo/A-6920-2009; Myers, Simon R/A-6792-2015	Peng, Bo/0000-0001-8225-2284; Myers, Simon R/0000-0002-2585-9626; Donnelly, Peter/0000-0001-9495-3408; Bottolo, Leonardo/0000-0002-6381-2327	NHGRI NIH HHS [U54 HG2750] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG002750] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Crawford DC, 2004, NAT GENET, V36, P700, DOI 10.1038/ng1376; Cullen M, 2002, AM J HUM GENET, V71, P759, DOI 10.1086/342973; FAN QQ, 1995, MOL CELL BIOL, V15, P1679; Fan QQ, 1997, GENETICS, V145, P661; Gilbert N, 2004, CELL, V118, P555, DOI 10.1016/j.cell.2004.08.011; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; HUDSON RR, 1985, GENETICS, V111, P147; Jeffreys AJ, 2005, HUM MOL GENET, V14, P2277, DOI 10.1093/hmg/ddi232; Jeffreys AJ, 2002, NAT GENET, V31, P267, DOI 10.1038/ng910; Jeffreys AJ, 2005, NAT GENET, V37, P601, DOI 10.1038/ng1565; Jensen-Seaman MI, 2004, GENOME RES, V14, P528, DOI 10.1101/gr.1970304; Jurka J, 2005, CYTOGENET GENOME RES, V110, P462, DOI 10.1159/000084979; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LANGLEY CH, 1988, GENET RES, V52, P223, DOI 10.1017/S0016672300027695; McVean GAT, 2004, SCIENCE, V304, P581, DOI 10.1126/science.1092500; MONTGOMERY E, 1987, GENET RES, V49, P31, DOI 10.1017/S0016672300026707; Petes TD, 2001, NAT REV GENET, V2, P360, DOI 10.1038/35072078; Ptak SE, 2004, PLOS BIOL, V2, P849, DOI 10.1371/journal.pbio.0020155; Ptak SE, 2005, NAT GENET, V37, P429, DOI 10.1038/ng1529; STAMBERG J, 1969, HEREDITY, V24, P361, DOI 10.1038/hdy.1969.54; Wall JD, 2003, AM J HUM GENET, V73, P1330, DOI 10.1086/380311; Winckler W, 2005, SCIENCE, V308, P107, DOI 10.1126/science.1105322; WU TC, 1995, GENETICS, V140, P55; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x; Yu A, 2001, NATURE, V409, P951, DOI 10.1038/35057185	28	788	811	2	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 14	2005	310	5746					321	324		10.1126/science.1117196	http://dx.doi.org/10.1126/science.1117196			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224025				2022-12-28	WOS:000232670100054
J	Kaplan, G				Kaplan, G			Rational vaccine development - A new trend in tuberculosis control	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Publ Hlth Res Inst, Int Ctr Publ Hlth, Newark, NJ 07103 USA		Kaplan, G (corresponding author), Publ Hlth Res Inst, Int Ctr Publ Hlth, Newark, NJ 07103 USA.							Grode L, 2005, J CLIN INVEST, V115, P2472, DOI 10.1172/JCI24617; Lazarevic V, 2002, AM J RESP CRIT CARE, V166, P1116, DOI 10.1164/rccm.2204027; Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998	3	12	12	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1624	1625		10.1056/NEJMcibr053426	http://dx.doi.org/10.1056/NEJMcibr053426			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221789				2022-12-28	WOS:000232486000021
J	Shankaran, S; Laptook, AR; Ehrenkranz, RA; Tyson, JE; McDonald, SA; Donovan, EF; Fanaroff, AA; Poole, WK; Wright, LL; Higgins, RD; Finer, NN; Carlo, WA; Duara, S; Oh, W; Cotten, CM; Stevenson, DK; Stoll, BJ; Lemons, JA; Guillet, R; Jobe, AH				Shankaran, S; Laptook, AR; Ehrenkranz, RA; Tyson, JE; McDonald, SA; Donovan, EF; Fanaroff, AA; Poole, WK; Wright, LL; Higgins, RD; Finer, NN; Carlo, WA; Duara, S; Oh, W; Cotten, CM; Stevenson, DK; Stoll, BJ; Lemons, JA; Guillet, R; Jobe, AH		Natl Inst Child Hlth Human Dev Neo	Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBRAL BLOOD-FLOW; POSTISCHEMIC HYPOTHERMIA; BRAIN TEMPERATURE; NEURONAL DAMAGE; SELECTIVE HEAD; POSTHYPOXIC HYPOTHERMIA; MODERATE HYPOTHERMIA; PERINATAL ASPHYXIA; MILD HYPOTHERMIA; CARDIAC-ARREST	BACKGROUND: Hypothermia is protective against brain injury after asphyxiation in animal models. However, the safety and effectiveness of hypothermia in term infants with encephalopathy is uncertain. METHODS: We conducted a randomized trial of hypothermia in infants with a gestational age of at least 36 weeks who were admitted to the hospital at or before six hours of age with either severe acidosis or perinatal complications and resuscitation at birth and who had moderate or severe encephalopathy. Infants were randomly assigned to usual care (control group) or whole-body cooling to an esophageal temperature of 33.5 degreesC for 72 hours, followed by slow rewarming (hypothermia group). Neurodevelopmental outcome was assessed at 18 to 22 months of age. The primary outcome was a combined end point of death or moderate or severe disability. RESULTS: Of 239 eligible infants, 102 were assigned to the hypothermia group and 106 to the control group. Adverse events were similar in the two groups during the 72 hours of cooling. Primary outcome data were available for 205 infants. Death or moderate or severe disability occurred in 45 of 102 infants (44 percent) in the hypothermia group and 64 of 103 infants (62 percent) in the control group (risk ratio, 0.72; 95 percent confidence interval, 0.54 to 0.95; P=0.01). Twenty-four infants (24 percent) in the hypothermia group and 38 (37 percent) in the control group died (risk ratio, 0.68; 95 percent confidence interval, 0.44 to 1.05; P=0.08). There was no increase in major disability among survivors; the rate of cerebral palsy was 15 of 77 (19 percent) in the hypothermia group as compared with 19 of 64 (30 percent) in the control group (risk ratio, 0.68; 95 percent confidence interval, 0.38 to 1.22; P=0.20). CONCLUSIONS: Whole-body hypothermia reduces the risk of death or disability in infants with moderate or severe hypoxic-ischemic encephalopathy.	Wayne State Univ, Div Neonatal Perinatal Med, Detroit, MI USA; Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA; Yale Univ, Sch Med, New Haven, CT USA; Univ Texas, Houston, TX USA; Res Triangle Inst, Res Triangle Pk, NC 27709 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA; Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; NICHHD, Bethesda, MD 20892 USA; Univ Calif San Diego, San Diego, CA 92103 USA; Univ Alabama, Birmingham, AL USA; Univ Miami, Dept Pediat, Miami, FL 33152 USA; Duke Univ, Med Ctr, Durham, NC USA; Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; Emory Univ, Sch Med, Atlanta, GA USA; Indiana Univ, Sch Med, Indianapolis, IN USA; Univ Rochester, Rochester, NY USA	Wayne State University; Women & Infants Hospital Rhode Island; Yale University; University of Texas System; Research Triangle Institute; University System of Ohio; University of Cincinnati; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California San Diego; University of Alabama System; University of Alabama Birmingham; University of Miami; Duke University; Stanford University; Emory University; Indiana University System; Indiana University-Purdue University Indianapolis; University of Rochester	Shankaran, S (corresponding author), Wayne State Univ, Childrens Hosp Michigan, Div Neonatal Perinatal Med, 3901 Beaubien Blvd,Rm 4H46, Detroit, MI 48201 USA.	sshankar@med.wayne.edu		Shankaran, Seetha/0000-0001-5512-9571; McDonald, Scott/0000-0002-0054-1099	NCRR NIH HHS [M01 RR 08084, M01 RR 00125, M01 RR 00039, M01 RR 0039-43, M01 RR 00750, M01 RR 00070, 5 M01 RR00044] Funding Source: Medline; NICHD NIH HHS [U10 HD27904, U10 HD27856, U10 HD40492, U10 HD21397, U10 HD40521, U01 HD36790, U10 HD21373, U10 HD21385, U10 HD27871, U10 HD40498, U10 HD34216, U10 HD27853, U10 HD40461, U10 HD27880, U10 HD27851, U10 HD40689, U10 HD021385] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD027856, U10HD027871, U10HD040461, U10HD027880, U10HD021385, U10HD040492, U10HD040689, U10HD027904, U10HD034216, U10HD027853, U10HD027851, U10HD021373] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD021397, U01HD036790, U10HD040521, U10HD040498] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070, M01RR000044, M01RR008084, M01RR000750, M01RR000039, M01RR000125] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		al Naqeeb N, 1999, PEDIATRICS, V103, P1263, DOI 10.1542/peds.103.6.1263; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; BALDWIN WA, 1991, AM J PHYSIOL, V261, pH774, DOI 10.1152/ajpheart.1991.261.3.H774; Barkovich AJ, 1998, AM J NEURORADIOL, V19, P143; BAYLEY N, 1993, BAYLEY SCALES INFANT, V2; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CARROLL M, 1992, METAB BRAIN DIS, V7, P45, DOI 10.1007/BF01000440; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Gelman B, 1996, CRIT CARE MED, V24, P1009, DOI 10.1097/00003246-199606000-00022; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gunn AJ, 1997, J CLIN INVEST, V99, P248, DOI 10.1172/JCI119153; Gunn AJ, 1998, PEDIATRICS, V102, P1098, DOI 10.1542/peds.102.5.1098; HORN M, 1991, ACTA NEUROPATHOL, V81, P443, DOI 10.1007/BF00293466; Krageloh-Mann I, 2002, DEV MED CHILD NEUROL, V44, P477; KULUZ JW, 1993, AM J PHYSIOL, V265, pH824, DOI 10.1152/ajpheart.1993.265.3.H824; Laptook AR, 1997, PEDIATR RES, V42, P17, DOI 10.1203/00006450-199707000-00004; Laptook AR, 2001, PEDIATRICS, V108, P1103, DOI 10.1542/peds.108.5.1103; Nedelcu J, 2000, BRAIN PATHOL, V10, P61; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; ROBERTSON CMT, 1989, J PEDIATR-US, V114, P753, DOI 10.1016/S0022-3476(89)80132-5; Roland EP, 1998, ANN NEUROL, V44, P161, DOI 10.1002/ana.410440205; Shankaran S, 2002, PEDIATRICS, V110, P377, DOI 10.1542/peds.110.2.377; SHANKARAN S, 1991, EARLY HUM DEV, V25, P135, DOI 10.1016/0378-3782(91)90191-5; SIMBRUNER G, 1994, AM J PERINAT, V11, P137, DOI 10.1055/s-2007-994574; Thoresen M, 1997, NEUROREPORT, V8, P3359, DOI 10.1097/00001756-199710200-00033; Thoresen M, 1996, ARCH DIS CHILD-FETAL, V74, pF3, DOI 10.1136/fn.74.1.F3; Thoresen M, 2001, PEDIATR RES, V49, P594, DOI 10.1203/00006450-200104000-00024; THORESEN M, 1995, PEDIATR RES, V37, P667, DOI 10.1203/00006450-199505000-00019; Toet MC, 1999, ARCH DIS CHILD-FETAL, V81, pF19, DOI 10.1136/fn.81.1.F19; TOWFIGHI J, 1994, ACTA NEUROPATHOL, V87, P598; Wagner BP, 2002, PEDIATR RES, V51, P354, DOI 10.1203/00006450-200203000-00015; WEINRAUCH V, 1992, STROKE, V23, P1454, DOI 10.1161/01.STR.23.10.1454	35	1836	1908	2	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1574	1584		10.1056/NEJMcps050929	http://dx.doi.org/10.1056/NEJMcps050929			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221780				2022-12-28	WOS:000232486000011
J	Carroll, MD; Lacher, DA; Sorlie, PD; Cleeman, JI; Gordon, DJ; Wolz, M; Grundy, SM; Johnson, CL				Carroll, MD; Lacher, DA; Sorlie, PD; Cleeman, JI; Gordon, DJ; Wolz, M; Grundy, SM; Johnson, CL			Trends in serum lipids and lipoproteins of adults, 1960-2002	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EDUCATION-PROGRAM RECOMMENDATIONS; CHOLESTEROL LEVELS; NATIONAL-HEALTH; CORONARY EVENTS; US ADULTS; DISEASE; PRAVASTATIN; PREVENTION; PREVALENCE; OBESITY	Context Serum total and low-density lipoprotein (LDL) cholesterol contribute significantly to atherosclerosis and its clinical sequelae. Previous analyses of data from the National Health and Nutrition Examination Surveys (NHANES) showed that mean levels of total cholesterol of US adults had declined from 1960-1962 to 1988-1994, and mean levels of LDL cholesterol (available beginning in 1976) had declined between 1976-1980 and 1988-1994. Objective To examine trends in serum lipid levels among US adults between 1960 and 2002, with a particular focus on changes since the 1988-1994 NHANES survey. Design, Setting, and Participants Blood lipid measurements taken from 6098 to 15 719 adults who were examined in 5 distinct cross-sectional surveys of the US population during 1960-1962, 1971-1974, 1976-1980, 1988-1994, and 1999-2002. Main Outcome Measures Mean serum total cholesterol, LDL cholesterol, high-density lipoprotein (HDL) cholesterol, and geometric mean serum triglyceride levels, and the percentage of adults with a serum total cholesterol level of at least 240 mg/dL (>= 6.22 mmol/L). Results Between 1988-1994 and 1999-2002, total serum cholesterol level of adults aged 20 years or older decreased from 206 mg/dL (5.34 mmol/L) to 203 mg/dL (5.26 mmol/L) (P=.009) and LDL cholesterol levels decreased from 129 mg/dL (3.34 mmol/L) to 123 mg/dL (3.19 mmol/L) (P<.001). Greater and significant decreases were observed in men 60 years or older and in women 50 years or older. The percentage of adults with a total cholesterol level of at least 240 mg/dL (>= 6.22 mmol/L) decreased from 20% during 1988-1994 to 17% during 1999-2002 (P<.001). There was no change in mean HDL cholesterol levels and a nonsignificant increase in geometric mean serum triglyceride levels (P=.06). Conclusions The decrease in total cholesterol level observed during 1960-1994 and LDL cholesterol level observed during 1976-1994 has continued during 1999-2002 in men 60 to 74 years and women 50 to 74 years. The target value of no more than 17% of US adults with a total cholesterol level of at least 240 mg/dL (>= 6.22 mmol/L), an objective of Healthy People 2010, has been attained. The increase in the proportion of adults using lipid-lowering medication, particularly in older age groups, likely contributed to the decreases in total and LDL cholesterol levels observed. The increased prevalence of obesity in the US population may have contributed to the increase in mean serum triglyceride levels.	Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; NHLBI, NIH, Bethesda, MD 20892 USA; Univ Texas, SW Med Ctr, Dallas, TX USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Carroll, MD (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4413, Hyattsville, MD 20782 USA.	mdc3@cdc.gov						*3 NAT HLTH NUTR E, 1994, VIT HLTH STAT, V31, P1; ALLAIN CC, 1974, CLIN CHEM, V20, P470; *AM HEART ASS, HLTH LIF DIET NUTR; ASHLEY FW, 1974, J CHRON DIS, V27, P103, DOI 10.1016/0021-9681(74)90079-4; BACHORIK PS, 1984, CLIN CHEM, V30, P839; DENKE MA, 1993, ARCH INTERN MED, V153, P1093, DOI 10.1001/archinte.153.9.1093; DENKE MA, 1994, ARCH INTERN MED, V154, P401, DOI 10.1001/archinte.154.4.401; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Ernst ND, 1997, AM J CLIN NUTR, V66, P965; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Ford ES, 2003, CIRCULATION, V107, P2185, DOI 10.1161/01.CIR.0000066320.27195.B4; FORTHOFER RN, 1983, AM J EPIDEMIOL, V117, P507, DOI 10.1093/oxfordjournals.aje.a113568; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Health, 2005, MED BENEFITS, V22, P12; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; HERSHCOPF RJ, 1982, J CHRON DIS, V35, P101, DOI 10.1016/0021-9681(82)90111-4; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KORN EL, 1999, WILEY S PRO STAT SUR, P1; *LAB STAND PAN NAT, 1988, CLIN CHEM, V34, P193; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; Matsuzaki Y, 1996, J ANAL BIOSC, V19, P419; MCDOWELL A, 1981, VITAL HLTH STAT, V1, P15; *MESA WEB, MULT STUD ATH; Millar J, 2001, J NEUROSCI METH, V110, P1, DOI 10.1016/S0165-0270(01)00411-3; MILLER RG, 1977, J AM STAT ASSOC, V72, P779, DOI 10.2307/2286459; Miller WT, 2001, SEMIN ROENTGENOL, V36, P1, DOI 10.1053/sroe.2001.20459; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; *NAT CHOL ED PROGR, 1994, CIRCULATION, V89, P1333; *NAT CTR HLTH STAT, 1998, HLTH US 1998 SOC STA; *NAT CTR HLTH STAT, NHANES 1999 2000 PUB; *NAT CTR HLTH STAT, NCHS DEF; *NAT CTR HLTH STAT, NHANES 2001 2002 DAT; *NAT CTR HLTH STAT, 1999 CURR NAT HLTH; *NAT CTR HLTH STAT, SURV QUEST EX COMP L; *NAT HEART LUNG BL, ATH RISK COMM; [National Center for Health Statistics Centers for Disease Control and Prevention], NHANES AN GUID; National Center for Health Statistics, LAB PROC US 3 NAT HL; National Heart Lung and Blood Institute, COR ART RISK DEV YOU; National Heart Lung and Blood Institute, CARD HLTH STUD; National Heart Lung and Blood Institute, FRAM HEART STUD; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STEIN EA, 1995, CLIN CHEM, V41, P1421; SUGIUCHI H, 1995, CLIN CHEM, V41, P717; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Tunstall-Pedoe H., 2003, MONICA MONOGRAPH MUL; *US BUR CENS, POP PROJ US AG SEX R; *US DEP HHS, DIET GUID AM 2005; US Department of Health and Human Services, 2010, HLTH PEOPL 2010, V2; *US DHEW, 1974, COMP AN EX NON PERS; WAHLEFELD A., 1974, METHOD ENZYMAT AN, P1831; WARNICK GR, 1995, CLIN CHEM, V41, P1427; Wolters K.M., 1990, VARIANCE ESTIMATION; 1965, VITAL HLTH STAT 1, V4, P1; [No title captured]	58	392	401	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	2005	294	14					1773	1781		10.1001/jama.294.14.1773	http://dx.doi.org/10.1001/jama.294.14.1773			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972RX	16219880	Bronze			2022-12-28	WOS:000232472000016
J	Fister, K				Fister, K			At the frontier of biomedical publication: Chicago 2005	BRITISH MEDICAL JOURNAL			English	Editorial Material									BMJ, London WC1H 9JR, England		Fister, K (corresponding author), BMJ, London WC1H 9JR, England.	kfister@bmj.com	Fišter, Kristina/AAG-3211-2022; Fišter, Kristina/AFK-4501-2022; Fišter, Kristina/A-9823-2018	Fišter, Kristina/0000-0002-5160-4694; Fišter, Kristina/0000-0002-5160-4694; Fišter, Kristina/0000-0002-5160-4694				ALTMAN DG, 2005, P 5 INT C PEER REV B; CALLAHAM M, 2005, P 5 INT C PEER REV B; CHEW M, 2005, P 5 INT C PEER REV B; DICKERSIN K, 2005, P 5 INT C PEER REV B; EGGER M, 2005, P 5 INT J EP P 5 INT; FISHER M, 1994, JAMA-J AM MED ASSOC, V272, P143, DOI 10.1001/jama.272.2.143; GARDNER W, 2005, P 5 INT C PEER REV B; GODLEE F, 1999, PEER REV HLTH SCI, pR6; GOLDSMITH LA, 2005, P 5 INT C PEER REV B; GOTZCHE P, 2005, P 5 INT C PEER REV B; HOPEWELL S, 2005, P 5 INT C PEER REV B; JORGENSEN AW, 2005, P 5 INT C PEER REV B; MARUSIC A, 2005, P 5 INT C PEER REV B; MILLS EJ, 2005, P 5 INT C PEER REV B; Overbeke J, 1999, PEER REV HLTH SCI, P32; Rennie D, 2002, JAMA-J AM MED ASSOC, V287, P2759, DOI 10.1001/jama.287.21.2759; ROSS JS, 2005, P 5 INT C PEER REV B; SAHU DKR, 2005, P 5 INT C PEER REV B; SATHER C, 2005, P 5 INT C PEER REV B; SCHRIGER DL, 2005, P 5 INT C PEER REV B; SCHROTER S, 2005, P 5 INT C PEER REV B; SCHWARTZ LM, 2005, P 5 INT C PEER REV B; SCOTT JR, 2005, P 5 INT C PEER REV B; SIEGEL PZ, 2005, P 5 INT C PEER REV B; SIM I, 2005, P 5 INT C PEER REV B; Smith R, 1998, BRIT MED J, V316, P1036; WAGER E, 2005, P 5 INT C PEER REV B; YANK V, 2005, P 5 INT C PEER REV B	28	9	9	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 8	2005	331	7520					838	840		10.1136/bmj.331.7520.838	http://dx.doi.org/10.1136/bmj.331.7520.838			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974BC	16210287	Green Published			2022-12-28	WOS:000232565300029
J	Merianos, A; Peiris, M				Merianos, A; Peiris, M			International Health Regulations (2005)	LANCET			English	Editorial Material									Curtin Univ Technol, Australian Biosecur CRC, Perth, WA 6008, Australia; Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Pokfulam, Hong Kong, Peoples R China	Curtin University; University of Hong Kong	Merianos, A (corresponding author), Curtin Univ Technol, Australian Biosecur CRC, Perth, WA 6008, Australia.	A.Merianos@exchange.curtin.edu.au						[Anonymous], MICROBIAL THREATS HL; Fouchier R, 2005, NATURE, V435, P419, DOI 10.1038/435419a; Smith R., 2003, GLOBAL PUBLIC GOODS; *WHO, 2000, WHO M GEN SWITZ APR	4	31	32	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 8	2005	366	9493					1249	1251		10.1016/S0140-6736(05)67508-3	http://dx.doi.org/10.1016/S0140-6736(05)67508-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	971ST	16214586	Bronze, Green Published			2022-12-28	WOS:000232405700009
J	Grebe, M				Grebe, M			Growth by auxin: When a weed needs acid	SCIENCE			English	Editorial Material							ARABIDOPSIS; TRANSPORT; PYROPHOSPHATASE; PIN		Swedish Univ Agr Sci, Dept Forest Genet & Plant Physiol, Umea Plant Sci Ctr, S-90183 Umea, Sweden	Swedish University of Agricultural Sciences; Umea University	Grebe, M (corresponding author), Swedish Univ Agr Sci, Dept Forest Genet & Plant Physiol, Umea Plant Sci Ctr, S-90183 Umea, Sweden.	markus.grebe@genfys.stu.se		Grebe, Markus/0000-0001-7571-0670				Blilou I, 2005, NATURE, V433, P39, DOI 10.1038/nature03184; Friml J, 2003, NATURE, V426, P147, DOI 10.1038/nature02085; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; Hager A, 2003, J PLANT RES, V116, P483, DOI 10.1007/s10265-003-0110-x; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; Leyser O, 2005, CELL, V121, P819, DOI 10.1016/j.cell.2005.06.005; Li JS, 2005, SCIENCE, V310, P121, DOI 10.1126/science.1115711; LIU CM, 1993, PLANT CELL, V5, P621, DOI 10.1105/tpc.5.6.621; Lomax Terri L., 1995, P509; Ratajczak R, 1999, PLANTA, V208, P205, DOI 10.1007/s004250050551	10	15	17	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 7	2005	310	5745					60	61		10.1126/science.1119735	http://dx.doi.org/10.1126/science.1119735			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210521				2022-12-28	WOS:000232477000030
J	Lehnart, SE; Wehrens, XHT; Reiken, S; Warrier, S; Belevych, AE; Harvey, RD; Richter, W; Jin, SLC; Conti, M; Marks, AR				Lehnart, SE; Wehrens, XHT; Reiken, S; Warrier, S; Belevych, AE; Harvey, RD; Richter, W; Jin, SLC; Conti, M; Marks, AR			Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias	CELL			English	Article							PROTEIN-KINASE-A; CAMP-SPECIFIC PHOSPHODIESTERASE; CYCLIC-AMP; SUDDEN-DEATH; CA2+ LEAK; RELEASE; PHOSPHORYLATION; FKBP12.6; MUSCLE; THEOPHYLLINE	Phosphodiesterases (PDEs) regulate the local concentration of 3',5' cyclic adenosine monophosphate (cAMP) within cells. cAMP activates the cAMP-dependent protein kinase (PKA). In patients, PDE inhibitors have been linked to heart failure and cardiac arrhythmias, although the mechanisms are not understood. We show that PDE4D gene inactivation in mice results in a progressive cardiomyopathy, accelerated heart failure after myocardial infarction, and cardiac arrhythmias. The phosphodiesterase 4D3 (PDE4D3) was found in the cardiac ryanodine receptor (RyR2)/calcium-release-channel complex (required for excitation-contraction [EC] coupling in heart muscle). PDE4D3 levels in the RyR2 complex were reduced in failing human hearts, contributing to PKA-hyperphosphorylated, "leaky" RyR2 channels that promote cardiac dysfunction and arrhythmias. Cardiac arrhythmias and dysfunction associated with PDE4 inhibition or deficiency were suppressed in mice harboring RyR2 that cannot be PKA phosphorylated. These data suggest that reduced PDE4D activity causes defective RyR2-channel function associated with heart failure and arrhythmias.	Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, Clyde & Helen Wu Ctr Mol Cardiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA	Columbia University; Columbia University; Case Western Reserve University; Stanford University	Marks, AR (corresponding author), Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, Clyde & Helen Wu Ctr Mol Cardiol, New York, NY 10032 USA.	arm42@columbia.edu	Harvey, Robert D/L-8496-2016; Tuluc, Petronel/C-2527-2011; Wehrens, Xander/AAQ-9574-2020	Harvey, Robert D/0000-0002-8499-8765; Wehrens, Xander/0000-0001-5044-672X; Richter, Wito/0000-0001-5588-9060; Belevych, Andriy/0000-0002-1272-5784; Warrier, Sunita/0000-0002-1981-4552	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083418, R01HL056180, R01HL061503, R01HL068170, P01HL067849] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL083418, R01 HL083418-03, R01 HL061503-13, R01 HL061503, R01-HL68170, P01 HL067849-10, R01 HL068170, R01 HL056180, R01 HL056180-15, P01 HL067849] Funding Source: Medline; NICHD NIH HHS [R01 HD020788, R01-HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Antos CL, 2001, CIRC RES, V89, P997, DOI 10.1161/hh2301.100003; Baillie GS, 2003, P NATL ACAD SCI USA, V100, P940, DOI 10.1073/pnas.262787199; Barnes PJ, 2003, AM J RESP CRIT CARE, V167, P813, DOI 10.1164/rccm.200210-1142PP; BITTAR G, 1991, CHEST, V99, P1415, DOI 10.1378/chest.99.6.1415; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Giembycz M A, 2002, Monaldi Arch Chest Dis, V57, P48; Gong B, 2004, J CLIN INVEST, V114, P1624, DOI 10.1172/JCI200422831; Gretarsdottir S, 2003, NAT GENET, V35, P131, DOI 10.1038/ng1245; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Jiang MT, 2002, CIRC RES, V91, P1015, DOI 10.1161/01.RES.0000043663.08689.05; Jin SLC, 1999, P NATL ACAD SCI USA, V96, P11998, DOI 10.1073/pnas.96.21.11998; Lehnart SE, 2004, CIRCULATION, V109, P3208, DOI 10.1161/01.CIR.0000132472.98675.EC; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Michel JJC, 2004, BIOCHEM J, V381, P587, DOI 10.1042/BJ20040846; Mongillo M, 2004, CIRC RES, V95, P67, DOI 10.1161/01.RES.0000134629.84732.11; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Pieske B, 1999, CIRC RES, V85, P38; REGITZZAGROSEK V, 1994, EUR HEART J, V15, P7, DOI 10.1093/eurheartj/15.suppl_D.7; Reiken S, 2003, CIRCULATION, V107, P2459, DOI 10.1161/01.CIR.0000068316.53218.49; Reiken S, 2003, J BIOL CHEM, V278, P444, DOI 10.1074/jbc.M207028200; Richter W, 2005, BIOCHEM J, V388, P803, DOI 10.1042/BJ20050030; Ruehr ML, 2003, J BIOL CHEM, V278, P24831, DOI 10.1074/jbc.M213279200; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; Shannon TR, 2003, CIRC RES, V93, P592, DOI 10.1161/01.RES.0000093399.11734.B3; Suissa S, 1996, AM J RESP CRIT CARE, V154, P1598, DOI 10.1164/ajrccm.154.6.8970341; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; VERDE I, 1999, BRIT J PHARMACOL, V217, P65; Vignola AM, 2004, RESP MED, V98, P495, DOI 10.1016/j.rmed.2003.12.012; Wang DG, 2003, CELL SIGNAL, V15, P883, DOI 10.1016/S0898-6568(03)00042-1; Wehrens XHT, 2005, P NATL ACAD SCI USA, V102, P9607, DOI 10.1073/pnas.0500353102; Wehrens XHT, 2004, SCIENCE, V304, P292, DOI 10.1126/science.1094301; Wehrens XHT, 2003, CELL, V113, P829, DOI 10.1016/S0092-8674(03)00434-3; Xiang Y, 2005, P NATL ACAD SCI USA, V102, P909, DOI 10.1073/pnas.0405263102; Yang JC, 1998, J CELL BIOL, V142, P511, DOI 10.1083/jcb.142.2.511; Yano M, 2000, CIRCULATION, V102, P2131, DOI 10.1161/01.CIR.102.17.2131; Yano M, 2003, CIRCULATION, V107, P477, DOI 10.1161/01.CIR.0000044917.74408.BE; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982	39	375	396	2	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 7	2005	123	1					25	35		10.1016/j.cell.2005.07.030	http://dx.doi.org/10.1016/j.cell.2005.07.030			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	973QD	16213210	Green Accepted, Bronze			2022-12-28	WOS:000232536800006
J	Machida, YJ; Hamlin, JL; Dutta, A				Machida, YJ; Hamlin, JL; Dutta, A			Right place, right time, and only once: Replication initiation in metazoans	CELL			English	Review							ORIGIN RECOGNITION COMPLEX; XENOPUS EGG EXTRACTS; MINICHROMOSOME MAINTENANCE PROTEINS; HISTONE ACETYLTRANSFERASE HBO1; CHROMOSOMAL DNA-REPLICATION; ATR-DEPENDENT CHECKPOINT; S-PHASE; DROSOPHILA-MELANOGASTER; MAMMALIAN-CELLS; INHIBITS INITIATION	DNA replication is tightly regulated at the initiation step by both the cell cycle machinery and checkpoint pathways. Here, we discuss recent advances in understanding how replication is initiated in metazoans at the correct chromosome positions, at the appropriate time, and only once per cell cycle.	Univ Virginia, Sch Med, Dept Mol Genet & Biochem, Charlottesville, VA 22908 USA	University of Virginia	Dutta, A (corresponding author), Univ Virginia, Sch Med, Dept Mol Genet & Biochem, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Machida, Yuichi/AAO-3533-2021; Dutta, Anindya/P-3203-2016	Machida, Yuichi/0000-0003-1414-0568; Dutta, Anindya/0000-0002-4319-0073	NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026108] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA060499-12, CA60499, R01 CA060499] Funding Source: Medline; NIGMS NIH HHS [GM26108] Funding Source: Medline; CGH CDC HHS [GH003157] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CGH CDC HHS		Abraham J, 2003, EMBO J, V22, P6137, DOI 10.1093/emboj/cdg580; Aggarwal BD, 2004, NATURE, V430, P372, DOI 10.1038/nature02694; Altman AL, 2004, MOL CELL BIOL, V24, P4138, DOI 10.1128/MCB.24.10.4138-4150.2004; Arias EE, 2005, GENE DEV, V19, P114, DOI 10.1101/gad.1255805; Ballabeni A, 2004, EMBO J, V23, P3122, DOI 10.1038/sj.emboj.7600314; Benard M, 1996, MOL CELL BIOL, V16, P968; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Chesnokov I, 2001, P NATL ACAD SCI USA, V98, P11997, DOI 10.1073/pnas.211342798; Chesnokov IN, 2003, P NATL ACAD SCI USA, V100, P9150, DOI 10.1073/pnas.1633580100; Claycomb JM, 2002, J CELL BIOL, V159, P225, DOI 10.1083/jcb.200207046; Collins N, 2002, NAT GENET, V32, P627, DOI 10.1038/ng1046; Cook JG, 2004, J BIOL CHEM, V279, P9625, DOI 10.1074/jbc.M311933200; Cook JG, 2002, P NATL ACAD SCI USA, V99, P1347, DOI 10.1073/pnas.032677499; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Danis E, 2004, NAT CELL BIOL, V6, P721, DOI 10.1038/ncb1149; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; DIJKWEL PA, 1994, NUCLEIC ACIDS RES, V22, P4989, DOI 10.1093/nar/22.23.4989; Dijkwel PA, 2000, EXP CELL RES, V256, P150, DOI 10.1006/excr.2000.4809; DIJKWEL PA, 1992, MOL CELL BIOL, V12, P3715, DOI 10.1128/MCB.12.9.3715; Dijkwel PA, 2002, MOL CELL BIOL, V22, P3053, DOI 10.1128/MCB.22.9.3053-3065.2002; DINGWALL C, 1981, NUCLEIC ACIDS RES, V9, P2659, DOI 10.1093/nar/9.12.2659; Duursma A, 2005, MOL CELL BIOL, V25, P6937, DOI 10.1128/MCB.25.16.6937-6947.2005; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Frolova NS, 2002, MOL BIOL CELL, V13, P1298, DOI 10.1091/mbc.01-08-0382; Gilbert DM, 2004, NAT REV MOL CELL BIO, V5, P848, DOI 10.1038/nrm1495; Gillespie PJ, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-15; Gillespie PJ, 2004, CURR BIOL, V14, P1598, DOI 10.1016/j.cub.2004.07.053; Giordano-Coltart J, 2005, P NATL ACAD SCI USA, V102, P69, DOI 10.1073/pnas.0408690102; Gladden AB, 2003, J BIOL CHEM, V278, P9754, DOI 10.1074/jbc.M212088200; Harvey KJ, 2003, J BIOL CHEM, V278, P48524, DOI 10.1074/jbc.M307661200; Harvey KJ, 2003, MOL CELL BIOL, V23, P6769, DOI 10.1128/MCB.23.19.6769-6779.2003; Hashimoto Y, 2003, EMBO J, V22, P2526, DOI 10.1093/emboj/cdg238; Herbig U, 1999, MOL BIOL CELL, V10, P2631, DOI 10.1091/mbc.10.8.2631; Hiratani I, 2004, P NATL ACAD SCI USA, V101, P16861, DOI 10.1073/pnas.0406687101; Hu J, 2004, NAT CELL BIOL, V6, P1003, DOI 10.1038/ncb1172; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; JACOB F, 1963, CR HEBD ACAD SCI, V256, P298; Jeon Y, 2005, P NATL ACAD SCI USA, V102, P6419, DOI 10.1073/pnas.0405088102; Karakaidos P, 2004, AM J PATHOL, V165, P1351, DOI 10.1016/S0002-9440(10)63393-7; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; Kondo T, 2004, J BIOL CHEM, V279, P27315, DOI 10.1074/jbc.M314023200; Kubota Y, 2003, GENE DEV, V17, P1141, DOI 10.1101/gad.1070003; Lee C, 2004, NATURE, V430, P913, DOI 10.1038/nature02813; Li A, 2005, EMBO J, V24, P395, DOI 10.1038/sj.emboj.7600520; Lipford JR, 2001, MOL CELL, V7, P21, DOI 10.1016/S1097-2765(01)00151-4; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; MacAlpine DM, 2004, GENE DEV, V18, P3094, DOI 10.1101/gad.1246404; Machida YJ, 2005, J BIOL CHEM, V280, P27624, DOI 10.1074/jbc.M502615200; Machida YJ, 2005, J BIOL CHEM, V280, P6253, DOI 10.1074/jbc.R400037200; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Maiorano D, 2005, CELL, V120, P315, DOI 10.1016/j.cell.2004.12.010; Marheineke K, 2004, J BIOL CHEM, V279, P28071, DOI 10.1074/jbc.M401574200; Masuda T, 2003, GENES CELLS, V8, P145, DOI 10.1046/j.1365-2443.2003.00621.x; Masumoto H, 2002, NATURE, V415, P651, DOI 10.1038/nature713; Mendez J, 2003, BIOESSAYS, V25, P1158, DOI 10.1002/bies.10370; MILBRANDT JD, 1981, P NATL ACAD SCI-BIOL, V78, P6043, DOI 10.1073/pnas.78.10.6043; Noguchi E, 2002, CURR BIOL, V12, P599, DOI 10.1016/S0960-9822(02)00739-X; Okuno Y, 2001, EMBO J, V20, P4263, DOI 10.1093/emboj/20.15.4263; Pacek M, 2004, EMBO J, V23, P3667, DOI 10.1038/sj.emboj.7600369; Paixao S, 2004, MOL CELL BIOL, V24, P2958, DOI 10.1128/MCB.24.7.2958-2967.2004; Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Raghuraman MK, 2001, SCIENCE, V294, P115, DOI 10.1126/science.294.5540.115; Remus D, 2004, EMBO J, V23, P897, DOI 10.1038/sj.emboj.7600077; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sangrithi MN, 2005, CELL, V121, P887, DOI 10.1016/j.cell.2005.05.015; Saxena S, 2004, MOL CELL, V15, P245, DOI 10.1016/j.molcel.2004.06.045; Schaarschmidt D, 2004, EMBO J, V23, P191, DOI 10.1038/sj.emboj.7600029; Schubeler D, 2002, NAT GENET, V32, P438, DOI 10.1038/ng1005; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; SHINOMIYA T, 1993, MOL CELL BIOL, V13, P4098, DOI 10.1128/MCB.13.7.4098; SHINOMIYA T, 1994, MOL CELL BIOL, V14, P7394, DOI 10.1128/MCB.14.11.7394; Stedman W, 2004, J VIROL, V78, P12566, DOI 10.1128/JVI.78.22.12566-12575.2004; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Takahashi TS, 2004, NAT CELL BIOL, V6, P991, DOI 10.1038/ncb1177; Takeda DY, 2005, J BIOL CHEM, V280, P23416, DOI 10.1074/jbc.M501208200; Takei Y, 2002, J BIOL CHEM, V277, P43121, DOI 10.1074/jbc.C200442200; Takei Y, 2001, EMBO REP, V2, P119, DOI 10.1093/embo-reports/kve026; Vashee S, 2003, GENE DEV, V17, P1894, DOI 10.1101/gad.1084203; Volkening M, 2005, MOL CELL BIOL, V25, P1560, DOI 10.1128/MCB.25.4.1560-1568.2005; Wang LX, 2004, MOL CELL BIOL, V24, P3373, DOI 10.1128/MCB.24.8.3373-3386.2004; White EJ, 2004, P NATL ACAD SCI USA, V101, P17771, DOI 10.1073/pnas.0408170101; Wohlschlegel JA, 2002, AM J PATHOL, V161, P267, DOI 10.1016/S0002-9440(10)64178-8; Woodfine K, 2004, HUM MOL GENET, V13, P191, DOI 10.1093/hmg/ddh016; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Yoo HY, 2004, J BIOL CHEM, V279, P53353, DOI 10.1074/jbc.M408026200; Zhang JM, 2002, NATURE, V420, P198, DOI 10.1038/nature01150; Zhou J, 2005, EMBO J, V24, P1406, DOI 10.1038/sj.emboj.7600609	97	226	233	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 7	2005	123	1					13	24		10.1016/j.cell.2005.09.019	http://dx.doi.org/10.1016/j.cell.2005.09.019			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	973QD	16213209	Bronze			2022-12-28	WOS:000232536800005
J	Akeda, Y; Galan, JE				Akeda, Y; Galan, JE			Chaperone release and unfolding of substrates in type III secretion	NATURE			English	Article							F0F1 ATPASE; PROTEINS; RECOGNITION; DELIVERY; DOMAINS; FAMILY; INVC; FLII	Type III protein secretion systems are essential virulence factors of many bacteria pathogenic to humans, animals and plants(1). These systems mediate the transfer of bacterial virulence proteins directly into the host cell cytoplasm. Proteins are thought to travel this pathway in a largely unfolded manner, and a family of customized cytoplasmic chaperones, which specifically bind cognate secreted proteins, are essential for secretion. Here we show that InvC, an ATPase associated with a Salmonella enterica type III secretion system(2), has a critical function in substrate recognition. Furthermore, InvC induces chaperone release from and unfolding of the cognate secreted protein in an ATP-dependent manner. Our results show a similarity between the mechanisms of substrate recognition by type III protein secretion systems and AAA+ ATPase disassembly machines.	Yale Univ, Sch Med, Sect Microbial Pathogenesis, New Haven, CT 06536 USA	Yale University	Galan, JE (corresponding author), Yale Univ, Sch Med, Sect Microbial Pathogenesis, 333 Cedar St, New Haven, CT 06536 USA.	jorge.galan@yale.edu						Akeda Y, 2004, J BACTERIOL, V186, P2402, DOI 10.1128/JB.186.8.2402-2412.2004; Birtalan SC, 2002, MOL CELL, V9, P971, DOI 10.1016/S1097-2765(02)00529-4; Claret L, 2003, MOL MICROBIOL, V48, P1349, DOI 10.1046/j.1365-2958.2003.03506.x; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Dougan DA, 2002, FEBS LETT, V529, P6, DOI 10.1016/S0014-5793(02)03179-4; DREYFUS G, 1993, J BACTERIOL, V175, P3131, DOI 10.1128/JB.175.10.3131-3138.1993; EICHELBERG K, 1994, J BACTERIOL, V176, P4501, DOI 10.1128/JB.176.15.4501-4510.1994; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; Fischer CJ, 2001, BBA-PROTEIN STRUCT M, V1545, P96, DOI 10.1016/S0167-4838(00)00266-1; Frickey T, 2004, J STRUCT BIOL, V146, P2, DOI 10.1016/j.jsb.2003.11.020; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; Gauthier A, 2003, J BACTERIOL, V185, P6747, DOI 10.1128/JB.185.23.6747-6755.2003; KANIGA K, 1994, MOL MICROBIOL, V13, P555, DOI 10.1111/j.1365-2958.1994.tb00450.x; Kaniga K, 1996, MOL MICROBIOL, V21, P633, DOI 10.1111/j.1365-2958.1996.tb02571.x; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Lara-Tejero M, 2001, INFECT IMMUN, V69, P4358, DOI 10.1128/IAI.69.7.4358-4365.2001; Lee SH, 2004, MOL MICROBIOL, V51, P483, DOI 10.1046/j.1365-2958.2003.03840.x; Lee VT, 2002, J BACTERIOL, V184, P3740, DOI 10.1128/JB.184.13.3740-3745.2002; Lloyd SA, 2001, TRENDS MICROBIOL, V9, P367, DOI 10.1016/S0966-842X(01)02100-X; Luo Y, 2001, NAT STRUCT BIOL, V8, P1031, DOI 10.1038/nsb717; Marlovits TC, 2004, SCIENCE, V306, P1040, DOI 10.1126/science.1102610; MICHIELS T, 1991, J BACTERIOL, V173, P1677, DOI 10.1128/jb.173.5.1677-1685.1991; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Pozidis C, 2003, J BIOL CHEM, V278, P25816, DOI 10.1074/jbc.M301903200; Ramamurthi KS, 2003, MOL MICROBIOL, V50, P1095, DOI 10.1046/j.1365-2958.2003.03777.x; Sauer RT, 2004, CELL, V119, P9, DOI 10.1016/j.cell.2004.09.020; Stebbins CE, 2003, NAT REV MOL CELL BIO, V4, P738, DOI 10.1038/nrm1201; Stebbins CE, 2000, MOL CELL, V6, P1449, DOI 10.1016/S1097-2765(00)00141-6; Stebbins CE, 2001, NATURE, V414, P77, DOI 10.1038/35102073	30	332	344	1	33	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					911	915		10.1038/nature03992	http://dx.doi.org/10.1038/nature03992			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208377				2022-12-28	WOS:000232338600052
J	Meine, TJ; Patel, MR; DePuy, V; Curtis, LH; Rao, SV; Gersh, BJ; Schulman, KA; Jollis, JG				Meine, TJ; Patel, MR; DePuy, V; Curtis, LH; Rao, SV; Gersh, BJ; Schulman, KA; Jollis, JG			Evidence-based therapies and mortality in patients hospitalized in December with acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	53rd Annual Scientific Session of the American-College-of-Cardiology	MAR 07-10, 2004	New Orleans, LA	Amer Coll Cardiol			COOPERATIVE CARDIOVASCULAR PROJECT; NATIONAL REGISTRY; DEATH; CARE	Background: Previous studies suggest that patients hospitalized with acute myocardial infarction (MI) in December have poor outcomes, and some studies have hypothesized that the cause may be the infrequent use of evidence-based therapies during the December holiday season. Objective: To compare the care and outcomes of patients with acute MI hospitalized in December and patients hospitalized during other months. Design: Retrospective analysis of data from the Cooperative Cardiovascular Project. Setting: Nonfederal, acute care hospitals in the United States. Patients: 127 959 Medicare beneficiaries hospitalized between January 1994 and February 1996 with confirmed acute MI. Measurements: Use of aspirin, beta-blockers, and reperfusion therapy (thrombolytic therapy or percutaneous coronary intervention), and 30-day mortality. Results: When the authors controlled for patient hospital, and physician characteristics, the use of evidence-based therapies was not significantly lower but 30-day mortality was higher (21.7% vs. 20.1%; adjusted odds ratio, 1.07 [95% CI, 1.02 to 1.12]) among patients hospitalized in December. Limitations: This was a nonrandomized, observational study. Unmeasured characteristics may have contributed to outcome differences. Conclusions: Thirty-day mortality rates were higher for Medicare patients hospitalized with acute MI in December than in other months, although the use of evidence-based therapies was not significantly lower.			Meine, TJ (corresponding author), 877-B W Faris Rd, Greenville, SC 29605 USA.							Aiken LH, 2002, JAMA-J AM MED ASSOC, V288, P1987, DOI 10.1001/jama.288.16.1987; Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; Kloner RA, 1999, CIRCULATION, V100, P1630, DOI 10.1161/01.CIR.100.15.1630; Kloner RA, 2001, AM J CARDIOL, V88, P1021, DOI 10.1016/S0002-9149(01)01981-6; Knight-Davis DK, 1998, J ROY COLL PHYS LOND, V32, P130; Krumholz HM, 2001, J AM COLL CARDIOL, V38, P453, DOI 10.1016/S0735-1097(01)01395-X; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; McCulloch C. E., 2001, GEN LINEAR MIXED MOD; Otto W, 1975, Z Gesamte Inn Med, V30, P231; PHILLIPS DP, 1990, JAMA-J AM MED ASSOC, V263, P1947, DOI 10.1001/jama.263.14.1947; Phillips DP, 2004, CIRCULATION, V110, P3781, DOI 10.1161/01.CIR.0000151424.02045.F7; Rogers WJ, 2000, J AM COLL CARDIOL, V36, P2056, DOI 10.1016/S0735-1097(00)00996-7; Spencer FA, 1998, J AM COLL CARDIOL, V31, P1226, DOI 10.1016/S0735-1097(98)00098-9; Spertus JA, 2003, J AM COLL CARDIOL, V41, P1653, DOI 10.1016/S0735-1097(03)00415-7; Tarnow-Mordi WO, 2000, LANCET, V356, P185, DOI 10.1016/S0140-6736(00)02478-8; Tran CTT, 2003, CAN J CARDIOL, V19, P38; Varnava AM, 2002, HEART, V87, P216, DOI 10.1136/heart.87.3.216	19	7	7	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 4	2005	143	7					481	485		10.7326/0003-4819-143-7-200510040-00006	http://dx.doi.org/10.7326/0003-4819-143-7-200510040-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	970FM	16204160				2022-12-28	WOS:000232290600002
J	McIntyre, JA				McIntyre, JA			Sex, pregnancy, hormones, and HIV	LANCET			English	Editorial Material							TO-CHILD TRANSMISSION; WOMEN; RISK		Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa	University of Witwatersrand	McIntyre, JA (corresponding author), Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa.	mcintyre@pixie.co.za	McIntyre, James/V-7115-2019					*AM COLL OBST GYN, 2004, OBSTET GYNECOL, V104, P1119; Duerr A, 2005, LANCET, V366, P261, DOI 10.1016/S0140-6736(05)66917-6; Dunkle KL, 2004, SOC SCI MED, V59, P1581, DOI 10.1016/j.socscimed.2004.02.003; Gray RH, 2005, LANCET, V366, P1182, DOI 10.1016/S0140-6736(05)67481-8; Jewkes R, 2001, SOC SCI MED, V52, P733, DOI 10.1016/S0277-9536(00)00177-5; Lavreys L, 2004, AIDS, V18, P695, DOI 10.1097/00002030-200403050-00017; LEROY V, 1994, AIDS, V8, P983, DOI 10.1097/00002030-199407000-00017; McIntyre J, 2005, BJOG-INT J OBSTET GY, V112, P1196, DOI 10.1111/j.1471-0528.2005.00716.x; RWKYENDELA O, 2002, 8 REPR HLTH PRIOR C; Sansom SL, 2003, OBSTET GYNECOL, V102, P782, DOI 10.1016/S0029-7844(03)00624-0; Shelton JD, 2004, LANCET, V364, P1916, DOI 10.1016/S0140-6736(04)17489-8; Sint TT, 2005, B WORLD HEALTH ORGAN, V83, P224; Taha TE, 1998, AIDS, V12, P197, DOI 10.1097/00002030-199802000-00010; US Preventive Serv Task Force, 2005, ANN INTERN MED, V143, P32, DOI 10.7326/0003-4819-143-1-200507050-00008; World Health Organization, 2002, PREV HIV INF YOUNG C	15	10	10	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	2005	366	9492					1141	1142		10.1016/S0140-6736(05)67458-2	http://dx.doi.org/10.1016/S0140-6736(05)67458-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970LK	16198749				2022-12-28	WOS:000232311300005
J	Heitman, J				Heitman, J			A fungal Achilles' heel	SCIENCE			English	Editorial Material							CANDIDA-ALBICANS; CYCLOSPORINE-A; CALCINEURIN; STRESS; HSP90; TOLERANCE; VIRULENCE; SURVIVAL		Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA	Duke University	Heitman, J (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.	heitm001@duke.edu	Heitman, Joseph/ABC-6006-2021					Bader T, 2003, INFECT IMMUN, V71, P5344, DOI 10.1128/IAI.71.9.5344-5354.2003; Blankenship JR, 2005, INFECT IMMUN, V73, P5767, DOI 10.1128/IAI.73.9.5767-5774.2005; Blankenship JR, 2003, EUKARYOT CELL, V2, P422, DOI 10.1128/EC.2.3.422-430.2003; Cowen LE, 2005, SCIENCE, V309, P2185, DOI 10.1126/science.1118370; Cruz MC, 2002, EMBO J, V21, P546, DOI 10.1093/emboj/21.4.546; Imai J, 2000, MOL CELL BIOL, V20, P9262, DOI 10.1128/MCB.20.24.9262-9270.2000; Ke HM, 2003, BIOCHEM BIOPH RES CO, V311, P1095, DOI 10.1016/S0006-291X(03)01537-7; Kumar R, 2005, MOL BIOCHEM PARASIT, V141, P29, DOI 10.1016/j.molbiopara.2005.01.012; Odom A, 1997, EMBO J, V16, P2576, DOI 10.1093/emboj/16.10.2576; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Sanglard D, 2003, MOL MICROBIOL, V48, P959, DOI 10.1046/j.1365-2958.2003.03495.x; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; White TC, 1998, CLIN MICROBIOL REV, V11, P382, DOI 10.1128/CMR.11.2.382; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Workman P, 2003, CURR CANCER DRUG TAR, V3, P297, DOI 10.2174/1568009033481868	16	32	34	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	2005	309	5744					2175	2176		10.1126/science.1119321	http://dx.doi.org/10.1126/science.1119321			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195450				2022-12-28	WOS:000232318000031
J	McGee, AW; Yang, YP; Fischer, QS; Daw, NW; Strittmatter, SM				McGee, AW; Yang, YP; Fischer, QS; Daw, NW; Strittmatter, SM			Experience-driven plasticity of visual cortex limited by myelin and Nogo receptor	SCIENCE			English	Article							OCULAR DOMINANCE PLASTICITY; SPINAL-CORD-INJURY; NEURITE GROWTH-INHIBITORS; AXONAL REGENERATION; CRITICAL-PERIOD; DEPENDENT PLASTICITY; OUTGROWTH INHIBITOR; CORTICAL PLASTICITY; FUNCTIONAL RECOVERY; GLYCOPROTEIN	Monocular deprivation normally alters ocular dominance in the visual cortex only during a postnatal critical period (20 to 32 days postnatal in mice). We find that mutations in the Nogo-66 receptor (NgR) affect cessation of ocular dominance plasticity. in NgR(-/-) mice, plasticity during the critical period is normal, but it continues abnormally such that ocular dominance at 45 or 120 days postnatal is subject to the same plasticity as at juvenile ages. Thus, physiological NgR signaling from myelin-derived Nogo, MAG, and OMgp consolidates the neural circuitry established during experience-dependent plasticity. After pathological trauma, similar NgR signaling limits functional recovery and axonal regeneration.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06520 USA	Yale University; Yale University	Strittmatter, SM (corresponding author), Yale Univ, Sch Med, Dept Neurol, 333 Cedar St, New Haven, CT 06520 USA.	stephen.strittmatter@yale.edu	Yang, Yupeng/G-5107-2018; Strittmatter, Stephen/F-5739-2011	Yang, Yupeng/0000-0002-9473-9994; Strittmatter, Stephen/0000-0001-8188-3092; Fischer, Quentin/0000-0002-7803-1179	NINDS NIH HHS [R01 NS039962-10, R01 NS056485, R37 NS033020, R01 NS042304, R37 NS033020-15, R01 NS056485-04, R01 NS039962, R01 NS042304-08] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042304, R37NS033020, R01NS056485, R01NS039962] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; DAW N, 1995, VISUAL DEV; DEFELIPE J, 1985, J NEUROSCI, V5, P3246; Fagiolini M, 2004, SCIENCE, V303, P1681, DOI 10.1126/science.1091032; Fagiolini M, 2000, NATURE, V404, P183, DOI 10.1038/35004582; Fischer QS, 2004, J NEUROSCI, V24, P9049, DOI 10.1523/JNEUROSCI.2409-04.2004; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Frenkel MY, 2004, NEURON, V44, P917, DOI 10.1016/j.neuron.2004.12.003; Gordon JA, 1996, J NEUROSCI, V16, P3274; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; Kim JE, 2003, NEURON, V38, P187, DOI 10.1016/S0896-6273(03)00147-8; Kim JE, 2004, NEURON, V44, P439, DOI 10.1016/j.neuron.2004.10.015; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Li SX, 2004, J NEUROSCI, V24, P10511, DOI 10.1523/JNEUROSCI.2828-04.2004; Mataga N, 2004, NEURON, V44, P1031, DOI 10.1016/j.neuron.2004.11.028; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Morales B, 2002, J NEUROSCI, V22, P8084; MOWER GD, 1991, DEV BRAIN RES, V58, P151, DOI 10.1016/0165-3806(91)90001-Y; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Pham TA, 2004, LEARN MEMORY, V11, P738, DOI 10.1101/lm.75304; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Rebsam A, 2005, J NEUROSCI, V25, P706, DOI 10.1523/JNEUROSCI.4191-04.2005; Sawtell NB, 2003, NEURON, V38, P977, DOI 10.1016/S0896-6273(03)00323-4; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Simonen M, 2003, NEURON, V38, P201, DOI 10.1016/S0896-6273(03)00226-5; SOMOGYI P, 1986, NEUROSCIENCE, V19, P1051, DOI 10.1016/0306-4522(86)90122-3; Tagawa Y, 2005, NAT NEUROSCI, V8, P380, DOI 10.1038/nn1410; Taha S, 2002, NEURON, V36, P483, DOI 10.1016/S0896-6273(02)00966-2; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3	38	457	477	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	2005	309	5744					2222	2226		10.1126/science.1114362	http://dx.doi.org/10.1126/science.1114362			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195464	Green Accepted			2022-12-28	WOS:000232318000046
J	Markwell, H				Markwell, H			End-of-life: a Catholic view	LANCET			English	Editorial Material									St Michaels Hosp, Ctr Clin Eth, Toronto, ON M6R 1B5, Canada; St Josephs Hlth Ctr, Toronto, ON M6R 1B5, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Joseph's Health Centre, Toronto; Western University (University of Western Ontario)	Markwell, H (corresponding author), St Michaels Hosp, Ctr Clin Eth, 30 Queensway, Toronto, ON M6R 1B5, Canada.	markwellh@smh.toronto.on.ca						BROCK I, 1997, DYING WELL PROSPECT, P59; *CATH HLTH ASS CAN, 2001, HLTH ETH GUID, P11; CRONIN DA, 1958, MORAL LAW REGARD ORD, P471; FLANNERY A, 1988, VATICAN COUNCIL 2 CO, P905; FLANNERY A, 1988, VATICAN COUNCIL 2 CO, P903; Katz Jay, 2002, SILENT WORLD DOCTOR; KELLY G, 1958, MEDICOMORAL PROBLEMS, P129; MAY WF, 1983, PHYSICIANS COVENANT, P109; MAY WF, 1994, HASTINGS CTR REP MAY; NOUWEN H, 1994, OUR GREATEST GIFT ME, P32; PELLEGRINO ED, 1997, HELPING HEALING RELI, P45; RAMSAY P, 1978, ETHICS EDGES LIFE; ROCHE J, 2000, FACING DEATH DISCOVE, P16; Singer PA, 2002, BMJ-BRIT MED J, V324, P1291, DOI 10.1136/bmj.324.7349.1291; Singer PA, 2001, BMC MED ETHICS, V2, P1, DOI DOI 10.1186/1472-6939-2-1; Sulmasy DP, 1999, ARCH INTERN MED, V159, P545, DOI 10.1001/archinte.159.6.545; *VAT 2, SACR CONC, V22; WILDES KW, 1997, CHOOSING LIFE DIALOG; 1999, BMJ, P318	19	33	34	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 24	2005	366	9491					1132	1135		10.1016/S0140-6736(05)67425-9	http://dx.doi.org/10.1016/S0140-6736(05)67425-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	967TL	16182902				2022-12-28	WOS:000232114000032
J	Medina-Elizalde, M; Lea, DW				Medina-Elizalde, M; Lea, DW			The mid-Pleistocene transition in the tropical Pacific	SCIENCE			English	Article							CLIMATE TRANSITION; ICE VOLUME; TEMPERATURE; CYCLE; EVOLUTION; ONSET; CORE	A sea surface temperature (SST) record based on planktonic foraminiferal magnesium/calcium ratios from a site in the western equatorial Pacific warm pool reveals that glacial-interglacial oscillations in SST shifted from a period of 41,000 to 100,000 years at the mid-Pleistocene transition, 950,000 years before the present. SST changes at both periodicities were synchronous with eastern Pacific cold-tongue SSTs but preceded changes in continental ice volume. The timing and nature of tropical Pacific SST changes over the mid-Pleistocene transition implicate a shift in the periodicity of radiative forcing by atmospheric carbon dioxide as the cause of the switch in climate periodicities at this time.	Univ Calif Santa Barbara, Dept Earth Sci, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Interdept Program Marine Sci, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Inst Marine Sci, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Lea, DW (corresponding author), Univ Calif Santa Barbara, Dept Earth Sci, Santa Barbara, CA 93106 USA.	lea@geol.ucsb.edu						Ashkenazy Y, 2004, QUATERNARY SCI REV, V23, P1879, DOI 10.1016/j.quascirev.2004.04.008; Augustin L, 2004, NATURE, V429, P623, DOI 10.1038/nature02599; Bemis BE, 1998, PALEOCEANOGRAPHY, V13, P150, DOI 10.1029/98PA00070; Berger A, 1999, QUATERNARY SCI REV, V18, P1, DOI 10.1016/S0277-3791(98)00033-X; BERGER WH, 1993, P OCEAN DRILLING PRO, V0130; Broccoli AJ, 2000, J CLIMATE, V13, P951, DOI 10.1175/1520-0442(2000)013<0951:TCATLG>2.0.CO;2; Cane MA, 2005, EARTH PLANET SC LETT, V230, P227, DOI 10.1016/j.epsl.2004.12.003; Clark PU, 1998, PALEOCEANOGRAPHY, V13, P1, DOI 10.1029/97PA02660; de Garidel-Thoron T, 2005, NATURE, V433, P294, DOI 10.1038/nature03189; Huybers P, 2005, NATURE, V434, P491, DOI 10.1038/nature03401; Lea DW, 2000, SCIENCE, V289, P1719, DOI 10.1126/science.289.5485.1719; Lea DW, 2004, J CLIMATE, V17, P2170, DOI 10.1175/1520-0442(2004)017<2170:TYCITS>2.0.CO;2; Liu ZH, 2004, NATURE, V427, P720, DOI 10.1038/nature02338; McClymont EL, 2005, GEOLOGY, V33, P389, DOI 10.1130/G21292.1; Mix A.C., 1995, Proceedings of the Ocean Drilling Program Scientific Results, V138, P371, DOI 10.2973/odp.proc.sr.138.120.1995; Mix A.C., 1995, Proceedings of the Ocean Drilling Program Scientific Results, V138, P839, DOI 10.2973/odp.proc.sr.138.160.1995; Mudelsee M, 1997, EARTH PLANET SC LETT, V151, P117, DOI 10.1016/S0012-821X(97)00114-3; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Philander SG, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000837; PISIAS NG, 1981, EARTH PLANET SC LETT, V52, P450, DOI 10.1016/0012-821X(81)90197-7; Saltzman B., 2002, DYNAMICAL PALEOCLIMA; Shackleton NJ, 2000, SCIENCE, V289, P1897, DOI 10.1126/science.289.5486.1897; SHACKLETON NJ, 1990, T ROY SOC EDIN-EARTH, V81, P251, DOI 10.1017/S0263593300020782; Sobel AH, 2002, J CLIMATE, V15, P2702, DOI 10.1175/1520-0442(2002)015<2702:TESITT>2.0.CO;2	24	157	172	3	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2005	310	5750					1009	1012		10.1126/science.1115933	http://dx.doi.org/10.1126/science.1115933			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16223985				2022-12-28	WOS:000233343400041
J	Baillat, D; Hakimi, MA; Naar, AM; Shilatifard, A; Cooch, N; Shiekhattar, R				Baillat, D; Hakimi, MA; Naar, AM; Shilatifard, A; Cooch, N; Shiekhattar, R			Integrator, a multiprotein mediator of small nuclear RNA processing, associates with the C-terminal repeat of RNA polymerase II	CELL			English	Article							3' END; BRCA2; INTERACTS; PROTEIN; RAD51; DOMAIN; RECOMBINATION; TRANSCRIPTION; INVOLVEMENT; PRECURSORS	The C-terminal domain (CTD) of RNA polymerase 11 (RNAPII) is an essential component of transcriptional regulation and RNA processing of protein-coding genes. A large body of data also implicates the CTD in the transcription and processing of RNAPII-mediated small nuclear RNAs (snRNAs). However, the identity of the complex (or complexes) that associates with the CTD and mediates the processing of snRNAs has remained elusive. Here, we describe an RNA polymerase 11 complex that contains at least 12 novel subunits, termed the Integrator, in addition to core RNAPII subunits. Two of the Integrator subunits display similarities to the subunits of the cleavage and polyadenylation specificity factor (CPSF) complex. We show that Integrator is recruited to the U1 and U2 snRNA genes and mediates the snRNAs' 3' end processing. The Integrator complex is evolutionarily conserved in metazoans and directly interacts with the C-terminal domain of the RNA polymerase 11 largest subunit.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Grenoble 1, CNRS, UMR 5163, F-38700 La Tronche, France; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; St Louis Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	The Wistar Institute; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Harvard University; Harvard University; Massachusetts General Hospital; Saint Louis University	Shiekhattar, R (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	shiekhattar@wistar.upenn.edu	HAKIMI, Mohamed-ali/GYJ-0879-2022; HAKIMI, Mohamed-Ali/F-9806-2014; HAKIMI, Mohamed-ali/Q-6475-2019	HAKIMI, Mohamed-Ali/0000-0002-2547-8233; HAKIMI, Mohamed-ali/0000-0002-2547-8233				Bjorklund S, 2004, ADV PROTEIN CHEM, V67, P43; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; DEVEGVAR HEN, 1986, CELL, V47, P259; Dominski Z, 2005, MOL CELL BIOL, V25, P1489, DOI 10.1128/MCB.25.4.1489-1500.2005; ELICEIRI GL, 1976, BIOCHEM BIOPH RES CO, V72, P507, DOI 10.1016/S0006-291X(76)80070-8; Funakoshi M, 2004, J CELL SCI, V117, P6447, DOI 10.1242/jcs.01575; Fury MG, 1996, EXP CELL RES, V228, P160, DOI 10.1006/excr.1996.0311; Gerber M, 2001, EMBO J, V20, P6104, DOI 10.1093/emboj/20.21.6104; HERNANDEZ N, 1986, CELL, V47, P249, DOI 10.1016/0092-8674(86)90447-2; HERNANDEZ N, 1985, EMBO J, V4, P1827, DOI 10.1002/j.1460-2075.1985.tb03857.x; Jacobs EY, 2004, MOL CELL BIOL, V24, P846, DOI 10.1128/MCB.24.2.846-855.2004; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLEINSCHMIDT AM, 1987, MOL CELL BIOL, V7, P3131, DOI 10.1128/MCB.7.9.3131; Kojic M, 2005, MOL CELL BIOL, V25, P2547, DOI 10.1128/MCB.25.7.2547-2557.2005; Kojic M, 2003, MOL CELL, V12, P1043, DOI 10.1016/S1097-2765(03)00367-8; Krogan NJ, 2004, MOL CELL, V16, P1027, DOI 10.1016/j.molcel.2004.11.033; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; Medlin JE, 2003, EMBO J, V22, P925, DOI 10.1093/emboj/cdg077; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Naar AM, 2002, GENE DEV, V16, P1339, DOI 10.1101/gad.987602; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Ryan K, 2004, RNA, V10, P565, DOI 10.1261/rna.5214404; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sone T, 2004, J BIOL CHEM, V279, P28807, DOI 10.1074/jbc.M403165200; Uguen P, 2003, EMBO J, V22, P4544, DOI 10.1093/emboj/cdg430; WIEBEN ED, 1985, J MOL BIOL, V183, P69, DOI 10.1016/0022-2836(85)90281-5; Wieland I, 2004, ONCOL REP, V12, P207; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; YOU CY, 1985, CELL, V1, P193	33	334	358	3	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	2005	123	2					265	276		10.1016/j.cell.2005.08.019	http://dx.doi.org/10.1016/j.cell.2005.08.019			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239144	Bronze			2022-12-28	WOS:000232794100013
J	Claypool, SM; Koehler, CM				Claypool, SM; Koehler, CM			Hereditary spastic paraplegia: Respiratory choke or unactivated substrate?	CELL			English	Editorial Material							M-AAA PROTEASE; MITOCHONDRIA; METALLOPROTEASE; IMPAIRMENT; MEMBRANE; COMPLEX	Defects in the mitochondrial AAA protease family member, paraplegin, result in an autosomal recessive form of hereditary spastic paraplegia (HSP). In this issue of Cell, Nolden et al. (2005) report a new molecular mechanism for HSP based on the requirement of paraplegin for the proteolysis of a specific mitochondrial ribosomal protein. The processing of this substrate is required for robust translation in mitochondria.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Claypool, SM (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Box 951569, Los Angeles, CA 90095 USA.			Claypool, Steven/0000-0001-5316-1623				Arlt H, 1998, EMBO J, V17, P4837, DOI 10.1093/emboj/17.16.4837; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; Arnold I, 2002, BBA-MOL CELL RES, V1592, P89, DOI 10.1016/S0167-4889(02)00267-7; Atorino L, 2003, J CELL BIOL, V163, P777, DOI 10.1083/jcb.200304112; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; Ferreirinha F, 2004, J CLIN INVEST, V113, P231, DOI 10.1172/JCI200420138; Hansen JJ, 2002, AM J HUM GENET, V70, P1328, DOI 10.1086/339935; Nolden M, 2005, CELL, V123, P277, DOI 10.1016/j.cell.2005.08.003; Shah ZH, 2000, FEBS LETT, V478, P267, DOI 10.1016/S0014-5793(00)01859-7	9	3	3	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 21	2005	123	2					183	185		10.1016/j.cell.2005.10.006	http://dx.doi.org/10.1016/j.cell.2005.10.006			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239134	Bronze			2022-12-28	WOS:000232794100003
J	Zhang, HY; Roberts, DN; Cairns, BR				Zhang, HY; Roberts, DN; Cairns, BR			Genome-wide dynamics of Htz1, a histone H2A variant that poises repressed/basal promoters for activation through histone loss	CELL			English	Article							CHROMATIN REMODELING COMPLEX; INACTIVE X-CHROMOSOME; SACCHAROMYCES-CEREVISIAE; EUKARYOTIC GENOME; GENE-EXPRESSION; H4 ACETYLATION; NUCLEOSOME; YEAST; HETEROCHROMATIN; OCCUPANCY	Histone variants help specialize chromatin regions; however, their impact on transcriptional regulation is largely unknown. Here, we determined the genome-wide localization and dynamics of Htz1, the yeast histone H2A variant. Htz1 localizes to hundreds of repressed/basal Pol II promoters and prefers TATA-less promoters' Specific Htz1 deposition requires the SWR1 complex, which largely colocalizes with Htz1. Htz1 occupancy correlates with particular histone modifications, and Htz1 deposition is partially reliant on Gcn5 (a histone acetyltransferase) and Bdf1, an SWR1 complex member that binds acetylated histones. Changes in growth conditions cause a striking redistribution of Htz1 from activated to repressed/basal promoters. Furthermore, Htz1 promotes full gene activation but does not generally impact repression. Importantly, Htz1 releases from purified chromatin in vitro under conditions where H2A and H3 remain associated. We suggest that Htz1 bearing nucleosomes are deposited at repressed/basal promoters but facilitate activation through their susceptibility to loss, thereby helping to expose promoter DNA.	Univ Utah, Sch Med, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Cairns, BR (corresponding author), Univ Utah, Sch Med, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA.	brad.cairns@hci.utah.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060415] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [CA24014] Funding Source: Medline; NIGMS NIH HHS [R01 GM060415-05, R01 GM060415, GM60415] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott DW, 2001, J BIOL CHEM, V276, P41945, DOI 10.1074/jbc.M108217200; Adam M, 2001, MOL CELL BIOL, V21, P6270, DOI 10.1128/MCB.21.18.6270-6279.2001; Ahmad K, 2002, P NATL ACAD SCI USA, V99, P16477, DOI 10.1073/pnas.172403699; Basehoar AD, 2004, CELL, V116, P699, DOI 10.1016/S0092-8674(04)00205-3; Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; Chadwick BP, 2001, J CELL BIOL, V152, P375, DOI 10.1083/jcb.152.2.375; Costanzi C, 2000, DEVELOPMENT, V127, P2283; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; Fan JY, 2004, MOL CELL, V16, P655, DOI 10.1016/j.molcel.2004.10.023; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Henikoff S, 2004, TRENDS GENET, V20, P320, DOI 10.1016/j.tig.2004.05.004; Henikoff S, 2000, P NATL ACAD SCI USA, V97, P716, DOI 10.1073/pnas.97.2.716; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Jackson JD, 1996, TRENDS BIOCHEM SCI, V21, P466, DOI 10.1016/S0968-0004(96)20028-3; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kamakaka RT, 2005, GENE DEV, V19, P295, DOI 10.1101/gad.1272805; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Krogan NJ, 2004, P NATL ACAD SCI USA, V101, P13513, DOI 10.1073/pnas.0405753101; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Larochelle M, 2003, EMBO J, V22, P4512, DOI 10.1093/emboj/cdg427; Leach TJ, 2000, J BIOL CHEM, V275, P23267, DOI 10.1074/jbc.M910206199; Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400; Matangkasombut O, 2000, GENE DEV, V14, P951; Matangkasombut O, 2003, MOL CELL, V11, P353, DOI 10.1016/S1097-2765(03)00033-9; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Owen-Hughes T, 2003, BIOCHEM SOC T, V31, P893; Park YJ, 2004, J BIOL CHEM, V279, P24274, DOI 10.1074/jbc.M313152200; Rangasamy D, 2003, EMBO J, V22, P1599, DOI 10.1093/emboj/cdg160; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Ren QH, 2001, MOL CELL, V7, P1329, DOI 10.1016/S1097-2765(01)00269-6; Roberts DN, 2003, P NATL ACAD SCI USA, V100, P14695, DOI 10.1073/pnas.2435566100; Santisteban MS, 2000, CELL, V103, P411, DOI 10.1016/S0092-8674(00)00133-1; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; Smith MM, 2002, CURR OPIN CELL BIOL, V14, P279, DOI 10.1016/S0955-0674(02)00331-9; STARGELL LA, 1993, GENE DEV, V7, P2641, DOI 10.1101/gad.7.12b.2641; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; Wyrick JJ, 2001, SCIENCE, V294, P2357, DOI 10.1126/science.1066101; Zanton SJ, 2004, P NATL ACAD SCI USA, V101, P16843, DOI 10.1073/pnas.0404988101; Zhang HY, 2004, MOL CELL BIOL, V24, P9424, DOI 10.1128/MCB.24.21.9424-9436.2004	48	379	388	0	15	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 21	2005	123	2					219	231		10.1016/j.cell.2005.08.036	http://dx.doi.org/10.1016/j.cell.2005.08.036			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239141	Green Accepted, Bronze			2022-12-28	WOS:000232794100010
J	Zingmond, DS; McGory, ML; Ko, CY				Zingmond, DS; McGory, ML; Ko, CY			Hospitalization before and after gastric bypass surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORBIDLY OBESE-PATIENTS; BARIATRIC SURGERY; COST-EFFECTIVENESS; CARE; METAANALYSIS; OUTCOMES; IMPACT	Context The use of Roux-en-Y gastric bypass (RYGB) has been reported to be effective in the treatment of obesity and its related comorbidities. Utilization of inpatient services after RYGB is less well understood. Objective To determine the rates and indications for inpatient hospital use before and after RYGB. Design, Setting, and Participants Retrospective study of Californians receiving RYGB in California hospitals from 1995 to 2004. Main Outcome Measure Hospitalization in the 1 to 3 years after RYGB. Results In California from 1995 to 2004, 60077 patients underwent RYGB - 11659 in 2004 alone. The rate of hospitalization in the year following RYGB was more than double the rate in the year preceding RYGB (19.3% vs 7.9%, P<.001). Furthermore, in the subset of patients (n = 24 678) with full 3-year follow-up, a mean of 8.4% were admitted a year before RYGB while 20.2% were readmitted in the year after RYGB, 18.4% in the second year after RYGB, and 14.9% in the third year after RYGB. The most common reasons for admission prior to RYGB were obesity-related problems (eg, osteoarthritis, lower extremity cellulitis), and elective operation (eg, hysterectomy), while the most common reasons for admission after RYGB were complications often thought to be procedure related, such as ventral hernia repair and gastric revision. In multivariate logistic regression models predicting 1-year readmission after RYGB, increasing Charlson Comorbidity Index score, and hospitalization in the 3-year period prior to RYGB were significantly associated with readmission within a year. Conclusions Increases in hospital use after surgery appear to be related to RYGB. Payers, clinicians, and patients must consider the not-inconsequential rate of rehospitalization after this type of surgery.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Ctr Surg Outcomes & Qual, Los Angeles, CA USA; W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Zingmond, DS (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, 911 Broxton Plaza, Los Angeles, CA 90095 USA.	dzingmond@mednet.ucla.edu			NATIONAL INSTITUTE ON AGING [K08AG023024] Funding Source: NIH RePORTER; NIA NIH HHS [K08 AG023024-01A1] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agren G, 2002, OBES RES, V10, P1276, DOI 10.1038/oby.2002.173; [Anonymous], 2004, WHAT WORKS OBESITY S; Buchwald H, 2004, JAMA-J AM MED ASSOC, V292, P1724, DOI 10.1001/jama.292.14.1724; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Christou NV, 2004, ANN SURG, V240, P416, DOI 10.1097/01.sla.0000137343.63376.19; Clegg A, 2003, INT J OBESITY, V27, P1167, DOI 10.1038/sj.ijo.0802394; Craig BM, 2002, AM J MED, V113, P491, DOI 10.1016/S0002-9343(02)01266-4; *CTR MED MED SERV, 2003, NAT HLTH DOLL 2003 W; Flum DR, 2004, J AM COLL SURGEONS, V199, P543, DOI 10.1016/j.jamcollsurg.2004.06.014; Liu JH, 2003, AM SURGEON, V69, P823; Maggard MA, 2005, ANN INTERN MED, V142, P547, DOI 10.7326/0003-4819-142-7-200504050-00013; Narbro K, 2002, ARCH INTERN MED, V162, P2061, DOI 10.1001/archinte.162.18.2061; Podnos YD, 2003, ARCH SURG-CHICAGO, V138, P957, DOI 10.1001/archsurg.138.9.957; Pope GD, 2002, J GASTROINTEST SURG, V6, P855, DOI 10.1016/S1091-255X(02)00085-9; Sampalis JS, 2004, OBES SURG, V14, P939, DOI 10.1381/0960892041719662; Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622; Snow V, 2005, ANN INTERN MED, V142, P525, DOI 10.7326/0003-4819-142-7-200504050-00011; Steinbrook R, 2004, NEW ENGL J MED, V350, P1075, DOI 10.1056/NEJMp048029; Zingmond DS, 2004, J CLIN EPIDEMIOL, V57, P21, DOI 10.1016/S0895-4356(03)00250-6	19	149	151	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	2005	294	15					1918	1924		10.1001/jama.294.15.1918	http://dx.doi.org/10.1001/jama.294.15.1918			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974OZ	16234498	Bronze			2022-12-28	WOS:000232602600021
J	Religa, TL; Markson, JS; Mayor, U; Freund, SMV; Fersht, AR				Religa, TL; Markson, JS; Mayor, U; Freund, SMV; Fersht, AR			Solution structure of a protein denatured state and folding intermediate	NATURE			English	Article							LONG-RANGE STRUCTURE; PARAMAGNETIC RELAXATION; STAPHYLOCOCCAL NUCLEASE; ENGRAILED HOMEODOMAIN; BACKBONE DYNAMICS; SH3 DOMAIN; NMR; PATHWAY	The most controversial area in protein folding concerns its earliest stages. Questions such as whether there are genuine folding intermediates, and whether the events at the earliest stages are just rearrangements of the denatured state(1) or progress from populated transition states(2), remain unresolved. The problem is that there is a lack of experimental high-resolution structural information about early folding intermediates and denatured states under conditions that favour folding because competent states spontaneously fold rapidly. Here we have solved directly the solution structure of a true denatured state by nuclear magnetic resonance under conditions that would normally favour folding, and directly studied its equilibrium and kinetic behaviour. We engineered a mutant of Drosophila melanogaster Engrailed homeodomain that folds and unfolds reversibly just by changing ionic strength. At high ionic strength, the mutant L16A is an ultra-fast folding native protein, just like the wild-type protein; however, at physiological ionic strength it is denatured. The denatured state is a well-ordered folding intermediate, poised to fold by docking helices and breaking some non-native interactions. It unfolds relatively progressively with increasingly denaturing conditions, and so superficially resembles a denatured state with properties that vary with conditions. Such ill-defined unfolding is a common feature of early folding intermediate states and accounts for why there are so many controversies about intermediates versus compact denatured states in protein folding.	MRC Ctr, Ctr Prot Engn, Cambridge CB2 2QH, England; Univ Cambridge, MRC Ctr, Chem Labs, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology; University of Cambridge; MRC Laboratory Molecular Biology; University of Cambridge	Fersht, AR (corresponding author), MRC Ctr, Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.	arf25@cam.ac.uk	Fersht, Alan R/B-2189-2008; Mayor, Ugo/F-5890-2011	Markson, Joseph/0000-0002-3167-3887; Mayor, Ugo/0000-0003-2812-8287				Bonvin AMJJ, 1996, J BIOMOL NMR, V7, P72; BONVIN AMJJ, 1995, J MOL BIOL, V250, P80, DOI 10.1006/jmbi.1995.0360; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CLARKE ND, 1994, PROTEIN SCI, V3, P1779, DOI 10.1002/pro.5560031018; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; Dyson HJ, 2001, METHOD ENZYMOL, V339, P258; FARROW NA, 1995, J BIOMOL NMR, V6, P153, DOI 10.1007/BF00211779; FARROW NA, 1995, BIOCHEMISTRY-US, V34, P868, DOI 10.1021/bi00003a021; Fushman D, 1998, J AM CHEM SOC, V120, P10947, DOI 10.1021/ja981686m; Gillespie JR, 1997, J MOL BIOL, V268, P158, DOI 10.1006/jmbi.1997.0954; Gillespie JR, 1997, J MOL BIOL, V268, P170, DOI 10.1006/jmbi.1997.0953; ISHIMA R, 1995, BIOCHEMISTRY-US, V34, P3162, DOI 10.1021/bi00010a005; Koharudin LMI, 2003, J MAGN RESON, V163, P228, DOI 10.1016/S1090-7807(03)00149-6; Korzhnev DM, 2004, NATURE, V430, P586, DOI 10.1038/nature02655; Krantz BA, 2002, J MOL BIOL, V324, P359, DOI 10.1016/S0022-2836(02)01029-X; Mayor U, 2003, NATURE, V421, P863, DOI 10.1038/nature01428; Mayor U, 2003, J MOL BIOL, V333, P977, DOI 10.1016/j.jmb.2003.08.062; Mohana-Borges R, 2004, J MOL BIOL, V340, P1131, DOI 10.1016/j.jmb.2004.05.022; Mok YK, 1999, J MOL BIOL, V289, P619, DOI 10.1006/jmbi.1999.2769; NERI D, 1992, SCIENCE, V257, P1559, DOI 10.1126/science.1523410; Oliveberg M, 1996, BIOCHEMISTRY-US, V35, P2738, DOI 10.1021/bi950967t; Rios MAD, 2005, BIOCHEMISTRY-US, V44, P1243, DOI 10.1021/bi0484441; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yang WY, 2003, NATURE, V423, P193, DOI 10.1038/nature01609	24	211	215	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	2005	437	7061					1053	1056		10.1038/nature04054	http://dx.doi.org/10.1038/nature04054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16222301				2022-12-28	WOS:000232496100051
J	Schefuss, E; Schouten, S; Schneider, RR				Schefuss, E; Schouten, S; Schneider, RR			Climatic controls on central African hydrology during the past 20,000 years	NATURE			English	Article							SEA-SURFACE TEMPERATURE; RAINFALL VARIABILITY; SOUTH-ATLANTIC; ISOTOPES; TERRESTRIAL; CIRCULATION; CALIBRATION; EQUATORIAL; DYNAMICS; HYDROGEN	Past hydrological changes in Africa have been linked to various climatic processes, depending on region and timescale. Long-term precipitation changes in the regions of northern and southern Africa influenced by the monsoons are thought to have been governed by precessional variations in summer insolation(1,2). Conversely, short-term precipitation changes in the northern African tropics have been linked to North Atlantic sea surface temperature anomalies, affecting the northward extension of the Intertropical Convergence Zone and its associated rainbelt(3,4). Our knowledge of large-scale hydrological changes in equatorial Africa and their forcing factors is, however, limited(5). Here we analyse the isotopic composition of terrigenous plant lipids, extracted from a marine sediment core close to the Congo River mouth, in order to reconstruct past central African rainfall variations and compare this record to sea surface temperature changes in the South Atlantic Ocean. We find that central African precipitation during the past 20,000 years was mainly controlled by the difference in sea surface temperatures between the tropics and subtropics of the South Atlantic Ocean, whereas we find no evidence that changes in the position of the Intertropical Convergence Zone had a significant influence on the overall moisture availability in central Africa. We conclude that changes in ocean circulation, and hence sea surface temperature patterns, were important in modulating atmospheric moisture transport onto the central African continent.	Univ Bremen, DFG Res Ctr Ocean Margins, D-28359 Bremen, Germany; Royal Netherlands Inst Sea Res, NL-1790 AB Den Burg, Texel, Netherlands; Univ Kiel, Inst Geowissensch, D-24118 Kiel, Germany	German Research Foundation (DFG); University of Bremen; Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ); University of Kiel	Schefuss, E (corresponding author), Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA.	eschefuss@whoi.edu	Schefuß, Enno/A-7101-2015	Schefuß, Enno/0000-0002-5960-930X; Schneider, Ralph/0000-0003-1453-9181				Bard E, 1998, GEOCHIM COSMOCHIM AC, V62, P2025, DOI 10.1016/S0016-7037(98)00130-6; Bemis BE, 1998, PALEOCEANOGRAPHY, V13, P150, DOI 10.1029/98PA00070; Camberlin P, 2001, INT J CLIMATOL, V21, P973, DOI 10.1002/joc.673; Chikaraishi Y, 2004, PHYTOCHEMISTRY, V65, P1369, DOI 10.1016/j.phytochem.2004.03.036; DANSGAARD W, 1964, TELLUS, V16, P436; EGLINTON G, 1967, SCIENCE, V156, P1322, DOI 10.1126/science.156.3780.1322; FAIRBANKS RG, 1992, RADIOCARBON AFTER FOUR DECADES, P473; Gasse F, 2000, QUATERNARY SCI REV, V19, P189, DOI 10.1016/S0277-3791(99)00061-X; HASTENRATH S, 1990, INT J CLIMATOL, V10, P459, DOI 10.1002/joc.3370100504; Jouzel J, 2000, QUATERNARY SCI REV, V19, P363, DOI 10.1016/S0277-3791(99)00069-4; Kim JH, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017557; Kutzbach JE, 1997, SCIENCE, V278, P440, DOI 10.1126/science.278.5337.440; Levitus S., 1994, WORLD OCEAN ATLAS 19, V4; LINDZEN RS, 1987, J ATMOS SCI, V44, P2418, DOI 10.1175/1520-0469(1987)044<2418:OTROSS>2.0.CO;2; Maley J, 1998, REV PALAEOBOT PALYNO, V99, P157, DOI 10.1016/S0034-6667(97)00047-X; Manabe S, 1997, PALEOCEANOGRAPHY, V12, P321, DOI 10.1029/96PA03932; Muller PJ, 1998, GEOCHIM COSMOCHIM AC, V62, P1757, DOI 10.1016/S0016-7037(98)00097-0; Nicholson SE, 2000, GLOBAL PLANET CHANGE, V26, P137, DOI 10.1016/S0921-8181(00)00040-0; NICHOLSON SE, 1987, J CLIM APPL METEOROL, V26, P561, DOI 10.1175/1520-0450(1987)026<0561:RVIEAS>2.0.CO;2; Partridge TC, 1997, QUATERNARY SCI REV, V16, P1125, DOI 10.1016/S0277-3791(97)00005-X; Ruhlemann C, 2004, PALEOCEANOGRAPHY, V19, DOI 10.1029/2003PA000948; SANGANGOIE K, 1996, J GEOPHYS RES, V101, P21351; Sauer PE, 2001, GEOCHIM COSMOCHIM AC, V65, P213, DOI 10.1016/S0016-7037(00)00520-2; SCHNEIDER RR, 1995, PALEOCEANOGRAPHY, V10, P197, DOI 10.1029/94PA03308; Sessions AL, 1999, ORG GEOCHEM, V30, P1193, DOI 10.1016/S0146-6380(99)00094-7; Steig EJ, 2001, SCIENCE, V293, P2015, DOI 10.1126/science.1061941; Still CJ, 2003, GLOBAL BIOGEOCHEM CY, V17, DOI 10.1029/2001GB001807; STREETPERROTT FA, 1990, NATURE, V343, P607, DOI 10.1038/343607a0; Stuiver M, 1998, RADIOCARBON, V40, P1127, DOI 10.1017/S0033822200019172; Stuiver M, 2000, QUATERNARY RES, V53, P277, DOI 10.1006/qres.2000.2127	30	349	365	2	107	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	2005	437	7061					1003	1006		10.1038/nature03945	http://dx.doi.org/10.1038/nature03945			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16222296				2022-12-28	WOS:000232496100041
J	Freemantle, N				Freemantle, N			How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?	BRITISH MEDICAL JOURNAL			English	Editorial Material							TRIALS		Univ Birmingham, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Freemantle, N (corresponding author), Univ Birmingham, Birmingham B15 2TT, W Midlands, England.	N.Freemande@bham.ac.uk		Freemantle, Nick/0000-0001-5807-5740				Fisher LD, 1999, CONTROL CLIN TRIALS, V20, P16, DOI 10.1016/S0197-2456(98)00054-3; Freemantle N, 2003, JAMA-J AM MED ASSOC, V289, P2554, DOI 10.1001/jama.289.19.2554; Freemantle N, 2001, BRIT MED J, V322, P989, DOI 10.1136/bmj.322.7292.989	3	30	32	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 8	2005	331	7520					836	838		10.1136/bmj.331.7520.836	http://dx.doi.org/10.1136/bmj.331.7520.836			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974BC	16210286	Green Published			2022-12-28	WOS:000232565300028
J	Norman, KR; Fazzio, RT; Mellem, JE; Espelt, MV; Strange, K; Beckerle, MC; Maricq, AV				Norman, KR; Fazzio, RT; Mellem, JE; Espelt, MV; Strange, K; Beckerle, MC; Maricq, AV			The Rho/Rac-family guanine nucleotide exchange factor VAV-1 regulates rhythmic behaviors in C-elegans	CELL			English	Article							CAENORHABDITIS-ELEGANS; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; MOSAIC ANALYSIS; B-CELLS; HOMOLOG; PROTEINS; ACTIVATION; RECEPTORS; PATHWAYS	Rhythmic behaviors are a fundamental feature of all organisms. Pharyngeal pumping, the defecation cycle, and gonadal-sheath-cell contractions are three well-characterized rhythmic behaviors in the nematode C. elegans. The periodicities of the rhythms range from subsecond (pharynx) to seconds (gonadal sheath) to minutes (defecation). However, the molecular mechanisms underlying these rhythmic behaviors are not well understood. Here, we show that the C. elegans Rho/Rac-family guanine nucleotide exchange factor, VAV-1, which is homologous to the mammalian Vav proto-oncogene, has a crucial role in all three behaviors. vav-1 mutants die as larvae because VAV-1 function is required in the pharynx for synchronous contraction of the musculature. In addition, ovulation and the defecation cycle are abnormal and arrhythmic. We show that Rho/Rac-family GTPases and the signaling molecule inositol triphosphate (IP3) act downstream of VAV-1 signaling and that the VAV-1 pathway modulates rhythmic behaviors by dynamically regulating the concentration of intracellular Ca2+.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Inst Brain, Salt Lake City, UT 84112 USA; Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN 37232 USA	Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Vanderbilt University	Maricq, AV (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.	maricq@biology.utah.edu		Espelt, M Victoria/0000-0002-0388-7853	NCI NIH HHS [T32 CA93247] Funding Source: Medline; NHLBI NIH HHS [HL60591] Funding Source: Medline; NIGMS NIH HHS [F32 GM0066579-02, F32 GM066579] Funding Source: Medline; NINDS NIH HHS [NS35812, R01 NS035812] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA093247] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM066579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035812] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; Avery L, 1995, METHOD CELL BIOL, V48, P251; AVERY L, 1997, C ELEGANS, V2, P679, DOI [10.1101/087969532.33.679, DOI 10.1101/087969532.33.679]; Baylis HA, 1999, J MOL BIOL, V294, P467, DOI 10.1006/jmbi.1999.3229; Branicky R, 2001, GENETICS, V159, P997; Bui YK, 2002, MOL BIOL CELL, V13, P1641, DOI 10.1091/mbc.02-01-0008; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHEN WI, 1993, J BIOL CHEM, V268, P320; CHEN WN, 1993, J BIOL CHEM, V268, P13280; CHEN WN, 1994, J BIOL CHEM, V269, P32394; Clandinin TR, 1998, CELL, V92, P523, DOI 10.1016/S0092-8674(00)80945-9; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dal Santo P, 1999, CELL, V98, P757, DOI 10.1016/S0092-8674(00)81510-X; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Horner MA, 1998, GENE DEV, V12, P1947, DOI 10.1101/gad.12.13.1947; Hornstein I, 2003, ONCOGENE, V22, P6774, DOI 10.1038/sj.onc.1207027; Iwasaki K, 1997, TRENDS GENET, V13, P111, DOI 10.1016/S0168-9525(97)01059-7; Kalb JM, 1998, DEVELOPMENT, V125, P2171; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kerr R, 2000, NEURON, V26, P583, DOI 10.1016/S0896-6273(00)81196-4; Lee RYN, 1997, EMBO J, V16, P6066, DOI 10.1093/emboj/16.20.6066; Li SL, 2003, MOL BIOL CELL, V14, P2630, DOI 10.1091/mbc.E02-11-0716; LIU DWC, 1994, J NEUROSCI, V14, P1953; Lundquist EA, 2001, DEVELOPMENT, V128, P4475; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Maryon EB, 1996, J CELL BIOL, V134, P885, DOI 10.1083/jcb.134.4.885; McCarter J, 1997, DEV BIOL, V181, P121, DOI 10.1006/dbio.1996.8429; McCarter J, 1999, DEV BIOL, V205, P111, DOI 10.1006/dbio.1998.9109; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Movilla N, 1999, MOL CELL BIOL, V19, P7870; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; OKKEMA PG, 1993, GENETICS, V135, P385; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Phelan P, 2001, BIOESSAYS, V23, P388, DOI 10.1002/bies.1057; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Saci A, 2005, MOL CELL, V17, P205, DOI 10.1016/j.molcel.2004.12.012; SAKUBE Y, 1993, ANN NY ACAD SCI, V707, P540, DOI 10.1111/j.1749-6632.1993.tb38121.x; Schuebel KE, 1996, ONCOGENE, V13, P363; SIMMER F, 2003, PLOS BIOL, pE12, DOI DOI 10.1317/JOURNAL.PBIO.0000012; Starich T, 2001, CELL COMMUN ADHES, V8, P311, DOI 10.3109/15419060109080744; Starich TA, 1996, J CELL BIOL, V134, P537, DOI 10.1083/jcb.134.2.537; THOMAS JH, 1990, GENETICS, V124, P855; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; TRENT C, 1983, GENETICS, V104, P619; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Walker DS, 2002, MOL BIOL CELL, V13, P1329, DOI 10.1091/mbc.01-08-0422; Yin XY, 2004, MOL BIOL CELL, V15, P3938, DOI 10.1091/mbc.E04-03-0198; Yochem J, 1998, GENETICS, V149, P1323; Yochem J, 2003, DEVELOPMENT, V130, P4761, DOI 10.1242/dev.00701; Zwaal RR, 2001, J BIOL CHEM, V276, P43557, DOI 10.1074/jbc.M104693200	55	44	60	2	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 7	2005	123	1					119	132		10.1016/j.cell.2005.08.001	http://dx.doi.org/10.1016/j.cell.2005.08.001			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	973QD	16213217	Bronze			2022-12-28	WOS:000232536800013
J	Aikins, AD				Aikins, AD			Healer shopping in Africa: new evidence from rural-urban qualitative study of Ghanaian diabetes experiences	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DISEASES; CARE	Objectives To provide counterevidence to existing literature on healer shopping in Africa through a systematic analysis of illness practices by Ghanaians with diabetes; to outline approaches towards improving patient centred health care and policy development regarding diabetes in Ghana. Design Longitudinal qualitative study with individual interviews, group interviews, and ethnographies. Settings Two urban towns (Accra, Tema) and two rural towns (Nkoranza and Kintampo) in Ghana. Participants 26 urban people and 41 rural people with diabetes with diverse profiles (sex, age, education, socioeconomic status, diabetes status). Results Six focus groups, 20 interviews, and three ethnographical studies were conducted to explore experiences and illness practices. Analysis identified four kinds of illness practice: biomedical management, spiritual action, cure seeking (passive and active), and medical inaction. Most participants privileged biomedicine over other health systems and emphasised biomedical management as ideal self care practice. However, the psychosocial impact of diabetes and the high cost of biomedical care drove cure seeking and medical inaction. Cure seeking constituted healer shopping between biomedicine, ethnomedicine, and faith healing; medical inaction constituted passive disengagement from medical management and active engagement with faith healing. Crucially, although spiritual causal theories of diabetes existed, they were secondary to dietary, lifestyle, and physiological theories and did not constitute the primary motivation for cure seeking. Cure seeking within unregulated ethnomedical systems and non-pharmacological faith healing systems exacerbated the complications of diabetes. Conclusions To minimise inappropriate healer shopping and maximise committed biomedical and regulated ethnomedical management for Ghanaians with diabetes, the greatest challenges lie in providing affordable pharmaceutical drugs, standardised ethnomedical drugs, recommended foods, and psychosocial support. For health systems, the greatest challenges lie in correcting structural deficiencies that impinge on biomedical practices, regulating ethnomedical diabetes treatment, and foregrounding faith healer practices within diabetes policy discussions.	Univ Cambridge, Fac Social & Polit Sci, Dept Social & Dev Psychol, Cambridge CB2 3RQ, England	University of Cambridge	Aikins, AD (corresponding author), Univ Cambridge, Fac Social & Polit Sci, Dept Social & Dev Psychol, Cambridge CB2 3RQ, England.	ada21@cam.ac.uk						Aikins AD, 2002, SOC SCI INFORM, V41, P625, DOI 10.1177/0539018402041004007; AIKINS AD, 2004, THESIS LONDON SCH EC; Aikins ADG, 2004, J HEALTH PSYCHOL, V9, P295, DOI 10.1177/1359105304040895; Aikins ADG, 2003, J HEALTH PSYCHOL, V8, P557, DOI 10.1177/13591053030085007; Amoah AGB, 2002, DIABETES RES CLIN PR, V56, P197, DOI 10.1016/S0168-8227(01)00374-6; Bediako K, 2000, AFR AFFAIRS, V99, P303, DOI 10.1093/afraf/99.395.303; De Jong J., 1991, TRADITIONAL MED SUBS; DEJONG J, 1909, TRADITIONAL MED SUBS; GASKELL G, 2000, QUALITATIVE RES TEXT, V39; *GOV GHAN MIN HLTH, 2001, HLTH NAT AN HLTH SEC; GREEN EC, 1992, SOC SCI MED, V35, P121, DOI 10.1016/0277-9536(92)90159-N; KIRBY JP, 1993, SOC SCI MED, V36, P237, DOI 10.1016/0277-9536(93)90007-Q; KITZINGER J, 1995, BRIT MED J, V311, P299, DOI 10.1136/bmj.311.7000.299; Krause M, 2003, J HEALTH PSYCHOL, V8, P599, DOI 10.1177/13591053030085010; KRIPPENDORFF K, 1980, CONTENT ANAL; KROEGER A, 1983, SOC SCI MED, V17, P147, DOI 10.1016/0277-9536(83)90248-4; *MON EV TEAM, 1998, FORM BAS RES DIAB ME; Moscovici S, 2000, SOCIAL REPRESENTATIO, P18; NKWI PN, 1994, J DIARRHOEAL DIS RES, V12, P35; NYAMWAYA D, 1987, SOC SCI MED, V25, P1277, DOI 10.1016/0277-9536(87)90126-2; OFEI F, 1996, SELF CARE BEHAV GHAN; OFEI F, 1996, UNPUB SELF CARE BEHA; Rekdal OB, 1999, MED ANTHROPOL Q, V13, P458, DOI 10.1525/maq.1999.13.4.458; ROSENTHAL K, 1995, SEMIN AVIAN EXOT PET, V4, P1; Ryan GW, 1998, SOC SCI MED, V46, P209, DOI 10.1016/S0277-9536(97)00151-2; SILVERMAN D, 2001, INTERPRETING QUALITA, V70; Unwin N, 2001, B WORLD HEALTH ORGAN, V79, P947; Valente TW, 1997, SOC SCI MED, V45, P677, DOI 10.1016/S0277-9536(96)00385-1	28	113	114	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	2005	331	7519					737	742		10.1136/bmj.331.7519.737	http://dx.doi.org/10.1136/bmj.331.7519.737			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971XB	16195290	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000232417100020
J	Pelejero, C; Calvo, E; McCulloch, MT; Marshall, JF; Gagan, MK; Lough, JM; Opdyke, BN				Pelejero, C; Calvo, E; McCulloch, MT; Marshall, JF; Gagan, MK; Lough, JM; Opdyke, BN			Preindustrial to modern interdecadal variability in coral reef pH	SCIENCE			English	Article							BORON ISOTOPIC COMPOSITION; ATMOSPHERIC CARBON-DIOXIDE; GREAT-BARRIER-REEF; NORTH PACIFIC; OCEAN; CALCIFICATION; SEAWATER; CO2; OSCILLATION; TEMPERATURE	The oceans are becoming more acidic due to absorption of anthropogenic carbon dioxide from the atmosphere. The impact of ocean acidification on marine ecosystems is unclear, but it will likely depend on species adaptability and the rate of change of seawater pH relative to its natural variability. To constrain the natural variability in reef-water pH, we measured boron isotopic compositions in a similar to 300-year-old massive Porites coral from the southwestern Pacific. Large variations in pH are found over similar to 50-year cycles that covary with the Interdecadal Pacific Oscillation of ocean-atmosphere anomalies, suggesting that natural pH cycles can modulate the impact of ocean acidification on coral reef ecosystems.	Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; Australian Inst Marine Sci, Townsville, Qld 4810, Australia; Australian Natl Univ, Dept Earth & Marine Sci, Canberra, ACT 0200, Australia	Australian National University; Australian Institute of Marine Science; Australian National University	Pelejero, C (corresponding author), CJIC, CMIMA, Inst Ciencies Mar, Barcelona 08003, Catalonia, Spain.	pelejero@cmima.csic.es; ecalvo@cmima.csic.es; Malcolm.McCulloch@anu.edu.au	McCulloch, Malcolm T/C-3651-2009; Gagan, Michael/L-5014-2018; Calvo, Eva/C-2618-2014; Lough, Janice M/L-1682-2013; Pelejero, Carles/AAF-4550-2019	McCulloch, Malcolm T/0000-0003-1538-1558; Gagan, Michael/0000-0002-8279-323X; Calvo, Eva/0000-0003-3659-4499; Lough, Janice M/0000-0002-3789-1009; Pelejero, Carles/0000-0002-7763-7769				ANDREWS JC, 1986, CONT SHELF RES, V6, P491, DOI 10.1016/0278-4343(86)90020-8; Bohm F, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000264; Caldeira K, 2003, NATURE, V425, P365, DOI 10.1038/425365a; CALVO E, UNPUB; CANE MA, 1983, SCIENCE, V222, P1189, DOI 10.1126/science.222.4629.1189; Dore JE, 2003, NATURE, V424, P754, DOI 10.1038/nature01885; FALLON SJ, 2003, GEOPHYS RES LETT, V30, DOI DOI 10.1029/2003GLO18049; Feely RA, 2004, SCIENCE, V305, P362, DOI 10.1126/science.1097329; Gaillardet J, 1995, EARTH PLANET SC LETT, V136, P665, DOI 10.1016/0012-821X(95)00180-K; Gattuso JP, 1999, AM ZOOL, V39, P160; Gershunov A, 1998, B AM METEOROL SOC, V79, P2715, DOI 10.1175/1520-0477(1998)079<2715:IMOET>2.0.CO;2; Hemming NG, 1998, GLOBAL BIOGEOCHEM CY, V12, P581, DOI 10.1029/98GB02337; HEMMING NG, 1992, GEOCHIM COSMOCHIM AC, V56, P537, DOI 10.1016/0016-7037(92)90151-8; Honisch B, 2004, GEOCHIM COSMOCHIM AC, V68, P3675, DOI 10.1016/j.gca.2004.03.002; Kleypas JA, 1999, SCIENCE, V284, P118, DOI 10.1126/science.284.5411.118; Kleypas JA, 1999, AM ZOOL, V39, P146; Lough JM, 1997, J EXP MAR BIOL ECOL, V211, P29, DOI 10.1016/S0022-0981(96)02710-4; Mantua NJ, 2002, J OCEANOGR, V58, P35, DOI 10.1023/A:1015820616384; Marubini F, 1999, MAR ECOL PROG SER, V188, P117, DOI 10.3354/meps188117; Minobe S, 1997, GEOPHYS RES LETT, V24, P683, DOI 10.1029/97GL00504; Palmer MR, 2003, SCIENCE, V300, P480, DOI 10.1126/science.1080796; Pearson PN, 1999, SCIENCE, V284, P1824, DOI 10.1126/science.284.5421.1824; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Power S, 1999, CLIM DYNAM, V15, P319, DOI 10.1007/s003820050284; Reynaud S, 2004, CORAL REEFS, V23, P539, DOI 10.1007/s00338-004-0399-5; Ridgwell A, 2005, EARTH PLANET SC LETT, V234, P299, DOI 10.1016/j.epsl.2005.03.006; Riebesell U, 2000, NATURE, V407, P364, DOI 10.1038/35030078; Sabine CL, 2004, SCIENCE, V305, P367, DOI 10.1126/science.1097403; Salinger MJ, 2001, INT J CLIMATOL, V21, P1705, DOI 10.1002/joc.691; SANYAL A, 1995, NATURE, V373, P234, DOI 10.1038/373234a0; SPIVACK AJ, 1993, NATURE, V363, P149, DOI 10.1038/363149a0; Suzuki A, 2003, TELLUS B, V55, P428, DOI 10.1034/j.1600-0889.2003.01442.x; TAFT BA, 1991, J GEOPHYS RES-OCEANS, V96, P12599, DOI 10.1029/91JC00781; VENGOSH A, 1991, GEOCHIM COSMOCHIM AC, V55, P2901, DOI 10.1016/0016-7037(91)90455-E; Wolf-Gladrow DA, 1999, TELLUS B, V51, P461, DOI 10.1034/j.1600-0889.1999.00023.x; Zachos JC, 2005, SCIENCE, V308, P1611, DOI 10.1126/science.1109004	36	149	163	6	126	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	2005	309	5744					2204	2207		10.1126/science.1113692	http://dx.doi.org/10.1126/science.1113692			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195458				2022-12-28	WOS:000232318000040
J	Barth, JV; Costantini, G; Kern, K				Barth, JV; Costantini, G; Kern, K			Engineering atomic and molecular nanostructures at surfaces	NATURE			English	Review							SCANNING-TUNNELING-MICROSCOPY; QUANTUM-DOT MOLECULES; MAGNETOCRYSTALLINE ANISOTROPY; SUPRAMOLECULAR ARCHITECTURES; MAGNETIC-ANISOTROPY; SELF-ORGANIZATION; METAL-SURFACES; TRANSITION; GROWTH; NANOTECHNOLOGY	The fabrication methods of the microelectronics industry have been refined to produce ever smaller devices, but will soon reach their fundamental limits. A promising alternative route to even smaller functional systems with nanometre dimensions is the autonomous ordering and assembly of atoms and molecules on atomically well-defined surfaces. This approach combines ease of fabrication with exquisite control over the shape, composition and mesoscale organization of the surface structures formed. Once the mechanisms controlling the self-ordering phenomena are fully understood, the self-assembly and growth processes can be steered to create a wide range of surface nanostructures from metallic, semiconducting and molecular materials.	Ecole Polytech Fed Lausanne, Inst Phys Nanostruct, CH-1015 Lausanne, Switzerland; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Phys & Astron, Vancouver, BC V6T 1Z4, Canada; Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of British Columbia; University of British Columbia; Max Planck Society	Kern, K (corresponding author), Ecole Polytech Fed Lausanne, Inst Phys Nanostruct, CH-1015 Lausanne, Switzerland.	k.kern@fkf.mpg.de	Costantini, Giovanni/C-2236-2009; BARTH, Johannes V/E-4060-2013	Costantini, Giovanni/0000-0001-7916-3440; BARTH, Johannes V/0000-0002-6270-2150				[Anonymous], 1999, QUANTUM DOT HETEROST; ARAKAWA Y, 1982, APPL PHYS LETT, V40, P939, DOI 10.1063/1.92959; BARENCO A, 1995, PHYS REV A, V52, P3457, DOI 10.1103/PhysRevA.52.3457; Barth JV, 2003, APPL PHYS A-MATER, V76, P645, DOI 10.1007/s00339-002-2003-6; Barth JV, 2002, J AM CHEM SOC, V124, P7991, DOI 10.1021/ja0256764; BARTH JV, 1990, PHYS REV B, V42, P9307, DOI 10.1103/PhysRevB.42.9307; Barth JV, 2000, SURF SCI REP, V40, P75, DOI 10.1016/S0167-5729(00)00002-9; Barth JV, 2000, ANGEW CHEM INT EDIT, V39, P1230, DOI 10.1002/(SICI)1521-3773(20000403)39:7<1230::AID-ANIE1230>3.0.CO;2-I; Bayer M, 2001, SCIENCE, V291, P451, DOI 10.1126/science.291.5503.451; BINNIG G, 1987, REV MOD PHYS, V59, P615, DOI 10.1103/RevModPhys.59.615; Bohr MT, 2002, IEEE T NANOTECHNOL, V1, P56, DOI 10.1109/TNANO.2002.1005426; Bohringer M, 1999, PHYS REV LETT, V83, P324, DOI 10.1103/PhysRevLett.83.324; Brune H, 1998, NATURE, V394, P451, DOI 10.1038/28804; Brune H, 1998, SURF SCI REP, V31, P121, DOI 10.1016/S0167-5729(99)80001-6; BRUNO P, 1989, PHYS REV B, V39, P865, DOI 10.1103/PhysRevB.39.865; Burkard G, 1999, PHYS REV B, V59, P2070, DOI 10.1103/PhysRevB.59.2070; CLAIR S, IN PRESS ANGEW CHEM; CLASSEN T, IN PRESS ANGEW CHEM; Cleland AN, 1998, NATURE, V392, P160, DOI 10.1038/32373; Cole T, 2001, PROG QUANT ELECTRON, V25, P165, DOI 10.1016/S0079-6727(01)00007-6; Corso M, 2004, SCIENCE, V303, P217, DOI 10.1126/science.1091979; Costantini G, 2004, APPL PHYS LETT, V85, P5673, DOI 10.1063/1.1829164; Daruka I, 1999, PHYS REV LETT, V82, P2753, DOI 10.1103/PhysRevLett.82.2753; De Feyter S, 2003, CHEM SOC REV, V32, P139, DOI 10.1039/b206566p; Dekker C, 1999, PHYS TODAY, V52, P22, DOI 10.1063/1.882658; Deng X, 1998, PHYS REV LETT, V81, P1473, DOI 10.1103/PhysRevLett.81.1473; DEUTSCH D, 1985, P ROY SOC LOND A MAT, V400, P97, DOI 10.1098/rspa.1985.0070; Dmitriev A, 2004, LANGMUIR, V20, P4799, DOI 10.1021/la049273o; Dmitriev A, 2003, ANGEW CHEM INT EDIT, V42, P2670, DOI 10.1002/anie.200250610; Dmitriev A, 2002, J PHYS CHEM B, V106, P6907, DOI 10.1021/jp014214u; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; Feynman R.P., 1992, J MICROELECTROMECH S, V1, P60, DOI 10.1109/84.128057; FEYNMAN RP, 1982, INT J THEOR PHYS, V21, P467, DOI 10.1007/BF02650179; Gambardella P, 2000, PHYS REV B, V61, P2254, DOI 10.1103/PhysRevB.61.2254; Gambardella P, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.077203; Gambardella P, 2003, SCIENCE, V300, P1130, DOI 10.1126/science.1082857; Gambardella P, 2002, NATURE, V416, P301, DOI 10.1038/416301a; Gates BD, 2005, CHEM REV, V105, P1171, DOI 10.1021/cr030076o; Gimzewski JK, 1999, SCIENCE, V283, P1683, DOI 10.1126/science.283.5408.1683; Griessl S, 2002, SINGLE MOL, V3, P25, DOI 10.1002/1438-5171(200204)3:1<25::AID-SIMO25>3.3.CO;2-B; Heidemeyer H, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.196103; Himpsel FJ, 1998, ADV PHYS, V47, P511, DOI 10.1080/000187398243519; Holliday BJ, 2001, ANGEW CHEM INT EDIT, V40, P2022, DOI 10.1002/1521-3773(20010601)40:11<2022::AID-ANIE2022>3.3.CO;2-4; Ibach H, 1997, SURF SCI REP, V29, P195, DOI 10.1016/S0167-5729(97)00010-1; Ito T, 2000, NATURE, V406, P1027, DOI 10.1038/35023233; Joachim C, 2000, NATURE, V408, P541, DOI 10.1038/35046000; KASTNER MA, 1993, PHYS TODAY, V46, P24, DOI 10.1063/1.881393; KERN K, 1991, PHYS REV LETT, V67, P855, DOI 10.1103/PhysRevLett.67.855; Kind H, 1999, ADV MATER, V11, P1285, DOI 10.1002/(SICI)1521-4095(199910)11:15<1285::AID-ADMA1285>3.0.CO;2-J; Kitagawa S, 2004, ANGEW CHEM INT EDIT, V43, P2334, DOI 10.1002/anie.200300610; Kuhnke K, 2003, J PHYS-CONDENS MAT, V15, pS3311, DOI 10.1088/0953-8984/15/47/007; Lee H, 2001, APPL PHYS LETT, V78, P105, DOI 10.1063/1.1336554; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; Leininger S, 2000, CHEM REV, V100, P853, DOI 10.1021/cr9601324; Li JL, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.066101; Lin N, 2002, ANGEW CHEM INT EDIT, V41, P4779, DOI 10.1002/anie.200290046; LINDSEY JS, 1991, NEW J CHEM, V15, P153; Lingenfelder MA, 2004, CHEM-EUR J, V10, P1913, DOI 10.1002/chem.200305589; Lukas S, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.028301; Messina P, 2002, J AM CHEM SOC, V124, P14000, DOI 10.1021/ja028553s; Michler P, 2000, SCIENCE, V290, P2282, DOI 10.1126/science.290.5500.2282; Nakajima F, 2003, APPL PHYS LETT, V83, P2680, DOI 10.1063/1.1614845; Nicolis G, 1977, SELF ORG NONEQUILIBR; Niemeyer CM, 2001, ANGEW CHEM INT EDIT, V40, P4128, DOI 10.1002/1521-3773(20011119)40:22<4128::AID-ANIE4128>3.0.CO;2-S; Otero R, 2004, ANGEW CHEM INT EDIT, V43, P2092, DOI 10.1002/anie.200353586; Ouyang M, 2003, SCIENCE, V301, P1074, DOI 10.1126/science.1086963; Philp D, 1996, ANGEW CHEM INT EDIT, V35, P1154, DOI 10.1002/anie.199611541; Prins LJ, 2001, ANGEW CHEM INT EDIT, V40, P2382, DOI 10.1002/1521-3773(20010702)40:13<2382::AID-ANIE2382>3.0.CO;2-G; RODER H, 1993, NATURE, V366, P141, DOI 10.1038/366141a0; Rosei F, 2003, PROG SURF SCI, V71, P95, DOI 10.1016/S0079-6816(03)00004-2; Ross FM, 1999, SCIENCE, V286, P1931, DOI 10.1126/science.286.5446.1931; Rusponi S, 2003, NAT MATER, V2, P546, DOI 10.1038/nmat930; Sarikaya M, 2003, NAT MATER, V2, P577, DOI 10.1038/nmat964; Schedelbeck G, 1997, SCIENCE, V278, P1792, DOI 10.1126/science.278.5344.1792; Seeman NC, 2002, P NATL ACAD SCI USA, V99, P6451, DOI 10.1073/pnas.221458298; Shchukin VA, 1999, REV MOD PHYS, V71, P1125, DOI 10.1103/RevModPhys.71.1125; Shor P. W., 1994, P 35 ANN S FDN COMP; Songmuang R, 2003, APPL PHYS LETT, V82, P2892, DOI 10.1063/1.1569992; Spillmann H, 2003, J AM CHEM SOC, V125, P10725, DOI 10.1021/ja0362353; Stepanow S, 2004, NAT MATER, V3, P229, DOI 10.1038/nmat1088; Sun SH, 2000, SCIENCE, V287, P1989, DOI 10.1126/science.287.5460.1989; Tans SJ, 1998, NATURE, V394, P761, DOI 10.1038/29494; Teichert C, 2002, PHYS REP, V365, P335, DOI 10.1016/S0370-1573(02)00009-1; Theobald JA, 2003, NATURE, V424, P1029, DOI 10.1038/nature01915; THOMSON DA, 2000, IBM J RES DEV, V3, P311; van der Laan G, 1998, J PHYS-CONDENS MAT, V10, P3239, DOI 10.1088/0953-8984/10/14/012; Vettiger P, 2002, IEEE T NANOTECHNOL, V1, P39, DOI 10.1109/TNANO.2002.1005425; Warburton RJ, 2000, NATURE, V405, P926, DOI 10.1038/35016030; Weckesser J, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.096101; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; WILDBERGER K, 1995, PHYS REV LETT, V75, P509, DOI 10.1103/PhysRevLett.75.509; Xia YN, 1999, CHEM REV, V99, P1823, DOI 10.1021/cr980002q; Yaghi OM, 2003, NATURE, V423, P705, DOI 10.1038/nature01650; Yokoyama T, 2001, NATURE, V413, P619, DOI 10.1038/35098059; Zhang ZY, 1997, SCIENCE, V276, P377, DOI 10.1126/science.276.5311.377	96	1836	1858	18	996	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					671	679		10.1038/nature04166	http://dx.doi.org/10.1038/nature04166			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193042				2022-12-28	WOS:000232157900041
J	Moscona, A				Moscona, A			Drug therapy - Neuraminidase inhibitors for influenza	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							AVIAN INFLUENZA; OSELTAMIVIR TREATMENT; INHALED ZANAMIVIR; VIRUS-REPLICATION; TISSUE-CULTURE; DOUBLE-BLIND; SIALIC-ACID; A VIRUSES; EFFICACY; PREVENTION		Cornell Univ, Weill Med Coll, Dept Pediat, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Cornell University; Cornell University	Moscona, A (corresponding author), Cornell Univ, Weill Med Coll, Dept Pediat, Box 309,515 E 71st St,Suite 600D, New York, NY 10021 USA.	anm2047@med.cornell.edu						Aoki FY, 2003, J ANTIMICROB CHEMOTH, V51, P123, DOI 10.1093/jac/dkg007; Balicer RD, 2004, BRIT MED J, V328, P1391, DOI 10.1136/bmj.328.7453.1391; Bowles SK, 2002, J AM GERIATR SOC, V50, P608, DOI 10.1046/j.1532-5415.2002.50153.x; Capasso L, 1999, LANCET, V353, P504, DOI 10.1016/S0140-6736(05)75184-9; Cass LMR, 1999, CLIN PHARMACOKINET, V36, P21, DOI 10.2165/00003088-199936001-00003; *CDCP, 2004, UPD INFL A H5N1 SARS; COLMAN PM, 1983, NATURE, V303, P41, DOI 10.1038/303041a0; *COMM SCI IND RES, CSIRO BAS DRUG EFF B; Cooper NJ, 2003, BRIT MED J, V326, P1235, DOI 10.1136/bmj.326.7401.1235; Cox NJ, 1999, LANCET, V354, P1277, DOI 10.1016/S0140-6736(99)01241-6; Freund B, 1999, DRUG SAFETY, V21, P267, DOI 10.2165/00002018-199921040-00003; Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3; Hayden FG, 2000, NEW ENGL J MED, V343, P1282, DOI 10.1056/NEJM200011023431801; Hayden FG, 2004, J INFECT DIS, V189, P440, DOI 10.1086/381128; Hayden FG, 1999, NEW ENGL J MED, V341, P1336, DOI 10.1056/NEJM199910283411802; Hayden FG, 1999, JAMA-J AM MED ASSOC, V282, P1240, DOI 10.1001/jama.282.13.1240; Hayden FG, 2001, PHILOS T R SOC B, V356, P1877, DOI 10.1098/rstb.2001.1007; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; Hayden Frederick G, 2004, Pediatr Infect Dis J, V23, pS262, DOI 10.1097/01.inf.0000144680.39895.ce; Hedrick JA, 2000, PEDIATR INFECT DIS J, V19, P410, DOI 10.1097/00006454-200005000-00005; Herlocher ML, 2004, J INFECT DIS, V190, P1627, DOI 10.1086/424572; *HLTH SCI AUTH, 2004, PROD SAF AL NEW PREC; Kaiser L, 2003, ARCH INTERN MED, V163, P1667, DOI 10.1001/archinte.163.14.1667; Kawai N, 2005, CLIN INFECT DIS, V40, P1309, DOI 10.1086/429241; Kim CU, 1997, J AM CHEM SOC, V119, P681, DOI 10.1021/ja963036t; Kiso M, 2004, LANCET, V364, P759, DOI 10.1016/S0140-6736(04)16934-1; Langley JM, 2004, CAN MED ASSOC J, V171, P1213, DOI 10.1503/cmaj.1031737; Leneva IA, 2001, ANTIMICROB AGENTS CH, V45, P1216, DOI 10.1128/AAC.45.4.1216-1224.2001; Leneva IA, 2000, ANTIVIR RES, V48, P101, DOI 10.1016/S0166-3542(00)00123-6; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; Makela MJ, 2000, J INFECTION, V40, P42, DOI 10.1053/jinf.1999.0602; Matrosovich MN, 2004, J VIROL, V78, P12665, DOI 10.1128/JVI.78.22.12665-12667.2004; Matsumoto K, 1999, ANTIVIR THER, V4, P61; McCullers JA, 2003, J INFECT DIS, V187, P1000, DOI 10.1086/368163; McKimm-Breschkin J, 2003, ANTIMICROB AGENTS CH, V47, P2264, DOI 10.1128/AAC.47.7.2264-2272.2003; MEINDL P, 1974, VIROLOGY, V58, P457, DOI 10.1016/0042-6822(74)90080-4; Mills CE, 2004, NATURE, V432, P904, DOI 10.1038/nature03063; MIST Study Grp, 1999, LANCET, V353, P1104; Monto AS, 2005, NEW ENGL J MED, V352, P323, DOI 10.1056/NEJMp048343; Monto AS, 2004, CLIN INFECT DIS, V39, P459, DOI 10.1086/422646; Monto AS, 1999, JAMA-J AM MED ASSOC, V282, P31, DOI 10.1001/jama.282.1.31; Monto AS, 1999, J INFECT DIS, V180, P254, DOI 10.1086/314904; Monto AS, 2002, J INFECT DIS, V186, P1582, DOI 10.1086/345722; Monto AS, 2000, ARCH INTERN MED, V160, P3243, DOI 10.1001/archinte.160.21.3243; MONTO AS, 2005, NEW ENGL J MED, V352, P1056; Moscona A, 2004, LANCET, V364, P733, DOI 10.1016/S0140-6736(04)16947-X; Murphy KR, 2000, CLIN DRUG INVEST, V20, P337, DOI 10.2165/00044011-200020050-00005; Nicholson KG, 2000, LANCET, V356, P1856; Oxford J, 2004, J ANTIMICROB CHEMOTH, V53, P133, DOI 10.1093/jac/dkh037; PALESE P, 1976, J GEN VIROL, V33, P159, DOI 10.1099/0022-1317-33-1-159; PALESE P, 1974, VIROLOGY, V59, P490, DOI 10.1016/0042-6822(74)90458-9; Peters PH, 2001, J AM GERIATR SOC, V49, P1025, DOI 10.1046/j.1532-5415.2001.49204.x; Silagy C, 1998, LANCET, V352, P1877, DOI 10.1016/S0140-6736(98)10190-3; Stohr K, 2005, NEW ENGL J MED, V352, P405, DOI 10.1056/NEJMe048344; Storch GA, 2003, CURR OPIN PEDIATR, V15, P77, DOI 10.1097/00008480-200302000-00013; Trampuz, 2004, MAYO CLIN PROC, V79, P833; Trampuz A, 2004, MAYO CLIN PROC, V79, P523, DOI 10.4065/79.4.523; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; Tumpey TM, 2002, P NATL ACAD SCI USA, V99, P13849, DOI 10.1073/pnas.212519699; Ungchusak K, 2005, NEW ENGL J MED, V352, P333, DOI 10.1056/NEJMoa044021; VARGHESE JN, 1992, PROTEINS, V14, P327, DOI 10.1002/prot.340140302; VARGHESE JN, 1995, PROTEIN SCI, V4, P1081, DOI 10.1002/pro.5560040606; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; Welliver R, 2001, JAMA-J AM MED ASSOC, V285, P748, DOI 10.1001/jama.285.6.748; Whitley RJ, 2001, PEDIATR INFECT DIS J, V20, P127, DOI 10.1097/00006454-200102000-00002; Whitley RJ, 2001, PEDIATR INFECT DIS J, V20, P421; *WHO, 2005, WHO INT COUNTR CONS; *WHO, 2005, CUM NUMB CONF HUM CA; World Health Organization, 2004, WHO CONS PRIOR PUBL; Zambon M, 2001, ANTIVIR RES, V49, P147, DOI 10.1016/S0166-3542(01)00124-3	70	803	973	3	230	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2005	353	13					1363	1373		10.1056/NEJMra050740	http://dx.doi.org/10.1056/NEJMra050740			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968FB	16192481	Bronze			2022-12-28	WOS:000232146200008
J	Onwuteaka-Philipsen, BD; van der Heide, A; Muller, MT; Rurup, M; Rietjens, JAC; Georges, JJ; Vrakking, AM; Cuperus-Bosma, JM; van der Wal, G; van der Maas, PJ				Onwuteaka-Philipsen, BD; van der Heide, A; Muller, MT; Rurup, M; Rietjens, JAC; Georges, JJ; Vrakking, AM; Cuperus-Bosma, JM; van der Wal, G; van der Maas, PJ			Dutch experience of monitoring euthanasia	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PHYSICIAN-ASSISTED SUICIDE; NETHERLANDS; ATTITUDES; DEATH		Vrije Univ Amsterdam Med Ctr, Inst Res Extramural Med, Dept Publ & Occupat Hlth, NL-1081 BT Amsterdam, Netherlands; Erasmus MC, Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Erasmus University Rotterdam; Erasmus MC	Onwuteaka-Philipsen, BD (corresponding author), Vrije Univ Amsterdam Med Ctr, Inst Res Extramural Med, Dept Publ & Occupat Hlth, NL-1081 BT Amsterdam, Netherlands.	b.philipsen@vumc.nl						*BOARD ROYAL DUTCH, 2003, CONC EUTH; Dyer Owen, 2003, BMJ, V327, P1186; Emanuel EJ, 2002, ARCH INTERN MED, V162, P142, DOI 10.1001/archinte.162.2.142; Forde R, 1997, SOC SCI MED, V45, P887, DOI 10.1016/S0277-9536(96)00430-3; Gordijn B, 2004, HEALTH CARE ANAL, V12, P195, DOI 10.1023/B:HCAN.0000044926.05523.ef; Hedberg K, 2003, NEW ENGL J MED, V348, P961, DOI 10.1056/NEJM200303063481022; Huxtable R, 2004, BRIT MED J, V328, P1088, DOI 10.1136/bmj.328.7448.1088; Kirschner R, 1998, Gesundheitswesen, V60, P247; Onwuteaka-Philipsen BD, 2003, LANCET, V362, P395, DOI 10.1016/S0140-6736(03)14029-9; *REG REV COMM EUTH, 2004, ANN REP 2003; Rietjens JAC, 2004, ANN INTERN MED, V141, P178, DOI 10.7326/0003-4819-141-3-200408030-00006; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6; van der Wal G, 2003, MED DECISION MAKING; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332; WATSON R, 2001, BRIT MED J, V323, P1024; Weide MCJVD, 2004, HEALTH POLICY, V69, P365, DOI 10.1016/j.healthpol.2004.04.010	17	24	25	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 24	2005	331	7518					691	693		10.1136/bmj.331.7518.691	http://dx.doi.org/10.1136/bmj.331.7518.691			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970HH	16179708	Green Published			2022-12-28	WOS:000232295400025
J	Meissner, A; Jaenisch, R				Meissner, A; Jaenisch, R			Generation of nuclear transfer-derived pluripotent ES cells from cloned Cdx2-deficient blastocysts	NATURE			English	Article							EMBRYONIC STEM-CELLS; GENE-THERAPY; CDX2; MICE; COMPLEMENTATION; DIFFERENTIATION; LINEAGES; CLONING	The derivation of embryonic stem (ES) cells by nuclear transfer holds great promise for research and therapy but involves the destruction of cloned human blastocysts. Proof of principle experiments have shown that 'customized' ES cells derived by nuclear transfer (NT-ESCs) can be used to correct immunodeficiency in mice. Importantly, the feasibility of the approach has been demonstrated recently in humans, bringing the clinical application of NT- ESCs within reach. Altered nuclear transfer (ANT) has been proposed as a variation of nuclear transfer because it would create abnormal nuclear transfer blastocysts that are inherently unable to implant into the uterus but would be capable of generating customized ES cells. To assess the experimental validity of this concept we have used nuclear transfer to derive mouse blastocysts from donor fibroblasts that carried a short hairpin RNA construct targeting Cdx2. Cloned blastocysts were morphologically abnormal, lacked functional trophoblast and failed to implant into the uterus. However, they efficiently generated pluripotent embryonic stem cells when explanted into culture.	MIT, Whitehead Inst, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Jaenisch, R (corresponding author), MIT, Whitehead Inst, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	jaenisch@wi.mit.edu						ADJAYE J, STEM CELLS; BRAMBRINK T, UNPUB P NATL ACAD SC; Chawengsaksophak K, 2004, P NATL ACAD SCI USA, V101, P7641, DOI 10.1073/pnas.0401654101; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hurlbut WB, 2005, PERSPECT BIOL MED, V48, P211, DOI 10.1353/pbm.2005.0055; Hwang Woo Suk, 2005, Science (Washington D C), V308, P1777, DOI 10.1126/science.1112286; Hyslop L, 2005, STEM CELLS, V23, P1035, DOI 10.1634/stemcells.2005-0080; Jaenisch R, 2004, NEW ENGL J MED, V351, P2787, DOI 10.1056/NEJMp048304; Melton DA, 2004, NEW ENGL J MED, V351, P2791, DOI 10.1056/NEJMp048348; Pfeifer A, 2002, P NATL ACAD SCI USA, V99, P2140, DOI 10.1073/pnas.251682798; President's Council on Bioethics, 2005, ALT SOURC HUM PLUR S; Rideout WM, 2002, CELL, V109, P17, DOI 10.1016/S0092-8674(02)00681-5; Strumpf D, 2005, DEVELOPMENT, V132, P2093, DOI 10.1242/dev.01801; Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101; Wakayama S, 2005, BIOL REPROD, V72, P932, DOI 10.1095/biolreprod.104.035105; Wang ZD, 2004, DEV BIOL, V275, P192, DOI 10.1016/j.ydbio.2004.06.026	18	165	179	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 12	2006	439	7073					212	215		10.1038/nature04257	http://dx.doi.org/10.1038/nature04257			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	001MT	16227971	Bronze			2022-12-28	WOS:000234538400042
J	Baird, J; Fisher, D; Lucas, P; Kleijnen, J; Roberts, H; Law, C				Baird, J; Fisher, D; Lucas, P; Kleijnen, J; Roberts, H; Law, C			Being big or growing fast: systematic review of size and growth in infancy and later obesity	BMJ-BRITISH MEDICAL JOURNAL			English	Review							BODY-MASS INDEX; WEIGHT-GAIN; FOLLOW-UP; YOUNG ADULTHOOD; EARLY-CHILDHOOD; RISK-FACTORS; FAT BABIES; OVERWEIGHT; COHORT; CHILDREN	Objectives To assess the association between infant size or growth and subsequent obesity and to determine if any association has been stable over time. Design Systematic review. Data sources Medline, Embase, bibliographies of included studies, contact with first authors of included studies and other experts. Inclusion criteria Studies that assessed the relation between infant size or growth during the first two years of life and subsequent obesity. Main outcome measure Obesity at any age after infancy. Results 24 studies met the inclusion criteria (22 cohort and two case-control studies). Of these, 18 assessed the relation between infant size and subsequent obesity, most showing that infants who were defined as "obese" or who were at the highest end of the distribution for weight or body mass index were at increased risk of obesity. Compared with non-obese infants, in those who had been obese odds ratios or relative risks for subsequent obesity ranged from 1.35 to 9.38. Ten studies assessed the relation of infant growth with subsequent obesity and most showed that infants who grew more rapidly were at increased risk of obesity. Compared with other infants, in infants with rapid growth odds ratios and relative risks of later obesity ranged from 1.17 to 5.70. Associations were consistent for obesity at different ages and for people born over a period from 1927 to 1994. Conclusions Infants who are at the highest end of the distribution for weight or body mass index or who grow rapidly during infancy are at increased risk of subsequent obesity.	Univ Southampton, Southampton Gen Hosp, MRC, Epidemiol Resource Ctr, Southampton SO16 6YD, Hants, England; Univ Bristol, Sch Policy Studies, Bristol BS8 1TZ, Avon, England; Univ York, Ctr Reviews & Disseminat, York YO10 5DD, N Yorkshire, England; City Univ London, Child Hlth Res & Policy Unit, London EC14 4TY, England; UCL, Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England	University of Southampton; University of Bristol; University of York - UK; City University London; University of London; University College London	Baird, J (corresponding author), Univ Southampton, Southampton Gen Hosp, MRC, Epidemiol Resource Ctr, Southampton SO16 6YD, Hants, England.	jb@mrc.soton.ac.uk	Lucas, Patricia/P-5349-2017; PAN, ZEQIANG/X-6341-2018; Law, Catherine/A-1353-2009	Fisher, David/0000-0002-2512-2296; Baird, Janis/0000-0002-4039-4361; Roberts, Helen/0000-0002-6319-061X; Law, Catherine/0000-0002-1777-9386; Lucas, Patricia Jane/0000-0002-0469-8085	MRC [G106/1077] Funding Source: UKRI; Medical Research Council [G106/1077] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ASHER P, 1966, ARCH DIS CHILD, V41, P672, DOI 10.1136/adc.41.220.672; CHARNEY E, 1976, NEW ENGL J MED, V295, P6, DOI 10.1056/NEJM197607012950102; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Cole TJ, 2000, P NUTR SOC, V59, P317, DOI 10.1017/S0029665100000355; *DEP HLTH, 2004, HLTH SURV ENGL 2003; EID EE, 1970, BMJ-BRIT MED J, V2, P74, DOI 10.1136/bmj.2.5701.74; Eriksson J, 2003, INT J OBESITY, V27, P722, DOI 10.1038/sj.ijo.0802278; GARN SM, 1985, AM J DIS CHILD, V139, P181, DOI 10.1001/archpedi.1985.02140040083033; GUO SS, 1994, AM J CLIN NUTR, V59, P810, DOI 10.1093/ajcn/59.4.810; He Q, 1999, PEDIATR RES, V46, P697, DOI 10.1203/00006450-199912000-00010; HEALD FP, 1965, J PEDIATR-US, V67, P35, DOI 10.1016/S0022-3476(65)80301-8; JOHNSTON FE, 1978, AM J DIS CHILD, V132, P862, DOI 10.1001/archpedi.1978.02120340038006; Mei ZG, 2003, SOZ PRAVENTIV MED, V48, P161, DOI 10.1007/s00038-003-2022-x; MELLBIN T, 1973, BRIT J PREV SOC MED, V27, P225; Monteiro POA, 2005, OBES REV, V6, P143, DOI 10.1111/j.1467-789X.2005.00183.x; Monteiro POA, 2003, INT J OBESITY, V27, P1274, DOI 10.1038/sj.ijo.0802409; MOSSBERG HO, 1989, LANCET, V2, P491; *NHS CTR REV DISS, 2001, 4 NHS CTR REV DISS; Parsons TJ, 1999, INT J OBESITY, V23, pS1; Parsons TJ, 2001, BRIT MED J, V323, P1331, DOI 10.1136/bmj.323.7325.1331; POSKITT EME, 1977, BMJ-BRIT MED J, V1, P7, DOI 10.1136/bmj.1.6052.7; Rasmussen F, 1998, EUR J EPIDEMIOL, V14, P373, DOI 10.1023/A:1007411613576; Reilly JJ, 2005, BMJ-BRIT MED J, V330, P1357, DOI 10.1136/bmj.38470.670903.E0; ROLLANDCACHERA MF, 1987, ANN HUM BIOL, V14, P219, DOI 10.1080/03014468700008991; STAMATAKIS E, 2002, HLTH SURVEY ENGLAND; Stettler N, 2003, AM J CLIN NUTR, V77, P1374, DOI 10.1093/ajcn/77.6.1374; Stettler N, 2002, INT J OBESITY, V26, P214, DOI 10.1038/sj.ijo.0801860; Stettler N, 2002, PEDIATRICS, V109, P194, DOI 10.1542/peds.109.2.194; Stettler N, 2005, CIRCULATION, V111, P1897, DOI 10.1161/01.CIR.0000161797.67671.A7; SUMMERBELL CD, 2005, COCHRANE DB SYST REV, V2; Tienboon P, 2002, ASIA PAC J CLIN NUTR, V11, P42, DOI 10.1046/j.1440-6047.2002.00281.x; Toschke AM, 2004, ARCH PEDIAT ADOL MED, V158, P449, DOI 10.1001/archpedi.158.5.449; Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301; WILKINSON PW, 1977, LANCET, V1, P350	34	811	849	0	53	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 22	2005	331	7522					929	931		10.1136/bmj.38586.411273.E0	http://dx.doi.org/10.1136/bmj.38586.411273.E0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979UR	16227306	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000232970900014
J	Van Sickle, MD; Duncan, M; Kingsley, PJ; Mouihate, A; Urbani, P; Mackie, K; Stella, N; Makriyannis, A; Piomelli, D; Davison, JS; Marnett, LJ; Di Marzo, V; Pittman, QJ; Patel, KD; Sharkey, KA				Van Sickle, MD; Duncan, M; Kingsley, PJ; Mouihate, A; Urbani, P; Mackie, K; Stella, N; Makriyannis, A; Piomelli, D; Davison, JS; Marnett, LJ; Di Marzo, V; Pittman, QJ; Patel, KD; Sharkey, KA			Identification and functional characterization of brainstem cannabinoid CB2 receptors	SCIENCE			English	Article							ACID AMIDE HYDROLASE; ENDOCANNABINOID SYSTEM; ANANDAMIDE; NEURONS; CLONING; TARGET; CELLS	The presence and function of CB2 receptors in central nervous system (CNS) neurons are controversial. We report the expression of CB2 receptor messenger RNA and protein localization on brainstem neurons. These functional CB2 receptors in the brainstem were activated by a CB2 receptor agonist, 2-arachidonoylglycerol, and by elevated endogenous levels of endocannabinoids, which also act at CB1 receptors. CB2 receptors represent an alternative site of action of endocannabinoids that opens the possibility of nonpsychotropic therapeutic interventions using enhanced endocannabinoid levels in localized brain areas.	Univ Calgary, Inst Infect Immun & Inflammat, Calgary, AB T2N 4N1, Canada; Univ Calgary, Hotchkiss Brain Inst, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr,Ctr Mol Toxicol, Vanderbilt Inst Chem Biol,Dept Biochem, Nashville, TN 37232 USA; CNR, Inst Biomol Chem, Endocannabinoid Res Grp, Naples, Italy; Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol Psychiat & Behav Sci, Seattle, WA 98195 USA; Northeastern Univ, Dept Pharmaceut Sci, Ctr Drug Discovery, Boston, MA 02115 USA; Univ Calif Irvine, Dept Pharmacol, Gillespie Neurosci Facil, Irvine, CA 92697 USA	University of Calgary; University of Calgary; Vanderbilt University; Consiglio Nazionale delle Ricerche (CNR); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Northeastern University; University of California System; University of California Irvine	Sharkey, KA (corresponding author), Univ Calgary, Inst Infect Immun & Inflammat, Calgary, AB T2N 4N1, Canada.	ksharkey@ucalgary.ca	Makriyannis, Alexandros/GRF-1518-2022; Mackie, Ken/E-3715-2013; Patel, Kamala D/AAX-1245-2021; Mackie, Kenneth P/B-7358-2011; Di Marzo, Vincenzo/AAD-7742-2019	Makriyannis, Alexandros/0000-0003-3272-3687; Mackie, Ken/0000-0001-8501-6199; Di Marzo, Vincenzo/0000-0002-1490-3070; Pittman, Quentin/0000-0003-0984-7665; Sepers, Marja/0000-0002-6510-2804; Sharkey, Keith/0000-0001-9560-1711	NIGMS NIH HHS [GM15431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benito C, 2005, J NEUROSCI, V25, P2530, DOI 10.1523/JNEUROSCI.3923-04.2005; Benito C, 2003, J NEUROSCI, V23, P11136; Bouaboula M, 1996, EUR J BIOCHEM, V237, P704, DOI 10.1111/j.1432-1033.1996.0704p.x; Brown SM, 2002, BBA-GENE STRUCT EXPR, V1576, P255, DOI 10.1016/S0167-4781(02)00341-X; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Chhatwal JP, 2005, NEUROPSYCHOPHARMACOL, V30, P516, DOI 10.1038/sj.npp.1300655; Cravatt BF, 2003, CURR OPIN CHEM BIOL, V7, P469, DOI 10.1016/S1367-5931(03)00079-6; De Petrocellis L, 2000, FEBS LETT, V483, P52, DOI 10.1016/S0014-5793(00)02082-2; De Petrocellis L, 2004, BRIT J PHARMACOL, V141, P765, DOI 10.1038/sj.bjp.0705666; Derbenev AV, 2004, J PHYSIOL-LONDON, V559, P923, DOI 10.1113/jphysiol.2004.067470; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Dinh TP, 2002, P NATL ACAD SCI USA, V99, P10819, DOI 10.1073/pnas.152334899; Fegley D, 2005, J PHARMACOL EXP THER, V313, P352, DOI 10.1124/jpet.104.078980; Freund TF, 2003, PHYSIOL REV, V83, P1017, DOI 10.1152/physrev.00004.2003; Gaetani S, 2003, TRENDS MOL MED, V9, P474, DOI 10.1016/j.molmed.2003.09.005; Golech SA, 2004, MOL BRAIN RES, V132, P87, DOI 10.1016/j.molbrainres.2004.08.025; Griffin G, 2000, J PHARMACOL EXP THER, V292, P886; Hornby PJ, 2001, AM J MED, V111, P106, DOI 10.1016/S0002-9343(01)00849-X; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Klein TW, 2003, J LEUKOCYTE BIOL, V74, P486, DOI 10.1189/jlb.0303101; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Matias I, 2002, EUR J BIOCHEM, V269, P3771, DOI 10.1046/j.1432-1033.2002.03078.x; Nunez E, 2004, SYNAPSE, V53, P208, DOI 10.1002/syn.20050; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; Valjent E, 2005, P NATL ACAD SCI USA, V102, P491, DOI 10.1073/pnas.0408305102; Van Sickle MD, 2001, GASTROENTEROLOGY, V121, P767, DOI 10.1053/gast.2001.28466; VANSICKLE MD, UNPUB	27	1133	1205	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					329	332		10.1126/science.1115740	http://dx.doi.org/10.1126/science.1115740			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224028	Green Submitted			2022-12-28	WOS:000232670100057
J	Badzey, RL; Mohanty, P				Badzey, RL; Mohanty, P			Coherent signal amplification in bistable nanomechanical oscillators by stochastic resonance	NATURE			English	Article							SYSTEM; NOISE	Stochastic resonance(1,2) is a counterintuitive concept: the addition of noise to a noisy system induces coherent amplification of its response. First suggested as a mechanism for the cyclic recurrence of ice ages, stochastic resonance has been seen in a wide variety of macroscopic physical systems: bistable ring lasers(3), superconducting quantum interference devices(4,5) (SQUIDs), magnetoelastic ribbons(6) and neurophysiological systems such as the receptors in crickets(7) and crayfish(8). Although fundamentally important as a mechanism of coherent signal amplification, stochastic resonance has yet to be observed in nanoscale systems. Here we report the observation of stochastic resonance in bistable nanomechanical silicon oscillators. Our nanomechanical systems consist of beams that are clamped at each end and driven into transverse oscillation with the use of a radiofrequency source. Modulation of the source induces controllable switching of the beams between two stable, distinct states. We observe that the addition of white noise causes a marked amplification of the signal strength. Stochastic resonance in nanomechanical systems could have a function in the realization of controllable high-speed nanomechanical memory cells, and paves the way for exploring macroscopic quantum coherence and tunnelling.	Boston Univ, Dept Phys, Boston, MA 02215 USA	Boston University	Mohanty, P (corresponding author), Boston Univ, Dept Phys, 590 Commonwealth Ave, Boston, MA 02215 USA.	mohanty@physics.bu.edu						Badzey RL, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1849848; Badzey RL, 2004, APPL PHYS LETT, V85, P3587, DOI 10.1063/1.1808507; BENZI R, 1983, SIAM J APPL MATH, V43, P565, DOI 10.1137/0143037; BENZI R, 1985, J PHYS A-MATH GEN, V18, P2239, DOI 10.1088/0305-4470/18/12/022; BULSARA A, 1991, J THEOR BIOL, V152, P531, DOI 10.1016/S0022-5193(05)80396-0; Carr SM, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.220101; Casado-Pascual J, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.067101; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; Gaidarzhy A, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.030402; Gammaitoni L, 1998, REV MOD PHYS, V70, P223, DOI 10.1103/RevModPhys.70.223; GAMMAITONI L, 1994, PHYS REV E, V49, P4878, DOI 10.1103/PhysRevE.49.4878; GREYWALL DS, 1994, PHYS REV LETT, V72, P2992, DOI 10.1103/PhysRevLett.72.2992; HIBBS AD, 1995, J APPL PHYS, V77, P2582, DOI 10.1063/1.358720; Inchiosa ME, 1997, PHYS REV E, V55, P4049, DOI 10.1103/PhysRevE.55.4049; Inchiosa ME, 1998, PHYS REV E, V58, P115, DOI 10.1103/PhysRevE.58.115; MCNAMARA B, 1988, PHYS REV LETT, V60, P2626, DOI 10.1103/PhysRevLett.60.2626; MCNAMARA B, 1989, PHYS REV A, V39, P4854, DOI 10.1103/PhysRevA.39.4854; MORILLO M, 1995, PHYS REV E, V51, P999, DOI 10.1103/PhysRevE.51.999; Nayfeh A.H., 1995, NONLINEAR OSCIL; ROUSE R, 1995, APPL PHYS LETT, V66, P108, DOI 10.1063/1.114161; SPANO ML, 1992, PHYS REV A, V46, P5253, DOI 10.1103/PhysRevA.46.5253; Weaver W., 1990, VIBRATION PROBLEMS E	23	219	222	1	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	2005	437	7061					995	998		10.1038/nature04124	http://dx.doi.org/10.1038/nature04124			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16222295	Green Submitted			2022-12-28	WOS:000232496100039
J	Nieburg, P; Waldman, RJ; Krumm, DM				Nieburg, P; Waldman, RJ; Krumm, DM			Hurricane Katrina - Evacuated populations - Lessons from foreign refugee crisis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA 22903 USA; Columbia Univ, Mailman Sch Publ Hlth, Program Forced Migrat, New York, NY USA; US Dept State, Washington, DC 20520 USA	University of Virginia; Columbia University	Nieburg, P (corresponding author), Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA 22903 USA.							*OFF FOR DIS ASS, 1994, FIELD OP GUID DIS AS; The Sphere Project, 2004, HUM CHART MIN STAND; Toole MJ, 2001, INTERNATIONAL PUBLIC HEALTH, P439	3	18	18	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1547	1549		10.1056/NEJMp058237	http://dx.doi.org/10.1056/NEJMp058237			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221774				2022-12-28	WOS:000232486000005
J	Albert, AYK; Otto, SP				Albert, AYK; Otto, SP			Sexual selection can resolve sex-linked sexual antagonism	SCIENCE			English	Article							EVOLUTION; LINKAGE	Sexual selection is a potent evolutionary force. However, very few models have considered the evolution of female preferences for traits expressed in both sexes. Here we explore how female preferences coevolve with sexually antagonistic traits, which involve alleles that are beneficial to one sex but harmful to the other. We show that with a sexually antagonistic trait on the X chromosome (males XY, females XX), females evolve to prefer mates carrying alleles beneficial to daughters. In contrast, with a Z-linked trait (mates ZZ, females ZW), females more often evolve mating preferences for mates carrying alleles beneficial to sons (that is, flashy displays).	Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada	University of British Columbia	Albert, AYK (corresponding author), Univ British Columbia, Dept Zool, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.	albert@zoology.ubc.ca	Albert, Arianne/AAG-7518-2019; Otto, Sarah Perin/K-5625-2012	Albert, Arianne/0000-0002-3050-0888; Otto, Sarah Perin/0000-0003-3042-0818				Andersson Malte, 1994; Andres JA, 2003, J EVOLUTION BIOL, V16, P219, DOI 10.1046/j.1420-9101.2003.00525.x; FEDOROVICH RD, 1994, PHYS LOW-DIMENS STR, V1, P83; Gibson JR, 2002, P ROY SOC B-BIOL SCI, V269, P499, DOI 10.1098/rspb.2001.1863; HASTINGS IM, 1994, P ROY SOC B-BIOL SCI, V258, P83, DOI 10.1098/rspb.1994.0146; Kingsolver JG, 2001, AM NAT, V157, P245, DOI 10.1086/319193; Kirkpatrick M, 2002, GENETICS, V161, P1727; KIRKPATRICK M, 1982, EVOLUTION, V36, P1, DOI [10.2307/2407961, 10.1111/j.1558-5646.1982.tb05003.x]; Kirkpatrick M, 2004, EVOLUTION, V58, P683; Kokko H, 2003, P ROY SOC B-BIOL SCI, V270, P653, DOI 10.1098/rspb.2002.2235; Lindholm A, 2002, AM NAT, V160, pS214, DOI 10.1086/342898; OTTO SP, 1991, EVOLUTION, V45, P1443, DOI [10.2307/2409891, 10.1111/j.1558-5646.1991.tb02647.x]; Reeve HK, 2003, P NATL ACAD SCI USA, V100, P1089, DOI 10.1073/pnas.0337427100; Reinhold K, 1998, BEHAV ECOL SOCIOBIOL, V44, P1, DOI 10.1007/s002650050508; RICE WR, 1984, EVOLUTION, V38, P735, DOI 10.1111/j.1558-5646.1984.tb00346.x; Rice WR, 2001, J EVOLUTION BIOL, V14, P685, DOI 10.1046/j.1420-9101.2001.00319.x; SEGER J, 1986, NATURE, V319, P771, DOI 10.1038/319771a0	17	75	75	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	2005	310	5745					119	121		10.1126/science.1115328	http://dx.doi.org/10.1126/science.1115328			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210543				2022-12-28	WOS:000232477000052
J	Daneman, R; Barres, BA				Daneman, R; Barres, BA			The blood-brain barrier - Lessons from moody flies	CELL			English	Review							SEPTATE JUNCTION ORGANIZATION; MOLECULAR PHYSIOLOGY; DROSOPHILA; SCHIZOPHRENIA	Despite the importance of the blood-brain barrier (BBB), little is known about the molecular mechanisms that control its integrity. The identification of moody, a gene required for the formation and maintenance of the Drosophila BBB, provides new insight into how paracellular junctions are formed at the barrier. Meanwhile, moody also has been identified in a screen for fly mutants with altered sensitivity to cocaine, remarkably implicating the BBB in the physiological response to narcotics.	Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University	Daneman, R (corresponding author), Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA.	rdaneman@stanford.edu						ALLEN NJ, 2005, IN PRESS CURR OPIN N; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Bishop GB, 2002, NEUROBIOL DIS, V10, P334, DOI 10.1006/nbdi.2002.0518; Bowers MS, 2004, NEURON, V42, P269, DOI 10.1016/S0896-6273(04)00159-X; Bowers MS, 2003, EUR J NEUROSCI, V17, P1273, DOI 10.1046/j.1460-9568.2003.02537.x; Chowdari KV, 2002, HUM MOL GENET, V11, P1373, DOI 10.1093/hmg/11.12.1373; Faivre-Sarrailh C, 2004, DEVELOPMENT, V131, P4931, DOI 10.1242/dev.01372; Genova JL, 2003, J CELL BIOL, V161, P979, DOI 10.1083/jcb.200212054; Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X; Nag Sukriti, 2003, Methods Mol Med, V89, P3; Poliak S, 2003, NAT REV NEUROSCI, V4, P968, DOI 10.1038/nrn1253; Sun ZY, 2004, EUR PSYCHIAT, V19, P354, DOI 10.1016/j.eurpsy.2004.06.007; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; Van Itallie CM, 2004, PHYSIOLOGY, V19, P331, DOI 10.1152/physiol.00027.2004; VENKATARAMAN C, 2005, IN PRESS IMMUNOL LET; Wolf FW, 2003, J NEUROBIOL, V54, P161, DOI 10.1002/neu.10166; Wu VM, 2004, J CELL BIOL, V164, P313, DOI 10.1083/jcb.200309134	17	46	52	0	11	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 7	2005	123	1					9	12		10.1016/j.cell.2005.09.017	http://dx.doi.org/10.1016/j.cell.2005.09.017			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	973QD	16213208	Bronze			2022-12-28	WOS:000232536800004
J	McHenry, CR; Cook, AG; Wroe, S				McHenry, CR; Cook, AG; Wroe, S			Bottom-feeding plesiosaurs	SCIENCE			English	Article							STOMACH STONES		Univ Newcastle, Sch Environm & Life Sci Geol, Newcastle, NSW 2308, Australia; Queensland Museum, Brisbane, Qld 4101, Australia; Univ Sydney, Key Ctr Microscopy & Microanal, Electron Microscope Unit, Sydney, NSW 2006, Australia	University of Newcastle; Queensland Museum; University of Sydney	McHenry, CR (corresponding author), Univ Newcastle, Sch Environm & Life Sci Geol, Newcastle, NSW 2308, Australia.	colin.mchenry@newcastle.edu.au	Wroe, Stephen/A-4462-2010	Wroe, Stephen/0000-0002-5813-9182; Wroe, Stephen/0000-0002-6365-5915				BAKKER RT, 1993, GEOLOGICAL ASS CANAD, V39, P641; Brown B., 1904, Science, V(2), P185; Cicimurri David J., 2001, Transactions of the Kansas Academy of Science, V104, P129, DOI 10.1660/0022-8443(2001)104[0129:AEWSCA]2.0.CO;2; DARBY DG, 1980, J PALEONTOL, V54, P548; Henderson DM, 2003, CAN J ZOOL, V81, P1346, DOI 10.1139/Z03-122; Massare J.A., 1987, Journal of Vertebrate Paleontology, V7, P121; Northwood C, 2005, PALAEONTOLOGY, V48, P49, DOI 10.1111/j.1475-4983.2004.00432.x; TAYLOR MA, 1981, NATURE, V290, P628, DOI 10.1038/290628a0; Thulborn Tony, 1993, Modern Geology, V18, P489; Wiffen J, 1995, GEOBIOS-LYON, V28, P625, DOI 10.1016/S0016-6995(95)80216-9; Williston SW, 1904, SCIENCE, V20, P565, DOI 10.1126/science.20.513.565-a; WILLISTON SW, 1903, MUS PUBL GEOL SER, V2, P1	12	52	57	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	2005	310	5745					75	75		10.1126/science.1117241	http://dx.doi.org/10.1126/science.1117241			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210529				2022-12-28	WOS:000232477000038
J	Dell'Anno, A; Danovaro, R				Dell'Anno, A; Danovaro, R			Extracellular DNA plays a key role in deep-sea ecosystem functioning	SCIENCE			English	Article							MARINE-SEDIMENTS; PHOSPHORUS; ATLANTIC		Polytech Univ Marche, Fac Sci, Dept Marine Sci, I-60131 Ancona, Italy	Marche Polytechnic University	Danovaro, R (corresponding author), Polytech Univ Marche, Fac Sci, Dept Marine Sci, Via Brecce Bianche, I-60131 Ancona, Italy.	r.danovaro@univpm.it	Dell'Anno, Antonio AD/G-9468-2012	Dell'Anno, Antonio AD/0000-0002-4324-7834				Clark LL, 1998, NATURE, V393, P426, DOI 10.1038/30881; Danovaro R, 2001, TRENDS ECOL EVOL, V16, P505, DOI 10.1016/S0169-5347(01)02215-7; Delaney ML, 1998, GLOBAL BIOGEOCHEM CY, V12, P563, DOI 10.1029/98GB02263; Dell'Anno A, 2002, LIMNOL OCEANOGR, V47, P899, DOI 10.4319/lo.2002.47.3.0899; Turley C, 2000, FEMS MICROBIOL ECOL, V33, P89, DOI 10.1111/j.1574-6941.2000.tb00731.x; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578; Wu JF, 2000, SCIENCE, V289, P759, DOI 10.1126/science.289.5480.759	7	237	244	4	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	2005	309	5744					2179	2179		10.1126/science.1117475	http://dx.doi.org/10.1126/science.1117475			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195451				2022-12-28	WOS:000232318000032
J	Mookadam, F; Cikes, M				Mookadam, F; Cikes, M			Cullen's and Turner's signs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Mayo Clin, Rochester, MN 55905 USA	Mayo Clinic	Mookadam, F (corresponding author), Mayo Clin, Rochester, MN 55905 USA.								0	13	15	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2005	353	13					1386	1386		10.1056/NEJMicm040796	http://dx.doi.org/10.1056/NEJMicm040796			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968FB	16192483				2022-12-28	WOS:000232146200010
J	George, RJD; Finlay, IG; Jeffrey, D				George, RJD; Finlay, IG; Jeffrey, D			Legalised euthanasia will violate the rights of vulnerable patients	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							LIFE DECISION-MAKING; ASSISTED SUICIDE; LAST WEEK; END; NETHERLANDS		Univ Coll, Ctr Bioeth & Philosophy Med, London UB1 3HW, England; House Lords, London SW1A 0PW, England; Assoc Palliat Med Great Britain & Ireland, Southampton SO17 1DL, Hants, England	University of London; University College London	George, RJD (corresponding author), Univ Coll, Ctr Bioeth & Philosophy Med, London UB1 3HW, England.	rob@palliativecare.org.uk						*BRIT MED ASS, 2005, ASS DYING; Deliens L, 2000, LANCET, V356, P1806, DOI 10.1016/S0140-6736(00)03233-5; Groenewoud JH, 2000, NEW ENGL J MED, V342, P551, DOI 10.1056/NEJM200002243420805; Haverkate I, 2000, BRIT MED J, V321, P865, DOI 10.1136/bmj.321.7265.865; Jochemsen H, 1998, ISSUES LAW MED, V13, P447; Jochemsen H, 1999, J MED ETHICS, V25, P16, DOI 10.1136/jme.25.1.16; Sheldon T, 2000, BRIT MED J, V321, P1174; Sheldon T, 1999, BRIT MED J, V319, P75, DOI 10.1136/bmj.319.7202.75b; Sheldon T, 2001, BRIT MED J, V322, P509; Sykes N, 2003, ARCH INTERN MED, V163, P341, DOI 10.1001/archinte.163.3.341; Thorns A, 2000, LANCET, V356, P398, DOI 10.1016/S0140-6736(00)02534-4; vanThiel GJMW, 1997, BRIT MED J, V315, P88, DOI 10.1136/bmj.315.7100.88	12	30	30	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 24	2005	331	7518					684	685		10.1136/bmj.331.7518.684	http://dx.doi.org/10.1136/bmj.331.7518.684			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970HH	16179705	Green Published			2022-12-28	WOS:000232295400022
J	Hammer, SM				Hammer, SM			Management of newly diagnosed HIV infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; CD4 CELL COUNT; SOCIETY-USA PANEL; VIRAL LOAD; DRUG-RESISTANCE; HETEROSEXUAL TRANSMISSION; METABOLIC COMPLICATIONS; HIV-1-INFECTED PATIENTS; MEDICINE-ASSOCIATION		Columbia Univ, Med Ctr, Div Infect Dis, New York, NY 10032 USA	Columbia University	Hammer, SM (corresponding author), Columbia Univ, Med Ctr, Div Infect Dis, 630 W 168th St,PH 8 W,Room 876, New York, NY 10032 USA.	smh48@columbia.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI048013, P30AI042848, U01AI041534, U01AI046386] Funding Source: NIH RePORTER; NIAID NIH HHS [AI42848, AI48013, AI46386, AI41534] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aberg JA, 2004, CLIN INFECT DIS, V39, P609, DOI 10.1086/423390; Ahdieh-Grant L, 2003, AM J EPIDEMIOL, V157, P738, DOI 10.1093/aje/kwg036; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; BARTLETT JA, 2005, 12 C RETR OPP INF BO; Benhamou Y, 2004, CLIN INFECT DIS, V38, pS98, DOI 10.1086/381451; BOZZETTE SA, 1995, NEW ENGL J MED, V332, P693, DOI 10.1056/NEJM199503163321101; Bulterys M, 2004, JAMA-J AM MED ASSOC, V292, P219, DOI 10.1001/jama.292.2.219; Chun TW, 2003, P NATL ACAD SCI USA, V100, P1908, DOI 10.1073/pnas.0437640100; Currier J, 2002, AIDS, V16, pS171, DOI 10.1097/00002030-200216004-00023; Davis KR, 1999, FAM PLANN PERSPECT, V31, P272, DOI 10.2307/2991537; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; *DEP HLTH HUM SERV, GUID US ANT AG HIV1; Dube MP, 2003, CLIN INFECT DIS, V37, P613, DOI 10.1086/378131; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; FriisMoller N, 2004, NEW ENGL J MED, V350, P955; Goulder PJR, 2002, NEW ENGL J MED, V347, P756, DOI 10.1056/NEJMe020091; Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772; Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; KALEEBU P, 2005, 3 IAS C HIV PATH TRE; Laine C, 1998, AIDS, V12, P417, DOI 10.1097/00002030-199804000-00011; Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552; Markowitz M, 2005, LANCET, V365, P1031, DOI 10.1016/S0140-6736(05)74227-6; MASUR H, 1993, NEW ENGL J MED, V329, P898, DOI 10.1056/NEJM199309163291228; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Moore RD, 1996, ANN INTERN MED, V124, P633, DOI 10.7326/0003-4819-124-7-199604010-00003; Moyle G J, 2001, HIV Med, V2, P105, DOI 10.1046/j.1468-1293.2001.00063.x; Nettles RE, 2005, JAMA-J AM MED ASSOC, V293, P817, DOI 10.1001/jama.293.7.817; Nickle DC, 2003, J VIROL, V77, P5540, DOI 10.1128/JVI.77.9.5540-5546.2003; Ohl J, 2003, HUM REPROD, V18, P1244, DOI 10.1093/humrep/deg258; Opravil M, 2002, AIDS, V16, P1371, DOI 10.1097/00002030-200207050-00009; Palella FJ, 2003, ANN INTERN MED, V138, P620, DOI 10.7326/0003-4819-138-8-200304150-00007; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paltiel AD, 2005, NEW ENGL J MED, V352, P586, DOI 10.1056/NEJMsa042088; Parera M, 2004, J INFECT DIS, V189, P1444, DOI 10.1086/382485; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; Phillips AN, 2001, JAMA-J AM MED ASSOC, V286, P2560, DOI 10.1001/jama.286.20.2560; Plosker GL, 2004, DRUGS, V64, P2823, DOI 10.2165/00003495-200464240-00009; POZNIAK AL, 2005, 3 IAS C PATH TREATM; *PUBL HLTH SERV TA, 2005, REC US ANT DRUGS PRE; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Sanders GD, 2005, NEW ENGL J MED, V352, P570, DOI 10.1056/NEJMsa042657; Schambelan M, 2002, JAIDS-J ACQ IMM DEF, V31, P257, DOI 10.1097/00126334-200211010-00001; Sterling TR, 2003, J INFECT DIS, V188, P1659, DOI 10.1086/379741; Sterling TR, 2003, CLIN INFECT DIS, V36, P812, DOI 10.1086/367934; Sterling TR, 2001, AIDS, V15, P2251, DOI 10.1097/00002030-200111230-00006; Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354; Wood E, 2004, REV INVEST CLIN, V56, P232; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251; Zeldin RK, 2004, J ANTIMICROB CHEMOTH, V53, P4, DOI 10.1093/jac/dkh029; Zhang LQ, 2000, J CLIN INVEST, V106, P839, DOI 10.1172/JCI10565; 2002, MMWR MORB MORTAL WEE, V51, P1; 2002, AIDS ALERT, V17, P8; 2004, MMWR MORB MORTAL WEE, V53, P1; 2004, MMWR MORB MORTAL WEE, V53, P1106	57	55	61	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 20	2005	353	16					1702	1710		10.1056/NEJMcp051203	http://dx.doi.org/10.1056/NEJMcp051203			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975IC	16236741	Bronze			2022-12-28	WOS:000232653200010
J	Rubenfeld, GD; Caldwell, E; Peabody, E; Weaver, J; Martin, DP; Neff, M; Stern, EJ; Hudson, LD				Rubenfeld, GD; Caldwell, E; Peabody, E; Weaver, J; Martin, DP; Neff, M; Stern, EJ; Hudson, LD			Incidence and outcomes of acute lung injury	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; QUALITY-OF-LIFE; UNITED-STATES; SEVERE SEPSIS; MORTALITY; EPIDEMIOLOGY; SURVIVORS; FAILURE; DEFINITIONS; CARE	BACKGROUND: Acute lung injury is a critical illness syndrome consisting of acute hypoxemic respiratory failure with bilateral pulmonary infiltrates that are not attributed to left atrial hypertension. Despite recent advances in our understanding of the mechanism and treatment of acute lung injury, its incidence and outcomes in the United States have been unclear. METHODS: We conducted a prospective, population-based, cohort study in 21 hospitals in and around King County, Washington, from April 1999 through July 2000, using a validated screening protocol to identify patients who met the consensus criteria for acute lung injury. RESULTS: A total of 1113 King County residents undergoing mechanical ventilation met the criteria for acute lung injury and were 15 years of age or older. On the basis of this figure, the crude incidence of acute lung injury was 78.9 per 100,000 person-years and the age-adjusted incidence was 86.2 per 100,000 person-years. The in-hospital mortality rate was 38.5 percent. The incidence of acute lung injury increased with age from 16 per 100,000 person-years for those 15 through 19 years of age to 306 per 100,000 person-years for those 75 through 84 years of age. Mortality increased with age from 24 percent for patients 15 through 19 years of age to 60 percent for patients 85 years of age or older (P<0.001). We estimate that each year in the United States there are 190,600 cases of acute lung injury, which are associated with 74,500 deaths and 3.6 million hospital days. CONCLUSIONS: Acute lung injury has a substantial impact on public health, with an incidence in the United States that is considerably higher than previous reports have suggested.	Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care Med, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Dept Radiol, Seattle, WA 98104 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Rubenfeld, GD (corresponding author), Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care Med, Box 359762,325 9th Ave, Seattle, WA 98104 USA.	nodrog@u.washington.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL030542] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30542] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Bernard GR, 1997, NEW ENGL J MED, V336, P912, DOI 10.1056/NEJM199703273361303; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bersten AD, 2002, AM J RESP CRIT CARE, V165, P443, DOI 10.1164/ajrccm.165.4.2101124; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Brower RG, 2004, NEW ENGL J MED, V351, P327; Davidson TA, 1999, JAMA-J AM MED ASSOC, V281, P354, DOI 10.1001/jama.281.4.354; Ferguson ND, 2002, INTENS CARE MED, V28, P1073, DOI 10.1007/s00134-002-1354-y; Freed LA, 1999, NEW ENGL J MED, V341, P1, DOI 10.1056/NEJM199907013410101; Garber BG, 1996, CRIT CARE MED, V24, P687, DOI 10.1097/00003246-199604000-00023; Goss CH, 2003, CRIT CARE MED, V31, P1607, DOI 10.1097/01.CCM.0000063475.65751.1D; Gowda MS, 1997, CRIT CARE MED, V25, P41, DOI 10.1097/00003246-199701000-00010; GRIFFIN MR, 1985, JAMA-J AM MED ASSOC, V254, P1199, DOI 10.1001/jama.254.9.1199; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Hoyert D L, 2001, Natl Vital Stat Rep, V49, P1; HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182; Hughes M, 2003, ANAESTHESIA, V58, P838, DOI 10.1046/j.1365-2044.2003.03287.x; LEWANDOWSKI K, 1995, AM J RESP CRIT CARE, V151, P1121; Linde-Zwirble WT, 2004, CRIT CARE, V8, P222, DOI 10.1186/cc2917; Linn Shai, 1995, Annals of Epidemiology, V5, P440, DOI 10.1016/1047-2797(95)00059-3; Luhr OR, 1999, AM J RESP CRIT CARE, V159, P1849, DOI 10.1164/ajrccm.159.6.9808136; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; *NAT HEART LUNG I, 1972, PUBL NIH; Nathens AB, 2004, J TRAUMA, V56, P173, DOI 10.1097/01.TA.0000056159.65396.7C; Nuckton TJ, 2002, NEW ENGL J MED, V346, P1281, DOI 10.1056/NEJMoa012835; Rainer TH, 1999, RESUSCITATION, V42, P187, DOI 10.1016/S0300-9572(99)00089-1; RUBENFELD GD, 2002, LUNG BIOL HLTH DIS, P37; Schelling G, 1998, CRIT CARE MED, V26, P651, DOI 10.1097/00003246-199804000-00011; THOMSEN GE, 1995, AM J RESP CRIT CARE, V152, P965, DOI 10.1164/ajrccm.152.3.7663811; WARE LB, 2000, NEW ENGL J MED, V342, P1334, DOI [DOI 10.1056/NEJM200005043421806, 10.1056/NEJM200005043421806]	33	2640	2819	7	153	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 20	2005	353	16					1685	1693		10.1056/NEJMoa050333	http://dx.doi.org/10.1056/NEJMoa050333			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975IC	16236739				2022-12-28	WOS:000232653200008
J	Canter, PH; Coon, JT; Ernst, E				Canter, PH; Coon, JT; Ernst, E			Cost effectiveness of complementary treatments in the United Kingdom: systematic review	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE; BACK-PAIN; MANIPULATION		Univ Exeter & Plymouth, Peninsula Med Sch, Exeter EX2 4NT, Devon, England	University of Exeter	Canter, PH (corresponding author), Univ Exeter & Plymouth, Peninsula Med Sch, Exeter EX2 4NT, Devon, England.	peter.canter@pms.ac.uk	Coon, Jo Thompson/C-7923-2017	Coon, Jo Thompson/0000-0002-5161-0234				Burton AK, 2000, EUR SPINE J, V9, P202, DOI 10.1007/s005869900113; Manca A, 2004, BMJ-BRIT MED J, V329, P1381, DOI 10.1136/bmj.38282.607859.AE; MEADE TW, 1995, BRIT MED J, V311, P349, DOI 10.1136/bmj.311.7001.349; Williams NH, 2004, FAM PRACT, V21, P643, DOI 10.1093/fampra/cmh612; Wonderling D, 2004, BMJ-BRIT MED J, V328, P747, DOI 10.1136/bmj.38033.896505.EB	5	23	24	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 15	2005	331	7521					880	881		10.1136/bmj.38625.575903.79	http://dx.doi.org/10.1136/bmj.38625.575903.79			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975SX	16223821	Bronze, Green Published			2022-12-28	WOS:000232683300022
J	Hossain, P; Sachdev, A; Malik, RA				Hossain, P; Sachdev, A; Malik, RA			Early detection of diabetic peripheral neuropathy with corneal confocal microscopy	LANCET			English	Editorial Material							SENSITIVITY; MELLITUS; RATS		Univ Southampton, Southampton Eye Unit, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England; Royal Liverpool Hosp, St Pauls Eye Unit, Liverpool L7 8XP, Merseyside, England; Manchester Royal Infirm, Acad Dept Med, Manchester M13 9WL, Lancs, England	University of Southampton; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Manchester	Hossain, P (corresponding author), Univ Southampton, Southampton Eye Unit, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.	parwez@soton.ac.uk	Sachdev, Atul/AAE-4831-2020; Hossain, Parwez/AAB-6065-2022; Malik, Rayaz/H-9231-2019	Malik, Rayaz/0000-0002-7188-8903; Hossain, Parwez/0000-0002-3131-2395				Boulton AJM, 2004, DIABETES CARE, V27, P1458, DOI 10.2337/diacare.27.6.1458; Bragheeth MA, 2005, BRIT J OPHTHALMOL, V89, P580, DOI 10.1136/bjo.2004.046888; Greene DA, 1999, NEUROLOGY, V53, P580, DOI 10.1212/WNL.53.3.580; Grupcheva CN, 2002, CLIN EXP OPHTHALMOL, V30, P187, DOI 10.1046/j.1442-9071.2002.00507.x; Holland NR, 1997, NEUROLOGY, V48, P708, DOI 10.1212/WNL.48.3.708; Hosotani H, 1996, CURR EYE RES, V15, P1005, DOI 10.3109/02713689609017648; HYNDIUK RA, 1977, ARCH OPHTHALMOL-CHIC, V95, P2193; Iqbal I, 2005, DIABETES S1, V54, P871; Jacot JL, 1998, J OCUL PHARMACOL TH, V14, P169, DOI 10.1089/jop.1998.14.169; Jalbert I, 2003, BRIT J OPHTHALMOL, V87, P225, DOI 10.1136/bjo.87.2.225; Kallinikos P, 2004, INVEST OPHTH VIS SCI, V45, P418, DOI 10.1167/iovs.03-0637; Kawabuchi M, 1998, RESTOR NEUROL NEUROS, V13, P117; Malik RA, 2001, ACTA NEUROPATHOL, V101, P367; Malik RA, 2003, DIABETOLOGIA, V46, P683, DOI 10.1007/s00125-003-1086-8; Oliveira-Soto L, 2001, CORNEA, V20, P374, DOI 10.1097/00003226-200105000-00008; Rosenberg ME, 2000, INVEST OPHTH VIS SCI, V41, P2915; Sumner CJ, 2003, NEUROLOGY, V60, P108, DOI 10.1212/WNL.60.1.108; Tesfaye S, 2005, NEW ENGL J MED, V352, P341, DOI 10.1056/NEJMoa032782; Urban P P, 1999, Electromyogr Clin Neurophysiol, V39, P267	19	122	128	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 15	2005	366	9494					1340	1343		10.1016/S0140-6736(05)67546-0	http://dx.doi.org/10.1016/S0140-6736(05)67546-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	973ZW	16226599				2022-12-28	WOS:000232562100008
J	Liu, QS; Pu, L; Poo, MM				Liu, QS; Pu, L; Poo, MM			Repeated cocaine exposure in vivo facilitates LTP induction in midbrain dopamine neurons	NATURE			English	Article							VENTRAL TEGMENTAL AREA; LONG-TERM POTENTIATION; GAMMA-VINYL GABA; FEEDFORWARD INHIBITION; SYNAPTIC PLASTICITY; VISUAL-CORTEX; ADDICTION; RAT; DRUGS; ABUSE	Drugs of abuse are known to cause persistent modification of neural circuits, leading to addictive behaviours(1-5). Changes in synaptic plasticity in dopamine neurons of the ventral tegmental area (VTA) may contribute to circuit modification induced by many drugs of abuse, including cocaine(6-13). Here we report that, following repeated exposure to cocaine in vivo, excitatory synapses to rat VTA dopamine neurons become highly susceptible to the induction of long-term potentiation (LTP) by correlated pre- and postsynaptic activity. This facilitated LTP induction is caused by cocaine-induced reduction of GABA(A) (gamma-aminobutyric acid) receptor- mediated inhibition of these dopamine neurons. In midbrain slices from rats treated with saline or a single dose of cocaine, LTP could not be induced in VTA dopamine neurons unless GABA-mediated inhibition was reduced by bicuculline or picrotoxin. However, LTP became readily inducible in slices from rats treated repeatedly with cocaine; this LTP induction was prevented by enhancing GABA-mediated inhibition using diazepam. Furthermore, repeated cocaine exposure reduced the amplitude of GABA-mediated synaptic currents and increased the probability of spike initiation in VTA dopamine neurons. This cocaine-induced enhancement of synaptic plasticity in the VTA may be important for the formation of drug-associated memory.	Univ Calif Berkeley, Helen Wills Neurosci Inst, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Poo, MM (corresponding author), Univ Calif Berkeley, Helen Wills Neurosci Inst, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA.	qsliu@berkeley.edu; mpoo@berkeley.edu		Pu, Lu/0000-0001-5370-2557	NINDS NIH HHS [R01 NS037831, R01 NS036999] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036999, R01NS037831] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; Bissiere S, 2003, NAT NEUROSCI, V6, P587, DOI 10.1038/nn1058; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; Borgland SL, 2004, J NEUROSCI, V24, P7482, DOI 10.1523/JNEUROSCI.1312-04.2004; Brodie JD, 2003, SYNAPSE, V50, P261, DOI 10.1002/syn.10278; Dong Y, 2004, P NATL ACAD SCI USA, V101, P14282, DOI 10.1073/pnas.0401553101; Eghbali M, 1997, NATURE, V388, P71, DOI 10.1038/40404; Faleiro LJ, 2004, NEUROPSYCHOPHARMACOL, V29, P2115, DOI 10.1038/sj.npp.1300495; Gardner EL, 2002, SYNAPSE, V46, P240, DOI 10.1002/syn.10138; HERRON CE, 1985, NEUROSCI LETT, V61, P255, DOI 10.1016/0304-3940(85)90473-2; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; Hyland BI, 2002, NEUROSCIENCE, V114, P475, DOI 10.1016/S0306-4522(02)00267-1; JOHNSON SW, 1992, J PHYSIOL-LONDON, V450, P455, DOI 10.1113/jphysiol.1992.sp019136; Jones S, 1999, J NEUROSCI, V19, P9780; Kauer JA, 2004, ANNU REV PHYSIOL, V66, P447, DOI 10.1146/annurev.physiol.66.032102.112534; Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016; Larkum ME, 1999, NATURE, V398, P338, DOI 10.1038/18686; Meredith RM, 2003, J NEUROSCI, V23, P11142, DOI 10.1523/jneurosci.23-35-11142.2003; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Pouille F, 2001, SCIENCE, V293, P1159, DOI 10.1126/science.1060342; Robinson TE, 2004, NEUROPHARMACOLOGY, V47, P33, DOI 10.1016/j.neuropharm.2004.06.025; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7; SCHULTZ W, 1993, J NEUROSCI, V13, P900; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; Thompson AM, 2002, NEUROPHARMACOLOGY, V42, P1039, DOI 10.1016/S0028-3908(02)00059-X; Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077; WIGSTROM H, 1983, NATURE, V301, P603, DOI 10.1038/301603a0; Wolf ME, 2004, NEUROPHARMACOLOGY, V47, P61, DOI 10.1016/j.neuropharm.2004.07.006; Yao WD, 2004, NEURON, V41, P625, DOI 10.1016/S0896-6273(04)00048-0	30	243	246	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	2005	437	7061					1027	1031		10.1038/nature04050	http://dx.doi.org/10.1038/nature04050			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16222299	Green Accepted			2022-12-28	WOS:000232496100046
J	Campbell, AJ; Robertson, MC; La Grow, SJ; Kerse, NM; Sanderson, GF; Jacobs, RJ; Sharp, DM; Hale, LA				Campbell, AJ; Robertson, MC; La Grow, SJ; Kerse, NM; Sanderson, GF; Jacobs, RJ; Sharp, DM; Hale, LA			Randomised controlled trial of prevention of falls in people aged >= 75 with severe visual impairment: the VIP trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOME EXERCISE PROGRAM; OLDER-PEOPLE; RISK-FACTORS; MULTIFACTORIAL INTERVENTION; ECONOMIC-EVALUATION	Objectives To assess the efficacy and cost effectiveness of a home safety programme and a home exercise programme to reduce falls and injuries in older people with low vision. Design Randomised controlled trial. Setting Dunedin and Auckland, New Zealand. Participants 391 women and men aged >= 75 with visual acuity of 6/24 or worse who were living in the community; 92% (361 of 391) completed one year of follow-up. Interventions Participants received a home safety assessment and modification programme delivered by an occupational therapist (n=100), an exercise programme prescribed at home by a physiotherapist plus vitamin D supplementation (n=97), both interventions (n=98), or social visits (n=96). Main outcome measures Numbers of falls and injuries resulting from falls, costs of implementing the home safety programme. Results Fewer falls occurred in people randomised to the home safety programme but not in those randomised to the exercise programme (incidence rate ratios 0.59 (95% confidence interval 0.42 to 0.83) and 1.15 (0.82 to 1.61), respectively). However, within the exercise programme, stricter adherence was associated with fewer falls (P = 0.001). A conservative analysis showed neither intervention was effective in reducing injuries from falls. Delivering the home safety programme cost $NZ650 (234; pound $432; 344) (at 2004 prices) per fall prevented. Conclusion The home safety programme reduced falls and was more cost effective than an exercise programme in this group of elderly people with poor vision. The Otago exercise programme with vitamin D supplementation was not effective in reducing falls or injuries in this group, possibly due to low levels of adherence.	Univ Otago Sch Med, Dept Med & Surg Sci, Dunedin, New Zealand; Massey Univ, Sch Hlth Sci, Palmerston North, New Zealand; Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand; Univ Auckland, Dept Optometry & Vis Sci, Auckland 1, New Zealand; Auckland Hosp, Auckland, New Zealand; Univ Otago, Sch Physiotherapy, Dunedin, New Zealand	University of Otago; Massey University; University of Auckland; University of Auckland; Auckland City Hospital; University of Otago	Campbell, AJ (corresponding author), Univ Otago Sch Med, Dept Med & Surg Sci, Dunedin, New Zealand.	john.campbell@stonebow.otago.ac.nz	Robertson, Mary Clare/A-3964-2009; Hale, Leigh Anne/AFD-2919-2022; Kerse, Ngaire/AFF-8119-2022	Jacobs, Robert/0000-0001-6709-1785				*ACC COMP CORP, 2003, OT EX PROGR PREV FAL; BUCHNER DM, 1993, J AM GERIATR SOC, V41, P297, DOI 10.1111/j.1532-5415.1993.tb06708.x; CAMPBELL AJ, 1989, J GERONTOL, V44, pM112, DOI 10.1093/geronj/44.4.m112; Campbell AJ, 1999, J AM GERIATR SOC, V47, P850, DOI 10.1111/j.1532-5415.1999.tb03843.x; Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; CLEMSON L, 1997, HOME FALL HAZARDS GU; CLEMSON L, 1997, HOME FULL HAZARDS GU; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; *CROWN CO MON ADV, 1999, HOSP HLTH SERV PERF; Cumming RG, 1999, J AM GERIATR SOC, V47, P1397, DOI 10.1111/j.1532-5415.1999.tb01556.x; Drummond MF, 2015, METHODS EC EVALUATIO; Gillespie Lesley D, 2012, Cochrane Database Syst Rev, pCD007146, DOI 10.1002/14651858.CD007146.pub3; Guideline for the prevention of falls in older persons, 2001, J AM GERIATR SOC, V49, P664, DOI DOI 10.1046/J.1532-5415.2001.49115.X; Harwood RH, 2005, BRIT J OPHTHALMOL, V89, P53, DOI 10.1136/bjo.2004.049478; Lamb SE, 2005, J AM GERIATR SOC, V53, P1618, DOI 10.1111/j.1532-5415.2005.53455.x; LORD SR, 1991, J AM GERIATR SOC, V39, P1194, DOI 10.1111/j.1532-5415.1991.tb03574.x; Lord SR, 2001, J AM GERIATR SOC, V49, P508, DOI 10.1046/j.1532-5415.2001.49107.x; McAlister FA, 2003, JAMA-J AM MED ASSOC, V289, P2545, DOI 10.1001/jama.289.19.2545; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; *NHS NAT I CLIN EX, 2004, FALLS ASS PREV FALLS; Nikolaus T, 2003, J AM GERIATR SOC, V51, P300, DOI 10.1046/j.1532-5415.2003.51102.x; Robertson MC, 2005, J GERONTOL A-BIOL, V60, P530, DOI 10.1093/gerona/60.4.530; Robertson MC, 2002, J AM GERIATR SOC, V50, P905, DOI 10.1046/j.1532-5415.2002.50218.x; Robertson MC, 2001, BRIT MED J, V322, P697, DOI 10.1136/bmj.322.7288.697; Robertson MC, 2001, BRIT MED J, V322, P701, DOI 10.1136/bmj.322.7288.701; Shaw FE, 2003, BRIT MED J, V326, P73, DOI 10.1136/bmj.326.7380.73; Tinetti ME, 1996, AM J EPIDEMIOL, V144, P389; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301	29	246	248	0	48	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 8	2005	331	7520					817	820A		10.1136/bmj.38601.447731.55	http://dx.doi.org/10.1136/bmj.38601.447731.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974BC	16183652	Green Published, Bronze			2022-12-28	WOS:000232565300022
J	Epstein, PR				Epstein, PR			Climate change and human health	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Med, Ctr Hlth & Global Environm, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Epstein, PR (corresponding author), Harvard Univ, Sch Med, Ctr Hlth & Global Environm, Boston, MA 02115 USA.							Epstein PR, 1998, B AM METEOROL SOC, V79, P409, DOI 10.1175/1520-0477(1998)079<0409:BAPSOC>2.0.CO;2; Hassol S., 2004, ACIA IMPACTS WARMING; HOUGHTON JT, 2001, 3 INT PAN CLIM CHANG; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; McMichael AJ, 2003, CLIMATE CHANGE HUMAN, P250	5	166	169	1	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 6	2005	353	14					1433	1436		10.1056/NEJMp058079	http://dx.doi.org/10.1056/NEJMp058079			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970LZ	16207843				2022-12-28	WOS:000232313000001
J	Neumann, PJ; Rosen, AB; Weinstein, MC				Neumann, PJ; Rosen, AB; Weinstein, MC			Medicare and cost-effectiveness analysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							OLDER PATIENTS; HEALTH-CARE; COVERAGE; QUALITY; NICE; AMERICANS; GUIDANCE; DRUGS; WORK; TIME		Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Boston, MA 02115 USA; Univ Michigan Hlth Syst, Div Gen Med, Ann Arbor, MI USA; Ann Arbor Vet Affairs Med Ctr, Ctr Practice Management & Outcomes Res, Ann Arbor, MI USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System	Neumann, PJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.							Adler GS, 2002, HEALTH CARE FINANC R, V23, P189; Atlas RF, 2004, HEALTH AFFAIR, V23, pW4504, DOI 10.1377/hlthaff.W4.504; Blendon RJ, 1997, JAMA-J AM MED ASSOC, V277, P1253, DOI 10.1001/jama.277.15.1253; Chapman S, 2003, BRIT MED J, V326, P707, DOI 10.1136/bmj.326.7391.707; Coffield AB, 2001, AM J PREV MED, V21, P1, DOI 10.1016/S0749-3797(01)00308-7; *CONS UN, 2004, CONS REP LAUNCH PUBL; Daniels N, 2002, SETTING LIMITS FAIRL; Danzon PM, 2005, AM J MANAG CARE, V11, P173; Dent THS, 2002, BRIT MED J, V324, P842, DOI 10.1136/bmj.324.7341.842; EVANS RG, 1995, ANN INTERN MED, V123, P59, DOI 10.7326/0003-4819-123-1-199507010-00010; Fonarow GC, 2001, CIRCULATION, V103, P38; Foote SB, 2002, J HEALTH POLIT POLIC, V27, P707, DOI 10.1215/03616878-27-5-707; Ganz DA, 2002, ANN INTERN MED, V136, P635, DOI 10.7326/0003-4819-136-8-200204160-00023; Ganz DA, 2000, ANN INTERN MED, V132, P780, DOI 10.7326/0003-4819-132-10-200005160-00003; Garber AM, 2004, HEALTH AFFAIR, V23, pW284, DOI 10.1377/hlthaff.W4.284; *GEN ACC OFF, 2004, GAO04450; Gillick MR, 2004, NEW ENGL J MED, V350, P2199, DOI 10.1056/NEJMsb032612; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; Greene J, 2001, HEALTH CARE FINANC R, V22, P141; Jauhar S, 2004, NEW ENGL J MED, V351, P2542, DOI 10.1056/NEJMe048303; Jencks SF, 2003, JAMA-J AM MED ASSOC, V289, P305, DOI 10.1001/jama.289.3.305; Jencks SF, 2002, JAMA-J AM MED ASSOC, V289, P2649; KASSIRER JP, 1994, NEW ENGL J MED, V331, P669, DOI 10.1056/NEJM199409083311009; Kim M, 2001, HEALTH AFFAIR, V20, P194, DOI 10.1377/hlthaff.20.5.194; Knopman DS, 2004, NEUROLOGY, V62, P506, DOI 10.1212/01.WNL.0000106827.39764.7E; Kolata Gina, 2004, N Y Times Web, pA15; Lipman T, 2001, BRIT MED J, V322, P489; Lynd LD, 2003, J CARDIOVASC ELECTR, V14, pS99, DOI 10.1046/j.1540-8167.14.s9.3.x; McClellan MB, 2005, NEW ENGL J MED, V352, P222, DOI 10.1056/NEJMp048354; McMahon PM, 2003, RADIOLOGY, V228, P515, DOI 10.1148/radiol.2282020915; Mitchell AS, 2002, INT J TECHNOL ASSESS, V18, P203, DOI 10.1017/S0266462302000223; Neumann PJ, 2005, HEALTH AFFAIR, V24, P243, DOI 10.1377/hlthaff.24.1.243; Neumann PJ, 2005, VALUE HEALTH, V8, P3, DOI 10.1111/j.1524-4733.2005.04010.x; Neumann PJ, 2004, AM J MANAG CARE, V10, P308; Neumann PJ, 2004, HEALTH AFFAIR, V23, P124, DOI 10.1377/hlthaff.23.1.124; Neumann PJ, 2002, AM J PREV MED, V23, P276, DOI 10.1016/S0749-3797(02)00516-0; Neumann PJ, 2005, USING COST EFFECTIVE; Newhouse JP, 2004, NEW ENGL J MED, V351, P1714, DOI 10.1056/NEJMp048161; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; PausJenssen AM, 2003, PHARMACOECONOMICS, V21, P285, DOI 10.2165/00019053-200321040-00006; Phillips KA, 2000, JAMA-J AM MED ASSOC, V284, P2748, DOI 10.1001/jama.284.21.2748; Ramsey SD, 2003, NEW ENGL J MED, V348, P2092; Ratnavalli E, 2002, NEUROLOGY, V58, P1615, DOI 10.1212/WNL.58.11.1615; Rawlins MD, 2004, NEW ENGL J MED, V351, P1383, DOI 10.1056/NEJMp048221; Rawlins MD, 2004, BRIT MED J, V329, P224, DOI 10.1136/bmj.329.7459.224; Reinhardt UE, 2004, HEALTH AFFAIR, V23, P107, DOI 10.1377/hlthaff.23.1.107; Rennie D, 2000, JAMA-J AM MED ASSOC, V283, P2158, DOI 10.1001/jama.283.16.2158; Robinson JC, 2001, JAMA-J AM MED ASSOC, V285, P2622, DOI 10.1001/jama.285.20.2622; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; SAMSON D, 2005, TEC ASSESSMENTS, V19, P1; Sanders GD, 2005, NEW ENGL J MED, V353, P1471, DOI 10.1056/NEJMsa051989; Sisk JE, 2000, JAMA-J AM MED ASSOC, V283, P341; Smith R, 2000, BRIT MED J, V321, P1363, DOI 10.1136/bmj.321.7273.1363; Stanton MS, 2005, HEALTH AFFAIR, V24, P52, DOI 10.1377/hlthaff.24.1.52; Taylor RS, 2004, BMJ-BRIT MED J, V329, P972, DOI 10.1136/bmj.329.7472.972; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Tunis SR, 2004, AM J MANAG CARE, V10, P301; Tunis SR, 2004, NEW ENGL J MED, V350, P2196, DOI 10.1056/NEJMe048091; *US PREV SERV TASK, OST SCREEN; Walker R, 2001, BRIT MED J, V322, P490; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; Winkelmayer WC, 2002, MED DECIS MAKING, V22, P417, DOI 10.1177/027298902236927; 2004, PINK SHEET, V66, P111; 1989, FED REG, V54, P4302	64	170	172	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 6	2005	353	14					1516	1522		10.1056/NEJMsb050564	http://dx.doi.org/10.1056/NEJMsb050564			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970LZ	16207857				2022-12-28	WOS:000232313000015
J	Sanders, GD; Hlatky, MA; Owens, DK				Sanders, GD; Hlatky, MA; Owens, DK			Cost-effectiveness of implantable cardioverter-defibrillators	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIAC-RESYNCHRONIZATION THERAPY; ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-LIFE; PROPHYLACTIC USE; RANDOMIZED-TRIAL; HIGH-RISK; AMIODARONE; SURVIVAL; PREVENTION; LONGEVITY	BACKGROUND: Eight randomized trials have evaluated whether the prophylactic use of an implantable cardioverter-defibrillator (ICD) improves survival among patients who are at risk for sudden death due to left ventricular systolic dysfunction but who have not had a life-threatening ventricular arrhythmia. We assessed the cost-effectiveness of the ICD in the populations represented in these primary-prevention trials. METHODS: We developed a Markov model of the cost, quality of life, survival, and incremental cost-effectiveness of the prophylactic implantation of an ICD, as compared with control therapy, among patients with survival and mortality rates similar to those in each of the clinical trials. We modeled the efficacy of the ICD as a reduction in the relative risk of death on the basis of the hazard ratios reported in the individual clinical trials. RESULTS: Use of the ICD increased lifetime costs in every trial. Two trials -- the Coronary Artery Bypass Graft (CABG) Patch Trial and the Defibrillator in Acute Myocardial Infarction Trial (DINAMIT) -- found that the prophylactic implantation of an ICD did not reduce the risk of death and thus was both more expensive and less effective than control therapy. For the other six trials -- the Multicenter Automatic Defibrillator Implantation Trial (MADIT) I, MADIT II, the Multicenter Unsustained Tachycardia Trial (MUSTT), the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial, the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial, and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) -- the use of an ICD was projected to add between 1.01 and 2.99 quality-adjusted life-years (QALY) and between $68,300 and $101,500 in cost. Using base-case assumptions, we found that the cost-effectiveness of the ICD as compared with control therapy in these six populations ranged from $34,000 to $70,200 per QALY gained. Sensitivity analyses showed that this cost-effectiveness ratio would remain below $100,000 per QALY as long as the ICD reduced mortality for seven or more years. CONCLUSIONS: Prophylactic implantation of an ICD has a cost-effectiveness ratio below $100,000 per QALY gained in populations in which a significant device-related reduction in mortality has been demonstrated.	Duke Univ, Duke Clin Res Inst, Durham, NC 27715 USA; Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA; Stanford Univ, Dept Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA	Duke University; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Sanders, GD (corresponding author), Duke Univ, Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA.	gillian.sanders@duke.edu		Hlatky, Mark/0000-0003-4686-9441				Al-Khatib SM, 2005, AM HEART J, V149, P1020, DOI 10.1016/j.ahj.2005.02.005; [Anonymous], 2004, Technol Eval Cent Assess Program Exec Summ, V19, P1; Bardy GH, 2005, NEW ENGL J MED, V352, P2146; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; Bigger JT, 1997, NEW ENGL J MED, V337, P1569, DOI 10.1056/NEJM199711273372201; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Buxton AE, 2000, NEW ENGL J MED, V343, P1813; Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503; Connolly SJ, 2000, CIRCULATION, V101, P1297, DOI 10.1161/01.CIR.101.11.1297; EVERY NR, 1995, J AM COLL CARDIOL, V26, P401, DOI 10.1016/0735-1097(95)80013-7; Every NR, 1997, CIRCULATION, V96, P1770, DOI 10.1161/01.CIR.96.6.1770; *EX OFF PRES US, BUDG US GOV; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; GABRY MD, 1987, J AM COLL CARDIOL, V9, P1349, DOI 10.1016/S0735-1097(87)80477-1; Gold MR, 1996, COST EFFECTIVENESS H; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; Hauser RG, 2005, J AM COLL CARDIOL, V45, P2022, DOI 10.1016/j.jacc.2005.02.077; Hlatky MA, 2005, HEALTH AFFAIR, V24, P42, DOI 10.1377/hlthaff.24.1.42; Hohnloser SH, 2004, NEW ENGL J MED, V351, P2481, DOI 10.1056/NEJMoa041489; Hsu J, 2002, AM HEART J, V144, P404, DOI 10.1067/mhj.2002.125497; Irvine J, 2002, AM HEART J, V144, P282, DOI 10.1067/mhj.2002.124049; Kadish A, 2004, NEW ENGL J MED, V350, P2151, DOI 10.1056/NEJMoa033088; Kuntz KM, 1996, CIRCULATION, V94, P957, DOI 10.1161/01.CIR.94.5.957; LARSEN GC, 1992, J AM COLL CARDIOL, V19, P1323, DOI 10.1016/0735-1097(92)90341-J; Lewis EF, 2001, J HEART LUNG TRANSPL, V20, P1016, DOI 10.1016/S1053-2498(01)00298-4; Lipscomb J., 1996, COST EFFECTIVENESS H, P214; Mankiw N.G., 2001, PRINCIPLES EC; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; McClellan MB, 2005, NEW ENGL J MED, V352, P222, DOI 10.1056/NEJMp048354; *MEDTR, 2005, INTR DUAL CHAMB ICD; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; MOYE LA, 1991, AM J CARDIOL, V68, pD70; Owens DK, 1997, ANN INTERN MED, V126, P1, DOI 10.7326/0003-4819-126-1-199701010-00001; SAKSENA S, 1992, J AM COLL CARDIOL, V19, P490, DOI 10.1016/S0735-1097(10)80260-8; Sanders GD, 2001, ANN INTERN MED, V135, P870, DOI 10.7326/0003-4819-135-10-200111200-00007; Shah M, 2005, AM HEART J, V149, P242; SIEBELS J, 1994, AM HEART J, V127, P1139, DOI 10.1016/0002-8703(94)90101-5; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; ZIPES DP, 1995, CIRCULATION, V92, P59, DOI 10.1161/01.CIR.92.1.59	42	391	394	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 6	2005	353	14					1471	1480		10.1056/NEJMsa051989	http://dx.doi.org/10.1056/NEJMsa051989			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970LZ	16207849				2022-12-28	WOS:000232313000007
J	Gostin, LO				Gostin, LO			The supreme court's influence on medicine and health - The Rehnquist Court, 1986-2005	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Georgetown Univ, Ctr Law, Washington, DC 20001 USA; Johns Bloomberg Sch Publ Hlth, Washington, DC USA; Johns Bloomberg Sch Publ Hlth, Baltimore, MD USA	Georgetown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu							0	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	2005	294	13					1685	1687		10.1001/jama.294.13.1685	http://dx.doi.org/10.1001/jama.294.13.1685			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970DC	16204668				2022-12-28	WOS:000232284400021
J	Abraham, E; Laterre, P; Garg, R; Levy, H; Talwar, D; Trzaskoma, BL; Francois, B; Guy, JS; Bruckmann, M; Rea-Neto, A; Rossaint, R; Perrotin, D; Sablotzki, A; Arkins, N; Utterback, BG; Macias, WL				Abraham, E; Laterre, P; Garg, R; Levy, H; Talwar, D; Trzaskoma, BL; Francois, B; Guy, JS; Bruckmann, M; Rea-Neto, A; Rossaint, R; Perrotin, D; Sablotzki, A; Arkins, N; Utterback, BG; Macias, WL		ADDRESS Study Grp	Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROTEIN-C; EPIDEMIOLOGY; SAFETY	BACKGROUND: In November 2001, the Food and Drug Administration (FDA) approved drotrecogin alfa (activated) (DrotAA) for adults who had severe sepsis and a high risk of death. The FDA required a study to evaluate the efficacy of DrotAA for adults who had severe sepsis and a low risk of death. METHODS: We randomly assigned adult patients with severe sepsis and a low risk of death (defined by an Acute Physiology and Chronic Health Evaluation [APACHE II] score <25 or single-organ failure) to receive an intravenous infusion of placebo or DrotAA (24 microg per kilogram of body weight per hour) for 96 hours in a double-blind, placebo-controlled, multicenter trial. The prospectively defined primary end point was death from any cause and was assessed 28 days after the start of the infusion. In-hospital mortality within 90 days after the start of the infusion was measured, and safety information was collected. RESULTS: Enrollment in the trial was terminated early because of a low likelihood of meeting the prospectively defined objective of demonstrating a significant reduction in the 28-day mortality rate with the use of DrotAA. The study enrolled 2640 patients and collected data on 2613 (1297 in the placebo group and 1316 in the DrotAA group) at the 28-day follow-up. There were no statistically significant differences between the placebo group and the DrotAA group in 28-day mortality (17.0 percent in the placebo group vs. 18.5 percent in the DrotAA group; P=0.34; relative risk, 1.08; 95 percent confidence interval, 0.92 to 1.28) or in in-hospital mortality (20.5 percent vs. 20.6 percent; P=0.98; relative risk, 1.00; 95 percent confidence interval, 0.86 to 1.16). The rate of serious bleeding was greater in the DrotAA group than in the placebo group during both the infusion (2.4 percent vs. 1.2 percent, P=0.02) and the 28-day study period (3.9 percent vs. 2.2 percent, P=0.01). CONCLUSIONS: The absence of a beneficial treatment effect, coupled with an increased incidence of serious bleeding complications, indicates that DrotAA should not be used in patients with severe sepsis who are at low risk for death, such as those with single-organ failure or an APACHE II score less than 25.	Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; Catholic Univ Louvain, St Luc Univ Hosp, Dept Crit Care Med, B-1200 Brussels, Belgium; Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA; Metro Hosp & Heart Inst, Noida, Uttar Pradesh, India; Hop Dupuytren, Ctr Hosp Univ Limoges, Limoges, France; Vanderbilt Univ, Med Ctr, Sect Surg Sci, Nashville, TN USA; Heidelberg Univ, Fac Clin Med Mannheim, Dept Med 1, D-6800 Mannheim, Germany; Univ Fed Parana, Hosp Clin, Adult Intens Care Unit, BR-80060000 Curitiba, Parana, Brazil; Univ Klin Aachen, Aachen, Germany; Hop Bretonneau, Ctr Hosp Univ Tours, Tours, France; Univ Halle Wittenberg, Klinikum Med Fak, Halle An Der Saale, Germany	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Eli Lilly; CHU Limoges; Vanderbilt University; Ruprecht Karls University Heidelberg; Universidade Federal do Parana; RWTH Aachen University; RWTH Aachen University Hospital; CHU Tours; Martin Luther University Halle Wittenberg	Abraham, E (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, 4200 E 9th Ave, Denver, CO 80262 USA.	edward.abraham@UCHSC.edu	Leditschke, Isabel A/M-1186-2015; François, Bruno/O-8404-2016; Sierra, Rafael/I-3441-2015; Réa-Neto, Álvaro/AAR-7909-2020	Leditschke, Isabel A/0000-0003-2212-2140; François, Bruno/0000-0002-2531-1652; Sierra, Rafael/0000-0002-6021-396X; Rea-Neto, Alvaro/0000-0001-5524-0907				Alberti C, 2002, INTENS CARE MED, V28, P525, DOI 10.1007/s00134-002-1284-8; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Angus DC, 2004, CRIT CARE MED, V32, P2199, DOI 10.1097/01.CCM.0000145228.62451.F6; Bernard GR, 2003, CRIT CARE, V7, P155, DOI 10.1186/cc2167; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Brun-Buisson C, 2004, INTENS CARE MED, V30, P580, DOI 10.1007/s00134-003-2121-4; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; DeMets DL, 1995, CONTROL CLIN TRIALS, V16, P408, DOI 10.1016/S0197-2456(95)00073-9; Dhainaut JFO, 2003, THROMB HAEMOSTASIS, V90, P642, DOI 10.1160/TH02-11-0270; Ely EW, 2003, CRIT CARE MED, V31, P12, DOI 10.1097/00003246-200301000-00002; Finfer S, 2004, INTENS CARE MED, V30, P1252, DOI 10.1007/s00134-004-2263-z; Finfer S, 2004, INTENS CARE MED, V30, P589, DOI 10.1007/s00134-004-2157-0; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Linde-Zwirble WT, 2004, CRIT CARE, V8, P222, DOI 10.1186/cc2917; Macias WL, 2004, CRIT CARE MED, V32, P2385, DOI 10.1097/01.CCM.0000147440.71142.AC; Padkin A, 2003, CRIT CARE MED, V31, P2332, DOI 10.1097/01.CCM.0000085141.75513.2B; Sands KE, 1997, JAMA-J AM MED ASSOC, V278, P234, DOI 10.1001/jama.278.3.234; Siegel JP, 2002, NEW ENGL J MED, V347, P1030, DOI 10.1056/NEJMsb021512; Silva E, 2004, CRIT CARE, V8, pR251, DOI 10.1186/cc2892; VINCENT JL, IN PRESS CRIT CARE M	20	647	691	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2005	353	13					1332	1341		10.1056/NEJMoa050935	http://dx.doi.org/10.1056/NEJMoa050935			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968FB	16192478				2022-12-28	WOS:000232146200005
J	Hu, DL; Bush, JWM				Hu, DL; Bush, JWM			Meniscus-climbing insects	NATURE			English	Article							WATER-SURFACE; LOCOMOTION	Water-walking insects and spiders rely on surface tension for static weight support(1,2) and use a variety of means to propel themselves along the surface(3-8). To pass from the water surface to land, they must contend with the slippery slopes of the menisci that border the water's edge. The ability to climb menisci is a skill exploited by water-walking insects as they seek land in order to lay eggs or avoid predators(4); moreover, it was a necessary adaptation for their ancestors as they evolved from terrestrials to live exclusively on the water surface(3). Many millimetre-scale water-walking insects are unable to climb menisci using their traditional means of propulsion(2,3,9). Through a combined experimental and theoretical study, here we investigate the meniscus-climbing technique that such insects use. By assuming a fixed body posture, they deform the water surface in order to generate capillary forces(10-13): they thus propel themselves laterally without moving their appendages. We develop a theoretical model for this novel mode of propulsion and use it to rationalize the climbers' characteristic body postures and predict climbing trajectories consistent with those reported here and elsewhere(3).	MIT, Dept Math, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Bush, JWM (corresponding author), MIT, Dept Math, Cambridge, MA 02139 USA.	bush@math.mit.edu						Alexander RM., 2003, PRINCIPLES ANIMAL LO; Andersen N.M., 1976, Videnskabelige Meddr dansk naturh Foren, V139, P337; Andersen NM, 1982, SEMIAQUATIC BUGS HEM; Baudoin R, 1955, B BIOL FR BELG, V89, P16; BIEWENER A, 2003, ANIMAL LOCMOTION; Brocher Frank, 1910, Annales de Biologie Lacustre, V4; BUSH JWM, IN PRESS ANN REV FLU, V38, P339; CHAN DYC, 1981, J COLLOID INTERF SCI, V79, P410, DOI 10.1016/0021-9797(81)90092-8; Dickinson MH, 2000, SCIENCE, V288, P100, DOI 10.1126/science.288.5463.100; Gao XF, 2004, NATURE, V432, P36, DOI 10.1038/432036a; Gennes P.-G.d., 2003, CAPILLARITY WETTING, V2004 ed.; GIFFORD WA, 1971, CHEM ENG SCI, V26, P287, DOI 10.1016/0009-2509(71)83003-8; Grzybowski BA, 2001, J PHYS CHEM B, V105, P404, DOI 10.1021/jp0026383; Hu DL, 2003, NATURE, V424, P663, DOI 10.1038/nature01793; Kralchevsky PA, 2001, CURR OPIN COLLOID IN, V6, P383, DOI 10.1016/S1359-0294(01)00105-4; Lauga E, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.238301; Manoharan VN, 2003, SCIENCE, V301, P483, DOI 10.1126/science.1086189; Miyamoto S., 1955, Kontyu Tokyo, V23, P45; NICOLSON MM, 1949, P CAMB PHILOS SOC, V45, P288, DOI 10.1017/S0305004100024841; Suter RB, 1997, J EXP BIOL, V200, P2523; Suter RB, 1999, J EXP BIOL, V202, P2771; Suter RB, 2000, J ARACHNOL, V28, P201, DOI 10.1636/0161-8202(2000)028[0201:PAOTWS]2.0.CO;2; Vella D, 2005, AM J PHYS, V73, P817, DOI 10.1119/1.1898523; VOGEL S, 2003, BIOMECHANICS LIFES P; Whitesides GM, 2002, SCIENCE, V295, P2418, DOI 10.1126/science.1070821	25	196	201	6	157	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					733	736		10.1038/nature03995	http://dx.doi.org/10.1038/nature03995			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193052				2022-12-28	WOS:000232157900052
J	Smits, M; Dippel, DWJ; de Haan, GG; Dekker, HM; Vos, PE; Kool, DR; Nederkoorn, PJ; Hofman, PAM; Twijnstra, A; Tanghe, HLJ; Hunink, MGM				Smits, M; Dippel, DWJ; de Haan, GG; Dekker, HM; Vos, PE; Kool, DR; Nederkoorn, PJ; Hofman, PAM; Twijnstra, A; Tanghe, HLJ; Hunink, MGM			External validation of the Canadian CT Head Rule and the New Orleans Criteria for CT scanning in patients with minor head injury	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MANAGEMENT; DIAGNOSIS	Context Two decision rules for indications of computed tomography (CT) in patients with minor head injury, the Canadian CT Head Rule (CCHR) and the New Orleans Criteria (NOC), suggest that CT scanning may be restricted to patients with certain risk factors, which would lead to important reductions in the use of CT scans. Objective To validate and compare these 2 published decision rules in Dutch patients with head injuries. Design, Setting, and Patients A prospective multicenter study conducted between February 11, 2002, and August 31, 2004, in 4 university hospitals in the Netherlands of 3181 consecutive adult patients with minor head injury who presented with a Glasgow Coma Scale (GCS) score of 13 to 14 or with a GCS score of 15 and at least 1 risk factor. Main Outcome Measures Primary outcome was any neurocranial traumatic finding on CT scan. Secondary outcomes were neurosurgical intervention and clinically important CT findings. Sensitivity and specificity were estimated for each outcome for the CCHR and the NOC, using both rules as originally derived and also as adapted to apply to an expanded patient population. Results Of 3181 patients with a GCS score of 13 to 15, neurosurgical intervention was performed in 17 patients (0.5%); neurocranial traumatic CT findings were present in 312 patients (9.8%). Sensitivity for neurosurgical intervention was 100% for both the CCHR and the NOC. The NOC had a higher sensitivity for neurocranial traumatic findings and for clinically important findings (97.7% -99.4%) than did the CCHR (83.4%-87.2%). Specificities were very low for the NOC (3.0%-5.6%) and higher for the CCHR (37.2%-39.7%). The estimated potential reduction in CT scans for patients with minor head injury would be 3.0% for the adapted NOC and 37.3 % for the adapted CCHR. Conclusions For patients with minor head injury and a GCS score of 13 to 15, the CCHR has a lower sensitivity than the NOC for neurocranial traumatic or clinically important CT findings, but would identify all cases requiring neurosurgical intervention, and has greater potential for reducing the use of CT scans.	Erasmus MC Univ Med Ctr, Dept Radiol, NL-3000 DR Rotterdam, Netherlands; Erasmus MC Univ Med Ctr, Dept Neurol, NL-3000 DR Rotterdam, Netherlands; Erasmus MC Univ Med Ctr, Dept Med Informat, NL-3000 DR Rotterdam, Netherlands; Erasmus MC Univ Med Ctr, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Univ Med Ctr Nijmegen St Radboud, Dept Radiol, Nijmegen, Netherlands; Univ Med Ctr Nijmegen St Radboud, Dept Neurol, Nijmegen, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Radiol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands; Univ Hosp Maastricht, Dept Radiol, Maastricht, Netherlands; Univ Hosp Maastricht, Dept Neurol, Maastricht, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Radboud University Nijmegen; Radboud University Nijmegen; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)	Hunink, MGM (corresponding author), Erasmus MC Univ Med Ctr, Dept Radiol, POB 1738, NL-3000 DR Rotterdam, Netherlands.	m.hunink@erasmusmc.nl	Smits, Marion/AAB-3985-2019; Dippel, Diederik/AAJ-2192-2020; Smits, Marion/E-4795-2011; Dekker, H.M./L-4262-2015; Vos, Pieter/A-6043-2012	Smits, Marion/0000-0001-5563-2871; Dippel, Diederik/0000-0002-9234-3515; 				BERRY CC, 1990, AM J ROENTGENOL, V154, P477, DOI 10.2214/ajr.154.3.2106207; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Graham ID, 1998, ACAD EMERG MED, V5, P134, DOI 10.1111/j.1553-2712.1998.tb02598.x; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Hunink MGM, 2005, RADIOLOGY, V235, P375, DOI 10.1148/radiol.2352040727; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Los RK, 2004, J AM MED INFORM ASSN, V11, P162, DOI 10.1197/jamia.M1375; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TWIJNSTRA A, GUIDELINES DIAGNOSIS; Vergouwe Y, 2005, J CLIN EPIDEMIOL, V58, P475, DOI 10.1016/j.jclinepi.2004.06.017; Vergouwe Y., 2003, VALIDATION CLIN PRED	18	236	244	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	2005	294	12					1519	1525		10.1001/jama.294.12.1519	http://dx.doi.org/10.1001/jama.294.12.1519			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TF	16189365	Bronze			2022-12-28	WOS:000232113400022
J	Tannsjo, T				Tannsjo, T			Moral dimensions	BRITISH MEDICAL JOURNAL			English	Editorial Material									Stockholm Univ, Dept Philosophy, S-10691 Stockholm, Sweden	Stockholm University	Tannsjo, T (corresponding author), Stockholm Univ, Dept Philosophy, S-10691 Stockholm, Sweden.	torbjorn.tannsjo@philosophy.su.se		Tannsjo, Torbjorn/0000-0001-9670-4608					0	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	SEP 24	2005	331	7518					689	691		10.1136/bmj.331.7518.689	http://dx.doi.org/10.1136/bmj.331.7518.689			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970HH	16179707	Green Published			2022-12-28	WOS:000232295400024
J	Heine, RJ; Van Gaal, LF; Johns, D; Mihm, MJ; Widel, MH; Brodows, RG				Heine, RJ; Van Gaal, LF; Johns, D; Mihm, MJ; Widel, MH; Brodows, RG		GWAA Study Grp	Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN NPH INSULIN; GLYCEMIC CONTROL; BASAL INSULIN; COMBINATION THERAPY; TREATED PATIENTS; ORAL-AGENTS; GLUCOSE; METFORMIN; SULFONYLUREA; EXENDIN-4	Background: Physicians may use either insulin or exenatide injections for patients with type 2 diabetes mellitus who have poor glycemic control despite taking oral blood glucose-lowering drugs. Objective: To compare effects of exenatide and insulin glargine on glycemic control in patients with type 2 diabetes mellitus that is suboptimally controlled with metformin and a sulfonylurea. Design: 26-week multicenter, open-label, randomized, controlled trial. Setting: 82 outpatient study centers in 13 countries. Patients: 551 patients with type 2 diabetes and inadequate glycemic control (defined as hemoglobin A(1c) level ranging from 7.0% to 10.0%) despite combination metformin and sulfonylurea. therapy. Intervention: Exenaticle, 10 mu g twice daily, or insulin glargine, 1 daily dose titrated to maintain fasting blood glucose levels of less than 5.6 mmol/L (< 100 mg/dL). Measurements: Hemoglobin A(1c) level, fasting plasma glucose level, body weight, 7-point self-monitored blood glucose, standardized test-meal challenge, safety, and tolerability. Results: Baseline mean hemoglobin A(1c) level was 8.2% for patients receiving exenatide and 8.3% for those receiving insulin glargine. At week 26, both exenatide and insulin glargine reduced hemoglobin Ale levels by 1.11% (difference, 0.017 percentage point [95% Cl, -0.123 to 0.157 percentage point]). Exenatide reduced postprandial glucose excursions more than insulin glargine, while insulin glargine reduced fasting glucose concentrations more than exenatide. Body weight decreased 2.3 kg with exenaticle and increased 1.8 kg with insulin glargine (difference, -4.1 kg [Cl, -4.6 to -3.5 kg]). Rates of symptomatic hypoglycemia were similar, but nocturnal hypoglycemia occurred less frequently with exenaticle (0.9 event/patient-year versus 2.4 events/ patient-year; difference, -1.6 events/patient-year [Cl, -2.3 to -0.9 event/patient year]). Gastrointestinal symptoms were more common in the exenaticle group than in the insulin glargine group, including nausea (57.1% vs. 8.6%), vomiting (17.4% vs. 3.7%) and diarrhea (8.5% vs. 3.0%). Limitations: The trial was open-label and did not assess clinical complications related to diabetes. Of the 551 participants, 19.4% of those receiving exenaticle and 9.7% of those receiving insulin glargine withdrew from the study. Only 21.6% of the insulin glargine group and 8.6% of the exenaticle group achieved the target level for fasting plasma glucose of less than 5.6 mmol/L (< 100 mg/dL). Conclusions: Exenatide and insulin glargine achieved similar improvements in overall glycemic control in patients with type 2 diabetes that was suboptimally controlled with oral combination therapy. Exenatide was associated with weight reduction and had a higher incidence of gastrointestinal adverse effects than insulin glargine.	Vrije Univ Amsterdam, Ctr Med, Diabet Ctr, NL-1007 MB Amsterdam, Netherlands; Univ Hosp Antwerp, Antwerp, Belgium; Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA	Vrije Universiteit Amsterdam; University of Antwerp; Eli Lilly	Heine, RJ (corresponding author), Vrije Univ Amsterdam, Ctr Med, Diabet Ctr, POB 7057, NL-1007 MB Amsterdam, Netherlands.							Bastyr EJ, 2000, DIABETES CARE, V23, P1236, DOI 10.2337/diacare.23.9.1236; Benedetti MM, 2003, HORM METAB RES, V35, P189; Buse JB, 2004, DIABETES CARE, V27, P2628, DOI 10.2337/diacare.27.11.2628; Coutinho M, 1999, DIABETES CARE, V22, P233, DOI 10.2337/diacare.22.2.233; Cryer PE, 1999, DIABETES-METAB RES, V15, P42, DOI 10.1002/(SICI)1520-7560(199901/02)15:1<42::AID-DMRR1>3.0.CO;2-B; DeFronzo RA, 2005, DIABETES CARE, V28, P1092, DOI 10.2337/diacare.28.5.1092; DEVECIANA M, 1995, NEW ENGL J MED, V333, P1237, DOI 10.1056/NEJM199511093331901; DONAHUE RP, 1987, DIABETES, V36, P689, DOI 10.2337/diabetes.36.6.689; Drucker DJ, 2003, DIABETES CARE, V26, P2929, DOI 10.2337/diacare.26.10.2929; Engelgau MM, 1997, DIABETES CARE, V20, P785, DOI 10.2337/diacare.20.5.785; Fehse FC, 2004, DIABETES, V53, pA82; Fineman MS, 2003, DIABETES CARE, V26, P2370, DOI 10.2337/diacare.26.8.2370; Fritsche A, 2003, ANN INTERN MED, V138, P952, DOI 10.7326/0003-4819-138-12-200306170-00006; Gerich JE, 2004, CURR MED RES OPIN, V20, P31, DOI 10.1185/030079903125002711; Heine RJ, 2002, DIABETOLOGIA, V45, P461, DOI 10.1007/s00125-001-0726-0; Janka HU, 2005, DIABETES CARE, V28, P254, DOI 10.2337/diacare.28.2.254; Kendall DM, 2005, DIABETES CARE, V28, P1083, DOI 10.2337/diacare.28.5.1083; Kerr D, 1999, DIABETES-METAB RES, V15, P219, DOI 10.1002/(SICI)1520-7560(199905/06)15:3<219::AID-DMRR32>3.0.CO;2-V; Klein S, 2004, DIABETES CARE, V27, P2067, DOI 10.2337/diacare.27.8.2067; KREYMANN B, 1987, LANCET, V2, P1300; Makimattila S, 1999, DIABETOLOGIA, V42, P406, DOI 10.1007/s001250051172; MCCANCE DR, 1994, BRIT MED J, V308, P1323, DOI 10.1136/bmj.308.6940.1323; MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432-1033.1993.tb17986.x; Monnier L, 2003, DIABETES CARE, V26, P881, DOI 10.2337/diacare.26.3.881; Mudaliar S, 2001, ENDOCRIN METAB CLIN, V30, P935, DOI 10.1016/S0889-8529(05)70222-X; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Raskin P, 2005, DIABETES CARE, V28, P260, DOI 10.2337/diacare.28.2.260; Riddle Matthew C., 2004, American Journal of Medicine, V116, p3S; Riddle MC, 2003, DIABETES CARE, V26, P3080, DOI 10.2337/diacare.26.11.3080; Rosenstock J, 2005, DIABETES CARE, V28, P950, DOI 10.2337/diacare.28.4.950; Rosenstock J, 2001, DIABETES CARE, V24, P631, DOI 10.2337/diacare.24.4.631; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; Van Gaal LF, 2003, DIABETOLOGIA, V46, pM44, DOI 10.1007/s00125-002-0936-0; Yki-Jarvinen H, 2000, DIABETES CARE, V23, P1130, DOI 10.2337/diacare.23.8.1130	34	598	650	3	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 18	2005	143	8					559	569		10.7326/0003-4819-143-8-200510180-00006	http://dx.doi.org/10.7326/0003-4819-143-8-200510180-00006			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975PI	16230722				2022-12-28	WOS:000232674000006
J	Frohlich, ED				Frohlich, ED			Hurricane Katrina - Aftershocks	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ochsner Clin Fdn, New Orleans, LA 70121 USA	Ochsner Health System	Frohlich, ED (corresponding author), Ochsner Clin Fdn, New Orleans, LA 70121 USA.								0	5	5	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1545	1545		10.1056/NEJMp058231	http://dx.doi.org/10.1056/NEJMp058231			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221773				2022-12-28	WOS:000232486000004
J	Robinson, BWS; Lake, RA				Robinson, BWS; Lake, RA			Medical progress - Advances in malignant mesothelioma	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							COMPARATIVE GENOMIC HYBRIDIZATION; EPITHELIAL MEMBRANE ANTIGEN; HUMAN PLEURAL MESOTHELIOMA; GROWTH-FACTOR RECEPTOR; GENE-THERAPY; LUNG-CANCER; PHASE-II; CONSECUTIVE PATIENTS; DISEASE PROGRESSION; PROGNOSTIC-FACTORS		Univ Western Australia, Sir Charles Gairdner Hosp, Sch Med & Pharmacol, Perth, WA 6009, Australia; Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA 6009, Australia; Sir Charles Gairdner Hosp, Western Australian Inst Med Res, Perth, WA 6009, Australia	University of Western Australia; University of Western Australia; University of Western Australia	Robinson, BWS (corresponding author), Univ Western Australia, Sir Charles Gairdner Hosp, Sch Med & Pharmacol, 4th Fl,G Block, Perth, WA 6009, Australia.	bwsrobin@cyllene.uwa.edu.au	Robinson, Bruce/N-1900-2014					Ahamad A, 2003, CANCER J, V9, P476, DOI 10.1097/00130404-200311000-00008; ARCHER VE, 1983, LANCET, V2, P112; Astoul P, 1999, Curr Opin Pulm Med, V5, P259, DOI 10.1097/00063198-199907000-00015; AULT JG, 1995, CANCER RES, V55, P792; Baldini Elizabeth H, 2004, Thorac Surg Clin, V14, P543; Balsara BR, 1999, CANCER RES, V59, P450; BIELEFELDTOHMANN H, 1995, CANCER IMMUNOL IMMUN, V40, P241, DOI 10.1007/s002620050169; Bjorkqvist AM, 1997, BRIT J CANCER, V75, P523, DOI 10.1038/bjc.1997.91; BOUTIN C, 1993, CANCER, V72, P389, DOI 10.1002/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V; Broaddus VC, 2005, J BIOL CHEM, V280, P12486, DOI 10.1074/jbc.M408190200; Byrne MJ, 1999, J CLIN ONCOL, V17, P25, DOI 10.1200/JCO.1999.17.1.25; CARBONE M, 1994, ONCOGENE, V9, P1781; Carroll Stephen J, ASBESTOS LITIGATION; Castagneto B, 2001, LUNG CANCER, V31, P303, DOI 10.1016/S0169-5002(00)00192-6; Chahininian AP, 2002, MESOTHELIOMA, P143; CICALA C, 1993, AM J PATHOL, V142, P1524; Creaney J, 2001, BRIT J CANCER, V84, P52, DOI 10.1054/bjoc.2000.1529; Davidson JA, 1998, J IMMUNOTHER, V21, P389, DOI 10.1097/00002371-199809000-00007; DAVIS MR, 1992, INT J CANCER, V52, P881, DOI 10.1002/ijc.2910520609; DAZZI H, 1990, BRIT J CANCER, V61, P924, DOI 10.1038/bjc.1990.207; de Klerk NH, 2002, MESOTHELIOMA, P339; Dhaene K, 2000, J PATHOL, V190, P80; Edwards JG, 2003, CHEST, V124, P1916, DOI 10.1378/chest.124.5.1916; Edwards JG, 2003, BRIT J CANCER, V88, P1553, DOI 10.1038/sj.bjc.6600920; Evans AL, 2004, RESPIROLOGY, V9, P300, DOI 10.1111/j.1440-1843.2004.00599.x; FITZPATRICK DR, 1994, GROWTH FACTORS, V11, P29, DOI 10.3109/08977199409015049; Flores RM, 2003, J THORAC CARDIOV SUR, V126, P11, DOI 10.1016/s0022-5223(03)00207-1; GARLEPP MJ, 1993, EUR RESPIR REV, V3, P192; Goerres GW, 2004, J NUCL MED, V45, p66S; Gordon GJ, 2002, CANCER RES, V62, P4963; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hassan R, 2004, CLIN CANCER RES, V10, P3937, DOI 10.1158/1078-0432.CCR-03-0801; Herndon JE, 1998, CHEST, V113, P723, DOI 10.1378/chest.113.3.723; Hodgson JT, 2000, ANN OCCUP HYG, V44, P565, DOI 10.1093/annhyg/44.8.565; Janne Pasi A, 2003, Clin Lung Cancer, V5, P98, DOI 10.3816/CLC.2003.n.023; KAMP DW, 1995, AM J PHYSIOL, V268, P471; Kindler HL, 2004, LUNG CANCER-J IASLC, V45, pS125, DOI 10.1016/j.lungcan.2004.04.022; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Lee Y C, 2000, Curr Opin Pulm Med, V6, P267, DOI 10.1097/00063198-200007000-00003; Lee Y.C., 2002, MESOTHELIOMA EDITORS, P111; Leigh J, 2002, MESOTHELIOMA, P55; MacLachlan DS, 2002, ANTICANCER RES, V22, P3495; Marzo AL, 1997, CANCER RES, V57, P3200; Masood R, 2003, INT J CANCER, V104, P603, DOI 10.1002/ijc.10996; Merritt RE, 2004, ANN THORAC SURG, V78, P1042, DOI 10.1016/j.athoracsur.2004.03.021; Mukherjee S, 2000, CANCER GENE THER, V7, P663, DOI 10.1038/sj.cgt.7700133; MUKHERJEE S, 2002, MESOTHELIOMA, P325; MURAYAMA T, 2004, P GLOB ASB C TOK NOV, P17; MUSK AW, 1991, AUST NZ J MED, V21, P460, DOI 10.1111/j.1445-5994.1991.tb01355.x; Mutsaers SE, 2004, INT J BIOCHEM CELL B, V36, P9, DOI 10.1016/S1357-2725(03)00242-5; Nowak AK, 2003, CANCER RES, V63, P4490; Nowak AK, 2002, SEMIN ONCOL, V29, P82, DOI 10.1053/sonc.2002.30234; Nowak AK, 2002, BRIT J CANCER, V87, P491, DOI 10.1038/sj.bjc.6600505; O'Byrne KJ, 2004, LUNG CANCER-J IASLC, V45, pS45, DOI 10.1016/j.lungcan.2004.04.025; Pass HI, 1997, ANN SURG ONCOL, V4, P215, DOI 10.1007/BF02306613; PASS HI, IN PRESS ASBESTOS EX; PELIN K, 1994, CARCINOGENESIS, V15, P2673, DOI 10.1093/carcin/15.11.2673; Peto J, 1999, BRIT J CANCER, V79, P666, DOI 10.1038/sj.bjc.6690105; Posadas EM, 2005, ANN ONCOL, V16, P16, DOI 10.1093/annonc/mdi004; Raben A, 1997, CHEST, V112, pS276, DOI 10.1378/chest.112.4_Supplement.276S; Raetz EA, 2004, CANCER INVEST, V22, P312, DOI 10.1081/CNV-120030219; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Robinson BWS, 2003, LANCET, V362, P1612, DOI 10.1016/S0140-6736(03)14794-0; ROBINSON BWS, 1991, CYTOKINES, V18, P5; Robinson C, 2000, AM J RESP CELL MOL, V22, P550, DOI 10.1165/ajrcmb.22.5.3930; Roggli VL, 2002, ULTRASTRUCT PATHOL, V26, P55, DOI 10.1080/01913120252959227; Roushdy-Hammady I, 2001, LANCET, V357, P444, DOI 10.1016/S0140-6736(00)04013-7; Rusch V W, 1999, Chest Surg Clin N Am, V9, P327; Rusch VW, 1996, LUNG CANCER-J IASLC, V14, P1, DOI 10.1016/0169-5002(95)00508-0; Saad RS, 2005, DIAGN CYTOPATHOL, V32, P156, DOI 10.1002/dc.20208; Schipper H, 2003, INT J ONCOL, V22, P1009; Schouwink H, 2001, CHEST, V120, P1167, DOI 10.1378/chest.120.4.1167; Scott B., 2000, TXB LUNG CANC, P273; Sebastien P, 1980, IARC Sci Publ, P237; SELJELID R, 1994, EUR J HAEMATOL, V52, P1; SHAH N, 2001, INSURANCE DIGEST EUR, P14; Shivapurkar N, 2002, LANCET, V359, P851, DOI 10.1016/S0140-6736(02)07921-7; Singhal S, 2003, CLIN CANCER RES, V9, P3080; Sterman DH, 1998, HEMATOL ONCOL CLIN N, V12, P553, DOI 10.1016/S0889-8588(05)70008-3; Stewart DJ, 2004, ANN THORAC SURG, V78, P245, DOI 10.1016/j.athoracsur.2004.01.034; Sugarbaker DJ, 2004, J THORAC CARDIOV SUR, V128, P138, DOI 10.1016/j.jtcvs.2004.02.021; Sugarbaker Paul H, 2003, Surg Oncol Clin N Am, V12, P605, DOI 10.1016/S1055-3207(03)00045-0; TAKAHASHI K, 2004, P GLOB ASB C TOK NOV, P2; van Kaick G, 1999, RADIAT RES, V152, pS64, DOI 10.2307/3580117; Van Marck E, 2004, LUNG CANCER, V45, pS35, DOI 10.1016/j.lungcan.2004.04.006; VERSNEL MA, 1991, ONCOGENE, V6, P2005; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; WAGNER J C, 1960, Br J Ind Med, V17, P260; Waller DA, 2004, LUNG CANCER, V45, pS81, DOI 10.1016/j.lungcan.2004.04.018; Wang ZY, 2004, RADIOGRAPHICS, V24, P105, DOI 10.1148/rg.241035058; WEBSTER I, 1982, S AFR MED J, V61, P277; WHITAKER D, 1992, SEMIN DIAGN PATHOL, V9, P151; Whitaker D, 2000, CYTOPATHOLOGY, V11, P139, DOI 10.1046/j.1365-2303.2000.00247.x; Wolanski KD, 1998, CANCER, V82, P583, DOI 10.1002/(SICI)1097-0142(19980201)82:3<583::AID-CNCR22>3.0.CO;2-X; Wong L, 2002, LUNG CANCER, V38, P131, DOI 10.1016/S0169-5002(02)00178-2; Yang CT, 2000, J NATL CANCER I, V92, P636, DOI 10.1093/jnci/92.8.636; Zanella CL, 1996, CANCER RES, V56, P5334	97	822	844	0	48	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1591	1603		10.1056/NEJMra050152	http://dx.doi.org/10.1056/NEJMra050152			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221782				2022-12-28	WOS:000232486000013
J	Zerhouni, EA				Zerhouni, EA			Translational and clinical science - Time for a new vision	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Zerhouni, EA (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.							Zerhouni E, 2003, SCIENCE, V302, P63, DOI 10.1126/science.1091867	1	471	491	1	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1621	1623		10.1056/NEJMsb053723	http://dx.doi.org/10.1056/NEJMsb053723			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221788				2022-12-28	WOS:000232486000020
J	Elley, CR; Arroll, B				Elley, CR; Arroll, B			Refining the exercise prescription for hypertension	LANCET			English	Editorial Material							BLOOD-PRESSURE; PHYSICAL-ACTIVITY; CONTROLLED TRIALS; METAANALYSIS; HEALTH		Univ Auckland, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand; Univ Otago, Wellington Sch Med, Dept Gen Practice, Wellington, New Zealand	University of Auckland; University of Otago	Arroll, B (corresponding author), Univ Auckland, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand.	b.arroll@auckland.ac.nz						Aldana SG, 2005, J AM DIET ASSOC, V105, P371, DOI 10.1016/j.jada.2004.12.007; BAGRIE E, 2004, EXERCISE BLOOD PRESS; Dickerson LM, 2005, AM FAM PHYSICIAN, V71, P469; Elley CR, 2003, BRIT MED J, V326, P793, DOI 10.1136/bmj.326.7393.793; Fagard RH, 2001, MED SCI SPORT EXER, V33, pS484, DOI 10.1097/00005768-200106001-00018; Hagberg JM, 2000, SPORTS MED, V30, P193, DOI 10.2165/00007256-200030030-00004; Halbert JA, 1997, J HUM HYPERTENS, V11, P641, DOI 10.1038/sj.jhh.1000509; Kokkinos PF, 2000, CORONARY ARTERY DIS, V11, P99, DOI 10.1097/00019501-200003000-00002; Murphy M, 2002, MED SCI SPORT EXER, V34, P1468, DOI 10.1097/00005768-200209000-00011; Rauramaa R, 2001, MED SCI SPORT EXER, V33, pS516, DOI 10.1097/00005768-200106001-00022; Rondon MUP, 2002, J AM COLL CARDIOL, V39, P676, DOI 10.1016/S0735-1097(01)01789-2; STEWART R, 2002, 79 NAT HEART FDN; Thompson PD, 2001, MED SCI SPORT EXER, V33, pS438, DOI 10.1097/00005768-200106001-00012; Whelton SP, 2002, ANN INTERN MED, V136, P493, DOI 10.7326/0003-4819-136-7-200204020-00006	14	7	9	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 8	2005	366	9493					1248	1249						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	971ST	16214585				2022-12-28	WOS:000232405700008
J	Pittet, D; Donaldson, L				Pittet, D; Donaldson, L			Clean Care is Safer Care: a worldwide priority	LANCET			English	Editorial Material							HAND HYGIENE; INFECTIONS; HEALTH; SARS		WHO, World Alliance Patient Safety, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Infect Control Programme, CH-1211 Geneva, Switzerland	World Health Organization; University of Geneva	Pittet, D (corresponding author), WHO, World Alliance Patient Safety, CH-1211 Geneva, Switzerland.	didier.pittet@hcuge.ch		Pittet, Didier/0000-0002-3667-7131				Donaldson L, 2004, LANCET, V364, P1567, DOI 10.1016/S0140-6736(04)17330-3; McDonald LC, 2004, EMERG INFECT DIS, V10, P777, DOI 10.3201/eid1005.030791; *NAT AUD OFF, 2004, IMPR PAT CAR RED RIS; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; Pittet D, 2005, LANCET, V366, P185, DOI 10.1016/S0140-6736(05)66886-9; Pittet D, 2004, INFECT CONT HOSP EP, V25, P264, DOI 10.1086/502389; PONCEDELEON RS, 1998, HOSP INFECT, P291; Seto WH, 2003, LANCET, V361, P1519, DOI 10.1016/S0140-6736(03)13168-6; Starfield B, 2000, JAMA-J AM MED ASSOC, V284, P483, DOI 10.1001/jama.284.4.483; TIKHOMIROV E, 1987, CHEMIOTERAPIA, V3, P148; Vincent JL, 2003, LANCET, V361, P2068, DOI 10.1016/S0140-6736(03)13644-6; *WHO, GLOB PAT SAF CHALL W; World Health Organization, WORLD ALL PAT SAF; Zaidi AKM, 2005, LANCET, V365, P1175, DOI 10.1016/S0140-6736(05)71881-X	14	130	132	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 8	2005	366	9493					1246	1247		10.1016/S0140-6736(05)67506-X	http://dx.doi.org/10.1016/S0140-6736(05)67506-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	971ST	16214584	Bronze, Green Published			2022-12-28	WOS:000232405700007
J	Bainton, RJ; Tsai, LTY; Schwabe, T; DeSalvo, M; Gaul, U; Heberlein, U				Bainton, RJ; Tsai, LTY; Schwabe, T; DeSalvo, M; Gaul, U; Heberlein, U			moody Encodes two GPCRs that regulate cocaine behaviors and blood-brain barrier permeability in Drosophila	CELL			English	Article							HETEROTRIMERIC G-PROTEINS; CIRCADIAN GENES; SENSITIZATION; DOPAMINE; ETHANOL; EXPRESSION; REWARD; SENSITIVITY; RESPONSES; NEURONS	We identified moody in a genetic screen for Drosophila mutants with altered cocaine sensitivity. Hypomorphic mutations in moody cause an increased sensitivity to cocaine and nicotine exposure. In contrast, sensitivity to the acute intoxicating effects of ethanol is reduced. The moody locus encodes two novel GPCRs, Moody-alpha and Moody-beta. While identical in their membrane-spanning domains, the two Moody proteins differ in their long carboxy-terminal domains, which are generated by use of alternative reading frames. Both Moody forms are required for normal cocaine sensitivity, suggesting that they carry out distinct but complementary functions. Moody-alpha and Moody-beta are coexpressed in surface glia that surround the nervous system, where they are actively required to maintain the integrity of the blood-brain barrier in the adult fly. We propose that a Moody-mediated signaling pathway functions in glia to regulate nervous system insulation and drug-related behaviors.	Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Neurosci Program, San Francisco, CA 94143 USA; Rockefeller Univ, Lab Dev Neurogenet, New York, NY 10021 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Rockefeller University	Bainton, RJ (corresponding author), Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA.	rolandb@itsa.ucsf.edu; ulrike@itsa.ucsf.edu	Schwabe, Tina/AAA-3822-2021	Tsai, Linus/0000-0002-0134-6949	NATIONAL EYE INSTITUTE [R01EY011560, R55EY011560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA014809] Funding Source: NIH RePORTER; NEI NIH HHS [EY011560, R01 EY011560, R01 EY011560-08] Funding Source: Medline; NIAAA NIH HHS [AA10035] Funding Source: Medline; NIDA NIH HHS [DA14809, DA444906-33821] Funding Source: Medline; NIGMS NIH HHS [T32 GM007618] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abarca C, 2002, P NATL ACAD SCI USA, V99, P9026, DOI 10.1073/pnas.142039099; Andretic R, 1999, SCIENCE, V285, P1066, DOI 10.1126/science.285.5430.1066; Bainton RJ, 2000, CURR BIOL, V10, P187, DOI 10.1016/S0960-9822(00)00336-5; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Bellen HJ, 1998, TRENDS NEUROSCI, V21, P444, DOI 10.1016/S0166-2236(98)01267-3; Bhat MA, 2003, CURR OPIN NEUROBIOL, V13, P552, DOI 10.1016/j.conb.2003.09.004; BRAND AH, 1993, DEVELOPMENT, V118, P401; Carlson SD, 2000, ANNU REV ENTOMOL, V45, P151, DOI 10.1146/annurev.ento.45.1.151; Carthew RW, 2001, CURR OPIN CELL BIOL, V13, P244, DOI 10.1016/S0955-0674(00)00204-0; DIANTONIO A, 1993, J NEUROSCI, V13, P4924; GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Granderath S, 1999, DEVELOPMENT, V126, P1781; Hiroi N, 1997, P NATL ACAD SCI USA, V94, P10397, DOI 10.1073/pnas.94.19.10397; Hirsh J., 2001, Pharmacogenomics Journal, V1, P97; Hortsch M, 2003, TRENDS CELL BIOL, V13, P557, DOI 10.1016/j.tcb.2003.09.004; Karlsson C, 2004, J BIOL CHEM, V279, P52033, DOI 10.1074/jbc.M408220200; Kelz MB, 1999, NATURE, V401, P272, DOI 10.1038/45790; Kunwar PS, 2003, PLOS BIOL, V1, P372, DOI 10.1371/journal.pbio.0000080; Laakso A, 2002, NEURON, V36, P213, DOI 10.1016/S0896-6273(02)00972-8; Li H, 2000, CURR BIOL, V10, P211, DOI 10.1016/S0960-9822(00)00340-7; MANNING G, 1993, DEV DROSPHILLA TRACH, V1; McClung C, 1998, CURR BIOL, V8, P109, DOI 10.1016/S0960-9822(98)70041-7; Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Rorth P, 1998, DEVELOPMENT, V125, P1049; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Rothenfluh A, 2002, CURR OPIN NEUROBIOL, V12, P639, DOI 10.1016/S0959-4388(02)00380-X; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Schenk S, 1997, PHARMACOL BIOCHEM BE, V57, P543, DOI 10.1016/S0091-3057(96)00447-9; Shaw SR, 1999, J NEUROBIOL, V41, P452, DOI 10.1002/(SICI)1097-4695(199912)41:4<452::AID-NEU2>3.3.CO;2-X; Sora I, 2001, P NATL ACAD SCI USA, V98, P5300, DOI 10.1073/pnas.091039298; Sora I, 1998, P NATL ACAD SCI USA, V95, P7699, DOI 10.1073/pnas.95.13.7699; Sullivan W., 2000, DROSOPHILA PROTOCOLS; Sun ZY, 2004, EUR PSYCHIAT, V19, P354, DOI 10.1016/j.eurpsy.2004.06.007; Tsai LTY, 2004, PLOS BIOL, V2, P2122, DOI 10.1371/journal.pbio.0020408; WEBER KE, 1990, GENETICS, V125, P585; Wolf FW, 2003, J NEUROBIOL, V54, P161, DOI 10.1002/neu.10166; XIONG WC, 1994, GENE DEV, V8, P981, DOI 10.1101/gad.8.8.981; Yager J, 2001, P NATL ACAD SCI USA, V98, P10445, DOI 10.1073/pnas.191107698	42	158	161	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 7	2005	123	1					145	156		10.1016/j.cell.2005.07.029	http://dx.doi.org/10.1016/j.cell.2005.07.029			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	973QD	16213219	Bronze			2022-12-28	WOS:000232536800015
J	Primavera, JH				Primavera, JH			Mangroves, fishponds, and the quest for sustainability	SCIENCE			English	Editorial Material									SE Asian Fisheries Dev Ctr, Dept Aquaculture, Iloilo 5021, Philippines	Southeast Asian Fisheries Development Center	Primavera, JH (corresponding author), SE Asian Fisheries Dev Ctr, Dept Aquaculture, Iloilo 5021, Philippines.	jhprima@aqd.saefdec.org.ph							0	83	91	3	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	2005	310	5745					57	59		10.1126/science.1115179	http://dx.doi.org/10.1126/science.1115179			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	972TV	16210520				2022-12-28	WOS:000232477000029
J	Brocks, JJ; Love, GD; Summons, RE; Knoll, AH; Logan, GA; Bowden, SA				Brocks, JJ; Love, GD; Summons, RE; Knoll, AH; Logan, GA; Bowden, SA			Biomarker evidence for green and purple sulphur bacteria in a stratified Palaeoproterozoic sea	NATURE			English	Article							PROTEROZOIC OCEAN CHEMISTRY; MCARTHUR BASIN; NORTHERN AUSTRALIA; PETROLEUM GEOLOGY; GEOCHEMISTRY; SULFATE; ANOXIA; ROCK	The disappearance of iron formations from the geological record similar to 1.8 billion years (Gyr) ago was the consequence of rising oxygen levels in the atmosphere starting 2.45 - 2.32 Gyr ago(1-3). It marks the end of a 2.5-Gyr period dominated by anoxic and iron-rich deep oceans. However, despite rising oxygen levels and a concomitant increase in marine sulphate concentration, related to enhanced sulphide oxidation during continental weathering(4), the chemistry of the oceans in the following mid-Proterozoic interval (similar to 1.8 - 0.8 Gyr ago) probably did not yet resemble our oxygen-rich modern oceans. Recent data(5-8) indicate that marine oxygen and sulphate concentrations may have remained well below current levels during this period, with one model indicating that anoxic and sulphidic marine basins were widespread, and perhaps even globally distributed(4). Here we present hydrocarbon biomarkers ( molecular fossils) from a 1.64-Gyr-old basin in northern Australia, revealing the ecological structure of mid-Proterozoic marine communities. The biomarkers signify a marine basin with anoxic, sulphidic, sulphate-poor and permanently stratified deep waters, hostile to eukaryotic algae. Phototrophic purple sulphur bacteria ( Chromatiaceae) were detected in the geological record based on the new carotenoid biomarker okenane, and they seem to have co-existed with communities of green sulphur bacteria ( Chlorobiaceae). Collectively, the biomarkers support mounting evidence for a long-lasting Proterozoic world in which oxygen levels remained well below modern levels.	Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; Macquarie Univ, Australian Ctr Astrobiol, Sydney, NSW 2109, Australia; Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Geosci Australia, Canberra, ACT 2601, Australia; Univ Aberdeen, Dept Geol & Petr Geol, Aberdeen AB24 3UE, Scotland	Australian National University; Massachusetts Institute of Technology (MIT); Macquarie University; Harvard University; Harvard University; Geoscience Australia; University of Aberdeen	Brocks, JJ (corresponding author), Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia.	jochen.brocks@anu.edu.au	Brocks, Jochen/E-3920-2012; Summons, Roger Everett/AAL-3789-2020	Brocks, Jochen/0000-0002-8430-8744; 				Anbar AD, 2002, SCIENCE, V297, P1137, DOI 10.1126/science.1069651; Arnold GL, 2004, SCIENCE, V304, P87, DOI 10.1126/science.1091785; Bekker A, 2004, NATURE, V427, P117, DOI 10.1038/nature02260; BIRD CW, 1971, NATURE, V230, P473, DOI 10.1038/230473a0; BROCKS JJ, 2003, TREATISE GEOCHEMISTR, V8, P63, DOI DOI 10.1016/B0-08-043751-6/08127-5; Bull SW, 1998, AUST J EARTH SCI, V45, P21, DOI 10.1080/08120099808728364; Canfield DE, 1998, NATURE, V396, P450, DOI 10.1038/24839; COLLISTER JW, 1992, ORG GEOCHEM, V19, P265, DOI 10.1016/0146-6380(92)90042-V; CRICK IH, 1988, AAPG BULL, V72, P1495; Farquhar J, 2000, SCIENCE, V289, P756, DOI 10.1126/science.289.5480.756; Hayes J.M., 1992, PROTEROZOIC BIOSPHER, P129; Hoehler TM, 1998, GEOCHIM COSMOCHIM AC, V62, P1745, DOI 10.1016/S0016-7037(98)00106-9; Holland HD., 2004, TREATISE GEOCHEMISTR, VVol. 6, P583; JACKSON MJ, 2000, 200003 AUSTR GEOL SU; Kah LC, 2004, NATURE, V431, P834, DOI 10.1038/nature02974; Kara AB, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2000JC000736; Page RW, 1998, AUST J EARTH SCI, V45, P219, DOI 10.1080/08120099808728383; PALMISANO AC, 1988, J MICROBIOL METH, V8, P209, DOI 10.1016/0167-7012(88)90003-6; REPETA DJ, 1989, NATURE, V342, P69, DOI 10.1038/342069a0; Schaeffer P, 1997, TETRAHEDRON LETT, V38, P8413, DOI 10.1016/S0040-4039(97)10235-0; Scholten JCM, 2002, FEMS MICROBIOL ECOL, V42, P375, DOI 10.1111/j.1574-6941.2002.tb01027.x; Shen Y, 2003, NATURE, V423, P632, DOI 10.1038/nature01651; Shen YN, 2002, AM J SCI, V302, P81, DOI 10.2475/ajs.302.2.81; SUMMONS RE, 1992, BIOLOGICAL MARKERS IN SEDIMENTS AND PETROLEUM, P182; Summons RE, 1999, NATURE, V400, P554, DOI 10.1038/23005; SUMMONS RE, 1988, GEOCHIM COSMOCHIM AC, V52, P1747, DOI 10.1016/0016-7037(88)90001-4; Van Gemerden H, 1995, ANOXYGENIC PHOTOSYNT, P49; Van Kaam-Peters HME, 1997, ORG GEOCHEM, V27, P371, DOI 10.1016/S0146-6380(97)00082-X; VEIZER J, 1992, GEOCHIM COSMOCHIM AC, V56, P2487, DOI 10.1016/0016-7037(92)90204-V; Volkman JK, 2003, APPL MICROBIOL BIOT, V60, P495, DOI 10.1007/s00253-002-1172-8	30	395	426	6	148	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					866	870		10.1038/nature04068	http://dx.doi.org/10.1038/nature04068			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208367				2022-12-28	WOS:000232338600042
J	Kimoto, H; Haga, S; Sato, K; Touhara, K				Kimoto, H; Haga, S; Sato, K; Touhara, K			Sex-specific peptides from exocrine glands stimulate mouse vomeronasal sensory neurons	NATURE			English	Article							PUTATIVE PHEROMONE RECEPTORS; ACCESSORY OLFACTORY-BULB; MULTIGENE FAMILY; GENES; MICE; AGGRESSION; ACTIVATION; BEHAVIOR; MAMMALS; SIGNALS	In mammals, social and reproductive behaviours are modulated by pheromones, which are chemical signals that convey information about sex and strain(1,2). The vomeronasal organ, located at the base of the nasal septum, is responsible for mediating pheromone information in mice(3-9). Two classes of putative pheromone receptor gene families, V1R and V2R, are expressed by vomeronasal sensory neurons in mutually segregated epithelial zones of the vomeronasal organ(10-14). Although numerous studies have suggested that pheromones originate from urine(15-18), direct recordings of behaving mice have shown that neuronal firing in the vomeronasal system is modulated by physical contact with the facial area(19). Here we identify a male-specific 7-kDa peptide secreted from the extraorbital lacrimal gland. This peptide, which we named exocrine gland-secreting peptide 1 (ESP1), is encoded by a gene from a previously unrecognized large family clustered in proximity to the class I major histocompatibility complex (MHC) region. ESP1 is secreted from the eyes and is transferred to the female vomeronasal organ, where it stimulates V2R-expressing vomeronasal sensory neurons and elicits an electrical response. Our results indicate that mice respond to sex-specific peptides released from exocrine glands through the vomeronasal system during direct contact.	Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan	University of Tokyo	Touhara, K (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan.	touhara@k.u-tokyo.ac.jp		xing zhi, zuo teng/0000-0001-6198-6406				Berghard A, 1996, J NEUROSCI, V16, P909; Boschat C, 2002, NAT NEUROSCI, V5, P1261, DOI 10.1038/nn978; Brennan PA, 2004, CURR BIOL, V14, pR81, DOI 10.1016/j.cub.2003.12.052; CLANCY AN, 1984, J NEUROSCI, V4, P2222; Dulac C, 2003, NAT REV NEUROSCI, V4, P551, DOI 10.1038/nrn1140; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Feldhoff Richard C., 1999, P117; Halem HA, 1999, J NEUROBIOL, V39, P249, DOI 10.1002/(SICI)1097-4695(199905)39:2<249::AID-NEU9>3.3.CO;2-I; Halem HA, 2001, J NEUROSCI, V21, P2474, DOI 10.1523/JNEUROSCI.21-07-02474.2001; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Hurst JL, 2001, NATURE, V414, P631, DOI 10.1038/414631a; Ishii T, 2003, CURR BIOL, V13, P394, DOI 10.1016/S0960-9822(03)00092-7; KIKUYAMA S, 1995, SCIENCE, V267, P1643, DOI 10.1126/science.7886452; Kimoto H, 2005, CHEM SENSES, V30, pI146, DOI 10.1093/chemse/bjh156; Krieger J, 1999, J BIOL CHEM, V274, P4655, DOI 10.1074/jbc.274.8.4655; Kumar A, 1999, J NEUROSCI, V19, DOI 10.1523/JNEUROSCI.19-20-j0003.1999; Leinders-Zufall T, 2004, SCIENCE, V306, P1033, DOI 10.1126/science.1102818; Leinders-Zufall T, 2000, NATURE, V405, P792, DOI 10.1038/35015572; Leypold BG, 2002, P NATL ACAD SCI USA, V99, P6376, DOI 10.1073/pnas.082127599; Loconto J, 2003, CELL, V112, P607, DOI 10.1016/S0092-8674(03)00153-3; Luo MM, 2003, SCIENCE, V299, P1196, DOI 10.1126/science.1082133; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; MEREDITH M, 1994, PHYSIOL BEHAV, V56, P345, DOI 10.1016/0031-9384(94)90205-4; Norlin EM, 2003, CURR BIOL, V13, P1214, DOI 10.1016/S0960-9822(03)00452-4; Rollmann SM, 1999, SCIENCE, V285, P1907, DOI 10.1126/science.285.5435.1907; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Stowers L, 2002, SCIENCE, V295, P1493, DOI 10.1126/science.1069259; Wabnitz PA, 1999, NATURE, V401, P444, DOI 10.1038/46724; WYSOCKI CJ, 1991, J STEROID BIOCHEM, V39, P661, DOI 10.1016/0960-0760(91)90265-7	29	280	291	2	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					898	901		10.1038/nature04033	http://dx.doi.org/10.1038/nature04033			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208374				2022-12-28	WOS:000232338600049
J	Mestel, L				Mestel, L			Hermann Bondi (1919-2005) - Obituary	NATURE			English	Biographical-Item									Univ Sussex, Brighton BN1 9QH, E Sussex, England	University of Sussex	Mestel, L (corresponding author), Univ Sussex, Brighton BN1 9QH, E Sussex, England.	lmestel@sussex.ac.uk							0	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 6	2005	437	7060					828	828		10.1038/437828a	http://dx.doi.org/10.1038/437828a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208358	Bronze			2022-12-28	WOS:000232338600032
J	Fairall, LR; Zwarenstein, M; Bateman, ED; Bachmann, M; Lombard, C; Majara, BP; Joubert, G; English, RG; Bheekie, A; van Rensburg, D; Mayers, P; Peters, AC; Chapman, RD				Fairall, LR; Zwarenstein, M; Bateman, ED; Bachmann, M; Lombard, C; Majara, BP; Joubert, G; English, RG; Bheekie, A; van Rensburg, D; Mayers, P; Peters, AC; Chapman, RD			Effect of educational outreach to nurses on tuberculosis case detection and primary care of respiratory illness: pragmatic cluster randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTERVENTION; COMMUNITY; EPIDEMIC; PATTERNS	Objectives To develop and implement an educational outreach programme for the integrated case management of priority respiratory diseases (practical approach to lung health in South Africa; PALSA) and to evaluate its effects on respiratory care and detection of tuberculosis among adults attending primary care clinics. Design Pragmatic cluster randomised controlled trial, with clinics as the unit of randomisation. Setting 40 primary care clinics, staffed by nurse practitioners, in the Free State province, South Africa. Participants 1999 patients aged 15 or over with cough or difficult breathing (1000 in intervention clinics, 999 in control clinics). Intervention Between two and six educational outreach sessions delivered to nurse practitioners by usual trainers from the health department. The emphasis was on key messages drawn from the customised clinical practice guideline for the outreach programme, with illustrative support materials. Main outcome measures Sputum screening for tuberculosis, tuberculosis case detection, inhaled corticosteroid prescriptions for obstructive lung disease, and antibiotic prescriptions for respiratory tract infections. Results All clinics and almost all patients (92.8%, 1856/1999) completed the trial. Although sputum testing for tuberculosis was similar between the groups (22.6% in outreach group v 19.3% in control group; odds ratio 1.22,95% confidence interval 0.83 to 1.80), the case detection of tuberculosis was higher in the outreach group (6.4% v 3.8%; 1.72,1.04 to 2.85). Prescriptions for inhaled corticosteroids were also higher (13.7% v 7.7%; 1.90,1.14 to 3.18) but the number of antibiotic prescriptions was similar (39.7% v 39.4%; 1.01, 0.74 to 1.38). Conclusions Combining educational outreach with integrated case management provides a promising model for improving quality of care and control of priority respiratory diseases, without extra staff, in resource poor settings.	Univ Cape Town, Univ Cape Town Lung Inst, Knowledge Translat Unit, Groote Schuur, South Africa; Univ Cape Town, Sch Hlth & Rehabil Sci, Div Nursing & Midwifery, ZA-7700 Rondebosch, South Africa; Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England; Univ Orange Free State, Dept Community Hlth, Bloemfontein, South Africa; Univ Orange Free State, Dept Biostat, Bloemfontein, South Africa; Univ Orange Free State, Ctr Hlth Serv Res & Dev, Bloemfontein, South Africa; MRC, Biostat Unit, Tygerberg, South Africa; Univ Western Cape, Sch Pharm, Cape Town, South Africa; TB Alliance DOTS Support Assoc, Pretoria, South Africa; Free State Dept Hlth, Bloemfontein, South Africa	University of Cape Town; University of Cape Town; University of East Anglia; University of the Free State; University of the Free State; University of the Free State; University of the Western Cape	Zwarenstein, M (corresponding author), Univ Toronto, St Michaels Hosp, Knowledge Translat Programme, 500 Univ Ave, Toronto, ON M5G 1V7, Canada.	merrick.zwarenstein@ices.on.ca	Joubert, Gina/I-2985-2018; Mayers, Pat M/B-7224-2016; Zwarenstein, Merrick F/P-5210-2014	Joubert, Gina/0000-0002-3728-6925; Mayers, Pat M/0000-0002-2622-1624; Zwarenstein, Merrick F/0000-0003-0162-7027; Bachmann, Max Oscar/0000-0003-1770-3506; Fairall, Lara/0000-0002-7460-4670				Adams G, 2004, J CLIN EPIDEMIOL, V57, P785, DOI 10.1016/j.jclinepi.2003.12.013; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Davis D, 2003, BMJ-BRIT MED J, V327, P33, DOI 10.1136/bmj.327.7405.33; Dye C, 2003, TUBERCULOSIS, V83, P35, DOI 10.1016/S1472-9792(02)00056-2; Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4; Grimshaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8060; GUILLEMIN F, 1993, J CLIN EPIDEMIOL, V46, P1417, DOI 10.1016/0895-4356(93)90142-N; Louwagie G M, 2002, Curationis, V25, P32; Makubalo L., 2003, NATL HIV SYPHILIS AN; Mash B, 1997, S AFR MED J, V87, P475; Morgenstern LB, 2003, ARCH INTERN MED, V163, P2198, DOI 10.1001/archinte.163.18.2198; Raviglione MC, 2003, TUBERCULOSIS, V83, P4, DOI 10.1016/S1472-9792(02)00071-9; *S AFR NAT DEP HLT, 2003, OP PLAN COMPR HIV AI; *S AFR NAT DEP HLT, 2003, 2002 TUB CAS FIND TR; *S AFR NAT DEP HLT, 2000, S AFR TUB CONTR PROG; *S AFR NAT DEP HLT, 1998, STAND TREATM GUID ES; Sanci LA, 2000, BRIT MED J, V320, P224, DOI 10.1136/bmj.320.7229.224; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; Sharma DC, 2004, LANCET, V363, P1122, DOI 10.1016/S0140-6736(04)15936-9; Stempel DA, 2004, CHEST, V126, P75, DOI 10.1378/chest.126.1.75; TUNIS SR, 2004, JAMA-J AM MED ASSOC, V291, P425; Veron LJ, 2004, INT J TUBERC LUNG D, V8, P139; *WHO, 2004, GLOB TUB CONTR SURV; *WHO, 2004, WHOHTMTB2004333	24	123	125	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	2005	331	7519					750	754A		10.1136/bmj.331.7519.750	http://dx.doi.org/10.1136/bmj.331.7519.750			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971XB	16195293	Green Published, Bronze			2022-12-28	WOS:000232417100023
J	Gray, RH; Li, XB; Kigozi, G; Serwadda, D; Brahmbhott, H; Wabwire-Mangen, F; Nalugoda, F; Kiddugavu, M; Sewankambo, N; Quinn, TC; Reynolds, SJ; Wawer, MJ				Gray, RH; Li, XB; Kigozi, G; Serwadda, D; Brahmbhott, H; Wabwire-Mangen, F; Nalugoda, F; Kiddugavu, M; Sewankambo, N; Quinn, TC; Reynolds, SJ; Wawer, MJ			Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study	LANCET			English	Article							UTERINE EPITHELIAL-CELLS; SEXUALLY-TRANSMITTED-DISEASES; PERINATAL TRANSMISSION; MENSTRUAL-CYCLE; COITAL ACT; INFECTION; WOMEN; COHORT; TRACT; STAGE	Background HIV acquisition is significantly higher during pregnancy than in the postpartum period. We did a prospective study to estimate HIV incidence rates during pregnancy and lactation. Methods We assessed 2188 HIV-negative sexually active women with 2625 exposure intervals during pregnancy and 2887 intervals during breastfeeding, and 8473 non-pregnant and non-lactating women with 24 258 exposure intervals. Outcomes were HIV incidence rates per 100 person years and incidence rate ratios estimated by Poisson multivariate regression, with the non-pregnant or non-lactating women as the reference group. We also assessed the husbands of the married women to study male risk behaviours. Findings HIV incidence rates were 2.3 per 100 person years during pregnancy, 1.3 per 100 person years during breastfeeding, and 1.1 per 100 person years in the non-pregnant and non-lactating women. The adjusted incidence rate ratios were 2.16 (95% Cl 1 . 39-3.37) during pregnancy and 1 . 16 (0.82-1.63) during breastfeeding. Pregnant women and their male partners reported significantly fewer external sexual partners than did the other groups. in married pregnant women who had a sexual relationship with their male spouses, the HIV incidence rate ratio was 1.36 (0.63-2.93). in married pregnant women in HIV-discordant relationships (ie, with HIV-positive men) the incidence rate ratio was 1.76 (0.62-4.03). Interpretation The risk of HIV acquisition rises during pregnancy. This change is unlikely to be due to sexual risk behaviours, but might be attributable to hormonal changes affecting the genital tract mucosa or immune responses. HIV prevention efforts are needed during pregnancy to protect mothers and their infants.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; Uganda Virus Res Inst, Rakai Hlth Sci Programme, Entebbe, Uganda; Makerere Univ, Inst Publ Hlth, Kampala, Uganda; Makerere Univ, Sch Med, Kampala, Uganda; NIAID, NIH, Bethesda, MD 20892 USA; Johns Hopkins Med Inst, Baltimore, MD 21205 USA; Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Rakai Health Sciences Program; Uganda Virus Research Institute; Makerere University; Makerere University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins Medicine; Columbia University	Gray, RH (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Suite 4030, Baltimore, MD 21205 USA.	rgray@jhsph.edu		Sewankambo, Nelson/0000-0001-9362-053X; Reynolds, Steven/0000-0002-5403-2759	NICHD NIH HHS [5P30HD06826] Funding Source: Medline; PHS HHS [R01 A13426S, R01 A134826] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000361] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmed S, 2001, AIDS, V15, P2171, DOI 10.1097/00002030-200111090-00013; Asin SN, 2004, J INFECT DIS, V190, P236, DOI 10.1086/421910; Asin SN, 2003, J INFECT DIS, V187, P1522, DOI 10.1086/374782; Beagley KW, 2003, FEMS IMMUNOL MED MIC, V38, P13, DOI 10.1016/S0928-8244(03)00202-5; Brabin L, 2002, AIDS PATIENT CARE ST, V16, P211, DOI 10.1089/10872910252972267; Garcia PM, 1999, NEW ENGL J MED, V341, P1699; Gray RH, 2001, AM J OBSTET GYNECOL, V185, P1209, DOI 10.1067/mob.2001.118158; Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2; HITCHCOCK PJ, 1999, SEXUALLY TRANSMITTED; Jacobson DL, 2000, SEX TRANSM DIS, V27, P313, DOI 10.1097/00007435-200007000-00003; Kiddugavu M, 2003, AIDS, V17, P233, DOI 10.1097/00002030-200301240-00014; LEROY V, 1994, AIDS, V8, P983, DOI 10.1097/00002030-199407000-00017; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; Michael CW, 1997, DIAGN CYTOPATHOL, V17, P99, DOI 10.1002/(SICI)1097-0339(199708)17:2<99::AID-DC4>3.3.CO;2-6; Prakash M, 2004, BJOG-INT J OBSTET GY, V111, P1468, DOI 10.1111/j.1471-0528.2004.00283.x; ROOGPISUTHIPONG A, 2001, J ACQ IMMUN DEF SYND, V26, P348; Shelton JD, 2004, LANCET, V364, P1916, DOI 10.1016/S0140-6736(04)17489-8; Smith SA, 2004, AIDS, V18, P1637, DOI 10.1097/01.aids.0000131393.76221.cc; Taha TE, 1998, AIDS, V12, P197, DOI 10.1097/00002030-199802000-00010; Taha TE, 2000, ANN NY ACAD SCI, V918, P84; Wang CC, 1999, J ACQ IMMUN DEF SYND, V21, P51, DOI 10.1097/00126334-199905010-00007; Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411; Wawer MJ, 1999, LANCET, V353, P525, DOI 10.1016/S0140-6736(98)06439-3; WESTOFF CF, 2001, UNMET NEED END CENTU; White HD, 1997, J IMMUNOL, V158, P3017; Yeaman GR, 1997, J LEUKOCYTE BIOL, V61, P427, DOI 10.1002/jlb.61.4.427; Yeaman GR, 2003, IMMUNOLOGY, V109, P137, DOI 10.1046/j.1365-2567.2003.01623.x; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	28	285	293	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	2005	366	9492					1182	1188		10.1016/S0140-6736(05)67481-8	http://dx.doi.org/10.1016/S0140-6736(05)67481-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970LK	16198767				2022-12-28	WOS:000232311300028
J	Haslam, DW; James, WPT				Haslam, DW; James, WPT			Obesity	LANCET			English	Review							CARDIOVASCULAR RISK-FACTORS; LOW-CARBOHYDRATE DIETS; BLOOD-PRESSURE LEVELS; ALL-CAUSE MORTALITY; BODY-MASS INDEX; METABOLIC SYNDROME; WEIGHT-LOSS; FOOD-INTAKE; LIFE-STYLE; INSULIN-RESISTANCE	Excess bodyweight is the sixth most important risk factor contributing to the overall burden of disease worldwide. 1 . 1 billion adults and 10% of children are now classified as overweight or obese. Average life expectancy is already diminished; the main adverse consequences are cardiovascular disease, type 2 diabetes, and several cancers. The complex pathological processes reflect environmental and genetic interactions, and individuals from disadvantaged communities seem to have greater risks than more affluent individuals partly because of fetal and postnatal imprinting. Obesity, with its array of comorbidities, necessitates careful clinical assessment to identify underlying factors and to allow coherent management. The epidemic reflects progressive secular and age-related decreases in physical activity, together with substantial dietary changes with passive over-consumption of energy despite the neurobiological processes controlling food intake. Effective long-term weight loss depends on permanent changes in dietary quality, energy intake, and activity. Neither the medical management nor the societal preventive challenges are currently being met.	Watton Pl Clin, Natl Obes Forum, Watton At Stone SG14 3SY, Herts, England; Int Obes Task Force, London, England; London Sch Hyg & Trop Med, London WC1, England	University of London; London School of Hygiene & Tropical Medicine	Haslam, DW (corresponding author), Watton Pl Clin, Natl Obes Forum, Watton At Stone SG14 3SY, Herts, England.	Dwhaslam@aol.com						Aktas MK, 2004, JAMA-J AM MED ASSOC, V292, P1462, DOI 10.1001/jama.292.12.1462; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530; Allison DB, 2001, NUTR HLTH, P147; Anker SD, 2003, LANCET, V361, P1077, DOI 10.1016/S0140-6736(03)12892-9; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Astrup A, 2004, LANCET, V364, P897, DOI 10.1016/S0140-6736(04)16986-9; Avenell A, 2004, HEALTH TECHNOL ASSES, V8, P1; Bhopal R, 2005, J PUBLIC HEALTH-UK, V27, P93, DOI 10.1093/pubmed/fdh202; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; BOUCHARD C, 1990, NEW ENGL J MED, V322, P1477, DOI 10.1056/NEJM199005243222101; Brage S, 2005, EUR J CLIN NUTR, V59, P561, DOI 10.1038/sj.ejcn.1602118; Bravata DM, 2003, JAMA-J AM MED ASSOC, V289, P1837, DOI 10.1001/jama.289.14.1837; BRAY GA, 2004, HDB OBESITY CLIN APP, P201; *BRIT NUTR TASK FO, 1999, OB; CAMPBELL I, 2004, YOUR QUESTIONS ANSWE; Cassano Patricia A., 1990, Annals of Epidemiology, V1, P33; Chan JCN, 2002, INT J OBESITY, V26, P994, DOI 10.1038/sj.ijo.0802017; Christou NV, 2004, ANN SURG, V240, P416, DOI 10.1097/01.sla.0000137343.63376.19; CICUTTINI FM, 1998, HDB OBESITY, P741; Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3; Corti R, 2004, J THROMB THROMBOLYS, V17, P35, DOI 10.1023/B:THRO.0000036027.39353.70; Cotton JR, 1996, BRIT J NUTR, V75, P545, DOI 10.1079/BJN19960158; D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180; Dansinger ML, 2005, JAMA-J AM MED ASSOC, V293, P43, DOI 10.1001/jama.293.1.43; Department of Health, 2004, CHOOS HLTH MAK HLTH; Drewnowski A, 1998, NUTR REV, V56, P347, DOI 10.1111/j.1753-4887.1998.tb01677.x; Erlichman J, 2002, Obes Rev, V3, P273, DOI 10.1046/j.1467-789X.2002.00078.x; Esposito K, 2004, JAMA-J AM MED ASSOC, V291, P2978, DOI 10.1001/jama.291.24.2978; Ezzati M, 2005, PLOS MED, V2, P404, DOI 10.1371/journal.pmed.0020133; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Fisher JO, 2003, AM J CLIN NUTR, V77, P1164, DOI 10.1093/ajcn/77.5.1164; Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; GREEN BB, 1988, FERTIL STERIL, V50, P721; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Guidance Document on Using In Vitro Data to Estimate In Vivo Starting Doses for Acute Toxicity, 2001, GUID DOC US IN VITR; Haddock CK, 2002, INT J OBESITY, V26, P262, DOI 10.1038/sj.ijo.0801889; Hastings G., 2003, REV RES EFFECTS FOOD; Heymsfield SB, 2003, INT J OBESITY, V27, P537, DOI 10.1038/sj.ijo.0802258; *INT DIAB FED, NEW WORLDW DEF MET S; James PT, 2004, EUR J CARDIOV PREV R, V11, P3, DOI 10.1097/01.hjr.0000114707.27531.48; James W. P. T., 1989, Nutrition, aging and the elderly., P129; James W. P. T., 1990, HUMAN ENERGY REQUIRE; James WPT, 2005, OBES REV, V6, P179, DOI 10.1111/j.1467-789X.2005.00214.x; James WPT, 2002, INT J OBESITY, V26, pS1, DOI 10.1038/sj.ijo.0802208; James WPT, 2004, COMP QUANTIFICATION, P497; Kasim-Karakas SE, 2004, J CLIN ENDOCR METAB, V89, P615, DOI 10.1210/jc.2003-030666; Kastarinen MJ, 2000, J HYPERTENS, V18, P255, DOI 10.1097/00004872-200018030-00003; Kenchaiah S, 2004, MED CLIN N AM, V88, P1273, DOI 10.1016/j.mcna.2004.04.011; KHEDR M, 2003, OBES PRACT, V5, P12; Kim MH, 2004, J KOREAN MED SCI, V19, P195, DOI 10.3346/jkms.2004.19.2.195; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kojima S, 2005, THROMB RES, V115, P483, DOI 10.1016/j.thromres.2004.09.012; Laven JSE, 2002, OBSTET GYNECOL SURV, V57, P755, DOI 10.1097/00006254-200211000-00022; LEAN MEJ, 1990, DIABETIC MED, V7, P228, DOI 10.1111/j.1464-5491.1990.tb01375.x; LEAN MEJ, 1986, LANCET, V1, P723; Liu J, 2004, JAMA-J AM MED ASSOC, V291, P2591, DOI 10.1001/jama.291.21.2591; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; Mokdad AH, 2005, JAMA-J AM MED ASSOC, V293, P293, DOI 10.1001/jama.293.3.293; Mokdad AH, 2004, JAMA-J AM MED ASSOC, V291, P1238, DOI 10.1001/jama.291.10.1238; MORRIS JN, 1953, LANCET, V265, P1053; MORRIS JN, 1973, LANCET, V1, P333; National Audit Office, 2001, TACKL OB ENGL REP CO; O'Rahilly S, 2002, NUTR REV, V60, pS30, DOI 10.1301/002966402320634904; Organization WH, 2000, WHO TECHN REP SER, DOI DOI 10.1016/J.BBI.2016.02.019; Ozanne SE, 2004, NATURE, V427, P411, DOI 10.1038/427411b; Padwal R, 2003, INT J OBESITY, V27, P1437, DOI 10.1038/sj.ijo.0802475; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; Pasquali R., 1997, Human Reproduction (Oxford), V12, P82; Peeters A, 2003, ANN INTERN MED, V138, P24, DOI 10.7326/0003-4819-138-1-200301070-00008; Pereira MA, 2005, LANCET, V365, P36, DOI 10.1016/S0140-6736(04)17663-0; Petersen L, 2004, INT J OBESITY, V28, P105, DOI 10.1038/sj.ijo.0802548; Petry CJ, 2001, MOL CELL ENDOCRINOL, V185, P81, DOI 10.1016/S0303-7207(01)00627-X; Pietinen P, 2001, J Nutr Health Aging, V5, P150; Popkin BM, 2004, INT J OBESITY, V28, pS2, DOI [10.1038/sj.ijo.0802804, 10.1038/sj.ijo.0802557]; Prentice A M, 2003, Obes Rev, V4, P187, DOI 10.1046/j.1467-789X.2003.00117.x; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; PUHL RM, 2005, CLIN OBESITY ADULTS, P29; Raben A, 2003, AM J CLIN NUTR, V77, P91, DOI 10.1093/ajcn/77.1.91; Raben A, 2002, AM J CLIN NUTR, V76, P721, DOI 10.1093/ajcn/76.4.721; RIMM AA, 1975, PUBLIC HEALTH REP, V90, P44; *RO6YAL COLL PHYS, 1983, J ROY COLL PHYS LOND, V17, P4; ROBERTS SB, 1995, JAMA-J AM MED ASSOC, V273, P702; Ryo M, 2004, CIRC J, V68, P975, DOI 10.1253/circj.68.975; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; Sanchez-Castillo CP, 2005, PUBLIC HEALTH NUTR, V8, P53, DOI [10.1079/PHN2004659, 10.1079/PHN2005659]; Sims E A, 1973, Recent Prog Horm Res, V29, P457; Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622; SJOSTROM L, 2004, HDB OBESITY CLIN APP, P359; Skurk T, 2004, INT J OBESITY, V28, P1357, DOI 10.1038/sj.ijo.0802778; Solomon CG, 2004, NEW ENGL J MED, V351, P2751, DOI 10.1056/NEJMe048308; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; Stevens J, 2001, OBES RES, V9, P696, DOI 10.1038/oby.2001.94; STUBBS RJ, 1995, AM J CLIN NUTR, V62, P316; Stunkard A. J., 2002, Handbook of obesity treatment, P107; Trichopoulou A, 2002, EUR J CLIN NUTR, V56, P37, DOI 10.1038/sj.ejcn.1601286; Tsalikian E, 2004, DIABETES CARE, V27, P722; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; U.S. Department of Health and Human Services, 2001, SURG GEN CALL ACT PR; *UKPDS, UKPDS RISK ENG MOD E; VAINIO H, 2002, INT AGENCY CANC HDB, V6; Van Gaal LF, 2005, LANCET, V365, P1389, DOI 10.1016/S0140-6736(05)66374-X; VANGAAL LF, 2004, HDB OBESITY CLIN APP, P253; Walker LO, 2005, JOGNN-J OBST GYN NEO, V34, P418, DOI 10.1177/0884217505278294; Wanless, 2002, SECURING OUR FUTURE; Wanless D., 2004, SECURING GOOD HLTH W; Wannamethee SG, 1999, DIABETES CARE, V22, P1266, DOI 10.2337/diacare.22.8.1266; Wannamethee SG, 1998, J HUM HYPERTENS, V12, P735, DOI 10.1038/sj.jhh.1000714; Wessel TR, 2004, JAMA-J AM MED ASSOC, V292, P1179, DOI 10.1001/jama.292.10.1179; WHO, 2003, WHO TECH REP SER, V916, P1; WHO/IASO/IOTF, 2000, ASIA PACIFIC PERSPEC; WILLIAMSON DF, 1995, AM J EPIDEMIOL, V141, P1128, DOI 10.1093/oxfordjournals.aje.a117386; Wolf HK, 1997, J HUM HYPERTENS, V11, P733, DOI 10.1038/sj.jhh.1000531; *WORLD HLTH ASS RE, 2004, WHA5717 WHO; Yajnik C, 2000, P NUTR SOC, V59, P257, DOI 10.1017/S0029665100000288; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	119	3155	3284	21	877	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	2005	366	9492					1197	1209		10.1016/S0140-6736(05)67483-1	http://dx.doi.org/10.1016/S0140-6736(05)67483-1			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970LK	16198769				2022-12-28	WOS:000232311300030
J	Khaldoun, A; Eiser, E; Wegdam, GH; Bonn, D				Khaldoun, A; Eiser, E; Wegdam, GH; Bonn, D			Liquefaction of quicksand under stress - A person trapped in salt-lake quicksand is not in any danger of being sucked under completely.	NATURE			English	Editorial Material									Univ Amsterdam, Van der Waals Zeeman Inst, NL-1018 XE Amsterdam, Netherlands; Univ Amsterdam, HIMS, NL-1018 XE Amsterdam, Netherlands; Ecole Normale Super, Phys Stat Lab, F-75231 Paris, France	University of Amsterdam; University of Amsterdam; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Khaldoun, A (corresponding author), Univ Amsterdam, Van der Waals Zeeman Inst, Kruislaan 403, NL-1018 XE Amsterdam, Netherlands.	bonn@science.uva.nl	Bonn, Daniel/F-9928-2011					Batchelor G.K., 2000, INTRO FLUID DYNAMICS; Coussot P, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.175501; Ferroir T, 2004, PHYS FLUIDS, V16, P594, DOI 10.1063/1.1640372; Huang N, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.028301; Lambe T.W., 1969, SOIL MECH; Lohse D, 2004, NATURE, V432, P689, DOI 10.1038/432689a; Van Olphen H., 1977, GEOLOGISTS SOIL SCI, V2nd	7	30	30	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					635	635		10.1038/437635a	http://dx.doi.org/10.1038/437635a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193035	Bronze			2022-12-28	WOS:000232157900034
J	Prasanth, KV; Prasanth, SG; Xuan, ZY; Hearn, S; Freier, SM; Bennett, CF; Zhang, MQ; Spector, DL				Prasanth, KV; Prasanth, SG; Xuan, ZY; Hearn, S; Freier, SM; Bennett, CF; Zhang, MQ; Spector, DL			Egulating gene expression through RNA nuclear retention	CELL			English	Article							INTERCHROMATIN GRANULE CLUSTERS; NITRIC-OXIDE SYNTHASE; IN-VIVO ANALYSIS; MESSENGER-RNA; TRANSLATIONAL CONTROL; HSR-OMEGA; ADENOSINE DEAMINASES; HUMAN TRANSCRIPTOME; NONCODING RNAS; POLY(A) RNA	Multiple mechanisms have evolved to regulate the eukaryotic genome. We have identified CTN-RNA, a mouse tissue-specific similar to 8 kb nuclear-retained poly(A)(+) RNA that regulates the level of its protein-coding partner. CTN-RNA is transcribed from the protein-coding mouse cationic amino acid transporter 2 (mCAT2) gene through alternative promoter and poly(A) site usage. CTN-RNA is diffusely distributed in nuclei and is also localized to paraspeckles. The 3'UTR of CTN-RNA contains elements for adenosine-to-inosine editing, involved in its nuclear retention. Interestingly, knockdown of CTN-RNA also downregulates mCAT2 mRNA. Under stress, CTN-RNA is posttranscriptionally cleaved to produce protein-coding mCAT2 mRNA. Our findings reveal a role of the cell nucleus in harboring RNA molecules that are not immediately needed to produce proteins but whose cytoplasmic presence is rapidly required upon physiologic stress. This mechanism of action highlights an important paradigm for the role of a nuclear-retained stable RNA transcript in regulating gene expression.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA	Cold Spring Harbor Laboratory; Isis Pharmaceuticals Inc	Spector, DL (corresponding author), Cold Spring Harbor Lab, 2 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	spector@cshl.org		Hearn, Stephen/0000-0002-2489-2424; Xuan, Zhenyu/0000-0001-9344-8493	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001696, R01HG002600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042694] Funding Source: NIH RePORTER; NCI NIH HHS [CA13016] Funding Source: Medline; NHGRI NIH HHS [HG01696, HG02600] Funding Source: Medline; NIGMS NIH HHS [GM42694, R01 GM042694] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Athanasiadis A, 2004, PLOS BIOL, V2, P2144, DOI 10.1371/journal.pbio.0020391; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chang Jinhong, 2004, RNA Biol, V1, P106, DOI 10.4161/rna.1.2.1066; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Dettwiler S, 2004, J BIOL CHEM, V279, P35788, DOI 10.1074/jbc.M403927200; FINI ME, 1989, J CELL BIOL, V108, P2045, DOI 10.1083/jcb.108.6.2045; FINLEY KD, 1995, P NATL ACAD SCI USA, V92, P9378, DOI 10.1073/pnas.92.20.9378; Fox AH, 2002, CURR BIOL, V12, P13, DOI 10.1016/S0960-9822(01)00632-7; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Hager GL, 2004, BBA-GENE STRUCT EXPR, V1677, P46, DOI 10.1016/j.bbaexp.2003.09.016; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; HERMAN RC, 1976, CELL, V7, P429, DOI 10.1016/0092-8674(76)90173-2; Hierholzer C, 1998, J EXP MED, V187, P917, DOI 10.1084/jem.187.6.917; Hirotsune S, 2003, NATURE, V423, P91, DOI 10.1038/nature01535; HOGAN NC, 1994, J CELL BIOL, V125, P21, DOI 10.1083/jcb.125.1.21; Huang CJ, 2002, NITRIC OXIDE-BIOL CH, V6, P79, DOI 10.1006/niox.2001.0402; HUANG S, 1994, J CELL BIOL, V126, P877, DOI 10.1083/jcb.126.4.877; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Kim DDY, 2004, GENOME RES, V14, P1719, DOI 10.1101/gr.2855504; Kumar M, 1997, P NATL ACAD SCI USA, V94, P3542, DOI 10.1073/pnas.94.8.3542; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; Lee J, 2003, P NATL ACAD SCI USA, V100, P4843, DOI 10.1073/pnas.0735876100; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Levanon EY, 2004, NAT BIOTECHNOL, V22, P1001, DOI 10.1038/nbt996; Lowenstein CJ, 2004, J CELL SCI, V117, P2865, DOI 10.1242/jcs.01166; MacLeod CL, 1996, BIOCHEM SOC T, V24, P846, DOI 10.1042/bst0240846; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Mattick JS, 2004, NAT REV GENET, V5, P316, DOI 10.1038/nrg1321; Mattick JS, 2003, BIOESSAYS, V25, P930, DOI 10.1002/bies.10332; McKay RA, 1999, J BIOL CHEM, V274, P1715, DOI 10.1074/jbc.274.3.1715; Mignone F, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews0004; Mintz PJ, 1999, EMBO J, V18, P4308, DOI 10.1093/emboj/18.15.4308; Morse DP, 1997, BIOCHEMISTRY-US, V36, P8429, DOI 10.1021/bi9709607; Morse DP, 2002, P NATL ACAD SCI USA, V99, P7906, DOI 10.1073/pnas.112704299; Nicholson B, 2001, J BIOL CHEM, V276, P15881, DOI 10.1074/jbc.M010030200; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Platani M, 2000, J CELL BIOL, V151, P1561, DOI 10.1083/jcb.151.7.1561; Plath K, 2002, ANNU REV GENET, V36, P233, DOI 10.1146/annurev.genet.36.042902.092433; Prasanth KV, 2000, J CELL SCI, V113, P3485; Prasanth KV, 2003, MOL BIOL CELL, V14, P1043, DOI 10.1091/mbc.E02-10-0669; Proudfoot N, 2004, CURR OPIN CELL BIOL, V16, P272, DOI 10.1016/j.ceb.2004.03.007; Rosen GM, 2002, CHEM REV, V102, P1191, DOI 10.1021/cr010187s; Saitoh N, 2004, MOL BIOL CELL, V15, P3876, DOI 10.1091/mbc.E04-03-0253; SPECTOR DL, 2001, CELLS LAB MANUAL; Stevens BR, 1996, J BIOL CHEM, V271, P24017, DOI 10.1074/jbc.271.39.24017; Suzuki M, 2004, BIOESSAYS, V26, P833, DOI 10.1002/bies.20084; Szymaski M, 2003, INT REV CYTOL, V231, P197, DOI 10.1016/S0074-7696(03)31005-8; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069; VISA N, 1993, EXP CELL RES, V208, P19, DOI 10.1006/excr.1993.1218; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; Zhang Z, 2001, CELL, V106, P465, DOI 10.1016/S0092-8674(01)00466-4	53	526	597	3	24	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 21	2005	123	2					249	263		10.1016/j.cell.2005.08.033	http://dx.doi.org/10.1016/j.cell.2005.08.033			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239143	Bronze			2022-12-28	WOS:000232794100012
J	Fisher, SE				Fisher, SE			On genes, speech, and language	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FOXP2						Fisher, Simon E./E-9130-2012	Fisher, Simon E./0000-0002-3132-1996				Bishop DVM, 2001, PHILOS T R SOC B, V356, P369, DOI 10.1098/rstb.2000.0770; Fisher SE, 2003, ANNU REV NEUROSCI, V26, P57, DOI 10.1146/annurev.neuro.26.041002.131144; Lichtenbelt KD, 2005, AM J MED GENET A, V132A, P93, DOI 10.1002/ajmg.a.30408; MacDermot KD, 2005, AM J HUM GENET, V76, P1074, DOI 10.1086/430841; Vargha-Khadem F, 2005, NAT REV NEUROSCI, V6, P131, DOI 10.1038/nrn1605	5	12	12	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	2005	353	16					1655	1657		10.1056/NEJMp058207	http://dx.doi.org/10.1056/NEJMp058207			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975IC	16236736				2022-12-28	WOS:000232653200005
J	Altman, DG; Bland, JM				Altman, DG; Bland, JM			Statistics notes - Standard deviations and standard errors	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Oxford Wolfson Coll, Canc Res UK, NHS Ctr Stat Med, Oxford OX2 6UD, England; Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England	Cancer Research UK; University of Oxford; University of York - UK	Altman, DG (corresponding author), Univ Oxford Wolfson Coll, Canc Res UK, NHS Ctr Stat Med, Oxford OX2 6UD, England.	doug.altman@cancer.org.uk						ALTMAN DG, 1994, BRIT MED J, V309, P996, DOI 10.1136/bmj.309.6960.996; ALTMAN DG, 1995, BRIT MED J, V310, P298, DOI 10.1136/bmj.310.6975.298; Nagele P, 2003, BRIT J ANAESTH, V90, P514, DOI 10.1093/bja/aeg087; Olsen CH, 2003, INFECT IMMUN, V71, P6689, DOI 10.1128/IAI.71.12.6689-6692.2003	4	392	407	4	84	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 15	2005	331	7521					903	903		10.1136/bmj.331.7521.903	http://dx.doi.org/10.1136/bmj.331.7521.903			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975SX	16223828	Bronze, Green Published			2022-12-28	WOS:000232683300031
J	Gesundheit, B; Greenberg, M				Gesundheit, B; Greenberg, M			Medical mystery - One brown eye and one blue eye	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hadassah Univ Hosp, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Gesundheit, B (corresponding author), Hadassah Univ Hosp, IL-91120 Jerusalem, Israel.		Gesundheit, Benjamin/ABA-2354-2021						0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 6	2005	353	14					1502	1502		10.1056/NEJMicm040370	http://dx.doi.org/10.1056/NEJMicm040370			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970LZ	16207852				2022-12-28	WOS:000232313000010
J	Tirosh, A; Shai, I; Tekes-Manova, D; Israeli, E; Pereg, D; Shochat, T; Kochba, I; Rudich, A				Tirosh, A; Shai, I; Tekes-Manova, D; Israeli, E; Pereg, D; Shochat, T; Kochba, I; Rudich, A		Israeli Diabetes Res Grp	Normal fasting plasma glucose levels and type 2 diabetes in young men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-HEART-DISEASE; INSULIN-RESISTANCE; CARDIOVASCULAR RISK; BLOOD-GLUCOSE; FATTY-ACIDS; FOLLOW-UP; TOLERANCE; PREVENTION; GLUCONEOGENESIS; COMPONENTS	BACKGROUND: The normal fasting plasma glucose level was recently defined as less than 100 mg per deciliter (5.55 mmol per liter). Whether higher fasting plasma glucose levels within this range independently predict type 2 diabetes in young adults is unclear. METHODS: We obtained blood measurements, data from physical examinations, and medical and lifestyle information from men in the Israel Defense Forces who were 26 to 45 years of age. RESULTS: A total of 208 incident cases of type 2 diabetes occurred during 74,309 person-years of follow-up (from 1992 through 2004) among 13,163 subjects who had baseline fasting plasma glucose levels of less than 100 mg per deciliter. A multivariate model, adjusted for age, family history of diabetes, body-mass index, physical-activity level, smoking status, and serum triglyceride levels, revealed a progressively increased risk of type 2 diabetes in men with fasting plasma glucose levels of 87 mg per deciliter (4.83 mmol per liter) or more, as compared with those whose levels were in the bottom quintile (less than 81 mg per deciliter [4.5 mmol per liter], P for trend <0.001). In multivariate models, men with serum triglyceride levels of 150 mg per deciliter (1.69 mmol per liter) or more, combined with fasting plasma glucose levels of 91 to 99 mg per deciliter (5.05 to 5.50 mmol per liter), had a hazard ratio of 8.23 (95 percent confidence interval, 3.6 to 19.0) for diabetes, as compared with men with a combined triglyceride level of less than 150 mg per deciliter and fasting glucose levels of less than 86 mg per deciliter (4.77 mmol per liter). The joint effect of a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or more and a fasting plasma glucose level of 91 to 99 mg per deciliter resulted in a hazard ratio of 8.29 (95 percent confidence interval, 3.8 to 17.8), as compared with a body-mass index of less than 25 and a fasting plasma glucose level of less than 86 mg per deciliter. CONCLUSIONS: Higher fasting plasma glucose levels within the normoglycemic range constitute an independent risk factor for type 2 diabetes among young men, and such levels may help, along with body-mass index and triglyceride levels, to identify apparently healthy men at increased risk for diabetes.	Chaim Sheba Med Ctr, Dept Internal Med A, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Israel Def Forces Med Corps, Med Corps Headquarters, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Israel Def Forces Med Corps, Ctr Med Serv, IL-52621 Tel Hashomer, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, S Daniel Abraham Int Ctr Hlth & Nutr, Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Dept Epidemiol, Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, Beer Sheva, Israel; Meir Hosp, Sapir Med Ctr, Dept Internal Med A, Kefar Sava, Israel	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Ben Gurion University; Ben Gurion University; Ben Gurion University; Tel Aviv University; Sackler Faculty of Medicine	Tirosh, A (corresponding author), Chaim Sheba Med Ctr, Dept Internal Med A, IL-52621 Tel Hashomer, Israel.	amirt@bgumail.bgu.ac.il		Tirosh, Amir/0000-0003-2210-5906; Shai, Iris/0000-0001-9050-4605; Rudich, Assaf/0000-0002-1366-1444				*AM DIAB ASS, 2004, DIABETES CARE S1, V27, pS11, DOI DOI 10.2337/DIACARE.27.2007.S11; Bajaj M, 2004, INT J OBESITY, V28, P783, DOI 10.1038/sj.ijo.0802625; Banerjee RR, 2004, SCIENCE, V303, P1195, DOI 10.1126/science.1092341; Bloomgarden ZT, 2004, DIABETES CARE, V27, P998, DOI 10.2337/diacare.27.4.998; Boden G, 1997, DIABETES, V46, P536; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Borch-Johnsen K, 2004, DIABETOLOGIA, V47, P1396, DOI 10.1007/s00125-004-1468-6; BORTHEIRY AL, 1994, DIABETES CARE, V17, P1269, DOI 10.2337/diacare.17.11.1269; Chiasson JL, 2004, DIABETOLOGIA, V47, P969, DOI 10.1007/s00125-004-1409-4; Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Durbin RJ, 2004, DIABETES OBES METAB, V6, P280, DOI 10.1111/j.1462-8902.2004.0348.x; Gabir MM, 2000, DIABETES CARE, V23, P1108, DOI 10.2337/diacare.23.8.1108; Gastaldelli A, 2004, J CLIN ENDOCR METAB, V89, P3914, DOI 10.1210/jc.2003-031941; Gavin JR, 1997, DIABETES CARE, V20, P1183; Genuth S, 2003, DIABETES CARE, V26, P3160; Genuth S, 2003, DIABETES CARE, V26, P3331, DOI 10.2337/diacare.26.12.3331; Juonala M, 2004, J INTERN MED, V255, P457, DOI 10.1111/j.1365-2796.2004.01308.x; Kim DJ, 2003, DIABETES CARE, V26, P3354, DOI 10.2337/diacare.26.12.3354; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Lam TKT, 2005, NAT MED, V11, P320, DOI 10.1038/nm1201; Muse ED, 2004, J CLIN INVEST, V114, P232, DOI 10.1172/JCI200421270; Navas-Nacher EL, 2001, ANN INTERN MED, V135, P71, DOI 10.7326/0003-4819-135-1-200107030-00042; Navas-Nacher EL, 2001, ANN INTERN MED, V134, P433, DOI 10.7326/0003-4819-134-6-200103200-00007; Piche ME, 2004, DIABETES CARE, V27, P2470, DOI 10.2337/diacare.27.10.2470; ROTHMAN DL, 1991, SCIENCE, V254, P573, DOI 10.1126/science.1948033; Rothman K., 1998, MODERN EPIDEMIOLOGY; Roux AVD, 2002, DIABETES CARE, V25, P1976, DOI 10.2337/diacare.25.11.1976; Schriger DL, 2004, DIABETES CARE, V27, P592, DOI 10.2337/diacare.27.2.592; Shaw JE, 2000, DIABETES CARE, V23, P34, DOI 10.2337/diacare.23.1.34; Simons LA, 2000, AUST NZ J MED, V30, P41, DOI 10.1111/j.1445-5994.2000.tb01053.x; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; Stern MP, 2002, ANN INTERN MED, V136, P575, DOI 10.7326/0003-4819-136-8-200204160-00006; Tai ES, 2004, DIABETES CARE, V27, P1728, DOI 10.2337/diacare.27.7.1728; Tanne D, 2004, STROKE, V35, P2351, DOI 10.1161/01.STR.0000140738.94047.55; Thomas GN, 2004, ARTERIOSCL THROM VAS, V24, P739, DOI 10.1161/01.ATV.0000118015.26978.07; Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155; Torgerson JS, 2004, DIABETES CARE, V27, P856; Unwin N, 2002, DIABETIC MED, V19, P708, DOI 10.1046/j.1464-5491.2002.00835.x; Urbina EM, 2004, ATHEROSCLEROSIS, V176, P157, DOI 10.1016/j.atherosclerosis.2004.04.023; Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI20514	41	349	368	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 6	2005	353	14					1454	1462		10.1056/NEJMoa050080	http://dx.doi.org/10.1056/NEJMoa050080			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970LZ	16207847	Bronze			2022-12-28	WOS:000232313000005
J	van den Elzen, P; Garg, S; Leon, L; Brigl, M; Leadbetter, EA; Gumperz, JE; Dascher, CC; Cheng, TY; Sacks, FM; Illarionov, PA; Besra, GS; Kent, SC; Moody, DB; Brenner, MB				van den Elzen, P; Garg, S; Leon, L; Brigl, M; Leadbetter, EA; Gumperz, JE; Dascher, CC; Cheng, TY; Sacks, FM; Illarionov, PA; Besra, GS; Kent, SC; Moody, DB; Brenner, MB			Apolipoprotein-mediated pathways of lipid antigen presentation	NATURE			English	Article							TRANSPORT PROTEIN; GENE-EXPRESSION; DENDRITIC CELLS; LYMPHOCYTES-T; NKT CELLS; RECEPTOR; LIPOPROTEINS; ATHEROSCLEROSIS; MACROPHAGES; METABOLISM	Peptide antigens are presented to T cells by major histocompatibility complex (MHC) molecules, with endogenous peptides presented by MHC class I and exogenous peptides presented by MHC class II. In contrast to the MHC system, CD1 molecules bind lipid antigens that are presented at the antigen-presenting cell (APC) surface to lipid antigen-reactive T cells(1). Because CD1 molecules survey endocytic compartments(2), it is self-evident that they encounter antigens from extracellular sources. However, the mechanisms of exogenous lipid antigen delivery to CD1-antigen-loading compartments are not known. Serum apolipoproteins are mediators of extracellular lipid transport for metabolic needs(3). Here we define the pathways mediating markedly efficient exogenous lipid antigen delivery by apolipoproteins to achieve T-cell activation. Apolipoprotein E binds lipid antigens and delivers them by receptor-mediated uptake into endosomal compartments containing CD1 in APCs. Apolipoprotein E mediates the presentation of serum-borne lipid antigens and can be secreted by APCs as a mechanism to survey the local environment to capture antigens or to transfer microbial lipids from infected cells to bystander APCs. Thus, the immune system has co-opted a component of lipid metabolism to develop immunological responses to lipid antigens.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University of Birmingham	Brenner, MB (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.	mbrenner@rics.bwh.harvard.edu	Garg, Salil/GXH-2201-2022; Eckhardt, Erik/G-1567-2010	Garg, Salil/0000-0002-7198-1833; van den Elzen, Peter/0000-0003-3933-4780; Besra, Gurdyal/0000-0002-5605-0395	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071590] Funding Source: Medline; NIGMS NIH HHS [T32 GM007753] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		BARAK LS, 1981, J CELL BIOL, V90, P595, DOI 10.1083/jcb.90.3.595; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Beatty WL, 2000, TRAFFIC, V1, P235, DOI 10.1034/j.1600-0854.2000.010306.x; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; Boullier A, 2001, ANN NY ACAD SCI, V947, P214; Brigl M, 2003, NAT IMMUNOL, V4, P1230, DOI 10.1038/ni1002; Brigl M, 2004, ANNU REV IMMUNOL, V22, P817, DOI 10.1146/annurev.immunol.22.012703.104608; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Chaussabel D, 2003, BLOOD, V102, P672, DOI 10.1182/blood-2002-10-3232; Fazekas F, 2001, NEUROLOGY, V57, P853, DOI 10.1212/WNL.57.5.853; Heeren J, 2001, CURR OPIN LIPIDOL, V12, P255, DOI 10.1097/00041433-200106000-00003; Innis-Whitehouse W, 1998, J LIPID RES, V39, P679; KRUL ES, 1985, J CLIN INVEST, V75, P361, DOI 10.1172/JCI111708; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; Le Naour F, 2001, J BIOL CHEM, V276, P17920, DOI 10.1074/jbc.M100156200; Mahley R.W., 2003, WILLIAMS TXB ENDOCRI, P1642; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Major AS, 2004, ARTERIOSCL THROM VAS, V24, P2351, DOI 10.1161/01.ATV.0000147112.84168.87; Matsunaga I, 2004, J EXP MED, V200, P1559, DOI 10.1084/jem.20041429; Moody DB, 2002, NAT IMMUNOL, V3, P435, DOI 10.1038/ni780; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; Prigozy TI, 2001, SCIENCE, V291, P664, DOI 10.1126/science.291.5504.664; REBBAA A, 1995, J LIPID RES, V36, P564; Sacks F M, 1996, Vasc Med, V1, P9; Shamshiev A, 1999, EUR J IMMUNOL, V29, P1667, DOI 10.1002/(SICI)1521-4141(199905)29:05<1667::AID-IMMU1667>3.0.CO;2-U; Sugita M, 2004, CURR OPIN IMMUNOL, V16, P90, DOI 10.1016/j.coi.2003.11.014; Tomiyasu K, 2001, ARTERIOSCL THROM VAS, V21, P1494, DOI 10.1161/hq0901.094489; Tupin E, 2004, J EXP MED, V199, P417, DOI 10.1084/jem.20030997	29	280	293	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					906	910		10.1038/nature04001	http://dx.doi.org/10.1038/nature04001			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208376				2022-12-28	WOS:000232338600051
J	Zhang, SYL; Yu, Y; Roos, J; Kozak, JA; Deerinck, TJ; Ellisman, MH; Stauderman, KA; Cahalan, MD				Zhang, SYL; Yu, Y; Roos, J; Kozak, JA; Deerinck, TJ; Ellisman, MH; Stauderman, KA; Cahalan, MD			STIM1 is a Ca2+ sensor that activates CRAC channels and migrates from the Ca2+ store to the plasma membrane	NATURE			English	Article							OPERATED CALCIUM-CHANNELS; T-LYMPHOCYTES; DEPLETION; INFLUX; CELLS; OSCILLATIONS; INHIBITION; MECHANISMS; FAMILY	As the sole Ca2+ entry mechanism in a variety of non-excitable cells, store-operated calcium (SOC) influx is important in Ca2+ signalling and many other cellular processes(1-3). A calcium-release-activated calcium ( CRAC) channel in T lymphocytes is the best-characterized SOC influx channel(4-6) and is essential to the immune response, sustained activity of CRAC channels being required for gene expression and proliferation(7-10). The molecular identity and the gating mechanism of SOC and CRAC channels have remained elusive. Previously we identified Stim and the mammalian homologue STIM1 as essential components of CRAC channel activation in Drosophila S2 cells and human T lymphocytes(11). Here we show that the expression of EF-hand mutants of Stim or STIM1 activates CRAC channels constitutively without changing Ca2+ store content. By immunofluorescence, EM localization and surface biotinylation we show that STIM1 migrates from endoplasmic-reticulum-like sites to the plasma membrane upon depletion of the Ca2+ store. We propose that STIM1 functions as the missing link between Ca2+ store depletion and SOC influx, serving as a Ca2+ sensor that translocates upon store depletion to the plasma membrane to activate CRAC channels.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Immunol, Irvine, CA 92697 USA; TorreyPines Therapeut Inc, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Natl Ctr Microscopy & Imaging Res, Ctr Res Biol Struct, La Jolla, CA 92093 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Diego; University of California System; University of California San Diego	Cahalan, MD (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	mcahalan@uci.edu			NCI NIH HHS [P30 CA062203] Funding Source: Medline; NINDS NIH HHS [R01 NS014609, R37 NS014609] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA062203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014609, R37NS014609] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BECKINGHAM K, 1991, J BIOL CHEM, V266, P6027; CHUNG SC, 1994, BRIT J PHARMACOL, V113, P861, DOI 10.1111/j.1476-5381.1994.tb17072.x; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; Eray M, 2001, CYTOMETRY, V43, P134, DOI 10.1002/1097-0320(20010201)43:2<134::AID-CYTO1028>3.0.CO;2-L; Fanger CM, 2001, J BIOL CHEM, V276, P12249, DOI 10.1074/jbc.M011342200; Ferrari D, 2002, CELL CALCIUM, V32, P413, DOI 10.1016/S0143416002002014; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Graber MN, 1996, J BIOL CHEM, V271, P883, DOI 10.1074/jbc.271.2.883; Lewis RS, 1999, ADV SEC MESS PHOSPH, V33, P279; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Manji SSM, 2000, BBA-PROTEIN STRUCT M, V1481, P147, DOI 10.1016/S0167-4838(00)00105-9; NAKAYAMA S, 1994, ANNU REV BIOPH BIOM, V23, P473, DOI 10.1146/annurev.bb.23.060194.002353; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney JW, 2001, J CELL SCI, V114, P2223; PUTNEY JW, 2004, SCI STKE, V243, pPE37, DOI DOI 10.1126/STKE.2432004PE37; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; ROSS PE, 1995, J GEN PHYSIOL, V106, P415, DOI 10.1085/jgp.106.3.415; Williams RT, 2001, BIOCHEM J, V357, P673, DOI 10.1042/0264-6021:3570673; Winslow MM, 2003, CURR OPIN IMMUNOL, V15, P299, DOI 10.1016/S0952-7915(03)00050-5; Yeromin AV, 2004, J GEN PHYSIOL, V123, P167, DOI 10.1085/jgp.200308982	25	1054	1115	0	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					902	905		10.1038/nature04147	http://dx.doi.org/10.1038/nature04147			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208375	Green Accepted			2022-12-28	WOS:000232338600050
J	DiVincenzo, DP				DiVincenzo, DP			Double quantum dot as a quantum bit	SCIENCE			English	Editorial Material									IBM Corp, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA	International Business Machines (IBM)	DiVincenzo, DP (corresponding author), IBM Corp, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA.	divince@watson.ibm.com	DiVincenzo, David P/H-5952-2013	DiVincenzo, David P/0000-0003-4332-645X				Burkard G, 1999, PHYS REV B, V60, P11404, DOI 10.1103/PhysRevB.60.11404; Johnson AC, 2005, NATURE, V435, P925, DOI 10.1038/nature03815; Khaetskii AV, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.186802; Koppens FHL, 2005, SCIENCE, V309, P1346, DOI 10.1126/science.1113719; Levy J, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.147902; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Petta JR, 2005, SCIENCE, V309, P2180, DOI 10.1126/science.1116955	7	61	63	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 30	2005	309	5744					2173	2174		10.1126/science.1118921	http://dx.doi.org/10.1126/science.1118921			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195448				2022-12-28	WOS:000232318000029
J	Dong, CJ; Flecks, S; Unversucht, S; Haupt, C; van Pee, KH; Naismith, JH				Dong, CJ; Flecks, S; Unversucht, S; Haupt, C; van Pee, KH; Naismith, JH			Tryptophan 7-halogenase (PrnA) structure suggests a mechanism for regioselective chlorination	SCIENCE			English	Article							BIOSYNTHETIC GENE-CLUSTER; PARA-HYDROXYBENZOATE HYDROXYLASE; CATION-PI INTERACTIONS; PSEUDOMONAS-FLUORESCENS; CHLOROPEROXIDASE; STREPTOMYCES; HALOGENATION; PYRROLNITRIN; REBECCAMYCIN; DERIVATIVES	Chlorinated natural products include vancomycin and cryptophycin A. Their biosynthesis involves regioselective chlorination by flavin-dependent halogenases. We report the structural characterization of tryptophan halogenase (PrnA), which regioselectively chlorinates tryptophan. Tryptophan and flavin adenine dinucleotide (FAD) are separated by a 10 angstrom-long tunnel and bound by distinct enzyme modules. The FAD module is conserved in halogenases and is related to flavin-dependent monooxygenases. On the basis of biochemical studies, crystal structures, and by analogy with monooxygenases, we predict that FADH(2) reacts with O-2 to make peroxyflavin, which is decomposed by Cl-. The resulting HOCl is guided through the tunnel to tryptophan, where it is activated to participate in electrophilic aromatic substitution.	Univ St Andrews, EaStchem, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Tech Univ Dresden, Inst Biochem, D-01062 Dresden, Germany	University of St Andrews; Technische Universitat Dresden	Naismith, JH (corresponding author), Univ St Andrews, EaStchem, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland.		Naismith, James Henderson/AAB-8614-2020; Naismith, James Henderson/H-3408-2012	Naismith, James Henderson/0000-0001-6744-5061; Naismith, James Henderson/0000-0001-6744-5061; Haupt, Caroline/0000-0002-4748-6736	Biotechnology and Biological Sciences Research Council [BBS/B/14426, BB/C000080/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ALA A, 2004, NATURE, V427, P561; BRESLOW R, 1969, J AM CHEM SOC, V91, P3085, DOI 10.1021/ja01039a044; Chiu HT, 2001, P NATL ACAD SCI USA, V98, P8548, DOI 10.1073/pnas.151246498; DAIRI T, 1995, BIOSCI BIOTECH BIOCH, V59, P1099, DOI 10.1271/bbb.59.1099; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; Eustaquio AS, 2003, CHEM BIOL, V10, P279, DOI 10.1016/S1074-5521(03)00051-6; Gribble GW, 2003, CHEMOSPHERE, V52, P289, DOI 10.1016/S0045-6535(03)00207-8; HAGER LP, 1966, J BIOL CHEM, V241, P1769; Hammer PE, 1997, APPL ENVIRON MICROB, V63, P2147, DOI 10.1128/AEM.63.6.2147-2154.1997; Hammer PE, 1999, FEMS MICROBIOL LETT, V180, P39, DOI 10.1111/j.1574-6968.1999.tb08775.x; Hofmann B, 1998, J MOL BIOL, V279, P889, DOI 10.1006/jmbi.1998.1802; Hohaus K, 1997, ANGEW CHEM INT EDIT, V36, P2012, DOI 10.1002/anie.199720121; Holzer M, 2001, ADV SYNTH CATAL, V343, P591; Hubbard BK, 2003, ANGEW CHEM INT EDIT, V42, P730, DOI 10.1002/anie.200390202; Keller S, 2000, ANGEW CHEM INT EDIT, V39, P2300, DOI 10.1002/1521-3773(20000703)39:13<2300::AID-ANIE2300>3.0.CO;2-I; Ligon JM, 2000, PEST MANAG SCI, V56, P688, DOI 10.1002/1526-4998(200008)56:8<688::AID-PS186>3.3.CO;2-M; Liu W, 2002, SCIENCE, V297, P1170, DOI 10.1126/science.1072110; Messerschmidt A, 1997, BIOL CHEM, V378, P309, DOI 10.1515/bchm.1997.378.3-4.309; Piraee M, 2004, MICROBIOL-SGM, V150, P85, DOI 10.1099/mic.0.26319-0; Puk O, 2002, CHEM BIOL, V9, P225, DOI 10.1016/S1074-5521(02)00101-1; Sailler B, 1999, NAT TOXINS, V7, P57, DOI 10.1002/(SICI)1522-7189(199903/04)7:2<57::AID-NT42>3.0.CO;2-F; Sanchez C, 2002, CHEM BIOL, V9, P519, DOI 10.1016/S1074-5521(02)00126-6; Sheng DW, 2001, BIOCHEMISTRY-US, V40, P11156, DOI 10.1021/bi011153h; Sundaramoorthy M, 1998, CHEM BIOL, V5, P461, DOI 10.1016/S1074-5521(98)90003-5; van Pee KH, 2003, CHEMOSPHERE, V52, P299, DOI 10.1016/S0045-6535(03)00204-2; Weitnauer G, 2001, CHEM BIOL, V8, P569, DOI 10.1016/S1074-5521(01)00040-0; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; Williams DH, 1999, ANGEW CHEM INT EDIT, V38, P1173, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1172::AID-ANIE1172>3.0.CO;2-C; Yeh E, 2005, P NATL ACAD SCI USA, V102, P3960, DOI 10.1073/pnas.0500755102; Zacharias N, 2002, TRENDS PHARMACOL SCI, V23, P281, DOI 10.1016/S0165-6147(02)02027-8; Ziegler DM, 2002, DRUG METAB REV, V34, P503, DOI 10.1081/DMR-120005650	32	270	284	4	114	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	2005	309	5744					2216	2219		10.1126/science.1116510	http://dx.doi.org/10.1126/science.1116510			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195462	Green Accepted			2022-12-28	WOS:000232318000044
J	Nigro, G; Adler, SP; La Torre, R; Best, AM				Nigro, G; Adler, SP; La Torre, R; Best, AM		Congenital Cytomegalovirus Collabo	Passive immunization during pregnancy for congenital cytomegalovirus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS-INFECTIONS; GLYCOPROTEIN-B; GUINEA-PIGS; PREVENTION; ANTIBODY; TRANSMISSION; DIAGNOSIS; GLOBULIN; IMMUNITY; DISEASES	BACKGROUND: Currently, there is no effective intervention for a primary cytomegalovirus (CMV) infection during pregnancy. METHODS: We studied pregnant women with a primary CMV infection. The therapy group comprised women whose amniotic fluid contained either CMV or CMV DNA and who were offered intravenous CMV hyperimmune globulin at a dose of 200 U per kilogram of maternal weight. A prevention group, consisting of women with a recent primary infection before 21 weeks' gestation or who declined amniocentesis, was offered monthly hyperimmune globulin (100 U per kilogram intravenously). RESULTS: In the therapy group, 31 women received hyperimmune globulin, only 1 (3 percent) of whom gave birth to an infant with CMV disease (symptomatic at birth and handicapped at two or more years of age), as compared with 7 of 14 women who did not receive hyperimmune globulin (50 percent). Thus, hyperimmune globulin therapy was associated with a significantly lower risk of congenital CMV disease (adjusted odds ratio, 0.02; 95 percent confidence interval, - (bullet) to 0.15; P<0.001). In the prevention group, 37 women received hyperimmune globulin, 6 (16 percent) of whom had infants with congenital CMV infection, as compared with 19 of 47 women (40 percent) who did not receive hyperimmune globulin. Thus, hyperimmune globulin therapy was associated with a significantly lower risk of congenital CMV infection (adjusted odds ratio, 0.32; 95 percent confidence interval, 0.10 to 0.94; P=0.04). Hyperimmune globulin therapy significantly (P<0.001) increased CMV-specific IgG concentrations and avidity and decreased natural killer cells and HLA-DR+ cells and had no adverse effects. CONCLUSIONS: Treatment of pregnant women with CMV-specific hyperimmune globulin is safe, and the findings of this nonrandomized study suggest that it may be effective in the treatment and prevention of congenital CMV infection. A controlled trial of this agent may now be appropriate.	Univ Roma La Sapienza, Dept Pediat, Rome, Italy; Univ Roma La Sapienza, Dept Gynecol Sci Perinatol & Child Hlth, Rome, Italy; Virginia Commonwealth Univ, Dept Pediat & Biostat, Richmond, VA USA	Sapienza University Rome; Sapienza University Rome; Virginia Commonwealth University	Nigro, G (corresponding author), Via Villini 35, I-00161 Rome, Italy.	nigrogio@libero.it	Best, Al/F-6425-2012	La torre, Renato/0000-0001-9330-0747				Adler SP, 1998, PEDIATR INFECT DIS J, V17, P200, DOI 10.1097/00006454-199803000-00006; ADLER SP, 1983, PEDIATR INFECT DIS J, V2, P114, DOI 10.1097/00006454-198303000-00009; ADLER SP, 1986, J PEDIATR-US, V108, P117, DOI 10.1016/S0022-3476(86)80785-5; ADLER SP, 1989, NEW ENGL J MED, V321, P1290, DOI 10.1056/NEJM198911093211903; ALFORD CA, 1990, REV INFECT DIS, V12, pS745; BALLOW M, 1994, PEDIATR INFECT DIS J, V13, P806, DOI 10.1097/00006454-199409000-00012; BRATCHER DF, 1995, J INFECT DIS, V172, P944, DOI 10.1093/infdis/172.4.944; Chatterjee A, 2001, J INFECT DIS, V183, P1547, DOI 10.1086/320714; Clark AL, 1997, AM J OBSTET GYNECOL, V176, P241, DOI 10.1016/S0002-9378(97)80043-9; Dokun AO, 2001, NAT IMMUNOL, V2, P951, DOI 10.1038/ni714; Fairweather D, 2001, J AUTOIMMUN, V16, P175, DOI 10.1006/jaut.2000.0492; Fowler KB, 2003, JAMA-J AM MED ASSOC, V289, P1008, DOI 10.1001/jama.289.8.1008; FOWLER KB, 1992, NEW ENGL J MED, V326, P663, DOI 10.1056/NEJM199203053261003; GrangeotKeros L, 1997, J INFECT DIS, V175, P944, DOI 10.1086/513996; HARRISON CJ, 1985, J INFECT DIS, V151, P301, DOI 10.1093/infdis/151.2.301; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Keller MA, 2000, CLIN MICROBIOL REV, V13, P602, DOI 10.1128/CMR.13.4.602-614.2000; LUBCHENCO LO, 1970, PEDIATR CLIN N AM, V17, P125; Nigro G, 1999, AM J OBSTET GYNECOL, V180, P1222, DOI 10.1016/S0002-9378(99)70620-4; Nigro G, 1999, OBSTET GYNECOL, V94, P909, DOI 10.1016/S0029-7844(99)00473-1; Pass RF, 1999, J INFECT DIS, V180, P970, DOI 10.1086/315022; Remington JS, 2001, INFECT DIS FETUS NEW, P389; ROOK AH, 1988, REV INFECT DIS, V10, pS460; Sawyer LA, 2000, ANTIVIR RES, V47, P57, DOI 10.1016/S0166-3542(00)00111-X; Sissons JGP, 2002, SPRINGER SEMIN IMMUN, V24, P169, DOI 10.1007/s00281-002-0104-0; SNYDMAN DR, 1987, NEW ENGL J MED, V317, P1049, DOI 10.1056/NEJM198710223171703; STAGNO S, 1985, NEW ENGL J MED, V313, P1270, DOI 10.1056/NEJM198511143132006; STAGNO S, 1986, JAMA-J AM MED ASSOC, V256, P1904, DOI 10.1001/jama.256.14.1904; Volpe JJ., 2001, NEUROLOGY NEWBORN, V4; YEAGER AS, 1981, J PEDIATR-US, V98, P281, DOI 10.1016/S0022-3476(81)80662-2; [No title captured]	31	514	559	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2005	353	13					1350	1362		10.1056/NEJMoa043337	http://dx.doi.org/10.1056/NEJMoa043337			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968FB	16192480	Bronze, Green Published			2022-12-28	WOS:000232146200007
J	Alberti, KGMM; Zimmet, P; Shaw, J				Alberti, KGMM; Zimmet, P; Shaw, J			The metabolic syndrome - a new worldwide definition	LANCET			English	Editorial Material							PROVISIONAL REPORT; DIAGNOSIS; RISK		St Marys Hosp, Dept Endocrinol & Metab, London W2 1NY, England; Int Diabet Inst, Melbourne, Vic, Australia	Imperial College London	Alberti, KGMM (corresponding author), St Marys Hosp, Dept Endocrinol & Metab, Praed St, London W2 1NY, England.	George.Alberti@newcastle.ac.uk	Zimmet, Paul/O-8486-2019; Shaw, Jonathan/E-7388-2010; Greiver, Michelle/N-8764-2015	Zimmet, Paul/0000-0003-0627-0776; Shaw, Jonathan/0000-0002-6187-2203; Greiver, Michelle/0000-0001-8957-0285				Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Balkau B, 1999, DIABETIC MED, V16, P442; Cameron AJ, 2004, ENDOCRIN METAB CLIN, V33, P351, DOI 10.1016/j.ecl.2004.03.005; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; GALE EAM, 2005, DIABETOLOGIA, V10, P1873; Genuth S, 2003, DIABETES CARE, V26, P3160; International Diabetes Federation, 2005, IDF CONS WORLDW DEF; Kahn R, 2005, DIABETES CARE, V28, P2289, DOI 10.2337/diacare.28.9.2289; KAHN R, 2005, DIABETOLOGIA    0804, DOI DOI 10.1007/S00125-005-1876-2; Kylin E., 1923, ZENTRALBLATT INNERE, V44, P105, DOI DOI 10.1002/(SICI)1096-9136(199807)15:7<539::; Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709; Lemieux I, 2000, CIRCULATION, V102, P179, DOI 10.1161/01.CIR.102.2.179; Lindstrom J, 2003, DIABETES CARE, V26, P3230, DOI 10.2337/diacare.26.12.3230; Matsuzawa Y, 2002, CIRC J, V66, P987, DOI 10.1253/circj.66.987; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Snehalatha C, 2003, DIABETES CARE, V26, P1380, DOI 10.2337/diacare.26.5.1380; Stern MP, 2004, DIABETES CARE, V27, P2676, DOI 10.2337/diacare.27.11.2676; Tan CE, 2004, DIABETES CARE, V27, P1182, DOI 10.2337/diacare.27.5.1182; Van Gaal LF, 2005, LANCET, V365, P1389, DOI 10.1016/S0140-6736(05)66374-X; WHO, 2004, LANCET, V363, P902; Zimmet P, 2003, DIABETIC MED, V20, P693, DOI 10.1046/j.1464-5491.2003.01052.x	22	5403	5858	18	145	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 24	2005	366	9491					1059	1062		10.1016/S0140-6736(05)67402-8	http://dx.doi.org/10.1016/S0140-6736(05)67402-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TL	16182882				2022-12-28	WOS:000232114000008
J	Colleoni, M; Li, SG; Gelber, RD; Price, KN; Coates, AS; Castiglione-Gertsch, M; Goldhirsch, A				Colleoni, M; Li, SG; Gelber, RD; Price, KN; Coates, AS; Castiglione-Gertsch, M; Goldhirsch, A		Int Breast Canc Study Grp	Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index	LANCET			English	Article							BREAST-CANCER; OBESITY	Clinicians often reduce chemotherapy doses when treating obese patients because of concerns about overdosing. We assessed dose-response according to body-mass index (BMI) and oestrogen receptor (ER) expression of the primary tumour in premenopausal patients with node-positive breast cancer treated with classical CMF (cyclophosphamide, methotrexate, and 5-fluorouracil). Obese patients were significantly more likely to receive a lower chemotherapy dose (<85% of expected dose) for the first course than were those with normal or intermediate BMI (39% vs 16%, p<0.0001). For obese patients and for the total population, reducing the dose of chemotherapy was associated with a significantly worse outcome for the ER-negative cohort (total population hazards ratio >= 85% vs <85% 0.68 [95% CI 0.54-0.86] for disease free survival; 0.72 [0.56-0.94] for overall survival) but not for the ER-positive cohort (1.16 [0.97-1.40] for disease-free survival; 1.16 [0.94-1.44] for overall survival) [interaction p values=0.0001 for disease-free survival and 0.0019 for overall survival]. Our findings suggest that for women with ER-absent or ER-low tumours, reduction in chemotherapy dose should be avoided.	European Inst Oncol, Div Med Oncol, I-20141 Milan, Italy; Dana Farber Canc Inst, IBCSG Stat Ctr, Boston, MA 02115 USA; Frontier Sci & Tehcnol Res Fdn, Boston, MA USA; Univ Sydney, Sydney, NSW 2006, Australia; Canc Council Australia, Sydney, NSW, Australia; IBCSG Coordinating Ctr, Bern, Switzerland; Oncol Inst So Switzerland, Lugano, Switzerland	IRCCS European Institute of Oncology (IEO); Harvard University; Dana-Farber Cancer Institute; Frontier Science Foundation; University of Sydney; Cancer Council New South Wales	Colleoni, M (corresponding author), European Inst Oncol, Div Med Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	marco.colleoni@ieo.it	Colleoni, Marco/AAN-8647-2020	Colleoni, Marco/0000-0002-5743-3013	NCI NIH HHS [CA-75362] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Goldhirsch A, 2003, J CLIN ONCOL, V21, P3357, DOI 10.1200/JCO.2003.04.576; GOODWIN PJ, 1990, BREAST CANCER RES TR, V16, P205, DOI 10.1007/BF01806329; HENDERSON IC, 1988, J CLIN ONCOL, V6, P1501, DOI 10.1200/JCO.1988.6.9.1501; Poikonen P, 2001, ACTA ONCOL, V40, P67; Rosner GL, 1996, J CLIN ONCOL, V14, P3000, DOI 10.1200/JCO.1996.14.11.3000	5	109	111	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 24	2005	366	9491					1108	1110		10.1016/S0140-6736(05)67110-3	http://dx.doi.org/10.1016/S0140-6736(05)67110-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TL	16182899	Bronze			2022-12-28	WOS:000232114000029
J	Hirota, T; Lipp, JJ; Toh, BH; Peters, JM				Hirota, T; Lipp, JJ; Toh, BH; Peters, JM			Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin	NATURE			English	Article							CHROMOSOME CONDENSATION; FISSION YEAST; LYSINE 9; H3; CENTROMERE; PROTEINS; CHROMATIN; CELLS; AUTOANTIGENS; RECRUITMENT	Histones are subject to numerous post-translational modifications(1). Some of these 'epigenetic' marks recruit proteins that modulate chromatin structure. For example, heterochromatin protein 1 (HP1) binds to histone H3 when its lysine 9 residue has been tri-methylated by the methyltransferase Suv39h ( refs 2 - 6). During mitosis, H3 is also phosphorylated by the kinase Aurora B-7. Although H3 phosphorylation is a hallmark of mitosis, its function remains mysterious. It has been proposed that histone phosphorylation controls the binding of proteins to chromatin(8), but any such mechanisms are unknown. Here we show that antibodies against mitotic chromosomal antigens that are associated with human autoimmune diseases(9) specifically recognize H3 molecules that are modified by both tri-methylation of lysine 9 and phosphorylation of serine 10 ( H3K9me3S10ph). The generation of H3K9me3S10ph depends on Suv39h and Aurora B, and occurs at pericentric heterochromatin during mitosis in different eukaryotes. Most HP1 typically dissociates from chromosomes during mitosis(10-12), but if phosphorylation of H3 serine 10 is inhibited, HP1 remains chromosome-bound throughout mitosis. H3 phosphorylation by Aurora B is therefore part of a 'methyl/ phos switch' mechanism(8) that displaces HP1 and perhaps other proteins from mitotic heterochromatin.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Monash Univ, Dept Immunol, Prahran, Vic 3181, Australia	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Monash University	Peters, JM (corresponding author), Res Inst Mol Pathol, Dr Bohrgasse 7, A-1030 Vienna, Austria.	peters@imp.univie.ac.at						Amor DJ, 2004, TRENDS CELL BIOL, V14, P359, DOI 10.1016/j.tcb.2004.05.009; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; EARNSHAW W, 1986, J CLIN INVEST, V77, P426, DOI 10.1172/JCI112320; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; Gimenez-Abian JF, 2004, CURR BIOL, V14, P1187, DOI 10.1016/j.cub.2004.06.052; Gitlits VM, 2000, J INVEST MED, V48, P172; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Grewal SIS, 2004, CURR OPIN CELL BIOL, V16, P230, DOI 10.1016/j.ceb.2004.04.002; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hirota T, 2004, J CELL SCI, V117, P6435, DOI 10.1242/jcs.01604; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Mateescu B, 2004, EMBO REP, V5, P490, DOI 10.1038/sj.embor.7400139; Mellone BG, 2003, CURR BIOL, V13, P1748, DOI 10.1016/j.cub.2003.09.031; Mellone BG, 2003, CURR OPIN GENET DEV, V13, P191, DOI 10.1016/S0959-437X(03)00019-4; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Schmiedeberg L, 2004, MOL BIOL CELL, V15, P2819, DOI 10.1091/mbc.E03-11-0827; Sessa F, 2005, MOL CELL, V18, P379, DOI 10.1016/j.molcel.2005.03.031; Sugimoto K, 2001, CELL STRUCT FUNCT, V26, P705, DOI 10.1247/csf.26.705; Sullivan BA, 2001, NAT REV GENET, V2, P584, DOI 10.1038/35084512; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7	30	491	510	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	2005	438	7071					1176	1180		10.1038/nature04254	http://dx.doi.org/10.1038/nature04254			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	995OF	16222244				2022-12-28	WOS:000234111500055
J	Redelmeier, DA; Scales, DC; Kopp, A				Redelmeier, DA; Scales, DC; Kopp, A			b blockers for elective surgery in elderly patients: population based, retrospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							PERIOPERATIVE BETA-BLOCKADE; ISCHEMIC-HEART-DISEASE; NONCARDIAC SURGERY; PROPRANOLOL-WITHDRAWAL; MYOCARDIAL-INFARCTION; ADRENERGIC-STIMULATION; HYPERTENSIVE PATIENTS; ANTIANGINAL THERAPY; MEDICATION ERRORS; ABRUPT WITHDRAWAL	Objective To test whether atenolol (a long acting beta blocker) and metoprolol (a short acting beta blocker) are associated with equivalent reductions in risk for elderly patients undergoing elective surgery. Design Population based, retrospective cohort analysis. Setting Acute care hospitals in Ontario, Canada, over one decade. Participants Consecutive patients older than 65 who were admitted for elective surgery, without symptomatic coronary disease. Main outcome measure Death or myocardial infarction. Results 37 151 patients were receiving atenolol or metoprolol before surgery, of which the most common operations were orthopaedic or abdominal procedures. As expected, the two groups were similar in demographic characteristics, medical therapy, and type of surgery. 1038 patients experienced a myocardial infarction or died, a rate that was significantly lower for patients receiving atenolol than for those receiving metoprolol (2.5% v 3.2%, P < 0.001). The decreased risk with atenolol persisted after adjustment for measured demographic, medical, and surgical factors; extended to comparisons of other long acting and short acting beta blockers; was accentuated in analyses that focused on patients with the clearest evidence of beta blocker treatment; and reflected the immediate postoperative interval. Conclusions Patients receiving metoprolol do not have as low a perioperative cardiac risk as patients receiving atenolol, in accord with possible acute withdrawal after missed doses.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med, Clin Epidemiol & Hlth Care Res Program, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Inst Clin Evaluat Sci, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Redelmeier, DA (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med, Clin Epidemiol & Hlth Care Res Program, G-151,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	DAR@ICES.ON.CA						ALDERMAN EL, 1974, ANN INTERN MED, V81, P625, DOI 10.7326/0003-4819-81-5-625; Armanious S, 2003, CAN J ANAESTH, V50, P131, DOI 10.1007/BF03017844; ASHTON CM, 1993, ANN INTERN MED, V118, P504, DOI 10.7326/0003-4819-118-7-199304010-00004; Auerbach AD, 2002, JAMA-J AM MED ASSOC, V287, P1435, DOI 10.1001/jama.287.11.1435; Austin PC, 2002, AM HEART J, V144, P290, DOI 10.1067/mhj.2002.123839; Barker KN, 2002, ARCH INTERN MED, V162, P1897, DOI 10.1001/archinte.162.16.1897; BEERS MH, 1990, J AM GERIATR SOC, V38, P1183, DOI 10.1111/j.1532-5415.1990.tb01496.x; Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376; BOUDOULAS H, 1977, ANN INTERN MED, V87, P433, DOI 10.7326/0003-4819-87-4-433; BROWNER WS, 1992, JAMA-J AM MED ASSOC, V268, P228, DOI 10.1001/jama.268.2.228; Cepeda MS, 2003, AM J EPIDEMIOL, V158, P280, DOI 10.1093/aje/kwg115; CROWE PF, 1985, CURR MED RES OPIN, V9, P431, DOI 10.1185/03007998509109615; Deeks J J, 2003, Health Technol Assess, V7, piii; Eagle KA, 2002, J AM COLL CARDIOL, V39, P542, DOI 10.1016/S0735-1097(01)01788-0; EGSTRUP K, 1988, AM J CARDIOL, V61, P1219, DOI 10.1016/0002-9149(88)91158-7; Fleisher LA, 2001, NEW ENGL J MED, V345, P1677, DOI 10.1056/NEJMcp002842; FLETCHER RH, 1996, CLIN EPIDEMIOLOGY TH, P142; Flynn EA, 2002, AM J HEALTH-SYST PH, V59, P436, DOI 10.1093/ajhp/59.5.436; Gilbert K, 2000, ANN INTERN MED, V133, P356, DOI 10.7326/0003-4819-133-5-200009050-00011; HOUSTON MC, 1988, AM HEART J, V116, P515, DOI 10.1016/0002-8703(88)90627-8; Jackevicius CA, 2003, CAN J CARDIOL, V19, P1359; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; Juurlink DN, 2004, ARCH INTERN MED, V164, P1179, DOI 10.1001/archinte.164.11.1179; Kosten TR, 2003, NEW ENGL J MED, V348, P1786, DOI 10.1056/NEJMra020617; KRUKEMYER JJ, 1990, AM HEART J, V120, P572, DOI 10.1016/0002-8703(90)90013-N; LANGOU RA, 1977, CIRCULATION S, V56, P154; LANGOU RA, 1977, CIRCULATION S, V56, P1154; Lawrence VA, 1995, J GEN INTERN MED, V10, P671, DOI 10.1007/BF02602761; Leenen FHH, 1996, BRIT J CLIN PHARMACO, V41, P83, DOI 10.1111/j.1365-2125.1996.tb00164.x; Lesar TS, 1997, ARCH INTERN MED, V157, P1569, DOI 10.1001/archinte.157.14.1569; Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67; Lindenauer PK, 2004, ARCH INTERN MED, V164, P762, DOI 10.1001/archinte.164.7.762; MALING TJB, 1979, BRIT MED J, V2, P366, DOI 10.1136/bmj.2.6186.366; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; MATTY PJ, 1987, J CLIN PHARM THER, V12, P409, DOI 10.1111/j.1365-2710.1987.tb00554.x; McAlister FA, 1999, JAMA-J AM MED ASSOC, V282, P1371, DOI 10.1001/jama.282.14.1371; McFalls EO, 2004, NEW ENGL J MED, V351, P2795, DOI 10.1056/NEJMoa041905; MILLER RD, 2000, ANESTHESIA, P559; MILLER RR, 1975, NEW ENGL J MED, V293, P416, DOI 10.1056/NEJM197508282930902; Nelson J, 1999, Can J Clin Pharmacol, V6, P69; Nettleman M D, 1996, Clin Perform Qual Health Care, V4, P148; NILSSON OR, 1984, ACTA MED SCAND, V216, P301; OLSSON G, 1984, AM HEART J, V108, P454, DOI 10.1016/0002-8703(84)90408-3; Pass SE, 2004, AM J HEALTH-SYST PH, V61, P899, DOI 10.1093/ajhp/61.9.899; PINNOCK C, 1999, FUNDAMENTALS ANAESTH, P31; Poldermans D, 1999, NEW ENGL J MED, V341, P1789, DOI 10.1056/NEJM199912093412402; Poole-Wilson PA, 2003, LANCET, V362, P7, DOI 10.1016/S0140-6736(03)13800-7; Price DJ, 2004, ANAESTHESIA, V59, P428, DOI 10.1111/j.1365-2044.2003.03656.x; PSATY BM, 1990, JAMA-J AM MED ASSOC, V263, P1653, DOI 10.1001/jama.263.12.1653; RANGNO RE, 1982, CLIN PHARMACOL THER, V31, P8, DOI 10.1038/clpt.1982.2; Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106; REDELMEIER DA, 1995, JAMA-J AM MED ASSOC, V273, P302, DOI 10.1001/jama.273.4.302; REEVES RA, 1989, CLIN PHARMACOL THER, V46, P279, DOI 10.1038/clpt.1989.139; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P144; Salpeter SR, 2002, ANN INTERN MED, V137, P715, DOI 10.7326/0003-4819-137-9-200211050-00035; SANDBERG A, 1988, EUR J CLIN PHARMACOL, V33, pS9, DOI 10.1007/BF00578406; Shammash JB, 2001, AM HEART J, V141, P148, DOI 10.1067/mhj.2001.111547; SHAMMASH JB, 2004, UPTODATE; SILAS JH, 1985, BRIT J CLIN PHARMACO, V20, P387, DOI 10.1111/j.1365-2125.1985.tb05082.x; Stevens RD, 2003, ANESTH ANALG, V97, P623, DOI 10.1213/01.ANE.0000074795.68061.16; SZECSI E, 1982, BR J CLIN PHARM, V13, pS358; TIERNEY LM, 2003, CURRENT MED DIAGNOSI, P30; VanDenKerkhof EG, 2003, ANESTH ANALG, V96, P1558, DOI 10.1213/01.ANE.0000058846.45458.9F; WEBSTER J, 1981, BRIT J CLIN PHARMACO, V12, P211; Williams J. I., 1996, PATTERNS HLTH CARE O, P339; Williams JI, 1996, INVENTORY STUDIES AC	67	104	109	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 22	2005	331	7522					932	934A		10.1136/bmj.38603.746944.3A	http://dx.doi.org/10.1136/bmj.38603.746944.3A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979UR	16210252	Green Published, Bronze			2022-12-28	WOS:000232970900019
J	McNamara, AK; Zhong, SJ				McNamara, AK; Zhong, SJ			Thermochemical structures beneath Africa and the Pacific Ocean	NATURE			English	Article							MANTLE CONVECTION; BOUNDARY-LAYER; SHEAR; HETEROGENEITY; INVERSION; VELOCITY; VISCOSITY; HOTSPOTS; MODELS; BASE	Large low-velocity seismic anomalies have been detected in the Earth's lower mantle beneath Africa and the Pacific Ocean that are not easily explained by temperature variations alone(1-11). The African anomaly has been interpreted to be a northwest southeast-trending structure(3-5,7) with a sharp-edged linear, ridgelike morphology(9,10). The Pacific anomaly, on the other hand, appears to be more rounded in shape(1-4,6,7,11). Mantle models with heterogeneous composition have related these structures to dense thermochemical piles or superplumes(12-19). It has not been shown, however, that such models can lead to thermochemical structures that satisfy the geometrical constraints, as inferred from seismological observations. Here we present numerical models of thermochemical convection in a three-dimensional spherical geometry using plate velocities inferred for the past 119 million years(20). We show that Earth's subduction history can lead to thermochemical structures similar in shape to the observed large, lower-mantle velocity anomalies. We find that subduction history tends to focus dense material into a ridge-like pile beneath Africa and a relatively more-rounded pile under the Pacific Ocean, consistent with seismic observations.	Univ Colorado, Dept Phys, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	McNamara, AK (corresponding author), Arizona State Univ, Dept Geol Sci, Tempe, AZ 85287 USA.	allen.mcnamara@asu.edu	Zhong, Shijie/A-5290-2010; McNamara, Allen/P-3144-2014	McNamara, Allen/0000-0003-3866-9503				Breger L, 1998, SCIENCE, V282, P718, DOI 10.1126/science.282.5389.718; Bunge HP, 1998, SCIENCE, V280, P91, DOI 10.1126/science.280.5360.91; Bunge HP, 2002, PHILOS T R SOC A, V360, P2545, DOI 10.1098/rsta.2002.1080; Davaille A, 2002, EARTH PLANET SC LETT, V203, P621, DOI 10.1016/S0012-821X(02)00897-X; Davaille A, 1999, NATURE, V402, P756, DOI 10.1038/45461; Grand SP, 2002, PHILOS T R SOC A, V360, P2475, DOI 10.1098/rsta.2002.1077; Ishii M, 2004, PHYS EARTH PLANET IN, V146, P113, DOI 10.1016/j.pepi.2003.06.012; Jellinek AM, 2004, REV GEOPHYS, V42, DOI 10.1029/2003RG000144; Jellinek AM, 2002, NATURE, V418, P760, DOI 10.1038/nature00979; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; Kuo BY, 2000, J GEOPHYS RES-SOL EA, V105, P28139, DOI 10.1029/2000JB900334; Lithgow-Bertelloni C, 1998, REV GEOPHYS, V36, P27, DOI 10.1029/97RG02282; MASTERS G, 2000, GEOPHYS MONOGR SER, V117, P63, DOI DOI 10.1029/GM117P0063; McNamara AK, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002847; Mitrovica JX, 2004, EARTH PLANET SC LETT, V225, P177, DOI 10.1016/j.epsl.2004.06.005; Ni SD, 2003, EARTH PLANET SC LETT, V206, P119, DOI 10.1016/S0012-821X(02)01072-5; Ni SD, 2002, SCIENCE, V296, P1850, DOI 10.1126/science.1070698; Ritsema J, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002610; Ritsema J, 1999, SCIENCE, V286, P1925, DOI 10.1126/science.286.5446.1925; Su WJ, 1997, PHYS EARTH PLANET IN, V100, P135, DOI 10.1016/S0031-9201(96)03236-0; Tackley PJ, 1998, GEODYNAMICS, V28, P231; Tackley PJ, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000167; Tackley PJ, 2000, SCIENCE, V288, P2002, DOI 10.1126/science.288.5473.2002; Wen LX, 2001, EARTH PLANET SC LETT, V189, P141, DOI 10.1016/S0012-821X(01)00365-X; Zhong SJ, 2000, J GEOPHYS RES-SOL EA, V105, P11063, DOI 10.1029/2000JB900003	25	332	335	1	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 20	2005	437	7062					1136	1139		10.1038/nature04066	http://dx.doi.org/10.1038/nature04066			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16237440				2022-12-28	WOS:000232660500040
J	Havrda, DE; Omundsen, BA; Bender, W; Kirkpatrick, MA				Havrda, DE; Omundsen, BA; Bender, W; Kirkpatrick, MA			Impact of the Medicare modernization act on low-income persons	ANNALS OF INTERNAL MEDICINE			English	Article								Background: Low-income Medicare beneficiaries without prescription benefits have high out-of-pocket medication expenses that can discourage adherence to treatment regimens. The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 created a temporary drug discount card program and a prescription benefit with low-income provisions to assist with medication expenditures for eligible seniors. Objective: To determine the impact of the new drug discount card and prescription benefit on medication expenditures by low-income Medicare recipients who require pharmaceutical company assistance for obtaining medications. Design: Retrospective, nonrandomized evaluation. Setting: Family practice physicians' office in northern Virginia. Patients: 137 Medicare recipients without prescription coverage who received assistance from pharmaceutical companies for medications. Measurements: Patients were stratified into 3 categories according to income, household size, and the federal poverty line (FPL), as defined by the new Medicare act. Participants' long-term oral and inhaled medications, dosages, and instructions for use were obtained. The MMA criteria for low-income provisions were applied for the drug discount program and for the prescription benefit. Medication costs under the new Medicare benefits were compared with those incurred without assistance and with the use of pharmaceutical company programs for the cohort and FPL categories. Results: In all income categories, medication costs were lower after enrollment in all programs than those of patients without assistance. Compared with pharmaceutical company assistance, Medicare drug discount cards resulted in less savings for all income groups. For the prescription benefit, persons with incomes less than 135% of FPL had the greatest benefit because of low-income subsidies. Persons ineligible for low-income subsidies receiving the standard benefit had a smaller reduction in out-of-pocket costs and variable monthly expenditures; they realized a superior savings with pharmaceutical company assistance programs. Limitations: The generalizability of these findings is limited because the authors used a discount pharmacy to determine drug costs for persons receiving no assistance, could not determine asset criteria for the MMA drug benefit low-income subsidy, and used a selected Medicare population. Conclusions: in a low-income Medicare population without prescription coverage, pharmaceutical company programs offered considerable savings and were superior to the Medicare drug discount cards. For the Medicare prescription plan, the greatest savings was among those eligible for low-income subsidies. Month-to-month medication costs may vary substantially for persons ineligible for such subsidies, and pharmaceutical company assistance may be a better alternative.	Shenandoah Univ, Sch Pharm, Winchester 22601, Hants, England; Amherst Family Practice, Winchester, Hants, England		Havrda, DE (corresponding author), Shenandoah Univ, Sch Pharm, 1775 N Sector Court, Winchester 22601, Hants, England.	dhavrda@su.edu						ANTOS J, 2004, PRIV DISC PUBL SUBS, P1; BRYANT J, 2004, ASSESSMENT BENEFICIA, pA1; CAPLAN C, 2003, OUT POCKET SPENDING; *CTR MED MED SERV, 2004, CMS STUD CONF SIGN S; *CTR MED MED SERV, 2004, PHARM DEM PROGR STAT; *CTR MED MED SERV, 2005, MLN MATTERS, P1; Doherty RB, 2004, ANN INTERN MED, V141, P391, DOI 10.7326/0003-4819-141-5-200409070-00100; Duke KS, 2005, AM J HEALTH-SYST PH, V62, P726, DOI 10.1093/ajhp/62.7.726; Ellingsen P, 2004, DETAILED DESCRIPTION, p[1, 4]; GROSS DJ, 2004, TRENDS MANUFACTURER, P1; Health and Safety Executive, 2004, MED DRUG DISC CARDS, P1; MAYS J, 2004, ESTIMATES MEDICARE B, P1; *MED RIGHTS CTR, 2005, STAT PRESCR DRUG RX; *PENN DEP AG, 2004, PACE PHARM ASS CONTR, P1; *PRICEWATERHOUSC, 2004, IMP MED PRESCR DRUG, P1; RICE T, 2005, LOW INCOME SUBSIDIES, P1; RODGERS J, 2004, MEICARE PRESCRIPTION, P1; SAFRAN DG, 2002, PRESCRIPTION DRUG CO, pW253; 2004, FEDERAL REGISTER, V69, P7336; 2005, FEDERAL REGISER, V70, P4464	20	9	9	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 18	2005	143	8					600	608		10.7326/0003-4819-143-8-200510180-00011	http://dx.doi.org/10.7326/0003-4819-143-8-200510180-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975PI	16230727				2022-12-28	WOS:000232674000011
J	Nachman, RL				Nachman, RL			Refractory autoimmune thrombocytopenia: response to antiplatelet therapy	LANCET			English	Editorial Material									Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Dept Med, New York, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital	Nachman, RL (corresponding author), Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Dept Med, 1300 York Ave,Box 130, New York, NY 10021 USA.	rlnachm@med.cornell.edu						Alliot C, 2001, AM J HEMATOL, V68, P215, DOI 10.1002/ajh.1182; Avcin T, 2003, J PEDIAT HEMATOL ONC, V25, P755; LOCKSHIN MD, 1987, J RHEUMATOL, V14, P214; SHOENFELD Y, 1989, CLIN IMMUNOL IMMUNOP, V51, P313, DOI 10.1016/0090-1229(89)90030-5	4	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 15	2005	366	9494					1410	1410		10.1016/S0140-6736(05)67571-X	http://dx.doi.org/10.1016/S0140-6736(05)67571-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	973ZW	16226620				2022-12-28	WOS:000232562100034
J	Tammemagi, CM; Nerenz, D; Neslund-Dudas, C; Feldkamp, C; Nathanson, D				Tammemagi, CM; Nerenz, D; Neslund-Dudas, C; Feldkamp, C; Nathanson, D			Comorbidity and survival disparities among black and white patients with breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RACIAL-DIFFERENCES; SOCIOECONOMIC-STATUS; ADMINISTRATIVE DATA; RACE; CARCINOMA; IMPACT; WOMEN; MODELS; AGE	Context Reasons for the shorter survival of black breast cancer patients compared with their white counterparts are not completely understood. Objective To evaluate the role of comorbidity in this racial disparity among breast cancer patients. Design, Setting, and Patients Historical cohort from the Henry Ford Health System (a large comprehensive health system in Detroit, Mich) followed up for a median of 10 years. Patients (n=906) included 264 black (29.1%) and 642 white (70.9%) women diagnosed as having breast cancer between 1985 and 1990. Detailed comorbidity data (268 comorbidities) and study data were abstracted from medical records and institutional, Surveillance, Epidemiology, and End Results, and Michigan State registries. Associations were analyzed with logistic and Cox regression. Main Outcome Measures Breast cancer recurrence/progression and survival to death from all, breast cancer, and competing (non-breast cancer) causes. Results Of blacks, 64 (24.9%) died of breast cancer and 95 (37.0%) died of competing causes. Comparable data for whites were 115 (18.3%) and 202 (32.1%). Blacks had worse all-cause survival (hazard ratio [HR], 1.34; 95% confidence interval [CI], 1.11-1.62), breast cancer-specific survival (HR, 1.47; 95% CI, 1.08-2.00), and competing causes survival (HR, 1.27; 95% CI, 1.00-1.63). A total of 77 adverse comorbidities were associated with reduced survival. Adverse comorbidity count was associated with all-cause (adjusted HR, 1.29; 95% CI, 1.19-1.40) and competing-causes survival but was not associated with recurrence/progression or breast cancer-specific survival. At least 1 adverse comorbidity was observed in 221 (86.0%) blacks and 407 (65.7%) whites (odds ratio, 3.20; 95% CI, 2.17-4.72). Comparisons of unadjusted and comorbidity-adjusted HRs indicated that adverse comorbidity explained 49.1% of all-cause and 76.7% of competing-causes survival disparity. Diabetes and hypertension, were particularly important in explaining disparity. Conclusions More black breast cancer patients die of competing causes than-of breast cancer. Effective control of comorbidity in black breast cancer patients should help improve life expectancy and lead to a reduction in survival disparities.	Brock Univ, Dept Community Hlth Sci, St Catharines, ON L2S 3A1, Canada; Henry Ford Hlth Syst, Ctr Hlth Serv Res, Detroit, MI USA; Henry Ford Hlth Syst, Josephine Ford Canc Ctr, Detroit, MI USA; Henry Ford Hlth Syst, Dept Pathol & Lab Med, Detroit, MI USA; Henry Ford Hlth Syst, Dept Gen Surg, Detroit, MI USA	Brock University; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital	Tammemagi, CM (corresponding author), Brock Univ, Dept Community Hlth Sci, 500 Glenridge Ave, St Catharines, ON L2S 3A1, Canada.	martin.tammemagi@brocku.ca		Tammemagi, Martin/0000-0002-4989-5058				[Anonymous], 1982, AM J CLIN PATHOL, V77, P123; Armstrong B.K., 1992, PRINCIPLES EXPOSURE; BASSETT MT, 1986, AM J PUBLIC HEALTH, V76, P1400, DOI 10.2105/AJPH.76.12.1400; Beahrs O. H., 1992, MANUAL STAGING CANC, V4th; Bradley CJ, 2002, J NATL CANCER I, V94, P490; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chu KC, 2003, CANCER, V97, P2853, DOI 10.1002/cncr.11411; COX DR, 1972, J R STAT SOC B, V34, P187; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; de Groot V, 2003, J CLIN EPIDEMIOL, V56, P221, DOI 10.1016/S0895-4356(02)00585-1; ELEY JW, 1994, JAMA-J AM MED ASSOC, V272, P947, DOI 10.1001/jama.272.12.947; ELIXHAUSER A, 2004, CLIN CLASSIFICATION; Ghafoor A, 2003, CA-CANCER J CLIN, V53, P342, DOI 10.3322/canjclin.53.6.342; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; HOSMER DW, 1999, APPL LOGISTIC REGRES; Houterman S, 2004, BRIT J CANCER, V90, P2332, DOI 10.1038/sj.bjc.6601844; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jones BA, 2004, CANCER, V101, P1293, DOI 10.1002/cncr.20500; Joslyn SA, 2000, CANCER-AM CANCER SOC, V88, P114, DOI 10.1002/(SICI)1097-0142(20000101)88:1<114::AID-CNCR16>3.0.CO;2-J; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kieszak SM, 1999, J CLIN EPIDEMIOL, V52, P137, DOI 10.1016/S0895-4356(98)00154-1; Krieger Nancy, 1997, Ethnicity and Disease, V7, P137; Lyman GH, 1997, ANN SURG ONCOL, V4, P80, DOI 10.1007/BF02316814; MALENKA DJ, 1994, J CLIN EPIDEMIOL, V47, P1027, DOI 10.1016/0895-4356(94)90118-X; Nagel G, 2004, J CANCER RES CLIN, V130, P664, DOI 10.1007/s00432-004-0594-3; Newman LA, 2001, CANCER, V91, P1834, DOI 10.1002/1097-0142(20010501)91:9<1834::AID-CNCR1204>3.0.CO;2-L; Newschaffer CJ, 1997, J CLIN EPIDEMIOL, V50, P725, DOI 10.1016/S0895-4356(97)00050-4; PARMAR MKB, 1995, SURIVAL ANAL PRACTIC; Powell H, 2001, J CLIN EPIDEMIOL, V54, P687, DOI 10.1016/S0895-4356(00)00364-4; Preen DB, 2004, J CLIN EPIDEMIOL, V57, P1295, DOI 10.1016/j.jclinepi.2004.03.016; *PUBL HLTH SERV HL, 1994, DHHS PUBL; Roetzheim RG, 2000, CANCER-AM CANCER SOC, V89, P2202, DOI 10.1002/1097-0142(20001201)89:11<2202::AID-CNCR8>3.0.CO;2-L; SATARIANO WA, 1994, ANN INTERN MED, V120, P104, DOI 10.7326/0003-4819-120-2-199401150-00002; SATARIANO WA, 1993, ADV EXP MED BIOL, V330, P1; SATARIANO WA, 1992, J GERONTOL, V47, P24; Simon MS, 1997, AM J OBSTET GYNECOL, V176, pS233, DOI 10.1016/S0002-9378(97)70381-8; Streiner D. L., 2003, HLTH MEASUREMENT SCA; Tammemagi CM, 2004, J CLIN EPIDEMIOL, V57, P597, DOI 10.1016/j.jclinepi.2003.11.002; Tammemagi CM, 2003, INT J CANCER, V103, P792, DOI 10.1002/ijc.10882; Velanovich V, 1999, SURGERY, V125, P375, DOI 10.1016/S0039-6060(99)70004-8; WEISS SE, 1995, CANCER, V76, P268, DOI 10.1002/1097-0142(19950715)76:2<268::AID-CNCR2820760217>3.0.CO;2-1; West DW, 1996, ANN EPIDEMIOL, V6, P413, DOI 10.1016/S1047-2797(96)00096-8; Yancik R, 2001, JAMA-J AM MED ASSOC, V285, P885, DOI 10.1001/jama.285.7.885; Yood MU, 1999, J NATL CANCER I, V91, P1487, DOI 10.1093/jnci/91.17.1487	46	306	307	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	2005	294	14					1765	1772		10.1001/jama.294.14.1765	http://dx.doi.org/10.1001/jama.294.14.1765			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972RX	16219879	Bronze			2022-12-28	WOS:000232472000015
J	Faught, E				Faught, E			Naming seizures	LANCET			English	Editorial Material							SPIKE		Univ Alabama Birmingham, Epilepsy Ctr, Civitan Int Res Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Faught, E (corresponding author), Univ Alabama Birmingham, Epilepsy Ctr, Civitan Int Res Ctr, Birmingham, AL 35294 USA.	faught@uab.edu	Faught, Raymond Edward/F-7767-2010					[Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; GLOOR P, 1968, EPILEPSIA, V9, P249, DOI 10.1111/j.1528-1157.1968.tb04624.x; Holmes MD, 2004, EPILEPSIA, V45, P1568, DOI 10.1111/j.0013-9580.2004.23204.x; Paus T, 2000, PROG BRAIN RES, V126, P65; Rodin E, 1999, CLIN NEUROPHYSIOL, V110, P1868, DOI 10.1016/S1388-2457(99)00163-7; SNEAD OC, 1995, ANN NEUROL, V37, P146, DOI 10.1002/ana.410370204; STEFAN H, 1997, EPILEPSY COMPREHENSI, P580; Tenney JR, 2004, EPILEPSIA, V45, P576, DOI 10.1111/j.0013-9580.2004.39303.x	9	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 8	2005	366	9493					1251	1252		10.1016/S0140-6736(05)67509-5	http://dx.doi.org/10.1016/S0140-6736(05)67509-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971ST	16214587				2022-12-28	WOS:000232405700010
J	Kumar, S; Yogesan, K				Kumar, S; Yogesan, K			Internet-based eye care: VISION 2020	LANCET			English	Editorial Material							TELEMEDICINE; OPHTHALMOLOGY; COST		Univ Western Australia, Lions Eye Inst, Ctr Excellence E Med, Nedlands, WA 6009, Australia	Lions Eye Institute; University of Western Australia	Kumar, S (corresponding author), Univ Western Australia, Lions Eye Inst, Ctr Excellence E Med, Nedlands, WA 6009, Australia.	sajeesh@cyllene.uwa.edu.au	Kanagasingam, Yogesan/C-4631-2011; kumar, sajeesh/C-1472-2010	Kanagasingam, Yogesan/0000-0001-7321-7495; 				Blomdahl S, 2001, J TELEMED TELECARE, V7, pS25; Buckley Dermot, 2002, Aust Health Rev, V25, P11; Camara JG, 1998, TELEMED J, V4, P375, DOI 10.1089/tmj.1.1998.4.375; Constable IJ, 2000, CLIN EXP OPHTHALMOL, V28, P129, DOI 10.1046/j.1442-9071.2000.00309.x; Frick KD, 2003, AM J OPHTHALMOL, V135, P471, DOI 10.1016/S0002-9394(02)02110-4; Johnston K, 2004, HEALTH POLICY PLANN, V19, P302, DOI 10.1093/heapol/czh035; Kennedy C, 2001, J TELEMED TELECARE, V7, pS20, DOI 10.1258/1357633011936895; Kumar S, 2005, BRIT J OPHTHALMOL, V89, P1382, DOI 10.1136/bjo.2005.072579; KUMAR S, 2003, INDIAN J OPHTHALMOL, V51, P295; Mitchell JW, 1999, HVAC&R RES, V5, P1, DOI 10.1080/10789669.1999.10391219; Samedov RN, 1998, J TELEMED TELECARE, V4, P42, DOI 10.1258/1357633981931399; Shanit D, 2002, J TELEMED TELECARE, V8, P76, DOI 10.1258/135763302320302127; *VISION 2020, 2005, RIGHT TO SIGHT; Yogesan K, 2000, J TELEMED TELECARE, V6, P41, DOI 10.1258/1357633001933934	14	15	16	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 8	2005	366	9493					1244	1245		10.1016/S0140-6736(05)67505-8	http://dx.doi.org/10.1016/S0140-6736(05)67505-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	971ST	16214583				2022-12-28	WOS:000232405700006
J	West, SK; Munoz, B; Mkocha, H; Holland, MJ; Aguirre, A; Solomon, AW; Foster, A; Bailey, RL; Mabey, DCW				West, SK; Munoz, B; Mkocha, H; Holland, MJ; Aguirre, A; Solomon, AW; Foster, A; Bailey, RL; Mabey, DCW			Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study	LANCET			English	Article							AZITHROMYCIN	Background Data from studies done in communities where trachoma is mesoendemic suggest that ocular infection with Chlamydia trachomatis can be eliminated after one mass treatment with antibiotics. However, there are no comparable long-term data from trachoma hyperendemic communities. Our aim, therefore, was two-fold: first, to ascertain the disease pattern of trachoma and ocular infection with C trachomatis in a trachoma hyperendemic community after mass treatment; and, second, to ascertain the risk factors for incident infection. Methods We did a longitudinal study of a trachoma hyperendemic community (n=1017) in Tanzania. We did surveys, including ocular swabs, at baseline, 2, 6, 12, and 18 months to identify the presence, and quantity, of C trachomatis after single mass treatment of all individuals aged 6 months or older with azithromycin 20 mg per kg; pregnant women without clinical disease received topical tetracycline. Findings Mass treatment (coverage 86%) significantly reduced the prevalence of infection from 57% (495 of 871) to 12% (85 of 705) at 2 months. infection remained fairly constant to 12 months, with evidence of increasing numbers and load of infection by 18 months post-treatment. Incident infection at 6 months was 3.5-times more likely if another member of the household had more than 19 organisms per swab at 2 months. Travel outside the village, and visitors to the household, did not increase the risk of infection within households up to 12 months. Interpretation In this trachoma hyperendemic community, infection levels after high antibiotic coverage persisted at a low level to 18 months, with evidence for re-emergence after 1 year. Fairly light loads of infection were associated with household transmission. Yearly mass treatment over a few years could be sufficient to eliminate infection.	Johns Hopkins Univ, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA; Kongwa Trachoma Project, Kongwa, Tanzania; London Sch Hyg & Trop Med, London WC1, England; MRC Labs, Banjul, Gambia	Johns Hopkins University; University of London; London School of Hygiene & Tropical Medicine; MRC Laboratory Molecular Biology	West, SK (corresponding author), Johns Hopkins Sch Med, Wilmer Eye Inst, Room 129,600 N Wolfe St, Baltimore, MD 21287 USA.	shwest@jhmi.edu	Holland, Martin J/K-6502-2012	Holland, Martin J/0000-0002-5828-6318; Foster, Allen/0000-0003-2368-4436; Andreasen, Aura/0000-0003-0664-7342; Mabey, David/0000-0002-0031-8276; Solomon, Anthony/0000-0001-7101-6649	MRC [MC_U190081961] Funding Source: UKRI; Medical Research Council [MC_U190081961] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X; Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107; Melese M, 2004, JAMA-J AM MED ASSOC, V292, P721, DOI 10.1001/jama.292.6.721; Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5; Smith A, 2001, Ophthalmic Epidemiol, V8, P127, DOI 10.1076/opep.8.2.127.4164; Solomon AW, 2004, NEW ENGL J MED, V351, P1962, DOI 10.1056/NEJMoa040979; Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8; THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477; West SK, 1996, AM J EPIDEMIOL, V143, P73, DOI 10.1093/oxfordjournals.aje.a008659; *WHO, 1993, PREV BLINDN PRIM HLT, P16	10	101	101	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 8	2005	366	9493					1296	1300		10.1016/S0140-6736(05)67529-0	http://dx.doi.org/10.1016/S0140-6736(05)67529-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971ST	16214600				2022-12-28	WOS:000232405700028
J	Vasan, RS; Pencina, MJ; Cobain, M; Freiberg, MS; D'Agostino, RB				Vasan, RS; Pencina, MJ; Cobain, M; Freiberg, MS; D'Agostino, RB			Estimated risks for developing obesity in the Framingham Heart Study	ANNALS OF INTERNAL MEDICINE			English	Article							MAJOR WEIGHT-GAIN; BODY-MASS INDEX; LIFETIME RISK; UNITED-STATES; ALZHEIMERS-DISEASE; US ADULTS; OVERWEIGHT; WHITE; PREVALENCE; HYPERTENSION	Background: The short- and long-term risks for developing overweight or obesity are unknown. Objectives: To estimate the short-term, long-term, and lifetime risks for developing overweight or obesity in adults in the community. Design: Prospective cohort study, 1971 to 2001. Setting: Community-based study, Framingham, Massachusetts. Participants: 4117 white participants (51.9% women) from the Framingham Heart Study. Measurements: The short-term (4 years) and long-term (10 to 30 years) risks for ever becoming overweight or more (body mass index [BMI] >= 25 kg/m(2)) or obese (BMI >= 30 kg/m(2)) for men and women at 30, 40, and 50 years of age with a normal BMI (between 18.5 kg/m(2) and 25.0 kg/m(2)). Results: The observed 4-year rates of developing overweight varied from 14% to 19% in women and 26% to 30% in men. Four-year rates of developing obesity ranged from 5% to 7% in women and 7% to 9% in men. The long-term (30-year) risk estimates were similar for the 2 sexes generally; varied somewhat with age (in men, being lower for those 50 years of age); and, overall, exceeded 1 in 2 persons for overweight or more, 1 in 4 individuals for obesity, and 1 in 10 people for stage 11 obesity (BMI >= 35 kg/m(2)) across different age groups. The 30-year estimates correspond to the residual lifetime risk for overweight or more or obesity for participants 50 years of age. Limitations: These findings may not be generalizable to other races or ethnicities. Conclusions: The long-term risks for overweight or more or obesity exceeded 50% and 25%, respectively, indicating a large public health burden. These estimates suggest that the future burden of obesity-associated diseases may be substantial.	Framingham Heart Dis Epidemiol Study, Framingham, MA 01702 USA	Framingham Heart Study	Vasan, RS (corresponding author), Framingham Heart Dis Epidemiol Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.	vasan@bu.edu	Ramachandran, Vasan/Y-2527-2019	Ramachandran, Vasan/0000-0001-7357-5970; Pencina, Michael/0000-0001-5798-8855	NHLBI NIH HHS [2K24 HL 04334, N01-HC-38038] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL004334] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beiser A, 2000, STAT MED, V19, P1495, DOI 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1495::AID-SIM441>3.0.CO;2-E; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Cupples LA, 1987, FRAMINGHAM STUDY EPI; Elandt-Johnson R C, 1980, SURVIVAL MODELS DATA; Field AE, 1999, AM J EPIDEMIOL, V150, P573, DOI 10.1093/oxfordjournals.aje.a010055; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Fortin J M, 2001, BMC Med Inform Decis Mak, V1, P2, DOI 10.1186/1472-6947-1-2; FRIEDLAENDER JS, 1977, HUM BIOL, V49, P541; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; Krauss R M, 1998, Circulation, V98, P1472; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Lloyd-Jones DM, 1999, LANCET, V353, P89, DOI 10.1016/S0140-6736(98)10279-9; Luepker RV, 1999, J PEDIATR-US, V134, P668, DOI 10.1016/S0022-3476(99)70279-9; McTigue KM, 2002, ANN INTERN MED, V136, P857, DOI 10.7326/0003-4819-136-12-200206180-00006; MELTON LJ, 1990, AM J PUBLIC HEALTH, V80, P500, DOI 10.2105/AJPH.80.4.500; Merrill RM, 1997, CANCER EPIDEM BIOMAR, V6, P763; Mokdad AH, 2000, JAMA-J AM MED ASSOC, V284, P1650, DOI 10.1001/jama.284.13.1650; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; Organization WH, 2000, WHO TECHN REP SER, DOI DOI 10.1016/J.BBI.2016.02.019; Phillips RL, 1999, NEW ENGL J MED, V340, P1681; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; RISSANEN A, 1988, INT J OBESITY, V12, P391; ROOKUS MA, 1987, HUM BIOL, V59, P617; Sasieni PD, 1999, AM J EPIDEMIOL, V149, P869; Seshadri S, 1997, NEUROLOGY, V49, P1498, DOI 10.1212/WNL.49.6.1498; Sheehan TJ, 2003, INT J OBESITY, V27, P498, DOI 10.1038/sj.ijo.0802263; Siervogel RM, 2000, OBES RES, V8, P422, DOI 10.1038/oby.2000.52; TAYLOR CB, 1994, EPIDEMIOLOGY, V5, P599, DOI 10.1097/00001648-199411000-00007; Vasan RS, 2002, JAMA-J AM MED ASSOC, V287, P1003, DOI 10.1001/jama.287.8.1003; WILLIAMSON DF, 1991, NEW ENGL J MED, V324, P739, DOI 10.1056/NEJM199103143241106; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665; WILLIAMSON DF, 1991, AM J CLIN NUTR, V53, pS1515, DOI 10.1093/ajcn/53.6.1515S; WILLIAMSON DF, 1993, ANN INTERN MED, V119, P646, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00004; World Health Organization, 1995, WHO TECH REP SER, V854, P1; Wun LM, 1998, LIFETIME DATA ANAL, V4, P169, DOI 10.1023/A:1009685507602	36	100	106	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 4	2005	143	7					473	480		10.7326/0003-4819-143-7-200510040-00005	http://dx.doi.org/10.7326/0003-4819-143-7-200510040-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970FM	16204159				2022-12-28	WOS:000232290600001
J	Siegfried, N; Clarke, M; Volmink, J				Siegfried, N; Clarke, M; Volmink, J			Randomised controlled trials in Africa of HIV and AIDS: descriptive study and spatial distribution	BRITISH MEDICAL JOURNAL			English	Article							SEXUALLY-TRANSMITTED-DISEASES; DEVELOPING-COUNTRIES; HEALTH RESEARCH; RURAL UGANDA; INFECTION; INTERVENTIONS; TRANSMISSION; REGISTRATION; MANAGEMENT; STATEMENT	Objectives To identify and describe randomised controlled trials on HIV and AIDS conducted in Africa and to map their spatial distribution using exact geographic coordinates. Design Construction and analysis of a database of trials conducted wholly or partly in Africa and reported before 2004. Data sources CENTRAL, Medline, Embase, and LILACS. Results Our comprehensive search yielded 284 distinct records that were potentially eligible for inclusion in the database. Of these, 150 articles reported on 77 eligible trials published or reported from 1987 to 2003. Seven trials were identified exclusively from the CENTRAL database. Trials were conducted in 18 of 48 countries in sub-Saharan Africa. None were conducted in north Africa. Only 19 had a principal investigator located in an African country. Forty two trials assessed prevention and 35 assessed treatment. Most studies were funded by government agencies outside Africa (n = 43), with the pharmaceutical industry providing partial support to 16 of these. The pharmaceutical industry provided full or partial support to a further 18 trials. Only 43 trials reported conducting a power calculation for determining sample size. There was no mention of ethical approval or informed consent in 19 and 17 trials, respectively. Conclusion The relatively small number of HIV/AIDS trials conducted in Africa is not commensurate with the burden of disease. Geographical mapping as an adjunct to prospective trial registration is a useful tool for researchers and decision makers to track existing and future trials.	UK Cochrane Ctr, Oxford OX2 7LG, England; Univ Cape Town, Primary Hlth Care Directorate, ZA-7925 Cape Town, South Africa	Cochrane Centre; University of Cape Town	Siegfried, N (corresponding author), UK Cochrane Ctr, Oxford OX2 7LG, England.	nsiegfried@cochrane.co.uk						[Anonymous], 2004, 2004 REP GLOB AIDS E; BASSETT M, 1998, SEX HLTH EXCH, V4, P14; Bhandari M, 2004, CAN MED ASSOC J, V170, P477; Bhandari M, 2004, EPIDEMIOLOGY, V15, P125, DOI 10.1097/01.ede.0000100282.03466.2c; BLANDARI M, 2004, CMAJ, V170, P477; Byrne DG, 1999, P NUTR SOC, V58, p154A; De Angelis C, 2004, LANCET, V364, P911, DOI 10.1016/S0140-6736(04)17034-7; Devereaux PJ, 2004, J CLIN EPIDEMIOL, V57, P1232, DOI 10.1016/j.jclinepi.2004.03.017; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; Edejer TTT, 1999, BMJ-BRIT MED J, V319, P438, DOI 10.1136/bmj.319.7207.438; Fawzi WW, 2000, J ACQ IMMUN DEF SYND, V23, P246; Fraser DW, 2000, B WORLD HEALTH ORGAN, V78, P1054; Gonzalez-Block Miguel A, 2004, Health Res Policy Syst, V2, P6, DOI 10.1186/1478-4505-2-6; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HOPEWELL S, 2004, CLIN TRIALS S1, V1, P216; Hyder AA, 2004, J MED ETHICS, V30, P68, DOI 10.1136/jme.2002.001933; Isaakidis P, 2002, BRIT MED J, V324, P702, DOI 10.1136/bmj.324.7339.702; ISTAKIDIS P, 2002, BRIT MED J, V324, P702; Kamali A, 2003, LANCET, V361, P645, DOI 10.1016/S0140-6736(03)12598-6; Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060; KREISS J, 1992, JAMA-J AM MED ASSOC, V268, P477, DOI 10.1001/jama.268.4.477; Krleza-Jeric K, 2005, BMJ-BRIT MED J, V330, P956, DOI 10.1136/bmj.330.7497.956; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; Nuffield Council on Bioethics, 2002, ETH RES REL HEALTHC; NYST MJ, 1992, ANN SOC BELG MED TR, V72, P45; PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204; Scherer R.W., 2005, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.MR000005.PUB2; Schulz KF, 2002, LANCET, V359, P515, DOI 10.1016/S0140-6736(02)07683-3; Wawer MJ, 1999, LANCET, V353, P525, DOI 10.1016/S0140-6736(98)06439-3; World Health Organization, 1996, INV HLTH RES DEV REP; Yusuf S, 2002, STAT MED, V21, P2859, DOI 10.1002/sim.1290; 2005, LANCET, V365, P1664	32	44	44	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 1	2005	331	7519					742	746B		10.1136/bmj.331.7519.742	http://dx.doi.org/10.1136/bmj.331.7519.742			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971XB	16195291	Green Published, Bronze			2022-12-28	WOS:000232417100021
J	Poulin, P				Poulin, P			New gets for mixing immiscible liquids	SCIENCE			English	Editorial Material									CNRS, Ctr Rech Paul Pascal, F-33600 Pessac, France	Centre de Recherche Paul Pascal; Centre National de la Recherche Scientifique (CNRS)	Poulin, P (corresponding author), CNRS, Ctr Rech Paul Pascal, Ave Schweitzer, F-33600 Pessac, France.	poulin@crpp-bordeaux.cnrs.fr		Poulin, Philippe/0000-0001-7748-8671				Aveyard R, 2003, ADV COLLOID INTERFAC, V100, P503, DOI 10.1016/S0001-8686(02)00069-6; CLEGG PS, UNPUCONDMAT0508088; Meeker SP, 2000, PHYS REV E, V61, pR6083, DOI 10.1103/PhysRevE.61.R6083; Safran S. A., 1994, STAT THERMODYNAMICS; Stratford K, 2005, SCIENCE, V309, P2198, DOI 10.1126/science.1116589; Tanaka H, 2000, J PHYS-CONDENS MAT, V12, pR207, DOI 10.1088/0953-8984/12/15/201	6	3	3	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	2005	309	5744					2174	2175		10.1126/science.1118123	http://dx.doi.org/10.1126/science.1118123			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195449				2022-12-28	WOS:000232318000030
J	Rao, M; Sockanathan, S				Rao, M; Sockanathan, S			Transmembrane protein GDE2 induces motor neuron differentiation in vivo	SCIENCE			English	Article							GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE; NEUROGENESIS; REQUIREMENT; EXPRESSION; IDENTITY; OLIG2	During neural development, coordinate regulation of cell-cycle exit and differentiation is essential for cell-fate specification, cell survival, and proper wiring of neuronal circuits. However, the molecules that direct these events remain poorly defined. In the developing spinal cord, the differentiation of motor neuron progenitors into postmitotic motor neurons is regulated by retinoid signaling. Here, we identify a retinoid-inducible gene, GDE2 (glycerophosphodiester phosphodiesterase 2), encoding a six-transmembrane protein that is necessary and sufficient to drive spinal motor neuron differentiation in vivo. A single amino acid mutation in the extracellular catalytic domain abolishes protein function. This reveals a critical role for glycerophosphodiester metabolism in motor neuron differentiation.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University	Sockanathan, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.	ssockan1@jhmi.edu						Arber S, 1999, NEURON, V23, P659, DOI 10.1016/S0896-6273(01)80026-X; Bylund M, 2003, NAT NEUROSCI, V6, P1162, DOI 10.1038/nn1131; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; Diez del Corral R, 2003, NEURON, V40, P65; Essen LO, 1997, BIOCHEMISTRY-US, V36, P1704, DOI 10.1021/bi962512p; Farah MH, 2000, DEVELOPMENT, V127, P693; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Hollyday M, 2001, INT J DEV NEUROSCI, V19, P161, DOI 10.1016/S0736-5748(00)00093-9; Kintner C, 2002, J NEUROSCI, V22, P639, DOI 10.1523/JNEUROSCI.22-03-00639.2002; Lee SK, 2005, GENE DEV, V19, P282, DOI 10.1101/gad.1257105; Mizuguchi R, 2001, NEURON, V31, P757, DOI 10.1016/S0896-6273(01)00413-5; Nogusa Y, 2004, GENE, V337, P173, DOI 10.1016/j.gene.2004.04.026; Novitch BG, 2003, NEURON, V40, P81, DOI 10.1016/j.neuron.2003.08.006; Novitch BG, 2001, NEURON, V31, P773, DOI 10.1016/S0896-6273(01)00407-X; PHELPS PE, 1991, J COMP NEUROL, V307, P77, DOI 10.1002/cne.903070108; Rao M, 2004, DEV DYNAM, V231, P592, DOI 10.1002/dvdy.20161; RAO MVV, UNPUB; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Shirasaki R, 2002, ANNU REV NEUROSCI, V25, P251, DOI 10.1146/annurev.neuro.25.112701.142916; Tanabe Y, 1998, CELL, V95, P67, DOI 10.1016/S0092-8674(00)81783-3; Thaler J, 1999, NEURON, V23, P675, DOI 10.1016/S0896-6273(01)80027-1; TOMMASSEN J, 1991, MOL GEN GENET, V226, P321, DOI 10.1007/BF00273621; Yanaka N, 2003, J BIOL CHEM, V278, P43595, DOI 10.1074/jbc.M302867200; Zheng B, 2003, P NATL ACAD SCI USA, V100, P1745, DOI 10.1073/pnas.0337605100; Zheng B, 2000, P NATL ACAD SCI USA, V97, P3999, DOI 10.1073/pnas.97.8.3999	25	67	72	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	2005	309	5744					2212	2215		10.1126/science.1117156	http://dx.doi.org/10.1126/science.1117156			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195461				2022-12-28	WOS:000232318000043
J	Calderon, CV; Carrera, JB				Calderon, CV; Carrera, JB			Aortic regurgitation - Bounding carotids	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Bellvitge Hosp, Barcelona 08907, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona	Calderon, CV (corresponding author), Bellvitge Hosp, Barcelona 08907, Spain.								0	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2005	353	13					E12	E12		10.1056/NEJMicm041024	http://dx.doi.org/10.1056/NEJMicm041024			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968FB	16192473				2022-12-28	WOS:000232146200011
J	Evangelista, A; Tornos, P; Sambola, A; Permanyer-Miralda, G; Soler-Soler, J				Evangelista, A; Tornos, P; Sambola, A; Permanyer-Miralda, G; Soler-Soler, J			Long-term vasodilator therapy in patients with severe aortic regurgitation.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ASYMPTOMATIC PATIENTS; EXERCISE HEMODYNAMICS; AFTERLOAD REDUCTION; FOLLOW-UP; NIFEDIPINE; INSUFFICIENCY; CAPTOPRIL; SYMPTOMS; REST; QUANTIFICATION	BACKGROUND: Vasodilator therapy can reduce the left ventricular volume and mass and improve left ventricular performance in patients with aortic regurgitation. Accordingly, it has been suggested that such therapy may reduce or delay the need for aortic-valve replacement. METHODS: We randomly assigned 95 patients with asymptomatic severe aortic regurgitation and normal left ventricular function to receive open-label nifedipine (20 mg every 12 hours), open-label enalapril (20 mg per day), or no treatment (control group) to identify the possible beneficial effects of vasodilator therapy on left ventricular function and the need for aortic-valve replacement. RESULTS: After a mean of seven years of follow-up, the rate of aortic-valve replacement was similar among the groups: 39 percent in the control group, 50 percent in the enalapril group, and 41 percent in the nifedipine group (P=0.62). In addition, there were no significant differences among the groups in aortic regurgitant volume, left ventricular size, left ventricular mass, mean wall stress, or ejection fraction. One year after valve replacement, the left ventricular end-diastolic diameter and end-systolic diameter had decreased to a similar degree among the patients who underwent surgery in each of the three groups, and all the patients had a normal ejection fraction. CONCLUSIONS: Long-term vasodilator therapy with nifedipine or enalapril did not reduce or delay the need for aortic-valve replacement in patients with asymptomatic severe aortic regurgitation and normal left ventricular systolic function. Furthermore, such therapy did not reduce the aortic regurgitant volume, decrease the size of the left ventricle, or improve left ventricular function.	Hosp Univ Vall Hebron, Serv Cardiol, Barcelona 08035, Spain	Hospital Universitari Vall d'Hebron	Evangelista, A (corresponding author), Hosp Univ Vall Hebron, Serv Cardiol, P Vall Hebron 119-129, Barcelona 08035, Spain.	aevangel@vhebron.net						Alehan D, 1998, AM HEART J, V135, P598, DOI 10.1016/S0002-8703(98)70273-X; ASHORE TM, 2005, J AM COLL CARDIOL, V45, P131; Banaszewski M, 1998, J HEART VALVE DIS, V7, P488; BOLEN JL, 1976, CIRCULATION, V53, P879, DOI 10.1161/01.CIR.53.5.879; BONOW RO, 1991, CIRCULATION, V84, P1625, DOI 10.1161/01.CIR.84.4.1625; Bonow RO, 1998, J AM COLL CARDIOL, V32, P1486, DOI 10.1016/S0735-1097(98)00454-9; Borer JS, 2003, CIRCULATION, V108, P2432, DOI 10.1161/01.CIR.0000096400.00562.A3; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; Dujardin KS, 1999, CIRCULATION, V99, P1851, DOI 10.1161/01.CIR.99.14.1851; Enriquez-Sarano M, 2004, NEW ENGL J MED, V351, P1539, DOI 10.1056/NEJMcp030912; Evangelista A, 2000, AM HEART J, V139, P773; FIORETTI P, 1982, AM J CARDIOL, V49, P1728, DOI 10.1016/0002-9149(82)90252-1; Gaasch WH, 2003, J AM COLL CARDIOL, V41, P1325, DOI 10.1016/S0735-1097(03)00130-X; Gaasch WH, 1997, CHEST, V111, P1702, DOI 10.1378/chest.111.6.1702; GREENBERG B, 1988, CIRCULATION, V78, P92, DOI 10.1161/01.CIR.78.1.92; GREENBERG BH, 1980, CIRCULATION, V62, P49, DOI 10.1161/01.CIR.62.1.49; GREENBERG BH, 1981, CIRCULATION, V63, P263, DOI 10.1161/01.CIR.63.2.263; Klodas E, 1997, J AM COLL CARDIOL, V30, P746, DOI 10.1016/S0735-1097(97)00205-2; Klodas E, 1996, CIRCULATION, V94, P2472, DOI 10.1161/01.CIR.94.10.2472; Levine HJ, 1996, J AM COLL CARDIOL, V28, P1083, DOI 10.1016/S0735-1097(96)00288-4; LIN M, 1994, J AM COLL CARDIOL, V24, P1046, DOI 10.1016/0735-1097(94)90868-0; Lung B., 2002, European Heart Journal, V23, P1253; MANYARI DE, 1995, NEW ENGL J MED, V332, P1302; NAUMAN D, 1992, CHEST, V102, P720, DOI 10.1378/chest.102.3.720; NOVO S, 1986, AM J NEPHROL, V6, P87, DOI 10.1159/000167226; QUINONES MA, 1980, AM J CARDIOL, V45, P782, DOI 10.1016/0002-9149(80)90122-8; RAHIMTOOLA SH, 1990, J AM COLL CARDIOL, V16, P430, DOI 10.1016/0735-1097(90)90597-I; ROSS J, 1974, CIRC RES, V35, P64; ROTHLISBERGER C, 1993, AM J CARDIOL, V72, P799, DOI 10.1016/0002-9149(93)91065-P; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Schon H R, 1994, J Heart Valve Dis, V3, P500; SCOGNAMIGLIO R, 1990, J AM COLL CARDIOL, V16, P424, DOI 10.1016/0735-1097(90)90596-H; Scognamiglio R, 2005, J AM COLL CARDIOL, V45, P1025, DOI 10.1016/j.jacc.2004.06.081; SCOGNAMIGLIO R, 1994, NEW ENGL J MED, V331, P689, DOI 10.1056/NEJM199409153311101; SHEN WF, 1984, J AM COLL CARDIOL, V4, P902, DOI 10.1016/S0735-1097(84)80049-2; Sondergaard L, 2000, AM HEART J, V139, P667, DOI 10.1016/S0002-8703(00)90046-2; TORNOS MP, 1995, AM HEART J, V130, P333, DOI 10.1016/0002-8703(95)90450-6; TORNOS MP, 1990, AM HEART J, V120, P649, DOI 10.1016/0002-8703(90)90023-Q; Wisenbaugh T, 1994, J Heart Valve Dis, V3, P197	39	125	128	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2005	353	13					1342	1349		10.1056/NEJMoa050666	http://dx.doi.org/10.1056/NEJMoa050666			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968FB	16192479	Bronze			2022-12-28	WOS:000232146200006
J	Williams, BR				Williams, BR			Targeting specific cell types with silencing RNA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Williams, BR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101	1	17	18	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2005	353	13					1410	1411		10.1056/NEJMcibr052492	http://dx.doi.org/10.1056/NEJMcibr052492			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968FB	16192490				2022-12-28	WOS:000232146200018
J	Cordell, HJ; Clayton, DG				Cordell, HJ; Clayton, DG			Genetic epidemiology 3 - Genetic association studies	LANCET			English	Review							SAMPLE-SIZE REQUIREMENTS; GENOTYPIC RELATIVE RISKS; FAMILY-BASED TESTS; LINKAGE DISEQUILIBRIUM; TRANSMISSION/DISEQUILIBRIUM TEST; POPULATION STRATIFICATION; QUANTITATIVE TRAITS; COMPLEX DISEASE; HAPLOTYPE; POWER	We review the rationale behind and discuss methods of design and analysis of genetic association studies. There are similarities between genetic association studies and classic epidemiological studies of environmental risk factors but there are also issues that are specific to studies of genetic risk factors such as the use of particular family-based designs, the need to account for different underlying genetic mechanisms, and the effect of population history. Association differs from linkage (covered elsewhere in this series) in that the alleles of interest will be the same across the whole population. As with other types of genetic epidemiological study, issues of design, statistical analysis, and interpretation are very important.	Univ Cambridge, Dept Med Genet,Adenbrookes Hosp, Juvenile Diabet Res Fdn,Cambridge Inst Med Res, Wellcome Trust Diabet & Inflammat Lab, Cambridge CB2 2XY, England	University of Cambridge	Cordell, HJ (corresponding author), Univ Cambridge, Dept Med Genet,Adenbrookes Hosp, Juvenile Diabet Res Fdn,Cambridge Inst Med Res, Wellcome Trust Diabet & Inflammat Lab, Wellcome Trust Med Res Council Bldg,Hills Rd, Cambridge CB2 2XY, England.	heather.cordell@cimr.cam.ac.uk		Cordell, Heather/0000-0002-1879-5572	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abecasis GR, 2000, AM J HUM GENET, V66, P279, DOI 10.1086/302698; Abecasis GR, 2000, EUR J HUM GENET, V8, P545, DOI 10.1038/sj.ejhg.5200494; Ardlie KG, 2002, NAT REV GENET, V3, P299, DOI 10.1038/nrg777; Bacanu SA, 2000, AM J HUM GENET, V66, P1933, DOI 10.1086/302929; Bacanu SA, 2002, GENET EPIDEMIOL, V22, P78, DOI 10.1002/gepi.1045; Bader JS, 2001, GENESCREEN, V1, P143; Barcellos LF, 1997, AM J HUM GENET, V61, P734, DOI 10.1086/515512; Barratt BJ, 2002, ANN HUM GENET, V66, P393, DOI [10.1046/j.1469-1809.2002.00125.x, 10.1017/S0003480002001252]; Bateson W, 1909, MENDELS PRINCIPLES H; Breslow NE., 1987, STAT METHODS CANC RE, P81; Byng MC, 2003, ANN HUM GENET, V67, P543, DOI 10.1046/j.1529-8817.2003.00055.x; Camp NJ, 1999, AM J HUM GENET, V64, P1485, DOI 10.1086/302387; Camp NJ, 1997, AM J HUM GENET, V61, P1424, DOI 10.1086/301648; Cardon LR, 2003, LANCET, V361, P598, DOI 10.1016/S0140-6736(03)12520-2; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Chapman JM, 2003, HUM HERED, V56, P18, DOI 10.1159/000073729; Chen WM, 2001, GENET EPIDEMIOL, V21, P53, DOI 10.1002/gepi.1018; Chiano MN, 1998, GENET EPIDEMIOL, V15, P135, DOI 10.1002/(SICI)1098-2272(1998)15:2<135::AID-GEPI3>3.0.CO;2-5; Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577; Clayton D, 2004, GENET EPIDEMIOL, V27, P415, DOI 10.1002/gepi.20032; Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2; CLAYTON D, SNPHAP PROGRAM ESTIM; Cordell HJ, 2002, HUM MOL GENET, V11, P2463, DOI 10.1093/hmg/11.20.2463; Cordell HJ, 2004, GENET EPIDEMIOL, V26, P167, DOI 10.1002/gepi.10307; Cordell HJ, 2002, AM J HUM GENET, V70, P124, DOI 10.1086/338007; Cordell HJ, 2001, GENETICS, V158, P357; Culverhouse R, 2002, AM J HUM GENET, V70, P461, DOI 10.1086/338759; Dahlman I, 2002, NAT GENET, V30, P149, DOI 10.1038/ng825; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; DARVASI A, 1994, GENETICS, V138, P1365; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Dudbridge F, 2000, AM J HUM GENET, V66, P2009, DOI 10.1086/302915; Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252; Efron B, 2002, GENET EPIDEMIOL, V23, P70, DOI 10.1002/gepi.1124; Eitan Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf062; Epstein MP, 2003, AM J HUM GENET, V73, P1316, DOI 10.1086/380204; FALK CT, 1987, ANN HUM GENET, V51, P227, DOI 10.1111/j.1469-1809.1987.tb00875.x; Fallin D, 2000, AM J HUM GENET, V67, P947, DOI 10.1086/303069; Fan RZ, 2003, AM J HUM GENET, V72, P850, DOI 10.1086/373966; Fisher R. A., 1919, Transactions of the Royal Society of Edinburgh, V52; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Gauderman WJ, 2002, STAT MED, V21, P35, DOI 10.1002/sim.973; Gauderman WJ, 2002, AM J EPIDEMIOL, V155, P478, DOI 10.1093/aje/155.5.478; HATTERSLEY AT, IN PRESS LANCET; Hills, 1993, STAT MODELS EPIDEMIO; Hoggart CJ, 2003, AM J HUM GENET, V72, P1492, DOI 10.1086/375613; Hoh J, 2003, NAT REV GENET, V4, P701, DOI 10.1038/nrg1155; Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625; Hotelling H, 1931, ANN MATH STAT, V2, P360, DOI 10.1214/aoms/1177732979; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Jeffreys AJ, 2004, NAT GENET, V36, P151, DOI 10.1038/ng1287; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; Khoury MJ, 1998, AM J EPIDEMIOL, V147, P1; KHOURY MJ, 1995, AM J HUM GENET, V56, P835; Knapp M, 1999, AM J HUM GENET, V64, P861, DOI 10.1086/302285; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D; Lake SL, 2000, AM J HUM GENET, V67, P1515, DOI 10.1086/316895; LEWONTIN RC, 1964, GENETICS, V49, P49; Lin S, 2004, NAT GENET, V36, P1181, DOI 10.1038/ng1457; LIVAK KJ, 1995, NAT GENET, V9, P341, DOI 10.1038/ng0495-341; Lowe CE, 2004, GENES IMMUN, V5, P301, DOI 10.1038/sj.gene.6364064; Lunetta KL, 2000, AM J HUM GENET, V66, P605, DOI 10.1086/302782; Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537; Martin ER, 2000, AM J HUM GENET, V67, P146, DOI 10.1086/302957; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; McGinnis R, 2000, AM J HUM GENET, V67, P1340; McGinnis R, 2002, BEHAV GENET, V32, P135, DOI 10.1023/A:1015205924326; MichalatosBeloin S, 1996, NUCLEIC ACIDS RES, V24, P4841, DOI 10.1093/nar/24.23.4841; Moore JH, 2003, HUM HERED, V56, P73, DOI 10.1159/000073735; Morton NE, 2001, P NATL ACAD SCI USA, V98, P5217, DOI 10.1073/pnas.091062198; O'Connell JR, 2000, GENET EPIDEMIOL, V19, pS64, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI10>3.0.CO;2-G; Phillips PC, 1998, GENETICS, V149, P1167; PIEGORSCH WW, 1994, STAT MED, V13, P153, DOI 10.1002/sim.4780130206; Pritchard JK, 2000, AM J HUM GENET, V67, P170, DOI 10.1086/302959; Pritchard JK, 1999, AM J HUM GENET, V65, P220, DOI 10.1086/302449; Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Sabatti C, 2003, GENETICS, V164, P829; Sasieni PD, 1997, BIOMETRICS, V53, P1253, DOI 10.2307/2533494; Satagopan JM, 2003, GENET EPIDEMIOL, V25, P149, DOI 10.1002/gepi.10260; Satten GA, 2001, AM J HUM GENET, V68, P466, DOI 10.1086/318195; SAUNDERS C, 2002, GENET EPIDEMIOL, V23, P302; Saunders CL, 2003, STATA J, V3, P47, DOI 10.1177/1536867X0300300103; SCHAID DJ, 1993, AM J HUM GENET, V53, P1114; Schaid DJ, 1996, GENET EPIDEMIOL, V13, P423, DOI 10.1002/(SICI)1098-2272(1996)13:5<423::AID-GEPI1>3.0.CO;2-3; Seltman H, 2001, AM J HUM GENET, V68, P1250, DOI 10.1086/320110; Sham P, 2002, NAT REV GENET, V3, P862, DOI 10.1038/nrg930; Sham PC, 2000, AM J HUM GENET, V66, P1616, DOI 10.1086/302891; Shpilberg O, 1997, J CLIN EPIDEMIOL, V50, P633, DOI 10.1016/S0895-4356(97)00052-8; SIEMIATYCKI J, 1981, INT J EPIDEMIOL, V10, P383, DOI 10.1093/ije/10.4.383; Sinsheimer JS, 2003, GENET EPIDEMIOL, V24, P1, DOI 10.1002/gepi.10211; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; SONQUIST JN, 1964, MONOGRAPH I SOCIAL R, V35; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Stram DO, 2003, HUM HERED, V55, P27, DOI 10.1159/000071807; TAUBES G, 1995, SCIENCE, V269, P164, DOI 10.1126/science.7618077; Thomas DC, 2004, JNCI-J NATL CANCER I, V96, P421, DOI 10.1093/jnci/djh094; THOMPSON WD, 1991, J CLIN EPIDEMIOL, V44, P221, DOI 10.1016/0895-4356(91)90033-6; Wacholder S, 2002, CANCER EPIDEM BIOMAR, V11, P513; Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075; Wall JD, 2003, NAT REV GENET, V4, P587, DOI 10.1038/nrg1123; Weinberg CR, 2000, AM J EPIDEMIOL, V152, P197, DOI 10.1093/aje/152.3.197; Weinberg CR, 1998, AM J HUM GENET, V62, P969, DOI 10.1086/301802; Weinberg CR, 1999, AM J HUM GENET, V65, P229, DOI 10.1086/302466; Weinberg CR, 2003, AM J HUM GENET, V72, P438, DOI 10.1086/346171; Wright S, 1920, P NATL ACAD SCI USA, V6, P320, DOI 10.1073/pnas.6.6.320	111	353	378	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 24	2005	366	9491					1121	1131		10.1016/S0140-6736(05)67424-7	http://dx.doi.org/10.1016/S0140-6736(05)67424-7			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TL	16182901				2022-12-28	WOS:000232114000031
J	Wang, CS; FitzGerald, JM; Schulzer, M; Mak, E; Ayas, NT				Wang, CS; FitzGerald, JM; Schulzer, M; Mak, E; Ayas, NT			Does this dyspneic patient in the emergency department have congestive heart failure?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BRAIN NATRIURETIC PEPTIDE; DIAGNOSTIC-VALUE; TASK-FORCE; DISEASE; ECHOCARDIOGRAPHY; UTILITY; ASSAY; RECOMMENDATIONS; HYPERTENSION; ASSOCIATION	Context Dyspnea is a common complaint in the emergency department where physicians must accurately make a rapid diagnosis. Objective To assess the usefulness of history, symptoms, and signs along with routine diagnostic studies (chest radiograph, electrocardiogram, and serum B-type natriuretic peptide [BNP]) that differentiate heart failure from other causes of dyspnea in the emergency department. Data Sources We searched MEDLINE (1966-July 2005) and the reference lists from retrieved articles, previous reviews, and physical examination textbooks. Study Selection We retained 22 studies of various findings for diagnosing heart failure in adult patients presenting with dyspnea to the emergency department. Data Extraction Two authors independently abstracted data (sensitivity, specificity, and likelihood ratios [LRs]) and assessed methodological quality. Data Synthesis Many features increased the probability of heart failure, with the best feature for each category being the presence of (1) past history of heart failure (positive LR=5.8; 95% confidence interval [01, 4.1-8.0); (2) the symptom of paroxysmal nocturnal dyspnea (positive LR=2.6; 95% Cl, 1.5-4.5); (3) the sign of the third heart sound (S-3) gallop (positive LR = 11; 95% Cl, 4.9-25.0); (4) the chest radiograph showing pulmonary venous congestion (positive LR = 12.0; 95 % Cl, 6.8-21.0); and (5) electrocardiogram showing atrial fibrillation (positive LR=3.8; 95% Cl, 1.7-8.8). The features that best decreased the probability of heart failure were the absence of (1) past history of heart failure (negative LR=0,45;95% Cl, 0.38-0.53); (2) the symptom of dyspnea on exertion (negative LR=0.48; 95% Cl, 0.35-0.67); (3) rales (negative LR=0.51; 95% Cl, 0.37-0.70); (4) the chest radiograph showing cardiomegaly (negative LR=0.33 95% Cl, 0.23-0.48); and (5) any electrocardiogram abnormality (negative LR=0.64; 9 % cl, 0.47-0.88). A low serum BNP proved to be the most useful test (serum B-type natriuretic peptide <100 pg/mL; negative LR=0.11; 95% Cl, 0.07-0.16). Conclusions For dyspneic adult emergency department patients, a directed history, physical examination, chest radiograph, and electrocardiography should be performed. If the suspicion of heart failure remains, obtaining a serum BNP level may be helpful, especially for excluding heart failure.	Univ British Columbia, Vancouver Hosp & Hlth Sci Ctr, Div Resp Med, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Dept Med, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Vancouver Coastal Hlth Res Inst, Ctr Clin Epidemiol & Evaluat, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Pacific Parkinson Res Ctr, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute; University of British Columbia	Ayas, NT (corresponding author), Univ British Columbia, Vancouver Hosp & Hlth Sci Ctr, Div Resp Med, 2775 Heather St, Vancouver, BC V5Z 3J5, Canada.	najib.ayas@vch.ca						Alibay Y, 2005, BIOMED PHARMACOTHER, V59, P20, DOI 10.1016/j.biopha.2004.06.002; ARD RW, 1957, AM J MED SCI, V234, P403; Badgett RG, 1996, J GEN INTERN MED, V11, P625, DOI 10.1007/BF02599031; Badgett RG, 1997, JAMA-J AM MED ASSOC, V277, P1712, DOI 10.1001/jama.277.21.1712; Bales AC, 1997, POSTGRAD MED, V101, P44, DOI 10.3810/pgm.1997.01.141; Baughman KL, 2002, NEW ENGL J MED, V347, P158, DOI 10.1056/NEJMp020057; Bayes-Genis A, 2004, EUR J HEART FAIL, V6, P301, DOI 10.1016/j.ejheart.2003.12.013; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; BRAUNWALD E, 1992, HEART DISEASE TXB CA, P393; Brauwald E., 2001, HARRISONS PRINCIPLES, P1318; Brown LH, 1998, CHEST, V113, P323, DOI 10.1378/chest.113.2.323; BUTMAN SM, 1993, J AM COLL CARDIOL, V22, P968, DOI 10.1016/0735-1097(93)90405-P; Cabanes L, 2001, CHEST, V120, P2047, DOI 10.1378/chest.120.6.2047; Choudhry NK, 1999, JAMA-J AM MED ASSOC, V281, P2231, DOI 10.1001/jama.281.23.2231; Chunilal SD, 2003, JAMA-J AM MED ASSOC, V290, P2849, DOI 10.1001/jama.290.21.2849; COATS AJS, 1990, LANCET, V335, P63, DOI 10.1016/0140-6736(90)90536-E; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P630, DOI 10.1001/jama.275.8.630; COOK DJ, 1990, AM J MED SCI, V299, P175, DOI 10.1097/00000441-199003000-00006; Cowie MR, 2003, EUR HEART J, V24, P1710, DOI 10.1016/S0195-668X(03)00476-7; Dao Q, 2001, J AM COLL CARDIOL, V37, P379, DOI 10.1016/S0735-1097(00)01156-6; DAVIS M, 1994, LANCET, V343, P440, DOI 10.1016/S0140-6736(94)92690-5; DEVEREUX RB, 1987, HYPERTENSION, V9, P97; Engstrom JW, 2001, HARRISONS PRINCIPLES, V2, P2416; Etchells E, 1997, JAMA-J AM MED ASSOC, V277, P564, DOI 10.1001/jama.277.7.564; Fleischer D, 1997, NEW ZEAL MED J, V110, P71; GADSBOLL N, 1989, EUR HEART J, V10, P1017, DOI 10.1093/oxfordjournals.eurheartj.a059414; Gold WM, 2000, TXB RESP MED, P781; HOLLEMAN DR, 1993, J GEN INTERN MED, V8, P63, DOI 10.1007/BF02599985; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; ISHMAIL AA, 1987, CHEST, V91, P870, DOI 10.1378/chest.91.6.870; Januzzi JL, 2005, AM J CARDIOL, V95, P948, DOI 10.1016/j.amjcard.2004.12.032; KNOWLES JH, 1956, JAMA-J AM MED ASSOC, V160, P44, DOI 10.1001/jama.1956.02960360046009a; Knudsen CW, 2004, AM J MED, V116, P363, DOI 10.1016/j.amjmed.2003.10.028; Knudsen CW, 2004, EUR J HEART FAIL, V6, P55, DOI 10.1016/j.ejheart.2003.10.006; Lainchbury JG, 2003, J AM COLL CARDIOL, V42, P728, DOI 10.1016/S0735-1097(03)00787-3; Lederle FA, 1999, JAMA-J AM MED ASSOC, V281, P77, DOI 10.1001/jama.281.1.77; Logeart D, 2002, J AM COLL CARDIOL, V40, P1794, DOI 10.1016/S0735-1097(02)02482-8; Maisel Alan, 2002, Rev Cardiovasc Med, V3 Suppl 4, pS10; Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233; MANNING HL, 1995, NEW ENGL J MED, V333, P1547, DOI 10.1056/NEJM199512073332307; MARANTZ PR, 1990, CHEST, V97, P776, DOI 10.1378/chest.97.4.776; Marcus GM, 2005, JAMA-J AM MED ASSOC, V293, P2238, DOI 10.1001/jama.293.18.2238; McCullough PA, 2002, J AM COLL CARDIOL, V39, P60, DOI 10.1016/S0735-1097(01)01700-4; McCullough PA, 2003, ACAD EMERG MED, V10, P198, DOI 10.1197/aemj.10.3.198; McCullough PA, 2003, AM J KIDNEY DIS, V41, P571, DOI 10.1053/ajkd.2003.50118; McCullough PA, 2002, CIRCULATION, V106, P416, DOI 10.1161/01.CIR.0000025242.79963.4C; MCNAMARA RM, 1992, CHEST, V101, P129, DOI 10.1378/chest.101.1.129; Meek PM, 1999, AM J RESP CRIT CARE, V159, P321; Metlay JP, 1997, JAMA-J AM MED ASSOC, V278, P1440, DOI 10.1001/jama.278.17.1440; Morrison LK, 2002, J AM COLL CARDIOL, V39, P202, DOI 10.1016/S0735-1097(01)01744-2; Mueller C, 2004, NEW ENGL J MED, V350, P647, DOI 10.1056/NEJMoa031681; Mueller T, 2005, HEART, V91, P606, DOI 10.1136/hrt.2004.037762; MULROW CD, 1993, J GEN INTERN MED, V8, P383, DOI 10.1007/BF02600079; Panju AA, 1998, JAMA-J AM MED ASSOC, V280, P1256, DOI 10.1001/jama.280.14.1256; POOLEWILSON PA, 1993, J AM COLL CARDIOL, V22, pA22, DOI 10.1016/0735-1097(93)90458-D; RAO CR, 1968, LINEAR STAT INFERENC; Ray P, 2004, INTENS CARE MED, V30, P2230, DOI 10.1007/s00134-004-2469-0; Redfield MM, 2002, NEW ENGL J MED, V347, P1442, DOI 10.1056/NEJMe020115; REEVES RA, 1995, JAMA-J AM MED ASSOC, V273, P1211, DOI 10.1001/jama.1995.03520390071036; Remme WJ, 2001, EUR HEART J, V22, P1527, DOI 10.1053/euhj.2001.2783; Rich MW, 1999, ARCH INTERN MED, V159, P1690, DOI 10.1001/archinte.159.15.1690; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; Seward JB, 2002, J AM SOC ECHOCARDIOG, V15, P369, DOI 10.1067/mje.2002.123026; Springfield Charles L, 2004, Congest Heart Fail, V10, P14, DOI 10.1111/j.1527-5299.2004.03409.x; Villacorta Humberto, 2002, Arq. Bras. Cardiol., V79, P569, DOI 10.1590/S0066-782X2002001500002; WASSERMAN K, 1988, ANNU REV MED, V39, P503, DOI 10.1146/annurev.med.39.1.503; WENGER NK, 1988, EUR HEART J, V9, P63, DOI 10.1093/eurheartj/9.suppl_F.63; WILSON JR, 1993, CIRCULATION, V87, P470, DOI 10.1161/01.CIR.87.2.470; WUERZ RC, 1992, ANN EMERG MED, V21, P669, DOI 10.1016/S0196-0644(05)82777-5	70	345	354	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	2005	294	15					1944	1956		10.1001/jama.294.15.1944	http://dx.doi.org/10.1001/jama.294.15.1944			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974OZ	16234501				2022-12-28	WOS:000232602600024
J	Rosenstock, J; Zinman, B; Murphy, LJ; Clement, SC; Moore, P; Bowering, K; Hendler, R; Lan, SP; Cefalu, WT				Rosenstock, J; Zinman, B; Murphy, LJ; Clement, SC; Moore, P; Bowering, K; Hendler, R; Lan, SP; Cefalu, WT			Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							MICROVASCULAR COMPLICATIONS; TREATMENT SATISFACTION; PATIENT SATISFACTION; MELLITUS; EFFICACY; 6-MONTH; SAFETY; AGENTS	Background: Patients with type 2 diabetes who do not achieve glycemic control with oral agent therapy eventually require insulin. Objective: To determine the effect on glycemic control of inhaled insulin alone or added to dual oral therapy (insulin secretagogue and sensitizer) after failure of dual oral therapy. Design: Open-label, randomized, controlled trial. Setting: 48 outpatient centers in the United States and Canada. Patients: 309 patients with type 2 diabetes, no clinically significant respiratory disease, and hemoglobin A,c level of 8% to 11% who were receiving dual oral therapy. Measurements: Primary end point was change in hemoglobin A(1c) level from baseline to 12 weeks. Secondary outcomes included hemoglobin A(1c) level less than 8% and less than 7%, hypoglycemia, weight, lipid levels, pulmonary function, insulin antibody binding, and adverse events. Intervention: inhaled insulin (Exubera; Pfizer Inc. [New York, New York], sanofi-aventis Group [Paris, France], and Nektar Therapeutics [San Carlos, California]), titrated to blood glucose, administered alone (n = 104) or added to dual oral agents (n = 103) versus oral therapy alone (n = 99). Results: Reductions in hemoglobin A(1c) level were greater with inhaled insulin. Adjusted treatment group differences for inhaled insulin plus oral agents and inhaled insulin alone compared with continued oral agent therapy were -1.67 percentage points (95% Cl, -1.90 to -1.44 percentage points; P < 0.001) and -1.18 percentage points (Cl, -1.41 to -0.95 percentage point; P < 0.001), respectively. Hemoglobin A(1c) level less than 7% was achieved by 32% (inhaled insulin plus oral agents) and by 1% (oral agent therapy) of patients (adjusted odds ratio, 44.7 [Cl, 6.0 to 335.2]). Hypoglycemia, mild weight gain, mild cough, and insulin antibodies were more frequent with inhaled insulin than with oral agent therapy alone. Pulmonary function was similar in all groups. Limitations: This study evaluated only patients with hemoglobin A(1c) levels of 8% to 11%, did not compare inhaled insulin with other insulins or oral therapy except a dual regimen of secretagogue and sensitizer, and lasted only 12 weeks. Conclusions: inhaled insulin improved overall glycemic control and hemoglobin A(1c) level when added to or substituted for dual oral agent therapy with an insulin secretagogue and sensitizer. Consistent with other insulin therapies, hypoglycemia and mild weight gain occurred. Pulmonary function showed no between-group differences.	Univ Texas, Dallas Diabet & Endocrine Ctr, Dallas, TX 75230 USA; Univ Toronto, Toronto, ON, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON, Canada; Univ Manitoba, Winnipeg, MB R3T 2N2, Canada; Georgetown Univ, Washington, DC 20057 USA; Univ Alberta, Edmonton, AB, Canada; Royal Alexandra Hosp Children, Edmonton, AB, Canada; Yale Univ, Sch Med, New Haven, CT USA; Pfizer Global Res & Dev, Groton, CT USA; Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA USA	Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Manitoba; Georgetown University; University of Alberta; Royal Alexandra Hospital; Yale University; Pfizer; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Rosenstock, J (corresponding author), Univ Texas, Dallas Diabet & Endocrine Ctr, 7777 Forest Lane,Suite C618, Dallas, TX 75230 USA.	juliorosenstock@dallasdiabetes.com	Zinman, Bernard/E-7266-2013		NCRR NIH HHS [M01 RR 00125] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		*AM DIAB ASS, 1998, DIABETES CARE S1, V21, pS40; Cappelleri JC, 2002, CLIN THER, V24, P552, DOI 10.1016/S0149-2918(02)85131-1; Chehade JM, 2000, DRUGS, V60, P95, DOI 10.2165/00003495-200060010-00006; DREYER M, 2004, DIABETES CARE S1, V27, pS15; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 1998, DIABETES CARE S1, V21, pS5; FRANZ MJ, 1994, DIABETES CARE, V17, P490, DOI 10.2337/diacare.17.5.490; Freemantle N, 2005, DIABETES CARE, V28, P427, DOI 10.2337/diacare.28.2.427; Genuth S, 2002, JAMA-J AM MED ASSOC, V287, P2563; Gerber RA, 2001, DIABETES CARE, V24, P1556, DOI 10.2337/diacare.24.9.1556; Hanefeld M, 1996, DIABETOLOGIA, V39, P1577, DOI 10.1007/s001250050617; Hollander PA, 2004, DIABETES CARE, V27, P2356, DOI 10.2337/diacare.27.10.2356; Hsu J., 1996, MULTIPLE COMP THEORY, DOI DOI 10.1007/978-1-4899-7180-7; Inzucchi SE, 2002, JAMA-J AM MED ASSOC, V287, P360, DOI 10.1001/jama.287.3.360; Korytkowski M, 2002, INT J OBESITY, V26, pS18, DOI 10.1038/sj.ijo.0802173; MARCUS R, 1976, BIOMETRIKA, V63, P655, DOI 10.1093/biomet/63.3.655; Mollema ED, 2001, DIABETIC MED, V18, P671, DOI 10.1046/j.1464-5491.2001.00547.x; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Patton JS, 2004, CLIN PHARMACOKINET, V43, P781, DOI 10.2165/00003088-200443120-00002; Quattrin T, 2004, DIABETES CARE, V27, P2622, DOI 10.2337/diacare.27.11.2622; Rave K, 2005, DIABETES CARE, V28, P1077, DOI 10.2337/diacare.28.5.1077; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; Riddle MC, 2002, DIABETES-METAB RES, V18, pS42, DOI 10.1002/dmrr.277; Riddle MC, 2003, DIABETES CARE, V26, P3080, DOI 10.2337/diacare.26.11.3080; Rosenstock J, 2004, DIABETES CARE, V27, P1318, DOI 10.2337/diacare.27.6.1318; ROSENSTOCK J, 2004, NEW YORK MED INFORM, P145; ROSENSTOCK J, 2003, TXB TYPE 2 DIABETES, P131; Rosenstock Julio, 2004, American Journal of Medicine, V116, p10S; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shichiri M, 2000, DIABETES CARE, V23, pB21; Stoever James A, 2002, Diabetes Technol Ther, V4, P157, DOI 10.1089/15209150260007372; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Testa MA, 2001, DIABETOLOGIA, V44, pA4; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Weiss SR, 2003, ARCH INTERN MED, V163, P2277, DOI 10.1001/archinte.163.19.2277; Yki-Jarvinen H, 2001, DIABETES CARE, V24, P758, DOI 10.2337/diacare.24.4.758; Zambanini A, 1999, DIABETES RES CLIN PR, V46, P239, DOI 10.1016/S0168-8227(99)00099-6	37	107	142	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 18	2005	143	8					549	558		10.7326/0003-4819-143-8-200510180-00005	http://dx.doi.org/10.7326/0003-4819-143-8-200510180-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975PI	16230721				2022-12-28	WOS:000232674000005
J	Halpern, SD				Halpern, SD			Towards evidence based bioethics	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							MAMMARY-ARTERY LIGATION; INFORMED-CONSENT; CARE; PARTICIPATION; SUBJECT; PAYMENT; RISK		Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Halpern, SD (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 115 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	shalpern@cceb.med.upenn.edu						[Anonymous], 1989, NEW ENGL J MED, V321, P406; Azoulay E, 2004, CRIT CARE MED, V32, P1832, DOI 10.1097/01.CCM.0000139693.88931.59; BAYER R, 2000, MORE DEMOCRATIC MED, P156; BEAUCHAMP TL, 1994, RESPECT AUTONOMY PRI, P120; Bentley JP, 2004, J MED ETHICS, V30, P293, DOI 10.1136/jme.2002.001594; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; *CDC, 1995, MMWR-MORBID MORTAL W, V44, P929; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; Coulter A, 2004, BRIT MED J, V329, P1197, DOI 10.1136/bmj.329.7476.1197; Dickert N, 1999, NEW ENGL J MED, V341, P198, DOI 10.1056/NEJM199907153410312; DIMOND EG, 1960, AM J CARDIOL, V5, P483, DOI 10.1016/0002-9149(60)90105-3; Dunn LB, 2005, JAMA-J AM MED ASSOC, V293, P609, DOI 10.1001/jama.293.5.609; FREEDMAN B, 1988, HASTINGS CTR REP APR, P20; Grady Christine, 2001, American Journal of Bioethics, V1, P40, DOI 10.1162/152651601300169031; Halpern SD, 2004, ARCH INTERN MED, V164, P801, DOI 10.1001/archinte.164.7.801; Heesen C, 2004, MULT SCLER J, V10, P643, DOI 10.1191/1352458504ms1112oa; Joffe S, 2003, J MED ETHICS, V29, P103, DOI 10.1136/jme.29.2.103; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; McGee G, 1997, JAMA-J AM MED ASSOC, V278, P199, DOI 10.1001/jama.278.3.199; McNeill P, 1997, BIOETHICS, V11, P390, DOI 10.1111/1467-8519.00079; Roberts LW, 2000, ARCH GEN PSYCHIAT, V57, P540, DOI 10.1001/archpsyc.57.6.540; VIENS AM, 2001, AM J BIOETHICS, V1; Wilkinson M, 1997, BIOETHICS, V11, P373, DOI 10.1111/1467-8519.00078	23	35	36	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 15	2005	331	7521					901	903		10.1136/bmj.331.7521.901	http://dx.doi.org/10.1136/bmj.331.7521.901			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975SX	16223827	Green Published			2022-12-28	WOS:000232683300030
J	Terkelsen, CJ; Vach, W				Terkelsen, CJ; Vach, W			Commentary: Can risk score models help in reducing serious outcome events in patients with stable angina?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Skejby Univ Hosp, Dept Cardiol B, DK-8200 Aarhus, Denmark; Univ So Denmark, Dept Stat, DK-5000 Odense, Denmark	Aarhus University; University of Southern Denmark	Terkelsen, CJ (corresponding author), Skejby Univ Hosp, Dept Cardiol B, DK-8200 Aarhus, Denmark.	christian_juhl_terkelsen@hotmail.com	Vach, Werner/F-2512-2011	Vach, Werner/0000-0003-1865-8399; terkelsen, christian juhl/0000-0003-0205-9551				Abrams J, 2005, NEW ENGL J MED, V352, P2524, DOI 10.1056/NEJMcp042317; Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5; Clayton TC, 2005, BMJ-BRIT MED J, V331, P869, DOI 10.1136/bmj.38603.656076.63; Daly CA, 2005, EUR HEART J, V26, P996, DOI 10.1093/eurheartj/ehi171; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207	5	0	0	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 15	2005	331	7521					872	872		10.1136/bmj.38607.495405.55	http://dx.doi.org/10.1136/bmj.38607.495405.55			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975SX	16210254	Green Published, Bronze			2022-12-28	WOS:000232683300016
J	Blumenthal, D				Blumenthal, D			Ecology - Interrelated causes of plant invasion	SCIENCE			English	Editorial Material							GROWTH-RATE; HERBIVORY; RELEASE; SPECIALIZATION; COMMUNITIES		ARS, USDA, Rangeland Resources Res Unit, Crops Res Lab, Ft Collins, CO 80526 USA	United States Department of Agriculture (USDA)	Blumenthal, D (corresponding author), ARS, USDA, Rangeland Resources Res Unit, Crops Res Lab, 1701 Ctr Ave, Ft Collins, CO 80526 USA.	dana.blumenthal@ars.usda.gov	Blumenthal, Dana M/J-3106-2012					BAKER H. G., 1965, The genetics of colonizing species: Proc. 1st Internat, Union biol Sci., Asilomar, California., P147; Callaway RM, 2000, SCIENCE, V290, P521, DOI 10.1126/science.290.5491.521; CEBRIAN J, 1994, FUNCT ECOL, V8, P518, DOI 10.2307/2390077; COLEY PD, 1985, SCIENCE, V230, P895, DOI 10.1126/science.230.4728.895; Daehler CC, 2003, ANNU REV ECOL EVOL S, V34, P183, DOI 10.1146/annurev.ecolsys.34.011802.132403; Davis MA, 2000, J ECOL, V88, P528, DOI 10.1046/j.1365-2745.2000.00473.x; DeWalt SJ, 2004, ECOLOGY, V85, P471, DOI 10.1890/02-0728; DiTomaso JM, 2000, WEED SCI, V48, P255, DOI 10.1614/0043-1745(2000)048[0255:IWIRSI]2.0.CO;2; Fine PVA, 2004, SCIENCE, V305, P663, DOI 10.1126/science.1098982; Fraser LH, 1999, J ECOL, V87, P514, DOI 10.1046/j.1365-2745.1999.00373.x; Grime JP, 1997, OIKOS, V79, P259, DOI 10.2307/3546011; Grotkopp E, 2002, AM NAT, V159, P396, DOI 10.1086/338995; Hoffland E, 1996, PLANT CELL ENVIRON, V19, P1281, DOI 10.1111/j.1365-3040.1996.tb00006.x; Keane RM, 2002, TRENDS ECOL EVOL, V17, P164, DOI 10.1016/S0169-5347(02)02499-0; MATTSON WJ, 1980, ANNU REV ECOL SYST, V11, P119, DOI 10.1146/annurev.es.11.110180.001003; Mitchell CE, 2003, NATURE, V421, P625, DOI 10.1038/nature01317; Shea K, 2002, TRENDS ECOL EVOL, V17, P170, DOI 10.1016/S0169-5347(02)02495-3	17	146	162	3	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 14	2005	310	5746					243	244		10.1126/science.1114851	http://dx.doi.org/10.1126/science.1114851			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224008				2022-12-28	WOS:000232670100031
J	Jensen, K; Murray, F				Jensen, K; Murray, F			Intellectual property - Intellectual property landscape of the human genome	SCIENCE			English	Editorial Material							RESEARCH-AND-DEVELOPMENT; GENETIC SEQUENCES; LAW; PATENTS; FUTURE; DNA		MIT, Alfred P Sloan Sch Management, Cambridge, MA 02139 USA; MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Murray, F (corresponding author), MIT, Alfred P Sloan Sch Management, Cambridge, MA 02139 USA.	fmurray@mit.edu						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Andrews LB, 2002, NAT REV GENET, V3, P803, DOI 10.1038/nrg909; Caulfield T, 2000, NAT REV GENET, V1, P227, DOI 10.1038/35042087; Crease DJ, 2003, NAT REV DRUG DISCOV, V2, P407, DOI 10.1038/nrd1089; Doll JJ, 1998, SCIENCE, V280, P689, DOI 10.1126/science.280.5364.689; Dufresne G, 2004, NAT BIOTECHNOL, V22, P231, DOI 10.1038/nbt0204-231; Dufresne G, 2002, NAT BIOTECHNOL, V20, P1269, DOI 10.1038/nbt1202-1269; Eisenberg R, 2003, CR BIOL, V326, P1115, DOI 10.1016/j.crvi.2003.10.001; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gans JS, 2000, J ECON MANAGE STRAT, V9, P485, DOI 10.1162/105864000567945; *GEORG U KENN I ET, DNA PAT DAT; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; Hollon T, 2000, NAT MED, V6, P362, DOI 10.1038/74591; *J HOPK U MCKUS NA, 2000, ONL MEND INH MAN; Keller Evelyn Fox, 2000, CENTURY GENE; LEVIN RC, 1987, BROOKINGS PAPERS EC, V3, P783, DOI DOI 10.2307/2534454; Maglott D, 2005, NUCLEIC ACIDS RES, V33, pD54, DOI 10.1093/nar/gki031; *NAT GEN INF CTR, PAT DAT; *NUFF COUNC BIOETH, 2002, ETH PAT DNA; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; SCOTCHMER S, 1991, J ECON PERSPECT, V5, P29, DOI 10.1257/jep.5.1.29; Stott M, 2004, NAT REV DRUG DISCOV, V3, P364, DOI 10.1038/nrd1348; Stott M, 2003, NAT BIOTECHNOL, V21, P729, DOI 10.1038/nbt0703-729; Thomas SM, 2002, NAT BIOTECHNOL, V20, P1185, DOI 10.1038/nbt1202-1185; Walsh JP, 2003, SCIENCE, V299, P1021, DOI 10.1126/science.299.5609.1021; Xu G. G., 2002, World Patent Information, V24, P95, DOI 10.1016/S0172-2190(02)00004-2; 2001, FED REG          JAN, V66, P1092	27	155	160	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					239	240		10.1126/science.1120014	http://dx.doi.org/10.1126/science.1120014			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	975NV	16224006				2022-12-28	WOS:000232670100029
J	Kuppers, M; Bertini, I; Fornasier, S; Gutierrez, PJ; Hviid, SF; Jorda, L; Keller, HU; Knollenberg, J; Koschny, D; Kramm, R; Lara, LM; Sierks, H; Thomas, N; Barbieri, C; Lamy, P; Rickman, H; Rodrigo, R				Kuppers, M; Bertini, I; Fornasier, S; Gutierrez, PJ; Hviid, SF; Jorda, L; Keller, HU; Knollenberg, J; Koschny, D; Kramm, R; Lara, LM; Sierks, H; Thomas, N; Barbieri, C; Lamy, P; Rickman, H; Rodrigo, R		OSIRIS Team	A large dust/ice ratio in the nucleus of comet 9P/Tempel 1	NATURE			English	Article							DEEP IMPACT; SIZE; EJECTA	Comets spend most of their life in a low-temperature environment far from the Sun. They are therefore relatively unprocessed and maintain information about the formation conditions of the planetary system, but the structure and composition of their nuclei are poorly understood. Although in situ(1) and remote(2) measurements have derived the global properties of some cometary nuclei, little is known about their interiors. The Deep Impact mission(3) shot a projectile into comet 9P/ Tempel 1 in order to investigate its interior. Here we report the water vapour content (1.5 x 10(32) water molecules or 4.5 x 10(6) kg) and the cross-section of the dust (330 km(2) assuming an albedo of 0.1) created by the impact. The corresponding dust/ice mass ratio is probably larger than one, suggesting that comets are 'icy dirtballs' rather than 'dirty snowballs' as commonly believed(4). High dust velocities ( between 110 m s(-1) and 300 m s(-1)) imply acceleration in the comet's coma, probably by water molecules sublimated by solar radiation. We did not find evidence of enhanced activity of 9P/ Tempel 1 in the days after the impact, suggesting that in general impacts of meteoroids are not the cause of cometary outbursts.	Max Planck Inst Sonnensyst Forsch, D-37191 Katlenburg Lindau, Germany; Univ Padua, Dept Astron, I-35100 Padua, Italy; Univ Padua, CISAS, I-35100 Padua, Italy; CSIC, Inst Astrofis Andalucia, E-18008 Granada, Spain; Traverse Siphon, Lab Astrophys Marseille, F-13376 Marseille, France; DLR Inst Planetary Res, D-12489 Berlin, Germany; European Space Agcy, ESTEC, SCI SB, NL-2200 AG Noordwijk, Netherlands; Univ Bern, Inst Phys, Abt Weltraumforsch & Planetol, CH-3012 Bern, Switzerland; Astron Observ, S-75120 Uppsala, Sweden	Max Planck Society; University of Padua; University of Padua; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Astrofisica de Andalucia (IAA); UDICE-French Research Universities; Aix-Marseille Universite; Helmholtz Association; German Aerospace Centre (DLR); European Space Agency; University of Bern	Kuppers, M (corresponding author), Max Planck Inst Sonnensyst Forsch, Max Planck Str 2, D-37191 Katlenburg Lindau, Germany.	kueppers@mps.mpg.de	Lara, Luisa M/F-5614-2012; Rickman, Hans/X-7631-2018; Gutiérrez, Pedro J/AAJ-6177-2020; Moreno, Jose Juan Lopez/M-5537-2019; Jorda, Laurent/AAA-1718-2021; Thomas, Nicolas/G-4693-2015	Lara, Luisa M/0000-0002-7184-920X; Rickman, Hans/0000-0002-9603-6619; Gutiérrez, Pedro J/0000-0002-7332-6269; Moreno, Jose Juan Lopez/0000-0002-7946-2624; Sanz-Andres, Angel/0000-0001-5890-6065; Thomas, Nicolas/0000-0002-0146-0071; Debei, Stefano/0000-0002-6757-6616; Bertini, Ivano/0000-0002-0616-2444; Cremonese, Gabriele/0000-0001-9021-1140; De Cecco, Mariolino/0000-0003-1562-0328; fulle, marco/0000-0001-8435-5287				A'Hearn MF, 2005, SPACE SCI REV, V117, P1, DOI 10.1007/s11214-005-3387-3; AHearn MF, 1995, ICARUS, V118, P223, DOI 10.1006/icar.1995.1190; Belton MJ, 2005, SPACE SCI REV, V117, P137, DOI 10.1007/s11214-005-3389-1; BUDZIEN SA, 1994, ICARUS, V107, P164, DOI 10.1006/icar.1994.1014; Combi MR, 2004, SPACE SCI S, P523; FULLE M, 1992, ASTRON ASTROPHYS, V253, P615; Fulle M, 1997, ASTRON ASTROPHYS, V324, P1197; Haser L., 1957, B ACAD ROY SCI BELGI, V43, P740; HOLSAPPLE KA, 1993, ANNU REV EARTH PL SC, V21, P333, DOI 10.1146/annurev.ea.21.050193.002001; HUEBNER WF, 1992, AP SS, V195, P7; Iseli M, 2002, ICARUS, V155, P350, DOI 10.1006/icar.2001.6722; Keller H. U., 1989, ESA SP, V302, P39; Keller HU, 2004, SPACE SCI S, P211; Kolokolova L, 2004, SPACE SCI S, P577; Koschny D, 2001, ICARUS, V154, P402, DOI 10.1006/icar.2001.6708; Lamy PL, 2004, SPACE SCI S, P223; OKEEFE JD, 1985, ICARUS, V62, P328, DOI 10.1016/0019-1035(85)90128-9; SCHLEICHER D, 2005, 8546 IAU; SCHLEICHER DG, 1988, ASTROPHYS J, V331, P1058, DOI 10.1086/166622; Schultz PH, 2005, SPACE SCI REV, V117, P207, DOI 10.1007/s11214-005-3383-7; SWAMY KSK, 1997, WORLD SCI SERIES AST, V2; WHIPPLE FL, 1950, ASTROPHYS J, V111, P375, DOI 10.1086/145272	22	110	110	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	2005	437	7061					987	990		10.1038/nature04236	http://dx.doi.org/10.1038/nature04236			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16229066	Green Published			2022-12-28	WOS:000232496100037
J	Schwartz, LM; Woloshin, S; Birkmeyer, JD				Schwartz, LM; Woloshin, S; Birkmeyer, JD			How do elderly patients decide where to go for major surgery? Telephone interview survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEW-YORK-STATE; PERFORMANCE REPORTS; CARE; INDICATORS	Objective To learn how patients in Medicare, the US medical insurance programme that covers elderly patients, made decisions about where to undergo major surgery and how they would make future decisions. Design National telephone interview study. Setting United States. Participants 510 randomly selected Medicare beneficiaries who had undergone an elective, high risk procedure about 3 years earlier-abdominal aneurysm repair (n=103), heart valve replacement surgery (n=96), or resection of the bladder (n=119), lung (n =128), or stomach (n = 64) for cancer. Response rates were 48% among eligible survivors and 68% among those able to participate. Results Although all participants could choose where to have surgery, only 55% said there was an alternative hospital in their area where they could have gone. Overall, only 10% of respondents seriously considered going elsewhere for surgery. Few respondents (11%) looked for information to compare hospitals. Almost all respondents thought their hospital and surgeon had good reputations (94% and 88%, respectively), beliefs mostly determined by what their referring doctors said. When asked how much various factors would influence their advice to a friend about choosing where to go for major surgery, surgeon reputation was the most influential (78% said it would influence their advice "a lot"), followed by the hospital having "nationally recognised" surgeons (63%), and then various performance data (surgeon volume (58%), nurse:patient ratios (49%), number of operations carried out by the hospital (48%), and hospital operative mortality (45%)). Forty per cent said they would act on mortality data, indicating that they would switch from their initial choice of hospital to a different one if its mortality was a percentage point lower (that is, 3% v 4%). Conclusion Some respondents claimed they would switch hospital for elective surgery on the basis of mortality data. Since most respondents relied on their referring physician's opinion to decide where to have surgery, surgical performance data ought to be accessible to referring physicians.	VA Med Ctr, VA Outcomes Grp 111B, White River Jct, VT 05009 USA; Dept Surg, Ann Arbor, MI 48109 USA	VA Outcomes Group	Woloshin, S (corresponding author), VA Med Ctr, VA Outcomes Grp 111B, 215 N Main St, White River Jct, VT 05009 USA.	steven.woloshin@dartmouth.edu	Wilkins, Thad/G-2541-2010		AHRQ HHS [R03 HS13049-01] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R03HS013049] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AG HEALTHC RES QU, AM HLTH CAR CONS UPD; *AM ASS PUBL OP RE, STAND BEST PRACT STA; Borsch-Supan A., 2005, HLTH AGEING RETIREME; BRIDGEWATER B, 2005, BRIT MED J, V330, P566; CARVEL J, 2005, GUARDIAN        0221, P10; FINLAYSON EVA, 2001, EFF CLIN PRACT, V4, P235; Finlayson SRG, 1999, MED CARE, V37, P204, DOI 10.1097/00005650-199902000-00010; Galvin R, 2002, NEW ENGL J MED, V347, P939, DOI 10.1056/NEJMsb012850; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; Hannan EL, 1997, AM HEART J, V134, P1120, DOI 10.1016/S0002-8703(97)70034-6; HANNAN EL, 1994, ANN THORAC SURG, V58, P1852, DOI 10.1016/0003-4975(94)91726-4; HARMAN E, 1990, JAMA-J AM MED ASSOC, V264, P2768; Hartz AJ, 1997, AM J PUBLIC HEALTH, V87, P1645, DOI 10.2105/AJPH.87.10.1645; Hartz AJ, 1999, MED CARE, V37, P93, DOI 10.1097/00005650-199901000-00013; Jewett JJ, 1996, HEALTH CARE FINANC R, V18, P75; KURZ RS, 1985, HOSP HEALTH SERV ADM, V30, P95; Levinson W, 2005, J GEN INTERN MED, V20, P531, DOI 10.1111/j.1525-1497.2005.04101.x; Magee H, 2003, J ROY SOC MED, V96, P338, DOI 10.1258/jrsm.96.7.338; Marshall MN, 2000, JAMA-J AM MED ASSOC, V283, P1866, DOI 10.1001/jama.283.14.1866; Milstein A, 2000, Eff Clin Pract, V3, P313; Mukamel DB, 1998, MED CARE, V36, P945, DOI 10.1097/00005650-199807000-00002; Robinson S, 1997, JOINT COMM J QUAL IM, V23, P239, DOI 10.1016/S1070-3241(16)30313-3; Romano PS, 2004, MED CARE, V42, P367, DOI 10.1097/01.mlr.0000118872.33251.11; Schneider EC, 1996, NEW ENGL J MED, V335, P251, DOI 10.1056/NEJM199607253350406; Schneider EC, 1998, JAMA-J AM MED ASSOC, V279, P1638, DOI 10.1001/jama.279.20.1638; [No title captured]	26	105	105	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 8	2005	331	7520					821	824A		10.1136/bmj.38614.449016.DE	http://dx.doi.org/10.1136/bmj.38614.449016.DE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	974BC	16192286	Green Published, Bronze			2022-12-28	WOS:000232565300023
J	Shirado, O; Nomoto, T; Kuwazawa, Y; Kim, YT; Oda, H; Hirose, T				Shirado, O; Nomoto, T; Kuwazawa, Y; Kim, YT; Oda, H; Hirose, T			Adolescent siblings with thigh pain at the same age	LANCET			English	Editorial Material							OSTEOID OSTEOMAS		Saitama Med Sch, Dept Orthopaed Surg, Moroyama, Saitama 3500495, Japan; Saitama Med Sch, Dept Pathol, Moroyama, Saitama 3500495, Japan	Saitama Medical University; Saitama Medical University	Shirado, O (corresponding author), Saitama Med Sch, Dept Orthopaed Surg, Moroyama, Saitama 3500495, Japan.	oshirado@m4.dion.ne.jp						Baruffi MR, 2001, CANCER GENET CYTOGEN, V124, P127, DOI 10.1016/S0165-4608(00)00327-7; Kalil RK, 2003, SKELETAL RADIOL, V32, P416, DOI 10.1007/s00256-003-0660-y; KAYE JJ, 1977, CLIN ORTHOP RELAT R, P273; Radig K, 1998, PATHOL RES PRACT, V194, P669, DOI 10.1016/S0344-0338(98)80125-8; Unni K.K., 1996, DAHLINS BONE TUMORS, V5th ed., P121	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 8	2005	366	9493					1330	1330		10.1016/S0140-6736(05)67533-2	http://dx.doi.org/10.1016/S0140-6736(05)67533-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971ST	16214605				2022-12-28	WOS:000232405700033
J	Takagi, M; Absalon, MJ; McLure, KG; Kastan, MB				Takagi, M; Absalon, MJ; McLure, KG; Kastan, MB			Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin	CELL			English	Article							ATM-DEPENDENT PHOSPHORYLATION; RNA-BINDING PROTEINS; HUMAN CANCER-CELLS; MESSENGER-RNA; THYMIDYLATE SYNTHASE; UNTRANSLATED REGION; CHECKPOINT PATHWAY; ONCOPROTEIN MDM2; IN-VIVO; ACTIVATION	Increases in p53 protein levels after DNA damage have largely been attributed to an increase in the half-life of p53 protein. Here we demonstrate that increased translation of p53 mRNA is also a critical step in the induction of p53 protein in irradiated cells. Ribosomal protein L26 (RPL26) and nucleolin were found to bind to the 5' untranslated region (UTR) of p53 mRNA and to control p53 translation and induction after DNA damage. RPL26 preferentially binds to the 5'UTR after DNA damage, and its overexpression enhances association of p53 mRNA with heavier polysomes, increases the rate of p53 translation, induces G1 cell-cycle arrest, and augments irradiation-induced apoptosis. Opposite effects were seen when RPL26 expression was inhibited. In contrast, nucleolin overexpression suppresses p53 translation and induction after DNA damage, whereas nucleolin downregulation promotes p53 expression. These findings demonstrate the importance of increased translation of p53 in DNA-damage responses and suggest critical roles for RPL26 and nucleolin in affecting p53 induction.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Kastan, MB (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	michael.kastan@stjude.org	Takagi, Masatoshi/F-3713-2011; Ogunwobi, Olorunseun/F-3172-2010	Takagi, Masatoshi/0000-0002-7580-9184; 	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005777, R37ES005777] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NIEHS NIH HHS [ES05777] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Beck-Engeser GB, 2001, J EXP MED, V194, P285, DOI 10.1084/jem.194.3.285; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chu E, 1999, MOL CELL BIOL, V19, P1582; Coulombe P, 2003, MOL CELL BIOL, V23, P4542, DOI 10.1128/MCB.23.13.4542-4558.2003; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Daniely Y, 2002, MOL CELL BIOL, V22, P6014, DOI 10.1128/MCB.22.16.6014-6022.2002; Deng J, 2002, CURR BIOL, V12, P1279, DOI 10.1016/S0960-9822(02)01037-0; DERENZINI M, 1995, LAB INVEST, V73, P497; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fu LN, 1999, ONCOGENE, V18, P6419, DOI 10.1038/sj.onc.1203064; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GILLET G, 1993, ONCOGENE, V8, P565; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Hanakahi LA, 2000, BIOCHEMISTRY-US, V39, P15493, DOI 10.1021/bi001683y; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Ju JF, 1999, P NATL ACAD SCI USA, V96, P3769, DOI 10.1073/pnas.96.7.3769; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kyrpides NC, 1996, TRENDS BIOCHEM SCI, V21, P425, DOI 10.1016/S0968-0004(96)30036-4; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; PRICE BD, 1993, ONCOGENE, V8, P3055; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; Rouillard JM, 2003, NUCLEIC ACIDS RES, V31, P3057, DOI 10.1093/nar/gkg426; ROUSSEL P, 1994, EXP CELL RES, V214, P465, DOI 10.1006/excr.1994.1283; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Thyagarajan B, 1998, SOMAT CELL MOLEC GEN, V24, P263, DOI 10.1023/B:SCAM.0000007129.98789.1f; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Whitfield ML, 2000, MOL CELL BIOL, V20, P4188, DOI 10.1128/MCB.20.12.4188-4198.2000; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z; Yang C, 2002, NUCLEIC ACIDS RES, V30, P2251, DOI 10.1093/nar/30.10.2251; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	58	475	488	2	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 7	2005	123	1					49	63		10.1016/j.cell.2005.07.034	http://dx.doi.org/10.1016/j.cell.2005.07.034			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	973QD	16213212	Bronze			2022-12-28	WOS:000232536800008
J	Weng, KC; Castilho, PC; Morrissette, JM; Landeira-Fernandez, AM; Holts, DB; Schallert, RJ; Goldman, KJ; Block, BA				Weng, KC; Castilho, PC; Morrissette, JM; Landeira-Fernandez, AM; Holts, DB; Schallert, RJ; Goldman, KJ; Block, BA			Satellite tagging and cardiac physiology reveal niche expansion in salmon sharks	SCIENCE			English	Article							TEMPERATURE	Shark populations are declining globally, yet the movements and habitats of most species are unknown. We used a satellite tag attached to the dorsal fin to track salmon sharks (Lamna ditropis) for up to 3.2 years. Here we show that salmon sharks have a subarctic-to-subtropical niche, ranging from 2 degrees to 24 degrees C, and they spend winter periods in waters as cold as 2 degrees to 8 degrees C. Functional assays and protein gels reveal that the expression of excitation-contraction coupling proteins is enhanced in salmon shark hearts, which may underlie the shark's ability to maintain heart function at cold temperatures and their niche expansion into subarctic seas.	Stanford Univ, Hopkins Marine Stn, Tuna Res & Conservat Ctr, 120 Oceanview Blvd, Pacific Grove, CA 93950 USA; Natl Marine Fisheries Serv, La Jolla, CA 92037 USA; Monterey Bay Aquarium Res Inst, Monterey, CA 93940 USA; Alaska Dept Fish & Game, Homer, AK 99603 USA	Stanford University; National Oceanic Atmospheric Admin (NOAA) - USA; Monterey Bay Aquarium Research Institute; Alaska Department of Fish & Game	Block, BA (corresponding author), Stanford Univ, Hopkins Marine Stn, Tuna Res & Conservat Ctr, 120 Oceanview Blvd, Pacific Grove, CA 93950 USA.	bblock@stanford.edu	Costa, Maria/G-9555-2011; Weng, Kevin Chi-Ming/C-4709-2013	Costa, Maria/0000-0002-9887-0973; Schallert, Robert/0000-0002-3584-2668; Weng, Kevin Chi-Ming/0000-0002-7069-7152				Blank JM, 2004, J EXP BIOL, V207, P881, DOI 10.1242/jeb.00820; Boustany AM, 2002, NATURE, V415, P35, DOI 10.1038/415035b; BRILL RW, 2001, TUNA PHYSL ECOLOGY E, P00079; CAREY FG, 1981, PHYSIOL ZOOL, V54, P334, DOI 10.1086/physzool.54.3.30159948; CAREY FG, 1982, COPEIA, P254; Eckert SA, 2001, ENVIRON BIOL FISH, V60, P299, DOI 10.1023/A:1007674716437; Goldman KJ, 2004, ENVIRON BIOL FISH, V71, P403, DOI 10.1007/s10641-004-6588-9; GOLDMAN KJ, IN PRESS FISH B; HULBERT L, 1999, TROPHIC MASS BALANCE, P42; Nagasawa Kazuya, 1998, North Pacific Anadromous Fish Commission Bulletin, V1, P419; Norcross BL, 2001, FISH OCEANOGR, V10, P42, DOI 10.1046/j.1054-6006.2001.00040.x; PAUST B, 1986, SALMON SHARK MANUAL; PRIEDE IG, 1984, FISH RES, V2, P201, DOI 10.1016/0165-7836(84)90003-1; RANDALL J, COMMUNICATION; Sims DW, 2003, MAR ECOL PROG SER, V248, P187, DOI 10.3354/meps248187; Stevens JD, 2000, ICES J MAR SCI, V57, P476, DOI 10.1006/jmsc.2000.0724; Teo SLH, 2004, MAR ECOL PROG SER, V283, P81, DOI 10.3354/meps283081; Yatani A, 2004, AM J PHYSIOL-HEART C, V286, pH2219, DOI 10.1152/ajpheart.01096.2003	18	162	166	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	2005	310	5745					104	106		10.1126/science.1114616	http://dx.doi.org/10.1126/science.1114616			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210538				2022-12-28	WOS:000232477000047
J	McLaughlin, JB; DePaola, A; Bopp, CA; Martinek, KA; Napolilli, NP; Allison, CG; Murray, SL; Thompson, EC; Bird, MM; Middaugh, JP				McLaughlin, JB; DePaola, A; Bopp, CA; Martinek, KA; Napolilli, NP; Allison, CG; Murray, SL; Thompson, EC; Bird, MM; Middaugh, JP			Outbreak of Vibrio parahaemolyticus gastroenteritis associated with Alaskan oysters	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALGINOLYTICUS; GENES; COAST; FOOD	BACKGROUND Vibrio parahaemolyticus, the leading cause of seafood-associated gastroenteritis in the United States, typically is associated with the consumption of raw oysters gathered from warm-water estuaries. We describe a recognized outbreak of V. parahaemolyticus infection associated with the consumption of seafood from Alaska. METHODS After we received reports of the occurrence of gastroenteritis on a cruise ship, we conducted a retrospective cohort study among passengers, as well as active surveillance throughout Alaska to identify additional cases, and an environmental study to identify sources of V. parahaemolyticus and contributors to the outbreak. RESULTS Of 189 passengers, 132 ( 70 percent) were interviewed; 22 of the interviewees ( 17 percent) met our case definition of gastroenteritis. In our multiple logistic-regression analysis, consumption of raw oysters was the only significant predictor of illness; the attack rate among people who consumed oysters was 29 percent. Active surveillance identified a total of 62 patients with gastroenteritis. V. parahaemolyticus serotype O6: K18 was isolated from the majority of patients tested and from environmental samples of oysters. Patterns on pulsed-field gel electrophoresis were highly related across clinical and oyster isolates. All oysters associated with the outbreak were harvested when mean daily water temperatures exceeded 15.0 degrees C ( the theorized threshold for the risk of V. parahaemolyticus illness from the consumption of raw oysters). Since 1997, mean water temperatures in July and August at the implicated oyster farm increased 0.21 degrees C per year (P< 0.001 by linear regression); 2004 was the only year during which mean daily temperatures in July and August at the shellfish farm did not drop below 15.0 degrees C. CONCLUSIONS This investigation extends by 1000 km the northernmost documented source of oysters that caused illness due to V. parahaemolyticus. Rising temperatures of ocean water seem to have contributed to one of the largest known outbreaks of V. parahaemolyticus in the United States.	Alaska Dept Hlth & Social Serv, Div Publ Hlth, Anchorage, AK 99503 USA; Alaska Dept Environm Conservat, Anchorage, AK USA; US FDA, Gulf Coast Seafood Lab, Dauphin Isl, AL USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA	US Food & Drug Administration (FDA); Centers for Disease Control & Prevention - USA	McLaughlin, JB (corresponding author), Alaska Dept Hlth & Social Serv, Div Publ Hlth, 3601 C St,Suite 540, Anchorage, AK 99503 USA.	joe_mclaughlin@health.state.ak.us						*AM PUBL HLTH ASS, 1970, REC PROC EX SEA WAT, P101; *APPL MATHS BVBA, 2002, 2002 BIONUMERICS VER; *BRIT COL SHELLF G, VIBR PAR CONTR PROGR; Cook DW, 2002, J FOOD PROTECT, V65, P1873, DOI 10.4315/0362-028X-65.12.1873; Cook DW, 2002, J FOOD PROTECT, V65, P445; *CTR FOOD SAF APPL, QUANT RISK ASS PUBL; Daniels NA, 2000, J INFECT DIS, V181, P1661, DOI 10.1086/315459; Daniels NA, 2000, JAMA-J AM MED ASSOC, V284, P1541, DOI 10.1001/jama.284.12.1541; DANIELS NA, 2001, JAMA-J AM MED ASSOC, V285, P169; DePaola A, 2003, APPL ENVIRON MICROB, V69, P1521, DOI 10.1128/AEM.69.3.1521-1526.2003; DePaola A, 2003, APPL ENVIRON MICROB, V69, P3999, DOI 10.1128/AEM.69.7.3999-4005.2003; DePaola A, 2000, APPL ENVIRON MICROB, V66, P4649, DOI 10.1128/AEM.66.11.4649-4654.2000; *FOOD DRUG ADM, FDA BACT AN MAN; GJERDE J, 1981, ACTA VET SCAND, V22, P331; Gonzalez-Escalona N, 2005, EMERG INFECT DIS, V11, P129, DOI 10.3201/eid1101.040762; Gooch JA, 2002, J FOOD PROTECT, V65, P970, DOI 10.4315/0362-028X-65.6.970; Greenberg E. P., 1982, Journal of Food Safety, V4, P113, DOI 10.1111/j.1745-4565.1982.tb00436.x; JOSEPH SW, 1982, CRC CR REV MICROBIOL, V10, P77, DOI 10.3109/10408418209113506; Matsumoto C, 2000, J CLIN MICROBIOL, V38, P578, DOI 10.1128/JCM.38.2.578-585.2000; McMichael A.J., 1996, CLIMATE CHANGE HUMAN; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; MIYAMOTO Y, 1969, J BACTERIOL, V100, P1147, DOI 10.1128/JB.100.2.1147-1149.1969; *NAT OC ATM ASS, STAT 46001 GULF AK 8; NISHIBUCHI M, 1992, INFECT IMMUN, V60, P3539, DOI 10.1128/IAI.60.9.3539-3545.1992; NISHIBUCHI M, 1985, INFECT IMMUN, V49, P481, DOI 10.1128/IAI.49.3.481-486.1985; Nordstrom JL, 2004, J FOOD PROTECT, V67, P2178, DOI 10.4315/0362-028X-67.10.2178; Okuda J, 1997, J CLIN MICROBIOL, V35, P1965, DOI 10.1128/JCM.35.8.1965-1971.1997; THOMPSON CA, 1976, J FOOD SCI, V41, P204, DOI 10.1111/j.1365-2621.1976.tb01138.x; *UN INT PAN CLIM C, 3 UN INT PAN CLIM CH; *UPD NAT SHELLF SA, 2002, UPD NAT SHELLF SAN P; VASCONCELOS GJ, 1975, APPL MICROBIOL, V29, P557, DOI 10.1128/AEM.29.4.557-559.1975; 1998, MMWR MORB MORTAL WKL, V47, P457	32	323	343	1	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 6	2005	353	14					1463	1470		10.1056/NEJMoa051594	http://dx.doi.org/10.1056/NEJMoa051594			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970LZ	16207848	Bronze			2022-12-28	WOS:000232313000006
J	Wang, XL; Kellner, AWA; Zhou, ZH; Campos, DD				Wang, XL; Kellner, AWA; Zhou, ZH; Campos, DD			Pterosaur diversity and faunal turnover in Cretaceous terrestrial ecosystems in China	NATURE			English	Article							JIUFOTANG FORMATION; INNER-MONGOLIA	New specimens and an analysis of the Jehol pterosaur faunae of northeastern China show an unexpected diversity of flying reptile groups in terrestrial Cretaceous ecosystems(1-4). Here we report two new pterosaurs that are referred to European groups previously unknown in deposits of northeastern China. Feilongus youngi, from the Yixian Formation(1,3), is closely related to the Gallodactylidae(5-6) and is distinguished by the presence of two independent sagittal crests and a protruding upper jaw. Nurhachius ignaciobritoi, from the Jiufotang Formation(2,3), has teeth formed by labiolingually compressed triangular crowns, only previously reported in Istiodactylus latidens(7) from England. With these new discoveries, the Jehol pterosaurs show a wide range of groups including both primitive and derived forms that are not matched by any other deposit in the world. The discoveries also document the turnover of pterosaur faunae, with the primitive Anurognathidae and early archaeopterodactyloids being replaced by derived pterodactyloids. Furthermore, these deposits offer an opportunity to examine the interaction and competition between birds and pterosaurs - it indicates that the avian fauna during the Lower Cretaceous ( and possibly most of the Mesozoic) dominated terrestrial, inland regions, whereas pterosaurs were more abundant in coastal areas.	Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China; Univ Fed Rio de Janeiro, Museu Nacl, Dept Geol & Paleontol, Paleovertebrate Sector, BR-20940040 Rio De Janeiro, Brazil; Museu Ciencias Terra, Dept Nacl Prod Mineral, BR-22290240 Rio De Janeiro, Brazil	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS; Universidade Federal do Rio de Janeiro	Wang, XL (corresponding author), Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, POB 643, Beijing 100044, Peoples R China.	xlinwang@263.net; kellner@acd.ufrj.br	Kellner, Alexander/ABE-9591-2020; Kellner, Alexander W/H-1023-2015	Kellner, Alexander/0000-0001-7174-9447; Kellner, Alexander W/0000-0001-7174-9447				Bennett S. Christopher, 2001, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V260, P1; Bennett SC, 2002, J VERTEBR PALEONTOL, V22, P43, DOI 10.1671/0272-4634(2002)022[0043:STPOTC]2.0.CO;2; Campos Diogenes De A., 1997, Anais da Academia Brasileira de Ciencias, V69, P83; Chang M., 2003, JEHOL BIOTA; Czerkas S. A., 2002, FEATHERED DINOSAURS, P15; Dong Z., 2003, GLOBAL GEOLOGY, V22, P1; He HY, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019790; Howse S.C.B., 2001, DINOSAURS ISLE WIGHT, P324; Ji SA, 1999, NATURE, V398, P573, DOI 10.1038/19221; KELLER JR, 1989, J CELL BIOCHEM, V39, P175, DOI 10.1002/jcb.240390209; Kellner Alexander W.A., 2003, Geological Society Special Publication, V217, P105, DOI 10.1144/GSL.SP.2003.217.01.10; Kellner AWA, 1996, J VERTEBR PALEONTOL, V16, P222, DOI 10.1080/02724634.1996.10011310; Kellner AWA, 2002, SCIENCE, V297, P389, DOI 10.1126/science.1073186; Kellner AWA, 2000, NATL SCI MUSEUM MONO, V17, P1, DOI 10.1159/000061634; KIELAN-JAWOROWSKA Z, 2004, MAMMALS AGE DINOSAUR; Li Jian-Jun, 2003, Acta Palaeontologica Sinica, V42, P442; Lu Jun-Chang, 2003, Memoir of the Fukui Prefectural Dinosaur Museum, V2, P153; PONTE FC, 1996, B 4 S CRET BRAS, P123; Swisher CC, 1999, NATURE, V400, P58, DOI 10.1038/21872; Unwin David M., 2003, Geological Society Special Publication, V217, P139, DOI 10.1144/GSL.SP.2003.217.01.11; Unwin David M., 2000, Mitteilungen aus dem Museum fuer Naturkunde in Berlin Geowissenschaftliche Reihe, V3, P181; Viohl G., 1985, P31; Wang XL, 2002, CHINESE SCI BULL, V47, P226, DOI 10.1360/02tb9054; Wang XL, 2001, CHINESE SCI BULL, V46, P1112; Wang XL, 2003, CHINESE SCI BULL, V48, P16, DOI 10.1360/03tb9003; WANG XL, 2002, VERTEBRAT PALASIATIC, V41, P34; Wellnhofer P, 1991, ILLUSTRATED ENCY PTE; Wellnhofer Peter, 1999, Palaeontologische Zeitschrift, V73, P133; Wu XC, 1996, CAN J EARTH SCI, V33, P599, DOI 10.1139/e96-044; Zhou ZH, 2003, NATURE, V421, P807, DOI 10.1038/nature01420	30	127	151	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					875	879		10.1038/nature03982	http://dx.doi.org/10.1038/nature03982			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208369				2022-12-28	WOS:000232338600044
J	Gilson, L; McIntyre, D				Gilson, L; McIntyre, D			Removing user fees for primary care in Africa: the need for careful action	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SOUTH-AFRICA; HEALTH; EXPERIENCE; LESSONS; TRUST		Univ Witwatersrand, Ctr Hlth Policy, ZA-2000 Johannesburg, South Africa; Univ Cape Town, Sch Publ Hlth & Family Med, Hlth Econ Unit, ZA-7925 Cape Town, South Africa	University of Witwatersrand; University of Cape Town	Gilson, L (corresponding author), Univ Witwatersrand, Ctr Hlth Policy, POB 1038, ZA-2000 Johannesburg, South Africa.	Lucy.gilson@nhls.ac.za	Gilson, Lucy/R-8846-2019	Gilson, Lucy/0000-0002-2775-7703; McIntyre, Diane/0000-0001-6319-4111				[Anonymous], 2004, HUM RES HLTH OV CRIS; Burnham GM, 2004, B WORLD HEALTH ORGAN, V82, P187; Commission for Africa, 2005, OUR COMMON INTEREST; *EQUINET STEER COM, 2004, EQUINET POL SER, V15; Gilson L, 1997, HEALTH POLICY PLANN, V12, P273, DOI 10.1093/oxfordjournals.heapol.a018882; Gilson L, 2005, SOC SCI MED, V61, P1418, DOI 10.1016/j.socscimed.2004.11.062; Gilson L, 2003, HEALTH POLICY PLANN, V18, P31, DOI 10.1093/heapol/18.1.31; GILSON L, 1995, HEALTH POLICY, V32, P215, DOI 10.1016/0168-8510(95)00737-D; GILSON L, 1997, REG M DEC CONT HLTH; James C, 2005, BMJ-BRIT MED J, V331, P747, DOI 10.1136/bmj.331.7519.747; McCoy D, 1996, FREE HLTH CARE PREGN; McIntyre D, 2003, REPROD HEALTH MATTER, V11, P108, DOI 10.1016/S0968-8080(03)02166-9; McIntyre D, 2002, HEALTH POLICY PLANN, V17, P30, DOI 10.1093/heapol/17.suppl_1.30; MCINTYRE D, IN PRESS SOC SCI MED; Mpuga Paul, 2004, 3276 WORLD BANK; Osborne S.P., 2005, MANAGING CHANGE INNO; Russell S, 2004, AM J TROP MED HYG, V71, P147, DOI 10.4269/ajtmh.2004.71.147; Tibandebage P, 2005, SOC SCI MED, V61, P1385, DOI 10.1016/j.socscimed.2004.11.072; VANDOORSLAER E, 1993, EQUITY FINANCE DELIV; Walker L, 2004, SOC SCI MED, V59, P1251, DOI 10.1016/j.socscimed.2003.12.020; *WHO, WORLD HLTH REP NHA A	21	144	145	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	2005	331	7519					762	765		10.1136/bmj.331.7519.762	http://dx.doi.org/10.1136/bmj.331.7519.762			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	971XB	16195296	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000232417100026
J	Charbonnel, C; Talon, S				Charbonnel, C; Talon, S			Influence of gravity waves on the internal rotation and Li abundance of solar-type stars	SCIENCE			English	Article							ANGULAR-MOMENTUM TRANSPORT; STELLAR RADIATIVE ZONES; LITHIUM ABUNDANCES; EVOLUTION; CONVECTION; DIFFUSION; MODELS; HYADES; M67	The Sun's rotation profile and lithium content have been difficult to understand in the context of conventional models of stellar evolution. Classical hydrodynamic models predict that the solar interior must rotate highly differentially, in disagreement with observations. it has recently been shown that internal waves produced by convection in solar-type stars produce an asymmetric, shear layer oscillation, similar to Earth's quasi-biennial oscillation, that leads to efficient angular momentum redistribution from the core to the envelope. We present results of a model that successfully reproduces both the rotation profile and the surface abundance of lithium in solar-type stars of various ages.	Univ Montreal, Dept Phys, Montreal, PQ H3C 3J7, Canada; Observ Midi Pyrenees, CNRS, Unite Mixte Rech 5572, Lab Astrophys Toulouse & Tarbes, F-31400 Toulouse, France; Observ Geneva, CH-1290 Sauverny, Switzerland	Universite de Montreal; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Geneva	Talon, S (corresponding author), Univ Montreal, Dept Phys, CP 6128, Montreal, PQ H3C 3J7, Canada.	talon@astro.umontreal.ca						BALACHANDRAN S, 1995, ASTROPHYS J, V446, P203, DOI 10.1086/175779; Baldwin MP, 2001, REV GEOPHYS, V39, P179, DOI 10.1029/1999RG000073; Barnes G, 1998, ASTROPHYS J, V498, pL169, DOI 10.1086/311328; Barnes G, 1999, ASTROPHYS J, V511, P466, DOI 10.1086/306639; CHABOYER B, 1995, ASTROPHYS J, V441, P865, DOI 10.1086/175408; Chaplin WJ, 1999, MON NOT R ASTRON SOC, V308, P405, DOI 10.1046/j.1365-8711.1999.02691.x; CHARBONNEAU P, 1993, ASTROPHYS J, V417, P762, DOI 10.1086/173357; Couvidat S, 2003, ASTROPHYS J, V597, pL77, DOI 10.1086/379698; Dintrans B, 2005, ASTRON ASTROPHYS, V438, P365, DOI 10.1051/0004-6361:20052831; Eggenberger P, 2005, ASTRON ASTROPHYS, V440, pL9, DOI 10.1051/0004-6361:200500156; GAIGE Y, 1993, ASTRON ASTROPHYS, V269, P267; GOLDREICH P, 1994, ASTROPHYS J, V424, P466, DOI 10.1086/173904; Gough DO, 1998, NATURE, V394, P755, DOI 10.1038/29472; HURLBURT NE, 1986, ASTROPHYS J, V311, P563, DOI 10.1086/164796; Jones BF, 1999, ASTRON J, V117, P330, DOI 10.1086/300664; KAWALER SD, 1988, ASTROPHYS J, V333, P236, DOI 10.1086/166740; Kumar P, 1999, ASTROPHYS J, V520, P859, DOI 10.1086/307464; Kumar P, 1997, ASTROPHYS J, V475, pL143, DOI 10.1086/310477; Maeder A, 2000, ANNU REV ASTRON ASTR, V38, P143, DOI 10.1146/annurev.astro.38.1.143; MATIAS J, 1998, IAU S, V181, P103; McIntyre ME, 2000, PERSPECTIVES IN FLUID DYNAMICS, P557; Pasquini L, 2004, ASTRON ASTROPHYS, V424, P951, DOI 10.1051/0004-6361:20040240; Randich S, 2000, ASTRON ASTROPHYS, V356, pL25; Ringot O, 1998, ASTRON ASTROPHYS, V335, pL89; Sestito P, 2004, ASTRON ASTROPHYS, V426, P809, DOI 10.1051/0004-6361:20041237; SODERBLOM DR, 1993, ASTRON J, V106, P1080, DOI 10.1086/116705; Talon S, 2005, ASTRON ASTROPHYS, V440, P981, DOI 10.1051/0004-6361:20053020; Talon S, 2002, ASTROPHYS J, V574, pL175, DOI 10.1086/342526; THORBURN JA, 1993, ASTROPHYS J, V415, P150, DOI 10.1086/173152; Zahn JP, 1997, ASTRON ASTROPHYS, V322, P320	30	254	254	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	2005	309	5744					2189	2191		10.1126/science.1116849	http://dx.doi.org/10.1126/science.1116849			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195453				2022-12-28	WOS:000232318000035
J	Atencia, J; Beebe, DJ				Atencia, J; Beebe, DJ			Controlled microfluidic interfaces	NATURE			English	Review							MONODISPERSE DOUBLE EMULSIONS; IMMISCIBLE LIQUIDS; ACTIVE CONTROL; FLOW; CHIP; SYSTEM; MICROCHANNELS; GENERATION; SEPARATION; GRADIENTS		Univ Wisconsin, Dept Biomed Engn, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Beebe, DJ (corresponding author), Univ Wisconsin, Dept Biomed Engn, 1550 Engn Dr,Rm 2142 ECB, Madison, WI 53706 USA.	djbeebe@wisc.edu	Atencia, Javier/K-8613-2012	Atencia, Javier/0000-0003-2276-7619				Adamson A. W., 1967, PHYS CHEM SURFACES; Anderson DM, 1998, ANNU REV FLUID MECH, V30, P139, DOI 10.1146/annurev.fluid.30.1.139; Anna SL, 2003, APPL PHYS LETT, V82, P364, DOI 10.1063/1.1537519; [Anonymous], 2001, TRANSPORT PHENOMENA; Bauer JA, 2004, J MICROELECTROMECH S, V13, P553, DOI 10.1109/JMEMS.2004.832181; Beebe D, 2002, THERIOGENOLOGY, V57, P125, DOI 10.1016/S0093-691X(01)00662-8; Bringer MR, 2004, PHILOS T R SOC A, V362, P1087, DOI 10.1098/rsta.2003.1364; Brody JP, 1996, BIOPHYS J, V71, P3430, DOI 10.1016/S0006-3495(96)79538-3; Brody JP, 1997, SENSOR ACTUAT A-PHYS, V58, P13, DOI 10.1016/S0924-4247(97)80219-1; CHAUDHURY MK, 1992, SCIENCE, V256, P1539, DOI 10.1126/science.256.5063.1539; Choban ER, 2004, J POWER SOURCES, V128, P54, DOI 10.1016/j.jpowsour.2003.11.052; Costin CD, 2004, ANAL CHEM, V76, P2725, DOI 10.1021/ac030405c; Dertinger SKW, 2001, ANAL CHEM, V73, P1240, DOI 10.1021/ac001132d; Dickinson E., 1994, COLLOID SURFACE B, V3, P1, DOI 10.1016/0927-7765(93)01116-9; Dorvee JR, 2004, NAT MATER, V3, P896, DOI 10.1038/nmat1253; Ferrigno R, 2002, J AM CHEM SOC, V124, P12930, DOI 10.1021/ja020812q; Gallardo BS, 1999, SCIENCE, V283, P57, DOI 10.1126/science.283.5398.57; GARIK P, 1991, PHYS REV LETT, V66, P1606, DOI 10.1103/PhysRevLett.66.1606; Gascoyne PRC, 2004, LAB CHIP, V4, P299, DOI 10.1039/b404130e; GIDDINGS JC, 1976, SCIENCE, V193, P1244, DOI 10.1126/science.959835; GIDDINGS JC, 1993, SCIENCE, V260, P1456, DOI 10.1126/science.8502990; HAGEN G, 1839, POGG ANN, V46, P423, DOI DOI 10.1002/ANDP.18391220304; Hansen CL, 2002, P NATL ACAD SCI USA, V99, P16531, DOI 10.1073/pnas.262485199; HARRISON DJ, 1993, SCIENCE, V261, P895, DOI 10.1126/science.261.5123.895; Hatch A, 2001, NAT BIOTECHNOL, V19, P461, DOI 10.1038/88135; Hibara A, 2005, ANAL CHEM, V77, P943, DOI 10.1021/ac0490088; Hibara A, 2002, ANAL CHEM, V74, P1724, DOI 10.1021/ac011038c; Hisamoto H, 2003, ANAL CHEM, V75, P350, DOI 10.1021/ac025794+; Ismagilov RF, 2000, APPL PHYS LETT, V76, P2376, DOI 10.1063/1.126351; JACOBSON SC, 1994, ANAL CHEM, V66, P1114, DOI 10.1021/ac00079a029; Jeon NL, 2000, LANGMUIR, V16, P8311, DOI 10.1021/la000600b; Jeon NL, 2002, NAT BIOTECHNOL, V20, P826, DOI 10.1038/nbt712; Jeong W, 2004, LAB CHIP, V4, P576, DOI 10.1039/b411249k; Jeong WJ, 2005, LANGMUIR, V21, P3738, DOI 10.1021/la050105l; Joseph D. D. R., 1993, FUNDAMENTALS 2 FLUID; Kamholz AE, 1999, ANAL CHEM, V71, P5340, DOI 10.1021/ac990504j; Kenis PJA, 1999, SCIENCE, V285, P83, DOI 10.1126/science.285.5424.83; Kenis PJA, 2000, ACCOUNTS CHEM RES, V33, P841, DOI 10.1021/ar000062u; Kobayashi J, 2004, SCIENCE, V304, P1305, DOI 10.1126/science.1096956; Koschmieder E.L., 1993, BENARD CELLS TAYLOR; Kotz KT, 2004, APPL PHYS LETT, V85, P2658, DOI 10.1063/1.1797538; Lee J, 2000, J MICROELECTROMECH S, V9, P171, DOI 10.1109/84.846697; Link DR, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.054503; Lu G, 2004, LANGMUIR, V20, P8401, DOI 10.1021/la049564x; Lucchetta EM, 2005, NATURE, V434, P1134, DOI 10.1038/nature03509; Lyuksyutov IF, 2004, APPL PHYS LETT, V85, P1817, DOI 10.1063/1.1781735; MANZ A, 1990, SENSOR ACTUAT B-CHEM, V1, P244, DOI 10.1016/0925-4005(90)80209-I; Mao HB, 2003, P NATL ACAD SCI USA, V100, P5449, DOI 10.1073/pnas.0931258100; Mao HB, 2002, ANAL CHEM, V74, P5071, DOI 10.1021/ac025851z; Maruyama T, 2004, ANALYST, V129, P1008, DOI 10.1039/b411630p; Maruyama T, 2004, ANAL CHEM, V76, P4495, DOI 10.1021/ac049844h; Maruyama T, 2004, LAB CHIP, V4, P159; Moorthy J, 2001, SENSOR ACTUAT B-CHEM, V75, P223, DOI 10.1016/S0925-4005(01)00557-3; Munson MS, 2004, LAB CHIP, V4, P438, DOI 10.1039/b407765b; NAVIER LMH, 1827, MEM ACAD R SCI, V6, P389; Okushima S, 2004, LANGMUIR, V20, P9905, DOI 10.1021/la0480336; Pearce TM, 2005, LAB CHIP, V5, P97, DOI 10.1039/b407871c; PETERSEN KE, 1982, P IEEE, V70, P420, DOI 10.1109/PROC.1982.12331; Poiseuille J.-L.-M., 1840, CR HEBD ACAD SCI, V11, P1041; Pollack MG, 2000, APPL PHYS LETT, V77, P1725, DOI 10.1063/1.1308534; Prins MWJ, 2001, SCIENCE, V291, P277, DOI 10.1126/science.291.5502.277; PURCELL EM, 1977, AM J PHYS, V45, P3, DOI 10.1119/1.10903; Raty S, 2004, LAB CHIP, V4, P186, DOI 10.1039/b316437c; Rayleigh L., 1879, P R SOC LOND, V29, P71, DOI [10.1098/rspl.1879.0015, DOI 10.1098/RSPL.1879.0015]; Ribbeck K, 2002, EMBO J, V21, P2664, DOI 10.1093/emboj/21.11.2664; Roach LS, 2005, ANAL CHEM, V77, P785, DOI 10.1021/ac049061w; Ross D, 2002, ANAL CHEM, V74, P2556, DOI 10.1021/ac025528w; Sawano A, 2002, DEV CELL, V3, P245, DOI 10.1016/S1534-5807(02)00224-1; Shestopalov I, 2004, LAB CHIP, V4, P316, DOI 10.1039/b403378g; Song H, 2003, J AM CHEM SOC, V125, P14613, DOI 10.1021/ja0354566; SQUIRES TM, IN PRESS REV MOD PHY; Srinivasan V, 2004, LAB CHIP, V4, P310, DOI 10.1039/b403341h; Stokes G.G., 1845, T CAMBRIDGE PHILOS S, V8, P287; Stone HA, 2004, ANNU REV FLUID MECH, V36, P381, DOI 10.1146/annurev.fluid.36.050802.122124; Surmeian M, 2002, ANAL CHEM, V74, P2014, DOI 10.1021/ac0112317; Tan YC, 2004, LAB CHIP, V4, P292, DOI 10.1039/b403280m; Taylor GI, 1934, P R SOC LOND A-CONTA, V146, P0501, DOI 10.1098/rspa.1934.0169; TAYLOR GI, 1953, P ROY SOC LOND A MAT, V219, P183; Thorsen T, 2001, PHYS REV LETT, V86, P4163, DOI 10.1103/PhysRevLett.86.4163; TRIMMER WSN, 1989, SENSOR ACTUATOR, V19, P267, DOI 10.1016/0250-6874(89)87079-9; Utada AS, 2005, SCIENCE, V308, P537, DOI 10.1126/science.1109164; VIERNES NOL, 2003, P 7 INT C MICR TOT A, P1041; Vogel S, 1996, LIFE MOVING FLUIDS; Weigl BH, 1999, SCIENCE, V283, P346, DOI 10.1126/science.283.5400.346; Weigl BH, 1997, SENSOR ACTUAT B-CHEM, V39, P452, DOI 10.1016/S0925-4005(96)02120-X; Wheeler AR, 2004, ANAL CHEM, V76, P4833, DOI 10.1021/ac0498112; WILLIAMS PS, 1992, IND ENG CHEM RES, V31, P2172, DOI 10.1021/ie00009a015; Xu QY, 2004, APPL PHYS LETT, V85, P3726, DOI 10.1063/1.1812380; XU S, 2004, ANGEW CHEM INT EDIT, V43, P2; YU H, 2005, LAB CHIP; Zhang T., 2002, NA MI EN TE; Zhao B, 2002, J AM CHEM SOC, V124, P5284, DOI 10.1021/ja025835j; Zhao B, 2001, SCIENCE, V291, P1023, DOI 10.1126/science.291.5506.1023; Zheng B, 2004, ANGEW CHEM INT EDIT, V43, P2508, DOI 10.1002/anie.200453974	94	723	765	13	617	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					648	655		10.1038/nature04163	http://dx.doi.org/10.1038/nature04163			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193039				2022-12-28	WOS:000232157900038
J	Chandler, D				Chandler, D			Interfaces and the driving force of hydrophobic assembly	NATURE			English	Review							FREE-ENERGIES; LIQUID WATER; HYDRATION; MODEL; SIMULATION; TEMPERATURE; TRANSITION; DEPENDENCE; SOLVATION; SOLUTES	The hydrophobic effect - the tendency for oil and water to segregate - is important in diverse phenomena, from the cleaning of laundry, to the creation of micro-emulsions to make new materials, to the assembly of proteins into functional complexes. This effect is multifaceted depending on whether hydrophobic molecules are individually hydrated or driven to assemble into larger structures. Despite the basic principles underlying the hydrophobic effect being qualitatively well understood, only recently have theoretical developments begun to explain and quantify many features of this ubiquitous phenomenon.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Chandler, D (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	chandler@cchem.berkeley.edu						Ashbaugh HS, 1999, J AM CHEM SOC, V121, P9243, DOI 10.1021/ja992119h; Ashbaugh HS, 2001, J AM CHEM SOC, V123, P10721, DOI 10.1021/ja016324k; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; Ball P, 2003, NATURE, V423, P25, DOI 10.1038/423025a; Barrat J.-L., 2003, BASIC CONCEPTS SIMPL; BENNAIM B, 1980, HYDROPHOBIC INTERACT, pCH3; BINDER K, 1994, BER BUNSEN PHYS CHEM, V98, P340, DOI 10.1002/bbpc.19940980311; Bolhuis PG, 2000, J CHEM PHYS, V113, P8154, DOI 10.1063/1.1315997; Bowron DT, 1998, PHYS REV LETT, V81, P4164, DOI 10.1103/PhysRevLett.81.4164; CHANDLER D, 1993, PHYS REV E, V48, P2898, DOI 10.1103/PhysRevE.48.2898; CHANDLER D, 1983, SCIENCE, V220, P787, DOI 10.1126/science.220.4599.787; DILL KA, 2003, MOL DRIVING FORCES, pCH16; Dixit S, 2002, NATURE, V416, P829, DOI 10.1038/416829a; Finney JL, 2004, PHILOS T R SOC B, V359, P1145, DOI 10.1098/rstb.2004.1495; Frenkel D., 2002, UNDERSTANDING MOL SI, V2nd; Gallagher KR, 2003, J AM CHEM SOC, V125, P9853, DOI 10.1021/ja029796n; Gallicchio E, 2000, J PHYS CHEM B, V104, P6271, DOI 10.1021/jp0006274; Garde S, 1996, PHYS REV LETT, V77, P4966, DOI 10.1103/PhysRevLett.77.4966; Gerstein M, 1996, P NATL ACAD SCI USA, V93, P10167, DOI 10.1073/pnas.93.19.10167; GERSTEIN M, 1993, J PHYS CHEM-US, V97, P2982, DOI 10.1021/j100114a026; Huang DM, 2000, PHYS REV E, V61, P1501, DOI 10.1103/PhysRevE.61.1501; Huang DM, 2000, P NATL ACAD SCI USA, V97, P8324, DOI 10.1073/pnas.120176397; Huang DM, 2002, J PHYS CHEM B, V106, P2047, DOI 10.1021/jp013289v; Huang DM, 2001, J PHYS CHEM B, V105, P6704, DOI 10.1021/jp0104029; Hummer G, 1996, P NATL ACAD SCI USA, V93, P8951, DOI 10.1073/pnas.93.17.8951; Jensen TR, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.086101; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; Larson R. G., 1999, STRUCTURE RHEOLOGY C; LARSON RG, 1992, J CHEM PHYS, V96, P7904, DOI 10.1063/1.462343; LEE CY, 1984, J CHEM PHYS, V80, P4448, DOI 10.1063/1.447226; Levy Y, 2004, P NATL ACAD SCI USA, V101, P3325, DOI 10.1073/pnas.0400157101; Lum K, 1998, INT J THERMOPHYS, V19, P845, DOI 10.1023/A:1022643006849; Lum K, 1999, J PHYS CHEM B, V103, P4570, DOI 10.1021/jp984327m; MACKAY D, 1981, J PHYS CHEM REF DATA, V10, P1175, DOI 10.1063/1.555654; Maibaum L, 2004, J PHYS CHEM B, V108, P6778, DOI 10.1021/jp037487t; Maibaum L, 2003, J PHYS CHEM B, V107, P1189, DOI 10.1021/jp0267196; MNACKAY D, 1993, ILLUSTRATED HDB PHYS, V3, P117; MORRISON TJ, 1952, J CHEM SOC, P3819, DOI 10.1039/jr9520003819; MURPHY KP, 1990, SCIENCE, V247, P559, DOI 10.1126/science.2300815; MURPHY KP, 1994, BIOPHYS CHEM, V51, P311, DOI 10.1016/0301-4622(94)00052-2; PARKER JL, 1994, J PHYS CHEM-US, V98, P8468, DOI 10.1021/j100085a029; PRATT LR, 1980, J CHEM PHYS, V73, P3430, DOI 10.1063/1.440540; PRATT LR, 1977, J CHEM PHYS, V67, P3683, DOI 10.1063/1.435308; PRATT LR, 1980, J SOLUTION CHEM, V9, P1, DOI 10.1007/BF00650133; Rabani E, 2003, NATURE, V426, P271, DOI 10.1038/nature02087; Raschke TM, 2001, P NATL ACAD SCI USA, V98, P5965, DOI 10.1073/pnas.111158498; ROWLINSON JS, 1982, MOL THEORY CAPILLARI, pCH8; SAFRON SA, 1994, STAT THERMODYNAMICS; Scatena LF, 2001, J PHYS CHEM B, V105, P11240, DOI 10.1021/jp0132174; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; Silverstein KAT, 2000, J AM CHEM SOC, V122, P8037, DOI 10.1021/ja000459t; SMIT B, 1990, NATURE, V348, P624, DOI 10.1038/348624a0; SMITH R, 1973, P NATL ACAD SCI USA, V70, P289, DOI 10.1073/pnas.70.2.289; Southall NT, 2000, J PHYS CHEM B, V104, P1326, DOI 10.1021/jp992860b; Stillinger FH, 1973, J SOLUTION CHEM, V2, P141, DOI 10.1007/BF00651970; SWOPE WC, 1984, J PHYS CHEM-US, V88, P6548, DOI 10.1021/j150670a016; TANFORD C, 1979, P NATL ACAD SCI USA, V76, P4175, DOI 10.1073/pnas.76.9.4175; TANFORD C, 1978, SCIENCE, V200, P1012, DOI 10.1126/science.653353; Tanford C, 1997, PROTEIN SCI, V6, P1358, DOI 10.1002/pro.5560060627; TANFORD C, 1980, HYDROPHOBIC EFFECT F, pCH1; TANFORD C, 2001, NATURES ROBOTS HIST, pCH12; TANFORD C, 2004, B FRANKLIN STILLED W, pCH14; ten Wolde PR, 2002, P NATL ACAD SCI USA, V99, P6539, DOI 10.1073/pnas.052153299; WALLQVIST A, 1995, J PHYS CHEM-US, V99, P2893, DOI 10.1021/j100009a053; Weeks JD, 2002, ANNU REV PHYS CHEM, V53, P533, DOI 10.1146/annurev.physchem.53.100201.133929; WU D, 1992, J PHYS CHEM-US, V96, P4077, DOI 10.1021/j100189a030; Zhang XY, 2002, SCIENCE, V295, P663, DOI 10.1126/science.1066854	68	2623	2642	52	1485	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					640	647		10.1038/nature04162	http://dx.doi.org/10.1038/nature04162			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193038				2022-12-28	WOS:000232157900037
J	Milne, S; Hinde, R				Milne, S; Hinde, R			Joseph Rotblat 1908-2005 - Physicist who committed his life to the cause of nuclear disarmament. Obituary	NATURE			English	Biographical-Item									Pugwash UK, Execut Comm, London WC1B 3BJ, England		Milne, S (corresponding author), Pugwash UK, Execut Comm, 63A Great Russell St, London WC1B 3BJ, England.	pugwash@mac.com							0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					634	634		10.1038/437634a	http://dx.doi.org/10.1038/437634a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193034	Bronze			2022-12-28	WOS:000232157900033
J	Godtfredsen, NS; Prescott, E; Osler, M				Godtfredsen, NS; Prescott, E; Osler, M			Effect of smoking reduction on lung cancer risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTE-SMOKING; PROSPECTIVE COHORT; PIPE SMOKING; DOUBLE-BLIND; FOLLOW-UP; CESSATION; MORTALITY; TOBACCO; ASSOCIATION; TRIAL	Context Many smokers are unable or unwilling to completely quit smoking. A proposed means of harm reduction is to reduce the number of cigarettes smoked per day. However, it is not clear whether this strategy decreases the risk for tobacco-related diseases. Objective To assess the effects of smoking reduction on lung cancer incidence. Design, Setting, and Participants Observational population-based cohort study with up to 31 years of follow-up from the Copenhagen Centre for Prospective Population Studies, which administrates data from 3 longitudinal studies conducted in Copenhagen and suburbs, the Copenhagen City Heart Study, the Copenhagen Male Study, and the Glostrup Population Studies, Denmark. Participants were 11151 men and 8563 women (N = 19 714) aged 20 to 93 years, who attended 2 consecutive examinations with a 5- to 10-year interval between 1964 and 1988. Participants underwent a physical examination and completed self-filled questionnaires about lifestyle habits. The study population was divided into 6 groups according to smoking habits: continued heavy smokers (>= 15 cigarettes/d), reducers (reduced from >= 15 cigarettes/d by minimum of 50% without quitting), continued light smokers (1-14 cigarettes/d), quitters (stopped between first and second examination), stable ex-smokers, and never smokers. Main Outcome Measure Incident primary lung cancer cases assessed by record linkage with the National Cancer Registry until December 31, 2003. Results There were 864 incident lung cancers during follow-up. Using Cox regression, the adjusted hazard ratio (HR) for lung cancer in reducers was 0.73 (95% confidence interval [CI], 0.54-0.98) compared with persistent heavy smokers. The HR for light smokers was 0.44 (95% Cl, 0.35-0.56); for quitters, HR 0.50 (95% Cl, 0.36-0.69), for stable ex-smokers, HR 0.17 (95% Cl, 0.13-0.23), and for never smokers, HR 0.09 (95% Cl, 0.06-0.13). Conclusion Among individuals who smoke 15 or more cigarettes per day, smoking reduction by 50% significantly reduces the risk of lung cancer.	Univ Copenhagen Hosp, Inst Prevent Med, Danish Epidemiol Sci Ctr, Copenhagen Ctr Prospect Populat Studies, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Hvidovre Hosp, Dept Cardiol & Pulm Med, DK-2650 Hvidovre, Denmark; Rigshosp, Dept Cardiol, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Inst Publ Hlth, Dept Social Med, Copenhagen, Denmark	Aarhus University; University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen	Godtfredsen, NS (corresponding author), Univ Copenhagen, Hvidovre Hosp, Dept Cardiol & Pulm Med 253, Kettegard Alle 30, DK-2650 Hvidovre, Denmark.	duegodt@dadlnet.dk	Osler, Merete/AAF-7885-2019; Prescott, Eva/AAJ-7441-2020	Prescott, Eva/0000-0002-4134-0349				APPLEYARD M, 1989, SCAND J SOC MED S, V41, P1; Armadans-Gil L, 1999, INT J EPIDEMIOL, V28, P614, DOI 10.1093/ije/28.4.614; Barnoya J, 2004, CANCER CAUSE CONTROL, V15, P689, DOI 10.1023/B:CACO.0000036187.13805.30; BENHAMOU E, 1989, BRIT J CANCER, V60, P601, DOI 10.1038/bjc.1989.322; BENHAMOU S, 1986, INT J CANCER, V37, P825, DOI 10.1002/ijc.2910370605; Boffetta P, 1999, JNCI-J NATL CANCER I, V91, P697, DOI 10.1093/jnci/91.8.697; Bolliger Chris T, 2002, Nicotine Tob Res, V4, P433, DOI 10.1080/1462220021000018380; Bolliger CT, 2000, BMJ-BRIT MED J, V321, P329, DOI 10.1136/bmj.321.7257.329; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; Ebbert JO, 2003, J CLIN ONCOL, V21, P921, DOI 10.1200/JCO.2003.05.085; Fagerstrom K O, 1997, Tob Control, V6, P311; Friend K, 2001, Nicotine Tob Res, V3, P299, DOI 10.1080/14622200110072165; Godtfredsen NS, 2003, J EPIDEMIOL COMMUN H, V57, P412, DOI 10.1136/jech.57.6.412; Godtfredsen NS, 2002, THORAX, V57, P967, DOI 10.1136/thorax.57.11.967; Godtfredsen NS, 2002, AM J EPIDEMIOL, V156, P994, DOI 10.1093/aje/kwf150; Godtfredsen NS, 2001, PREV MED, V33, P46, DOI 10.1006/pmed.2001.0852; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hagerup L, 1981, Scand J Soc Med Suppl, V20, P1; Harris JE, 2004, BMJ-BRIT MED J, V328, P72, DOI 10.1136/bmj.37936.585382.44; Hecht SS, 2004, JNCI-J NATL CANCER I, V96, P107, DOI 10.1093/jnci/djh016; Hein HO, 1996, BRIT MED J, V312, P736, DOI 10.1136/bmj.312.7033.736; Henley SJ, 2004, JNCI-J NATL CANCER I, V96, P853, DOI 10.1093/jnci/djh144; HIGGINS ITT, 1988, PREV MED, V17, P116, DOI 10.1016/0091-7435(88)90077-1; Hughes JR, 2000, ADDICTION, V95, pS3; Hurt R D, 2000, Nicotine Tob Res, V2, P327, DOI 10.1080/713688154; Kabat GC, 2003, INHAL TOXICOL, V15, P1059, DOI 10.1080/08958370390228547; LANGE P, 1992, EUR RESPIR J, V5, P1111; Mendez D, 2004, AM J PUBLIC HEALTH, V94, P251, DOI 10.2105/AJPH.94.2.251; Mulder I, 2004, EUR J PUBLIC HEALTH, V14, P79, DOI 10.1093/eurpub/14.1.79; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; Shapiro JA, 2000, JNCI-J NATL CANCER I, V92, P333, DOI 10.1093/jnci/92.4.333; Shields PG, 2002, JNCI-J NATL CANCER I, V94, P1435, DOI 10.1093/jnci/94.19.1435; Storm HH, 1997, DAN MED BULL, V44, P535; Thun MJ, 2001, TOB CONTROL, V10, pI4; Wald NJ, 1997, BMJ-BRIT MED J, V314, P1860, DOI 10.1136/bmj.314.7098.1860; Wennike P, 2003, ADDICTION, V98, P1395, DOI 10.1046/j.1360-0443.2003.00489.x	36	188	191	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	2005	294	12					1505	1510		10.1001/jama.294.12.1505	http://dx.doi.org/10.1001/jama.294.12.1505			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	967TF	16189363	Bronze			2022-12-28	WOS:000232113400020
J	Janes, PW; Saha, N; Barton, WA; Kolev, MV; Wimmer-Kleikamp, SH; Nievergall, E; Blobel, CP; Himanen, JP; Lackmann, M; Nikolov, DB				Janes, PW; Saha, N; Barton, WA; Kolev, MV; Wimmer-Kleikamp, SH; Nievergall, E; Blobel, CP; Himanen, JP; Lackmann, M; Nikolov, DB			Adam meets Eph: An ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans	CELL			English	Article							CRYSTAL-STRUCTURE; CELL-ADHESION; RECEPTOR; DISINTEGRIN; PROTEASE; ROLES; ALPHA; ENDOCYTOSIS; BINDING; FAMILY	The Eph family of receptor tyrosine kinases and their ephrin ligands are mediators of cell-cell communication. Cleavage of ephrin-A2 by the ADAM10 membrane metalloprotease enables contact repulsion between Eph- and ephrin-expressing cells. How ADAM10 interacts with ephrins in a regulated manner to cleave only Eph bound ephrin molecules remains unclear. The structure of ADAM10 disintegrin and cysteine-rich domains and the functional studies presented here define an essential substrate-recognition module for functional interaction of ADAM10 with the ephrin-A5/EphA3 complex. While ADAM10 constitutively associates with EphA3, the formation of a functional EphA3/ephrin-A5 complex creates a new molecular recognition motif for the ADAM10 cysteine-rich domain that positions the proteinase domain for effective ephrin-A5 cleavage. Surprisingly, the cleavage occurs in trans, with ADAM10 and its substrate being on the membranes of opposing cells. Our data suggest a simple mechanism for regulating ADAM10-mediated ephrin proteolysis, which ensures that only Eph bound ephrins are recognized and cleaved.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia; Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10021 USA; Hosp Special Surg, New York, NY 10021 USA	Monash University; Memorial Sloan Kettering Cancer Center	Lackmann, M (corresponding author), Monash Univ, Dept Biochem & Mol Biol, POB 13D, Clayton, Vic 3168, Australia.	martin.lackmann@med.monash.edu.au; nikolovd@mskcc.org	kolev, mihail/D-1476-2015	kolev, mihail/0000-0002-5226-4759; Janes, Peter/0000-0002-9039-1097	NINDS NIH HHS [R02-NS-38486] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038486] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Fischer OM, 2004, MOL CELL BIOL, V24, P5172, DOI 10.1128/MCB.24.12.5172-5183.2004; FLANAGAN JG, 1996, ANNU REV NEUROSCI, V21, P309; Fujii Y, 2003, J MOL BIOL, V332, P1115, DOI 10.1016/S0022-2836(03)00991-4; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Himanen JP, 2004, NAT NEUROSCI, V7, P501, DOI 10.1038/nn1237; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Himanen JP, 2003, TRENDS NEUROSCI, V26, P46, DOI 10.1016/S0166-2236(02)00005-X; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; Lackmann M, 1998, J BIOL CHEM, V273, P20228, DOI 10.1074/jbc.273.32.20228; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Marston DJ, 2003, NAT CELL BIOL, V5, P879, DOI 10.1038/ncb1044; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pascall JC, 2004, BIOCHEM BIOPH RES CO, V317, P244, DOI 10.1016/j.bbrc.2004.03.039; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SENN H, 1993, J MOL BIOL, V232, P907, DOI 10.1006/jmbi.1993.1439; Smith FM, 2004, J BIOL CHEM, V279, P9522, DOI 10.1074/jbc.M309326200; Smith KM, 2002, J CELL BIOL, V159, P893, DOI 10.1083/jcb.200206023; White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001; Wimmer-Kleikamp SH, 2004, J CELL BIOL, V164, P661, DOI 10.1083/jcb.200312001; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Zimmer M, 2003, NAT CELL BIOL, V5, P869, DOI 10.1038/ncb1045	34	346	363	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	2005	123	2					291	304		10.1016/j.cell.2005.08.014	http://dx.doi.org/10.1016/j.cell.2005.08.014			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239146	Bronze			2022-12-28	WOS:000232794100015
J	Bonardi, V; Pesaresi, P; Becker, T; Schleiff, E; Wagner, R; Pfannschmidt, T; Jahns, P; Leister, D				Bonardi, V; Pesaresi, P; Becker, T; Schleiff, E; Wagner, R; Pfannschmidt, T; Jahns, P; Leister, D			Photosystem II core phosphorylation and photosynthetic acclimation require two different protein kinases	NATURE			English	Article							HARVESTING COMPLEX-II; ARABIDOPSIS-THALIANA; STATE TRANSITIONS; REDOX SIGNALS; GENE-EXPRESSION; OUTER ENVELOPE; NUCLEAR GENES; REPAIR CYCLE; IN-VIVO; CHLOROPLAST	Illumination changes elicit modifications of thylakoid proteins and reorganization of the photosynthetic machinery. This involves, in the short term, phosphorylation of photosystem II (PSII) and light-harvesting (LHCII) proteins. PSII phosphorylation is thought to be relevant for PSII turnover(1,2), whereas LHCII phosphorylation is associated with the relocation of LHCII and the redistribution of excitation energy (state transitions) between photosystems(3,4). In the long term, imbalances in energy distribution between photosystems are counteracted by adjusting photosystem stoichiometry(5,6). In the green alga Chlamydomonas and the plant Arabidopsis, state transitions require the orthologous protein kinases STT7 and STN7, respectively(7,8). Here we show that in Arabidopsis a second protein kinase, STN8, is required for the quantitative phosphorylation of PSII core proteins. However, PSII activity under high-intensity light is affected only slightly in stn8 mutants, and D1 turnover is indistinguishable from the wild type, implying that reversible protein phosphorylation is not essential for PSII repair. Acclimation to changes in light quality is defective in stn7 but not in stn8 mutants, indicating that short-term and long-term photosynthetic adaptations are coupled. Therefore the phosphorylation of LHCII, or of an unknown substrate of STN7, is also crucial for the control of photosynthetic gene expression.	Univ Munich, Dept Biol 1, Inst Bot, D-80638 Munich, Germany; Max Planck Inst Zuchtungsforsch, Abt Pflanzenzuchtung & Genet, D-50829 Cologne, Germany; Fdn Parco Tecnol Padano, I-26900 Lodi, Italy; Univ Jena, Lehrstuhl Pflanzenphysiol, D-07743 Jena, Germany; Univ Dusseldorf, Inst Biochem Pflanzen, D-40225 Dusseldorf, Germany	University of Munich; Max Planck Society; Friedrich Schiller University of Jena; Heinrich Heine University Dusseldorf	Leister, D (corresponding author), Univ Munich, Dept Biol 1, Inst Bot, Menzinger Str 67, D-80638 Munich, Germany.	leister@lrz.uni-muenchen.de	Becker, Thomas/AAS-9404-2020; Leister, Dario/D-5587-2009; Schleiff, Enrico/C-5105-2017; Pfannschmidt, Thomas/AAH-5916-2021; Pesaresi, Paolo/F-9476-2014	Leister, Dario/0000-0003-1897-8421; Schleiff, Enrico/0000-0002-0518-3489; Pesaresi, Paolo/0000-0002-3236-7005				Allen JF, 2000, PHILOS T R SOC B, V355, P1351, DOI 10.1098/rstb.2000.0697; Allen JF, 2001, TRENDS PLANT SCI, V6, P317, DOI 10.1016/S1360-1385(01)02010-6; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; ARO EM, 1993, PLANT PHYSIOL, V103, P835, DOI 10.1104/pp.103.3.835; Baena-Gonzalez E, 1999, PLANTA, V208, P196, DOI 10.1007/s004250050550; Bailey S, 2002, J BIOL CHEM, V277, P2006, DOI 10.1074/jbc.M105878200; Bellafiore S, 2005, NATURE, V433, P892, DOI 10.1038/nature03286; Biehl A, 2005, GENE, V344, P33, DOI 10.1016/j.gene.2004.09.009; DELOSME R, 1994, BBA-BIOENERGETICS, V1185, P56, DOI 10.1016/0005-2728(94)90193-7; Depege N, 2003, SCIENCE, V299, P1572, DOI 10.1126/science.1081397; Fey V, 2005, J BIOL CHEM, V280, P5318, DOI 10.1074/jbc.M406358200; Fujita Y, 1997, PHOTOSYNTH RES, V53, P83, DOI 10.1023/A:1005870301868; Grasses T, 2002, PLANT PHYSIOL BIOCH, V40, P41, DOI 10.1016/S0981-9428(01)01346-8; Ihnatowicz A, 2004, PLANT J, V37, P839, DOI 10.1111/j.1365-313X.2004.02011.x; Koivuniemi A, 1995, BIOCHEMISTRY-US, V34, P16022, DOI 10.1021/bi00049a016; MELIS A, 1991, BIOCHIM BIOPHYS ACTA, V1058, P87, DOI 10.1016/S0005-2728(05)80225-7; Pesaresi P, 2002, PLANTA, V215, P940, DOI 10.1007/s00425-002-0835-0; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; Pfannschmidt T, 2003, TRENDS PLANT SCI, V8, P33, DOI 10.1016/S1360-1385(02)00005-5; Pfannschmidt T, 2001, J BIOL CHEM, V276, P36125, DOI 10.1074/jbc.M105701200; Pursiheimo S, 2001, PLANT J, V26, P317, DOI 10.1046/j.1365-313X.2001.01033.x; Qbadou S, 2003, J CELL SCI, V116, P837, DOI 10.1242/jcs.00291; Richly E, 2003, EMBO REP, V4, P491, DOI 10.1038/sj.embor.embor828; Rintamaki E, 1997, J BIOL CHEM, V272, P30476, DOI 10.1074/jbc.272.48.30476; Rintamaki E, 1996, J BIOL CHEM, V271, P14870, DOI 10.1074/jbc.271.25.14870; Schleiff E, 2003, J CELL BIOL, V160, P541, DOI 10.1083/jcb.200210060; Snyders S, 1999, J BIOL CHEM, V274, P9137, DOI 10.1074/jbc.274.14.9137; VALLON O, 1991, P NATL ACAD SCI USA, V88, P8262, DOI 10.1073/pnas.88.18.8262; Wollman FA, 2001, EMBO J, V20, P3623, DOI 10.1093/emboj/20.14.3623	30	342	362	1	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 20	2005	437	7062					1179	1182		10.1038/nature04016	http://dx.doi.org/10.1038/nature04016			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16237446	Green Published			2022-12-28	WOS:000232660500049
J	Piccart-Gebhart, MJ; Procter, M; Leyland-Jones, B; Goldhirsch, A; Untch, M; Smith, I; Gianni, L; Baselga, J; Bell, R; Jackisch, C; Cameron, D; Dowsett, M; Barrios, CH; Steger, G; Huang, CS; Andersson, M; Inbar, M; Lichinitser, M; Lang, I; Nitz, U; Iwata, H; Thomssen, C; Lohrisch, C; Suter, TM; Ruschoff, J; Suto, T; Greatorex, V; Ward, C; Straehle, C; McFadden, E; Dolci, MS; Gelber, RD				Piccart-Gebhart, MJ; Procter, M; Leyland-Jones, B; Goldhirsch, A; Untch, M; Smith, I; Gianni, L; Baselga, J; Bell, R; Jackisch, C; Cameron, D; Dowsett, M; Barrios, CH; Steger, G; Huang, CS; Andersson, M; Inbar, M; Lichinitser, M; Lang, I; Nitz, U; Iwata, H; Thomssen, C; Lohrisch, C; Suter, TM; Ruschoff, J; Suto, T; Greatorex, V; Ward, C; Straehle, C; McFadden, E; Dolci, MS; Gelber, RD		HERA Trial Study Team	Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONOCLONAL-ANTIBODY; PHASE-II; 1ST-LINE TREATMENT; RECEPTOR; EFFICACY; THERAPY; SAFETY; PLUS; HER2; PROTOONCOGENE	BACKGROUND: Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy. METHODS: This international, multicenter, randomized trial compared one or two years of trastuzumab given every three weeks with observation in patients with HER2-positive and either node-negative or node-positive breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy. RESULTS: Data were available for 1694 women randomly assigned to two years of treatment with trastuzumab, 1694 women assigned to one year of trastuzumab, and 1693 women assigned to observation. We report here the results only of treatment with trastuzumab for one year or observation. At the first planned interim analysis (median follow-up of one year), 347 events (recurrence of breast cancer, contralateral breast cancer, second nonbreast malignant disease, or death) were observed: 127 events in the trastuzumab group and 220 in the observation group. The unadjusted hazard ratio for an event in the trastuzumab group, as compared with the observation group, was 0.54 (95 percent confidence interval, 0.43 to 0.67; P<0.0001 by the log-rank test, crossing the interim analysis boundary), representing an absolute benefit in terms of disease-free survival at two years of 8.4 percentage points. Overall survival in the two groups was not significantly different (29 deaths with trastuzumab vs. 37 with observation). Severe cardiotoxicity developed in 0.5 percent of the women who were treated with trastuzumab. CONCLUSIONS: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.	Univ Libre Bruxelles, Inst Jules Bordet, Dept Med, B-1000 Brussels, Belgium; Univ Libre Bruxelles, Inst Jules Bordet, Breast Int Grp Secretariat, B-1000 Brussels, Belgium; Univ Libre Bruxelles, Inst Jules Bordet, Breast European Adjuvant Study Team Data Ctr, B-1000 Brussels, Belgium; Frontier Sci Scotland, Kingussie, Scotland; McGill Univ, Dept Oncol, Gerald Bronfman Ctr Clin Res Oncol, Montreal, PQ, Canada; European Inst Oncol, Dept Med, Milan, Italy; Oncol Inst So Switzerland, Bellinzona, Switzerland; Univ Munich, Klin Frauenheilkunde & Geburtshilfe, Munich, Germany; Royal Marsden Hosp, Breast Unit, London SW3 6JJ, England; Inst Canc Res, London SW3 6JB, England; Ist Nazl Studie & Cura Tumori, Milan, Italy; Vall Hebron Univ, Med Oncol Serv, Barcelona, Spain; Geelong Hosp, Andrew Love Canc Ctr, Geelong, Vic, Australia; Univ Marburg, Dept Gynecol, Marburg, Germany; Western Gen Hosp, Dept Oncol, Edinburgh EH4 2XU, Midlothian, Scotland; Royal Marsden Natl Hlth Serv Trust, Dept Acad Biochem, London, England; Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Sch Med, Porto Alegre, RS, Brazil; Med Univ Vienna, Dept Internal Med, Vienna, Austria; Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Taipei, Taiwan; Rigshosp, Univ Hosp, Finsen Ctr, Dept Oncol, DK-2100 Copenhagen, Denmark; Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel; NN Blokhin Canc Res Ctr, Moscow, Russia; Natl Inst Oncol, Dept Oncol, Budapest, Hungary; Univ Dusseldorf, Frauenklin, D-4000 Dusseldorf, Germany; Aichi Canc Ctr, Dept Breast Oncol, Aichi, Japan; Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Gynakol, Hamburg, Germany; British Columbia Canc Agcy, Vancouver Ctr, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada; Swiss Cardiovasc Ctr, Bern, Switzerland; Klinikum Kassel, Inst Pathol, Kassel, Germany; F Hoffmann La Roche, Basel, Switzerland; Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA	Institut Jules Bordet; Universite Libre de Bruxelles; Institut Jules Bordet; Universite Libre de Bruxelles; Institut Jules Bordet; Universite Libre de Bruxelles; McGill University; IRCCS European Institute of Oncology (IEO); Institute of Oncology Research (IOR); University of Munich; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Fondazione IRCCS Istituto Nazionale Tumori Milan; Geelong Hospital; Philipps University Marburg; University of Edinburgh; Royal Marsden NHS Foundation Trust; Pontificia Universidade Catolica Do Rio Grande Do Sul; Medical University of Vienna; National Taiwan University; National Taiwan University Hospital; National Taiwan University; Rigshospitalet; University of Copenhagen; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; N.N. Blokhin Russian Cancer Research Center; National Institute of Oncology Hungary; Heinrich Heine University Dusseldorf; Aichi Cancer Center; University of Hamburg; University Medical Center Hamburg-Eppendorf; British Columbia Cancer Agency; Klinikum Kassel; Roche Holding; Harvard University; Dana-Farber Cancer Institute	Piccart-Gebhart, MJ (corresponding author), Univ Libre Bruxelles, Inst Jules Bordet, Dept Med, Blvd Waterloo 125, B-1000 Brussels, Belgium.	martine.piccart@bordet.be	Cameron, David A/C-7781-2013; Barrios, Carlos H/G-8525-2015; Suto, Tamas/AAC-4127-2020; Thomssen, Christoph/ABC-3102-2021; Kwong, Ava/D-8005-2013	Cameron, David A/0000-0002-2717-7979; Huang, Chiun-Sheng/0000-0002-6557-211X; GIANNI, LUCA/0000-0002-2372-9625; Kwong, Ava/0000-0002-6968-9489				Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; Baselga J, 2005, J CLIN ONCOL, V23, P2162, DOI 10.1200/JCO.2005.01.014; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baselga J, 1998, CANCER RES, V58, P2825; Bell R, 2002, ONCOLOGY-BASEL, V63, P39, DOI 10.1159/000066200; Bendell JC, 2003, CANCER-AM CANCER SOC, V97, P2972, DOI 10.1002/cncr.11436; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Goldhirsch A, 2003, J CLIN ONCOL, V21, P3357, DOI 10.1200/JCO.2003.04.576; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LACROIX H, 1989, ONCOGENE, V4, P145; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Menard S, 1999, BREAST CANCER RES TR, V55, P169; Paik S, 2002, JNCI-J NATL CANCER I, V94, P852, DOI 10.1093/jnci/94.11.852; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Pietras RJ, 1998, ONCOGENE, V17, P2235, DOI 10.1038/sj.onc.1202132; PIETRAS RJ, 1992, ONCOGENE, V7, P1859; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Tan-Chiu E, 2002, ONCOLOGY-BASEL, V63, P57, DOI 10.1159/000066201; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	37	3775	3934	10	311	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 20	2005	353	16					1659	1672		10.1056/NEJMoa052306	http://dx.doi.org/10.1056/NEJMoa052306			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975IC	16236737				2022-12-28	WOS:000232653200006
J	Rouse, H; Dawson, SJ				Rouse, H; Dawson, SJ			Cerebral metastases in breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									St Vincents Hosp, Fitzroy, Vic 3065, Australia	St Vincent's Hospital Melbourne	Rouse, H (corresponding author), St Vincents Hosp, Fitzroy, Vic 3065, Australia.			Dawson, Sarah-Jane/0000-0002-8276-0374					0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	2005	353	16					1724	1724		10.1056/NEJMicm050569	http://dx.doi.org/10.1056/NEJMicm050569			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975IC	16236743				2022-12-28	WOS:000232653200012
J	Shinada, T; Okamoto, S; Kobayashi, T; Ohdomari, I				Shinada, T; Okamoto, S; Kobayashi, T; Ohdomari, I			Enhancing semiconductor device performance using ordered dopant arrays	NATURE			English	Article							SINGLE-ION IMPLANTATION; IMPURITY ATOMS; FLUCTUATION; MOSFETS; NUMBER	As the size of semiconductor devices continues to shrink, the normally random distribution of the individual dopant atoms within the semiconductor becomes a critical factor in determining device performance-homogeneity can no longer be assumed(1-5). Here we report the fabrication of semiconductor devices in which both the number and position of the dopant atoms are precisely controlled. To achieve this, we make use of a recently developed single-ion implantation technique(6-9), which enables us to implant dopant ions one-by-one into a fine semiconductor region until the desired number is reached. Electrical measurements of the resulting transistors reveal that device-to-device fluctuations in the threshold voltage (V-th; the turn-on voltage of the device) are less for those structures with ordered dopant arrays than for those with conventional random doping. We also find that the devices with ordered dopant arrays exhibit a shift in V-th, relative to the undoped semiconductor, that is twice that for a random dopant distribution (-0.4 V versus -0.2 V); we attribute this to the uniformity of electrostatic potential in the conducting channel region due to the ordered distribution of dopant atoms. Our results therefore serve to highlight the improvements in device performance that can be achieved through atomic-scale control of the doping process. Furthermore, ordered dopant arrays of this type may enhance the prospects for realizing silicon-based solid-state quantum computers(10).	Waseda Univ, Consolidated Res Inst Adv Sci & Med Care, Shinjuku Ku, Tokyo 1620041, Japan; Waseda Univ, Sch Sci & Engn, Shinjuku Ku, Tokyo 1620041, Japan	Waseda University; Waseda University	Shinada, T (corresponding author), Waseda Univ, Consolidated Res Inst Adv Sci & Med Care, Shinjuku Ku, 513 Wasedatsurumaki Cho, Tokyo 1620041, Japan.	shina@waseda.jp						Ebert P, 2004, J VAC SCI TECHNOL B, V22, P2018, DOI 10.1116/1.1771680; Kane BE, 1998, NATURE, V393, P133, DOI 10.1038/30156; KEYES RW, 1975, APPL PHYS, V8, P251, DOI 10.1007/BF00896619; Matsukawa T, 1997, APPL SURF SCI, V117, P677, DOI 10.1016/S0169-4332(97)80163-8; MIZUNO T, 1994, IEEE T ELECTRON DEV, V41, P2216, DOI 10.1109/16.333844; Ohdomari I., 1994, P 1 INT S CONTR SEM, P223; Sano N, 2001, APPL PHYS LETT, V79, P2267, DOI 10.1063/1.1406980; Shinada T, 2000, JPN J APPL PHYS 2, V39, pL265, DOI 10.1143/JJAP.39.L265; Shinada T, 2002, JPN J APPL PHYS 2, V41, pL287, DOI 10.1143/JJAP.41.L287; SZE S. M., 2001, PHYS SEMICONDUCTOR D; Wong HSP, 1998, MICROELECTRON RELIAB, V38, P1447, DOI 10.1016/S0026-2714(98)00053-5	11	275	278	2	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 20	2005	437	7062					1128	1131		10.1038/nature04086	http://dx.doi.org/10.1038/nature04086			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16237438				2022-12-28	WOS:000232660500038
J	Schon, MP				Schon, MP			Advances in psoriasis treatment	LANCET			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; DOUBLE-BLIND; THERAPIES		Univ Wurzburg, Rudolf Virchow Ctr, DFG Res Ctr Expt Biomed, D-97078 Wurzburg, Germany; Univ Wurzburg, Dept Dermatol, D-97078 Wurzburg, Germany	German Research Foundation (DFG); University of Wurzburg; University of Wurzburg	Schon, MP (corresponding author), Univ Wurzburg, Rudolf Virchow Ctr, DFG Res Ctr Expt Biomed, D-97078 Wurzburg, Germany.	michael.schoen@virchow.uni-wuerzburg.de		Schon, Michael/0000-0002-0698-4130				Antoni C, 2005, ANN RHEUM DIS, V64, P1150, DOI 10.1136/ard.2004.032268; Feldman SR, 2005, BRIT J DERMATOL, V152, P954, DOI 10.1111/j.1365-2133.2005.06510.x; Gottlieb AB, 2004, J AM ACAD DERMATOL, V51, P534, DOI 10.1016/j.jaad.2004.02.021; Gottlieb AB, 2005, NAT REV DRUG DISCOV, V4, P19, DOI 10.1038/nrd1607; Hamilton CD, 2004, CURR OPIN RHEUMATOL, V16, P393, DOI 10.1097/01.bor.0000127594.92432.7c; Krueger G, 2001, ARCH DERMATOL, V137, P280; Kupper TS, 2003, NEW ENGL J MED, V349, P1987, DOI 10.1056/NEJMp038164; Lebwohl M, 2003, LANCET, V361, P1197, DOI 10.1016/S0140-6736(03)12954-6; MUELLER W, 1979, NEW ENGL J MED, V301, P555; Oh CJ, 2000, J AM ACAD DERMATOL, V42, P829, DOI 10.1067/mjd.2000.105948; Rapp SR, 1999, J AM ACAD DERMATOL, V41, P401, DOI 10.1016/S0190-9622(99)70112-X; Reich K, 2005, LANCET, V366, P1367, DOI 10.1016/S0140-6736(05)67566-6; Schon MP, 2003, J INVEST DERMATOL, V121, P951, DOI 10.1046/j.1523-1747.2003.12563.x; Schon MP, 1999, J INVEST DERMATOL, V112, P405, DOI 10.1046/j.1523-1747.1999.00538.x; Schon MP, 2005, NEW ENGL J MED, V352, P1899, DOI 10.1056/NEJMra041320; Schon MP, 2001, NAT IMMUNOL, V2, P91, DOI 10.1038/84293; Sterry W, 2004, BRIT J DERMATOL, V151, P3, DOI 10.1111/j.1365-2133.2004.06070.x; Winterfield Laura S, 2004, Dermatol Ther, V17, P409, DOI 10.1111/j.1396-0296.2004.04044.x	18	21	22	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 15	2005	366	9494					1333	1335		10.1016/S0140-6736(05)67542-3	http://dx.doi.org/10.1016/S0140-6736(05)67542-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	973ZW	16226595				2022-12-28	WOS:000232562100004
J	Johansson, P; Hall, L; Sikstrom, S; Olsson, A				Johansson, P; Hall, L; Sikstrom, S; Olsson, A			Failure to detect mismatches between intention and outcome in a simple decision task	SCIENCE			English	Article							MOTOR CONTROL; CORTEX	A fundamental assumption of theories of decision-making is that we detect mismatches between intention and outcome, adjust our behavior in the face of error, and adapt to changing circumstances. Is this always the case? We investigated the relation between intention, choice, and introspection. Participants made choices between presented face pairs on the basis of attractiveness, while we covertly manipulated the relationship between choice and outcome that they experienced. Participants failed to notice conspicuous mismatches between their intended choice and the outcome they were presented with, while nevertheless offering introspectively derived reasons for why they chose the way they did. We call this effect choice blindness.	Lund Univ, Kungshuset Lundagard, S-22222 Lund, Sweden; NYU, Dept Psychol, New York, NY 10003 USA	Lund University; New York University	Hall, L (corresponding author), Lund Univ, Kungshuset Lundagard, S-22222 Lund, Sweden.	lars.hall@lucs.lu.se		Sikstrom, Sverker/0000-0003-2644-9626				Dennett, 1987, INTENTIONAL STANCE; Grush R, 2004, BEHAV BRAIN SCI, V27, P377, DOI 10.1017/S0140525X04000093; Haggard P, 2003, CONSCIOUS COGN, V12, P695, DOI 10.1016/S1053-8100(03)00052-7; Hester R, 2004, CEREB CORTEX, V14, P986, DOI 10.1093/cercor/bhh059; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Lau HC, 2004, SCIENCE, V303, P1208, DOI 10.1126/science.1090973; NISBETT RE, 1977, PSYCHOL REV, V84, P231, DOI 10.1037/0033-295X.84.3.231; Rensink RA, 2002, ANNU REV PSYCHOL, V53, P245, DOI 10.1146/annurev.psych.53.100901.135125; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Ridderinkhof KR, 2004, BRAIN COGNITION, V56, P129, DOI 10.1016/j.bandc.2004.09.016; Simons DJ, 2005, TRENDS COGN SCI, V9, P16, DOI 10.1016/j.tics.2004.11.006; Ullsperger M, 2004, CORTEX, V40, P593, DOI 10.1016/S0010-9452(08)70155-2; Walton ME, 2004, NAT NEUROSCI, V7, P1259, DOI 10.1038/nn1339; Wegner D.M., 2003, ILLUSION CONSCIOUS W; Wolpert DM, 2003, PHILOS T R SOC B, V358, P593, DOI 10.1098/rstb.2002.1238	15	299	303	3	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	2005	310	5745					116	119		10.1126/science.1111709	http://dx.doi.org/10.1126/science.1111709			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210542	Green Submitted			2022-12-28	WOS:000232477000051
J	Rowland, D				Rowland, D			Medicaid - Implications for the health safety net	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Henry J Kaiser Family Fdn, Menlo Pk, CA 94025 USA; Kaiser Commiss Medicaid & Uninsured, Washington, DC USA		Rowland, D (corresponding author), Henry J Kaiser Family Fdn, Menlo Pk, CA 94025 USA.							Bruen B., 2003, SHIFTING COST DUAL E; *C BUDG OFF, 2005, FACT SHEET CBOS MARC; *KAIS COMM MED UN, 2005, MED PROGR GLANC; Wright BJ, 2005, HEALTH AFFAIR, V24, P1106, DOI 10.1377/hlthaff.24.4.1106	4	11	11	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 6	2005	353	14					1439	1441		10.1056/NEJMp058063	http://dx.doi.org/10.1056/NEJMp058063			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970LZ	16207845				2022-12-28	WOS:000232313000003
J	Qaseem, A; Aronson, M; Fitterman, N; Snow, V; Weiss, KB; Owens, DK				Qaseem, A; Aronson, M; Fitterman, N; Snow, V; Weiss, KB; Owens, DK		Amer Coll Phys; Clin Efficacy Assessment Subcommi	Screening or hereditary hemochromatosis: A clinical practice guideline from the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY-CARE PATIENTS; SERUM FERRITIN LEVEL; LONG-TERM SURVIVAL; TRANSFERRIN SATURATION; NONINVASIVE PREDICTION; POPULATION; PREVALENCE; EXPRESSION; MUTATION; FIBROSIS	Hereditary hemochromatosis is a genetic disorder of iron metabolism. Diagnosis of hereditary hemochromatosis is usually based on a combination of various genetic or phenotypic criteria. Decisions regarding screening are difficult because of the variable penetrance of mutations of the HFE gene and the absence of any definitive trials addressing the benefits and risks of therapeutic phlebotomy in asymptomatic patients or those with only laboratory abnormalities. The purpose of this guideline is to increase physician awareness of hereditary hemochromatosis, particularly the variable penetrance of genetic mutations; aid in case finding; and explain the role of genetic testing. This guideline provides recommendations based on a review of evidence in the accompanying background paper by Schmitt and colleagues. The target audience for this guideline is internists and other primary care physicians. The target patient population is all persons who have a probability or susceptibility of developing hereditary hemochromatosis, including the relatives of individuals who already have the disease.	Amer Coll Physicians, Philadelphia, PA 19106 USA	American College of Physicians	Qaseem, A (corresponding author), Amer Coll Physicians, 190 N Independence Mall, Philadelphia, PA 19106 USA.	aqaseem@acponline.org						Adams PC, 2005, NEW ENGL J MED, V352, P1769, DOI 10.1056/NEJMoa041534; Andersen RV, 2004, BLOOD, V103, P2914, DOI 10.1182/blood-2003-10-3564; BAER DM, 1995, AM J MED, V98, P464, DOI 10.1016/S0002-9343(99)80346-5; Beaton M, 2002, HEPATOLOGY, V36, P673, DOI 10.1053/jhep.2002.35343; Beutler E, 2002, LANCET, V359, P211, DOI 10.1016/S0140-6736(02)07447-0; Gochee PA, 2002, GASTROENTEROLOGY, V122, P646, DOI 10.1016/S0016-5085(02)80116-0; Guyader D, 1998, GASTROENTEROLOGY, V115, P929, DOI 10.1016/S0016-5085(98)70265-3; Looker AC, 1998, ANN INTERN MED, V129, P940, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00004; Mainous AG, 2004, ANN FAM MED, V2, P133, DOI 10.1370/afm.25; McLaren CE, 2003, AM J MED SCI, V325, P53, DOI 10.1097/00000441-200302000-00001; Milman N, 2001, ANN HEMATOL, V80, P737, DOI 10.1007/s002770100371; Morrison ED, 2003, ANN INTERN MED, V138, P627, DOI 10.7326/0003-4819-138-8-200304150-00008; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; Niederau C, 1998, ANN INTERN MED, V128, P337, DOI 10.7326/0003-4819-128-5-199803010-00001; Olynyk JK, 1999, NEW ENGL J MED, V341, P718, DOI 10.1056/NEJM199909023411002; Olynyk JK, 2004, MAYO CLIN PROC, V79, P309, DOI 10.4065/79.3.309; Phatak PD, 1998, ANN INTERN MED, V129, P954, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00006; Powell LW, 2000, J HEPATOL, V32, P48, DOI 10.1016/S0168-8278(00)80415-8; Schmitt B, 2005, ANN INTERN MED, V143, P522, DOI 10.7326/0003-4819-143-7-200510040-00011; Shaheen NJ, 2003, AM J GASTROENTEROL, V98, P1175, DOI 10.1016/S0002-9270(03)00109-6; Yamashita C, 2003, CLIN GASTROENTEROL H, V1, P388, DOI 10.1053/S1542-3565(03)00187-3	21	66	70	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 4	2005	143	7					517	521		10.7326/0003-4819-143-7-200510040-00010	http://dx.doi.org/10.7326/0003-4819-143-7-200510040-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970FM	16204164				2022-12-28	WOS:000232290600006
J	Bright, RA; Medina, MJ; Xu, XY; Perez-Oronoz, G; Wallis, TR; Davis, XHM; Povinelli, L; Cox, NJ; Klimov, AI				Bright, RA; Medina, MJ; Xu, XY; Perez-Oronoz, G; Wallis, TR; Davis, XHM; Povinelli, L; Cox, NJ; Klimov, AI			Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern	LANCET			English	Article							H5N1 INFLUENZA; NURSING-HOMES; AMANTADINE; RIMANTADINE; EMERGENCE; SURVEILLANCE; TRANSMISSION; PROPHYLAXIS; GENOME	Background Adamantanes have been used to treat influenza A virus infections for many years. Studies have shown a low incidence of resistance to these drugs among circulating influenza viruses; however, their use is rising worldwide and drug resistance has been reported among influenza A (H5N1) viruses isolated from poultry and human beings in Asia. We sought to assess adamantane resistance among influenza A viruses isolated during the past decade from countries participating in WHO's global influenza surveillance network. Methods We analysed data for influenza field isolates that were obtained worldwide and submitted to the WHO Collaborating Center for Influenza at the US Centers for Disease Control and Prevention between Oct 1, 1994, and Mar 31, 2005. We used pyrosequencing, confirmatory sequence analysis, and phenotypic testing to detect drug resistance among circulating influenza A H3N2 (n=6524), H1N1 (n=589), and H1N2 (n=83) viruses. Findings More than 7000 influenza A field isolates were screened for specific aminoacid substitutions in the M2 gene known to confer drug resistance. During the decade of surveillance a significant increase in drug resistance was noted, from 0.4% in 1994-1995 to 12.3% in 2003-2004. This increase in the proportion of resistant viruses was weighted heavily by those obtained from Asia with 61% of resistant viruses isolated since 2003 being from people in Asia. Interpretation Our data raise concerns about the appropriate use of adamantanes and draw attention to the importance of tracking the emergence and spread of drug-resistant influenza A viruses.	Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Influenza Branch, Atlanta, GA 30333 USA; Univ Wisconsin, Wisconsin State Lab Hyg, Madison, WI 53706 USA	Centers for Disease Control & Prevention - USA; University of Wisconsin System; University of Wisconsin Madison	Bright, RA (corresponding author), Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Influenza Branch, Atlanta, GA 30333 USA.	rbright@cdc.gov						BEAN WJ, 1989, J INFECT DIS, V159, P1050, DOI 10.1093/infdis/159.6.1050; BELSHE RB, 1989, J INFECT DIS, V159, P430, DOI 10.1093/infdis/159.3.430; BELSHE RB, 1988, J VIROL, V62, P1508, DOI 10.1128/JVI.62.5.1508-1512.1988; Boivin G, 2002, CLIN INFECT DIS, V34, pE23, DOI 10.1086/338870; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P97; *CHIN NONPR MED AS, 2002, ACT INGR OTC PROD SE; COX NJ, 1994, EUR J EPIDEMIOL, V10, P467, DOI 10.1007/BF01719678; DEGELAU J, 1992, ARCH INTERN MED, V152, P390, DOI 10.1001/archinte.152.2.390; DOLIN R, 1982, NEW ENGL J MED, V307, P580, DOI 10.1056/NEJM198209023071002; Englund JA, 1998, CLIN INFECT DIS, V26, P1418, DOI 10.1086/516358; Guan Y, 2004, P NATL ACAD SCI USA, V101, P8156, DOI 10.1073/pnas.0402443101; HAY AJ, 1986, J ANTIMICROB CHEMOTH, V18, P19, DOI 10.1093/jac/18.Supplement_B.19; HAYDEN FG, 1991, ANTIMICROB AGENTS CH, V35, P1741, DOI 10.1128/AAC.35.9.1741; HAYDEN FG, 1992, CURR TOP MICROBIOL, V176, P119; HAYDEN FG, 1989, NEW ENGL J MED, V321, P1696, DOI 10.1056/NEJM198912213212502; Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419; HOUCK P, 1995, ARCH INTERN MED, V155, P533, DOI 10.1001/archinte.155.5.533; KLIMOV AI, 1995, J INFECT DIS, V172, P1352, DOI 10.1093/infdis/172.5.1352; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; MAST EE, 1991, AM J EPIDEMIOL, V134, P988, DOI 10.1093/oxfordjournals.aje.a116184; Masuda H, 2000, MICROBIOL IMMUNOL, V44, P833, DOI 10.1111/j.1348-0421.2000.tb02571.x; *MIN HLTH RUSS FED, 1999, N287 MIN HLTH RUSS F; OXFORD JS, 1984, VIRAL CHEMOTHERAPY, V1, P169; Peiris JSM, 2004, LANCET, V363, P617, DOI 10.1016/S0140-6736(04)15595-5; Puthavathana P, 2005, J GEN VIROL, V86, P423, DOI 10.1099/vir.0.80368-0; REUMAN PD, 1989, ANTIVIR RES, V11, P27, DOI 10.1016/0166-3542(89)90018-1; Shiraishi K, 2003, J INFECT DIS, V188, P57, DOI 10.1086/375799; SWEET C, 1991, J INFECT DIS, V164, P969, DOI 10.1093/infdis/164.5.969; Tominack R L, 1987, Infect Dis Clin North Am, V1, P459; VALETTE M, 1993, ANTIMICROB AGENTS CH, V37, P2239, DOI 10.1128/AAC.37.10.2239; Viseshakul N, 2004, VIROLOGY, V328, P169, DOI 10.1016/j.virol.2004.06.045; WANG C, 1993, J VIROL, V67, P5585, DOI 10.1128/JVI.67.9.5585-5594.1993; Xu XY, 2002, J INFECT DIS, V186, P1490, DOI 10.1086/344738; YOUNKIN SW, 1983, ANTIMICROB AGENTS CH, V23, P577, DOI 10.1128/AAC.23.4.577; Ziegler T, 1999, J INFECT DIS, V180, P935, DOI 10.1086/314994; 2004, MMWR MORB MORTAL WKL, V53, P100	36	557	641	2	53	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	2005	366	9492					1175	1181		10.1016/S0140-6736(05)67338-2	http://dx.doi.org/10.1016/S0140-6736(05)67338-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970LK	16198766				2022-12-28	WOS:000232311300027
J	Zurovac, D; Ndhlovu, M; Rowe, AK; Hamer, DH; Thea, DM; Snow, RW				Zurovac, D; Ndhlovu, M; Rowe, AK; Hamer, DH; Thea, DM; Snow, RW			Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							PLASMODIUM-FALCIPARUM MALARIA; OUTPATIENT HEALTH FACILITIES; SULFADOXINE-PYRIMETHAMINE; CHILDREN; AFRICA; POLICY; CHLOROQUINE; AMODIAQUINE; ARTESUNATE; PREDICTORS	Objective To evaluate treatment practices for uncomplicated malaria after the policy change from chloroquine to sulfadoxine-pyrimediamine and to artemether-lumefantrine in Zambia. Design Cross sectional survey. Setting Outpatient departments of all government and mission facilities in four districts in Zambia. Participants 944 children with uncomplicated malaria seen by 103 health workers at 94 health facilities. Main outcome measures Antimalarial prescriptions in accordance with national guidelines and influence of factors on health workers' decision to prescribe artemether-lumefantrine. Results Artemether-lumefantrine, sulfadoxine-pyrimethamine, and chloroquine were available, respectively, at 48 (51%), 94 (100%), and 71 (76%) of the 94 facilities. Of 944 children with uncomplicated malaria, only one child (0.1%) received chloroquine. Among children weighing less than 10 kg, sulfadoxine-pyrimethamine was commonly prescribed in accordance with guidelines (439/550, 79.8%). Among the children weighing 10 kg or more, sulfadoxine-pyrimethamine was commonly prescribed (266/394,68%), whereas recommended artemether-lumefantrine was prescribed for only 42/394 (11%) children. Among children weighing 10 kg or more seen at facilities where artemether-lumefantrine was available, the same pattern was observed: artemether-lumefantrine was prescribed for only 42/192 (22%) children and sulfadoxine-pyrimethamine remained the drug of choice (103/192, 54%). Programmatic activities such as in-service training and provision of job aids did not seem to influence the prescribing of artemether-lumefantrine. Conclusion Although the use of chloroquine for uncomplicated malaria was succesfully discontinued in Zambia, the change of drug policy towards artemether-lumefantrine does not necessarily translate into adequate use of this drug at the point of care.	KEMRI Wellcome Trust Collaborat Programme, Ctr Geog Med, Malaria Publ Hlth & Epidemiol Grp, Nairobi, Kenya; Chainama Hills Coll Hosp Hlth Sci, Lusaka, Zambia; Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA 30341 USA; Boston Univ, Sch Publ Hlth, Ctr Int Hlth & Dev, Boston, MA 02118 USA	Centers for Disease Control & Prevention - USA; Boston University	Zurovac, D (corresponding author), KEMRI Wellcome Trust Collaborat Programme, Ctr Geog Med, Malaria Publ Hlth & Epidemiol Grp, POB 43640,00100 GPO, Nairobi, Kenya.	dzurovac@wtnairobi.mimcom.net	Snow, Robert William/AFR-1436-2022	Snow, Robert William/0000-0003-3725-6088; Hamer, Davidson/0000-0002-4700-1495; Thea, Donald/0000-0002-6933-1030	Wellcome Trust [058992] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; Bijl HM, 2000, TROP MED INT HEALTH, V5, P692, DOI 10.1046/j.1365-3156.2000.00629.x; Central Board of Health (Zambia), 2003, GUID DIAGN TREATM MA; CHANDA P, 2004, AM J TROP MED HYG S, V71; Falade C, 2005, T ROY SOC TROP MED H, V99, P459, DOI 10.1016/j.trstmh.2004.09.013; Hamer DH, 2003, T ROY SOC TROP MED H, V97, P422, DOI 10.1016/S0035-9203(03)90076-9; Horton NJ, 1999, AM STAT, V53, P160, DOI 10.2307/2685737; Korenromp EL, 2003, LANCET INFECT DIS, V3, P349, DOI 10.1016/S1473-3099(03)00657-1; Mutabingwa TK, 2005, LANCET, V365, P1474, DOI 10.1016/S0140-6736(05)66417-3; Myint HY, 2004, T ROY SOC TROP MED H, V98, P73, DOI 10.1016/S0035-9203(03)00014-2; NAIMOLI J, 2001, THESIS HARVARD SCH P; *NAT MAL CONTR CTR, 2000, NAT MAL SIT AN; Piola P, 2005, LANCET, V365, P1467, DOI 10.1016/S0140-6736(05)66416-1; Rapuoda B, 2003, TROP MED INT HEALTH, V8, P860, DOI 10.1046/j.1360-2276.2003.01114.x; Rowe AK, 2000, AM J EPIDEMIOL, V151, P1029, DOI 10.1093/oxfordjournals.aje.a010131; Rowe AK, 2003, INT J EPIDEMIOL, V32, P296, DOI 10.1093/ije/dyg063; Rowe AK, 2002, TROP DOCT, V32, P166, DOI 10.1177/004947550203200317; Shretta R, 2000, TROP MED INT HEALTH, V5, P755, DOI 10.1046/j.1365-3156.2000.00643.x; Snow RW, 2001, TRENDS PARASITOL, V17, P593, DOI 10.1016/S1471-4922(01)02031-1; Talisuna AO, 2004, CLIN MICROBIOL REV, V17, P235, DOI 10.1128/CMR.17.1.235-254.2004; Williams HA, 2004, HEALTH POLICY PLANN, V19, P356, DOI 10.1093/heapol/czh051; World Health Organization, 2001, WHOCDSCSRDRS20019; Zurovac D, 2004, INT J EPIDEMIOL, V33, P1080, DOI 10.1093/ije/dyh253	23	58	58	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 1	2005	331	7519					734	737		10.1136/bmj.331.7519.734	http://dx.doi.org/10.1136/bmj.331.7519.734			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971XB	16195289	Green Published, Bronze			2022-12-28	WOS:000232417100019
J	Fox, RC				Fox, RC			Becoming a physician - Cutural competence and the culture of medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EDUCATION		Univ Penn, Dept Sociol, Philadelphia, PA 19104 USA	University of Pennsylvania	Fox, RC (corresponding author), Univ Penn, Dept Sociol, Philadelphia, PA 19104 USA.							CHRISTAKIS NA, 1995, JAMA-J AM MED ASSOC, V274, P706, DOI 10.1001/jama.274.9.706; FADIMAN A, 1997, SPIRIT CATCHES YOU Y; Fox RC, 1999, DAEDALUS-US, V128, P1; Nussbaum Martha, 1996, LOVE COUNTRY DEBATIN, P3	4	67	69	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2005	353	13					1316	1319		10.1056/NEJMp058066	http://dx.doi.org/10.1056/NEJMp058066			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	968FB	16192475				2022-12-28	WOS:000232146200002
J	Vallance, P				Vallance, P			Developing an open relationship with the drug industry	LANCET			English	Editorial Material									UCL, Div Med, London WC1E 6JJ, England	University of London; University College London	Vallance, P (corresponding author), UCL, Div Med, London WC1E 6JJ, England.	patrick.vallance@ucl.ac.uk						ALTMAN RD, 2005, RECOMMENDATIONS MED; *AM COLL RHEUM, 2004, COX2 AG HAV DRAM CHA; *AM MED ASS, 2005, MOD 4 AM MED ASS ETH; [Anonymous], 1988, LANCET, V2, P349; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Elliott C, 2004, HASTINGS CENT REP, V34, P18, DOI 10.2307/3527586; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2; International Committee of Medical Journal Editors, 2004, UN REQ MAN SUBM BIOM; KWOH CK, 2004, NEW TREATMENTS ARE R; MEIKLE J, 2005, GUARDIAN        0314, P8; *NAT I CLIN EXC, 2000, APPR BET INT GLAT TR; Schneeweiss S, 2005, J CLIN EPIDEMIOL, V58, P98, DOI 10.1016/j.jclinepi.2004.06.002; Tive L, 2000, RHEUMATOLOGY, V39, P21, DOI 10.1093/rheumatology/39.suppl_2.21; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; 2000, DRUG THER B, V38, P81; 2005, GUARDIAN        0107, P19; 2004, SCRIP REP       0224; 2005, DRUG THER B, V43, P1	19	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 24	2005	366	9491					1062	1064		10.1016/S0140-6736(05)66835-3	http://dx.doi.org/10.1016/S0140-6736(05)66835-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	967TL	16182883				2022-12-28	WOS:000232114000009
J	Erturk-Hasdemir, D; Silverman, N				Erturk-Hasdemir, D; Silverman, N			Eater: A big bite into phagocytosis	CELL			English	Editorial Material							PEPTIDOGLYCAN RECOGNITION PROTEIN; DROSOPHILA; IDENTIFICATION; BACTERIA; RECEPTOR; GAMBIAE; CELLS	The phagocytosis of invading microorganisms by specialized blood cells is a crucial element of innate immunity in both mammals and insects. In this issue of Cell, Kocks et al. (2005) demonstrate that Eater, a scavenger receptor, plays an important role in the recognition and phagocytosis of bacteria in the fruit fly Drosophila.	Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Erturk-Hasdemir, D (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis, Worcester, MA 01605 USA.			Silverman, Neal/0000-0002-4259-456X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060025] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Kocks C, 2005, CELL, V123, P335, DOI 10.1016/j.cell.2005.08.034; Levashina EA, 2001, CELL, V104, P709, DOI 10.1016/S0092-8674(01)00267-7; Meister M, 2004, CURR OPIN IMMUNOL, V16, P10, DOI 10.1016/j.coi.2003.11.002; Moita LF, 2005, IMMUNITY, V23, P65, DOI 10.1016/j.immuni.2005.05.006; Pearson AM, 2003, MICROBES INFECT, V5, P815, DOI 10.1016/S1286-4579(03)00157-6; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Ramet M, 2001, IMMUNITY, V15, P1027, DOI 10.1016/S1074-7613(01)00249-7; Watson FL, 2005, SCIENCE, V309, P1874, DOI 10.1126/science.1116887	10	12	12	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 21	2005	123	2					190	192		10.1016/j.cell.2005.10.005	http://dx.doi.org/10.1016/j.cell.2005.10.005			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239137	Bronze			2022-12-28	WOS:000232794100006
J	Yokoyama, A; Somervaille, TCP; Smith, KS; Rozenblatt-Rosen, O; Meyerson, M; Cleary, ML				Yokoyama, A; Somervaille, TCP; Smith, KS; Rozenblatt-Rosen, O; Meyerson, M; Cleary, ML			The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis	CELL			English	Article							HISTONE METHYLTRANSFERASE COMPLEX; MULTIPLE ENDOCRINE NEOPLASIA; LINEAGE-LEUKEMIA GENE; MYELOID PROGENITORS; MUTANT MICE; HEMATOLOGICAL MALIGNANCIES; HEMATOPOIETIC PROGENITORS; DROSOPHILA-TRITHORAX; ONCOPROTEIN MLL; FACTOR JUND	The Mixed-Lineage Leukemia (MLL) protein is a histone methyltransferase that is mutated in clinically and biologically distinctive subsets of acute leukemia. MLL normally associates with a cohort of highly conserved cofactors to form a macromolecular complex that includes menin, a product of the MEN1 tumor suppressor gene, which is mutated in heritable and sporadic endocrine tumors. We demonstrate here that oncogenic MLL fusion proteins retain an ability to stably associate with menin through a high-affinity, amino-terminal, conserved binding motif and that this interaction is required for the initiation of MLL-mediated leukemogenesis. Furthermore, menin is essential for maintenance of MILL-associated but not other oncogene induced myeloid transformation. Acute genetic ablation of menin reverses aberrant Hox gene expression mediated by MLL-menin promoter-associated complexes, and specifically abrogates the differentiation arrest and oncogenic properties of MLL-transformed leukemic blasts. These results demonstrate that a human oncoprotein is critically dependent on direct physical interaction with a tumor suppressor protein for its oncogenic activity, validate a potential target for molecular therapy, and suggest central roles for menin in altered epigenetic functions underlying the pathogenesis of hematopoietic cancers.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Dept Pathol, Boston, MA 02115 USA	Stanford University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Cleary, ML (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.	mcleary@stanford.edu	Rozenblatt-Rosen, Orit/HDN-4182-2022; Meyerson, Matthew L/E-7123-2012	Yokoyama, Akihiko/0000-0002-5639-8068; Somervaille, Tim/0000-0002-9188-4379	NATIONAL CANCER INSTITUTE [R01CA055029] Funding Source: NIH RePORTER; NCI NIH HHS [CA55029, CA116601] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal SK, 2003, P NATL ACAD SCI USA, V100, P10770, DOI 10.1073/pnas.1834524100; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Bertolino P, 2003, MOL ENDOCRINOL, V17, P1880, DOI 10.1210/me.2003-0154; Bertolino P, 2003, MECH DEVELOP, V120, P549, DOI 10.1016/S0925-4773(03)00039-X; Caldas C, 1998, ONCOGENE, V16, P3233, DOI 10.1038/sj.onc.1201873; Chandrasekharappa SC, 2003, J INTERN MED, V253, P606, DOI 10.1046/j.1365-2796.2003.01165.x; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; Daser A, 2004, GENE DEV, V18, P965, DOI 10.1101/gad.1195504; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; Ernst P, 2004, CURR BIOL, V14, P2063, DOI 10.1016/j.cub.2004.11.012; Ernst P, 2004, DEV CELL, V6, P437, DOI 10.1016/S1534-5807(04)00061-9; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Huntsman DG, 1999, ONCOGENE, V18, P7975, DOI 10.1038/sj.onc.1203291; Kim H, 2003, CANCER RES, V63, P6135; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kumar AR, 2004, BLOOD, V103, P1823, DOI 10.1182/blood-2003-07-2582; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Mitterbauer-Hohendanner G, 2004, EUR J CLIN INVEST, V34, P12, DOI 10.1111/j.0960-135X.2004.01366.x; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nie ZQ, 2003, MOL CELL BIOL, V23, P2942, DOI 10.1128/MCB.23.8.2942-2952.2003; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Rozovskaia T, 2001, ONCOGENE, V20, P874, DOI 10.1038/sj.onc.1204174; Schnabel CA, 2000, ONCOGENE, V19, P608, DOI 10.1038/sj.onc.1203371; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Smith KS, 1999, MOL CELL BIOL, V19, P4443; So CW, 2004, BLOOD, V103, P3192, DOI 10.1182/blood-2003-10-3722; So CW, 2003, CANCER CELL, V3, P161, DOI 10.1016/S1535-6108(03)00019-9; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Tanabe S, 1996, GENE CHROMOSOME CANC, V15, P206, DOI 10.1002/(SICI)1098-2264(199604)15:4<206::AID-GCC2>3.0.CO;2-5; Vargas DA, 2003, ADV CANCER RES, V89, P1, DOI 10.1016/S0065-230X(03)01001-7; Verlinden SFF, 1998, EXP HEMATOL, V26, P627; Wang J, 2005, EMBO J, V24, P368, DOI 10.1038/sj.emboj.7600521; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wright DE, 2001, BLOOD, V97, P2278, DOI 10.1182/blood.V97.8.2278; Yagi H, 1998, BLOOD, V92, P108, DOI 10.1182/blood.V92.1.108.413k11_108_117; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Yokoyama A, 2002, BLOOD, V100, P3710, DOI 10.1182/blood-2002-04-1015; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004	51	394	417	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	2005	123	2					207	218		10.1016/j.cell.2005.09.025	http://dx.doi.org/10.1016/j.cell.2005.09.025			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239140	Bronze			2022-12-28	WOS:000232794100009
J	Burstein, HJ				Burstein, HJ			The distinctive nature of HER2-positive breast cancers	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Burstein, HJ (corresponding author), Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.							Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	4	344	370	1	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	2005	353	16					1652	1654		10.1056/NEJMp058197	http://dx.doi.org/10.1056/NEJMp058197			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975IC	16236735				2022-12-28	WOS:000232653200004
J	Romond, EH; Perez, EA; Bryant, J; Suman, VJ; Geyer, CE; Davidson, NE; Tan-Chiu, E; Martino, S; Paik, S; Kaufman, PA; Swain, SM; Pisansky, TM; Fehrenbacher, L; Kutteh, LA; Vogel, VG; Visscher, DW; Yothers, G; Jenkins, RB; Brown, AM; Dakhil, SR; Mamounas, EP; Lingle, WL; Klein, PM; Ingle, JN; Wolmark, N				Romond, EH; Perez, EA; Bryant, J; Suman, VJ; Geyer, CE; Davidson, NE; Tan-Chiu, E; Martino, S; Paik, S; Kaufman, PA; Swain, SM; Pisansky, TM; Fehrenbacher, L; Kutteh, LA; Vogel, VG; Visscher, DW; Yothers, G; Jenkins, RB; Brown, AM; Dakhil, SR; Mamounas, EP; Lingle, WL; Klein, PM; Ingle, JN; Wolmark, N			Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METASTASES; TRIAL; WOMEN; HER2	BACKGROUND: We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer. METHODS: The National Surgical Adjuvant Breast and Bowel Project trial B-31 compared doxorubicin and cyclophosphamide followed by paclitaxel every 3 weeks (group 1) with the same regimen plus 52 weeks of trastuzumab beginning with the first dose of paclitaxel (group 2). The North Central Cancer Treatment Group trial N9831 compared three regimens: doxorubicin and cyclophosphamide followed by weekly paclitaxel (group A), the same regimen followed by 52 weeks of trastuzumab after paclitaxel (group B), and the same regimen plus 52 weeks of trastuzumab initiated concomitantly with paclitaxel (group C). The studies were amended to include a joint analysis comparing groups 1 and A (the control group) with groups 2 and C (the trastuzumab group). Group B was excluded because trastuzumab was not given concurrently with paclitaxel. RESULTS: By March 15, 2005, 394 events (recurrent, second primary cancer, or death before recurrence) had been reported, triggering the first scheduled interim analysis. Of these, 133 were in the trastuzumab group and 261 in the control group (hazard ratio, 0.48; P<0.0001). This result crossed the early stopping boundary. The absolute difference in disease-free survival between the trastuzumab group and the control group was 12 percent at three years. Trastuzumab therapy was associated with a 33 percent reduction in the risk of death (P=0.015). The three-year cumulative incidence of class III or IV congestive heart failure or death from cardiac causes in the trastuzumab group was 4.1 percent in trial B-31 and 2.9 percent in trial N9831. CONCLUSIONS: Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer.	Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA USA; Univ Kentucky, Lexington, KY USA; N Cent Canc Treatment Grp, Rochester, MN USA; Mayo Clin Jacksonville, Jacksonville, FL 32224 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA; Mayo Clin, Rochester, MN USA; Allegheny Gen Hosp, Pittsburgh, PA 15212 USA; Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; Canc Res Network, Plantation, FL USA; Angeles Clin & Res Inst, Santa Monica, CA USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA; NCI, Canc Therapeut Branch, Bethesda, MD 20892 USA; Kaiser Permanente Med Ctr No Calif, Vallejo, CA USA; Oncol Associates Cedar Rapids, Cedar Rapids, IA USA; Wichita Community Clin Oncol Program, Wichita, KS USA; Aultman Hlth Fdn, Canton, OH USA; Genentech Inc, San Francisco, CA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; University of Kentucky; Mayo Clinic; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Mayo Clinic; Allegheny General Hospital; Johns Hopkins University; Johns Hopkins Medicine; Angeles Clinic & Research Institute; Dartmouth College; Norris Cotton Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kaiser Permanente; Roche Holding; Genentech	Geyer, CE (corresponding author), Allegheny Canc Ctr, 5th Fl,320 E North Ave, Pittsburgh, PA 15212 USA.	cgeyer@wpahs.org	Geyer, Charles/AGY-0119-2022	Geyer, Charles/0000-0002-2379-5702; Paik, Soonmyung/0000-0001-9688-6480; Swain, Sandra/0000-0002-1320-3830; Yothers, Greg/0000-0002-7965-7333	NCI NIH HHS [U10-CA-69651, U10-CA-37377, U10-CA-32102, U10-CA-31946, U10-CA-25224, U10-CA-021115, U10-CA-12027, U10-CA-69974] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA037377, U10CA069651, U10CA012027, U10CA032102, U10CA025224, U10CA069974, U10CA031946, U10CA021115] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albain KS, 2002, P AN M AM SOC CLIN, V21, p37a; Baum M, 2002, LANCET, V359, P2131; Baum M, 2002, LANCET, V360, P1520; Bendell JC, 2003, CANCER-AM CANCER SOC, V97, P2972, DOI 10.1002/cncr.11436; CHIU ET, IN PRESS J CLIN ONCO; Clayton AJ, 2004, BRIT J CANCER, V91, P639, DOI 10.1038/sj.bjc.6601970; EWER MS, 2002, P AN M AM SOC CLIN, V21, pA123; Lewis S, 2001, BMJ-BRIT MED J, V322, P1479, DOI 10.1136/bmj.322.7300.1479; Lin NU, 2004, J CLIN ONCOL, V22, P3608, DOI 10.1200/JCO.2004.01.175; Paik S, 2000, J NATL CANCER I, V92, P1991, DOI 10.1093/jnci/92.24.1991; PEREZ EA, HER2 TESTING LOCAL C; PICCARTGEBHART M, RANDOMIZED 3 GROUP M; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Seidman A, 2002, J CLIN ONCOL, V20, P1215, DOI 10.1200/JCO.20.5.1215; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; WHITE SJ, 1978, BRIT J CANCER, V37, P849, DOI 10.1038/bjc.1978.124	17	4046	4235	11	364	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 20	2005	353	16					1673	1684		10.1056/NEJMoa052122	http://dx.doi.org/10.1056/NEJMoa052122			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975IC	16236738				2022-12-28	WOS:000232653200007
J	Jackman, DM; Johnson, BE				Jackman, DM; Johnson, BE			Small-cell lung cancer	LANCET			English	Review							EATON-MYASTHENIC-SYNDROME; PROPHYLACTIC CRANIAL IRRADIATION; MULTICENTER RANDOMIZED-TRIAL; COOPERATIVE-ONCOLOGY-GROUP; GASTRIN-RELEASING-PEPTIDE; COLONY-STIMULATING FACTOR; LONG-TERM SURVIVAL; ACID RECEPTOR-BETA; PHASE-III TRIAL; INTENSIVE WEEKLY CHEMOTHERAPY	Small-cell lung carcinoma is an aggressive form of lung cancer that is strongly associated with cigarette smoking and has a tendency for early dissemination. Increasing evidence has implicated autocrine growth loops, proto-oncogenes, and tumour-suppressor genes in its development. At presentation, the vast majority of patients are symptomatic, and imaging typically reveals a hilar mass. Pathology, in most cases of samples obtained by bronchoscopic biopsy, should be undertaken by pathologists with pulmonary expertise, with the provision of additional tissue for immunohistochemical stains as needed. Staging should aim to identify any evidence of distant disease, by imaging of the chest, upper abdomen, head, and bones as appropriate. Limited-stage disease should be treated with etoposide and cisplatin and concurrent early chest irradiation. All patients who achieve complete remission should be considered for treatment with prophylactic cranial irradiation, owing to the high frequency of brain metastases in this disease. Extensive-stage disease should be managed by combination chemotherapy, with a regimen such as etoposide and cisplatin administered for four to six cycles. Thereafter, patients with progressive or recurrent disease should be treated with additional chemotherapy. For patients who survive long term, careful monitoring for development of a second primary tumour is necessary, with further investigation and treatment as appropriate.	Dana Farber Canc Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital	Jackman, DM (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	djackman@partners.org						Akie K, 2000, ANTISENSE NUCLEIC A, V10, P243, DOI 10.1089/108729000421420; ALBAIN KS, 1990, J CLIN ONCOL, V8, P1563, DOI 10.1200/JCO.1990.8.9.1563; Ardizzoni A, 2003, CLIN CANCER RES, V9, P143; Ardizzoni A, 1997, J CLIN ONCOL, V15, P2090, DOI 10.1200/JCO.1997.15.5.2090; Argiris A, 2001, CANCER J, V7, P437; ARRIAGADA R, 1995, JNCI-J NATL CANCER I, V87, P183, DOI 10.1093/jnci/87.3.183; ARRIAGADA R, 1993, NEW ENGL J MED, V329, P1848, DOI 10.1056/NEJM199312163292504; Auperin A, 1999, NEW ENGL J MED, V341, P476, DOI 10.1056/NEJM199908123410703; Barnard WG, 1926, J PATHOL BACTERIOL, V29, P241, DOI 10.1002/path.1700290304; Beith JM, 1996, EUR J CANCER, V32A, P438, DOI 10.1016/0959-8049(95)00608-7; BISHOP JF, 1987, J CLIN ONCOL, V5, P1574, DOI 10.1200/JCO.1987.5.10.1574; Boldrini L, 2004, CLIN CANCER RES, V10, P4101, DOI 10.1158/1078-0432.CCR-03-0664; BORK E, 1991, J CLIN ONCOL, V9, P1627, DOI 10.1200/JCO.1991.9.9.1627; Bradley JD, 2004, J CLIN ONCOL, V22, P3248, DOI 10.1200/JCO.2004.11.089; Breneman JC, 1997, CANCER, V79, P551, DOI 10.1002/(SICI)1097-0142(19970201)79:3<551::AID-CNCR18>3.0.CO;2-2; BRENNAN J, 1991, CANCER RES, V51, P1708; BROWNSON RC, 1992, EPIDEMIOLOGY, V3, P61, DOI 10.1097/00001648-199201000-00012; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; BYRNE MJ, 1989, BRIT J CANCER, V60, P413, DOI 10.1038/bjc.1989.296; CAMPLING BG, 1995, CANCER, V75, P2442, DOI 10.1002/1097-0142(19950515)75:10<2442::AID-CNCR2820751009>3.0.CO;2-Q; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CARDONA C, 1991, CANCER RES, V51, P5205; CAVALLI F, 1978, CANCER TREAT REP, V62, P473; CHALK CH, 1990, NEUROLOGY, V40, P1552, DOI 10.1212/WNL.40.10.1552; Chaudhry A, 1999, CLIN CANCER RES, V5, P3385; Chin R, 2000, MAYO CLIN PROC, V75, P796, DOI 10.4065/75.8.796; CHUTE CG, 1985, CANCER, V56, P2107, DOI 10.1002/1097-0142(19851015)56:8<2107::AID-CNCR2820560837>3.0.CO;2-T; Chute JP, 1999, J CLIN ONCOL, V17, P1794, DOI 10.1200/JCO.1999.17.6.1794; COHEN MH, 1979, CANCER TREAT REP, V63, P163; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Delgado PI, 2000, CANCER CYTOPATHOL, V90, P279, DOI 10.1002/1097-0142(20001025)90:5<279::AID-CNCR3>3.3.CO;2-4; DY GK, 2005, P AM CLIN SOC ONCOL; ECKARDT JR, 2005, P AM SOC CLIN ONCOL; Elias A, 1999, J CLIN ONCOL, V17, P1175, DOI 10.1200/JCO.1999.17.4.1175; ETTINGER DS, 1990, J CLIN ONCOL, V8, P230, DOI 10.1200/JCO.1990.8.2.230; EVANS WK, 1987, ANN INTERN MED, V107, P451, DOI 10.7326/0003-4819-107-4-451; EVANS WK, 1995, AM J CLIN ONCOL-CANC, V18, P149, DOI 10.1097/00000421-199504000-00011; Felip E, 2005, ANN ONCOL, V16, P30, DOI 10.1093/annonc/mdi829; Fetscher S, 1997, ANN ONCOL, V8, P57, DOI 10.1023/A:1008209713568; Field RW, 2004, J NATL CANCER I, V96, P1105, DOI 10.1093/jnci/djh189; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; FORREST JN, 1978, NEW ENGL J MED, V298, P173, DOI 10.1056/NEJM197801262980401; FOX W, 1973, LANCET, V2, P63; FUKUOKA M, 1991, J NATL CANCER I, V83, P855, DOI 10.1093/jnci/83.12.855; Furuse K, 1998, J CLIN ONCOL, V16, P2126, DOI 10.1200/JCO.1998.16.6.2126; GEORGE JM, 1972, J CLIN INVEST, V51, P141, DOI 10.1172/JCI106784; GIACCONE G, 1993, J CLIN ONCOL, V11, P1230, DOI 10.1200/JCO.1993.11.7.1230; Girling DJ, 1996, LANCET, V348, P563, DOI 10.1016/S0140-6736(96)02005-3; Gregor A, 1997, EUR J CANCER, V33, P1752, DOI 10.1016/S0959-8049(97)00135-4; Groen HJM, 1999, J CLIN ONCOL, V17, P927, DOI 10.1200/JCO.1999.17.3.927; GROSS AJ, 1993, CANCER RES, V53, P67; HANNA NH, 2005, P AM SOC CLIN ONCOL; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; HEYMACH JV, 2002, P AN M AM SOC CLIN, V21, pA319; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1991, ONCOGENE, V6, P2291; Hochstenbag MMH, 2000, J NEURO-ONCOL, V48, P243, DOI 10.1023/A:1006427407281; HUMBLET Y, 1987, J CLIN ONCOL, V5, P1864, DOI 10.1200/JCO.1987.5.12.1864; IHDE DC, 1994, J CLIN ONCOL, V12, P2022, DOI 10.1200/JCO.1994.12.10.2022; Ito I, 2004, CANCER GENE THER, V11, P733, DOI 10.1038/sj.cgt.7700756; Janne PA, 2002, CANCER-AM CANCER SOC, V95, P1528, DOI 10.1002/cncr.10841; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jeremic B, 1997, J CLIN ONCOL, V15, P893, DOI 10.1200/JCO.1997.15.3.893; JOHL J, 2005, P AM SOC CLIN ONCOL; Johnson BE, 2003, CLIN CANCER RES, V9, P5880; JOHNSON BE, 1988, CANCER RES, V48, P5163; Johnson BE, 1997, AM J RESP CRIT CARE, V156, P1669, DOI 10.1164/ajrccm.156.5.96-10075; JOHNSON BE, 1986, J CLIN INVEST, V78, P525, DOI 10.1172/JCI112604; JOHNSON BE, 2005, NCCN PRACTICE GUIDEL; Jones AM, 2001, RESP MED, V95, P374, DOI 10.1053/rmed.2001.1051; KAMOI K, 1990, J CLIN ENDOCR METAB, V70, P1385, DOI 10.1210/jcem-70-5-1385; KARRER K, 1989, J THORAC CARDIOV SUR, V97, P168; Kaye FJ, 2002, ONCOGENE, V21, P6908, DOI 10.1038/sj.onc.1205834; Khuder SA, 2001, CHEST, V120, P1577, DOI 10.1378/chest.120.5.1577; Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832; LAMBERT EH, 1971, ANN NY ACAD SCI, V183, P183, DOI 10.1111/j.1749-6632.1971.tb30750.x; LASSEN U, 1995, J CLIN ONCOL, V13, P1215, DOI 10.1200/JCO.1995.13.5.1215; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li BS, 2000, INT J CANCER, V90, P37, DOI 10.1002/(SICI)1097-0215(20000220)90:1<37::AID-IJC5>3.0.CO;2-7; Lin F, 2000, CANCER RES, V60, P3271; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOEHRER PJ, 1995, J CLIN ONCOL, V13, P2594, DOI 10.1200/JCO.1995.13.10.2594; Masuda N, 1998, J CLIN ONCOL, V16, P3329, DOI 10.1200/JCO.1998.16.10.3329; Matsui K, 1998, BRIT J CANCER, V77, P1961, DOI 10.1038/bjc.1998.325; MCEVOY KM, 1989, NEW ENGL J MED, V321, P1567, DOI 10.1056/NEJM198912073212303; MILLER AA, 1995, J CLIN ONCOL, V13, P1871, DOI 10.1200/JCO.1995.13.8.1871; Motomura M, 2000, Ther Apher, V4, P287, DOI 10.1046/j.1526-0968.2000.004004287.x; MOUNTAIN CF, 1978, SEMIN ONCOL, V5, P272; MURRAY N, 1993, J CLIN ONCOL, V11, P336, DOI 10.1200/JCO.1993.11.2.336; MURRAY N, 1991, J CLIN ONCOL, V9, P1632, DOI 10.1200/JCO.1991.9.9.1632; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Noda W, 2002, NEW ENGL J MED, V346, P85, DOI 10.1056/NEJMoa003034; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; OSTERLIND K, 1986, EUR J CANCER CLIN ON, V22, P589, DOI 10.1016/0277-5379(86)90048-9; OSTERLIND K, 1986, CANCER RES, V46, P4189; Paesmans M, 2000, CANCER, V89, P523, DOI 10.1002/1097-0142(20000801)89:3<523::AID-CNCR7>3.0.CO;2-6; PANDYA KJ, 2005, P AM SOC CLIN ONCOL; Pekarsky Y, 2002, CANCER BIOL THER, V1, P232, DOI 10.4161/cbt.73; PerezSoler R, 1996, J CLIN ONCOL, V14, P2785, DOI 10.1200/JCO.1996.14.10.2785; PIGNON JP, 1992, NEW ENGL J MED, V327, P1618, DOI 10.1056/NEJM199212033272302; PRINS J, 1993, ANTICANCER RES, V13, P1373; Pujol JL, 2001, J NATL CANCER I, V93, P300, DOI 10.1093/jnci/93.4.300; Rea F, 1998, EUR J CARDIO-THORAC, V14, P398, DOI 10.1016/S1010-7940(98)00203-6; RICHARDSON GE, 1993, ARCH INTERN MED, V153, P329, DOI 10.1001/archinte.153.3.329; Rigas J.R., 2003, LUNG CANCER, V41, pS34; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; ROTH BJ, 1992, J CLIN ONCOL, V10, P282, DOI 10.1200/JCO.1992.10.2.282; RYGAARD K, 1993, BRIT J CANCER, V67, P37, DOI 10.1038/bjc.1993.7; SALAZAR OM, 1991, INT J RADIAT ONCOL, V21, P645, DOI 10.1016/0360-3016(91)90682-T; Sanders DB, 2003, ANN NY ACAD SCI, V998, P500, DOI 10.1196/annals.1254.065; SAUSVILLE EA, 1986, J BIOL CHEM, V261, P2451; Schiller JH, 2001, J CLIN ONCOL, V19, P2114, DOI 10.1200/JCO.2001.19.8.2114; Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548; Sculier JP, 2001, BRIT J CANCER, V85, P1444, DOI 10.1054/bjoc.2001.2114; Sculier JP, 1996, J CLIN ONCOL, V14, P2337, DOI 10.1200/JCO.1996.14.8.2337; SEKIDO Y, 1991, CANCER RES, V51, P2416; SHEPHERD FA, 1991, J THORAC CARDIOV SUR, V101, P385; Shepherd FA, 2002, J CLIN ONCOL, V20, P4434, DOI 10.1200/JCO.2002.02.108; SHEPHERD FA, 1992, J CLIN ONCOL, V10, P21, DOI 10.1200/JCO.1992.10.1.21; SHER E, 1989, LANCET, V2, P640; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; SKARLOS DV, 1994, ANN ONCOL, V5, P601, DOI 10.1093/oxfordjournals.annonc.a058931; SLEVIN ML, 1989, J CLIN ONCOL, V7, P1333, DOI 10.1200/JCO.1989.7.9.1333; Souhami RL, 1997, J NATL CANCER I, V89, P577, DOI 10.1093/jnci/89.8.577; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SPIEGELMAN D, 1989, J CLIN ONCOL, V7, P344, DOI 10.1200/JCO.1989.7.3.344; SPINDEL ER, 1987, J CLIN INVEST, V80, P1172, DOI 10.1172/JCI113176; Stephens RJ, 1996, LUNG CANCER-J IASLC, V15, P297, DOI 10.1016/0169-5002(95)00594-3; Steward WP, 1998, J CLIN ONCOL, V16, P642, DOI 10.1200/JCO.1998.16.2.642; STEWART PM, 1994, CLIN ENDOCRINOL, V40, P199, DOI 10.1111/j.1365-2265.1994.tb02468.x; Sundstrom S, 2002, J CLIN ONCOL, V20, P4665, DOI 10.1200/JCO.2002.12.111; Takada M, 2002, J CLIN ONCOL, V20, P3054, DOI 10.1200/JCO.2002.12.071; Thatcher N, 2000, J CLIN ONCOL, V18, P395, DOI 10.1200/JCO.2000.18.2.395; Tim RW, 1998, ANN NY ACAD SCI, V841, P823, DOI 10.1111/j.1749-6632.1998.tb11024.x; ToiScott M, 1996, LUNG CANCER-J IASLC, V15, P341, DOI 10.1016/0169-5002(95)00597-8; TONDINI M, 1989, TUMORI, V75, P266, DOI 10.1177/030089168907500316; TRAVIS WD, 1999, HIST TYPING LUNG PLE, P25; Tucker MA, 1997, J NATL CANCER I, V89, P1782, DOI 10.1093/jnci/89.23.1782; Turrisi AT, 1999, NEW ENGL J MED, V340, P265, DOI 10.1056/NEJM199901283400403; Tyczynski JE, 2003, LANCET ONCOL, V4, P45, DOI 10.1016/S1470-2045(03)00960-4; Uno F, 2004, CANCER RES, V64, P2969, DOI 10.1158/0008-5472.CAN-03-3702; VANDERGAAST A, 1993, BRIT J CANCER, V67, P822, DOI 10.1038/bjc.1993.150; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Voltz R, 1999, MUSCLE NERVE, V22, P119, DOI 10.1002/(SICI)1097-4598(199901)22:1<119::AID-MUS19>3.0.CO;2-5; von Pawel J, 1999, J CLIN ONCOL, V17, P658, DOI 10.1200/JCO.1999.17.2.658; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698; WATSON WL, 1962, CANCER, V15, P759, DOI 10.1002/1097-0142(196207/08)15:4<759::AID-CNCR2820150410>3.0.CO;2-6; Westeel V, 1998, J CLIN ONCOL, V16, P1940, DOI 10.1200/JCO.1998.16.5.1940; WINQUIST EW, 1995, J CLIN ONCOL, V13, P157, DOI 10.1200/JCO.1995.13.1.157; WOLF M, 1991, BRIT J CANCER, V63, P986, DOI 10.1038/bjc.1991.215; Wolff NC, 2004, CLIN CANCER RES, V10, P3528, DOI 10.1158/1078-0432.CCR-0957-03; Wong LL, 2002, ENDOCRIN METAB CLIN, V31, P121, DOI 10.1016/S0889-8529(01)00007-X; ZELEN M, 1973, CANCER CHEMOTH REP 3, V4, P31	157	416	442	0	38	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 15	2005	366	9494					1385	1396		10.1016/S0140-6736(05)67569-1	http://dx.doi.org/10.1016/S0140-6736(05)67569-1			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	973ZW	16226617				2022-12-28	WOS:000232562100031
J	Ramadhani, MK; Elias, SG; van Noord, PAH; Grobbee, DE; Peeters, PHM; Uiterwaal, CSPM				Ramadhani, MK; Elias, SG; van Noord, PAH; Grobbee, DE; Peeters, PHM; Uiterwaal, CSPM			Innate left handedness and risk of breast cancer: case-cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WOMEN		Univ Med Care Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Uiterwaal, CSPM (corresponding author), Univ Med Care Utrecht, Julius Ctr Hlth Sci & Primary Care, POB 85500, NL-3508 GA Utrecht, Netherlands.	c.s.p.m.uiterwaal@umcutrecht.nl	Grobbee, Diederick/C-7651-2014; Elias, Sjoerd G/E-6057-2011	Grobbee, Diederick/0000-0003-4472-4468; Elias, Sjoerd G/0000-0003-3903-4024				Barlow WE, 1999, J CLIN EPIDEMIOL, V52, P1165, DOI 10.1016/S0895-4356(99)00102-X; SCHEIRS JGM, 1995, J CLIN EXP NEUROPSYC, V17, P725, DOI 10.1080/01688639508405162; Titus-Ernstoff L, 2000, EPIDEMIOLOGY, V11, P181, DOI 10.1097/00001648-200003000-00017; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z	4	22	22	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 15	2005	331	7521					882	883		10.1136/bmj.38572.440359.AE	http://dx.doi.org/10.1136/bmj.38572.440359.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975SX	16186135	Green Published, Bronze			2022-12-28	WOS:000232683300023
J	Seeger, H; Heikenwalder, M; Zeller, N; Kranich, J; Schwarz, P; Gaspert, A; Seifert, B; Miele, G; Aguzzi, A				Seeger, H; Heikenwalder, M; Zeller, N; Kranich, J; Schwarz, P; Gaspert, A; Seifert, B; Miele, G; Aguzzi, A			Coincident scrapie infection and nephritis lead to urinary prion excretion	SCIENCE			English	Article							CREUTZFELDT-JAKOB-DISEASE; BLOOD-TRANSFUSION; TRANSMISSION; RESISTANT; PROTEIN; PARTICLES; VARIANT; MOUSE; MICE; PRP	Prion infectivity is typically restricted to the central nervous and lymphatic systems of infected hosts, but chronic inflammation can expand the distribution of prions. We tested whether chronic inflammatory kidney disorders would trigger excretion of prion infectivity into urine. Urinary proteins from scrapie-infected mice with lymphocytic nephritis induced scrapie upon inoculation into noninfected indicator mice. Prionuria was found in presymptomatic scrapie-infected and in sick mice, whereas neither prionuria nor urinary PrPSSc was detectable in prion-infected wild-type or PrPC-overexpressing mice, or in nephritic mice inoculated with noninfectious brain. Thus, urine may provide a vector for horizontal prion transmission, and inflammation of excretory organs may influence prion spread.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Inst Clin Pathol, CH-8091 Zurich, Switzerland; Univ Zurich, Inst Biostat, CH-8006 Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich	Aguzzi, A (corresponding author), Univ Zurich Hosp, Inst Neuropathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	adriano@pathol.unizh.ch	Heikenwalder, Mathias/AAA-2269-2020; Aguzzi, Adriano/A-3351-2008; Miele, Gennaro/AAG-6782-2020	Miele, Gennaro/0000-0002-2028-0578; Kranich, Jan/0000-0002-9928-4132; Aguzzi, Adriano/0000-0002-0344-6708; Seifert, Burkhardt/0000-0002-5829-2478				Aguzzi A, 2005, IMMUNITY, V22, P145, DOI 10.1016/j.immuni.2004.12.007; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; FRASER H, 1970, NATURE, V226, P462, DOI 10.1038/226462a0; Furukawa H, 2004, J BIOL CHEM, V279, P23661, DOI 10.1074/jbc.M400187200; GAJDUSEK DC, 1967, SCIENCE, V155, P212; Head MW, 2005, NEUROLOGY, V64, P1794, DOI 10.1212/01.WNL.0000161842.68793.8A; Heikenwalder M, 2005, SCIENCE, V307, P1107, DOI 10.1126/science.1106460; Houston F, 2000, LANCET, V356, P999, DOI 10.1016/S0140-6736(00)02719-7; JONES SR, 1990, AM J MED, V88, pS30, DOI 10.1016/0002-9343(90)90085-R; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P11666, DOI 10.1073/pnas.1834432100; Llewelyn CA, 2004, LANCET, V363, P417, DOI 10.1016/S0140-6736(04)15486-X; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Serban A, 2004, J BIOL CHEM, V279, P48817, DOI 10.1074/jbc.M409107200; Shaked GM, 2001, J BIOL CHEM, V276, P31479, DOI 10.1074/jbc.C100278200; SHIBAYAMA Y, 1982, ACTA PATHOL JAPON, V32, P695; TATEISHI J, 1980, ACTA NEUROPATHOL, V51, P127, DOI 10.1007/BF00690454	18	141	143	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					324	326		10.1126/science.1118829	http://dx.doi.org/10.1126/science.1118829			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224026				2022-12-28	WOS:000232670100055
J	Wu, JQ; Pollard, TD				Wu, JQ; Pollard, TD			Counting cytokinesis proteins globally and locally in fission yeast	SCIENCE			English	Article							SINGLE LIVING CELLS; SPINDLE-POLE BODY; SCHIZOSACCHAROMYCES-POMBE; MYOSIN-II; CONTRACTILE RING; ACTIN NUCLEATION; ARP2/3 COMPLEX; F-ACTIN; CYCLE; DIVISION	We used fluorescence microscopy to measure global and local concentrations of 28 cytoskeletal and signaling proteins fused to yellow fluorescent protein (YFP) in the fission yeast Schizosaccharomyces pombe. Native promoters controlled the expression of these functional YFP fusion proteins. Fluorescence measured by microscopy or flow cytometry was directly, proportional to protein concentration measured by quantitative immunoblotting. Global cytoplasmic concentrations ranged from 0.04 (formin Cdc12p) to 63 micromolar (actin). Proteins concentrated up to 100 times in contractile rings and 7500 times in spindle pole bodies at certain times in the cell cycle. This approach can be used to measure the global and local concentrations of any fusion protein.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Cell Biol & Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University; Yale University	Pollard, TD (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.	thomas.pollard@yale.edu	Wu, Jian-qiu/G-6835-2012		NIGMS NIH HHS [GM-26231, R01 GM026132] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026132] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson M, 2002, EMBO J, V21, P5745, DOI 10.1093/emboj/cdf564; Bahler J, 1998, J CELL BIOL, V143, P1603, DOI 10.1083/jcb.143.6.1603; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Balasubramanian MK, 2004, CURR BIOL, V14, pR806, DOI 10.1016/j.cub.2004.09.022; Bezanilla M, 2000, MOL BIOL CELL, V11, P79, DOI 10.1091/mbc.11.1.79; Blessing CA, 2004, TRENDS CELL BIOL, V14, P435, DOI 10.1016/j.tcb.2004.07.009; Carnahan RH, 2003, J CELL BIOL, V162, P851, DOI 10.1083/jcb.200305012; Chang F, 1997, J CELL BIOL, V137, P169, DOI 10.1083/jcb.137.1.169; D'souza VM, 2001, CELL STRUCT FUNCT, V26, P555, DOI 10.1247/csf.26.555; Desautels M, 2001, J BIOL CHEM, V276, P5932, DOI 10.1074/jbc.M008715200; Ding R, 1997, MOL BIOL CELL, V8, P1461, DOI 10.1091/mbc.8.8.1461; Dundr M, 2002, J STRUCT BIOL, V140, P92, DOI 10.1016/S1047-8477(02)00521-X; FANKHAUSER C, 1995, CELL, V82, P435, DOI 10.1016/0092-8674(95)90432-8; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Grallert A, 2004, GENE DEV, V18, P1007, DOI 10.1101/gad.296204; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Hirschberg K, 2000, METHOD ENZYMOL, V327, P69, DOI 10.1016/S0076-6879(00)27268-6; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; KANBE T, 1989, J CELL SCI, V94, P647; Kovar DR, 2005, MOL BIOL CELL, V16, P2313, DOI 10.1091/mbc.E04-09-0781; Kovar DR, 2004, P NATL ACAD SCI USA, V101, P14725, DOI 10.1073/pnas.0405902101; Lord M, 2004, J CELL BIOL, V167, P315, DOI 10.1083/jcb.200404045; Morrell JL, 2004, CURR BIOL, V14, P579, DOI 10.1016/j.cub.2004.03.036; Nabeshima K, 1998, MOL BIOL CELL, V9, P3211, DOI 10.1091/mbc.9.11.3211; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; Paoletti A, 2000, MOL BIOL CELL, V11, P2757, DOI 10.1091/mbc.11.8.2757; Pelham RJ, 2002, NATURE, V419, P82, DOI 10.1038/nature00999; Peng X, 2005, MOL BIOL CELL, V16, P1026, DOI 10.1091/mbc.E04-04-0299; Piston DW, 1999, METHOD CELL BIOL, V58, P31; Robinson DN, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-4; Rodal AA, 2005, MOL BIOL CELL, V16, P372, DOI 10.1091/mbc.e04-08-0734; Rustici G, 2004, NAT GENET, V36, P809, DOI 10.1038/ng1377; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; Sirotkin V, 2005, J CELL BIOL, V170, P637, DOI 10.1083/jcb.200502053; Sohrmann M, 1996, GENE DEV, V10, P2707, DOI 10.1101/gad.10.21.2707; Takagi T, 2003, J ELECTRON MICROSC, V52, P161, DOI 10.1093/jmicro/52.2.161; Tasto JJ, 2003, J CELL BIOL, V160, P1093, DOI 10.1083/jcb.200211126; Wolfe BA, 2005, TRENDS CELL BIOL, V15, P10, DOI 10.1016/j.tcb.2004.11.006; Wong KCY, 2002, CURR BIOL, V12, P724, DOI 10.1016/S0960-9822(02)00790-X; Wu JQ, 2003, DEV CELL, V5, P723, DOI 10.1016/S1534-5807(03)00324-1; Young ME, 2004, J CELL BIOL, V166, P629, DOI 10.1083/jcb.200404159	41	409	414	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					310	314		10.1126/science.1113230	http://dx.doi.org/10.1126/science.1113230			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224022				2022-12-28	WOS:000232670100051
J	Xi, ZY; Khoo, CCH; Dobson, SL				Xi, ZY; Khoo, CCH; Dobson, SL			Wolbachia establishment and invasion in an Aedes aegypti laboratory population	SCIENCE			English	Article							INDUCED CYTOPLASMIC INCOMPATIBILITY; ALBOPICTUS; INFECTION; MOSQUITO	A proposed strategy to aid in controlling the growing burden of vector-borne disease is population replacement, in which a natural vector population is replaced by a population with a reduced capacity for disease transmission. An important component of such a strategy is the drive system; which serves to spread a desired genotype into the targeted field population. Endosymbiotic Wolbachia. bacteria are potential transgene drivers, but infections do not naturally occur in some important mosquito vectors, notably Aedes aegypti. In this work, stable infections of wAlbB Wolbachia were established in A. aegypti and caused high rates of cytoplasmic incompatibility (that is, elimination of egg hatch). Laboratory cage tests demonstrated the ability of wAlbB to spread into an A. aegypti population after seeding of an uninfected population with infected females, reaching infection fixation within seven generations.	Univ Kentucky, Dept Entomol, Lexington, KY 40546 USA	University of Kentucky	Dobson, SL (corresponding author), Univ Kentucky, Dept Entomol, Lexington, KY 40546 USA.	sdobson@uky.edu	Xi, Zhiyong/AAD-7936-2022; Dobson, Stephen L/E-5853-2010	Xi, Zhiyong/0000-0001-7786-012X; Dobson, Stephen L/0000-0001-5486-8225	NIAID NIH HHS [AI-51533] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adelman ZN, 2002, MOL BIOCHEM PARASIT, V121, P1, DOI 10.1016/S0166-6851(02)00028-2; Atkinson PW, 2002, GENESIS, V32, P42, DOI 10.1002/gene.10026; Dobson SL, 2002, GENETICS, V160, P1087; Dobson SL, 2002, P ROY SOC B-BIOL SCI, V269, P437, DOI 10.1098/rspb.2001.1876; Dutton TJ, 2004, INSECT MOL BIOL, V13, P317, DOI 10.1111/j.0962-1075.2004.00490.x; Gould F, 2004, ANNU REV ENTOMOL, V49, P193, DOI 10.1146/annurev.ento.49.061802.123344; HOFFMANN AA, 1990, GENETICS, V126, P933; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; Scott TW, 2002, SCIENCE, V298, P117, DOI 10.1126/science.298.5591.117; Tram U, 2002, SCIENCE, V296, P1124, DOI 10.1126/science.1070536; Werren JH, 2000, P ROY SOC B-BIOL SCI, V267, P1277, DOI 10.1098/rspb.2000.1139; Xi ZY, 2005, INSECT BIOCHEM MOLEC, V35, P903, DOI 10.1016/j.ibmb.2005.03.015	12	353	375	3	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					326	328		10.1126/science.1117607	http://dx.doi.org/10.1126/science.1117607			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224027				2022-12-28	WOS:000232670100056
J	Ikari, K; Momohara, S				Ikari, K; Momohara, S			Bone changes in rheumatoid arthritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Tokyo Womens Med Univ, Tokyo 1620054, Japan	Tokyo Women's Medical University	Ikari, K (corresponding author), Tokyo Womens Med Univ, Tokyo 1620054, Japan.								0	9	10	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					E13	E13		10.1056/NEJMicm050315	http://dx.doi.org/10.1056/NEJMicm050315			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221769				2022-12-28	WOS:000232486000015
J	Graveley, BR				Graveley, BR			Mutuallv exclusive splicing of the insect Dscam Pre-mRNA directed by competing intronic RNA secondary structures	CELL			English	Article							WEB SERVER; GENOME; EXPRESSION; DIVERSITY; SEQUENCE; ANIMALS; EXONS; WORLD	Drosophila Dscam encodes 38,016 distinct axon guidance receptors through the mutually exclusive alternative splicing of 95 variable exons. Importantly, known mechanisms that ensure the mutually exclusive splicing of pairs of exons cannot explain this phenomenon in Dscam. I have identified two classes of conserved elements in the Dscam exon 6 cluster, which contains 48 alternative exons-the docking site, located in the intron downstream of constitutive exon 5, and the selector sequences, which are located upstream of each exon 6 variant. Strikingly, each selector sequence is complementary to a portion of the docking site, and this pairing juxtaposes one, and only one, alternative exon to the upstream constitutive exon. The mutually exclusive nature of the docking site:selector sequence interactions suggests that the formation of these competing RNA structures is a central component of the mechanism guaranteeing that only one exon 6 variant is included in each Dscam mRNA.	Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA	University of Connecticut	Graveley, BR (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, 263 Farmington Ave, Farmington, CT 06030 USA.	graveley@neuron.uchc.edu	Graveley, Brenton R/C-3108-2013	Graveley, Brenton/0000-0001-5777-5892	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067842] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM067842-04, R01 GM067842, GM67842] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Graveley BR, 2004, RNA, V10, P1499, DOI 10.1261/rna.7105504; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Jones RB, 2001, J BIOL CHEM, V276, P4158, DOI 10.1074/jbc.M006151200; Kennedy CF, 1997, MOL CELL BIOL, V17, P2774, DOI 10.1128/MCB.17.5.2774; Letunic I, 2002, HUM MOL GENET, V11, P1561, DOI 10.1093/hmg/11.13.1561; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Neves G, 2004, NAT GENET, V36, P240, DOI 10.1038/ng1299; Park JW, 2004, P NATL ACAD SCI USA, V101, P15974, DOI 10.1073/pnas.0407004101; Patel AA, 2003, NAT REV MOL CELL BIO, V4, P960, DOI 10.1038/nrm1259; Powell J. R., 1997, PROGR PROSPECTS EVOL; Reenan RA, 2001, TRENDS GENET, V17, P53, DOI 10.1016/S0168-9525(00)02169-7; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; Southby J, 1999, MOL CELL BIOL, V19, P2699; Stolc V, 2004, SCIENCE, V306, P655, DOI 10.1126/science.1101312; Thanaraj TA, 2004, NUCLEIC ACIDS RES, V32, pD64, DOI 10.1093/nar/gkh030; Xia QY, 2004, SCIENCE, V306, P1937, DOI 10.1126/science.1102210; Zhan XL, 2004, NEURON, V43, P673, DOI 10.1016/j.neuron.2004.07.020; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	24	188	194	2	23	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 7	2005	123	1					65	73		10.1016/j.cell.2005.07.028	http://dx.doi.org/10.1016/j.cell.2005.07.028			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	973QD	16213213	Bronze, Green Accepted			2022-12-28	WOS:000232536800009
J	Huang, CS; Shi, SH; Ule, J; Ruggiu, M; Barker, LA; Darnell, RB; Jan, YN; Jan, LY				Huang, CS; Shi, SH; Ule, J; Ruggiu, M; Barker, LA; Darnell, RB; Jan, YN; Jan, LY			Common molecular pathways mediate long-term potentiation of synaptic excitation and slow synaptic inhibition	CELL			English	Article							RNA-BINDING PROTEIN; ACTIVATING TRANSCRIPTION FACTOR-4; RECTIFYING POTASSIUM CHANNELS; GABA(B) RECEPTORS; CYTOPLASMIC LOCALIZATION; RAT HIPPOCAMPUS; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; SIGNALING PROTEINS; DENDRITIC SPINES	Synaptic plasticity, the cellular correlate for learning and memory, involves signaling cascades in the dendritic spine. Extensive studies have shown that long-term potentiation (LTP) of the excitatory postsynaptic current (EPSC) through glutamate receptors is induced by activation of N-methyl-D-asparate receptor (NMDA-R)-the coincidence detector-and Ca2+/calmodulin-dependent protein kinase II (CaMKII). Here we report that the same signaling pathway in the postsynaptic CA1 pyramidal neuron also causes LTP of the slow inhibitory postsynaptic current (sIPSC) mediated by metabotropic GABA(B) receptors (GABA(B)-Rs) and G protein-activated inwardly rectifying K+ (GIRK) channels, both residing in dendritic spines as well as shafts. Indicative of intriguing differences in the regulatory mechanisms for excitatory and inhibitory synaptic plasticity, LTP of sIPSC but not EPSC was abolished in mice lacking Nova-2, a neuronal-specific RNA binding protein that is an autoimmune target in paraneoplastic opsoclonus myoclonus ataxia (POMA) patients with latent cancer, reduced inhibitory control of movements, and dementia.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Program Neurosci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Program Oral & Craniofacial Sci, San Francisco, CA 94143 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Mol Neurooncol Lab, New York, NY 10021 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University	Jan, LY (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	gkw@itsa.ucsf.edu	Ule, Jernej/C-6315-2013; Darnell, Robert B/B-9022-2008	Ule, Jernej/0000-0002-2452-4277; Darnell, Robert B/0000-0002-5134-8088; Ruggiu, Matteo/0000-0002-6404-1210; Jan, Lily/0000-0003-3938-8498	NIMH NIH HHS [MH63981] Funding Source: Medline; NINDS NIH HHS [R01 NS40955, NS047200] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH063981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040955, R01NS047200] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albert ML, 2004, NAT REV CANCER, V4, P36, DOI 10.1038/nrc1255; Aniksztejn L, 1995, J NEUROPHYSIOL, V74, P2349, DOI 10.1152/jn.1995.74.6.2349; Baranauskas G, 2003, NAT NEUROSCI, V6, P258, DOI 10.1038/nn1019; BASHIR ZI, 1991, NATURE, V349, P156, DOI 10.1038/349156a0; Bell TJ, 2004, NEURON, V41, P127, DOI 10.1016/S0896-6273(03)00801-8; Bichet D, 2004, P NATL ACAD SCI USA, V101, P4441, DOI 10.1073/pnas.0401195101; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSER DC, 1995, J PHARMACOL EXP THER, V274, P1393; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; BUCKANOVICH RJ, 1993, NEURON, V11, P657, DOI 10.1016/0896-6273(93)90077-5; Charles KJ, 2001, NEUROSCIENCE, V106, P447, DOI 10.1016/S0306-4522(01)00296-2; Chevaleyre V, 2003, NEURON, V38, P461, DOI 10.1016/S0896-6273(03)00235-6; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; COLLINGRIDGE GL, 1988, J PHYSIOL-LONDON, V399, P283; Couve A, 2004, J BIOL CHEM, V279, P13934, DOI 10.1074/jbc.M311737200; Couve A, 2001, MOL CELL NEUROSCI, V17, P317, DOI 10.1006/mcne.2000.0938; DAW NW, 1993, ANNU REV NEUROSCI, V16, P207, DOI 10.1146/annurev.ne.16.030193.001231; Debanne D, 2004, NAT REV NEUROSCI, V5, P304, DOI 10.1038/nrn1397; Debanne D, 1997, NATURE, V389, P286, DOI 10.1038/38502; Drake CT, 1997, P NATL ACAD SCI USA, V94, P1007, DOI 10.1073/pnas.94.3.1007; Dredge BK, 2005, EMBO J, V24, P1608, DOI 10.1038/sj.emboj.7600630; Dredge BK, 2003, MOL CELL BIOL, V23, P4687, DOI 10.1128/MCB.23.13.4687-4700.2003; Fettiplace R, 1999, ANNU REV PHYSIOL, V61, P809, DOI 10.1146/annurev.physiol.61.1.809; Gu W, 2002, J CELL BIOL, V156, P41, DOI 10.1083/jcb.200105133; Hachet O, 2004, NATURE, V428, P959, DOI 10.1038/nature02521; Harris KM, 1999, CURR OPIN NEUROBIOL, V9, P343, DOI 10.1016/S0959-4388(99)80050-6; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; HORMIGO A, 1994, ANN NEUROL, V36, P896, DOI 10.1002/ana.410360615; Hyman JM, 2003, J NEUROSCI, V23, P11725; Isomoto S, 1998, BIOCHEM BIOPH RES CO, V253, P10, DOI 10.1006/bbrc.1998.9706; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; Kataoka N, 2000, MOL CELL, V6, P673, DOI 10.1016/S1097-2765(00)00065-4; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; Kopysova IL, 1998, J NEUROSCI, V18, P7436; Kulik A, 2003, J NEUROSCI, V23, P11026; Kuzhikandathil EV, 2002, MOL PHARMACOL, V62, P119, DOI 10.1124/mol.62.1.119; Liao YJ, 1996, J NEUROSCI, V16, P7137; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; LUQUE FA, 1991, ANN NEUROL, V29, P241, DOI 10.1002/ana.410290303; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; Malinow R, 2003, PHILOS T ROY SOC B, V358, P707, DOI 10.1098/rstb.2002.1233; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; Martin SC, 2004, J COMP NEUROL, V473, P16, DOI 10.1002/cne.20094; Martin SC, 2001, GENE, V278, P63, DOI 10.1016/S0378-1119(01)00678-3; Musunuru K, 2001, ANNU REV NEUROSCI, V24, P239, DOI 10.1146/annurev.neuro.24.1.239; Nehring RB, 2000, J BIOL CHEM, V275, P35185, DOI 10.1074/jbc.M002727200; Nicoll RA, 2003, PHILOS T R SOC B, V358, P721, DOI 10.1098/rstb.2002.1228; O'Keefe J, 1993, Curr Opin Neurobiol, V3, P917, DOI 10.1016/0959-4388(93)90163-S; Palacios IM, 2002, CURR BIOL, V12, pR50, DOI 10.1016/S0960-9822(01)00671-6; Pfaff T, 1999, EUR J NEUROSCI, V11, P2874, DOI 10.1046/j.1460-9568.1999.00704.x; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; PRANZATELLI MR, 1992, CLIN NEUROPHARMACOL, V15, P186, DOI 10.1097/00002826-199206000-00002; QIAN N, 1990, P NATL ACAD SCI USA, V87, P8145, DOI 10.1073/pnas.87.20.8145; Scanziani M, 2000, NEURON, V25, P673, DOI 10.1016/S0896-6273(00)81069-7; Sederberg PB, 2003, J NEUROSCI, V23, P10809; Seidenbecher T, 2003, SCIENCE, V301, P846, DOI 10.1126/science.1085818; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; Somogyi P, 1998, BRAIN RES REV, V26, P113, DOI 10.1016/S0165-0173(97)00061-1; Steiger JL, 2004, J NEUROSCI, V24, P6115, DOI 10.1523/JNEUROSCI.1200-04.2004; Stein V, 2003, J NEUROSCI, V23, P5503; Ule J, 2005, NAT GENET, V37, P844, DOI 10.1038/ng1610; Ule J, 2003, SCIENCE, V302, P1212, DOI 10.1126/science.1090095; Vernon E, 2001, MOL CELL NEUROSCI, V17, P637, DOI 10.1006/mcne.2000.0960; Vida I, 1998, J PHYSIOL-LONDON, V506, P755, DOI 10.1111/j.1469-7793.1998.755bv.x; Watt AJ, 2004, NAT NEUROSCI, V7, P518, DOI 10.1038/nn1220; Wei JJ, 1998, GENOMICS, V51, P379, DOI 10.1006/geno.1998.5369; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197; Wickman K, 2000, J NEUROSCI, V20, P5608, DOI 10.1523/JNEUROSCI.20-15-05608.2000; Wilson RI, 2001, NATURE, V410, P588, DOI 10.1038/35069076; Yamada M, 1998, PHARMACOL REV, V50, P723; Yang YYL, 1998, P NATL ACAD SCI USA, V95, P13254, DOI 10.1073/pnas.95.22.13254	77	123	127	1	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 7	2005	123	1					105	118		10.1016/j.cell.2005.07.033	http://dx.doi.org/10.1016/j.cell.2005.07.033			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	973QD	16213216	Bronze			2022-12-28	WOS:000232536800012
J	Yan, N; Chai, JJ; Lee, ES; Gu, LC; Liu, Q; He, JQ; Wu, JW; Kokel, D; Li, HL; Hao, Q; Xue, D; Shi, YG				Yan, N; Chai, JJ; Lee, ES; Gu, LC; Liu, Q; He, JQ; Wu, JW; Kokel, D; Li, HL; Hao, Q; Xue, D; Shi, YG			Structure of the CED-4-CED-9 complex provides insights into programmed cell death in Caenorhabditis elegans	NATURE			English	Article							REGULATORS CED-9; PROTEIN; ENCODES; EGL-1; OLIGOMERIZATION; RECOGNITION; ASSOCIATION; ACTIVATION	Interplay among four genes - egl-1, ced-9, ced-4 and ced-3 - controls the onset of programmed cell death in the nematode Caenorhabditis elegans. Activation of the cell-killing protease CED-3 requires CED-4. However, CED-4 is constitutively inhibited by CED-9 until its release by EGL-1. Here we report the crystal structure of the CED-4 - CED-9 complex at 2.6 angstrom resolution, and a complete reconstitution of the CED-3 activation pathway using homogeneous proteins of CED-4, CED-9 and EGL-1. One molecule of CED-9 binds to an asymmetric dimer of CED-4, but specifically recognizes only one of the two CED-4 molecules. This specific interaction prevents CED-4 from activating CED-3. EGL-1 binding induces pronounced conformational changes in CED-9 that result in the dissociation of the CED-4 dimer from CED-9. The released CED-4 dimer further dimerizes to form a tetramer, which facilitates the autoactivation of CED-3. Together, our studies provide important insights into the regulation of cell death activation in C. elegans.	Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Cornell Univ, Ithaca, NY 14853 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Princeton University; University of Colorado System; University of Colorado Boulder; Gwangju Institute of Science & Technology (GIST); Cornell University; United States Department of Energy (DOE); Brookhaven National Laboratory	Shi, YG (corresponding author), Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Washington Rd, Princeton, NJ 08544 USA.	yshi@molbio.princeton.edu	He, Jiaqing/A-2245-2010; Hao, Quan/C-4304-2009; Liu, Qun/A-8757-2011	He, Jiaqing/0000-0003-3954-6003; Liu, Qun/0000-0002-1179-290X; Li, Huilin/0000-0001-8085-8928; Shi, Yigong/0000-0003-2030-168X; Chai, Jijie/0000-0001-7591-3873; Hao, Quan/0000-0002-9642-0514; XUE, DING/0000-0002-8429-8136; kokel, david/0000-0002-1981-1511				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; del Peso L, 2000, J BIOL CHEM, V275, P27205; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; Hao Q, 2004, J APPL CRYSTALLOGR, V37, P498, DOI 10.1107/S0021889804008696; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Horvitz HR, 2003, CHEMBIOCHEM, V4, P697, DOI 10.1002/cbic.200300614; Horvitz HR, 1999, CANCER RES, V59, p1701S; Hugunin M, 1996, J BIOL CHEM, V271, P3517, DOI 10.1074/jbc.271.7.3517; Irmler M, 1997, FEBS LETT, V406, P189, DOI 10.1016/S0014-5793(97)00271-8; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; Jaroszewski L, 2000, PROTEINS, V39, P197, DOI 10.1002/(SICI)1097-0134(20000515)39:3<197::AID-PROT10>3.0.CO;2-V; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liu JY, 2000, MOL CELL, V6, P637, DOI 10.1016/S1097-2765(00)00062-9; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ottilie S, 1997, CELL DEATH DIFFER, V4, P526, DOI 10.1038/sj.cdd.4400288; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parrish J, 2000, P NATL ACAD SCI USA, V97, P11916, DOI 10.1073/pnas.210391597; Riedl SJ, 2005, NATURE, V434, P926, DOI 10.1038/nature03465; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Singleton MR, 2004, J MOL BIOL, V343, P547, DOI 10.1016/j.jmb.2004.08.044; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; Woo JS, 2003, CELL DEATH DIFFER, V10, P1310, DOI 10.1038/sj.cdd.4401303; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yan NG, 2004, MOL CELL, V15, P999, DOI 10.1016/j.molcel.2004.08.022; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	40	170	182	4	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					831	837		10.1038/nature04002	http://dx.doi.org/10.1038/nature04002			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208361				2022-12-28	WOS:000232338600035
J	Lo, B; Katz, MH				Lo, B; Katz, MH			Clinical decision making during public health emergencies: Ethical considerations	ANNALS OF INTERNAL MEDICINE			English	Article							REIMBURSEMENT RULES; INTERVIEW; MODEL; ME	Recent public health emergencies involving anthrax, the severe acute respiratory syndrome (SARS), and shortages of influenza vaccine have dramatized the need for restrictive public health measures such as quarantine, isolation, and rationing. Front-line physicians will face ethical dilemmas during public health emergencies when patients disagree with these measures. Patients might request interventions that are not recommended or for which they are not eligible, or they might object to intrusive or restrictive measures. The physician's primary responsibility in such emergencies is to the public rather than to the individual patient. In public health emergencies, physicians need to address the patient's needs and concerns, recognize their changed roles, and work closely with public health officials. Physicians can still work on behalf of patients by advocating for changes in policies and exceptions when warranted and by mitigating the adverse consequences of public health measures. Before an emergency occurs, physicians should think through how they will respond to foreseeable dilemmas arising when patients disagree with public health recommendations.	Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Lo, B (corresponding author), Univ Calif San Francisco, Div Gen Internal Med, Room C 126,521 Parnassus Ave, San Francisco, CA 94143 USA.	bernie@medicine.ucsf.edu						Beauchamp T L, 2012, PRINCIPLES BIOMEDICA; Beauchamp TL, 2001, PRINCIPLES BIOMEDICA, P227; Blendon R. J., 2004, Morbidity and Mortality Weekly Report, V53, P1153; Bok S., 1982, SECRETS; *CAL DEP HLTH SERV, 2004, STAT PUBL HLTH OFF O; *CDCP, 2004, COMM CONT MEAS INCL; *CDCP, 2004, MMWR-MORBID MORTAL W, V53, P923; Childress JF, 2002, J LAW MED ETHICS, V30, P170, DOI 10.1111/j.1748-720X.2002.tb00384.x; Coulehan JL, 2001, ANN INTERN MED, V135, P221, DOI 10.7326/0003-4819-135-3-200108070-00022; Gostin LO, 2003, JAMA-J AM MED ASSOC, V290, P3229, DOI 10.1001/jama.290.24.3229; Gostin LO, 2002, HEALTH AFFAIR, V21, P79, DOI 10.1377/hlthaff.21.6.79; Gostin LO, 2002, JAMA-J AM MED ASSOC, V288, P622, DOI 10.1001/jama.288.5.622; Gostin LO, 2000, PUBLIC HLTH LAW POWE; LIPKIN M, 1995, MEDICAL INTERVIEW; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; LO B, 2000, RESOLVING ETHICAL DI, P53; LO B, 2000, RESOLVING ETHICAL DI, P11; Low DE, 2004, LEARNING SARS PREPAR; Maunder R, 2003, CAN MED ASSOC J, V168, P1245; Pearson SD, 2000, ANN INTERN MED, V133, P148, DOI 10.7326/0003-4819-133-2-200007180-00014; Platt FW, 2001, ANN INTERN MED, V134, P1079, DOI 10.7326/0003-4819-134-11-200106050-00020; Suchman AL, 1997, JAMA-J AM MED ASSOC, V277, P678, DOI 10.1001/jama.277.8.678; *U LOUISV SCH MED, 2004, QUAR IS LESS LEARN S; Werner RM, 2002, ARCH INTERN MED, V162, P1134, DOI 10.1001/archinte.162.10.1134; Wynia MK, 2000, JAMA-J AM MED ASSOC, V283, P1858, DOI 10.1001/jama.283.14.1858; 2004, MMWR MORB MORTAL WKL, V53, P1183	26	31	32	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 4	2005	143	7					493	498		10.7326/0003-4819-143-7-200510040-00008	http://dx.doi.org/10.7326/0003-4819-143-7-200510040-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970FM	16204162				2022-12-28	WOS:000232290600004
J	Gaffan, D				Gaffan, D			Widespread cortical networks underlie memory and attention	SCIENCE			English	Editorial Material							UNILATERAL LESIONS; RHESUS-MONKEYS; NEGLECT; FOREBRAIN; FORNIX; CORTEX		Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England	University of Oxford	Gaffan, D (corresponding author), Univ Oxford, Dept Expt Psychol, S Parks Rd, Oxford OX1 3UD, England.	gaffan@psy.ox.ac.uk						BISIACH E, 1979, BRAIN, V102, P609, DOI 10.1093/brain/102.3.609; Easton A, 2001, NEUROPSYCHOLOGIA, V39, P71, DOI 10.1016/S0028-3932(00)00098-1; Easton A, 2002, CEREB CORTEX, V12, P729, DOI 10.1093/cercor/12.7.729; Gaffan D, 1997, BRAIN, V120, P1647, DOI 10.1093/brain/120.9.1647; Gaffan D, 2001, NEUROPSYCHOLOGIA, V39, P51, DOI 10.1016/S0028-3932(00)00097-X; Gaffan D, 2002, PHILOS T R SOC B, V357, P1111, DOI 10.1098/rstb.2002.1110; HORNAK J, 1995, NEUROPSYCHOLOGIA, V33, P305, DOI 10.1016/0028-3932(94)00117-8; Thiebaut de Schotten M, 2005, SCIENCE, V309, P2226, DOI 10.1126/science.1116251	8	27	29	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 30	2005	309	5744					2172	2173		10.1126/science.1119445	http://dx.doi.org/10.1126/science.1119445			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195447				2022-12-28	WOS:000232318000028
J	Thiebaut de Schotten, M; Urbanski, M; Duffau, H; Voue, E; Levy, R; Dubois, B; Bartolomeo, P				Thiebaut de Schotten, M; Urbanski, M; Duffau, H; Voue, E; Levy, R; Dubois, B; Bartolomeo, P			Direct evidence for a parietal-frontal pathway subserving spatial awareness in humans	SCIENCE			English	Article							LINE BISECTION; VISUAL NEGLECT; ATTENTION; REPRESENTATION; ANATOMY; DISCONNECTION; MECHANISMS; INSIGHTS; MONKEY; BRAIN	Intraoperative electrical stimulation, which temporarily inactivates restricted regions during brain surgery, can map cognitive functions in humans with spatiotemporal resolution unmatched by other methods. Using this technique, we found that stimulation of the right inferior parietal lobule or the caudal superior temporal gyrus, but not of its rostra[ portion, determined rightward deviations on line bisection. However, the strongest shifts occurred with subcortical stimulation. Fiber tracking identified the stimulated site as a section of the superior occipitofrontal fasciculus, a poorly known parietal-frontal pathway. These findings suggest that parietal-frontal communication is necessary for the symmetrical processing of the visual scene.	Hop La Pitie Salpetriere, INSERM, U610, F-75013 Paris, France; Hop La Pitie Salpetriere, Dept Neurosurg, F-75013 Paris, France; Hop La Pitie Salpetriere, Dept Neuroimagery, F-75013 Paris, France; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Dept Neurol, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite	Bartolomeo, P (corresponding author), Hop La Pitie Salpetriere, INSERM, U610, F-75013 Paris, France.	paolo.bartotomeo@chups.jussieu.fr	Levy, Richard/D-8411-2011; de Schotten, Michel Thiebaut/H-1496-2011; Bartolomeo, Paolo/B-3046-2009; Volle, Emmanuelle/J-4164-2017	de Schotten, Michel Thiebaut/0000-0002-0329-1814; Bartolomeo, Paolo/0000-0002-2640-6426; Volle, Emmanuelle/0000-0001-8420-4155				Anderson B, 1996, BRAIN, V119, P841, DOI 10.1093/brain/119.3.841; Azouvi P, 2002, J NEUROL NEUROSUR PS, V73, P160, DOI 10.1136/jnnp.73.2.160; Bartolomeo P, 2002, NEUROSCI BIOBEHAV R, V26, P217, DOI 10.1016/S0149-7634(01)00065-3; Bisley JW, 2003, SCIENCE, V299, P81, DOI 10.1126/science.1077395; Catani M, 2002, NEUROIMAGE, V17, P77, DOI 10.1006/nimg.2002.1136; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Crawford JR, 2002, NEUROPSYCHOLOGIA, V40, P1196, DOI 10.1016/S0028-3932(01)00224-X; DEJERINE MJ, 1895, ANATOMIE CENTRES NER; Doricchi F, 2003, NEUROREPORT, V14, P2239, DOI 10.1097/00001756-200312020-00021; Duffau H, 2005, BRAIN, V128, P797, DOI 10.1093/brain/awh423; Ellison A, 2004, BRAIN, V127, P2307, DOI 10.1093/brain/awh244; Fink GR, 2002, NEUROPSYCHOLOGIA, V40, P119, DOI 10.1016/S0028-3932(01)00087-2; Gaffan D, 1997, BRAIN, V120, P1647, DOI 10.1093/brain/120.9.1647; Gottlieb JP, 1998, NATURE, V391, P481, DOI 10.1038/35135; Husain M, 2003, NAT REV NEUROSCI, V4, P26, DOI 10.1038/nrn1005; Karnath HO, 2001, NAT REV NEUROSCI, V2, P568, DOI 10.1038/35086057; Karnath HO, 2004, CEREB CORTEX, V14, P1164, DOI 10.1093/cercor/bhh076; MARSHALL JC, 1990, COGNITIVE NEUROPSYCH, V7, P107, DOI 10.1080/02643299008253438; Mesulam MM, 1999, PHILOS T R SOC B, V354, P1325, DOI 10.1098/rstb.1999.0482; Milner A. D., 1995, VISUAL BRAIN ACTION; Mort DJ, 2003, BRAIN, V126, P1986, DOI 10.1093/brain/awg200; Nieuwenhuys R., 1988, HUMAN CENTRAL NERVOU; PETRIDES M, 2002, PRINCIPLES FRONTAL L, P31, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0003; RORDEN C, 2005, COGNIT BRAIN RE 0219, DOI DOI 10.1016/J.COGBRAINRES.2004.10.022; Rousseaux M, 2001, REV NEUROL-FRANCE, V157, P1385; SCHENKENBERG T, 1980, NEUROLOGY, V30, P509, DOI 10.1212/WNL.30.5.509; Vallar G, 2001, NEUROIMAGE, V14, pS52, DOI 10.1006/nimg.2001.0822	27	450	451	4	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 30	2005	309	5744					2226	2228		10.1126/science.1116251	http://dx.doi.org/10.1126/science.1116251			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195465				2022-12-28	WOS:000232318000047
J	Du, LQ; Poovaiah, BW				Du, LQ; Poovaiah, BW			Ca2+/calmodulin is critical for brassinosteroid biosynthesis and plant growth	NATURE			English	Article							TRANSCRIPTION ACTIVATORS; ARABIDOPSIS-DET3 MUTANT; LIGHT; CALMODULIN; RECEPTOR; PROTEIN; GENE; KINASE; FAMILY; EXPRESSION	Brassinosteroids are plant-specific steroid hormones(1,2) that have an important role in coupling environmental factors, especially light, with plant growth and development(3). How the endogenous brassinosteroids change in response to environmental stimuli is largely unknown. Ca2+/calmodulin has an essential role in sensing and transducing environmental stimuli(4,5). Arabidopsis DWARF1 (DWF1) is responsible for an early step in brassinosteroid biosynthesis that converts 24-methylenecholesterol to campesterol(6,7). Here we show that DWF1 is a Ca2+/calmodulin-binding protein and this binding is critical for its function. Molecular genetic analysis using site-directed and deletion mutants revealed that loss of calmodulin binding completely abolished the function of DWF1 in planta, whereas partial loss of calmodulin binding resulted in a partial dwarf phenotype in complementation studies. These results provide direct proof that Ca2+/calmodulin-mediated signalling has a critical role in controlling the function of DWF1. Furthermore, we observed that DWF1 orthologues from other plants have a similar Ca2+/calmodulin-binding domain, implying that Ca2+/calmodulin regulation of DWF1 and its homologues is common in plants. These results raise the possibility of producing size-engineered crops by altering the Ca2+/calmodulin-binding property of their DWF1 orthologues.	Washington State Univ, Ctr Integrated Biotechnol, Pullman, WA 99164 USA; Washington State Univ, Dept Hort, Pullman, WA 99164 USA	Washington State University; Washington State University	Poovaiah, BW (corresponding author), Washington State Univ, Ctr Integrated Biotechnol, Pullman, WA 99164 USA.	poovaiah@wsu.edu						Allen GJ, 2000, SCIENCE, V289, P2338, DOI 10.1126/science.289.5488.2338; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Baum G, 1999, P NATL ACAD SCI USA, V96, P13554, DOI 10.1073/pnas.96.23.13554; Bouche N, 2002, J BIOL CHEM, V277, P21851, DOI 10.1074/jbc.M200268200; Choe S, 2000, PLANT J, V21, P431, DOI 10.1046/j.1365-313x.2000.00693.x; Choe S, 1999, PLANT PHYSIOL, V119, P897, DOI 10.1104/pp.119.3.897; Chory J, 1997, PLANT CELL ENVIRON, V20, P801, DOI 10.1046/j.1365-3040.1997.d01-99.x; Clouse SD, 2002, MOL CELL, V10, P973, DOI 10.1016/S1097-2765(02)00744-X; Clouse SD, 2001, TRENDS PLANT SCI, V6, P443, DOI 10.1016/S1360-1385(01)02102-1; Du LQ, 2004, PLANT MOL BIOL, V54, P549, DOI 10.1023/B:PLAN.0000038269.98972.bb; Fujioka S, 2003, ANNU REV PLANT BIOL, V54, P137, DOI 10.1146/annurev.arplant.54.031902.134921; Hall DB, 2002, J BIOL CHEM, V277, P46043, DOI 10.1074/jbc.M208911200; Kang JG, 2001, CELL, V105, P625, DOI 10.1016/S0092-8674(01)00370-1; Klahre U, 1998, PLANT CELL, V10, P1677, DOI 10.1105/tpc.10.10.1677; Li J, 2002, CELL, V110, P213, DOI 10.1016/S0092-8674(02)00812-7; Li JM, 2002, SCIENCE, V295, P1299; Li JM, 1996, SCIENCE, V272, P398, DOI 10.1126/science.272.5260.398; Nam KH, 2002, CELL, V110, P203, DOI 10.1016/S0092-8674(02)00814-0; Nemhauser JL, 2004, J EXP BOT, V55, P265, DOI 10.1093/jxb/erh024; Poovaiah BW, 1996, J PLANT PHYSIOL, V149, P553, DOI 10.1016/S0176-1617(96)80333-6; POOVAIAH BW, 1987, CRC CR REV PLANT SCI, V6, P47, DOI 10.1080/07352688709382247; Schumacher K, 1999, GENE DEV, V13, P3259, DOI 10.1101/gad.13.24.3259; SHACKLOCK PS, 1992, NATURE, V358, P753, DOI 10.1038/358753a0; Snedden WA, 2001, NEW PHYTOL, V151, P35, DOI 10.1046/j.1469-8137.2001.00154.x; Szekeres M, 1996, CELL, V85, P171, DOI 10.1016/S0092-8674(00)81094-6; Thummel CS, 2002, GENE DEV, V16, P3113, DOI 10.1101/gad.1042102; Wang ZY, 2001, NATURE, V410, P380, DOI 10.1038/35066597; Yang TB, 2003, TRENDS PLANT SCI, V8, P505, DOI 10.1016/j.tplants.2003.09.004; Zielinski RE, 2002, PLANTA, V214, P446, DOI 10.1007/s004250100636	29	109	130	3	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					741	745		10.1038/nature03973	http://dx.doi.org/10.1038/nature03973			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193053				2022-12-28	WOS:000232157900054
J	Lanfear, DE; Jones, PG; Marsh, S; Cresci, S; McLeod, HL; Spertus, JA				Lanfear, DE; Jones, PG; Marsh, S; Cresci, S; McLeod, HL; Spertus, JA			beta(2)-Adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BETA(1)-ADRENERGIC RECEPTOR POLYMORPHISMS; MYOCARDIAL-INFARCTION; DESENSITIZATION; HAPLOTYPES; ALBUTEROL; QUALITY; CARE	Context Previous data support an association between polymorphisms of the beta(1)- and beta(2)-adrenergic receptors (ADRB1 and ADRB2) and surrogate end points of response to beta-adrenergic blocker therapy. However, no associations between these polymorphisms and mortality have been demonstrated. Objective To evaluate the effect of ADRB1 Arg389Gly (1165 CG), Ser49Gly (145 AG), and ADRB2 Gly16Arg (46 GA), Gln27GIu (79 CG) genotypes on survival among patients discharged with prescribed beta-blockers after an acute coronary syndrome (ACS). Design, Setting, and Patients Prospective cohort study of 735 ACS patients admitted to 2 Kansas City, Mo, medical centers between March 2001 and October 2002; 597 patients were discharged with beta-blocker therapy. Main Outcome Measure Multivariable-adjusted time to all-cause 3-year mortality. Results There were 84 deaths during follow-up. There was a significant association between ADRB2 genotype and 3-year mortality among patients prescribed beta-blocker therapy. For the 79 CG polymorphism, Kaplan-Meier 3-year mortality rates were 16% (35 deaths), 11% (27 deaths), and 6% (4 deaths) for the CC, CG, and GG genotypes, respectively (P=.03; adjusted hazard ratios [AHRs], 0.51 [95% confidence interval (0), 0.30-0.87] for CG vs CC and 0.24 (95% Cl, 0.09-0.68) for GG vs CC, P=.004). For the ADRB2 46 GA polymorphism, 3-year Kaplan-Meier mortality estimates were 10% (17 deaths), 10% (28 deaths), and 20% (20 deaths) for the GG, GA, and AA genotypes, respectively (P=.005; AHRs, 0.48 [95% Cl, 0.27-0.86] for GA vs AA and 0.44 [95% Cl, 0.22-0.85] for GG vs AA, P=.02). No mortality difference between genotypes was found among patients not discharged with beta-blocker therapy for either the 79 CG or 46 GA polymorphisms (P=.98 and P=.49, respectively). The ADRB2 diplotype and compound genotypes were predictive of survival in patients treated with beta-blockers (P=.04 and P=.002; AHRs, 5.36 [95% Cl, 1.83-15.69] and 2.41 [95% CI,0.86-6.74] for 46 A homozygous and composite heterozygous vs 79 G homozygous, respectively). No association of the ADRB1 variants with mortality was observed in either the beta-blocker or no p-blocker groups. Conclusions Patients prescribed beta-blocker therapy after an ACS have differential survival associated with their ADRB2 genotypes. Further assessment of the benefits of beta-blocker therapy in high-risk genotype groups may be warranted.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA; Univ Missouri, Dept Med, Kansas City, MO 64110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Saint Luke's Hospital - Missouri; Saint Luke's Mid America Heart Institute; University of Missouri System; University of Missouri Kansas City	McLeod, HL (corresponding author), Washington Univ, Sch Med, Dept Med, 660 S Euclid Ave,Campus Box 8069, St Louis, MO 63110 USA.	hmcleod@im.wustl.edu	McLeod, Howard/ABD-8364-2021	McLeod, Howard/0000-0002-9004-9232	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS011282] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL077113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM063340] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS11282-01] Funding Source: Medline; NHLBI NIH HHS [P50 HL077113] Funding Source: Medline; NIGMS NIH HHS [U01 GM63340] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; *AM HEART ASS, 2004, HEART DIS STROK STAT; [Anonymous], 1986, Lancet, V2, P57; Belfer I, 2005, EUR J HUM GENET, V13, P341, DOI 10.1038/sj.ejhg.5201313; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; Chong LK, 2000, PHARMACOGENETICS, V10, P153, DOI 10.1097/00008571-200003000-00007; Dishy V, 2001, NEW ENGL J MED, V345, P1030, DOI 10.1056/NEJMoa010819; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Evrengul H, 2004, JPN HEART J, V45, P11, DOI 10.1536/jhj.45.11; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; Heckbert SR, 2003, CIRCULATION, V107, P2021, DOI 10.1161/01.CIR.0000065231.07729.92; HENNEKENS CH, 1999, CLIN TRIALS CARDIOVA; HERLITZ J, 1988, CARDIOLOGY, V75, P117, DOI 10.1159/000174358; Hoit BD, 2000, AM HEART J, V139, P537, DOI 10.1016/S0002-8703(00)90099-1; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Israel E, 2001, INT ARCH ALLERGY IMM, V124, P183, DOI 10.1159/000053705; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; Johnson JA, 2003, CLIN PHARMACOL THER, V74, P44, DOI 10.1016/S0009-9236(03)00068-7; Kaye DM, 2003, PHARMACOGENETICS, V13, P379, DOI 10.1097/00008571-200307000-00002; Levin MC, 2002, J BIOL CHEM, V277, P30429, DOI 10.1074/jbc.M200681200; Liggett SB, 2000, AM J RESP CRIT CARE, V161, pS197, DOI 10.1164/ajrccm.161.supplement_2.a1q4-10; Liu J, 2003, CLIN PHARMACOL THER, V74, P372, DOI 10.1016/S0009-9236(03)00224-8; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; Mason DA, 1999, J BIOL CHEM, V274, P12670, DOI 10.1074/jbc.274.18.12670; Muhlestein JB, 2001, AM J CARDIOL, V87, P257, DOI 10.1016/S0002-9149(00)01354-0; Ohte N, 2002, J NUCL MED, V43, P780; Perez JM, 2003, NAT MED, V9, P1300, DOI 10.1038/nm930; *R DEV COR TEAM, 2005, R LANG ENV STAT COMP; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Spertus John A., 2003, Circulation, V107, P1681, DOI 10.1161/01.CIR.0000062026.90014.63; Terra Steven G, 2005, Pharmacogenet Genomics, V15, P227, DOI 10.1097/01213011-200504000-00006; White HL, 2003, EUR J HEART FAIL, V5, P463, DOI 10.1016/S1388-9842(03)00044-8	34	147	162	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	2005	294	12					1526	1533		10.1001/jama.294.12.1526	http://dx.doi.org/10.1001/jama.294.12.1526			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TF	16189366				2022-12-28	WOS:000232113400023
J	Mort, M; Convery, I; Baxter, J; Bailey, C				Mort, M; Convery, I; Baxter, J; Bailey, C			Psychosocial effects of the 2001 UK foot and mouth disease epidemic in a rural population: qualitative diary based study	BRITISH MEDICAL JOURNAL			English	Article							HUMAN CONSEQUENCES; HEALTH; TOOL	Objectives To understand the health and social consequences of the 2001 foot and mouth disease epidemic for a rural population. Design Longitudinal qualitative analysis. Setting North Cumbria, the worst affected area in Britain. Sample Purposive sample of 54 respondents divided into six demographically balanced rural occupational and population groups. Main outcome measures 3071 weekly diaries contributed over 18 months; 72 semistructured interviews (with the 54 diarists and 18 others); 12 group discussions with diarists. Results The disease epidemic was a human tragedy, not just an animal one. Respondents' reports showed that life after the foot and mouth disease epidemic was accompanied by distress, feelings of bereavement, fear of a new disaster, loss of trust in authority and systems of control, and the undermining of the value of local knowledge. Distress was experienced across diverse groups well beyond the farming community. Many of these effects continued to feature in the diaries throughout the 18 month period. Conclusions The use of a rural citizens' panel allowed data capture from a wide spectrum of the rural population and showed that a greater number of workers and residents had traumatic experiences than has previously been reported. Recommendations for future disaster management include joint service reviews of what counts as a disaster, regular NHS and voluntary sector sharing of intelligence, debriefing and peer support for front line workers, increased community involvement in disposal site or disaster management, and wider, more flexible access to regeneration funding and rural health outreach work.	Univ Lancaster, Inst Hlth Res, Lancaster LA1 4YT, England; Univ Cent Lancashire, Preston PR1 2HE, Lancs, England; Univ Lancaster, Int Ctr Uplands, Lancaster LA1 4YW, England	Lancaster University; University of Central Lancashire; Lancaster University	Mort, M (corresponding author), Univ Lancaster, Inst Hlth Res, Lancaster LA1 4YT, England.	m.mort@lancaster.ac.uk	Bailey, Catherine/AAJ-1121-2020; Convery, Ian/C-7141-2008	Convery, Ian/0000-0003-2527-5660; Mort, Margaret Mary Elizabeth/0000-0003-0188-324X				Anderson I., 2002, FOOT MOUTH DIS 2001; Barnes DM, 1996, QUAL HEALTH RES, V6, P429, DOI 10.1177/104973239600600309; Calvert N, 2001, BRIT MED J, V323, P236, DOI 10.1136/bmj.323.7306.236/a; Campbell D, 2003, SOC LEGAL STUD, V12, P425, DOI 10.1177/0964663903012004002; Coote A., 1997, CITIZENS JURIES THEO; *CUMBR FOOT MOUTH, 2002, INQ REP; ELLIOT H, 1997, SOCIOLOGICAL RES ONL, P2; Erikson K., 1994, NEW SPECIES TROUBLE; ERIKSON K, IN WAKE OF FLOOD; Erikson K. T., 1976, WAKE FLOOD; FAGBO S, 2001, BMJ; Gibson G, 2001, BRIT MED J, V322, P1491, DOI 10.1136/bmj.322.7300.1491; Hunter M, 2001, BRIT MED J, V322, P881, DOI 10.1136/bmj.322.7291.881; Jones RK, 2000, QUAL HEALTH RES, V10, P555, DOI 10.1177/104973200129118543; Kashefi E, 2004, HEALTH EXPECT, V7, P290, DOI 10.1111/j.1369-7625.2004.00295.x; MCLEAN I, 2000, ABERFAN GOVT DISASTE; McMillen JC, 1997, J CONSULT CLIN PSYCH, V65, P733, DOI 10.1037/0022-006X.65.5.733; Morse JM, 2003, QUAL HEALTH RES, V13, P447, DOI 10.1177/1049732302250719; MORTON HG, 2001, BMJ; National Audit Office, 2002, 2001 OUTBR FOOT MOUT; PERROS C, 2003, NORMAL ACCIDENTS; PERROW C, 2003, NORMAL ACCIDENTS; Polanyi M., 2009, TACIT DIMENSION; POPE C, 1995, BRIT MED J, V311, P42, DOI 10.1136/bmj.311.6996.42; Prempeh H, 2001, BMJ-BRIT MED J, V322, P565, DOI 10.1136/bmj.322.7286.565; Ruston A, 1998, BRIT MED J, V316, P1060; Strauss A., 1998, BASICS QUALITATIVE R; SYED AA, 2002, DIABETES TODAY, V5, P75; VERBRUGGE LM, 1980, MED CARE, V18, P73, DOI 10.1097/00005650-198001000-00006; WYNNE B, 1997, RISK ENV MODERNITY N, P45; [No title captured]	31	70	73	0	14	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	NOV 26	2005	331	7527					1234	1237		10.1136/bmj.38603.375856.68	http://dx.doi.org/10.1136/bmj.38603.375856.68			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	988NB	16214809	Green Published, Bronze			2022-12-28	WOS:000233606800017
J	Allwright, S; Paul, G; Greiner, B; Mullally, BJ; Pursell, L; Kelly, A; Bonner, B; D'Eath, M; McConnell, B; McLaughlin, JP; O'Donovan, D; O'Kane, E; Perry, IJ				Allwright, S; Paul, G; Greiner, B; Mullally, BJ; Pursell, L; Kelly, A; Bonner, B; D'Eath, M; McConnell, B; McLaughlin, JP; O'Donovan, D; O'Kane, E; Perry, IJ			Legislation for smoke-free workplaces and health of bar workers in Ireland: before and after study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; HOSPITALITY WORKERS; PASSIVE SMOKING; EXPOSURE; POPULATION; NICOTINE; COTININE; LAW	Objectives To compare exposure to secondhand smoke and respiratory health in bar staff in the Republic of Ireland and Northern Ireland before and after the introduction of legislation for smoke-free workplaces in the Republic. Design Comparisons before and after the legislation in intervention and control regions. Setting Public houses in three areas in the Republic (intervention) and one area in Northern Ireland (control). Participants 329 bar staff enrolled in baseline survey; 249 (76%) followed up one year later. Of these, 158 were non-smokers both at baseline and follow-up. Main outcome measures Salivary cotinine concentration, self reported exposure to secondhand smoke, and respiratory and sensory irritation symptoms. Results In bar staff in the Republic who did not themselves smoke, salivary cotinine concentrations dropped by 80% after the smoke-free law (from median 29.0 nmol/l (95% confidence interval 18.2 to 43.2 nmol/l) to 5.1 nmol/l (2.8 to 13.1 nmol/l) in contrast with a 20% decline in Northern Ireland over the same period (from median 25.3 nmol/l (10.4 to 59.2 nmol/l) to 20.4 nmol/l (13.2 to 33.8 nmol/l)). Changes in self reported exposure to secondhand smoke were consistent with the changes in cotinine concentrations. Reporting any respiratory symptom declined significantly in the Republic (down 16.7%, - 26.1% to - 7.3%) but not in Northern Ireland (0% difference, - 32.7% to 32.7%). After adjustment for confounding, respiratory symptoms declined significantly more in the Republic than in Northern Ireland and the decline in cotinine concentration was twice as great. Conclusion The smoke-free law in the Republic of Ireland protects non-smoking bar workers from exposure to secondhand smoke.	Univ Dublin Trinity Coll, Trinity Coll Ctr Hlth Sci, AMNCH, Dept Publ Hlth & Primary Care, Dublin 24, Ireland; Natl Univ Ireland Univ Coll Cork, Dept Epidemiol & Publ Hlth, Cork, Ireland; Natl Univ Ireland, Dept Hlth Promot, Galway, Ireland; Western Investing Hlth Partnership, Londonderry BT47 6FN, North Ireland; Western Hlth & Social Serv Board, Dept Publ Hlth Med, Londonderry BT47 6FN, North Ireland; Natl Univ Ireland Univ Coll Dublin, Sch Phys, Dublin 4, Ireland; Altnagelvin Hosp, Old Nursing Home, Derry Healthy Cities, Londonderry BT47 6SB, North Ireland	Trinity College Dublin; University College Cork; Ollscoil na Gaillimhe-University of Galway; University College Dublin	Allwright, S (corresponding author), Univ Dublin Trinity Coll, Trinity Coll Ctr Hlth Sci, AMNCH, Dept Publ Hlth & Primary Care, Dublin 24, Ireland.	sllwrght@tcd.ie	Greiner, Birgit/L-2262-2019; Pursell, Lisa/AAU-7978-2020; Allwright, Shane/A-1537-2012	Greiner, Birgit/0000-0002-2749-6662; Pursell, Lisa/0000-0002-2894-6303; Allwright, Shane/0000-0003-1841-4781; O'Donovan, Diarmuid/0000-0001-8771-7271; Perry, Ivan/0000-0002-4965-9792	NCI NIH HHS [R01 CA90955] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allwright S, 2004, BRIT J GEN PRACT, V54, P811; ALLWRIGHT S, 2003, REPORT HLTH EFFECTSE; [Anonymous], 2005, GOING SMOK FREE MED; Bates MN, 2002, TOB CONTROL, V11, P125, DOI 10.1136/tc.11.2.125; *CAL ENV PROT AG, 1997, HLTH EFF EXP ENV TOB; Chen R, 2002, J Cancer Epidemiol Prev, V7, P85, DOI 10.1080/147666502321082746; Eisner MD, 1998, JAMA-J AM MED ASSOC, V280, P1909, DOI 10.1001/jama.280.22.1909; *EUR NETW SMOK PRE, 2001, SMOK WORKPL IMPR HLT; Farrelly MC, 2005, TOB CONTROL, V14, P236, DOI 10.1136/tc.2004.008839; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; FONG GT, TOB CONTROL; FONG GT, IN PRESS TOB CONTROL; Heloma A, 2003, ADDICTION, V98, P1111, DOI 10.1046/j.1360-0443.2003.00429.x; HINCHLIFFE D, 2005, CMND6374; HINCHLIFFE D, 2005, 6374 CM; Howell F, 2004, BRIT MED J, V328, P847, DOI 10.1136/bmj.328.7444.847; International Agency for Research on Cancer of WHO, 2004, TOB SMOK INV SMOK; Jacob P, 1999, AM J PUBLIC HEALTH, V89, P731, DOI 10.2105/AJPH.89.5.731; Jarvis MJ, 2003, NICOTINE TOB RES, V5, P349, DOI 10.1080/1462220031000094213; JARVIS MJ, 1992, BRIT J ADDICT, V87, P111; Kawachi I, 2005, BRIT MED J, V330, P265, DOI 10.1136/bmj.330.7486.265; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LUND J, 2005, SMOKE FREE BURS REST; Lund J., 2005, SMOKE FREE BARS REST; MULCAHY M, 2002, 9 INT C IND AIR QUAL, P44; MULCAHY M, 2005, INDOOR AIR S11, V15, P86; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233, DOI 10.1001/jama.275.16.1233; Royal College of Physicians' Tobacco Advisory Group, 2005, GOING SMOK FREE MED; SPROSTON K, 2004, HLTH SURVEY ENGLAND, V3; TUNNEY M, 2005, IRISH TIMES     0824	30	163	164	1	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	2005	331	7525					1117	+		10.1136/bmj.38636.499225.55	http://dx.doi.org/10.1136/bmj.38636.499225.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	985ZI	16230313	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000233417300015
J	Reddy, GV; Meyerowitz, EM				Reddy, GV; Meyerowitz, EM			Stem-cell homeostasis and growth dynamics can be uncoupled in the Arabidopsis shoot apex	SCIENCE			English	Article							MERISTEM; CLAVATA1; WUSCHEL; REGULATOR; THALIANA; LOOP; FATE; GENE	The shoot apical meristem (SAM) is a collection of stem cells that resides at the tip of each shoot and provides the cells of the shoot. It is divided into functional regions. The central zone (CZ) at the tip of the meristem is the domain of expression of the CLAVATA3 (CLV3) gene, encoding a putative ligand for a transmembrane receptor kinase, CLAVATA1, active in cells of the rib meristem (RM), located just below the CZ. We show here that CLV3 restricts its own domain of expression (the CZ) by preventing differentiation of peripheral zone cells (PZ), which surround the CZ, into CZ Celts and restricts overall SAM size by a separate, tong-range effect on cell division rate.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Meyerowitz, EM (corresponding author), CALTECH, Div Biol, MC 156-29,1200 E Calif Blvd, Pasadena, CA 91125 USA.	meyerow@its.caltech.edu	Meyerowitz, Elliot M/A-7118-2009					Brand U, 2000, SCIENCE, V289, P617, DOI 10.1126/science.289.5479.617; Chuang CF, 2000, P NATL ACAD SCI USA, V97, P4985, DOI 10.1073/pnas.060034297; CLARK SE, 1993, DEVELOPMENT, V119, P397; CLARK SE, 1995, DEVELOPMENT, V121, P2057; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Craft J, 2005, PLANT J, V41, P899, DOI 10.1111/j.1365-313X.2005.02342.x; Fletcher LC, 1999, SCIENCE, V283, P1911, DOI 10.1126/science.283.5409.1911; Laufs P, 1998, PLANT CELL, V10, P1375, DOI 10.1105/tpc.10.8.1375; Laux T, 1996, DEVELOPMENT, V122, P87; Lenhard M, 2002, DEVELOPMENT, V129, P3195; Mayer KFX, 1998, CELL, V95, P805, DOI 10.1016/S0092-8674(00)81703-1; Meyerowitz EM, 1997, CELL, V88, P299, DOI 10.1016/S0092-8674(00)81868-1; Reddy GV, 2004, DEVELOPMENT, V131, P4225, DOI 10.1242/dev.01261; Schoof H, 2000, CELL, V100, P635, DOI 10.1016/S0092-8674(00)80700-X; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227	15	185	198	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2005	310	5748					663	667		10.1126/science.1116261	http://dx.doi.org/10.1126/science.1116261			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	980ET	16210497				2022-12-28	WOS:000232997700038
J	Al-Shahi, R; Vousden, C; Warlow, C				Al-Shahi, R; Vousden, C; Warlow, C		SIVMS Steering Committ	Bias from. requiring explicit consent from all participants in observational research: Prospective, population based study	BRITISH MEDICAL JOURNAL			English	Article								Objective To evaluate the differences between adults who consent to participate in observational research, and those who do not. Design Prospective, population based cohort study. Setting Primary and secondary care throughout Scotland. Participants 187 adults (aged >= 16 years) resident in Scotland at the time of their first diagnosis of a brain arteriovenous malformation in 1999-2002. Intervention Postal consent form sent via participants' general practitioner. Main outcome measures Differences between consenters and non-consenters in demographic and clinical features at first presentation, and outcome during follow-up. Results 111 adults (59%) consented to participate in the study. These consenters were not significantly different from non-consenters in age, sex, or socioeconomic status at first presentation. However, consenters were significantly more likely than non-consenters to present alive and independent, and with a seizure. During follow-up, consenters were Significantly more likely to receive interventional treatment. Although consenters' survival was significantly better, they were more likely to have a seizure during follow-up. Presentation with intracranial haemorrhage conferred a higher risk of subsequent haemorrhage when the whole cohort was analysed, but not when it was restricted to consenters. Conclusions We have found differences between adults who consent to participate in observational records-based research and those who do not, or cannot, consent. Blanket requirements for explicit consent for the use of individuals' identifiable data can bias disease registers, epidemiological studies, and health services research.	Univ Edinburgh, Western Gen Hosp, Div Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Al-Shahi, R (corresponding author), Univ Edinburgh, Western Gen Hosp, Div Clin Neurosci, Bramwell Dott Bldg, Edinburgh EH4 2XU, Midlothian, Scotland.	Rustam.Al-Shahi@ed.ac.uk		Al-Shahi Salman, Rustam/0000-0002-2108-9222				Al-Shahi R, 2000, BMJ-BRIT MED J, V321, P1031, DOI 10.1136/bmj.321.7268.1031; Al-Shahi R, 2003, STROKE, V34, P1156, DOI 10.1161/01.STR.0000069012.23858.69; Al-Shahi R, 2001, BRAIN, V124, P1900, DOI 10.1093/brain/124.10.1900; [Anonymous], 2001, LANCET, V358, P597; Jacobsen SJ, 1999, MAYO CLIN PROC, V74, P330, DOI 10.4065/74.4.330; Melton LJ, 1997, NEW ENGL J MED, V337, P1466, DOI 10.1056/NEJM199711133372012; Tu JV, 2004, NEW ENGL J MED, V350, P1414, DOI 10.1056/NEJMsa031697; 2001, LANCET, V338, P597	8	73	74	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 22	2005	331	7522					942	945		10.1136/bmj.38624.397569.68	http://dx.doi.org/10.1136/bmj.38624.397569.68			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979UR	16223793	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000232970900023
J	Mancia, F; Shapiro, L				Mancia, F; Shapiro, L			ADAM and Eph: How ephrin-signaling cells become detached	CELL			English	Editorial Material							CLEAVAGE	Ephrin ligands presented on one cell surface associate with their receptors on the surface of a juxtaposed cell, often resulting in cell-cell repulsion. In this issue of Cell, Janes et al. (2005) show that the ephrin ligand can be proteolytically released from its membrane tether by a complex on the opposing cell composed of the ephrin receptor and an ADAM metalloprotease.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Edward S Harkness Eye Inst, New York, NY 10032 USA	Columbia University; Columbia University	Mancia, F (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA.		Shapiro, Lawrence/AAE-7172-2019	Mancia, Filippo/0000-0003-3293-2200				Barton WA, 2004, ADV PROTEIN CHEM, V68, P65; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Brown A, 2000, CELL, V102, P77, DOI 10.1016/S0092-8674(00)00012-X; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Janes PW, 2005, CELL, V123, P291, DOI 10.1016/j.cell.2005.08.014; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856	8	17	17	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 21	2005	123	2					185	187		10.1016/j.cell.2005.10.004	http://dx.doi.org/10.1016/j.cell.2005.10.004			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239135	Bronze			2022-12-28	WOS:000232794100004
J	Jude, E; Chakraborty, A				Jude, E; Chakraborty, A			Left sixth cranial nerve palsy with herpes zoster ophthalmicus	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Tameside Gen Hosp, Ashton Under Lyne OL6 9RW, England		Jude, E (corresponding author), Tameside Gen Hosp, Ashton Under Lyne OL6 9RW, England.								0	7	7	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	2005	353	16					E14	E14		10.1056/NEJMicm040899	http://dx.doi.org/10.1056/NEJMicm040899			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975IC	16236731				2022-12-28	WOS:000232653200013
J	Phimister, EG				Phimister, EG			A tetraploid twist on the embryonic stem cell	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Cowan CA, 2005, SCIENCE, V309, P1369, DOI 10.1126/science.1116447	1	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	2005	353	16					1646	1647		10.1056/NEJMp058254	http://dx.doi.org/10.1056/NEJMp058254			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975IC	16236733				2022-12-28	WOS:000232653200002
J	Srivastava, R; Fraser, C; Gentleman, D; Jamieson, LA; Murphy, MJ				Srivastava, R; Fraser, C; Gentleman, D; Jamieson, LA; Murphy, MJ			Lesson of the week - Hyperamylasaemia: not the usual suspects	BRITISH MEDICAL JOURNAL			English	Review							ISOAMYLASE		Ninewells Hosp, Dept Biochem Med, Dundee DD1 9SY, Scotland; Royal Victoria Hosp, Ctr Brain Injury Rehabil, Dundee, Scotland; Ninewells Hosp, Dept Histopathol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Srivastava, R (corresponding author), Ninewells Hosp, Dept Biochem Med, Dundee DD1 9SY, Scotland.	rajeev.srivastava@tuht.scot.nhs.uk	Murphy, Michael J/K-4008-2012	Murphy, Michael J/0000-0001-6735-125X				BOYLE CEL, 1985, BRIT MED J, V291, P1389, DOI 10.1136/bmj.291.6506.1389; GRIFFIN NR, 1990, INT J GYNECOL PATHOL, V9, P41, DOI 10.1097/00004347-199001000-00003; Juang C M, 2000, Zhonghua Yi Xue Za Zhi (Taipei), V63, P710; KOSCHES DS, 1989, J CLIN GASTROENTEROL, V11, P43, DOI 10.1097/00004836-198902000-00010; MAEDA M, 1982, EUR J CANCER CLIN ON, V18, P123, DOI 10.1016/0277-5379(82)90054-2; Nakao M, 1996, Kyobu Geka, V49, P1069; ORIORDAN T, 1990, GYNECOL ONCOL, V36, P432, DOI 10.1016/0090-8258(90)90158-H; PERRIER NAD, 1994, MAYO CLIN PROC, V69, P366; Ross CM, 2002, ANN CLIN BIOCHEM, V39, P616, DOI 10.1258/000456302760413450; Tanaka Y, 1986, Gan No Rinsho, V32, P111	10	9	9	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 15	2005	331	7521					890	891		10.1136/bmj.331.7521.890	http://dx.doi.org/10.1136/bmj.331.7521.890			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975SX	16223823	Green Published			2022-12-28	WOS:000232683300026
J	Sudbo, J; Lee, JJ; Lippman, SM; Mork, J; Sagen, S; Flatner, N; Ristimaki, A; Sudbo, A; Mao, L; Zhou, X; Kildal, W; Evensen, JF; Reith, A; Dannenberg, AJ				Sudbo, J; Lee, JJ; Lippman, SM; Mork, J; Sagen, S; Flatner, N; Ristimaki, A; Sudbo, A; Mao, L; Zhou, X; Kildal, W; Evensen, JF; Reith, A; Dannenberg, AJ			RETRACTED: Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study (Retracted Article. See vol 367, pg 382, 2006)	LANCET			English	Article; Retracted Publication							SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; ASPIRIN USE; CYCLOOXYGENASE-2; PREVENTION; HEAD; SMOKING; NECK; PROSTAGLANDINS; INHIBITION	Background Non-steroidal anti-inflammatory drugs (NSAIDs) seem to prevent several types of cancer, but could increase the risk of cardiovascular complications. We investigated whether use of NSAIDs was associated with a change in the incidence of oral cancer or overall or cardiovascular mortality. Methods We undertook a nested case-control study to analyse data from a population-based database (Cohort of Norway; CONOR), which consisted of prospectively obtained health data from all regions of Norway. People with oral cancer were identified from the 9241 individuals in CONOR who were at increased risk of oral cancer because of heavy smoking (>= 15 pack-years), and matched controls were selected from the remaining heavy smokers (who did not have cancer). Findings We identified and analysed 454 (5%) people with oral cancer (279 men, 175 women, mean [SD] age at diagnosis 63.3 [13.2] years) and 454 matched controls (n=908); 263 (29%) had used NSAIDs, 83 (9%) had used paracetamol (for a minimum of 6 months), and 562 (62%) had used neither drug. NSAID use (but not paracetamol use) was associated with a reduced risk of oral cancer (including in active smokers; hazard ratio 0.47, 95% CI 0.37-0.60, p<0.0001). Smoking cessation also lowered the risk of oral cancer (0.41, 0.32-0.52, p<0.0001). Additionally, long-term use of NSAIDs (but not paracetamol) was associated with an increased risk of cardiovascular-disease-related death (2.06, 1.34-3.18, p=0.001). NSAID use did not significantly reduce overall mortality (p=0.17). Interpretation Long-term use of NSAIDs is associated with a reduced incidence of oral cancer (including in active smokers), but also with an increased risk of death due to cardiovascular disease. These findings highlight the need for a careful risk-benefit analysis when the long-term use of NSAIDs is considered.	Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, N-0310 Oslo, Norway; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; Univ Oslo, Natl Hosp, Oslo, Norway; Canc Registry Norway, Oslo, Norway; Norwegian Radium Hosp, Res Fdn, Montebello, Norway; Norwegian Radium Hosp, Dept Pathol, Div Cytol, Montebello, Norway; Norwegian Radium Hosp, Dept Med Informat, Oslo, Norway; Univ Helsinki, Cent Hosp, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki, Biomedicum Helsinki, Mol & Canc Biol Res Programme, FIN-00014 Helsinki, Finland; Norwegian Univ Sci & Technol, Dept Phys, N-7034 Trondheim, Norway; Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, Montebello, Norway; Cornell Univ, Weill Med Coll, Dept Med, New York, NY USA	University of Oslo; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Oslo; National Hospital Norway; University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Norwegian University of Science & Technology (NTNU); University of Oslo; Cornell University	Sudbo, J (corresponding author), Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, N-0310 Oslo, Norway.	jon.sudbo@rh.uio.no	Mao, Li/C-7570-2011; Lee, Jack/P-7331-2019; Center, Univ of Texas-M D Anderson Cancer/AAE-8182-2019	Mao, Li/0000-0001-7263-3358; Lee, Jack/0000-0002-4584-929X; Center, Univ of Texas-M D Anderson Cancer/0000-0001-5469-9214	NCI NIH HHS [R01 CA082578, P01CA106451] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA106451, R01CA082578] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbruzzese JL, 2004, CANCER CELL, V6, P321, DOI 10.1016/j.ccr.2004.09.021; AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; Baron JA, 2003, PROG EXP TUMOR RES, V37, P1; BLOT WJ, 1988, CANCER RES, V48, P3282; Bosetti C, 2003, BRIT J CANCER, V88, P672, DOI 10.1038/sj.bjc.6600820; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Buskens CJ, 2003, SCAND J GASTROENTERO, V38, P87, DOI 10.1080/00855920310002753; Chan G, 1999, CANCER RES, V59, P991; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; CORNWALL H, 1983, J ORAL MAXIL SURG, V41, P795, DOI 10.1016/S0278-2391(83)80046-9; Dannenberg AJ, 2001, LANCET ONCOL, V2, P544, DOI 10.1016/S1470-2045(01)00488-0; Dannenberg AJ, 2005, J CLIN ONCOL, V23, P254, DOI 10.1200/JCO.2005.09.112; ELING TE, 1990, ANNU REV PHARMACOL, V30, P1, DOI 10.1146/annurev.pa.30.040190.000245; Engeland A, 1996, CANCER CAUSE CONTROL, V7, P366, DOI 10.1007/BF00052943; Farrow DC, 1998, CANCER EPIDEM BIOMAR, V7, P97; Gray N, 2004, ACTA ONCOL, V43, P8, DOI 10.1080/02841860310017937; Greenspan D, 2004, NEW ENGL J MED, V350, P1382, DOI 10.1056/NEJMp048028; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Johnsen SP, 2005, ARCH INTERN MED, V165, P978, DOI 10.1001/archinte.165.9.978; JUNG TTK, 1985, LARYNGOSCOPE, V95, P307; KARMALI RA, 1984, CANCER LETT, V22, P333, DOI 10.1016/0304-3835(84)90171-X; Keller S, 2000, Educ Health (Abingdon), V13, P387; LUBIN JH, 1986, J CHRON DIS, V39, P379, DOI 10.1016/0021-9681(86)90124-4; Mann JR, 2004, CANCER J, V10, P145, DOI 10.1097/00130404-200405000-00001; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; MARNETT LJ, 1978, BIOCHEM BIOPH RES CO, V82, P210, DOI 10.1016/0006-291X(78)90597-1; Moraitis D, 2005, CANCER RES, V65, P664; MORK J, 1995, APMIS, V103, P375, DOI 10.1111/j.1699-0463.1995.tb01121.x; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; PARKIN DM, 2002, CANC INCIDENCE 5 CON, V8, P516; PERKINS TM, 1982, ORAL SURG ORAL MED O, V53, P170, DOI 10.1016/0030-4220(82)90283-3; Quinn MJ, 2003, ANN ONCOL, V14, P1148, DOI 10.1093/annonc/mdg307; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Sokka T, 2004, RHEUM DIS CLIN N AM, V30, P851, DOI 10.1016/j.rdc.2004.07.002; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Sorensen HT, 2003, BRIT J CANCER, V88, P1687, DOI 10.1038/sj.bjc.6600945; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Sudbo J, 2005, J CLIN ONCOL, V23, P1927, DOI 10.1200/JCO.2005.03.172; Sudbo J, 2004, NEW ENGL J MED, V350, P1405, DOI 10.1056/NEJMoa033374; Sudbo J, 2003, ORAL ONCOL, V39, P497, DOI 10.1016/S1368-8375(03)00012-5; Sudbo J, 2001, NEW ENGL J MED, V344, P1270, DOI 10.1056/NEJM200104263441702; Terry MB, 2004, JAMA-J AM MED ASSOC, V291, P2433, DOI 10.1001/jama.291.20.2433; THUN MJ, 1993, CANCER RES, V53, P1322; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Tingle LR, 2003, J SCHOOL HEALTH, V73, P64, DOI 10.1111/j.1746-1561.2003.tb03574.x; Wiesner M, 2002, J EARLY ADOLESCENCE, V22, P5, DOI 10.1177/0272431602022001001; World Health Organization, 1955, INT CLASS DIS	47	54	57	1	36	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 15	2005	366	9494					1359	1366		10.1016/S0140-6736(05)67488-0	http://dx.doi.org/10.1016/S0140-6736(05)67488-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	973ZW	16226613	Bronze			2022-12-28	WOS:000232562100027
J	Nisoli, E; Tonello, C; Cardile, A; Cozzi, V; Bracale, R; Tedesco, L; Falcone, S; Valerio, A; Cantoni, O; Clementi, E; Moncada, S; Carruba, MO				Nisoli, E; Tonello, C; Cardile, A; Cozzi, V; Bracale, R; Tedesco, L; Falcone, S; Valerio, A; Cantoni, O; Clementi, E; Moncada, S; Carruba, MO			Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS	SCIENCE			English	Article							LIFE-SPAN EXTENSION; SACCHAROMYCES-CEREVISIAE; NITRIC-OXIDE; CELL-SURVIVAL; PPAR-GAMMA; MICE; METABOLISM; MAMMALS; WEIGHT; TISSUE	Calorie restriction extends life span in organisms ranging from yeast to mammals. Here, we report that Calorie restriction for either 3 or 12 months induced endothelial nitric oxide synthase (eNOS) expression and 3',5'-cyclic guanosine monophosphate formation in various tissues of male mice. This was accompanied by mitochondrial biogenesis, with increased oxygen consumption and adenosine triphosphate production, and an enhanced expression of sirtuin 1. These effects were strongly attenuated in eNOS null-mutant mice. Thus, nitric oxide plays a fundamental role in the processes induced by calorie restriction and may be involved in the extension of Life span in mammals.	Univ Milan, Luigi Sacco Hosp, Dept Preclin Sci, Integrated Labs Network, I-20157 Milan, Italy; Ist Auxol Italiano, I-20149 Milan, Italy; Eugenio Medea Sci Inst, I-23842 Bosisio Parini, Italy; Univ Urbino, Ist Farmacol & Farmacognosia, I-61029 Urbino, Italy; Osped San Raffaele, Dipartimento Biotecnol, Stem Cell Res Inst, I-20132 Milan, Italy; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of Milan; Luigi Sacco Hospital; IRCCS Istituto Auxologico Italiano; IRCCS Eugenio Medea; University of Urbino; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of London; University College London	Nisoli, E (corresponding author), Univ Milan, Luigi Sacco Hosp, Dept Preclin Sci, Integrated Labs Network, I-20157 Milan, Italy.	enzo.nisoli@unimi.it	Nisoli, Enzo/D-6526-2014; Tedesco, Laura/HHZ-5493-2022; Valerio, Alessandra/B-3413-2009; FALCONE, Sestina/F-6103-2014	Nisoli, Enzo/0000-0002-6670-1630; Valerio, Alessandra/0000-0001-5844-2256; FALCONE, Sestina/0000-0002-3574-0602; Carruba, Michele/0000-0003-4589-387X; BRACALE, Renata/0000-0003-3650-7033				Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Chin CH, 2004, GENE DEV, V18, P1970, DOI 10.1101/gad.1213104; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Cook S, 2003, SWISS MED WKLY, V133, P360; Dere E, 2002, GENES BRAIN BEHAV, V1, P204, DOI 10.1034/j.1601-183X.2002.10402.x; Dessi-Fulgheri P, 1999, HYPERTENSION, V33, P658, DOI 10.1161/01.HYP.33.2.658; Fenster CP, 2004, FREE RADICAL BIO MED, V37, P695, DOI 10.1016/j.freeradbiomed.2004.05.021; GOODRICK CL, 1990, MECH AGEING DEV, V55, P69, DOI 10.1016/0047-6374(90)90107-Q; Higami Y, 2003, FASEB J, V17, P415, DOI 10.1096/fj.03-0678fje; Houthoofd K, 2002, EXP GERONTOL, V37, P1359, DOI 10.1016/S0531-5565(02)00172-9; Ingram DK, 2004, ANN NY ACAD SCI, V1019, P412, DOI 10.1196/annals.1297.074; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793; Larrouy D, 1999, INT J OBESITY, V23, P1327, DOI 10.1038/sj.ijo.0801106; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; MASORO EJ, 1982, P NATL ACAD SCI-BIOL, V79, P4239, DOI 10.1073/pnas.79.13.4239; Miwa S, 2004, ANN NY ACAD SCI, V1019, P388, DOI 10.1196/annals.1297.069; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59	26	849	878	1	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					314	317		10.1126/science.1117728	http://dx.doi.org/10.1126/science.1117728			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224023				2022-12-28	WOS:000232670100052
J	Baigent, C; Keech, A; Kearney, PM; Blackwell, L; Buck, G; Pollicino, C; Kirby, A; Sourjina, T; Peto, R; Collins, R; Simes, J				Baigent, C; Keech, A; Kearney, PM; Blackwell, L; Buck, G; Pollicino, C; Kirby, A; Sourjina, T; Peto, R; Collins, R; Simes, J		CTT Collaborators	Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins	LANCET			English	Article							CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; PRIMARY-PREVENTION; SERUM-CHOLESTEROL; CARDIAC OUTCOMES; RISK-FACTORS; ATORVASTATIN; EVENTS; MEN; MULTICENTER	Background Results of previous randomised trials have shown that interventions that lower LDL cholesterol concentrations can significantly reduce the incidence of coronary heart disease (CHD) and other major vascular events in a wide range of individuals. But each separate trial has limited power to assess particular outcomes or particular categories of participant. Methods A prospective meta-analysis of data from 90 056 individuals in 14 randomised trials of statins was done. Weighted estimates were obtained of effects on different clinical outcomes per 1.0 mmol/L reduction in LDL cholesterol. Findings During a mean of 5 years, there were 8186 deaths, 14 348 individuals had major vascular events, and 5103 developed cancer. Mean LDL cholesterol differences at 1 year ranged from 0.35 mmol/L to 1.77 mmol/L (mean 1.09) in these trials. There was a 12% proportional reduction in all-cause mortality per mmol/L reduction in LDL cholesterol (rate ratio [RR] 0.88, 95% CI 0.84-0.91; p<0.0001). This reflected a 19% reduction in coronary mortality (0.81, 0.76-0.85; p<0.0001), and non-significant reductions in non-coronary vascular mortality (0.93, 0.83-1.03; p=0.2) and non-vascular mortality (0.95, 0.90-1.01; p=0.1). There were corresponding reductions in myocardial infarction or coronary death (0.77, 0.74-0.80; p<0.0001), in the need for coronary revascularisation (0.76, 0.73-0.80; p<0.0001), in fatal or non-fatal stroke (0.83, 0.78-0.88; p<0.0001), and, combining these, of 21% in any such major vascular event (0.79, 0.77-0.81; p<0.0001). The proportional reduction in major vascular events differed significantly (p<0.0001) according to the absolute reduction in LDL cholesterol achieved, but not otherwise. These benefits were significant within the first year, but were greater in subsequent years. Taking all years together, the overall reduction of about one fifth per mmol/L LDL cholesterol reduction translated into 48 (95% CI 39-57) fewer participants having major vascular events per 1000 among those with pre-existing CHD at baseline, compared with 25 (19-31) per 1000 among participants with no such history. There was no evidence that statins increased the incidence of cancer overall (1.00, 0.95-1.06; p=0.9) or at any particular site. Interpretation Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics. The absolute benefit relates chiefly to an individual's absolute risk of such events and to the absolute reduction in LDL cholesterol achieved. These findings reinforce the need to consider prolonged statin treatment with substantial LDL cholesterol reductions in all patients at high risk of any type of major vascular event.	Clin Trial Serv Unit, Oxford OX3 7LF, England; Epidemiol Studies Unit, Oxford OX3 7LF, England; Univ Sydney, Natl Hlth & Med Res Council Clin Trials Ctr, Sydney, NSW 2006, Australia	University of Oxford; University of Oxford; University of Sydney	Baigent, C (corresponding author), Clin Trial Serv Unit, Richard Doll Bldg,Old Rd Campus, Oxford OX3 7LF, England.	ctt@ctsu.ox.ac.uk	Simes, Robert John/P-1497-2014; Adiels, Martin/C-9278-2011; Collins, Rory/ABA-8487-2020	Kearney, Patricia/0000-0001-9599-3540; Buck, Georgina/0000-0001-5909-4265	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI DOI 10.1016/S1062-1458(03)00049-7; [Anonymous], 1995, Am J Cardiol, V75, P1130; Athyros VG, 2002, CURR MED RES OPIN, V18, P220, DOI 10.1185/030079902125000787; Campeau L, 1997, NEW ENGL J MED, V336, P153; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; Colhoun HM, 2004, LANCET, V364, P685, DOI 10.1016/S0140-6736(04)16895-5; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins R, 2003, LANCET, V361, P2005; Cullen P, 1997, AM J CARDIOL, V80, P1287, DOI 10.1016/S0002-9149(97)00667-X; CUMMINGS P, 1994, ANN INTERN MED, V120, P848, DOI 10.7326/0003-4819-120-10-199405150-00006; De Backer G, 2003, ATHEROSCLEROSIS, V171, P145, DOI 10.1016/j.atherosclerosis.2003.10.001; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATM EARL BREAST C; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GISSI Prevenzione Investigators, 2000, ITAL HEART J, V1, P810; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Holdaas H, 2003, LANCET, V361, P2024, DOI 10.1016/S0140-6736(03)13638-0; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1991, CANCER CAUSE CONTROL, V2, P253, DOI 10.1007/BF00052142; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071; OLIVER MF, 1991, LANCET, V337, P1529, DOI 10.1016/0140-6736(91)93208-Q; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedersen TR, 1999, ATHEROSCLEROSIS, V144, P38, DOI 10.1016/S0021-9150(99)80143-9; Poynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; *SEARCH INV, STUD EFF ADD RED CHO; Serruys PWJC, 2002, JAMA-J AM MED ASSOC, V287, P3215, DOI 10.1001/jama.287.24.3215; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Shannon J, 2005, AM J EPIDEMIOL, V162, P318, DOI 10.1093/aje/kwi203; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Thompson PD, 2003, JAMA-J AM MED ASSOC, V289, P1681, DOI 10.1001/jama.289.13.1681; Tobert JA, 2003, NAT REV DRUG DISCOV, V2, P517, DOI 10.1038/nrd1112; Tolman KG, 2002, AM J CARDIOL, V89, P1374, DOI 10.1016/S0002-9149(02)02355-X; Tonkin A, 1998, NEW ENGL J MED, V339, P1349	46	5057	5340	11	463	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 8	2005	366	9493					1267	1278		10.1016/S0140-6736(05)67394-1	http://dx.doi.org/10.1016/S0140-6736(05)67394-1			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971ST	16214597				2022-12-28	WOS:000232405700025
J	Dreyfus, R; Baudry, J; Roper, ML; Fermigier, M; Stone, HA; Bibette, J				Dreyfus, R; Baudry, J; Roper, ML; Fermigier, M; Stone, HA; Bibette, J			Microscopic artificial swimmers	NATURE			English	Article							LOW-REYNOLDS-NUMBER; ROD-LIKE CHAINS; DRIVEN MICROFILAMENTS; FRICTION COEFFICIENT; FILAMENTS; DYNAMICS; PROPULSION; SPHERES; FLUID	Microorganisms such as bacteria and many eukaryotic cells propel themselves with hair-like structures known as flagella, which can exhibit a variety of structures and movement patterns(1). For example, bacterial flagella are helically shaped(2) and driven at their bases by a reversible rotary engine(3), which rotates the attached flagellum to give a motion similar to that of a corkscrew. In contrast, eukaryotic cells use flagella that resemble elastic rods(4) and exhibit a beating motion: internally generated stresses give rise to a series of bends that propagate towards the tip(5-7). In contrast to this variety of swimming strategies encountered in nature, a controlled swimming motion of artificial micrometre-sized structures has not yet been realized. Here we show that a linear chain of colloidal magnetic particles linked by DNA and attached to a red blood cell can act as a flexible artificial flagellum. The filament aligns with an external uniformmagnetic field and is readily actuated by oscillating a transverse field. We find that the actuation induces a beating pattern that propels the structure, and that the external fields can be adjusted to control the velocity and the direction of motion.	ParisTech, ESPCI, CNRS,UMR 7612, Lab Colloides & Mat Div, F-75005 Paris, France; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; Ecole Super Phys & Chim Ind Ville Paris, CNRS, UMR 7636, Lab Phys & mecan Milieux Heterogenes, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Harvard University; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Sorbonne Universite; Universite Paris Cite	Dreyfus, R (corresponding author), ParisTech, ESPCI, CNRS,UMR 7612, Lab Colloides & Mat Div, 10 Rue Vauquelin, F-75005 Paris, France.	remi.dreyfus@espci.fr	Baudry, Jean/A-7344-2016; Dreyfus, Remi/H-7028-2013; Baudry, Jean/AAX-6267-2020; Stone, Howard A/B-6435-2008	Baudry, Jean/0000-0002-5526-499X; Dreyfus, Remi/0000-0002-4498-2582; Baudry, Jean/0000-0002-5526-499X; Roper, Marcus/0000-0001-8756-0112				Avron JE, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.186001; Becker LE, 2003, J FLUID MECH, V490, P15, DOI 10.1017/S0022112003005184; BERG HC, 1973, NATURE, V245, P380, DOI 10.1038/245380a0; BRAY D, 1992, CELL MOVEMENTS MOL M, P6; BRENNEN C, 1976, Journal of Mechanochemistry and Cell Motility, V3, P207; Camalet S, 1999, PHYS REV LETT, V82, P1590, DOI 10.1103/PhysRevLett.82.1590; Cosentino Lagomarsino M, 2003, J THEOR BIOL, V224, P215, DOI 10.1016/S0022-5193(03)00159-0; COX RG, 1971, J FLUID MECH, V45, P791; Darnton N, 2004, BIOPHYS J, V86, P1863, DOI 10.1016/S0006-3495(04)74253-8; Gibbons I.R., 1981, Journal of Cell Biology, V91, P107; Goubault C, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.260802; GRAY J, 1955, J EXP BIOL, V32, P802; ISHIJIMA S, 1994, CELL STRUCT FUNCT, V19, P349, DOI 10.1247/csf.19.349; KOENIG A, IN PRESS PHYS REV LE; Lowe CP, 2003, PHILOS T ROY SOC B, V358, P1543, DOI 10.1098/rstb.2003.1340; MEUNIER A, 1994, J PHYS II, V4, P561, DOI 10.1051/jp2:1994141; Najafi A, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.062901; PURCELL EM, 1977, AM J PHYS, V45, P3, DOI 10.1119/1.10903; SATIR P, 1968, J CELL BIOL, V39, P77, DOI 10.1083/jcb.39.1.77; SCHUSTER SC, 1994, ANNU REV BIOPH BIOM, V23, P509, DOI 10.1146/annurev.bb.23.060194.002453; Strick TR, 1996, SCIENCE, V271, P1835, DOI 10.1126/science.271.5257.1835; TAYLOR G, 1951, PROC R SOC LON SER-A, V209, P447, DOI 10.1098/rspa.1951.0218; Terray A, 2002, SCIENCE, V296, P1841, DOI 10.1126/science.1072133; Wiggins CH, 1998, BIOPHYS J, V74, P1043, DOI 10.1016/S0006-3495(98)74029-9; Wiggins CH, 1998, PHYS REV LETT, V80, P3879, DOI 10.1103/PhysRevLett.80.3879; ZAHN K, 1994, J PHYS II, V4, P555, DOI 10.1051/jp2:1994146	26	1382	1406	18	534	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 6	2005	437	7060					862	865		10.1038/nature04090	http://dx.doi.org/10.1038/nature04090			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208366				2022-12-28	WOS:000232338600041
J	MacLennan, A; Nelson, KB; Hankins, G; Speer, M				MacLennan, A; Nelson, KB; Hankins, G; Speer, M			Who will deliver our grandchildren? Implications of cerebral palsy litigation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MALPRACTICE; INTRAPARTUM; INSURANCE; INFANTS; CRISIS		NINDS, Neuroepidemiol Branch, NIH, Bethesda, MD 20892 USA; Univ Adelaide, Womens & Childrens Hosp, Dept Obstet & Gynaecol, Adelaide, SA, Australia; Univ Texas, Med Branch, Dept Obstet, Galveston, TX 77550 USA; Baylor Coll Med, Dept Pediat, Sect Neonatol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Adelaide; Womens & Childrens Hospital Australia; University of Texas System; University of Texas Medical Branch Galveston; Baylor College of Medicine	Nelson, KB (corresponding author), NINDS, Neuroepidemiol Branch, NIH, Bldg 10,Room 5S221, Bethesda, MD 20892 USA.	knelson@helix.nih.gov						*AM COLL OBST GYN, 2003, SURV PROF LIAB; [Anonymous], 2005, OBSTET GYNECOL, V105, P1161; BLAIR E, 1988, J PEDIATR-US, V112, P515, DOI 10.1016/S0022-3476(88)80161-6; BLynch C, 1996, BRIT J OBSTET GYNAEC, V103, P1236, DOI 10.1111/j.1471-0528.1996.tb09635.x; BUSSARD P, COMMUNICATION; *CA BIRTH DEF MON, DISC DAT ALL BIRTH D; Clark SL, 2003, AM J OBSTET GYNECOL, V188, P628, DOI 10.1067/mob.2003.204; Dodd JM, 2005, BEST PRACT RES CL OB, V19, P131, DOI 10.1016/j.bpobgyn.2004.11.004; FREEMAN AD, 1989, J HEALTH POLIT POLIC, V14, P707, DOI 10.1215/03616878-14-4-707; Freeman JM, 2003, HARVARD MED I FORUM, P5; Gibbs RS, 2004, AM J OBSTET GYNECOL, V191, P1, DOI 10.1016/j.ajog.2004.03.026; Gibson CS, 2003, OBSTET GYNECOL SURV, V58, P209, DOI 10.1097/01.OGX.0000055205.21611.6E; Hoffman DN, 2005, HASTINGS CENT REP, V35, P15; HOHMANN SF, 1994, J HLTH CARE FINANCE, V21, P6; HOWARD PK, 2004, PHILADELPHIA IN 0516; Koman LA, 2004, LANCET, V363, P1619, DOI 10.1016/S0140-6736(04)16207-7; KUBAN KCK, 1994, NEW ENGL J MED, V330, P188, DOI 10.1056/NEJM199401203300308; LILFORD RJ, 1990, BRIT J OBSTET GYNAEC, V97, P883, DOI 10.1111/j.1471-0528.1990.tb02442.x; MacLennan AH, 2002, MED J AUSTRALIA, V176, P425, DOI 10.5694/j.1326-5377.2002.tb04484.x; Martin JA, 2005, PEDIATRICS, V115, P619, DOI 10.1542/peds.2004-2695; Mello MM, 2005, OBSTET GYNECOL, V105, P1287, DOI 10.1097/01.AOG.0000163255.56004.b5; Milunsky A, 2003, J CHILD NEUROL, V18, P413, DOI 10.1177/08830738030180060401; Natale Renato, 2003, J Obstet Gynaecol Can, V25, P1007; Nelson KB, 2005, PEDIATR RES, V57, P494, DOI 10.1203/01.PDR.0000156477.00386.E7; Nelson KB, 1998, AM J OBSTET GYNECOL, V179, P507, DOI 10.1016/S0002-9378(98)70387-4; Nelson KB, 2003, NEW ENGL J MED, V349, P1765, DOI 10.1056/NEJMsb035364; Redline RW, 2003, HUM PATHOL, V34, P523, DOI 10.1016/S0046-8177(03)00229-6; Robinson P, 2005, OBSTET GYNECOL, V105, P1296, DOI 10.1097/01.AOG.0000157468.12907.1a; *ROYAL AUSTR NZ CO, 2004, OBST CLAIMS REV; Thacker SB, 2001, COCHRANE DB SYST REV, V2; Tussing AD, 1997, MED CARE, V35, P172, DOI 10.1097/00005650-199702000-00007; Werth B., 1998, DAMAGES ONE FAMILYS	32	65	65	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	2005	294	13					1688	1690		10.1001/jama.294.13.1688	http://dx.doi.org/10.1001/jama.294.13.1688			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970DC	16204669				2022-12-28	WOS:000232284400022
J	Kanner, AM				Kanner, AM			Depression and the risk of neurological disorders	LANCET			English	Editorial Material							RECURRENT MAJOR DEPRESSION; HIPPOCAMPAL VOLUME LOSS; PARKINSONS-DISEASE; REGISTER; SEIZURES; STROKE; ADULTS; STUDY/		Rush Univ, Med Ctr, Rush Epilepsy Ctr, Rush Med Coll,Dept Neurol Sci, Chicago, IL 60612 USA	Rush University	Kanner, AM (corresponding author), Rush Univ, Med Ctr, Rush Epilepsy Ctr, Rush Med Coll,Dept Neurol Sci, Chicago, IL 60612 USA.	andres_M_kanner@rush.edu						FORSGREN L, 1990, EPILEPSY RES, V6, P66, DOI 10.1016/0920-1211(90)90010-S; Hesdorffer DC, 2000, ANN NEUROL, V47, P246, DOI 10.1002/1531-8249(200002)47:2<246::AID-ANA17>3.3.CO;2-5; Kessing LV, 2004, J NEUROL NEUROSUR PS, V75, P1662, DOI 10.1136/jnnp.2003.031773; Larson SL, 2001, STROKE, V32, P1979, DOI 10.1161/hs0901.094623; Leentjens AFG, 2003, MOVEMENT DISORD, V18, P414, DOI 10.1002/mds.10387; Lewis AJ, 1934, J MENT SCI, V80, P1; MacQueen GM, 2003, P NATL ACAD SCI USA, V100, P1387, DOI 10.1073/pnas.0337481100; May M, 2002, STROKE, V33, P7, DOI 10.1161/hs0102.100529; Nilsson FM, 2001, ACTA PSYCHIAT SCAND, V104, P380, DOI 10.1034/j.1600-0447.2001.00372.x; Paterniti S, 2002, BRIT J PSYCHIAT, V181, P406, DOI 10.1192/bjp.181.5.406; Shah PJ, 1998, BRIT J PSYCHIAT, V172, P527, DOI 10.1192/bjp.172.6.527; Sheline YI, 2003, AM J PSYCHIAT, V160, P1516, DOI 10.1176/appi.ajp.160.8.1516; Sheline YI, 1996, P NATL ACAD SCI USA, V93, P3908, DOI 10.1073/pnas.93.9.3908; Sheline YI, 1999, J NEUROSCI, V19, P5034	14	17	18	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 1	2005	366	9492					1147	1148		10.1016/S0140-6736(05)67461-2	http://dx.doi.org/10.1016/S0140-6736(05)67461-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970LK	16198752				2022-12-28	WOS:000232311300008
J	Holmberg, L; Tamini, R				Holmberg, L; Tamini, R			Reducing cancer drug doses in obese patients: dogma disputed	LANCET			English	Editorial Material							TREATMENT-RELATED TOXICITY; BODY-MASS INDEX; BREAST-CANCER; CHEMOTHERAPY; SUBGROUP; OUTCOMES; TRIALS		Univ Uppsala Hosp, Reg Oncol Ctr, S-75185 Uppsala, Sweden; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA	Uppsala University; Uppsala University Hospital; Harvard University; Brigham & Women's Hospital	Holmberg, L (corresponding author), Univ Uppsala Hosp, Reg Oncol Ctr, S-75185 Uppsala, Sweden.	lars.holmberg@akademiska.se						Chlebowski RT, 2002, J CLIN ONCOL, V20, P1128, DOI 10.1200/JCO.20.4.1128; CHLEBOWSKI RT, 2005, P ASCO, V10; Colleoni M, 2005, LANCET, V366, P1108, DOI 10.1016/S0140-6736(05)67110-3; Griggs JJ, 2005, ARCH INTERN MED, V165, P1267, DOI 10.1001/archinte.165.11.1267; Holmes MD, 2005, JAMA-J AM MED ASSOC, V293, P2479, DOI 10.1001/jama.293.20.2479; Madarnas Y, 2001, BREAST CANCER RES TR, V66, P123, DOI 10.1023/A:1010635328299; Meyerhardt JA, 2003, CANCER, V98, P484, DOI 10.1002/cncr.11544; Meyerhardt JA, 2004, J CLIN ONCOL, V22, P648, DOI 10.1200/JCO.2004.07.121; Popper K, 2003, ALL LIFE IS PROBLEM, P3; Rosenau F, 2004, CHEMBIOCHEM, V5, P153, DOI 10.1002/cbic.200300761; Rosner GL, 1996, J CLIN ONCOL, V14, P3000, DOI 10.1200/JCO.1996.14.11.3000; Rothwell PM, 2005, LANCET, V365, P176, DOI 10.1016/S0140-6736(05)17709-5; Schulz KF, 2005, LANCET, V365, P1657, DOI 10.1016/S0140-6736(05)66516-6	13	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 24	2005	366	9491					1056	1057		10.1016/S0140-6736(05)67111-5	http://dx.doi.org/10.1016/S0140-6736(05)67111-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TL	16182880				2022-12-28	WOS:000232114000006
J	Selva-O'Calloghan, A; Gomez-Acha, J; Munne, P; Vilardell-Tarres, M				Selva-O'Calloghan, A; Gomez-Acha, J; Munne, P; Vilardell-Tarres, M			A 21-year-old girl with recurrent abdominal pain after a robbery	LANCET			English	Article									Hosp Gen Valle Hebron, Dept Internal Med, Barcelona 08035, Spain; Hosp Clin Barcelona, Toxicol Unit, Barcelona 08036, Spain	Hospital Universitari Vall d'Hebron; University of Barcelona; Hospital Clinic de Barcelona	Selva-O'Calloghan, A (corresponding author), Hosp Gen Valle Hebron, Dept Internal Med, Passeig Vall dHebron 119-120, Barcelona 08035, Spain.	aselva@vhebron.net		Selva-O'Callaghan, Albert/0000-0003-2823-9761				Bolanos AA, 1996, J BONE JOINT SURG AM, V78A, P422, DOI 10.2106/00004623-199603000-00014; McQuirter JL, 2001, J TRAUMA, V50, P892, DOI 10.1097/00005373-200105000-00020; Murdock CS, 1999, J TRAUMA, V47, P766, DOI 10.1097/00005373-199910000-00025	3	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 24	2005	366	9491					1136	1136		10.1016/S0140-6736(05)67426-0	http://dx.doi.org/10.1016/S0140-6736(05)67426-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TL	16182903				2022-12-28	WOS:000232114000033
J	Fraser, JA; Giles, SS; Wenink, EC; Geunes-Boyer, SG; Wright, JR; Diezmann, S; Allen, A; Stajich, JE; Dietrich, FS; Perfect, JR; Heitman, J				Fraser, JA; Giles, SS; Wenink, EC; Geunes-Boyer, SG; Wright, JR; Diezmann, S; Allen, A; Stajich, JE; Dietrich, FS; Perfect, JR; Heitman, J			Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak	NATURE			English	Article							NEOFORMANS VAR. GATTII; PATHOGENIC YEAST; RECOMBINATION; REPRODUCTION; TOXOPLASMA; AUSTRALIA; VIRULENCE; CANADA	Genealogy can illuminate the evolutionary path of important human pathogens. In some microbes, strict clonal reproduction predominates, as with the worldwide dissemination of Mycobacterium leprae, the cause of leprosy(1). In other pathogens, sexual reproduction yields clones with novel attributes, for example, enabling the efficient, oral transmission of the parasite Toxoplasma gondii(2). However, the roles of clonal or sexual propagation in the origins of many other microbial pathogen outbreaks remain unknown, like the recent fungal meningoencephalitis outbreak on Vancouver Island, Canada, caused by Cryptococcus gattii(3). Here we show that the C. gattii outbreak isolates comprise two distinct genotypes. The majority of isolates are hypervirulent and have an identical genotype that is unique to the Pacific Northwest. A minority of the isolates are significantly less virulent and share an identical genotype with fertile isolates from an Australian recombining population. Genotypic analysis reveals evidence of sexual reproduction, in which the majority genotype is the predicted offspring. However, instead of the classic a - alpha sexual cycle, the majority outbreak clone appears to have descended from two alpha mating-type parents. Analysis of nuclear content revealed a diploid environmental isolate homozygous for the major genotype, an intermediate produced during same-sex mating. These studies demonstrate how cryptic same-sex reproduction can enable expansion of a human pathogen to a new geographical niche and contribute to the ongoing production of infectious spores. This has implications for the emergence of other microbial pathogens and inbreeding in host range expansion in the fungal and other kingdoms.	Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Inst Genome Sci & Policy, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University; Duke University	Heitman, J (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.	heitm001@duke.edu	Stajich, Jason Eric/C-7297-2008; Fraser, James A/B-4918-2012; Heitman, Joseph/ABC-6006-2021	Stajich, Jason Eric/0000-0002-7591-0020; Fraser, James A/0000-0001-5724-5285; Diezmann, Stephanie/0000-0002-9528-1495	NIAID NIH HHS [R01 AI039115, R01 AI050113] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050113, R01AI039115] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALANO P, 1990, ANNU REV MICROBIOL, V44, P429, DOI 10.1146/annurev.mi.44.100190.002241; Boekhout T, 2001, MICROBIOL-UK, V147, P891, DOI 10.1099/00221287-147-4-891; Campbell LT, 2005, EUKARYOT CELL, V4, P1403, DOI 10.1128/EC.4.8.1403-1409.2005; Campbell LT, 2005, EUKARYOT CELL, V4, P1410, DOI 10.1128/EC.4.8.1410-1419.2005; Casadevall A, 1998, CRYPTOCOCCUS NEOFORM; Cox GM, 2003, INFECT IMMUN, V71, P173, DOI 10.1128/IAI.71.1.173-180.2003; Diaz MR, 2000, SYST APPL MICROBIOL, V23, P535, DOI 10.1016/S0723-2020(00)80028-4; Fraser JA, 2004, PLOS BIOL, V2, P2243, DOI 10.1371/journal.pbio.0020384; Fraser JA, 2003, EUKARYOT CELL, V2, P1036, DOI 10.1128/EC.2.5.1036-1045.2003; Gaunt MW, 2003, NATURE, V421, P936, DOI 10.1038/nature01438; Grigg ME, 2001, SCIENCE, V294, P161, DOI 10.1126/science.1061888; Halliday CL, 2003, J CLIN MICROBIOL, V41, P703, DOI 10.1128/JCM.41.2.703-711.2003; Hoang LMN, 2004, J MED MICROBIOL, V53, P935, DOI 10.1099/jmm.0.05427-0; Hull CM, 2005, EUKARYOT CELL, V4, P526, DOI 10.1128/EC.4.3.526-535.2005; Hull CM, 2002, ANNU REV GENET, V36, P557, DOI 10.1146/annurev.genet.36.052402.152652; Kidd SE, 2004, P NATL ACAD SCI USA, V101, P17258, DOI 10.1073/pnas.0402981101; Kwon-Chung Kyung J., 2002, Taxon, V51, P804, DOI 10.2307/1555045; KWONCHUNG KJ, 1976, MYCOLOGIA, V68, P942, DOI 10.2307/3758813; Lin XR, 2005, NATURE, V434, P1017, DOI 10.1038/nature03448; LITVINTSEVA AP, IN PRESS GENETICS; Loftus BJ, 2005, SCIENCE, V307, P1321, DOI 10.1126/science.1103773; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; Monot M, 2005, SCIENCE, V308, P1040, DOI 10.1126/science/1109759; RUIZ A, 1981, APPL ENVIRON MICROB, V41, P1225, DOI 10.1128/AEM.41.5.1225-1229.1981; Shimizu KK, 2004, SCIENCE, V306, P2081, DOI 10.1126/science.1103776; Su C, 2003, SCIENCE, V299, P414, DOI 10.1126/science.1078035; Sukroongreung S, 1998, MED MYCOL, V36, P419, DOI 10.1080/02681219880000661; Thomas CF, 2004, NEW ENGL J MED, V350, P2487, DOI 10.1056/NEJMra032588; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wickes BL, 1996, P NATL ACAD SCI USA, V93, P7327, DOI 10.1073/pnas.93.14.7327	30	382	409	0	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					1360	1364		10.1038/nature04220	http://dx.doi.org/10.1038/nature04220			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16222245				2022-12-28	WOS:000232829100055
J	O'Reilly, D; Rosato, M; Patterson, C				O'Reilly, D; Rosato, M; Patterson, C			Self reported health and mortality: ecological analysis based on electoral wards across the United Kingdom	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland	Queens University Belfast	O'Reilly, D (corresponding author), Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland.	d.oreilly@qub.ac.uk						Beatty C, 2000, REG STUD, V34, P617, DOI 10.1080/00343400050178429; Bentham G, 1995, J EPIDEMIOL COMMUN H, V49, pS57, DOI 10.1136/jech.49.Suppl_2.S57; CARRHILL RA, 1994, BRIT MED J, V309, P1046, DOI 10.1136/bmj.309.6961.1046; Kyffin RGE, 2004, BRIT MED J, V329, P887, DOI 10.1136/bmj.38238.508021.F7; Salomon JA, 2004, BMJ-BRIT MED J, V328, P258, DOI 10.1136/bmj.37963.691632.44	5	20	20	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 22	2005	331	7522					938	939		10.1136/bmj.38594.490532.AE	http://dx.doi.org/10.1136/bmj.38594.490532.AE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979UR	16195258	Bronze, Green Published			2022-12-28	WOS:000232970900021
J	Bierhaus, EB; Chapman, CR; Merline, WJ				Bierhaus, EB; Chapman, CR; Merline, WJ			Secondary craters on Europa and implications for cratered surfaces	NATURE			English	Article							IMPACT CRATERS; RATES; ICE; VELOCITY; SIZE	For several decades, most planetary researchers have regarded the impact crater populations on solid-surfaced planets and smaller bodies as predominantly reflecting the direct ('primary') impacts of asteroids and comets(1). Estimates of the relative and absolute ages of geological units on these objects have been based on this assumption(2). Here we present an analysis of the comparatively sparse crater population on Jupiter's icy moon Europa and suggest that this assumption is incorrect for small craters. We find that 'secondaries' (craters formed by material ejected from large primary impact craters) comprise about 95 per cent of the small craters (diameters less than 1 km) on Europa. We therefore conclude that large primary impacts into a solid surface (for example, ice or rock) produce far more secondaries than previously believed, implying that the small crater populations on the Moon, Mars and other large bodies must be dominated by secondaries. Moreover, our results indicate that there have been few small comets (less than 100 m diameter) passing through the jovian system in recent times, consistent with dynamical simulations(3)	Lockheed Martin, Space Explorat Syst, Denver, CO 80201 USA; SW Res Inst, Boulder, CO 80302 USA	Lockheed Martin	Bierhaus, EB (corresponding author), Lockheed Martin, Space Explorat Syst, MS S8110,POB 179, Denver, CO 80201 USA.	edward.b.bierhaus@lmco.com						Arakawa M, 1995, ICARUS, V118, P341, DOI 10.1006/icar.1995.1195; BERSTEIN GM, 2004, ASTRON J, V128, P1364; Bierhaus E. B., 2004, THESIS U COLORADO BO; Bierhaus EB, 2001, ICARUS, V153, P264, DOI 10.1006/icar.2001.6690; BIERHAUS EB, 2001, LUNAR PLANET SCI C, V32; Duda R. O., 1973, PATTERN CLASSIFICATI; Duncan M, 2004, SPACE SCI S, P193; FIELDER G, 1962, ASTROPHYS J, V135, P632, DOI 10.1086/147296; Hartmann WK, 1999, METEORIT PLANET SCI, V34, P167, DOI 10.1111/j.1945-5100.1999.tb01743.x; Hauber E, 2005, NATURE, V434, P356, DOI 10.1038/nature03423; Ivanov B.A., 2002, ASTEROIDS, P89; KATO M, 1995, ICARUS, V113, P423, DOI 10.1006/icar.1995.1032; Kato M, 2001, J GEOPHYS RES-PLANET, V106, P17567, DOI 10.1029/2000JE001269; KAULA WM, 1981, BASALTIC VOLCANISM T, pCH8; KOPAL Z, 1966, ICARUS, V5, P201, DOI 10.1016/0019-1035(66)90025-X; Levison HF, 2000, ICARUS, V143, P415, DOI 10.1006/icar.1999.6313; Levison HF, 1997, ICARUS, V127, P13, DOI 10.1006/icar.1996.5637; LUCCHITTA BK, 1977, ICARUS, V30, P80, DOI 10.1016/0019-1035(77)90123-3; McEwen AS, 2005, ICARUS, V176, P351, DOI 10.1016/j.icarus.2005.02.009; Murray JB, 2005, NATURE, V434, P352, DOI 10.1038/nature03379; Neukum G, 2001, SPACE SCI REV, V96, P55, DOI 10.1023/A:1011989004263; ROBERTS WA, 1964, ICARUS, V3, P348, DOI 10.1016/0019-1035(64)90045-4; Schenk PM, 2004, CAMB PLANET, P427; Shoemaker E. M., 1960, P LUNAR PLANETARY CO, V2, P7; Shoemaker E. M., 1965, 32700 JET PROP LAB, P75; Shoemaker EM, 1963, ADV ASTRONAUT SCI, V8, p70 ; VICKERY AM, 1987, GEOPHYS RES LETT, V14, P726, DOI 10.1029/GL014i007p00726; VICKERY AM, 1986, ICARUS, V67, P224, DOI 10.1016/0019-1035(86)90105-3; Zahnle K, 1998, ICARUS, V136, P202, DOI 10.1006/icar.1998.6015; Zahnle K, 2003, ICARUS, V163, P263, DOI 10.1016/S0019-1035(03)00048-4	30	80	83	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 20	2005	437	7062					1125	1127		10.1038/nature04069	http://dx.doi.org/10.1038/nature04069			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16237437				2022-12-28	WOS:000232660500037
J	Rual, JF; Venkatesan, K; Hao, T; Hirozane-Kishikawa, T; Dricot, A; Li, N; Berriz, GF; Gibbons, FD; Dreze, M; Ayivi-Guedehoussou, N; Klitgord, N; Simon, C; Boxem, M; Milstein, S; Rosenberg, J; Goldberg, DS; Zhang, LV; Wong, SL; Franklin, G; Li, SM; Albala, JS; Lim, JH; Fraughton, C; Llamosas, E; Cevik, S; Bex, C; Lamesch, P; Sikorski, RS; Vandenhaute, J; Zoghbi, HY; Smolyar, A; Bosak, S; Sequerra, R; Doucette-Stamm, L; Cusick, ME; Hill, DE; Roth, FP; Vidal, M				Rual, JF; Venkatesan, K; Hao, T; Hirozane-Kishikawa, T; Dricot, A; Li, N; Berriz, GF; Gibbons, FD; Dreze, M; Ayivi-Guedehoussou, N; Klitgord, N; Simon, C; Boxem, M; Milstein, S; Rosenberg, J; Goldberg, DS; Zhang, LV; Wong, SL; Franklin, G; Li, SM; Albala, JS; Lim, JH; Fraughton, C; Llamosas, E; Cevik, S; Bex, C; Lamesch, P; Sikorski, RS; Vandenhaute, J; Zoghbi, HY; Smolyar, A; Bosak, S; Sequerra, R; Doucette-Stamm, L; Cusick, ME; Hill, DE; Roth, FP; Vidal, M			Towards a proteome-scale map of the human protein-protein interaction network	NATURE			English	Article							ORFEOME VERSION 1.1; DATABASE; GENOME; ANNOTATION; RESOURCE; PLATFORM	Systematic mapping of protein-protein interactions, or 'interactome' mapping, was initiated in model organisms, starting with defined biological processes(1,2) and then expanding to the scale of the proteome(3-7). Although far from complete, such maps have revealed global topological and dynamic features of interactome networks that relate to known biological properties(8,9), suggesting that a human interactome map will provide insight into development and disease mechanisms at a systems level. Here we describe an initial version of a proteome-scale map of human binary protein-protein interactions. Using a stringent, high-throughput yeast two-hybrid system, we tested pairwise interactions among the products of similar to 8,100 currently available Gateway-cloned open reading frames and detected similar to 2,800 interactions. This data set, called CCSB-HI1, has a verification rate of similar to 78% as revealed by an independent co-affinity purification assay, and correlates significantly with other biological attributes. The CCSB-HI1 data set increases by similar to 70% the set of available binary interactions within the tested space and reveals more than 300 new connections to over 100 disease-associated proteins. This work represents an important step towards a systematic and comprehensive human interactome project.	Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Fac Notre Dame Paix, Unite Rech Biol Mol, B-5000 Namur, Belgium; Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Univ, Dept Pediat, Houston, TX 77030 USA; Baylor Univ, Dept Neurol, Houston, TX 77030 USA; Baylor Univ, Dept Neurosci, Houston, TX 77030 USA; Baylor Univ, Dept Mol & Human Genet, Houston, TX 77030 USA; Arcbay Inc, Boston, MA 01915 USA; Agencourt Biosci Corp, Beverly, MA 01915 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Baylor University; Baylor University; Baylor University; Baylor University	Vidal, M (corresponding author), Dana Farber Canc Inst, Ctr Canc Syst Biol, 44 Binney St, Boston, MA 02115 USA.	david_hill@dfci.harvard.edu; fritz_roth@hms.harvard.edu; marc_vidal@dfci.harvard.edu	Roth, Frederick P/H-6308-2011; Hill, David E/B-6617-2011; Boxem, Mike/B-8857-2011; Dreze, Matija/AAZ-3293-2020; Vidal, Marc/Y-2466-2019; Klitgord, Niels/B-5121-2009	Vidal, Marc/0000-0003-3391-5410; Cevik, Sebiha/0000-0002-0935-1929; /0000-0001-7002-8488; Roth, Frederick/0000-0002-6628-649X; Zoghbi, Huda/0000-0002-0700-3349; Rual, Jean-Francois/0000-0003-4465-8819	NATIONAL CANCER INSTITUTE [R33CA132073] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL098166] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG001715, RC4HG006066, R01HG001715, P50HG004233] Funding Source: NIH RePORTER; NCI NIH HHS [R33 CA132073] Funding Source: Medline; NHGRI NIH HHS [R01 HG001715, RC4 HG006066, P50 HG004233, U01 HG001715] Funding Source: Medline; NHLBI NIH HHS [U01 HL098166] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2; Bader GD, 2003, NUCLEIC ACIDS RES, V31, P248, DOI 10.1093/nar/gkg056; Berriz GF, 2003, BIOINFORMATICS, V19, P2502, DOI 10.1093/bioinformatics/btg363; Camon E, 2004, NUCLEIC ACIDS RES, V32, pD262, DOI 10.1093/nar/gkh021; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Eppig JT, 2005, NUCLEIC ACIDS RES, V33, pD471, DOI 10.1093/nar/gki113; Formstecher E, 2005, GENOME RES, V15, P376, DOI 10.1101/gr.2659105; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Gunsalus KC, 2005, NATURE, V436, P861, DOI 10.1038/nature03876; Han JDJ, 2004, NATURE, V430, P88, DOI 10.1038/nature02555; Huang X, 2004, CLIN NEUROPATHOL, V23, P1; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Lehner B, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r63; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Pagel P, 2005, BIOINFORMATICS, V21, P832, DOI 10.1093/bioinformatics/bti115; Peri S, 2003, GENOME RES, V13, P2363, DOI 10.1101/gr.1680803; Reboul J, 2003, NAT GENET, V34, P35, DOI 10.1038/ng1140; Rual JF, 2004, GENOME RES, V14, P2128, DOI 10.1101/gr.2973604; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vidal M, 2001, CELL, V104, P333, DOI 10.1016/S0092-8674(01)00221-5; Wagner A, 2001, MOL BIOL EVOL, V18, P1283, DOI 10.1093/oxfordjournals.molbev.a003913; Walhout AJM, 1999, GENOME RES, V9, P1128, DOI 10.1101/gr.9.11.1128; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Xenarios I, 2000, NUCLEIC ACIDS RES, V28, P289, DOI 10.1093/nar/28.1.289; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Zanzoni A, 2002, FEBS LETT, V513, P135, DOI 10.1016/S0014-5793(01)03293-8	30	2098	2192	9	274	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 20	2005	437	7062					1173	1178		10.1038/nature04209	http://dx.doi.org/10.1038/nature04209			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16189514				2022-12-28	WOS:000232660500048
J	Wilczek, F				Wilczek, F			An explorer and surveyor - Hermann Weyl	NATURE			English	Biographical-Item									MIT, Ctr Theoret Phys, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT)	Wilczek, F (corresponding author), MIT, Ctr Theoret Phys, Cambridge, MA 02142 USA.							Atiyah M, 2002, BIOGRAPHICAL MEMOIRS, V82, P1; WEYL H, PUBLICATION LIST	2	0	0	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 20	2005	437	7062					1095	1095		10.1038/4371095a	http://dx.doi.org/10.1038/4371095a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16237425	Bronze			2022-12-28	WOS:000232660500024
J	Nanda, R; Schumm, LP; Cummings, S; Fackenthal, JD; Sveen, L; Ademuyiwa, F; Cobleigh, M; Esserman, L; Lindor, NM; Neuhausen, SL; Olopade, OI				Nanda, R; Schumm, LP; Cummings, S; Fackenthal, JD; Sveen, L; Ademuyiwa, F; Cobleigh, M; Esserman, L; Lindor, NM; Neuhausen, SL; Olopade, OI			Genetic testing in an ethnically diverse cohort of high-risk women - A comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PEUTZ-JEGHERS-SYNDROME; CANCER-SUSCEPTIBILITY GENES; BREAST-OVARIAN CANCER; GENOMIC REARRANGEMENTS; PREVALENCE; HISTORY; OOPHORECTOMY; INDIVIDUALS; PENETRANCE; FREQUENCY	Context Ten years after BRCA1 and BRCA2 were first identified as major breast cancer susceptibility genes, the spectrum of mutations and modifiers of risk among many ethnic minorities remain undefined. Objectives To characterize the clinical predictors, spectrum, and frequency of BRCA1 and BRCA2 mutations in an ethnically diverse high-risk clinic population and to evaluate the performance of the BRCAPRO statistical model in predicting the likelihood of a mutation. Design, Setting, and Participants Comparative analysis of families (white, Ashkenazi Jewish, African American, Hispanic, Asian) with 2 or more cases of breast and/or ovarian cancer among first- and second-degree relatives. Families were identified at US sites between February 1992 and May 2003; in each family, the individual with the highest probability of being a mutation carrier was tested. Main Outcome Measures Frequency of BRCA1 and BRCA2 mutations and area under the receiver operating characteristic curve for the BRCAPRO model. Results The mutation spectrum was vastly different between families of African and European ancestry. Compared with non-Hispanic, non-Jewish whites, African Americans had a lower rate of deleterious BRCA1 and BRCA2 mutations but a higher rate of sequence variations (27.9% vs 46.2% and 44.2% vs 11.5%; P<.001 for overall comparison). Deleterious mutations in BRCA1 and BRCA2 were highest for Ashkenazi Jewish families (69.0%). Early age at diagnosis of breast cancer and number of first- and second-degree relatives with breast and ovarian cancer were significantly associated with an increased likelihood of carrying a BRCA1 or BRCA2 mutation. In discriminating between mutation carriers, BRCAPRO performed as well in African American families as it did in white and Jewish families, with an area under the curve of 0.77 (95% confidence interval, 0.61-0.88) for African American families and 0.70 (95% confidence interval, 0.60-0.79) for white and Jewish families combined. Conclusions These data support the use of BRCAPRO and genetic testing for BRCA1 and BRCA2 mutations in the management of high-risk African American families. Irrespective of ancestry, early age at diagnosis and a family history of breast and ovarian cancer are the most powerful predictors of mutation status and should be used to guide clinical decision making.	Univ Chicago, Med Ctr, Dept Med, Sect Hematol Oncol,Ctr Clin Canc Genet, Chicago, IL 60637 USA; Univ Chicago, Med Ctr, Dept Hlth Studies, Chicago, IL 60637 USA; Rush Med Coll, Chicago, IL 60612 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Mayo Clin, Rochester, MN USA; Univ Calif Irvine, Dept Med, Div Epidemiol, Irvine, CA 92717 USA	University of Chicago; University of Chicago Medical Center; University of Chicago; University of Chicago Medical Center; Rush University; University of California System; University of California San Francisco; Mayo Clinic; University of California System; University of California Irvine	Olopade, OI (corresponding author), Univ Chicago, Med Ctr, Dept Med, Sect Hematol Oncol,Ctr Clin Canc Genet, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.	folopade@medicine.bsd.uchicago.edu		Cobleigh, Melody/0000-0001-6385-4693; Schumm, Phil/0000-0002-3050-2429	NATIONAL CANCER INSTITUTE [R01CA074415, R01CA089085] Funding Source: NIH RePORTER; NCI NIH HHS [CA74415, R01 CA89085-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armstrong K, 2005, JAMA-J AM MED ASSOC, V293, P1729, DOI 10.1001/jama.293.14.1729; *BAYESMENDEL LAB, BRCAPRO; Berry DA, 2002, J CLIN ONCOL, V20, P2701, DOI 10.1200/JCO.2002.05.121; Berry DA, 1997, J NATL CANCER I, V89, P227, DOI 10.1093/jnci/89.3.227; Boardman LA, 1998, ANN INTERN MED, V128, P896, DOI 10.7326/0003-4819-128-11-199806010-00004; BROWNSTEIN MH, 1978, CANCER, V41, P2393, DOI 10.1002/1097-0142(197806)41:6<2393::AID-CNCR2820410644>3.0.CO;2-K; Bruinooge SS, 2003, J CLIN ONCOL, V21, P2397, DOI 10.1200/JCO.2003.03.189; Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; EASTON DF, 1993, AM J HUM GENET, V52, P678; Eng C, 2001, J MED GENET, V38, P824, DOI 10.1136/jmg.38.12.824; Euhus DM, 2002, J NATL CANCER I, V94, P844, DOI 10.1093/jnci/94.11.844; Fackenthal JD, 2005, J MED GENET, V42, P276, DOI 10.1136/jmg.2004.020446; Frank TS, 1998, J CLIN ONCOL, V16, P2417, DOI 10.1200/JCO.1998.16.7.2417; Frank TS, 2002, J CLIN ONCOL, V20, P1480, DOI 10.1200/JCO.20.6.1480; Gao Q, 2000, HUM GENET, V107, P186, DOI 10.1007/s004390000290; Gao Q, 1997, AM J HUM GENET, V60, P1233; Gayther SA, 1997, AM J HUM GENET, V60, P1239; Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228; Gorski B, 2000, AM J HUM GENET, V66, P1963, DOI 10.1086/302922; Hall M, 2005, JAMA-J AM MED ASSOC, V293, P1783, DOI 10.1001/jama.293.14.1783; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; Kriege M, 2004, NEW ENGL J MED, V351, P427, DOI 10.1056/NEJMoa031759; LI FP, 1988, CANCER RES, V48, P5358; Liede A, 2000, BRIT J CANCER, V82, P705; Lim W, 2003, BRIT J CANCER, V89, P308, DOI 10.1038/sj.bjc.6601030; MCCULLAGH P, 1991, GENERALIZED LINEAR M; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Montagna M, 2003, HUM MOL GENET, V12, P1055, DOI 10.1093/hmg/ddg120; *NAT CANC I, 2003, SEER STAT DAT INC; National Human Genome Research Institute, BREAST CANC INF COR; Newman B, 1998, JAMA-J AM MED ASSOC, V279, P915, DOI 10.1001/jama.279.12.915; Parmigiani G, 1998, AM J HUM GENET, V62, P145, DOI 10.1086/301670; Puget N, 1997, CANCER RES, V57, P828; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Schubert EK, 1997, AM J HUM GENET, V60, P1031; Shih HA, 2002, J CLIN ONCOL, V20, P994, DOI 10.1200/JCO.20.4.994; *STAT CORP, 2005, STATA STAT SOFTW REL; StoppaLyonnet D, 1997, AM J HUM GENET, V60, P1021; Szabo CI, 1997, AM J HUM GENET, V60, P1013; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; Unger MA, 2000, AM J HUM GENET, V67, P841, DOI 10.1086/303076; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	48	185	187	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	2005	294	15					1925	1933		10.1001/jama.294.15.1925	http://dx.doi.org/10.1001/jama.294.15.1925			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974OZ	16234499	Bronze			2022-12-28	WOS:000232602600022
J	Brahmer, JR				Brahmer, JR			Update in oncology	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							METASTATIC COLORECTAL-CANCER; CELL LUNG-CANCER; TAMOXIFEN THERAPY; BREAST-CANCER; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; PROSTATE-CANCER; PLUS IRINOTECAN; DOCETAXEL; MUTATIONS		Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Brahmer, JR (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,Room G94, Baltimore, MD 21231 USA.							Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312; Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Sinibaldi VJ, 2002, CANCER-AM CANCER SOC, V94, P1457, DOI 10.1002/cncr.10350; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736	13	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 18	2005	143	8					587	592		10.7326/0003-4819-143-8-200510180-00009	http://dx.doi.org/10.7326/0003-4819-143-8-200510180-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975PI	16230725				2022-12-28	WOS:000232674000009
J	Janisch, CP; Potts, M				Janisch, CP; Potts, M			Smart aid - the role of output-based assistance	LANCET			English	Editorial Material									KfW Banking Grp, Frankfurt, Germany; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Janisch, CP (corresponding author), KfW Banking Grp, Frankfurt, Germany.	pottsmalcolm@yahoo.com						*INT FERT RES PROG, 1981, SURG FAM PLANN METH; Prata N, 2005, B WORLD HEALTH ORGAN, V83, P274; 2005, DAILY TELEGRAPH 0604	3	14	14	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 15	2005	366	9494					1343	1344		10.1016/S0140-6736(05)67547-2	http://dx.doi.org/10.1016/S0140-6736(05)67547-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	973ZW	16226600	Bronze			2022-12-28	WOS:000232562100009
J	Joppi, R; Bertele', V; Garattini, S				Joppi, R; Bertele', V; Garattini, S			Disappointing biotech	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							THERAPY; LEUKEMIA; DRUGS; RISK		Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Garattini, S (corresponding author), Mario Negri Inst Pharmacol Res, Via Eritrea 62, I-20157 Milan, Italy.	garattini@marionegri.it	Garattini, Silvio/AAA-6390-2020; Bertele, Vittorio/AAA-6461-2020	Garattini, Silvio/0000-0003-0647-9297; Bertele, Vittorio/0000-0002-0032-7033				DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Eng CM, 2001, NEW ENGL J MED, V345, P9, DOI 10.1056/NEJM200107053450102; Eriksson BI, 1996, LANCET, V347, P635, DOI 10.1016/S0140-6736(96)91200-3; Garattini S, 1997, J NEPHROL, V10, P283; Gardam MA, 2003, LANCET INFECT DIS, V3, P148, DOI 10.1016/S1473-3099(03)00545-0; Goldman SC, 2001, BLOOD, V97, P2998, DOI 10.1182/blood.V97.10.2998; *INT JOINT EFF COM, 1995, LANCET, V346, P329; Nashan B, 1997, LANCET, V350, P1193, DOI 10.1016/S0140-6736(97)09278-7; Olsen NJ, 2004, NEW ENGL J MED, V350, P2167, DOI 10.1056/NEJMra032906; Perez EA, 2004, J CLIN ONCOL, V22, P322, DOI 10.1200/JCO.2004.01.120; Uppenkamp M, 2002, ANN HEMATOL, V81, P26, DOI 10.1007/s00277-001-0394-7; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; Winkler U, 1999, BLOOD, V94, P2217, DOI 10.1182/blood.V94.7.2217.419k02_2217_2224	13	33	36	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 15	2005	331	7521					895	897		10.1136/bmj.331.7521.895	http://dx.doi.org/10.1136/bmj.331.7521.895			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975SX	16223825	Green Published			2022-12-28	WOS:000232683300028
J	Sullivan, F; Wyatt, JC				Sullivan, F; Wyatt, JC			ABC of health informatics - How computers can help to share understanding with patients	BRITISH MEDICAL JOURNAL			English	Review							CANCER; BREAST		Univ Dundee, Dundee DD1 4HN, Scotland	University of Dundee	Sullivan, F (corresponding author), Univ Dundee, Dundee DD1 4HN, Scotland.		Sullivan, Frank m/A-7767-2009; Wyatt, Jeremy/F-8160-2010; Sullivan, Frank/L-8286-2019	Wyatt, Jeremy/0000-0001-7008-1473; Sullivan, Frank/0000-0002-6623-4964				Brassey J, 2001, BRIT MED J, V322, P529, DOI 10.1136/bmj.322.7285.529; Dickinson D, 2003, BRIT MED J, V327, P861, DOI 10.1136/bmj.327.7419.861-a; Emery J, 1999, BRIT MED J, V319, P32, DOI 10.1136/bmj.319.7201.32; Hersh WR, 1998, JAMA-J AM MED ASSOC, V280, P1347, DOI 10.1001/jama.280.15.1347; JENNETT B, 1976, LANCET, V1, P1031; Jones R, 1999, BRIT MED J, V319, P1241, DOI 10.1136/bmj.319.7219.1241; Lundin J, 2003, BRIT MED J, V326, P29, DOI 10.1136/bmj.326.7379.29; MURRAY E, 2004, COCHRANE DATABASE SY, DOI UNSP CD4274; RIDSDALE L, 1994, BRIT J GEN PRACT, V44, P367; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001	10	12	12	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 15	2005	331	7521					892	894		10.1136/bmj.331.7521.892	http://dx.doi.org/10.1136/bmj.331.7521.892			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975SX	16223824	Green Published			2022-12-28	WOS:000232683300027
J	Elvin, CM; Carr, AG; Huson, MG; Maxwell, JM; Pearson, RD; Vuocolo, T; Liyou, NE; Wong, DCC; Merritt, DJ; Dixon, NE				Elvin, CM; Carr, AG; Huson, MG; Maxwell, JM; Pearson, RD; Vuocolo, T; Liyou, NE; Wong, DCC; Merritt, DJ; Dixon, NE			Synthesis and properties of crosslinked recombinant pro-resilin	NATURE			English	Article							ELASTIC PROTEINS; SOUND PRODUCTION; IDENTIFICATION; LINKING; TIMBAL	Resilin is a member of a family of elastic proteins that includes elastin, as well as gluten, gliadin, abductin and spider silks. Resilin is found in specialized regions of the cuticle of most insects, providing low stiffness, high strain and efficient energy storage(1,2); it is best known for its roles in insect flight(3,4) and the remarkable jumping ability of fleas(5,6) and spittle bugs(7). Previously, the Drosophila melanogaster CG15920 gene was tentatively identified as one encoding a resilin-like protein(8,9) (pro-resilin). Here we report the cloning and expression of the first exon of the Drosophila CG15920 gene as a soluble protein in Escherichia coli. We show that this recombinant protein can be cast into a rubber-like biomaterial by rapid photochemical crosslinking. This observation validates the role of the putative elastic repeat motif in resilin function. The resilience ( recovery after deformation) of crosslinked recombinant resilin was found to exceed that of unfilled synthetic polybutadiene, a high resilience rubber. We believe that our work will greatly facilitate structural investigations into the functional properties of resilin and shed light on more general aspects of the structure of elastomeric proteins. In addition, the ability to rapidly cast samples of this biomaterial may enable its use in situ for both industrial and biomedical applications.	CSIRO Livestock Ind, St Lucia, Qld 4072, Australia; CSIRO Text & Fibre Technol, Geelong, Vic 3216, Australia; Univ Queensland, Sch Integrat Biol, St Lucia, Qld 4072, Australia; Australian Natl Univ, Res Sch Chem, Canberra, ACT 0200, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Queensland; Australian National University	Elvin, CM (corresponding author), CSIRO Livestock Ind, Queensland Biosci Precinct, St Lucia, Qld 4072, Australia.	chris.elvin@csiro.au	Merritt, David J/D-2318-2010; Huson, Mickey/K-2474-2012; Dixon, Nicholas E/A-1226-2008; elvin, chris/H-2333-2013; Vuocolo, Tony/H-7533-2013	Merritt, David J/0000-0002-8573-7508; Huson, Mickey/0000-0003-1859-7805; Dixon, Nicholas E/0000-0002-5958-6945; Vuocolo, Tony/0000-0002-5574-8126				AARON BB, 1981, BIOPOLYMERS, V20, P1247, DOI 10.1002/bip.1981.360200611; ANDERSEN SO, 1964, BIOCHIM BIOPHYS ACTA, V93, P213, DOI 10.1016/0304-4165(64)90289-2; Andersen SO, 2002, ELASTOMERIC PROTEINS; ANDERSEN SVEND OLAV, 1964, ADVANCES INSECT PHYSIOL, V2, P1, DOI 10.1016/S0065-2806(08)60071-5; Anderson S O, 1966, Acta Physiol Scand Suppl, V263, P1; Ardell DH, 2001, INSECT BIOCHEM MOLEC, V31, P965, DOI 10.1016/S0965-1748(01)00044-3; Burrows M, 2003, NATURE, V424, P509, DOI 10.1038/424509a; Cowie J.M.G., 1973, POLYM CHEM PHYS MODE; Fancy DA, 1999, P NATL ACAD SCI USA, V96, P6020, DOI 10.1073/pnas.96.11.6020; Gorb SN, 1999, NATURWISSENSCHAFTEN, V86, P552, DOI 10.1007/s001140050674; Gosline J, 2002, PHILOS T R SOC B, V357, P121, DOI 10.1098/rstb.2001.1022; Keeley FW, 2002, PHILOS T R SOC B, V357, P185, DOI 10.1098/rstb.2001.1027; Lehmann FO, 2001, J EXP BIOL, V204, P627; Li B, 2002, J MUSCLE RES CELL M, V23, P561, DOI 10.1023/A:1023474909980; Malencik DA, 1996, BIOCHEMISTRY-US, V35, P4375, DOI 10.1021/bi9526037; Neff D, 2000, ARTHROPOD STRUCT DEV, V29, P75, DOI 10.1016/S1467-8039(00)00014-1; Neville A., 1967, P R ENTOMOL SOC LOND, V32, P9; Pometun MS, 2004, J BIOL CHEM, V279, P7982, DOI 10.1074/jbc.M310948200; ROTHSCHILD M, 1975, PHILOS T ROY SOC B, V271, P457, DOI 10.1098/rstb.1975.0062; Rousseau R, 2004, BIOPHYS J, V86, P1393, DOI 10.1016/S0006-3495(04)74210-1; SINGARAVELU G, 1991, NATL ACAD SCI LETT, V14, P147; Skals N, 1999, J EXP BIOL, V202, P2937; Tatham AS, 2002, PHILOS T R SOC B, V357, P229, DOI 10.1098/rstb.2001.1031; Treloar L. R. G., 1975, PHYS TODAY, DOI DOI 10.1063/1.3060678; URRY DW, 2002, ELASTOMERIC PROTEINS, P54; VARMAN AR, 1980, EXPERIENTIA, V36, P564, DOI 10.1007/BF01965802; Weis-Fogh T., 1960, J EXP BIOL, V37, P887; WEISFOGH T, 1961, J MOL BIOL, V3, P520, DOI 10.1016/S0022-2836(61)80018-1; WEISFOGH T, 1961, CELL ORGANISM, P283; YOUNG D, 1995, J EXP BIOL, V198, P1001	30	377	409	10	205	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 13	2005	437	7061					999	1002		10.1038/nature04085	http://dx.doi.org/10.1038/nature04085			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16222249				2022-12-28	WOS:000232496100040
J	Kay, J; McCluskey, RT				Kay, J; McCluskey, RT			A 60-year-old man with skin lesions and renal insufficiency - Type II cryoglobulinemia with renal disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEPATITIS-C VIRUS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; MIXED CRYOGLOBULINEMIA; GLOMERULONEPHRITIS; INTERFERON; INFECTION		Massachusetts Gen Hosp, Rheumatol Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kay, J (corresponding author), Massachusetts Gen Hosp, Rheumatol Unit, Boston, MA 02114 USA.			Kay, Jonathan/0000-0002-8970-4260				AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3; Casato M, 1998, NEW ENGL J MED, V338, P1386, DOI 10.1056/NEJM199805073381914; CATTELL V, 1994, KIDNEY INT, V45, P945, DOI 10.1038/ki.1994.128; D'Amico G, 1998, KIDNEY INT, V54, P650, DOI 10.1046/j.1523-1755.1998.00028.x; EARLE DP, 1959, ANN INTERN MED, V51, P851, DOI 10.7326/0003-4819-51-5-851; FEINER H, 1977, AM J PATHOL, V88, P145; FERRARIO F, 1985, KIDNEY INT, V28, P513, DOI 10.1038/ki.1985.158; GLADMAN DD, 1978, J RHEUMATOL, V5, P142; GOREVIC PD, 1980, AM J MED, V69, P287, DOI 10.1016/0002-9343(80)90390-3; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Jennette JC, 1997, NEW ENGL J MED, V337, P1512, DOI 10.1056/NEJM199711203372106; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; MISIANI R, 1994, NEW ENGL J MED, V330, P751, DOI 10.1056/NEJM199403173301104; MONGA G, 1979, AM J PATHOL, V94, P271; MONTI G, 1995, QJM-MON J ASSOC PHYS, V88, P115; PASCUAL M, 1990, J INFECT DIS, V162, P569, DOI 10.1093/infdis/162.2.569; RENNKE HG, 1995, KIDNEY INT, V47, P643, DOI 10.1038/ki.1995.82; Sansonno D, 2003, BLOOD, V101, P3818, DOI 10.1182/blood-2002-10-3162; Zaja F, 2003, BLOOD, V101, P3827, DOI 10.1182/blood-2002-09-2856	20	9	10	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1605	1613		10.1056/NEJMcpc059026	http://dx.doi.org/10.1056/NEJMcpc059026			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221784				2022-12-28	WOS:000232486000016
J	Fruhwald, S; Frottier, P				Fruhwald, S; Frottier, P			Suicide in prison	LANCET			English	Editorial Material							CUSTODY		Caritas St Poelten, Community Mental Hlth Serv, St Polten, Austria; Justizanstalt Mittersteig, Vienna, Austria		Fruhwald, S (corresponding author), Caritas St Poelten, Community Mental Hlth Serv, St Polten, Austria.	psd.fruehwald@stpoelten.caritas.at						Bland RC, 1998, INT J LAW PSYCHIAT, V21, P273, DOI 10.1016/S0160-2527(98)00005-3; Fazel S, 2005, LANCET, V366, P1301, DOI 10.1016/S0140-6736(05)67325-4; Frottier P, 2001, FORTSCHR NEUROL PSYC, V69, P90, DOI 10.1055/s-2001-11173; Fruehwald S, 2000, SUICIDE LIFE-THREAT, V30, P272; Fruehwald S, 2004, BRIT J PSYCHIAT, V185, P494, DOI 10.1192/bjp.185.6.494; Joukamaa M, 1997, FORENSIC SCI INT, V89, P167, DOI 10.1016/S0379-0738(97)00119-9; Laishes J, 1997, Crisis, V18, P157, DOI 10.1027/0227-5910.18.4.157; MATSCHNIG T, IN PRESS PSYCHIAT PR; Priebe S, 2005, BMJ-BRIT MED J, V330, P123, DOI 10.1136/bmj.38296.611215.AE; *SCOTT PRIS SERV, 2003, SUIC RISK MAN CUST C; Spinellis C D, 1997, Crisis, V18, P152; Tatarelli R, 1999, EUR PSYCHIAT, V14, P109	12	25	25	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 8	2005	366	9493					1242	1244		10.1016/S0140-6736(05)67327-8	http://dx.doi.org/10.1016/S0140-6736(05)67327-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	971ST	16214582				2022-12-28	WOS:000232405700005
J	Pasche, B; Knobloch, TJ; Bian, YS; Liu, JJ; Phukan, S; Rosman, D; Kaklamani, V; Baddi, L; Siddiqui, FS; Frankel, W; Prior, TW; Schuller, DE; Agrawal, A; Lang, J; Dolan, ME; Vokes, EE; Lane, WS; Huang, CC; Caldes, T; Di Cristofano, A; Hampel, H; Nilsson, I; von Heijne, G; Fodde, R; Murty, VVVS; de la Chapelle, A; Weghorst, CM				Pasche, B; Knobloch, TJ; Bian, YS; Liu, JJ; Phukan, S; Rosman, D; Kaklamani, V; Baddi, L; Siddiqui, FS; Frankel, W; Prior, TW; Schuller, DE; Agrawal, A; Lang, J; Dolan, ME; Vokes, EE; Lane, WS; Huang, CC; Caldes, T; Di Cristofano, A; Hampel, H; Nilsson, I; von Heijne, G; Fodde, R; Murty, VVVS; de la Chapelle, A; Weghorst, CM			Somatic acquisition and signaling of TGFBR1*6A in cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GROWTH-FACTOR-BETA; CELL-CYCLE ARREST; II RECEPTOR GENE; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; CARCINOMA-CELLS; OVARIAN CARCINOMAS; REPLICATION ERROR	Context TGFBR1*6A is a common polymorphism of the type I transforming growth factor 0 receptor (TGFBR1). Epidemiological studies suggest that TGFBR1*6A may act as a tumor susceptibility allele. How TGFBR1*6A contributes to cancer development is largely unknown.. Objectives To determine whether TGFBR1*6A is somatically acquired by primary tumors and metastases during cancer development and whether the 3-amino acid deletion that differentiates TGFBR1*6A from TGFBR1 is part of the mature receptor or part of the signal sequence and to investigate TGFBR1*6A signaling in cancer cells. Design, Setting, and Patients Tumor And germline tissues from 531 patients with a diagnosis of head and neck, colorectal, or breast cancer recruited from 3 centers in the United States and from 1 center in Spain from June 1, 1994, through June 30, 2004, In vitro translation assays, MCF-7 breast cancer cells stably transfected with TGFBR1*6A, TGFBR1, or the vector alone, DLD-1 colorectal cancer cells that endogenously carry TGFBR1*6A, and SW48 colorectal cancer cells that do not carry TGFBR1*6A. Main Outcome Measures TGFBR1*6A somatic acquisition in cancer. Determination of the amino terminus of the mature TGFBR1*6A and TGFBR1 receptors. Determination of TGF-beta-dependent cell proliferation. Results TGFBR1*6A was somatically acquired in 13 of 44 (29.5%) colorectal cancer metastases, in 4 of 157 (2.5%) of colorectal tumors, in 4 of 226 (1.8%) head and neck primary tumors, and in none of the 104 patients with breast cancer. TGFBR1*6A somatic acquisition is not associated with loss of heterozygosity, microsatellite instability, or a mutator phenotype. The signal sequences of TGFBR1 and TGFBR1*6A are cleaved at the same site resulting in identical mature receptors. TGFBR1*6A may switch TGF-beta growth inhibitory signals into growth stimulatory signals in MCF-7 breast cancer cells and in DLD-1 colorectal cancer cells. Conclusions TGFBR1*6A is somatically acquired in 29.5% of liver metastases from colorectal cancer and may bestow cancer cells with a growth advantage in the presence of TGF-beta. The functional consequences of this conversion appear to be mediated by the TGFBR1*6A signal sequence rather than by the mature receptor. The results highlight a new facet of TGF-beta signaling in cancer and suggest that TGFBR1*6A may represent a potential therapeutic target in cancer.	Ohio State Univ, Div Environm Hlth Sci, Sch Publ Hlth, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Dept Otolaryngol, Columbus, OH 43210 USA; Ohio State Univ, Human Canc Genet Program, Columbus, OH 43210 USA; Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; Univ Chicago, Ctr Canc Res, Chicago, IL 60637 USA; Harvard Univ, Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA; Hosp Clin San Carlos, Oncol Mol Lab, Madrid, Spain; Fox Chase Canc Ctr, Human Genet Program, Div Populat Sci, Philadelphia, PA 19111 USA; Stockholm Univ, Arrhenius Lab, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; Erasmus Univ, Med Ctr, Josephine Nefkens Inst, Dept Pathol, Rotterdam, Netherlands; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Chicago; University of Chicago; Harvard University; Hospital Clinico San Carlos; Fox Chase Cancer Center; Stockholm University; Erasmus University Rotterdam; Erasmus MC; Columbia University	Pasche, B (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Med,Div Hematol Oncol,Canc Genet Program, 676 N St Clair St,Suite 880, Chicago, IL 60611 USA.	b-pasche@northwestern.edu	Di Cristofano, Antonio/B-4148-2016; von Heijne, Gunnar/AAH-9389-2019; di cristofano, antonio/AAJ-3796-2020; Vokes, Everett/Q-2146-2019; von Heijne, Gunnar/F-5576-2011; Fodde, Riccardo/AAW-9394-2021; Nilsson, IngMarie/H-2887-2012	di cristofano, antonio/0000-0003-2537-3228; von Heijne, Gunnar/0000-0002-4490-8569; Fodde, Riccardo/0000-0001-9839-4324; Frankel, Wendy/0000-0003-1658-1009; Weghorst, Christopher/0000-0003-2973-3980	NATIONAL CANCER INSTITUTE [P50CA090386, R01CA067941, P30CA016058, P50CA089018, U01CA067941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012704, R01DE011943, P50DE011921] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA16058, CA67941, CA90386, P30 CA016058, CA89018] Funding Source: Medline; NIDCR NIH HHS [R01 DE011943, P01 DE12704, P01 DE012704, DE/CA 11921] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baxter SW, 2002, CANCER EPIDEM BIOMAR, V11, P211; Bebenek K, 2000, COLD SPRING HARB SYM, V65, P81, DOI 10.1101/sqb.2000.65.81; Bellone G, 2001, EUR J CANCER, V37, P224, DOI 10.1016/S0959-8049(00)00391-9; Bian Y, 2005, J CLIN ONCOL, V23, P3074, DOI 10.1200/JCO.2005.00.281; Bitzer M, 2000, GENE DEV, V14, P187; Boland CR, 1998, CANCER RES, V58, P5248; Canzian F, 1996, CANCER RES, V56, P3331; CHAOUCHI N, 1995, ONCOGENE, V11, P1615; Chen T, 2001, CANCER RES, V61, P4679; Chen TP, 1999, INT J CANCER, V82, P43; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Edmonston TB, 2000, HUM PATHOL, V31, P1506, DOI 10.1053/hupa.2000.20383; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FRIEDMAN E, 1995, CANCER EPIDEM BIOMAR, V4, P549; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; Goggins M, 1998, CANCER RES, V58, P5329; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Im YH, 2001, CANCER RES, V61, P6665; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kaklamani V, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-28; Kaklamani VG, 2005, CANCER RES, V65, P3454, DOI 10.1158/0008-5472.CAN-04-2961; Kaklamani VG, 2003, J CLIN ONCOL, V21, P3236, DOI 10.1200/JCO.2003.11.524; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Knobloch TJ, 2001, MUTAT RES-FUND MOL M, V479, P131, DOI 10.1016/S0027-5107(01)00157-9; Ko Y, 1998, J CELL PHYSIOL, V176, P424, DOI 10.1002/(SICI)1097-4652(199808)176:2<424::AID-JCP21>3.3.CO;2-N; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; LAVARONE A, 1997, NATURE, V387, P417; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nilsson I, 2003, J BIOL CHEM, V278, P29389, DOI 10.1074/jbc.M212310200; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Pasche B, 1999, CANCER RES, V59, P5678; Pasche B, 1998, CANCER RES, V58, P2727; Pasche B, 2004, J CLIN ONCOL, V22, P756, DOI 10.1200/JCO.2004.99.271; Pasche B, 2002, BEST PRACT RES CL GA, V16, P331, DOI 10.1053/bega.2002.0289; Pasche B, 2001, CANCER RES, V61, P8351; Patil S, 2000, J BIOL CHEM, V275, P38363, DOI 10.1074/jbc.M004861200; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Pihan G, 2003, CANCER CELL, V4, P89, DOI 10.1016/S1535-6108(03)00195-8; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wang D, 1997, CARCINOGENESIS, V18, P2285, DOI 10.1093/carcin/18.11.2285; Wang D, 2000, CANCER RES, V60, P4507; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Warren ST, 1997, SCIENCE, V275, P408, DOI 10.1126/science.275.5298.408; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhou XP, 1997, ONCOGENE, V15, P1713, DOI 10.1038/sj.onc.1201337	67	74	83	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	2005	294	13					1634	1646		10.1001/jama.294.13.1634	http://dx.doi.org/10.1001/jama.294.13.1634			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970DC	16204663				2022-12-28	WOS:000232284400016
J	Chandramohan, D; Owusu-Agyei, S; Carneiro, I; Awine, T; Amponsa-Achiano, K; Mensah, N; Jaffar, S; Baiden, R; Hodgson, A; Binka, F; Greenwood, B				Chandramohan, D; Owusu-Agyei, S; Carneiro, I; Awine, T; Amponsa-Achiano, K; Mensah, N; Jaffar, S; Baiden, R; Hodgson, A; Binka, F; Greenwood, B			Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLASMODIUM-FALCIPARUM; TANZANIAN INFANTS; ANEMIA; INTENSE; AMODIAQUINE; CHILDREN; BURDEN	Objective To evaluate the effects of intermittent preventive treatment for malaria in infants (IPTi) with sulfadoxine-pyrimethamine in an area of intense, seasonal transmission. Design Cluster randomised placebo controlled trial, with 96 clusters allocated randomly to sulfadoxine-pyrimethamine or placebo in blocks of eight. Interventions Children received sulfadoxine-pyrimethamine or placebo and one month of iron supplementation when they received DPT-2, DPT-3, or measles vaccinations and at 12 months of age. Main outcome measures Incidence of malaria and of anaemia determined through passive case detection. Results 89% (1103/1242) of children in the placebo group and 88% (1088/1243) in the IPTi group completed follow-up to 24 months of age. The protective efficacy of IPTi against all episodes of malaria was 24.8% (95% confidence interval 14.3% to 34.0%) up to 15 months of age. IPTi had no protective effect against malaria between 16 and 24 months of age (protective efficacy -4.9%, - 21.3% to 9.3%). The incidence of high parasite density malaria (>= 5000 parasites/mu l) was higher in the IPTi group than in the placebo group between 16 and 24 months of age (protective efficacy - 19.5%, - 39.8% to - 22%). IPTi reduced hospital admissions with anaemia by 35.1% (10.5% to 52.9%) up to 15 months of age. IPTi had no significant effect on anaemia between 16 and 24 months of age (protective efficacy - 6.4%, - 76.8% to 35.9%). The relative risk of death up to 15 months of age in the IPTi group was 1.26 (95% confidence interval 0.81 to 1.96; P = 0.31), and from 16 to 24 months it was 1.28 (0.77 to 2.14; P = 0.35). Conclusions Intermittent preventive treatment for malaria with sulfadoxine-pyrimethamine can reduce malaria and anaemia in infants even in seasonal, high transmission areas, but concern exists about possible rebound in the incidence of malaria in the second year of life.	Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Kintampo Hlth Res Ctr, Kintampo, Ghana; Navrongo Hlth Res Ctr, Navrongo, Ghana; INDEPTH Network, Accra, Ghana	University of London; London School of Hygiene & Tropical Medicine; Kintampo Health Research Centre; Navrongo Health Research Center; INDEPTH Network	Chandramohan, D (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	daniel.chandramohan@lshtm.ac.uk	Mensah, Nathan/GYR-0802-2022; AMPONSA-ACHIANO, KWAME/O-9941-2014	AMPONSA-ACHIANO, KWAME/0000-0001-8145-970X; Jaffar, Shabbar/0000-0002-9615-1588; Awine, Timothy/0000-0002-7340-6111; Owusu-Agyei, Seth/0000-0002-0807-1781				[Anonymous], 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000363.PUB2; Appawu M, 2004, TROP MED INT HEALTH, V9, P164, DOI 10.1046/j.1365-3156.2003.01162.x; CISSE B, 2004, AM J TROP MED HYG S, V71; DICKO A, 2004, AM J TROP MED HYG S, V71; DICKO A, 2004, AM J TROP MED HYG, V71; Drakeley C, 2003, TROP MED INT HEALTH, V8, P767, DOI 10.1046/j.1365-3156.2003.01100.x; Grabowsky M, 2005, B WORLD HEALTH ORGAN, V83, P195; GREENWOOD BM, 1988, LANCET, V1, P1121; *INT DEV RES CTR, 2002, POP HLTH SURV IND SI; Kitua AY, 1997, TROP MED INT HEALTH, V2, P325; Lengeler C, 2004, COCHRANE DATABASE SY; Massaga JJ, 2003, LANCET, V361, P1853, DOI 10.1016/S0140-6736(03)13504-0; Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3; Murphy SC, 2001, AM J TROP MED HYG, V64, P57, DOI 10.4269/ajtmh.2001.64.57; MURRAY CJ, 1996, GLOBAL BURDEN DIS IN, P820; MURRAY CJ, 1996, GLOBAL BURDEN DIS IN, P320; Oduro AR, 2005, TROP MED INT HEALTH, V10, P279, DOI 10.1111/j.1365-3156.2004.01382.x; Schellenberg D, 1999, AM J TROP MED HYG, V61, P431, DOI 10.4269/ajtmh.1999.61.431; Schellenberg D, 2005, LANCET, V365, P1481, DOI 10.1016/S0140-6736(05)66418-5; Schellenberg D, 2003, B WORLD HEALTH ORGAN, V81, P581; Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2; Snow RW, 2002, ADV PARASIT, V52, P235, DOI 10.1016/S0065-308X(02)52013-3; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342	23	130	132	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	2005	331	7519					727	733		10.1136/bmj.331.7519.727	http://dx.doi.org/10.1136/bmj.331.7519.727			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971XB	16195288	Green Accepted, Green Published, Bronze			2022-12-28	WOS:000232417100018
J	Tanaka, M; Sackmann, E				Tanaka, M; Sackmann, E			Polymer-supported membranes as models of the cell surface	NATURE			English	Review							LIPID-BILAYER-MEMBRANES; TIN-OXIDE ELECTRODES; HUMAN ERYTHROCYTE-MEMBRANES; SILICON-SILICON DIOXIDE; IMPEDANCE SPECTROSCOPY; ULTRATHIN FILMS; FLUORESCENCE MICROSCOPY; PHOSPHOLIPID-MEMBRANES; NEUTRON REFLECTIVITY; LATERAL DIFFUSION	Lipid-bilayer membranes supported on solid substrates are widely used as cell-surface models that connect biological and artificial materials. They can be placed either directly on solids or on ultrathin polymer supports that mimic the generic role of the extracellular matrix. The tools of modern genetic engineering and bioorganic chemistry make it possible to couple many types of biomolecule to supported membranes. This results in sophisticated interfaces that can be used to control, organize and study the properties and function of membranes and membrane-associated proteins. Particularly exciting opportunities arise when these systems are coupled with advanced semiconductor technology.	Tech Univ Munich, Dept Phys, D-85748 Garching, Germany	Technical University of Munich	Tanaka, M (corresponding author), Univ Heidelberg, Inst Phys Chem, D-69120 Heidelberg, Germany.	mtanaka@ph.tum.de	Wunder, Stephanie L/B-5066-2012; Tanaka, Motomu/S-5949-2016; Zdilla, Michael J/B-4145-2011; Taylor, Graham/A-4027-2012	Tanaka, Motomu/0000-0003-3663-9554; 				Ashkenasy G, 2002, ACCOUNTS CHEM RES, V35, P121, DOI 10.1021/ar990047t; Baksh MM, 2004, NATURE, V427, P139, DOI 10.1038/nature02209; BAYERL TM, 1990, BIOPHYS J, V58, P357, DOI 10.1016/S0006-3495(90)82382-1; Borisenko V, 2003, BIOPHYS J, V84, P612, DOI 10.1016/S0006-3495(03)74881-4; BRIAN AA, 1984, P NATL ACAD SCI-BIOL, V81, P6159, DOI 10.1073/pnas.81.19.6159; Bruinsma R, 2000, PHYS REV E, V61, P4253, DOI 10.1103/PhysRevE.61.4253; Bunjes N, 1997, LANGMUIR, V13, P6188, DOI 10.1021/la970317l; CHAN P, 1991, J CELL BIOL, V10, P245; COHEN CM, 1977, J CELL BIOL, V75, P119, DOI 10.1083/jcb.75.1.119; Cornell BA, 1997, NATURE, V387, P580, DOI 10.1038/42432; Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711; Dean C, 2003, NAT NEUROSCI, V6, P708, DOI 10.1038/nn1074; Deme B, 2000, EUR PHYS J E, V2, P125, DOI 10.1007/s101890050046; ELENDER G, 1994, J PHYS II, V4, P455, DOI 10.1051/jp2:1994107; Erb EM, 1997, BIOCHEMISTRY-US, V36, P7395, DOI 10.1021/bi9702187; Fertig N, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.040901; Fischer M, 2001, CHEMPHYSCHEM, V2, P623, DOI 10.1002/1439-7641(20011015)2:10<623::AID-CPHC623>3.0.CO;2-R; FROMHERZ P, 1991, SCIENCE, V252, P1290, DOI 10.1126/science.1925540; Galneder R, 2001, BIOPHYS J, V80, P2298, DOI 10.1016/S0006-3495(01)76201-7; Goennenwein S, 2003, BIOPHYS J, V85, P646, DOI 10.1016/S0006-3495(03)74508-1; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Gritsch S, 1998, LANGMUIR, V14, P3118, DOI 10.1021/la9710381; Groves JT, 2003, J IMMUNOL METHODS, V278, P19, DOI 10.1016/S0022-1759(03)00193-5; Groves JT, 1996, BIOPHYS J, V71, P2716, DOI 10.1016/S0006-3495(96)79462-6; Groves JT, 1997, P NATL ACAD SCI USA, V94, P13390, DOI 10.1073/pnas.94.25.13390; Groves JT, 2001, LANGMUIR, V17, P5129, DOI 10.1021/la010481f; Groves JT, 2002, ACCOUNTS CHEM RES, V35, P149, DOI 10.1021/ar950039m; Groves JT, 1997, SCIENCE, V275, P651, DOI 10.1126/science.275.5300.651; Hillebrandt H, 1999, LANGMUIR, V15, P8451, DOI 10.1021/la990341u; Hillebrandt H, 2002, J PHYS CHEM B, V106, P477, DOI 10.1021/jp011693o; Hovis JS, 2000, LANGMUIR, V16, P894, DOI 10.1021/la991175t; JACOBSON BS, 1977, SCIENCE, V195, P302, DOI 10.1126/science.831278; JOHNSON SJ, 1991, BIOPHYS J, V59, P289, DOI 10.1016/S0006-3495(91)82222-6; KALB E, 1990, BIOCHEMISTRY-US, V29, P1607, DOI 10.1021/bi00458a036; KALB E, 1992, BIOCHIM BIOPHYS ACTA, V1103, P307, DOI 10.1016/0005-2736(92)90101-Q; Kaufmann S, 2003, CHEMPHYSCHEM, V4, P699, DOI 10.1002/cphc.200200537; KJAER K, 1987, PHYS REV LETT, V58, P2224, DOI 10.1103/PhysRevLett.58.2224; Kloboucek A, 1999, BIOPHYS J, V77, P2311, DOI 10.1016/S0006-3495(99)77070-0; Knoll W, 2000, J Biotechnol, V74, P137, DOI 10.1016/S1389-0352(00)00012-X; Koenig BW, 1996, LANGMUIR, V12, P1343, DOI 10.1021/la950580r; KUHNER M, 1994, BIOPHYS J, V67, P217; Kung LA, 2000, LANGMUIR, V16, P6773, DOI 10.1021/la000653t; Lambacher A, 1996, APPL PHYS A-MATER, V63, P207, DOI 10.1007/BF01567871; LANG H, 1994, LANGMUIR, V10, P197, DOI 10.1021/la00013a029; LoidlStahlhofen A, 1996, NAT BIOTECHNOL, V14, P999, DOI 10.1038/nbt0896-999; Luber SM, 2004, PHYSICA E, V21, P1111, DOI 10.1016/j.physe.2003.11.189; MCLAUGHLIN S, 1981, BIOPHYS J, V34, P85, DOI 10.1016/S0006-3495(81)84838-2; MERKEL R, 1989, J PHYS-PARIS, V50, P1535, DOI 10.1051/jphys:0198900500120153500; Morigaki K, 2001, ANGEW CHEM INT EDIT, V40, P172, DOI 10.1002/1521-3773(20010105)40:1<172::AID-ANIE172>3.0.CO;2-G; Nissen J, 1999, EUR PHYS J B, V10, P335, DOI 10.1007/s100510050862; Olson DJ, 2001, LANGMUIR, V17, P7396, DOI 10.1021/la010475j; PLANT AL, 1994, BIOPHYS J, V67, P1126, DOI 10.1016/S0006-3495(94)80579-X; Purrucker O, 2001, ELECTROCHIM ACTA, V47, P791, DOI 10.1016/S0013-4686(01)00759-9; Purrucker O, 2005, J AM CHEM SOC, V127, P1258, DOI 10.1021/ja045713m; Purrucker O, 2004, CHEMPHYSCHEM, V5, P327, DOI 10.1002/cphc.200300863; Qi SY, 2001, P NATL ACAD SCI USA, V98, P6548, DOI 10.1073/pnas.111536798; Rehfeldt F, 2003, LANGMUIR, V19, P1467, DOI 10.1021/la0261702; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; Sackmann E, 2000, TRENDS BIOTECHNOL, V18, P58, DOI 10.1016/S0167-7799(99)01412-2; Sackmann E, 2002, CHEMPHYSCHEM, V3, P262, DOI 10.1002/1439-7641(20020315)3:3<262::AID-CPHC262>3.0.CO;2-U; SAFFMAN PG, 1975, P NATL ACAD SCI USA, V72, P3111, DOI 10.1073/pnas.72.8.3111; SAKMANN B, 1985, SINGLE CHANNEL RECOR; Salafsky J, 1996, BIOCHEMISTRY-US, V35, P14773, DOI 10.1021/bi961432i; Sapuri AR, 2003, LANGMUIR, V19, P1606, DOI 10.1021/la026296z; SCHAUB M, 1993, ADV MATER, V5, P919, DOI 10.1002/adma.19930051209; Schiller SM, 2003, ANGEW CHEM INT EDIT, V42, P208, DOI 10.1002/anie.200390080; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Steinem C, 1996, BBA-BIOMEMBRANES, V1279, P169, DOI 10.1016/0005-2736(95)00274-X; Steinhoff G, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1853531; Steinhoff G, 2003, ADV FUNCT MATER, V13, P841, DOI 10.1002/adfm.200304397; STELZLE M, 1992, BIOPHYS J, V63, P1346, DOI 10.1016/S0006-3495(92)81712-5; STENBERG M, 1979, J COLLOID INTERF SCI, V72, P255, DOI 10.1016/0021-9797(79)90107-3; Straub B, 2001, NAT BIOTECHNOL, V19, P121, DOI 10.1038/84369; TAMM LK, 1985, BIOPHYS J, V47, P105, DOI 10.1016/S0006-3495(85)83882-0; Tanaka M, 2001, PHYS CHEM CHEM PHYS, V3, P4091, DOI 10.1039/b105007a; Tanaka M, 2004, J AM CHEM SOC, V126, P3257, DOI 10.1021/ja038981d; Tanaka M, 2005, J PHYS-CONDENS MAT, V17, pS649, DOI 10.1088/0953-8984/17/9/022; TATULIAN SA, 1995, EMBO J, V14, P5514, DOI 10.1002/j.1460-2075.1995.tb00238.x; TERRETTAZ S, 1993, LANGMUIR, V9, P1361, DOI 10.1021/la00029a033; van Oudenaarden A, 1999, SCIENCE, V285, P1046, DOI 10.1126/science.285.5430.1046; Wagner ML, 2001, BIOPHYS J, V81, P266, DOI 10.1016/S0006-3495(01)75697-4; Wagner ML, 2000, BIOPHYS J, V79, P1400, DOI 10.1016/S0006-3495(00)76392-2; WATTS TH, 1986, NATURE, V320, P179, DOI 10.1038/320179a0; Wiegand G, 2000, REV SCI INSTRUM, V71, P2309, DOI 10.1063/1.1150447; Wiegand G, 2002, J PHYS CHEM B, V106, P4245, DOI 10.1021/jp014337e; Yang TL, 2003, J AM CHEM SOC, V125, P4779, DOI 10.1021/ja029469f; Yoshina-Ishii C, 2003, J AM CHEM SOC, V125, P3696, DOI 10.1021/ja029783+	87	782	801	4	394	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 29	2005	437	7059					656	663		10.1038/nature04164	http://dx.doi.org/10.1038/nature04164			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193040				2022-12-28	WOS:000232157900039
J	Ueguchi-Tanaka, M; Ashikari, M; Nakajima, M; Itoh, H; Katoh, E; Kobayashi, M; Chow, TY; Hsing, YIC; Kitano, H; Yamaguchi, I; Matsuoka, M				Ueguchi-Tanaka, M; Ashikari, M; Nakajima, M; Itoh, H; Katoh, E; Kobayashi, M; Chow, TY; Hsing, YIC; Kitano, H; Yamaguchi, I; Matsuoka, M			GIBBERELLIN INSENSITIVE DWARF1 encodes a soluble receptor for gibberellin	NATURE			English	Article							SIGNALING PATHWAY; RICE; PROTEIN; MUTANT; GENE; METABOLISM; ALEURONE; SUBUNIT; CLONING; GROWTH	Gibberellins ( GAs) are phytohormones that are essential for many developmental processes in plants. It has been postulated that plants have both membrane-bound and soluble GA receptors; however, no GA receptors have yet been identified. Here we report the isolation and characterization of a new GA-insensitive dwarf mutant of rice, gid1. The GID1 gene encodes an unknown protein with similarity to the hormone-sensitive lipases, and we observed preferential localization of a GID1 - green fluorescent protein (GFP) signal in nuclei. Recombinant glutathione S-transferase (GST) - GID1 had a high affinity only for biologically active GAs, whereas mutated GST - GID1 corresponding to three gid1 alleles had no GA-binding affinity. The dissociation constant for GA(4) was estimated to be around 10(-7) M, enough to account for the GA dependency of shoot elongation. Moreover, GID1 bound to SLR1, a rice DELLA protein, in a GA-dependent manner in yeast cells. GID1 overexpression resulted in a GA-hypersensitive phenotype. Together, our results indicate that GID1 is a soluble receptor mediating GA signalling in rice.	Nagoya Univ, Biosci & Biotechnol Ctr, Nagoya, Aichi 4648601, Japan; Univ Tokyo, Dept Appl Biol Chem, Tokyo 1138657, Japan; Natl Inst Agrobiol Sci, Dept Biochem, Tsukuba, Ibaraki 3058602, Japan; RIKEN, Bioresources Ctr, Tsukuba, Ibaraki 3050074, Japan; Acad Sinica, Inst Bot, Taipei 11529, Taiwan; Univ Tokyo, Biotechnol Res Ctr, Tokyo 1138657, Japan	Nagoya University; University of Tokyo; National Institute of Agrobiological Sciences - Japan; RIKEN; Academia Sinica - Taiwan; University of Tokyo	Matsuoka, M (corresponding author), Nagoya Univ, Biosci & Biotechnol Ctr, Nagoya, Aichi 4648601, Japan.	makoto@nuagr1.agr.nagoya-u.ac.jp	Kobayashi, Masatomo/A-5945-2016					Davies P. J, 1995, PLANT HORMONES; Dharmasiri N, 2005, NATURE, V435, P441, DOI 10.1038/nature03543; Gomi K, 2004, PLANT J, V37, P626, DOI 10.1111/j.1365-313X.2003.01990.x; Gubler F, 2002, PLANT PHYSIOL, V129, P191, DOI 10.1104/pp.010918; Hedden P, 2000, TRENDS PLANT SCI, V5, P523, DOI 10.1016/S1360-1385(00)01790-8; HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x; HOOLEY R, 1992, BIOCHEM SOC T, V20, P85, DOI 10.1042/bst0200085; Ikeda A, 2001, PLANT CELL, V13, P999, DOI 10.1105/tpc.13.5.999; Itoh H, 2005, PLANT CELL PHYSIOL, V46, P1392, DOI 10.1093/pcp/pci152; Itoh H, 2002, PLANT CELL, V14, P57, DOI 10.1105/tpc.010319; Itoh H, 2003, TRENDS PLANT SCI, V8, P492, DOI 10.1016/j.tplants.2003.08.002; Itoh H, 2001, P NATL ACAD SCI USA, V98, P8909, DOI 10.1073/pnas.141239398; KEINSKI S, 2005, NATURE, V435, P446; KOBAYASHI M, 1995, BIOSCI BIOTECH BIOCH, V59, P1969, DOI 10.1271/bbb.59.1969; Lovegrove A, 1998, PLANT J, V15, P311, DOI 10.1046/j.1365-313X.1998.00209.x; Manco G, 2000, ARCH BIOCHEM BIOPHYS, V373, P182, DOI 10.1006/abbi.1999.1497; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; Nakajima M, 1997, BIOCHEM BIOPH RES CO, V241, P782, DOI 10.1006/bbrc.1997.7896; NAKAYAMA I, 1990, PLANT CELL PHYSIOL, V31, P195; Natsume T, 1999, BIOCHEM BIOPH RES CO, V260, P527, DOI 10.1006/bbrc.1999.0905; NISHIJIMA T, 1994, BIOSCI BIOTECH BIOCH, V58, P572, DOI 10.1271/bbb.58.572; Nishimura A, 2002, PLANT J, V30, P189, DOI 10.1046/j.1365-313X.2002.01279.x; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; Osterlund T, 2001, EUR J BIOCHEM, V268, P1899, DOI 10.1046/j.1432-1327.2001.02097.x; Peng JR, 1997, GENE DEV, V11, P3194, DOI 10.1101/gad.11.23.3194; Sakamoto T, 2004, PLANT PHYSIOL, V134, P1642, DOI 10.1104/pp.103.033696; Sasaki A, 2003, SCIENCE, V299, P1896, DOI 10.1126/science.1081077; Sasaki A, 2002, NATURE, V416, P701, DOI 10.1038/416701a; Silverstone AL, 1998, PLANT CELL, V10, P155, DOI 10.1105/tpc.10.2.155; Thornton TM, 1999, TRENDS PLANT SCI, V4, P424, DOI 10.1016/S1360-1385(99)01485-5; Ueguchi-Tanaka M, 2000, P NATL ACAD SCI USA, V97, P11638, DOI 10.1073/pnas.97.21.11638	31	853	993	22	329	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					693	698		10.1038/nature04028	http://dx.doi.org/10.1038/nature04028			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193045				2022-12-28	WOS:000232157900044
J	Xavier, KB; Bassler, BL				Xavier, KB; Bassler, BL			Interference with Al-2-mediated bacterial cell-cell communication	NATURE			English	Article							QUORUM-SENSING SIGNAL; VIBRIO-HARVEYI; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; EXPRESSION; CHOLERAE; LUMINESCENCE; SEQUENCE; AL-2; FAMILY	Bacteria communicate by means of chemical signal molecules called autoinducers. This process, called quorum sensing, allows bacteria to count the members in the community and to alter gene expression synchronously across the population. Quorum-sensing-controlled processes are often crucial for successful bacterial - host relationships - both symbiotic and pathogenic. Most quorum-sensing autoinducers promote intraspecies communication, but one autoinducer, called AI-2, is produced and detected by a wide variety of bacteria and is proposed to allow interspecies communication(1,2). Here we show that some species of bacteria can manipulate AI-2 signalling and interfere with other species' ability to assess and respond correctly to changes in cell population density. AI-2 signalling, and the interference with it, could have important ramifications for eukaryotes in the maintenance of normal microflora and in protection from pathogenic bacteria.	Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University	Bassler, BL (corresponding author), Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ 08544 USA.	bbassler@molbio.princeton.edu	Xavier, Karina/B-9425-2008	Xavier, Karina/0000-0001-5210-1434; Bassler, Bonnie/0000-0002-0043-746X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065859] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM065859] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASSLER BL, 1993, MOL MICROBIOL, V9, P773, DOI 10.1111/j.1365-2958.1993.tb01737.x; BASSLER BL, 1994, MOL MICROBIOL, V13, P273, DOI 10.1111/j.1365-2958.1994.tb00422.x; Bassler BL, 1997, J BACTERIOL, V179, P4043, DOI 10.1128/jb.179.12.4043-4045.1997; Chen X, 2002, NATURE, V415, P545, DOI 10.1038/415545a; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; Hacker J, 2000, ANNU REV MICROBIOL, V54, P641, DOI 10.1146/annurev.micro.54.1.641; Henke JM, 2004, J BACTERIOL, V186, P3794, DOI 10.1128/JB.186.12.3794-3805.2004; Lenz DH, 2004, CELL, V118, P69, DOI 10.1016/j.cell.2004.06.009; Miller MB, 2002, CELL, V110, P303, DOI 10.1016/S0092-8674(02)00829-2; Miller ST, 2004, MOL CELL, V15, P677, DOI 10.1016/j.molcel.2004.07.020; Schauder S, 2001, MOL MICROBIOL, V41, P463, DOI 10.1046/j.1365-2958.2001.02532.x; Silva AJ, 2004, J BACTERIOL, V186, P6374, DOI 10.1128/JB.186.19.6374-6382.2004; SLAUCH JM, 1991, J BACTERIOL, V173, P4039, DOI 10.1128/jb.173.13.4039-4048.1991; Surette MG, 1999, P NATL ACAD SCI USA, V96, P1639, DOI 10.1073/pnas.96.4.1639; Taga ME, 2003, MOL MICROBIOL, V50, P1411, DOI 10.1046/j.1365-2958.2003.03781.x; Taga ME, 2001, MOL MICROBIOL, V42, P777, DOI 10.1046/j.1365-2958.2001.02669.x; Thelin KH, 1996, INFECT IMMUN, V64, P2853, DOI 10.1128/IAI.64.7.2853-2856.1996; Xavier KB, 2003, CURR OPIN MICROBIOL, V6, P191, DOI 10.1016/S1369-5274(03)00028-6; Xavier KB, 2005, J BACTERIOL, V187, P238, DOI 10.1128/JB.187.1.238-248.2005	19	221	240	3	104	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					750	753		10.1038/nature03960	http://dx.doi.org/10.1038/nature03960			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193054	Green Accepted			2022-12-28	WOS:000232157900056
J	Stone, J; Smyth, R; Carson, A; Lewis, S; Prescott, R; Warlow, C; Sharpe, M				Stone, J; Smyth, R; Carson, A; Lewis, S; Prescott, R; Warlow, C; Sharpe, M			Systematic review of misdiagnosis of conversion symptoms and "hysteria"	BRITISH MEDICAL JOURNAL			English	Review							5-YEAR FOLLOW-UP; NONEPILEPTIC SEIZURES; TORSION DYSTONIA; DIAGNOSIS; DISORDER; PROGNOSIS; PSEUDOSEIZURES; IDENTIFICATION; EXPERIENCE; FREQUENCY	Objective Paralysis, seizures, and sensory symptoms that are unexplained by organic disease are commonly referred to as "conversion" symptoms. Some patients who receive this diagnosis subsequently turn out to have a disease that explains their initial presentation. We aimed to determine how frequently this misdiagnosis occurs, and whether it has become less common since the widespread availability of brain imaging. Design Systematic reviews Data sources Medline, Embase, PsycINFO, Cinahl databases, and searches of reference lists. Review methods We included studies published since 1965 on the diagnostic outcome of adults with motor and sensory symptoms unexplained by disease. We critically appraised these papers, and carried out a multivariate, random effect, meta-analysis of the data. Results Twenty seven studies including a total of 1466 patients and a median duration of follow-up of five years were eligible for inclusion. Early studies were of poor quality. There was a significant (P < 0.02) decline in the mean rate of misdiagnosis from the 1950s to the present day; 29% (95% confidence interval 23% to 36%) in the 1950s; 17% (12% to 24%) in the 1960s; 4% (2% to 7%) in the 1970s; 4% (2% to 6%) in the 1980s; and 4% (2% to 6%) in the 1990s. This decline was independent of age, sex, and duration of symptom in people included in the studies. Conclusions A high rate of misdiagnosis of conversion symptoms was reported in early studies but this rate has been only 4% on average in studies of this diagnosis since 1970. This decline is probably due to improvements in study quality rather than improved diagnostic accuracy arising from die introduction of computed tomography of the brain.	Univ Edinburgh, Sch Mol & Clin Med, Med Stat Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Stone, J (corresponding author), Univ Edinburgh, Sch Mol & Clin Med, Med Stat Unit, Edinburgh EH4 2XU, Midlothian, Scotland.	Jon.Stone@ed.ac.uk	Stone, Jon/C-3119-2014	Stone, Jon/0000-0001-9829-8092; Lewis, Steff/0000-0003-1210-2314; sharpe, michael/0000-0002-6474-9980				Akagi H., 2001, CONT APPROACHES STUD, P73; BAKER JHE, 1987, J NEUROL NEUROSUR PS, V50, P375, DOI 10.1136/jnnp.50.4.375; BARRIS MC, 1992, DOC OPHTHALMOL, V82, P369, DOI 10.1007/BF00161025; Betts T, 1992, Seizure, V1, P19, DOI 10.1016/1059-1311(92)90050-B; Binzer M, 1998, PSYCHOSOMATICS, V39, P519, DOI 10.1016/S0033-3182(98)71284-8; BROOKS DN, 1992, BRIT J AUDIOL, V26, P347, DOI 10.3109/03005369209076658; CABANIS EA, 2002, 17 S NEUR; CARTER AB, 1949, BRIT MED J, V1, P1076, DOI 10.1136/bmj.1.4615.1076; CHANDRASEKARAN R, 1994, ACTA PSYCHIAT SCAND, V89, P78, DOI 10.1111/j.1600-0447.1994.tb01490.x; Cooper I S, 1976, Adv Neurol, V14, P157; COUPRIE W, 1995, J NEUROL NEUROSUR PS, V58, P750, DOI 10.1136/jnnp.58.6.750; Crimlisk HL, 1998, BRIT MED J, V316, P582, DOI 10.1136/bmj.316.7131.582; ELDRIDGE R, 1969, J AMER MED ASSOC, V210, P705, DOI 10.1001/jama.210.4.705; Feinstein A, 2001, NEUROPSY NEUROPSY BE, V14, P169; FISHBAIN DA, 1991, GEN HOSP PSYCHIAT, V13, P177, DOI 10.1016/0163-8343(91)90140-R; GARFIELD PD, 1962, DIS NERV SYST, V23, P623; Glick TH, 2000, ACAD EMERG MED, V7, P1272, DOI 10.1111/j.1553-2712.2000.tb00474.x; Groeneweg C E, 1991, Schweiz Rundsch Med Prax, V80, P529; Hankey G J, 1987, Clin Exp Neurol, V24, P11; Jongsma MJ, 1999, SEIZURE-EUR J EPILEP, V8, P146, DOI 10.1053/seiz.1998.0247; KATHOL RG, 1983, ARCH OPHTHALMOL-CHIC, V101, P729, DOI 10.1001/archopht.1983.01040010729005; KENT DA, 1995, PSYCHOSOMATICS, V36, P138, DOI 10.1016/S0033-3182(95)71683-8; KRILL AE, 1968, ARCH OPHTHALMOL-CHIC, V79, P254; KRISTENSEN O, 1992, ACTA NEUROL SCAND, V85, P177; KUTZ I, 1983, GEN HOSP PSYCHIAT, V5, P197; LESSER RP, 1978, AM J PSYCHIAT, V135, P349; LEWIS A, 1975, PSYCHOL MED, V5, P9, DOI 10.1017/S0033291700007169; LJUNGBERG L, 1957, Acta Psychiatr Neurol Scand Suppl, V112, P1; Mace CJ, 1996, BRIT J PSYCHIAT, V169, P282, DOI 10.1192/bjp.169.3.282; MARSDEN CD, 1974, BRAIN, V97, P793, DOI 10.1093/brain/97.1.793; MCKEGNEY FP, 1967, AM J PSYCHIAT, V124, P542, DOI 10.1176/ajp.124.4.542; MEIERKORD H, 1991, NEUROLOGY, V41, P1643, DOI 10.1212/WNL.41.10.1643; MERSKEY H, 1975, BRIT J MED PSYCHOL, V48, P359, DOI 10.1111/j.2044-8341.1975.tb02342.x; MILLER BL, 1986, AM FAM PHYSICIAN, V34, P157; Moene FC, 2000, J PSYCHOSOM RES, V49, P7, DOI 10.1016/S0022-3999(99)00107-5; Parra J, 1999, SEIZURE-EUR J EPILEP, V8, P223, DOI 10.1053/seiz.1999.0285; Ramani V, 1996, EPILEPSIA, V37, P416, DOI 10.1111/j.1528-1157.1996.tb00581.x; RASKIN M, 1966, J AMER MED ASSOC, V197, P530, DOI 10.1001/jama.197.7.530; REED JL, 1975, PSYCHOL MED, V5, P13, DOI 10.1017/S0033291700007170; RIEF W, 1995, PSYCHOSOMATICS, V36, P376, DOI 10.1016/S0033-3182(95)71647-4; Schuepbach WMM, 2002, PSYCHOTHER PSYCHOSOM, V71, P11, DOI 10.1159/000049339; Selwa LM, 2000, EPILEPSIA, V41, P1330, DOI 10.1111/j.1528-1157.2000.tb04613.x; SLATER E, 1965, BRIT MED J, V1, P1395, DOI 10.1136/bmj.1.5447.1395; SLATER ETO, 1965, J PSYCHOSOM RES, V9, P9, DOI 10.1016/0022-3999(65)90004-8; Smith D, 1999, QJM-INT J MED, V92, P15, DOI 10.1093/qjmed/92.1.15; STEFANSSON JG, 1976, ACTA PSYCHIAT SCAND, V53, P119, DOI 10.1111/j.1600-0447.1976.tb00066.x; Stone J, 2003, J NEUROL NEUROSUR PS, V74, P591, DOI 10.1136/jnnp.74.5.591; Teasell RW, 2002, AM J PHYS MED REHAB, V81, P236, DOI 10.1097/00002060-200203000-00015; TISSENBAUM MJ, 1951, JAMA-J AM MED ASSOC, V147, P1519, DOI 10.1001/jama.1951.03670330011004; Toth C, 2003, J NEUROL NEUROSUR PS, V74, P1113, DOI 10.1136/jnnp.74.8.1113; Vuilleumier P, 2001, BRAIN, V124, P1077, DOI 10.1093/brain/124.6.1077; WALCZAK TS, 1995, EPILEPSIA, V36, P1131, DOI 10.1111/j.1528-1157.1995.tb00472.x; WATSON CG, 1979, J NERV MENT DIS, V167, P243, DOI 10.1097/00005053-197904000-00008; WESSELY S, 2001, CONT APPROACHES SCI, P63; WHITLOCK FA, 1967, ACTA PSYCHIAT SCAND, V43, P144, DOI 10.1111/j.1600-0447.1967.tb11023.x; Wig N N, 1982, Indian J Psychiatry, V24, P120; Ziegler DK, 1954, DIS NERV SYST, V15, P301	57	181	186	0	14	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 29	2005	331	7523					989	991		10.1136/bmj.38628.466898.55	http://dx.doi.org/10.1136/bmj.38628.466898.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	981AU	16223792	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000233060200014
J	Bass, BL; Hellwig, S; Hundley, HA				Bass, BL; Hellwig, S; Hundley, HA			A nuclear RNA is cut out for translation	CELL			English	Editorial Material							ADENOSINE DEAMINASES; RETENTION; ACT	In this issue of Cell, Prasanth et al. (2005) provide evidence that an inosine-containing RNA that is normally retained in the nucleus is cleaved within its 3' untranslated region following cellular stress. It is then transported to the cytoplasm and translated into protein. These findings suggest that the nucleus may store RNAs destined for translation that then can be released, as needed, in response to specific cellular signals.	Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Bass, BL (corresponding author), Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA.		Hundley, Heather/AAV-2808-2020	Hellwig, Sabine/0000-0002-9809-947X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044073] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM044073] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Kumar M, 1997, P NATL ACAD SCI USA, V94, P3542, DOI 10.1073/pnas.94.8.3542; Levanon EY, 2004, NAT BIOTECHNOL, V22, P1001, DOI 10.1038/nbt996; Morse DP, 2002, P NATL ACAD SCI USA, V99, P7906, DOI 10.1073/pnas.112704299; Prasanth KV, 2005, CELL, V123, P249, DOI 10.1016/j.cell.2005.08.033; Zhang Z, 2001, CELL, V106, P465, DOI 10.1016/S0092-8674(01)00466-4	6	5	5	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 21	2005	123	2					181	183		10.1016/j.cell.2005.10.009	http://dx.doi.org/10.1016/j.cell.2005.10.009			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239133	Green Accepted, Bronze			2022-12-28	WOS:000232794100002
J	McDonald, MA; Simpson, SH; Ezekowitz, JA; Gyenes, G; Tsuyuki, RT				McDonald, MA; Simpson, SH; Ezekowitz, JA; Gyenes, G; Tsuyuki, RT			Angiotensin receptor blockers and risk of myocardial infarction: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CHRONIC HEART-FAILURE; VENTRICULAR SYSTOLIC FUNCTION; CONVERTING-ENZYME INHIBITORS; RANDOMIZED-TRIAL; CANDESARTAN CILEXETIL; LOSARTAN; MORTALITY; CAPTOPRIL; ENALAPRIL; MORBIDITY	Objective To evaluate the effect of angiotensin receptor blockers on the risk of myocardial infarction in patients at risk for cardiovascular events. Design Systematic review of controlled trials of angiotensin receptor blockers. Data sources Medline, Embase, Cochrane central register of controlled trials, hand search, and contact with investigators. Selection of studies Predefined criteria were used to select controlled clinical trials comparing use of angiotensin receptor Mockers with angiotensin converting enzyme (ACE) inhibitors or placebo in patients at risk for cardiovascular events. Data were extracted for patients' characteristics, interventions, quality of trials, and rates of myocardial infarction. Results 19 studies with 31569 patients were included in the analysis. Two studies investigated the use of angiotensin receptor blockers in hypertensive patients, four studies in patients with diabetes and nephropathy, 10 studies in patients with heart failure, and three in patients with recent myocardial infarction or ischaernic syndrome. 11 studies of 21062 patients allowed for comparison between angiotensin receptor blockers and placebo; nine studies of 10 625 patients allowed for comparison between angiotensin receptor blockers and ACE inhibitors. Use of angiotensin receptor blockers was not associated with increased risk of myocardial infarction compared with placebo (odds ratio 0.94, 95% confidence interval 0.75 to 1.16) nor with increased risk of myocardial infarction compared with ACE inhibitors (1.01, 0.87 to 1.16). Conclusions Treatment with angiotensin receptor blockers was not associated with a significantly increased risk of myocardial infarction. The 95% confidence intervals do not, however, exclude an increase of up to 16% in the risk of myocardial infarction or a reduction in risk of up to 25%. Until further information specifically dealing with this issue is available from large prospective trials, our findings may alleviate recent concerns over the safety of this class of medications.	Univ Alberta, Div Cardiol, Edmonton, AB T6G 2M7, Canada; Univ Alberta, Univ Alberta Hosp, Div Cardiol, Edmonton, AB T6G 2B7, Canada; Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada	University of Alberta; University of Alberta; University of Alberta	Tsuyuki, RT (corresponding author), Univ Alberta, Div Cardiol, Edmonton, AB T6G 2M7, Canada.	ross.tsuyuki@ualberta.ca	Ezekowitz, Justin A/C-4579-2013; Tsuyuki, Ross T/E-2462-2016	Ezekowitz, Justin A/0000-0002-2724-4086; Tsuyuki, Ross T/0000-0002-3724-598X; Simpson, Scot/0000-0002-9880-2129				ALDERSON P, 2003, COCHRANE REV HDB; AMBROSIONI E, 1995, NEW ENGL J MED, V332, P80, DOI 10.1056/NEJM199501123320203; Bakris G, 2002, AM J HYPERTENS, V15, P53, DOI 10.1016/S0895-7061(01)02254-3; BALL SG, 1993, LANCET, V342, P821; Barnett AH, 2004, NEW ENGL J MED, V351, P1952, DOI 10.1056/NEJMoa042274; Berl T, 2003, ANN INTERN MED, V138, P542, DOI 10.7326/0003-4819-138-7-200304010-00010; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Di Pasquale P, 1999, HEART, V81, P606, DOI 10.1136/hrt.81.6.606; Dickstein K, 2002, LANCET, V360, P752, DOI 10.1016/S0140-6736(02)09895-1; Dunselman PHJM, 2001, INT J CARDIOL, V77, P131, DOI 10.1016/S0167-5273(00)00426-5; Granger CB, 2000, AM HEART J, V139, P609, DOI 10.1016/S0002-8703(00)90037-1; Granger CB, 2003, LANCET, V362, P772, DOI 10.1016/S0140-6736(03)14284-5; Haneda M, 2004, DIABETES RES CLIN PR, V66, P87, DOI 10.1016/j.diabres.2004.02.015; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Julius S, 2004, LANCET, V363, P2022, DOI 10.1016/S0140-6736(04)16451-9; Kondo J, 2003, AM HEART J, V146, DOI 10.1016/S0002-8703(03)00443-5; Lee VC, 2004, ANN INTERN MED, V141, P693, DOI 10.7326/0003-4819-141-9-200411020-00011; Levy BI, 2004, CIRCULATION, V109, P8, DOI 10.1161/01.CIR.0000096609.73772.C5; Light R.J., 1984, SUMMING SCI REV RES; Lindholm LH, 2003, J HYPERTENS, V21, P1563, DOI 10.1097/00004872-200308000-00022; Lithell H, 2003, J HYPERTENS, V21, P875, DOI 10.1097/00004872-200305000-00011; MANTEL N, 1959, J NATL CANCER I, V22, P719; Matsumori A, 2003, EUR J HEART FAIL, V5, P669, DOI 10.1016/S1388-9842(03)00162-4; McKelvie RS, 1999, CIRCULATION, V100, P1056, DOI 10.1161/01.CIR.100.10.1056; McMurray JJV, 2003, LANCET, V362, P767, DOI 10.1016/S0140-6736(03)14283-3; McMurray JJV, 2001, HEART, V86, P97, DOI 10.1136/heart.86.1.97; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Spinar J, 2000, EUR J HEART FAIL, V2, P91, DOI 10.1016/S1388-9842(99)00070-7; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Swedberg K, 2004, EUR HEART J, V25, P357, DOI 10.1016/j.ehj.2003.12.023; TARGUM SL, 2001, MED STAT REV NDA2066; TARGUM SL, 2001, MED STAT REV NDA 20; Teo KK, 2004, AM HEART J, V148, P52, DOI 10.1016/j.ahj.2004.03.020; Verma S, 2004, BMJ-BRIT MED J, V329, P1248, DOI 10.1136/bmj.329.7477.1248; Willenheimer R, 2002, INT J CARDIOL, V85, P261, DOI 10.1016/S0167-5273(02)00154-7; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Yusuf S, 2003, LANCET, V362, P777, DOI 10.1016/S0140-6736(03)14285-7; Yusuf S, 2000, NEW ENGL J MED, V342, P145	46	58	57	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 15	2005	331	7521					873	876B		10.1136/bmj.38595.518542.3A	http://dx.doi.org/10.1136/bmj.38595.518542.3A			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975SX	16183653	Green Published, Bronze			2022-12-28	WOS:000232683300017
J	Nussey, DH; Postma, E; Gienapp, P; Visser, ME				Nussey, DH; Postma, E; Gienapp, P; Visser, ME			Selection on heritable phenotypic plasticity in a wild bird population	SCIENCE			English	Article							CLIMATE-CHANGE; GENETIC-VARIATION; REACTION NORMS; LIFE-HISTORY; PHENOLOGY; RESPONSES	Theoretical and laboratory research suggests that phenotypic plasticity can evolve under selection. However, evidence for its evolutionary potential from the wild is lacking. We present evidence from a Dutch, population of great tits (Parus major) for variation in individual plasticity in the timing of reproduction, and we show that this variation is heritable. Selection favoring highly plastic individuals has intensified over a 32-year period. This temporal trend is concurrent with climate change causing a mismatch between the breeding times of the birds and their caterpillar prey. Continued selection on plasticity can act to alleviate this mismatch.	Netherlands Inst Ecol NIOO KNAW, NL-6666 ZG Heteren, Netherlands; Univ Edinburgh, Inst Evolutionary Biol, Edinburgh EH9 3JT, Midlothian, Scotland	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW); University of Edinburgh	Nussey, DH (corresponding author), Netherlands Inst Ecol NIOO KNAW, POB 40, NL-6666 ZG Heteren, Netherlands.	d.h.nussey@sms.ed.ac.uk	Nussey, Daniel H/F-4155-2010; Vazquez-Dominguez, Guillermo GVD/L-7818-2014; Postma, Erik/B-7258-2008; Visser, Marcel E/A-9151-2009; Gienapp, Phillip/A-2261-2014	Postma, Erik/0000-0003-0856-1294; Visser, Marcel E/0000-0002-1456-1939; Gienapp, Phillip/0000-0002-9368-8769				Both C, 2004, P ROY SOC B-BIOL SCI, V271, P1657, DOI 10.1098/rspb.2004.2770; Brommer JE, 2005, EVOLUTION, V59, P1362; Durant JM, 2003, P ROY SOC B-BIOL SCI, V270, P1461, DOI 10.1098/rspb.2003.2397; Edwards M, 2004, NATURE, V430, P881, DOI 10.1038/nature02808; Kruuk LEB, 2004, PHILOS T R SOC B, V359, P873, DOI 10.1098/rstb.2003.1437; Lynch M., 1998, GENETICS ANAL QUANTI; McCleery RH, 1998, NATURE, V391, P30, DOI 10.1038/34073; NEWMAN RA, 1994, EVOLUTION, V48, P1773, DOI 10.1111/j.1558-5646.1994.tb02213.x; Nussey DH, 2005, J ANIM ECOL, V74, P387, DOI 10.1111/j.1365-2656.2005.00941.x; NUSSEY DH, IN PRESS BIOL LETT; Pigliucci M., 2001, SYN ECO EVO; Reale D, 2003, P ROY SOC B-BIOL SCI, V270, P591, DOI 10.1098/rspb.2002.2224; SCHEINER SM, 1993, ANNU REV ECOL SYST, V24, P35, DOI 10.1146/annurev.es.24.110193.000343; Scheiner SM, 2002, J EVOLUTION BIOL, V15, P889, DOI 10.1046/j.1420-9101.2002.00468.x; Stenseth NC, 2002, P NATL ACAD SCI USA, V99, P13379, DOI 10.1073/pnas.212519399; Stenseth NC, 2002, SCIENCE, V297, P1292, DOI 10.1126/science.1071281; Stinchcombe JR, 2004, J EVOLUTION BIOL, V17, P197, DOI 10.1046/j.1420-9101.2003.00641.x; VIA S, 1995, TRENDS ECOL EVOL, V10, P212, DOI 10.1016/S0169-5347(00)89061-8; Visser ME, 1998, P ROY SOC B-BIOL SCI, V265, P1867, DOI 10.1098/rspb.1998.0514; Visser ME, 2004, ADV ECOL RES, V35, P89, DOI 10.1016/S0065-2504(04)35005-1; Visser ME, 2001, P ROY SOC B-BIOL SCI, V268, P289, DOI 10.1098/rspb.2000.1363; Walther GR, 2002, NATURE, V416, P389, DOI 10.1038/416389a; WEIS AE, 1990, EVOLUTION, V44, P820, DOI 10.1111/j.1558-5646.1990.tb03807.x	23	476	485	5	329	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					304	306		10.1126/science.1117004	http://dx.doi.org/10.1126/science.1117004			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224020				2022-12-28	WOS:000232670100049
J	Mello, MM; Brennan, TA				Mello, MM; Brennan, TA			Legal concerns and the influenza vaccine shortage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INJURY COMPENSATION PROGRAM; US		Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Mello, MM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.	mmello@hsph.harvard.edu		Mello, Michelle/0000-0003-2877-4270				*AM TRIAL LAW ASS, LAWS DO NOT CAUS VAC; Baicker K., 2005, FRONTIERS HLTH POLIC, V8; Coleman MS, 2005, HEALTH AFFAIR, V24, P635, DOI 10.1377/hlthaff.24.3.635; Danzon PM, 2005, HEALTH AFFAIR, V24, P706, DOI 10.1377/hlthaff.24.3.706; HABER P, 2004, JAMA-J AM MED ASSOC, V292, P248; *HLTH RES SERV ADM, FAQ ANSW; *I MED, 1985, VACC SUPPL INN; *I MED, 1993, CHILDR VACC IN ACH V; Lieu TA, 2005, HEALTH AFFAIR, V24, P666, DOI 10.1377/hlthaff.24.3.666; Lloyd-Puryear M, 1998, PUBLIC HEALTH REP, V113, P236; LUDDEN M, 2004, POLL MOST DONT BLAME; NEUSTADT RE, 1978, SWINE FLUE AFFAIR; Offit PA, 2005, HEALTH AFFAIR, V24, P622, DOI 10.1377/hlthaff.24.3.622; Pauly MV, 2005, HEALTH AFFAIR, V24, P680, DOI 10.1377/hlthaff.24.3.680; Poland GA, 2004, NAT IMMUNOL, V5, P1195, DOI 10.1038/ni1204-1195; Ridgway D, 1999, J HEALTH POLIT POLIC, V24, P59, DOI 10.1215/03616878-24-1-59; Schattner A, 2005, VACCINE, V23, P3876, DOI 10.1016/j.vaccine.2005.03.005; Silverstein ArthurM., 1981, PURE POLITICS IMPURE; Sloan FA, 2004, NEW ENGL J MED, V351, P2443, DOI 10.1056/NEJMsb033394; *US GAO, 2002, CHILDH VACC CHALL PR; *US HOUS REPR, 2004, JOINT HEAR FLU VACC; 2004, NY TIMES        1014, pA22; 2004, NY TIMES        1027, pA7	23	14	14	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	2005	294	14					1817	1820		10.1001/jama.294.14.1817	http://dx.doi.org/10.1001/jama.294.14.1817			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972RX	16219886				2022-12-28	WOS:000232472000022
J	Fletcher, SP; Dumur, F; Pollard, MM; Feringa, BL				Fletcher, SP; Dumur, F; Pollard, MM; Feringa, BL			A reversible, unidirectional molecular rotary motor driven by chemical energy	SCIENCE			English	Article							DIRECTED BIARYL SYNTHESIS; ATP SYNTHASE; ROTATION; MOTION; TRANSDUCTION; MACHINES; SPEED; ROTOR	With the long-term goal of producing nanometer-scale machines, we describe here the unidirectional rotary motion of a synthetic molecular structure fueled by chemical conversions. The basis of the rotation is the movement,of a phenyl rotor relative to a naphthyl stator about a single bond axle. The sense of rotation is governed by the choice of chemical reagents that power the motor through four chemically distinct stations. Within the stations, the rotor is held in place by structural features that limit the extent of the rotor's Brownian motion relative to the stator.	Univ Groningen, Dept Organ & Mol Inorgan Chem, Stratingh Inst, NL-9747 AG Groningen, Netherlands	University of Groningen	Feringa, BL (corresponding author), Univ Groningen, Dept Organ & Mol Inorgan Chem, Stratingh Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	b.l.feringa@chem.rug.nl	Feringa, Ben L./C-1665-2013; Fletcher, Stephen/A-2262-2013; Dumur, frederic/N-1856-2013	Dumur, frederic/0000-0003-4872-094X				Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; Balzani V, 2000, ANGEW CHEM INT EDIT, V39, P3348, DOI 10.1002/1521-3773(20001002)39:19<3348::AID-ANIE3348>3.0.CO;2-X; Balzani V., 2003, MOL DEVICES MACHINES, VSecond; Boyer PD, 1998, ANGEW CHEM INT EDIT, V37, P2297, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2296::AID-ANIE2296>3.0.CO;2-W; Bringmann G, 2002, J ORGANOMET CHEM, V661, P31, DOI 10.1016/S0022-328X(02)01804-1; BRINGMANN G, 1992, ANGEW CHEM INT EDIT, V31, P761, DOI 10.1002/anie.199207611; Bustamante C, 2001, ACCOUNTS CHEM RES, V34, P412, DOI 10.1021/ar0001719; Corey EJ, 1998, ANGEW CHEM INT EDIT, V37, P1987, DOI 10.1002/(SICI)1521-3773(19980817)37:15<1986::AID-ANIE1986>3.0.CO;2-Z; Dahl BJ, 2004, TETRAHEDRON LETT, V45, P9599, DOI 10.1016/j.tetlet.2004.10.147; Davis AP, 1998, ANGEW CHEM INT EDIT, V37, P909, DOI 10.1002/(SICI)1521-3773(19980420)37:7<909::AID-ANIE909>3.0.CO;2-X; Drexler K.E., 1992, NANOSYSTEMS MOL MACH; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Fennimore AM, 2003, NATURE, V424, P408, DOI 10.1038/nature01823; Feynman R.P., 1963, FEYNMAN LECT PHYS; Feynman RP, 1961, MINIATURIZATION; Hawthorne MF, 2004, SCIENCE, V303, P1849, DOI 10.1126/science.1093846; Hernandez JV, 2004, SCIENCE, V306, P1532, DOI 10.1126/science.1103949; Hoki K, 2003, ANGEW CHEM INT EDIT, V42, P2976, DOI 10.1002/anie.200250872; Kelly TR, 2000, J AM CHEM SOC, V122, P6935, DOI 10.1021/ja001048f; Kelly TR, 1999, NATURE, V401, P150, DOI 10.1038/43639; Kelly TR, 1997, ANGEW CHEM INT EDIT, V36, P1866, DOI 10.1002/anie.199718661; Kinbara K, 2005, CHEM REV, V105, P1377, DOI 10.1021/cr030071r; Kottas GS, 2005, CHEM REV, V105, P1281, DOI 10.1021/cr0300993; Koumura N, 1999, NATURE, V401, P152, DOI 10.1038/43646; Koumura N, 2002, J AM CHEM SOC, V124, P5037, DOI 10.1021/ja012499i; Leigh DA, 2003, NATURE, V424, P174, DOI 10.1038/nature01758; Mandl CP, 2004, ANGEW CHEM INT EDIT, V43, P1622, DOI 10.1002/anie.200301697; OSTER G, 2000, BIOCHIM BIOPHYS ACTA, V482, P1458; SCHLIWA M, 2002, MOL MOTORS; ter Wiel MKJ, 2003, J AM CHEM SOC, V125, P15076, DOI 10.1021/ja036782o; Tu ZC, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.033404; Walker JE, 1998, ANGEW CHEM INT EDIT, V37, P2309, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2308::AID-ANIE2308>3.0.CO;2-W; Wang HY, 1998, NATURE, V396, P279, DOI 10.1038/24409; Yamaki M, 2005, J AM CHEM SOC, V127, P7300, DOI 10.1021/ja0437757	34	345	345	5	209	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	2005	310	5745					80	82		10.1126/science.1117090	http://dx.doi.org/10.1126/science.1117090			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210531	Green Submitted			2022-12-28	WOS:000232477000040
J	Sowa, Y; Rowe, AD; Leake, MC; Yakushi, T; Homma, M; Ishijima, A; Berry, RM				Sowa, Y; Rowe, AD; Leake, MC; Yakushi, T; Homma, M; Ishijima, A; Berry, RM			Direct observation of steps in rotation of the bacterial flagellar motor	NATURE			English	Article							TORQUE-GENERATING UNITS; ESCHERICHIA-COLI; ROTARY MOTOR; NA+-DRIVEN; VIBRIO-ALGINOLYTICUS; PROTONMOTIVE FORCE; F-1-ATPASE; MECHANISM; SPEED; ROTOR	The bacterial flagellar motor is a rotary molecular machine that rotates the helical filaments that propel many species of swimming bacteria(1,2). The rotor is a set of rings up to 45 nm in diameter in the cytoplasmic membrane(3); the stator contains about ten torque-generating units anchored to the cell wall at the perimeter of the rotor(4,5). The free-energy source for the motor is an inward-directed electrochemical gradient of ions across the cytoplasmic membrane, the protonmotive force or sodium-motive force for H+-driven and Na+-driven motors, respectively. Here we demonstrate a stepping motion of a Na+-driven chimaeric flagellar motor in Escherichia coli(6) at low sodium-motive force and with controlled expression of a small number of torque-generating units. We observe 26 steps per revolution, which is consistent with the periodicity of the ring of FliG protein, the proposed site of torque generation on the rotor(7,8). Backwards steps despite the absence of the flagellar switching protein CheY indicate a small change in free energy per step, similar to that of a single ion transit.	Nagoya Univ, Grad Sch Engn, Dept Appl Phys, Chikusa Ku, Aichi 4648603, Japan; Univ Oxford, Dept Phys, Clarendon Lab, Oxford OX1 3PU, England; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Aichi 4648602, Japan; JST, PRESTO, Kawagoe, Saitama 3320012, Japan	Nagoya University; University of Oxford; Nagoya University; Japan Science & Technology Agency (JST)	Berry, RM (corresponding author), Nagoya Univ, Grad Sch Engn, Dept Appl Phys, Chikusa Ku, Aichi 4648603, Japan.	r.berry1@physics.ox.ac.uk	Leake, Mark/C-1245-2011; Ishijima, Akihiko/F-4603-2012	Leake, Mark/0000-0002-1715-1249; Ishijima, Akihiko/0000-0002-8919-9268; Sowa, Yoshiyuki/0000-0002-1691-2018				ARMITAGE JP, 1985, BIOCHIM BIOPHYS ACTA, V806, P42, DOI 10.1016/0005-2728(85)90080-5; Asai Y, 2003, J MOL BIOL, V327, P453, DOI 10.1016/S0022-2836(03)00096-2; Berg HC, 2003, ANNU REV BIOCHEM, V72, P19, DOI 10.1146/annurev.biochem.72.121801.161737; BERG HC, 1993, BIOPHYS J, V65, P2201, DOI 10.1016/S0006-3495(93)81278-5; BERG HC, 1976, CELL MOTILITY, VA, P47; Berry RM, 1999, ADV MICROB PHYSIOL, V41, P291, DOI 10.1016/S0065-2911(08)60169-1; BERRY RM, 1995, BIOPHYS J, V69, P280, DOI 10.1016/S0006-3495(95)79900-3; BLAIR DF, 1988, SCIENCE, V242, P1678, DOI 10.1126/science.2849208; BLOCK SM, 1989, NATURE, V338, P514, DOI 10.1038/338514a0; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Diez M, 2004, NAT STRUCT MOL BIOL, V11, P135, DOI 10.1038/nsmb718; FUNG DC, 1995, NATURE, V375, P809, DOI 10.1038/375809a0; Gabel CV, 2003, P NATL ACAD SCI USA, V100, P8748, DOI 10.1073/pnas.1533395100; KUWAJIMA G, 1988, J BACTERIOL, V170, P3305, DOI 10.1128/jb.170.7.3305-3309.1988; LIU JZ, 1990, J BACTERIOL, V172, P5236, DOI 10.1128/jb.172.9.5236-5244.1990; Lloyd SA, 1997, J MOL BIOL, V266, P733, DOI 10.1006/jmbi.1996.0836; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; MEISTER M, 1987, CELL, V49, P643, DOI 10.1016/0092-8674(87)90540-X; Neuman KC, 1999, BIOPHYS J, V77, P2856, DOI 10.1016/S0006-3495(99)77117-1; Ryu WS, 2000, NATURE, V403, P444, DOI 10.1038/35000233; Samatey FA, 2004, NATURE, V431, P1062, DOI 10.1038/nature02997; Samuel ADT, 1996, BIOPHYS J, V71, P918, DOI 10.1016/S0006-3495(96)79295-0; Scharf BE, 1998, P NATL ACAD SCI USA, V95, P201, DOI 10.1073/pnas.95.1.201; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; Sowa Y, 2003, J MOL BIOL, V327, P1043, DOI 10.1016/S0022-2836(03)00176-1; Suzuki H, 2004, J MOL BIOL, V337, P105, DOI 10.1016/j.jmb.2004.01.034; Thomas DR, 1999, P NATL ACAD SCI USA, V96, P10134, DOI 10.1073/pnas.96.18.10134; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Yorimitsu T, 2001, BBA-BIOENERGETICS, V1505, P82, DOI 10.1016/S0005-2728(00)00279-6	30	238	240	1	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					916	919		10.1038/nature04003	http://dx.doi.org/10.1038/nature04003			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208378				2022-12-28	WOS:000232338600053
J	Cowen, LE; Lindquist, S				Cowen, LE; Lindquist, S			Hsp90 potentiates the rapid evotution of new traits: Drug resistance in diverse fungi	SCIENCE			English	Article							CANDIDA-ALBICANS; MOLECULAR CHAPERONE; IN-VITRO; CALCINEURIN; EVOLUTION; CAPACITOR; STRESS; HEAT-SHOCK-PROTEIN-90; INHIBITION; MECHANISMS	Hsp90 is a molecular chaperone for many signal transducers and may influence evolution by releasing previously silent genetic variation in response to environmental change. In fungi separated by similar to 800 million years of evolution, Hsp90 potentiated the evolution of drug resistance in a different way, by enabling new mutations' to have immediate phenotypic consequences. Resistance was abrogated by Hsp90 inhibitors and by febrile temperatures, suggesting new therapeutic strategies and a clinical benefit of fever. During selection in a human host, drug resistance that was initially Hsp90-dependent evolved toward independence. Thus, Hsp90 can act in diverse ways to couple environmental contingency to the emergence and fixation of new traits.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute	Lindquist, S (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lindquist_admin@wi.mit.edu		Cowen, Leah/0000-0001-5797-0110	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30ES02109] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anderson JB, 2004, GENETICS, V168, P1915, DOI 10.1534/genetics.104.033266; Anderson JB, 2003, GENETICS, V163, P1287; Bagatell R, 2004, MOL CANCER THER, V3, P1021; Bergman A, 2003, NATURE, V424, P549, DOI 10.1038/nature01765; Blankenship Jill R, 2003, Curr Opin Investig Drugs, V4, P192; Cowen LE, 2002, ANNU REV MICROBIOL, V56, P139, DOI 10.1146/annurev.micro.56.012302.160907; COWEN LE, UNPUB; Cruz MC, 2002, EMBO J, V21, P546, DOI 10.1093/emboj/21.4.546; Falsone SF, 2004, J MOL BIOL, V344, P281, DOI 10.1016/j.jmb.2004.08.091; Fox DS, 2002, BIOESSAYS, V24, P894, DOI 10.1002/bies.10157; Hasday JD, 2000, MICROBES INFECT, V2, P1891, DOI 10.1016/S1286-4579(00)01337-X; Heckman DS, 2001, SCIENCE, V293, P1129, DOI 10.1126/science.1061457; Hemenway Charles S., 1999, Cell Biochemistry and Biophysics, V30, P115, DOI 10.1007/BF02737887; Imai J, 2000, MOL CELL BIOL, V20, P9262, DOI 10.1128/MCB.20.24.9262-9270.2000; Kamal A, 2004, TRENDS MOL MED, V10, P283, DOI 10.1016/j.molmed.2004.04.006; Kirschner M, 1998, P NATL ACAD SCI USA, V95, P8420, DOI 10.1073/pnas.95.15.8420; Kontoyiannis DP, 2003, J ANTIMICROB CHEMOTH, V51, P313, DOI 10.1093/jac/dkg090; Kumar R, 2005, MOL BIOCHEM PARASIT, V141, P29, DOI 10.1016/j.molbiopara.2005.01.012; Odds FC, 2003, TRENDS MICROBIOL, V11, P272, DOI 10.1016/S0966-842X(03)00117-3; Pfaller MA, 2004, J CLIN MICROBIOL, V42, P4419, DOI 10.1128/JCM.42.10.4419-4431.2004; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Sanglard D, 2003, MOL MICROBIOL, V48, P959, DOI 10.1046/j.1365-2958.2003.03495.x; Sanglard D, 2002, CURR OPIN MICROBIOL, V5, P379, DOI 10.1016/S1369-5274(02)00344-2; Sangster TA, 2004, BIOESSAYS, V26, P348, DOI 10.1002/bies.20020; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Steinbach WJ, 2004, ANTIMICROB AGENTS CH, V48, P1664, DOI 10.1128/AAC.48.5.1664-1669.2004; True HL, 2004, NATURE, V431, P184, DOI 10.1038/nature02885; White TC, 1997, ANTIMICROB AGENTS CH, V41, P1482, DOI 10.1128/AAC.41.7.1482; White TC, 1998, CLIN MICROBIOL REV, V11, P382, DOI 10.1128/CMR.11.2.382; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	37	497	544	0	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	2005	309	5744					2185	2189		10.1126/science.1118370	http://dx.doi.org/10.1126/science.1118370			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195452				2022-12-28	WOS:000232318000034
J	Mossel, E; Vigoda, E				Mossel, E; Vigoda, E			Phylogenetic MCMC algorithms are misleading on mixtures of trees	SCIENCE			English	Article							BAYESIAN-INFERENCE; LIKELIHOOD; EVOLUTION	Markov chain Monte Carlo (MCMC) algorithms play a critical role in the Bayesian approach to phylogenetic inference. We present a theoretical analysis of the rate of convergence of many of the widely used Markov chains. For N characters generated from a uniform mixture of two trees, we prove that the Markov chains take an exponentially long (in N) number of iterations to converge to the posterior distribution. Nevertheless, the likelihood plots for sample runs of the Markov chains deceivingly suggest that the chains converge rapidly to a unique tree. Our results rely on novel mathematical understanding of the log-likelihood function on the space of phylogenetic trees. The practical implications of our work are that Bayesian MCMC methods can be misleading when the data are generated from a mixture of trees. Thus, in cases of data containing potentially conflicting phylogenetic signals, phylogenetic reconstruction should be performed separately on each signal.	Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA; Georgia Inst Technol, Coll Comp, Atlanta, GA 30332 USA	University of California System; University of California Berkeley; University System of Georgia; Georgia Institute of Technology	Mossel, E (corresponding author), Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA.	mossel@stat.berkeley.edu; vigoda@cc.gatech.edu		Mossel, Elchanan/0000-0001-7812-7886				Bhatnagar N., 2004, P 15 ANN ACM SIAM S, P478; Billera LJ, 2001, ADV APPL MATH, V27, P733, DOI 10.1006/aama.2001.0759; CAVENDER JA, 1978, MATH BIOSCI, V40, P271, DOI 10.1016/0025-5564(78)90089-5; Chang JT, 1996, MATH BIOSCI, V134, P189, DOI 10.1016/0025-5564(95)00172-7; Chor B, 2000, MOL BIOL EVOL, V17, P1529, DOI 10.1093/oxfordjournals.molbev.a026252; Develin M., 2004, DOC MATH, V9, P1; Diaconis PW, 1998, P NATL ACAD SCI USA, V95, P14600, DOI 10.1073/pnas.95.25.14600; FARRIS JS, 1973, SYST ZOOL, V22, P50, DOI 10.2307/2412378; Felsenstein J., 2004, INFERRING PHYLOGENIE; GEYER CJ, 1991, COMPUTING SCIENCE AND STATISTICS, P156; Graur D., 1999, FUNDAMENTALS MOL EVO; Huelsenbeck JP, 2002, SYST BIOL, V51, P673, DOI 10.1080/10635150290102366; Huelsenbeck JP, 2001, SCIENCE, V294, P2310, DOI 10.1126/science.1065889; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Kolaczkowski B, 2004, NATURE, V431, P980, DOI 10.1038/nature02917; Larget B, 1999, MOL BIOL EVOL, V16, P750, DOI 10.1093/oxfordjournals.molbev.a026160; Li SY, 2000, J AM STAT ASSOC, V95, P493, DOI 10.2307/2669394; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; Nei M., 2000, MOL EVOLUTION PHYLOG, P352; NEYMAN J, 1971, STAT DECISION THEORY, P1; Rannala B, 1996, J MOL EVOL, V43, P304, DOI 10.1007/PL00006090; Sinclair A., 1993, ALGORITHMS RANDOM GE; Speyer D, 2004, ADV GEOM, V4, P389, DOI 10.1515/advg.2004.023; Steel M, 2005, TRENDS GENET, V21, P307, DOI 10.1016/j.tig.2005.04.001; Steel M A, 1994, J Comput Biol, V1, P153, DOI 10.1089/cmb.1994.1.153; Yang ZH, 2000, P ROY SOC B-BIOL SCI, V267, P109, DOI 10.1098/rspb.2000.0974; Yang ZH, 1997, MOL BIOL EVOL, V14, P717, DOI 10.1093/oxfordjournals.molbev.a025811	27	115	118	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	2005	309	5744					2207	2209		10.1126/science.1115493	http://dx.doi.org/10.1126/science.1115493			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195459				2022-12-28	WOS:000232318000041
J	Safran, RJ; Neuman, CR; McGraw, KJ; Lovette, IJ				Safran, RJ; Neuman, CR; McGraw, KJ; Lovette, IJ			Dynamic paternity allocation as a function of male plumage color in barn swallows	SCIENCE			English	Article							EXTRA-PAIR PATERNITY; FEMALE PREFERENCE; PARENTAL CARE; QUALITY; ORNAMENTATION; COMPETITION; SIGNAL; SPERM; TRAIT; BIRDS	Paternity in mate animals can be influenced by their phenotypic signals of quality. Accordingly, the behavior underlying patterns of paternity should be flexible as signals of quality change. To evaluate the dynamics of paternity allocation, we analyzed paternity before and after manipulating plumage coloration, a known signal of quality, in mate barn swallows Hirundo rustica. We found that, in successive breeding bouts, only mates whose plumage color was experimentally enhanced received greater paternity from their social mates, demonstrating evidence for flexible and dynamic paternity allocation and the importance for males of maintaining signals of quality wet[ after pair bond formation.	Cornell Univ, Dept Ecol & Evolutionary Biol, Ithaca, NY 14853 USA; Cornell Lab Ornithol, Evolut Biol Program, Ithaca, NY 14850 USA; Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA	Cornell University; Cornell University; Arizona State University; Arizona State University-Tempe	Safran, RJ (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	rsafran@princeton.edu						Andersson Malte, 1994; Birkhead TR, 2002, NAT REV GENET, V3, P262, DOI 10.1038/nrg774; Conrad KF, 1998, AUK, V115, P497, DOI 10.2307/4089213; Dale J, 2001, AM NAT, V158, P75, DOI 10.1086/320861; Darwin C., 1871, P475; Ellegren H, 1995, MOL ECOL, V4, P739, DOI 10.1111/j.1365-294X.1995.tb00274.x; FreemanGallant CR, 1996, P ROY SOC B-BIOL SCI, V263, P157, DOI 10.1098/rspb.1996.0025; Griffith SC, 2002, MOL ECOL, V11, P2195, DOI 10.1046/j.1365-294X.2002.01613.x; Jennions MD, 2000, BIOL REV, V75, P21, DOI 10.1017/S0006323199005423; Johnsen A, 1998, P ROY SOC B-BIOL SCI, V265, P1313, DOI 10.1098/rspb.1998.0435; KEMPENAERS B, 1992, NATURE, V357, P494, DOI 10.1038/357494a0; Mays HL, 2004, TRENDS ECOL EVOL, V19, P554, DOI 10.1016/j.tree.2004.07.018; McGraw KJ, 2004, CAN J ZOOL, V82, P734, DOI 10.1139/Z04-043; McGraw KJ, 2004, BEHAV ECOL, V15, P889, DOI 10.1093/beheco/arh109; Mennill DJ, 2002, SCIENCE, V296, P873, DOI 10.1126/science.296.5569.873; Neff BD, 2005, MOL ECOL, V14, P19, DOI 10.1111/j.1365-294X.2004.02395.x; Neff BD, 2003, NATURE, V422, P716, DOI 10.1038/nature01528; Ornborg J, 2002, BIOL J LINN SOC, V76, P237, DOI 10.1046/j.1095-8312.2002.00061.x; Otter KA, 2001, J AVIAN BIOL, V32, P338, DOI 10.1111/j.0908-8857.2001.320408.x; ROHWER S, 1978, ANIM BEHAV, V26, P1012, DOI 10.1016/0003-3472(78)90090-8; Safran RJ, 2004, BEHAV ECOL, V15, P455, DOI 10.1093/beheco/arh035; Saino N, 1997, EVOLUTION, V51, P562, DOI 10.1111/j.1558-5646.1997.tb02443.x; Sheldon BC, 1998, P ROY SOC B-BIOL SCI, V265, P1737, DOI 10.1098/rspb.1998.0496; Smith HG, 1991, BEHAV ECOL, V2, P90, DOI 10.1093/beheco/2.1.90; Snook RR, 2005, TRENDS ECOL EVOL, V20, P46, DOI 10.1016/j.tree.2004.10.011; Tarof SA, 2005, P ROY SOC B-BIOL SCI, V272, P1121, DOI 10.1098/rspb.2005.3053; Tibbetts EA, 2004, NATURE, V432, P218, DOI 10.1038/nature02949; Westneat DF, 2003, ANNU REV ECOL EVOL S, V34, P365, DOI 10.1146/annurev.ecolsys.34.011802.132439	28	111	115	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	2005	309	5744					2210	2212		10.1126/science.1115090	http://dx.doi.org/10.1126/science.1115090			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195460				2022-12-28	WOS:000232318000042
J	Brennan, TA; Gawande, A; Thomas, E; Studdert, D				Brennan, TA; Gawande, A; Thomas, E; Studdert, D			Accidental deaths, saved lives, and improved quality	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EVIDENCE-BASED MEDICINE; ADVERSE EVENTS; PATIENT SAFETY; HEALTH-CARE; WORK HOURS; ERRORS		Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Univ Texas, Houston, TX USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University of Texas System	Brennan, TA (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.		Studdert, David/AAF-3116-2021	Studdert, David/0000-0003-0585-5537; Gawande, Atul/0000-0002-1824-9176				Adams K., 2003, PRIORITY AREAS NATL; Altman DE, 2004, NEW ENGL J MED, V351, P2041, DOI 10.1056/NEJMp048243; Andrews LB, 1997, LANCET, V349, P309, DOI 10.1016/S0140-6736(96)08268-2; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; Brennan T., 1996, NEW RULES REGULATION; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1987, ANN INTERN MED, V107, P741, DOI 10.7326/0003-4819-107-5-741; CLEARY PD, 1991, HEALTH AFFAIR, V10, P254, DOI 10.1377/hlthaff.10.4.254; *COMM FUND QUAL IM, PAT SAF 5 YEARS ERR; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gawande A., 2004, NEW YORKER      1206, P82; Hayward RA, 2001, JAMA-J AM MED ASSOC, V286, P415, DOI 10.1001/jama.286.4.415; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, VVolume 600; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; Leape LL, 2002, JAMA-J AM MED ASSOC, V288, P501, DOI 10.1001/jama.288.4.501; Leape LL, 2005, JAMA-J AM MED ASSOC, V293, P2384, DOI 10.1001/jama.293.19.2384; Localio AR, 1996, ANN INTERN MED, V125, P457, DOI 10.7326/0003-4819-125-6-199609150-00005; Lockley SW, 2004, NEW ENGL J MED, V351, P1829, DOI 10.1056/NEJMoa041404; McDonald CJ, 2000, JAMA-J AM MED ASSOC, V284, P93, DOI 10.1001/jama.284.1.93; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Mello MM, 2005, J HEALTH POLIT POLIC, V30, P375, DOI 10.1215/03616878-30-3-375; Needleman J, 2002, NEW ENGL J MED, V346, P1715, DOI 10.1056/NEJMsa012247; ROLLINS G, 2003, REP MED GUIDELINES O, V14, P12; ROLLINS G, 2003, REP MED GUIDELINES O, V14, P10; Rosenthal MB, 2004, HEALTH AFFAIR, V23, P127, DOI 10.1377/hlthaff.23.2.127; SHOJANIA K, 2001, AHRQ PUBLICATION; Shojania KG, 2002, JAMA-J AM MED ASSOC, V288, P508, DOI 10.1001/jama.288.4.508; Thomas EJ, 2002, ANN INTERN MED, V136, P812, DOI 10.7326/0003-4819-136-11-200206040-00009; Thomas EJ, 2003, J GEN INTERN MED, V18, P61, DOI 10.1046/j.1525-1497.2003.20147.x; Thomas EJ, 2000, MED CARE, V38, P261, DOI 10.1097/00005650-200003000-00003; Wachter R.M., 2004, END BEGINNING PATIEN; WEILER PC, 1991, MED MALPRACTICE TRIA; WENNBERG DE, 2003, ADD VARIATIONS HOPE; Woolf SH, 2004, ANN INTERN MED, V140, P33, DOI 10.7326/0003-4819-140-1-200401060-00009	37	106	110	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2005	353	13					1405	1409		10.1056/NEJMsb051157	http://dx.doi.org/10.1056/NEJMsb051157			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	968FB	16192489				2022-12-28	WOS:000232146200017
J	Oransky, I				Oransky, I			Sir Richard Doll - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com							0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 6	2005	366	9484					448	448		10.1016/S0140-6736(05)67047-X	http://dx.doi.org/10.1016/S0140-6736(05)67047-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952RD	16208779				2022-12-28	WOS:000231022300014
J	Chung, Y; Klimanskaya, I; Becker, S; Marh, J; Lu, SJ; Johnson, J; Meisner, L; Lanza, R				Chung, Y; Klimanskaya, I; Becker, S; Marh, J; Lu, SJ; Johnson, J; Meisner, L; Lanza, R			Embryonic and extraembryonic stem cell lines derived from single mouse blastomeres	NATURE			English	Article							IN-VITRO; HUMAN BLASTOCYSTS; 8-CELL STAGE; PROLIFERATION; ESTABLISHMENT; DERIVATION; DIAGNOSIS; INVITRO; MORULAE; BIOPSY	The most basic objection to human embryonic stem (ES) cell research is rooted in the fact that ES cell derivation deprives embryos of any further potential to develop into a complete human being(1,2). ES cell lines are conventionally isolated from the inner cell mass of blastocysts(3-5) and, in a few instances, from cleavage stage embryos(6-9). So far, there have been no reports in the literature of stem cell lines derived using an approach that does not require embryo destruction. Here we report an alternative method of establishing ES cell lines - using a technique of single-cell embryo biopsy similar to that used in pre-implantation genetic diagnosis of genetic defects(10) - that does not interfere with the developmental potential of embryos. Five putative ES and seven trophoblast stem (TS) cell lines were produced from single blastomeres, which maintained normal karyotype and markers of pluripotency or TS cells for up to more than 50 passages. The ES cells differentiated into derivatives of all three germ layers in vitro and in teratomas, and showed germ line transmission. Single-blastomere-biopsied embryos developed to term without a reduction in their developmental capacity. The ability to generate human ES cells without the destruction of ex utero embryos would reduce or eliminate the ethical concerns of many.	Adv Cell Technol, Worcester, MA 01605 USA; Univ Wisconsin, State Lab Hyg Mol Cytogenet, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI 53706 USA; Wake Forest Univ, Bowman Gray Sch Med, Inst Regenerat Med, Winston Salem, NC 27157 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Wake Forest University; Wake Forest Baptist Medical Center	Lanza, R (corresponding author), Adv Cell Technol, Worcester, MA 01605 USA.	rlanza@advancedcell.com		Lanza, Robert/0000-0002-3047-3074				ARMANT DR, 1986, DEV BIOL, V116, P519, DOI 10.1016/0012-1606(86)90152-1; Chan AWS, 2000, SCIENCE, V287, P317, DOI 10.1126/science.287.5451.317; *COMM BIOL BIOM AP, 2002, STEM CELLS FUT REG M; Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330; Delhaise F, 1996, EUR J MORPHOL, V34, P237, DOI 10.1076/ejom.34.4.237.13046; EISTETTER HR, 1989, DEV GROWTH DIFFER, V31, P275; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; GEBER S, 1995, HUM REPROD, V10, P1492, DOI 10.1093/HUMREP/10.6.1492; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; LANZA R, 2004, HDB STEM CELLS, V1; MENINO AR, 1983, BIOL REPROD, V28, P433, DOI 10.1095/biolreprod28.2.433; Mitalipova M, 2001, Cloning, V3, P59, DOI 10.1089/15204550152475563; MOORE NW, 1968, J REPROD FERTIL, V17, P527, DOI 10.1530/jrf.0.0170527; Nagy A., 2002, MANIPULATING MOUSE E; NIEMANN H, 1993, J REPROD FERTIL, P75; ROSSANT J, 1976, J EMBRYOL EXP MORPH, V36, P283; SAITO S, 1991, BIOL REPROD, V44, P927, DOI 10.1095/biolreprod44.5.927; Staessen C, 2004, HUM REPROD, V19, P2849, DOI 10.1093/humrep/deh536; Strelchenko N, 2004, REPROD BIOMED ONLINE, V9, P623, DOI 10.1016/S1472-6483(10)61772-5; SUKOYAN MA, 1993, MOL REPROD DEV, V36, P148, DOI 10.1002/mrd.1080360205; Tao T, 2000, HUM REPROD, V15, P881, DOI 10.1093/humrep/15.4.881; TARKOWSKI AK, 1967, J EMBRYOL EXP MORPH, V18, P155; Tesar PJ, 2005, P NATL ACAD SCI USA, V102, P8239, DOI 10.1073/pnas.0503231102; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; WILLADSEN SM, 1981, J EMBRYOL EXP MORPH, V65, P165; WILTON LJ, 1989, BIOL REPROD, V40, P145, DOI 10.1095/biolreprod40.1.145	26	245	269	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 12	2006	439	7073					216	219		10.1038/nature04277	http://dx.doi.org/10.1038/nature04277			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	001MT	16227970	Bronze			2022-12-28	WOS:000234538400043
J	Gao, YQ; Yang, W; Karplus, M				Gao, YQ; Yang, W; Karplus, M			A structure-based model for the synthesis and hydrolysis of ATP by F-1-ATPase	CELL			English	Article							ESCHERICHIA-COLI F-1-ATPASE; FREE-ENERGY SIMULATIONS; CATALYTIC SITES; CONFORMATIONAL-CHANGE; BOVINE F-1-ATPASE; MOLECULAR MACHINE; SYNTHASE; MECHANISM; ROTATION; F1-ATPASE	Many essential functions of living cells are performed by nanoscale protein motors. The best characterized of these is F0F1-ATP synthase, the smallest rotary motor. This rotary motor catalyzes the synthesis of ATP with high efficiency under conditions where the reactants (ADP, H2PO4-) and the product (ATP) are present in the cell at similar concentrations. We present a detailed structure-based kinetic model for the mechanism of action of F-1-ATPase and demonstrate the role of different protein conformations for substrate binding during ATP synthesis and ATP hydrolysis. The model shows that the pathway for ATP hydrolysis is not simply the pathway for ATP synthesis in reverse. The findings of the model also explain why the cellular concentration of ATP does not inhibit ATP synthesis.	Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Univ Strasbourg 1, Lab Chim Biophys, ISIS, F-67000 Strasbourg, France	Harvard University; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Karplus, M (corresponding author), Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.	marci@tammy.harvard.edu	Yang, Wei/H-5428-2011					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ahmad Z, 2004, J BIOL CHEM, V279, P31505, DOI 10.1074/jbc.M404621200; Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; Allison WS, 1998, ACCOUNTS CHEM RES, V31, P819, DOI 10.1021/ar960257v; AlShawi MK, 1997, BIOCHEMISTRY-US, V36, P12961, DOI 10.1021/bi971478r; Antes I, 2003, BIOPHYS J, V85, P695, DOI 10.1016/S0006-3495(03)74513-5; Bockmann RA, 2002, NAT STRUCT BIOL, V9, P198, DOI 10.1038/nsb760; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Braig K, 2000, STRUCTURE, V8, P567, DOI 10.1016/S0969-2126(00)00145-3; Cui Q, 2004, J MOL BIOL, V340, P345, DOI 10.1016/j.jmb.2004.04.044; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; Diez M, 2004, NAT STRUCT MOL BIOL, V11, P135, DOI 10.1038/nsmb718; Dittrich M, 2004, BIOPHYS J, V87, P2954, DOI 10.1529/biophysj.104.046128; Gao YQ, 2003, P NATL ACAD SCI USA, V100, P11339, DOI 10.1073/pnas.1334188100; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Greene MD, 2003, J BIOL CHEM, V278, P51594, DOI 10.1074/jbc.M309948200; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; Itoh H, 2004, NATURE, V427, P465, DOI 10.1038/nature02212; Kagawa R, 2004, EMBO J, V23, P2734, DOI 10.1038/sj.emboj.7600293; Karplus M, 2004, CURR OPIN STRUC BIOL, V14, P250, DOI 10.1016/j.sbi.2004.03.012; Kinosita K, 2004, ANNU REV BIOPH BIOM, V33, P245, DOI 10.1146/annurev.biophys.33.110502.132716; Ma JP, 2002, STRUCTURE, V10, P921, DOI 10.1016/S0969-2126(02)00789-X; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Nadanaciva S, 1999, BIOCHEMISTRY-US, V38, P15493, DOI 10.1021/bi9917683; Nakamoto RK, 2000, BBA-BIOENERGETICS, V1458, P289, DOI 10.1016/S0005-2728(00)00081-5; Nelson DL, 2000, LEHNINGER PRINCIPLES; Nicholls D., 2002, BIOENERGETICS, V3; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; SENIOR AE, 1992, J BIOENERG BIOMEMBR, V24, P479, DOI 10.1007/BF00762365; Simonson T, 2002, ACCOUNTS CHEM RES, V35, P430, DOI 10.1021/ar010030m; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; Sun S, 2003, EUR BIOPHYS J BIOPHY, V32, P676, DOI 10.1007/s00249-003-0335-6; VOET D, 1995, BIOCHEMISTRY-US, P433; Wang HY, 1998, NATURE, V396, P279, DOI 10.1038/24409; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Yagi H, 2004, J AM CHEM SOC, V126, P16632, DOI 10.1021/ja045279o; Yang W, 2004, J CHEM PHYS, V120, P2618, DOI 10.1063/1.1638996; Yang W, 2003, P NATL ACAD SCI USA, V100, P874, DOI 10.1073/pnas.0337432100; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	44	123	129	1	47	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	2005	123	2					195	205		10.1016/j.cell.2005.10.001	http://dx.doi.org/10.1016/j.cell.2005.10.001			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239139	Bronze			2022-12-28	WOS:000232794100008
J	Ha, SC; Lowenhaupt, K; Rich, A; Kim, YG; Kim, KK				Ha, SC; Lowenhaupt, K; Rich, A; Kim, YG; Kim, KK			Crystal structure of a junction between B-DNA and Z-DNA reveals two extruded bases	NATURE			English	Article							HANDED Z-DNA; BIOLOGICAL FUNCTION; BINDING; GENE; PROMOTER; COMPLEX; FORMS; MODEL	Left-handed Z-DNA is a higher-energy form of the double helix, stabilized by negative supercoiling generated by transcription or unwrapping nucleosomes(1). Regions near the transcription start site frequently contain sequence motifs favourable for forming Z-DNA(2), and formation of Z-DNA near the promoter region stimulates transcription(3,4). Z-DNA is also stabilized by specific protein binding; several proteins have been identified with low nanomolar binding constants(5-9). Z-DNA occurs in a dynamic state, forming as a result of physiological processes then relaxing to the right-handed B-DNA(1). Each time a DNA segment turns into Z-DNA, two B-Z junctions form. These have been examined extensively(10-12), but their structure was unknown. Here we describe the structure of a B-Z junction as revealed by X-ray crystallography at 2.6 angstrom resolution. A 15-base-pair segment of DNA is stabilized at one end in the Z conformation by Z-DNA binding proteins, while the other end remains B-DNA. Continuous stacking of bases between B-DNA and Z-DNA segments is found, with the breaking of one base pair at the junction and extrusion of the bases on each side (Fig. 1). These extruded bases may be sites for DNA modification.	Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Dept Mol Cell Biol, Suwon 440746, South Korea; Sungkyunkwan Univ, Sungkyunkwan Adv Inst Nanotecnol, Suwon 440746, South Korea; MIT, Dept Biol, Cambridge, MA 02139 USA; Chung Ang Univ, Coll Med, Dept Biochem, Seoul 156756, South Korea	Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Massachusetts Institute of Technology (MIT); Chung Ang University; Chung Ang University Hospital	Kim, KK (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Dept Mol Cell Biol, Suwon 440746, South Korea.	ygkimmit@cau.ac.kr; kkim@med.skku.ac.kr		/0000-0002-8187-6498				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Champ PC, 2004, NUCLEIC ACIDS RES, V32, P6501, DOI 10.1093/nar/gkh988; DAI Z, 1989, BIOCHEMISTRY-US, V28, P6991, DOI 10.1021/bi00443a032; Daniels DS, 2004, NAT STRUCT MOL BIOL, V11, P714, DOI 10.1038/nsmb791; DREW HR, 1981, P NATL ACAD SCI-BIOL, V78, P2179, DOI 10.1073/pnas.78.4.2179; Ha SC, 2004, P NATL ACAD SCI USA, V101, P14367, DOI 10.1073/pnas.0405586101; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; JIANG H, 1991, NUCLEIC ACIDS RES, V19, P6943, DOI 10.1093/nar/19.24.6943; Kim YG, 2003, P NATL ACAD SCI USA, V100, P6974, DOI 10.1073/pnas.0431131100; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; Kwon JA, 2005, P NATL ACAD SCI USA, V102, P12759, DOI 10.1073/pnas.0506011102; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Lu XJ, 2000, J MOL BIOL, V300, P819, DOI 10.1006/jmbi.2000.3690; Mao CD, 1999, NATURE, V397, P144, DOI 10.1038/16437; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Oh DB, 2002, P NATL ACAD SCI USA, V99, P16666, DOI 10.1073/pnas.262672699; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rich A, 2003, NAT REV GENET, V4, P566, DOI 10.1038/nrg1115; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Rothenburg S, 2005, P NATL ACAD SCI USA, V102, P1602, DOI 10.1073/pnas.0408714102; Rothenburg S, 2001, P NATL ACAD SCI USA, V98, P8985, DOI 10.1073/pnas.121176998; Schwartz T, 2001, NAT STRUCT BIOL, V8, P761, DOI 10.1038/nsb0901-761; Schwartz T, 1999, SCIENCE, V284, P1841, DOI 10.1126/science.284.5421.1841; SHEARDY RD, 1989, BIOCHEMISTRY-US, V28, P720, DOI 10.1021/bi00428a046; SHEARDY RD, 1994, BIOCHEMISTRY-US, V33, P1385, DOI 10.1021/bi00172a014; Tashiro R, 2003, ANGEW CHEM INT EDIT, V42, P6018, DOI 10.1002/anie.200352752; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1763, DOI 10.1107/S0907444901013749; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; Wolfl S, 1995, BBA-GENE STRUCT EXPR, V1264, P294, DOI 10.1016/0167-4781(95)00155-7	31	196	204	6	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 20	2005	437	7062					1183	1186		10.1038/nature04088	http://dx.doi.org/10.1038/nature04088			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16237447				2022-12-28	WOS:000232660500050
J	Martin, A; Baker, TA; Sauer, RT				Martin, A; Baker, TA; Sauer, RT			Rebuilt AAA plus motors reveal operating principles for ATP-fuelled machines	NATURE			English	Article							CLPXP DEGRADATION MACHINE; ESCHERICHIA-COLI; DEPENDENT PROTEASES; CRYSTAL-STRUCTURE; SEQUENTIAL HYDROLYSIS; PROTEIN; HELICASE; RECOGNITION; MECHANISM; CHAPERONE	Hexamericring- shaped ATPases of the AAA+ (for ATPases associated with various cellular activities) superfamily power cellular processes in which macromolecular structures and complexes are dismantled or denatured, but the mechanisms used by these machine-like enzymes are poorly understood. By covalently linking active and inactive subunits of the ATPase ClpX to form hexamers, here we show that diverse geometric arrangements can support the enzymatic unfolding of protein substrates and translocation of the denatured polypeptide into the ClpP peptidase for degradation. These studies indicate that the ClpX power stroke is generated by ATP hydrolysis in a single subunit, rule out concerted and strict sequential ATP hydrolysis models, and provide evidence for a probabilistic sequence of nucleotide hydrolysis. This mechanism would allow any ClpX subunit in contact with a translocating polypeptide to hydrolyse ATP to drive substrate spooling into ClpP, and would prevent stalling if one subunit failed to bind or hydrolyse ATP. Energy-dependent machines with highly diverse quaternary architectures and molecular functions could operate by similar asymmetric mechanisms.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Sauer, RT (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	bobsauer@mit.edu		Sauer, Robert/0000-0002-1719-5399; Martin, Andreas/0000-0003-0923-3284				Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Bolon DN, 2004, MOL CELL, V16, P343, DOI 10.1016/j.molcel.2004.10.001; Bowman GD, 2005, FEBS LETT, V579, P863, DOI 10.1016/j.febslet.2004.11.038; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Burton RE, 2001, EMBO J, V20, P3092, DOI 10.1093/emboj/20.12.3092; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; Flynn JM, 2001, P NATL ACAD SCI USA, V98, P10584, DOI 10.1073/pnas.191375298; Gai' DH, 2004, CELL, V119, P47, DOI 10.1016/j.cell.2004.09.017; Gottesman S, 2003, ANNU REV CELL DEV BI, V19, P565, DOI 10.1146/annurev.cellbio.19.110701.153228; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Hishida T, 2004, P NATL ACAD SCI USA, V101, P9573, DOI 10.1073/pnas.0403584101; Joshi SA, 2004, NAT STRUCT MOL BIOL, V11, P404, DOI 10.1038/nsmb752; Kenniston JA, 2003, CELL, V114, P511, DOI 10.1016/S0092-8674(03)00612-3; Kenniston JA, 2005, P NATL ACAD SCI USA, V102, P1390, DOI 10.1073/pnas.0409634102; Kim DY, 2003, J BIOL CHEM, V278, P50664, DOI 10.1074/jbc.M305882200; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Lee SY, 2003, GENE DEV, V17, P2552, DOI 10.1101/gad.1125603; Levchenko I, 2000, SCIENCE, V289, P2354, DOI 10.1126/science.289.5488.2354; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Sakato M, 2004, J STRUCT BIOL, V146, P58, DOI 10.1016/j.jsb.2003.09.026; Sauer RT, 2004, CELL, V119, P9, DOI 10.1016/j.cell.2004.09.020; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Skordalakes E, 2003, CELL, V114, P135, DOI 10.1016/S0092-8674(03)00512-9; Stitt BL, 1998, J BIOL CHEM, V273, P26477, DOI 10.1074/jbc.273.41.26477; Stitt BL, 2001, BIOCHEMISTRY-US, V40, P2276, DOI 10.1021/bi002253a; Toth EA, 2003, MOL CELL, V12, P1113, DOI 10.1016/S1097-2765(03)00442-8; Wojtyra UA, 2003, J BIOL CHEM, V278, P48981, DOI 10.1074/jbc.M307825200; Zalk R, 2003, BIOCHEM J, V374, P473, DOI 10.1042/BJ20030219	37	287	293	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 20	2005	437	7062					1115	1120		10.1038/nature04031	http://dx.doi.org/10.1038/nature04031			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16237435				2022-12-28	WOS:000232660500035
J	Rupp, ME; Lisco, SJ; Lipsett, PA; Ped, TM; Keating, K; Civetta, JM; Mermel, LA; Lee, D; Dellinger, EP; Donahoe, M; Giles, D; Pfaller, MA; Maki, DG; Sherertz, R				Rupp, ME; Lisco, SJ; Lipsett, PA; Ped, TM; Keating, K; Civetta, JM; Mermel, LA; Lee, D; Dellinger, EP; Donahoe, M; Giles, D; Pfaller, MA; Maki, DG; Sherertz, R			Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter - Related infections - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							BLOOD-STREAM INFECTION; CRITICALLY-ILL PATIENTS; PREVENTION; COLONIZATION; RISK; CARE	Background: central venous catheter-related infections are a significant medical problem. Improved preventive measures are needed. Objective: To ascertain 1) effectiveness of a second -generation antiseptic-coated catheter in the prevention of microbial colonization and infection; 2) safety and tolerability of this device; 3) microbiology of infected catheters; and 4) propensity for the development of antiseptic resistance. Design: Multicenter, randomized, double-blind, controlled trial. Setting: 9 university-affiliated medical centers. Patients: 780 patients in intensive care units who required central venous catheterization. Intervention: Patients received either a standard catheter or a catheter coated with chlorhexidine and silver sulfadiazine. Measurements: The authors assessed catheter colonization and catheter-related infection, characterized microbes by molecular typing, and determined their susceptibility to antiseptics. Patient tolerance of the catheter was monitored. Results: Patients with the 2 types of catheters had similar demographic features, clinical interventions, laboratory values, and risk factors for infection. Antiseptic catheters were less likely to be colonized at the time of removal compared with control catheters (13.3 vs. 24.1 colonized catheters per 1000 catheter-days; P < 0.01). The center-stratified Cox regression hazard ratio for colonization controlling for sampling design and potentially confounding variables was 0.45 (95% Cl, 0.25 to 0.78). The rate of definitive catheter-related bloodstream infection was 1.24 per 1000 catheter-days (Cl, 0.26 to 3.62 per 1000 catheter-days) for the control group versus 0.42 per 1000 catheter-days (Cl, 0.01 to 2.34 per 1000 catheter-days) for the antiseptic catheter group (P = 0.6). Coagulase-negative staphylococci and other gram-positive organisms were the most frequent microbes to colonize catheters. Noninfectious adverse events were similar in both groups. Antiseptic susceptibility was similar for microbes recovered from either group. Limitations: The antiseptic catheter was not compared with an antibiotic-coated catheter, and no conclusion can be made regarding its effect on bloodstream infection. Conclusions: The second-generation chlorhexicline-silver sulfadiazine catheter is well tolerated. Antiseptic coating appears to reduce microbial colonization of the catheter compared with an uncoated catheter.	Univ Nebraska, Med Ctr, Omaha, NE 68198 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Univ Hartford, Hartford, CT USA; Univ Connecticut, Farmington, CT USA; Rhode Isl Hosp, Providence, RI USA; Brown Med Sch, Providence, RI USA; Rochester Gen Hosp, New York, NY USA; Univ Washington, Seattle, WA 98195 USA; Univ Pittsburgh, Pittsburgh, PA USA; Univ Iowa, Iowa City, IA USA; Univ Wisconsin, Madison, WI 53706 USA; Wake Forest Univ, Winston Salem, NC 27109 USA	University of Nebraska System; University of Nebraska Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Johns Hopkins University; University of Hartford; University of Connecticut; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Rochester General Hospital; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Iowa; University of Wisconsin System; University of Wisconsin Madison; Wake Forest University	Rupp, ME (corresponding author), Univ Nebraska, Med Ctr, 600 S 42nd St, Omaha, NE 68198 USA.	merupp@unmc.edu	Lisco, Steven J/R-7124-2019; Mermel, Leonard/Z-1475-2019	Lisco, Steven/0000-0003-4307-9807				[Anonymous], DISINFECTION STERILI; ARMSTRONG CW, 1986, J INFECT DIS, V154, P808, DOI 10.1093/infdis/154.5.808; Bassetti S, 2001, ANTIMICROB AGENTS CH, V45, P1535, DOI 10.1128/AAC.45.5.1535-1538.2001; BYERS K, 1995, INFECT CONT HOSP E S, V16, P23; *CDCP, 2001, DIV HEALTHC QUAL PRO; Chaiyakunapruk N, 2002, ANN INTERN MED, V136, P792, DOI 10.7326/0003-4819-136-11-200206040-00007; Crnich CJ, 2002, CLIN INFECT DIS, V34, P1232, DOI 10.1086/339863; Darouiche RO, 1999, NEW ENGL J MED, V340, P1, DOI 10.1056/NEJM199901073400101; Denton GW, 2001, DISINFECTION STERILI, P321; Dimick JB, 2001, ARCH SURG-CHICAGO, V136, P229, DOI 10.1001/archsurg.136.2.229; Farr Barry M., 1999, P157; Gerberding J, 2000, AM J INFECT CONTROL, V28, P429, DOI 10.1067/mic.2000.110544; Gotz F, 2002, MOL MICROBIOL, V43, P1367, DOI 10.1046/j.1365-2958.2002.02827.x; *GUID PREV INTR CA, 2002, MMWR-MORBID MORTAL W, V51, P1; HEISELMAN D, 1994, JAMA-J AM MED ASSOC, V272, P1819, DOI 10.1001/jama.272.23.1819; Maki DG, 1997, ANN INTERN MED, V127, P257, DOI 10.7326/0003-4819-127-4-199708150-00001; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; Mermel LA, 2000, ANN INTERN MED, V132, P391, DOI 10.7326/0003-4819-132-5-200003070-00009; National Committee for Clinical Laboratory Standards, 2000, M2A7 NCCLS; PFALLER MA, 2004, MOL MICROBIOLOGY DIA, P245; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Raad I, 1997, ANN INTERN MED, V127, P267, DOI 10.7326/0003-4819-127-4-199708150-00002; RAAD II, 1994, INFECT CONT HOSP EP, V15, P231; Rello J, 2000, AM J RESP CRIT CARE, V162, P1027, DOI 10.1164/ajrccm.162.3.9911093; Rijnders BJA, 2002, CLIN INFECT DIS, V35, P1053, DOI 10.1086/342905; RUPP ME, 1994, CLIN INFECT DIS, V19, P231, DOI 10.1093/clinids/19.2.231; SHERERTZ RJ, 1990, J CLIN MICROBIOL, V28, P76, DOI 10.1128/JCM.28.1.76-82.1990; Solomon S, 2003, AM J INFECT CONTROL, V31, P481; Tambe SM, 2001, J ANTIMICROB CHEMOTH, V47, P589, DOI 10.1093/jac/47.5.589; *US FOOD DRUG ADM, 1998, POT HYP REACT CHL IM; Veenstra DL, 1999, JAMA-J AM MED ASSOC, V282, P554, DOI 10.1001/jama.282.6.554	31	157	166	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 18	2005	143	8					570	580		10.7326/0003-4819-143-8-200510180-00007	http://dx.doi.org/10.7326/0003-4819-143-8-200510180-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975PI	16230723				2022-12-28	WOS:000232674000007
J	Hopper, JL; Bishop, DT; Easton, DF				Hopper, JL; Bishop, DT; Easton, DF			Genetic Epidemiology 6 - Population-based family studies in genetic epidemiology	LANCET			English	Article							BREAST-CANCER FAMILIES; BRCA2 GERMLINE MUTATIONS; ORAL-CONTRACEPTIVE USE; OVARIAN-CANCER; TWIN REGISTRY; RISK-FACTORS; FOLLOW-UP; HISTORICAL COHORT; CUMULATIVE RISK; RESPONSE RATES	Designs that involve families (the traditional strength of genetic epidemiology) and population-based sampling (the traditional strength of environmental epidemiology) allow investigation of both genes and environment, separately or together, and allow valid inference to the population. These case-control-family designs (including those involving twin pairs), can be regarded as retrospective cohort studies of relatives, and can be used for: determining familial risks and genetic models; estimating risk (penetrance) for measured genotypes; genetic association studies; stratifying risks by family history and known mutation status; and studying modifiers of risk in genetically susceptible individuals. Follow-up of families allows genetic and environmental risks to be studied prospectively. We discuss statistical methods, theoretical and practical strengths, limitations, and other issues. Given their versatility, population-based family studies could become a principal framework in epidemiology, and move genetics from its traditional focus on high-risk families to give it a wider clinical and population health relevance.	Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Carlton, Vic 3053, Australia; St Jamess Hosp Leeds, Div Epidemiol, Canc Res UK Genet, Leeds, W Yorkshire, England; Strangeways Res Lab, Epidemiol Unit, Canc Res UK Genet, Cambridge CB1 4RN, England	University of Melbourne; Saint James's University Hospital	Hopper, JL (corresponding author), Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, 723 Swanston St, Carlton, Vic 3053, Australia.	j.hopper@unimelb.edu.au		Bishop, Tim/0000-0002-8752-8785				Amundadottir LT, 2004, PLOS MED, V1, P229, DOI 10.1371/journal.pmed.0010065; ANDERSON VE, 1958, VARIABLES RELATED HU; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Antoniou AC, 2002, BRIT J CANCER, V86, P76, DOI 10.1038/sj.bjc.6600008; Antoniou AC, 2004, BRIT J CANCER, V91, P1580, DOI 10.1038/sj.bjc.6602175; Antoniou AC, 2003, GENET EPIDEMIOL, V25, P190, DOI 10.1002/gepi.10261; Armes JE, 1998, CANCER-AM CANCER SOC, V83, P2335, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.3.CO;2-E; Armes JE, 1999, CANCER RES, V59, P2011; Becher H, 2003, INT J EPIDEMIOL, V32, P38, DOI 10.1093/ije/dyg003; Begg CB, 2002, J NATL CANCER I, V94, P1221; Beral V, 2001, LANCET, V358, P1389, DOI 10.1016/S0140-6736(01)06524-2; Bergem ALM, 2002, TWIN RES, V5, P407, DOI 10.1375/twin.5.5.407; Burton PR, 2005, LANCET, V366, P941, DOI 10.1016/S0140-6736(05)67322-9; Cardon LR, 2003, LANCET, V361, P598, DOI 10.1016/S0140-6736(03)12520-2; Cerhan JR, 2004, CANCER CAUSE CONTROL, V15, P1, DOI 10.1023/B:CACO.0000016566.30377.4e; CLEMMESEN J, 1965, ACTA PATHOL MIC SC, V54, P1; Cordell HJ, 2005, LANCET, V366, P1121, DOI 10.1016/S0140-6736(05)67424-7; Croft ML, 2002, TWIN RES, V5, P317, DOI 10.1375/twin.5.5.317; Cui JS, 2003, GENET EPIDEMIOL, V24, P161, DOI 10.1002/gepi.10222; Cui JS, 2001, AM J HUM GENET, V68, P420, DOI 10.1086/318187; D'Onofrio BM, 2003, J CHILD PSYCHOL PSYC, V44, P1130, DOI 10.1111/1469-7610.00196; Dite GS, 2003, J NATL CANCER I, V95, P448, DOI 10.1093/jnci/95.6.448; Dunlop MG, 1997, HUM MOL GENET, V6, P105, DOI 10.1093/hmg/6.1.105; Easton DF, 2004, SCIENCE, V306, P2187; Elbaz A, 2003, NEUROLOGY, V61, P11, DOI 10.1212/01.WNL.0000068007.58423.C2; ELSTON RC, 1971, HUM HERED, V21, P523, DOI 10.1159/000152448; Evans A, 2003, TWIN RES, V6, P432, DOI 10.1375/136905203770326439; Fisher R. A., 1919, Transactions of the Royal Society of Edinburgh, V52; Gabrick DM, 2000, JAMA-J AM MED ASSOC, V284, P1791, DOI 10.1001/jama.284.14.1791; Gauderman WJ, 2002, AM J EPIDEMIOL, V155, P478, DOI 10.1093/aje/155.5.478; Goldberg J, 2002, TWIN RES, V5, P476, DOI 10.1375/twin.5.5.476; GOLDGAR DE, 1994, J NATL CANCER I, V86, P1600, DOI 10.1093/jnci/86.21.1600; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Haile R W, 1999, J Natl Cancer Inst Monogr, P89; Hamilton AS, 2003, NEW ENGL J MED, V348, P2313, DOI 10.1056/NEJMoa021293; Hansen J, 2004, TWIN RES, V7, P149, DOI 10.1375/136905204323016131; Harrap SB, 2000, AM J EPIDEMIOL, V152, P704, DOI 10.1093/aje/152.8.704; Hemminki K, 2004, INT J CANCER, V111, P944, DOI 10.1002/ijc.20355; Hicks BM, 2004, ARCH GEN PSYCHIAT, V61, P922, DOI 10.1001/archpsyc.61.9.922; Hopper J L, 1999, J Natl Cancer Inst Monogr, P95; Hopper JL, 1999, CANCER EPIDEM BIOMAR, V8, P741; HOPPER JL, 1992, AM J EPIDEMIOL, V136, P1138, DOI 10.1093/oxfordjournals.aje.a116580; Hopper JL, 2003, INT J EPIDEMIOL, V32, P48, DOI 10.1093/ije/dyg114; HOPPER JL, 1992, ACTA GENET MED GEMEL, V41, P261, DOI 10.1017/S0001566000002129; Hsu L, 2002, STAT MED, V21, P863, DOI 10.1002/sim.1055; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; John EM, 2004, BREAST CANCER RES, V6, pR375, DOI 10.1186/bcr801; Kaprio J, 2002, TWIN RES, V5, P358, DOI 10.1375/twin.5.5.358; Kendler KS, 1999, ARCH GEN PSYCHIAT, V56, P39, DOI 10.1001/archpsyc.56.1.39; Keogh LA, 2004, CANCER EPIDEM BIOMAR, V13, P2258; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milne RL, 2005, CANCER EPIDEM BIOMAR, V14, P350, DOI 10.1158/1055-9965.EPI-04-0376; Murff HJ, 2004, JAMA-J AM MED ASSOC, V292, P1480, DOI 10.1001/jama.292.12.1480; Parmigiani G, 1998, AM J HUM GENET, V62, P145, DOI 10.1086/301670; Pedersen NL, 2002, TWIN RES, V5, P427, DOI 10.1375/twin.5.5.427; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; PETO J, 1980, BANBURY REPORT, V4, P203; Pharoah PDP, 2003, J NATL CANCER I, V95, P75, DOI 10.1093/jnci/95.1.75; Rasmussen F, 2002, TWIN RES, V5, P433, DOI 10.1375/twin.5.5.433; Risch N, 2001, CANCER EPIDEM BIOMAR, V10, P733; Rogers A, 2004, AM J EPIDEMIOL, V160, P85, DOI 10.1093/aje/kwh176; Scott CL, 2003, HUM GENET, V112, P542, DOI 10.1007/s00439-003-0908-6; Scurrah KJ, 2000, GENET EPIDEMIOL, V19, P127, DOI 10.1002/1098-2272(200009)19:2<127::AID-GEPI2>3.0.CO;2-S; SELLERS TA, 1995, GENET EPIDEMIOL, V12, P417, DOI 10.1002/gepi.1370120409; Sellers TA, 1999, CANCER EPIDEM BIOMAR, V8, P1051; Seybolt LM, 1997, GENET EPIDEMIOL, V14, P85, DOI 10.1002/(SICI)1098-2272(1997)14:1<85::AID-GEPI7>3.0.CO;2-4; Skytthe A, 2002, TWIN RES, V5, P352; Southey MC, 2005, J CLIN ONCOL, V23, P6524, DOI 10.1200/JCO.2005.04.671; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; SUSSER E, 1989, AM J EPIDEMIOL, V129, P23, DOI 10.1093/oxfordjournals.aje.a115119; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Thomas DC, 2002, CANCER EPIDEM BIOMAR, V11, P505; Thompson D, 2003, AM J HUM GENET, V73, P652, DOI 10.1086/378100; Tyrer J, 2004, STAT MED, V23, P1111, DOI 10.1002/sim.1668; Vachon CM, 2001, CANCER, V92, P240, DOI 10.1002/1097-0142(20010715)92:2<240::AID-CNCR1315>3.0.CO;2-I; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; Wacholder S, 1998, AM J EPIDEMIOL, V148, P623, DOI 10.1093/aje/148.7.623; Whittemore AS, 2004, BRIT J CANCER, V91, P1911, DOI 10.1038/sj.bjc.6602239; Whittemore AS, 2003, GENET EPIDEMIOL, V25, P177, DOI 10.1002/gepi.10267; Willer CJ, 2003, P NATL ACAD SCI USA, V100, P12877, DOI 10.1073/pnas.1932604100; WOOLF C M, 1955, Publ Public Health Univ Calif, V2, P265	85	99	105	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 15	2005	366	9494					1397	1406		10.1016/S0140-6736(05)67570-8	http://dx.doi.org/10.1016/S0140-6736(05)67570-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	973ZW	16226618				2022-12-28	WOS:000232562100032
J	Barnes, JW; Brown, RH; Turtle, EP; McEwen, AS; Lorenz, RD; Janssen, M; Schaller, EL; Brown, ME; Buratti, BJ; Sotin, C; Griffith, C; Clark, R; Perry, J; Fussner, S; Barbara, J; West, R; Elachi, C; Bouchez, AH; Roe, HG; Baines, KH; Bellucci, G; Bibring, JP; Capaccioni, F; Cerroni, P; Combes, M; Coradini, A; Cruikshank, DP; Drossart, P; Formisano, V; Jaumann, R; Langevin, Y; Matson, DL; McCord, TB; Nicholson, PD; Sicardy, B				Barnes, JW; Brown, RH; Turtle, EP; McEwen, AS; Lorenz, RD; Janssen, M; Schaller, EL; Brown, ME; Buratti, BJ; Sotin, C; Griffith, C; Clark, R; Perry, J; Fussner, S; Barbara, J; West, R; Elachi, C; Bouchez, AH; Roe, HG; Baines, KH; Bellucci, G; Bibring, JP; Capaccioni, F; Cerroni, P; Combes, M; Coradini, A; Cruikshank, DP; Drossart, P; Formisano, V; Jaumann, R; Langevin, Y; Matson, DL; McCord, TB; Nicholson, PD; Sicardy, B			A 5-micron-bright spot on Titan: Evidence for surface diversity	SCIENCE			English	Article							CASSINI RADAR	Observations from the Cassini Visual and Infrared Mapping Spectrometer show an anomalously bright spot on Titan located at 80 degrees W and 20 degrees S. This area is bright in reflected tight at all. observed wavelengths, but is most noticeable at 5 microns. The spot is associated with a surface albedo feature identified in images taken by the Cassini Imaging Science Subsystem. We discuss various hypotheses about the source of the spot, reaching the conclusion that the spot is probably due to variation in surface composition, perhaps associated with recent geophysical phenomena.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; CALTECH, Pasadena, CA 91125 USA; Univ Nantes, CNRS, UMR 6112, Lab Planetol & Geodynam, F-44035 Nantes, France; US Geol Survey, Flagstaff, AZ 86001 USA; NASA, Goddard Inst Space Studies, New York, NY 10025 USA; WM Keck Observ, Kamuela, HI 96743 USA; CNR, Ist Fis Spazio Interplanetario, I-00133 Rome, Italy; Univ Paris 11, Inst Astrophys Spatiale, F-91405 Orsay, France; CNR, Ist Astrofis Spaziale & Fis Cosm, Rome, Italy; Observ Paris, Meudon, France; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; German Aerosp Ctr, Inst Planetary Explorat, D-12489 Berlin, Germany; Univ Washington, Dept Earth & Space Sci, Seattle, WA 98195 USA; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA	University of Arizona; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); California Institute of Technology; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Nantes Universite; United States Department of the Interior; United States Geological Survey; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale Astrofisica (INAF); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale Astrofisica (INAF); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Helmholtz Association; German Aerospace Centre (DLR); University of Washington; University of Washington Seattle; Cornell University	Barnes, JW (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.	jbarnes@lpl.arizona.edu	Lorenz, Ralph D/B-8759-2016; Barnes, Jason W/B-1284-2009; Bellucci, Giancarlo/ABA-9201-2020; Turtle, Elizabeth/K-8673-2012; Drossart, Pierre/H-8670-2013; Jaumann, Ralf/N-1001-2018	Lorenz, Ralph D/0000-0001-8528-4644; Barnes, Jason W/0000-0002-7755-3530; Bellucci, Giancarlo/0000-0003-0867-8679; Turtle, Elizabeth/0000-0003-1423-5751; Jaumann, Ralf/0000-0002-9759-6597; Brown, Michael E./0000-0002-8255-0545; Capaccioni, Fabrizio/0000-0003-1631-4314; Barbara, John/0000-0002-2190-4290; Schaller, Emily/0000-0001-8967-5423; Cerroni, Priscilla/0000-0003-0239-2741				Brown RH, 2003, ICARUS, V164, P461, DOI 10.1016/S0019-1035(03)00134-9; Campbell DB, 2003, SCIENCE, V302, P431, DOI 10.1126/science.1088969; Elachi C, 2005, SCIENCE, V308, P970, DOI 10.1126/science.1109919; GRIFFITH CA, 1991, ICARUS, V93, P362, DOI 10.1016/0019-1035(91)90219-J; Griffith CA, 1998, NATURE, V395, P575, DOI 10.1038/26920; Griffith CA, 2003, SCIENCE, V300, P628, DOI 10.1126/science.1081897; Hartung M, 2004, ASTRON ASTROPHYS, V421, pL17, DOI 10.1051/0004-6361:20040171; Kress ME, 2004, ICARUS, V168, P475, DOI 10.1016/j.icarus.2003.10.013; Lorenz RD, 2003, PLANET SPACE SCI, V51, P353, DOI 10.1016/S0032-0633(02)00148-4; Lunine J.I, 1992, ESA, P233; Porco CC, 2005, NATURE, V434, P159, DOI 10.1038/nature03436; Porco CC, 2004, SPACE SCI REV, V115, P363, DOI 10.1007/s11214-004-1456-7; ROE HG, 2004, GEOPHYS RES LETT, V31, P17; Smith PH, 1996, ICARUS, V119, P336, DOI 10.1006/icar.1996.0023	14	68	69	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 7	2005	310	5745					92	95		10.1126/science.1117075	http://dx.doi.org/10.1126/science.1117075			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210535				2022-12-28	WOS:000232477000044
J	Dominski, Z; Yang, XC; Marzluff, WF				Dominski, Z; Yang, XC; Marzluff, WF			The polyadenylation factor CPSF-73 is involved in histone-pre-mRNA processing	CELL			English	Article							LOOP BINDING-PROTEIN; U7 SNRNP; 3' ENDS; CLEAVAGE; 3'-END; MECHANISM; INTERACTS; PRODUCTS; SITE	During 3' end processing, histone pre-mRNAs are cleaved 5 nucleotides after a conserved stem loop by an endonuclease dependent on the U7 small nuclear ribonucleoprotein (snRNP). The upstream cleavage product corresponds to the mature histone mRNA, while the downstream product is degraded by a 5'-3' exonuclease, also dependent on the U7 snRNP. To identify the two nuclease activities, we carried out UV-crosslinking studies using both the complete RNA substrate and the downstream cleavage product, each containing a single radioactive phosphate and a phosphorothioate modification at the cleavage site. We detected a protein migrating at 85 kDa that crosslinked to each substrate in a 1.17-dependent manner. Immunoprecipitation experiments identified this protein as CPSF-73, a known component of the cleavage/polyadenylation machinery. These studies suggest that CPSF-73 is both the endonuclease and 5'-3' exonuclease in histone-pre-mRNA processing and reveal an evolutionary link between 3' end formation of histone mRNAs and polyadenylated mRNAs.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Dominski, Z (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	dominski@med.unc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029832] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29832] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, In Silico Biol, V1, P69; BIRNSTIEL ML, 1988, STRUCTURE FUNCTION M, P155; BOND UM, 1991, GENE DEV, V5, P1709, DOI 10.1101/gad.5.9.1709; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; CHEN F, 1995, NUCLEIC ACIDS RES, V23, P2614, DOI 10.1093/nar/23.14.2614; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Dominski Z, 1999, GENE, V239, P1, DOI 10.1016/S0378-1119(99)00367-4; Dominski Z, 1999, MOL CELL BIOL, V19, P3561; Dominski Z, 2005, MOL CELL BIOL, V25, P1489, DOI 10.1128/MCB.25.4.1489-1500.2005; Dominski Z, 2003, MOL CELL, V12, P295, DOI 10.1016/S1097-2765(03)00278-8; Dominski Z, 2002, GENE DEV, V16, P58, DOI 10.1101/gad.932302; Dronkert MLG, 2000, MOL CELL BIOL, V20, P4553, DOI 10.1128/MCB.20.13.4553-4561.2000; Even S, 2005, NUCLEIC ACIDS RES, V33, P2141, DOI 10.1093/nar/gki505; GICK O, 1986, EMBO J, V5, P1319, DOI 10.1002/j.1460-2075.1986.tb04362.x; Koziolkiewicz M, 1997, ANTISENSE NUCLEIC A, V7, P43, DOI 10.1089/oli.1.1997.7.43; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; Moore MJ, 2000, METHOD ENZYMOL, V317, P109; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; MOWRY KL, 1988, TRENDS BIOCHEM SCI, V13, P447, DOI 10.1016/0968-0004(88)90220-4; Ryan K, 2004, RNA, V10, P565, DOI 10.1261/rna.5214404; SCHARL EC, 1994, EMBO J, V13, P2432, DOI 10.1002/j.1460-2075.1994.tb06528.x; Schumperli D, 2004, CELL MOL LIFE SCI, V61, P2560, DOI 10.1007/s00018-004-4190-0; SHEETS MD, 1987, MOL CELL BIOL, V7, P1518, DOI 10.1128/MCB.7.4.1518; Sollner-Webb B, 2001, METHOD ENZYMOL, V342, P378, DOI 10.1016/S0076-6879(01)42560-2; Takaku H, 2003, NUCLEIC ACIDS RES, V31, P2272, DOI 10.1093/nar/gkg337; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; Walther TN, 1998, RNA, V4, P1034, DOI 10.1017/S1355838298971771; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	29	156	157	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 7	2005	123	1					37	48		10.1016/j.cell.2005.08.002	http://dx.doi.org/10.1016/j.cell.2005.08.002			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	973QD	16213211	Bronze, Green Published			2022-12-28	WOS:000232536800007
J	Maret, S; Franken, P; Dauvilliers, Y; Ghyselinck, NB; Chambon, P; Tafti, M				Maret, S; Franken, P; Dauvilliers, Y; Ghyselinck, NB; Chambon, P; Tafti, M			Retinoic acid signaling affects cortical synchrony during steep	SCIENCE			English	Article							SLOW-WAVE SLEEP; EEG; RECEPTORS; OSCILLATIONS; EXPRESSION; ADULT; BETA	Delta oscillations, characteristic of the electroencephalogram (EEG) of slow wave steep, estimate sleep depth and need and are thought to be closely linked to the recovery function of sleep. The cellular mechanisms underlying the generation of delta waves at the cortical and thalamic levels are well documented, but the molecular regulatory mechanisms remain elusive. Here we demonstrate in the mouse that the gene encoding the retinoic acid receptor beta determines the contribution of delta oscillations to the steep EEG. Thus, retinoic acid signaling, which is involved in the patterning of the brain and dopaminergic pathways, regulates cortical synchrony in the adult.	Univ Lausanne, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Hop Gui De Chauliac, Serv Neurol B, F-34295 Montpellier, France; Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Inst Clin Souris, F-67404 Illkirch Graffenstaden, France	University of Lausanne; Stanford University; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tafti, M (corresponding author), Univ Lausanne, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland.	medhi.tafti@unil.ch	GHYSELINCK, Norbert/I-6999-2015; Franken, Paul/A-9633-2018; Tafti, Mehdi/A-8887-2017	GHYSELINCK, Norbert/0000-0003-4042-6818; Franken, Paul/0000-0002-2500-2921; Tafti, Mehdi/0000-0002-6997-3914; Dauvilliers, yves/0000-0003-0683-6506				Benington JH, 2003, PROG NEUROBIOL, V69, P71, DOI 10.1016/S0301-0082(03)00018-2; BO P, 1988, NEUROPHARMACOLOGY, V27, P799, DOI 10.1016/0028-3908(88)90094-9; CARSKADON MA, 1982, NEUROBIOL AGING, V3, P321, DOI 10.1016/0197-4580(82)90020-3; Chiang MY, 1998, NEURON, V21, P1353, DOI 10.1016/S0896-6273(00)80654-6; DAAN S, 1984, AM J PHYSIOL, V246, pR161, DOI 10.1152/ajpregu.1984.246.2.R161; DIJK DJ, 1989, NEUROBIOL AGING, V10, P677, DOI 10.1016/0197-4580(89)90004-3; FAROOQUI SM, 1994, LIFE SCI, V55, P1887, DOI 10.1016/0024-3205(94)00520-6; Feart C, 2005, NEUROBIOL AGING, V26, P729, DOI 10.1016/j.neurobiolaging.2004.06.004; FEINBERG I, 1978, ELECTROEN CLIN NEURO, V44, P202, DOI 10.1016/0013-4694(78)90266-3; Frank MG, 1997, AM J PHYSIOL-REG I, V272, pR1792, DOI 10.1152/ajpregu.1997.272.6.R1792; Frank MG, 2001, NEURON, V30, P275, DOI 10.1016/S0896-6273(01)00279-3; Frank MG, 1997, AM J PHYSIOL-REG I, V273, pR472, DOI 10.1152/ajpregu.1997.273.2.R472; FRANKEN P, 1991, AM J PHYSIOL, V261, pR198, DOI 10.1152/ajpregu.1991.261.1.R198; Franken P, 2001, J NEUROSCI, V21, P2610, DOI 10.1523/JNEUROSCI.21-08-02610.2001; Franken P, 1998, AM J PHYSIOL-REG I, V275, pR1127, DOI 10.1152/ajpregu.1998.275.4.R1127; Goodman AB, 1998, P NATL ACAD SCI USA, V95, P7240, DOI 10.1073/pnas.95.13.7240; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Jouvet-Mounier D, 1970, Dev Psychobiol, V2, P216; Krezel W, 1999, NEUROSCIENCE, V89, P1291, DOI 10.1016/S0306-4522(98)00342-X; Krezel W, 1998, SCIENCE, V279, P863, DOI 10.1126/science.279.5352.863; MARK M, IN PRESS ANN REV PHA; Miyamoto H, 2003, NAT NEUROSCI, V6, P553, DOI 10.1038/nn1064; NECKELMANN D, 1993, SLEEP, V16, P467; PEDERSEN WA, 1995, J NEUROCHEM, V69, P4198; ROFFWARG HP, 1966, SCIENCE, V152, P604, DOI 10.1126/science.152.3722.604; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Tafti M, 2003, NAT GENET, V34, P320, DOI 10.1038/ng1174; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202	28	73	78	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	2005	310	5745					111	113		10.1126/science.1117623	http://dx.doi.org/10.1126/science.1117623			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210540				2022-12-28	WOS:000232477000049
J	Mohammed, OF; Pines, D; Dreyer, J; Pines, E; Nibbering, ETJ				Mohammed, OF; Pines, D; Dreyer, J; Pines, E; Nibbering, ETJ			Sequential proton transfer through water bridges in acid-base reactions	SCIENCE			English	Article							INFRARED-SPECTRUM; HYDRATED PROTON; PREDISSOCIATION SPECTROSCOPY; MOLECULAR-MECHANISM; TRANSFER PATHWAYS; MONTE-CARLO; GAS-PHASE; CLUSTERS; STATE; BACTERIORHODOPSIN	The proton transfer mechanism between aqueous Bronsted acids and bases, forming an encounter pair, has been studied in real time with ultrafast infrared spectroscopy. The transient intermediacy of a hydrated proton, formed by ultrafast dissociation from an optically triggered photoacid proton donor ROH, is implicated by the appearance of an infrared absorption marker band before protonation of the base, B-. Thus, proton exchange between an acid and a base in aqueous solution is shown to proceed by a sequential, von Grotthuss-type, proton-hopping mechanism through water bridges. The spectra suggest a hydronium cation H3O+ structure for the intermediate, stabilized in the Eigen configuration in the ionic complex RO-center dot center dot center dot H3O+center dot center dot center dot B-.	Ben Gurion Univ Negev, Dept Chem, IL-84125 Beer Sheva, Israel; Max Born Inst Nichtlineare Opt & Kurzzeitspektros, D-12489 Berlin, Germany	Ben Gurion University; Max Born Institute for Nonlinear Optics & Short Term Spectroscopy	Pines, E (corresponding author), Ben Gurion Univ Negev, Dept Chem, POB 653, IL-84125 Beer Sheva, Israel.	epines@bgumail.bgu.ac.il; nibberin@mbi-berlin.de	Mohammed, Omar F./Q-5092-2016	Mohammed, Omar F./0000-0001-8500-1130				AGMON N, 1995, CHEM PHYS LETT, V244, P456, DOI 10.1016/0009-2614(95)00905-J; Ando K, 1999, J PHYS CHEM A, V103, P10398, DOI 10.1021/jp992481i; Ando K, 1997, J PHYS CHEM B, V101, P10464, DOI 10.1021/jp970173j; Asmis KR, 2003, SCIENCE, V299, P1375, DOI 10.1126/science.1081634; AULT BS, 1973, J PHYS CHEM-US, V77, P57, DOI 10.1021/j100620a012; Corcelli SA, 2005, J PHYS CHEM A, V109, P6154, DOI 10.1021/jp0506540; de Grotthuss C, 1806, ANN CHIM, V58, P54; Decoursey TE, 2003, PHYSIOL REV, V83, P475, DOI 10.1152/physrev.00028.2002; DELZEIT L, 1993, J PHYS CHEM-US, V97, P10312, DOI 10.1021/j100142a009; EIGEN M, 1964, ANGEW CHEM INT EDIT, V3, P1, DOI 10.1002/anie.196400011; Fridgen TD, 2004, J PHYS CHEM A, V108, P9008, DOI 10.1021/jp040486w; Geissler PL, 2001, SCIENCE, V291, P2121, DOI 10.1126/science.1056991; Headrick JM, 2005, SCIENCE, V308, P1765, DOI 10.1126/science.1113094; Headrick JM, 2004, J CHEM PHYS, V121, P11523, DOI 10.1063/1.1834566; Hynes JT, 1999, NATURE, V397, P565, DOI 10.1038/17487; Kim J, 2002, J CHEM PHYS, V116, P737, DOI 10.1063/1.1423327; Kuhlbrandt W, 2000, NATURE, V406, P569, DOI 10.1038/35020654; Lapid H, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1814973; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; Marx D, 1999, NATURE, V397, P601, DOI 10.1038/17579; MEIBOOM S, 1961, J CHEM PHYS, V34, P375, DOI 10.1063/1.1700960; Miyazaki M, 2004, SCIENCE, V304, P1134, DOI 10.1126/science.1096037; Mohammed OF, 2005, CHEMPHYSCHEM, V6, P625, DOI 10.1002/cphc.200400510; OKUMURA M, 1990, J PHYS CHEM-US, V94, P3416, DOI 10.1021/j100372a014; PINES E, 1988, J CHEM PHYS, V88, P5620, DOI 10.1063/1.454572; Rini M, 2004, J CHEM PHYS, V121, P9593, DOI 10.1063/1.1804172; Rini M, 2003, SCIENCE, V301, P349, DOI 10.1126/science.1085762; Rousseau R, 2004, ANGEW CHEM INT EDIT, V43, P4804, DOI 10.1002/anie.200453857; Shin JW, 2004, SCIENCE, V304, P1137, DOI 10.1126/science.1096466; Stoner-Ma D, 2005, J AM CHEM SOC, V127, P2864, DOI 10.1021/ja042466d; Vener MV, 2001, J CHEM PHYS, V114, P240, DOI 10.1063/1.1330748; Vuilleumier R, 1999, J CHEM PHYS, V111, P4251, DOI 10.1063/1.479723; WILLIAMS JM, 1976, HYDROGEN BOND, V2, P655; Zimmer M, 2002, CHEM REV, V102, P759, DOI 10.1021/cr010142r; Zundel G, 2000, ADV CHEM PHYS, V111, P1	35	444	452	5	187	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 7	2005	310	5745					83	86		10.1126/science.1117756	http://dx.doi.org/10.1126/science.1117756			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210532				2022-12-28	WOS:000232477000041
J	Pascual, O; Casper, KB; Kubera, C; Zhang, J; Revilla-Sanchez, R; Sul, JY; Takano, H; Moss, SJ; McCarthy, K; Haydon, PG				Pascual, O; Casper, KB; Kubera, C; Zhang, J; Revilla-Sanchez, R; Sul, JY; Takano, H; Moss, SJ; McCarthy, K; Haydon, PG			Astrocytic purinergic signaling coordinates synaptic networks	SCIENCE			English	Article							CULTURED HIPPOCAMPAL-NEURONS; CALCIUM WAVES; ADENINE-NUCLEOTIDES; RAT HIPPOCAMPUS; NERVOUS-SYSTEM; GLUTAMATE; ADENOSINE; RELEASE; TRANSMISSION; ATP	To investigate the rote of astrocytes in regulating synaptic transmission, we generated inducible transgenic mice that express a dominant-negative SNARE domain selectively in astrocytes to block the release of transmitters from these glial cells. By releasing adenosine triphosphate, which accumulates as adenosine, astrocytes tonically suppressed synaptic transmission, thereby enhancing the dynamic range for long-term potentiation and mediated activity-dependent, heterosynaptic depression. These results indicate that astrocytes are intricately linked in the regulation of synaptic strength and plasticity and provide a pathway for synaptic cross-talk.	Univ Penn, Sch Med, Dept Neurosci, Conte Ctr Integrat Tripartite Synapse, Philadelphia, PA 19104 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill	Haydon, PG (corresponding author), Univ Penn, Sch Med, Dept Neurosci, Conte Ctr Integrat Tripartite Synapse, Philadelphia, PA 19104 USA.	pghaydon@mail.med.upenn.edu	Pascual, Olivier/E-9533-2017; Pascual, Olivier/AAE-1449-2020; Takano, Hajime/AAD-4589-2019	Pascual, Olivier/0000-0002-5730-9880; Pascual, Olivier/0000-0002-5730-9880; Takano, Hajime/0000-0003-3033-2412; Kubera, Cathryn/0000-0003-3598-8365				Ackley MA, 2003, J PHYSIOL-LONDON, V548, P507, DOI 10.1113/jphysiol.2002.038091; Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; Araque A, 1998, J NEUROSCI, V18, P6822; Araque A, 1998, EUR J NEUROSCI, V10, P2129, DOI 10.1046/j.1460-9568.1998.00221.x; Basheer R, 2004, PROG NEUROBIOL, V73, P379, DOI 10.1016/j.pneurobio.2004.06.004; Bezzi P, 2004, NAT NEUROSCI, V7, P613, DOI 10.1038/nn1246; Coco S, 2003, J BIOL CHEM, V278, P1354, DOI 10.1074/jbc.M209454200; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DUNWIDDIE TV, 1980, BRIT J PHARMACOL, V69, P59, DOI 10.1111/j.1476-5381.1980.tb10883.x; Dunwiddie TV, 1997, J NEUROSCI, V17, P7673; Dunwiddie TV, 2001, ANNU REV NEUROSCI, V24, P31, DOI 10.1146/annurev.neuro.24.1.31; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Fiacco TA, 2004, J NEUROSCI, V24, P722, DOI 10.1523/JNEUROSCI.2859-03.2004; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Kukley M, 2005, J NEUROSCI, V25, P2832, DOI 10.1523/JNEUROSCI.4260-04.2005; MANZONI OJ, 1994, SCIENCE, V265, P2098, DOI 10.1126/science.7916485; Moore KA, 2003, P NATL ACAD SCI USA, V100, P14397, DOI 10.1073/pnas.1835831100; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pasti L, 2001, J NEUROSCI, V21, P477, DOI 10.1523/JNEUROSCI.21-02-00477.2001; Porkka-Heiskanen T, 2002, SLEEP MED REV, V6, P321, DOI 10.1053/smrv.2001.0201; Porter JT, 1996, J NEUROSCI, V16, P5073; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; Verkhratsky A, 1996, TRENDS NEUROSCI, V19, P346, DOI 10.1016/0166-2236(96)10048-5; Zhang JM, 2003, NEURON, V40, P971, DOI 10.1016/S0896-6273(03)00717-7; Zhang Q, 2004, J BIOL CHEM, V279, P12724, DOI 10.1074/jbc.M312845200; Zimmermann H, 1996, J AUTON PHARMACOL, V16, P397, DOI 10.1111/j.1474-8673.1996.tb00062.x	27	932	961	0	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 7	2005	310	5745					113	116		10.1126/science.1116916	http://dx.doi.org/10.1126/science.1116916			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210541				2022-12-28	WOS:000232477000050
J	Ahn, S; Joyner, AL				Ahn, S; Joyner, AL			In vivo analysis of quiescent adult neural stem cells responding to Sonic hedgehog	NATURE			English	Article							MAMMALIAN BRAIN; PROGENITOR PROLIFERATION; SUBVENTRICULAR ZONE; DENTATE GYRUS; HIPPOCAMPUS; PRECURSORS; NEURONS; NEUROGENESIS; REGENERATION; ASTROCYTES	Sonic hedgehog (Shh) has been implicated in the ongoing neurogenesis in postnatal rodent brains(1,2). Here we adopted an in vivo genetic fate-mapping strategy, using Gli1 (GLI-Kruppel family member) as a sensitive readout of Shh activity, to systematically mark and follow the fate of Shh-responding cells in the adult mouse forebrain. We show that initially, only a small population of cells ( including both quiescent neural stem cells and transit-amplifying cells) responds to Shh in regions undergoing neurogenesis. This population subsequently expands markedly to continuously provide new neurons in the forebrain. Our study of the behaviour of quiescent neural stem cells provides in vivo evidence that they can self-renew for over a year and generate multiple cell types. Furthermore, we show that the neural stem cell niches in the subventricular zone and dentate gyrus are established sequentially and not until late embryonic stages.	NYU, Sch Med, Howard Hughes Med Inst, Dev Genet Program,Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA	Howard Hughes Medical Institute; New York University; New York University; New York University	Joyner, AL (corresponding author), NICHHD, Unit Dev Neurogenet, Lab Mammalian Genes & Dev, NIH, 9000 Rockville Pike,Bldg 6B, Bethesda, MD 20892 USA.	joyner@saturn.med.nyu.edu						Ahn S, 2004, CELL, V118, P505, DOI 10.1016/j.cell.2004.07.023; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Arnett HA, 2004, SCIENCE, V306, P2111, DOI 10.1126/science.1103709; Bai CB, 2004, DEV CELL, V6, P103, DOI 10.1016/S1534-5807(03)00394-0; Bai CB, 2002, DEVELOPMENT, V129, P4753; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Doetsch F, 1997, J NEUROSCI, V17, P5046; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Hack MA, 2004, MOL CELL NEUROSCI, V25, P664, DOI 10.1016/j.mcn.2003.12.012; Herrera DG, 1999, ANN NEUROL, V46, P867, DOI 10.1002/1531-8249(199912)46:6<867::AID-ANA9>3.0.CO;2-Z; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Yoon SO, 1996, P NATL ACAD SCI USA, V93, P11974, DOI 10.1073/pnas.93.21.11974; Zervas M, 2004, NEURON, V43, P345, DOI 10.1016/j.neuron.2004.07.010	27	544	569	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					894	897		10.1038/nature03994	http://dx.doi.org/10.1038/nature03994			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208373				2022-12-28	WOS:000232338600048
J	Nanork, P; Paar, J; Chapman, NC; Wongsiri, S; Oldroyd, BP				Nanork, P; Paar, J; Chapman, NC; Wongsiri, S; Oldroyd, BP			Asian honeybees parasitize the future dead	NATURE			English	Editorial Material							COLONIES		Chulalongkorn Univ, Dept Biol, Bangkok 10330, Thailand; Univ Sydney, Sch Biol Sci A12, Sydney, NSW 2006, Australia; Mahasarakham Univ, Dept Biol, Mahasarakham 44150, Thailand	Chulalongkorn University; University of Sydney; Mahasarakham University	Nanork, P (corresponding author), Chulalongkorn Univ, Dept Biol, Bangkok 10330, Thailand.	boldroyd@bio.usyd.edu.au	Oldroyd, Benjamin/A-4800-2008	Oldroyd, Benjamin/0000-0001-6831-3677; Chapman, Nadine/0000-0003-1824-0240				Halling LA, 2001, BEHAV ECOL SOCIOBIOL, V49, P509, DOI 10.1007/s002650100325; Martin CG, 2004, BEHAV ECOL SOCIOBIOL, V56, P42, DOI 10.1007/s00265-004-0755-z; Miller DG, 2001, INSECT SOC, V48, P178, DOI 10.1007/PL00001762; PAGE RE, 1994, BEHAV ECOL SOCIOBIOL, V35, P99, DOI 10.1007/BF00171499; RATNIEKS FLW, 1989, NATURE, V342, P796, DOI 10.1038/342796a0	5	57	58	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					829	829		10.1038/437829a	http://dx.doi.org/10.1038/437829a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	970VB	16208359				2022-12-28	WOS:000232338600033
J	Sanders, DM; Todd, C; Chopra, M				Sanders, DM; Todd, C; Chopra, M			Confronting Africa's health crisis: more of the same will not be enough	BRITISH MEDICAL JOURNAL			English	Editorial Material							SECTOR REFORMS		Univ Western Cape, Sch Publ Hlth, ZA-7535 Bellville, South Africa; MRC, Hlth Syst Res Unit, Tygerberg, South Africa; Wendover Hlth Ctr, Aylesbury HP22 6LD, Bucks, England	University of the Western Cape	Sanders, DM (corresponding author), Univ Western Cape, Sch Publ Hlth, ZA-7535 Bellville, South Africa.	dsanders@uwc.ac.za						[Anonymous], 2001, MACR HLTH INV HLTH E; [Anonymous], 1999, DEV FREEDOM; Chopra M., 2004, 22 EQUINET; *DEP INT DEV, CHILD MORT SHOWS SIG; GILSON L, 1995, HEALTH POLICY, V32, P215, DOI 10.1016/0168-8510(95)00737-D; *GLOB FUND, DISTR FUND 4 ROUNDS; *INT C PRIM HLTH C, 1978, DECL ALM AT; *JOINT LEARN I, 2005, HUM RES HLTH OV CRIS; Kavishe F. P., 1993, TANZANIA FOOD NUTR C; Mackintosh M, 2002, J DEV STUD, V39, P1; *OXF, 2005, WHAT REALL HAPP G8 S; SANDERS D, 1988, SOC SCI MED, V27, P723, DOI 10.1016/0277-9536(87)90332-7; *SCN UN SYST STAND, 5 SCN UN SYST STAND; Szreter S, 2004, BRIT MED BULL, V69, P75, DOI 10.1093/bmb/ldh005; TARIMO E, 1994, WHOSHSCC942; The World Bank, 1993, INV HLTH; The World Bank Group, MILL DEV GOALS; Whitehead M, 2001, LANCET, V358, P833, DOI 10.1016/S0140-6736(01)05975-X; [No title captured]	19	31	31	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 1	2005	331	7519					755	758		10.1136/bmj.331.7519.755	http://dx.doi.org/10.1136/bmj.331.7519.755			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	971XB	16195294	Green Published, Bronze			2022-12-28	WOS:000232417100024
J	Arslan, I; Yates, TJV; Browning, ND; Midgley, PA				Arslan, I; Yates, TJV; Browning, ND; Midgley, PA			Embedded nanostructures revealed in three dimensions	SCIENCE			English	Article							TRANSMISSION ELECTRON-MICROSCOPE; QUANTUM DOTS; GROWTH; SEMICONDUCTOR; SN; SI	Nanotechnology creates a new challenge for materials characterization because device properties now depend on size and shape as much as they depend on the traditional parameters of structure and composition. Here we show that Z-contrast tomography in the scanning transmission electron microscope has been developed to determine the complete three-dimensional size and shape of embedded structures with a resolution of approximately 1 cubic nanometer. The results from a tin/silicon quantum dot system show that the positions of the quantum dots and their size, shape, structure, and formation mechanism can be determined directly. These methods are applicable to any system, providing a unique and versatile three-dimensional visualization tool.	Univ Cambridge, Dept Mat Sci & Met, Cambridge CB2 3QZ, England; Univ Calif Davis, Dept Chem Engn & Mat Sci, Davis, CA 95616 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Natl Ctr Electron Microscopy, Berkeley, CA 94720 USA	University of Cambridge; University of California System; University of California Davis; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Arslan, I (corresponding author), Univ Cambridge, Dept Mat Sci & Met, Pembroke St, Cambridge CB2 3QZ, England.	ia250@cam.ac.uk	Yates, Timothy/C-5248-2009	Midgley, Paul/0000-0002-6817-458X; Yates, Timothy/0000-0003-0615-5073; Browning, Nigel/0000-0003-0491-251X	Engineering and Physical Sciences Research Council [GR/R30457/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Alivisatos A. P., 1996, J PHYS CHEM-US, V100, P13266; Arslan I, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.025504; Batson PE, 2002, NATURE, V418, P617, DOI 10.1038/nature00972; BROWNING ND, 1993, NATURE, V366, P143, DOI 10.1038/366143a0; Charrier A, 2001, J PHYS-CONDENS MAT, V13, pL521, DOI 10.1088/0953-8984/13/22/112; Chikkannanavar SB, 2005, NANO LETT, V5, P151, DOI 10.1021/nl049854y; COWLEY JM, 1976, PRINCIPLES TECHNIQUE, V6; EAGLESHAM DJ, 1993, PHYS REV LETT, V70, P1643, DOI 10.1103/PhysRevLett.70.1643; GOLDSTEIN L, 1985, APPL PHYS LETT, V47, P1099, DOI 10.1063/1.96342; James EM, 1999, ULTRAMICROSCOPY, V78, P125, DOI 10.1016/S0304-3991(99)00018-2; Jinschek J, 2001, J ELECTRON MICROSC, V50, P3, DOI 10.1093/jmicro/50.1.3; Lei Y, 2003, APPL PHYS LETT, V82, P4262, DOI 10.1063/1.1584073; LEONARD D, 1993, APPL PHYS LETT, V63, P3203, DOI 10.1063/1.110199; Lin Y, 2005, NATURE, V434, P55, DOI 10.1038/nature03310; Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274; Midgley PA, 2003, ULTRAMICROSCOPY, V96, P413, DOI 10.1016/S0304-3991(03)00105-0; Mock P, 2002, PROC SPIE, V4807, P71, DOI 10.1117/12.450998; Mokari T, 2004, SCIENCE, V304, P1787, DOI 10.1126/science.1097830; PEARSALL TP, 2000, QUANTUM SEMICONDUCTO; PENNYCOOK SJ, 1988, NATURE, V336, P565, DOI 10.1038/336565a0; Ragan R, 2001, MAT SCI ENG B-SOLID, V87, P204, DOI 10.1016/S0921-5107(01)00732-2; RICH DH, 1988, PHYS REV B, V37, P10221, DOI 10.1103/PhysRevB.37.10221; Su J, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1843281; Vook R. W., 1982, International Metals Reviews, V27, P209; Voronkov VV, 1999, J CRYST GROWTH, V198, P399, DOI 10.1016/S0022-0248(98)00978-6; Yoshimura M, 1998, APPL PHYS A-MATER, V66, pS1047, DOI 10.1007/s003390051294; ZANGWILL A, 1988, PHYS SURFACES, P427	27	135	136	0	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	2005	309	5744					2195	2198		10.1126/science.1116745	http://dx.doi.org/10.1126/science.1116745			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195455				2022-12-28	WOS:000232318000037
J	Crooker, SA; Furis, M; Lou, X; Adelmann, C; Smith, DL; Palmstrom, CJ; Crowell, PA				Crooker, SA; Furis, M; Lou, X; Adelmann, C; Smith, DL; Palmstrom, CJ; Crowell, PA			Imaging spin transport in lateral ferromagnet/semiconductor structures	SCIENCE			English	Article							FERROMAGNET-SEMICONDUCTOR INTERFACE; INJECTION	We directly imaged electrical spin injection and accumulation in the gallium arsenide channel of lateral spin-transport devices, which have. ferromagnetic source and drain tunnel-barrier contacts. The emission of spins from the source was observed, and a region of spin accumulation was imaged near the ferromagnetic drain contact. Both injected and accumulated spins have the same orientation (antiparallel to the contact magnetization), and we show that the accumulated spin polarization flows away from the drain (against the net electron current), indicating that electron spins are polarized by reflection from the ferromagnetic drain contact. The electrical conductance can be modulated by controlling the spin orientation of optically injected electrons flowing through the drain.	Los Alamos Natl Lab, Natl High Magnet Field Lab, Los Alamos, NM 87545 USA; Univ Minnesota, Sch Phys & Astron, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA; Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; United States Department of Energy (DOE); Los Alamos National Laboratory	Crooker, SA (corresponding author), Los Alamos Natl Lab, Natl High Magnet Field Lab, POB 1663, Los Alamos, NM 87545 USA.	crooker@lanl.gov	Crowell, Paul/AAT-9541-2021; Adelmann, Christoph/C-1507-2014; Furis, Madalina/F-8090-2015	Crowell, Paul/0000-0002-1163-9614; Adelmann, Christoph/0000-0002-4831-3159; Furis, Madalina/0000-0001-9007-5492				Adelmann C, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.121301; Ciuti C, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLetL89.156601; Crooker SA, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.236601; DATTA S, 1990, APPL PHYS LETT, V56, P665, DOI 10.1063/1.102730; Epstein RJ, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.121202; Hammar PR, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.066806; Hammar PR, 1999, PHYS REV LETT, V83, P203, DOI 10.1103/PhysRevLett.83.203; Hanbicki AT, 2003, APPL PHYS LETT, V82, P4092, DOI 10.1063/1.1580631; Hirohata A, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.104425; Isakovic AF, 2002, J APPL PHYS, V91, P7261, DOI 10.1063/1.1455606; Jedema FJ, 2002, NATURE, V416, P713, DOI 10.1038/416713a; Jiang X, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.056601; JOHNSON M, 1985, PHYS REV LETT, V55, P1790, DOI 10.1103/PhysRevLett.55.1790; Kato Y, 2004, NATURE, V427, P50, DOI 10.1038/nature02202; Kato YK, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.1994930; Kato YK, 2004, SCIENCE, V306, P1910, DOI 10.1126/science.1105514; Kato YK, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.176601; Kawakami RK, 2001, SCIENCE, V294, P131, DOI 10.1126/science.1063186; Kikkawa JM, 1999, NATURE, V397, P139, DOI 10.1038/16420; Monzon FG, 2000, PHYS REV LETT, V84, P5022, DOI 10.1103/PhysRevLett.84.5022; Motsnyi VF, 2002, APPL PHYS LETT, V81, P265, DOI 10.1063/1.1491010; Pikus G E, 1984, OPTICAL ORIENTATION, P73; Stephens J, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.097602; van Wees BJ, 2000, PHYS REV LETT, V84, P5023, DOI 10.1103/PhysRevLett.84.5023; Wunderlich J, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.047204; Yu ZG, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.201202	26	292	299	2	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	2005	309	5744					2191	2195		10.1126/science.1116865	http://dx.doi.org/10.1126/science.1116865			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195454				2022-12-28	WOS:000232318000036
J	Stiell, IG; Clement, CM; Rowe, BH; Schull, MJ; Brison, R; Cass, D; Eisenhauer, MA; McKnight, RD; Bandiera, G; Holroyd, B; Lee, JS; Dreyer, J; Worthington, JR; Reardon, M; Greenberg, G; Lesiuk, H; MacPhail, L; Wells, GA				Stiell, IG; Clement, CM; Rowe, BH; Schull, MJ; Brison, R; Cass, D; Eisenhauer, MA; McKnight, RD; Bandiera, G; Holroyd, B; Lee, JS; Dreyer, J; Worthington, JR; Reardon, M; Greenberg, G; Lesiuk, H; MacPhail, L; Wells, GA			Comparison of the Canadian CT Head Rule and the New Orleans Criteria in patients with minor head injury	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL DECISION RULES; ACUTE ANKLE INJURIES; ACUTE KNEE INJURIES; OTTAWA ANKLE; METHODOLOGICAL STANDARDS; PROSPECTIVE VALIDATION; COMPUTED-TOMOGRAPHY; PREDICTION RULES; SPINE RULE; RADIOGRAPHY	Context Current use of cranial computed tomography (CT) for minor head injury is increasing rapidly, highly variable, and inefficient. The Canadian CT Head Rule (CCHR) and New Orleans Criteria (NOC) are previously developed clinical decision rules to guide CT use for patients with minor head injury and with Glasgow Coma Scale (GCS) scores of 13 to 15 for the CCHR and a score of 15 for the NOC. However, uncertainty about the clinical performance of these rules exists. Objective To compare the clinical performance of these 2 decision rules for detecting the need for neurosurgical intervention and clinically important brain injury. Design, Setting, and Patients In a prospective cohort study (June 2000-December 2002) that included 9 emergency departments in large Canadian community and university hospitals, the CCHR was evaluated in a convenience sample of 2707 adults who presented to the emergency department with blunt head trauma resulting in witnessed loss of consciousness, disorientation, or definite amnesia and a GCS score of 13 to 15. The CCHR and NOC were compared in a subgroup of 1822 adults with minor head injury and GCS score of 15. 1 Main Outcome Measures Neurosurgical intervention and clinically important brain injury evaluated by CT and a structured follow-up telephone interview. Results Among 1822 patients with GCS score of 15, 8 (0.4%) required neurosurgical intervention and 97 (5.3%) had clinically important brain injury. The NOC and the CCHR both had 100% sensitivity but the CCHR was more specific (76.3% vs 12.1 %, P<001) for predicting need for neurosurgical intervention. For clinically important brain injury, the CCHR and the NOC had similar sensitivity (100% vs 100%; 95% confidence interval [CI], 96%-100%) but the CCHR was more specific (50.6% vs 12.7%, P<001), and would result in lower CT rates (52.1 % vs 88.0%, P<.001). The K values for physician interpretation of the rules, CCHR vs NOC, were 0.85 vs 0.47, Physicians misinterpreted the rules as not requiring imaging for 4.0% of patients according to CCHR and 5.5% according to NOC (P =.04). Among all 2707 patients with a GCS score of 13 to 15, the CCHR had sensitivities of 100% (95% Cl, 91 %-100%) for 41 patients requiring neurosurgical intervention and 100% (95% Cl, 98%-100%) for 231 patients with clinically important brain injury. Conclusion For patients with minor head injury and GCS score of 15, the CCHR and the NOC have equivalent high sensitivities for need for neurosurgical intervention and clinically important brain injury, but the CCHR has higher specificity for important clinical outcomes than does the NOC, and its use may result in reduced imaging rates.	Univ Ottawa, Dept Emergency Med, Ottawa, ON, Canada; Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada; Univ Ottawa, Div Neurosurg, Ottawa, ON, Canada; Univ Ottawa, Clin Epidemiol Program, Ottawa, ON, Canada; Univ Alberta, Dept Emergency Med, Edmonton, AB, Canada; Univ Toronto, Div Emergency Med, Toronto, ON, Canada; Queens Univ, Dept Emergency Med, Kingston, ON, Canada; Univ Western Ontario, Div Emergency Med, London, ON, Canada; Univ British Columbia, Div Emergency Med, Vancouver, BC V5Z 1M9, Canada	University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Alberta; University of Toronto; Queens University - Canada; Western University (University of Western Ontario); University of British Columbia	Stiell, IG (corresponding author), Ottawa Hlth Res Inst, Clin Epidemiol Unit, F657,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.		Lee, Jacques/CAF-4380-2022; Schull, Michael J/A-7955-2013; Reardon, Michael/ABF-8880-2021	Lee, Jacques/0000-0002-9143-6285; Schull, Michael J/0000-0002-1318-6364; Holroyd, Brian/0000-0001-8221-1327; Stiell, Ian/0000-0002-2583-6408				ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; CHAN BT, 2001, EMERGENCY DEP SERV O; CHARLSON ME, 1987, ARCH INTERN MED, V147, P2155, DOI 10.1001/archinte.147.12.2155; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Feinstein AR, 1987, CLINIMETRICS; GALBRAITH S, 1976, BMJ-BRIT MED J, V1, P1438, DOI 10.1136/bmj.1.6023.1438; Graham ID, 1998, ACAD EMERG MED, V5, P134, DOI 10.1111/j.1553-2712.1998.tb02598.x; Graham ID, 2001, ANN EMERG MED, V37, P259, DOI 10.1067/mem.2001.113506; GRIMSHAW JM, 2001, MED CARE S2, V39, P2, DOI DOI 10.1097/00005650-200108002-00002; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; LEE TH, 1990, J GEN INTERN MED, V5, P528, DOI 10.1007/BF02600886; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Marx JA, 2002, ROSENS EMERGENCY MED, V5th; MCCAIG LF, 2002, ADV DATA, V327, P1; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; MILLER JD, 1986, NEUROSURG REV, V9, P135, DOI 10.1007/BF01743065; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; Schull Michael J, 2002, CJEM, V4, P76; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; STEIN SC, 1993, ANN EMERG MED, V22, P1193, DOI 10.1016/S0196-0644(05)80989-8; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STIELL I, 1995, BRIT MED J, V311, P594, DOI 10.1136/bmj.311.7005.594; Stiell I.G., 2000, ACAD EMERG MED, V7, P572; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Stiell IG, 2003, NEW ENGL J MED, V349, P2510, DOI 10.1056/NEJMoa031375; STIELL IG, 1993, JAMA-J AM MED ASSOC, V269, P1127, DOI 10.1001/jama.269.9.1127; Stiell IG, 1997, JAMA-J AM MED ASSOC, V278, P2075, DOI 10.1001/jama.278.23.2075; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P611, DOI 10.1001/jama.275.8.611; STIELL IG, 1994, JAMA-J AM MED ASSOC, V271, P827, DOI 10.1001/jama.271.11.827; Stiell IG, 2001, JAMA-J AM MED ASSOC, V286, P1841, DOI 10.1001/jama.286.15.1841; STIELL IG, 2000, ACAD EMERG MED, V7, P533; TEASDALE G, 1974, LANCET, V2, P81; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306	38	311	313	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	2005	294	12					1511	1518		10.1001/jama.294.12.1511	http://dx.doi.org/10.1001/jama.294.12.1511			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TF	16189364	Bronze			2022-12-28	WOS:000232113400021
J	Oransky, I				Oransky, I			Clarence Dennis - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com						DENNIS C, PUBLICATION LIST	1	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 3	2005	366	9488					802	802		10.1016/S0140-6736(05)67203-0	http://dx.doi.org/10.1016/S0140-6736(05)67203-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	960XR	16196128	Bronze			2022-12-28	WOS:000231627000014
J	Lewis, SJ; Ebrahim, S; Smith, GD				Lewis, SJ; Ebrahim, S; Smith, GD			Meta-analysis of MTHFR 677C -> T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; METHYLENETETRAHYDROFOLATE-REDUCTASE; MYOCARDIAL-INFARCTION; MENDELIAN RANDOMIZATION; ISCHEMIC-STROKE; FOLIC-ACID; RISK; ASSOCIATION	Objectives To investigate the association between the MTHFR 677C-->T polymorphism and coronary heart disease, assessing small study bias and heterogeneity between studies. Data sources Medline and Embase citation searches between January 2001 and August 2004; no language restrictions. Study selection Case-control and prospective studies of association between MTHFR 677C-->T variant and myocardial infarction, coronary artery occlusion, or both; 80 studies were included. Data extraction Data on genotype frequency mid mean homocysteine concentrations by genotype were extracted. Odds ratios were calculated for TT genotype versus CC genotype. Heterogeneity was explored, with stratification by geographical region of the study samples, and meta-regression by difference in mean serum homocysteine concentrations (CC minus TT genotypes) was carried out. Results 26 000 cases and 31 183 controls were included. An overall random effects odds ratio of 1.14 (95% confidence intervals 1.05 to 1.24) was found for TT versus CC genotype. There was strong evidence of heterogeneity (P < 0.001, I-2 = 38.4%), which largely disappeared after stratification by geographical region. Odds ratios in Europe, Australia, and North America attenuated towards the null, unlike those in the Middle East and Asia. Conclusions No strong evidence exists to support an association of the MTHFR 677C-->T polymorphism and coronary heart disease in Europe, North America, or Australia. Geographical variability may be due to higher folate intake in North America and Europe or to publication bias. The conclusion drawn from previous meta-analyses that folic acid, through lowering homocysteine, has a role in prevention of cardiovascular disease is in some doubt.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Lewis, SJ (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	s.j.lewis@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Venkatasubramanian, Siddharth/0000-0002-5860-0768; Lewis, Sarah/0000-0003-4311-6890; s, hema/0000-0002-3440-9475				Abu-Amero KK, 2003, ARCH PATHOL LAB MED, V127, P1349; Ashfield-Watt PAL, 2002, AM J CLIN NUTR, V76, P180, DOI 10.1093/ajcn/76.1.180; Baker F, 2002, CIRCULATION, V106, P741; Brattstrom L, 2000, AM J CLIN NUTR, V72, P315; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; Casas JP, 2005, LANCET, V365, P224, DOI 10.1016/S0140-6736(05)70152-5; Clarke R, 2002, INT J EPIDEMIOL, V31, P70, DOI 10.1093/ije/31.1.70; Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8; Cronin S, 2005, STROKE, V36, P1581, DOI 10.1161/01.STR.0000169946.31639.af; Dusitanond P, 2005, STROKE, V36, P144, DOI 10.1161/01.STR.0000150494.91762.70; Ford ES, 2002, INT J EPIDEMIOL, V31, P59, DOI 10.1093/ije/31.1.59; Frederiksen J, 2004, BLOOD, V104, P3046, DOI 10.1182/blood-2004-03-0897; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Khoury MJ, 2000, AM J EPIDEMIOL, V151, P2; Klerk M, 2002, JAMA-J AM MED ASSOC, V288, P2023, DOI 10.1001/jama.288.16.2023; Man AMES, 2004, NETH J MED, V62, P246; Minelli C, 2004, AM J EPIDEMIOL, V160, P445, DOI 10.1093/aje/kwh228; Oi SZ, 2003, CHILD NERV SYST, V19, P596, DOI 10.1007/s00381-003-0778-1; Shioji K, 2004, J THROMB HAEMOST, V2, P527, DOI 10.1111/j.1538-7933.2003.00595.x; Smith GD, 2004, QJM-INT J MED, V97, P163, DOI 10.1093/qjmed/hch025; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; SMITH GD, 2005, IN PRESS LANCET; Taguchi Hirokuni, 2004, Asian Pac J Cancer Prev, V5, P374; Toole JF, 2004, JAMA-J AM MED ASSOC, V291, P565, DOI 10.1001/jama.291.5.565; Ueland PM, 2000, AM J CLIN NUTR, V72, P324; Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Yamada Y, 2002, NEW ENGL J MED, V347, P1916, DOI 10.1056/NEJMoa021445	28	230	245	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	2005	331	7524					1053	1056A		10.1136/bmj.38611.658947.55	http://dx.doi.org/10.1136/bmj.38611.658947.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983DL	16216822	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000233211200019
J	Whincup, PH; Owen, CG; Sattar, N; Cook, DG				Whincup, PH; Owen, CG; Sattar, N; Cook, DG			School dinners and markers of cardiovascular health and type 2 diabetes in 13-16 year olds: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									Univ London, St Georges, Div Community Hlth Sci, London SW17 0RE, England; Univ Glasgow, Dept Vasc Biochem, Div Cardiovasc & Med Sci, Glasgow G31 2ER, Lanark, Scotland	St Georges University London; University of London; University of Glasgow	Whincup, PH (corresponding author), Univ London, St Georges, Div Community Hlth Sci, London SW17 0RE, England.	pwhincup@sgul.ac.uk		Owen, Christopher/0000-0003-1135-5977; Whincup, Peter/0000-0002-5589-4107; Cook, Derek/0000-0002-9723-5759				*DEP ED SKILLS FOO, 2004, RR557 FOOD STAND AG; Department of Health, 2004, CHOOS HLTH MAK HLTH; Owen CG, 2002, PEDIATRICS, V110, P597, DOI 10.1542/peds.110.3.597; Taylor SJC, 2001, PAEDIATR PERINAT EP, V15, P88; Whincup PH, 2005, DIABETIC MED, V22, P1275, DOI 10.1111/j.1464-5491.2005.01587.x	5	13	13	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	NOV 5	2005	331	7524					1060	1061		10.1136/bmj.38618.540729.AE	http://dx.doi.org/10.1136/bmj.38618.540729.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983DL	16210251	Green Published, Bronze			2022-12-28	WOS:000233211200021
J	Oh, SH; Kauffmann, Y; Scheu, C; Kaplan, WD; Ruhle, M				Oh, SH; Kauffmann, Y; Scheu, C; Kaplan, WD; Ruhle, M			Ordered liquid aluminum at the interface with sapphire	SCIENCE			English	Article							TRANSMISSION ELECTRON-MICROSCOPY; X-RAY REFLECTIVITY; RADIATION-DAMAGE; MOLECULAR-DYNAMICS; CRYSTAL-MELT; FLUID; TEMPERATURE; ALPHA-AL2O3; CONTACT; SYSTEMS	Understanding the nature of solid-liquid interfaces is important for many processes of technological interest, such as solidification, liquid-phase epitaxial growth, wetting, liquid-phase joining, crystal growth, and lubrication. Recent studies have reported on indirect evidence of density fluctuations at solid-liquid interfaces on the basis of x-ray scattering methods that have been complemented by atomistic simulations. We provide evidence for ordering of liquid atoms adjacent to an interface with a crystal, based on real-time high-temperature observations of alumina-aluminum solid-liquid interfaces at the atomic-length scale. In addition, crystal growth of alumina into liquid aluminum, facilitated by interfacial transport of oxygen from the microscope column, was observed in situ with the use of high-resolution transmission electron microscopy.	Technion Israel Inst Technol, Dept Mat Engn, IL-32000 Haifa, Israel; Max Planck Inst Met Res, D-70569 Stuttgart, Germany	Technion Israel Institute of Technology; Max Planck Society	Kaplan, WD (corresponding author), Technion Israel Inst Technol, Dept Mat Engn, IL-32000 Haifa, Israel.	kaplan@tx.technion.ac.il	Kaplan, Wayne D./C-9100-2011; Kauffmann, Yaron/B-7301-2013; Oh, Sang Ho/AAG-1891-2020	Kaplan, Wayne D./0000-0001-9202-391X; Oh, Sang Ho/0000-0001-5808-7821; Kauffmann, Yaron/0000-0002-0117-6222				ABRAHAM FF, 1977, J CHEM PHYS, V67, P2384, DOI 10.1063/1.435080; Arai S, 2000, MICROSC MICROANAL, V6, P358; BONEVICH JE, 1991, ULTRAMICROSCOPY, V35, P161, DOI 10.1016/0304-3991(91)90101-B; BROUGHTON JQ, 1986, J CHEM PHYS, V84, P5749, DOI 10.1063/1.449883; CHEN ET, 1989, PHYS REV B, V40, P924, DOI 10.1103/PhysRevB.40.924; Davidchack RL, 2000, PHYS REV LETT, V85, P4751, DOI 10.1103/PhysRevLett.85.4751; Dehm G, 2002, ACTA MATER, V50, P5021, DOI 10.1016/S1359-6454(02)00347-6; Dehm G, 1996, ULTRAMICROSCOPY, V63, P49, DOI 10.1016/0304-3991(96)00025-3; Doerr AK, 2000, EUROPHYS LETT, V52, P330, DOI 10.1209/epl/i2000-00443-7; Donnelly SE, 2002, SCIENCE, V296, P507, DOI 10.1126/science.1068521; ERCOLESSI F, 1994, EUROPHYS LETT, V26, P583, DOI 10.1209/0295-5075/26/8/005; Hashibon A, 2001, INTERFACE SCI, V9, P175, DOI 10.1023/A:1015190207719; HOCH M, 1954, J AM CHEM SOC, V76, P2560, DOI 10.1021/ja01638a076; Howe JM, 1996, PHILOS MAG A, V74, P761, DOI 10.1080/01418619608243540; Howe JM, 2004, MRS BULL, V29, P951, DOI 10.1557/mrs2004.266; Huisman WJ, 1997, NATURE, V390, P379, DOI 10.1038/37069; Levi G, 2002, ACTA MATER, V50, P75, DOI 10.1016/S1359-6454(01)00333-0; MAGNUSSEN OM, 1995, PHYS REV LETT, V74, P4444, DOI 10.1103/PhysRevLett.74.4444; OTTEN MT, 1993, ULTRAMICROSCOPY, V48, P77, DOI 10.1016/0304-3991(93)90173-U; PELLS GP, 1994, J AM CERAM SOC, V77, P368, DOI 10.1111/j.1151-2916.1994.tb07004.x; PELLS GP, 1979, J NUCL MATER, V80, P215, DOI 10.1016/0022-3115(79)90184-3; PELLS GP, 1979, J NUCL MATER, V80, P207, DOI 10.1016/0022-3115(79)90183-1; PHILLIPP F, 1994, ULTRAMICROSCOPY, V56, P1, DOI 10.1016/0304-3991(94)90141-4; Reichert H, 2000, NATURE, V408, P839, DOI 10.1038/35048537; Saka H, 2005, J MATER RES, V20, P1629, DOI 10.1557/JMR.2005.0212; STADELMANN PA, 1987, ULTRAMICROSCOPY, V21, P131, DOI 10.1016/0304-3991(87)90080-5; Strecker A, 2003, Z METALLKD, V94, P290, DOI 10.3139/146.030290; Swiler TP, 2000, ACTA MATER, V48, P4419, DOI 10.1016/S1359-6454(00)00228-7; Yu CJ, 1999, PHYS REV LETT, V82, P2326, DOI 10.1103/PhysRevLett.82.2326	29	262	272	1	184	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2005	310	5748					661	663		10.1126/science.1118611	http://dx.doi.org/10.1126/science.1118611			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	980ET	16210498				2022-12-28	WOS:000232997700037
J	Kaksonen, M; Toret, CP; Drubin, DG				Kaksonen, M; Toret, CP; Drubin, DG			A modular design for the clathrin- and actin-mediated endocytosis machinery	CELL			English	Article							BUDDING YEAST; ARP2/3 COMPLEX; CAPPING PROTEIN; SH3 DOMAIN; I MYOSINS; CYTOSKELETON; BINDING; RECRUITMENT; PATCHES; ORGANIZATION	Endocytosis depends on an extensive network of interacting proteins that execute a series of distinct subprocesses. Previously, we used live-cell imaging of six budding-yeast proteins to define a pathway for association of receptors, adaptors, and actin during endocytic internalization. Here, we analyzed the effects of 61 deletion mutants on the dynamics of this pathway, revealing functions for 15 proteins, and we analyzed the dynamics of 8 of these proteins. Our studies provide evidence for four protein modules that cooperate to drive coat formation, membrane invagination, actin-meshwork assembly, and vesicle scission during clathrin/actin-mediated endocytosis. We found that clathrin facilitates the initiation of endocytic-site assembly but is not needed for membrane invagination or vesicle formation. Finally, we present evidence that the actin-meshwork assembly that drives membrane invagination is nucleated proximally to the plasma membrane, opposite to the orientation observed for previously studied actin-assembly-driven motility processes.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Drubin, DG (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 16 Barker Hall, Berkeley, CA 94720 USA.	drubin@socrates.berkeley.edu		Kaksonen, Marko/0000-0003-3645-7689	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR019290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042759, R01GM050399] Funding Source: NIH RePORTER; NCRR NIH HHS [S10-RR019290] Funding Source: Medline; NIGMS NIH HHS [R01GM50399, R01GM42759] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1991, NATURE, V354, P404, DOI 10.1038/354404a0; AMATRUDA JF, 1992, J CELL BIOL, V119, P1151, DOI 10.1083/jcb.119.5.1151; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Baggett JJ, 2001, TRAFFIC, V2, P297, DOI 10.1034/j.1600-0854.2001.002005297.x; Balguerie A, 1999, J CELL SCI, V112, P2529; Belmont LD, 1998, J CELL BIOL, V142, P1289, DOI 10.1083/jcb.142.5.1289; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chu DS, 1996, J BIOL CHEM, V271, P33123, DOI 10.1074/jbc.271.51.33123; Cope MJTV, 1999, J CELL BIOL, V144, P1203, DOI 10.1083/jcb.144.6.1203; Doyle T, 1996, P NATL ACAD SCI USA, V93, P3886, DOI 10.1073/pnas.93.9.3886; Ehrlich M, 2004, CELL, V118, P591, DOI 10.1016/j.cell.2004.08.017; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; Fazi B, 2002, J BIOL CHEM, V277, P5290, DOI 10.1074/jbc.M109848200; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Howard JP, 2002, J CELL BIOL, V157, P315, DOI 10.1083/jcb.200110027; Huckaba TM, 2004, J CELL BIOL, V167, P519, DOI 10.1083/jcb.200404173; Jonsdottir GA, 2004, CURR BIOL, V14, P1604, DOI 10.1016/j.cub.2004.08.055; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Kim K, 2004, J CELL BIOL, V164, P567, DOI 10.1083/jcb.200308061; Lechler T, 2000, J CELL BIOL, V148, P363, DOI 10.1083/jcb.148.2.363; Martin AC, 2005, J CELL BIOL, V168, P315, DOI 10.1083/jcb.200408177; McCann RO, 1997, P NATL ACAD SCI USA, V94, P5679, DOI 10.1073/pnas.94.11.5679; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Merrifield CJ, 2005, CELL, V121, P593, DOI 10.1016/j.cell.2005.03.015; Merrifield CJ, 2004, EUR J CELL BIOL, V83, P13, DOI 10.1078/0171-9335-00356; Mochida J, 2002, GENETICS, V160, P923; Naqvi SN, 1998, CURR BIOL, V8, P959, DOI 10.1016/S0960-9822(98)70396-3; Newpher TM, 2005, DEV CELL, V9, P87, DOI 10.1016/j.devcel.2005.04.014; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; PAYNE GS, 1988, J CELL BIOL, V106, P1453, DOI 10.1083/jcb.106.5.1453; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Rodal AA, 2005, MOL BIOL CELL, V16, P372, DOI 10.1091/mbc.e04-08-0734; Rodal AA, 2003, CURR BIOL, V13, P1000, DOI 10.1016/S0960-9822(03)00383-X; Sekiya-Kawasaki M, 2003, J CELL BIOL, V162, P765, DOI 10.1083/jcb.200305077; SIVADON P, 1995, MOL GEN GENET, V246, P485, DOI 10.1007/BF00290452; Smith MG, 2001, J CELL SCI, V114, P1505; Stefan CJ, 2005, MOL CELL BIOL, V25, P2910, DOI 10.1128/MCB.25.8.2910-2923.2005; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tang HY, 2000, MOL CELL BIOL, V20, P12, DOI 10.1128/MCB.20.1.12-25.2000; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; Toshima J, 2005, NAT CELL BIOL, V7, P246, DOI 10.1038/ncb1229; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Warren DT, 2002, J CELL SCI, V115, P1703; Yarar D, 2005, MOL BIOL CELL, V16, P964, DOI 10.1091/mbc.e04-09-0774; Young ME, 2004, J CELL BIOL, V166, P629, DOI 10.1083/jcb.200404159	50	553	560	2	48	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	2005	123	2					305	320		10.1016/j.cell.2005.09.024	http://dx.doi.org/10.1016/j.cell.2005.09.024			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239147	Bronze			2022-12-28	WOS:000232794100016
J	Hughes, MD; Xu, YJ; Jenkins, P; McMorn, P; Landon, P; Enache, DI; Carley, AF; Attard, GA; Hutchings, GJ; King, F; Stitt, EH; Johnston, P; Griffin, K; Kiely, CJ				Hughes, MD; Xu, YJ; Jenkins, P; McMorn, P; Landon, P; Enache, DI; Carley, AF; Attard, GA; Hutchings, GJ; King, F; Stitt, EH; Johnston, P; Griffin, K; Kiely, CJ			Tunable gold catalysts for selective hydrocarbon oxidation under mild conditions	NATURE			English	Article							HYDROGEN-PEROXIDE; EPOXIDATION; ACID; AU; NANOPARTICLES; CONVERSION; GLYCEROL; AIR; PD	Oxidation is an important method for the synthesis of chemical intermediates in the manufacture of high-tonnage commodities, high-value fine chemicals, agrochemicals and pharmaceuticals: but oxidations are often inefficient(1). The introduction of catalytic systems using oxygen from air is preferred for 'green' processing(2). Gold catalysis is now showing potential in selective redox processes(3-6), particularly for alcohol oxidation(7-10) and the direct synthesis of hydrogen peroxide(11,12). However, a major challenge that persists is the synthesis of an epoxide by the direct electrophilic addition of oxygen to an alkene(13). Although ethene is epoxidized efficiently using molecular oxygen with silver catalysts in a large-scale industrial process(14), this is unique because higher alkenes can only be effectively epoxidized using hydrogen peroxide(15-17), hydroperoxides(16) or stoichiometric oxygen donors. Here we show that nanocrystalline gold catalysts can provide tunable active catalysts for the oxidation of alkenes using air, with exceptionally high selectivity to partial oxidation products (similar to 98%) and significant conversions. Our finding significantly extends the discovery by Haruta(18,19) that nanocrystalline gold can epoxidize alkenes when hydrogen is used to activate the molecular oxygen; in our case, no sacrificial reductant is needed. We anticipate that our finding will initiate attempts to understand more fully the mechanism of oxygen activation at gold surfaces, which might lead to commercial exploitation of the high redox activity of gold nanocrystals.	Cardiff Univ, Sch Chem, Cardiff CF10 3AT, Wales; Johnson Matthey Catalysts, Middlesbrough TS23 1LB, England; Johnson Matthey Catalysts, Royston SG8 5HE, Herts, England; Lehigh Univ, Ctr Adv Mat & Nanotechnol, Bethlehem, PA 18015 USA	Cardiff University; Lehigh University	Hutchings, GJ (corresponding author), Cardiff Univ, Sch Chem, Main Bldg,Pk Pl, Cardiff CF10 3AT, Wales.	hutch@cardiff.ac.uk	Kiely, Christopher/B-1959-2008; Carley, Albert/A-7372-2010; Xu, Yi-Jun/B-2566-2016	Xu, Yi-Jun/0000-0002-2195-1695; Enache, Dan/0000-0002-9291-8198; Kiely, Christopher/0000-0001-5412-0970	Engineering and Physical Sciences Research Council [GR/S41906/01, GR/R54590/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Attard GA, 2001, APPL CATAL A-GEN, V222, P393, DOI 10.1016/S0926-860X(01)00845-6; Bailie JE, 1999, CHEM COMMUN, P2151, DOI 10.1039/a906538e; Biella S, 2003, INORG CHIM ACTA, V349, P253, DOI 10.1016/S0020-1693(03)00040-9; Biella S, 2002, J CATAL, V206, P242, DOI 10.1006/jcat.2001.3497; Bond GC, 1999, CATAL REV, V41, P319, DOI 10.1081/CR-100101171; BOXHOORN G, 1988, Patent No. 19870727; Brust M, 1998, J AM CHEM SOC, V120, P12367, DOI 10.1021/ja982776u; Carrettin S, 2003, PHYS CHEM CHEM PHYS, V5, P1329, DOI 10.1039/b212047j; Carrettin S, 2002, CHEM COMMUN, P696, DOI 10.1039/b201112n; CLAVILIER J, 1988, J ELECTROANAL CHEM, V243, P419, DOI 10.1016/0022-0728(88)80045-7; Fordham P, 1997, STUD SURF SCI CATAL, V108, P429; Fu Q, 2003, SCIENCE, V301, P935, DOI 10.1126/science.1085721; Gallezot P, 1997, CATAL TODAY, V37, P405, DOI 10.1016/S0920-5861(97)00024-2; Grigoropoulou G, 2003, GREEN CHEM, V5, P1, DOI 10.1039/b208925b; Landon P, 2003, PHYS CHEM CHEM PHYS, V5, P1917, DOI 10.1039/b211338b; Landon P, 2002, CHEM COMMUN, P2058, DOI 10.1039/b205248m; Lee SO, 2003, ANGEW CHEM INT EDIT, V42, P1520, DOI 10.1002/anie.200250351; Mohr C, 1999, CHEM-ING-TECH, V71, P869, DOI 10.1002/cite.330710819; Monnier JR, 2001, APPL CATAL A-GEN, V221, P73, DOI 10.1016/S0926-860X(01)00799-2; Sheldon R. A., 2001, FINE CHEM HETEROGENE, P611; SHELDON RA, 1991, STUD SURF SCI CATAL, V59, P33; Sinha AK, 2004, TOP CATAL, V29, P95, DOI 10.1023/B:TOCA.0000029791.69935.53; Sinha AK, 2004, ANGEW CHEM INT EDIT, V43, P1546, DOI 10.1002/anie.200352900; Xu YJ, 2005, CATAL LETT, V101, P175, DOI 10.1007/s10562-005-4886-2	24	901	933	7	627	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 20	2005	437	7062					1132	1135		10.1038/nature04190	http://dx.doi.org/10.1038/nature04190			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	975KD	16237439				2022-12-28	WOS:000232660500039
J	Seiffert, ER; Simons, EL; Clyde, WC; Rossie, JB; Attia, Y; Bown, TM; Chatrath, P; Mathison, ME				Seiffert, ER; Simons, EL; Clyde, WC; Rossie, JB; Attia, Y; Bown, TM; Chatrath, P; Mathison, ME			Basal anthropoids from Egypt and the antiquity of Africa's higher primate radiation	SCIENCE			English	Article							MIDDLE EOCENE; PONDAUNG; AGE	Early anthropoid evolution in Afro-Arabia is poorly documented, with only a few isolated teeth known from before similar to 35 million years ago. Here we describe craniodental remains of the primitive anthropoid Biretia from similar to 37-million-year-old rocks in Egypt. Biretia is unique among early anthropoids in exhibiting evidence for nocturnality, but derived dental features shared with younger parapithecids draw this genus, and possibly >45-million-year-old Algeripithecus, into a morphologically and behaviorally diverse parapithecoid clade of great antiquity.	Univ Oxford, Dept Earth Sci, Oxford OX1 3PW, England; Univ Oxford, Museum Hist Nat, Oxford OX1 3PW, England; Duke Univ, Dept Biol Anthropol & Anat, Durham, NC 27705 USA; Duke Primate Ctr, Div Fossil Primates, Durham, NC 27705 USA; Univ New Hampshire, Dept Earth Sci, Durham, NH 03824 USA; SUNY Stony Brook, Dept Anthropol, Stony Brook, NY 11794 USA; Egyptian Geol Museum, Cairo, Egypt; Erathem Vanir Geol, Boulder, CO 80302 USA; Iowa State Univ, Dept Geol & Atmospher Sci, Ames, IA 50011 USA	University of Oxford; University of Oxford; Duke University; Duke University; University System Of New Hampshire; University of New Hampshire; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Iowa State University	Seiffert, ER (corresponding author), Univ Oxford, Dept Earth Sci, Parks Rd, Oxford OX1 3PW, England.	erik.seiffert@earth.ox.ac.uk	Clyde, William/C-9595-2017	Clyde, William/0000-0001-8814-3409				Beadnell HJL, 1905, TOPOGRAPHY GEOLOGY F; Beard K.C., 2004, HUNT DAWN MONKEY UNE; Beard KC, 2002, CAM S BIO EVOL ANTHR, V33, P133; Benammi M, 2002, J GEOL, V110, P748, DOI 10.1086/342868; Bown T.M., 1988, US GEOL SURV PROF PA, V1452, P1; CONROY GC, 1987, INT J PRIMATOL, V8, P115, DOI 10.1007/BF02735160; DEBONIS L, 1988, CR ACAD SCI II, V306, P929; Eizirik Eduardo, 2004, P45; GINGERICH PD, 1992, U MICHIGAN PAPERS PA, V30, P1; GODINOT M, 1994, CR ACAD SCI II, V319, P357; GODINOT M, 1992, NATURE, V357, P324, DOI 10.1038/357324a0; HAGGAG M A Y, 1985, Revista Espanola de Micropaleontologia, V17, P27; Heesy Christopher P., 2004, P665; KAPPELMAN J, 1992, J GEOL, V100, P647, DOI 10.1086/629619; Kirk E. Christopher, 2004, P539; Mebrouk F, 1997, GEOBIOS-LYON, V30, P171, DOI 10.1016/S0016-6995(97)80221-5; OGG JG, 2004, GEOLOGIC TIME SCALE, P63, DOI [DOI 10.1017/CBO9780511536045.006, DOI 10.2277/0511074050]; Seiffert ER, 2003, NATURE, V422, P421, DOI 10.1038/nature01489; Seiffert Erik R., 2004, P157; Shigehara N, 2002, J HUM EVOL, V43, P143, DOI 10.1006/jhev.2002.0567; Simons EL, 2001, FOLIA PRIMATOL, V72, P316, DOI 10.1159/000052748; Simons Elwyn L., 1994, P179; Strougo A., 1984, NEUES JB GEOL PALAON, V1, P46; Takai M, 2001, J HUM EVOL, V40, P393, DOI 10.1006/jhev.2001.0463; Toumarkine M., 1985, PLANKTON STRATIGRAPH, P88	25	112	125	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					300	304		10.1126/science.1116569	http://dx.doi.org/10.1126/science.1116569			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	975NV	16224019				2022-12-28	WOS:000232670100048
J	Hu, RG; Sheng, J; Qi, X; Xu, ZM; Takahashi, TT; Varshavsky, A				Hu, RG; Sheng, J; Qi, X; Xu, ZM; Takahashi, TT; Varshavsky, A			The N-end rule pathway as a nitric oxide sensor controlling the levels of multiple regulators	NATURE			English	Article							RNA-PROTEIN TRANSFERASE; UBIQUITIN LIGASE; MICE LACKING; S-NITROSYLATION; DEGRADATION; RGS4; EXPRESSION; COMPONENT; AMIDASE; FAMILY	The conjugation of arginine to proteins is a part of the N- end rule pathway of protein degradation. Three amino (N)-terminal residues - aspartate, glutamate and cysteine - are arginylated by ATE1-encoded arginyl-transferases. Here we report that oxidation of N- terminal cysteine is essential for its arginylation. The in vivo oxidation of N- terminal cysteine, before its arginylation, is shown to require nitric oxide. We reconstituted this process in vitro as well. The levels of regulatory proteins bearing N- terminal cysteine, such as RGS4, RGS5 and RGS16, are greatly increased in mouse ATE1(-/-) embryos, which lack arginylation. Stabilization of these proteins, the first physiological substrates of mammalian N- end rule pathway, may underlie cardiovascular defects in ATE1(-/-) embryos. Our findings identify the N- end rule pathway as a new nitric oxide sensor that functions through its ability to destroy specific regulatory proteins bearing N- terminal cysteine, at rates controlled by nitric oxide and apparently by oxygen as well.	CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Varshavsky, A (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	avarsh@caltech.edu	Xu, Zhenming/C-4134-2012; Takahashi, Terry T/F-3463-2010	hu, rong gui/0000-0001-8323-239X				Albig AR, 2005, MOL BIOL CELL, V16, P609, DOI 10.1091/mbc.e04-06-0479; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1995, J BIOL CHEM, V270, P12065, DOI 10.1074/jbc.270.20.12065; BALZI E, 1990, J BIOL CHEM, V265, P7464; Barouch LA, 2002, NATURE, V416, P337, DOI 10.1038/416337a; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Boehning D, 2003, ANNU REV NEUROSCI, V26, P105, DOI 10.1146/annurev.neuro.26.041002.131047; Davydov IV, 2000, J BIOL CHEM, V275, P22931, DOI 10.1074/jbc.M001605200; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Du FY, 2002, P NATL ACAD SCI USA, V99, P14110, DOI 10.1073/pnas.172527399; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Feng QP, 2002, CIRCULATION, V106, P873, DOI 10.1161/01.CIR.0000024114.82981.EA; GONDA DK, 1989, J BIOL CHEM, V264, P16700; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Ignarro LJ, 2002, J PHYSIOL PHARMACOL, V53, P503; Kempf T, 2004, BIOESSAYS, V26, P608, DOI 10.1002/bies.20049; Krumins AM, 2004, J BIOL CHEM, V279, P2593, DOI 10.1074/jbc.M311600200; Kwon YT, 2003, MOL CELL BIOL, V23, P8255, DOI 10.1128/MCB.23.22.8255-8271.2003; Kwon YT, 2000, MOL CELL BIOL, V20, P4135, DOI 10.1128/MCB.20.11.4135-4148.2000; Kwon YT, 1999, MOL CELL BIOL, V19, P182; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Mulsch A, 1999, FREE RADICAL BIO MED, V27, P636, DOI 10.1016/S0891-5849(99)00122-7; Nathan C, 2003, J CLIN INVEST, V111, P769, DOI 10.1172/JCI200318174; Packer MA, 2003, P NATL ACAD SCI USA, V100, P9566, DOI 10.1073/pnas.1633579100; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Rogers JH, 2001, J MOL CELL CARDIOL, V33, P209, DOI 10.1006/jmcc.2000.1307; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Suzuki T, 1999, EMBO J, V18, P6017, DOI 10.1093/emboj/18.21.6017; Tanaka K., 2004, BIOCHIM BIOPHYS ACTA, V1695, P226; Tasaki T, 2005, MOL CELL BIOL, V25, P7120, DOI 10.1128/MCB.25.16.7120-7136.2005; Turner GC, 2000, NATURE, V405, P579, DOI 10.1038/35014629; Varshavsky A, 2003, NAT CELL BIOL, V5, P373, DOI 10.1038/ncb0503-373; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Varshavsky A, 2004, CURR BIOL, V14, pR181, DOI 10.1016/j.cub.2004.02.014; von Coelln R, 2004, CELL TISSUE RES, V318, P175, DOI 10.1007/s00441-004-0924-4; Vossenaar ER, 2003, BIOESSAYS, V25, P1106, DOI 10.1002/bies.10357; Wieland T, 2003, PHARMACOL THERAPEUT, V97, P95, DOI 10.1016/S0163-7258(02)00326-1; Yao DD, 2004, P NATL ACAD SCI USA, V101, P10810, DOI 10.1073/pnas.0404161101	43	230	237	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	2005	437	7061					981	986		10.1038/nature04027	http://dx.doi.org/10.1038/nature04027			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16222293				2022-12-28	WOS:000232496100036
J	Abbott, R; Silber, E; Felber, J; Ekpo, E				Abbott, R; Silber, E; Felber, J; Ekpo, E			Lesson of the week - Osmotic demyelination syndrome	BRITISH MEDICAL JOURNAL			English	Review							CENTRAL PONTINE MYELINOLYSIS; EXTRAPONTINE MYELINOLYSIS; HYPONATREMIA		Queen Elizabeth Hosp, London SE18 4QH, England		Abbott, R (corresponding author), Queen Elizabeth Hosp, London SE18 4QH, England.	rachel.abbott@nhs.net	Ekpo, Okobi E/T-1522-2017; Abbott, Rachel Angharad/U-7777-2019	Ekpo, Okobi E/0000-0003-3193-7499; Abbott, Rachel Angharad/0000-0002-3415-7132				ADAMS RD, 1959, ARCH NEURO PSYCHIATR, V81, P154, DOI 10.1001/archneurpsyc.1959.02340140020004; Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; Brown WD, 2000, CURR OPIN NEUROL, V13, P691, DOI 10.1097/00019052-200012000-00014; Ghosh N, 2004, J NEUROL SCI, V222, P29, DOI 10.1016/j.jns.2004.03.032; Liamis GL, 2000, ALCOHOL ALCOHOLISM, V35, P612, DOI 10.1093/alcalc/35.6.612; Martinez LJ, 2004, SOIL TILL RES, V75, P3, DOI 10.1016/j.still.2003.12.001; Menger H, 1999, J NEUROL, V246, P700, DOI 10.1007/s004150050435; Newell KL, 1996, J NEUROL SCI, V142, P134, DOI 10.1016/0022-510X(96)00175-X; TOMLINSON BE, 1976, Q J MED, V45, P373; Uchino A, 2003, NEURORADIOLOGY, V45, P877, DOI 10.1007/s00234-003-1095-9	10	34	37	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 8	2005	331	7520					829	830		10.1136/bmj.331.7520.829	http://dx.doi.org/10.1136/bmj.331.7520.829			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974BC	16210283	Green Published			2022-12-28	WOS:000232565300025
J	Yki-Jarvinen, H				Yki-Jarvinen, H			The PROactive study: some answers, many questions	LANCET			English	Editorial Material									Univ Helsinki, Dept Med, Div Diabet, FIN-00290 Helsinki, Finland	University of Helsinki	Yki-Jarvinen, H (corresponding author), Univ Helsinki, Dept Med, Div Diabet, POB 340,Haartmaninkatu 4, FIN-00290 Helsinki, Finland.	ykijarvi@mappi.helsinki.fi						Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; *IMS HLTH, IMS MIDAS; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001; Yki-Jarvinen H, 2001, DIABETES CARE, V24, P758, DOI 10.2337/diacare.24.4.758	4	102	105	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 8	2005	366	9493					1241	1242		10.1016/S0140-6736(05)67504-6	http://dx.doi.org/10.1016/S0140-6736(05)67504-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971ST	16214581				2022-12-28	WOS:000232405700004
J	Talapin, DV; Murray, CB				Talapin, DV; Murray, CB			PbSe nanocrystal solids for n- and p-channel thin film field-effect transistors	SCIENCE			English	Article							QUANTUM; CDSE; INJECTION; ELECTRON	Initially poorly conducting PbSe nanocrystal solids (quantum dot arrays or superlattices) can be chemically "activated" to fabricate n- and p-channel field effect transistors with electron and hole mobilities of 0.9 and 0.2 square centimeters per volt-second, respectively; with current modulations of about 10(3) to 10(4); and with current density approaching 3x10(4) amperes per square centimeter. Chemical treatments engineer the interparticle spacing, electronic coupling, and doping while passivating electronic traps. These nanocrystal field-effect transistors allow reversible switching between n- and p-transport, providing options for complementary metal oxide semiconductor circuits and enabling a range of low-cost, large-area electronic, optoelectronic, thermoelectric, and sensing applications.	IBM Corp, Div Res, TJ Watson Res Ctr, Yorktown Hts, NY 10598 USA	International Business Machines (IBM)	Talapin, DV (corresponding author), IBM Corp, Div Res, TJ Watson Res Ctr, 1101 Kitchawan Rd, Yorktown Hts, NY 10598 USA.	dmitrit@us.ibm.com						Allan G, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.245321; Artukovic E, 2005, NANO LETT, V5, P757, DOI 10.1021/nl050254o; Ben-Porat CH, 2004, J PHYS CHEM A, V108, P7814, DOI 10.1021/jp037418e; Collier CP, 1997, SCIENCE, V277, P1978, DOI 10.1126/science.277.5334.1978; Duan XF, 2003, NATURE, V425, P274, DOI 10.1038/nature01996; Ginger DS, 2000, J APPL PHYS, V87, P1361, DOI 10.1063/1.372021; Jarosz MV, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.195327; Kagan CR, 1999, SCIENCE, V286, P945, DOI 10.1126/science.286.5441.945; Klinke C, 2005, NANO LETT, V5, P555, DOI 10.1021/nl048055c; Lazarenkova OL, 2001, J APPL PHYS, V89, P5509, DOI 10.1063/1.1366662; Mitzi DB, 2004, NATURE, V428, P299, DOI 10.1038/nature02389; Mitzi DB, 2003, THIN-FILM TRANSISTORS, P475; Morgan NY, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.075339; Mott N., 1993, CONDUCTION NONCRYSTA; Remacle F, 2003, J PHYS CHEM B, V107, P13892, DOI 10.1021/jp036357h; Ridley BA, 1999, SCIENCE, V286, P746, DOI 10.1126/science.286.5440.746; Steckel JS, 2003, ADV MATER, V15, P1862, DOI 10.1002/adma.200305449; Talapin DV, 2001, NANO LETT, V1, P207, DOI 10.1021/nl0155126; TALAPIN DV, UNPUB; Vanmaekelbergh D, 2005, CHEM SOC REV, V34, P299, DOI 10.1039/b314945p; Wehrenberg BL, 2003, J AM CHEM SOC, V125, P7806, DOI 10.1021/ja035369d; Yu D, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.216802; Yu D, 2003, SCIENCE, V300, P1277, DOI 10.1126/science.1084424	23	1443	1498	10	612	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	2005	310	5745					86	89		10.1126/science.1116703	http://dx.doi.org/10.1126/science.1116703			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210533				2022-12-28	WOS:000232477000042
J	Villasenor, JS; Lamb, DQ; Ricker, GR; Atteia, JL; Kawai, N; Butler, N; Nakagawa, Y; Jernigan, JG; Boer, M; Crew, GB; Donaghy, TQ; Doty, J; Fenimore, EE; Galassi, M; Graziani, C; Hurley, K; Levine, A; Martel, F; Matsuoka, M; Olive, JF; Prigozhin, G; Sakamoto, T; Shirasaki, Y; Suzuki, M; Tamagawa, T; Vanderspek, R; Woosley, SE; Yoshida, A; Braga, J; Manchanda, R; Pizzichini, G; Takagishi, K; Yamauchi, M				Villasenor, JS; Lamb, DQ; Ricker, GR; Atteia, JL; Kawai, N; Butler, N; Nakagawa, Y; Jernigan, JG; Boer, M; Crew, GB; Donaghy, TQ; Doty, J; Fenimore, EE; Galassi, M; Graziani, C; Hurley, K; Levine, A; Martel, F; Matsuoka, M; Olive, JF; Prigozhin, G; Sakamoto, T; Shirasaki, Y; Suzuki, M; Tamagawa, T; Vanderspek, R; Woosley, SE; Yoshida, A; Braga, J; Manchanda, R; Pizzichini, G; Takagishi, K; Yamauchi, M			Discovery of the short gamma-ray burst GRB 050709	NATURE			English	Article							AFTERGLOW; SPECTRA; FLARE	Gamma-ray bursts (GRBs) fall into two classes: short-hard and long-soft bursts(1-3). The latter are now known to have X-ray(4) and optical(5) afterglows, to occur at cosmological distances(6) in star-forming galaxies(7), and to be associated with the explosion of massive stars(8,9). In contrast, the distance scale, the energy scale and the progenitors of the short bursts have remained a mystery. Here we report the discovery of a short-hard burst whose accurate localization has led to follow-up observations that have identified the X-ray afterglow(10) and ( for the first time) the optical afterglow(10,11) of a short-hard burst; this in turn led to the identification of the host galaxy of the burst as a late-type galaxy at z = 0.16 (ref. 10). These results show that at least some short-hard bursts occur at cosmological distances in the outskirts of galaxies, and are likely to be caused by the merging of compact binaries.	MIT, Kavli Inst, Cambridge, MA 02139 USA; Univ Chicago, Dept Astron & Astrophys, Chicago, IL 60637 USA; Observ Midi Pyrenees, Astrophys Lab, F-31400 Toulouse, France; Tokyo Inst Technol, Dept Phys, Meguro Ku, Tokyo 1528551, Japan; Aoyama Gakuin Univ, Dept Math & Phys, Kanagawa 2298558, Japan; Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; Observ Midi Pyrenees, Ctr Etud Spatiale Rayonnements, F-31028 Toulouse, France; Noqsi Aerosp Ltd, Pine, CO 80470 USA; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Espace Inc, Hull, MA 02045 USA; Japan Aerosp Explorat Agcy, Tsukuba Space Ctr, Tsukuba, Ibaraki 3058505, Japan; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Natl Astron Observ, Tokyo 1818588, Japan; RIKEN, Wako, Saitama 3510198, Japan; Univ Calif Santa Cruz, Dept Astron & Astrophys, Santa Cruz, CA 95064 USA; Inst Nacl Pesquisas Espaciais, BR-12227010 Sao Jose Dos Campos, Brazil; Tata Inst Fundamental Res, Dept Astron & Astrophys, Bombay 400005, Maharashtra, India; INAF IASF Bologna, I-40129 Bologna, Italy; Miyazaki Univ, Fac Engn, Miyazaki 8892192, Japan	Massachusetts Institute of Technology (MIT); University of Chicago; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Tokyo Institute of Technology; Aoyama Gakuin University; University of California System; University of California Berkeley; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; United States Department of Energy (DOE); Los Alamos National Laboratory; Japan Aerospace Exploration Agency (JAXA); National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); RIKEN; University of California System; University of California Santa Cruz; Instituto Nacional de Pesquisas Espaciais (INPE); Tata Institute of Fundamental Research (TIFR); Istituto Nazionale Astrofisica (INAF); University of Miyazaki	Ricker, GR (corresponding author), MIT, Kavli Inst, 70 Vassar St, Cambridge, MA 02139 USA.	jsvilla@space.mit.edu; grr@space.mit.edu	Braga, Joao/M-7493-2014; Boer, Michel/Q-4428-2019	Braga, Joao/0000-0003-3338-3186; Boer, Michel/0000-0001-9157-4349; Yamauchi, Makoto/0000-0003-1100-1423; Donaghy, Timothy/0000-0001-6449-3228; Crew, Geoffrey/0000-0002-2079-3189				Amati L, 2002, ASTRON ASTROPHYS, V390, P81, DOI 10.1051/0004-6361:20020722; Bloom JS, 2002, ASTRON J, V123, P1111, DOI 10.1086/338893; Castander FJ, 1999, ASTROPHYS J, V523, P593, DOI 10.1086/307746; Connaughton V, 2002, ASTROPHYS J, V567, P1028, DOI 10.1086/338695; Costa E, 1997, NATURE, V387, P783, DOI 10.1038/42885; EICHLER D, 1989, NATURE, V340, P126, DOI 10.1038/340126a0; Frail DA, 2001, ASTROPHYS J, V562, pL55, DOI 10.1086/338119; FREDERIKS DD, 2004, GAMMA RAY BURSTS AFT, P197; Fryer CL, 1999, ASTROPHYS J, V526, P152, DOI 10.1086/307992; Ghirlanda G, 2004, ASTRON ASTROPHYS, V422, pL55, DOI 10.1051/0004-6361:20048008; Hurley K, 2005, NATURE, V434, P1098, DOI 10.1038/nature03519; HURLEY K, 1992, AIP CONF PROC, V265, P3; KOUVELIOTOU C, 1993, ASTROPHYS J, V413, pL101, DOI 10.1086/186969; LAMB DQ, 1993, ASTROPHYS J, V413, pL11, DOI 10.1086/186947; Lamb DQ, 2004, NEW ASTRON REV, V48, P423, DOI 10.1016/j.newar.2003.12.042; LAMB DQ, 2004, GAMMA RAY BURSTS AFT, P94; Lazzati D, 2001, ASTRON ASTROPHYS, V379, pL39, DOI 10.1051/0004-6361:20011485; Metzger MR, 1997, NATURE, V387, P878, DOI 10.1038/43132; Paciesas WS, 2001, ESO ASTROPHY SYMP, P13, DOI 10.1007/10853853_3; Paciesas WS, 1999, ASTROPHYS J SUPPL S, V122, P465, DOI 10.1086/313224; Palmer DM, 2005, NATURE, V434, P1107, DOI 10.1038/nature03525; Preece RD, 2000, ASTROPHYS J SUPPL S, V126, P19, DOI 10.1086/313289; Reichart DE, 2001, ASTROPHYS J, V552, P57, DOI 10.1086/320434; Ricker GR, 2003, AIP CONF PROC, V662, P3; Stanek KZ, 2003, ASTROPHYS J, V591, pL17, DOI 10.1086/376976; vanParadijs J, 1997, NATURE, V386, P686, DOI 10.1038/386686a0; WOOSLEY SE, 1993, ASTROPHYS J, V405, P273, DOI 10.1086/172359; Yonetoku D, 2004, ASTROPHYS J, V609, P935, DOI 10.1086/421285	28	221	223	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					855	858		10.1038/nature04213	http://dx.doi.org/10.1038/nature04213			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208364	Green Submitted			2022-12-28	WOS:000232338600039
J	Stevenson, LW; Binanay, C; Califf, RM; Hasselblad, V; O'Connor, CM; Shah, MR; Sopko, G; Francis, GS; Leier, CV; Miller, LW				Stevenson, LW; Binanay, C; Califf, RM; Hasselblad, V; O'Connor, CM; Shah, MR; Sopko, G; Francis, GS; Leier, CV; Miller, LW		ESCAPE Investigators; ESCAPE Study Coordinators	Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness - The ESCAPE trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-LIFE; VASCULAR-SURGERY; CARDIAC TRANSPLANTATION; MITRAL REGURGITATION; VASODILATOR THERAPY; EXERCISE CAPACITY; FILLING PRESSURES; RANDOMIZED-TRIAL; MEDICAL THERAPY	Context Pulmonary artery catheters (PACs) have been used to guide therapy in multiple settings, but recent studies have raised concerns that PACs may lead to increased mortality in hospitalized patients. Objective To determine whether PAC use is safe and improves clinical outcomes in patients hospitalized with severe symptomatic and recurrent heart failure. Design, Setting, and Participants The Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) Was a randomized controlled trial of 433 patients at 26 sites conducted from January 18, 2000, to November 17, 2003. Patients were assigned to receive therapy guided by clinical assessment and a PAC or clinical assessment alone. The target in both groups was resolution of clinical congestion, with additional PAC targets of a pulmonary capillary wedge pressure of 15 mm Hg and a right atrial pressure of 8 mm Hg. Medications were not specified, but inotrope use was explicitly discouraged. Main Outcome Measures The primary end point was days alive out of the, hospital during the first 6 months, with secondary end points of exercise, quality of life, biochemical, and echocardiographic changes. Results Severity of illness was reflected by-the following values: average left ventricular ejection fraction, 19%; systolic blood pressure, 1,06 mm Hg; sodium,level, 137 mEq/L; urea nitrogen, 35 mg/dL (12.40 mmol/L); and creatinine, 1.5 mg/d. L (132.6 mu mol/L). Therapy in both groups led to substantial reduction in symptoms, jugular venous pressure, and edema. Use of the PAC did not significantly affect the primary end point of days alive and out of the hospital during the first 6 months (133 days vs 135 days; hazard ratio [HR], 1.00 [95% confidence interval {CI}, 0.82-1.1]; P = .99), mortality (43 patients [10%] vs 38 patients [9%]; odds ratio [OR], 1.26 [95% CI, 0.78-2.03]; P = .35), or the number of days hospitalized (8.7 vs 8.3; HR, 1.04 [95% CI, 0.86-1.27]; P = .67). In-hospital adverse events were more common among patients in the PAC group (47 [21.9%] vs 25 [11.5%]; P = .04). There were no deaths related to PAC use, and no difference for. in-hospital plus 30-day mortality (10 [4.7%] vs 11 [5.0%]; OR, 0.97 [95% CI, 0.38-2.22]; P = 37). Exercise and quality of life end points improved in both groups with a trend toward greater improvement with the PAC, which reached significance for the time trade-off at all time points after randomization. Conclusions Therapy to reduce volume overload during hospitalization for heart failure led to marked improvement in signs and symptoms of elevated filling pressures with or without the PAC. Addition of the PAC to careful clinical assessment increased anticipated adverse events, but did not affect overall mortality and hospitalization. Future trials should test noninvasive assessments with specific treatment strategies that could be used to better tailor therapy for both survival time and survival quality as valued by patients.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Stevenson, LW (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St,PBB-1, Boston, MA 02115 USA.	lstevenson@partners.org	Fonarow, Gregg/D-5988-2014	Fonarow, Gregg/0000-0002-3192-8093; Frantz, Robert/0000-0003-4128-3978	NHLBI NIH HHS [N01-HV-98177] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV098177] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660; Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Bender JS, 1997, ANN SURG, V226, P229, DOI 10.1097/00000658-199709000-00002; BERLAUK JF, 1991, ANN SURG, V214, P289, DOI 10.1097/00000658-199109000-00011; BITTNER V, 1993, JAMA-J AM MED ASSOC, V270, P1702, DOI 10.1001/jama.270.14.1702; Bonazzi M, 2002, EUR J VASC ENDOVASC, V23, P445, DOI 10.1053/ejvs.2002.1617; Butler J, 2004, AM HEART J, V147, P331, DOI 10.1016/j.ahj.2003.08.012; CAMPANA C, 1993, J HEART LUNG TRANSPL, V12, P756; Chomsky DB, 1997, J HEART LUNG TRANSPL, V16, P846; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Dalen JE, 1996, JAMA-J AM MED ASSOC, V276, P916, DOI 10.1001/jama.276.11.916; Davidian M, 2005, STAT SCI, V20, P261, DOI 10.1214/088342305000000151; Drazner MH, 1999, J HEART LUNG TRANSPL, V18, P1126, DOI 10.1016/S1053-2498(99)00070-4; FONAROW GC, 1992, J AM COLL CARDIOL, V19, P842, DOI 10.1016/0735-1097(92)90529-V; Fonarow GC, 1997, J AM COLL CARDIOL, V30, P725, DOI 10.1016/S0735-1097(97)00208-8; Fonarow GC, 2005, JAMA-J AM MED ASSOC, V293, P572, DOI 10.1001/jama.293.5.572; GORE JM, 1987, CHEST, V92, P721, DOI 10.1378/chest.92.4.721; HAMILTON MA, 1991, AM J CARDIOL, V67, P259, DOI 10.1016/0002-9149(91)90556-Z; Harvey S, 2005, LANCET, V366, P472, DOI 10.1016/S0140-6736(05)67061-4; Havranek EP, 1999, J CARD FAIL, V5, P85, DOI 10.1016/S1071-9164(99)90030-1; KAYE DM, 1994, J AM COLL CARDIOL, V23, P570, DOI 10.1016/0735-1097(94)90738-2; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KOVICK RB, 1976, CIRCULATION, V53, P322, DOI 10.1161/01.CIR.53.2.322; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lee DS, 2003, JAMA-J AM MED ASSOC, V290, P2581, DOI 10.1001/jama.290.19.2581; Leri A, 1998, J CLIN INVEST, V101, P1326, DOI 10.1172/JCI316; Lewis EF, 2001, J HEART LUNG TRANSPL, V20, P1016, DOI 10.1016/S1053-2498(01)00298-4; Lucas C, 2000, AM HEART J, V140, P840, DOI 10.1067/mhj.2000.110933; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; PIERPONT GL, 1982, J HEART TRANSPLANT, V2, P18; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Rector T S, 1995, J Card Fail, V1, P201, DOI 10.1016/1071-9164(95)90025-X; Rosario LB, 1998, J AM COLL CARDIOL, V32, P1819, DOI 10.1016/S0735-1097(98)00461-6; Rose EA, 2001, NEW ENGL J MED, V345, P1435, DOI 10.1056/NEJMoa012175; Sackner-Bernstein JD, 2005, JAMA-J AM MED ASSOC, V293, P1900, DOI 10.1001/jama.293.15.1900; Sandham JD, 2003, NEW ENGL J MED, V348, P5, DOI 10.1056/NEJMoa021108; Shah MR, 2001, AM HEART J, V141, P528, DOI 10.1067/mhj.2001.113995; SHAH MR, IN PRESS JAMA; Steimle AE, 1997, CIRCULATION, V96, P1165, DOI 10.1161/01.CIR.96.4.1165; STEVENSON LW, 1989, AM J CARDIOL, V63, P461, DOI 10.1016/0002-9149(89)90320-2; STEVENSON LW, 1990, AM J CARDIOL, V66, P1348, DOI 10.1016/0002-9149(90)91166-4; STEVENSON LW, 1990, CIRCULATION, V81, P78, DOI 10.1161/01.CIR.81.1.78; STEVENSON LW, 1995, J AM COLL CARDIOL, V25, P163, DOI 10.1016/0735-1097(94)00357-V; STEVENSON LW, 1990, J AM COLL CARDIOL, V15, P174, DOI 10.1016/0735-1097(90)90196-V; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; Trottier S J, 1997, New Horiz, V5, P201; Valentine RJ, 1998, J VASC SURG, V27, P203, DOI 10.1016/S0741-5214(98)70351-9; Weinfeld MS, 1999, AM HEART J, V138, P285, DOI 10.1016/S0002-8703(99)70113-4; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; ZION MM, 1990, CHEST, V98, P1331, DOI 10.1378/chest.98.6.1331	51	882	932	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	2005	294	13					1625	1633						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970DC	16204662				2022-12-28	WOS:000232284400015
J	Baggini, J; Pym, M				Baggini, J; Pym, M			End of life: the humanist view	LANCET			English	Editorial Material									Philosophers Magazine, Surrey SM2 6LZ, England; British Humanist Assoc, London W1E 6HD, England		Baggini, J (corresponding author), Philosophers Magazine, Surrey SM2 6LZ, England.	Editor@philosophers.co.uk							0	15	15	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	2005	366	9492					1235	1237		10.1016/S0140-6736(05)67486-7	http://dx.doi.org/10.1016/S0140-6736(05)67486-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	970LK	16198772				2022-12-28	WOS:000232311300033
J	Verheugt, FWA; Smith, SC				Verheugt, FWA; Smith, SC			The lady aspirin for cardiovascular disease	LANCET			English	Editorial Material							PRIMARY PREVENTION; HEART; RISK; THERAPY		Univ Med Ctr, Heartctr, Dept Cardiol, Nijmegen, Netherlands; Univ N Carolina, Ctr Cardiovasc Sci & Med, Chapel Hill, NC USA	Radboud University Nijmegen; University of North Carolina; University of North Carolina Chapel Hill	Verheugt, FWA (corresponding author), Univ Med Ctr, Heartctr, Dept Cardiol, Nijmegen, Netherlands.	f.verheugt@cardio.umcn.nl	Verheugt, F.W.A./H-8105-2014					Awtry EH, 2000, CIRCULATION, V101, P1206, DOI 10.1161/01.CIR.101.10.1206; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; DUENWALD M, 2005, NY TIMES        0816, pF5; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Hayden M, 2002, ANN INTERN MED, V136, P161, DOI 10.7326/0003-4819-136-2-200201150-00016; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Kjeldsen SE, 2000, J HYPERTENS, V18, P629, DOI 10.1097/00004872-200018050-00017; Levin RI, 2005, NEW ENGL J MED, V352, P1366, DOI 10.1056/NEJMe058051; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Merz NB, 2004, CIRCULATION, V109, P805, DOI 10.1161/01.CIR.0000116205.96440.FE; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; Vasan RS, 2001, NEW ENGL J MED, V345, P1291, DOI 10.1056/NEJMoa003417	12	8	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 1	2005	366	9492					1148	1150		10.1016/S0140-6736(05)67462-4	http://dx.doi.org/10.1016/S0140-6736(05)67462-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970LK	16198753				2022-12-28	WOS:000232311300009
J	Falkowski, PG; Katz, ME; Milligan, AJ; Fennel, K; Cramer, BS; Aubry, MP; Berner, RA; Novacek, MJ; Zapol, WM				Falkowski, PG; Katz, ME; Milligan, AJ; Fennel, K; Cramer, BS; Aubry, MP; Berner, RA; Novacek, MJ; Zapol, WM			The rise of oxygen over the past 205 million years and the evolution of large placental mammals	SCIENCE			English	Article							ATMOSPHERIC OXYGEN; CARBON; FRACTIONATION; O-2	On the basis of a carbon isotopic record of both marine carbonates and organic matter from the Triassic-Jurassic boundary to the present, we modeled oxygen concentrations over the past 205 million years. Our analysis indicates that atmospheric oxygen approximately doubled over this period, with relatively rapid increases in the early Jurassic and the Eocene. We suggest that the overall increase in oxygen, mediated by the formation of passive continental margins along the Atlantic Ocean during the opening phase of the current Wilson cycle, was a critical factor in the evolution, radiation, and subsequent increase in average size of placental mammals.	Rutgers State Univ, Inst Marine & Coastal Sci, New Brunswick, NJ 08901 USA; Rutgers State Univ, Dept Geol Sci, Piscataway, NJ 08854 USA; Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA; Amer Museum Nat Hist, Div Paleontol, New York, NY 10024 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care, Boston, MA 02114 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Yale University; American Museum of Natural History (AMNH); Harvard University; Harvard Medical School; Massachusetts General Hospital	Falkowski, PG (corresponding author), Rutgers State Univ, Inst Marine & Coastal Sci, 71 Dudley Rd, New Brunswick, NJ 08901 USA.	falko@imcs.rutgers.edu	Cramer, Benjamin/A-5303-2008; Fennel, Katja/A-7470-2009	Fennel, Katja/0000-0003-3170-2331				Alroy J, 1999, SYST BIOL, V48, P107, DOI 10.1080/106351599260472; Andrews RM, 2002, PHYSIOL BIOCHEM ZOOL, V75, P145, DOI 10.1086/339388; Asher RJ, 2005, SCIENCE, V307, P1091, DOI 10.1126/science.1107808; Berner RA, 2001, GEOCHIM COSMOCHIM AC, V65, P685, DOI 10.1016/S0016-7037(00)00572-X; BERNER RA, 1989, AM J SCI, V289, P333, DOI 10.2475/ajs.289.4.333; Berner RA, 2000, SCIENCE, V287, P1630, DOI 10.1126/science.287.5458.1630; Carroll RL, 1988, VERTEBRATE PALEONTOL; Cerling TE, 1997, NATURE, V389, P153, DOI 10.1038/38229; ELSE PL, 1981, AM J PHYSIOL, V240, pR3, DOI 10.1152/ajpregu.1981.240.1.R3; Emery KO, 1972, AM ASS PET GEOL MEM, V17, P532; Falkowski PG, 2004, SCIENCE, V305, P354, DOI 10.1126/science.1095964; GARRELS R, 1984, AM J SCI, V303, P94; Ghil M, 2002, REV GEOPHYS, V40, DOI 10.1029/2000RG000092; Hayes JM, 1999, CHEM GEOL, V161, P103, DOI 10.1016/S0009-2541(99)00083-2; Hochachka P. W., 2002, BIOCH ADAPTATION MEC, DOI 10.1002/bmb.2002.494030030071; Holland HD., 1984, CHEM EVOLUTION ATMOS; Huey RB, 2005, SCIENCE, V308, P398, DOI 10.1126/science.1108019; Katz ME, 2005, MAR GEOL, V217, P323, DOI 10.1016/j.margeo.2004.08.005; Kump LR, 1999, CHEM GEOL, V161, P181, DOI 10.1016/S0009-2541(99)00086-8; Mortola J. P., 2001, RESP PHYSL NEWBORN M; Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179; Reinfelder JR, 2000, NATURE, V407, P996, DOI 10.1038/35039612; Sage R.F., 1999, C4 PLANT BIOL, P3; SHACKLETON NJ, 1984, INITIAL REP DEEP SEA, V74, P613; SHINE R, 2005, ANNU REV ECOL EVOL S, DOI DOI 10.1146/ANNUREV.ECOLSYS36.102003.152631; Smetacek V, 1999, PROTIST, V150, P25, DOI 10.1016/S1434-4610(99)70006-4; Springer MS, 2004, TRENDS ECOL EVOL, V19, P430, DOI 10.1016/j.tree.2004.05.006; Springer MS, 2003, P NATL ACAD SCI USA, V100, P1056, DOI 10.1073/pnas.0334222100; Weibel ER, 2005, J EXP BIOL, V208, P1635, DOI 10.1242/jeb.01548; [No title captured]	30	216	239	2	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	2005	309	5744					2202	2204		10.1126/science.1116047	http://dx.doi.org/10.1126/science.1116047			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195457				2022-12-28	WOS:000232318000039
J	Shelton, JD; Cassell, MM; Adetunji, J				Shelton, JD; Cassell, MM; Adetunji, J			Is poverty or wealth at the root of HIV?	LANCET			English	Editorial Material									US Agcy Int Dev, Bur Global Hlth, Washington, DC 20523 USA	United States Agency for International Development (USAID)	Shelton, JD (corresponding author), US Agcy Int Dev, Bur Global Hlth, Washington, DC 20523 USA.	JShelton@USAID.GOV						*CBS MOH ORC MACR, 2004, KEN DEM HLTH SURV 20; Fenton L, 2004, LANCET, V364, P1186, DOI 10.1016/S0140-6736(04)17109-2; Halperin D, 2000, AIDS ANAL AFRICA, V11, P1; Halperin DT, 2004, LANCET, V364, P4, DOI 10.1016/S0140-6736(04)16606-3; *TACAIDS NBS ORC M, 2005, TANZ HIV AIDS IND SU	5	103	103	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 24	2005	366	9491					1057	1058		10.1016/S0140-6736(05)67401-6	http://dx.doi.org/10.1016/S0140-6736(05)67401-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	967TL	16182881				2022-12-28	WOS:000232114000007
J	Oransky, I				Oransky, I			Dame Cicely Mary Strode Saunders - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com							0	5	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 20	2005	366	9486					628	628		10.1016/S0140-6736(05)67127-9	http://dx.doi.org/10.1016/S0140-6736(05)67127-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958EB	16189851				2022-12-28	WOS:000231426400016
J	Ohrr, H; Tandan, JB; Sohn, YM; Shin, SH; Pradhan, DP; Halstead, SB				Ohrr, H; Tandan, JB; Sohn, YM; Shin, SH; Pradhan, DP; Halstead, SB			Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study	LANCET			English	Article							SA14-14-2; EFFICACY	Background In July, 1999, a single dose of live-attenuated SA 14-14-2 Japanese encephalitis vaccine was given to children aged 1-15 years in the Terai region of Nepal. Cases of natural infection occurred almost immediately. Our aim was to assess the long-term protective effect of this vaccination. Methods In 2000, this same population had a second seasonal exposure to the virus. We therefore did a case-control study to measure the prevalence of vaccination against Japanese encephalitis in 35 patients hospitalised for the disease 1 year after immunisation, and in age-sex matched village controls. Findings Of 35 children resident in Bardiya and Banke districts admitted to the Bheri Zonal Hospital with serologically confirmed Japanese encephalitis, only one had been vaccinated in 1999. In 430 age-sex matched village controls, 234 (54.4%) were vaccinated. We calculated a median unbiased estimate of the odds ratio of 0.0155, with lower and upper confidence limits of 0.0004 and 0.0986. The protective effect of vaccine after 12-15 months was 98.5% (CI 90.1-99.2%). Interpretation Our study provides evidence of sustained high protection afforded by one dose of live attenuated SA 14-14-2 vaccine in Nepalese children.	Yonsei Univ, Coll Med, Dept Prevent Med, Seoul 120752, South Korea; Council Tech Educ & Vocat Training, Sanothimi, Bhaktapur, Nepal; Yonsei Univ, Coll Med, Dept Paediat, Seoul 120752, South Korea; London Sch Hyg & Trop Med, London WC1, England; Bheri Zonal Hosp, Nepalganj, Nepal; Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biostat, Bethesda, MD 20814 USA	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; University of London; London School of Hygiene & Tropical Medicine; Uniformed Services University of the Health Sciences - USA	Ohrr, H (corresponding author), Yonsei Univ, Coll Med, Dept Prevent Med, Seoul 120752, South Korea.	ohrr@yumc.yonsei.ac.kr	Pradhan, Debi Prasad/AFW-7470-2022					AO J, 1983, CHIN J MICROBIOL IMM, V3, P245; Bista MB, 2001, LANCET, V358, P791, DOI 10.1016/S0140-6736(01)05967-0; BISTA MB, 2001, JAPANESE ENCEPHALITI, P13; Hennessy S, 1996, LANCET, V347, P1583, DOI 10.1016/S0140-6736(96)91075-2; HIRJI KF, 1988, BIOMETRICS, V44, P803, DOI 10.2307/2531592; INNIS BL, 1989, AM J TROP MED HYG, V40, P418, DOI 10.4269/ajtmh.1989.40.418; ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055; Rodrigues LC, 1999, EPIDEMIOL REV, V21, P56, DOI 10.1093/oxfordjournals.epirev.a017988; Rothman K., 1998, MODERN EPIDEMIOLOGY; Shepard D.S., 1993, DIS CONTROL PRIORITI, P303; Sohn YM, 1999, VACCINE, V17, P2259, DOI 10.1016/S0264-410X(99)00006-7; TSAI CJ, 1999, VACCINES, P672; Tsai TF, 1998, J INFECT DIS, V177, P221, DOI 10.1086/517358; Tsai YB, 2000, EARTHQ ENG ENG SEISM, V2, P1; *UNICEF, 1994, STAT WORLDS CHILDR; VAUGHN DW, 1992, EPIDEMIOL REV, V14, P197, DOI 10.1093/oxfordjournals.epirev.a036087	16	82	89	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 15	2005	366	9494					1375	1378		10.1016/S0140-6736(05)67567-8	http://dx.doi.org/10.1016/S0140-6736(05)67567-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	973ZW	16226615				2022-12-28	WOS:000232562100029
J	Zanetti, AR; Mariano, A; Romano, L; D'Amelio, R; Chironna, M; Coppola, RC; Cuccia, M; Mangione, R; Marrone, F; Negrone, FS; Parlato, A; Zamparo, E; Zotti, C; Stroffolini, T; Mele, A				Zanetti, AR; Mariano, A; Romano, L; D'Amelio, R; Chironna, M; Coppola, RC; Cuccia, M; Mangione, R; Marrone, F; Negrone, FS; Parlato, A; Zamparo, E; Zotti, C; Stroffolini, T; Mele, A		Study Grp	Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study	LANCET			English	Article							15-YEAR FOLLOW-UP; HEPATOCELLULAR-CARCINOMA; MASS VACCINATION; VIRAL-HEPATITIS; SURFACE-ANTIGEN; VIRUS-INFECTION; CHILDREN; IMMUNIZATION; EFFICACY; PERSISTENCE	Background Universal anti-hepatitis-B vaccination of infants and adolescents was implemented in Italy in 1991. We undertook a multicentre study in previously vaccinated individuals to assess the duration of immunity and need for booster, over 10 years after vaccination. Methods In 1212 children and 446 Italian Air Force recruits vaccinated as infants and adolescents, respectively, we measured the concentrations of antibodies to hepatitis-B surface antigen (anti-HBs) and the presence of antibodies to hepatitis-B core antigen (anti-HBc) at enrolment; postimmunisation values were not available. Individuals positive for anti-HBc were tested for hepatitis B surface antigen (HBsAg) and hepatitis B viral DNA. Individuals with anti-HBs concentrations at 10 IU/L or more were regarded as protected; those with antibody less than 10 IU/L were given a booster dose and retested 2 weeks later. Individuals showing postbooster anti-HBs concentrations of less than 10 IU/L were offered two additional vaccine doses and retested 1 month after the third dose. Findings Protective anti-HBs concentrations were retained in 779 (64%, 95% CI 61.6-67) children and 398 (89%, 86.4-92.1) recruits. We recorded antibody amounts of less than 10 IU/L in 433 children (36%, 33-38.4) and 48 (11%, 7.9-13.6) recruits. One child and four recruits were positive for anti-HBc, but negative for HBsAg and hepatitis B viral DNA. Antibody concentrations were higher in recruits than in children (geometric mean titre 234.8 IU/L vs 32.1 IU/L, p=0.0001). 332 (97%) of 342 children and 46 (96%) of 48 recruits who received a booster showed an anamnestic response, whereas ten (3%) children and two (4%) recruits remained negative for anti-HBs or had antibody concentrations of less than 10 IU/L. Prebooster and postbooster antibody titres were strongly correlated with each other in both groups. All individuals given two additional vaccine doses (eight children and two recruits) showed anti-HBs amounts of more than 10 IU/L at 1 month after vaccination. Interpretation Strong immunological memory persists more than 10 years after immunisation of infants and adolescents with a primary course of vaccination. Booster doses of vaccine do not seem necessary to ensure long-term protection.	Univ Milan, Inst Virol, I-20133 Milan, Italy; Ist Super Sanita, Ctr Nazl Epidemiol Sorveglianza & Promoz Salute, I-00161 Rome, Italy; Minit Difesa, Direz Gen Sanita Mil, Rome, Italy; Univ Roma La Sapienza, Fac Med & Chirurg 2, Rome, Italy; Univ Bari, Dipartimento Med Interna & Med Pubbl, Sez Igiene, Bari, Italy; Univ Cagliari, Dipartimento Sanita Pubbl, Cagliari, Italy; AUSL3 Catania, Dipartimento Prevenz, Serv Epidemiol & Prevenz, Catania, Italy; AUSL1 Agrigento, Serv Sanita Pubbl Epidemiol Med Prevent, Unita Operat Licata, Licata, Italy; ASL Cesena, Cesena, Italy; ASL2 Potenza, Unita Operat Igiene & Sanita Pubbl, Potenza, Italy; ASL NA2, Dipartimento Epidemiol & Prevenz, Naples, Italy; ASS6 Friuli Occidentale, Dipartimento Prevenz, Pordenone, Italy; Univ Turin, Dipartimento Sanita Pubbl & Microbiol, Turin, Italy; Osped S Giacomo, Dipartimento Gastroenterol, Rome, Italy	University of Milan; Istituto Superiore di Sanita (ISS); Sapienza University Rome; Universita degli Studi di Bari Aldo Moro; University of Cagliari; University of Turin	Zanetti, AR (corresponding author), Univ Milan, Inst Virol, Via C Pascal 38, I-20133 Milan, Italy.	alessandro.zanetti@unimi.it	Ibrahim, Essam Hassan/G-1960-2018; cuccia, mario/AAK-8243-2020	Ibrahim, Essam Hassan/0000-0003-0130-2257; Coppola, Rosa Cristina/0000-0002-1592-8093; chironna, maria/0000-0002-1043-1256; Zotti, Carla Maria/0000-0003-3898-1206				*ACIP, 1982, MMWR-MORBID MORTAL W, V31, P317; Banatvala J, 2000, LANCET, V355, P561, DOI 10.1016/S0140-6736(99)07239-6; Boxall EH, 2004, J INFECT DIS, V190, P1264, DOI 10.1086/423818; Chang MH, 2003, LIVER INT, V23, P309, DOI 10.1034/j.1478-3231.2003.00865.x; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Chen DS, 2005, ANN INTERN MED, V142, P384, DOI 10.7326/0003-4819-142-5-200503010-00014; Faustini A, 2001, VACCINE, V19, P2812, DOI 10.1016/S0264-410X(01)00005-6; FitzSimons D, 2004, VACCINE, V22, P4092, DOI 10.1016/j.vaccine.2004.03.051; Gaeta GB, 2000, HEPATOLOGY, V32, P824, DOI 10.1053/jhep.2000.17711; Harpaz R, 2000, J INFECT DIS, V181, P413, DOI 10.1086/315259; Huang LM, 1999, HEPATOLOGY, V29, P954, DOI 10.1002/hep.510290349; Kane MA, 1996, LANCET, V348, P696, DOI 10.1016/S0140-6736(05)65598-5; Kao JH, 2001, J PEDIATR-US, V139, P349, DOI 10.1067/mpd.2001.116277; Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406; Lemon SM, 1997, NEW ENGL J MED, V336, P196, DOI 10.1056/NEJM199701163360307; Liao SS, 1999, VACCINE, V17, P2661, DOI 10.1016/S0264-410X(99)00031-6; Lin YC, 2003, J INFECT DIS, V187, P134, DOI 10.1086/345871; McMahon BJ, 2005, ANN INTERN MED, V142, P333, DOI 10.7326/0003-4819-142-5-200503010-00008; Mele A, 2002, J MED VIROL, V67, P440, DOI 10.1002/jmv.10092; Mele A, 2001, J INFECT DIS, V184, P905, DOI 10.1086/323396; Ni YH, 2001, ANN INTERN MED, V135, P796, DOI 10.7326/0003-4819-135-9-200111060-00009; PIAZZA M, 1988, LANCET, V2, P1132; Stroffolini T, 2000, J HEPATOL, V33, P980, DOI 10.1016/S0168-8278(00)80132-4; VanDamme P, 1997, BRIT MED J, V314, P1033, DOI 10.1136/bmj.314.7086.1033; West DJ, 1996, VACCINE, V14, P1019, DOI 10.1016/0264-410X(96)00062-X; Whittle H, 2002, BMJ-BRIT MED J, V325, P569, DOI 10.1136/bmj.325.7364.569; World Health Organization, 1992, WHODMPCFD92, Vthird, P11; ZANETTI AR, 1993, VACCINE, V11, P521, DOI 10.1016/0264-410X(93)90222-J; Zanetti AR, 2001, VACCINE, V19, P2380, DOI 10.1016/S0264-410X(00)00458-8; 1991, MMWR MORBID MORTAL W, V40, P1	30	266	293	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 15	2005	366	9494					1379	1384		10.1016/S0140-6736(05)67568-X	http://dx.doi.org/10.1016/S0140-6736(05)67568-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	973ZW	16226616				2022-12-28	WOS:000232562100030
J	Schroeder, C; Vernino, S; Birkenfeld, AL; Tank, J; Heusser, K; Lipp, A; Benter, T; Lindschau, C; Kettritz, R; Luft, FC; Jordan, J				Schroeder, C; Vernino, S; Birkenfeld, AL; Tank, J; Heusser, K; Lipp, A; Benter, T; Lindschau, C; Kettritz, R; Luft, FC; Jordan, J			Plasma exchange for primary autoimmune autonomic failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENOUS IMMUNOGLOBULIN; NEUROPATHY; PANDYSAUTONOMIA; RECOVERY; BLOCKADE; THERAPY	We report on a patient with long-standing severe autonomic failure that affected his and parasympathetic nervous systems. Antibodies against the ganglionic receptors were detected in the serum. Removal of the antibodies by of plasma exchange resulted in a dramatic clinical improvement.	Franz Volhard Clin Res Ctr, Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Med Univ Charite, Dept Neurol, Berlin, Germany; Helios Klinikum, Berlin, Germany; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helios Kliniken; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Schroeder, C (corresponding author), Franz Volhard Clin Res Ctr, Berlin, Germany.		Vernino, Steven/AAD-5181-2020; Birkenfeld, Andreas L./U-3954-2019; Lindschau, Carsten/G-1798-2011; Lindschau, Carsten/AAE-6721-2020	Vernino, Steven/0000-0001-7799-8495; Birkenfeld, Andreas L./0000-0003-1407-9023; Lindschau, Carsten/0000-0003-1960-099X; Kettritz, Ralph/0000-0001-5821-6718; Luft, Friedrich/0000-0002-8635-1199; Tank, Jens/0000-0002-5672-1187; Heusser, Karsten/0000-0002-2571-5585				Dalakas MC, 2004, PHARMACOL THERAPEUT, V102, P177, DOI 10.1016/j.pharmthera.2004.04.002; GOLDSTEIN DS, 1986, HYPERTENSION, V8, P471, DOI 10.1161/01.HYP.8.6.471; Heafield MTE, 1996, LANCET, V347, P28, DOI 10.1016/S0140-6736(96)91559-7; Jordan J, 1998, HYPERTENSION, V31, P1178, DOI 10.1161/01.HYP.31.5.1178; Klein CM, 2003, ANN NEUROL, V53, P752, DOI 10.1002/ana.10556; Lennon VA, 2003, J CLIN INVEST, V111, P907, DOI 10.1172/JCI200317429; Low PA, 2003, SEMIN NEUROL, V23, P407; Mericle RA, 1997, J NEUROL NEUROSUR PS, V62, P529, DOI 10.1136/jnnp.62.5.529; PATON WDM, 1954, PHARMACOL REV, V6, P59; Shannon JR, 1998, HYPERTENSION, V32, P101, DOI 10.1161/01.HYP.32.1.101; Smit AAJ, 1997, MAYO CLIN PROC, V72, P333, DOI 10.4065/72.4.333; Tank J, 2003, CIRCULATION, V107, P2949, DOI 10.1161/01.CIR.0000072786.99163.FE; Venkataraman S, 1998, NEUROLOGY, V51, P1764, DOI 10.1212/WNL.51.6.1764; Vernino S, 1998, NEUROLOGY, V50, P1806, DOI 10.1212/WNL.50.6.1806; Vernino S, 2000, NEW ENGL J MED, V343, P847, DOI 10.1056/NEJM200009213431204; Vernino S, 2004, J NEUROSCI, V24, P7037, DOI 10.1523/JNEUROSCI.1485-04.2004; Vernino S, 2003, J NEUROPHYSIOL, V90, P2053, DOI 10.1152/jn.00408.2003; Vernino S, 2001, AUTON NEUROSCI-BASIC, V88, P187, DOI 10.1016/S1566-0702(01)00239-9	18	83	87	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1585	1590		10.1056/NEJMoa051719	http://dx.doi.org/10.1056/NEJMoa051719			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221781	Green Accepted			2022-12-28	WOS:000232486000012
J	Oransky, I				Oransky, I			Horace W Davenport - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com						DAVENPORT HW, PUBLICATION LIST	1	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 8	2005	366	9493					1260	1260		10.1016/S0140-6736(05)67517-4	http://dx.doi.org/10.1016/S0140-6736(05)67517-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971ST	16231418				2022-12-28	WOS:000232405700015
J	Assmann, SM				Assmann, SM			G proteins go green: A plant g protein signaling FAQ sheet	SCIENCE			English	Article							HETEROTRIMERIC G-PROTEIN; ARABIDOPSIS SEED-GERMINATION; GTP-BINDING PROTEINS; ALPHA-SUBUNIT GPA1; COUPLED RECEPTORS; PLASMA-MEMBRANE; BETA-SUBUNIT; CELL-PROLIFERATION; GAMMA-SUBUNIT; GUARD-CELLS	Plants, like animals, use signal transduction pathways based on heterotrimeric guanine nucleotide-binding proteins (G proteins) to regulate many aspects of development and cell signaling. Some components of G protein signaling are highly conserved between plants and animals and some are not. This Viewpoint compares key aspects of G protein signal transduction in plants and animals and describes the current knowledge of this system in plants, the questions that still await exploration, and the value of research on plant G proteins to scientists who do not study plants. Pathways in Science's Signal Transduction Knowledge Environment Connections Maps database provide details about the emerging roles of G proteins in several cellular processes of plants.	Penn State Univ, Dept Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Assmann, SM (corresponding author), Penn State Univ, Dept Biol, 208 Mueller Lab, University Pk, PA 16802 USA.	sma3@psu.edu						Abramowitz J, 2004, P NATL ACAD SCI USA, V101, P8366, DOI 10.1073/pnas.0308758101; Aharon GS, 1998, FEBS LETT, V424, P17, DOI 10.1016/S0014-5793(98)00129-X; Apone F, 2003, PLANT PHYSIOL, V133, P571, DOI 10.1104/pp.103.026005; Assmann Sarah M, 2004, Sci STKE, V2004, pre20; Assmann SM, 2002, PLANT CELL, V14, pS355, DOI 10.1105/tpc.001792; ASSMANN SM, 2005, SCI STKE         OCT; ASSMANNN SM, 2005, SCI STKE         OCT; Brzostowski JA, 2001, TRENDS BIOCHEM SCI, V26, P291, DOI 10.1016/S0968-0004(01)01804-7; Bulenger S, 2005, TRENDS PHARMACOL SCI, V26, P131, DOI 10.1016/j.tips.2005.01.004; Carroll K, 2004, NAT REV MOL CELL BIO, V5, P55, DOI 10.1038/nrm1278; Chen JG, 2004, PLANT PHYSIOL, V135, P907, DOI 10.1104/pp.104.038992; Chen JG, 2003, SCIENCE, V301, P1728, DOI 10.1126/science.1087790; Coursol S, 2005, PLANT PHYSIOL, V137, P724, DOI 10.1104/pp.104.055806; Coursol S, 2003, NATURE, V423, P651, DOI 10.1038/nature01643; Devoto A, 1999, J BIOL CHEM, V274, P34993, DOI 10.1074/jbc.274.49.34993; Holsbeeks I, 2004, TRENDS BIOCHEM SCI, V29, P556, DOI 10.1016/j.tibs.2004.08.010; ISHIDA S, 1993, P NATL ACAD SCI USA, V90, P11152, DOI 10.1073/pnas.90.23.11152; Jones AM, 2004, EMBO REP, V5, P572, DOI 10.1038/sj.embor.7400174; JOO JH, 2005, PLANT CELL; Kato C, 2004, PLANT J, V38, P320, DOI 10.1111/j.1365-313X.2004.02046.x; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kim MC, 2002, NATURE, V416, P447, DOI 10.1038/416447a; Kristiansen K, 2004, PHARMACOL THERAPEUT, V103, P21, DOI 10.1016/j.pharmthera.2004.05.002; Lai CP, 2004, PLANT PHYSIOL, V134, P1586, DOI 10.1104/pp.103.037820; Lapik YR, 2003, PLANT CELL, V15, P1578, DOI 10.1105/tpc.011890; Lease KA, 2001, PLANT CELL, V13, P2631, DOI 10.1105/tpc.13.12.2631; Lieberherr D, 2005, PLANT PHYSIOL, V138, P1644, DOI 10.1104/pp.104.057414; MA H, 1994, PLANT MOL BIOL, V26, P1611, DOI 10.1007/BF00016493; Mason MG, 2001, BBA-GENE STRUCT EXPR, V1520, P147, DOI 10.1016/S0167-4781(01)00262-7; Mason MG, 2000, P NATL ACAD SCI USA, V97, P14784, DOI 10.1073/pnas.97.26.14784; McCudden CR, 2005, CELL MOL LIFE SCI, V62, P551, DOI 10.1007/s00018-004-4462-3; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Pandey S, 2004, PLANT CELL, V16, P1616, DOI 10.1105/tpc.020321; Perfus-Barbeoch L, 2004, CURR OPIN PLANT BIOL, V7, P719, DOI 10.1016/j.pbi.2004.09.013; Ritchie S, 2000, PLANT PHYSIOL, V124, P693, DOI 10.1104/pp.124.2.693; Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127; Schwacke R, 2003, PLANT PHYSIOL, V131, P16, DOI 10.1104/pp.011577; Spiegel AM, 2004, ANNU REV MED, V55, P27, DOI 10.1146/annurev.med.55.091902.103843; Suharsono U, 2002, P NATL ACAD SCI USA, V99, P13307, DOI 10.1073/pnas.192244099; Ueguchi-Tanaka M, 2000, P NATL ACAD SCI USA, V97, P11638, DOI 10.1073/pnas.97.21.11638; Ullah H, 2003, PLANT CELL, V15, P393, DOI 10.1105/tpc.006148; Ullah H, 2002, PLANT PHYSIOL, V129, P897, DOI 10.1104/pp.005017; Ullah H, 2001, SCIENCE, V292, P2066, DOI 10.1126/science.1059040; Wang XQ, 2001, SCIENCE, V292, P2070, DOI 10.1126/science.1059046; Willard FS, 2004, METHOD ENZYMOL, V389, P320; Wise A, 2004, ANNU REV PHARMACOL, V44, P43, DOI 10.1146/annurev.pharmtox.44.101802.121419; Zhao J, 2004, J BIOL CHEM, V279, P1794, DOI 10.1074/jbc.M309529200; 2004, NAT REV DRUG DISCOV, V3, P539	48	59	70	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 7	2005	310	5745					71	73		10.1126/science.1118580	http://dx.doi.org/10.1126/science.1118580			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210528				2022-12-28	WOS:000232477000037
J	Diebold, AC				Diebold, AC			Subsurface, imaging with scanning ultrasound holography	SCIENCE			English	Editorial Material									SEMATECH, Austin, TX 78741 USA	Samsung	Diebold, AC (corresponding author), SEMATECH, Austin, TX 78741 USA.	alain.diebold@sematech.org						Dinelli F, 2000, PHYS REV B, V61, P13995, DOI 10.1103/PhysRevB.61.13995; Geer RE, 2002, J APPL PHYS, V91, P4549, DOI 10.1063/1.1447330; OUELLETTE J, 2004, IND PHYS, V10, P14; Shekhawat GS, 2005, SCIENCE, V310, P89, DOI 10.1126/science.1117694	4	20	20	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 7	2005	310	5745					61	62		10.1126/science.1119259	http://dx.doi.org/10.1126/science.1119259			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210522				2022-12-28	WOS:000232477000031
J	Gromley, A; Yeaman, C; Rosa, J; Redick, S; Chen, CT; Mirabelle, S; Guha, M; Sillibourne, J; Doxsey, SJ				Gromley, A; Yeaman, C; Rosa, J; Redick, S; Chen, CT; Mirabelle, S; Guha, M; Sillibourne, J; Doxsey, SJ			Centriolin anchoring of exocyst and SNARE complexes at the midbody is required for secretory-vesicle-mediated abscission	CELL			English	Article							BUDDING YEAST; MEMBRANE TRAFFICKING; EPITHELIAL-CELLS; BINDING-PROTEIN; CLEAVAGE FURROW; CYTOKINESIS; CENTROSOME; SNAPIN; POLARITY; FISSION	The terminal step in cytokinesis, called abscission, requires resolution of the membrane connection between two prospective daughter cells. Our previous studies demonstrated that the coiled-coil protein centriolin localized to the midbody during cytokinesis and was required for abscission. Here we show that centriolin interacts with proteins of vesicle-targeting exocyst complexes and vesicle-fusion SNARE complexes. These complexes require centriolin for localization to a unique midbody-ring structure, and disruption of either complex inhibits abscission. Exocyst disruption induces accumulation of v-SNARE-containing vesicles at the midbody ring. In control cells, these v-SNARE vesicles colocalize with a GFP-tagged secreted polypeptide. The vesicles move to the midbody ring asymmetrically from one prospective daughter cell; the GFP signal is rapidly lost, suggesting membrane fusion; and subsequently the cell cleaves at the site of vesicle delivery/fusion. We propose that centriolin anchors protein complexes required for vesicle targeting and fusion and integrates membrane-vesicle fusion with abscission.	Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA; Univ Iowa, Dept Cell Biol & Anat, Iowa City, IA 52242 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Iowa	Doxsey, SJ (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA.	stephen.doxsey@umassmed.edu	Yeaman, Charles A/A-1624-2009	Sillibourne, James/0000-0001-6755-3644; Yeaman, Charles/0000-0001-6149-628X	NIGMS NIH HHS [R01 GM067002, R01 GM051994, GM51994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051994, R56GM051994, R01GM067002] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albertson R, 2005, TRENDS CELL BIOL, V15, P92, DOI 10.1016/j.tcb.2004.12.008; Antonin W, 2000, MOL BIOL CELL, V11, P3289, DOI 10.1091/mbc.11.10.3289; Blum R, 2000, J CELL SCI, V113, P3151; Buxton P, 2003, BIOCHEM J, V375, P433, DOI 10.1042/BJ20030427; Chen C, 2004, ANN NY ACAD SCI, V1019, P355, DOI 10.1196/annals.1297.061; Chheda MG, 2001, NAT CELL BIOL, V3, P331, DOI 10.1038/35070000; Cuif MH, 1999, EMBO J, V18, P1772, DOI 10.1093/emboj/18.7.1772; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; Dobbelaere J, 2004, SCIENCE, V305, P393, DOI 10.1126/science.1099892; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; DOXSEY S, 2005, ANN REV CELL DEV, V21, P688; Echard A, 2004, CURR BIOL, V14, P1685, DOI 10.1016/j.cub.2004.08.063; Finger FP, 2002, CELL, V108, P727, DOI 10.1016/S0092-8674(02)00668-2; Finger FP, 1998, CELL, V92, P559, DOI 10.1016/S0092-8674(00)80948-4; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Grallert A, 2004, GENE DEV, V18, P1007, DOI 10.1101/gad.296204; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Gromley A, 2003, J CELL BIOL, V161, P535, DOI 10.1083/jcb.200301105; Guertin DA, 2002, MICROBIOL MOL BIOL R, V66, P155, DOI 10.1128/MMBR.66.2.155-178.2002; Guo W, 2000, TRENDS CELL BIOL, V10, P251, DOI 10.1016/S0962-8924(00)01754-2; HARLOW E, ANTIBODIES LAB MANAU; Jurgens G, 2005, TRENDS CELL BIOL, V15, P277, DOI 10.1016/j.tcb.2005.03.005; Low SH, 2003, DEV CELL, V4, P753, DOI 10.1016/S1534-5807(03)00122-9; Molk JN, 2004, MOL BIOL CELL, V15, P1519, DOI 10.1091/mbc.E03-09-0708; Mondesert G, 1997, GENETICS, V147, P421; Monzo P, 2005, MOL BIOL CELL, V16, P2891, DOI 10.1091/mbc.E04-09-0773; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; MULLINS JM, 1977, J CELL BIOL, V73, P672, DOI 10.1083/jcb.73.3.672; Murthy M, 2004, DEVELOPMENT, V131, P377, DOI 10.1242/dev.00931; Papoulas O, 2005, NAT CELL BIOL, V7, P612, DOI 10.1038/ncb1264; PAWELETZ N, 1967, NATURWISSENSCHAFTEN, V54, P533, DOI 10.1007/BF00627210; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; Prigent M, 2003, J CELL BIOL, V163, P1111, DOI 10.1083/jcb.200305029; SALMINEN A, 1989, J CELL BIOL, V109, P1023, DOI 10.1083/jcb.109.3.1023; SAXTON WM, 1987, J CELL BIOL, V105, P875, DOI 10.1083/jcb.105.2.875; Skop AR, 2004, SCIENCE, V305, P61, DOI 10.1126/science.1097931; Skop AR, 2001, CURR BIOL, V11, P735, DOI 10.1016/S0960-9822(01)00231-7; Strickland LI, 2004, TRENDS CELL BIOL, V14, P115, DOI 10.1016/j.tcb.2004.01.006; Takahashi N, 2004, J CELL BIOL, V165, P255, DOI 10.1083/jcb.200312033; Takeda T, 2004, NAT CELL BIOL, V6, P1142, DOI 10.1038/ncb1189; Thakur P, 2004, J NEUROSCI, V24, P6476, DOI 10.1523/JNEUROSCI.0590-04.2004; Thompson HM, 2002, CURR BIOL, V12, P2111, DOI 10.1016/S0960-9822(02)01390-8; VerPlank L, 2005, MOL BIOL CELL, V16, P2529, DOI 10.1091/mbc.E04-12-1090; Vites O, 2004, J BIOL CHEM, V279, P26251, DOI 10.1074/jbc.M404079200; Wang HY, 2002, MOL BIOL CELL, V13, P515, DOI 10.1091/mbc.01-11-0542; Wilson GM, 2005, MOL BIOL CELL, V16, P849, DOI 10.1091/mbc.e04-10-0927; Yeaman C, 2004, J CELL SCI, V117, P559, DOI 10.1242/jcs.00893; Yeaman C, 2003, METHODS, V30, P198, DOI 10.1016/S1046-2023(03)00026-4	50	323	338	2	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 7	2005	123	1					75	87		10.1016/j.cell.2005.07.027	http://dx.doi.org/10.1016/j.cell.2005.07.027			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	973QD	16213214	Bronze			2022-12-28	WOS:000232536800010
J	Smith, CWJ				Smith, CWJ			A cellular response to an internal energy crisis	CELL			English	Editorial Material							ACTIVATION; APOPTOSIS; SURVIVAL; COMPLEX; ARK5	Lack of an appropriate energy supply has been thought to induce cell death in a nonspecific manner by causing a decline in metabolism and a gradual cessation of cellular function. In this issue of Cell, Nutt et al. (2005) describe a new mechanism that directly links nutrient availability to apoptosis in Xenopus oocytes and show that age-dependent changes in the nutritional state of a cell might lead to caspase activation and apoptotic cell death.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Smith, CWJ (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.			Lipinski, Marta/0000-0002-7537-9014				Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Hammerman PS, 2004, TRENDS BIOCHEM SCI, V29, P586, DOI 10.1016/j.tibs.2004.09.008; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Suzuki A, 2004, ONCOGENE, V23, P7067, DOI 10.1038/sj.onc.1207963; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432	8	5	5	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 7	2005	123	1					3	5		10.1016/j.cell.2005.09.015	http://dx.doi.org/10.1016/j.cell.2005.09.015			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	973QD	16213206	Bronze			2022-12-28	WOS:000232536800002
J	Fox, DB; Frail, DA; Price, PA; Kulkarni, SR; Berger, E; Piran, T; Soderberg, AM; Cenko, SB; Cameron, PB; Gal-Yam, A; Kasliwal, MM; Moon, DS; Harrison, FA; Nakar, E; Schmidt, BP; Penprase, B; Chevalier, RA; Kumar, P; Roth, K; Watson, D; Lee, BL; Shectman, S; Phillips, MM; Roth, M; McCarthy, PJ; Rauch, M; Cowie, L; Peterson, BA; Rich, J; Kawai, N; Aoki, K; Kosugi, G; Totani, T; Park, HS; MacFadyen, A; Hurley, KC				Fox, DB; Frail, DA; Price, PA; Kulkarni, SR; Berger, E; Piran, T; Soderberg, AM; Cenko, SB; Cameron, PB; Gal-Yam, A; Kasliwal, MM; Moon, DS; Harrison, FA; Nakar, E; Schmidt, BP; Penprase, B; Chevalier, RA; Kumar, P; Roth, K; Watson, D; Lee, BL; Shectman, S; Phillips, MM; Roth, M; McCarthy, PJ; Rauch, M; Cowie, L; Peterson, BA; Rich, J; Kawai, N; Aoki, K; Kosugi, G; Totani, T; Park, HS; MacFadyen, A; Hurley, KC			The afterglow of GRB 050709 and the nature of the short-hard gamma-ray bursts	NATURE			English	Article							UNUSUAL SUPERNOVA; SHORT-DURATION; ENERGY; EMISSION; LONG	The final chapter in the long-standing mystery of the gamma-ray bursts (GRBs) centres on the origin of the short-hard class of bursts, which are suspected on theoretical grounds to result from the coalescence of neutron-star or black-hole binary systems. Numerous searches for the afterglows of short-hard bursts have been made, galvanized by the revolution in our understanding of long-duration GRBs that followed the discovery in 1997 of their broadband (X-ray, optical and radio) afterglow emission. Here we present the discovery of the X-ray afterglow of a short-hard burst, GRB 050709, whose accurate position allows us to associate it unambiguously with a star-forming galaxy at redshift z = 0.160, and whose optical lightcurve definitively excludes a supernova association. Together with results from three other recent short-hard bursts, this suggests that short-hard bursts release much less energy than the long-duration GRBs. Models requiring young stellar populations, such as magnetars and collapsars, are ruled out, while coalescing degenerate binaries remain the most promising progenitor candidates.	Natl Radio Astron Observ, Socorro, NM 87801 USA; CALTECH, Div Phys Math & Astron, Pasadena, CA 91125 USA; Penn State Univ, Dept Astron & Astrophys, Davey Lab 525, University Pk, PA 16802 USA; Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; Carnegie Observ, Pasadena, CA 91101 USA; Hebrew Univ Jerusalem, Racah Inst Phys, IL-91904 Jerusalem, Israel; Australian Natl Univ, Res Sch Astron & Astrophys, Weston, ACT 2611, Australia; Pomona Coll, Claremont, CA 91711 USA; Univ Virginia, Dept Astron, Charlottesville, VA 22903 USA; Univ Texas, Dept Astron, Austin, TX 78731 USA; Gemini Observ, Hilo, HI 96720 USA; Univ Copenhagen, Niels Bohr Inst, DK-2100 Copenhagen, Denmark; Univ Toronto, Dept Astron & Astrophys, Toronto, ON M5S 3H8, Canada; Tokyo Inst Technol, Dept Phys, Meguro Ku, Tokyo 1528551, Japan; Natl Astron Observ Japan, Subaru Telescope, Hilo, HI 96720 USA; Kyoto Univ, Sch Sci, Dept Astron, Sakyo Ku, Kyoto 6068502, Japan; Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; Inst Adv Study, Princeton, NJ 08540 USA; Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA	National Radio Astronomy Observatory (NRAO); California Institute of Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Hawaii System; Carnegie Institution for Science; Hebrew University of Jerusalem; Australian National University; Claremont Colleges; Pomona College; University of Virginia; University of Texas System; University of Texas Austin; University of Copenhagen; Niels Bohr Institute; University of Toronto; Tokyo Institute of Technology; National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); Kyoto University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Institute for Advanced Study - USA; University of California System; University of California Berkeley	Frail, DA (corresponding author), Natl Radio Astron Observ, POB O, Socorro, NM 87801 USA.	dfox@astro.psu.edu; dfrail@nrao.edu	Watson, Darach/E-4521-2015	Watson, Darach/0000-0002-4465-8264; Fox, Derek/0000-0002-3714-672X; Nakar, Ehud/0000-0002-4534-7089; Schmidt, Brian/0000-0001-6589-1287; MacFadyen, Andrew/0000-0002-0106-9013				Balazs LG, 2003, ASTRON ASTROPHYS, V401, P129, DOI 10.1051/0004-6361:20021863; Berger E, 2003, ASTROPHYS J, V590, P379, DOI 10.1086/374892; Berger E, 2003, NATURE, V426, P154, DOI 10.1038/nature01998; BERGER E, UNPUB NATURE; BERGER E, UNPUB ASTROPHYS J; Bloom JS, 2002, ASTRON J, V123, P1111, DOI 10.1086/338893; BLOOM JS, UNPU ASTROPHYS J; BURROWS DN, 2005, SCIENCE, V150, P1; Condon JJ, 1998, ASTRON J, V115, P1693, DOI 10.1086/300337; COVINO S, 2005, 3665 GCN; EICHLER D, 1989, NATURE, V340, P126, DOI 10.1038/340126a0; EISENSTEIN DJ, 2005, 3418 GRB; FOX DB, 2004, 3585 GRB; Frail DA, 2001, ASTROPHYS J, V562, pL55, DOI 10.1086/338119; Friedman AS, 2005, ASTROPHYS J, V627, P1, DOI 10.1086/430292; Galama TJ, 1998, NATURE, V395, P670, DOI 10.1038/27150; Garmire GP, 2003, PROC SPIE, V4851, P28, DOI 10.1117/12.461599; Guetta D, 2005, ASTRON ASTROPHYS, V435, P421, DOI 10.1051/0004-6361:20041702; Hjorth J, 2003, NATURE, V423, P847, DOI 10.1038/nature01750; Hjorth J, 2005, ASTROPHYS J, V630, pL117, DOI 10.1086/491733; Hurley K, 2002, ASTROPHYS J, V567, P447, DOI 10.1086/338420; Janka HT, 2002, ASTR SOC P, V263, P333; JENSEN BL, 2005, 3589 GRB; Katz JI, 1996, ASTROPHYS J, V471, P915, DOI 10.1086/178018; KOUVELIOTOU C, 1993, ASTROPHYS J, V413, pL101, DOI 10.1086/186969; Kulkarni SR, 1998, NATURE, V395, P663, DOI 10.1038/27139; KULKARNI SR, UNPUB NATURE; Kumar P, 2000, ASTROPHYS J, V538, pL125, DOI 10.1086/312821; Li LX, 1998, ASTROPHYS J, V507, pL59, DOI 10.1086/311680; Mannucci F, 2005, ASTRON ASTROPHYS, V433, P807, DOI 10.1051/0004-6361:20041411; MORGAN A, 2005, 3577 CGN; Motohara K, 2002, PUBL ASTRON SOC JPN, V54, P315, DOI 10.1093/pasj/54.2.315; NARAYAN R, 1992, ASTROPHYS J, V395, pL83, DOI 10.1086/186493; Peng CY, 2002, ASTRON J, V124, P266, DOI 10.1086/340952; PIRAN T, 1996, P IAU S, V165, P489; Rhoads JE, 1999, ASTROPHYS J, V525, P737, DOI 10.1086/307907; Schlegel DJ, 1998, ASTROPHYS J, V500, P525, DOI 10.1086/305772; Schmidt M, 2001, ASTROPHYS J, V559, pL79, DOI 10.1086/324011; SIRIANNI M, 2005, IN PRESS PUBL ASTRON; Stanek KZ, 2003, ASTROPHYS J, V591, pL17, DOI 10.1086/376976; Totani T, 1999, ASTROPHYS J, V511, P41, DOI 10.1086/306664; Zhang B, 2004, INT J MOD PHYS A, V19, P2385, DOI 10.1142/S0217751X0401746X	43	434	442	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					845	850		10.1038/nature04189	http://dx.doi.org/10.1038/nature04189			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208362	Green Submitted			2022-12-28	WOS:000232338600037
J	Nehme-Schuster, W; Youssef, C; Roy, C; Brettes, JP; Martin, T; Pasquali, JL; Korganow, AS				Nehme-Schuster, W; Youssef, C; Roy, C; Brettes, JP; Martin, T; Pasquali, JL; Korganow, AS			Alcock's canal syndrome revealing endometriosis	LANCET			English	Editorial Material									Serv Immunol, Clin Med Interne A, F-67091 Strasbourg, France; Serv Gynecol & Obstet, F-67091 Strasbourg, France; Serv Radiol, F-67091 Strasbourg, France		Korganow, AS (corresponding author), Serv Immunol, Clin Med Interne A, 11 Pl Hop, F-67091 Strasbourg, France.	Anne-Sophie.Korganow@chru-strasbourg.fr		Martin, Thierry/0000-0002-2776-2641; Korganow, Anne-Sophie/0000-0002-1664-6311				AMARENCO G, 1991, PRESSE MED, V20, P71; AMARENCO G, 1987, PRESSE MED, V16, P339; Bazot M, 2004, RADIOLOGY, V232, P379, DOI 10.1148/radiol.2322030762; Reitz A, 2003, NEUROUROL URODYNAM, V22, P597, DOI 10.1002/nau.10134; TURNER MLC, 1991, AM J OBSTET GYNECOL, V165, P1233, DOI 10.1016/S0002-9378(12)90733-4	5	9	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	2005	366	9492					1238	1238		10.1016/S0140-6736(05)67487-9	http://dx.doi.org/10.1016/S0140-6736(05)67487-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970LK	16198773				2022-12-28	WOS:000232311300034
J	Malina, D				Malina, D			Compliance, caricature, and cuturally aware care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	7	8	2	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2005	353	13					1317	1318		10.1056/NEJMp058064	http://dx.doi.org/10.1056/NEJMp058064			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968FB	16192476				2022-12-28	WOS:000232146200003
J	Parman, SW; Kurz, MD; Hart, SR; Grove, TL				Parman, SW; Kurz, MD; Hart, SR; Grove, TL			Helium solubility in olivine and implications for high (3)He/(4)He in ocean island basalts	NATURE			English	Article							NOBLE-GASES; MANTLE HETEROGENEITY; EARTHS MANTLE; SYSTEMATICS; EVOLUTION; RIDGE; MELTS; NEON; FRACTIONATION; CONSTRAINTS	High (3)He/(4) He ratios found in ocean island basalts are the main evidence for the existence of an undegassed mantle reservoir(1-3). However, models of helium isotope evolution depend critically on the chemical behaviour of helium during mantle melting. It is generally assumed that helium is strongly enriched in mantle melts relative to uranium and thorium, yet estimates of helium partitioning in mantle minerals have produced conflicting results(4-6). Here we present experimental measurements of helium solubility in olivine at atmospheric pressure. Natural and synthetic olivines were equilibrated with a 50% helium atmosphere and analysed by crushing in vacuo followed by melting, and yield a minimum olivine-melt partition coefficient of 0.0025 +/- 0.0005 (s.d.) and a maximum of 0.0060 +/- 0.0007 (s.d.). The results indicate that helium might be more compatible than uranium and thorium during mantle melting and that high (3)He/(4) He ratios can be preserved in depleted residues of melting. A depleted source for high (3)He/(4) He ocean island basalts would resolve the apparent discrepancy(7) in the relative helium concentrations of ocean island and mid-ocean-ridge basalts.	MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA	Massachusetts Institute of Technology (MIT); Woods Hole Oceanographic Institution	Parman, SW (corresponding author), Univ Durham, Sci Labs, Dept Earth Sci, Durham DH1 3LE, England.	stephen.parman@durham.ac.uk	Grove, Timothy/M-9638-2013	Grove, Timothy/0000-0003-0628-1969; Kurz, Mark/0000-0003-1745-2356; Parman, Stephen/0000-0002-7523-8684				ALLEGRE CJ, 1983, NATURE, V303, P762, DOI 10.1038/303762a0; Anderson DL, 1998, P NATL ACAD SCI USA, V95, P4822, DOI 10.1073/pnas.95.9.4822; BAKER MB, 1994, GEOCHIM COSMOCHIM AC, V58, P2811, DOI 10.1016/0016-7037(94)90116-3; BOYET M, 2005, IN PRESS SCIENCE; BROADHURST CL, 1992, GEOCHIM COSMOCHIM AC, V56, P709, DOI 10.1016/0016-7037(92)90092-W; Brooker RA, 2003, NATURE, V423, P738, DOI 10.1038/nature01708; BROOKER RA, 2003, EOS, V84; Burnard PG, 2002, EARTH PLANET SC LETT, V203, P131, DOI 10.1016/S0012-821X(02)00828-2; Class C, 2005, NATURE, V436, P1107, DOI 10.1038/nature03930; DICK HJB, 1984, EARTH PLANET SC LETT, V69, P88, DOI 10.1016/0012-821X(84)90076-1; DUNAI TJ, 1995, GEOCHIM COSMOCHIM AC, V59, P2767, DOI 10.1016/0016-7037(95)00172-V; Gill J., 1981, OROGENIC ANDESITES P; Graham DW, 2002, REV MINERAL GEOCHEM, V47, P247, DOI 10.2138/rmg.2002.47.8; HIYAGON H, 1986, GEOCHIM COSMOCHIM AC, V50, P2045, DOI 10.1016/0016-7037(86)90258-9; Honda M, 1999, GEOCHIM COSMOCHIM AC, V63, P2863, DOI 10.1016/S0016-7037(99)00206-9; JAMBON A, 1986, GEOCHIM COSMOCHIM AC, V50, P401, DOI 10.1016/0016-7037(86)90193-6; KURZ MD, 1982, NATURE, V297, P43, DOI 10.1038/297043a0; KURZ MD, 1993, PHILOS T ROY SOC A, V342, P91, DOI 10.1098/rsta.1993.0007; KURZ MD, 2004, GEOCHEM GEOPHYS GEOS, V5; Landwehr D, 2001, EARTH PLANET SC LETT, V188, P329, DOI 10.1016/S0012-821X(01)00328-4; LUX G, 1987, GEOCHIM COSMOCHIM AC, V51, P1549, DOI 10.1016/0016-7037(87)90336-X; MARTY B, 1993, CHEM GEOL, V106, P1, DOI 10.1016/0009-2541(93)90162-C; Meibom A, 2003, EARTH PLANET SC LETT, V208, P197, DOI 10.1016/S0012-821X(03)00038-4; Moreira M, 2004, GEOCHIM COSMOCHIM AC, V68, pA283; NAKAMURA A, 1983, PHYS CHEM MINER, V10, P27, DOI 10.1007/BF01204323; Stuart FM, 2003, NATURE, V424, P57, DOI 10.1038/nature01711; TRULL TW, 1993, GEOCHIM COSMOCHIM AC, V57, P1313, DOI 10.1016/0016-7037(93)90068-8; WORKMAN RK, 2004, GEOCHEM GEOPHYS GEOS, V5; Yamamoto J, 2005, GEOCHIM COSMOCHIM AC, V69, P727, DOI 10.1016/j.gca.2004.07.014; YOKOCHI R, 2005, GEOCHEM GEOPHYS GEOS, V6	30	111	112	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 20	2005	437	7062					1140	1143		10.1038/nature04215	http://dx.doi.org/10.1038/nature04215			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16237441				2022-12-28	WOS:000232660500041
J	Santry, HP; Gillen, DL; Lauderdale, DS				Santry, HP; Gillen, DL; Lauderdale, DS			Trends in bariatric surgical procedures	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Meeting of the Chicago-Surgical-Society	MAR 03, 2005	Chicago, IL	Chicago Surg Soc			Y GASTRIC BYPASS; UNITED-STATES; BILIOPANCREATIC DIVERSION; WEIGHT-LOSS; NATIONAL TRENDS; SURGERY; OBESITY; OUTCOMES; COMPLICATIONS; PREVALENCE	Context The increasing prevalence and associated sociodemographic disparities of morbid obesity are serious public health concerns. Bariatric surgical procedures provide greater and more durable weight reduction than behavioral and pharmacological interventions for morbid obesity. Objective To examine trends for elective bariatric surgical procedures, patient characteristics, and in-hospital complications from 1998 to 2003 in the United States. Design, Setting, and Patients The Nationwide Inpatient Sample was used to identify bariatric surgery admissions from 1998-2002 (with preliminary data for 12 states from 2003) using International Classification of Diseases, Ninth Revision, codes for foregut surgery with a confirmatory diagnosis of obesity or by diagnosis related group code for obesity surgery. Annual-estimates and trends were determined for procedures, patient characteristics, and adjusted complication rates. Main Outcome Measures Trends in bariatric surgical procedures, patient characteristics, and complications. Results The estimated number of bariatric surgical procedures increased from 13 365 in 1998 to 72 177 in 2002 (P<.001). Based on preliminary state-level data (19982003), the number of bariatric surgical procedures is projected to be 102 794 in 2003. Gastric bypass procedures accounted for more than 80% of all bariatric surgical procedures. From 1998 to 2002, there were upward trends in the proportion of females (81% to 84%; P=.003), privately insured patients (75% to 83%; P=.001), patients from ZIP code areas with highest annual household income (32% to 60%, P<.001), and patients aged 50 to 64 years (15% to 24%; P<.001). Length of stay decreased from 4.5 days in 1998 to 3.3 days in 2002 (P<.001). The adjusted in-hospital mortality rate ranged from 0.1% to 0.2%. The rates of unexpected reoperations for surgical complications ranged from 6% to 9% and pulmonary complications ranged from 4% to 7%. Rates of other in-hospital complications were low. Conclusions These findings suggest that use of bariatric surgical procedures increased substantially from 1998 to 2003, while rates of in-hospital complications were stable and length of stay decreased. However, disparities in the use of these procedures, with disproportionate and increasing use among women, those with private insurance, and those in wealthier ZIP code areas should be explored further.	Univ Chicago, Dept Surg, Chicago, IL 60637 USA; Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA; Univ Calif Irvine, Dept Stat, Irvine, CA USA	University of Chicago; University of Chicago; University of California System; University of California Irvine	Santry, HP (corresponding author), 5841 S Maryland Ave,MC 6040, Chicago, IL 60637 USA.	hpatel@surgery.bsd.uchicago.edu	Kohn, Geoffrey P/A-9056-2009	Santry, Heena/0000-0003-2352-1557	NATIONAL INSTITUTE ON AGING [P30AG012857] Funding Source: NIH RePORTER; NIA NIH HHS [P30 AG-12857-08] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLON N, 1982, PSYCHOL ASPECTS OBES, P130; [Anonymous], 1992, AM J CLIN NUTR S, V55, p487S; Barker FG, 2003, NEUROSURGERY, V52, P995, DOI 10.1227/01.NEU.0000057743.56678.5F; Bray GA, 2004, J CLIN ENDOCR METAB, V89, P2583, DOI 10.1210/jc.2004-0535; BRECHNER RJ, 2004, SUMMARY EVIDENCE BAR; Buchwald H, 2004, JAMA-J AM MED ASSOC, V292, P1724, DOI 10.1001/jama.292.14.1724; Buchwald H, 2002, OBES SURG, V12, P705, DOI 10.1381/096089202321019747; Byrne TK, 2001, SURG CLIN N AM, V81, P1181, DOI 10.1016/S0039-6109(05)70190-0; Carbonell AM, 2005, AM SURGEON, V71, P308; Courcoulas A, 2003, SURGERY, V134, P613, DOI 10.1016/S0039-6060(03)00306-4; *CTR MED MED SERV, PROGR MEM INT CARR; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Encinosa WE, 2005, HEALTH AFFAIR, V24, P1039, DOI 10.1377/hlthaff.24.4.1039; Erickson Jennifer L, 2004, WMJ, V103, P32; Fisher BL, 2002, AM J SURG, V184, p9S, DOI 10.1016/S0002-9610(02)01173-X; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Flum DR, 2004, J AM COLL SURGEONS, V199, P543, DOI 10.1016/j.jamcollsurg.2004.06.014; Fontaine K R, 2001, Obes Rev, V2, P173, DOI 10.1046/j.1467-789x.2001.00032.x; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; Gregg EW, 2005, JAMA-J AM MED ASSOC, V293, P1868, DOI 10.1001/jama.293.15.1868; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; Hess DS, 1998, OBES SURG, V8, P267, DOI 10.1381/096089298765554476; July Fannie M, 2003, ABNF J, V14, P55; Kelly J, 2005, OBES RES, V13, P227, DOI 10.1038/oby.2005.31; Kral JG, 2001, SURG CLIN N AM, V81, P1039, DOI 10.1016/S0039-6109(05)70183-3; Liu JH, 2003, AM SURGEON, V69, P823; Livingston EH, 2004, AM J SURG, V188, P105, DOI 10.1016/j.amjsurg.2004.03.001; Livingston EH, 2004, SURGERY, V135, P288, DOI 10.1016/j.surg.2003.07.008; Livingston EH, 2003, J SURG RES, V109, P138, DOI 10.1016/S0022-4804(02)00085-9; Livingston EH, 2002, AM J SURG, V184, P103, DOI 10.1016/S0002-9610(02)00914-5; Maggard MA, 2005, ANN INTERN MED, V142, P547, DOI 10.7326/0003-4819-142-7-200504050-00013; Mitka M, 2003, JAMA-J AM MED ASSOC, V289, P1761, DOI 10.1001/jama.289.14.1761; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI [10.1001/jama.289.1.76, DOI 10.1001/JAMA.289.1.76]; Mun EC, 2001, GASTROENTEROLOGY, V120, P669, DOI 10.1053/gast.2001.22430; Perugini RA, 2003, ARCH SURG-CHICAGO, V138, P541, DOI 10.1001/archsurg.138.5.541; Podnos YD, 2003, ARCH SURG-CHICAGO, V138, P957, DOI 10.1001/archsurg.138.9.957; Pope GD, 2002, J GASTROINTEST SURG, V6, P855, DOI 10.1016/S1091-255X(02)00085-9; PORTIER C, 1984, COMMUN STAT-THEOR M, V13, P1, DOI 10.1080/03610928408828657; Puhl R, 2001, OBES RES, V9, P788, DOI 10.1038/oby.2001.108; Rabkin RA, 1998, OBES SURG, V8, P53, DOI 10.1381/096089298765555060; Ren CJ, 2000, OBES SURG, V10, P514, DOI 10.1381/096089200321593715; Resnick HE, 1998, DIABETES CARE, V21, P1828, DOI 10.2337/diacare.21.11.1828; Safadi BY, 2004, AM J SURG, V188, P606, DOI 10.1016/j.amjsurg.2004.07.021; Schauer PR, 2001, SURG CLIN N AM, V81, P1145, DOI 10.1016/S0039-6109(05)70189-4; Schauer PR, 2000, ANN SURG, V232, P515, DOI 10.1097/00000658-200010000-00007; SHEKELLE PG, 2004, AGENCY HEALTHCARE RE; Steinbrook R, 2004, NEW ENGL J MED, V350, P1075, DOI 10.1056/NEJMp048029; Sturm R, 2003, ARCH INTERN MED, V163, P2146, DOI 10.1001/archinte.163.18.2146; Taub DA, 2004, UROLOGY, V63, P862, DOI 10.1016/j.urology.2003.11.037; Tilghman Joan, 2003, ABNF J, V14, P66; Trus TL, 2005, SURG ENDOSC, V19, P616, DOI 10.1007/s00464-004-8827-8; Wainess RM, 2003, J GASTROINTEST SURG, V7, P879, DOI 10.1016/S1091-255X(03)00150-1; World Health Organisation, 1977, INT CLASS DIS 9 REV; Zhang Q, 2004, SOC SCI MED, V58, P1171, DOI 10.1016/S0277-9536(03)00288-0; Zizza CA, 2003, OBES RES, V11, P1519, DOI 10.1038/oby.2003.203	56	686	701	0	33	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	2005	294	15					1909	1917		10.1001/jama.294.15.1909	http://dx.doi.org/10.1001/jama.294.15.1909			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	974OZ	16234497	Bronze			2022-12-28	WOS:000232602600020
J	Punnoose, A; Finkel'stein, AM				Punnoose, A; Finkel'stein, AM			Metal-insulator transition in disordered two-dimensional electron systems	SCIENCE			English	Article							2 DIMENSIONS; SCALING THEORY; LOCALIZATION	We present a theory of the metal-insulator transition in a disordered two-dimensional electron gas. A quantum critical point, separating the metallic phase, which is stabilized by electronic interactions, from the insulating phase, where disorder prevails over the electronic interactions, has been identified. The existence of the quantum critical point leads to a divergence in the density of states of the underlying collective modes at the transition, causing the thermodynamic properties to behave critically as the transition is approached. We show that the interplay of electron-electron interactions and disorder can explain the observed transport properties and the anomalous enhancement of the spin susceptibility near the metal-insulator transition.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; Weizmann Inst Sci, Dept Condensed Matter Phys, IL-76100 Rehovot, Israel	Alcatel-Lucent; Lucent Technologies; AT&T; Weizmann Institute of Science	Punnoose, A (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.	punnoose@lucent.com						ALTSHULER BL, 1980, PHYS REV LETT, V44, P1288, DOI 10.1103/PhysRevLett.44.1288; Baranov MA, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.075317; CASTELLANI C, 1986, PHYS REV B, V34, P5935, DOI 10.1103/PhysRevB.34.5935; CASTELLANI C, 1987, PHYS REV LETT, V59, P323, DOI 10.1103/PhysRevLett.59.323; CASTELLANI C, 1984, PHYS REV B, V30, P1596, DOI 10.1103/PhysRevB.30.1596; Efetov K. B., 1982, SOV PHYS JETP, V55, P514; Finkel'shtein A. M., 1983, Soviet Physics - JETP, V57, P97; FINKELSHTEIN AM, 1983, JETP LETT+, V37, P517; FINKELSTEIN AM, 1984, Z PHYS B CON MAT, V56, P189, DOI 10.1007/BF01304171; Ilani S, 2001, SCIENCE, V292, P1354, DOI 10.1126/science.1058645; Kravchenko SV, 2000, PHYS REV LETT, V84, P2909, DOI 10.1103/PhysRevLett.84.2909; Pollak M, 1985, MODERN PROBLEMS COND, V10; Prus O, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.205407; Punnoose A, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.016802; WILSON KG, 1973, PHYS REV D, V7, P2911, DOI 10.1103/PhysRevD.7.2911	20	220	225	6	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 14	2005	310	5746					289	291		10.1126/science.1115660	http://dx.doi.org/10.1126/science.1115660			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224015	Green Submitted			2022-12-28	WOS:000232670100044
J	Makovicky, PJ; Apesteguia, S; Agnolin, FL				Makovicky, PJ; Apesteguia, S; Agnolin, FL			The earliest dromaeosaurid theropod from South America	NATURE			English	Article							DINOSAUR	The evolutionary history of Maniraptora, the clade of carnivorous dinosaurs that includes birds and the sickle-clawed Dromaeosauridae, has hitherto been largely restricted to Late Jurassic and Cretaceous deposits on northern continents. The stunning Early Cretaceous diversity of maniraptorans from Liaoning, China(1-3), coupled with a longevity implied by derived Late Jurassic forms such as Archaeopteryx, pushes the origins of maniraptoran lineages back to Pangaean times and engenders the possibility that such lineages existed in Gondwana. A few intriguing, but incomplete, maniraptoran specimens have been reported from South America(4-8), Africa(9) and Madagascar(10). Their affinities remain contested(11-13), however, and they have been interpreted as biogeographic anomalies relative to other faunal components of these land-masses. Here we describe a near-complete, small dromaeosaurid that is both the most complete and the earliest member of the Maniraptora from South America, and which provides new evidence for a unique Gondwanan lineage of Dromaeosauridae with an origin predating the separation between northern and southern landmasses.	Field Museum Nat Hist, Dept Geol, Chicago, IL 60605 USA; Museo Argentino Ciencias Nat Bernardino Rivadavia, Secc Paleontol Vertebrados, RA-1405 Buenos Aires, DF, Argentina; Museo Argentino Ciencias Nat Bernardino Rivadavia, Lab Anat Comparada, RA-1405 Buenos Aires, DF, Argentina; Univ Maimonides, CAECNA, Fdn Hist Nat Felix de Azara, RA-1405 Buenos Aires, DF, Argentina	Field Museum of Natural History (Chicago); Museo Argentino de Ciencias Naturales Bernardino Rivadavia (MACN); Museo Argentino de Ciencias Naturales Bernardino Rivadavia (MACN)	Makovicky, PJ (corresponding author), Field Museum Nat Hist, Dept Geol, 1400 S Lake Shore Dr, Chicago, IL 60605 USA.	paleoninja@yahoo.com.ar	Apesteguía, Sebastian/F-4034-2018	Apesteguía, Sebastian/0000-0002-0414-0524				Apesteguia S, 2003, NATURE, V425, P609, DOI 10.1038/nature01995; Apesteguia Sebastian, 2001, Journal of Vertebrate Paleontology, V21, p29A; Bonaparte J.F., 1986, ACTAS 4 CONGRESO ARG, V4, P63; Bonaparte J.F., 1999, P INDIAN NATL SCI A, V65, P427; Brochu CA, 2000, J VERTEBR PALEONTOL, V20, P197, DOI 10.1671/0272-4634(2000)020[0197:TCATOO]2.0.CO;2; Calvo Jorge O., 1995, Gaia, V11, P13; Calvo Jorge O., 2004, Arquivos do Museu Nacional Rio de Janeiro, V62, P549; Carignano A.P., 2002, AMEGHINIANA, V39, p7R; Clark James M., 2002, P31; Corbella Hugo, 2004, Revista del Museo Argentino de Ciencias Naturales Nueva Serie, V6, P227; CORIA RA, 1995, NATURE, V377, P224, DOI 10.1038/377224a0; Currie PJ, 1995, J VERTEBR PALEONTOL, V15, P576, DOI 10.1080/02724634.1995.10011250; DEVALAIS S, 2001, AMEGHINIANA, V38, pR9; Forster CA, 1998, SCIENCE, V279, P1915, DOI 10.1126/science.279.5358.1915; GALLINA P.A., 2002, AMEGHINIANA, V39, p10R; GOLOBOFF PA, 1993, NONA V 2 0; Hwang SH, 2002, AM MUS NOVIT, P1, DOI 10.1206/0003-0082(2002)381<0001:NSOMZT>2.0.CO;2; Makovicky PJ, 2003, AM MUS NOVIT, P1; NIXON K, 2000, WINCLADA BETA V 0 9; Novas FE, 2004, LIFE O PAST, P150; Novas FE, 1997, NATURE, V387, P390, DOI 10.1038/387390a0; Novas FE, 2005, NATURE, V433, P858, DOI 10.1038/nature03285; NOVAS FE, 1996, QUEENSLAND MUS MEM, V39, P675; Novas F, 2004, J VERTEBR PALEONTOL, V24, p98A; Novas Fernando E., 2004, Revista del Museo Argentino de Ciencias Naturales Nueva Serie, V6, P61; Rauhut Oliver W. M., 1995, Palaeontologische Zeitschrift, V69, P475; Sereno Paul C., 1998, Neues Jahrbuch fuer Geologie und Palaeontologie Abhandlungen, V210, P41; Sereno PC, 2001, NEW PERSPECTIVES ON THE ORIGIN AND EARLY EVOLUTION OF BIRDS, P69; Xu X, 1999, NATURE, V401, P262, DOI 10.1038/45769; Xu X, 2002, NATURE, V415, P780, DOI 10.1038/415780a	30	183	198	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	2005	437	7061					1007	1011		10.1038/nature03996	http://dx.doi.org/10.1038/nature03996			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16222297				2022-12-28	WOS:000232496100042
J	Pass, HI; Lott, D; Lonardo, F; Harbut, M; Liu, ZD; Tang, NM; Carbone, M; Webb, C; Wali, A				Pass, HI; Lott, D; Lonardo, F; Harbut, M; Liu, ZD; Tang, NM; Carbone, M; Webb, C; Wali, A			Asbestos exposure, pleural mesothelioma, and serum osteopontin levels	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MESSENGER-RNA EXPRESSION; MALIGNANT MESOTHELIOMA; CYFRA 21-1; HYALURONIC-ACID; LUNG-CANCER; OVARIAN-CANCER; DIAGNOSIS; BIOMARKER; MARKERS; BREAST	BACKGROUND: We investigated the presence of osteopontin in pleural mesothelioma and determined serum osteopontin levels in three populations: subjects without cancer who were exposed to asbestos, subjects without cancer who were not exposed to asbestos, and patients with pleural mesothelioma who were exposed to asbestos. METHODS: A group of 69 subjects with asbestos-related nonmalignant pulmonary disease were compared with 45 subjects without exposure to asbestos and 76 patients with surgically staged pleural mesothelioma. Tumor tissue was examined for osteopontin by immunohistochemical analysis, and serum osteopontin levels were measured by an enzyme-linked immunosorbent assay. Results: There were no significant differences in mean (+/-SE) serum osteopontin levels between age-matched subjects with exposure to asbestos and subjects without exposure to asbestos (30+/-3 ng per milliliter and 20+/-4 ng per milliliter, respectively; P=0.06). In the group with exposure to asbestos, elevated serum osteopontin levels were associated with pulmonary plaques and fibrosis (56+/-13 ng per milliliter) but not with normal radiographic findings (21+/-5 ng per milliliter), plaques alone (23+/-3 ng per milliliter), or fibrosis alone (32+/-7 ng per milliliter) (P=0.004). Serum osteopontin levels were significantly higher in the group with pleural mesothelioma than in the group with exposure to asbestos (133+/-10 ng per milliliter vs. 30+/-3 ng per milliliter, P<0.001). Immunohistochemical analysis revealed osteopontin staining of the tumor cells in 36 of 38 samples of pleural mesothelioma. An analysis of serum osteopontin levels comparing the receiver-operating-characteristic curve in the group exposed to asbestos with that of the group with mesothelioma had a sensitivity of 77.6 percent and a specificity of 85.5 percent at a cutoff value of 48.3 ng of osteopontin per milliliter. Subgroup analysis comparing patients with stage I mesothelioma with subjects with exposure to asbestos revealed a sensitivity of 84.6 percent and a specificity of 88.4 percent at a cutoff value of 62.4 ng of osteopontin per milliliter. CONCLUSIONS: Serum osteopontin levels can be used to distinguish persons with exposure to asbestos who do not have cancer from those with exposure to asbestos who have pleural mesothelioma.	Wayne State Univ, John A Dingell Vet Hosp, Karmanos Canc Inst, Dept Surg, Detroit, MI USA; Wayne State Univ, John A Dingell Vet Hosp, Karmanos Canc Inst, Dept Pathol, Detroit, MI USA; Wayne State Univ, John A Dingell Vet Hosp, Karmanos Canc Inst, Dept Med, Detroit, MI USA; Wayne State Univ, John A Dingell Vet Hosp, Karmanos Canc Inst, Dept Comp Sci, Detroit, MI USA; Wayne State Univ, John A Dingell Vet Hosp, Karmanos Canc Inst, Ctr Mol Genet, Detroit, MI USA; Loyola Univ, Cardinal Bernardin Canc Ctr, Dept Pathol, Maywood, IL 60153 USA; Van Andel Res Inst, Lab Tumor Metastasis & Angiogenesis, Grand Rapids, MI USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Loyola University Chicago; Van Andel Institute	Pass, HI (corresponding author), NYU, Sch Med, Dept Cardiothorac Surg, 530 1st Ave,Suite 9V, New York, NY 10016 USA.	harvey.pass@med.nyu.edu	Webb, Craig/I-8123-2012	Liu, Zhandong/0000-0002-7608-0831; Pass, Harvey/0000-0003-3222-3471				Bercero EA, 1997, HISTOPATHOLOGY, V31, P267, DOI 10.1046/j.1365-2559.1997.2510855.x; BOERSMA A, 1980, B EUR PHYSIOPATH RES, V16, P41; Bonfrer JMG, 1997, ANTICANCER RES, V17, P2971; Brakora KA, 2004, GYNECOL ONCOL, V93, P361, DOI 10.1016/j.ygyno.2004.01.050; CHIU B, 1984, CANCER, V54, P2195, DOI 10.1002/1097-0142(19841115)54:10<2195::AID-CNCR2820541021>3.0.CO;2-L; Coppola D, 2004, CLIN CANCER RES, V10, P184, DOI 10.1158/1078-0432.CCR-1405-2; Cullen MR, 2005, AM J EPIDEMIOL, V161, P260, DOI 10.1093/aje/kwi034; Denhardt D, 2005, J INVEST DERMATOL, V124, pXVI, DOI 10.1111/j.0022-202X.2005.23708.x; Ding Ling, 2002, Zhonghua Wai Ke Za Zhi, V40, P773; Ebert W, 1997, ANTICANCER RES, V17, P2875; Fedarko NS, 2001, CLIN CANCER RES, V7, P4060; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FREBOURG T, 1987, CANCER, V59, P2104, DOI 10.1002/1097-0142(19870615)59:12<2104::AID-CNCR2820591224>3.0.CO;2-I; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HELLSTROM PE, 1977, SCAND J RESPIR DIS, V58, P97; Kim JH, 2002, JAMA-J AM MED ASSOC, V287, P1671, DOI 10.1001/jama.287.13.1671; Koopmann J, 2004, CANCER EPIDEM BIOMAR, V13, P487; Lee YC, 1999, AUST NZ J MED, V29, P765, DOI 10.1111/j.1445-5994.1999.tb00777.x; Martinetti A, 2004, ENDOCR-RELAT CANCER, V11, P771, DOI 10.1677/erc.1.00775; Martino Derlis, 2004, Clin Lung Cancer, V5, P290, DOI 10.3816/CLC.2004.n.008; Marukawa M, 1998, ACTA MED OKAYAMA, V52, P119; McIntosh MW, 2004, GYNECOL ONCOL, V95, P9, DOI 10.1016/j.ygyno.2004.07.039; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; *NAT I OCC SAF HLT, 2003, SAF HLTH TOP ASB; Paganuzzi M, 2001, CHEST, V119, P1138, DOI 10.1378/chest.119.4.1138; Pass HI, 2004, CLIN CANCER RES, V10, P849, DOI 10.1158/1078-0432.CCR-0607-3; Pass HI, 1998, J THORAC CARDIOV SUR, V115, P310, DOI 10.1016/S0022-5223(98)70274-0; PETTERSSON T, 1988, CHEST, V94, P1037, DOI 10.1378/chest.94.5.1037; Pluygers E, 1992, Eur J Cancer Prev, V1, P129, DOI 10.1097/00008469-199202000-00005; Robinson BWS, 2003, LANCET, V362, P1612, DOI 10.1016/S0140-6736(03)14794-0; ROBOZ J, 1989, J NATL CANCER I, V81, P924, DOI 10.1093/jnci/81.12.924; Roggli VL, 2002, ULTRASTRUCT PATHOL, V26, P55, DOI 10.1080/01913120252959227; Rusch VW, 1996, LUNG CANCER-J IASLC, V14, P1, DOI 10.1016/0169-5002(95)00508-0; Rusch VW, 1996, J THORAC CARDIOV SUR, V111, P815, DOI 10.1016/S0022-5223(96)70342-2; Rusch VW, 1999, ANN THORAC SURG, V68, P1799, DOI 10.1016/S0003-4975(99)01038-3; Sandhu H, 2000, CARCINOGENESIS, V21, P1023, DOI 10.1093/carcin/21.5.1023; Schneider S, 2004, CLIN CANCER RES, V10, P1588, DOI 10.1158/1078-0432.CCR-0565-3; Schorge JO, 2004, CLIN CANCER RES, V10, P3474, DOI 10.1158/1078-0432.CCR-03-0365; Schottenfeld D, 1982, CANC EPIDEMIOLOGY PR; Schouwink H, 1999, LUNG CANCER-J IASLC, V25, P25, DOI 10.1016/S0169-5002(99)00044-6; SELIKOFF IJ, 1984, CA-CANCER J CLIN, V34, P48, DOI 10.3322/canjclin.34.1.48; Singhal H, 1997, CLIN CANCER RES, V3, P605; Thylen A, 2001, CANCER, V92, P1224, DOI 10.1002/1097-0142(20010901)92:5<1224::AID-CNCR1441>3.0.CO;2-U; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Weill H, 2004, OCCUP ENVIRON MED, V61, P438, DOI 10.1136/oem.2003.010165; ZWEIG MH, 1993, CLIN CHEM, V39, P561; ZWEIG MH, 1993, CLIN CHEM, V39, P1589	48	301	305	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1564	1573		10.1056/NEJMoa051185	http://dx.doi.org/10.1056/NEJMoa051185			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221779	Bronze			2022-12-28	WOS:000232486000010
J	Carter, GL; Clover, K; Whyte, IM; Dawson, AH; D'Este, C				Carter, GL; Clover, K; Whyte, IM; Dawson, AH; D'Este, C			Postcards from the EDge project: randomised controlled trial of an intervention using postcards to reduce repetition of hospital treated deliberate self poisoning	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREVENTION	Objective To determine whether an intervention using postcards (postcards from the EDge project) reduces repetitions of hospital treated deliberate self poisoning. Design Randomised controlled trial. Setting Regional referral service for general hospital treated deliberate self poisoning in Newcastle, Australia. Participants 772 patients aged over 16 years with deliberate self poisoning. Intervention Non-obligatory intervention using eight postcards over 7 2 months along with standard treatment compared with standard treatment alone. Main outcome measures Proportion of patients with one or more repeat episodes of deliberate self poisoning and the number of repeat episodes for deliberate self poisoning per person in 12 months. Results The proportion of repeaters with deliberate self poisoning in the intervention group did not differ significantly from that in the control group (57/378, 15.1%, 95% confidence interval 11.5'% to 18.7% v 68/394,17.3%,13.5% to 21.0%: difference between groups - 2%, - 7% to 3%). In unadjusted analysis the number of repetitions were significantly reduced (incidence risk ratio 0.55, 0.35 to 0.87). Conclusion A postcard intervention reduced repetitions of deliberate self poisoning, although it did not significantly reduce the proportion of individual repeaters.	Univ Newcastle, Fac Hlth, Ctr Mental Hlth Studies, Suicide Prevent Res Unit, Newcastle, NSW 2308, Australia; Univ Newcastle, Discipline Clin Pharmacol, Newcastle, NSW 2308, Australia; Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2308, Australia	University of Newcastle; University of Newcastle; University of Newcastle	Carter, GL (corresponding author), Hunter Reg Mail Ctr, Dept Consultat Liaison Psychiat, Locked Bag 7, Hunter, NSW 2310, Australia.	gregorycarter@newcastle.edu.au	D'ESTE, CATHERINE ANNE/G-7392-2013; Carter, Gregory L/G-5429-2010; Dawson, Andrew H/U-8041-2019; Dawson, Andrew/D-5085-2012; Whyte, Ian/A-1621-2010	Carter, Gregory L/0000-0001-8180-1798; Dawson, Andrew H/0000-0002-8047-397X; Dawson, Andrew/0000-0002-8047-397X; Whyte, Ian/0000-0001-7693-3948; Clover, Kerrie/0000-0001-8310-7003				ALUNAN DG, 1995, EUR J CANCER, V31, P1934; [Anonymous], EFF HLTH CARE B; Bateman A, 1999, AM J PSYCHIAT, V156, P1563, DOI 10.1176/ajp.156.10.1563; Buckley NA, 1999, ANN EMERG MED, V34, P476, DOI 10.1016/S0196-0644(99)80049-3; CARTER G, DELIBERATE SELF HARM; Guthrie E, 2001, BRIT MED J, V323, P135, DOI 10.1136/bmj.323.7305.135; Hawton K, 1998, BRIT MED J, V317, P441; LINEHAN MM, 1991, ARCH GEN PSYCHIAT, V48, P1060; MCGRATH J, 1989, MED J AUSTRALIA, V150, P317, DOI 10.5694/j.1326-5377.1989.tb136492.x; Motto JA, 2001, PSYCHIATR SERV, V52, P828, DOI 10.1176/appi.ps.52.6.828; MOTTO JA, 1976, SUICIDE LIFE-THREAT, V6, P223; Torgerson DJ, 1998, BRIT MED J, V316, P606, DOI 10.1136/bmj.316.7131.606; Turnbull DA, 2004, LANCET, V363, P1104, DOI 10.1016/S0140-6736(04)15893-5; van Buuren HR, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-22; vanderSande R, 1997, ACTA PSYCHIAT SCAND, V96, P43; Whyte IM, 1997, MED J AUSTRALIA, V167, P142, DOI 10.5694/j.1326-5377.1997.tb138813.x; Whyte IM, 2002, J TOXICOL-CLIN TOXIC, V40, P223, DOI 10.1081/CLT-120005492; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; ZELEN M, 1990, STAT MED, V9, P645, DOI 10.1002/sim.4780090611	19	186	186	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 8	2005	331	7520					805	+		10.1136/bmj.38579.455266.E0	http://dx.doi.org/10.1136/bmj.38579.455266.E0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974BC	16183654	Bronze, Green Published			2022-12-28	WOS:000232565300017
J	Drumm, ML; Konstan, MW; Schluchter, MD; Handler, A; Pace, R; Zou, F; Zariwala, M; Fargo, D; Xu, AR; Dunn, JM; Darrah, RJ; Dorfman, R; Sandford, AJ; Corey, M; Zielenski, J; Durie, P; Goddard, K; Yankaskas, JR; Wright, FA; Knowles, MR				Drumm, ML; Konstan, MW; Schluchter, MD; Handler, A; Pace, R; Zou, F; Zariwala, M; Fargo, D; Xu, AR; Dunn, JM; Darrah, RJ; Dorfman, R; Sandford, AJ; Corey, M; Zielenski, J; Durie, P; Goddard, K; Yankaskas, JR; Wright, FA; Knowles, MR		Gene Modifier Study Grp	Genetic modifiers of lung disease in cystic fibrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MANNOSE-BINDING LECTIN; OBSTRUCTIVE PULMONARY-DISEASE; GROWTH-FACTOR-BETA; DEFICIENCY ALLELES; ASSOCIATION; POLYMORPHISMS; SEVERITY; PHENOTYPE; ALPHA(1)-ANTITRYPSIN; GENOTYPE	BACKGROUND Polymorphisms in genes other than the cystic fibrosis transmembrane conductance regulator ( CFTR) gene may modify the severity of pulmonary disease in patients with cystic fibrosis. METHODS We performed two studies with different patient samples. We first tested 808 patients who were homozygous for the Delta F508 mutation and were classified as having either severe or mild lung disease, as defined by the lowest or highest quartile of forced expiratory volume in one second (FEV1), respectively, for age. We genotyped 16 polymorphisms in 10 genes reported by others as modifiers of disease severity in cystic fibrosis and tested for an association in patients with severe disease ( 263 patients) or mild disease ( 545). In the replication ( second) study, we tested 498 patients, with various CFTR genotypes and a range of FEV1 values, for an association of the TGF beta 1 codon 10 CC genotype with low FEV1. RESULTS In the initial study, significant allelic and genotypic associations with phenotype were seen only for TGF beta 1 ( the gene encoding transforming growth factor beta 1), particularly the - 509 and codon 10 polymorphisms ( with P values obtained with the use of Fisher's exact test and logistic regression ranging from 0.006 to 0.0002). The odds ratio was about 2.2 for the highest-risk TGF beta 1 genotype ( codon 10 CC) in association with the phenotype for severe lung disease. The replication study confirmed the association of the TGF beta 1 codon 10 CC genotype with more severe lung disease in comparisons with the use of dichotomized FEV1 for severity status ( P= 0.0002) and FEV1 values directly ( P= 0.02). CONCLUSIONS Genetic variation in the 5' end of TGF beta 1 or a nearby upstream region modifies disease severity in cystic fibrosis.	Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA; Univ N Carolina, Mol Biol Biotechnol Ctr Bioinformat, Chapel Hill, NC 27599 USA; Hosp Sick Children, Program Integrat Biol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; Univ British Columbia, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, Vancouver, BC V5Z 1M9, Canada	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of British Columbia	Knowles, MR (corresponding author), Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, 7019 Thurston Bowles Bldg,CB 7248, Chapel Hill, NC 27599 USA.	knowles@med.unc.edu		Rovitelli, Amy MK/0000-0002-8587-4502; Konstan, Michael/0000-0002-0557-7277; Dorfman, Ruslan/0000-0002-3421-5582; Pace, Rhonda/0000-0001-8606-0327	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068890] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00046, RR00059] Funding Source: Medline; NHLBI NIH HHS [HL68890] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182; Akhurst RJ, 2004, NAT GENET, V36, P1024, DOI 10.1038/ng0904-1024a; Arkwright PD, 2000, THORAX, V55, P459, DOI 10.1136/thorax.55.6.459; Arkwright PD, 2003, AM J RESP CRIT CARE, V167, P384, DOI 10.1164/rccm.200204-364OC; Baranov VS, 1996, HUM GENET, V97, P516, DOI 10.1007/BF02267078; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bronsveld I, 2001, J CLIN INVEST, V108, P1705; Buscher R, 2002, PHARMACOGENETICS, V12, P347, DOI 10.1097/00008571-200207000-00002; Cardon LR, 2003, LANCET, V361, P598, DOI 10.1016/S0140-6736(03)12520-2; Carlsson M, 2005, CLIN EXP IMMUNOL, V139, P306, DOI 10.1111/j.1365-2249.2004.02690.x; Celedon JC, 2004, HUM MOL GENET, V13, P1649, DOI 10.1093/hmg/ddh171; Corey M, 1997, J PEDIATR-US, V131, P809, DOI 10.1016/S0022-3476(97)70025-8; Davies JC, 2004, EUR RESPIR J, V24, P798, DOI 10.1183/09031936.04.00055404; DORING G, 1994, PEDIATR PULM, V18, P3, DOI 10.1002/ppul.1950180104; Dunning AM, 2003, CANCER RES, V63, P2610; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Flamant C, 2004, PHARMACOGENETICS, V14, P295, DOI 10.1097/00008571-200405000-00004; Frangolias DD, 2003, AM J RESP CELL MOL, V29, P390, DOI 10.1165/rcmb.2002-0271OC; Gabolde M, 1999, BRIT MED J, V319, P1166, DOI 10.1136/bmj.319.7218.1166; Garred P, 1999, J CLIN INVEST, V104, P431, DOI 10.1172/JCI6861; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Grainger DJ, 1999, HUM MOL GENET, V8, P93, DOI 10.1093/hmg/8.1.93; Grasemann H, 2003, AM J RESP CRIT CARE, V167, P390, DOI 10.1164/rccm.200202-155OC; Henry MT, 2001, EUR J HUM GENET, V9, P273, DOI 10.1038/sj.ejhg.5200623; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Hull J, 1998, THORAX, V53, P1018, DOI 10.1136/thx.53.12.1018; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KEREM E, 1992, NEW ENGL J MED, V326, P1187, DOI 10.1056/NEJM199204303261804; Mahadeva R, 1998, THORAX, V53, P1022, DOI 10.1136/thx.53.12.1022; Mekus F, 2003, HUM GENET, V112, P1, DOI 10.1007/s00439-002-0839-7; Morris DG, 2003, NATURE, V422, P169, DOI 10.1038/nature01413; Nielsen DM, 1998, AM J HUM GENET, V63, P1531, DOI 10.1086/302114; Pulleyn LJ, 2001, HUM GENET, V109, P623, DOI 10.1007/s00439-001-0617-y; Qin ZHS, 2002, AM J HUM GENET, V71, P1242, DOI 10.1086/344207; Schluchter MD, 2002, STAT MED, V21, P1271, DOI 10.1002/sim.1104; Silverman ES, 2004, AM J RESP CRIT CARE, V169, P214, DOI 10.1164/rccm.200307-973OC; Sterner-Kock A, 2002, GENE DEV, V16, P2264, DOI 10.1101/gad.229102; Suthanthiran M, 2000, P NATL ACAD SCI USA, V97, P3479, DOI 10.1073/pnas.050420897; Welsh MJ, 2001, METABOLIC MOL BASES, P5121; Wu L, 2004, THORAX, V59, P126, DOI 10.1136/thorax.2003.005769; Xaubet A, 2003, AM J RESP CRIT CARE, V168, P431, DOI 10.1164/rccm.200210-1165OC; Yamada Y, 1998, J BONE MINER RES, V13, P1569, DOI 10.1359/jbmr.1998.13.10.1569; Yarden J, 2004, J MED GENET, V41, P629, DOI 10.1136/jmg.2003.017947	43	344	346	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 6	2005	353	14					1443	1453		10.1056/NEJMoa051469	http://dx.doi.org/10.1056/NEJMoa051469			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970LZ	16207846	Bronze, Green Published			2022-12-28	WOS:000232313000004
J	Knight, TM; McCoy, MW; Chase, JM; McCoy, KA; Holt, RD				Knight, TM; McCoy, MW; Chase, JM; McCoy, KA; Holt, RD			Trophic cascades across ecosystems	NATURE			English	Article							FOOD WEBS; PREDATOR; TERRESTRIAL; VISITATION; DIVERSITY; SUBSIDIES; ECOLOGY; PREY	Predation can be intense, creating strong direct and indirect effects throughout food webs(1-4). In addition, ecologists increasingly recognize that fluxes of organisms across ecosystem boundaries can have major consequences for community dynamics(5,6). Species with complex life histories often shift habitats during their life cycles(7) and provide potent conduits coupling ecosystems(5,6). Thus, local interactions that affect predator abundance in one ecosystem ( for example a larval habitat) may have reverberating effects in another ( for example an adult habitat). Here we show that fish indirectly facilitate terrestrial plant reproduction through cascading trophic interactions across ecosystem boundaries. Fish reduce larval dragonfly abundances in ponds, leading to fewer adult dragonflies nearby. Adult dragonflies consume insect pollinators and alter their foraging behaviour. As a result, plants near ponds with fish receive more pollinator visits and are less pollen limited than plants near fish-free ponds. Our results confirm that strong species interactions can reverberate across ecosystems, and emphasize the importance of landscape-level processes in driving local species interactions.	Univ Florida, Dept Zool, Gainesville, FL 32611 USA; Washington Univ, Dept Biol, St Louis, MO 63130 USA	State University System of Florida; University of Florida; Washington University (WUSTL)	Knight, TM (corresponding author), Univ Florida, Dept Zool, Gainesville, FL 32611 USA.	tknight@biology2.wustl.edu		McCoy, Michael/0000-0002-7993-6236				[Anonymous], 2004, FOOD WEBS LANDSCAPE; BYERS CF, 1930, CONTRIBUTION KNOWLED; Corbet P. S., 1999, DRAGONFLIES BEHAV EC; Dukas R, 2003, OIKOS, V101, P157, DOI 10.1034/j.1600-0706.2003.12143.x; Dunkle S. W., 1989, DRAGONFLIES FLORIDA; Finke DL, 2004, NATURE, V429, P407, DOI 10.1038/nature02554; Johansson F, 2003, J FRESHWATER ECOL, V18, P415, DOI 10.1080/02705060.2003.9663977; Knapp RA, 2001, ECOL MONOGR, V71, P401, DOI 10.1890/0012-9615(2001)071[0401:RAROAL]2.0.CO;2; Knight TM, 2005, ANNU REV ECOL EVOL S, V36, P467, DOI 10.1146/annurev.ecolsys.36.102403.115320; Kremen C, 2000, CONSERV BIOL, V14, P1226, DOI 10.1046/j.1523-1739.2000.00013.x; Leibold MA, 2004, ECOL LETT, V7, P601, DOI 10.1111/j.1461-0248.2004.00608.x; MORIN PJ, 1984, ECOLOGY, V65, P53, DOI 10.2307/1939457; Moyle P.B., 1986, Ecological Studies, P27; Munoz AA, 2004, OECOLOGIA, V138, P66, DOI 10.1007/s00442-003-1405-2; Murakami M, 2002, ECOL LETT, V5, P333, DOI 10.1046/j.1461-0248.2002.00321.x; Nakano S, 2001, P NATL ACAD SCI USA, V98, P166, DOI 10.1073/pnas.98.1.166; Needham James G., 1945, BULL BROOKLYN ENT SOC, V40, P104; Pace ML, 1999, TRENDS ECOL EVOL, V14, P483, DOI 10.1016/S0169-5347(99)01723-1; Polis GA, 1997, ANNU REV ECOL SYST, V28, P289, DOI 10.1146/annurev.ecolsys.28.1.289; Sabo JL, 2002, ECOLOGY, V83, P1860, DOI 10.2307/3071770; Shurin JB, 2002, ECOL LETT, V5, P785, DOI 10.1046/j.1461-0248.2002.00381.x; Sinclair ARE, 2003, NATURE, V425, P288, DOI 10.1038/nature01934; Suttle KB, 2003, ECOL LETT, V6, P688, DOI 10.1046/j.1461-0248.2003.00490.x; Takhtajan A, 1997, DIVERSITY CLASSIFICA; Terborgh J, 2001, SCIENCE, V294, P1923, DOI 10.1126/science.1064397; WERNER EE, 1984, ANNU REV ECOL SYST, V15, P393, DOI 10.1146/annurev.es.15.110184.002141; Worm B, 2002, NATURE, V417, P848, DOI 10.1038/nature00830; Wright M., 1944, Journal of the Tennessee Academy of Science, V19, P295	28	357	368	6	394	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 6	2005	437	7060					880	883		10.1038/nature03962	http://dx.doi.org/10.1038/nature03962			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208370				2022-12-28	WOS:000232338600045
J	Taubenberger, JK; Reid, AH; Lourens, RM; Wang, RX; Jin, GZ; Fanning, TG				Taubenberger, JK; Reid, AH; Lourens, RM; Wang, RX; Jin, GZ; Fanning, TG			Characterization of the 1918 influenza virus polymerase genes	NATURE			English	Article							A VIRUS; RNA-POLYMERASE; AMINO-ACID; HEMAGGLUTININ; PROTEIN; ORIGIN; PATHOGENICITY; LINEAGES; GENOME	The influenza A viral heterotrimeric polymerase complex (PA, PB1, PB2) is known to be involved in many aspects of viral replication and to interact with host factors(1), thereby having a role in host specificity(2,3). The polymerase protein sequences from the 1918 human influenza virus differ from avian consensus sequences at only a small number of amino acids, consistent with the hypothesis that they were derived from an avian source shortly before the pandemic. However, when compared to avian sequences, the nucleotide sequences of the 1918 polymerase genes have more synonymous differences than expected, suggesting evolutionary distance from known avian strains. Here we present sequence and phylogenetic analyses of the complete genome of the 1918 influenza virus(4-8), and propose that the 1918 virus was not a reassortant virus ( like those of the 1957 and 1968 pandemics(9,10)), but more likely an entirely avian-like virus that adapted to humans. These data support prior phylogenetic studies suggesting that the 1918 virus was derived from an avian source(11). A total of ten amino acid changes in the polymerase proteins consistently differentiate the 1918 and subsequent human influenza virus sequences from avian virus sequences. Notably, a number of the same changes have been found in recently circulating, highly pathogenic H5N1 viruses that have caused illness and death in humans and are feared to be the precursors of a new influenza pandemic. The sequence changes identified here may be important in the adaptation of influenza viruses to humans.	Armed Forces Inst Pathol, Dept Mol Pathol, Rockville, MD 20850 USA	United States Department of Defense	Taubenberger, JK (corresponding author), Armed Forces Inst Pathol, Dept Mol Pathol, Rockville, MD 20850 USA.	taubenberger@afip.osd.mil	Taubenberger, Jeffery/AAQ-1407-2021	Reid, Ann/0000-0002-8899-5246	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050619] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Basler CF, 2001, P NATL ACAD SCI USA, V98, P2746, DOI 10.1073/pnas.031575198; BISWAS SK, 1994, J VIROL, V68, P1819, DOI 10.1128/JVI.68.3.1819-1826.1994; Chen H, 2005, NATURE, V436, P191, DOI 10.1038/nature03974; Chen WS, 2001, NAT MED, V7, P1306, DOI 10.1038/nm1201-1306; Fodor E, 2002, PERSP MED V, V7, P1; Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P1356, DOI 10.1073/pnas.0308352100; Geiss GK, 2002, P NATL ACAD SCI USA, V99, P10736, DOI 10.1073/pnas.112338099; Gonzalez S, 1999, EMBO J, V18, P3767, DOI 10.1093/emboj/18.13.3767; Guo YJ, 2000, VIROLOGY, V267, P279, DOI 10.1006/viro.1999.0115; Holmes EC, 2005, PLOS BIOL, V3, P1579, DOI 10.1371/journal.pbio.0030300; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Kash JC, 2004, J VIROL, V78, P9499, DOI 10.1128/JVI.78.17.9499-9511.2004; KAWAOKA Y, 1989, J VIROL, V63, P4603, DOI 10.1128/JVI.63.11.4603-4608.1989; Kobasa D, 2004, NATURE, V431, P703, DOI 10.1038/nature02951; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; Masunaga K, 1999, VIROLOGY, V256, P130, DOI 10.1006/viro.1999.9625; Naffakh N, 2000, J GEN VIROL, V81, P1283, DOI 10.1099/0022-1317-81-5-1283; Ohtsu Y, 2002, MICROBIOL IMMUNOL, V46, P167, DOI 10.1111/j.1348-0421.2002.tb02682.x; Puthavathana P, 2005, J GEN VIROL, V86, P423, DOI 10.1099/vir.0.80368-0; Reid AH, 2000, P NATL ACAD SCI USA, V97, P6785, DOI 10.1073/pnas.100140097; Reid AH, 2004, NAT REV MICROBIOL, V2, P909, DOI 10.1038/nrmicro1027; Reid AH, 2004, J VIROL, V78, P12462, DOI 10.1128/JVI.78.22.12462-12470.2004; Reid AH, 1999, P NATL ACAD SCI USA, V96, P1651, DOI 10.1073/pnas.96.4.1651; Reid AH, 2002, J VIROL, V76, P10717, DOI 10.1128/JVI.76.21.10717-10723.2002; SCHOLTISSEK C, 1978, VIROLOGY, V87, P13, DOI 10.1016/0042-6822(78)90153-8; Shinya K, 2004, VIROLOGY, V320, P258, DOI 10.1016/j.virol.2003.11.030; SUBBARAO EK, 1993, J VIROL, V67, P1761, DOI 10.1128/JVI.67.4.1761-1764.1993; Toyoda T, 1996, J GEN VIROL, V77, P2149, DOI 10.1099/0022-1317-77-9-2149; Tumpey TM, 2004, P NATL ACAD SCI USA, V101, P3166, DOI 10.1073/pnas.0308391100; Tumpey TM, 2002, P NATL ACAD SCI USA, V99, P13849, DOI 10.1073/pnas.212519699	30	704	810	2	98	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					889	893		10.1038/nature04230	http://dx.doi.org/10.1038/nature04230			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208372				2022-12-28	WOS:000232338600047
J	Dare, L; Reeler, A				Dare, L; Reeler, A			Health systems financing: putting together the "back office"	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							AID		Ctr Hlth Sci Training Res & Dev, Ibadan, Nigeria; Axios Int, Paris, France		Dare, L (corresponding author), Ctr Hlth Sci Training Res & Dev, Ibadan, Nigeria.	acoshed@yahoo.com						Buse K, 1999, HEALTH POLICY PLANN, V14, P219, DOI 10.1093/heapol/14.3.219; Butler D, 2005, NATURE, V435, P257, DOI 10.1038/435257b; COCKSHOTT WP, 1979, AM J ROENTGENOL, V132, P339, DOI 10.2214/ajr.132.3.339; DARE O, 2005, 32 C GLOB HLTH COUNC; DARE OO, 2003, 7 GLOB FOR HLTH RES; GOTTRET P, 2005, CONS HUM RES HLTH OS; Halstead S, 1985, GOOD HLTH LOW COST; HELLER P, 2005, CONS HUM RES HLTH OS; Levine Ruth, 2004, MILLIONS SAVED PROVE; MARIEHELENE B, 2004, TANZ NAT AIDS C TANZ; Mayhew SH, 2002, INT FAM PLAN PERSPEC, V28, P220, DOI 10.2307/3088225; *OND STAT MIN HLTH, 2004, OND STAT HLTH PLAN; *OV DEV I, 2005, AID AFR UKS 2005 AG; Saltman RB, 2000, B WORLD HEALTH ORGAN, V78, P732; SETTALA R, 2004, INT AIDS C BANGK 11; *UN DEV PROGR, 2003, MILL DEV GOALS HUM D; World Health Organization, 2000, HLTH SYST IMPR PERF; World Health Organization, 2005, HLTH MILL DEV GOALS; World Health Organization, 2005, WORLD HLTH REP 2005	19	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	2005	331	7519					759	762		10.1136/bmj.331.7519.759	http://dx.doi.org/10.1136/bmj.331.7519.759			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	971XB	16195295	Bronze, Green Published			2022-12-28	WOS:000232417100025
J	Massimini, M; Ferrarelli, F; Huber, R; Esser, SK; Singh, H; Tononi, G				Massimini, M; Ferrarelli, F; Huber, R; Esser, SK; Singh, H; Tononi, G			Breakdown of cortical effective connectivity during sleep	SCIENCE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; CORTICOSPINAL EXCITABILITY; COHERENCE; STATES; BRAIN; OSCILLATIONS; CORTEX; CYCLE; ELECTROENCEPHALOGRAM; SYNCHRONIZATION	When we fall asleep, consciousness fades yet the brain remains active. Why is this so? To investigate whether changes in cortical information transmission play a role, we used. transcranial magnetic stimulation together with high-density electroencephalography and asked how the activation of one cortical area (the premotor area) is transmitted to the rest of the brain. During quiet wakefulness, an initial response.(similar to 15 milliseconds) at the stimulation site was followed by a sequence of waves that moved to connected cortical areas several centimeters away. During non-rapid eye movement sleep, the initial response was stronger but was rapidly extinguished and did not propagate beyond the stimulation site. Thus, the fading of consciousness during certain stages of steep may be related to a breakdown in cortical effective connectivity.	Univ Wisconsin, Dept Psychiat, Madison, WI 53719 USA; Univ Milan, Dept Clin Sci, I-20157 Milan, Italy	University of Wisconsin System; University of Wisconsin Madison; University of Milan	Tononi, G (corresponding author), Univ Wisconsin, Dept Psychiat, 6001 Res Pk Blvd, Madison, WI 53719 USA.	gtononi@wisc.edu	Ferrarelli, Fabio/D-3219-2019; Tononi, Giulio/B-8387-2009; ferrarelli, fabio/C-2945-2011; Massimini, Marcello/T-8115-2017	Ferrarelli, Fabio/0000-0003-0560-0227; Massimini, Marcello/0000-0003-2271-957X				Achermann P, 1998, NEUROSCIENCE, V85, P1195, DOI 10.1016/S0306-4522(97)00692-1; Bazhenov M, 2002, J NEUROSCI, V22, P8691; Bertini M, 2004, J SLEEP RES, V13, P31, DOI 10.1046/j.1365-2869.2003.00379.x; BULLOCK TH, 1995, P NATL ACAD SCI USA, V92, P11568, DOI 10.1073/pnas.92.25.11568; Cantero JL, 2004, NEUROIMAGE, V22, P1271, DOI 10.1016/j.neuroimage.2004.03.014; CRICK F, 1990, COLD SH Q B, V55, P953; Destexhe A, 1998, J NEUROPHYSIOL, V79, P999; Duckrow RB, 2005, CLIN NEUROPHYSIOL, V116, P1088, DOI 10.1016/j.clinph.2004.12.002; DUMERMUTH G, 1981, EUR NEUROL, V20, P429, DOI 10.1159/000115274; Engel AK, 2001, TRENDS COGN SCI, V5, P16, DOI 10.1016/S1364-6613(00)01568-0; Grosse P, 2002, NEUROLOGY, V59, P1988, DOI 10.1212/01.WNL.0000038762.11894.DA; Hill S, 2005, J NEUROPHYSIOL, V93, P1671, DOI 10.1152/jn.00915.2004; Ilmoniemi RJ, 1997, NEUROREPORT, V8, P3537, DOI 10.1097/00001756-199711100-00024; Kakigi R, 2003, SLEEP MED, V4, P493, DOI 10.1016/S1389-9457(03)00169-2; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Lee L, 2003, NEUROIMAGE, V19, P457, DOI 10.1016/S1053-8119(03)00062-4; Llinas R, 1998, PHILOS T ROY SOC B, V353, P1841, DOI 10.1098/rstb.1998.0336; Marconi B, 2003, EUR J NEUROSCI, V18, P775, DOI 10.1046/j.1460-9568.2003.02807.x; Pedroarena C, 1997, P NATL ACAD SCI USA, V94, P724, DOI 10.1073/pnas.94.2.724; Picard N, 2001, CURR OPIN NEUROBIOL, V11, P663, DOI 10.1016/S0959-4388(01)00266-5; Sachdev RNS, 2004, J NEUROPHYSIOL, V92, P3511, DOI 10.1152/jn.00347.2004; Salih F, 2005, J PHYSIOL-LONDON, V565, P695, DOI 10.1113/jphysiol.2004.082040; Sanchez-Vives MV, 2000, NAT NEUROSCI, V3, P1027, DOI 10.1038/79848; Steriade M, 1976, Prog Neurobiol, V6, P155; Steriade M, 2004, PROG BRAIN RES, V145, P179, DOI 10.1016/S0079-6123(03)45013-9; Steriade M, 1996, J NEUROSCI, V16, P2788; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Steriade M, 2001, J NEUROPHYSIOL, V85, P1969, DOI 10.1152/jn.2001.85.5.1969; STERIADE M, 1974, BASIC SLEEP MECH, P144; Stickgold R, 2001, SLEEP, V24, P171, DOI 10.1093/sleep/24.2.171; Tononi Giulio, 2004, BMC Neurosci, V5, P42, DOI 10.1186/1471-2202-5-42; Vanderwolf CH, 2000, BRAIN RES, V855, P217, DOI 10.1016/S0006-8993(99)02351-3; von Stein A, 2000, P NATL ACAD SCI USA, V97, P14748, DOI 10.1073/pnas.97.26.14748; Worgotter F, 1998, NATURE, V396, P165, DOI 10.1038/24157	34	937	950	4	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 30	2005	309	5744					2228	2232		10.1126/science.1117256	http://dx.doi.org/10.1126/science.1117256			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195466				2022-12-28	WOS:000232318000048
J	Ghofrani, HA; Seeger, W; Grimminger, F				Ghofrani, HA; Seeger, W; Grimminger, F			Imatinib for the treatment of pulmonary arterial hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							INHALED ILOPROST; SILDENAFIL; THERAPY		Univ Giessen Klinikum, D-35392 Giessen, Germany	University Hospital of Giessen & Marburg	Ghofrani, HA (corresponding author), Univ Giessen Klinikum, D-35392 Giessen, Germany.	ardeschir.ghofrani@inner.med.uni-giessen.de	Ghofrani, Ardeschir/AAD-5293-2020; Ghofrani, Hossein Ardeschir/AAD-2856-2022	Ghofrani, Ardeschir/0000-0002-2029-4419; Seeger, Werner/0000-0003-1946-0894; Grimminger, Friedrich/0000-0001-8725-6276				Ghofrani HA, 2002, ANN INTERN MED, V136, P515, DOI 10.7326/0003-4819-136-7-200204020-00008; Ghofrani HA, 2002, LANCET, V360, P895, DOI 10.1016/S0140-6736(02)11024-5; Olschewski H, 2002, NEW ENGL J MED, V347, P322, DOI 10.1056/NEJMoa020204; Rubin LJ, 2002, NEW ENGL J MED, V346, P1258; Rubin LJ, 2002, NEW ENGL J MED, V346, P896, DOI 10.1056/NEJMoa012212; SCHERMULY RT, IN PRESS J CLIN INVE	6	346	370	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2005	353	13					1412	1413		10.1056/NEJMc051946	http://dx.doi.org/10.1056/NEJMc051946			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968FB	16192491				2022-12-28	WOS:000232146200019
J	Barnfather, KD; Cope, GF; Chapple, IL				Barnfather, KD; Cope, GF; Chapple, IL			Effect of incorporating a 10 minute point of care test for salivary nicotine metabolites into a general practice based smoking cessation programme: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SELF-REPORTED SMOKING; FEEDBACK; SMOKERS; ADVICE	Objective To investigate the effect of immediate feedback from a point of care test for salivary nicotine metabolites in promoting smoking cessation and reduction in tobacco use. Design Prospective, operator blinded, randomised controlled trial. Setting General dental practice, London. Participants 100 adult smokers. Interventions Participants completed a questionnaire on smoking, undertook a clinical examination, and received counselling in smoking cessation. Saliva samples were analysed at presentation and at eight weeks for salivary nicotine metabolites using a 10 minute semiquantitative point of care test. Main outcome measures Smoking cessation measured by salivary nicotine metabolite values (scale 0-6), patient feedback on the perceived value of the test (visual analogue scale) in quitting, and reduction in tobacco use. Results A higher smoking quit rate was achieved with the point of care test (23% cases v 7% controls; P < 0.039), and overall tobacco use also decreased (68% cases v 28% controls; P < 0.001). Baseline values for salivary nicotine metabolites did not differ between the groups (cases, mean 4.1, SD 1.3 and controls, 4.3, 1.4; P = 0.51). 87 participants reattended at eight weeks (44 cases, 43 controls). Mean nicotine metabolite values at eight weeks were 2.58 (2.0) for cases and 4.29 (1.8) for controls (P < 0.001). Conclusion Incorporation of individualised personal feedback using a point of care test for salivary nicotine metabolites into a general practice based smoking cessation programme increased quit rates by 17% at eight weeks and reduced tobacco use.	Univ Birmingham, Periodontal Res Grp, Birmingham B4 6NN, W Midlands, England; Queen Elizabeth Med Ctr, Wolfson Appl Technol Lab, Birmingham B15 2TH, W Midlands, England	University of Birmingham; Birmingham City University; University of Birmingham	Chapple, IL (corresponding author), Univ Birmingham, Periodontal Res Grp, St Chads Queensway, Birmingham B4 6NN, W Midlands, England.	I.L.C.Chapple@bham.ac.uk	Chapple, Iain L C/T-2986-2017	Chapple, Iain L C/0000-0003-2697-7082				Binnie V, 2004, ORAL DIS, V10, P287, DOI 10.1111/j.1601-0825.2004.01018.x; COHEN SJ, 1989, J AM DENT ASSOC, V118, P41, DOI 10.14219/jada.archive.1989.0018; Cope G, 2000, ANN CLIN BIOCHEM, V37, P666, DOI 10.1258/0004563001899717; Cope GF, 2003, ANN CLIN BIOCHEM, V40, P674, DOI 10.1258/000456303770367289; *DEP HLTH, 2004, PUBL STAT SUMM JUL; DiClemente CC, 2001, AM J HEALTH BEHAV, V25, P217, DOI 10.5993/AJHB.25.3.8; JARVIS MJ, 1997, AM J PUBLIC HEALTH, V77, P1435; John JH, 2003, BRIT DENT J, V195, P270, DOI 10.1038/sj.bdj.4810480; JOLM JH, 2003, BR DENT J, V195, P270; Macgregor IDM, 1996, BRIT DENT J, V180, P292, DOI 10.1038/sj.bdj.4809067; Parrott S, 2004, BMJ-BRIT MED J, V328, P947, DOI 10.1136/bmj.328.7445.947; PETO R, UPDATED NATL INT EST; RAW M, 1998, THORAX S, V5, P1; REVILL SI, 1976, ANAESTHESIA, V31, P1191, DOI 10.1111/j.1365-2044.1976.tb11971.x; *ROYAL COLL PHYS T, 2001, NIC ADD BRIT; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; RUSSELL MAH, 1993, BRIT MED J, V306, P1308, DOI 10.1136/bmj.306.6888.1308; SECKERWALKER RH, 1994, PREV MED, V23, P800, DOI 10.1006/pmed.1994.1137; Smith SE, 1998, BRIT DENT J, V185, P299, DOI 10.1038/sj.bdj.4809796; Spiekerman CF, 2003, J DENT RES, V82, P345, DOI 10.1177/154405910308200504; Vartiainen E, 2002, J EPIDEMIOL COMMUN H, V56, P167, DOI 10.1136/jech.56.3.167; Warnakulasuriya KAAS, 1999, BRIT DENT J, V187, P319, DOI 10.1038/sj.bdj.4800269a; *WHO, 1999, ANN REP WHOS TOB FRE	23	28	29	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 29	2005	331	7523					999	1001		10.1136/bmj.38621.463900.7C	http://dx.doi.org/10.1136/bmj.38621.463900.7C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981AU	16210250	Green Published, Bronze			2022-12-28	WOS:000233060200018
J	Beckman, R; Johnston-Halperin, E; Luo, Y; Green, JE; Heath, JR				Beckman, R; Johnston-Halperin, E; Luo, Y; Green, JE; Heath, JR			Bridging dimensions: Demultiplexing ultrahigh-density nanowire circuits	SCIENCE			English	Article							FIELD-EFFECT TRANSISTORS; HAFNIUM SILICATE; DEVICES; FABRICATION; DIELECTRICS; GROWTH	A demultiplexer is an electronic circuit designed to separate two or more combined signals. We report on a demultiplexer architecture for bridging from the submicrometer dimensions of lithographic patterning to the nanometer-scale dimensions that can be achieved through nanofabrication methods for the selective addressing of ultrahigh-density nanowire circuits. Order log(2)(N) large wires are required to address N nanowires, and the demultiplexer architecture is tolerant of low-precision manufacturing. This concept is experimentally demonstrated on submicrometer wires and on an array of 150 silicon nanowires patterned at nanowire widths of 13 nanometers and a pitch of 34 nanometers.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology	Heath, JR (corresponding author), CALTECH, Div Chem & Chem Engn, MC 127-72,1200 E Calif Blvd, Pasadena, CA 91125 USA.	heath@caltech.edu	Johnston-Halperin, Ezekiel/B-5902-2012; Johnston-Halperin, Ezekiel/AAM-2564-2021	Johnston-Halperin, Ezekiel/0000-0002-6240-3505				Beckman RA, 2004, J APPL PHYS, V96, P5921, DOI 10.1063/1.1801155; Bjork MT, 2002, NANO LETT, V2, P87, DOI 10.1021/nl010099n; Bunimovich YL, 2004, LANGMUIR, V20, P10630, DOI 10.1021/la047913h; Chen Y, 2003, APPL PHYS LETT, V82, P1610, DOI 10.1063/1.1559439; Chou SY, 1996, SCIENCE, V272, P85, DOI 10.1126/science.272.5258.85; Chung SW, 1998, J PHYS CHEM B, V102, P6685, DOI 10.1021/jp981441w; Cui Y, 2001, SCIENCE, V291, P851, DOI 10.1126/science.291.5505.851; DeHon A, 2003, IEEE T NANOTECHNOL, V2, P165, DOI 10.1109/TNANO.2003.816658; Diehl MR, 2002, ANGEW CHEM INT EDIT, V41, P353, DOI 10.1002/1521-3773(20020118)41:2<353::AID-ANIE353>3.0.CO;2-Y; Feynman R., 1996, FEYNMAN LECT COMPUTA; Gudiksen MS, 2002, NATURE, V415, P617, DOI 10.1038/415617a; Hausmann DM, 2002, CHEM MATER, V14, P4350, DOI 10.1021/cm020357x; Heath JR, 2003, PHYS TODAY, V56, P43, DOI 10.1063/1.1583533; Heath JR, 1998, SCIENCE, V280, P1716, DOI 10.1126/science.280.5370.1716; HERGENROTHER J, 2001, EL DEV M 2001 IEDM; Hood L, 2004, SCIENCE, V306, P640, DOI 10.1126/science.1104635; Javey A, 2004, NANO LETT, V4, P447, DOI 10.1021/nl035185x; Javey A, 2002, NAT MATER, V1, P241, DOI 10.1038/nmat769; Jin S, 2004, NANO LETT, V4, P915, DOI 10.1021/nl049659j; KUEKEN PJ, 2001, Patent No. 6256767; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Melosh NA, 2003, SCIENCE, V300, P112, DOI 10.1126/science.1081940; PETERS L, 1998, SEMICONDUCTOR IN SEP; Puthenkovilakam R, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1927273; Quevedo-Lopez M, 2001, APPL PHYS LETT, V79, P4192, DOI 10.1063/1.1425466; Royea WJ, 2000, APPL PHYS LETT, V77, P1988, DOI 10.1063/1.1312203; Sear RP, 1999, PHYS REV E, V59, pR6255, DOI 10.1103/PhysRevE.59.R6255; Wang DW, 2003, APPL PHYS LETT, V83, P2432, DOI 10.1063/1.1611644; Wilk GD, 1999, APPL PHYS LETT, V74, P2854, DOI 10.1063/1.124036; Wu YY, 2002, NANO LETT, V2, P83, DOI 10.1021/nl0156888; Yang PD, 2002, CHEMPHYSCHEM, V3, P503, DOI 10.1002/1439-7641(20020617)3:6<503::AID-CPHC503>3.0.CO;2-U; Yu HB, 2005, J PHYS CHEM B, V109, P671, DOI 10.1021/jp047672m; Zhong ZH, 2003, SCIENCE, V302, P1377, DOI 10.1126/science.1090899	33	145	159	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	2005	310	5747					465	468		10.1126/science.1114757	http://dx.doi.org/10.1126/science.1114757			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16195426				2022-12-28	WOS:000232786000038
J	Somerville, MJ; Mervis, CB; Young, EJ; Seo, EJ; del Campo, M; Bamforth, S; Peregrine, E; Loo, W; Lilley, M; Perez-Jurado, LA; Morris, CA; Scherer, SW; Osborne, LR				Somerville, MJ; Mervis, CB; Young, EJ; Seo, EJ; del Campo, M; Bamforth, S; Peregrine, E; Loo, W; Lilley, M; Perez-Jurado, LA; Morris, CA; Scherer, SW; Osborne, LR			Severe expressive-language delay related to duplication of the Williams-Beuren locus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MENTAL-RETARDATION; GENE; SPEECH; MECHANISMS; FAMILIES	Williams - Beuren syndrome (WBS) locus, at 7q11.23, is prone to recurrent chromosomal rearrangements, including the microdeletion that causes WBS, a multisystem condition with characteristic cardiovascular, cognitive, and behavioral features. It is hypothesized that reciprocal duplications of the WBS interval should also occur, and here we present such a case description. The most striking phenotype was a severe delay in expressive speech, in contrast to the normal articulation and fluent expressive language observed in persons with WBS. Our results suggest that specific genes at 7q11.23 are exquisitely sensitive to dosage alterations that can influence human language and visuospatial capabilities.	Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada; Univ Alberta, Dept Med Genet, Edmonton, AB, Canada; Univ Louisville, Dept Psychol & Brain Sci, Louisville, KY 40292 USA; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Unitat Genet, Barcelona, Spain; Univ Nevada, Sch Med, Dept Pediat, Las Vegas, NV 89154 USA	University of Toronto; University of Alberta; University of Louisville; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Pompeu Fabra University; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas	Osborne, LR (corresponding author), Univ Toronto, Inst Med Sci, 7238 Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	lucy.osborne@utoronto.ca	Scherer, Stephen W./B-3785-2013; Pérez Jurado, Luis Alberto/M-7706-2015	Scherer, Stephen W./0000-0002-8326-1999; Young, Ted (Edwin)/0000-0003-4882-6752	Canadian Institutes of Health Research [67342] Funding Source: Medline; NICHD NIH HHS [R01 HD029957, HD29957, R37 HD029957] Funding Source: Medline; NINDS NIH HHS [R01 NS035102, NS35102] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD029957] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035102] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bayes M, 2003, AM J HUM GENET, V73, P131, DOI 10.1086/376565; Bertrand J, 1997, DEV NEUROPSYCHOL, V13, P41, DOI 10.1080/87565649709540667; Chantot-Bastaraud S, 2004, ANN GENET-PARIS, V47, P241, DOI 10.1016/j.anngen.2004.02.003; Christiansen J, 2004, CIRC RES, V94, P1429, DOI 10.1161/01.RES.0000130528.72330.5c; Conners C.K., 1997, CONNERS RATING SCALE; DELCAMPOM, 2001, EUR J HUM GENET, V9; Dunn L.M., 2009, PEABODY PICTURE VOCA; Elliott C. D., 1990, DIFFERENTIAL ABILITY; Fisher SE, 2003, ANNU REV NEUROSCI, V26, P57, DOI 10.1146/annurev.neuro.26.041002.131144; Frangiskakis JM, 1996, CELL, V86, P59, DOI 10.1016/S0092-8674(00)80077-X; Hinsley TA, 2004, PROTEIN SCI, V13, P2588, DOI 10.1110/ps.04747604; Inoue K, 2002, ANNU REV GENOM HUM G, V3, P199, DOI 10.1146/annurev.genom.3.032802.120023; Lai CSL, 2001, NATURE, V413, P519, DOI 10.1038/35097076; Lichtenbelt KD, 2005, AM J MED GENET A, V132A, P93, DOI 10.1002/ajmg.a.30408; MacDermot KD, 2005, AM J HUM GENET, V76, P1074, DOI 10.1086/430841; Mervis CB, 2000, MENT RETARD DEV D R, V6, P148; Morris CA, 2003, AM J MED GENET A, V123A, P45, DOI 10.1002/ajmg.a.20496; Morris CA, 2005, MANAGEMENT GENETIC S, P655; Osborne LR, 2001, NAT GENET, V29, P321, DOI 10.1038/ng753; Scherer SW, 2003, SCIENCE, V300, P767, DOI 10.1126/science.1083423; Stromme P, 2002, J CHILD NEUROL, V17, P269, DOI 10.1177/088307380201700406; Tan-Sindhunata G, 2000, AM J MED GENET, V92, P147, DOI 10.1002/(SICI)1096-8628(20000515)92:2<147::AID-AJMG13>3.0.CO;2-I; Tassabehji M, 2003, HUM MOL GENET, V12, pR229, DOI 10.1093/hmg/ddg299; Wiig E.H., 2004, CELF PRESCHOOL 2, V2nd ed; Williams K.T., 2007, EXPRESSIVE VOCABULAR, V2nd	25	214	217	2	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 20	2005	353	16					1694	1701		10.1056/NEJMoa051962	http://dx.doi.org/10.1056/NEJMoa051962			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975IC	16236740	Green Accepted			2022-12-28	WOS:000232653200009
J	Wood, SF				Wood, SF			Women's health and the FDA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		HUXLEY TH, 1907, APHORISMS REFLECTION; Wood AJJ, 2005, NEW ENGL J MED, V353, P1197, DOI 10.1056/NEJMp058222	2	16	16	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	2005	353	16					1650	1651		10.1056/NEJMp058225	http://dx.doi.org/10.1056/NEJMp058225			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975IC	16236734				2022-12-28	WOS:000232653200003
J	Chen, MS; Kumar, D; Yi, CW; Goodman, DW				Chen, MS; Kumar, D; Yi, CW; Goodman, DW			The promotional effect of gold in catalysis by palladium-gold	SCIENCE			English	Article							VINYL-ACETATE SYNTHESIS; CARBIDE FORMATION; CO CHEMISORPTION; PD; MECHANISM; SURFACES; ETHYLENE; FILMS; AU; ELUCIDATION	Acetoxylation of ethylene to vinyl acetate (VA) was used to investigate the mechanism of the promotional effect of gold (Au) in a palladium (Pd)-Au alloy catalyst. The enhanced rates of VA formation for low Pd coverages relative to high Pd coverages on Au single-crystal surfaces demonstrate that the critical reaction site for VA synthesis consists of two noncontiguous, suitably spaced, Pd monomers. The role of Au is to isolate single Pd sites that facilitate the coupling of critical surface species to product, while inhibiting the formation of undesirable reaction by-products.	Texas A&M Univ, Dept Chem, College Stn, TX 77842 USA	Texas A&M University System; Texas A&M University College Station	Goodman, DW (corresponding author), Texas A&M Univ, Dept Chem, College Stn, TX 77842 USA.	goodman@mail.chem.tamu.edu	Kalra, D/H-6661-2019; Chen, Mingshu/G-4590-2010; Yi, Cheol-Woo/B-3082-2010	Kalra, D/0000-0001-5254-4067; Chen, Mingshu/0000-0002-4923-9632; Yi, Cheol-Woo/0000-0003-4549-5433				ABEL R, 1997, HDB HETEROGENEOUS CA, V5, P2298; ALLISON EG, 1972, CATAL REV, V7, P233, DOI 10.1080/01614947208062259; BADDELEY CJ, 1994, SURF SCI, V314, P1, DOI 10.1016/0039-6028(94)90208-9; Bonarowska M, 2001, APPL CATAL B-ENVIRON, V30, P187, DOI 10.1016/S0926-3373(00)00231-9; Bowker M, 2004, CATAL LETT, V98, P67, DOI 10.1007/s10562-004-6448-4; Campbell CT, 1998, CURR OPIN SOLID ST M, V3, P439, DOI 10.1016/S1359-0286(98)80004-1; Hammer B, 1996, PHYS REV LETT, V76, P2141, DOI 10.1103/PhysRevLett.76.2141; Han YF, 2005, J CATAL, V230, P353, DOI 10.1016/j.jcat.2004.12.018; Han YF, 2004, CATAL LETT, V94, P131, DOI 10.1023/B:CATL.0000020537.33875.46; JABLONSKI A, 1977, SURF SCI, V65, P578, DOI 10.1016/0039-6028(77)90467-8; KOEL BE, 1992, PHYS REV B, V46, P7846, DOI 10.1103/PhysRevB.46.7846; KUHN WK, 1992, SURF SCI, V274, pL611, DOI 10.1016/0039-6028(92)90834-S; Macleod N, 2004, APPL CATAL A-GEN, V261, P37, DOI 10.1016/j.apcata.2003.10.032; Maroun F, 2001, SCIENCE, V293, P1811, DOI 10.1126/science.1061696; NAKAMURA S, 1970, J CATAL, V17, P366, DOI 10.1016/0021-9517(70)90113-2; Neurock M, 2003, J CATAL, V216, P73, DOI 10.1016/S0021-9517(02)00115-X; Provine WD, 1996, STUD SURF SCI CATAL, V101, P191; RODRIGUEZ JA, 1992, SCIENCE, V257, P897, DOI 10.1126/science.257.5072.897; Rylander P.N., 1979, CATALYTIC HYDROGENAT; SAMANOS B, 1971, J CATAL, V23, P19, DOI 10.1016/0021-9517(71)90019-4; SELLIDJ A, 1994, PHYS REV B, V49, P8367, DOI 10.1103/PhysRevB.49.8367; Stacchiola D, 2005, ANGEW CHEM INT EDIT, V44, P4572, DOI 10.1002/anie.200500782; Stacchiola D, 2004, J AM CHEM SOC, V126, P15384, DOI 10.1021/ja044641w; SWARTZFAGER DG, 1981, J VAC SCI TECHNOL, V19, P185, DOI 10.1116/1.571102; Trimm DL, 2001, CATAL REV, V43, P31, DOI 10.1081/CR-100104386; Venezia AM, 2002, J CATAL, V212, P56, DOI 10.1006/jcat.2002.3778; Wolter K, 1998, SURF SCI, V402, P428, DOI 10.1016/S0039-6028(97)01053-4; YI CW, IN PRESS J PHYS CH B	28	868	878	19	592	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					291	293		10.1126/science.1115800	http://dx.doi.org/10.1126/science.1115800			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224016				2022-12-28	WOS:000232670100045
J	Bakun, WH; Aagaard, B; Dost, B; Ellsworth, WL; Hardebeck, JL; Harris, RA; Ji, C; Johnston, MJS; Langbein, J; Lienkaemper, JJ; Michael, AJ; Murray, JR; Nadeau, RM; Reasenberg, PA; Reichle, MS; Roeloffs, EA; Shakal, A; Simpson, RW; Waldhauser, F				Bakun, WH; Aagaard, B; Dost, B; Ellsworth, WL; Hardebeck, JL; Harris, RA; Ji, C; Johnston, MJS; Langbein, J; Lienkaemper, JJ; Michael, AJ; Murray, JR; Nadeau, RM; Reasenberg, PA; Reichle, MS; Roeloffs, EA; Shakal, A; Simpson, RW; Waldhauser, F			Implications for prediction and hazard assessment from the 2004 Parkfield earthquake	NATURE			English	Article							SAN-ANDREAS FAULT; CALIFORNIA EARTHQUAKE; RECURRENCE; SLIP; BEHAVIOR; RUPTURE; MICROEARTHQUAKES; SEISMICITY; SEGMENT; MODELS	Obtaining high-quality measurements close to a large earthquake is not easy: one has to be in the right place at the right time with the right instruments. Such a convergence happened, for the first time, when the 28 September 2004 Parkfield, California, earthquake occurred on the San Andreas fault in the middle of a dense network of instruments designed to record it. The resulting data reveal aspects of the earthquake process never before seen. Here we show what these data, when combined with data from earlier Parkfield earthquakes, tell us about earthquake physics and earthquake prediction. The 2004 Parkfield earthquake, with its lack of obvious precursors, demonstrates that reliable short-term earthquake prediction still is not achievable. To reduce the societal impact of earthquakes now, we should focus on developing the next generation of models that can provide better predictions of the strength and location of damaging ground shaking.	US Geol Survey, Menlo Pk, CA 94025 USA; Royal Netherlands Meteorol Inst, Seismol Div, NL-3730 AE De Bilt, Netherlands; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Univ Calif Berkeley, Seismol Lab, Berkeley, CA 94720 USA; Calif Geol Survey, Sacramento, CA 95814 USA; US Geol Survey, Vancouver, WA 98683 USA; Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA	United States Department of the Interior; United States Geological Survey; Royal Netherlands Meteorological Institute; California Institute of Technology; University of California System; University of California Berkeley; United States Department of the Interior; United States Geological Survey; Columbia University	Bakun, WH (corresponding author), US Geol Survey, 345 Middlefield Rd, Menlo Pk, CA 94025 USA.	bakun@usgs.gov	Nadeau, Robert/G-1884-2017; Dost, Bernard/B-9268-2012; Harris, Ruth A/C-4184-2013; Michael, Andrew J/A-5059-2010	Nadeau, Robert/0000-0003-1255-0643; Harris, Ruth A/0000-0002-9247-0768; Michael, Andrew J/0000-0002-2403-5019; Hardebeck, Jeanne/0000-0002-6737-7780; Aagaard, Brad/0000-0002-8795-9833; Dost, Bernard/0000-0002-3839-7934				BAKUN WH, 1979, SCIENCE, V205, P1375, DOI 10.1126/science.205.4413.1375; BAKUN WH, 1984, J GEOPHYS RES, V89, P3051, DOI 10.1029/JB089iB05p03051; BAKUN WH, 1985, SCIENCE, V229, P619, DOI 10.1126/science.229.4714.619; BAKUN WH, 1987, 87192 USGS, P1; Beeler NM, 2001, B SEISMOL SOC AM, V91, P1797, DOI 10.1785/0120000096; BEN-ZION Y, 1993, J GEOPHYS RES-SOL EA, V98, P2135, DOI 10.1029/92JB02154; Boore D. M., 1997, SEISMOL RES LETT, V68, P128, DOI DOI 10.1785/GSSRL.68.1.128; *CA GEOL SURV, 1998, ALQ PRIOL EARTHQ FAU; *CISN SHAKEMAP, 1997, EST INSTR INT; Dragert H, 2001, SCIENCE, V292, P1525, DOI 10.1126/science.1060152; *EARTHSC PROJ, 2003, EXPL STRUCT EV N AM; EBERHARTPHILLIPS D, 1993, J GEOPHYS RES-SOL EA, V98, P15737, DOI 10.1029/93JB01029; Frankel A., 2000, EARTHQ SPECTRA, V16, P1, DOI DOI 10.1193/1.1586079; Harris RA, 2004, PURE APPL GEOPHYS, V161, P2171, DOI 10.1007/s00024-004-2556-8; HARRIS RA, 1987, J GEOPHYS RES-SOLID, V92, P7945, DOI 10.1029/JB092iB08p07945; Hickman S, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020688; HILL DP, 1991, 91270 USGS, P1; IRWIN WP, 1975, GEOLOGY, V3, P713, DOI 10.1130/0091-7613(1975)3<713:EOGSAM>2.0.CO;2; JI C, 2004, EOS, V85; Johnston M J S, 2002, INT HDB EARTHQUAKE E, P589, DOI [DOI 10.1016/S0074-6142(02)80239-X, 10.1016/S0074-6142(02)80239-X]; KAGAN YY, 1995, J GEOPHYS RES-SOL EA, V100, P3943, DOI 10.1029/94JB03014; KAWASAKI I, 1995, J PHYS EARTH, V43, P105, DOI 10.4294/jpe1952.43.105; Langbein J, 2005, SEISMOL RES LETT, V76, P10, DOI 10.1785/gssrl.76.1.10; LIENKAEMPER JJ, 1989, J GEOPHYS RES-SOLID, V94, P17647, DOI 10.1029/JB094iB12p17647; LIENKAEMPER JJ, 2004, EOS, V85; LINDH AG, 1981, B SEISMOL SOC AM, V71, P95; Liu J, 2004, GEOLOGY, V32, P649, DOI 10.1130/G20478.1; MAIN I, 1999, IS REALIABLE EARTHQU; MICHAEL AJ, 1991, SCIENCE, V253, P651, DOI 10.1126/science.253.5020.651; Michael AJ, 1998, B SEISMOL SOC AM, V88, P117; Murray J, 2002, NATURE, V419, P287, DOI 10.1038/nature00984; Nadeau RM, 1999, SCIENCE, V285, P718, DOI 10.1126/science.285.5428.718; Nadeau RM, 2005, SCIENCE, V307, P389, DOI 10.1126/science.1107142; *NAT EARTHQ PRED E, 1994, US GEOL SURV CIRC, V1116, P1; NISHENKO SP, 1991, PURE APPL GEOPHYS, V135, P169, DOI 10.1007/BF00880240; Rikitake T., 1976, EARTHQUAKE PREDICTIO, P7; SAVAGE JC, 1993, B SEISMOL SOC AM, V83, P1; SCHAFF DP, 1998, GEOPHYS RES LETT, V107, pB9, DOI DOI 10.1029/2001JB000633; SCHWARTZ DP, 1984, J GEOPHYS RES, V89, P5681, DOI 10.1029/JB089iB07p05681; SEGALL P, 1993, J GEOPHYS RES-SOL EA, V98, P4527, DOI 10.1029/92JB02408; Shakal A, 2005, SEISMOL RES LETT, V76, P27, DOI 10.1785/gssrl.76.1.27; SHEARER CF, 1985, 85507 USGS, P173; SHERBURNE RW, 1988, CALIF GEOL, V41, P27; SHIMAZAKI K, 1980, GEOPHYS RES LETT, V7, P279, DOI 10.1029/GL007i004p00279; SIEH KE, 1978, B SEISMOL SOC AM, V68, P1421; Toppozada TR, 2002, B SEISMOL SOC AM, V92, P2555, DOI 10.1785/0120000614; Uchida N, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017452; *USGS EARTHQ HAZ P, 2000, ADV NAT SEISM SYST; Waldhauser F, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020649; Waldhauser F, 2000, B SEISMOL SOC AM, V90, P1353, DOI 10.1785/0120000006; *WORK GROUP CA EAR, 2003, 03214 USGS, V214, P1	51	278	294	4	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	2005	437	7061					969	974		10.1038/nature04067	http://dx.doi.org/10.1038/nature04067			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16222291				2022-12-28	WOS:000232496100034
J	Cranmer, HH				Cranmer, HH			Hurricane Katrina - Volunteer work - Logistics first	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Dept Emergency Med, Div Int Hlth & Humanitarian Programs, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Cranmer, HH (corresponding author), Brigham & Womens Hosp, Dept Emergency Med, Div Int Hlth & Humanitarian Programs, 75 Francis St, Boston, MA 02115 USA.								0	14	15	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1541	+		10.1056/NEJMp058234	http://dx.doi.org/10.1056/NEJMp058234			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221770				2022-12-28	WOS:000232486000001
J	Morwood, MJ; Brown, P; Jatmiko; Sutikna, T; Saptomo, EW; Westaway, KE; Due, RA; Roberts, RG; Maeda, T; Wasisto, S; Djubiantono, T				Morwood, MJ; Brown, P; Jatmiko; Sutikna, T; Saptomo, EW; Westaway, KE; Due, RA; Roberts, RG; Maeda, T; Wasisto, S; Djubiantono, T			Further evidence for small-bodied hominins from the Late Pleistocene of Flores, Indonesia	NATURE			English	Article							DENTAL MORPHOLOGY; HADAR FORMATION; AL 288-1; BRAIN; HOMO; ETHIOPIA; SKELETON; STATURE; DMANISI; GEORGIA	Homo floresiensis was recovered from Late Pleistocene deposits on the island of Flores in eastern Indonesia, but has the stature, limb proportions and endocranial volume of African Pliocene Australopithecus(1). The holotype of the species (LB1), excavated in 2003 from Liang Bua, consisted of a partial skeleton minus the arms. Here we describe additional H. floresiensis remains excavated from the cave in 2004. These include armbones belonging to the holotype skeleton, a second adult mandible, and postcranial material from other individuals. We can now reconstruct the body proportions of H. floresiensis with some certainty. The finds further demonstrate that LB1 is not just an aberrant or pathological individual, but is representative of a long-term population that was present during the interval 95 - 74 to 12 thousand years ago. The excavation also yielded more evidence for the depositional history of the cave and for the behavioural capabilities of H. floresiensis, including the butchery of Stegodon and use of fire.	Univ New England, Sch Human & Environm Studies, Armidale, NSW 2351, Australia; Indonesian Ctr Archaeol, Jakarta 12001, Indonesia; Univ Wollongong, Sch Earth & Environm Sci, GeoQuEST Res Ctr, Wollongong, NSW 2522, Australia	University of New England; University of Wollongong	Morwood, MJ (corresponding author), Univ New England, Sch Human & Environm Studies, Armidale, NSW 2351, Australia.	mmorwood@pobox.une.edu.au; pbrown3@pobox.une.edu.au	Brown, Peter/C-8763-2018; Roberts, Richard Graham/B-8245-2013; Sutikna, Thomas/C-4709-2018	Roberts, Richard Graham/0000-0002-0128-4119; Westaway, Kira/0000-0001-5315-778X; Sutikna, Thomas/0000-0002-9742-4226				AIELLO A, 1990, INTRO HUMAN EVOLUTIO; Brown P, 2004, NATURE, V431, P1055, DOI 10.1038/nature02999; EVANS FG, 1945, AM J ANAT, V76, P303, DOI 10.1002/aja.1000760303; Falk D, 2005, SCIENCE, V308, P242, DOI 10.1126/science.1109727; Gabounia L, 2002, CR PALEVOL, V1, P243, DOI 10.1016/S1631-0683(02)00032-5; Haeusler M, 2004, J HUM EVOL, V46, P433, DOI 10.1016/j.jhevol.2004.01.004; Hens SM, 2000, J HUM EVOL, V38, P767, DOI 10.1006/jhev.1999.0382; HIRALAL GM, 1998, J CLIN ENDOCR METAB, V83, P4065; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P403, DOI 10.1002/ajpa.1330570403; KAIFU Y, 2005, AM J PHYS ANTHR; Kohler M, 2004, BRAIN BEHAV EVOLUT, V63, P125, DOI 10.1159/000076239; LARSON SG, 1988, AM J PHYS ANTHROPOL, V76, P449, DOI 10.1002/ajpa.1330760405; Lavelle C L, 1986, Br J Orthod, V13, P13; LAVELLE CLB, 1986, ACTA ANAT, V125, P238; MARTIN RD, 1981, NATURE, V293, P57, DOI 10.1038/293057a0; Morwood MJ, 2004, NATURE, V431, P1087, DOI 10.1038/nature02956; OLIVIER G, 1976, J HUM EVOL, V5, P529, DOI 10.1016/0047-2484(76)90001-4; ROBERTS DF, 1973, ADDISONWESLEY MODULE, P1; Ruff Christopher B., 1994, Yearbook of Physical Anthropology, V37, P65; SCHMID P, 1983, FOLIA PRIMATOL, V40, P283, DOI 10.1159/000156111; Schwartz JH, 2000, J HUM EVOL, V38, P367, DOI 10.1006/jhev.1999.0339; van der Geer Alexandra A.E., 1999, Deinsea, V7, P325; Vekua A, 2002, SCIENCE, V297, P85, DOI 10.1126/science.1072953; Walker A., 1993, NARIOKOTOME HOMO ERE; WEIDENREICH F, 1936, PALAEONTOLOGICA SI D, V7, P1; WHITE TD, 1982, AM J PHYS ANTHROPOL, V57, P501, DOI 10.1002/ajpa.1330570405; Wolpoff M. H., 1985, SIZE SCALING PRIMATE, P273; WOOD BA, 1987, J ANAT, V154, P121; WOOD BA, 1988, J ANAT, V156, P107	29	223	229	2	121	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 13	2005	437	7061					1012	1017		10.1038/nature04022	http://dx.doi.org/10.1038/nature04022			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16229067				2022-12-28	WOS:000232496100043
J	Siegel, J				Siegel, J			Inventing the nanomolecular wheel	SCIENCE			English	Editorial Material							MOLECULAR MOTOR		Univ Zurich, Inst Organ Chem, CH-8006 Zurich, Switzerland	University of Zurich	Siegel, J (corresponding author), Univ Zurich, Inst Organ Chem, Winterthurerstr 190, CH-8006 Zurich, Switzerland.	jss@oci.unizh.ch	Siegel, Jay/E-6415-2011	Siegel, Jay/0000-0002-3226-3521				Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; Bringmann G, 2002, J ORGANOMET CHEM, V661, P31, DOI 10.1016/S0022-328X(02)01804-1; Bustamante C, 2001, ACCOUNTS CHEM RES, V34, P412, DOI 10.1021/ar0001719; Drexler K.E., 1992, NANOSYSTEMS MOL MACH; FEYNMAN R, THERES PLENTY ROOM B; Feynman R.P., 1963, FEYNMAN LECT PHYS; Fletcher SP, 2005, SCIENCE, V310, P80, DOI 10.1126/science.1117090; Garcia-Garibay MA, 2005, P NATL ACAD SCI USA, V102, P10771, DOI 10.1073/pnas.0502816102; Hernandez JV, 2004, SCIENCE, V306, P1532, DOI 10.1126/science.1103949; IWAMURA H, 1988, ACCOUNTS CHEM RES, V21, P175, DOI 10.1021/ar00148a007; Kelly TR, 2000, J AM CHEM SOC, V122, P6935, DOI 10.1021/ja001048f; Linke H, 2005, CHAOS, V15, DOI 10.1063/1.1871432; Mislow K, 1988, CHEMTRACTS ORG CHEM, V2, P151; Reimann P, 2002, PHYS REP, V361, P57, DOI 10.1016/S0370-1573(01)00081-3; von Smoluchowski M, 1912, PHYS Z, V13, P1069	15	8	8	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	2005	310	5745					63	64		10.1126/science.1118765	http://dx.doi.org/10.1126/science.1118765			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210524				2022-12-28	WOS:000232477000033
J	Ferrone, CR; Ben Porat, L; Panageas, KS; Berwick, M; Halpern, AC; Patel, A; Coit, DG				Ferrone, CR; Ben Porat, L; Panageas, KS; Berwick, M; Halpern, AC; Patel, A; Coit, DG			Clinicopathological features of and risk factors for multiple primary melanomas	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CUTANEOUS MELANOMA; DYSPLASTIC NAEVI; PREVALENCE; FAMILIES; NEVI	Context The,incidence of multiple primary melanomas ranges from 1.3% to 8.0% in large retrospective reviews; however, the impact of certain risk factors is not understood. Objectives To determine the incidence of multiple primary melanomas (MPM) from a prospective, single-institution, multidisciplinary database, and to describe the clinical and pathological characteristics and risk factors specific to these patients. Design and Setting Review of a prospectively maintained database at Memorial Sloan-Kettering Cancer Center in New York, NY. Patients A total of 4484 patients diagnosed with a first primary melanoma between January 1, 1996, and December 31, 2002. Main Outcome Measures Incidence of and risk factors for MPM. Results Three hundred eighty-five patients (8.6%) had 2 or more primary melanomas, with an average of 2.3 melanomas per MPM patient. Seventy-eight percent had 2 primary melanomas. For 74% of patients, the initial melanoma was the thickest tumor. Fifty-nine percent presented with their second primary tumor within 1 year. Twenty-one percent of MPM patients had a positive family history of melanoma compared with only 12% of patients with a single primary melanoma (SPM) (P<.001). Thirty-eight percent of MPM patients had dysplastic nevi compared with 18% of SPM patients (P<.001). The estimated cumulative 5-year risk of a second primary tumor for the entire cohort was 11.4%, with almost half of that risk occurring within the first year. For patients with a positive family history or dysplastic nevi, the estimated 5-year risk of MPM was significantly higher at 19.1% and 23.7%, respectively. The most striking increase in incidence for the MPM population was seen for development of a third primary melanoma from the time of second primary melanoma, which was 15.6% at 1 year and 30.9% at 5 years. Conclusions The incidence of MPM is increased in patients with a positive family history and/or dysplastic nevi. These patients should undergo intensive dermatologic screening and should consider genetic testing.	Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Dermatol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Coit, DG (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.	coitd@mskcc.org	Berwick, Marianne/E-9608-2010	halpern, allan/0000-0001-7320-1901; Berwick, Marianne/0000-0001-5062-2180				*AM CANC SOC, IN PRESS FACTS FIG 2; Blackwood MA, 2002, CANCER, V94, P2248, DOI 10.1002/cncr.10454; Brobeil A, 1997, ANN SURG ONCOL, V4, P19, DOI 10.1007/BF02316806; CASCINELLI N, 1975, TUMORI, V61, P481, DOI 10.1177/030089167506100508; COOKE KR, 1989, CANCER, V63, P1240, DOI 10.1002/1097-0142(19890315)63:6<1240::AID-CNCR2820630635>3.0.CO;2-9; CRUTCHER WA, 1984, LANCET, V1, P729; DiFronzo LA, 1999, ANN SURG ONCOL, V6, P705, DOI 10.1007/s10434-999-0705-0; GILES G, 1995, MELANOMA RES, V5, P433, DOI 10.1097/00008390-199512000-00007; Goggins WB, 2003, CANCER, V97, P639, DOI 10.1002/cncr.11116; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Hansen CB, 2004, LANCET ONCOL, V5, P314, DOI 10.1016/S1470-2045(04)01469-X; Hughes-Davies TH, 1998, NEW ENGL J MED, V339, P347; Johnson TM, 1998, J AM ACAD DERMATOL, V39, P422, DOI 10.1016/S0190-9622(98)70318-4; KANG S, 1992, CANCER, V70, P1911, DOI 10.1002/1097-0142(19921001)70:7<1911::AID-CNCR2820700718>3.0.CO;2-Q; Mantelli M, 2002, AM J MED GENET, V107, P214, DOI 10.1002/ajmg.10137; NEUGUT AI, 1999, MULTIPLE PRIMARY CAN, P445; PACK GT, 1952, CANCER, V5, P1110, DOI 10.1002/1097-0142(195211)5:6<1110::AID-CNCR2820050607>3.0.CO;2-7; Puig S, 2005, J CLIN ONCOL, V23, P3043, DOI 10.1200/JCO.2005.08.034; SLINGLUFF CL, 1993, SURGERY, V113, P330; TITUSERNSTOFF L, 1988, CANCER RES, V48, P1016; Tucker MA, 2002, CANCER, V94, P3192, DOI 10.1002/cncr.10605	21	152	152	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	2005	294	13					1647	1654		10.1001/jama.294.13.1647	http://dx.doi.org/10.1001/jama.294.13.1647			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970DC	16204664	Bronze			2022-12-28	WOS:000232284400017
J	Stratford, K; Adhikari, R; Pagonabarraga, I; Desplat, JC; Cates, ME				Stratford, K; Adhikari, R; Pagonabarraga, I; Desplat, JC; Cates, ME			Colloidal jamming at interfaces: A route to fluid-bicontinuous gels	SCIENCE			English	Article							SPINODAL DECOMPOSITION; BINARY; DYNAMICS	Colloidal particles or nanoparticles, with equal affinity for two fluids, are known to adsorb irreversibly to the fluid-fluid interface. We present large-scale computer simulations of the demixing of a binary solvent containing such particles. The newly formed interface sequesters the colloidal particles; as the interface coarsens, the particles are forced into close contact by interfacial tension. Coarsening is markedly curtailed, and the jammed colloidal layer seemingly enters a glassy state, creating a multiply connected, solidlike film in three dimensions. The resulting gel contains percolating domains of both fluids, with possible uses as, for example, a microreaction medium.	Univ Edinburgh, Sch Phys, SUPA, Edinburgh EH9 3JZ, Midlothian, Scotland; Univ Edinburgh, Sch Phys, EPCC, Edinburgh EH9 3JZ, Midlothian, Scotland; Univ Barcelona, Dept Fis Fonamental, E-08028 Barcelona, Spain; Dublin Inst Adv Studies, Irish Ctr High End Comp, Dublin 2, Ireland	University of Edinburgh; University of Edinburgh; University of Barcelona; Dublin Institute for Advanced Studies	Cates, ME (corresponding author), Univ Edinburgh, Sch Phys, SUPA, James Clerk Maxwell Bldg,Kings Bldg, Edinburgh EH9 3JZ, Midlothian, Scotland.	m.e.cates@ed.ac.uk	Adhikari, Ronojoy/B-7157-2011; Pagonabarraga, Ignacio/A-8867-2010	Pagonabarraga, Ignacio/0000-0002-6187-5025	Engineering and Physical Sciences Research Council [GR/S10377/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Adhikari R, 2005, EUROPHYS LETT, V71, P473, DOI 10.1209/epl/i2004-10542-5; Anderson VJ, 2002, NATURE, V416, P811, DOI 10.1038/416811a; Anderson VJ, 2001, EUR PHYS J E, V4, P11, DOI 10.1007/PL00013680; Arditty S, 2004, J COLLOID INTERF SCI, V275, P659, DOI 10.1016/j.jcis.2004.03.001; Aveyard R, 2003, ADV COLLOID INTERFAC, V100, P503, DOI 10.1016/S0001-8686(02)00069-6; Beysens D, 1999, J STAT PHYS, V95, P997, DOI 10.1023/A:1004506601807; BRAY AJ, 1994, ADV PHYS, V43, P357, DOI 10.1080/00018739400101505; Cates ME, 2004, J PHYS-CONDENS MAT, V16, pS3903, DOI 10.1088/0953-8984/16/38/009; CLEGG PS, UNPUB; Desplat JC, 2001, COMPUT PHYS COMMUN, V134, P273, DOI 10.1016/S0010-4655(00)00205-8; Dinsmore AD, 2002, SCIENCE, V298, P1006, DOI 10.1126/science.1074868; Donev A, 2005, J COMPUT PHYS, V202, P737, DOI 10.1016/j.jcp.2004.08.014; Imhof A, 1997, NATURE, V389, P948, DOI 10.1038/40105; Kendon VM, 2001, J FLUID MECH, V440, P147, DOI 10.1017/S0022112001004682; LADD AJC, 1994, J FLUID MECH, V271, P285, DOI 10.1017/S0022112094001771; Liu AJ, 1998, NATURE, V396, P21, DOI 10.1038/23819; LUISI PL, 1988, BIOCHIM BIOPHYS ACTA, V947, P209, DOI 10.1016/0304-4157(88)90025-1; Manoharan VN, 2003, SCIENCE, V301, P483, DOI 10.1126/science.1086189; Nguyen NQ, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.046708; Peng GW, 2000, SCIENCE, V288, P1802, DOI 10.1126/science.288.5472.1802; Pham KN, 2002, SCIENCE, V296, P104, DOI 10.1126/science.1068238; Poon WCK, 1999, PHYS REV LETT, V83, P1239, DOI 10.1103/PhysRevLett.83.1239; Poulin P, 1997, SCIENCE, V275, P1770, DOI 10.1126/science.275.5307.1770; Russel WB, 1999, COLLOIDAL DISPERSION; Safran S. A., 1994, STAT THERMODYNAMICS; SIGGIA ED, 1979, PHYS REV A, V20, P595, DOI 10.1103/PhysRevA.20.595; STRATFORD K, IN PRESS J STAT PHYS; Whitesides GM, 2002, SCIENCE, V295, P2418, DOI 10.1126/science.1070821; 0417437; 0414829	30	398	405	11	204	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	2005	309	5744					2198	2201		10.1126/science.1116589	http://dx.doi.org/10.1126/science.1116589			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195456	Green Submitted			2022-12-28	WOS:000232318000038
J	Allen, JT; Brown, L; Sanders, R; Moore, CM; Mustard, A; Fielding, S; Lucas, M; Rixen, M; Savidge, G; Henson, S; Mayor, D				Allen, JT; Brown, L; Sanders, R; Moore, CM; Mustard, A; Fielding, S; Lucas, M; Rixen, M; Savidge, G; Henson, S; Mayor, D			Diatom carbon export enhanced by silicate upwelling in the northeast Atlantic	NATURE			English	Article							ALMERIA-ORAN FRONT; MESOSCALE SUBDUCTION; PHYTOPLANKTON; BLOOM; NUTRIENTS; OCEAN; JUNE	Diatoms are unicellular or chain-forming phytoplankton that use silicon ( Si) in cell wall construction. Their survival during periods of apparent nutrient exhaustion enhances carbon sequestration in frontal regions of the northern North Atlantic. These regions may therefore have a more important role in the 'biological pump' than they have previously been attributed(1), but how this is achieved is unknown. Diatom growth depends on silicate availability, in addition to nitrate and phosphate(2,3), but northern Atlantic waters are richer in nitrate than silicate(4). Following the spring stratification, diatoms are the first phytoplankton to bloom(2,5). Once silicate is exhausted, diatom blooms subside in a major export event(6,7). Here we show that, with nitrate still available for new production, the diatom bloom is prolonged where there is a periodic supply of new silicate: specifically, diatoms thrive by 'mining' deep-water silicate brought to the surface by an unstable ocean front. The mechanism we present here is not limited to silicate fertilization; similar mechanisms could support nitrate-,phosphate- or iron-limited frontal regions in oceans elsewhere.	Natl Oceanog Ctr, Southampton SO14 3ZH, Hants, England; N Highland Coll, UHI Millenium Inst, Environm Res Inst, Thurso KW14 7JD, Caithness, Scotland; Univ St Andrews, Sch Geog & Geosci, St Andrews KY16 9AJ, Fife, Scotland; NATO Undersea Res Ctr, I-19138 La Spezia, Italy; Queens Univ Belfast, Marine Lab, Portaferry BT22 1PF, North Ireland	NERC National Oceanography Centre; UHI Millennium Institute; University of St Andrews; NATO (North Atlantic Treaty Organisation); Queens University Belfast	Allen, JT (corresponding author), Natl Oceanog Ctr, Southampton SO14 3ZH, Hants, England.	jta@noc.soton.ac.uk	Allen, John Taylor/AHB-3419-2022; Mayor, Daniel/HDN-8520-2022; Henson, Stephanie/AAC-9709-2019; Sanders, Richard J/B-8717-2012; Fielding, Sophie/E-5137-2012	Allen, John Taylor/0000-0001-7357-6623; Mayor, Daniel/0000-0002-1295-0041; Sanders, Richard J/0000-0002-6884-7131; Fielding, Sophie/0000-0002-3152-4742; Moore, Mark/0000-0002-9541-6046				Allen J, 2002, SEA TECHNOL, V43, P35; ALLEN JT, 1994, DEEP-SEA RES PT I, V41, P51, DOI 10.1016/0967-0637(94)90026-4; Allen JT, 1996, J PHYS OCEANOGR, V26, P2611, DOI 10.1175/1520-0485(1996)026<2611:PVAVVA>2.0.CO;2; Allen JT, 2001, J MARINE SYST, V30, P263, DOI 10.1016/S0924-7963(01)00062-8; ALLEN JT, 2001, RRS DISCOVERY CRUISE; Brown L, 2003, LIMNOL OCEANOGR, V48, P1831, DOI 10.4319/lo.2003.48.5.1831; Brzezinski MA, 1998, MAR ECOL PROG SER, V167, P89, DOI 10.3354/meps167089; Brzezinski MA, 1997, LIMNOL OCEANOGR, V42, P856, DOI 10.4319/lo.1997.42.5.0856; DUCKLOW HW, 1993, DEEP-SEA RES PT II, V40, P1, DOI 10.1016/0967-0645(93)90003-6; Dugdale RC, 1998, NATURE, V391, P270, DOI 10.1038/34630; DUGDALE RC, 1995, DEEP-SEA RES PT I, V42, P697, DOI 10.1016/0967-0637(95)00015-X; EGGE JK, 1992, MAR ECOL PROG SER, V83, P281, DOI 10.3354/meps083281; Fielding S, 2001, J MARINE SYST, V30, P287, DOI 10.1016/S0924-7963(01)00063-X; Garabato ACN, 2002, DEEP-SEA RES PT II, V49, P3771; HONJO S, 1993, DEEP-SEA RES PT II, V40, P587, DOI 10.1016/0967-0645(93)90034-K; Koeve W, 2001, MAR CHEM, V74, P245, DOI 10.1016/S0304-4203(01)00016-0; Levy M, 2001, J MAR RES, V59, P535, DOI 10.1357/002224001762842181; Longhurst, 2006, ECOLOGICAL GEOGRAPHY; Louanchi F, 2001, DEEP-SEA RES PT II, V48, P2155, DOI 10.1016/S0967-0645(00)00185-5; Lovejoy C, 2002, AQUAT MICROB ECOL, V29, P267, DOI 10.3354/ame029267; Martin-Jezequel V, 2000, J PHYCOL, V36, P821, DOI 10.1046/j.1529-8817.2000.00019.x; Moore CM, 2005, DEEP-SEA RES PT I, V52, P401, DOI 10.1016/j.dsr.2004.09.003; Munk W, 2000, P ROY SOC A-MATH PHY, V456, P1217, DOI 10.1098/rspa.2000.0560; SAVIDGE G, 1995, DEEP-SEA RES PT I, V42, P599, DOI 10.1016/0967-0637(95)00016-Y; Shearman RK, 1999, J PHYS OCEANOGR, V29, P651, DOI 10.1175/1520-0485(1999)029<0651:DOTTDC>2.0.CO;2; SIERACKI ME, 1993, DEEP-SEA RES PT II, V40, P213, DOI 10.1016/0967-0645(93)90014-E; STRASS VH, 1992, DEEP-SEA RES, V39, P75, DOI 10.1016/0198-0149(92)90021-K; Sverdrup H.U., 1953, J CONSEILCONSEIL PER, V18, P287, DOI [10.1093/icesjms/18.3.287, DOI 10.1093/ICESJMS/18.3.287]; Yallop ML, 2001, DEEP-SEA RES PT II, V48, P825, DOI 10.1016/S0967-0645(00)00099-0; Yool A, 2003, GLOBAL BIOGEOCHEM CY, V17, DOI 10.1029/2002GB002018	30	131	136	7	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					728	732		10.1038/nature03948	http://dx.doi.org/10.1038/nature03948			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193051				2022-12-28	WOS:000232157900051
J	Griffith, S; Goldwater, D; Jacobson, JM				Griffith, S; Goldwater, D; Jacobson, JM			Robotics - Self-replication from random parts	NATURE			English	Editorial Material									MIT, Media Lab, Ctr Bits & Atoms, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Griffith, S (corresponding author), MIT, Media Lab, Ctr Bits & Atoms, Cambridge, MA 02139 USA.	jacobson@media.mit.edu		Jacobson, Joseph/0000-0002-1332-3197				Alberts B, 2001, MOL BIOL CELL; BANKS ER, 1971, THESIS MIT; Griffith S., 2004, THESIS MIT; JACOBSON H, 1958, AM SCI, V46, P255; Merkle R. C, 2004, KINEMATIC SELF REPLI; Neumann J.V.A.W., 1966, THEORY SELF REPRODUC; PENROSE LS, 1957, NATURE, V179, P1183, DOI 10.1038/1791183a0; PENROSE LS, 1961, AUTOMATIC MECH SELF; Suthakorn J., 2003, P 2003 IEEE ASME INT; Zykov V, 2005, NATURE, V435, P163, DOI 10.1038/435163a	10	98	98	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					636	636		10.1038/437636a	http://dx.doi.org/10.1038/437636a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193036	Bronze			2022-12-28	WOS:000232157900035
J	Noren, T				Noren, T			Outbreak from a high-toxin intruder: Clostridium difficile	LANCET			English	Editorial Material							DIARRHEA; EPIDEMIOLOGY		Orebro Univ Hosp, Dept Infect Dis, S-70185 Orebro, Sweden; Univ Orebro, Dept Clin Med, S-70185 Orebro, Sweden	Orebro University; Orebro University	Noren, T (corresponding author), Orebro Univ Hosp, Dept Infect Dis, S-70185 Orebro, Sweden.	torbjorn.noren@orebroll.se						Brazier JS, 2001, CLIN MICROBIOL INFEC, V7, P428, DOI 10.1046/j.1198-743x.2001.00288.x; Bricker E, 2005, COCHRANE DB SYST REV, DOI 10.1002/1461858.CD004610.pub2; DAVIDSON D, 2004, 14 EUR C CLIN MICR I; Djuretic T, 1999, J HOSP INFECT, V41, P213, DOI 10.1016/S0195-6701(99)90018-X; Giannasca PJ, 2004, VACCINE, V22, P848, DOI 10.1016/j.vaccine.2003.11.030; Karlstrom O, 1998, CLIN INFECT DIS, V26, P141, DOI 10.1086/516277; Musher DM, 2005, CLIN INFECT DIS, V40, P1586, DOI 10.1086/430311; Noren T, 2004, J CLIN MICROBIOL, V42, P3635, DOI [10.1128/JCM.42.8.3635-3643.2004, 10.1128/jcm.42.8.3635-3643.2004]; Pelaez T, 2002, ANTIMICROB AGENTS CH, V46, P1647, DOI 10.1128/AAC.46.6.1647-1650.2002; Pepin J, 2004, CAN MED ASSOC J, V171, P466, DOI 10.1503/cmaj.1041104; Thomas C, 2003, J ANTIMICROB CHEMOTH, V51, P1339, DOI 10.1093/jac/dkg254; Thomas C, 2002, CLIN INFECT DIS, V35, P1457, DOI 10.1086/342691; Warny M, 2005, LANCET, V366, P1079, DOI 10.1016/S0140-6736(05)67420-X	13	12	12	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 24	2005	366	9491					1053	1054		10.1016/S0140-6736(05)67400-4	http://dx.doi.org/10.1016/S0140-6736(05)67400-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TL	16182878				2022-12-28	WOS:000232114000004
J	Warny, M; Pepin, J; Fang, A; Killgore, G; Thompson, A; Brazier, J; Frost, E; McDonald, LC				Warny, M; Pepin, J; Fang, A; Killgore, G; Thompson, A; Brazier, J; Frost, E; McDonald, LC			Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe	LANCET			English	Article							BINARY TOXIN; ADP-RIBOSYLTRANSFERASE; PATHOGENICITY LOCUS; GENES; TOXINOTYPES; POLYMORPHISM	Background Toxins A and B are the primary virulence factors of Clostridium difficile. Since 2002, an epidemic of C difficile-associated disease with increased morbidity and mortality has been present in Quebec province, Canada. We characterised the dominant strain of this epidemic to determine whether it produces higher amounts of toxins A and B than those produced by non-epidemic strains. Methods We obtained isolates from 124 patients from Centre Hospitalier Universitaire de Sherbrooke in Quebec. Additional isolates from the USA, Canada, and the UK were included to increase the genetic diversity of the toxinotypes tested. Isolate characterisation included toxinotyping, pulsed-field gel electrophoresis (PFGE), PCR ribotyping, detection of a binary toxin gene, and detection of deletions in a putative negative regulator for toxins A and B (tcdC). By use of an enzyme-linked immunoassay, we measured the in-vitro production of toxins A and B by epidemic strain and non-dominant strain isolates. Findings The epidemic strain was characterised as toxinotype III, North American PFGE type 1, and PCR-ribotype 027 (NAP1/027). This strain carried the binary toxin gene cdtB and an 18-bp deletion in tcdC. We isolated this strain from 72 patients with C difficile-associated disease (58 [67%] of 86 with health-care-associated disease; 14 [37%] of 38 with community-acquired disease). Peak median (IQR) toxin A and toxin B concentrations produced in vitro by NAP1/027 were 16 and 23 times higher, respectively, than those measured in isolates representing 12 different PFGE types, known as toxinotype 0 (toxin A, median 848 mu g/L [IQR 504-10221 vs 54 mu g/L [23-203]; toxin B, 180 mu g/L [137-210] vs 8 mu g/L [5-25]; p< 0.0001 for both toxins). Interpretation The severity of C difficile-associated disease caused by NAP1/027 could result from hyperproduction of toxins A and B. Dissemination of this strain in North America and Europe could lead to important changes in the epidemiology of C difficile-associated disease.	Acambis Inc, Cambridge, MA 02139 USA; Univ Sherbrooke, Sherbrooke, PQ J1K 2R1, Canada; Ctr Dis Control & Prevent, Atlanta, GA USA; Microbiol Cardiff Univ Hosp Wales, Natl Publ Hlth Serv Wales, Anaerobe Reference Lab, Cardiff, S Glam, Wales	Sanofi-Aventis; University of Sherbrooke; Centers for Disease Control & Prevention - USA	Warny, M (corresponding author), Acambis Inc, Cambridge, MA 02139 USA.	michel.warny@acambis.com		McDonald, L. Clifford/0000-0003-3044-5572; Frost, Eric/0000-0001-8958-4388				Barbut F, 2005, J MED MICROBIOL, V54, P181, DOI 10.1099/jmm.0.45804-0; BOYCE JM, 2005, P 15 ANN SCI M SOC H; Eggertson L, 2004, CAN MED ASSOC J, V171, P1331, DOI 10.1503/cmaj.1041694; EHRICH M, 1980, INFECT IMMUN, V28, P1041; Geric B, 2003, J CLIN MICROBIOL, V41, P5227, DOI 10.1128/JCM.41.11.5227-5232.2003; Geric B, 2004, J MED MICROBIOL, V53, P887, DOI 10.1099/jmm.0.45610-0; Goncalves C, 2004, J CLIN MICROBIOL, V42, P1933, DOI 10.1128/JCM.42.5.1933-1939.2004; *HLTH PROT AG, 2005, CDR WEEKLY, V15, P1; Hundsberger T, 1997, EUR J BIOCHEM, V244, P735, DOI 10.1111/j.1432-1033.1997.t01-1-00735.x; Institut National de Sante Publique du Quebec, 2011, SURV DIARRH ASS CLOS; Johnson S, 2003, J CLIN MICROBIOL, V41, P1543, DOI 10.1128/JCM.41.4.1543-1547.2003; Klaassen CHW, 2002, J CLIN MICROBIOL, V40, P101, DOI 10.1128/JCM.40.1.101-104.2002; Linder JA, 2005, AM J MED, V118, P259, DOI 10.1016/j.amjmed.2004.09.015; MARLER LM, 1992, J CLIN MICROBIOL, V30, P514, DOI 10.1128/JCM.30.2.514-516.1992; MCDONALD LC, 2004, P 42 ANN M INF DIS S; McEllistrem MC, 2005, CLIN INFECT DIS, V40, P265, DOI 10.1086/427113; PATEL S, 2005, P 15 ANN SCI M SOC H; Pepin J, 2005, CLIN INFECT DIS, V40, P1591, DOI 10.1086/430315; Pepin J, 2004, CAN MED ASSOC J, V171, P466, DOI 10.1503/cmaj.1041104; PEPIN J, IN PRESS CLIN INFECT; PEPIN J, IN PRESS CMAJ; POPOFF MR, 1988, INFECT IMMUN, V56, P2299, DOI 10.1128/IAI.56.9.2299-2306.1988; RIEGLER M, 1995, J CLIN INVEST, V95, P2004, DOI 10.1172/JCI117885; Rupnik M, 1998, J CLIN MICROBIOL, V36, P2240, DOI 10.1128/JCM.36.8.2240-2247.1998; Rupnik M, 2001, MICROBIOL-UK, V147, P439, DOI 10.1099/00221287-147-2-439; Spigaglia P, 2002, J CLIN MICROBIOL, V40, P3470, DOI 10.1128/JCM.40.9.3470-3475.2002; Stubbs S, 2000, FEMS MICROBIOL LETT, V186, P307, DOI 10.1016/S0378-1097(00)00162-2; VANSTEENBERGEN J, ISOLATION CLOSTRIDIU; Warny M, 2003, MICROBIAL PATHOGENESIS AND THE INTESTINAL EPITHELIAL CELL, P503; WREN B, 1987, J CLIN PATHOL, V40, P1397, DOI 10.1136/jcp.40.12.1397; RESULTS 1 YEAR MANDA	31	1085	1141	1	60	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 24	2005	366	9491					1079	1084		10.1016/S0140-6736(05)67420-X	http://dx.doi.org/10.1016/S0140-6736(05)67420-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TL	16182895				2022-12-28	WOS:000232114000025
J	Hung, DT; Shakhnovich, EA; Pierson, E; Mekalanos, JJ				Hung, DT; Shakhnovich, EA; Pierson, E; Mekalanos, JJ			Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVATORS; PSEUDOMONAS-AERUGINOSA; EXPRESSION; GENES; TOXR; INFECTION; CASCADE	Increasing antibiotic resistance requires the development of new approaches to combating infection. Virulence gene expression in vivo represents a target for antibiotic discovery that has not yet been explored. A high-throughput, phenotypic screen was used to identify a small molecule 4-[N-(1,8-naphthalimide)]-n-butyric acid, virstatin, that inhibits virulence regulation in Vibrio cholerae. By inhibiting the transcriptional regulator ToxT, virstatin prevents expression of two critical V. cholerae virulence factors, cholera toxin and the toxin coregulated. pilus. Orogastric administration. of virstatin protects infant mice from intestinal colonization by V. cholerae.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Hung, DT (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	dhung@partners.org			NIAID NIH HHS [AI26289, K08 AI060708-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI060708, R01AI026289] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753; Angelichio MJ, 1999, INFECT IMMUN, V67, P3733, DOI 10.1128/IAI.67.8.3733-3739.1999; Bina J, 2003, P NATL ACAD SCI USA, V100, P2801, DOI 10.1073/pnas.2628026100; Blatny JM, 1997, PLASMID, V38, P35, DOI 10.1006/plas.1997.1294; BROWN RC, 1995, MOL MICROBIOL, V16, P425, DOI 10.1111/j.1365-2958.1995.tb02408.x; Champion GA, 1997, MOL MICROBIOL, V23, P323, DOI 10.1046/j.1365-2958.1997.2191585.x; DIRITA VJ, 1992, MOL MICROBIOL, V6, P451, DOI 10.1111/j.1365-2958.1992.tb01489.x; Hentzer M, 2003, EMBO J, V22, P3803, DOI 10.1093/emboj/cdg366; HIGGINS DE, 1992, J BACTERIOL, V174, P6974, DOI 10.1128/JB.174.21.6974-6980.1992; Kauppi AM, 2003, CHEM BIOL, V10, P241, DOI 10.1016/S1074-5521(03)00046-2; Krukonis ES, 2000, MOL MICROBIOL, V38, P67, DOI 10.1046/j.1365-2958.2000.02111.x; Lee SH, 1999, CELL, V99, P625, DOI 10.1016/S0092-8674(00)81551-2; RABBANI GH, 1989, ANTIMICROB AGENTS CH, V33, P1447, DOI 10.1128/AAC.33.9.1447; ROYCHOUDHURY S, 1993, P NATL ACAD SCI USA, V90, P965, DOI 10.1073/pnas.90.3.965; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; Turk BE, 2004, NAT STRUCT MOL BIOL, V11, P60, DOI 10.1038/nsmb708; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; Waldor MK., 1996, ENTERIC INFECT IMMUN, P37, DOI [10.1007/978-1-4899-0313-6_3, DOI 10.1007/978-1-4899-0313-6_3]; Wright JS, 2005, P NATL ACAD SCI USA, V102, P1691, DOI 10.1073/pnas.0407661102	19	276	291	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 28	2005	310	5748					670	674		10.1126/science.1116739	http://dx.doi.org/10.1126/science.1116739			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	980ET	16223984				2022-12-28	WOS:000232997700040
J	Andolfatto, P				Andolfatto, P			Adaptive evolution of non-coding DNA in Drosophila	NATURE			English	Article							BACKGROUND SELECTION; MOLECULAR EVOLUTION; PROTEIN EVOLUTION; PATTERNS; MELANOGASTER; SEQUENCE; GENE; CONSTRAINTS; GENOMES	A large fraction of eukaryotic genomes consists of DNA that is not translated into protein sequence, and little is known about its functional significance. Here I show that several classes of non-coding DNA in Drosophila are evolving considerably slower than synonymous sites, and yet show an excess of between-species divergence relative to polymorphism when compared with synonymous sites. The former is a hallmark of selective constraint, but the latter is a signature of adaptive evolution, resembling general patterns of protein evolution in Drosophila(1,2). I estimate that about 40-70% of nucleotides in intergenic regions, untranslated portions of mature mRNAs ( UTRs) and most intronic DNA are evolutionarily constrained relative to synonymous sites. However, I also use an extension to the McDonald-Kreitman test(3) to show that a substantial fraction of the nucleotide divergence in these regions was driven to fixation by positive selection (about 20% for most intronic and intergenic DNA, and 60% for UTRs). On the basis of these observations, I suggest that a large fraction of the non-translated genome is functionally important and subject to both purifying selection and adaptive evolution. These results imply that, although positive selection is clearly an important facet of protein evolution, adaptive changes to non-coding DNA might have been considerably more common in the evolution of D. melanogaster.	Univ Calif San Diego, Div Biol Sci, Sect Ecol Behav & Evolut, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Andolfatto, P (corresponding author), Univ Calif San Diego, Div Biol Sci, Sect Ecol Behav & Evolut, La Jolla, CA 92093 USA.	pandolfatto@ucsd.edu		Andolfatto, Peter/0000-0003-3393-4574				Bachtrog D, 2005, GENOME RES, V15, P1393, DOI 10.1101/gr.3543605; Bergman CM, 2001, GENOME RES, V11, P1335, DOI 10.1101/gr.178701; Bustamante CD, 2002, NATURE, V416, P531, DOI 10.1038/416531a; Carroll S. B., 2001, DNA DIVERSITY MOL GE; Charlesworth B, 1996, GENET RES, V68, P131, DOI 10.1017/S0016672300034029; CHARLESWORTH B, 1994, GENET RES, V63, P213, DOI 10.1017/S0016672300032365; Clark AG, 2001, GENOME RES, V11, P1319, DOI 10.1101/gr.201601; Cliften PF, 2001, GENOME RES, V11, P1175, DOI 10.1101/gr.182901; Fay JC, 2002, NATURE, V415, P1024, DOI 10.1038/4151024a; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Glinka S, 2003, GENETICS, V165, P1269; Haddrill PR, 2005, GENOME RES, V15, P790, DOI 10.1101/gr.3541005; Haddrill PR, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r67; Halligan DL, 2004, GENOME RES, V14, P273, DOI 10.1101/gr.1329204; HUDSON RR, 1987, GENETICS, V116, P153; Jareborg N, 1999, GENOME RES, V9, P815, DOI 10.1101/gr.9.9.815; Kimura M., 1983, NEUTRAL THEORY MOL E; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Li W. H, 1997, MOL EVOLUTION; Ludwig MZ, 2005, PLOS BIOL, V3, P588, DOI 10.1371/journal.pbio.0030093; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Miller W, 2004, ANNU REV GENOM HUM G, V5, P15, DOI 10.1146/annurev.genom.5.061903.180057; MISRA S, 2002, GENOME BIOL, V3, P83, DOI [DOI 10.1186/GB-2002-3-12-RESEARCH0083, 10.1186/gb-2002-3-12-research0083]; Richards S, 2005, GENOME RES, V15, P1, DOI 10.1101/gr.3059305; Shabalina SA, 1999, GENET RES, V74, P23, DOI 10.1017/S0016672399003821; Smith NGC, 2002, NATURE, V415, P1022, DOI 10.1038/4151022a; TAJIMA F, 1989, GENETICS, V123, P585; Templeton AR, 1996, GENETICS, V144, P1263; Yu J, 2002, GENOME RES, V12, P1185, DOI 10.1101/gr.224602	29	479	484	1	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 20	2005	437	7062					1149	1152		10.1038/nature04107	http://dx.doi.org/10.1038/nature04107			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975KD	16237443				2022-12-28	WOS:000232660500043
J	Holmes, WC; Sammel, MD				Holmes, WC; Sammel, MD			Brief communication: Physical abuse of boys and possible associations with poor adult outcomes	ANNALS OF INTERNAL MEDICINE			English	Article							PARTNER VIOLENCE; CHILDHOOD ABUSE; SEXUAL-ABUSE; WOMEN; INSTRUMENT; VALIDITY; DISORDER; HEALTH	Background: men's childhood physical abuse experiences are understudied. Objective: To obtain descriptions about men's personal childhood physical abuse histories and estimate their association with adult outcomes. Design: Population-based telephone survey. Setting: urban areas with high frequency of domestic violence against girls and women. Participants: 298 men recruited through random-digit dialing. Measurements: 6 Conflict Tactics Scale items and psychiatric, sexual, and legal history questions. Results: One hundred of 197 (51%) participants had a history of childhood physical abuse. Most (73%) participants were abused by a parent. Childhood physical abuse history was associated with depression symptoms (P = 0.003), post-traumatic stress disorder symptoms (P < 0.001), number of lifetime sexual partners (P = 0.035), legal troubles (P = 0.002), and incarceration (P = 0.007) in unadjusted analyses and with depression symptoms (P = 0.015) and post-traumatic stress disorder symptoms (P = 0.003) in adjusted analyses. Limitations: There may have been inaccurate recall of past events. Lack of exposure time data disallowed direct comparison of abuse perpetration by mothers versus fathers. Other unmeasured variables related to childhood physical abuse might better explain poor adult outcomes. Conclusions: The high frequency of childhood physical abuse histories in this population-based male sample, coupled with the high proportion of parent perpetrators and the association between childhood physical abuse and adult outcomes that are often associated with perpetration of violence, argues for more study of and clinical attentiveness to potential adult outcomes of men's own childhood physical abuse histories.	Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Vet Affairs Med Ctr, Philadelphia, PA USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Holmes, WC (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 733 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	holmeswc@mail.med.upenn.edu		Sammel, Mary/0000-0003-1248-4199	NATIONAL INSTITUTE ON DRUG ABUSE [R03DA015635] Funding Source: NIH RePORTER; NIDA NIH HHS [DA015635] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Cohen M, 2000, AM J PUBLIC HEALTH, V90, P560, DOI 10.2105/AJPH.90.4.560; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1007/BF00974317; Halpern CT, 2001, AM J PUBLIC HEALTH, V91, P1679, DOI 10.2105/AJPH.91.10.1679; Koziol-McLain J, 2001, AM J PREV MED, V21, P93, DOI 10.1016/S0749-3797(01)00325-7; MacMillan HL, 1997, JAMA-J AM MED ASSOC, V278, P131, DOI 10.1001/jama.278.2.131; MALINOSKYRUMMELL R, 1993, PSYCHOL BULL, V114, P68, DOI 10.1037/0033-2909.114.1.68; Miller PM, 1999, J INTERPERS VIOLENCE, V14, P642, DOI 10.1177/088626099014006005; Nelson HD, 2004, ANN INTERN MED, V140, P387, DOI 10.7326/0003-4819-140-5-200403020-00015; PARKER G, 1979, BRIT J MED PSYCHOL, V52, P1, DOI 10.1111/j.2044-8341.1979.tb02487.x; *PHIL DEP PUBL HLT, 2000, AIDS SURV Q UPD, P16; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rosen LN, 1996, MIL MED, V161, P342, DOI 10.1093/milmed/161.6.342; Rosen LN, 1998, CHILD ABUSE NEGLECT, V22, P197, DOI 10.1016/S0145-2134(97)00171-3; Shira JE, 1998, PEDIATRICS, V101, P715; SPENCE JT, 1979, J PERS SOC PSYCHOL, V37, P1673, DOI 10.1037/0022-3514.37.10.1673; Straus M.A., 1997, OUT DARKNESS CONT PE, P119; *US DEP HHS, 2002, CHILD MALTR 2000; WARSHAW C, 1996, IMPROVING HLTH CARE; 1990, PHYS VIOLENCE AM FAM, P49	20	24	27	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 18	2005	143	8					581	586		10.7326/0003-4819-143-8-200510180-00008	http://dx.doi.org/10.7326/0003-4819-143-8-200510180-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975PI	16230724				2022-12-28	WOS:000232674000008
J	Gneiting, T; Raftery, AE				Gneiting, T; Raftery, AE			Atmospheric science - Weather forecasting with ensemble methods	SCIENCE			English	Editorial Material							PREDICTION SYSTEM; ECMWF; MESOSCALE		Univ Washington, Dept Stat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Gneiting, T (corresponding author), Univ Washington, Dept Stat, Box 354322, Seattle, WA 98195 USA.	tilmann@stat.washington.edu	Gneiting, Tilmann/A-8773-2009	Gneiting, Tilmann/0000-0001-9397-3271				Buizza R, 1999, Q J ROY METEOR SOC, V125, P2887, DOI 10.1256/smsqj.56005; Buizza R, 2005, MON WEATHER REV, V133, P1076, DOI 10.1175/MWR2905.1; de Elia R, 2005, MON WEATHER REV, V133, P1129, DOI 10.1175/MWR2913.1; Eckel FA, 2005, WEATHER FORECAST, V20, P328, DOI 10.1175/WAF843.1; EVENSEN G, 1994, J GEOPHYS RES-OCEANS, V99, P10143, DOI 10.1029/94JC00572; Grimit EP, 2002, WEATHER FORECAST, V17, P192, DOI 10.1175/1520-0434(2002)017<0192:IROAMS>2.0.CO;2; Houtekamer PL, 1996, MON WEATHER REV, V124, P1225, DOI 10.1175/1520-0493(1996)124<1225:ASSATE>2.0.CO;2; JOTLIFFE IT, 2004, FORECAST VERIFICATIO; Molteni F, 1996, Q J ROY METEOR SOC, V122, P73, DOI 10.1002/qj.49712252905; Palmer T, 2005, TELLUS A, V57, P217, DOI 10.1111/j.1600-0870.2005.00129.x; Palmer TN, 2002, Q J ROY METEOR SOC, V128, P747, DOI 10.1256/0035900021643593; Palmer TN, 2004, B AM METEOROL SOC, V85, P853, DOI 10.1175/BAMS-85-6-853; Raftery AE, 2005, MON WEATHER REV, V133, P1155, DOI 10.1175/MWR2906.1; TOTH Z, 1993, B AM METEOROL SOC, V74, P2317, DOI 10.1175/1520-0477(1993)074<2317:EFANTG>2.0.CO;2	14	337	349	3	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					248	249		10.1126/science.1115255	http://dx.doi.org/10.1126/science.1115255			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224011				2022-12-28	WOS:000232670100034
J	Teo, KBK; Minoux, E; Hudanski, L; Peauger, F; Schnell, JP; Gangloff, L; Legagneux, P; Dieumegard, D; Amaratunga, GAJ; Milne, WI				Teo, KBK; Minoux, E; Hudanski, L; Peauger, F; Schnell, JP; Gangloff, L; Legagneux, P; Dieumegard, D; Amaratunga, GAJ; Milne, WI			Microwave devices - Carbon nanotubes as cold cathodes	NATURE			English	Editorial Material									Univ Cambridge, Dept Engn, Cambridge CB2 1PZ, England; Thales Res & Technol, F-91767 Palaiseau, France; Thales Electron Devices, F-78141 Velizy Villacoublay, France	University of Cambridge; Thales Group; Thales Group	Teo, KBK (corresponding author), Univ Cambridge, Dept Engn, Cambridge CB2 1PZ, England.	wim@eng.cam.ac.uk						de Jonge N, 2004, PHILOS T R SOC A, V362, P2239, DOI 10.1098/rsta.2004.1438; Nilsson L, 2000, APPL PHYS LETT, V76, P2071, DOI 10.1063/1.126258; Teo KBK, 2003, NANOTECHNOLOGY, V14, P204, DOI 10.1088/0957-4484/14/2/321	3	393	419	10	134	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	2005	437	7061					968	968		10.1038/437968a	http://dx.doi.org/10.1038/437968a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16222290				2022-12-28	WOS:000232496100033
J	Aylin, P; Williams, S; Jarman, B; Bottle, A				Aylin, P; Williams, S; Jarman, B; Bottle, A			Dr Foster's case notes - Trends in day surgery rates	BRITISH MEDICAL JOURNAL			English	Article									Univ London Imperial Coll Sci & Technol, Dr Foster Unit, London, England	Imperial College London	Aylin, P (corresponding author), Univ London Imperial Coll Sci & Technol, Dr Foster Unit, London, England.		Aylin, Paul/A-1073-2014	Aylin, Paul/0000-0003-4589-1743; Bottle, Alex/0000-0001-9978-2011					0	25	25	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 8	2005	331	7520					803	+		10.1136/bmj.331.7520.803	http://dx.doi.org/10.1136/bmj.331.7520.803			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974BC	16210281	Green Published			2022-12-28	WOS:000232565300016
J	Breckenridge, A; Woods, K				Breckenridge, A; Woods, K			Medicines regulation and the pharmaceutical industry	BRITISH MEDICAL JOURNAL			English	Editorial Material									Med & Healthcare Prod Regulatory Agcy, London SW8 5NQ, England	The Medicines & Healthcare Products Regulatory Agency	Breckenridge, A (corresponding author), Med & Healthcare Prod Regulatory Agcy, London SW8 5NQ, England.	alasdair.breckenridge@mhra.gsi.gov.uk						*HOUS COMM HLTH CO, 2005, 4 HOUS COMM HLTH COM; *MED HEALTHC PROD, 2004, CURRENT PROBLEMS PHA, V30, P4; National Audit Office, 2003, SAF QUAL EFF REG MED	3	7	7	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 8	2005	331	7520					834	836		10.1136/bmj.331.7520.834	http://dx.doi.org/10.1136/bmj.331.7520.834			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974BC	16210285	Green Published			2022-12-28	WOS:000232565300027
J	Khan, SA; Thomas, HC; Davidson, BR; Taylor-Robinson, SD				Khan, SA; Thomas, HC; Davidson, BR; Taylor-Robinson, SD			Cholangiocarcinoma	LANCET			English	Review							PRIMARY SCLEROSING CHOLANGITIS; INTRAHEPATIC PERIPHERAL CHOLANGIOCARCINOMA; MALIGNANT HILAR OBSTRUCTION; BILIARY-TRACT CARCINOMA; BILE-DUCT CARCINOMA; PHASE-II; LIVER-CANCER; HEPATITIS-C; CHOLANGIOCELLULAR CARCINOMA; POSTOPERATIVE RADIOTHERAPY	Cholangiocarcinoma is a devastating malignancy that presents late, is notoriously difficult to diagnose, and is associated with a high mortality. The incidence of intrahepatic cholangiocarcinoma is increasing worldwide. The cause for this rise is unclear, although it could be related to an interplay between predisposing genetic factors and environmental triggers. MRI and CT with endoscopic ultrasound and PET provide useful diagnostic information in certain patients. Surgical resection is the only chance for cure, with results depending on careful technique and patient selection. Data suggest that liver transplantation could offer long-term survival in selected patients when combined with neoadjuvant chemoradiotherapy. Chemotherapy and radiotherapy have been ineffective for patients with inoperable tumours. For most of these patients biliary drainage is the mainstay of palliation. However, controversy exists over the type and positioning of biliary stents. Photodynamic treatment is a new palliative technique that might improve quality of life.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Med, Liver Unit, London, England; Royal Free Hosp, Dept Surg, London NW3 2QG, England	Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Khan, SA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Med, Liver Unit, St Marys Hosp Campus, London, England.	shahid.khan@imperial.ac.uk	Thomas, Howard C/A-3152-2009					Abdalla EK, 2002, ARCH SURG-CHICAGO, V137, P675, DOI 10.1001/archsurg.137.6.675; Abu-Hamda EM, 2004, SEMIN LIVER DIS, V24, P165, DOI 10.1055/s-2004-828893; Aishima SI, 2002, HISTOPATHOLOGY, V40, P269, DOI 10.1046/j.1365-2559.2002.00353.x; ALBERT MB, 1988, DIGEST DIS SCI, V33, P1223, DOI 10.1007/BF01536670; Anderson CD, 2004, ONCOLOGIST, V9, P43, DOI 10.1634/theoncologist.9-1-43; Anderson CD, 2004, J GASTROINTEST SURG, V8, P90, DOI 10.1016/j.gassur.2003.10.003; Baron TH, 2004, CLIN GASTROENTEROL H, V2, P214, DOI 10.1016/S1542-3565(04)00006-0; Bergquist A, 1998, HEPATOLOGY, V27, P311, DOI 10.1002/hep.510270201; Berr F, 2004, SEMIN LIVER DIS, V24, P177, DOI 10.1055/s-2004-828894; Berthiaume EP, 2004, SEMIN LIVER DIS, V24, P127, DOI 10.1055/s-2004-828890; BISMUTH H, 1992, ANN SURG, V215, P31, DOI 10.1097/00000658-199201000-00005; Broome U, 1996, GUT, V38, P610, DOI 10.1136/gut.38.4.610; Burke EC, 1998, ANN SURG, V228, P385, DOI 10.1097/00000658-199809000-00011; CAMERON JL, 1990, AM J SURG, V159, P91, DOI 10.1016/S0002-9610(05)80612-9; CARRIAGA MT, 1995, CANCER-AM CANCER SOC, V75, P171, DOI 10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2; Chalasani N, 2000, HEPATOLOGY, V31, P7, DOI 10.1002/hep.510310103; Chang WH, 1998, GASTROINTEST ENDOSC, V47, P354, DOI 10.1016/S0016-5107(98)70218-4; CHARI RS, 2003, UP TO DATE; Chen MF, 1999, J GASTROEN HEPATOL, V14, P1144, DOI 10.1046/j.1440-1746.1999.01983.x; CHEUNG KL, 1995, ARCH SURG-CHICAGO, V130, P204; Choi CW, 2000, AM J CLIN ONCOL-CANC, V23, P425, DOI 10.1097/00000421-200008000-00023; Corvera Carlos U, 2002, Surg Oncol Clin N Am, V11, P877, DOI 10.1016/S1055-3207(02)00033-9; De Palma GD, 2001, GASTROINTEST ENDOSC, V53, P547, DOI 10.1067/mge.2001.113381; De Palma GD, 2003, GASTROINTEST ENDOSC, V58, P50, DOI 10.1067/mge.2003.310; DEVIERE J, 1988, GASTROINTEST ENDOSC, V34, P95, DOI 10.1016/S0016-5107(88)71271-7; Donato F, 2001, CANCER CAUSE CONTROL, V12, P959, DOI 10.1023/A:1013747228572; DOWLATI A, 2003, P AN M AM SOC CLIN, V22, pA267; DOWSETT JF, 1989, GASTROENTEROLOGY, V96, P1180, DOI 10.1016/0016-5085(89)91639-9; Ducreux M, 1998, ANN ONCOL, V9, P653, DOI 10.1023/A:1008241008379; Ebata T, 2003, ANN SURG, V238, P720, DOI 10.1097/01.sla.0000094437.68038.a3; ELLIS PA, 1995, EUR J CANCER, V31A, P1594, DOI 10.1016/0959-8049(95)00323-B; FARLEY DR, 1995, MAYO CLIN PROC, V70, P425, DOI 10.4065/70.5.425; Figueras J, 2000, LIVER TRANSPLANT, V6, P786, DOI 10.1053/jlts.2000.18507; Fong Y, 1996, BRIT J SURG, V83, P1712, DOI 10.1002/bjs.1800831217; Freeman ML, 2003, GASTROINTEST ENDOSC, V58, P41, DOI 10.1067/mge.2003.292; Fritscher-Ravens A, 2000, GASTROINTEST ENDOSC, V52, P534, DOI 10.1067/mge.2000.109589; Fritscher-Ravens A, 2001, NUCL MED COMMUN, V22, P1277, DOI 10.1097/00006231-200112000-00002; Gebbia V, 2001, J CLIN ONCOL, V19, P4089, DOI 10.1200/JCO.2001.19.20.4089; Gerhards MF, 2003, WORLD J SURG, V27, P173, DOI 10.1007/s00268-002-6434-1; Gonzalez DG, 1999, ANN ONCOL, V10, P215, DOI 10.1023/A:1008339709327; HADJIS NS, 1990, SURGERY, V107, P597; HARDELL L, 1984, BRIT J CANCER, V50, P389, DOI 10.1038/bjc.1984.188; Harnois DM, 1997, HEPATOLOGY, V26, P884, DOI 10.1053/jhep.1997.v26.pm0009328309; Heimbach JK, 2004, SEMIN LIVER DIS, V24, P201, DOI 10.1055/s-2004-828896; Hemming AW, 2003, ANN SURG, V237, P686, DOI 10.1097/00000658-200305000-00011; Isa T, 2002, HEPATO-GASTROENTEROL, V49, P604; Isayama H, 2004, GUT, V53, P729, DOI 10.1136/gut.2003.018945; Ishak KG, 1994, WHO INT HISTOLOGICAL; Itoi T, 1999, PATHOL INT, V49, P30, DOI 10.1046/j.1440-1827.1999.00821.x; Jacquemin E, 2001, SEMIN LIVER DIS, V21, P551, DOI 10.1055/s-2001-19033; Jarnagin WR, 2004, SEMIN LIVER DIS, V24, P189, DOI 10.1055/s-2004-828895; Jarnagin WR, 2001, ANN SURG, V234, P507, DOI 10.1097/00000658-200110000-00010; Jeyarajah D R, 1998, J Hepatobiliary Pancreat Surg, V5, P48, DOI 10.1007/PL00009950; Kaassis M, 2003, GASTROINTEST ENDOSC, V57, P178, DOI 10.1067/mge.2003.66; Kato T, 2002, EUR J NUCL MED MOL I, V29, P1047, DOI 10.1007/s00259-002-0852-z; Khan SA, 2002, GUT, V51, P1; Khan SA, 2002, J HEPATOL, V37, P806, DOI 10.1016/S0168-8278(02)00297-0; Khan SA, 2003, GUT, V52, P586, DOI 10.1136/gut.52.4.586; Kim YJ, 2003, EUR J NUCL MED MOL I, V30, P1467, DOI 10.1007/s00259-003-1297-8; Kitagawa Y, 2001, ANN SURG, V233, P385, DOI 10.1097/00000658-200103000-00013; Knox JJ, 2005, J CLIN ONCOL, V23, P2332, DOI 10.1200/JCO.2005.51.008; Kobayashi M, 2000, CANCER, V88, P2471, DOI 10.1002/1097-0142(20000601)88:11<2471::AID-CNCR7>3.0.CO;2-T; KUBO S, 1995, WORLD J SURG, V19, P637, DOI 10.1007/BF00294744; Lamerz R, 1999, ANN ONCOL, V10, P145, DOI 10.1023/A:1008386130283; Lillemoe K D, 2000, J Hepatobiliary Pancreat Surg, V7, P115, DOI 10.1007/s005340050164; LIPSETT PA, 1994, ANN SURG, V220, P644, DOI 10.1097/00000658-199411000-00007; Liver Cancer Study Group of Japan, 2000, GEN RUL CLIN PATH ST; Manfredi R, 2001, Radiol Med, V102, P48; Manfredi R, 2004, SEMIN LIVER DIS, V24, P155, DOI 10.1055/s-2004-828892; Meier Y, 2004, HEPATOLOGY, V40, p471A; Meyer CG, 2000, TRANSPLANTATION, V69, P1633; Nakeeb A, 1996, ANN SURG, V224, P463, DOI 10.1097/00000658-199610000-00005; Nakeeb A, 2002, SURGERY, V132, P555, DOI 10.1067/msy.2002.127555; Nehls O, 2004, SEMIN LIVER DIS, V24, P139, DOI 10.1055/s-2004-828891; Nehls O, 2002, BRIT J CANCER, V87, P702, DOI 10.1038/sj.bjc.6600543; NIMURA Y, 1990, WORLD J SURG, V14, P535, DOI 10.1007/BF01658686; Nimura Y, 2000, J Hepatobiliary Pancreat Surg, V7, P155, DOI 10.1007/s005340050170; OHNISHI H, 1995, HEPATO-GASTROENTEROL, V42, P265; Ohtsuka T, 2001, ENDOSCOPY, V33, P614, DOI 10.1055/s-2001-15324; Okaro AC, 2001, J CLIN PATHOL, V54, P927, DOI 10.1136/jcp.54.12.927; Okuda K, 2002, J GASTROEN HEPATOL, V17, P1049, DOI 10.1046/j.1440-1746.2002.02781.x; Olnes MJ, 2004, ONCOLOGY-BASEL, V66, P167, DOI 10.1159/000077991; Ortner MEJ, 2003, GASTROENTEROLOGY, V125, P1355, DOI 10.1016/j.gastro.2003.07.015; Papakostas P, 2001, EUR J CANCER, V37, P1833, DOI 10.1016/S0959-8049(01)00214-3; PARKIN DM, 1991, INT J CANCER, V48, P323, DOI 10.1002/ijc.2910480302; Patel AH, 2000, AM J GASTROENTEROL, V95, P204; Patel T, 2001, HEPATOLOGY, V33, P1353, DOI 10.1053/jhep.2001.25087; Patel T, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-10; Patt YZ, 2001, CLIN CANCER RES, V7, P3375; Pichlmayr R, 1996, ANN SURG, V224, P628, DOI 10.1097/00000658-199611000-00007; PITT HA, 1995, CURR PROB SURG, V32, P1, DOI 10.1016/S0011-3840(05)80011-5; PITT HA, 1995, ANN SURG, V221, P788, DOI 10.1097/00000658-199506000-00017; Prat F, 1998, GUT, V42, P76, DOI 10.1136/gut.42.1.76; RAMAGE JK, 1995, GASTROENTEROLOGY, V108, P865, DOI 10.1016/0016-5085(95)90462-X; Sahani D, 2003, ABDOM IMAGING, V28, P72, DOI 10.1007/s00261-001-0148-y; Saini S, 1997, NEW ENGL J MED, V336, P1889, DOI 10.1056/NEJM199706263362607; Schima W, 1997, CLIN RADIOL, V52, P213, DOI 10.1016/S0009-9260(97)80275-9; SCOTT J, 1980, AM J GASTROENTEROL, V73, P113; Shaib Y, 2004, SEMIN LIVER DIS, V24, P115, DOI 10.1055/s-2004-828889; Shaib YH, 2005, GASTROENTEROLOGY, V128, P620, DOI 10.1053/j.gastro.2004.12.048; Shaib YH, 2004, J HEPATOL, V40, P472, DOI 10.1016/j.jhep.2003.11.030; Shin HR, 1996, INT J EPIDEMIOL, V25, P933, DOI 10.1093/ije/25.5.933; Simeone D., 1999, TXB GASTROENTEROLOGY, P2244; Siqueira E, 2002, GASTROINTEST ENDOSC, V56, P40, DOI 10.1067/mge.2002.125105; Sorensen HT, 1998, HEPATOLOGY, V28, P921, DOI 10.1002/hep.510280404; Su CH, 1996, ANN SURG, V223, P384, DOI 10.1097/00000658-199604000-00007; Sung J, 2004, NAT CLIN PRACT GASTR, V1, P20, DOI 10.1038/ncpgasthep0014; Taniai M, 2002, GASTROENTEROLOGY, V123, P1090, DOI 10.1053/gast.2002.36021; Taylor-Robinson SD, 2001, GUT, V48, P816, DOI 10.1136/gut.48.6.816; THAMAVIT W, 1978, CANCER RES, V38, P4634; Thompson R, 2001, SEMIN LIVER DIS, V21, P545, DOI 10.1055/s-2001-19038; Thongprasert S, 2005, ANN ONCOL, V16, P279, DOI 10.1093/annonc/mdi046; Todoroki T, 2000, INT J RADIAT ONCOL, V46, P581, DOI 10.1016/S0360-3016(99)00472-1; Tullo A, 2000, EUR J CLIN INVEST, V30, P798; Valls C, 2000, ABDOM IMAGING, V25, P490, DOI 10.1007/s002610000079; van Leeuwen DJ, 1999, ANN ONCOL, V10, P89, DOI 10.1023/A:1008305307085; van Mil SWC, 2001, SEMIN LIVER DIS, V21, P535, DOI 10.1055/s-2001-19034; VAUTHEY JN, 1994, SEMIN LIVER DIS, V14, P109, DOI 10.1055/s-2007-1007302; Wade TP, 1997, J SURG ONCOL, V64, P242, DOI 10.1002/(SICI)1096-9098(199703)64:3<242::AID-JSO12>3.0.CO;2-6; Wang Y, 2002, J GASTROENTEROL, V37, P831, DOI 10.1007/s005350200137; Watanapa P, 1996, BRIT J SURG, V83, P1062, DOI 10.1002/bjs.1800830809; Watanapa P, 2002, BRIT J SURG, V89, P962, DOI 10.1046/j.1365-2168.2002.02143.x; Yeh TS, 2000, AM J GASTROENTEROL, V95, P432; Yin FZ, 1998, CHINESE MED J-PEKING, V111, P1068; Zhang Y, 1999, J COMPUT ASSIST TOMO, V23, P670, DOI 10.1097/00004728-199909000-00004; Zidi SH, 2000, GUT, V46, P103, DOI 10.1136/gut.46.1.103	126	920	1006	10	180	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 8	2005	366	9493					1303	1314		10.1016/S0140-6736(05)67530-7	http://dx.doi.org/10.1016/S0140-6736(05)67530-7			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971ST	16214602				2022-12-28	WOS:000232405700030
J	Hashkes, PJ; Laxer, RM				Hashkes, PJ; Laxer, RM			Medical treatment of juvenile idiopathic arthritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ANTITUMOR NECROSIS FACTOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; USSR DOUBLE-BLIND; TERM-FOLLOW-UP; INTRAARTICULAR TRIAMCINOLONE HEXACETONIDE; INDUCED GASTRODUODENAL INJURY; ACTING ANTIRHEUMATIC DRUGS; STEM-CELL TRANSPLANTATION; RHEUMATOID-ARTHRITIS; METHOTREXATE THERAPY	Context The treatment of-juvenile idiopathic arthritis (JIA) has changed markedly in the last 15 years. Many children with JIA are not treated by pediatric rheumatologists. Objective To review the best evidence for the treatment of JIA. Data Sources English-language trials of JIA between 1966 and 2005 were searched using MEDLINE, EMBASE, the Cochrane database, and abstracts from recent rheumatology and pediatric scientific meetings. Study Selection Randomized controlled trials and-open studies including at least 10 patients for medications without controlled trials. Data Extraction For studies after 1997, the American College of Rheumatology Pediatric 30 outcome measure was used to define patients as responders. For older studies, the primary response outcome measure defined by the authors was used. Data Synthesis Thirty-four controlled studies were identified. Nonsteroidal anti-inflammatory drugs are effective only for a minority of patients, mainly those with oligoarthritis. Intra-articular corticosteroid injections are very effective for oligoarthritis. Methotrexate is effective for the treatment of extended oligoarthritis And polyarthritis and less effective for systemic arthritis. Sulfasalazine and leflunomide may be alternatives to methotrexate. Antitumor necrosis factor medications are highly effective for polyarticular course JIA not responsive to methotrexate but are less effective in systemic arthritis. There is a lack of evidence for the optimal treatment of systemic and enthesitis-related arthritis. Conclusions Despite many advances in the treatment of AA, there is still a lack of evidence for treatment of several disease subtypes. The treatment plan needs to be individualized based on the JIA subtype.	Cleveland Clin Fdn, Dept Rheumat Dis, Sect Pediat Rheumatol, Cleveland, OH 44195 USA; Hosp Sick Children, Dept Clin & Acad Affairs, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pediat & Med, Toronto, ON, Canada	Cleveland Clinic Foundation; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Hashkes, PJ (corresponding author), Cleveland Clin Fdn, Dept Rheumat Dis A50, 9500 Euclid Ave, Cleveland, OH 44195 USA.	hashkep@ccf.org						Alsufyani K, 2004, J RHEUMATOL, V31, P179; Armbrust W, 2004, RHEUMATOLOGY, V43, P527, DOI 10.1093/rheumatology/keh074; BALIS FM, 1983, CANCER RES, V43, P2342; Balogh Z, 1987, Scand J Rheumatol Suppl, V67, P80; Barnett ML, 1996, ARTHRITIS RHEUM, V39, P623, DOI 10.1002/art.1780390413; BHETTAY E, 1986, S AFR MED J, V70, P724; BHETTAY E, 1978, S AFR MED J, V54, P276; Bloom BJ, 2000, ARTHRITIS RHEUM, V43, P2606, DOI 10.1002/1529-0131(200011)43:11<2606::AID-ANR31>3.0.CO;2-X; Breit W, 2000, J RHEUMATOL, V27, P2696; BREWER EJ, 1986, NEW ENGL J MED, V314, P1269, DOI 10.1056/NEJM198605153142001; BREWER EJ, 1982, J RHEUMATOL, V9, P123; Brooks CD, 2001, J RHEUMATOL, V28, P845; Burgos-Vargas R, 2002, ANN RHEUM DIS, V61, P941, DOI 10.1136/ard.61.10.941; BURIOT D, 1979, ARCH FR PEDIATR, V36, P592; Cleary AG, 2002, ARCH DIS CHILD, V86, P47, DOI 10.1136/adc.86.1.47; Cleary AG, 2003, ARCH DIS CHILD, V88, P192, DOI 10.1136/adc.88.3.192; Crandall WV, 2003, ALIMENT PHARM THER, V17, P75, DOI 10.1046/j.1365-2036.2003.01411.x; Cron RQ, 1998, J PEDIATR-US, V132, P901, DOI 10.1016/S0022-3476(98)70331-2; De Benedetti F, 2003, ARTHRITIS RHEUM, V48, P1398, DOI 10.1002/art.10882; de Kleer IM, 2004, ANN RHEUM DIS, V63, P1318, DOI 10.1136/ard.2003.017798; De Silva B, 2000, PEDIATR DERMATOL, V17, P480, DOI 10.1046/j.1525-1470.2000.01827.x; DOWD JE, 1995, ARTHRITIS RHEUM, V38, P1225, DOI 10.1002/art.1780380908; DUPUIS LL, 1995, J RHEUMATOL, V22, P1570; Eberhard BA, 2004, J RHEUMATOL, V31, P2507; Falcini F, 1997, ARTHRITIS RHEUM, V40, P175, DOI 10.1002/art.1780400122; Fantini F, 2003, J RHEUMATOL, V30, P579; Ferucci ED, 2005, ARTHRITIS RHEUM-US, V52, P239, DOI 10.1002/art.20773; Foell D, 2004, ANN RHEUM DIS, V63, P206, DOI 10.1136/ard.2003.005686; Foster HE, 2003, ARTHRITIS RHEUM-US, V48, P767, DOI 10.1002/art.10863; French AR, 2001, ARTHRITIS RHEUM-US, V44, P523, DOI 10.1002/1529-0131(200103)44:3<523::AID-ANR99>3.3.CO;2-T; Garcia-Morteo O, 1987, Eur J Rheumatol Inflamm, V8, P49; GARE BA, 1995, J RHEUMATOL, V22, P308; Gedalia A, 2004, ARTHRITIS RHEUM, V50, pS95; Gerloni V, 2005, ARTHRITIS RHEUM, V52, P548, DOI 10.1002/art.20793; Gerloni V, 2001, RHEUMATOLOGY, V40, P907, DOI 10.1093/rheumatology/40.8.907; Giannini EH, 1996, J RHEUMATOL, V23, P919; GIANNINI EH, 1995, PEDIATR CLIN N AM, V42, P1099; Giannini EH, 1997, ARTHRITIS RHEUM, V40, P1202; GIANNINI EH, 1988, ARTHRITIS RHEUM, V31, P15, DOI 10.1002/art.1780310103; GIANNINI EH, 1992, NEW ENGL J MED, V326, P1043, DOI 10.1056/NEJM199204163261602; GIANNINI EH, 1990, ARTHRITIS RHEUM, V33, P466, DOI 10.1002/art.1780330402; GIANNINI EH, 1993, SEMIN ARTHRITIS RHEU, V23, P34, DOI 10.1016/S0049-0172(05)80025-3; GIANNINI EH, 1990, J PEDIATR-US, V117, P645, DOI 10.1016/S0022-3476(05)80708-5; Goodman S, 2003, J RHEUMATOL, V30, P829; Gottlieb BS, 1997, PEDIATRICS, V100, P994, DOI 10.1542/peds.100.6.994; Guillaume S, 2000, ARTHRITIS RHEUM, V43, P1858, DOI 10.1002/1529-0131(200008)43:8<1858::AID-ANR23>3.0.CO;2-A; Gylys-Morin VM, 2001, RADIOLOGY, V220, P696, DOI 10.1148/radiol.2203000461; HAAPASAARI J, 1983, SCAND J RHEUMATOL, V12, P325, DOI 10.3109/03009748309099735; HAGELBERG S, 2000, J RHEUMATOL S58, V27, P95; HALLE F, 1991, CLIN EXP RHEUMATOL, V9, P297; HAREL L, 1993, ARTHRITIS RHEUM, V36, P1370, DOI 10.1002/art.1780361007; Hashkes PJ, 1997, ARTHRITIS RHEUM, V40, P2226, DOI 10.1002/art.1780401218; Hashkes PJ, 2003, CLIN EXP RHEUMATOL, V21, P645; Hashkes PJ, 1999, J PEDIATR-US, V134, P47, DOI 10.1016/S0022-3476(99)70371-9; Horneff G, 2004, ARTHRITIS RHEUM, V50, pS91; Horneff G, 2004, ARTHRITIS RHEUM, V50, pS93; Horneff G, 2004, ANN RHEUM DIS, V63, P1638, DOI 10.1136/ard.2003.014886; Hoza J, 1991, Acta Univ Carol Med (Praha), V37, P80; Hunt PG, 1997, J RHEUMATOL, V24, P2230; HUPPERTZ HI, 1995, J PEDIATR-US, V127, P317, DOI 10.1016/S0022-3476(95)70320-9; Ilowite NT, 2003, ANN RHEUM DIS, V62, P87; Irigoyen PI, 2004, ARTHRITIS RHEUM, V50, pS437; KEENAN GF, 1995, J RHEUMATOL, V22, P1149; Kimura Y, 2000, ARTHRITIS RHEUM, V43, pS257; Kimura Y, 2002, ARTHRITIS RHEUM-US, V46, pS481; Kimura Y, 2000, J RHEUMATOL, V27, P2018; Kiss MH, 2003, ARTHRITIS RHEUM, V48, pS650; Klein-Gitelman MS, 1998, J RHEUMATOL, V25, P1995; KOREN G, 1990, PEDIATR RES, V27, P432, DOI 10.1203/00006450-199005000-00003; Krugmann J, 2000, HUM PATHOL, V31, P253, DOI 10.1016/S0046-8177(00)80230-0; KVIEN TK, 1986, J RHEUMATOL, V13, P118; KVIEN TK, 1985, J RHEUMATOL, V12, P533; KVIEN TK, 1985, SCAND J RHEUMATOL, V14, P346, DOI 10.3109/03009748509102037; KVIEN TK, 1984, SCAND J RHEUMATOL, V13, P342, DOI 10.3109/03009748409111307; Lahdenne P, 2003, ANN RHEUM DIS, V62, P245, DOI 10.1136/ard.62.3.245; LAXER RM, 1988, CLIN THER, V10, P381; LEAK AM, 1988, CLIN EXP RHEUMATOL, V6, P157; Lee JH, 2002, ARTHRITIS RHEUM-US, V46, P2565, DOI 10.1002/art.10583; Lehman TJA, 2004, J PEDIATR-US, V145, P856, DOI 10.1016/j.jpeds.2004.08.020; Lepore L, 2003, CLIN EXP RHEUMATOL, V21, P276; LEVINSON JE, 1992, J RHEUMATOL, V19, P6; LEVINSON JE, 1977, J PEDIATR-US, V91, P799, DOI 10.1016/S0022-3476(77)81045-7; Livermore PA, 2002, RHEUMATOLOGY, V41, P1450, DOI 10.1093/rheumatology/41.12.1450; Lomater C, 2000, J RHEUMATOL, V27, P491; Londino AV, 1998, J RHEUMATOL, V25, P1245; Lovell DJ, 2004, ARTHRITIS RHEUM, V50, pS436; Lovell DJ, 2000, NEW ENGL J MED, V342, P763, DOI 10.1056/NEJM200003163421103; Lovell DJ, 2003, ARTHRITIS RHEUM, V48, P218, DOI 10.1002/art.10710; LOVELL DJ, 1984, ARTHRITIS RHEUM, V27, P1433, DOI 10.1002/art.1780271216; MAKELA AL, 1977, SCAND J RHEUMATOL, V6, P193; MALLESON PN, 1990, ARTHRITIS RHEUM, V33, P1560, DOI 10.1002/art.1780331014; Manners PJ, 2002, J RHEUMATOL, V29, P1520; Masatlioglu S, 2002, ARTHRITIS RHEUM-US, V46, pS481; Mayer ML, 2004, PEDIATRICS, V113, pE173, DOI 10.1542/peds.113.3.e173; Mehta S, 1999, ARTHRITIS RHEUM, V42, P2252, DOI 10.1002/1529-0131(199910)42:10<2252::AID-ANR33>3.0.CO;2-2; Minden K, 2002, ARTHRITIS RHEUM-US, V46, P2392, DOI 10.1002/art.10444; Mohan N, 2001, ARTHRITIS RHEUM-US, V44, P2862, DOI 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W; Moroldo MB, 1998, J RHEUMATOL, V25, P986; Mouy R, 1996, J PEDIATR-US, V129, P750, DOI 10.1016/S0022-3476(96)70160-9; MULBERG AE, 1993, J PEDIATR-US, V122, P647, DOI 10.1016/S0022-3476(05)83556-5; Muzaffer MA, 1996, J PEDIATR-US, V128, P698, DOI 10.1016/S0022-3476(96)80139-9; Neidel J, 2002, ARTHRITIS RHEUM, V46, P1620, DOI 10.1002/art.10313; Oen K, 2002, J RHEUMATOL, V29, P1989; Ogilvie EM, 2003, ARTHRITIS RHEUM-US, V48, P3202, DOI 10.1002/art.11300; Ortiz-Alvarez O, 2004, J RHEUMATOL, V31, P2501; Packham JC, 2002, RHEUMATOLOGY, V41, P1428, DOI 10.1093/rheumatology/41.12.1428; Padeh S, 1998, ARTHRITIS RHEUM, V41, P1210, DOI 10.1002/1529-0131(199807)41:7<1210::AID-ART10>3.0.CO;2-5; Padeh S, 1997, J RHEUMATOL, V24, P2035; Pascual V, 2005, J EXP MED, V201, P1479, DOI 10.1084/jem.20050473; Passo MH, 1998, B RHEUM DIS, V47, P1; Peterson LS, 1997, ARTHRITIS RHEUM, V40, P2235, DOI 10.1002/art.1780401219; Petty RE, 2004, J RHEUMATOL, V31, P390; Picco P, 1996, SCAND J RHEUMATOL, V25, P24, DOI 10.3109/03009749609082663; Pignatti P, 2001, J RHEUMATOL, V28, P1670; PRIEUR AM, 1985, ARTHRITIS RHEUM, V28, P376, DOI 10.1002/art.1780280404; Quartier P, 2003, ARTHRITIS RHEUM, V48, P1093, DOI 10.1002/art.10885; Ravelli A, 1999, J PEDIATR-US, V135, P316, DOI 10.1016/S0022-3476(99)70127-7; RAVELLI A, 1995, J RHEUMATOL, V22, P1574; Ravelli A, 1999, CLIN EXP RHEUMATOL, V17, P625; RAVELLI A, 1994, ACTA PAEDIATR, V83, P428, DOI 10.1111/j.1651-2227.1994.tb18135.x; Ravelli A, 1998, CLIN EXP RHEUMATOL, V16, P181; Ravelli A, 1998, J PEDIATR-US, V133, P262, DOI 10.1016/S0022-3476(98)70231-8; Ravelli A, 2002, CLIN EXP RHEUMATOL, V20, P569; Ravelli A, 2001, J RHEUMATOL, V28, P2100; Reiff A, 1997, J RHEUMATOL, V24, P2436; Ruperto N, 2005, ARTHRITIS RHEUM-US, V52, P563, DOI 10.1002/art.20860; Ruperto N, 2004, ARTHRITIS RHEUM-US, V50, P2191, DOI 10.1002/art.20288; Russo RAG, 2002, CLIN EXP RHEUMATOL, V20, P723; Savolainen HA, 1999, J RHEUMATOL, V26, P898; SAVOLAINEN HA, 1993, J RHEUMATOL, V20, P1201; Schmeling H, 2002, Z RHEUMATOL, V61, P168, DOI 10.1007/s003930200025; SHAIKOV AV, 1992, J RHEUMATOL, V19, P612; Sherry DD, 1999, ARTHRITIS RHEUM, V42, P2330, DOI 10.1002/1529-0131(199911)42:11<2330::AID-ANR11>3.0.CO;2-B; Silverman E, 2005, NEW ENGL J MED, V352, P1655, DOI 10.1056/NEJMoa041810; Silverman E, 2005, ARTHRITIS RHEUM-US, V52, P554, DOI 10.1002/art.20861; SILVERMAN ED, 1994, J RHEUMATOL, V21, P2353; Smolen JS, 2005, ARTHRITIS RHEUM, V52, P1020, DOI 10.1002/art.20982; Spiegel LR, 2000, ARTHRITIS RHEUM-US, V43, P2402, DOI 10.1002/1529-0131(200011)43:11<2402::AID-ANR5>3.0.CO;2-C; Stephan JL, 2001, RHEUMATOLOGY, V40, P1285, DOI 10.1093/rheumatology/40.11.1285; SZER IS, 1991, J PEDIATR-US, V119, P815, DOI 10.1016/S0022-3476(05)80309-9; Takei S, 2001, J RHEUMATOL, V28, P1677; Takken T, 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003129, DOI 10.1002/14651858.CD003129]; Thomas E, 2003, J RHEUMATOL, V30, P958; Tse SML, 2005, ARTHRITIS RHEUM, V52, P2103, DOI 10.1002/art.21121; Uziel Y, 1996, J RHEUMATOL, V23, P910; van Rossum MAJ, 1998, ARTHRITIS RHEUM, V41, P808, DOI 10.1002/1529-0131(199805)41:5<808::AID-ART6>3.0.CO;2-T; VINJE O, 2000, ANN RHEUM DIS, V59, P25; VOUGIOUKA O, 2001, ANN RHEUM DIS, V60, P176; Wallace CA, 1998, ARTHRITIS RHEUM-US, V41, P381, DOI 10.1002/1529-0131(199803)41:3<381::AID-ART2>3.0.CO;2-3; WALLACE CA, 1991, RHEUM DIS CLIN N AM, V17, P891; WALLACE CA, 2003, RUDOLPHS PEDIAT JUVE, P836; WILLIAMS PL, 1986, BRIT J RHEUMATOL, V25, P67; Woo P, 2000, ARTHRITIS RHEUM-US, V43, P1849, DOI 10.1002/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F; Wulffraat N, 1999, LANCET, V353, P550, DOI 10.1016/S0140-6736(98)05399-9; Yokota S, 2005, ARTHRITIS RHEUM, V52, P818, DOI 10.1002/art.20944; Zak M, 2000, RHEUMATOLOGY, V39, P198, DOI 10.1093/rheumatology/39.2.198; Zulian F, 2004, RHEUMATOLOGY, V43, P1288, DOI 10.1093/rheumatology/keh313; Zulian F, 2003, RHEUMATOLOGY, V42, P1254, DOI 10.1093/rheumatology/keg358	158	213	262	2	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	2005	294	13					1671	1684		10.1001/jama.294.13.1671	http://dx.doi.org/10.1001/jama.294.13.1671			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970DC	16204667	Bronze			2022-12-28	WOS:000232284400020
J	Custer, B; Busch, MP; Marfin, AA; Petersen, LR				Custer, B; Busch, MP; Marfin, AA; Petersen, LR			The cost-effectiveness of screening the u.S. blood supply for West Nile virus	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; TRANSMISSION; TRANSFUSION; DONATION; HEALTH; RECOMMENDATIONS; MEDICINE; PANEL; HCV	Background: The spread of West Nile virus across North America and evidence of transmission by transfusion prompted the U.S. Food and Drug Administration to encourage the development of methods to screen the blood supply. Objective: To assess the cost-effectiveness of nucleic acid amplification testing for West Nile virus in the U.S. blood supply. Design: Markov cohort simulation. Data Sources: Outcome probabilities estimated from nucleic acid testing done for West Nile virus in 2003, data from the Centers for Disease Control and Prevention, and published literature. Costs were taken from an economic study of West Nile virus infection and from estimated test costs. Target Populations: Transfusion recipients, 60 years of age or older, with and without underlying immunocompromise. Time Horizon: Lifetime. Perspective: Societal. Interventions: The authors compared 6 strategies, taking into consideration minipool (pools of 6 to 16 donations) versus individual donation testing, and the geographic and seasonal nature of West Nile virus activity. Outcome Measures: Costs and effects of each strategy based on the prevention of transfusion-transmitted West Nile virus. Results of Base-Case Analysis: The cost-effectiveness of annual, national minipool testing was $483 000 per quality-adjusted life-year (QALY), whereas the cost-effectiveness of annual, national individual donation testing was $897 000/QALY. The cost-effectiveness of targeted individual donation testing in an area experiencing an outbreak coupled with minipool testing elsewhere was $520 000/QALY. Results of Sensitivity Analysis: in 1-way analyses, the most important influences were the prevalence of West Nile virus and the cost of minipool testing and individual donation testing. The 95% range of results from probabilistic sensitivity analysis for targeted individual donation testing was $256 000 to $1 044 000/ QALY. Limitations: The Outcomes of West Nile virus infection were based on data from the general population rather than from the population who received transfusions. The results are most useful in the context of geographically focused outbreaks of West Nile virus infection. Conclusions: Using targeted individual donation testing to interdict blood donations that are positive for the West Nile virus is relatively cost-effective but is highly dependent on West Nile virus prevalence.	Blood Syst Res Inst, San Francisco, CA 94118 USA	Vitalant; Vitalant Research Institute	Custer, B (corresponding author), Blood Syst Res Inst, 270 Mason Ave, San Francisco, CA 94118 USA.	bcuster@bloodsystems.org						AuBuchon JP, 1997, TRANSFUSION, V37, P45, DOI 10.1046/j.1537-2995.1997.37197176950.x; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; BIRKMEYER JD, 1994, ANN THORAC SURG, V57, P161, DOI 10.1016/0003-4975(94)90386-7; BUSCH MP, 2005, IN PRESS N ENGL J ME; Custer B, 2004, TRANSFUSION, V44, P1547, DOI 10.1111/j.0041-1132.2004.04227.x; Grosse S.D., 2003, PREVENTION EFFECTIVE, V2nd ed., P245; HOFFER S, 1998, PUBLICATION FEDERAL; Iwamoto M, 2003, NEW ENGL J MED, V348, P2196, DOI 10.1056/NEJMoa022987; Jackson BR, 2003, TRANSFUSION, V43, P721, DOI 10.1046/j.1537-2995.2003.00392.x; Jackson BR, 2000, TRANSFUSION, V40, P1063, DOI 10.1046/j.1537-2995.2000.40091063.x; Kleinman S, 2005, TRANSFUSION, V45, P469, DOI 10.1111/j.0041-1132.2005.04315.x; LLEWELYN C, 2004, EUR 19 OCT 2004 TRAN; Marshall DA, 2004, VOX SANG, V86, P28, DOI 10.1111/j.0042-9007.2004.00379.x; Pealer LN, 2003, NEW ENGL J MED, V349, P1236, DOI 10.1056/NEJMoa030969; Petersen LR, 2004, NEW ENGL J MED, V351, P2257, DOI 10.1056/NEJMp048261; Siegel JE, 1997, PHARMACOECONOMICS, V11, P159, DOI 10.2165/00019053-199711020-00005; Stramer SL, 2004, NEW ENGL J MED, V351, P760, DOI 10.1056/NEJMoa040085; STRAMER SL, 2005, IN PRESS N ENGL J ME; *US DEP HHS FDA CT, 2002, WORKSH DEV DON SCREE; *US DEP HHS US FDA, 2005, DRAFT GUID IND ASS D; Wallace EL, 1998, TRANSFUSION, V38, P625, DOI 10.1046/j.1537-2995.1998.38798346630.x; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; Weinstein MC, 1980, CLIN DECISION ANAL; Winkelmayer WC, 2002, MED DECIS MAKING, V22, P417, DOI 10.1177/027298902236927; Zohrabian A, 2004, EMERG INFECT DIS, V10, P1736, DOI 10.3201/eid1010.030925; 2003, MMWR MORB MORTAL WKL, V52, P769	26	58	61	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 4	2005	143	7					486	492		10.7326/0003-4819-143-7-200510040-00007	http://dx.doi.org/10.7326/0003-4819-143-7-200510040-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970FM	16204161				2022-12-28	WOS:000232290600003
J	Schmitt, B; Golub, RM; Green, R				Schmitt, B; Golub, RM; Green, R			Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: Systematic review for the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Review							LONG-TERM SURVIVAL; COST-EFFECTIVENESS ANALYSIS; BLOOD-DONORS; IRON-OVERLOAD; GENETIC HEMOCHROMATOSIS; NATURAL-HISTORY; PHENOTYPIC HEMOCHROMATOSIS; IDIOPATHIC HEMOCHROMATOSIS; NONINVASIVE PREDICTION; CLINICAL EXPRESSION	Background: Therapeutic phlebotomy for hereditary hemochromatosis is relatively safe and presumably efficacious when offered before cirrhosis develops, so screening primary care patients is of substantial interest. Purpose: To conduct a systematic review of the evidence on 1) the prevalence of the disease in primary care, 2) the risk for morbid or fatal complications for untreated patients, 3) the diagnostic usefulness of transferrin saturation and serum ferritin level in identifying early disease, 4) the efficacy of early treatment, and 5) whether the benefits of screening outweigh the risks. Data Sources: MEDLINE search from 1966 through April 2004, complemented by reference review of identified original studies and review articles published in English. Study Selection: PubMed Clinical Queries filters search of prognosis, diagnosis, etiology, or treatment were used depending on the question. Two authors reviewed all titles and abstracts. Data Extraction: Two investigators independently reviewed extracted data. Data Synthesis: The prevalence of hereditary hemochromatosis was 1 in 169 patients to I in 556 patients (n = 3 studies). Uncontrolled, prospective studies of genetic homozygous patients did not consistently identify a link to overt hereditary hemochromatosis. A serum ferritin level less than 1000 mu g/L was predictive of absence of cirrhosis. Six studies demonstrated reduced survival in patients with cirrhosis. Diagnostic studies varied with respect to case definition. No blinded, independent comparisons of screening tests with the gold standard (biopsy or results of quantitative phlebotomy) or randomized, controlled trials of phlebotomy were identified. Cost-effectiveness analysis was limited by lack of prospective data on the natural history of the disease. Limitations: varied case definition and lack of prospective cohort studies or randomized trials. Conclusions: The available evidence does not demonstrate that benefits outweigh the risks and costs of screening for hemochromatosis.	Hines Vet Affairs Hosp, Med & Neurol Serv Line 111, Hines, IL 60141 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	Schmitt, B (corresponding author), Hines Vet Affairs Hosp, Med & Neurol Serv Line 111, Hines, IL 60141 USA.	brian.schmitt2@med.va.gov						Adams PC, 1995, HEPATOLOGY, V22, P1720, DOI 10.1016/0270-9139(95)90197-3; Adams PC, 2005, NEW ENGL J MED, V352, P1769, DOI 10.1056/NEJMoa041534; ADAMS PC, 1995, GASTROENTEROLOGY, V109, P177, DOI 10.1016/0016-5085(95)90283-X; Adams PC, 1999, AM J GASTROENTEROL, V94, P1593; ADAMS PC, 1991, GASTROENTEROLOGY, V101, P368, DOI 10.1016/0016-5085(91)90013-B; Adams PC, 2001, AM J GASTROENTEROL, V96, P567; AMMANN RW, 1980, SCAND J GASTROENTERO, V15, P733, DOI 10.3109/00365528009181523; Andersen RV, 2004, BLOOD, V103, P2914, DOI 10.1182/blood-2003-10-3564; Asberg A, 2001, SCAND J GASTROENTERO, V36, P1108; Asberg A, 2002, SCAND J GASTROENTERO, V37, P1212, DOI 10.1080/003655202760373443; BAER DM, 1995, AM J MED, V98, P464, DOI 10.1016/S0002-9343(99)80346-5; Barton JC, 2002, J OCCUP ENVIRON MED, V44, P745, DOI 10.1097/00043764-200208000-00009; Barton JC, 1998, ANN INTERN MED, V129, P932, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00003; Beaton M, 2002, HEPATOLOGY, V36, P673, DOI 10.1053/jhep.2002.35343; BENN HP, 1994, BEITR INFUS, V32, P314; Brittenham GM, 1998, ANN INTERN MED, V129, P993, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00011; BUFFONE GJ, 1994, CLIN CHEM, V40, P1631; Burt MJ, 1998, GUT, V43, P830, DOI 10.1136/gut.43.6.830; Cogswell ME, 1998, ANN INTERN MED, V129, P971, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00008; DEUGNIER YM, 1993, HEPATOLOGY, V18, P1363, DOI 10.1002/hep.1840180613; DEUGNIER YM, 1993, GASTROENTEROLOGY, V104, P228, DOI 10.1016/0016-5085(93)90856-8; Dubois S, 2003, ARCH INTERN MED, V163, P2424, DOI 10.1001/archinte.163.20.2424; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; El-Serag HB, 2000, ANN INTERN MED, V132, P261, DOI 10.7326/0003-4819-132-4-200002150-00003; Ellervik C, 2001, LANCET, V358, P1405, DOI 10.1016/S0140-6736(01)06526-6; FARGION S, 1992, HEPATOLOGY, V15, P655, DOI 10.1002/hep.1840150417; FARGION S, 1994, HEPATOLOGY, V20, P1426, DOI 10.1002/hep.1840200608; Franks AL, 1999, ANN INTERN MED, V130, P1018, DOI 10.7326/0003-4819-130-12-199906150-00021; Gochee PA, 2002, GASTROENTEROLOGY, V122, P646, DOI 10.1016/S0016-5085(02)80116-0; Guyader D, 1998, GASTROENTEROLOGY, V115, P929, DOI 10.1016/S0016-5085(98)70265-3; GUYATT G, 2002, USERS GUIDES MED LIT, P453; Imperatore G, 2003, GENET MED, V5, P1, DOI 10.1097/00125817-200301000-00001; Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; Looker AC, 1998, ANN INTERN MED, V129, P940, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00004; Mahon NG, 2000, HEART, V84, P541, DOI 10.1136/heart.84.5.541; Mainous AG, 2004, ANN FAM MED, V2, P133, DOI 10.1370/afm.25; Mainous AG, 2002, J FAM PRACTICE, V51, P933; McDonnell SM, 2003, ARCH INTERN MED, V163, P2421, DOI 10.1001/archinte.163.20.2421; McDonnell SM, 1998, ANN INTERN MED, V129, P962, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00007; McDonnell SM, 1998, ANN INTERN MED, V129, P987, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00010; McDonnell SM, 1999, AM J MED, V107, P30, DOI 10.1016/S0002-9343(99)00163-1; McLaren CE, 2003, AM J MED SCI, V325, P53, DOI 10.1097/00000441-200302000-00001; Milman N, 2001, ANN HEMATOL, V80, P737, DOI 10.1007/s002770100371; Morrison ED, 2003, ANN INTERN MED, V138, P627, DOI 10.7326/0003-4819-138-8-200304150-00008; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; Niederau C, 1998, ANN INTERN MED, V128, P337, DOI 10.7326/0003-4819-128-5-199803010-00001; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; OLSSON KS, 1984, ACTA MED SCAND, V215, P105; Olynyk JK, 1999, NEW ENGL J MED, V341, P718, DOI 10.1056/NEJM199909023411002; Olynyk JK, 2004, MAYO CLIN PROC, V79, P309, DOI 10.4065/79.3.309; PHATAK PD, 1994, ARCH INTERN MED, V154, P769, DOI 10.1001/archinte.154.7.769; Phatak PD, 1998, ANN INTERN MED, V129, P954, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00006; Pietrangelo A, 2004, NEW ENGL J MED, V350, P2383, DOI 10.1056/NEJMra031573; Pietrangelo A, 1999, NEW ENGL J MED, V341, P725, DOI 10.1056/NEJM199909023411003; Powell LW, 1998, ANN INTERN MED, V129, P925, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00002; Salonen JT, 1998, BRIT MED J, V317, P727, DOI 10.1136/bmj.317.7160.727; Smith BN, 1997, HEPATOLOGY, V25, P1439, DOI 10.1002/hep.510250622; Tavill AS, 1999, NEW ENGL J MED, V341, P755, DOI 10.1056/NEJM199909023411010; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P231; VELATI C, 1990, HAEMATOLOGICA, V75, P309; WIGGERS P, 1991, J INTERN MED, V230, P265, DOI 10.1111/j.1365-2796.1991.tb00441.x; Wojcik JP, 2002, CAN J GASTROENTEROL, V16, P297, DOI 10.1155/2002/161569; Yamashita C, 2003, CLIN GASTROENTEROL H, V1, P388, DOI 10.1053/S1542-3565(03)00187-3; Yang QH, 1998, ANN INTERN MED, V129, P946, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00005	65	52	53	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 4	2005	143	7					522	536		10.7326/0003-4819-143-7-200510040-00011	http://dx.doi.org/10.7326/0003-4819-143-7-200510040-00011			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970FM	16204165				2022-12-28	WOS:000232290600007
J	Nair, DT; Johnson, RE; Prakash, L; Prakash, S; Aggarwal, AK				Nair, DT; Johnson, RE; Prakash, L; Prakash, S; Aggarwal, AK			Rev1 employs a novel mechanism of DNA synthesis using a protein template	SCIENCE			English	Article							POLYMERASE-IOTA; CRYSTAL-STRUCTURE; YEAST REV1; NUCLEOTIDE INCORPORATION; ERROR-PRONE; REPLICATION; BYPASS; ETA; FIDELITY; BASE	The Rev1 DNA polymerase is highly specialized for the incorporation of C opposite template G. We present here the crystal structure of yeast Rev1 bound to template G and incoming 2'-deoxycytidine 5'-triphosphate (dCTP); which reveals that the polymerase itself dictates the identity of the incoming nucleotide, as well as the identity of the templating base. Template G and incoming dCTP do not pair with each other. Instead, the template G is evicted from the DNA helix, and it makes optimal hydrogen bonds with a segment of Rev1. Also, unlike other DNA polymerases, incoming dCTP pairs with an arginine rather than the templating base, which ensures the incorporation of dCTP over other incoming nucleotides. This mechanism provides an elegant means for promoting proficient and error-free synthesis through N-2-adducted guanines that obstruct replication.	Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77755 USA	Icahn School of Medicine at Mount Sinai; University of Texas System; University of Texas Medical Branch Galveston	Aggarwal, AK (corresponding author), Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, Box 1677,1425 Madison Ave, New York, NY 10029 USA.	aggarwal@inka.mssm.edu	Prakash, Satya/C-6420-2013; Nair, Deepak T/AAR-5234-2020; Prakash, Louise/C-7891-2012	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444; Nair, Deepak/0000-0002-0677-9444				Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Haracska L, 2002, J BIOL CHEM, V277, P15546, DOI 10.1074/jbc.M112146200; Haracska L, 2001, P NATL ACAD SCI USA, V98, P14256, DOI 10.1073/pnas.261560798; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Nair DT, 2004, NATURE, V430, P377, DOI 10.1038/nature02692; NAIR DT, IN PRESS STRUCTURE C; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Uijon SN, 2004, STRUCTURE, V12, P1395, DOI 10.1016/j.str.2004.05.011; Washington MT, 2004, MOL CELL BIOL, V24, P6900, DOI 10.1128/MCB.24.16.6900-6906.2004; Washington MT, 2004, MOL CELL BIOL, V24, P936, DOI 10.1128/MCB.24.2.936-943.2004; Washington MT, 2003, MOL CELL BIOL, V23, P5107, DOI 10.1128/MCB.23.14.5107-5112.2003; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835; Wolfle WT, 2005, MOL CELL BIOL, V25, P7137, DOI 10.1128/MCB.25.16.7137-7143.2005; Xiong Y, 2004, NATURE, V430, P640, DOI 10.1038/nature02711; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	26	200	204	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	2005	309	5744					2219	2222		10.1126/science.1116336	http://dx.doi.org/10.1126/science.1116336			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970NX	16195463				2022-12-28	WOS:000232318000045
J	Orr, JC; Fabry, VJ; Aumont, O; Bopp, L; Doney, SC; Feely, RA; Gnanadesikan, A; Gruber, N; Ishida, A; Joos, F; Key, RM; Lindsay, K; Maier-Reimer, E; Matear, R; Monfray, P; Mouchet, A; Najjar, RG; Plattner, GK; Rodgers, KB; Sabine, CL; Sarmiento, JL; Schlitzer, R; Slater, RD; Totterdell, IJ; Weirig, MF; Yamanaka, Y; Yool, A				Orr, JC; Fabry, VJ; Aumont, O; Bopp, L; Doney, SC; Feely, RA; Gnanadesikan, A; Gruber, N; Ishida, A; Joos, F; Key, RM; Lindsay, K; Maier-Reimer, E; Matear, R; Monfray, P; Mouchet, A; Najjar, RG; Plattner, GK; Rodgers, KB; Sabine, CL; Sarmiento, JL; Schlitzer, R; Slater, RD; Totterdell, IJ; Weirig, MF; Yamanaka, Y; Yool, A			Anthropogenic ocean acidification over the twenty-first century and its impact on calcifying organisms	NATURE			English	Article							ATMOSPHERIC CARBON-DIOXIDE; PRINCE-WILLIAM-SOUND; TERRA-NOVA BAY; ROSS SEA; ARAGONITE PRODUCTION; PACIFIC SECTOR; SOUTHERN-OCEAN; VERTICAL FLUX; CO2; ANTARCTICA	Today's surface ocean is saturated with respect to calcium carbonate, but increasing atmospheric carbon dioxide concentrations are reducing ocean pH and carbonate ion concentrations, and thus the level of calcium carbonate saturation. Experimental evidence suggests that if these trends continue, key marine organisms - such as corals and some plankton - will have difficulty maintaining their external calcium carbonate skeletons. Here we use 13 models of the ocean - carbon cycle to assess calcium carbonate saturation under the IS92a 'business-as-usual' scenario for future emissions of anthropogenic carbon dioxide. In our projections, Southern Ocean surface waters will begin to become undersaturated with respect to aragonite, a metastable form of calcium carbonate, by the year 2050. By 2100, this undersaturation could extend throughout the entire Southern Ocean and into the subarctic Pacific Ocean. When live pteropods were exposed to our predicted level of undersaturation during a two-day shipboard experiment, their aragonite shells showed notable dissolution. Our findings indicate that conditions detrimental to high-latitude ecosystems could develop within decades, not centuries as suggested previously.	CEA Saclay, UMR CEA CNRS, Lab Sci Climat & Environm, F-91191 Gif Sur Yvette, France; Calif State Univ San Marcos, Dept Biol Sci, San Marcos, CA 92096 USA; Ctr IRD Bretagne, LOCEAN, F-29280 Plouzane, France; Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; NOAA, Pacific Marine Environm Lab, Seattle, WA 98115 USA; NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA; Frontier Res Ctr Global Change, Yokohama, Kanagawa 2360001, Japan; Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; Princeton Univ, Atmospher & Ocean Sci Program, Princeton, NJ 08544 USA; Natl Ctr Atmospher Res, Boulder, CO 80307 USA; Max Planck Inst Meteorol, D-20146 Hamburg, Germany; CSIRO, Marine Res & Antarctic Climate & Ecosyst CRC, Hobart, Tas 7001, Australia; Univ Liege, Astrophys & Geophys Inst, B-4000 Liege, Belgium; Penn State Univ, Dept Meteorol, University Pk, PA 16802 USA; Univ Paris 06, LOCEAN, F-75252 Paris, France; Alfred Wegener Inst Polar & Marine Res, D-27515 Bremerhaven, Germany; Natl Oceanog Ctr Southampton, Southampton SO14 3ZH, Hants, England	UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); California State University System; California State University San Marcos; Institut de Recherche pour le Developpement (IRD); Museum National d'Histoire Naturelle (MNHN); UDICE-French Research Universities; Sorbonne Universite; Woods Hole Oceanographic Institution; National Oceanic Atmospheric Admin (NOAA) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; University of California System; University of California Los Angeles; Japan Agency for Marine-Earth Science & Technology (JAMSTEC); University of Bern; National Oceanic Atmospheric Admin (NOAA) - USA; Princeton University; National Center Atmospheric Research (NCAR) - USA; Max Planck Society; Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Liege; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Museum National d'Histoire Naturelle (MNHN); UDICE-French Research Universities; Sorbonne Universite; Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research; NERC National Oceanography Centre; University of Southampton	Orr, JC (corresponding author), CEA Saclay, UMR CEA CNRS, Lab Sci Climat & Environm, F-91191 Gif Sur Yvette, France.	orr@cea.fr	Orr, James/C-5221-2009; Yamanaka, Yasuhiro/H-7393-2012; Doney, Scott C/F-9247-2010; Yool, Andrew/B-4799-2012; matear, richard J/C-5133-2011; Plattner, Gian-Kasper/A-5245-2016; bopp, laurent/ABF-5302-2020; Joos, Fortunat/B-4118-2018; MONFRAY, Patrick/AAB-8665-2020; Gnanadesikan, Anand/A-2397-2008; Aumont, Olivier/G-5207-2016; Feely, Richard A./ABI-5740-2020; Gruber, Nicolas/B-7013-2009; Mouchet, Anne/K-1911-2014; Rodgers, Keith/AAL-4329-2021	Yamanaka, Yasuhiro/0000-0003-3369-3248; Doney, Scott C/0000-0002-3683-2437; Yool, Andrew/0000-0002-9879-2776; matear, richard J/0000-0002-3225-0800; Plattner, Gian-Kasper/0000-0002-3765-0045; bopp, laurent/0000-0003-4732-4953; Joos, Fortunat/0000-0002-9483-6030; MONFRAY, Patrick/0000-0002-3028-5591; Gnanadesikan, Anand/0000-0001-5784-1116; Aumont, Olivier/0000-0003-3954-506X; Gruber, Nicolas/0000-0002-2085-2310; Mouchet, Anne/0000-0002-8846-3063; Orr, James/0000-0002-8707-7080				Accornero A, 2003, ANTARCT SCI, V15, P175, DOI 10.1017/S0954102003001214; BATHMANN UV, 1991, DEEP-SEA RES, V38, P1341, DOI 10.1016/0198-0149(91)90031-A; Be AWH, 1977, OCEANIC MICROPALEONT, V1, P733; Berner R.A., 1977, FATE FOSSIL FUEL CO, P243; BETZER PR, 1984, SCIENCE, V226, P1074, DOI 10.1126/science.226.4678.1074; Boldt JL, 2003, T AM FISH SOC, V132, P1035, DOI 10.1577/T02-091; Bopp L, 2001, GLOBAL BIOGEOCHEM CY, V15, P81, DOI 10.1029/1999GB001256; Brewer PG, 1997, GEOPHYS RES LETT, V24, P1367, DOI 10.1029/97GL01179; BROECKER WS, 1979, SCIENCE, V206, P409, DOI 10.1126/science.206.4417.409; BYRNE RH, 1984, NATURE, V312, P321, DOI 10.1038/312321a0; Caldeira K, 2003, NATURE, V425, P365, DOI 10.1038/425365a; Collier R, 2000, DEEP-SEA RES PT II, V47, P3491, DOI 10.1016/S0967-0645(00)00076-X; DADON JR, 1992, MAR BIOL, V114, P439, DOI 10.1007/BF00350035; Dayton P.K., 1990, P631; FABRY VJ, 1989, DEEP-SEA RES, V36, P1735, DOI 10.1016/0198-0149(89)90069-1; FABRY VJ, 1990, J MAR RES, V48, P209, DOI 10.1357/002224090784984614; FEELY RA, 1988, MAR CHEM, V25, P227, DOI 10.1016/0304-4203(88)90052-7; FEELY RA, 1984, J GEOPHYS RES-OCEANS, V89, P631, DOI 10.1029/JC089iC06p10631; Feely RA, 2004, SCIENCE, V305, P362, DOI 10.1126/science.1097329; FOSTER BA, 1993, ENVIRON BIOL FISH, V36, P313, DOI 10.1007/BF00001727; Gattuso JP, 1998, GLOBAL PLANET CHANGE, V18, P37, DOI 10.1016/S0921-8181(98)00035-6; Gruber N, 1998, GLOBAL BIOGEOCHEM CY, V12, P165, DOI 10.1029/97GB03658; Haugan PM, 1996, ENERG CONVERS MANAGE, V37, P1019, DOI 10.1016/0196-8904(95)00292-8; Heinze C, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020613; Honjo S, 2000, DEEP-SEA RES PT II, V47, P3521, DOI 10.1016/S0967-0645(00)00077-1; Iglesias-Rodriguez MD, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001454; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Key RM, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2004GB002247; Kleypas JA, 1999, SCIENCE, V284, P118, DOI 10.1126/science.284.5411.118; KOBAYASHI HA, 1974, MAR BIOL, V26, P295, DOI 10.1007/BF00391513; La Mesa M, 2000, POLAR BIOL, V23, P38; LALLI C M, 1970, Journal of Experimental Marine Biology and Ecology, V4, P101, DOI 10.1016/0022-0981(70)90018-3; LALLI CM, 2004, BIODIVERSITY SERIES, V22; Langdon C, 2003, GLOBAL BIOGEOCHEM CY, V17, DOI 10.1029/2002GB001941; Orr JC, 2001, GLOBAL BIOGEOCHEM CY, V15, P43, DOI 10.1029/2000GB001273; Pakhomov EA, 1997, POLAR BIOL, V18, P180, DOI 10.1007/s003000050175; Pakhomov EA, 1996, MAR ECOL PROG SER, V134, P1, DOI 10.3354/meps134001; Pearson PN, 1999, SCIENCE, V284, P1824, DOI 10.1126/science.284.5421.1824; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Riebesell U, 2000, NATURE, V407, P364, DOI 10.1038/35030078; Sabine CL, 2004, SCIENCE, V305, P367, DOI 10.1126/science.1097403; Sarmiento JL, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002134; SARMIENTO JL, 1995, GLOBAL BIOGEOCHEM CY, V9, P121, DOI 10.1029/94GB01779; SARMIENTO JL, 1992, J GEOPHYS RES-OCEANS, V97, P3621, DOI 10.1029/91JC02849; Seibel BA, 2003, BIOL BULL-US, V205, P93, DOI 10.2307/1543229; Shirayama Y, 2005, J GEOPHYS RES-OCEANS, V110, DOI 10.1029/2004JC002618; Urban-Rich J, 2001, DEEP-SEA RES PT II, V48, P4223, DOI 10.1016/S0967-0645(01)00087-X; Willette TM, 2001, FISH OCEANOGR, V10, P14, DOI 10.1046/j.1054-6006.2001.00043.x; Zondervan I, 2001, GLOBAL BIOGEOCHEM CY, V15, P507, DOI 10.1029/2000GB001321	49	2975	3123	95	3069	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 29	2005	437	7059					681	686		10.1038/nature04095	http://dx.doi.org/10.1038/nature04095			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193043	Green Submitted, Green Published			2022-12-28	WOS:000232157900042
J	Nolden, M; Ehses, S; Koppen, M; Bernacchia, A; Rugarli, EI; Langer, T				Nolden, M; Ehses, S; Koppen, M; Bernacchia, A; Rugarli, EI; Langer, T			The m-AAA protease defective in hereditary spastic paraplegia controls ribosome assembly in mitochondria	CELL			English	Article							TRANSLATIONAL ACTIVATOR PROTEINS; SACCHAROMYCES-CEREVISIAE; INNER MEMBRANE; DEGRADATION; SUBUNIT; COMPLEX; GENES; MAINTENANCE; PROTEOLYSIS; MUTATIONS	AAA proteases comprise a conserved family of membrane bound ATP-dependent proteases that ensures the quality control of mitochondrial inner-membrane proteins. Inactivation of AAA proteases causes pleiotropic phenotypes in various organisms, including respiratory deficiencies, mitochondrial morphology defects, and axonal degeneration in hereditary spastic paraplegia (HSP). The molecular basis of these defects, however, remained unclear. Here, we describe a regulatory role of an AAA protease for mitochondrial protein synthesis in yeast. The mitochondrial ribosomal protein MrpL32 is processed by the m-AAA protease, allowing its association with preassembled ribosomal particles and completion of ribosome assembly in close proximity to the inner membrane. Maturation of MrpL32 and mitochondrial protein synthesis are also impaired in a HSP mouse model lacking the m-AAA protease subunit paraplegin, demonstrating functional conservation. Our findings therefore rationalize mitochondrial defects associated with m-AAA protease mutants in yeast and shed new light on the mechanism of axonal degeneration in HSR	Univ Cologne, Genet Inst, D-50674 Cologne, Germany; Univ Cologne, Ctr Mol Med, D-50674 Cologne, Germany; Telethon Inst Genet & Med, I-80131 Naples, Italy	University of Cologne; University of Cologne; Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM)	Langer, T (corresponding author), Univ Cologne, Genet Inst, D-50674 Cologne, Germany.	thomas.langer@uni-koeln.de		Rugarli, Elena/0000-0002-5782-1067; Langer, Thomas/0000-0003-1250-1462	Telethon [GGP05057] Funding Source: Medline	Telethon(Fondazione Telethon)		Arlt H, 1998, EMBO J, V17, P4837, DOI 10.1093/emboj/17.16.4837; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; Atorino L, 2003, J CELL BIOL, V163, P777, DOI 10.1083/jcb.200304112; CAMPBELL CL, 1994, MOL BIOL CELL, V5, P899, DOI 10.1091/mbc.5.8.899; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Ferreirinha F, 2004, J CLIN INVEST, V113, P231, DOI 10.1172/JCI200420138; Fiori A, 2003, EUKARYOT CELL, V2, P651, DOI 10.1128/EC.2.3.651-653.2003; Galluhn D, 2004, J BIOL CHEM, V279, P38338, DOI 10.1074/jbc.M405871200; GROHMANN L, 1991, FEBS LETT, V284, P51, DOI 10.1016/0014-5793(91)80759-V; GUELIN E, 1994, YEAST, V10, P1389, DOI 10.1002/yea.320101016; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Jacobs HT, 2005, TRENDS GENET, V21, P312, DOI 10.1016/j.tig.2005.04.003; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; Jia LX, 2003, EMBO J, V22, P6438, DOI 10.1093/emboj/cdg624; Kambacheld M, 2005, J BIOL CHEM, V280, P20132, DOI 10.1074/jbc.M500398200; Knittler MR, 1998, J IMMUNOL, V161, P5967; Krause-Buchholz U, 2004, CURR GENET, V46, P20, DOI 10.1007/s00294-004-0503-y; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; Liu MQ, 2000, J BIOL CHEM, V275, P29400, DOI 10.1074/jbc.M002173200; McDermott CJ, 2000, J NEUROL NEUROSUR PS, V69, P150, DOI 10.1136/jnnp.69.2.150; MCMULLIN TW, 1993, J BIOL CHEM, V268, P11737; MICHAELIS U, 1991, MOL GEN GENET, V230, P177, DOI 10.1007/BF00290666; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; Naithani S, 2003, MOL BIOL CELL, V14, P324, DOI 10.1091/mbc.E02-08-0490; NOLDEN M, 2005, IN PRESS CURR TOPICS; Rape M, 2004, BBA-MOL CELL RES, V1695, P209, DOI 10.1016/j.bbamcr.2004.09.022; Rep M, 1996, CURR GENET, V30, P206, DOI 10.1007/s002940050122; Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594; SPITHILL TW, 1978, MOL GEN GENET, V164, P155, DOI 10.1007/BF00267380; Steglich G, 1999, MOL CELL BIOL, V19, P3435; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; Szyrach G, 2003, EMBO J, V22, P6448, DOI 10.1093/emboj/cdg623; TATSUTA T, 2005, IN PRESS CURR TOPICS; Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; Van Dyck L, 1999, CELL MOL LIFE SCI, V56, P825, DOI 10.1007/s000180050029; VANDERKLEI IJ, 1994, MICROSC RES TECHNIQ, V27, P284, DOI 10.1002/jemt.1070270404; VANDYCK L, 1994, J BIOL CHEM, V269, P238	41	280	286	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	2005	123	2					277	289		10.1016/j.cell.2005.08.003	http://dx.doi.org/10.1016/j.cell.2005.08.003			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239145	Bronze			2022-12-28	WOS:000232794100014
J	Okie, S				Okie, S			An offshore haven for human embryonic stem-cell research?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	2005	353	16					1645	1649		10.1056/NEJMp058228	http://dx.doi.org/10.1056/NEJMp058228			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975IC	16236732				2022-12-28	WOS:000232653200001
J	Santos, NC; Benz, W; Mayor, M				Santos, NC; Benz, W; Mayor, M			Extrasolar planets: Constraints for planet formation models	SCIENCE			English	Review							NEPTUNE-MASS PLANET; STATISTICAL PROPERTIES; TRANSITING PLANET; GIANT PLANETS; DETERMINISTIC MODEL; PERIOD DISTRIBUTION; ORBITAL MIGRATION; SOLAR PLANETS; BROWN DWARF; HOST STARS	Since 1995, more than 150 extrasolar planets have been discovered, most of them in orbits quite different from those of the giant planets in our own solar system. The number of discovered extrasolar planets demonstrates that planetary systems are common but also that they may possess a large variety of properties. As the number of detections grows, statistical studies of the properties of exoplanets and their host stars can be conducted to unravel some of the key physical and chemical processes leading to the formation of planetary systems.	Univ Lisbon, Ctr Astron & Astrofis, Observ Astron Lisboa, P-1349018 Lisbon, Portugal; Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; Observ Geneva, CH-1290 Sauverny, Switzerland	Universidade de Lisboa; University of Bern; University of Geneva	Santos, NC (corresponding author), Univ Lisbon, Ctr Astron & Astrofis, Observ Astron Lisboa, P-1349018 Lisbon, Portugal.	nuno.santos@oal.ul.pt	Santos, Nuno C/E-9957-2011	Santos, Nuno C/0000-0003-4422-2919				Alibert Y, 2005, ASTROPHYS J, V626, pL57, DOI 10.1086/431325; Alibert Y, 2004, ASTRON ASTROPHYS, V417, pL25, DOI 10.1051/0004-6361:20040053; Alonso R, 2004, ASTROPHYS J, V613, pL153, DOI 10.1086/425256; Baraffe I, 2004, ASTRON ASTROPHYS, V419, pL13, DOI 10.1051/0004-6361:20040129; Beckwith SVW, 1996, NATURE, V383, P139, DOI 10.1038/383139a0; Boss AP, 2002, ICARUS, V156, P291, DOI 10.1006/icar.2002.6816; Boss AP, 2002, ASTROPHYS J, V567, pL149, DOI 10.1086/340108; Bouchy F, 2004, ASTRON ASTROPHYS, V421, pL13, DOI 10.1051/0004-6361:20040170; Brown TM, 2001, ASTROPHYS J, V552, P699, DOI 10.1086/320580; Butler RP, 2004, ASTROPHYS J, V617, P580, DOI 10.1086/425173; Butler RP, 2003, ASTROPHYS J, V582, P455, DOI 10.1086/344570; Charbonneau D, 2000, ASTROPHYS J, V529, pL45, DOI 10.1086/312457; Charbonneau D, 2002, ASTROPHYS J, V568, P377, DOI 10.1086/338770; Chauvin G, 2004, ASTRON ASTROPHYS, V425, pL29, DOI 10.1051/0004-6361:200400056; Cumming A, 1999, ASTROPHYS J, V526, P890, DOI 10.1086/308020; Eggenberger A, 2004, ASTRON ASTROPHYS, V417, P353, DOI 10.1051/0004-6361:20034164; Gaudi BS, 2005, ASTROPHYS J, V623, P472, DOI 10.1086/428478; Gonzalez G, 1998, ASTRON ASTROPHYS, V334, P221; Haisch KE, 2001, ASTROPHYS J, V553, pL153, DOI 10.1086/320685; Halbwachs JL, 2000, ASTRON ASTROPHYS, V355, P581; Halbwachs JL, 2005, ASTRON ASTROPHYS, V431, P1129, DOI 10.1051/0004-6361:20041219; Hartmann L, 1998, ASTROPHYS J, V495, P385, DOI 10.1086/305277; HENRY GW, 2000, APJ, V529, P41; Ida S, 2004, ASTROPHYS J, V616, P567, DOI 10.1086/424830; Ida S, 2004, ASTROPHYS J, V604, P388, DOI 10.1086/381724; Jorissen A, 2001, ASTRON ASTROPHYS, V379, P992, DOI 10.1051/0004-6361:20011373; Konacki M, 2003, NATURE, V421, P507, DOI 10.1038/nature01379; LATHAM DW, 1989, NATURE, V339, P38, DOI 10.1038/339038a0; Lin DNC, 1996, NATURE, V380, P606, DOI 10.1038/380606a0; Lissauer JJ, 2002, NATURE, V419, P355, DOI 10.1038/419355a; Livio M, 2003, MON NOT R ASTRON SOC, V346, pL42, DOI 10.1111/j.1365-2966.2003.07318.x; Marcy GW, 2002, ASTROPHYS J, V581, P1375, DOI 10.1086/344298; Marzari F, 2002, ICARUS, V156, P570, DOI 10.1006/icar.2001.6786; Mayor M., 2003, MESSENGER, V114, P20; Mazeh T, 2005, MON NOT R ASTRON SOC, V356, P955, DOI 10.1111/j.1365-2966.2004.08511.x; McArthur BE, 2004, ASTROPHYS J, V614, pL81, DOI 10.1086/425561; Moutou C, 2004, ASTRON ASTROPHYS, V424, pL31, DOI 10.1051/0004-6361:200400048; Murray N, 1998, SCIENCE, V279, P69, DOI 10.1126/science.279.5347.69; Murray N, 2002, ASTROPHYS J, V565, P608, DOI 10.1086/324536; Pinsonneault MH, 2001, ASTROPHYS J, V556, pL59, DOI 10.1086/323531; Pollack JB, 1996, ICARUS, V124, P62, DOI 10.1006/icar.1996.0190; Pont F, 2004, ASTRON ASTROPHYS, V426, pL15, DOI 10.1051/0004-6361:200400066; Rasio FA, 1996, SCIENCE, V274, P954, DOI 10.1126/science.274.5289.954; Reid IN, 2002, PUBL ASTRON SOC PAC, V114, P306, DOI 10.1086/339257; Santos NC, 2001, ASTRON ASTROPHYS, V373, P1019, DOI 10.1051/0004-6361:20010648; Santos NC, 2004, ASTRON ASTROPHYS, V426, pL19, DOI 10.1051/0004-6361:200400076; Sari R, 2004, ASTROPHYS J, V606, pL77, DOI 10.1086/421080; Sasselov DD, 2000, ASTROPHYS J, V528, P995, DOI 10.1086/308209; Saumon D, 1996, ASTROPHYS J, V460, P993, DOI 10.1086/177027; Sozzetti A, 2004, MON NOT R ASTRON SOC, V354, P1194, DOI 10.1111/j.1365-2966.2004.08281.x; Tanaka H, 2002, ASTROPHYS J, V565, P1257, DOI 10.1086/324713; Torres G, 2004, ASTROPHYS J, V609, P1071, DOI 10.1086/421286; Trilling DE, 1998, ASTROPHYS J, V500, P428, DOI 10.1086/305711; Udry S, 2003, ASTRON ASTROPHYS, V407, P369, DOI 10.1051/0004-6361:20030843; Udry S, 2002, ASTRON ASTROPHYS, V390, P267, DOI 10.1051/0004-6361:20020685; Vauclair S, 2004, ASTROPHYS J, V605, P874, DOI 10.1086/382668; Vidal-Madjar A, 2004, ASTROPHYS J, V604, pL69, DOI 10.1086/383347; Vogt SS, 2000, ASTROPHYS J, V536, P902, DOI 10.1086/308981; Ward WR, 1997, ASTROPHYS J, V482, pL211, DOI 10.1086/310701; WOLSZCZAN A, 1992, NATURE, V355, P145, DOI 10.1038/355145a0; Zucker S, 2002, ASTROPHYS J, V568, pL113, DOI 10.1086/340373	66	38	38	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					251	255		10.1126/science.1100210	http://dx.doi.org/10.1126/science.1100210			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224012				2022-12-28	WOS:000232670100035
J	Grigg, SP; Canales, C; Hay, A; Tsiantis, M				Grigg, SP; Canales, C; Hay, A; Tsiantis, M			SERRATE coordinates shoot meristem function and leaf axial patterning in Arabidopsis	NATURE			English	Article							CLASS IIIHD-ZIP; INSERTIONAL MUTAGENESIS; GENE; ORGANOGENESIS; PHABULOSA; THALIANA; PROTEINS; POLARITY; GENOME; MEMBER	Leaves of flowering plants are determinate organs produced by pluripotent structures termed shoot apical meristems. Once specified, leaves differentiate an adaxial ( upper) side specialized for light capture, and an abaxial ( lower) side specialized for gas exchange. A functional relationship between meristem activity and the differentiation of adaxial leaf fate has been recognized for over fifty years, but the molecular basis of this interaction is unclear. In Arabidopsis thaliana, activity of the class I KNOX (KNOTTED1-like homeobox) genes SHOOTMERISTEMLESS (STM) and BREVIPEDICELLUS ( BP) is required for meristem function but excluded from leaves(1-3), whereas members of the HD-Zip III ( class III homeodomain leucine zipper) protein family function to promote both meristem activity and adaxial leaf fate(4-6). Here we show that the zinc-finger protein SERRATE acts in a microRNA ( miRNA) gene-silencing pathway to regulate expression of the HD-Zip III gene PHABULOSA (PHB) while also limiting the competence of shoot tissue to respond to KNOX expression. Thus, SERRATE acts to coordinately regulate meristem activity and leaf axial patterning.	Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England	University of Oxford	Tsiantis, M (corresponding author), Univ Oxford, Dept Plant Sci, S Parks Rd, Oxford OX1 3RB, England.	miltos.tsiantis@plants.ox.ac.uk						Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Bao N, 2004, DEV CELL, V7, P653, DOI 10.1016/j.devcel.2004.10.003; Bougourd S, 2000, PLANT J, V24, P543, DOI 10.1046/j.1365-313x.2000.00892.x; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; Byrne ME, 2002, DEVELOPMENT, V129, P1957; Chuck G, 1996, PLANT CELL, V8, P1277, DOI 10.1105/tpc.8.8.1277; Emery JF, 2003, CURR BIOL, V13, P1768, DOI 10.1016/j.cub.2003.09.035; Englbrecht CC, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-39; Gallois JL, 2002, DEVELOPMENT, V129, P3207; Golling G, 2002, NAT GENET, V31, P135, DOI 10.1038/ng896; Green KA, 2005, PLANT CELL, V17, P691, DOI 10.1105/tpc.104.026179; Hay A, 2002, CURR BIOL, V12, P1557, DOI 10.1016/S0960-9822(02)01125-9; Juarez MT, 2004, NATURE, V428, P84, DOI 10.1038/nature02363; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; Mallory AC, 2004, EMBO J, V23, P3356, DOI 10.1038/sj.emboj.7600340; McConnell JR, 1998, DEVELOPMENT, V125, P2935; McConnell JR, 2001, NATURE, V411, P709, DOI 10.1038/35079635; Ori N, 2000, DEVELOPMENT, V127, P5523; Prigge MJ, 2001, PLANT CELL, V13, P1263, DOI 10.1105/tpc.13.6.1263; Smith HMS, 2003, PLANT CELL, V15, P1717, DOI 10.1105/tpc.012856; SUSSEX I. M., 1955, PHYTOMORPHOLOGY [DELHI], V5, P286	22	173	182	4	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	2005	437	7061					1022	1026		10.1038/nature04052	http://dx.doi.org/10.1038/nature04052			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16222298				2022-12-28	WOS:000232496100045
J	Smith, CWJ				Smith, CWJ			Alternative splicing - When two's a crowd	CELL			English	Editorial Material							RNA SECONDARY STRUCTURE; PRE-MESSENGER-RNA; BINDING-PROTEIN; DSCAM; EXPRESSION	Various mechanisms have been proposed to explain mutually exclusive splicing of pairs of exons. A paper in this issue of Cell (Graveley, 2005) provides a fascinating insight into the perplexing question of how only one exon at a time is chosen from an array of 48 exons in the Drosophila Dscam gene.	Dept Biochem, Cambridge CB2 1GA, England		Smith, CWJ (corresponding author), Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.							Buratti E, 2004, MOL CELL BIOL, V24, P10505, DOI 10.1128/MCB.24.24.10505-10514.2004; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; Graveley BR, 2004, RNA, V10, P1499, DOI 10.1261/rna.7105504; Gromak N, 2003, RNA, V9, P443, DOI 10.1261/rna.2191903; Jin Y, 2003, EMBO J, V22, P905, DOI 10.1093/emboj/cdg089; Jones RB, 2001, J BIOL CHEM, V276, P4158, DOI 10.1074/jbc.M006151200; Letunic I, 2002, HUM MOL GENET, V11, P1561, DOI 10.1093/hmg/11.13.1561; Neves G, 2004, NAT GENET, V36, P240, DOI 10.1038/ng1299; Park JW, 2004, P NATL ACAD SCI USA, V101, P15974, DOI 10.1073/pnas.0407004101; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8	11	42	43	1	20	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 7	2005	123	1					1	3		10.1016/j.cell.2005.09.010	http://dx.doi.org/10.1016/j.cell.2005.09.010			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	973QD	16213205	Bronze			2022-12-28	WOS:000232536800001
J	Spierings, D; McStay, G; Saleh, M; Bender, C; Chipuk, J; Maurer, U; Green, DR				Spierings, D; McStay, G; Saleh, M; Bender, C; Chipuk, J; Maurer, U; Green, DR			Connected to death: The (unexpurgated) mitochondrial pathway of apoptosis	SCIENCE			English	Article							CELL-DEATH	The mitochondrial pathway of apoptosis in vertebrates is dependent on the process of mitochondrial outer membrane permeabilization (MOMP), which leads to the release of proteins from the mitochondrial intermembrane space into the cytosol. "Upstairs" of this event are the Bcl-2 family proteins that regulate and mediate MOMP; "downstairs" is the activation of caspases that orchestrate the dismantling of the cell. In the Connections Map database at Science's Signal Transduction Knowledge Environment (STKE), the pathways that define the mitochondrial pathway of apotosis are illustrated, with the bulk of control occurring. "upstairs" of MOMP.	La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Green, DR (corresponding author), St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale St, Memphis, TN 38105 USA.	dgreen5240@aol.com	Green, Douglas R/N-8083-2018; McStay, Gavin/K-9574-2013	Green, Douglas R/0000-0002-7332-1417; McStay, Gavin/0000-0003-1363-8719; Saleh, Maya/0000-0003-1538-9146; Chipuk, Jerry Edward/0000-0002-1337-842X; Spierings, Diana/0000-0001-8403-474X				BENDER C, 2005, SCI STKE; BENDER C, 2005, SCI STKE         OCT; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Kauffman S., 1995, HOME UNIVERSE SEARCH; 2005, SCI STKE         OCT	8	228	256	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 7	2005	310	5745					66	67		10.1126/science.1117105	http://dx.doi.org/10.1126/science.1117105			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972TV	16210526				2022-12-28	WOS:000232477000035
J	Gomberg, J; Johnson, P				Gomberg, J; Johnson, P			Seismology - Dynamic triggering of earthquakes	NATURE			English	Editorial Material									US Geol Survey, Memphis, TN 38152 USA; Los Alamos Natl Lab, Geophys Grp EES11, Los Alamos, NM 87545 USA	United States Department of the Interior; United States Geological Survey; United States Department of Energy (DOE); Los Alamos National Laboratory	Gomberg, J (corresponding author), US Geol Survey, Suite 2, Memphis, TN 38152 USA.	gomberg@usgs.gov						Field EH, 1997, NATURE, V390, P599, DOI 10.1038/37586; Gomberg J, 2001, NATURE, V411, P462, DOI 10.1038/35078053; Gomberg J, 2004, NATURE, V427, P621, DOI 10.1038/nature02335; Gomberg J, 2003, B SEISMOL SOC AM, V93, P118, DOI 10.1785/0120020075; Gomberg J, 1996, B SEISMOL SOC AM, V86, P212; Guyer RA, 1999, PHYS TODAY, V52, P30, DOI 10.1063/1.882648; Johnson PA, 2005, NATURE, V437, P871, DOI 10.1038/nature04015; KANAMORI H, 2004, REPORTS PROGR PHYS, P1429; Pankow KL, 2004, B SEISMOL SOC AM, V94, pS332, DOI 10.1785/0120040609; RUDNICKI JW, 1977, J GEOPHYS RES, V82, P844, DOI 10.1029/JB082i005p00844	10	103	106	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	2005	437	7060					830	830		10.1038/437830a	http://dx.doi.org/10.1038/437830a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	970VB	16208360				2022-12-28	WOS:000232338600034
J	Gebrekristos, HT; Mlisana, KP; Karim, QA				Gebrekristos, HT; Mlisana, KP; Karim, QA			Patients readiness to start highly active antiretroviral treatment for HIV	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HEALTH LITERACY; 21ST-CENTURY; MOTIVATION; CHALLENGE; INFECTION; THERAPY; SEARCH; SCALE		Nelson R Mandela Sch Med, CAPRISA, Durban, South Africa	University of Kwazulu Natal	Gebrekristos, HT (corresponding author), Nelson R Mandela Sch Med, CAPRISA, Durban, South Africa.	hgebrekr@jhsph.edu	Abdool Karim, Quarraisha/GVS-1160-2022; Mlisana, Koleka/N-6204-2013	Abdool Karim, Quarraisha/0000-0002-0985-477X; Mlisana, Koleka/0000-0002-8436-3268	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI051794, P30AI042853] Funding Source: NIH RePORTER; NIAID NIH HHS [1U19AI51794, P30 AI42853-05S1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Audrain J, 1997, Womens Health, V3, P139; *BHIVA WRIT COMM B, 2003, BRIT HIV ASS BHIVA G; BLUMENTHAL RN, 2001, DRUG ALCOHOL DEPEN, V62, P225; *BRIT HIV ASS, 2000, HIV MED, V1, P133; DELEON G, 1994, AM J DRUG ALCOHOL AB, V20, P495; Department of Health and Human Services, 2003, GUID US ANT AG HIV 1; Department of Health South Africa, 2003, OP PLAN COMPR HIV AI; Enriquez M, 2004, J ADV NURS, V45, P438, DOI 10.1046/j.1365-2648.2003.02928.x; Harrington M, 2000, LANCET, V355, P2147, DOI 10.1016/S0140-6736(00)02388-6; Lane HC, 2003, ANN INTERN MED, V138, P680, DOI 10.7326/0003-4819-138-8-200304150-00018; Miller WR, 1996, PSYCHOL ADDICT BEHAV, V10, P81, DOI 10.1037/0893-164X.10.2.81; *MIN HLTH REP UG, 2003, ANT TREATM POL; Neff JA, 2000, SUBST USE MISUSE, V35, P585, DOI 10.3109/10826080009147473; Nutbeam D, 2000, HEALTH PROMOT INT, V15, P259, DOI 10.1093/heapro/15.3.259; Nutbeam D, 2000, HEALTH PROMOT INT, V15, P183, DOI 10.1093/heapro/15.3.183; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; ROHREN CL, 1994, PREV MED, V23, P335, DOI 10.1006/pmed.1994.1047; Skolnik PR, 2003, NEW ENGL J MED, V349, P2351, DOI 10.1056/NEJMe038173; Wagner Glenn, 2002, HIV Clin Trials, V3, P475; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222	20	30	31	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	2005	331	7519					772	775		10.1136/bmj.331.7519.772	http://dx.doi.org/10.1136/bmj.331.7519.772			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	971XB	16195299	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000232417100029
J	Anderson, PW				Anderson, PW			Thinking big	NATURE			English	Editorial Material									Princeton Univ, Dept Phys, Princeton, NJ 08544 USA	Princeton University	Anderson, PW (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.								0	5	5	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 29	2005	437	7059					625	625		10.1038/437625a	http://dx.doi.org/10.1038/437625a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193027				2022-12-28	WOS:000232157900027
J	Koehler, JE; Duncan, LM; Harris, NL; Basgoz, N				Koehler, JE; Duncan, LM; Harris, NL; Basgoz, N			A 56-year-old man with fever and axillary lymphadenopathy - Bartonella henselae infection (cat scratch disease) in an immunocompromised host.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							BACILLARY ANGIOMATOSIS; DOMESTIC CATS; RISK-FACTORS; EPIDEMIOLOGY; RECOMMENDATIONS; TRANSMISSION; PREVALENCE		Univ Calif San Francisco, Div Infect Dis, San Francisco, CA 94143 USA; Massachusetts Gen Hosp, Dept Pathol, Dermatopathol Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Koehler, JE (corresponding author), Univ Calif San Francisco, Div Infect Dis, San Francisco, CA 94143 USA.							ANTINORI S, 1992, AIDS, V6, P740, DOI 10.1097/00002030-199207000-00022; BAXBY D, 1994, BRIT J DERMATOL, V131, P598, DOI 10.1111/j.1365-2133.1994.tb04969.x; Breitschwerdt EB, 2000, CLIN MICROBIOL REV, V13, P428, DOI 10.1128/CMR.13.3.428-438.2000; CARITHERS HA, 1985, AM J DIS CHILD, V139, P1124, DOI 10.1001/archpedi.1985.02140130062031; CHAPMAN S, 2000, MANDELL DOUGLAS BENN, P2733; Chapman S W, 1990, Semin Respir Infect, V5, P74; Chian CA, 2002, INT J DERMATOL, V41, P461, DOI 10.1046/j.1365-4362.2002.01489.x; CHOMEL BB, 1995, J CLIN MICROBIOL, V33, P2445, DOI 10.1128/JCM.33.9.2445-2450.1995; Chomel BB, 1996, J CLIN MICROBIOL, V34, P1952, DOI 10.1128/JCM.34.8.1952-1956.1996; Dharnidharka VR, 2002, PEDIATR TRANSPLANT, V6, P327, DOI 10.1034/j.1399-3046.2002.01091.x; DIAMOND RD, 2000, MANDELL DOUGLAS BENN, P2707; EVANS ME, 1985, MEDICINE, V64, P251, DOI 10.1097/00005792-198507000-00006; Gurfield AN, 2001, VET MICROBIOL, V80, P185, DOI 10.1016/S0378-1135(01)00304-2; JACKSON LA, 1993, AM J PUBLIC HEALTH, V83, P1707, DOI 10.2105/AJPH.83.12.1707; Koehler JE, 2003, CLIN INFECT DIS, V37, P559, DOI 10.1086/375586; Koehler JE, 1997, NEW ENGL J MED, V337, P1876, DOI 10.1056/NEJM199712253372603; KOEHLER JE, 1994, JAMA-J AM MED ASSOC, V271, P531, DOI 10.1001/jama.271.7.531; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; KOSTMAN JR, 1993, ANN INTERN MED, V118, P883, DOI 10.7326/0003-4819-118-11-199306010-00009; Kravetz JD, 2002, ARCH INTERN MED, V162, P1945, DOI 10.1001/archinte.162.17.1945; Masur H, 2002, ANN INTERN MED, V137, P435, DOI 10.7326/0003-4819-137-5_Part_2-200209031-00002; REBOLI AC, 2000, MANDELL DOUGLAS BENN, P2226; REED KD, 1993, CLIN INFECT DIS, V16, P384, DOI 10.1093/clind/16.3.384; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; Rolain JM, 2004, ANTIMICROB AGENTS CH, V48, P1921, DOI 10.1128/AAC.48.6.1921-1933.2004; Rolain JM, 2001, J CLIN MICROBIOL, V39, P2978, DOI 10.1128/JCM.39.8.2978-2980.2001; SATTERWHITE TK, 1979, JAMA-J AM MED ASSOC, V242, P333, DOI 10.1001/jama.242.4.333; Schulein R, 2001, J EXP MED, V193, P1077, DOI 10.1084/jem.193.9.1077; TAPPERO JW, 1993, JAMA-J AM MED ASSOC, V269, P770, DOI 10.1001/jama.269.6.770; ZANGWILL KM, 1993, NEW ENGL J MED, V329, P8, DOI 10.1056/NEJM199307013290102	30	18	18	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2005	353	13					1387	1394		10.1056/NEJMcpc059027	http://dx.doi.org/10.1056/NEJMcpc059027			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968FB	16192484				2022-12-28	WOS:000232146200012
J	Raisner, RM; Hartley, PD; Meneghini, MD; Bao, MZ; Liu, CL; Schreiber, SL; Rando, OJ; Madhani, HD				Raisner, RM; Hartley, PD; Meneghini, MD; Bao, MZ; Liu, CL; Schreiber, SL; Rando, OJ; Madhani, HD			Histone variant H2A.Z marks the 5 ' ends of both active and inactive genes in euchromatin	CELL			English	Article							DNA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; GENOME-WIDE; NUCLEOSOME CORE; YEAST; ACETYLATION; H3; METHYLATION; HETEROCHROMATIN; TRANSCRIPTION	In S. cerevisiae, histone variant H2A.Z is deposited in euchromatin at the flanks of silent heterochromatin to prevent its ectopic spread. We show that H2A.Z nucleosomes are found at promoter regions of nearly all genes in euchromatin. They generally occur as two positioned nucleosomes that flank a nucleosome-free region (NFR) that contains the transcription start site. Astonishingly, enrichment at 5' ends is observed not only at actively transcribed genes but also at inactive loci. Mutagenesis of a typical promoter revealed a 22 bp segment,of DNA sufficient to program formation of a NFR flanked by two H2A.Z nucleosomes. This segment contains a binding site of the Myb-related protein Reb1 and an adjacent dT:dA tract. Efficient deposition of H2A.Z is further promoted by a specific pattern of histone H3 and H4 tall acetylation and the bromodomain protein Bdf1, a component of the Swr1 remodeling complex that deposits H2A.Z.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Harvard Univ, Bauer Ctr Genom Res, Cambridge, MA 02138 USA	University of California System; University of California San Francisco; Harvard University	Madhani, HD (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, 600 16th St, San Francisco, CA 94143 USA.	hiten@biochem.ucsf.edu		Rando, Oliver/0000-0003-1516-9397; Madhani, Hiten/0000-0001-7400-6657	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071801] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM071801] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angermayr M, 2003, J BIOL CHEM, V278, P17918, DOI 10.1074/jbc.M301806200; Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Bolton EC, 2003, GENOME RES, V13, P254, DOI 10.1101/gr.612203; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; Donze D, 1999, GENE DEV, V13, P698, DOI 10.1101/gad.13.6.698; Elemento O, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-2-r18; Erdman S, 1998, J CELL BIOL, V140, P461, DOI 10.1083/jcb.140.3.461; Fourel G, 2002, J BIOL CHEM, V277, P41736, DOI 10.1074/jbc.M202578200; Fraser HB, 2004, PLOS BIOL, V2, P834, DOI 10.1371/journal.pbio.0020137; Heiman MG, 2000, J CELL BIOL, V151, P719, DOI 10.1083/jcb.151.3.719; Howe L, 2001, GENE DEV, V15, P3144, DOI 10.1101/gad.931401; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; Kim M, 2004, NATURE, V432, P517, DOI 10.1038/nature03041; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400; LIAW PCY, 1994, YEAST, V10, P771, DOI 10.1002/yea.320100608; Ling XF, 1996, GENE DEV, V10, P686, DOI 10.1101/gad.10.6.686; Liu CL, 2005, PLOS BIOL, V3, P1753, DOI 10.1371/journal.pbio.0030328; Matangkasombut O, 2003, MOL CELL, V11, P353, DOI 10.1016/S1097-2765(03)00033-9; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Ng HH, 2003, P NATL ACAD SCI USA, V100, P1820, DOI 10.1073/pnas.0437846100; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Santisteban MS, 2000, CELL, V103, P411, DOI 10.1016/S0092-8674(00)00133-1; Santos-Rosa H, 2004, J BIOL CHEM, V279, P47506, DOI 10.1074/jbc.M407949200; SCHULDINER M, 2005, IN PRESS CELL; Sekinger EA, 2005, MOL CELL, V18, P735, DOI 10.1016/j.molcel.2005.05.003; Storici F, 2003, P NATL ACAD SCI USA, V100, P14994, DOI 10.1073/pnas.2036296100; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Yu Q, 2003, NUCLEIC ACIDS RES, V31, P1224, DOI 10.1093/nar/gkg200; Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178	43	498	515	1	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	2005	123	2					233	248		10.1016/j.cell.2005.10.002	http://dx.doi.org/10.1016/j.cell.2005.10.002			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239142	Green Accepted, Bronze			2022-12-28	WOS:000232794100011
J	Le, QM; Kiso, M; Someya, K; Sakai, YT; Nguyen, TH; Nguyen, KHL; Pham, ND; Ngyen, HH; Yamada, S; Muramoto, Y; Horimoto, T; Takada, A; Goto, H; Suzuki, T; Suzuki, Y; Kawaoka, Y				Le, QM; Kiso, M; Someya, K; Sakai, YT; Nguyen, TH; Nguyen, KHL; Pham, ND; Ngyen, HH; Yamada, S; Muramoto, Y; Horimoto, T; Takada, A; Goto, H; Suzuki, T; Suzuki, Y; Kawaoka, Y			Avian flu - Isolation of drug-resistant H5N1 virus	NATURE			English	Editorial Material							INFLUENZA; NEURAMINIDASE		Natl Inst Hyg & Epidemiol, Hanoi, Vietnam; Univ Tokyo, Dept Microbiol & Immunol, Div Virol, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Int Res Ctr Infect Dis, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Daiichi Pharmaceut Co Ltd, Tokyo 1348630, Japan; Natl Inst Clin Res Trop Med, Hanoi, Vietnam; Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem, Shizuoka 4228526, Japan; COE Program 21st Century, Shizuoka 4228526, Japan; Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA	National Institute of Hygiene & Epidemiology (NIHE); University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); Daiichi Sankyo Company Limited; University of Shizuoka; University of Wisconsin System; University of Wisconsin Madison	Le, QM (corresponding author), Natl Inst Hyg & Epidemiol, Hanoi, Vietnam.	kawaoka@ims.u-tokyo.ac.jp	Takada, Ayato/A-6679-2012	Yasuo, Suzuki/0000-0003-3518-5642				Enserink M, 2005, SCIENCE, V309, P371; Gubareva LV, 2001, J INFECT DIS, V183, P523, DOI 10.1086/318537; Gubareva LV, 2000, LANCET, V355, P827, DOI 10.1016/S0140-6736(99)11433-8; Hurt AC, 2004, ANTIVIR RES, V62, P37, DOI 10.1016/j.antiviral.2003.11.008; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; Shinya K, 2005, J VIROL, V79, P9926, DOI 10.1128/JVI.79.15.9926-9932.2005; TOMS GL, 1976, BRIT J EXP PATHOL, V57, P37; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VARGHESE JN, 1992, PROTEINS, V11, P49; ZAMBON M, 2000, ANTIVIR RES, V47, P1	11	581	665	1	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 20	2005	437	7062					1108	1108		10.1038/4371108a	http://dx.doi.org/10.1038/4371108a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	975KD	16228009	Bronze			2022-12-28	WOS:000232660500033
J	Flum, DR; Salem, L; Elrod, JAB; Dellinger, EP; Cheadle, A; Chan, L				Flum, DR; Salem, L; Elrod, JAB; Dellinger, EP; Cheadle, A; Chan, L			Early mortality among medicare beneficiaries undergoing bariatric surgical procedures	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GASTRIC BYPASS; MORBID-OBESITY; CARDIOVASCULAR RISK; HOSPITAL VOLUME; SURGERY; AGE; GENDER; ADULTS; OLDER; LIFE	Context Case series demonstrate that bariatric surgery can be performed with a low rate of perioperative mortality (0.5%), but the rate among high-risk patients and the community at large is unknown. Objectives To evaluate the risk of early mortality among Medicare beneficiaries and to determine the relative risk of death among older patients. Design Retrospective cohort study. Setting and Patients All fee-for-service Medicare beneficiaries, 1997-2002. Main Outcome Measures Thirty-day, 90-day, and 1-year postsurgical all-cause mortality among patients undergoing bariatric procedures. Results A total of 16 155 patients underwent bariatric procedures (mean age, 47.7 years [SD, 11.3 years]; 75.8% women). The rates of 30-day, 90-day, and 1-year mortality were 2.0%, 2.8%, and 4.6%, respectively. Men had higher rates of early death than women (3.7% vs 1.5%, 4.8% vs 2.1 %, and 7.5% vs 3.7% at 30 days, 90 days, and 1 year, respectively; P<.001). Mortality rates were greater for those aged 65 years or older compared with younger patients (4.8% vs 1.7% at 30 days, 6.9% vs 2.3% at 90 days, and 11.1 % vs 3.9% at 1 year; P<.001). After adjustment for sex and comorbidity index, the odds of death within 90 days were 5-fold greater for older Medicare beneficiaries (aged >= 75 years; n = 136) than for those aged 65 to 74 years (n = 1381; odds ratio, 5.0; 95% confidence interval, 3.1-8.0). The odds of death at 90 days were 1.6 times higher (95% confidence interval, 1.3-2.0) for patients of surgeons with less than the median surgical volume of bariatric procedures (among Medicare beneficiaries during the study period) after adjusting for age, sex, and comorbidity index. Conclusions Among Medicare beneficiaries, the risk of early death after bariatric surgery is considerably higher than previously suggested and associated with advancing age, male sex, and lower surgeon volume of bariatric procedures. Patients aged 65 years or older had a substantially higher risk of death within the early postoperative period than younger patients.	Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Ctr Medicare & Medicaid Serv, Div Clin Stand & Qual, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centers for Medicare & Medicaid Services	Flum, DR (corresponding author), Univ Washington, Dept Surg, Box 356410,1959 NE Pacific St, Seattle, WA 98195 USA.	daveflum@u.washington.edu	Flum, David/GPX-7976-2022		NIDDK NIH HHS [R21 DK069677-01, 1UO1DK066568-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK066568, R21DK069677] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arterburn DE, 2004, J AM GERIATR SOC, V52, P1907, DOI 10.1111/j.1532-5415.2004.52517.x; Birkmeyer JD, 2003, NEW ENGL J MED, V349, P2117, DOI 10.1056/NEJMsa035205; Buchwald H., 2004, JAMA (Journal of the American Medical Association), V292, P1724, DOI 10.1001/jama.292.14.1724; Christou NV, 2004, ANN SURG, V240, P416, DOI 10.1097/01.sla.0000137343.63376.19; Clegg A, 2003, INT J OBESITY, V27, P1167, DOI 10.1038/sj.ijo.0802394; Courcoulas A, 2003, SURGERY, V134, P613, DOI 10.1016/S0039-6060(03)00306-4; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Evans S, 2005, STAT MED, V24, P1245, DOI 10.1002/sim.2023; Flum DR, 2004, J AM COLL SURGEONS, V199, P543, DOI 10.1016/j.jamcollsurg.2004.06.014; Frostick SP, 2000, HAEMOSTASIS, V30, P84; Gonzalez R, 2003, AM SURGEON, V69, P547; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; Harris TB, 1997, AM J CLIN NUTR, V66, P837, DOI 10.1093/ajcn/66.4.837; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; KRAL JG, 1992, AM J CLIN NUTR, V55, P611, DOI 10.1093/ajcn/55.2.611s; Livingston EH, 2002, ANN SURG, V236, P576, DOI 10.1097/00000658-200211000-00007; MacDonald K G Jr, 1997, J Gastrointest Surg, V1, P213, DOI 10.1016/S1091-255X(97)80112-6; McTigue KM, 2003, ANN INTERN MED, V139, P933, DOI 10.7326/0003-4819-139-11-200312020-00013; Nguyen NT, 2004, ANN SURG, V240, P586, DOI 10.1097/01.sla.0000140752.74893.24; PORIES W J, 1992, American Journal of Clinical Nutrition, V55, p582S, DOI 10.1093/ajcn/55.2.582s; PRINTEN KJ, 1977, SURG GYNECOL OBSTET, V144, P192; Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622; Sosa JL, 2004, OBES SURG, V14, P1398, DOI 10.1381/0960892042583833; Sugerman HJ, 2004, ANN SURG, V240, P243, DOI 10.1097/01.sla.0000133361.68436.da; Zenilman M E, 1998, Curr Probl Surg, V35, P99, DOI 10.1016/S0011-3840(98)80003-8; Zizza CA, 2003, OBES RES, V11, P1519, DOI 10.1038/oby.2003.203	26	418	438	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	2005	294	15					1903	1908		10.1001/jama.294.15.1903	http://dx.doi.org/10.1001/jama.294.15.1903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974OZ	16234496	Bronze			2022-12-28	WOS:000232602600019
J							Combinat Pharmacptherapy Publ	Combination pharmacotherapy for cardiovascular disease	ANNALS OF INTERNAL MEDICINE			English	Article							COGNITIVE FUNCTION; RANDOMIZED-TRIAL; LOWERING DRUGS; GLOBAL BURDEN; RISK-FACTORS; PREVENTION; DEMENTIA; CORONARY; STATINS; COST	Cardiovascular disease (CVD) is the major cause of death in developed countries and is rapidly becoming the major cause of death in the developing world. The increasing rates of obesity and type 2 diabetes, however, may slow the current favorable trends for deaths attributable to CVD in many developed countries. To improve control of risk factors for CVD, Wald and Law proposed a "polypill," containing a statin, a diuretic, beta-blocker, an angiotensin-converting enzyme inhibitor, aspirin, and folic acid. This combination pharmacotherapy (CP) could be made widely available without treating specific risk factors or individuals. A workshop sponsored by the Centers for Disease Control and Prevention reviewed the concept of CP for both primary and secondary prevention. Combination pharmacotherapy may prove to be efficacious but may also have side effects and poor adherence, which may be greater than or less than that of other preventive approaches. Randomized trials are needed to study these issues, although the design for such trials is uncertain. The ability of CP to prevent CVD in a cost-effective manner must be demonstrated. Minority groups and people with low socioeconomic status in the United States have an increased risk for CVD, and the effectiveness of such pharmacotherapy must be considered for these populations. Combination pharmacotherapy may prove especially effective in the developing world, where studies of CP may precede those done in wealthier countries. Combination pharmacotherapy may have tremendous potential, but additional study and detailed evaluation are necessary.	Emory Univ, Emory Ctr Outcomes Res, Atlanta, GA 30322 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Ctr Dis Control & Prevent, Atlanta, GA USA	Emory University; University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA	Combinat Pharmacptherapy Publ (corresponding author), Emory Univ, Emory Ctr Outcomes Res, Briarcliff Campus,Mail Stop 1256-001-1AR, Atlanta, GA 30322 USA.							Amarenco P, 2004, STROKE, V35, P2902, DOI 10.1161/01.STR.0000147965.52712.fa; American Heart Association, 2005, HEART DIS STROKE STA; [Anonymous], 2005, MMWR MORB MORTAL WKL; Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; BERG JS, 1993, ANN PHARMACOTHER, V27, pS1; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; *CDCP, 2005, MMWR-MORBID MORTAL W, V54, P75; Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P113; Chapman RH, 2005, ARCH INTERN MED, V165, P1147, DOI 10.1001/archinte.165.10.1147; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Connor J, 2004, B WORLD HEALTH ORGAN, V82, P935; COOK NR, 1999, MED GEN MED, pE1; Eron JJ, 2000, AIDS, V14, P671, DOI 10.1097/00002030-200004140-00006; Etminan M, 2003, PHARMACOTHERAPY, V23, P726, DOI 10.1592/phco.23.6.726.32184; Glasgow RE, 2001, PATIENT EDUC COUNS, V44, P119, DOI 10.1016/S0738-3991(00)00186-5; Glover M. J., 2005, Morbidity and Mortality Weekly Report, V54, P7; Green A, 2003, DIABETES-METAB RES, V19, P3, DOI 10.1002/dmrr.340; Grimm RH, 2002, AM J HYPERTENS, V15, P31, DOI 10.1016/S0895-7061(01)02224-5; Haan MN, 2004, ANNU REV PUBL HEALTH, V25, P1, DOI 10.1146/annurev.publhealth.25.101802.122951; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Hajjar I, 2003, JAMA-J AM MED ASSOC, V290, P199, DOI 10.1001/jama.290.2.199; Hanon O, 2004, J NEUROL SCI, V226, P71, DOI 10.1016/j.jns.2004.09.015; Heffler S, 2002, HEALTH AFFAIR, V21, P207, DOI 10.1377/hlthaff.21.2.207; HENNEKENS CH, 1989, CIRCULATION, V80, P749, DOI 10.1161/01.CIR.80.4.749; HENNEKENS CH, 1988, NEW ENGL J MED, V318, P923; Kochanek Kenneth D, 2004, Natl Vital Stat Rep, V53, P1; Krumholz HM, 2002, J AM COLL CARDIOL, V40, P603, DOI 10.1016/S0735-1097(02)02083-1; Law MR, 2003, BRIT MED J, V326, P1427, DOI 10.1136/bmj.326.7404.1427; Levit K, 2002, HEALTH AFFAIR, V21, P172, DOI 10.1377/hlthaff.21.1.172; Mahoney EM, 2003, CONTEMP CARDIOL, P123; McGinnis JM, 2002, HEALTH AFFAIR, V21, P78, DOI 10.1377/hlthaff.21.2.78; Monane M, 1997, AM J HYPERTENS, V10, P697, DOI 10.1016/S0895-7061(97)00056-3; Muldoon MF, 2004, AM J MED, V117, P823, DOI 10.1016/j.amjmed.2004.07.041; Mulrow C, 2005, ANN INTERN MED, V142, P467, DOI 10.7326/0003-4819-142-6-200503150-00012; Narayan KMV, 2003, JAMA-J AM MED ASSOC, V290, P1884, DOI 10.1001/jama.290.14.1884; OLSHANSKY SJ, 2005, OBSTET GYNECOL SURV, V60, P450, DOI DOI 10.1097/01.OGX.0000167407.83915.E7; Paluck EC, 2003, EVAL HEALTH PROF, V26, P380, DOI 10.1177/0163278703258104; PEDERSEN TR, 1994, LANCET, V344, P1383; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; Piette JD, 2004, AM J PUBLIC HEALTH, V94, P1782, DOI 10.2105/AJPH.94.10.1782; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Shiffman S, 1998, ANNU REV PUBL HEALTH, V19, P335, DOI 10.1146/annurev.publhealth.19.1.335; SMITH R, 2003, BMJ             0426, P326; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Weintraub WS, 1997, AM J MANAG C, V3, P743; Yach D, 2005, SCIENCE, V307, P317, DOI 10.1126/science.307.5708.317; Yaffe K, 2002, ARCH NEUROL-CHICAGO, V59, P378, DOI 10.1001/archneur.59.3.378; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Yusuf S, 2001, CIRCULATION, V104, P2855, DOI 10.1161/hc4701.099488; Zandi PP, 2005, ARCH GEN PSYCHIAT, V62, P217, DOI 10.1001/archpsyc.62.2.217; 2005, MMWR MORB MORTAL WKL, V54, P7	53	47	47	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 18	2005	143	8					593	599		10.7326/0003-4819-143-8-200510180-00010	http://dx.doi.org/10.7326/0003-4819-143-8-200510180-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975PI	16230726				2022-12-28	WOS:000232674000010
J	Clark, MJ				Clark, MJ			Historical keywords - Forensic	LANCET			English	Editorial Material									UCL, Wellcome Trust Ctr Hist Med, London, England	University of London; University College London	Clark, MJ (corresponding author), UCL, Wellcome Trust Ctr Hist Med, London, England.	mikejclark01@hotmail.com							0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 15	2005	366	9494					1351	1351		10.1016/S0140-6736(05)67552-6	http://dx.doi.org/10.1016/S0140-6736(05)67552-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	973ZW	16226601				2022-12-28	WOS:000232562100013
J	Cha, TL; Zhou, BHP; Xia, WY; Wu, YD; Yang, CC; Chen, CT; Ping, B; Otte, AP; Hung, MC				Cha, TL; Zhou, BHP; Xia, WY; Wu, YD; Yang, CC; Chen, CT; Ping, B; Otte, AP; Hung, MC			Akt-mediated phsophorylationof EZH2 suppresses methylation of lysine 27 in histone H3	SCIENCE			English	Article							CANCER; BIOLOGY; H3	Enhancer of Zeste homolog 2 (EZH2) is a methyltransferase that plays an important role in many biological processes through its ability to trimethylate lysine 27 in histone H3. Here, we show that Akt phosphorylates EZH2 at serine 21 and suppresses its methyltransferase activity by impeding EZH2 binding to histone H3, which results in a decrease of lysine 27 trimethylation and derepression of silenced genes. Our results imply that Akt regulates the methylation activity, through phosphorylation of EZH2, which may contribute to oncogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA; Univ Amsterdam, Swammerdam Inst Life Sci, NL-1098 SM Amsterdam, Netherlands	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Amsterdam	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	PHS HHS [R01 109311, P01 099031] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kubicek S, 2004, CELL, V119, P903, DOI 10.1016/j.cell.2004.12.006; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; Raaphorst FM, 2001, TRENDS IMMUNOL, V22, P682, DOI 10.1016/S1471-4906(01)02082-8; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; Zhang Y, 2004, NATURE, V431, P637, DOI 10.1038/431637a; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	18	414	437	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					306	310		10.1126/science.1118947	http://dx.doi.org/10.1126/science.1118947			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224021				2022-12-28	WOS:000232670100050
J	Eggermont, AMM; Suciu, S; MacKie, R; Ruka, W; Testori, A; Kruit, W; Punt, CJA; Delauney, M; Sales, F; Groenewegen, G; Ruiter, DJ; Jagiello, I; Stoitchkov, K; Keilholz, U; Lienard, D				Eggermont, AMM; Suciu, S; MacKie, R; Ruka, W; Testori, A; Kruit, W; Punt, CJA; Delauney, M; Sales, F; Groenewegen, G; Ruiter, DJ; Jagiello, I; Stoitchkov, K; Keilholz, U; Lienard, D		EORTC Melanoma Grp	Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial	LANCET			English	Article							HIGH-RISK MELANOMA; COOPERATIVE-ONCOLOGY-GROUP; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; NODE METASTASES; ALPHA-2A; MM	Background Individuals affected by melanoma with thick primary tumours or regional node involvement have a poor outlook, with only 30-50% alive at 5 years. High-dose and low-dose interferon alfa have been assessed for the treatment of these patients, with the former having considerable toxicity and a consistent effect on disease free survival, but not on overall survival, and the latter no consistent effect on either. Our aim was, therefore, to assess the effect of two regimens of interferon of intermediate dose versus observation alone on distant metastasis-free interval (DMFI) and overall survival in such patients. Methods We did a randomised controlled trial in 1388 patients who had had a thick primary tumour (thickness >= 4 mm) resected (stage IIb) or regional lymph node metastases dissected (stage III) and had been assigned to 13 months (n=553) or 25 months (n=556) of treatment with subcutaneous interferon alfa 2b, or observation (n=279) Treatment comprised 4 weeks of 10 million units (MU) of interferon alfa (5 days per week) followed by either 10 MU three times a week for 1 year or 5 MU three times a week for 2 years, to a total dose of 1760 MU. Our primary endpoint was DMFI. Analyses were by intent to treat. Findings After a median follow-up of 4.65 years, we had recorded 760 distant metastases and 681 deaths. At 4. 5 years, the 25-month interferon group showed a 7.2% increase in rate of DMFI (hazard ratio 0.83, 97 . 5% CI 0 . 66-1.03) and a 5.4% improvement in overall survival. The 13-month interferon group showed a 3.2% increase in rate of DMFI at 4.5 years (0.93, 0.75-1.16) and no extension of overall survival. Toxicity was acceptable, with 18% (195 of 1076) of patients going off study because of toxicity or as a result of refusal of treatment because of side-effects. Interpretation Interferon alfa as used in the regimens studied does not improve outcome for patients with stage IIb/III melanomas, and cannot be recommended. With respect to efficacy of the drug, duration of treatment seemed more important than dose, and should be assessed in future trials.	Erasmus Univ, Med Ctr, Dr Daniel den Hoed Canc Ctr, Dept Surg Oncol, NL-3008 AE Rotterdam, Netherlands; EORTC Data Ctr, Brussels, Belgium; Univ Glasgow, Glasgow, Lanark, Scotland; M Sklodowska Curie Mem Canc Ctr, Warsaw, Poland; Ist Europeo Oncol, Milan, Italy; Univ Med Ctr Nijmegen, Nijmegen, Netherlands; CHU Pellegrin, Bordeaux, France; Inst Jules Bordet, B-1000 Brussels, Belgium; Univ Utrecht, Med Ctr, Utrecht, Netherlands; Natl Oncol Ctr, BU-1157 Sofia, Bulgaria; Free Univ Berlin, Benjamin Franklin Hosp, D-1000 Berlin, Germany; CHU Vaudois, Lausanne, Switzerland	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; European Organisation for Research & Treatment of Cancer; University of Glasgow; Maria Sklodowska-Curie National Research Institute of Oncology; IRCCS European Institute of Oncology (IEO); Radboud University Nijmegen; CHU Bordeaux; Institut Jules Bordet; Utrecht University; National Oncology Center - Bulgaria; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Eggermont, AMM (corresponding author), Erasmus Univ, Med Ctr, Dr Daniel den Hoed Canc Ctr, Dept Surg Oncol, NL-3008 AE Rotterdam, Netherlands.	a.m.m.eggermont@erasmusmc.nl	Ruiter, D.J./L-4617-2015	groenewegen, gerard/0000-0002-0752-1744; TESTORI, ALESSANDRO/0000-0003-3685-0210	NATIONAL CANCER INSTITUTE [U10CA011488] Funding Source: NIH RePORTER; NCI NIH HHS [5U10 CA11488-32, 5U10 CA11488-35, 5U10 CA11488-2, 5U10 CA11488-34, 5U10 CA11488-26, 5U10 CA11488-33, 5U10 CA11488-27, 5U10 CA11488-28, 5U10 CA11488-30, 5U10 CA11488-31] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cameron DA, 2001, BRIT J CANCER, V84, P1146, DOI 10.1054/bjoc.2000.1623; Cascinelli N, 2001, LANCET, V358, P866, DOI 10.1016/S0140-6736(01)06068-8; *CYT SOFTW CORP, 2004, EAST; Eggermont AMM, 2004, EUR J CANCER, V40, P1825, DOI 10.1016/j.ejca.2004.04.030; Eggermont AMM, 2002, SEMIN ONCOL, V29, P382, DOI 10.1053/sonc.2002.34117; Eggermont AMM, 2001, EUR J CANCER, V37, P2147, DOI 10.1016/S0959-8049(01)00272-6; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Grob JJ, 1998, LANCET, V351, P1905, DOI 10.1016/S0140-6736(97)12445-X; Hancock PK, 2002, NURS EDUC TODAY, V22, P53, DOI 10.1054/nedt.2001.0726; Kalbfleisch JD, 2002, SURVIVAL ANAL FAILUR; Kirkwood JM, 2000, J CLIN ONCOL, V18, P2444, DOI 10.1200/JCO.2000.18.12.2444; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; Kirkwood JM, 2001, J CLIN ONCOL, V19, P2370, DOI 10.1200/JCO.2001.19.9.2370; Kirkwood JM, 2004, CLIN CANCER RES, V10, P1670, DOI 10.1158/1078-0432.CCR-1103-3; Kleeberg UR, 2004, EUR J CANCER, V40, P390, DOI 10.1016/j.ejca.2003.07.004; Lens MB, 2002, J CLIN ONCOL, V20, P1818, DOI 10.1200/JCO.2002.07.070; Pehamberger H, 1998, J CLIN ONCOL, V16, P1425, DOI 10.1200/JCO.1998.16.4.1425; Wheatley K, 2003, CANCER TREAT REV, V29, P241, DOI 10.1016/S0305-7372(03)00074-4	18	259	269	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 1	2005	366	9492					1189	1196		10.1016/S0140-6736(05)67482-X	http://dx.doi.org/10.1016/S0140-6736(05)67482-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970LK	16198768				2022-12-28	WOS:000232311300029
J	Nates, JL; Moyer, VA				Nates, JL; Moyer, VA			Lessons from Hurricane Katrina, tsunamis, and other disasters	LANCET			English	Editorial Material									Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ Texas, Ctr Clin Res & Evidence Based Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Nates, JL (corresponding author), Univ Texas, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jlnates@mdanderson.org						*COCHR COLL, 2005, RESP TSUN HUM CRIS; *DEP HLTH HUM SERV, 2005, HURR HLTH SAF; *EM DAT, 2005, OFDA CRED INT DIS DA; Farmer JC, 2003, FUNDAMENTALS DISASTE; FEMA, 2004, HURR PAM EX CONCL; International Strategy for Disaster Reduction, 1994, YOK STRAT PLAN ACT S; Nates JL, 2004, CRIT CARE MED, V32, P686, DOI 10.1097/01.CCM.0000114995.14120.6D; UN, 2005, WORLD C DIS RED; *UN DEP EC SOC AFF, 2004, JOH PLAN IMPL	9	17	19	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 1	2005	366	9492					1144	1146		10.1016/S0140-6736(05)67460-0	http://dx.doi.org/10.1016/S0140-6736(05)67460-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970LK	16198751				2022-12-28	WOS:000232311300007
J	Dekel, A; Stoehr, F; Mamon, GA; Cox, TJ; Novak, GS; Primack, JR				Dekel, A; Stoehr, F; Mamon, GA; Cox, TJ; Novak, GS; Primack, JR			Lost and found dark matter in elliptical galaxies	NATURE			English	Article							CCD SURFACE PHOTOMETRY; COSMOLOGICAL SIMULATIONS; PLANETARY-NEBULAE; KINEMATICAL DATA; DYNAMICS; CONDENSATION; EVOLUTION; ROTATION; PROFILE; DEARTH	There is strong evidence that the mass of the Universe is dominated by dark matter, which exerts gravitational attraction but whose exact nature is unknown. In particular, all galaxies are believed to be embedded in massive haloes of dark matter(1,2). This view has recently been challenged by the observation of surprisingly low random stellar velocities in the outskirts of ordinary elliptical galaxies, which has been interpreted as indicating a lack of dark matter(3,4). Here we show that the low velocities are in fact compatible with galaxy formation in dark-matter haloes. Using numerical simulations of disk-galaxy mergers(5,6), we find that the stellar orbits in the outer regions of the resulting ellipticals are very elongated. These stars were torn by tidal forces from their original galaxies during the first close passage and put on outgoing trajectories. The elongated orbits, combined with the steeply falling density profile of the observed tracers, explain the observed low velocities even in the presence of large amounts of dark matter. Projection effects when viewing a triaxial elliptical can lead to even lower observed velocities along certain lines of sight.	Hebrew Univ Jerusalem, Racah Inst Phys, IL-91904 Jerusalem, Israel; Inst Astrophys, F-75014 Paris, France; Observ Paris, F-92195 Meudon, France; Univ Calif Santa Cruz, Univ Calif Observ, Lick Observ, Dept Phys, Santa Cruz, CA 95064 USA; Harvard Univ, Ctr Astrophys, Cambridge, MA 02138 USA	Hebrew University of Jerusalem; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; University of California System; University of California Santa Cruz; Harvard University	Dekel, A (corresponding author), Hebrew Univ Jerusalem, Racah Inst Phys, IL-91904 Jerusalem, Israel.	dekel@phys.huji.ac.il	Dekel, Avishai/ABF-9516-2021; Mamon, Gary A/Q-4575-2017	Dekel, Avishai/0000-0003-4174-0374; Mamon, Gary A/0000-0001-8956-5953				ABADI MG, 2005, STARS GALAXIES ORIGI; BINNEY J, 1987, GALACTIC DYNAMICS, P4; BLUMENTHAL GR, 1984, NATURE, V311, P517, DOI 10.1038/311517a0; Bullock JS, 2001, MON NOT R ASTRON SOC, V321, P559, DOI 10.1046/j.1365-8711.2001.04068.x; Cote P, 2001, ASTROPHYS J, V559, P828, DOI 10.1086/322347; COX TJ, 2005, EFFECTS FEEDBACK SIM; COX TJ, 2004, SIMULATIONS GALAXY M; de Vaucouleurs G., 1948, ANN DAP, V11, P247; DEVAUCOULEURS G, 1979, ASTROPHYS J SUPPL S, V40, P699, DOI 10.1086/190602; FALL SM, 1979, NATURE, V281, P200, DOI 10.1038/281200a0; Gnedin OY, 2004, ASTROPHYS J, V616, P16, DOI 10.1086/424914; GOUDFROOIJ P, 1994, ASTRON ASTROPHYS SUP, V104, P179; Keeton CR, 2001, ASTROPHYS J, V561, P46, DOI 10.1086/323237; MAMON GA, 2005, IN PRESS MON NOT R A; Marigo P, 2004, ASTRON ASTROPHYS, V423, P995, DOI 10.1051/0004-6361:20040234; Mathews WG, 2003, ANNU REV ASTRON ASTR, V41, P191, DOI 10.1146/annurev.astro.41.090401.094542; Mendez RH, 2001, ASTROPHYS J, V563, P135, DOI 10.1086/323794; Milgrom M, 2003, ASTROPHYS J, V599, pL25, DOI 10.1086/381138; Napolitano NR, 2005, MON NOT R ASTRON SOC, V357, P691, DOI 10.1111/j.1365-2966.2005.08683.x; Navarro JF, 1997, ASTROPHYS J, V490, P493, DOI 10.1086/304888; Neto GBL, 1999, MON NOT R ASTRON SOC, V309, P481, DOI 10.1046/j.1365-8711.1999.02849.x; PELETIER RF, 1990, ASTRON J, V100, P1091, DOI 10.1086/115582; Peng EW, 2004, ASTROPHYS J, V602, P685, DOI 10.1086/381160; Romanowsky AJ, 2003, SCIENCE, V301, P1696, DOI 10.1126/science.1087441; Saiz A, 2004, ASTROPHYS J, V601, pL131, DOI 10.1086/382025; Sofue Y, 2001, ANNU REV ASTRON ASTR, V39, P137, DOI 10.1146/annurev.astro.39.1.137; Springel V, 2001, NEW ASTRON, V6, P79, DOI 10.1016/S1384-1076(01)00042-2; Valluri M, 2004, ASTROPHYS J, V602, P66, DOI 10.1086/380896	30	160	161	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 29	2005	437	7059					707	710		10.1038/nature03970	http://dx.doi.org/10.1038/nature03970			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193046	Green Submitted			2022-12-28	WOS:000232157900046
J	Kessel, R; Schmidt, MW; Ulmer, P; Pettke, T				Kessel, R; Schmidt, MW; Ulmer, P; Pettke, T			Trace element signature of subduction-zone fluids, melts and supercritical liquids at 120-180 km depth	NATURE			English	Article							HIGH-PRESSURE EXPERIMENTS; PHASE-RELATIONS; UPPER-MANTLE; ARC MAGMAS; GPA; CONSTRAINTS; ECLOGITE; SYSTEM; CRUST; SLAB	Fluids and melts liberated from subducting oceanic crust recycle lithophile elements back into the mantle wedge, facilitate melting and ultimately lead to prolific subduction-zone arc volcanism(1,2). The nature and composition of the mobile phases generated in the subducting slab at high pressures have, however, remained largely unknown(3-7). Here we report direct LA-ICPMS measurements of the composition of fluids and melts equilibrated with a basaltic eclogite at pressures equivalent to depths in the Earth of 120 - 180 km and temperatures of 700 - 1,200 degrees C. The resultant liquid/mineral partition coefficients constrain the recycling rates of key elements. The dichotomy of dehydration versus melting at 120 km depth is expressed through contrasting behaviour of many trace elements (U/Th, Sr, Ba, Be and the light rare-earth elements). At pressures equivalent to 180 km depth, however, a supercritical liquid with melt-like solubilities for the investigated trace elements is observed, even at low temperatures. This mobilizes most of the key trace elements ( except the heavy rare-earth elements, Y and Sc) and thus limits fluid-phase transfer of geochemical signatures in subduction zones to pressures less than 6 GPa.	Hebrew Univ Jerusalem, Inst Earth Sci, IL-91904 Jerusalem, Israel; ETH Zentrum, Inst Mineral & Petrog, CH-8092 Zurich, Switzerland	Hebrew University of Jerusalem; Swiss Federal Institutes of Technology Domain; ETH Zurich	Kessel, R (corresponding author), Hebrew Univ Jerusalem, Inst Earth Sci, IL-91904 Jerusalem, Israel.	kessel@vms.huji.ac.il	Schmidt, Max/A-1676-2008; Ulmer, Peter/G-4694-2018; Pettke, Thomas/M-5834-2018; Kessel, Ronit/A-3885-2017	Ulmer, Peter/0000-0001-9131-0669; Pettke, Thomas/0000-0002-5784-0639; Schmidt, Max W./0000-0002-3870-5781				BAKER MB, 1994, GEOCHIM COSMOCHIM AC, V58, P2811, DOI 10.1016/0016-7037(94)90116-3; BRENAN JM, 1995, GEOCHIM COSMOCHIM AC, V59, P3331, DOI 10.1016/0016-7037(95)00215-L; Brenan JM, 1998, GEOCHIM COSMOCHIM AC, V62, P3337, DOI 10.1016/S0016-7037(98)00224-5; Domanik KJ, 2000, LITHOS, V52, P51, DOI 10.1016/S0024-4937(99)00084-5; Elliott T, 1997, J GEOPHYS RES-SOL EA, V102, P14991, DOI 10.1029/97JB00788; Fumagalli P, 2005, J PETROL, V46, P555, DOI 10.1093/petrology/egh088; Green TH, 2000, LITHOS, V53, P165, DOI 10.1016/S0024-4937(00)00023-2; Hawkesworth CJ, 1997, SCIENCE, V276, P551, DOI 10.1126/science.276.5312.551; Johnson MC, 1999, GEOCHEM GEOPHY GEOSY, V1, DOI 10.1029/1999GC000014; Kelemen P.B., 2007, TREATISE GEOCHEMISTR, V3, P1, DOI [10.1016/B0-08-043751-6/03035-8, DOI 10.1016/B0-08-043751-6/03035-8]; Kerrick DM, 2001, NATURE, V411, P293, DOI 10.1038/35077056; Kessel R, 2005, EARTH PLANET SC LETT, V237, P873, DOI 10.1016/j.epsl.2005.06.018; Kessel R, 2004, AM MINERAL, V89, P1078; Kincaid C, 1997, J GEOPHYS RES-SOL EA, V102, P12295, DOI 10.1029/96JB03553; Klemme S, 2002, GEOCHIM COSMOCHIM AC, V66, P3109, DOI 10.1016/S0016-7037(02)00859-1; KUSHIRO I, 1992, P JPN ACAD B-PHYS, V68, P63, DOI 10.2183/pjab.68.63; KUSHIRO K, 1987, SPECIAL PUBLICATION, V1, P165; Martin H, 1999, LITHOS, V46, P411, DOI 10.1016/S0024-4937(98)00076-0; MORRIS JD, 1990, NATURE, V344, P31, DOI 10.1038/344031a0; Morris JD, 2003, TREATISE GEOCHEMISTR, V2, P451, DOI DOI 10.1016/B0-08-043751-6/02011-9; RYAN JG, 1995, SCIENCE, V270, P625, DOI 10.1126/science.270.5236.625; Schmidt MW, 2004, EARTH PLANET SC LETT, V228, P65, DOI 10.1016/j.epsl.2004.09.020; Schmidt MW, 2004, GEOCHIM COSMOCHIM AC, V68, P1889, DOI 10.1016/j.gca.2003.10.031; Schmidt MW, 1998, EARTH PLANET SC LETT, V163, P361, DOI 10.1016/S0012-821X(98)00142-3; Shen AH, 1997, NATURE, V385, P710, DOI 10.1038/385710a0; Sigmarsson O, 1998, NATURE, V394, P566, DOI 10.1038/29052; Stalder R, 1998, GEOCHIM COSMOCHIM AC, V62, P1781, DOI 10.1016/S0016-7037(98)00101-X; Stalder R, 2001, CONTRIB MINERAL PETR, V140, P607, DOI 10.1007/s004100000212; TATSUMI Y, 1986, J VOLCANOL GEOTH RES, V29, P293, DOI 10.1016/0377-0273(86)90049-1; Tatsumi Y., 1995, SUBDUCTION ZONE MAGM; Turner S, 1997, NATURE, V389, P568, DOI 10.1038/39257; YAXLEY GM, 1994, EARTH PLANET SC LETT, V128, P313, DOI 10.1016/0012-821X(94)90153-8	32	962	1019	14	259	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 29	2005	437	7059					724	727		10.1038/nature03971	http://dx.doi.org/10.1038/nature03971			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193050				2022-12-28	WOS:000232157900050
J	Marris, E				Marris, E			Taking quackery out of conservation	NATURE			English	News Item								In the past few years, efforts have been launched to make evaluation of conservation projects more rigorous and transparent. One such goal is to harmonize the terminology use. But measuring the effectiveness of a particular project isonly the start the data must be disseminated to be useful.											0	1	1	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 29	2005	437	7059					616	616						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16211691				2022-12-28	WOS:000232157900018
J	Zou, XD; Conradsson, T; Klingstedt, M; Dadachov, MS; O'Keeffe, M				Zou, XD; Conradsson, T; Klingstedt, M; Dadachov, MS; O'Keeffe, M			A mesoporous germanium oxide with crystalline pore walls and its chiral derivative	NATURE			English	Article							MOLECULAR-SIEVE; CHANNELS; SURFACES; DENSITY; SILICA	Microporous oxides are inorganic materials with wide applications in separations, ion exchange and catalysis(1-3). In such materials, an important determinant of pore size is the number of M ( where M = Si, Ge and so on) atoms in the rings delineating the channels(1). The important faujasite structure exhibits 12-ring structures while those of zeolites(4,5), germanates(6-8) and other(8) materials can be much larger. Recent attention has focused on mesoporous materials with larger pores of nanometre scale(9-11); however, with the exception of an inorganic - organic hybrid(12), these have amorphous pore walls, limiting many applications. Chiral porous oxides are particularly desirable for enantioselective sorption and catalysis(13). However, they are very rare in microporous(14,15) and mesoporous(16) materials. Here we describe a mesoporous germanium oxide, SU-M, with gyroidal channels separated by crystalline walls that lie about the G ( gyroid) minimal surface as in the mesoporous MCM-48 (ref. 9). It has the largest primitive cell and lowest framework density of any inorganic material and channels that are defined by 30-rings. One of the two gyroidal channel systems of SU-M can be filled with additional oxide, resulting in a mesoporous crystal (SU-MB) with chiral channels.	Stockholm Univ, SE-10691 Stockholm, Sweden; Corpuscular Inc, Mahopac, NY 10541 USA; Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA	Stockholm University; Arizona State University; Arizona State University-Tempe	Zou, XD (corresponding author), Stockholm Univ, SE-10691 Stockholm, Sweden.	zou@struc.su.se						ANDERSSON S, 1988, CHEM REV, V88, P221, DOI 10.1021/cr00083a011; ANDERSSON S, 1977, NATURE, V267, P605, DOI 10.1038/267605b0; Baiker A, 1998, CURR OPIN SOLID ST M, V3, P86, DOI 10.1016/S1359-0286(98)80070-3; Che S, 2004, NATURE, V429, P281, DOI 10.1038/nature02529; Cheetham AK, 1999, ANGEW CHEM INT EDIT, V38, P3268, DOI 10.1002/(SICI)1521-3773(19991115)38:22<3268::AID-ANIE3268>3.0.CO;2-U; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DAVIS ME, 1988, NATURE, V331, P698, DOI 10.1038/331698a0; Davis ME, 2002, NATURE, V417, P813, DOI 10.1038/nature00785; ESTERMANN M, 1991, NATURE, V352, P320, DOI 10.1038/352320a0; Ferey G, 2000, J SOLID STATE CHEM, V152, P37, DOI 10.1006/jssc.2000.8667; Friedrichs OD, 2003, ACTA CRYSTALLOGR A, V59, P22, DOI 10.1107/S0108767302018494; Gier TE, 1998, NATURE, V395, P154, DOI 10.1038/25960; HRILJAC JA, 1993, J SOLID STATE CHEM, V106, P66, DOI 10.1006/jssc.1993.1265; Inagaki S, 2002, NATURE, V416, P304, DOI 10.1038/416304a; Jacobs P., 2001, INTRO ZEOLITE SCI PR; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Lu QY, 2002, MICROPOR MESOPOR MAT, V56, P219, DOI 10.1016/S1387-1811(02)00488-2; Muller A, 1998, CHEM COMMUN, P1501, DOI 10.1039/a801804i; O'Keeffe M, 1999, NATURE, V400, P617, DOI 10.1038/23139; OKEEFFE M, 1996, CRYST STRUCT, V1, P289; OKEEFFE M, 2004, RETICULAR CHEM STRUC; Plevert J, 2001, J AM CHEM SOC, V123, P12706, DOI 10.1021/ja016996a; Plevert J, 2003, CHEM MATER, V15, P714, DOI 10.1021/cm020469o; Ravikovitch PI, 1998, ADV COLLOID INTERFAC, V76, P203, DOI 10.1016/S0001-8686(98)00047-5; Tang LQ, 2005, CHEM MATER, V17, P2530, DOI 10.1021/cm049373f; Terasaki O., 2004, MESOPOROUS RELATED N; Wang Y, 2003, ANGEW CHEM INT EDIT, V42, P4089, DOI 10.1002/anie.200351643; Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548; Zhou YM, 2001, ANGEW CHEM INT EDIT, V40, P2166, DOI 10.1002/1521-3773(20010601)40:11<2166::AID-ANIE2166>3.0.CO;2-C	29	246	251	3	130	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					716	719		10.1038/nature04097	http://dx.doi.org/10.1038/nature04097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193048				2022-12-28	WOS:000232157900048
J	Saha, D; Khan, WA; Karim, MM; Chowdhury, HR; Salam, MA; Bennish, ML				Saha, D; Khan, WA; Karim, MM; Chowdhury, HR; Salam, MA; Bennish, ML			Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial	LANCET			English	Article							DOUBLE-BLIND TRIAL; VIBRIO-CHOLERAE; CLINICAL-TRIAL; TYPHOID-FEVER; CHILDREN; TETRACYCLINE; DOXYCYCLINE; EFFICACY; ADULTS; SUSCEPTIBILITY	Background Single-dose ciprofloxacin is effective for the treatment of severe cholera in adults. We assessed whether single-dose ciprofloxacin would be as effective as 3-day, 12-dose erythromycin in achieving clinical cure in children with severe cholera. Methods We did a randomised, open label, controlled trial in children age 2-15 years with V cholerae 01 or 0139 present in stool on dark-field microscopy. Children received either a single 20 mg/kg dose of ciprofloxacin (n=90) or 12.5 mg/kg of erythromycin (n=90) every 6 h for 3 days, and remained in hospital for 5 days. The primary outcome was clinical success of treatment, defined as cessation of watery stools within 48 h of start of drug treatment. Analysis was per protocol. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN00142272. Findings Of 180 children randomised 162 completed the study. Treatment was clinically successful in 60% (47/78) of children treated with ciprofloxacin and in 55% (46/84) of those treated with erythromycin (difference 5% [95% Cl -10 to 21]). Children receiving ciprofloxacin vomited less often (58% vs 74%; difference 16% [2 to 30]), had fewer stools (15 vs 21; 6 [0 to 91), and less stool volume (152 vs 196 mL/kg; 43 mL/kg [13 to 87]) than those receiving erythromycin. Bacteriological failure was more common in ciprofloxacin-treated patients (58% vs 30%; 28% [13 to 43]) than erythromycin-treated patients. Interpretation Single-dose ciprofloxacin achieves clinical outcomes similar to, or better than, those achieved with 12-dose erythromycin treatment in childhood cholera, but is,less effective in eradicating V cholerae from stool.	Int Ctr Diarrhoeal Dis Res, Div Clin Sci, Ctr Hlth & Populat Res, Dhaka 1000, Bangladesh; Africa Ctr Hlth & Populat Studies, Mtubatuba, South Africa; Tufts Univ, Sch Med, New England Med Ctr, Div Geog Med & Infect Dis, Boston, MA 02111 USA; Univ Oxford, Nuffield Dept Clin Med, Oxford, England	International Centre for Diarrhoeal Disease Research (ICDDR); University of Kwazulu Natal; Tufts Medical Center; Tufts University; University of Oxford	Saha, D (corresponding author), Int Ctr Diarrhoeal Dis Res, Div Clin Sci, Ctr Hlth & Populat Res, GPO Box 128, Dhaka 1000, Bangladesh.	dsaha@icddrb.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI001671] Funding Source: NIH RePORTER; NIAID NIH HHS [K24 AI/HDO01671, UO1 AI45508-01] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALAM AN, 1990, BRIT MED J, V300, P1619, DOI 10.1136/bmj.300.6740.1619; [Anonymous], 2005, HSB (Health Science Bulletin), V3, P1; Bhattacharya MK, 2003, ACTA PAEDIATR, V92, P676, DOI 10.1080/08035250310002344; Doherty CP, 2000, ANN TROP PAEDIATR, V20, P297, DOI 10.1080/02724936.2000.11748151; ECHEVARRIA J, 1995, CLIN INFECT DIS, V20, P1480, DOI 10.1093/clinids/20.6.1480; FARRINGTON CP, 1990, STAT MED, V9, P1447, DOI 10.1002/sim.4780091208; Garg P, 2000, EPIDEMIOL INFECT, V124, P393, DOI 10.1017/S0950268899003957; GLASS RI, 1985, J INFECT DIS, V151, P236, DOI 10.1093/infdis/151.2.236; GLASS RI, 1980, J INFECT DIS, V142, P939, DOI 10.1093/infdis/142.6.939; GOTUZZO E, 1995, CLIN INFECT DIS, V20, P1485, DOI 10.1093/clinids/20.6.1485; Grady R, 2003, PEDIATR INFECT DIS J, V22, P1128, DOI 10.1097/01.inf.0000101994.25947.12; GREENOUGH WB, 1964, LANCET, V1, P355; Gupta R, 2001, SCIENCE, V293, P1049, DOI 10.1126/science.1061861; ISLAM MR, 1987, GUT, V28, P1029, DOI 10.1136/gut.28.8.1029; Jesudason MV, 2002, INDIAN J MED RES, V116, P96; Kabir I, 1996, J DIARRHOEAL DIS RES, V14, P243; KARCHMER A W, 1970, Bulletin of the World Health Organization, V43, P373; KHAN WA, 1995, T ROY SOC TROP MED H, V89, P103, DOI 10.1016/0035-9203(95)90675-4; Khan WA, 1996, LANCET, V348, P296, DOI 10.1016/S0140-6736(96)01180-4; Khan WA, 2002, LANCET, V360, P1722, DOI 10.1016/S0140-6736(02)11680-1; LEVINE M M, 1988, Lancet, V2, P467; LEVINE MM, 1988, INFECT IMMUN, V56, P161, DOI 10.1128/IAI.56.1.161-167.1988; LINDENBAUM J, 1967, B WORLD HEALTH ORGAN, V37, P529; *NAT CTR HLTH STAT, NAT CTR HLTH STAT GR; RABBANI GH, 1989, ANTIMICROB AGENTS CH, V33, P1447, DOI 10.1128/AAC.33.9.1447; RABBANI GH, 1991, ANTIMICROB AGENTS CH, V35, P1864, DOI 10.1128/AAC.35.9.1864; Roy SK, 1998, T ROY SOC TROP MED H, V92, P460, DOI 10.1016/S0035-9203(98)91094-X; SACK DA, 1978, ANTIMICROB AGENTS CH, V14, P462, DOI 10.1128/AAC.14.3.462; Slinger R, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-36; STROEHER UH, 1992, P NATL ACAD SCI USA, V89, P2566, DOI 10.1073/pnas.89.7.2566; Thomsen LL, 1998, SCAND J INFECT DIS, V30, P355, DOI 10.1080/00365549850160639; WHO, TREATM DIARRH MAN PH; 2002, PEDIAT INFECT DIS J, V21, P1136	33	29	30	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 24	2005	366	9491					1085	1093		10.1016/S0140-6736(05)67290-X	http://dx.doi.org/10.1016/S0140-6736(05)67290-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TL	16182896				2022-12-28	WOS:000232114000026
J	Gardosi, J; Kady, SM; McGeown, P; Francis, A; Tonks, A				Gardosi, J; Kady, SM; McGeown, P; Francis, A; Tonks, A			Classification of stillbirth by relevant condition at death (ReCoDe): population based cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLASSIFYING PERINATAL DEATH; BIRTH-WEIGHT; ANTEPARTUM STILLBIRTHS; GESTATIONAL-AGE; FETAL; MORTALITY; GROWTH	Objective To develop and test a new classification system. for stillbirths to help improve understanding of the main causes and conditions associated with fetal death. Design Population based cohort study. Setting West Midlands region. Subjects 2625 stillbirths from 1997 to 2003. Main outcome measures Categories of death according to conventional classification methods and a newly developed system (ReCoDe, relevant condition at death). Results By the conventional Wigglesworth classification, 66.2% of the stillbirths (1738 of 2625) were unexplained. The median gestational age of the unexplained group was 237 days, significantly higher than the stillbirths in the other categories (2 10 days; P < 0.001). The proportion of stillbirths that were unexplained was high regardless of whether a postmortem examination had been carried out or not (67% and 65%; P = 0.3). By the ReCoDe classification, the most common condition was fetal growth restriction (43.0%), and only 15.2% of stillbirths remained unexplained. ReCoDe identified 57.7% of the Wigglesworth unexplained stillbirths as growth restricted. The size of the category for intrapartum asphyxia was reduced from 11.7% (Wigglesworth) to 3.4% (ReCoDe). Conclusion The new ReCoDe classification system reduces the predominance of stillbirths currently categorised as unexplained. Fetal growth restriction is a common antecedent of stillbirth, but its high prevalence is hidden by current classification systems. This finding has profound implications for maternity services, and raises the question whether some hitherto "unexplained" stillbirths may be avoidable.	Perinatal Inst, Birmingham B6 5RQ, W Midlands, England		Gardosi, J (corresponding author), Perinatal Inst, Birmingham B6 5RQ, W Midlands, England.	gardosi@perinatal.nhs.uk	Francis, Andre/AAY-3807-2021; Gardosi, Jason/GXN-1375-2022	Gardosi, Jason/0000-0002-3230-1292				ALESSANDRI LM, 1992, BRIT J OBSTET GYNAEC, V99, P711, DOI 10.1111/j.1471-0528.1992.tb13868.x; BOUND JP, 1956, BMJ-BRIT MED J, V2, P1260, DOI 10.1136/bmj.2.5004.1260; BOUND JP, 1956, BRIT MED J, V2, P1191, DOI 10.1136/bmj.2.5003.1191; CHISWICK ML, 1986, J OBSTET GYNAECOLOGY, V86, P1236; Clausson B, 2001, BRIT J OBSTET GYNAEC, V108, P830, DOI 10.1111/j.1471-0528.2001.00205.x; COLE SK, 1986, BRIT J OBSTET GYNAEC, V93, P1204, DOI 10.1111/j.1471-0528.1986.tb07853.x; *CONF ENQ MAT CHIL, 2005, STILLB NEON POST NEO; Gardosi J, 1998, BRIT J OBSTET GYNAEC, V105, P524, DOI 10.1111/j.1471-0528.1998.tb10153.x; GARDOSI J, 1995, ULTRASOUND OBST GYN, V6, P168, DOI 10.1046/j.1469-0705.1995.06030168.x; GARDOSI J, 1992, LANCET, V339, P283, DOI 10.1016/0140-6736(92)91342-6; GENEST DR, 1992, OBSTET GYNECOL, V80, P575; HEPBURN M, 1986, BRIT J OBSTET GYNAEC, V93, P212, DOI 10.1111/j.1471-0528.1986.tb07895.x; HEY EN, 1986, BRIT J OBSTET GYNAEC, V93, P1213, DOI 10.1111/j.1471-0528.1986.tb07854.x; Huang DY, 2000, OBSTET GYNECOL, V95, P215, DOI 10.1016/S0029-7844(99)00536-0; MacLennan A, 1999, BMJ-BRIT MED J, V319, P1054, DOI 10.1136/bmj.319.7216.1054; *MAT CHILD HLTH CO, 2001, CESDI 8 ANN REP CONF; McCowan LME, 2005, BJOG-INT J OBSTET GY, V112, P1026, DOI 10.1111/j.1471-0528.2005.00656.x; MCILWAINE GM, 1979, BMJ-BRIT MED J, V2, P1103, DOI 10.1136/bmj.2.6198.1103; *SCOTT PROGR CLIN, 2000, SCOTT STILLB INF DEA; WHITFIELD CR, 1986, BRIT J OBSTET GYNAEC, V93, P694, DOI 10.1111/j.1471-0528.1986.tb08054.x; WIGGLESWORTH JS, 1980, LANCET, V2, P684; WILLIAMS RL, 1982, OBSTET GYNECOL, V59, P624	22	336	349	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	2005	331	7525					1113	1117		10.1136/bmj.38629.587639.7C	http://dx.doi.org/10.1136/bmj.38629.587639.7C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	985ZI	16236774	Green Published, Bronze			2022-12-28	WOS:000233417300014
J	Greenhalgh, T; Peacock, R				Greenhalgh, T; Peacock, R			Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources	BRITISH MEDICAL JOURNAL			English	Article								Objective To describe where papers come from in a systematic review of complex evidence. Method Audit of how the 495 primary sources for the review were originally identified. Results Only 30% of sources were obtained from the protocol defined at the outset of the study (that is, from the database and hand searches). Fifty one per cent were identified by "snowballing" (such as pursuing references of references), and 24% by personal knowledge or personal contacts. Conclusion Systematic reviews of complex evidence cannot rely solely on protocol-driven search strategies.	UCL, Sch Med, Dept Primary Care & Populat Sci, London N19 5LW, England; Archway Healthcare Lib, London, England	University of London; University College London; UCL Medical School	Greenhalgh, T (corresponding author), UCL, Sch Med, Dept Primary Care & Populat Sci, Holborn Union Bldg, London N19 5LW, England.	p.greenhalgh@pcps.ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015; Jolugbo, Olajide/D-3216-2017	Greenhalgh, Trisha/0000-0003-2369-8088; Jolugbo, Olajide/0000-0001-6512-4117				Dixon-Woods Mary, 2005, J Health Serv Res Policy, V10, P45, DOI 10.1258/1355819052801804; Greenhalgh T, 2005, SOC SCI MED, V61, P417, DOI 10.1016/j.socscimed.2004.12.001; Robert G., 2005, DIFFUSION INNOVATION; Royle P, 2003, INT J TECHNOL ASSESS, V19, P591, DOI 10.1017/S0266462303000552	4	971	986	2	47	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 5	2005	331	7524					1064	1065		10.1136/bmj.38636.593461.68	http://dx.doi.org/10.1136/bmj.38636.593461.68			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983DL	16230312	Green Published, Bronze			2022-12-28	WOS:000233211200026
J	Marmot, M; Horton, R; Grant, M				Marmot, M; Horton, R; Grant, M			International Institute for Society and Health	LANCET			English	Editorial Material									UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; The Lancet, London, England	University of London; University College London	Marmot, M (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Mortimer St, London WC1E 6BT, England.	m.marmot@ucl.ac.uk	Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G19/35, G0100222, G8802774] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Beaglehole R., 2003, WORLD HLTH REPORT 20; Farmer P., 1999, INFECT INEQUALITIES; KALACHE A, 2002, B WORLD HEALTH ORGAN, V80, P245; Lee JW, 2005, LANCET, V365, P1005; Manandhar DS, 2004, LANCET, V364, P970, DOI 10.1016/S0140-6736(04)17021-9; Marmot M, 2005, LANCET, V365, P1099, DOI 10.1016/S0140-6736(05)74234-3; Marmot M, 2004, STATUS SYNDROME; Marmot M, 2003, HLTH WEALTH LIFESTYL; *UNDP, 2005, HUM DEV REP 2005 INT; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7	10	2	2	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 15	2005	366	9494					1339	1340		10.1016/S0140-6736(05)67545-9	http://dx.doi.org/10.1016/S0140-6736(05)67545-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	973ZW	16226598				2022-12-28	WOS:000232562100007
J	Simpson, C; Franks, C; Morrison, C; Lempp, H				Simpson, C; Franks, C; Morrison, C; Lempp, H			The patient's journey: rheumatoid arthritis	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Guys Kings Coll, Univ London Kings Coll, Sch Med, Acad Dept Rheumatol, London SE5 9RJ, England; Kings Coll Hosp NHS Trust, Dept Rheumatol, London SE5 9RS, England	University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital	Lempp, H (corresponding author), Guys Kings Coll, Univ London Kings Coll, Sch Med, Acad Dept Rheumatol, London SE5 9RJ, England.	heidi.k.lempp@kcl.ac.uk	Lempp, Heidi/E-4959-2010; Lempp, Heidi/T-2914-2017	Lempp, Heidi/0000-0003-2509-3656				Scott DL, 2005, BEST PRACT RES CL RH, V19, P117, DOI 10.1016/j.berh.2004.08.007	1	24	26	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 15	2005	331	7521					887	889		10.1136/bmj.331.7521.887	http://dx.doi.org/10.1136/bmj.331.7521.887			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975SX	16223822	Green Published			2022-12-28	WOS:000232683300025
J	Fujiwara, T; Bandi, M; Nitta, M; Ivanova, EV; Bronson, RT; Pellman, D				Fujiwara, T; Bandi, M; Nitta, M; Ivanova, EV; Bronson, RT; Pellman, D			Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells	NATURE			English	Article							MAMMALIAN-CELLS; CHROMOSOME INSTABILITY; TELOMERE DYSFUNCTION; CANCER PROGRESSION; GENOME INSTABILITY; P53; MODEL; TRANSLOCATIONS; SEGREGATION; SUPPRESSOR	A long-standing hypothesis on tumorigenesis is that cell division failure, generating genetically unstable tetraploid cells, facilitates the development of aneuploid malignancies(1-3). Here we test this idea by transiently blocking cytokinesis in p53-null (p53(-/-)) mouse mammary epithelial cells (MMECs), enabling the isolation of diploid and tetraploid cultures. The tetraploid cells had an increase in the frequency of whole-chromosome mis-segregation and chromosomal rearrangements. Only the tetraploid cells were transformed in vitro after exposure to a carcinogen. Furthermore, in the absence of carcinogen, only the tetraploid cells gave rise to malignant mammary epithelial cancers when transplanted subcutaneously into nude mice. These tumours all contained numerous non-reciprocal translocations and an 8-30-fold amplification of a chromosomal region containing a cluster of matrix metalloproteinase (MMP) genes. MMP overexpression is linked to mammary tumours in humans and animal models(4). Thus, tetraploidy enhances the frequency of chromosomal alterations and promotes tumour development in p53(-/-) MMECs.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Tufts Univ, Sch Vet, Dept Biomed Sci, North Grafton, MA 01536 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Tufts University	Pellman, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.	david_pellman@dfci.harvard.edu		Ivanova, Elena/0000-0002-5069-4974				Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; Boveri T, 1929, ORIGIN MALIGNANT TUM; Brennan C, 2004, CANCER RES, V64, P4744, DOI 10.1158/0008-5472.CAN-04-1241; CARTER SB, 1967, NATURE, V213, P261, DOI 10.1038/213261a0; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; David G, 2003, GENE DEV, V17, P2396, DOI 10.1101/gad.1109403; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Feldser DM, 2003, NAT REV CANCER, V3, P623, DOI 10.1038/nrc1142; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; Lin HJ, 2001, J CELL BIOL, V155, P1173, DOI 10.1083/jcb.200108119; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MAYER VW, 1990, MUTAT RES, V231, P177, DOI 10.1016/0027-5107(90)90024-X; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; OLAHARSKI AJ, 2005, CARCINOGENESIS; Pihan GA, 2003, CANCER RES, V63, P1398; SHACKNEY SE, 1989, CANCER RES, V49, P3344; SHI Q, NATURE; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Stukenberg PT, 2004, J CELL BIOL, V165, P607, DOI 10.1083/jcb.200405089; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140	30	767	775	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	2005	437	7061					1043	1047		10.1038/nature04217	http://dx.doi.org/10.1038/nature04217			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16222300				2022-12-28	WOS:000232496100049
J	Greenough, PG; Kirsch, TD				Greenough, PG; Kirsch, TD			Hurricane Katrina - Public health response - Assessing needs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Amer Red Cross, Washington, DC 20006 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; American Red Cross	Greenough, PG (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.							[Anonymous], 1997, PUBLIC HLTH CONSEQUE; Centers for Disease Control and Prevention, HLTH AL NETW; EHRENKRANZ NJ, 1971, NEW ENGL J MED, V285, P1460, DOI 10.1056/NEJM197112232852606; Health, 2005, MED BENEFITS, V22, P12; Saenz R, 1995, Prehosp Disaster Med, V10, P154	5	36	36	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1544	1546		10.1056/NEJMp058238	http://dx.doi.org/10.1056/NEJMp058238			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221772				2022-12-28	WOS:000232486000003
J	Hopkin, M				Hopkin, M			The life of a hobbit	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 13	2005	437	7061					935	935						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16237785				2022-12-28	WOS:000232496100007
J	Ward, JI; Cherry, JD; Chang, SJ; Partridge, S; Lee, H; Treanor, J; Greenberg, DP; Keitel, W; Barenkamp, S; Bernstein, DI; Edelman, R; Edwards, K				Ward, JI; Cherry, JD; Chang, SJ; Partridge, S; Lee, H; Treanor, J; Greenberg, DP; Keitel, W; Barenkamp, S; Bernstein, DI; Edelman, R; Edwards, K		APERT Study Grp	Efficacy of an acellular pertussis vaccine among adolescents and adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BORDETELLA-PERTUSSIS; UNITED-STATES; ANTIBODY; TRIAL; ANTIGENS; IDENTIFICATION; EPIDEMIOLOGY; INFECTION; SPECIMENS; RESPONSES	BACKGROUND: Pertussis immunization of adults may be necessary to improve the control of a rising burden of disease and infection. This trial of an acellular pertussis vaccine among adolescents and adults evaluated the incidence of pertussis, vaccine safety, immunogenicity, and protective efficacy. METHODS: Bordetella pertussis infections and illnesses were prospectively assessed in 2781 healthy subjects between the ages of 15 and 65 years who were enrolled in a national multicenter, randomized, double-blind trial of an acellular pertussis vaccine. Subjects received either a dose of a tricomponent acellular pertussis vaccine or a hepatitis A vaccine (control) and were monitored for 2.5 years for illnesses with cough that lasted for more than 5 days. Each illness was evaluated with use of a nasopharyngeal aspirate for culture and polymerase-chain-reaction assay, and serum samples from patients in both acute and convalescent stages of illness were analyzed for changes in antibodies to nine B. pertussis antigens. RESULTS: Of the 2781 subjects, 1391 received the acellular pertussis vaccine and 1390 received the control vaccine. The groups had similar ages and demographic characteristics, and the median duration of follow-up was 22 months. The acellular pertussis vaccine was safe and immunogenic. There were 2672 prolonged illnesses with cough, but the incidence of this nonspecific outcome did not vary between the groups, even when stratified according to age, season, and duration of cough. On the basis of the primary pertussis case definition, vaccine protection was 92 percent (95 percent confidence interval, 32 to 99 percent). Among unimmunized controls with illness, 0.7 percent to 5.7 percent had B. pertussis infection, and the percentage increased with the duration of cough. On the basis of other case definitions, the incidence of pertussis in the controls ranged from 370 to 450 cases per 100,000 person-years. CONCLUSIONS: The acellular pertussis vaccine was protective among adolescents and adults, and its routine use might reduce the overall disease burden and transmission to children.	Univ Calif Los Angeles, David Geffen Sch Med, Harbor UCLA Med Ctr, Res & Educ Inst,Ctr Vaccine Res,LA Biomed, Torrance, CA 90502 USA; Univ Rochester, Rochester, NY USA; Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Pittsburgh, PA USA; Baylor Coll Med, Houston, TX 77030 USA; St Louis Univ, St Louis, MO 63103 USA; Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA; Vanderbilt Univ, Med Ctr, Pediat Clin Res Off, Nashville, TN USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Lundquist Institute; University of Rochester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Baylor College of Medicine; Saint Louis University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Vanderbilt University	Ward, JI (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Harbor UCLA Med Ctr, Res & Educ Inst,Ctr Vaccine Res,LA Biomed, Torrance, CA 90502 USA.		Datta, Samik/S-3822-2016; Barenkamp, Stephen J./I-9390-2019	Barenkamp, Stephen J./0000-0002-3054-8910	NIAID NIH HHS [N01-AI-45249] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045249] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baron S, 1998, PEDIATR INFECT DIS J, V17, P412, DOI 10.1097/00006454-199805000-00013; BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; Bisgard KM, 2004, PEDIATR INFECT DIS J, V23, P985, DOI 10.1097/01.inf.0000145263.37198.2b; Cherry J D, 1984, Curr Probl Pediatr, V14, P1; Cherry JD, 1999, CLIN INFECT DIS, V28, pS112, DOI 10.1086/515058; Cherry JD, 2005, PEDIATRICS, V115, P1422, DOI 10.1542/peds.2004-2648; Cherry JD, 2005, PEDIATRICS, V116, P755, DOI 10.1542/peds.2005-0960; Cherry JD, 2004, CLIN INFECT DIS, V39, P1715, DOI 10.1086/425003; CHERRY JD, 1995, CLIN INFECT DIS, V20, P1271, DOI 10.1093/clinids/20.5.1271; CHERRY JD, 2004, TXB PEDIAT INFECT DI, P1588; Crowcroft NS, 2003, ARCH DIS CHILD, V88, P802, DOI 10.1136/adc.88.9.802; DEEN JL, 1995, CLIN INFECT DIS, V21, P1211, DOI 10.1093/clinids/21.5.1211; EDWARDS KM, 2004, VACCINES, P471; HALLANDER HO, 1993, J CLIN MICROBIOL, V31, P50, DOI 10.1128/JCM.31.1.50-52.1993; HEININGER U, 1993, PEDIATR INFECT DIS J, V12, P504, DOI 10.1097/00006454-199306000-00009; Heininger U, 2004, CLIN INFECT DIS, V38, P591, DOI 10.1086/381439; Hodder SL, 2000, CLIN INFECT DIS, V31, P7, DOI 10.1086/313913; HOUARD S, 1989, RES MICROBIOL, V140, P477, DOI 10.1016/0923-2508(89)90069-7; Keitel WA, 1999, J INFECT DIS, V180, P397, DOI 10.1086/314869; Le T, 2004, J INFECT DIS, V190, P535, DOI 10.1086/422035; Manclark CR, 1986, MANUAL CLIN LAB IMMU, V3rd, P388; MINK CM, 1992, CLIN INFECT DIS, V14, P464, DOI 10.1093/clinids/14.2.464; Nelson S, 1997, J CLIN MICROBIOL, V35, P117, DOI 10.1128/JCM.35.1.117-120.1997; PICHICHERO ME, IN PRESS PEDIATRICS; PICKERING LK, 2003, RED BOOK 2003 REPORT, P472; Purdy KW, 2004, CLIN INFECT DIS, V39, P20, DOI 10.1086/421091; SCHLAPFER G, 1995, PEDIATR INFECT DIS J, V14, P209, DOI 10.1097/00006454-199503000-00008; Southern J, 2005, VACCINE, V23, P3829, DOI 10.1016/j.vaccine.2005.02.030; Strebel P, 2001, J INFECT DIS, V183, P1353, DOI 10.1086/319853; Tanaka M, 2003, JAMA-J AM MED ASSOC, V290, P2968, DOI 10.1001/jama.290.22.2968; Van der Wielen M, 2000, VACCINE, V18, P2075, DOI 10.1016/S0264-410X(99)00568-X; Van Rie A, 2004, VACCINE, V22, P3154, DOI 10.1016/j.vaccine.2004.01.067; Vincent JM, 2000, CLIN INFECT DIS, V30, P534, DOI 10.1086/313707; Vitek CR, 2003, PEDIATR INFECT DIS J, V22, P628, DOI 10.1097/00006454-200307000-00012; 2002, MMWR MORB MORTAL WKL, V51, P73	35	278	293	2	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1555	1563		10.1056/NEJMoa050824	http://dx.doi.org/10.1056/NEJMoa050824			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221778				2022-12-28	WOS:000232486000009
J	Finne, P; Reunanen, A; Stenman, S; Groop, PH; Gronhagen-Riska, C				Finne, P; Reunanen, A; Stenman, S; Groop, PH; Gronhagen-Riska, C			Incidence of end-stage renal disease in patients with type 1 diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DECLINING INCIDENCE; IDDM PATIENTS; NEPHROPATHY; MELLITUS; MORTALITY; PROTEINURIA; FINLAND; AGE; MICROALBUMINURIA; PREDICTOR	Context End-stage renal disease (ESRD) is one of the most severe complications of type 1 diabetes. Yet, data on patients' risk of developing ESRD are sparse. Objectives To estimate the long-term risk of developing ESRD and to assess how age at diagnosis of diabetes, time period of diagnosis, and sex affect the risk. Design, Setting, and Patients A cohort of all patients younger than 30 years diagnosed as having type 1 diabetes in Finland in 1965-1999 (n=20005)was identified from the Finnish Diabetes Register. The cohort was followed up from diagnosis of diabetes until development of ESRD (dialysis or kidney transplantation as identified from the Finnish Registry for Kidney Diseases), death, or end of follow-up on December 31, 2001. Main Outcome Measure Cumulative incidence of ESRD, accounting for death as a competing risk. Results The cohort was followed up for maximally 37 years, with a median of 16.7 years. During 346851 person-years, 632 patients developed ESRD. The cumulative incidence of ESRD was 2.2% at 20 years and 7.8% at 30 years after diagnosis. The risk of developing ESRD was lowest in patients whose diagnosis occurred at younger than 5 years. The risk of ESRD was lower for patients diagnosed as having type 1 diabetes in later years. The risk did not differ significantly between sexes. Conclusions With regard to ESRD, the prognosis of type 1 diabetes has improved during the past 4 decades. Children diagnosed as having diabetes before age 5 years have the most favorable prognosis. Overall, incidence of ESRD appears to be lower than previously estimated.	Univ Helsinki, Cent Hosp, Finnish Registry Kidney Dis, Helsinki, Finland; Univ Helsinki, Cent Hosp, Natl Publ Hlth Inst, Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Med, Div Nephrol, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital	Finne, P (corresponding author), Univ Helsinki, Biomedicum Helsinki A424B, Dept Clin Chem, POB 700, FIN-00029 Helsinki, Finland.	patrik.finne@hus.fi						ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; Asao K, 2003, DIABETES CARE, V26, P2037, DOI 10.2337/diacare.26.7.2037; BOJESTIG M, 1994, NEW ENGL J MED, V330, P15, DOI 10.1056/NEJM199401063300103; BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; CAILLATZUCMAN S, 1992, J CLIN INVEST, V90, P2242, DOI 10.1172/JCI116110; DEMAINE AG, 1995, DIABETOLOGIA, V38, P623, DOI 10.1007/s001250050329; Donaghue KC, 2003, DIABETES CARE, V26, P1224, DOI 10.2337/diacare.26.4.1224; EKSTRAND A, 1987, ACTA MED SCAND, V222, P251; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; *FINN REG KIDN DIS, 2004, REP 2003; Hovind P, 2004, BRIT MED J, V328, P1105, DOI 10.1136/bmj.38070.450891.FE; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; Karvonen M, 2000, DIABETES CARE, V23, P1516, DOI 10.2337/diacare.23.10.1516; KOFOEDENEVOLDSEN A, 1987, DIABETES, V36, P205, DOI 10.2337/diabetes.36.2.205; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; Krolewski M, 1996, KIDNEY INT, V50, P2041, DOI 10.1038/ki.1996.527; LAPORTE RE, 1991, DIABETES CARE, V14, P49; MATSUSHIMA M, 1995, DIABETOLOGIA, V38, P236, DOI 10.1007/BF00400100; Schultz CJ, 1999, DIABETES CARE, V22, P495, DOI 10.2337/diacare.22.3.495; TUOMILEHTO J, 1995, INT J EPIDEMIOL, V24, P984, DOI 10.1093/ije/24.5.984; Tuomilehto J, 1997, DIABETES CARE, V20, P1081, DOI 10.2337/diacare.20.7.1081; *US REN DAT SYST, 2003, USRDS 2003 ANN DAT R; Wysocki T, 2003, DIABETES CARE, V26, P2043, DOI 10.2337/diacare.26.7.2043	24	182	186	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	2005	294	14					1782	1787		10.1001/jama.294.14.1782	http://dx.doi.org/10.1001/jama.294.14.1782			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972RX	16219881	Bronze, Green Accepted			2022-12-28	WOS:000232472000017
J	Fazel, S; Benning, R; Danesh, J				Fazel, S; Benning, R; Danesh, J			Suicides in male prisoners in England and Wales, 1978-2003	LANCET			English	Article							MORTALITY	The number of suicides in English and Welsh prisons is increasing, but the excess compared with the general population has not been reliably quantified. We therefore compared, in narrow age bands, all 1312 suicides of male prisoners in England and Wales between 1978 and 2003 with suicide rates in the general male population. The overall standardised mortality ratio for suicide was 5.1 (95% Cl, 4.8-5.3), suggesting a five-fold excess of suicides in male prisoners, with a particulary striking excess in boys aged 15-17 years (standardised mortality ratio 18 [13-26]). The proportional excess of suicides of male prisoners has been increasing during the past quarter of a century, which underscores the need for substantial improvements in suicide prevention in prisons.	Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England	University of Oxford; University of Cambridge	Fazel, S (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.	seena.fazel@psychiatry.oxford.ac.uk	Fazel, Seena/B-5307-2008	Fazel, Seena/0000-0002-5383-5365				DOOLEY E, 1990, BRIT J PSYCHIAT, V156, P40, DOI 10.1192/bjp.156.1.40; DREVER F, 1997, HLTH INEQUALITIES S; Fazel S, 2002, LANCET, V359, P545, DOI 10.1016/S0140-6736(02)07740-1; Gunnell D, 2003, LANCET, V362, P961, DOI 10.1016/S0140-6736(03)14367-X; Rose David, 1998, ESRC REV GOVT SOCIAL; SALIVE ME, 1989, JAMA-J AM MED ASSOC, V262, P365; Shaw J, 2004, BRIT J PSYCHIAT, V184, P263, DOI 10.1192/bjp.184.3.263; SKEGG K, 1991, LANCET, V338, P1436, DOI 10.1016/0140-6736(91)92732-H	8	104	104	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 8	2005	366	9493					1301	1302		10.1016/S0140-6736(05)67325-4	http://dx.doi.org/10.1016/S0140-6736(05)67325-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	971ST	16214601				2022-12-28	WOS:000232405700029
J	Frenz, P; Videla, C				Frenz, P; Videla, C			A public-health campaign to raise awareness of children' wellbeing with images drawn by children	LANCET			English	Editorial Material									Minist Salud, Santiago, Chile; Corp Municipal San Joaquin, Direcc Salud, Santiago, Chile		Frenz, P (corresponding author), Minist Salud, Maclver 541, Santiago, Chile.	pfrenz@minsal.cl						*DIR SAL CORP MUN, 2004, ESC CONT PROT SAL ME; LARRAIN S, 2001, ESTUDIO COMP MALTRAT	2	3	3	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 8	2005	366	9493					1324	1329		10.1016/S0140-6736(05)67532-0	http://dx.doi.org/10.1016/S0140-6736(05)67532-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	971ST	16214604				2022-12-28	WOS:000232405700032
J	Giles, J				Giles, J			Innovation endgame	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 6	2005	437	7060					813	813		10.1038/437813a	http://dx.doi.org/10.1038/437813a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	970VB	16208341	hybrid			2022-12-28	WOS:000232338600017
J	Yager, J; Andersen, AE				Yager, J; Andersen, AE			Anorexia nervosa	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EATING-DISORDERS; ANXIETY DISORDERS; INPATIENT TREATMENT; INDIVIDUAL THERAPY; BEHAVIOR-THERAPY; CLINICAL-COURSE; FOLLOW-UP; MORTALITY; ADOLESCENTS; COMORBIDITY		Univ New Mexico, Sch Med, Dept Psychiat, Albuquerque, NM 87131 USA; Univ Iowa, Sch Med, Dept Psychiat, Iowa City, IA 52242 USA	University of New Mexico; University of Iowa	Yager, J (corresponding author), Univ New Mexico 1, Dept Psychiat, MSC09 5030, Albuquerque, NM 87131 USA.	jyager@unm.edu						American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], 2000, Am J Psychiatry, V157, P1; Attia E, 1998, AM J PSYCHIAT, V155, P548, DOI 10.1176/ajp.155.4.548; Barbarich NC, 2004, J CLIN PSYCHIAT, V65, P1480, DOI 10.4088/JCP.v65n1106; Beumont P, 2004, AUST NZ J PSYCHIAT, V38, P819; Bulik CM, 2004, J CLIN PSYCHIAT, V65, P1000; Bulik CM, 1997, ACTA PSYCHIAT SCAND, V96, P101, DOI 10.1111/j.1600-0447.1997.tb09913.x; Bulik CM, 1999, J CLIN PSYCHIAT, V60, P130, DOI 10.4088/JCP.v60n0212; CRISP AH, 1992, BRIT J PSYCHIAT, V161, P104, DOI 10.1192/bjp.161.1.104; Crow SJ, 2004, INT J EAT DISORDER, V35, P155, DOI 10.1002/eat.10258; Dare C, 2001, BRIT J PSYCHIAT, V178, P216, DOI 10.1192/bjp.178.3.216; DIX A, 2004, HLTH SERV J, V114, P28; Ebeling H, 2003, ANN MED, V35, P488, DOI 10.1080/07853890310000727; ECKERT ED, 1995, PSYCHOL MED, V25, P143, DOI 10.1017/S0033291700028166; Eisler I, 1997, ARCH GEN PSYCHIAT, V54, P1025; Garfinkel PE, 1996, BRIT J PSYCHIAT, V168, P500, DOI 10.1192/bjp.168.4.500; Godart NT, 2003, PSYCHIAT RES, V117, P245, DOI 10.1016/S0165-1781(03)00038-6; Golden Neville H, 2003, Adolesc Med, V14, P97; Golden Neville H, 2002, J Pediatr Adolesc Gynecol, V15, P135, DOI 10.1016/S1083-3188(02)00145-6; Grinspoon S, 2002, J CLIN ENDOCR METAB, V87, P2883, DOI 10.1210/jc.87.6.2883; Halmi KA, 2003, INT J EAT DISORDER, V33, P308, DOI 10.1002/eat.10138; HALMI KA, 1991, ARCH GEN PSYCHIAT, V48, P712; Harris EC, 1998, BRIT J PSYCHIAT, V173, P11, DOI 10.1192/bjp.173.1.11; Hay P, 2004, AUST NZ J PSYCHIAT, V38, P659, DOI 10.1080/j.1440-1614.2004.01449.x; HAY P, 2003, COCHRANE DB SYST REV, V4; Herzog DB, 2000, INT J EAT DISORDER, V28, P20, DOI 10.1002/(SICI)1098-108X(200007)28:1&lt;20::AID-EAT3&gt;3.0.CO;2-X; Hoek HW, 2003, INT J EAT DISORDER, V34, P383, DOI 10.1002/eat.10222; Howard WT, 1999, AM J PSYCHIAT, V156, P1697; Johnson JG, 2002, ARCH GEN PSYCHIAT, V59, P545, DOI 10.1001/archpsyc.59.6.545; Kaplan DW, 2003, PEDIATRICS, V111, P204, DOI 10.1542/peds.111.1.204; Kaye WH, 2004, AM J PSYCHIAT, V161, P2215, DOI 10.1176/appi.ajp.161.12.2215; Kaye WH, 2001, BIOL PSYCHIAT, V49, P644, DOI 10.1016/S0006-3223(00)01013-1; Keel PK, 2003, ARCH GEN PSYCHIAT, V60, P179, DOI 10.1001/archpsyc.60.2.179; Kohn MR, 1998, J ADOLESCENT HEALTH, V22, P239, DOI 10.1016/S1054-139X(97)00163-8; Lambe EK, 1997, ARCH GEN PSYCHIAT, V54, P537; Lantzouni E, 2002, J ADOLESCENT HEALTH, V31, P162, DOI 10.1016/S1054-139X(02)00342-7; Malina A, 2003, INT J EAT DISORDER, V33, P234, DOI 10.1002/eat.10122; McIntosh VVW, 2005, AM J PSYCHIAT, V162, P741, DOI 10.1176/appi.ajp.162.4.741; Okamoto A, 2002, PSYCHIAT CLIN NEUROS, V56, P515, DOI 10.1046/j.1440-1819.2002.01047.x; Pike KM, 2003, AM J PSYCHIAT, V160, P2046, DOI 10.1176/appi.ajp.160.11.2046; Powers PS, 2002, INT J EAT DISORDER, V32, P146, DOI 10.1002/eat.10084; RIGOTTI NA, 1991, JAMA-J AM MED ASSOC, V265, P1133, DOI 10.1001/jama.265.9.1133; Robb AS, 2002, AM J PSYCHIAT, V159, P1347, DOI 10.1176/appi.ajp.159.8.1347; Robin AL, 1999, J AM ACAD CHILD PSY, V38, P1482, DOI 10.1097/00004583-199912000-00008; Spear BA, 2001, J AM DIET ASSOC, V101, P810, DOI 10.1016/S0002-8223(01)00201-2; Steiner H., 2003, EUR CHILD ADOLES PSY, V12, pI38, DOI [10.1007/s00787-003-1106-8, DOI 10.1007/S00787-003-1106-8, DOI 10.1007/s00787-003-1106-8]; Strober M, 1999, INT J EAT DISORDER, V25, P135, DOI 10.1002/(SICI)1098-108X(199903)25:2<135::AID-EAT2>3.0.CO;2-1; Strober M, 1999, J CHILD ADOL PSYCHOP, V9, P195, DOI 10.1089/cap.1999.9.195; Strober M, 1997, INT J EAT DISORDER, V22, P339, DOI 10.1002/(SICI)1098-108X(199712)22:4&lt;339::AID-EAT1&gt;3.0.CO;2-N; Urwin RE, 2005, EUR J HUM GENET, V13, P370, DOI 10.1038/sj.ejhg.5201328; Vestergaard P, 2002, INT J EAT DISORDER, V32, P301, DOI 10.1002/eat.10101; Vitousek K, 1998, CLIN PSYCHOL REV, V18, P391, DOI 10.1016/S0272-7358(98)00012-9; Watson TL, 2000, AM J PSYCHIAT, V157, P1806, DOI 10.1176/appi.ajp.157.11.1806; Westen D, 2001, AM J PSYCHIAT, V158, P547, DOI 10.1176/appi.ajp.158.4.547; Wolfe BE, 2003, NURS CLIN N AM, V38, P75, DOI 10.1016/S0029-6465(02)00064-6	55	79	83	2	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 6	2005	353	14					1481	1488		10.1056/NEJMcp050187	http://dx.doi.org/10.1056/NEJMcp050187			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970LZ	16207850				2022-12-28	WOS:000232313000008
J	Nybakken, GE; Oliphant, T; Johnson, S; Burke, S; Diamond, MS; Fremont, DH				Nybakken, GE; Oliphant, T; Johnson, S; Burke, S; Diamond, MS; Fremont, DH			Structural basis of West Nile virus neutralization by a therapeutic antibody	NATURE			English	Article							DENGUE VIRUS; ENVELOPE PROTEIN; ENCEPHALITIS-VIRUS; MEMBRANE-FUSION; DOMAIN-III; DISSEMINATED INFECTION; MONOCLONAL-ANTIBODY; BINDING; CELLS; GLYCOPROTEIN	West Nile virus is a mosquito-borne flavivirus closely related to the human epidemic-causing dengue, yellow fever and Japanese encephalitis viruses(1). In establishing infection these icosahedral viruses undergo endosomal membrane fusion catalysed by envelope glycoprotein rearrangement of the putative receptor-binding domain III (DIII) and exposure of the hydrophobic fusion loop(2-4). Humoral immunity has an essential protective function early in the course of West Nile virus infection(5,6). Here, we investigate the mechanism of neutralization by the E16 monoclonal antibody that specifically binds DIII. Structurally, the E16 antibody Fab fragment engages 16 residues positioned on four loops of DIII, a consensus neutralizing epitope sequence conserved in West Nile virus and distinct in other flaviviruses. The E16 epitope protrudes from the surface of mature virions in three distinct environments(7), and docking studies predict Fab binding will leave fivefold clustered epitopes exposed. We also show that E16 inhibits infection primarily at a step after viral attachment, potentially by blocking envelope glycoprotein conformational changes. Collectively, our results suggest that a vaccine strategy targeting the dominant DIII epitope may elicit safe and effective immune responses against flaviviral diseases.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; MacroGenics, Rockville, MD 20850 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Fremont, DH (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.	Fremont@wustl.edu	Diamond, Michael/AAH-1733-2019	Diamond, Michael/0000-0002-8791-3165; Fremont, Daved/0000-0002-8544-2689				Booy FP, 1998, J MOL BIOL, V281, P95, DOI 10.1006/jmbi.1998.1920; Bressanelli S, 2004, EMBO J, V23, P728, DOI 10.1038/sj.emboj.7600064; Chao G, 2004, J MOL BIOL, V342, P539, DOI 10.1016/j.jmb.2004.07.053; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001; Diamond MS, 2003, VIRAL IMMUNOL, V16, P259, DOI 10.1089/088282403322396082; Diamond MS, 2003, J VIROL, V77, P2578, DOI 10.1128/JVI.77.4.2578-2586.2003; Earp LJ, 2005, CURR TOP MICROBIOL, V285, P25; GOLLINS SW, 1986, NATURE, V321, P244, DOI 10.1038/321244a0; Granwehr BP, 2004, LANCET INFECT DIS, V4, P547, DOI 10.1016/S1473-3099(04)01128-4; Halstead SB, 2003, ADV VIRUS RES, V60, P421, DOI 10.1016/S0065-3527(03)60011-4; HALSTEAD SB, 1977, NATURE, V265, P739, DOI 10.1038/265739a0; Hiramatsu K, 1996, VIROLOGY, V224, P437, DOI 10.1006/viro.1996.0550; Hung SL, 1999, VIROLOGY, V257, P156, DOI 10.1006/viro.1999.9633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067; Mukhopadhyay S, 2003, SCIENCE, V302, P248, DOI 10.1126/science.1089316; Oliphant T, 2005, NAT MED, V11, P522, DOI 10.1038/nm1240; Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Sundberg EJ, 2003, ADV PROTEIN CHEM, V61, P119; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; Tio PH, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-25; Volk DE, 2004, J BIOL CHEM, V279, P38755, DOI 10.1074/jbc.M402385200; Wang T, 2004, CURR OPIN IMMUNOL, V16, P519, DOI 10.1016/j.coi.2004.05.008; Wu KP, 2003, J BIOL CHEM, V278, P46007, DOI 10.1074/jbc.M307776200; Zolla-Pazner S, 2004, NAT REV IMMUNOL, V4, P199, DOI 10.1038/nri1307	30	279	305	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 29	2005	437	7059					764	768		10.1038/nature03956	http://dx.doi.org/10.1038/nature03956			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193056	Bronze, Green Published			2022-12-28	WOS:000232157900059
J	Ayscough, KR				Ayscough, KR			Defining protein modules for endocytosis	CELL			English	Editorial Material							MEDIATED ENDOCYTOSIS; ACTIN; CLATHRIN; RECRUITMENT; MACHINERY; DYNAMICS	Endocytosis is a complex process that controls the composition of the plasma membrane, nutrient uptake, and the regulation of cell signaling in eukaryotic cells. In this issue of Cell, Kaksonen et al. (2005) use real-time microscopy of yeast to reveal major insights, at the molecular level, into the spatial and temporal aspects of this critical process.	Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Ayscough, KR (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, 5th Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.							Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Jonsdottir GA, 2004, CURR BIOL, V14, P1604, DOI 10.1016/j.cub.2004.08.055; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Kaksonen M, 2005, CELL, V123, P305, DOI 10.1016/j.cell.2005.09.024; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Merrifield CJ, 2004, EUR J CELL BIOL, V83, P13, DOI 10.1078/0171-9335-00356; Newpher TM, 2005, DEV CELL, V9, P87, DOI 10.1016/j.devcel.2005.04.014; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Warren DT, 2002, J CELL SCI, V115, P1703	10	6	6	1	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	2005	123	2					188	190		10.1016/j.cell.2005.10.008	http://dx.doi.org/10.1016/j.cell.2005.10.008			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239136	Bronze			2022-12-28	WOS:000232794100005
J	Kao, JH; Chen, DS				Kao, JH; Chen, DS			Hepatitis B vaccination: to boost or not to boost?	LANCET			English	Editorial Material							VIRUS-INFECTION; VIRAL-HEPATITIS; PROTECTION; TAIWAN; IMMUNOGENICITY; IMMUNITY; CHILDREN; INFANTS; LESSONS		Natl Taiwan Univ Hosp, Dept Internal Med, Grad Inst Clin Med, Hepatitis Res Ctr, Taipei 10051, Taiwan; Natl Taiwan Univ Hosp, Dept Med Res, Grad Inst Clin Med, Hepatitis Res Ctr, Taipei 10051, Taiwan; Natl Taiwan Univ, Coll Med, Taipei 10051, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Chen, DS (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, Grad Inst Clin Med, Hepatitis Res Ctr, Taipei 10051, Taiwan.	dschen@ha.mc.ntu.edu.tw	Kao, Jia-Horng/AAB-8947-2019	Kao, Jia-Horng/0000-0002-2442-7952; CHEN, DING-SHINN/0000-0001-7791-6154				Banatvala J, 2000, VACCINE, V19, P877, DOI 10.1016/S0264-410X(00)00224-3; Boxall EH, 2004, J INFECT DIS, V190, P1264, DOI 10.1086/423818; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; CHEN DS, 1993, SCIENCE, V262, P369, DOI 10.1126/science.8211155; CHEN DS, 1987, JAMA-J AM MED ASSOC, V257, P2597; Chen DS, 2005, ANN INTERN MED, V142, P384, DOI 10.7326/0003-4819-142-5-200503010-00014; Chen DS, 1996, J FORMOS MED ASSOC, V95, P6; Ganem D, 2004, NEW ENGL J MED, V350, P1118, DOI 10.1056/NEJMra031087; Kao JH, 2002, LANCET INFECT DIS, V2, P395, DOI 10.1016/S1473-3099(02)00315-8; Kao JH, 2001, J PEDIATR-US, V139, P349, DOI 10.1067/mpd.2001.116277; Lin YC, 2003, J INFECT DIS, V187, P134, DOI 10.1086/345871; Lu CY, 2004, HEPATOLOGY, V40, P1415, DOI 10.1002/hep.20490; McMahon BJ, 2005, ANN INTERN MED, V142, P333, DOI 10.7326/0003-4819-142-5-200503010-00008; Ni YH, 2001, ANN INTERN MED, V135, P796, DOI 10.7326/0003-4819-135-9-200111060-00009; Yuen MF, 2004, CLIN GASTROENTEROL H, V2, P941, DOI 10.1016/S1542-3565(04)00384-2; Zanetti AR, 2005, LANCET, V366, P1379, DOI 10.1016/S0140-6736(05)67568-X	16	29	31	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 15	2005	366	9494					1337	1338		10.1016/S0140-6736(05)67544-7	http://dx.doi.org/10.1016/S0140-6736(05)67544-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	973ZW	16226597				2022-12-28	WOS:000232562100006
J	Chen, HH; Urquidez, OA; Ichim, S; Rodriguez, LH; Brenner, MP; Aziz, MJ				Chen, HH; Urquidez, OA; Ichim, S; Rodriguez, LH; Brenner, MP; Aziz, MJ			Shocks in ion sputtering sharpen steep surface features	SCIENCE			English	Article							UNDERCOMPRESSIVE SHOCKS; PATTERN-FORMATION; MORPHOLOGY; EVOLUTION; YIELD	We report a regime of ion beam sputtering that occurs for sufficiently steep slopes. High slopes propagate over large distances without dissipating the steepest features. Both the propagation velocity and the dynamically selected slope are universal, independent of the details of the initial shape of the surface. The resulting behavior can be understood as the propagation of a shock front that self-selects a stable slope, as has been previously observed in thin-film fluid flows. Experiments confirm predictions of the theory. An important implication of the propagative behavior at high surface slopes is that a pattern can be fabricated at a large length scale and, through uniform ion irradiation, reduced to a smaller length scale while preserving or even sharpening, the sharpest features.	Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; Harvard Univ, Dept Phys, Cambridge, MA 02138 USA	Harvard University; Harvard University	Aziz, MJ (corresponding author), Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA.	maziz@harvard.edu	Aziz, Michael/AAK-4866-2020	Aziz, Michael/0000-0001-9657-9456				Adams DP, 2003, J VAC SCI TECHNOL B, V21, P2334, DOI 10.1116/1.1619421; Bertozzi AL, 1999, PHYSICA D, V134, P431, DOI 10.1016/S0167-2789(99)00134-7; Bertozzi AL, 1998, PHYS REV LETT, V81, P5169, DOI 10.1103/PhysRevLett.81.5169; Bertozzi AL, 2000, SIAM J MATH ANAL, V32, P194, DOI 10.1137/S0036141099350894; BRADLEY RM, 1988, J VAC SCI TECHNOL A, V6, P2390, DOI 10.1116/1.575561; Carter G, 1996, PHYS REV B, V54, P17647, DOI 10.1103/PhysRevB.54.17647; Castro M, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.016102; CUENAT A, IN PRESS ADV MAT; CUERNO R, 1995, PHYS REV LETT, V74, P4746, DOI 10.1103/PhysRevLett.74.4746; Erlebacher J, 1999, PHYS REV LETT, V82, P2330, DOI 10.1103/PhysRevLett.82.2330; Erlebacher J, 2000, J VAC SCI TECHNOL A, V18, P115, DOI 10.1116/1.582127; Facsko S, 1999, SCIENCE, V285, P1551, DOI 10.1126/science.285.5433.1551; Frost F, 2000, PHYS REV LETT, V85, P4116, DOI 10.1103/PhysRevLett.85.4116; Habenicht S, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.125419; Li J, 2001, NATURE, V412, P166, DOI 10.1038/35084037; Makeev MA, 2002, NUCL INSTRUM METH B, V197, P185, DOI 10.1016/S0168-583X(02)01436-2; MULLINS WW, 1957, J APPL PHYS, V28, P333, DOI 10.1063/1.1722742; Park S, 1999, PHYS REV LETT, V83, P3486, DOI 10.1103/PhysRevLett.83.3486; SIGMUND P, 1969, PHYS REV, V184, P383, DOI 10.1103/PhysRev.184.383; SIGMUND P, 1973, J MATER SCI, V8, P1545, DOI 10.1007/BF00754888; Stein D, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.276106; Sur J, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.126105; Umbach CC, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.246104; Valbusa U, 2002, J PHYS-CONDENS MAT, V14, P8153, DOI 10.1088/0953-8984/14/35/301; Vasile MJ, 1997, J VAC SCI TECHNOL B, V15, P2350, DOI 10.1116/1.589644; Whitham G., 1974, LINEAR NONLINEAR WAV; Ziegler JF., 1985, TREATISE HEAVY ION S	27	41	43	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					294	297		10.1126/science.1117219	http://dx.doi.org/10.1126/science.1117219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224017				2022-12-28	WOS:000232670100046
J	Nutt, LK; Margolis, SS; Jensen, M; Herman, CE; Dunphy, WG; Rathmell, JC; Kornbluth, S				Nutt, LK; Margolis, SS; Jensen, M; Herman, CE; Dunphy, WG; Rathmell, JC; Kornbluth, S			Metabolic regulation of oocyte cell death through the CaMKII-mediated phosphorylation of caspase-2	CELL			English	Article							CYTOCHROME-C RELEASE; XENOPUS EGG EXTRACTS; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE ACTIVITY; INDUCED APOPTOSIS; ACTIVATION; BCL-2; GROWTH; EXPRESSION; SURVIVAL; KINASE	Vertebrate female reproduction is limited by the oocyte stockpiles acquired during embryonic development. These are gradually depleted over the organism's lifetime through the process of apoptosis. The timer that triggers this cell death is yet to be identified. We used the Xenopus egg/oocyte system to examine the hypothesis that nutrient stores can regulate oocyte viability. We show that pentose-phosphate-pathway generation of NADPH is critical for oocyte survival and that the target of this regulation is caspase-2, previously shown to be required for oocyte death in mice. Pentose-phosphate-pathway-mediated inhibition of cell death was due to the inhibitory phosphorylation of caspase-2 by calcium/calmodulin-dependent protein kinase II (CaMKII). These data suggest that exhaustion of oocyte nutrients, resulting in an inability to generate NADPH, may contribute to ooctye apoptosis. These data also provide unexpected links between oocyte metabolism, CaMKII, and caspase-2.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Sarah Stedman Ctr Nutr & Metab, Durham, NC 27710 USA; CALTECH, Dept Biol, Pasadena, CA 91125 USA	Duke University; Duke University; Duke University; California Institute of Technology	Kornbluth, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	kornb001@mc.duke.edu			NATIONAL CANCER INSTITUTE [R01CA102707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM072242, R01GM080333, R01GM056518] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102707, R01 CA 102727, R01 CA102707-04] Funding Source: Medline; NIGMS NIH HHS [R01 GM080333-02, F32 GM072242-02, R01 GM056518, R01 GM 56518, R01 GM080333] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagowski CP, 2001, J BIOL CHEM, V276, P1459, DOI 10.1074/jbc.M008050200; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bhuyan AK, 2001, CELL DEATH DIFFER, V8, P63, DOI 10.1038/sj.cdd.4400773; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; Braun T, 2003, MOL CANCER RES, V1, P186; COHEN AI, 1954, PHYSIOL ZOOL, V27, P128, DOI 10.1086/physzool.27.2.30154521; Comin-Anduix B, 2002, J BIOL CHEM, V277, P46408, DOI 10.1074/jbc.M206150200; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; Deming PB, 2004, MOL CELL BIOL, V24, P10289, DOI 10.1128/MCB.24.23.10289-10299.2004; Demirci B, 2003, THERIOGENOLOGY, V60, P999, DOI 10.1016/S0093-691X(03)00121-3; Demirci B, 2002, FERTIL STERIL, V77, P595, DOI 10.1016/S0015-0282(01)03205-8; Demirci B, 2001, FERTIL STERIL, V75, P754, DOI 10.1016/S0015-0282(00)01787-8; DESCHEPPER GG, 1987, HISTOCHEM J, V19, P467, DOI 10.1007/BF01675415; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; DWORKIN MB, 1989, DEV BIOL, V132, P524, DOI 10.1016/0012-1606(89)90247-9; Evans EK, 1997, EMBO J, V16, P7372, DOI 10.1093/emboj/16.24.7372; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hutchins JRA, 2003, MOL BIOL CELL, V14, P4003, DOI 10.1091/mbc.E03-02-0061; JAEGER L, 1945, J CELL COMPAR PHYSL, V25, P97, DOI 10.1002/jcp.1030250204; Kim MR, 2004, BBA-MOL CELL RES, V1644, P205, DOI 10.1016/j.bbamcr.2003.10.012; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOVACEVIC Z, 1972, CANCER RES, V32, P326; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; MALLER JL, 1985, CELL DIFFER DEV, V16, P211, DOI 10.1016/0045-6039(85)90570-6; Morita Y, 1999, DEV BIOL, V213, P1, DOI 10.1006/dbio.1999.9344; Morita Y, 1999, MOL ENDOCRINOL, V13, P841, DOI 10.1210/me.13.6.841; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Perez GI, 1999, NAT GENET, V21, P200, DOI 10.1038/5985; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Rathmell JC, 2001, J IMMUNOL, V167, P6869, DOI 10.4049/jimmunol.167.12.6869; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; RATTS VS, 1995, ENDOCRINOLOGY, V136, P3665, DOI 10.1210/en.136.8.3665; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Schwartz AG, 2004, AGEING RES REV, V3, P171, DOI 10.1016/j.arr.2003.05.001; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; Tian WN, 1999, AM J PHYSIOL-CELL PH, V276, pC1121, DOI 10.1152/ajpcell.1999.276.5.C1121; Tilly JL, 2001, NAT REV MOL CELL BIO, V2, P838, DOI 10.1038/35099086; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tuttle S, 2000, RADIAT RES, V153, P781, DOI 10.1667/0033-7587(2000)153[0781:GPDATO]2.0.CO;2; Ureta T, 2000, FEBS LETT, V475, P145, DOI 10.1016/S0014-5793(00)01646-X; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Voronina E, 2001, MOL REPROD DEV, V60, P553, DOI 10.1002/mrd.1120; Watanabe M, 1997, EXP CELL RES, V230, P76, DOI 10.1006/excr.1996.3366	52	190	194	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 7	2005	123	1					89	103		10.1016/j.cell.2005.07.032	http://dx.doi.org/10.1016/j.cell.2005.07.032			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	973QD	16213215	Green Accepted, Bronze			2022-12-28	WOS:000232536800011
J	Carmona, RH				Carmona, RH			The global challenges of birth defects and disabilities	LANCET			English	Editorial Material							NEURAL-TUBE DEFECTS; FOLIC-ACID; PREVENTION				Carmona, RH (corresponding author), Parklawn Bldg 18-67, Rockville, MD 20857 USA.	jessica.badger@hhs.gov						[Anonymous], 1991, Lancet, V338, P131, DOI 10.1016/0140-6736(91)90133-A; Bale JR, 2003, REDUCING BIRTH DEFEC; Bale JR, 2003, IMPROVING BIRTH OUTC; Berry RJ, 1999, NEW ENGL J MED, V341, P1485, DOI 10.1056/NEJM199911113412001; Botto LD, 1999, NEW ENGL J MED, V341, P1509, DOI 10.1056/NEJM199911113412006; Botto LD, 2005, BMJ-BRIT MED J, V330, P571, DOI 10.1136/bmj.38336.664352.82; *CDCP, 2005, BEH RISK FACT SURV S; Centers for Disease C., 2005, MMWR MORB MORTAL WKL, V54, P279; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P362; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; U.S Department of Health and Human Services, 2005, SURG GEN CALL ACT IM; *US DEP HHS, 2005, US SURG GEN ANN NEW; Wald NJ, 2004, NEW ENGL J MED, V350, P101, DOI 10.1056/NEJMp038186	14	32	43	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	2005	366	9492					1142	1144		10.1016/S0140-6736(05)67459-4	http://dx.doi.org/10.1016/S0140-6736(05)67459-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970LK	16198750				2022-12-28	WOS:000232311300006
J	Lowsky, R; Takahashi, T; Liu, YP; Dejbakhsh-Jones, S; Grumet, FC; Shizuru, JA; Laport, GG; Stockerl-Goldstein, KE; Johnston, LJ; Hoppe, RT; Bloch, DA; Blume, KG; Negrin, RS; Strober, S				Lowsky, R; Takahashi, T; Liu, YP; Dejbakhsh-Jones, S; Grumet, FC; Shizuru, JA; Laport, GG; Stockerl-Goldstein, KE; Johnston, LJ; Hoppe, RT; Bloch, DA; Blume, KG; Negrin, RS; Strober, S			Protective conditioning for acute graft-versus-host disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; T-CELLS; HEMATOLOGIC MALIGNANCIES; LYMPHOID IRRADIATION; CHIMERISM; THERAPY; ENGRAFTMENT; MICE	BACKGROUND: Conditioning with total lymphoid irradiation plus antithymocyte serum protects mice against acute graft-versus-host disease (GVHD) after hematopoietic-cell transplantation. We tested this strategy in humans. METHODS: Thirty-seven patients with lymphoid malignant diseases or acute leukemia underwent an experimental conditioning regimen with 10 doses of total lymphoid irradiation (80 cGy each) plus antithymocyte globulin, followed by an infusion of HLA-matched peripheral-blood mononuclear cells from related or unrelated donors who received granulocyte colony-stimulating factor. RESULTS: Of the 37 transplant recipients, only 2 had acute GVHD after hematopoietic-cell transplantation. Potent antitumor effects in patients with lymphoid malignant diseases were shown by the change from partial to complete remission. In the transplant recipients who underwent conditioning with total lymphoid irradiation and antithymocyte globulin, the fraction of donor CD4+ T cells that produced interleukin-4 after in vitro stimulation increased by a factor of five, and the proliferative response to alloantigens in vitro was reduced, as compared with normal control subjects and control subjects who underwent conditioning with a single dose of total-body irradiation (200 cGy). CONCLUSIONS: A regimen of total lymphoid irradiation plus antithymocyte globulin decreases the incidence of acute GVHD and allows graft antitumor activity in patients with lymphoid malignant diseases or acute leukemia treated with hematopoietic-cell transplantation.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University	Lowsky, R (corresponding author), Ctr Clin Sci Res Bldg,Rm 2215,269 W Campus Dr, Stanford, CA 94305 USA.			Stockerl-Goldstein, Keith/0000-0002-7234-1715	NCI NIH HHS [P01-CA49605] Funding Source: Medline; NHLBI NIH HHS [R01-HL-58250, P01-HL-075462, P01-HL-57443] Funding Source: Medline; NIAID NIH HHS [R01-AI-37683] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049605] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057443, R01HL058250, P01HL075462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037683] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; Childs R, 1999, BLOOD, V94, P3234, DOI 10.1182/blood.V94.9.3234.421k16_3234_3241; Edinger M, 2003, NAT MED, V9, P1144, DOI 10.1038/nm915; FOWLER DH, 1994, J IMMUNOL, V152, P1004; FOWLER DH, 1994, BLOOD, V84, P3540; Georges GE, 2002, INT J HEMATOL, V76, P184, DOI 10.1007/BF03165242; Giralt S, 2001, BLOOD, V97, P631, DOI 10.1182/blood.V97.3.631; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Hoffmann P, 2002, J EXP MED, V196, P389, DOI 10.1084/jem.20020399; KAPLAN HS, 1966, CANCER RES, V26, P1268; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; Lan FS, 2003, BIOL BLOOD MARROW TR, V9, P355, DOI 10.1016/S1083-8791(03)00108-3; Lan FS, 2001, J IMMUNOL, V167, P2087, DOI 10.4049/jimmunol.167.4.2087; Maloney DG, 2003, BLOOD, V102, P3447, DOI 10.1182/blood-2002-09-2955; Maris MB, 2004, BLOOD, V104, P3535, DOI 10.1182/blood-2004-06-2275; McSweeney PA, 2001, BLOOD, V97, P3390, DOI 10.1182/blood.V97.11.3390; Mielcarek M, 2003, BLOOD, V102, P756, DOI 10.1182/blood-2002-08-2628; Millan TLT, 2002, TRANSPLANTATION, V73, P1386, DOI 10.1097/00007890-200205150-00005; Niederwieser D, 2003, BLOOD, V101, P1620, DOI 10.1182/blood-2002-05-1340; PAN LY, 1995, BLOOD, V86, P4422, DOI 10.1182/blood.V86.12.4422.bloodjournal86124422; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Regan JF, 2001, TRANSPL IMMUNOL, V9, P29, DOI 10.1016/S0966-3274(01)00048-X; Schetelig J, 2002, HAEMATOLOGICA, V87, P299; Seino K, 2004, TRENDS IMMUNOL, V25, P219, DOI 10.1016/j.it.2004.03.001; Slavin S, 1998, BLOOD, V91, P756, DOI 10.1182/blood.V91.3.756.756_756_763; Spitzer TR, 2000, BIOL BLOOD MARROW TR, V6, P309, DOI 10.1016/S1083-8791(00)70056-5; Strober S, 2000, TRANSPLANTATION, V69, P1549; SULLIVAN KM, 1991, SEMIN HEMATOL, V28, P250; Sutherland D R, 1996, J Hematother, V5, P213, DOI 10.1089/scd.1.1996.5.213; Zeng DF, 1999, J EXP MED, V189, P1073, DOI 10.1084/jem.189.7.1073	31	245	249	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2005	353	13					1321	1331		10.1056/NEJMoa050642	http://dx.doi.org/10.1056/NEJMoa050642			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968FB	16192477				2022-12-28	WOS:000232146200004
J	Yin, Y; Alivisatos, AP				Yin, Y; Alivisatos, AP			Colloidal nanocrystal synthesis and the organic-inorganic interface	NATURE			English	Review							ORIENTED ATTACHMENT MECHANISM; SEMICONDUCTOR QUANTUM RODS; CDSE NANOCRYSTALS; CONTROLLED GROWTH; SELECTIVE GROWTH; SHAPE-CONTROL; SOLAR-CELLS; SIZE; NANOPARTICLES; DOTS	Colloidal nanocrystals are solution-grown, nanometre-sized, inorganic particles that are stabilized by a layer of surfactants attached to their surface. The inorganic cores possess useful properties that are controlled by their composition, size and shape, and the surfactant coating ensures that these structures are easy to fabricate and process further into more complex structures. This combination of features makes colloidal nanocrystals attractive and promising building blocks for advanced materials and devices. Chemists are achieving ever more exquisite control over the composition, size, shape, crystal structure and surface properties of nanocrystals, thus setting the stage for fully exploiting the potential of these remarkable materials.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Mol Foundry, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Alivisatos, AP (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	alivis@berkeley.edu	Yin, Yadong/D-5987-2011; Alivisatos, Paul/N-8863-2015; Selopal, Gurpreet Singh/D-5801-2018	Yin, Yadong/0000-0003-0218-3042; Alivisatos, Paul/0000-0001-6895-9048; 				Adachi M, 2004, J AM CHEM SOC, V126, P14943, DOI 10.1021/ja048068s; Alivisatos AP, 2005, ANNU REV BIOMED ENG, V7, P55, DOI 10.1146/annurev.bioeng.7.060804.100432; Alivisatos AP, 2000, SCIENCE, V289, P736, DOI 10.1126/science.289.5480.736; Alivisatos AP, 1997, ENDEAVOUR, V21, P56, DOI 10.1016/S0160-9327(97)01018-1; Alivisatos AP, 1996, J PHYS CHEM-US, V100, P13226, DOI 10.1021/jp9535506; Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; BIANCONI PA, 1991, NATURE, V349, P315, DOI 10.1038/349315a0; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; BUFFAT P, 1976, PHYS REV A, V13, P2287, DOI 10.1103/PhysRevA.13.2287; Chan EM, 2003, NANO LETT, V3, P199, DOI 10.1021/nl0259481; Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016; Collier CP, 1998, ANNU REV PHYS CHEM, V49, P371, DOI 10.1146/annurev.physchem.49.1.371; Cushing BL, 2004, CHEM REV, V104, P3893, DOI 10.1021/cr030027b; El-Sayed MA, 2004, ACCOUNTS CHEM RES, V37, P326, DOI 10.1021/ar020204f; Fu AH, 2004, J AM CHEM SOC, V126, P10832, DOI 10.1021/ja046747x; Gu HW, 2004, J AM CHEM SOC, V126, P5664, DOI 10.1021/ja0496423; Huynh WU, 2002, SCIENCE, V295, P2425, DOI 10.1126/science.1069156; Jun YW, 2003, J AM CHEM SOC, V125, P15981, DOI 10.1021/ja0369515; KATARI JEB, 1994, J PHYS CHEM-US, V98, P4109, DOI 10.1021/j100066a034; Kazes M, 2002, ADV MATER, V14, P317, DOI 10.1002/1521-4095(20020219)14:4<317::AID-ADMA317>3.0.CO;2-U; Klein DL, 1997, NATURE, V389, P699, DOI 10.1038/39535; Kudera S, 2005, NANO LETT, V5, P445, DOI 10.1021/nl048060g; Kuno M, 1997, J CHEM PHYS, V106, P9869, DOI 10.1063/1.473875; Li LS, 2002, NANO LETT, V2, P557, DOI 10.1021/nl0255146; MANN S, 1988, NATURE, V332, P119, DOI 10.1038/332119a0; Manna L, 2000, J AM CHEM SOC, V122, P12700, DOI 10.1021/ja003055+; Manna L, 2005, J PHYS CHEM B, V109, P6183, DOI 10.1021/jp0445573; Manna L, 2003, NAT MATER, V2, P382, DOI 10.1038/nmat902; Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274; Milliron DJ, 2004, NATURE, V430, P190, DOI 10.1038/nature02695; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; Mokari T, 2004, SCIENCE, V304, P1787, DOI 10.1126/science.1097830; Murray CB, 2001, MRS BULL, V26, P985, DOI 10.1557/mrs2001.254; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; Nirmal M, 1999, ACCOUNTS CHEM RES, V32, P407, DOI 10.1021/ar9700320; Pacholski C, 2002, ANGEW CHEM INT EDIT, V41, P1188, DOI 10.1002/1521-3773(20020402)41:7<1188::AID-ANIE1188>3.0.CO;2-5; Peng XG, 2000, NATURE, V404, P59, DOI 10.1038/35003535; Peng XG, 1998, J AM CHEM SOC, V120, P5343, DOI 10.1021/ja9805425; Peng XG, 2003, ADV MATER, V15, P459, DOI 10.1002/adma.200390107; Penn RL, 1998, SCIENCE, V281, P969, DOI 10.1126/science.281.5379.969; Penn RL, 1999, GEOCHIM COSMOCHIM AC, V63, P1549, DOI 10.1016/S0016-7037(99)00037-X; Penn RL, 1998, AM MINERAL, V83, P1077; Pileni MP, 2003, NAT MATER, V2, P145, DOI 10.1038/nmat817; Puntes VF, 2001, SCIENCE, V291, P2115, DOI 10.1126/science.1057553; Puntes VF, 2002, J AM CHEM SOC, V124, P12874, DOI 10.1021/ja027262g; Puzder A, 2004, NANO LETT, V4, P2361, DOI 10.1021/nl0485861; Redl FX, 2003, NATURE, V423, P968, DOI 10.1038/nature01702; REISS H, 1951, J CHEM PHYS, V19, P482, DOI 10.1063/1.1748251; Steckel JS, 2003, ADV MATER, V15, P1862, DOI 10.1002/adma.200305449; STEIGERWALD ML, 1994, POLYHEDRON, V13, P1245, DOI 10.1016/S0277-5387(00)80258-2; STUCZYNSKI SM, 1989, INORG CHEM, V28, P4431, DOI 10.1021/ic00324a001; Sun SH, 2000, SCIENCE, V287, P1989, DOI 10.1126/science.287.5460.1989; VOSSMEYER T, 1994, J PHYS CHEM-US, V98, P7665, DOI 10.1021/j100082a044; Wang DL, 2003, NAT MATER, V2, P355, DOI 10.1038/nmat908; Whaley SR, 2000, NATURE, V405, P665, DOI 10.1038/35015043; Yan HQ, 2003, ADV MATER, V15, P402, DOI 10.1002/adma.200390091; YEH CY, 1992, PHYS REV B, V46, P10086, DOI 10.1103/PhysRevB.46.10086; Yu H, 2005, NANO LETT, V5, P379, DOI 10.1021/nl047955q; Yu JH, 2005, J AM CHEM SOC, V127, P5662, DOI 10.1021/ja044593f; Yu WW, 2003, CHEM MATER, V15, P4300, DOI 10.1021/cm034729t	62	2742	2841	58	2539	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					664	670		10.1038/nature04165	http://dx.doi.org/10.1038/nature04165			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193041	Green Submitted			2022-12-28	WOS:000232157900040
J	Yoshida, H; Kawane, K; Koike, M; Mori, Y; Uchiyama, Y; Nagata, S				Yoshida, H; Kawane, K; Koike, M; Mori, Y; Uchiyama, Y; Nagata, S			Phosphatidylserine-dependent engulfment by macrophages of nuclei from erythroid precursor cells	NATURE			English	Article							APOPTOTIC CELLS; ERYTHROPOIETIN RECEPTOR; PLASMA-MEMBRANE; MICE; DIFFERENTIATION; IDENTIFICATION; PHAGOCYTOSIS; DEFICIENT; INVITRO; BINDING	Definitive erythropoiesis usually occurs in the bone marrow or fetal liver, where erythroblasts are associated with a central macrophage in anatomical units called 'blood islands'(1,2). Late in erythropoiesis, nuclei are expelled from the erythroid precursor cells and engulfed by the macrophages in the blood island(2,3). Here we show that the nuclei are engulfed by macrophages only after they are disconnected from reticulocytes, and that phosphatidylserine, which is often used as an 'eat me' signal for apoptotic cells, is also used for the engulfment of nuclei expelled from erythroblasts. We investigated the mechanism behind the enucleation and engulfment processes by isolating late-stage erythroblasts from the spleens of phlebotomized mice. When these erythroblasts were cultured, the nuclei protruded spontaneously from the erythroblasts. A weak physical force could disconnect the nuclei from the reticulocytes. The released nuclei contained an undetectable level of ATP, and quickly exposed phosphatidylserine on their surface. Fetal liver macrophages efficiently engulfed the nuclei; masking the phosphatidylserine on the nuclei with the dominant-negative form of milk-fat-globule EGF8 (MFG-E8) prevented this engulfment.	Osaka Univ, Grad Sch Med, Dept Genet, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Integrated Biol Labs, Genet Lab, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Suita, Osaka 5650871, Japan; Sakura Mot Picture Co Ltd, Shibuya Ku, Tokyo 1510051, Japan	Osaka University; Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Nagata, S (corresponding author), Osaka Univ, Grad Sch Med, Dept Genet, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	Nagata@genetic.med.osaka-u.ac.jp	Koike, Masato/F-9584-2010; Nagata, Shigekazu/AAG-3203-2019	Koike, Masato/0000-0002-3174-5684; Nagata, Shigekazu/0000-0001-9758-8426; Kawane, Kohki/0000-0003-1125-9483				Asano K, 2004, J EXP MED, V200, P459, DOI 10.1084/jem.20040342; Balasubramanian K, 2003, ANNU REV PHYSIOL, V65, P701, DOI 10.1146/annurev.physiol.65.092101.142459; BESSIS M, 1978, BLOOD CELLS, V4, P155; BROUDY VC, 1991, BLOOD, V77, P2583, DOI 10.1182/blood.V77.12.2583.2583; Carlile GW, 2004, BLOOD, V103, P4310, DOI 10.1182/blood-2003-09-3362; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; GEIDUSCHEK JB, 1979, CELL, V16, P149, DOI 10.1016/0092-8674(79)90196-X; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2004, J IMMUNOL, V172, P3876, DOI 10.4049/jimmunol.172.6.3876; Hanspal M, 1997, Curr Opin Hematol, V4, P142; Kawane K, 2001, SCIENCE, V292, P1546, DOI 10.1126/science.292.5521.1546; Kawane K, 2003, NAT IMMUNOL, V4, P138, DOI 10.1038/ni881; Kawasaki Y, 2002, J BIOL CHEM, V277, P27559, DOI 10.1074/jbc.M202879200; Krahling S, 1999, CELL DEATH DIFFER, V6, P183, DOI 10.1038/sj.cdd.4400473; PANNACCIULLI IM, 1977, ACTA HAEMATOL-BASEL, V58, P27, DOI 10.1159/000207802; REPASKY EA, 1981, CELL TISSUE RES, V221, P85, DOI 10.1007/BF00216572; Sadahira Y, 1999, PATHOL INT, V49, P841, DOI 10.1046/j.1440-1827.1999.00954.x; SCHLEGEL RA, 1980, CELL, V20, P321, DOI 10.1016/0092-8674(80)90618-2; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; Strehler EE, 2004, CURR MOL MED, V4, P323, DOI 10.2174/1566524043360735; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; Williamson Patrick, 2004, J Biol, V3, P14, DOI 10.1186/jbiol14; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zhang DY, 2001, EXP HEMATOL, V29, P1278, DOI 10.1016/S0301-472X(01)00725-1; Zhou QS, 2002, BLOOD, V99, P4030, DOI 10.1182/blood-2001-12-0271; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240	30	243	253	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					754	758		10.1038/nature03964	http://dx.doi.org/10.1038/nature03964			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16193055				2022-12-28	WOS:000232157900057
J	Deen, JL; Clemens, JD				Deen, JL; Clemens, JD			Antimicrobial treatment for cholera	LANCET			English	Editorial Material							THERAPY		Int Vaccine Inst, Seoul 151818, South Korea	International Vaccine Institute	Clemens, JD (corresponding author), Int Vaccine Inst, Seoul 151818, South Korea.	jclemens@ivi.int						[Anonymous], 2002, WKLY EPIDEMIOL REC, V78, P269; CARPENTER CCJ, 1992, J INFECT DIS, V166, P2, DOI 10.1093/infdis/166.1.2; GHOSH S, 1992, J COMMUN DISORD, V24, P5; Khan WA, 2002, LANCET, V360, P1722, DOI 10.1016/S0140-6736(02)11680-1; LINDENBA.J, 1967, B WORLD HEALTH ORGAN, V36, P871; MAHALANABIS D, 1973, JOHNS HOPKINS MED J, V132, P197; Saha D, 2005, LANCET, V366, P1085, DOI 10.1016/S0140-6736(05)67290-X; *WHO, 2005, CHOL W AFR; World Health Organization, 2005, TREATM DIARRH MAN PH	9	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 24	2005	366	9491					1054	1055		10.1016/S0140-6736(05)67326-6	http://dx.doi.org/10.1016/S0140-6736(05)67326-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TL	16182879				2022-12-28	WOS:000232114000005
J	Sommerville, A				Sommerville, A			Changes in BMA policy on assisted dying	BRITISH MEDICAL JOURNAL			English	Editorial Material									BMA, London WC1H 9JP, England		Sommerville, A (corresponding author), BMA, London WC1H 9JP, England.	asommerville@bma.org.uk						Dobscha Steven K, 2004, J Palliat Med, V7, P451, DOI 10.1089/1096621041349374; IDDON B, 2005, BRIT MED ASS VOTE EU; MEDIX UK, 2004, PHYS ASSISTED SUICID; Miller LL, 2004, PALLIATIVE MED, V18, P685, DOI 10.1191/0269216304pm961oa; *OR DEP HUM SERV, 2003, 5 OR DEP HUM SERV; Purvis J., DYING DIGNITY CONSUL; van der Maas P. J., 1992, EUTHANASIA OTHER MED; WINTERTON A, 2005, BRIT MED ASS DEBATE	8	8	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	SEP 24	2005	331	7518					686	688		10.1136/bmj.331.7518.686	http://dx.doi.org/10.1136/bmj.331.7518.686			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970HH	16179706	Green Published			2022-12-28	WOS:000232295400023
